[redacted]

INDEX TABLE

NOT TO BE TAKEN FROM LIBRARY...
FOR ROOM USE ONLY

LIBRARY

INDEX TABLE

ational Institute
Mental Health

The National Clearinghouse
for Mental Health Information

OL. 15 Cumulative Index June 1978

Psychopharmacology Abstracts

DEPOSITORY
OF ILL. LIBRARY
AT URBANA-CHAMPAIGN

S

N

LIBRARY

U.S. Department
of Health,
Education, and
Welfare

Public Health
Service

Alcohol,
Drug Abuse, and
Mental Health
Administration

PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse for Mental Health Information of the National Institute of Mental Health. It is a specialized information medium designed to assist the Institute in meeting its obligation to foster and support laboratory and clinical research into the nature and causes of mental disorders and methods of treatment and prevention. Specifically, this information service is designed to meet the needs of investigators in the field of psychopharmacology for rapid and comprehensive information about new developments and research results. For information or correspondence with the National Institute of Mental Health concerning *Psychopharmacology Abstracts*, changes of address, or removal of names from the mailing list see the inside back cover page.

The Secretary of Health, Education, and Welfare has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through October 30, 1979.

NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION
PSYCHOPHARMACOLOGY ABSTRACTS

615.7005
FS
v.15
index

Volume 14

Cumulative Index

June 1977

Page

Author Index A1

Subject Index S1

Carrie Lee Rothgeb, *Editor*
Bette L. Shannon, *Managing Editor*

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service

Alcohol, Drug Abuse and Mental Health Administration
National Institute of Mental Health
National Clearinghouse for Mental Health Information
5600 Fishers Lane
Rockville, Maryland 20857

DHEW Publication No. (ADM) 79-150
Printed 1979

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Subscription price per year in the United States, Canada, and Mexico: $14.00; other countries, $17.50. Single copy $3.50; other countries $4.40. Index issue $2.10. The Clearinghouse does not sell copies of *Psychopharmacology Abstracts*. Persons wishing to subscribe by the year or to purchase single copies should send their orders, accompanied by check or money order, directly to the Superintendent of Documents.

AUTHOR INDEX

[The 6-digit number is the abstract accession number. The next two digits are the issue number, digits after hyphen are the category number.]

A

AADAMSCO A 000705 01-10
AASETH J 002197 03-03, 002198 03-03
ABBOTT D 000720 01-10
ABBRUZZESE G 002694 03-09
ABDALLAH AH 001119 02-03
ABELL CW 000281 01-04
ABERG H 002957 03-17
ABIKOFF H 002862 03-14
ABLAD B 000028 01-03, 001011 01-17
ABOOD LG 003091 04-03
ABRAHAMSSON L 001769 02-09
ABRAMS R 002952 03-16
ABT K 001653 02-07
ABUZZAHAB FS 000580 01-09
ACETO MD 003072 04-02, 003077 04-03, 003426 04-04
ACKENHEIL M 001410 02-03, 001878 02-13
ADAM K 002848 03-14
ADAMS AJ 000873 01-14
ADAMS BE 003759 04-15
ADAMS GK 000029 01-03
ADAMS JG 000030 01-03
ADAMS MD 003426 04-04
ADAMS PE 003844 04-17
ADAMS PM 000270 01-04, 000281 01-04, 001433 02-04
ADAMS R 000910 01-14
ADAMS RN 000388 01-04
ADAMS T 002799 03-13
ADAMSON L 002848 03-14
ADDABBO A 001012 01-17
ADEN GC 001813 02-11
ADOMAKOH CC 002958 03-17
ADRIANI J 002007 02-15
AFELTOWICZ Z 002608 03-08
AGARWAL RA 001120 02-03, 003248 04-03
AGEDAIRA T 000524 01-08
AGER IR 003062 04-02
AGHAJANIAN GK 000309 01-04, 001164 02-03, 002246 03-03, 002247 03-03, 002580 03-05, 003078 04-03, 003320 04-03, 003371 04-04, 003372 04-04
AGID R 001352 02-03
AGMO A 001434 02-04
AGNATI L 000100 01-03
AGNOLI A 001953 02-14
AGOSIN M 001121 02-03
AGRANOFF BW 000427 01-04, 001590 02-04
AGRELL B 002736 03-11
AGUDELO R 002415 03-04
AHLENIUS S 003079 04-03
AHN HS 003881 04-17
AHTEE L 002199 03-03, 003188 04-03
AIELLO E 001389 02-03
AIKAWA H 002820 03-13
AIKEN JW 001208 02-03
AIRAKSINEN M 002959 03-17
AIROLDI L 003207 04-03
AJEMIAN I 000847 01-13
AKAIKE A 002200 03-03
AKAMATSU T 002921 03-15
AKERA T 000153 01-03
AKERMAN A 002018 02-15
AKERMAN KE 003080 04-03
AKIMOV YA 002201 03-03
AKIYAMA S 003410 04-04
ALATORRE E 001850 02-11
ALBALA B 000399 01-04, 001559 02-04
ALBAN J 003753 04-14
ALBANO C 002694 03-09
ALBERT J 002960 03-17
ALBIERO L 003301 04-03
ALBRECHT J 001B79 02-13
ALESSANDRI L 000723 01-11
ALEVIZOS B 000491 01-07
ALEXANDER CS 002008 02-15
ALEXANDER FW 001947 02-13
ALEXANDER GJ 000031 01-03
ALFREDSSON G 001422 02-03, 002086 02-16, 002835 03-13, 002836 03-13, 003653 04-13, 003704 04-13
ALHAVA E 000454 01-05
ALKANA RL 001954 02-14
ALLANIC H 002081 02-15
ALLEN D 001898 02-13
ALLEN HE 002737 03-11
ALLEN MD 003788 04-15, 003789 04-15
ALLEN R 001855 02-11
ALLEN RE 003760 04-15
ALLERT M 000929 01-15
ALLIEZ J 002182 03-01
ALLONEN H 000032 01-03
ALLWEIS C 002416 03-04
ALM B 001122 02-03
ALMEIDA M 001775 02-09
ALPERN HP 000114 01-03
ALPERT M 002009 02-15
ALRIC R 000977 01-15
ALTMAN J 001613 02-05
ALTMAN JL 002960 03-17
ALTMANN H 000033 01-03
ALTSCHULE MD 000525 01-08, 000526 01-08, 000527 01-08, 000528 01-08
ALTSHULER HL 000442 01-04
ALTSTETTER R 003349 04-04
ALTURA BM 001123 02-03
AMAN MG 000927 01-14, 003649 04-11
AMBROZI L 002588 03-07
AMELUNG U 001757 02-09, 002682 03-09
AMERY A 000866 01-13
AMINOFF MJ 000215 01-03
AMIT Z 000271 01-04, 003081 04-03, 003481 04-04, 003508 04-05
AMLADI SR 003228 04-03
AMORICO L 002448 03-04
AMPHOUX G 000477 01-07
AMREIN R 000856 01-13
ANAND M 002417 03-04
ANANTH J 000628 01-09, 000672 01-10, 002010 02-15, 002097 02-17, 002649 03-08, 002738 03-11, 003579 04-10, 003845 04-17, 003846 04-17
ANCH MA 001973 02-14
ANDEN N 002202 03-03, 003479 04-04
ANDERSEN B 001664 02-07
ANDERSEN J 001205 02-03
ANDERSEN ME 000034 01-03
ANDERSON A 002177 02-17
ANDERSON DE 001124 02-03
ANDERSON SD 003082 04-03
ANDERSON WH 000529 01-08, 001726 02-09
ANDERSSON P 000836 01-13
ANDO F 002567 03-05
ANDO K 000272 01-04, 002546 03-04
ANDO S 002609 03-08
ANDOLFI M 002961 03-17
ANDREASEN PB 000798 01-13, 000898 01-14, 002813 03-13
ANDREOLI A 002796 03-12
ANDREOLI V 000507 01-07, 000508 01-07, 001953 02-14
ANDRESEN BD 000799 01-13
ANDREWS P 000530 01-08
ANDREYEVA NI 002205 03-03
ANDRIEU L 003139 04-03
ANDRY DK 003341 04-04
ANEZAKI K 002281 03-03
ANGEL C 001125 02-03
ANGELINI F 000207 01-03
ANGERMEYER M 002153 02-17
ANGRIST B 000478 01-07, 001955 02-14, 003861 04-17
ANGRIST BM 002832 03-13
ANGST J 001723 02-08, 002098 02-17, 002793 03-11, 002962 03-17
ANISMAN H 000361 01-04, 001126 02-03, 001435 02-04, 001568 02-04, 003413 04-04
ANLEZARK G 000273 01-04, 003304 04-03
ANNABLE L 000693 01-10, 001683 02-08, 003553 04-09, 003594 04-10
ANNAU Z 003342 04-04
ANSOMS C 003549 04-09
ANTAL J 001880 02-13
ANTELMAN SM 000274 01-04, 003343 04-04
ANTKIEWICZ-MICHALUK L 002418 03-04
ANTONELLI F 000673 01-10
ANTONIN K 001921 02-13
ANTONIN KH 003683 04-13
ANTOSIK I 000724 01-11
ANWEILER J 002953 03-16
APFELBACH R 003459 04-04
APOSHIAN D 000015 01-01
APPEL JB 000295 01-04, 000355 01-04, 003003 03-17
APPEL PW 001956 02-14
AQUILONIUS S 000035 01-03
AQUINO JP 000479 01-07
ARAKI K 002045 02-15
ARANDA G 003083 04-03
ARCUNI OJ 001999 02-14
ARDILA R 002415 03-04
AREFOLOV VA 002203 03-03
AREFYEVA AK 002572 03-05
ARESCHKA A 000275 01-04, 000276 01-04
ARGIOLAS A 001387 02-03, 002438 03-04
ARIA M 002610 03-08
ARIEFF AJ 002934 03-15
ARIENTI G 000036 01-03, 001127 02-03
ARION J 002723 03-10
ARISTIGUETA N 001691 02-08
ARKO RS 000988 01-15
ARMSTRONG J 000001 01-01
ARNAUD MJ 001128 02-03
ARNOLD E 000480 01-07
ARNOLD VW 001497 02-04
ARONOW WS 003730 04-14
ARONSON CE 003084 04-03
ARONSON M 000478 01-07
ARONSON MD 002013 02-15
ARONSTAM R 003091 04-03
ARORA RC 001129 02-03, 003085 04-03
ARRETHCHE-BERTHELOT N 002019 02-15
ARRINGTON WS 003605 04-10
ARROTTA M 000679 01-10
ARTEMENKO GN 002187 03-02, 002395 03-03
ARUSHANYAN EB 002204 03-03, 002206 03-03
ARUTYUNYAN LG 001305 02-03
ARUTYUNYAN SP 001305 02-03
ARY M 003086 04-03
ASADA S 000531 01-08
ASAI H 003073 04-02
ASAKAWA T 000037 01-03
ASAM U 000725 01-11
ASANO K 000581 01-09
ASANO Y 000654 01-09, 002820 03-13
ASBERG M 002666 03-09, 003654 04-13
ASHKENAZI JJ 002871 03-14
ASHKENAZI R 002419 03-04, 003518 04-06
ASK A 003044 03-17
ASNINA VV 002205 03-03
ASPER H 001159 02-03, 001359 02-03
ASSAEL M 002905 03-15
ASSAF SY 002420 03-04
ASTRACHAN DI 003461 04-04
ATANASIO G 000726 01-11
ATHEN O 000532 01-08
ATKINSON CA 003346 04-04
ATKINSON J 001436 02-04
ATKINSON S 002440 03-04
ATRENS DM 000346 01-04, 003087 04-03
ATSMON A 002739 03-11
ATSUMI Y 002931 03-15
ATTA K 002931 03-15
ATTERWILL CK 001130 02-03
ATTEWELL PA 003734 04-14, 003735 04-14
ATTILA M 000454 01-05
ATWEH SF 000038 01-03, 003088 04-03
AUDIGIER Y 000039 01-03, 003089 04-03
AUDISIO M 001013 01-17
AUFDEMBRINKE B 001659 02-07
AUGUSTIN P 000727 01-11
AURON ZALTZMAN D 002709 03-10
AUSTIN JH 000040 01-03
AUTRET A 001025 01-17, 002849 03-14
AVADHANI NG 001421 02-03
AVAKYAN OM 002323 03-03
AVAKYAN RM 001131 02-03, 001132 02-03, 002206 03-03
AVERY D 001727 02-09
AVERY DH 001872 02-12

AVERY ME 003761 04-15
AWAD AG 002837 03-13
AXELROD J 001014 01-17, 001313 02-03, 001881 02-13
AXELSSON R 003655 04-13, 003762 04-15
AYD FJ 002099 02-17, 002611 03-08
AYHAN IH 000858 01-13, 001133 02-03
AYIM JSK 001084 02-01
AYUSO GUTIERREZ JL 000627 01-09
AZYAVCHIK AV 002395 03-03

B

BAASTRUP PC 000585 01-09, 000623 01-09, 002026 02-15, 002665 03-09
BABA A 002264 03-03
BABA O 000608 01-09, 001661 02-07
BABBINI M 000277 01-04, 001437 02-04, 003344 04-04
BABCOCK DA 002421 03-04
BABINEAU R 001875 02-12
BABOR TF 002850 03-14
BACH MJ 000874 01-14
BACH O 002612 03-08
BACH-MORTENSEN N 001782 02-09
BACK DJ 001134 02-03
BACKSTROM M 003044 03-17
BADAWI I 003114 04-03
BADE P 001569 02-04
BADICHE A 002740 03-11
BAEZ LA 003345 04-04
BAFAQEEH HH 000930 01-15
BAGCHI SP 000041 01-03
BAGNOLI M 000604 01-09
BAHR B 001664 02-07
BAILE WF 003763 04-15
BAILEY AR 00268B 03-09
BAILEY J 000589 01-09, 001740 02-09
BAILEY JE 000590 01-09
BAILEY PT 000179 01-03, 003435 04-04
BAILEY R 000129 01-03
BAINES AD 002218 03-03
BAJUSZ S 001344 02-03, 003296 04-03
BAK W 001637 02-05
BAKALAR JB 003732 04-14
BAKE B 002031 02-15
BAKER EP 000537 01-08
BAKER GA 003656 04-13
BAKER GB 000002 01-01, 001135 02-03
BAKER JC 002242 03-03, 003147 04-03
BAKER M 003692 04-13
BAKER TB 003346 04-04, 003359 04-04
BAKER WW 001438 02-04
BAKKER JB 002011 02-15
BALA S 001612 02-05
BALAZS R 001295 02-03
BALAZS T 001610 02-04
BALDEO W 003090 04-03
BALDESSARINI RJ 000278 01-04, 000279 01-04, 000429 01-04, 000430 01-04, 001643 02-05, 002883 03-15, 002884 03-15, 002903 03-15
BALESTRIERI A 000571 01-08
BALKA EB 002767 03-11, 003652 04-11
BALL TJ 003049 04-01
BALLARD IM 003648 04-11
BALLARD JE 001814 02-11
BALLDIN J 001769 02-09
BALLHAUSE H 001439 02-04
BALLINGER BR 003842 04-16
BALLIVET J 000948 01-15
BALSTER RL 000327 01-04
BALTHAZART J 000312 01-04
BALYNINA YS 002582 03-06
BAN TA 002100 02-17, 002613 03-08, 002614 03-08, 002770 03-11, 002851 03-14, 0035B0 04-10, 003581 04-10
BANDO T 002408 03-03
BANERJEE A 000042 01-03
BANERJEE U 001440 02-04, 001557 02-04
BANGHAM AD 002963 03-17
BAR J 001015 01-17
BARANY S 001504 02-04
BARBARA L 000728 01-11
BARBEAU A 003875 04-17
BARCAI A 003610 04-11
BARCHAS JD 001500 02-04, 002278 03-03
BARDAKDJIAN J 001137 02-03
BARITUSSIO A 002117 02-17
BARKER E 002073 02-15
BARKER JL 000043 01-03, 001338 02-03, 003210 04-03
BARKER LM 001597 02-04
BARKER WM 003662 04-13
BARKLEY RA 002852 03-14
BARLOW RB 000001 01-01
BARNARD EA 002207 03-03
BARNES CD 003225 04-03
BARNES RJ 003582 04-10
BARNETT A 000371 01-04
BARNETT JM 000110 01-03
BARNHART CC 002101 02-17
BARON CUERVO LF 002831 03-13
BARON DP 000582 01-09
BARON M 003847 04-17
BARR GA 000280 01-04, 003347 04-04
BARRACLOUGH BM 002012 02-15, 002102 02-17
BARRATT ES 000270 01-04, 000281 01-04, 001433 02-04
BARRECA T 000044 01-03
BARRETT JE 001607 02-04, 002422 03-04
BARRITT DW 003742 04-14
BARRY H 000282 01-04, 001531 02-04, 002964 03-17, 003002 03-17
BARTHOLINI G 000003 01-01
BARTHWAL JP 000072 01-03
BARTMUS D 002208 03-03
BARTOLETTI M 000277 01-04, 001437 02-04, 003344 04-04
BARTOLOME M 001377 02-03, 001378 02-03, 002370 03-03
BARTON HR 001882 02-13
BARTUS RT 000283 01-04
BARUZZI A 000728 01-11
BARZAGHI F 001101 02-02
BASBAUM AI 003082 04-03
BASSANO J 001024 01-17
BASSOT J 003611 04-11
BASSUK EL 002103 02-17
BASSUS J 000004 01-01, 00384B 04-17
BASTECKY J 000674 01-10
BASTIAN PD 002070 02-15
BATES A 003278 04-03
BATHAI H 002062 02-15
BATHIEN N 000875 01-14
BATSON JD 003351 04-04
BATTACCHI MW 000770 01-11
BATTAGGIA PG 000609 01-09
BATURIN VA 000284 01-04
BAUDIS P 002657 03-08
BAUER-MOFFETT C 001613 02-05
BAUGH R 001441 02-04
BAUM T 002562 03-05
BAUMANN P 000665 01-09
BAUMANN U 001653 02-07, 002098 02-17
BAUMGARTL I 001627 02-05
BAUMGOLD J 003091 04-03
BAUMLER G 000B76 01-14
BAUSHER J 002013 02-15
BAUST W 001957 02-14
BAXTER BL 000045 01-03
BAXTER MG 0002B5 01-04
BAYERL H 001429 02-03
BAZHIN AA 001815 02-11
BEACH RC 002760 03-11, 003B70 04-17
BEAL JL 001097 02-01, 00109B 02-01
BEAN JW 003430 04-04
BEAN NJ 002316 03-03
BEATON JM 001988 02-14, 002423 03-04
BEATTIE MS 002424 03-04
BEAUBIEN AR 000455 01-05, 003092 04-03
BEAUMONT G 003657 04-13, 003764 04-15, 003765 04-15, 003B07 04-15, 003866 04-17
BECH P 001747 02-09, 001816 02-11
BECHGAARD E 000629 01-09
BECK EC 000796 01-12, 001586 02-04, 003509 04-05
BECK SL 000286 01-04
BECKA DR 000988 01-15
BECKER AL 001784 02-10
BECKER B 003469 04-04
BECKER FT 000346 01-04
BECKER KE 000122 01-03
BECKER RE 000568 01-08, 003658 04-13
BECKETT AH 001081 02-01
BECKMAN AL 001136 02-03
BECKMAN BS 000071 01-03
BECKMANN H 001016 01-17, 001442 02-04, 001728 02-09, 001729 02-09
BEDFORD JA 002556 03-04
BEDORET JM 000481 01-07
BEENEN F 000709 01-10
8EHRMANN PJ 001979 02-14
BEIN HJ 002954 03-16
BELAND C 002092 02-16
BEL8ECK LW 001968 02-14
BELENO GE 002142 02-17
BELIN M 001137 02-03
8ELKNAP JK 003348 04-04
BELL JA 003093 04-03
BELL R 002532 03-04
BELL RD 003116 04-03
BELL RW 003507 04-05
BELLAK L 000533 01-08, 002741 03-11
BELLINI M 000492 01-07
BELLODI L 002834 03-13
BELMAKER R 002800 03-13
BELMAKER RH 001687 02-08, 002014 02-15, 002209 03-03, 003668 04-13
BELOZERTSEV YA 002204 03-03
BELVEDERE G 000046 01-03, 000190 01-03
BELYAKOVA LI 001958 02-14
BEN-ARI Y 001235 02-03
BEN-BASSAT AA 000482 01-07
BEN-ISHAY D 002413 03-03
BENDER DA 000047 01-03, 001883 02-13
BENDER G 002953 03-16
BENDING MR 001138 02-03
BENDOTTI C 003455 04-04
BENEDEK-JASZMANN LJ 001817 02-11
BENEDETTI G 000790 01-12
BENEZET HJ 000048 01-03
BENGESSER G 000800 01-13
BENJAMIN FB 003766 04-15
BENKERT O 001730 02-09, 001760 02-09
BENNER SC 002449 03-04
BENNFTT DR 001841 02-11
BENNETT JP 001909 02-13
BENNETT PN 001138 02-03
BENNIE EH 000583 01-09, 001731 02-09
BENNING CD 000232 01-03
BENOIT-GUYOD J 000433 01-04
BENOWITZ NL 003767 04-15
BENSON R 001732 02-09
BENTE D 000532 01-08, 000663 01-09, 001884 02-13, 001885 02-13
BENUCK M 000049 01-03
BERENDSEN H 002188 03-02
BEREZOVSKAYA IV 002582 03-06
BERG J 003348 04-04
BERGER BD 003513 04-06
BERGER D 003094 04-03
BERGER FM 001017 01-17, 002965 03-17
BERGER G 002966 03-17
BERGER PA 000539 01-08, 002029 02-15, 003665 04-13, 003B16 04-15
BERGMAN L 000523 01-07, 000721 01-10
BERGMANN F 003349 04-04
BERGONZI P 000B01 01-13
BERKOWITZ BA 001139 02-03
BERLE BB 000575 01-08
BERMAN RF 003346 04-04, 003359 04-04
BERMINGHAM P 001767 02-09
BERMOND B 001443 02-04
BERNAREGGI V 002210 03-03
BERNASCONI S 000475 01-06, 001140 02-03, 003455 04-04
BERNSTEIN DA 003403 04-04
BERNTSON GG 002424 03-04, 003319 04-03
BERRY CA 001266 02-03
BERRY JL 001207 02-03
BERRY PA 000287 01-04
BERT J 003350 04-04
BERTI F 002210 03-03
BERTILSSON L 002666 03-09
BERTOLETTI P 002756 03-11
BERTOLINI R 0028B5 03-15
BERTOLINO A 001221 02-03
BERTOLLINI A 000002 01-01, 000207 01-03, 001135 02-03, 003247 04-03
BERTORELLO MC 00272B 03-10
BERTUZZI GL 002615 03-08
BESSER GM 002943 03-15
BEST MR 003351 04-04
BEST PJ 003506 04-05
BEUBLER E 003205 04-03
BEVAN P 001141 02-03, 001142 02-03, 003095 04-03, 003295 04-03

BEYER C 001444 02-04
BEYER JR 001100 02-02
BHARGAVA AK 002207 03-03
BHARGAVA HN 001445 02-04, 003352 04-04, 003353 04-04
BHARGAVA KP 002417 03-04
BHATACHARYA SK 000050 01-03
BHATTACHARJEE G 001177 02-03
BHATTACHARYA 8K 000306 01-04, 003119 04-03
BHATTACHARYA SK 001143 02-03, 001446 02-04
BIALER I 003652 04-11
BIANCHI A 000675 01-10
BIANCHI GN 001886 02-13
BIANCHI M 001101 02-02
BIANCHI S 000149 01-03, 001170 02-03, 001269 02-03
BIANCHINE JR 002967 03-17
BICHONSKI R 002616 03-08, 002617 03-08
BICKEL MH 0025B3 03-06
BICKEL P 001867 02-12, 002797 03-12
BICKFORD RG 001390 02-03
BIDZINSKA E 00261B 03-08
BIDZINSKI A 000362 01-04, 002618 03-08
BIECK PR 001921 02-13, 003683 04-13
BIEDERMAN J 001687 02-08, 002800 03-13
BIELICKI L 001144 02-03, 002402 03-03
BIELSKI RJ 002667 03-09
BIEN RD 002015 02-15
BIENIOWA A 000751 01-11, 000802 01-13
BIGELOW GE 001046 01-17
BIGELOW LB 000525 01-08, 000526 01-08, 000527 01-08, 000528 01-08, 000534 01-08, 000535 01-08
BIGG DCH 000019 01-02
BIGGER JT 003659 04-13
BIGGIO G 000051 01-03, 001145 02-03, 002211 03-03, 002212 03-03, 002256 03-03, 003096 04-03, 003097 04-03, 003354 04-04
BIGGS JT 001002 01-16, 002708 03-09, 003723 04-13, 003768 04-15
BIGLER ED 001146 02-03, 002425 03-04, 002426 03-04
BIGNAMI G 000288 01-04, 002448 03-04
BIKADOROW V 000532 01-08
BILIBIN DP 001168 02-03
BILIKIEWICZ A 001679 02-08, 002619 03-08
BILINSKA-NIGOT B 000159 01-03
BINDER H 001654 02-07
BINDER S 002968 03-17
BINNIE CD 001920 02-13
BIONDI PA 002834 03-13
BIRCH H 001954 02-14
BIRD RM 000525 01-08, 000535 01-08
BIRD SJ 00309B 04-03
BIRDSALL NJM 001147 02-03
BIRENBAUM C 002741 03-11
BIRKET-SMITH E 000969 01-15
BIRKMAYER W 002588 03-07
BIRNBAUM IM 002069 02-15
BIRNBOM F 002598 03-07
BISHOP GA 003615 04-11
BISHOP MP 003527 04-08
BISHOP SB 000307 01-04
BISIO B 002969 03-17
BISOGNI A 000726 01-11
BIXLER EO 000748 01-11, 000877 01-14, 001972 02-14, 003737 04-14
BJERKENSTEDT L 002835 03-13, 002836 03-13, 003704 04-13
BJORKQVIST S 001818 02-11
BJORUM N 000614 01-09
BLACHLY PH 002742 03-11
BLACK IB 001149 02-03
BLACK KE 001333 02-03
BLACK KL 003317 04-03
BLACKBURN JL 002970 03-17
BLACKMAN DE 000413 01-04, 001572 02-04, 001573 02-04, 002529 03-04
BLACKWELL B 002177 02-17
BLAINE JD 001919 02-13
BLAKLEY A 003402 04-04
BLANC G 000240 01-03, 001397 02-03
BLANK CL 0003B8 01-04
BLANK DL 000052 01-03
BLANTON CD 002196 03-02
BLASIG J 001148 02-03, 001447 02-04, 002491 03-04, 003272 04-03
BLASS JP 003627 04-11
BLAU B 001959 02-14
BLAU SP 001959 02-14
BLAYAC J 000977 01-15
BLAZER DG 001733 02-09
BLEIWEISS H 000B03 01-13
BLISS EL 000525 01-08, 000526 01-08, 00052B 01-0B
BLITT CD 002743 03-11
BLOOM AS 000289 01-04, 003099 04-03
BLOOM EM 001149 02-03
BLOOM F 003397 04-04
BLOOM FE 002369 03-03
BLOOR BC 002250 03-03
BLOUIN P 000980 01-15, 002926 03-15
BLUDAU J 001569 02-04
BLUM K 002971 03-17, 003100 04-03, 003355 04-04, 003491 04-05
BLUMBERG JB 000053 01-03
BLUMENSTEIN J 003656 04-13
BLUMENTHAL I 003769 04-15
BLUNDELL C 000290 01-04
BLUNDELL JE 000291 01-04
BO P 000633 01-09
BOBON J 001655 02-07
BOCCI U 000757 01-11
BOCHNIK HJ 001906 02-13
BOCK E 001205 02-03
BOCK PR 000473 01-06, 001645 02-06
BOCKAERT J 000120 01-03, 001150 02-03, 001151 02-03, 002342 03-03
BOCKENHEIMER S 002801 03-13
BODDY K 000456 01-05
BODIN N 000054 01-03, 000457 01-05
BODNER L 003670 04-13
BODZENTA A 003101 04-03
BOECK V 003070 04-02
BOECKLER WH 001119 02-03
BOETHIUS G 003849 04-17
BOGDANOWICZ E 000483 01-07
BOGGAN WO 001156 02-03, 003102 04-03
BOHME K 001018 01-17
BOHUS B 000112 01-03, 003356 04-04
BOILEAU RA 001814 02-11, 003633 04-11
BOISSE NR 002516 03-04
BOISSIER JJR 001589 02-04
BOISSIER JR 001448 02-04, 002427 03-04, 002544 03-04
BOJDECKI K 0004B3 01-07, 000931 01-15, 002618 03-08, 002972 03-17
BOLDREY EB 002792 03-11
BOLDYREV AI 002B86 03-15
BOLLER F 002744 03-11
BOLLIG I 001479 02-04
BOLM W 002016 02-15
BOLTON R 002B02 03-13
BOMBARDT PA 003144 04-03
BOND MR 002087 02-16
BOND N 003375 04-04
BONESE K 000353 01-04
BONIERBALE M 002589 03-07
BONKOWSKY HL 002017 02-15
BONOLLO L 002106 02-17
BOOSINGER JK 003770 04-15
BOOTH GH 001973 02-14
BOOTH JCD 000752 01-11
BOREN JL 001449 02-04
BORG KO 000054 01-03, 000055 01-03, 000056 01-03, 000804 01-13, 001011 01-17
BORG S 002018 02-15, 003555 04-09, 003574 04-09
BORGEN LA 000707 01-10
BORGHI G 000770 01-11
BORGMAN RJ 000229 01-03, 00027B 01-04
BORISENKO SA 002428 03-04
BORISON RL 001351 02-03, 002833 03-13
BORISOVA LN 002187 03-02
BORJESSON I 000028 01-03
BORKOWSKA G 001637 02-05
BORNSTEIN S 000484 01-07
BORODKIN S 003492 04-05
BORRACCINI A 000017 01-01
BORRI P 003103 04-03
BORRI-VOLTATTORNI C 003103 04-03
BORRONI E 003455 04-04
BORSY J 000239 01-03, 002485 03-04
BORTNIK TL 001836 02-11
BORTOLOTTI M 000728 01-11, 000805 01-13
BORYS HK 003306 04-03
BOS ERH 001781 02-09
BOSHES LD 001819 02-11
BOSSANGE KA 002005 02-14
BOSSE A 000057 01-03, 003104 04-03
BOSTOGANASHVILI VS 000005 01-01
BOTH R 002826 03-13
BOUCHARD M 002092 02-16
BOUCHARLAT J 002652 03-08
BOUCHE R 0010B9 02-01
BOUCHER R 003B55 04-17
BOUCHERLE A 000433 01-04
BOUCLY JY 002626 03-08
BOUCSEIN W 000292 01-04, 001960 02-14
BOUDIER HAJS 000077 01-03
BOUDRY C 00094B 01-15
BOUEY P 002887 03-15
BOULANGER M 003130 04-03
BOULENGER J 000806 01-13, 002973 03-17
BOULET J 000977 01-15
BOULLIN DJ 002429 03-04, 002461 03-04
BOULTON AA 000087 01-03, 000088 01-03
BOUREL J 000650 01-09
BOURGEOIS M 002019 02-15, 002887 03-15, 002888 03-15
BOURGOIN S 000120 01-03
BOURNE R 0026B8 03-09
BOURNE RC 003234 04-03
BOUSQUET B 000815 01-13
BOUSSAT M 000613 01-09
BOVET D 002974 03-17
BOWEN FP 002430 03-04
BOWERS MB 001152 02-03, 001910 02-13
BOWERY NG 00005B 01-03, 001102 02-02, 001153 02-03
BOXENBAUM HG 000079 01-03
BOXER CM 001961 02-14
BOYAR RM 001887 02-13, 003660 04-13
BOYD EL 000878 01-14
BOYKO SS 002576 03-05
BOZZETTI LP 001919 02-13
BRADBURY AF 001147 02-03, 002453 03-04
BRADLEY PB 000059 01-03
BRADLOW HL 001BB7 02-13, 003660 04-13
BRADSHAW CM 001141 02-03, 001142 02-03, 003095 04-03, 003295 04-03
BRADY JV 001124 02-03, 001503 02-04, 001646 02-06
BRAESTRUP C 001154 02-03, 0032B7 04-03, 003357 04-04
BRAGA PC 000323 01-04, 000324 01-04
BRAGONIER JR 002020 02-15
BRAIDWOOD AE 003696 04-13
BRAILOWSKY S 002431 03-04
BRAMBILLA F 000536 01-08, 001680 02-08, 001681 02-08
BRAMWELL GJ 000060 01-03
BRANCHEY MH 0009B5 01-15, 002021 02-15
BRAND E 003692 04-13
BRAND HL 003584 04-10
BRAND M 000676 01-10
BRAND SJ 002228 03-03
BRANDRUP E 003583 04-10
BRANDT R 000932 01-15
BRANDT S 000969 01-15
BRANNON WL 002072 02-15
BRANSON R 003850 04-17
BRASE DA 000933 01-15, 001600 02-04, 00229B 03-03
BRAU H 001878 02-13
BRAUDE M 001167 02-03
BRAUDE MC 001644 02-05, 003445 04-04
BRAUN JJ 001536 02-04
BRAY GA 003622 04-11
BRAZIER MAB 001BB8 02-13
BREAKEFIELD XO 002213 03-03
BREATHNACH CS 002104 02-17
BRECKENRIDGE A 000987 01-15
BREESE GR 000061 01-03, 000145 01-03, 000300 01-04, 000343 01-04, 001530 02-04
BRENER J 000381 01-04
BRESEE RR 000191 01-03
BRETSCHNEIDER A 001851 02-11
BREUKER E 001450 02-04
BREUKER ELM 000140 01-03
BREWER C 001019 01-17, 001734 02-09
BREWERTON CN 001282 02-03
BREWSTER JM 000424 01-04, 001451 02-04, 002540 03-04
BREYER U 001711 02-0B, 001B89 02-13, 002214 03-03
BREZENOFF HE 000062 01-03

BREZINOVA V 002848 03-14
BRIANT RH 003851 04-17
BRICK J 000063 01-03
BRIDENBAUGH RH 001020 01-17
BRIDGER WH 000280 01-04, 001276 02-03, 003347 04-04, 003394 04-04
BRIDGES CI 001842 02-11, 001996 02-14
BRIDGES-WEBB C 002975 03-17
BRIEN JF 000401 01-04, 003439 04-04
BRIGATI DJ 001327 02-03
BRIGGS AH 003491 04-05
BRIGGS W 000860 01-13
BRIGHTWELL D 002867 03-14
BRIGHTWELL DR 003743 04-14
BRIMBLECOME RW 001021 01-17
BRION S 000806 01-13, 002668 03-09, 002973 03-17
BRISBANE J 002017 02-15
BRODERSEN PE 002976 03-17
BRODIE NH 001735 02-09, 003612 04-11
BRODY TM 000153 01-03
BROEKKAMP CLE 000293 01-04, 003367 04-04
BROISSIN MC 002730 03-10
BROLL M 000275 01-04, 000276 01-04, 000433 01-04
BROMBERG S 002899 03-15
BRONAUGH RL 000007 01-01, 000064 01-03
BROOKMAN S 003105 04-03
BROOKS DC 000108 01-03, 003106 04-03
BROOKS DS 001282 02-03
BROOKS MA 002805 03-13
BROSIUS KK 000289 01-04, 003099 04-03
BROSTEANU E 002754 03-11
BROSZKIEWICZ E 002710 03-10
BROUGHTON R 002590 03-07
BROUSSOLLE P 000758 01-11
BROUWERS EYM 001967 02-14
BROVERMAN DM 003801 04-15
BROWER KJ 003358 04-04
BROWN A 002022 02-15
BROWN B 000873 01-14
BROWN CC 003678 04-13
BROWN D 000824 01-13
BROWN DJ 001480 02-04
BROWN OR 000074 01-03, 002221 03-03
BROWN HC 002591 03-07
BROWN JR 002949 03-15
BROWN K 000410 01-04, 002002 02-14, 002348 03-03
BROWN MM 003770 04-15
BROWN RA 000B93 01-14
BROWN RF 001452 02-04
BROWN RL 001920 02-13
BROWN TCK 002889 03-15
BROWN TS 001588 02-04
BROWN ZW 000271 01-04, 003081 04-03
BROWNE TR 001022 01-17
BROWNSTEIN MJ 003207 04-03
BRUCE OL 000874 01-14
BRUCK C 000879 01-14
BRUCKNER JV 003115 04-03
BRUGEL H 003683 04-13
BRUGGENCATE GT 001306 02-03
BRUHN JG 001082 02-01
BRUINVELS J 000172 01-03, 003123 04-03
BRUNELLE R 002092 02-16
BRUNELLI M 001155 02-03
BRUNET C 001103 02-02
BRUNK SF 001B72 02-12
BRUNSWICK D 003568 04-09
BRUNSWICK OJ 003107 04-03
BRUS R 002463 03-04
BRUUN RD 000807 01-13
BRUZZESE D 003591 04-10
BRYS J 002621 03-08, 002659 03-08, 002669 03-09, 002745 03-11
BUCHANAN FH 000537 01-08
BUCHSBAUM MS 003550 04-09, 003708 04-13
BUCKHOLTZ NS 001156 02-03
BUCKINGHAM RL 000065 01-03
BUCKLEY JP 003067 04-02, 0031B2 04-03, 003183 04-03, 003208 04-03
BUCZKO W 001614 02-05
BUDHIMAN M 000743 01-11
BUECKERT A 000B56 01-13
BUELKE J 002556 03-04
BUENO J 003606 04-10
BUENO JR 001B10 02-10
BUENO MA 002711 03-10
BUERKI HR 001540 02-04
BUKOWCZYK A 000485 01-07, 002620 03-08, 002621 03-0B, 002669 03-09, 002745 03-11
BUKSOWICZ C 000734 01-11
BULAT M 003065 04-02
BULPITT CJ 002854 03-14
BUNAG RD 001157 02-03
BUNNEY BS 003078 04-03
BUNNEY WE 000584 01-09, 001696 02-08, 001962 02-14, 002673 03-09, 003041 03-17, 003727 04-14
BURCKHARDT D 002890 03-15
BURCKHARDT PG 003473 04-04
BURG C 002872 03-14
BURGEN ASV 001147 02-03
BURGUS R 003397 04-04
BURKARD WP 001158 02-03, 002215 03-03
BURKHART A 001878 02-13
BURKI HR 001159 02-03, 001359 02-03, 001576 02-04
BURMAN KO 001890 02-13
BURMEISTER P 000833 01-13
BURNER M 001023 01-17
BURNETT GB 001701 02-0B
BURNS B 001740 02-09
BURNS BH 003569 04-09
BURNS D 003107 04-03, 003551 04-09
BURNSTEIN MH 002649 03-08
BUROV YV 002432 03-04
BURROW DO 002070 02-15
BURROWS G 000593 01-09, 002623 03-08
BURROWS GD 000655 01-09, 000677 01-10, 000880 01-14, 001193 02-03, 002023 02-15, 002024 02-15, 003552 04-09
BURT DR 001909 02-13, 003235 04-03, 003493 04-05
BURT R 000066 01-03
BURZA ZB 002368 03-03
BUSCH H 000651 01-09, 001772 02-09, 002692 03-09
BUSCH N 002183 03-01
BUSH MF 002500 03-04
BUSSEL B 002B49 03-14
BUSTAMANTE LA 003209 04-03
BUTCHER SH 002216 03-03
BUTLER JL 001963 02-14
BUTLER RN 001820 02-11
BUTTERWORTH RF 003875 04-17
BUTTI A 001101 02-02
BUTZ F 002562 03-05
BUTZER T 003458 04-04
BUYNISKI JP 003471 04-04
BYCK R 001891 02-13
BYE C 000910 01-14
BYKOVA AA 002412 03-03
BYLUND DB 000071 01-03
BYMASTER FP 000263 01-03, 001423 02-03
BYRD GJ 002025 02-15
BYRD LD 001453 02-04
BYRNE DG 002712 03-10

C

CADE CM 000791 01-12
CAFFEY EM 000772 01-11, 003896 04-17
CAGNASSO M 002834 03-13
CAHILL AL 001160 02-03
CAILLE E 001024 01-17
CAINE EO 003661 04-13
CALANDRA JC 001644 02-05
CALDWELL J 001892 02-13
CALIARI B 002028 02-15
CALLAGHAN OH 003308 04-03
CALLAWAY E 002863 03-14
CALLEJA JM 001108 02-02
CALLERY PS 003047 04-01
CALNE DB 000500 01-07, 000501 01-07, 002592 03-07, 002600 03-07
CALTAGIRONE C 003634 04-11
CALVERT EJ 000972 01-15
CALVERT RT 001441 02-04
CAMARDESE M 000763 01-11
CAMERON IL 003339 04-03
CAMP VM 00313B 04-03
CAMPBELL IC 002217 03-03
CAMPBELL M 000729 01-11, 000730 01-11
CANBERK A 00319B 04-03
CANCIAN O 000429 01-04, 000430 01-04
CANCRO R 000525 01-08, 000526 01-08, 000528 01-08, 000535 01-08
CANDELISE L 001893 02-13
CANERO E 002656 03-08
CANFIELD OR 000274 01-04
CANGER R 001994 02-14
CANKAT TULUNAY F 001161 02-03
CANNON DS 000742 01-11, 003346 04-04, 003359 04-04
CANNON JG 000067 01-03, 000068 01-03, 001104 02-02, 002498 03-04
CANNON WO 000194 01-03
CANTER A 001872 02-12
CANTONI L 000190 01-03
CAPDEVILA J 001121 02-03
CAPPELL H 000116 01-03, 003360 04-04
CAPSTICK N 001821 02-11
CARATSCH CG 000069 01-03
CARDELLINI M 003048 04-01
CARDENAS HL 000070 01-03
CARDENAS TRIGOS M 002713 03-10
CARDER B 000310 01-04
CARDO B 000234 01-03
CAREY JC 000307 01-04
CAREY MS 002105 02-17
CAREY RJ 000335 01-04, 001162 02-03, 001623 02-05
CARINI A 002746 03-11
CARLINI EA 000419 01-04, 001300 02-03
CARLISLE HJ 000026 01-02
CARLSON K 0019B4 02-14
CARLSON KR 001195 02-03, 001619 02-05
CARLSON RH 000416 01-04, 0034B7 04-04
CARLSSON A 001174 02-03, 002844 03-13, 002977 03-17, 003466 04-04, 003647 04-11
CARLSSON C 002622 03-08, 002855 03-14, 00297B 03-17
CARLSSON E 00002B 01-03, 000055 01-03, 000804 01-13, 001011 01-17
CARMAN JS 001500 02-04
CARMICHAEL N 003500 04-05
CARNATHAN G 000372 01-04, 000379 01-04
CARNE HJ 003604 04-10
CARNEY JM 001454 02-04, 003361 04-04, 003426 04-04
CAROLEI A 000467 01-06
CARPENTER DC 000455 01-05
CARPENTER JR 001163 02-03
CARPENTER WT 003B52 04-17
CARR A 003651 04-11
CARR F 000338 01-04
CARR JD 003445 04-04
CARR RH 00310B 04-03
CARRANZA J 000486 01-07
CARRARA MC 00221B 03-03
CARRER H 000294 01-04
CARRERE J 002593 03-07
CARRIGAN PJ 003662 04-13
CARROLL BJ 000973 01-15, 001736 02-09, 003411 04-04
CARRUBA MO 003109 04-03, 003241 04-03
CARRUTHERS SG 002591 03-07
CARSKADON M 000741 01-11
CARSON S 003110 04-03
CARTER AC 003661 04-13
CARTER OA 000200 01-03
CARTER G 003697 04-13
CARTER R 000824 01-13
CARTER RB 000295 01-04
CARTER RG 003528 04-08
CARTY RW 000325 01-04
CARUSO FS 001662 02-07
CARUTHERS SG 00080B 01-13
CARVALHO FV 001556 02-04
CASACCHIA M 001953 02-14
CASADO O 002856 03-14
CASE WG 001805 02-10, 003597 04-10
CASEY DE 001B94 02-13
CASPER R 001689 02-0B, 003590 04-10
CASPER RC 000415 01-04, 001895 02-13
CASSANO GB 001331 02-03, 002106 02-17
CASSAR J 000987 01-15
CASSIDY CE 002307 03-03
CASTAGNOLI N 003340 04-03
CASTAIGNE P 001025 01-17, 002849 03-14
CASTAIGNS G 0004B7 01-07
CASTELDEN CM 003724 04-14
CASTELLANI A 000BB1 01-14, 001670 02-07

CASTELLANO C 000296 01-04, 000297 01-04, 003362 04-04
CASTELLUCCI V 001155 02-03
CASTELNAU D 000977 01-15
CASTROGIOVANNI P 002106 02-17
CATANZANO DM 001726 02-09
CATAPANE E 001389 02-03
CATHALA HP 002849 03-14
CATRAVAS GN 002481 03-04, 003111 04-03, 003177 04-03, 003191 04-03
CAVADINI RM 000547 01-08
CAVALHEIRO EA 002478 03-04
CAVANAGH JB 003500 04-05
CAVAZZUTI F 000770 01-11
CAVENAR JO 001822 02-11
CAVNESS C 000792 01-12
CAZALA P 001455 02-04
CAZIN J 001103 02-02
CAZIN M 001103 02-02
CEDARBAUM JM 001164 02-03, 003371 04-04
CEPEDA C 003313 04-03
CERBO R 001953 02-14
CERLETTI C 000161 01-03
CERNY VA 001456 02-04
CERRETA KV 003141 04-03
CERVANTES LEON G 002979 03-17
CERVANTES P 003529 04-08
CERVENKI J 000674 01-10
CHABERT J 001116 02-02
CHABI E 003297 04-03
CHADWICK D 002891 03-15
CHADWICK GL 001026 01-17
CHAIMOVITZ M 003349 04-04
CHAKRABARTY M 001083 02-01
CHALFIE M 001165 02-03
CHAMBERLAIN JH 003470 04-04, 003471 04-04
CHAMBERLAINE C 000667 01-09
CHAN AWK 001166 02-03, 001373 02-03
CHAN CH 003772 04-15
CHAN PKH 001968 02-14
CHANCE WT 002526 03-04
CHANG J 002193 03-02
CHANG S 001665 02-07, 002939 03-15
CHANG SS 001002 01-16
CHANNABASAVANNA SM 003585 04-10
CHAO F 001167 02-03
CHAO GC 003662 04-13
CHAPLAIN RA 001442 02-04
CHAPMAN LF 001574 02-04
CHAPMAN SF 002980 03-17
CHAPPA H 001785 02-10
CHAPPUIS-ARNDT E 001952 02-13
CHARALAMPOUS KD 003519 04-07
CHAREIRE M 000004 01-01
CHARLES J 002021 02-15
CHARLTON MH 003640 04-11
CHARNESS ME 000071 01-03
CHARTRES JP 000487 01-07
CHARUVASTRA VC 000951 01-15
CHASE TN 000192 01-03, 000853 01-13, 001860 02-11, 002803 03-13
CHASSAING C 001615 02-05
CHASSAN J 003843 04-16
CHATTERJEE A 001083 02-01
CHATWIN JC 001964 02-14
CHAU-WONG M 000474 01-06
CHAUDHARY M 000072 01-03, 003236 04-03
CHAUDHARY SK 000072 01-03, 003236 04-03
CHAUDHURI NK 003049 04-01
CHAULK R 003794 04-15
CHEFURKA CM 001868 02-12
CHEN A 000744 01-11
CHEN CS 001457 02-04
CHEN PC 002365 03-03
CHENEY DL 001430 02-03, 001431 02-03, 001432 02-03, 002226 03-03, 002571 03-05, 002584 03-06
CHENG HC 001104 02-02
CHERAMY A 001397 02-03
CHERKIN A 003112 04-03
CHERNICK V 003761 04-15
CHESHER GB 000129 01-03, 000346 01-04, 002857 03-14
CHESSA P 000099 01-03
CHEUNG AL 003050 04-01
CHEVALIER JF 002668 03-09
CHIAPPINELLI V 003137 04-03
CHIAROTTI M 003498 04-05
CHIEL HJ 002219 03-03
CHIEN C 001682 02-08
CHILAND C 003613 04-11
CHIMINI R 000941 01-15
CHINN NG 003207 04-03
CHIODINI PG 002943 03-15
CHISTYAKOV VV 002295 03-03
CHIU E 002623 03-08
CHIU P 003306 04-03
CHIUEH CC 002254 03-03
CHIURULLA C 000801 01-13
CHLOPOCKA-WOZNIAK M 002696 03-09
CHO A 003670 04-13
CHO AK 001217 02-03, 002216 03-03, 002238 03-03, 003329 04-03
CHOI SJ 001737 02-09
CHOU DT 003113 04-03
CHOU F 001656 02-07
CHOUINARD G 001683 02-08, 003553 04-09
CHRETIEN M 003875 04-17
CHRIST W 001896 02-13
CHRISTENSEN AV 000073 01-03, 001547 02-04
CHRISTENSEN CW 000203 01-03
CHRISTENSEN H 000934 01-15
CHRISTENSEN S 003114 04-03
CHRISTIAN EL 000175 01-03
CHRISTIAN ST 001320 02-03
CHRISTIANSEN C 000585 01-09, 002026 02-15
CHRISTIANSEN J 002813 03-13
CHRUSCIEL TL 001048 01-17
CHU CK 003115 04-03
CHUDIN AS 002034 02-15
CHUGUNOV VV 002220 03-03, 002295 03-03
CHUN AHC 003662 04-13, 003713 04-13
CHUNG H 000074 01-03, 002221 03-03
CHUNG HR 001805 02-10
CHURYUKANOV VV 001168 02-03
CIANCHETTI C 000488 01-07
CIARIMBOLI M 001837 02-11
CICCONE M 001738 02-09
CICERO TJ 001315 02-03, 003116 04-03
CIESIELSKA J 002303 03-03
CIESIELSKI L 002501 03-04
CIMA L 000017 01-01, 000018 01-01, 000247 01-03
CIUREZU T 000538 01-08
CLAEYS AE 000814 01-13
CLAMAGE DM 002222 03-03
CLARK ML 003530 04-08
CLARK RW 003748 04-14
CLARK WG 002498 03-04
CLARKE CH 001657 02-07
CLARKE SW 002907 03-15
CLAUDI F 003048 04-01
CLAVIER RM 001458 02-04
CLAY GA 000157 01-03
CLAYTON AB 000882 01-14
CLAYTON PJ 002708 03-09
CLEMENS JA 002243 03-03
CLEMENS LG 001616 02-05
CLIFFORD JM 001294 02-03
CLIFT AD 001027 01-17
CLINESCHMIDT BV 001459 02-04
CLOSSE A 001169 02-03
CLOUET DH 000809 01-13
CLUM JM 000572 01-08
CO BT 002708 03-09, 003723 04-13
COCCHI R 001786 02-10
COCHIN J 000372 01-04, 000379 01-04, 001336 02-03
COCHRAN E 000883 01-14
COCITO L 002694 03-09
CODY J 003531 04-08
COELLE EF 002223 03-03
COGHLAN JP 000655 01-09
COHEN D 001415 02-03, 002224 03-03
COHEN G 000528 01-08, 000535 01-08
COHEN HB 001954 02-14
COHEN I 003478 04-04
COHEN J 001787 02-10
COHEN LB 003892 04-17
COHEN MJ 001982 02-14
COHEN MN 003633 04-11
COHEN S 000097 01-03
COHEN Y 001401 02-03
COLAS N 000497 01-07
COLASANTI BK 003363 04-04
COLBURN R 002217 03-03
COLE EN 000586 01-09, 001745 02-09
COLE JO 000678 01-10, 001028 01-17, 001682 02-08, 002594 03-07, 003536 04-08, 003751 04-14
COLE SO 000331 01-04
COLEMAN JH 002949 03-15
COLEMAN L 001823 02-11
COLEMAN M 003771 04-15
COLEMAN N 000884 01-14
COLLARD KJ 000075 01-03
COLLIER HOJ 000298 01-04, 002225 03-03
COLLINS AC 000114 01-03
COLLINS JF 000058 01-03, 003134 04-03
COLLINS RL 003482 04-04, 003494 04-05
COLLOMB H 000613 01-09
COLONNA L 002892 03-15
COLPAERT FC 000299 01-04, 001460 02-04, 001461 02-04, 001462 02-04, 002433 03-04, 003010 03-17, 003364 04-04, 003853 04-17
COLSON JD 001897 02-13
COMAISH JS 003803 04-15
COMBS AM 003864 04-17
COMER WH 003675 04-13
COMFORT A 003554 04-09
COMOY E 003631 04-11
CONDINI A 002670 03-09
CONELY L 002532 03-04
CONIGLIO LP 001616 02-05
CONNELLY JF 003365 04-04
CONNELLY JM 003365 04-04
CONNER R 002462 03-04
CONNEY AH 000819 01-13
CONSBRUCH U 000937 01-15
CONSOLO S 000149 01-03, 001170 02-03, 001269 02-03
CONSOLONI E 000757 01-11
CONSROE P 001649 02-06, 002434 03-04, 003366 04-04
CONSROE PF 001521 02-04
CONSTANTINESCU E 000076 01-03
CONTI L 002106 02-17
CONTRERA JF 000303 01-04
CONWAY A 001788 02-10
COOK DA 001282 02-03
COOK L 002435 03-04
COOLS AR 000077 01-03, 001562 02-04, 003268 04-03, 003367 04-04
COOPER BR 000061 01-03, 000300 01-04, 000343 01-04
COOPER SD 000778 01-11
COOPER SJ 002348 03-03
COOPER TB 001898 02-13, 001899 02-13
COPELAND AP 002872 03-14
COPELAND GP 002907 03-15
COPER H 000587 01-09, 001824 02-11, 001896 02-13, 002747 03-11, 003140 04-03, 003211 04-03
COPPEN A 000588 01-09, 000589 01-09, 000590 01-09, 001740 02-09, 002027 02-15, 002674 03-09, 002981 03-17, 003521 04-07, 003663 04-13
COPPEN AJ 001739 02-09
CORAZZI L 001127 02-03
CORBIN DR 003293 04-03
CORCORAN ME 001171 02-03, 003428 04-04, 003726 04-14
CORMACK M 002875 03-14
CORNETT T 002867 03-14
CORNETT TL 003743 04-14
CORONA GL 000591 01-09
CORREA FMA 001172 02-03
CORSINI GU 000488 01-07
CORYELL MR 001421 02-03
COSTA E 000051 01-03, 000078 01-03, 001173 02-03, 001303 02-03, 001430 02-03, 001431 02-03, 001432 02-03, 002211 03-03, 002212 03-03, 002226 03-03, 002227 03-03, 002256 03-03, 002301 03-03, 002571 03-05, 002584 03-06, 003096 04-03
COSTA JL 002804 03-13
COSTALL B 000068 01-03, 000301 01-04, 001105 02-02, 002189 03-02, 002436 03-04, 003368 04-04
COSTENTIN J 002521 03-04
COSTILOE JP 003530 04-08
COTLER S 000079 01-03
COTMAN CW 003170 04-03
COTT J 001174 02-03, 003117 04-03
COTZIAS GC 000023 01-02, 003118 04-03, 003473 04-04

COUCH JR 000080 01-03
COUDERT J 000771 01-11
COUPER GS 001611 02-04
COUPET J 001106 02-02
COURIOL A 002597 03-07
COUSSE H 000151 01-03
COVI L 001755 02-09, 002982 03-17
COWDRY RW 003863 04-17
COWEN MA 001684 02-08
COX B 001577 02-04, 003086 04-03
COX BM 003155 04-03
COX JR 003584 04-10
COX RD 003390 04-04
COX T 000302 01-04
COX VC 002552 03-04
COXON A 002815 03-13
COXON RV 001329 02-03
COY DH 000203 01-03, 002480 03-04, 003319 04-03
CRAFTS D 002792 03-11
CRAIGMILL A 001385 02-03
CRAIGMILL AL 001386 02-03
CRAMER H 001175 02-03
CRAMMER J 003693 04-13
CRANDALL PH 001888 02-13
CRANE AM 001227 02-03
CRANSTON JW 000924 01-14
CRAVENS J 000896 01-14
CRAWFORD IL 001115 02-02
CRAWFORD WA 002858 03-14
CRAWLEY JN 000303 01-04
CREECH DM 003293 04-03
CREEL D 002563 03-05
CREESE I 001909 02-13, 003235 04-03, 003493 04-05
CREPALDI G 002117 02-17
CRESPIN J 000656 01-09
CRISTAU B 003059 04-01
CRNIC LS 000304 01-04
CROME P 003831 04-15
CROMIE BW 002088 02-16
CRONHOLM B 000885 01-14, 001845 02-11
CRONLUND A 001087 02-01
CROOK TH 001986 02-14
CROSIGNANI PG 001900 02-13
CROSNIER J 001001 01-15
CROSSMAN AR 000290 01-04
CROW TJ 000081 01-03, 001685 02-08, 002624 03-08, 002688 03-09
CROWLEY TJ 000935 01-15, 001831 02-11
CRUMPTON E 002942 03-15
CSANALOSI I 003600 04-10
CUBITT T 000936 01-15
CUCULIC Z 001778 02-09
CULEBRAS A 000810 01-13
CULETTO M 000151 01-03
CULPAN RH 002107 02-17
CUPARENCU B 000411 01-04, 003201 04-03
CURELARU S 000538 01-08
CURLEY AD 002307 03-03
CURRAN JD 003726 04-14
CURRAN SF 001856 02-11
CURRIER RD 001832 02-11
CURRY SH 000811 01-13, 001003 01-16, 001951 02-13
CURTIS DR 002228 03-03
CURTIS GC 001736 02-09
CURZON G 001176 02-03, 001292 02-03, 001463 02-04
CUSANO PP 003854 04-17
CUSHMAN P 001901 02-13
CUTLER MG 000305 01-04
CUTLER NR 003532 04-08
CUZZOLARO M 002028 02-15
CWYNAR S 002748 03-11
CZARNY G 001744 02-09
CZERNIAK P 002983 03-17
CZERNIEJEWSKA M 002108 02-17
CZERNIEJEWSKI K 002108 02-17
CZLONKOWSKI A 002486 03-04

D

DOELIA G 003533 04-08
DA PRADA M 000083 01-03, 000156 01-03, 000468 01-06
DA RE P 000017 01-01, 000018 01-01, 000247 01-03
DA SILVA JAR 001810 02-10
DACH L 002167 02-17
DACHARY J 000961 01-15
DACKIS C 003712 04-13
DADKAR NK 000306 01-04, 003119 04-03
DAFALIAS C 002945 03-15
DAHL KE 003473 04-04
DAHL SG 000084 01-03, 003664 04-13
DAHLMAN HC 000580 01-09
DAHMS WT 003622 04-11
DAIGLE L 002904 03-15, 003544 04-08
DAIGUJI S 000654 01-09
DAJANI EZ 000157 01-03
DALBECK R 003374 04-04
DALBERTSON A 001900 02-13
DALBY MA 002749 03-11
DALE EP 003651 04-11
DALESSIO DJ 001034 01-17
DALHOUSE AD 001464 02-04
DALSKE HF 000731 01-11
DALTON J 001974 02-14
DALTON TK 000008 01-01, 003177 04-03
DALTON WS 001902 02-13
DALY J. W. SP 001239 02-03
DALY JW 000085 01-03, 001375 02-03, 001376 02-03, 001591 02-04, 002358 03-03
DALZELL HC 001339 02-03, 003061 04-01
DAM H 001929 02-13
DAMICO DJ 000082 01-03
DAMICO N 000679 01-10
DANA JB 000998 01-15
DANG JC 003884 04-17
DANGUIR J 001465 02-04
DANIEL PM 003120 04-03
DANIELSEN A 000812 01-13
DANIELSON TJ 000086 01-03, 000087 01-03, 000088 01-03
DANKOVA J 003855 04-17
DANNESKIOLD-SAMSOE P 001466 02-04, 003070 04-02
DANTZER R 001467 02-04, 003369 04-04, 003370 04-04
DAQUILA R 000020 01-02
DARCOURT G 001658 02-07, 002637 03-08
DARGENT J 000789 01-11
DARWISH SAE 003121 04-03
DAS BN 002078 02-15
DAS M 003495 04-05
DAS P 001440 02-04
DAS PK 000228 01-03, 001143 02-03
DASGUPTA B 001446 02-04
DATTA RK 001177 02-03
DAUBECH M 002888 03-15
DAUDEL R 002183 03-01
DAULOUEDE J 002888 03-15
DAVENPORT JW 000307 01-04
DAVID J 001178 02-03, 003122 04-03
DAVIDSON AB 000469 01-06
DAVIDSON D 003136 04-03
DAVIDSON JRT 000592 01-09
DAVIDSON S 003651 04-11, 003775 04-15
DAVIDSON WJ 002003 02-14
DAVIES B 000593 01-09, 000655 01-09, 000677 01-10, 000880 01-14, 001193 02-03, 002023 02-15, 003552 04-09
DAVIES J 001179 02-03, 002229 03-03
DAVIES JK 000308 01-04
DAVIS DC 003651 04-11
DAVIS GA 001400 02-03
DAVIS HG 003538 04-08
DAVIS HK 002109 02-17
DAVIS HN 001499 02-04
DAVIS J 003590 04-10
DAVIS JM 000415 01-04, 000543 01-08, 000813 01-13, 001090 02-01, 001583 02-04, 001665 02-07, 001689 02-08, 001895 02-13, 002110 02-17, 002157 02-17, 002939 03-15
DAVIS KL 000539 01-08, 001965 02-14, 002029 02-15, 003665 04-13
DAVIS L 000063 01-03, 001990 02-14
DAVIS M 000020 01-02, 000309 01-04, 000423 01-04, 001371 02-03, 003371 04-04, 003372 04-04, 003461 04-04
DAVIS W 002072 02-15
DAVIS WL 002232 03-03
DAVIS WM 000255 01-03, 002437 03-04, 002543 03-04
DAWES GS 000456 01-05
DAWES I 000987 01-15
DAWES P 001468 02-04, 002111 02-17
DAWLEY HH 001903 02-13
DAWSON S 002879 03-14
DAY AR 001180 02-03
DAYTON PG 003138 04-03
DE ACETIS L 002448 03-04
DE ANDA AM 003313 04-03
DE ANGELIS L 002544 03-04
DE BACKER-DIERICK G 003549 04-09
DE BARBENZA CM 002984 03-17
DE BASQUIAT M 000497 01-07
DE BOER T 003123 04-03
DE CARVALHO D 001004 01-16
DE FRAITES EG 003665 04-13
DE GAETANO G 001652 02-06, 002846 03-13
DE GROOT G 002955 03-16
DE GUBAREFF T 001315 02-03
DE JONG H 000709 01-10
DE LA VEGA CE 003666 04-13
DE LEAN J 001904 02-13
DE LEENHEER AP 000814 01-13
DE MAXIMY B 002134 02-17
DE MORAES S 003261 04-03
DE OBALDIA R 003373 04-04
DE PAULO JR 003763 04-15
DE RENTERIA CD 002714 03-10
DE REPENTIGNY L 002230 03-03
DE RIDDER JJ 001740 02-09, 002271 03-03
DE RIOS MD 002985 03-17
DE SAGHER RM 000814 01-13
DE SAINT-BLANQUAT G 001181 02-03, 001270 02-03
DE SILVA FRP 001789 02-10
DE SIMONE G 000848 01-13
DE SOLA POOL N 001041 01-17
DE WIED D 000112 01-03, 001107 02-02, 002453 03-04, 003311 04-03, 003477 04-04
DEAKIN JFW 001685 02-08, 002624 03-08
DEBENEDETTI M 001768 02-09
DEBERDT R 000680 01-10, 001825 02-11
DEBNATH PK 000050 01-03
DEBUS G 001653 02-07, 001659 02-07
DECKARD B 003124 04-03
DECKARD BS 003374 04-04
DECKER BL 002648 03-08
DEETS AC 000383 01-04
DEFERDINANDO A 000639 01-09
DEFRANCISCO D 002677 03-09
DEGENHARDT M 000232 01-03
DEGKWITZ R 000937 01-15, 001029 01-17
DEGUCHI T 003215 04-03, 003427 04-04
DEHLIN O 001030 01-17, 002736 03-11
DEIKEL SM 000310 01-04
DEKIRMENJIAN H 000543 01-08, 001090 02-01, 001665 02-07, 001689 02-08
DEL CARMINE R 000002 01-01, 001135 02-03, 003247 04-03
DEL FIACCO M 001528 02-04
DEL RIO J 002231 03-03
DEL ZOMPO M 000488 01-07
DELAUNAY J 001031 01-17
DELBARRE B 001469 02-04
DELGADO JMR 000311 01-04
DELGADO-GARCIA JM 000311 01-04
DELIA G 000489 01-07, 003555 04-09, 003574 04-09
DELIA H 002502 03-04
DELINI-STULA A 000089 01-03
DELISSER-MATTHEWS LA 002184 03-01
DELIZ AJ 003856 04-17
DELL A 003604 04-10
DELL H 001182 02-03
DELLA BELLA D 003354 04-04
DELLANTONIO R 000760 01-11
DELLUNTO A 000726 01-11
DELONG AF 001905 02-13
DELUCA DC 001125 02-03
DELVAUX V 002750 03-11
DELVECCHIO FR 002596 03-07
DELWARDRE C 002715 03-10
DELWARDRE G 002715 03-10
DEMARTINI JE 002581 03-05
DEMARTY C 003383 04-04
DEMENT W 000741 01-11, 002112 02-17
DEMENT WC 000460 01-05, 002421 03-04
DEMISCH L 001906 02-13
DEMPSEY GM 002030 02-15
DEMPSEY MJ 002970 03-17
DENBEIGH P 000868 01-13
DENBER HCB 002595 03-07

DENCKER SJ 001741 02-09, 002031 02-15, 002622 03-08
DENIKER MP 001032 01-17
DENIKER P 000815 01-13, 001042 01-17, 002625 03-08
DENIZEAU F 003125 04-03
DENNER LJ 003817 04-15
DENNEY DR 003821 04-15
DENNIS BJ 000140 01-03
DEPIN J 001116 02-02
DEPOORTERE H 001540 02-04
DERACHE R 001181 02-03, 001270 02-03
DEREUX J 001790 02-10
DERKEVORKIAN KS 002770 03-11
DERMER SW 003646 04-11
DES LAURIERS A 000643 01-09
DESAIAH D 003126 04-03
DESANTIS F 002190 03-02
DESCAMPS M 000275 01-04, 000276 01-04
DESMEDT LKC 000299 01-04
DESOIZE B 001183 02-03
DETRE TP 003793 04-15
DEUTSCH M 002770 03-11
DEVANTHAN S 003585 04-10
DEVICHE P 000312 01-04
DEVLIN D 000540 01-08
DEVROYE Y 002750 03-11
DEWEY WL 000098 01-03, 000134 01-03, 000289 01-04, 001180 02-03, 001255 02-03, 002404 03-03, 003099 04-03, 003426 04-04
DEWS PB 001470 02-04
DEWSBURY DA 001499 02-04
DEXHEIMER P 000884 01-14
DEY PK 001184 02-03
DEZA PC 000968 01-15
DHOEMADI E 000743 01-11
DI CHIARA G 001382 02-03, 002438 03-04
DI DONATO R 000673 01-10, 000689 01-10, 000B86 01-14
DI LEO F 003514 04-06
DIA A 002626 03-08
DIAMOND BI 003262 04-03
DIAMOND F 002009 02-15
DIAMOND H 001033 01-17
DIAMOND S 001034 01-17
DIAN DA 003750 04-14
DIAZ SOLANO C 002716 03-10
DICK DAT 000849 01-13
DICK EG 000849 01-13
DICK P 001907 02-13
DICKERSON LL 001966 02-14
DICKSON DE 001099 02-01
DIEHL LW 000732 01-11, 000938 01-15
DIETZ V 000992 01-15
DIEZ JA 001185 02-03
DIGIACOMO J 000515 01-07
DIGIUSTO EL 003375 04-04
DILEO F 001877 02-12
DILL RE 002232 03-03
DILTS SL 003614 04-11
DIMASCIO A 000646 01-09, 000884 01-14
DIMOND RC 001890 02-13
DIMOND SJ 000887 01-14, 001967 02-14
DINGELL JV 000250 01-03
DINGLEDINE R 001450 02-04
DINITZ S 002737 03-11
DINNENDAHL V 00220B 03-03, 002459 03-04
DIODATO S 000689 01-10, 000B86 01-14
DIORIO A 003280 04-03
DISMUKES K 003127 04-03
DISMUKES RK 001591 02-04
DITTBRENNER M 00101B 01-17
DITTRICH A 001867 02-12, 002797 03-12
DIVASTO P 002899 03-15
DIXON R 002805 03-13
DIXSON AF 003376 04-04
DOBBING J 003303 04-03
DOBRZANSKI S 000313 01-04, 001471 02-04, 001472 02-04
DOCHERTY JP 003041 03-17, 003857 04-17
DOCTOR BP 002375 03-03
DODDABELA P 002968 03-17
DOEPFNER W 002239 03-03
DOGGETT NS 000313 01-04, 001471 02-04, 001472 02-04, 003496 04-05
DOGGRELL SA 00312B 04-03
DOHADWALLA AN 000306 01-04, 003119 04-03
DOHI T 000244 01-03
DOI T 002200 03-03
DOLCE G 002789 03-11
DOLFINI E 003186 04-03
DOLL R 000966 01-15
DOLLER HJ 002233 03-03
DOLLERY CT 002854 03-14
DOLMAN L 000868 01-13
DOLPHIN A 001186 02-03, 002234 03-03, 002439 03-04
DOLPHIN AC 000314 01-04
DOMAGALSKI J 002621 03-08, 002745 03-11
DOMATO GC 003412 04-04
DOME L 001880 02-13
DOMEY R 003491 04-05
DOMINO EF 000090 01-03, 000363 01-04, 003317 04-03, 003377 04-04, 003468 04-04
DOMINO KB 003377 04-04
DOMJAN M 003378 04-04, 003497 04-05
DOMZAL T 000733 01-11
DONALD JF 001798 02-10
DONALDSON IM 000195 01-03, 002234 03-03
DONLON PT 000939 01-15, 001686 02-08, 002986 03-17, 003534 04-08
DOORENBOS H 001781 02-09
DOPPELFELD IS 003159 04-03
DORFMAN W 001035 01-17
DORGAN R 002156 02-17
DORING C 003192 04-03
DORMAN T 003586 04-10
DORR C 000594 01-09
DORUS W 003898 04-17
DOTTI A 000595 01-09
DOUBILET P 001304 02-03
DOUGLAS RJ 001473 02-04
DOUST JWL 002798 03-12
DOW RC 001187 02-03
DOWNEY DJ 000315 01-04
DOWNING RW 003599 04-10
DOWRICK P 003649 04-11
DOWZENKO A 000734 01-11, 002751 03-11
DRAGO F 000560 01-08
DRAGO FC 000764 01-11
DRAPER AJ 001188 02-03
DRAWBAUGH R 002292 03-03
DRAWBAUGH RB 000091 01-03
DRAY A 000059 01-03, 001102 02-02, 0011B9 02-03, 001190 02-03, 002113 02-17, 002229 03-03
DREIFUSS F 003643 04-11
DREN AT 003066 04-02
DRESSE A 001191 02-03, 001408 02-03
DREUX C 000815 01-13
DREW R 000316 01-04
DREW WG 002867 03-14, 003743 04-14
DREYFUS LR 000142 01-03, 001264 02-03, 003197 04-03
DRINGOLI R 000735 01-11
DRISCOLL JS 001656 02-07
DRUEKE T 001001 01-15
DRUMMOND AH 000092 01-03
DRYBANSKI A 001509 02-04, 002463 03-04
DRYMIOTIS A 001826 02-11
DUBE KC 000541 01-08
DUBENKO EG 0020B9 02-16
DUBNER R 003676 04-13
DUBOIS M 001191 02-03
DUBOST M 001192 02-03
DUBOWSKI KM 003824 04-15
DUCHE D 000736 01-11
DUCHENE-MARULLAZ P 001615 02-05
DUCKROW RB 003379 04-04
DUDEK BC 003380 04-04
DUDLEY DL 000742 01-11
DUE SL 002329 03-03
DUFOUR H 000656 01-09, 002589 03-07
DUGAS M 002752 03-11
DUGGAN AW 001617 02-05, 003129 04-03
DUHAULT J 001137 02-03, 003130 04-03
DUHM J 001915 02-13
DULSKA E 002557 03-04, 003327 04-03
DUMEUR G 001474 02-04
DUMONT C 001448 02-04
DUMOVIC P 001193 02-03
DUNAI-KOVACS Z 000239 01-03, 001344 02-03, 003296 04-03
DUNGES W 003667 04-13
DUNN AJ 000407 01-04, 003874 04-17
DUNN CG 003587 04-10
DUNN WJI 003B76 04-17
DUNNER DL 000596 01-09, 000601 01-09, 000603 01-09, 002030 02-15, 002809 03-13
DUNNETT CW 003527 04-08
DUNPHY M 000338 01-04
DUNSTAN R 001194 02-03
DUONG T 000140 01-03
DUPONT E 002753 03-11
DURET-COSYNS S 000816 01-13
DUSTMAN RE 000796 01-12, 001586 02-04, 003509 04-05
DUTOV AA 002235 03-03
DUTT JE 001618 02-05
DUTTA P 000397 01-04
DWUMA-BADU D 001084 02-01
DYBING E 000093 01-03
DYER DC 000226 01-03
DYER RS 000317 01-04
DYKEN PR 003643 04-11
DYKSTRA LA 003381 04-04
DYSKEN MW 003772 04-15
DZHORBENADZE RP 000005 01-01
DZIALEK E 000940 01-15

E

EADES CG 000164 01-03
EARLL JM 001B90 02-13
EARNHART JT 003426 04-04
EASTON JD 0006B1 01-10, 002729 03-10
EBERSOLE JS 003131 04-03
EBERT JN 003535 04-08
EBERT M 003041 03-17
EBERT MH 003661 04-13
EBRANATI E 000941 01-15
EBSTEIN B 000007 01-01
EBSTEIN R 002014 02-15, 002800 03-13
EBSTEIN RP 0016B7 02-08, 002209 03-03, 003668 04-13
ECKARDT MJ 003112 04-03
ECKERNAS S 000035 01-03
ECKERT E 003590 04-10
ECKMANN F 000597 01-09, 001688 02-08
EDELFORS S 003132 04-03
EDENIUS B 001693 02-08
EDERY H 0004B2 01-07
EDIS RH 003773 04-15
EDSTROM A 003774 04-15
EDSTROM JP 002336 03-03
EDVINSSON L 002114 02-17
EDWARDS DJ 003343 04-04
EGATA K 001742 02-09
EGELMAN A 001697 02-08
EGGERS C 000942 01-15
EGHBALI B 000464 01-05
EHRENPREIS S 002115 02-17
EHRENSING RH 003615 04-11
EHSANULLAH RSB 001660 02-07, 003520 04-07
EIBERGEN RD 000318 01-04, 001195 02-03, 001619 02-05
EICHNER M 000360 01-04
EIDELBERG E 001146 02-03, 002426 03-04
EILERS MK 002177 02-17
EINON D 002440 03-04
EINSPRUCH BC 002859 03-14
EIRIN AM 001108 02-02
EISENRIED F 001915 02-13
EISENSTEIN D 003366 04-04
EISSENBERG E 0003B1 01-04
EK L 000055 01-03, 001011 01-17
EKLUND KL 002627 03-08
EL-ETR AA 002250 03-03
ELDER ST 000319 01-04
ELDRIDGE FL 000460 01-05
ELEFTHERIOU BE 0008B8 01-14
ELIASSEN HMM 001664 02-07
ELIASSON M 001475 02-04, 002441 03-04
ELITHORN A 003635 04-11
ELIZUR A 003775 04-15
ELKHAWAD AO 000264 01-03
ELLEY JH 001908 02-13
ELLINGBOE J 001930 02-13
ELLINWOOD EH 002987 03-17, 003196 04-03, 003291 04-03
ELLIOT PNC 000094 01-03
ELLIOT S 000259 01-03
ELLIOTT FA 003616 04-11
ELLIOTT GR 001500 02-04, 002278 03-03
ELLIOTT HW 001100 02-02
ELLIOTT PNC 002439 03-04

ELLIS FW 000152 01-03
ELLITHROPE 08 001903 02-13
ELONEN E 000458 01-05
ELSASS P 000898 01-14
ELSMORE TF 001476 02-04
EMERY OE 001477 02-04
EMLEY GS 003406 04-04
EMSON PC 001196 02-03, 001256 02-03
ENDE W 000599 01-09
ENOLER S 002806 03-13
ENOO H 000749 01-11
ENDO M 000749 01-11
ENEROTH P 002835 03-13, 002836 03-13, 003704 04-13
ENGEL J 000459 01-05, 001174 02-03, 001478 02-04, 002442 03-04, 002807 03-13, 002978 03-17, 003079 04-03, 003117 04-03
ENGEL RR 002893 03-15
ENGELHAROT OM 002116 02-17, 002988 03-17
ENGELMANN W 001479 02-04
ENGIN L 003625 04-11
ENJALBERT A 000120 01-03, 003133 04-03
ENNA SJ 001909 02-13, 003134 04-03
ENOKIOO H 001706 02-08
ENOT KJ 002792 03-11
ENSLEN M 001436 02-04
ENZI G 002117 02-17
ER8LER HC 003171 04-03
ERCOLE MA 000397 01-04
EROOSOVA R 003135 04-03
ERHAROT PW 000229 01-03
ERICKSEN S 000543 01-08
ERICKSON CK 002236 03-03, 003214 04-03, 003757 04-14
ERICKSON HM 001763 02-09
ERIKSON OJ 003285 04-03
ERIKSSON M 001943 02-13
ERLIJ O 001409 02-03
ERPINO MJ 001486 02-04
ERVIK M 000470 01-06
ERVIN OK 000784 01-11
ERWIN VG 000095 01-03
ESCANOE C 000815 01-13
ESCANOE M 000943 01-15
ESCHER M 000676 01-10
ESCO8AR JI 000600 01-09, 001791 02-10, 003669 04-13
ESCOUSSE A 001192 02-03
ESCRIU JM 003740 04-14
ESCUETA AV 003136 04-03
ESCURET E 000914 01-14
ESNAULT L 002183 03-01
ESPOSITO R 003382 04-04
ESSMAN W8 002989 03-17
ESTEY SJ 000199 01-03
ESTLER C 000320 01-04, 000817 01-13, 001036 01-17, 001197 02-03
ETTEN8ERG A 001198 02-03
EU8ANKS EE 000441 01-04
EVANS JM 002808 03-13
EVANS MA 000889 01-14, 001480 02-04, 002032 02-15
EVANS RH 001199 02-03
EVANS S 000811 01-13
EVANS WE 002949 03-15
EVERSON A 001858 02-11
EWING JH 003535 04-08
EXTEIN I 001910 02-13
EYRE P 000124 01-03
EZAWA K 000351 01-04
EZER E 000321 01-04
EZRIN-WATERS C 001481 02-04

F

FA8RE LF 000490 01-07, 000682 01-10, 003617 04-11
FAOOA F 000233 01-03, 001387 02-03, 001388 02-03
FAFF J 001637 02-05
FAGLIONI P 000737 01-11
FAHN S 001585 02-04
FAHNORICH C 003211 04-03
FAHNORICH E 000587 01-09, 001772 02-09
FAIL L 000677 01-10
FAIN W 001494 02-04
FAIRCHILO MO 000506 01-07
FAIRMAN K 003137 04-03
FAKATSU R 000581 01-09
FALENI A 000683 01-10
FALENI RA 001037 01-17
FALK RH 003776 04-15
FALKHEDEN T 001030 01-17, 002736 03-11
FALTER H 001560 02-04
FAMA PG 003777 04-15
FANOO JL 003321 04-03
FANELLI O 000247 01-03
FANG VS 002310 03-03, 003220 04-03, 003221 04-03, 003222 04-03, 003689 04-13
FANN WE 000818 01-13, 000944 01-15, 001038 01-17, 002033 02-15, 003556 04-09, 003778 04-15, 003858 04-17
FARAJ 8A 003138 04-03
FAR8ER PO 002443 03-04, 002444 03-04
FARKAS T 002030 02-15, 002809 03-13
FARQUHAR JA 001648 02-06
FARQUHARSON RG 002646 03-08
FARSKA I 001200 02-03
FARTHMANN E 000223 01-03
FASS8ENOER W 001182 02-03
FATOME M 003139 04-03
FAUNCH R 001163 02-03
FAUQUET JP 003383 04-04
FAUX EJ 003779 04-15
FEAZELL O 003841 04-16
FEOER J 000532 01-08, 000663 01-09
FEOERMESSER KI 001836 02-11
FEOOTOV OO 002034 02-15
FEHR KA 000322 01-04
FEIN8ERG I 000792 01-12
FEINGLASS SJ 003491 04-05
FEL8Y S 000934 01-15
FELO8ERG W 001184 02-03
FELDMAN HS 002118 02-17
FELOMAN L 000684 01-10
FELOMANN H 002595 03-07
FELINE A 000945 01-15
FELIX O 000069 01-03, 001277 02-03
FELLENIUS E 000056 01-03
FENICHEL RL 001278 02-03
FENNELL W 000890 01-14
FENOGLIO L 000591 01-09, 000722 01-10
FERGUSON GG 002279 03-03
FERNANOES M 001482 02-04, 003140 04-03
FERNANOEZ PG 000946 01-15
FERNANOO JCR 001176 02-03
FERNER U 000915 01-14, 001653 02-07
FERRARO OP 001966 02-14
FERRAZZI O 002746 03-11
FERRENOELLI JA 002237 03-03
FERRI S 000323 01-04, 000324 01-04
FERRIS GN 002119 02-17
FERTZIGER AP 003422 04-04
FESTAL O 001116 02-02
FESZT G 003201 04-03
FEX J 001085 02-01
FIAG8E NY 001084 02-01
FI8IGER HC 000200 01-03, 001334 02-03, 001458 02-04, 003443 04-04
FICI F 000604 01-09
FICKENTSCHER K 001620 02-05
FIOETZIS K 001760 02-09
FIELOING S 001535 02-04
FIELOS HL 003082 04-03
FIELOS WS 001039 01-17
FIESCHI C 000848 01-13
FIEVE R 003780 04-15
FIEVE RR 000596 01-09, 000601 01-09, 000602 01-09, 000603 01-09, 000634 01-09, 002030 02-15, 002809 03-13
FIGUEIRA L 000645 01-09
FILE SE 001483 02-04, 001484 02-04, 003384 04-04, 003385 04-04
FILHO HT 001743 02-09
FILHO NGS 003386 04-04
FILICHEVA AP 002914 03-15
FILIPOVIC N 000096 01-03, 000126 01-03
FILLION G 001201 02-03
FILLION MP 001201 02-03
FILTSANOVA GA 002572 03-05
FINANCE F 002928 03-15
FINCH AA 001485 02-04
FINCH N 003049 04-01
FINCK AO 001139 02-03
FINK M 000819 01-13, 002874 03-14, 003859 04-17
FINK SA 001202 02-03
FINNEGAN KT 002445 03-04
FINNERTY R 000884 01-14
FINNERTY RJ 001792 02-10, 003589 04-10
FINNEY HC 001486 02-04
FIORENTINI C 001917 02-13
FIREMARK HM 003670 04-13
FIRKO M 002669 03-09
FIRNAU G 001968 02-14
FISCHER E 000021 01-02, 000495 01-07
FISCHER GJ 000111 01-03
FISCHER J 002893 03-15
FISCHER JF 002238 03-03
FISCHER RL 000456 01-05
FISCHMAN MW 000890 01-14
FISH 8S 002446 03-04
FISH I 000406 01-04
FISHER A 000097 01-03
FISHER AE 000274 01-04
FISHER MH 003063 04-02
FISHKIN SM 003603 04-10
FISKE JC 001264 02-03
FISZER T 002669 03-09
FITZGERALO TJ 001621 02-05
FJALLANO 8 000073 01-03
FLACH O 001760 02-09
FLAHERTY CF 000997 01-15, 002005 02-14, 003744 04-14
FLAMMANG M 001109 02-02
FLANOIN F 000738 01-11
FLANNELLY KJ 000325 01-04
FLATAKER LM 003063 04-02
FLEOEL T 000872 01-13
FLEISCHHAUER H 002890 03-15
FLEISCHHAUER J 002035 02-15, 002095 02-16
FLEISS JF 002581 03-05
FLEISS JL 000596 01-09, 003560 04-09
FLEMEN8AUM A 000326 01-04
FLENER R 002873 03-14
FLETCHER ON 001040 01-17
FLEXNER J8 001487 02-04
FLEXNER L8 001487 02-04
FLOOH H 000457 01-05
FLOM MC 000873 01-14
FLORA RE 003077 04-03
FLORSHEIM WH 001396 02-03
FLORU L 001744 02-09, 002036 02-15, 002754 03-11
FLOYO J8 002894 03-15
FLOYO T 000792 01-12
FLUCKIGER E 002239 03-03
FLUOOER JM 001203 02-03, 001204 02-03
FLYNN EJ 003141 04-03
FLYNN NM 002860 03-14
FLYNN NW 003057 04-01
FOENANOER G 000880 01-14
FOERSTER K 000947 01-15
FOG R 000858 01-13, 001205 02-03, 003548 04-08
FOLCO GC 002210 03-03
FOLOES FF 003860 04-17
FOLSCH G 003671 04-13
FONG 8TW 002193 03-02
FONNUM F 001626 02-05
FONTAINE P 002092 02-16
FOOKES 8H 002037 02-15
FOR8ES JE 000098 01-03
FORO 8K 003519 04-07
FORO OH 001327 02-03
FORO RO 000327 01-04
FORMAN AJ 002063 02-15
FORNEY E 000142 01-03, 001206 02-03, 001264 02-03, 003197 04-03
FORNEY R 001902 02-13
FORNEY R8 000889 01-14, 001391 02-03, 001480 02-04, 002032 02-15, 003290 04-03
FORREST IS 001167 02-03
FORREST J 003793 04-15
FORREST WA 003557 04-09, 003604 04-10
FORSEN A 000542 01-08
FORSHELL GP 003574 04-09
FORSMAN A 001911 02-13, 003671 04-13
FORSYTHE A 003651 04-11
FORTUNE OH 000301 01-04
FOSTER FG 001055 01-17
FOSTER JR 003781 04-15
FOSTER TW 000685 01-10, 002737 03-11
FOWLER SC 002447 03-04
FOX S 002838 03-13
FOX W 002090 02-16
FOZARO JR 001207 02-03

FRACASSI MJ 002596 03-07
FRACCHIA J 002162 02-17, 002163 02-17
FRAME AH 000752 01-11
FRANCESCONI G 000604 01-09
FRANCIS AA 001199 02-03
FRANCIS AF 001745 02-09
FRANCIS DL 002225 03-03
FRANCO J 000605 01-09
FRANE JW 003525 04-07
FRANK P 003672 04-13
FRANKE A 001878 02-13
FRANKE K 001862 02-11, 003705 04-13, 003731 04-14
FRANKEL HL 003701 04-13
FRANKL MB 000453 01-04
FRANKLIN C 002822 03-13
FRANKLIN CJG 003604 04-10
FRANKLIN KBJ 000340 01-04, 000428 01-04, 003142 04-03
FRANKLIN-SMYTH W 001294 02-03
FRANKS HM 002857 03-14, 002858 03-14
FRANZEN G 002755 03-11
FRAS I 003782 04-15
FRASER TR 000987 01-15
FRATTA W 000099 01-03
FRATTOLA L 000242 01-03
FRAUSTO DA SILVA JJR 002810 03-13
FRAZER A 003558 04-09, 003568 04-09
FREDERICKSON RCA 000006 01-01, 001208 02-03, 001209 02-03
FREDHOLM 88 000100 01-03
FREE SM 003588 04-10
FREED G 000686 01-10
FREED WJ 000328 01-04
FREEDMAN AM 001853 02-11, 001950 02-13
FREEDMAN DX 000890 01-14, 001326 02-03
FREEDMAN R 001239 02-03, 003143 04-03
FREEMAN WJ 002361 03-03
FREEMESSER GF 003519 04-07
FREER RJ 001180 02-03
FREMMING KH 000637 01-09
FRESIA P 001225 02-03
FRESTON JW 000066 01-03, 000166 01-03
FREY JJ 002105 02-17
FREYE E 001210 02-03
FREYHAN FA 000606 01-09
FRICK K 001884 02-13, 001885 02-13
FRIED PA 001622 02-05
FRIEDEL RO 002667 03-09, 003144 04-03
FRIEDER 8 002416 03-04
FRIEDHOFF AJ 000564 01-08, 000793 01-12, 001091 02-01, 003145 04-03, 003219 04-03
FRIEDMAN AS 000607 01-09
FRIEDMAN E 001211 02-03, 002164 02-17, 002385 03-03, 003146 04-03, 003219 04-03
FRIEDMAN H 001623 02-05
FRIEDMAN MA 001212 02-03
FRIEDMAN MI 000373 01-04
FRIESEN H 000408 01-04, 000409 01-04, 003451 04-04
FRIGENI V 003354 04-04
FRIGERIO A 000046 01-03, 000190 01-03, 002240 03-03
FRITH CD 001827 02-11
FRITSCH W 002691 03-09
FRITZ RR 000281 01-04
FRIVIK PT 000812 01-13
FROLICHSTEIN CF 000194 01-03
FROMM GH 003618 04-11
FRONTALI M 002448 03-04
FRUMKINA LY 002341 03-03
FRY JP 001428 02-03
FRYER RI 001096 02-01
FU T 003216 04-03
FUCHS A 001645 02-06
FUCHS AM 000473 01-06
FUENTES J 001213 02-03
FUJIEDA T 000581 01-09, 000654 01-09, 000745 01-11, 002241 03-03
FUJII S 000891 01-14, 000909 01-14
FUJII T 002564 03-05
FUJIMORI K 002565 03-05
FUJIMURA H 003073 04-02
FUJISAKI T 002262 03-03
FUJIWARA J 000608 01-09, 001661 02-07
FUJIWARA M 003233 04-03, 003450 04-04
FUKATSU R 002895 03-15
FUKAZAWA E 002245 03-03
FUKS Z 000096 01-03
FUKUDA K 000687 01-10
FUKUDA S 000347 01-04, 001488 02-04
FUKUDA T 003292 04-03
FUKUDA Y 002472 03-04, 002476 03-04
FUKUMA E 000696 01-10
FUKUSHIMA DK 003660 04-13
FUKUSHIMA H 000392 01-04, 001241 02-03, 001552 02-04, 001553 02-04, 002386 03-03
FULGINITI S 001214 02-03
FULKERSON FG 003530 04-08
FULLAM S 002899 03-15
FULLE P 001197 02-03
FULLER RW 000101 01-03, 002242 03-03, 002243 03-03, 003051 04-01, 003147 04-03, 003148 04-03
FULTON SC 001215 02-03
FUMAGALLI R 002210 03-03
FUMI S 000723 01-11, 002756 03-11
FUNG F 003146 04-03
FURLAN PM 000609 01-09
FURLONG W 003544 04-08
FURMAN 8L 003121 04-03
FURNESS JA 002646 03-08
FURST Z 003860 04-17
FURUKAWA K 000139 01-03, 002244 03-03, 002273 03-03
FURUKAWA T 000102 01-03, 002245 03-03, 002284 03-03, 002566 03-05
FURUTA Y 001216 02-03
FUTTERMAN S 003100 04-03
FUXE K 000100 01-03, 001514 02-04
FYRO 8 000513 01-07, 002835 03-13, 002836 03-13, 003653 04-13, 003704 04-13

G

GA8RIEL E 002671 03-09
GA8RIELLI F 000688 01-10, 002717 03-10
GADDY JR 001489 02-04
GAE8ELEIN CJ 000329 01-04
GAERTNER HJ 001889 02-13
GAGE FH 000103 01-03
GAGLIARDI G 003387 04-04
GAIARDI M 000277 01-04, 001437 02-04, 003344 04-04
GAILLARD AWK 001912 02-13, 003673 04-13
GAILLARD J 001522 02-04, 001969 02-14
GAILLY M 000750 01-11
GAINES LS 001963 02-14
GAINEY A 003617 04-11
GAINOTTI G 003634 04-11
GAITI A 000036 01-03
GAITONDE 88 003149 04-03
GAJEWSKA S 000362 01-04
GAJKOWSKI K 000739 01-11
GAL EM 002364 03-03, 002574 03-05
GAL J 001217 02-03, 003064 04-02, 003329 04-03
GALANTER M 002838 03-13
GALATULAS I 003301 04-03
GALE KN 000104 01-03, 002191 03-02
GALLAGER DW 002246 03-03, 002247 03-03, 002580 03-05, 003372 04-04
GALLANT DM 001746 02-09, 001843 02-11
GALLETTI G 002615 03-08
GALLI CL 003516 04-06
GALLUP GG 001449 02-04, 001506 02-04
GAM8I D 000801 01-13
GAM8ILL JD 001490 02-04
GAMMON C8 000924 01-14
GAMNA G 002628 03-08
GANDOLFI O 000238 01-03
GANDOLFO C 002694 03-09
GANGJEE A 000067 01-03
GANGULY DK 003495 04-05
GANZ V' 002896 03-15
GARATINI S 000149 01-03, 001140 02-03, 001652 02-06, 002811 03-13, 002846 03-13, 003455 04-04
GARBER E 002934 03-15
GARDNER RE 003783 04-15
GARDOS G 003536 04-08, 003784 04-15
GAREY RE 000105 01-03
GARFINKEL D 003107 04-03
GARFINKEL PE 002672 03-09
GARG KN 001612 02-05
GARGIULO G 001310 02-03
GARLAND WA 003150 04-03
GARNETT ES 001968 02-14
GARRETT NJ 000163 01-03, 001289 02-03
GARRETTO S 003060 04-01
GARSKY V 001278 02-03
GARVER D 001665 02-07
GARVER DL 000064 01-03, 000415 01-04, 000543 01-08, 001689 02-08
GASCON AL 003151 04-03
GASPARINI M 000737 01-11
GASPARO M 000860 01-13
GAST J 001938 02-13
GATARSKI J 002710 03-10
GATES GR 001457 02-04
GATHIER M 002689 03-09
GATRAD AR 002038 02-15
GAUDEFROY A 003139 04-03
GAUJOUX M 000464 01-05
GAULD A 000791 01-12
GAULTIER M 002039 02-15
GAURON EF 000330 01-04, 001491 02-04
GAVIN DL 000286 01-04
GAVLIK I 002248 03-03
GAY G 001852 02-11
GAY PE 000331 01-04, 002449 03-04
GAYRAL L 000943 01-15
GAZZILLO FL 003867 04-17
GE8ER WF 000106 01-03
GE8HART GF 000224 01-03
GEHRMANN JE 001218 02-03
GEISLER A 001747 02-09, 003114 04-03
GEL8OIN HV 000259 01-03
GELEN8ERG AJ 002040 02-15
GELLER HM 001219 02-03
GELLERT VF 003388 04-04
GENC E 003198 04-03
GENDELMAN DS 003371 04-04
GENEVIEVE J 002597 03-07
GENOVESE E 003301 04-03
GENTIL V 000491 01-07
GENTRY RT 002450 03-04
GEORGE AJ 000107 01-03
GEORGE CF 003724 04-14
GEORGE G 003152 04-03
GERALD MC 001341 02-03, 003153 04-03, 003164 04-03, 003252 04-03, 003253 04-03, 003389 04-04
GER8ER N 002041 02-15, 003694 04-13
GERETY M 002899 03-15
GERHARD RJ 002156 02-17
GERHARDS HJ 003200 04-03
GERLACH J 000820 01-13, 003537 04-08, 003785 04-15
GERNER RH 001748 02-09, 002673 03-09
GERO A 001913 02-13
GERSHELL WJ 003781 04-15
GERSHON ES 001703 02-08
GERSHON MD 000108 01-03, 001347 02-03, 003106 04-03
GERSHON S 000341 01-04, 000478 01-07, 000821 01-13, 001211 02-03, 001775 02-09, 001955 02-14, 002076 02-15, 002164 02-17, 002385 03-03, 002832 03-13, 003146 04-03, 003172 04-03, 003173 04-03, 003559 04-09, 003861 04-17
GERSTEN8RAND F 001654 02-07
GERVAIS RH 002917 03-15
GESSA GL 000233 01-03, 000488 01-07, 001387 02-03, 001388 02-03, 002438 03-04
GEYER G 001853 02-11
GEYER MA 000418 01-04
GHONEIM MM 003725 04-14
GHOSE K 001739 02-09, 001740 02-09, 002027 02-15, 002674 03-09, 003520 04-07, 003521 04-07
GHOSH AK 001083 02-01
GHOSH JJ 000042 01-03
GHOSH MN 000109 01-03
GIACOBINI E 003137 04-03
GIANFRANCESCHI G 000492 01-07
GIANNELLA M 000013 01-01
GIANNINI AJ 003786 04-15
GIANNOVOLA E 001738 02-09
GIANROSSI R 000044 01-03
GIANUTSOS G 000332 01-04, 001220 02-03, 001492 02-04, 001493 02-04, 002249 03-03, 002451 03-04, 002469 03-04, 003005 03-17
GIARDINA WJ 001351 02-03
GIB8INS RJ 001537 02-04
GIBBONS JL 000280 01-04, 002452 03-04, 003347 04-04

GI8S IS 001086 02-01
GI8S ME 000110 01-03, 000333 01-04, 001254 02-03
GI8SON H8 003726 04-14
GI8SON JE 001635 02-05
GIELES LCM 003367 04-04
GIFFORO L 002906 03-15
GIFFORO LA 000610 01-09
GIFFORO S 002897 03-15
GIFT T 003843 04-16
GILBERT JC 001828 02-11
GIL8ERT JNT 003090 04-03
GIL8ERT MM 001041 01-17, 003619 04-11
GIL8ERT MS 001662 02-07
GIL8ERT PE 000164 01-03
GIL8ERT RM 003787 04-15
GILOER OA 001494 02-04
GILL M 002280 03-03
GILLER EL 002213 03-03
GILLIN JC 000022 01-02, 000235 01-03, 000387 01-04, 000439 01-04, 001501 02-04, 001696 02-08, 002504 03-04, 002505 03-04, 002629 03-08, 002879 03-14, 003041 03-17, 003431 04-04, 003708 04-13, 003727 04-14, 003749 04-14
GILLIS A 001703 02-08
GILLIS JS 003538 04-08, 003728 04-14
GILMAN SC 000111 01-03
GINESTET O 001032 01-17, 001042 01-17, 002653 03-08, 002668 03-09
GINOS JZ 000023 01-02
GINS8URG 8E 000334 01-04, 001609 02-04, 003488 04-04
GIOFFRE PA 001673 02-07
GIOVINE A 001221 02-03
GIRALOI G 001663 02-07
GIRARO J 002898 03-15, 002898 03-15
GISPEN WH 000112 01-03, 002453 03-04
GISSELMANN A 000611 01-09, 000948 01-15, 001043 01-17
GITTELMAN R 003620 04-11
GITTELMAN-KLEIN R 000740 01-11, 002861 03-14, 002862 03-14
GITTER S 000097 01-03, 002827 03-13
GIURGEA C 000892 01-14, 002454 03-04
GIUSTI GV 003498 04-05
GIZHLARYAN MS 002568 03-05
GJESSING LR 000525 01-08, 000526 01-08, 000527 01-08, 000528 01-08, 000535 01-08
GLASSMAN A 001749 02-09
GLASSMAN AH 001935 02-13, 003560 04-09, 003659 04-13, 003674 04-13
GLASSMAN R8 002042 02-15
GLATT MM 003862 04-17
GLAZIER S 001435 02-04
GLEN AIM 001759 02-09
GLICK SO 000260 01-03, 000352 01-04, 000384 01-04, 001227 02-03, 001592 02-04, 002990 03-17, 003390 04-04, 003434 04-04
GLISSON SN 002250 03-03
GLOISTEN AC 002862 03-14
GLOVER O 002899 03-15
GLOWINSKI J 000120 01-03, 000217 01-03, 000240 01-03, 001150 02-03, 001151 02-03, 001397 02-03
GLUCKMAN MI 000045 01-03
GLYNN JP 002087 02-16
GMUER M 002793 03-11
GNEGY ME 002227 03-03
GO8EL U 001851 02-11
GO8LE FC 000822 01-13
GOCHFELO L 003818 04-15
GOOSE OO 002837 03-13
GOOWIN S 003110 04-03
GOETZ C 000448 01-04
GOGGIN JE 001763 02-09
GOLO 8I 003154 04-03
GOLO OO 002900 03-15
GOLO JA 003648 04-11
GOLO PE 002455 03-04
GOLO PW 002675 03-09
GOLO8ERG A 000752 01-11
GOLD8ERG CS 001587 02-04
GOLD8ERG OM 001495 02-04
GOLO8ERG E 003841 04-16
GOLO8ERG F 003898 04-17
GOLO8ERG GJ 002912 03-15
GOLO8ERG HL 001792 02-10, 003589 04-10
GOLO8ERG L 003690 04-13
GOLD8ERG SC 003539 04-08, 003590 04-10
GOLO8ERG SR 001495 02-04, 002456 03-04, 002457 03-04, 003391 04-04, 003392 04-04
GOLO8ERGER E 000943 01-15
GOLO8ORT R 000237 01-03
GOLOEN8ERG EO 003651 04-11
GOLOENSOHN ES 003209 04-03
GOLOFAR8 AI 003781 04-15
GOLOFAR8 J 002990 03-17
GOLOFOOT OA 001400 02-03
GOLOMAN AS 001368 02-03
GOLOMAN O 000493 01-07
GOLOMAN H 002737 03-11
GOLOMAN T 003692 04-13
GOLOSTEIN A 000535 01-08, 001496 02-04, 003050 04-01, 003155 04-03
GOLOSTEIN O8 001497 02-04
GOLOSTEIN H 003156 04-03
GOLOSTEIN HS 002013 02-15
GOLOSTEIN M 000007 01-01, 000155 01-03
GOLDSTEIN MJ 000506 01-07
GOLOSTEIN SE 002598 03-07
GOLOSTONE S 002901 03-15
GOLEM8IOWSKA-NIKITIN K 002503 03-04, 002557 03-04
GOLOVANOVA IV 002251 03-03
GOMES 8 001222 02-03
GOMES C 001223 02-03
GOMEZ E 001787 02-10
GOMEZ LOZANO P 002718 03-10
GOMEZ O 003669 04-13
GOMITA Y 002512 03-04
GONCALVES N 000949 01-15, 001690 02-08
GONNARO P 001137 02-03
GONYE T 000060 01-03
GONYE TJ 001189 02-03
GONZALEZ FA 002457 03-04, 003392 04-04
GOOO MI 000950 01-15, 002043 02-15
GOOOALE 08 001224 02-03
GOOOALL E8 000335 01-04, 000336 01-04
GOOOELL NA 002508 03-04
GOOOLET I 001393 02-03
GOOOMAN LI 000707 01-10
GOOOMAN R 000015 01-01
GOOOMAN RE 003729 04-14
GOOOWIN OW 000846 01-13
GOOOWIN FK 001044 01-17, 001729 02-09, 001750 02-09, 002675 03-09, 002812 03-13, 003863 04-17
GORAJ A 000574 01-08, 002662 03-08
GOR8UNOVA NA 002034 02-15
GOROON E 003692 04-13
GOROON JH 003158 04-03
GOROON N8 001956 02-14
GOROON WC 001498 02-04, 003393 04-04
GOROON-WEEKS P 003157 04-03
GORECKI OKJ 000113 01-03
GORELICK OA 003394 04-04
GORMAN JE 002443 03-04
GORNIEWICZ A 000631 01-09
GOROOILOVA YP 001829 02-11
GOROOISCHER R 002816 03-13
GOSENFELO L 000543 01-08, 001895 02-13
GOSSAIN VV 002902 03-15
GOSTICK NK 003621 04-11
GOTESTAM KG 000768 01-11, 003395 04-04
GOTO T 002262 03-03
GOTO Y 002707 03-09
GOTOH Y 002227 03-03
GOTTFRIES C 000823 01-13
GOTTFRIES CG 002991 03-17
GOTTLIE8 8 002127 02-17
GOTTLIE8 J 003568 04-09
GOTTLIE8 S 003597 04-10
GOTTSCHALK LA 002120 02-17, 003522 04-07, 003730 04-14
GOTTWALO K 002880 03-14
GOUOIE AJ 000337 01-04
GOULOING R 003831 04-15
GOURET C 003190 04-03
GOVONI S 001225 02-03, 001383 02-03
GOWAROMAN M 000893 01-14
GOWOEY CW 001598 02-04
GRA8OWSKA M 002202 03-03
GRA8OWSKI EJJ 003063 04-02
GRA8OWSKI J 001647 02-06
GRAEFF FG 001172 02-03, 002458 03-04, 003386 04-04
GRAF E 003159 04-03
GRAF L 001260 02-03, 001344 02-03, 003296 04-03
GRAFF E 003775 04-15
GRAHAM J 000854 01-13
GRAHAM JDP 002992 03-17
GRAHAM JR 001034 01-17
GRAHAME-SMITH OG 001226 02-03, 002121 02-17, 002461 03-04, 003160 04-03
GRAM LF 002813 03-13, 003695 04-13
GRAMSCH C 001447 02-04
GRANACHER RP 002903 03-15
GRANO M 001116 02-02
GRANT DA 001698 02-08
GRANT I 000894 01-14, 002044 02-15
GRANT NH 001278 02-03
GRANT RW 001297 02-03
GRASSO A 003052 04-01, 003060 04-01
GRAU C 000311 01-04
GRAUX C 002019 02-15
GRAVES C 001841 02-11
GRAY GO 001499 02-04
GRAY JA 002814 03-13
GRAY JM8 001833 02-11
GRAY P 000338 01-04
GRAY TJ 003776 04-15
GRE8OWICZ K 002777 03-11
GRECO N 000679 01-10
GREEN AR 001226 02-03, 002429 03-04, 002461 03-04, 003160 04-03, 003396 04-04
GREEN OE 001167 02-03
GREEN JP 001227 02-03
GREEN JR 000788 01-11
GREEN K 003161 04-03
GREEN RA 001500 02-04, 001501 02-04
GREENACRE JK 002815 03-13
GREEN8ERG OA 002253 03-03
GREEN8ERG I 000907 01-14, 002960 03-17
GREEN8ERG L 001998 02-14
GREEN8LATT OJ 000976 01-15, 001862 02-11, 001914 02-13, 002599 03-07, 003675 04-13, 003705 04-13, 003731 04-14, 003788 04-15, 003789 04-15
GREEN8LATT EN 001106 02-02
GREENE FE 000269 01-03
GREENGRASS PM 000665 01-09, 001228 02-03
GREENSPAN SI 002143 02-17
GREENWAY FL 003622 04-11
GREER CA 000114 01-03
GREGG 8 003378 04-04
GREIG AM 001515 02-04
GREIL W 001045 01-17, 001915 02-13, 002893 03-15
GREINOL MG 001502 02-04
GREIST JH 003864 04-17
GRENET P 002752 03-11
GREWAL RS 001178 02-03, 003122 04-03
GREY WH 000572 01-08
GRIFANTINI M 003048 04-01
GRIFFIN R8 002817 03-13
GRIFFITH FF 000279 01-04
GRIFFITHS R 000115 01-03
GRIFFITHS RR 001046 01-17, 001503 02-04, 001646 02-06
GRIGGS EA 003790 04-15
GRIGGS R 003629 04-11
GRIGGS RC 003640 04-11
GRIM8Y G 002622 03-08
GRIMES O 001188 02-03
GRIMM RJ 003524 04-07
GRIMSSON A 003865 04-17
GRINGRAS M 003839 04-16, 003866 04-17
GRINNAN EL 000006 01-01
GRINSPOON L 003732 04-14
GRIPEN8ERG J 000131 01-03
GRITZ ER 000951 01-15
GRO8ECKER H 002254 03-03
GROF P 002904 03-15, 003544 04-08
GRONAN RJ 000339 01-04
GROOM GV 000586 01-09
GROSS O 003587 04-10
GROSS LJ 000895 01-14
GROSS M 003645 04-11
GROSZ HJ 002757 03-11
GROTE S 000883 01-14
GROVES PM 002122 02-17, 002328 03-03, 002344 03-03
GROWOON JH 000429 01-04, 000430 01-04, 003162 04-03, 003624 04-11
GRUCHOW HW 002123 02-17

GRUEN PH 001916 02-13, 003684 04-13
GRUN8ERGER J 001654 02-07, 001773 02-09, 002873 03-14
GRUNOIG E 001654 02-07
GRUNE8ERG F 000949 01-15
GRUNER W 000952 01-15
GRUNFELO Y 000097 01-03
GRUPP LA 000116 01-03
GRUZELIER J 003540 04-08
GRZYWA A 000631 01-09
GUALTIERI CT 003791 04-15
GUALTIERI F 000013 01-01
GUANTIERI G 000689 01-10
GUASTALLA A 000536 01-08, 001680 02-08, 001681 02-08
GUAZZI 8 000735 01-11
GUAZZI M 001917 02-13
GU8ANOVA TI 002251 03-03
GUEREMY C 002392 03-03
GUERIN R 002668 03-09
GUERRERO J 002415 03-04
GUERRINI A 000536 01-08, 001680 02-08, 001681 02-08
GUI8ERT S 001031 01-17
GUIOOTTI A 000051 01-03, 000104 01-03, 001145 02-03, 001303 02-03, 002191 03-02, 002211 03-03, 002212 03-03, 002255 03-03, 002256 03-03, 003096 04-03, 003097 04-03, 003354 04-04
GUIOOTTI N 001793 02-10
GUIGOU G 002993 03-17
GUIL8AUO G 001274 02-03
GUILLAUME MF 002823 03-13
GUILLEMIN R 003397 04-04
GUILLEMINAULT C 000460 01-05, 000741 01-11, 002112 02-17
GULATI OD 001229 02-03
GULINI U 003048 04-01
GULLEY 8L 002335 03-03
GULLIS RJ 000117 01-03
GULMANN NC 001664 02-07
GUMMOW L 003524 04-07
GUMNIT RJ 003246 04-03
GUMULKA SW 002208 03-03, 002459 03-04
GUNN CG 003824 04-15
GUNNE L 001504 02-04, 003546 04-08
GUPTA O 000360 01-04
GUPTA GP 002417 03-04
GUPTA PK 003163 04-03
GUPTA R 000589 01-09, 001740 02-09, 003521 04-07
GUPTA RC 003163 04-03
GUPTA RK 000590 01-09
GUPTA TK 003153 04-03, 003164 04-03, 003389 04-04
GURAN P 000494 01-07
GUTHRIE O 003747 04-14
GUTHRIE M8 003625 04-11
GUTHY H 002758 03-11
GUTIN P 002792 03-11
GUTMAN Y 002413 03-03
GUYOA H 003529 04-08
GUZMAN G 001088 02-01
GYLYS JA 001114 02-02, 003470 04-04, 003471 04-04
GYMOESE E 000898 01-14

H

HAACKE H 000118 01-03
HAARMANN I 001240 02-03
HAASE HJ 000544 01-08
HA8ER 8 000528 01-08
HACHIJIMA Y 002759 03-11, 002763 03-11
HACKETT JT 001291 02-03
HACKMAN MR 002805 03-13
HAODAD RI 003792 04-15
HADOEN8ROCK S 000937 01-15
HADISOEMARTO S 002843 03-13
HAOORN D 001505 02-04
HAEFELY W 000358 01-04, 001158 02-03, 001230 02-03, 001332 02-03, 002215 03-03, 002337 03-03
HAEGERSTROM-PORTNOY G 000873 01-14
HAFFNER JFW 000812 01-13
HAGA Y 002707 03-09
HAGEN GA 002902 03-15
HAGGENOAL J 002622 03-08
HAGLUNO 8 003614 04-11
HAGUE WH 000742 01-11
HAHER EJ 001715 02-08
HAHN OS 000119 01-03
HAIORI NH 003867 04-17
HAIGLER HJ 001231 02-03
HAIK Z 002816 03-13
HAKEREM G 002830 03-13
HALARIS A 003453 04-04
HALARIS AE 001326 02-03, 003409 04-04
HAL8REICH U 002905 03-15
HALL JG 001617 02-05, 003129 04-03
HALL JN 000530 01-08
HALL PF 002563 03-05
HALL RA 002817 03-13
HALL RC 000824 01-13
HALLETT C 003724 04-14
HALLIOAY R 002863 03-14
HALLMARK MR 003317 04-03
HALLSTEAD C 003412 04-04
HALLSTROM C 002906 03-15
HALLSTROM COS 000612 01-09
HALMI KA 003590 04-10
HALPERN FS 002832 03-13, 003684 04-13
HAM MT 003398 04-04
HAM8URG MD 001232 02-03
HAMILL RW 001149 02-03
HAMILTON LW 000997 01-15
HAMLET MA 002257 03-03
HAMMER RH 000799 01-13
HAMMOND MO 000298 01-04
HAMMOND N 003540 04-08
HAMON M 000120 01-03
HAN WW 002258 03-03, 003165 04-03
HANAOKA M 001661 02-07
HANASONO GK 002230 03-03
HANCK C 000613 01-09
HANDLEY SL 003166 04-03
HANDRICK GR 003061 04-01
HANIN I 001936 02-13, 002829 03-13, 003700 04-13
HANLON TE 001856 02-11, 003623 04-11
HANNINEN O 003212 04-03
HANOVER RM 001662 02-07
HANSEN CE 000623 01-09, 001908 02-13
HANSEN L 003537 04-08
HANSEN S 000196 01-03
HANSEN V 003695 04-13
HANSON HM 001459 02-04
HANSON R 003651 04-11
HANSSON L 002978 03-17
HARA A 002357 03-03
HARA T 001047 01-17, 001550 02-04, 002259 03-03
HARADA S 002261 03-03
HARAKAL JJ 003285 04-03
HARANATH PSRK 003399 04-04
HARAOKA Y 000545 01-08, 002820 03-13
HARASIEWICZ A 003327 04-03
HARASZTI J 000543 01-08, 001665 02-07, 001689 02-08
HARASZTI JS 002939 03-15
HAR8ERT CA 003075 04-02
HARBISON RD 001480 02-04, 003502 04-05
HARCLEROOE J 003156 04-03
HARDING TW 001048 01-17
HARDJAWANA 8 000743 01-11
HARMATZ JS 003705 04-13, 003731 04-14
HARMS K 002095 02-16
HARNRYD C 002835 03-13, 003704 04-13
HARPER AM 003217 04-03
HARPER ST 003409 04-04
HARRELL CE 000006 01-01
HARRIS AM 001666 02-07
HARRIS LS 000289 01-04, 001180 02-03, 003077 04-03, 003099 04-03
HARRIS RT 000377 01-04, 000490 01-07
HARRISON DR 003062 04-02
HARSTON CT 001506 02-04
HART AW 000791 01-12
HARTHOORN AM 002994 03-17
HARTING J 001507 02-04
HARTMANN E 000896 01-14, 001624 02-05, 003167 04-03
HARTMANN R 001479 02-04
HARTO NE 002468 03-04
HASCEWICZ-RZECKA M 002645 03-08
HASHIMOTO M 000668 01-09
HASSAR M 003868 04-17
HATA F 002263 03-03
HATA H 000909 01-14, 002676 03-09
HATA S 000897 01-14
HATA T 002460 03-04
HATEGAN O 000076 01-03
HATFIELO F 003869 04-17
HATTON DC 000453 01-04
HATTORI E 002045 02-15
HATTORI T 003168 04-03
HAUPT R 000499 01-07, 001692 02-08
HAUPTMAN M 000362 01-04
HAURI P 001972 02-14
HAUSER O 001169 02-03
HAVARO CWH 002607 03-07, 002663 03-08
HAVOALA HS 003262 04-03
HAVEMANN U 003169 04-03
HAVLICEK V 000408 01-04, 000409 01-04, 003451 04-04
HAWKINS DJ 002046 02-15
HAWKINS M 001245 02-03
HAYASHI M 002365 03-03, 002536 03-04
HAYASHI Y 000668 01-09
HAYASHIDA M 002930 03-15
HAYCOCK JW 003170 04-03, 003400 04-04
HAYES R 003676 04-13
HAYES RL 003401 04-04
HAYES SL 003677 04-13
HAYHURST VF 000450 01-04
HAYMAN M 000624 01-09
HAZZI N 002050 02-15
HEADLEY PM 001617 02-05
HEAL DJ 001226 02-03, 002461 03-04, 003160 04-03
HEALD A 001086 02-01
HEALY MD 001215 02-03
HEARN-STURTEVANT MD 001817 02-11
HEATH RG 000105 01-03
HEBER I 002612 03-08
HEFFNER TG 000373 01-04
HEFTI F 001233 02-03, 001234 02-03, 001277 02-03
HEGMANN JP 003402 04-04
HEIMANN H 001005 01-16, 001653 02-07, 002864 03-14
HEINANEN V 000131 01-03
HEINOEL ND 003055 04-01
HEINEMANN H 001728 02-09
HEINONEN E 000131 01-03
HEINRICH K 001049 01-17, 002995 03-17
HEINZE G 002821 03-13
HEISE GA 002462 03-04
HEISER JF 002677 03-09
HELLER 8 000495 01-07
HELLMAN L 001887 02-13, 003838 04-15
HELLMAN LD 003660 04-13
HELLNER 8 000513 01-07
HELMCHEN H 000663 01-09
HELT8ERG J 000496 01-07, 000614 01-09
HELT8ERG JP 000629 01-09
HELWIG H 000567 01-08
HENDEL J 000825 01-13, 000898 01-14
HENDERSON G 003322 04-03
HENOERSON GI 003499 04-05
HENOERSON M 003770 04-15
HENINGER GR 001508 02-04, 001804 02-10, 003561 04-09
HENKER 8 001866 02-11
HENNIES RS 000307 01-04
HENRIKSSON 8G 001518 02-04
HENRY 8W 003888 04-17
HENRY JL 001235 02-03
HENSCHKE PH 002070 02-15
HENSLEY VR 002857 03-14, 002858 03-14
HENSLEY WJ 002857 03-14, 002858 03-14
HER8ERG LJ 000340 01-04, 000428 01-04, 003142 04-03
HER8ERT J 000265 01-03, 003376 04-04
HER8ST JJ 000166 01-03
HERCEG N 000690 01-10
HERLIHY P 001339 02-03
HERMAN ZS 001509 02-04, 002463 03-04, 002578 03-05
HERMANN HU 001760 02-09
HERMANN L 003555 04-09
HERMES K 001948 02-13
HERNDON JG 001510 02-04
HERRMANN JM 000916 01-14
HERRMANN L 001783 02-09
HERRMANN WM 002760 03-11, 003870 04-17
HERRSCHAFT H 001830 02-11, 002818 03-13

HERSHON HI 002688 03-09
HERTING T 003171 04-03
HERTTING G 000202 01-03
HERVY C 000497 01-07
HERY F 000120 01-03
HERZ A 000222 01-03, 001148 02-03, 001240 02-03, 001357 02-03, 001428 02-03, 001447 02-04, 002491 03-04, 003272 04-03
HERZBERG JL 001961 02-14
HESBACHER P 001050 01-17, 002124 02-17
HESE R 002630 03-08
HESS K 002793 03-11
HESSE C 000009 01-01
HESSION M 000338 01-04
HESTON WDW 000095 01-03
HEWES CR 000006 01-01, 001208 02-03
HEXTER C 003349 04-04
HEYDEN T 003044 03-17
HEYKANTS J 002824 03-13
HICKS LE 001511 02-04
HIEB E 003754 04-14
HIEP A 000899 01-14, 002644 03-08
HIETALA O 001838 02-11
HIGASHI K 002930 03-15
HIGGINS D 000181 01-03
HIGGINS RL 003757 04-14
HIGUCHI Y 002513 03-04, 003416 04-04
HILEY CR 001512 02-04
HILL GE 003820 04-15
HILL LE 002090 02-16
HILL P 003721 04-13
HILL RG 000058 01-03, 001236 02-03
HILL RM 002047 02-15
HILL SY 000169 01-03, 000846 01-13, 001513 02-04, 002585 03-06, 003403 04-04
HILLIER K 001237 02-03
HILLYARD IW 003066 04-02
HIMMELHOCH JM 001936 02-13, 002066 02-15, 002829 03-13, 003700 04-13, 003793 04-15
HIMORI N 000121 01-03
HINDMARCH I 000900 01-14, 001667 02-07
HINE B 000341 01-04, 003172 04-03, 003173 04-03
HINO K 002467 03-04
HINRICHS H 001918 02-13
HINSCHBERGER A 002501 03-04
HINSVARK ON 001009 01-16
HIPPIUS H 002996 03-17
HIRAGA Y 002245 03-03
HIRANO M 001251 02-03
HIROSE T 000901 01-14
HIRSCH MJ 003624 04-11
HIRSCH SR 002631 03-08
HIRST M 001598 02-04
HISHIKAWA Y 002937 03-15
HITCHENS EA 003B71 04-17
HITZEMANN RJ 001238 02-03
HO BT 000134 01-03, 001255 02-03, 001399 02-03, 003034 03-17
HO IK 000122 01-03, 000342 01-04, 001604 02-04, 003126 04-03, 003307 04-03
HOADLEY D 001165 02-03
HOBEL M 002953 03-16
HOBI V 001987 02-14, 003690 04-13
HOCH N 001633 02-05
HOCKEL S 003174 04-03
HODGES MR 003820 04-15
HOEBEL BG 001529 02-04, 003338 04-03
HOEHN MM 000935 01-15, 001831 02-11
HOELL NL 001787 02-10
HOENIG J 003794 04-15
HOFFBRAND BI 002854 03-14
HOFFER B 001398 02-03
HOFFER BJ 001239 02-03, 002369 03-03
HOFFLER D 000253 01-03
HOFFMAN DJ 003662 04-13
HOFFMAN PL 003065 04-02
HOFFMAN WE 000123 01-03, 003404 04-04
HOFFMANN I 003200 04-03
HOFFMANN K 000804 01-13
HOFFMEISTER F 002464 03-04, 003175 04-03
HOGARTY GE 000546 01-08, 001691 02-08, 003539 04-08, 003541 04-08
HOGBEN G 003889 04-17
HOGE G 003614 04-11
HOGG MIJ 002808 03-13
HOGUE-ANGELETTI RA 003052 04-01, 003060 04-01
HOLADAY JW 001554 02-04
HOLAZO A 000079 01-03
HOLBE R 003702 04-13
HOLDEN C 002125 02-17
HOLE G 002705 03-09
HOLE K 001514 02-04
HOLINGER PC 002048 02-15
HOLLAND WH 001002 01-16
HOLLENBERG MD 000071 01-03
HOLLISTER AS 000343 01-04
HOLLISTER LE 000539 01-08, 001051 01-17, 001052 01-17, 001965 02-14, 002029 02-15, 003872 04-17
HOLLNAGEL P 002665 03-09
HOLLT V 001240 02-03
HOLM P 000969 01-15
HOLMAN RB 002112 02-17, 002278 03-03
HOLMGREN B 000344 01-04, 002465 03-04
HOLMGREN S 000691 01-10
HOLROYDE MC 000124 01-03
HOLTZMAN SG 000421 01-04, 002362 03-03, 002466 03-04, 003457 04-04, 003460 04-04
HOLZMAN BS 003257 04-03
HOMMA M 000010 01-01
HONDA F 002355 03-03
HONECKER H 001896 02-13
HONIG W 003268 04-03
HONIG WMM 001562 02-04
HONMA T 001241 02-03
HOPKINS KH 002817 03-13
HOPPIN CR 000068 01-03
HORI M 003073 04-02
HORIBE M 002467 03-04
HORISBERGER B 000676 01-10
HORITA A 001381 02-03, 002523 03-04, 003341 04-04
HORIUCHI S 002565 03-05
HORN AS 000125 01-03, 000615 01-09
HORNG JS 001242 02-03, 00332B 04-03
HORNYKIEWICZ O 001904 02-13, 002260 03-03
HORODNICKI J 000485 01-07, 002620 03-08, 002621 03-08, 002659 03-08, 002745 03-11
HOROWITZ GP 003482 04-04, 003494 04-05
HORRELL RI 000209 01-03
HORROBIN DF 000616 01-09, 003012 03-17
HORROM NJ 003678 04-13
HORSFALL PAL 003832 04-15
HORTON RW 002522 03-04
HORYD W 000498 01-07
HOSHINO K 000851 01-13
HOSKO MJ 000219 01-03
HOSOYA E 000188 01-03, 000396 01-04, 001558 02-04, 002384 03-03, 002575 03-05, 003289 04-03, 003437 04-04, 003472 04-04
HOTICO T 000711 01-10
HOTTA N 002045 02-15
HOTUJAC L 000126 01-03
HOUBEN C 000275 01-04, 000276 01-04
HOUPT KA 001452 02-04
HOUSER VP 000127 01-03, 000345 01-04
HOUSLAY MD 001289 02-03
HOWARD JL 002468 03-04
HOWARD P 002174 02-17
HOWELL HG 001114 02-02
HOWELL R 003338 04-03
HOWES JF 001339 02-03
HOYER S 002051 02-15
HRDINA PD 000455 01-05
HSU LL 001326 02-03
HSU MS 000744 01-11
HUANG JT 003176 04-03
HUBBARD B 003735 04-14, 003736 04-14
HUBBARD RB 003734 04-14
HUBER G 000833 01-13
HUBER J 000656 01-09
HUDDLESTON JA 003092 04-03
HUDECKI MS 002207 03-03
HUDICK JP 003318 04-03
HUDSON LD 000960 01-15
HUE B 001474 02-04
HUEY K 003873 04-17
HUEY L 003733 04-14
HUEY LY 003734 04-14, 003735 04-14, 003736 04-14
HUGELIN A 000875 01-14
HUGHES D 001745 02-09
HUGHES J 002317 03-03, 003322 04-03
HUGHES JA 000461 01-05
HUGHES JR 001B32 02-11
HUGHES KR 000408 01-04, 000409 01-04, 003451 04-04
HUGHES RN 001515 02-04, 001516 02-04, 003405 04-04
HUGHES WC 000671 01-09
HUGONOT R 002091 02-16
HUI K 001243 02-03
HUIDOBRO F 001244 02-03
HUIDOBRO-TORO JP 001244 02-03
HUIZING G 000094 01-03
HUKOVIC S 001594 02-04
HULLIN RP 000617 01-09, 003562 04-09
HULME EC 001147 02-03, 002453 03-04
HULSHOFF A 002828 03-13, 003053 04-01
HULTGREN HN 002840 03-13
HUMPHREYS RB 001245 02-03
HUNG CY 000106 01-03
HUNT D 002023 02-15
HUNT DM 001625 02-05
HUNT GE 000346 01-04
HUNT HT 001868 02-12
HUNT RD 000500 01-07
HUNT WA 000008 01-01, 000370 01-04, 001287 02-03, 003177 04-03
HUNTER WM 002848 03-14
HUPPLER RE 000164 01-03
HUPRIKAR SV 001611 02-04
HUQUE MF 003625 04-11
HURTER BP 003316 04-03
HURWITZ E 002793 03-11
HUSAIN S 003445 04-04
HUSMANN F 002719 03-10
HUSSER J 000009 01-01
HUSZKA L 002798 03-12
HUTCHESON JS 003430 04-04
HUTCHINSON RR 003406 04-04
HUTT C 001585 02-04
HVIDBERG EF 000623 01-09, 000B98 01-14
HYAMS SW 003795 04-15
HYDE J 001484 02-04
HYDE PR 001988 02-14
HYMAN PR 003748 04-14
HYNES MD 001492 02-04, 002469 03-04
HYTTEL J 001246 02-03, 001547 02-04, 003054 04-01, 003178 04-03, 003179 04-03

I

IADEVAIA FMG 002725 03-10
ICHIDA S 002263 03-03
ICHIMURA M 002470 03-04
ICK A 003702 04-13
IDONE F 000673 01-10
IFABUMUYI OI 002761 03-11
IGNATOWICZ R 002762 03-11
IISALO E 000032 01-03
IIZUKA H 002366 03-03
IKEDA M 002261 03-03
IKEDA T 000745 01-11
IKEDA Y 001550 02-04, 002378 03-03
IKEMI Y 000692 01-10
ILHAN M 00006B 01-03
ILSKY E 003526 04-07
IMAI H 000551 01-08
IMAMURA G 002471 03-04
IMBERT D 002888 03-15
IMHOF PR 001228 02-03
INABA DS 001852 02-11
INABA T 0036B0 04-13
INAMI M 001550 02-04
INANAGA K 000902 01-14
INDRANI N 003721 04-13
INGOGLIA NA 001247 02-03
INOUE G 002410 03-03
INOUE T 002921 03-15
IONESCU R 000538 01-08
IPAKTCHI M 003108 04-03
IPAR OJ 000547 01-08
IRACHE E 002145 02-17
IRISAWA N 000347 01-04
IRIZAWA N 002472 03-04
IRWIN P 000819 01-13, 002874 03-14
ISAAC L 003206 04-03
ISAAC W 000356 01-04, 001542 02-04, 003515 04-06
ISAAC WL 003515 04-06
ISAACSON RL 000220 01-03, 003418 04-04
ISERMANN H 000499 01-07, 001692 02-08
ISHIDA R 002538 03-04

ISHIDA Y 001248 02-03
ISHIGURO T 002732 03-10
ISHII A 000687 01-10
ISHII H 002262 03-03
ISHII Y 000010 01-01
ISHIKAWA K 000348 01-04, 001372 02-03, 002473 03-04
ISHIMARU T 000531 01-08
ISHINO H 001661 02-07
ISHISHITA K 002759 03-11, 002763 03-11
ISHITANI R 001249 02-03, 002586 03-06
ISHIZU H 000563 01-08
ISOHANNI M 001818 02-11
ISOZAKI H 000902 01-14
ISRAEL L 002091 02-16
ISSE K 002732 03-10
ISSIDORIDES MR 001946 02-13
ITIL TM 003625 04-11
ITO H 000622 01-09, 000692 01-10
ITO I 002049 02-15
ITO N 002820 03-13
ITO R 000869 01-13
ITO T 001250 02-03
ITO Y 002262 03-03
ITOH M 001251 02-03
ITOH T 002263 03-03, 002567 03-05
IUVONE PM 000407 01-04, 003874 04-17
IVERSEN L 003180 04-03
IVERSEN LL 000171 01-03, 001450 02-04, 002997 03-17
IVERSEN SD 000412 01-04, 001526 02-04, 001528 02-04, 001538 02-04, 002997 03-17, 003475 04-04
IVESON-IVESON J 002126 02-17
IVKOV NN 002321 03-03
IWAHARA S 000347 01-04, 000351 01-04, 001488 02-04, 002472 03-04, 003476 04-04
IWAI H 000668 01-09
IWAKI Y 002318 03-03
IWAMOTO ET 000128 01-03, 000349 01-04, 000350 01-04, 001604 02-04
IWAMOTO T 001249 02-03, 002586 03-06
IWANGOFF P 002308 03-03
IWASAKI M 002474 03-04
IWASAKI T 000351 01-04, 002475 03-04
IWATA H 002264 03-03
IWATSUBO K 002265 03-03
IWAZAKI Y 002476 03-04
IWENS J 003506 04-05
IZAWA M 002057 02-15
IZQUIERDO I 002477 03-04, 002478 03-04, 003181 04-03
IZUMI K 003073 04-02, 003875 04-17
IZUMI T 000746 01-11, 002545 03-04

J

JAASKELAINEN J 000662 01-09
JACKSON D 000129 01-03
JACKSON DM 001194 02-03, 002857 03-14
JACKSON MC 003424 04-04
JACOB J 001201 02-03
JACOB JJ 001252 02-03
JACOBOWITZ DM 000382 01-04, 002266 03-03
JACOBS BL 000016 01-01, 000441 01-04, 001253 02-03, 001298 02-03, 001404 02-03, 001517 02-04, 001570 02-04, 003407 04-04
JACOBS JM 003500 04-05
JACOBS WJ 000913 01-14
JACOBSON AE 003072 04-02, 003876 04-17
JACOBSON H 001086 02-01
JACOBSSON L 001693 02-08, 002632 03-08, 003533 04-08
JACQUES W 003544 04-08
JACQUET YF 002267 03-03
JACQUOT C 001401 02-03
JAFFE CM 003796 04-15
JAFFE RA 000215 01-03
JAGIELLO-WOJTOWICZ E 001272 02-03
JAIN M 001751 02-09
JAKOBOVITS A 003635 04-11
JAKOUBEK B 000130 01-03, 002268 03-03
JALFRE M 001230 02-03, 003071 04-02
JAMES IM 003635 04-11
JAMES NM 001713 02-08, 001780 02-09, 003542 04-08
JANDHYALA BS 003182 04-03, 003183 04-03, 003208 04-03
JANICKI A 002620 03-08
JANKOWSKA H 002633 03-08
JANOWSKY DS 001919 02-13, 001970 02-14, 002768 03-11, 003733 04-14, 003734 04-14, 003735 04-14, 003736 04-14
JANSA S 000513 01-07
JANSSEN F 000953 01-15
JANSSEN PAJ 000299 01-04, 001460 02-04, 001461 02-04, 001462 02-04, 002433 03-04, 003364 04-04
JANSSON S 000131 01-03
JANZIK HH 000360 01-04, 000775 01-11
JAQUES R 002269 03-03
JAQUET G 002752 03-11
JARBE TUC 001518 02-04, 003408 04-04
JARDILLIER JC 001183 02-03
JAREMKO A 002762 03-11
JAROSZYNSKI J 001053 01-17, 001694 02-08
JARRIGE A 000943 01-15
JARVIK LF 001752 02-09, 003216 04-03, 003374 04-04
JARVIK ME 000424 01-04, 000951 01-15, 001451 02-04, 002540 03-04
JARVISALO JO 003080 04-03
JASKARI MO 000618 01-09
JATON AL 002192 03-02, 003314 04-03
JAWAD K 002606 03-07
JAYARATNA PS 002127 02-17
JEFFERSON JW 003797 04-15, 003864 04-17
JEFFREY PL 001254 02-03
JEFFRIES JJ 002761 03-11
JEHLE J 002367 03-03
JELLINEK T 003798 04-15
JENDEN D 003670 04-13
JENDEN DJ 000506 01-07
JENKINS LJ 000034 01-03
JENNER P 000094 01-03, 000195 01-03, 000314 01-04, 001186 02-03, 002234 03-03, 002439 03-04
JENNER PG 001519 02-04
JENNETT B 002606 03-07
JENSEN J 000189 01-03, 002383 03-03
JEPPSSON R 000132 01-03
JERUSSI TP 000352 01-04
JIANG WD 003115 04-03
JICK H 003799 04-15
JIMERSON D 002812 03-13
JIMERSON DC 001696 02-08, 003041 03-17
JINKS M 001971 02-14
JOBE PC 001695 02-08
JOBSIS FF 003294 04-03
JOFFE JM 000133 01-03
JOGLEKAR SN 003149 04-03
JOH TH 000211 01-03
JOHANNESEN M 001747 02-09
JOHANSON CE 000353 01-04
JOHANSSON JO 001518 02-04, 003408 04-04
JOHANSSON R 000054 01-03, 000055 01-03, 000056 01-03, 001741 02-09
JOHN V 003807 04-15, 003866 04-17
JOHNS WL 001964 02-14
JOHNSEN K 000118 01-03
JOHNSON A 001965 02-14, 002998 03-17
JOHNSON BCA 002764 03-11
JOHNSON CA 000424 01-04, 001451 02-04, 002540 03-04
JOHNSON DAW 002999 03-17
JOHNSON EA 001177 02-03
JOHNSON FN 001520 02-04, 002128 02-17, 003877 04-17
JOHNSON G 002720 03-10
JOHNSON GE 002794 03-11
JOHNSON GFS 000954 01-15, 002129 02-17
JOHNSON GW 000808 01-13
JOHNSON HL 000013 01-01
JOHNSON HR 000283 01-04
JOHNSON KM 000134 01-03, 001255 02-03
JOHNSON LC 001941 02-13
JOHNSON NM 002907 03-15
JOHNSON RA 000955 01-15
JOHNSON RL 001586 02-04
JOHNSON TC 001360 02-03
JOHNSSON G 000028 01-03, 000826 01-13, 000827 01-13, 000828 01-13, 000859 01-13, 001011 01-17, 002622 03-08
JOHNSTON GAR 002228 03-03
JOHNSTON GD 002591 03-07
JOHNSTON JA 000206 01-03
JOHNSTONE EC 001685 02-08, 001827 02-11, 002624 03-08, 002688 03-09
JONES B 002434 03-04
JONES BC 001521 02-04
JONES BE 001342 02-03, 002524 03-04, 003409 04-04
JONES DP 001920 02-13
JONES EAD 000354 01-04
JONES FD 001689 02-08
JONES GT 002195 03-02
JONES LV 003090 04-03
JONES R 000792 01-12
JONES RB 000135 01-03, 000136 01-03, 003679 04-13, 003807 04-15, 003866 04-17
JONES RT 000873 01-14, 001873 02-12, 003767 04-15
JONES TA 001390 02-03
JONNARD D 000758 01-11
JONSSON G 001514 02-04
JONSSON J 003184 04-03
JONSSON T 000804 01-13
JONSSON U 001030 01-17
JORDAN WS 001841 02-11
JORDO L 000859 01-13
JORGENSEN A 000829 01-13
JORGENSEN KD 003185 04-03
JORGENSEN OS 001205 02-03
JORI A 001269 02-03, 003186 04-03
JOSEPH A 000656 01-09
JOSEPH JA 000355 01-04
JOSEPH MH 001256 02-03, 001827 02-11
JOSS E 001054 01-17
JOUBREL J 002740 03-11
JOUBREL M 000650 01-09
JOUGLARD J 002924 03-15
JOURDAN MG 001599 02-04
JOVANOVIC UJ 000830 01-13, 001794 02-10, 003626 04-11
JOYCE TH 003675 04-13
JUBIZ W 000166 01-03
JUDD LL 002044 02-15, 003733 04-14, 003734 04-14, 003735 04-14, 003736 04-14
JUN HW 000137 01-03
JUNGERS P 001001 01-15
JUNGI WF 003825 04-15
JUNGINGER W 002214 03-03
JUORIO AV 000138 01-03, 003187 04-03
JURNA I 001274 02-03
JUS A 002050 02-15, 002092 02-16
JUS K 002092 02-16, 002658 03-08
JUUL P 001205 02-03

K

KAAKKOLA S 003188 04-03
KAARIAINEN I 001257 02-03, 002270 03-03, 003189 04-03
KABES J 002678 03-09
KADAR D 003680 04-13
KADDEN RM 003270 04-03
KADLECOVA O 000165 01-03
KAESERMANN HP 002479 03-04
KAFI S 001522 02-04
KAFOE WF 000154 01-03, 002271 03-03
KAHLING J 001439 02-04
KAHN A 000978 01-15
KAI Y 002634 03-08
KAISER H 000747 01-11
KAJI S 002908 03-15
KAJIWARA K 002930 03-15
KAJIWARA Y 002510 03-04
KALACHEV BP 001795 02-10
KALANDARISHVILI AS 001836 02-11
KALANT H 000322 01-04, 001537 02-04
KALES A 000748 01-11, 000877 01-14, 001972 02-14, 003737 04-14
KALES JD 000748 01-11, 003737 04-14
KALLMAN MD 000356 01-04
KALLMAN MJD 002272 03-03
KALOW W 003680 04-13
KALYANARAMAN K 003804 04-15
KAMEI C 002515 03-04
KAMEYAMA T 001523 02-04, 002391 03-03
KAMINO T 002918 03-15
KAMIOKA T 003410 04-04
KAMOUN A 000484 01-07, 000750 01-11
KAMP R 001182 02-03
KAN J 003190 04-03
KANABUS P 000831 01-13
KANAPA DJ 002553 03-04
KANAYAN AS 002568 03-05

KANDEL DA 000353 01-04
KANDEL ER 001155 02-03
KANE FJ 002025 02-15
KANE J 003547 04-08
KANE M 001808 02-10
KANEKO M 000851 01-13
KANEKO T 002565 03-05
KANEKO Z 002937 03-15
KANEMORI K 003000 03-17
KANEYA A 002909 03-15
KANEYA S 002909 03-15
KANGAS L 000832 01-13, 000864 01-13
KANNER MI 002445 03-04
KANOWSKI S 001824 02-11, 002747 03-11
KANTO J 000517 01-07, 000832 01-13, 000862 01-13, 000863 01-13
KANTOR S 001749 02-09
KANTOR SJ 001935 02-13, 003560 04-09, 003659 04-13, 003674 04-13
KAO JJ 002840 03-13
KAPLAN JA 002629 03-08
KAPLAN JN 001167 02-03
KAPLAN SA 000079 01-03
KAPPUS H 001258 02-03
KAPTURKIEWICZ Z 001544 02-04
KARACAN I 001973 02-14, 001997 02-14, 002176 02-17, 003563 04-09, 003858 04-17
KARASAWA T 000139 01-03, 002244 03-03, 002273 03-03
KARASSIK S 001938 02-13
KARASU TB 002741 03-11, 002765 03-11
KARBOWSKI MJ 002274 03-03
KARCH FE 003800 04-15
KARIYA T 000619 01-09
KARK RAP 003627 04-11
KARLAVAGE J 003782 04-15
KARLER R 001379 02-03, 003306 04-03
KARLINER J 000983 01-15
KARLINSKI A 000159 01-03
KARLSEN RL 001626 02-05
KARMALI RA 000616 01-09
KARNIOL IG 001974 02-14
KAROBATH M 001259 02-03
KAROUM F 001696 02-08
KARP EG 001856 02-11
KARPIAK SE 001260 02-03
KARPLUS M 002816 03-13
KARPOV VN 001524 02-04, 002204 03-03
KARRASS W 000725 01-11
KARSTEN OJ 001668 02-07
KARTZINEL R 000500 01-07, 000501 01-07, 002592 03-07, 002600 03-07, 003661 04-13
KASAHARA Y 002687 03-09
KASE T 002676 03-09
KASIMOV RY 002394 03-03
KASSIR S 000634 01-09
KASTIN AJ 000203 01-03, 000402 01-04, 002480 03-04, 003319 04-03, 003615 04-11
KATAGIRI M 002275 03-03
KATES W 002862 03-14
KATO G 000713 01-10, 003110 04-03
KATO H 000749 01-11, 002049 02-15
KATO I 000749 01-11
KATO K 003073 04-02
KATO N 000551 01-08
KATO R 003878 04-17
KATZ J 002481 03-04, 003660 04-13
KATZ JB 003191 04-03
KATZ RJ 000357 01-04, 001525 02-04, 002276 03-03, 003411 04-04
KATZ S 002861 03-14, 002862 03-14
KAUFFMANN H 003192 04-03
KAUFMAN A 002899 03-15
KAUL CL 003122 04-03
KAVALLINIS GP 003681 04-13
KAWAAI Y 000552 01-08
KAWAMURA K 000753 01-11, 002277 03-03, 002918 03-15
KAWAMURA T 000563 01-08
KAWASAKI K 002200 03-03
KAWASAKI M 002057 02-15
KAWASAKI T 002302 03-03
KAWASAKI Y 002569 03-05
KAWASHIMA S 002537 03-04
KAY SR 001717 02-08, 002654 03-08
KAZARYAN AS 002568 03-05
KEANE BP 001997 02-14
KEANE PE 000002 01-01
KEELER MH 003578 04-09
KEHR W 001261 02-03, 002373 03-03, 003193 04-03
KEIM KL 003194 04-03
KELEHER OL 003614 04-11
KELLAR KJ 002278 03-03
KELLEHER RT 002482 03-04
KELLER HH 000083 01-03, 000358 01-04
KELLER WJ 002279 03-03
KELLER-TESCHKE M 003167 04-03
KELLERMANN G 003682 04-13
KELLEY K 003469 04-04
KELLNER R 001697 02-08, 001778 02-09, 003591 04-10, 003592 04-10, 003840 04-16
KELLY JG 000808 01-13, 002591 03-07
KELLY PH 000264 01-03, 001226 02-03, 001526 02-04, 002483 03-04
KELLY PT 000359 01-04
KELSEY JE 001527 02-04
KEMNITZ J 001530 02-04
KEMP K 003879 04-17
KEMPF E 002280 03-03, 002555 03-04
KEMPLE S 003617 04-11
KENDALL MJ 000824 01-13
KENNEDY PM 002956 03-16
KENNEWELL PD 003062 04-02
KEPLINGER ML 001644 02-05
KERNS RD 003345 04-04
KEROUB C 003795 04-15
KERR A 001232 02-03
KERR DB 000140 01-03
KERR WC 002679 03-09
KESSON CM 001833 02-11
KESTENBAUM RS 000512 01-07, 001853 02-11, 001950 02-13, 003745 04-14
KETTNER B 001693 02-08
KETY S 000525 01-08, 000526 01-08, 000528 01-08, 000535 01-08
KETY SS 002130 02-17, 003543 04-08
KEUL J 000833 01-13
KEUP W 002766 03-11
KEY BJ 003195 04-03
KEYES DM 000360 01-04
KEYSERLINGK HV 002131 02-17
KHALAJ A 002184 03-01
KHAN AH 001656 02-07
KHANNA S 001604 02-04
KHAZAN N 000390 01-04, 002559 03-04
KHORRAMZADEH E 000794 01-12
KIBBE AH 002556 03-04
KICZAK J 000548 01-08
KIEJNA A 002621 03-08
KIELHOLZ P 000620 01-09, 002680 03-09, 003690 04-13
KIELY WF 000956 01-15
KIESSLING M 001175 02-03
KIGER JL 002823 03-13
KIHAR M 001248 02-03
KILBEY MM 003196 04-03
KILLAM KF 001218 02-03
KILOH LG 001698 02-08
KILTIE H 003527 04-08
KIM H 001262 02-03
KIM K 000621 01-09, 003161 04-03
KIM KH 000141 01-03
KIMISHIMA K 002410 03-03
KIMURA M 000622 01-09, 000692 01-10
KIMURA N 000697 01-10
KINAWI A 001627 02-05
KINDERMANN W 000833 01-13
KING MG 002480 03-04
KINGSTONE E 003544 04-08
KINSBOURNE M 000922 01-14
KIRALY I 002485 03-04
KIRBY MJ 003520 04-07
KIRIKAE T 003001 03-17
KIRK L 000496 01-07, 000614 01-09, 000637 01-09
KIRKPATRICK WE 003066 04-02
KIRSTEIN L 003561 04-09
KISARA K 002281 03-03, 002539 03-04
KISELEVA IP 002313 03-03
KISHIKAWA H 000767 01-11
KISHIMOTO A 000696 01-10, 001708 02-08
KITA T 002460 03-04
KITAGAWA S 000392 01-04, 002386 03-03, 002387 03-03
KITAMIKADO T 003073 04-02
KITANO H 002776 03-11, 003452 04-04
KITAY D 000257 01-03
KITTNER S 000834 01-13
KLAIBER EL 003801 04-15
KLAWANS HL 000082 01-03, 000448 01-04, 002048 02-15, 002553 03-04, 002910 03-15, 003835 04-15
KLEBER HD 000982 01-15
KLEE WA 001263 02-03, 002819 03-13, 003072 04-02, 003155 04-03, 003876 04-17
KLEIN DF 000549 01-08, 000740 01-11, 000988 01-15, 002157 02-17, 002861 03-14, 002862 03-14, 002927 03-15, 003547 04-08, 003593 04-10, 003818 04-15
KLEIN SB 003412 04-04, 003503 04-05
KLEINROK Z 002340 03-03, 002484 03-04, 002561 03-04, 002573 03-05
KLEMM WR 000142 01-03, 001206 02-03, 001264 02-03, 003197 04-03
KLERMAN G 003545 04-08
KLERMAN GL 000550 01-08, 000646 01-09
KLETT CJ 000772 01-11
KLIMEK V 001286 02-03, 002503 03-04
KLINE NS 001865 02-11, 001876 02-12, 002876 03-14, 002897 03-15, 002935 03-15
KLING A 002161 02-17
KLING MA 000218 01-03
KLINGER W 001416 02-03
KLINGMAN JD 001318 02-03
KLOEPFER HG 001222 02-03
KLOTZ U 001921 02-13, 003683 04-13
KLUWE S 001482 02-04, 003140 04-03
KLYGUL TA 002282 03-03
KNAPP JE 001084 02-01
KNAPP RB 000878 01-14
KNAPP S 000143 01-03, 000632 01-09
KNIGHT J 002179 02-17
KNIGHT M 003787 04-15
KNIGHT RG 000582 01-09
KNOBLOCH LC 000426 01-04, 003285 04-03
KNOLL J 003860 04-17
KNOPP W 002684 03-09
KNOR K 000915 01-14
KNOWLES CO 000048 01-03
KNOWLES JA 001914 02-13, 003675 04-13
KOBAYASHI K 001006 01-16, 002569 03-05
KOBAYASHI M 002252 03-03, 002277 03-03, 002474 03-04, 002530 03-04
KOBAYASHI RM 002911 03-15
KOBAYASHI S 001248 02-03
KOBAYASHI T 001117 02-02, 001699 02-08
KOBAYASHI Y 000745 01-11, 000851 01-13
KOCH-WESER J 000976 01-15, 001862 02-11, 002599 03-07, 003705 04-13, 003731 04-14
KOCHER R 001834 02-11
KOCHERGA VY 002283 03-03
KOCSIS JH 001999 02-14
KODAMA H 000531 01-08, 000563 01-08, 000563 01-08
KODAMA U 000670 01-09
KODLUBOY DW 000903 01-14
KOE BK 001265 02-03
KOELLA WP 001975 02-14, 001976 02-14
KOGA I 001709 02-08, 002921 03-15
KOGA M 000102 01-03
KOGA Y 000471 01-06
KOHL RL 003332 04-03
KOHL U 002966 03-17
KOHLER C 000750 01-11
KOHLER F 001620 02-05
KOHLER H 000253 01-03
KOHN BA 003067 04-02
KOHN H 003067 04-02
KOHNEN R 002093 02-16
KOHNO Y 000102 01-03, 002284 03-03, 002510 03-04
KOIDE T 001319 02-03
KOIKE K 002707 03-09
KOIZUMI S 000851 01-13
KOJECKA I 002601 03-07
KOJIMA K 002262 03-03
KOKKINIDIS L 000361 01-04, 001435 02-04, 003413 04-04
KOLASA M 000751 01-11, 000802 01-13
KOLASIEWICZ W 003485 04-04
KOLDAYEV VM 002285 03-03
KOLENDA K 000118 01-03
KOLLER WC 001266 02-03
KOMADA J 000631 01-09
KOMATSU J 000644 01-09
KOMENDANTOVA MV 002286 03-03

KOMISARUK BR 002S2S 03-04
KOMLOS M 003267 04-03
KON Y 002356 03-03
KONDO H 000551 01-08
KONDO Y 002384 03-03
KONIG L 002681 03-09
KONISHI T 000753 01-11
KOO8 G 001528 02-04
KOOLHAAS JM 001296 02-03
KOPANDA RT 000911 01-14, 001333 02-03
KOPELL BS 002001 02-14, 003894 04-17
KOPELOFF LM 000031 01-03
KOPIN IJ 001402 02-03, 002115 02-17, 002254 03-03
KOPPENHAVER RE 000034 01-03
KORANYI EK 002865 03-14, 003628 04-11
KORANYI L 002485 03-04
KORCZYN AD 002827 03-13, 002912 03-15, 003414 04-04
KORDON C 003133 04-03
KORENYI C 001826 02-11
KORF J 0002S6 01-03, 001417 02-03, 001418 02-03, 001419 02-03, 001420 02-03, 001722 02-08, 001922 02-13, 002841 03-13, 003043 03-17, 003323 04-03
KORN8LITH CL 001529 02-04
KORNETSKY C 001490 02-04, 002132 02-17, 002635 03-08, 003382 04-04
KORO8OV NV 001407 02-03
KOROLENKO TA 002287 03-03
KORSGAARD S 001923 02-13
KORTTILA K 000835 01-13, 000836 01-13, 000840 01-13
KOSCIELAK M 000174 01-03
KOSERSKY DS 002345 03-03
KOSHINO Y 000552 01-08, 001706 02-08
KOSS MC 000144 01-03
KOSTERLITZ HW 002317 03-03, 003322 04-03
KOSTOWSKI W 000024 01-02, 000362 01-04, 002486 03-04
KOSTRZEWA RM 000376 01-04
KOTAS KM 000877 01-14
KOTIN J 001787 02-10
KOUKKOU M 001869 02-12, 001924 02-13
KOUROUNAKIS P 003105 04-03
KOUYOUMDJIAN J 001137 02-03
KOVACIC 8 000363 01-04
KOVACS GL 000364 01-04, 002487 03-04, 003415 04-04
KOVALEV IY 001628 02-05
KOWALCZYK A 002645 03-08
KOWALCZYK L 000243 01-03
KOYAMA T 002820 03-13
KOYUNCUOGLU H 003198 04-03
KOZ8UR X 001396 02-03
KOZLOVSKAYA MM 002548 03-04
KOZLOWSKI LT 003707 04-13
KRAEMER GW 000145 01-03, 001530 02-04
KRAGH-SORENSEN P 000623 01-09
KRAL VA 001753 02-09
KRASNEGOR N 001554 02-04
KRASNEGOR NA 000890 01-14, 003406 04-04
KRASNER N 000752 01-11
KRATSKIN IL 002394 03-03
KRAUS J 000011 01-01
KRAUS M 002268 03-03, 003135 04-03
KRETSCHMAR C 001835 02-11
KRETSCHMAR JH 001835 02-11
KRETZSCHMAR R 001110 02-02
KRIEGLSTEIN J 000253 01-03, 001144 02-03, 002402 03-03, 003274 04-03
KRIER N 000916 01-14
KRIMMER EC 001531 02-04, 002964 03-17, 003002 03-17
KRISTENSEN V 003738 04-14
KRISTJANSEN P 003537 04-08
KRIVOY WA 003199 04-03
KRIWANEK W 000202 01-03
KROEGER DC 003199 04-03
KROL K 002664 03-08
KRONENWERTH D 000786 01-11
KRSIAK M 000404 01-04, 001532 02-04
KRUGER G 002051 02-15
KRUGER H 002153 02-17
KRUK ZL 001267 02-03
KRULIK R 001200 02-03
KRULL F 000916 01-14
KRUPENINA LB 002395 03-03
KRUSE H 000146 01-03, 003200 04-03
KRYNICKI V 003637 04-11
KRYSTOF J 002664 03-08, 003036 03-17
KUBO S 000531 01-08, 000563 01-08, 000668 01-09
KUCHEROVA NF 002187 03-02
KUCZENSKI R 000842 01-13, 003880 04-17
KUDA K 002921 03-15
KUDO Y 000502 01-07, 000753 01-11
KUDRIN VS 002327 03-03
KUEHNLE J 0028S0 03-14
KUEHNLE JC 000S29 01-08, 000907 01-14, 001726 02-09, 003746 04-14
KUFFERLE B 002671 03-09
KUFNER M 002532 03-04, 003507 04-05
KUHAR MJ 000038 01-03, 003088 04-03, 003098 04-03
KUHL V 001861 02-11
KUHN CM 000343 01-04
KUHN DM 003003 03-17
KUHN FJ 001111 02-02
KUHN R 001700 02-08
KULIG BM 001533 02-04
KULIK J 000943 01-15
KUMAKURA K 001383 02-03, 002372 03-03
KUMAR A 001534 02-04
KUMAR N 000541 01-08
KUMBARACI T 000601 01-09, 000603 01-09
KUN I 003201 04-03
KUNIN RA 000957 01-15, 000958 01-15
KUNKEL H 001918 02-13, 001925 02-13
KUNZ F 001671 02-07
KUNZ H 003825 04-15
KUNZE U 002052 02-15
KUPFER DJ 001055 01-17
KUPIETZ SS 002767 03-11
KURAN W 000498 01-07, 000734 01-11, 000754 01-11, 001056 01-17
KURIBARA H 002488 03-04, 002489 03-04, 002490 03-04, 003416 04-04
KURIHARA E 003336 04-03
KURIYAMA K 000180 01-03, 002288 03-03, 002319 03-03, 002411 03-03, 003336 04-03
KURLAND AA 001877 02-12, 003623 04-11
KURLAND ML 000624 01-09, 002721 03-10
KUROCHKIN IG 002289 03-03
KURODA S 000147 01-03
KUROE K 002930 03-15
KUROMI H 001268 02-03
KURSAWE HK 002681 03-09
KURTSIN IT 002290 03-03
KURTZ P 003417 04-04
KURTZ PJ 000365 01-04
KURUVILLA K 003721 04-13
KUSCHINSKY K 000057 01-03, 000148 01-03, 001210 02-03, 001363 02-03, 002291 03-03, 002359 03-03
KUSHIKU K 002245 03-03
KUSUBOV N 002352 03-03
KUTSCHER CL 003202 04-03
KUYPS JJMD 001460 02-04, 001461 02-04
KUZNETSOVA EK 002290 03-03
KVANTALIANI EK 000005 01-01
KWAK DI 000625 01-09
KYRIAKOPOULOS AA 001914 02-13, 003675 04-13

L

LABET R 000484 01-07
LABO G 000805 01-13
LABRID C 002183 03-01
LABRIE R 001682 02-08
LACH JL 003688 04-13
LACOURSIERE RB 002133 02-17
LADER M 000837 01-13, 001974 02-14, 002006 02-14, 002722 03-10, 003693 04-13
LADER MH 000491 01-07, 000671 01-09, 000959 01-15, 001926 02-13
LADEWIG D 003690 04-13
LADINSKY H 000149 01-03, 001170 02-03, 001269 02-03
LAFONT A 002637 03-08
LAFRANCE R 003629 04-11
LAFRENIERE GF 001560 02-04
LAGERGREN K 000885 01-14
LAI JCK 003234 04-03
LAIRD H 002434 03-04
LAIRD HE 001521 02-04
LAITAR RA 001099 02-01
LAKE CR 000818 01-13, 003666 04-13
LAKSHMINARAYAN S 000960 01-15
LAL H 000091 01-03, 000332 01-04, 001492 02-04, 001493 02-04, 001535 02-04, 001S57 02-04, 002249 03-03, 002292 03-03, 002469 03-04, 002499 03-04, 003004 03-17, 003005 03-17, 003244 04-03
LAL S 001395 02-03, 003467 04-04, 003S29 04-08
LAMANNA JC 003203 04-03, 003294 04-03
LAMBERT GA 003501 04-05
LAMBERT J 002183 03-01, 002689 03-09
LAMBERT P 000503 01-07, 000961 01-15, 002134 02-17
LAMBERT PA 001754 02-09
LAMBOEUF Y 001270 02-03
LAMONTAGNE Y 000693 01-10, 003594 04-10
LAMPEN E 000927 01-14
LAMPEN EL 003649 04-11
LAMPUGNANI E 000703 01-10
LANDBLOOM RP 001791 02-10
LANDO LI 002395 03-03
LANG WJ 003501 04-05
LANGE E 002681 03-09
LANGER G 002821 03-13, 003684 04-13, 003881 04-17
LANIER LP 003418 04-04
LANOIR J 003419 04-04
LANZONI L 000735 01-11
LAPIERRE YD 002636 03-08, 003248 04-03, 003449 04-04
LAPIN I 001272 02-03
LAPIN IP 001271 02-03, 002293 03-03, 002313 03-03, 002331 03-03, 002518 03-04
LAPLANE D 001025 01-17
LARA PP 001840 02-11
LARDENNOIS D 003419 04-04
LARGEY B 000977 01-15
LARINI L 001004 01-16
LARSEN A 000782 01-11
LARSEN F 003445 04-04
LARSEN JK 000614 01-09, 000629 01-09
LARSEN N 001908 02-13
LARSON AA 003204 04-03
LARSON C 003607 04-10
LARSONS PF 003615 04-11
LARSSON K 001444 02-04
LARSSON M 003671 04-13
LARSSON R 003512 04-05
LASAGNA L 000861 01-13, 001669 02-07, 002135 02-17, 003800 04-15, 003868 04-17
LASCHKA E 001447 02-04, 002491 03-04, 003272 04-03
LASETER JL 001564 02-04
LASKI EM 002009 02-15
LASSEN JB 000025 01-02, 001273 02-03, 003420 04-04
LASZLO I 001187 02-03
LATHAM AN 002822 03-13
LATHAM CJ 000291 01-04
LATIES VG 002881 03-14
LATOUR R 003525 04-07
LAU A 000744 01-11
LAU C 000150 01-03, 001377 02-03, 001378 02-03, 002370 03-03, 003299 04-03
LAUDENSLAGER ML 000026 01-02, 002294 03-03
LAURENCE HL 003339 04-03
LAURESSERGUES H 000151 01-03
LAURITSEN B 001929 02-13
LAUZEL J 001710 02-08
LAVAGNA J 002637 03-08
LAVAL J 003139 04-03
LAVALLE Y 000693 01-10
LAVALLEE J 002636 03-08
LAVALLEE Y 003594 04-10
LAVENE D 002823 03-13
LAVERTY R 002519 03-04
LAVIE D 000482 01-07
LAVRETSKAYA EF 002295 03-03
LAWN D 001007 01-16
LAWRENCE BE 003603 04-10
LAWSON AH 003882 04-17
LAWSON DH 001833 02-11
LAWSON DM 002004 02-14
LAWSON JS 002105 02-17
LAWSON T 000720 01-10
LAXDAL OE 002970 03-17
LAZZARETTO R 001677 02-07
LE BARS D 001274 02-03, 001275 02-03
LE BLANC AE 003360 04-04

LE FUR G 002392 03-03
LE GALL A 002136 02-17
LE PETIT GF 000012 01-01
LE PICHON M 003071 04-02
LEACH LR 001536 02-04
LEACH MJ 000285 01-04
LEAF RC 000331 01-04, 002449 03-04
LEANDER JD 000152 01-03, 000366 01-04, 001545 02-04, 002492 03-04
LEARD B 003503 04-05
LEBEDINSKIY MS 001836 02-11
LEBLANC A 000004 01-01
LEBLANC AE 000322 01-04, 001537 02-04
LEBRECHT U 002303 03-03
LECHAT P 002053 02-15
LECOMTE G 002638 03-08
LEDNICER D 003068 04-02
LEDRU J 002652 03-08
LEE BY 000625 01-09
LEE C 000153 01-03
LEE CK 000119 01-03
LEE J 000302 01-04
LEE JH 000985 01-15, 001778 02-09
LEE NM 002324 03-03
LEE R 003883 04-17
LEE RH 001070 01-17
LEE SC 000744 01-11
LEE SY 000625 01-09
LEE T 000068 01-03, 000474 01-06
LEE Y 002922 03-15
LEEDS AA 002137 02-17, 003006 03-17
LEEMAN M 002720 03-10
LEFF JP 002639 03-08
LEFKOWITZ SS 000106 01-03
LEFROY RB 003007 03-17
LEGER C 001183 02-03
LEGER RM 003694 04-13
LEGG JF 000626 01-09
LEGHEAND J 003848 04-17
LEGNANI G 001680 02-08
LEHMANN D 001869 02-12, 001924 02-13
LEHMANN E 001977 02-14
LEHMANN H 000462 01-05, 003008 03-17
LEHMANN HE 001057 01-17, 002770 03-11, 003580 04-10
LEHNE RA 002296 03-03
LEIBY RW 003055 04-01
LEICHNER PP 002768 03-11
LEIFER MW 001276 02-03
LEITH N 003880 04-17
LEJEUNE B 003323 04-03
LEMAIRE P 001103 02-02
LEMBECK F 003205 04-03
LEMBERGER L 000854 01-13, 000889 01-14, 001902 02-13, 002032 02-15, 002838 03-13
LEMERCIER C 001013 01-17
LEMMENS HHJ 002955 03-16
LENOX JR 001963 02-14
LENZ G 002671 03-09
LENZER II 000444 01-04
LEONARD BE 000154 01-03, 002188 03-02, 002271 03-03, 003447 04-04
LEONHARDT H 003702 04-13
LEONHARDT K 000838 01-13
LEPOETRE M 001013 01-17
LEPORE F 000435 01-04
LEPORE R 000604 01-09
LEPP H 000705 01-10
LERER MP 003630 04-11
LERER RJ 003630 04-11
LESCOVELLI M 000881 01-14, 001670 02-07
LESHEM MB 000291 01-04
LESIEUR D 001103 02-02
LESLIE J 003047 04-01
LESPAGNOL C 001103 02-02
LESTER BR 002333 03-03
LETERRIER F 002297 03-03
LEVANDER S 000885 01-14
LEVANDER SE 001845 02-11
LEVEN M 003200 04-03
LEVENSON AJ 001701 02-08
LEVERGER J 002081 02-15
LEVI G 003247 04-03
LEVIN E 001785 02-10
LEVIN VA 002792 03-11
LEVINE A 002142 02-17
LEVINE C 003884 04-17
LEVINE J 000776 01-11, 001058 01-17, 002138 02-17, 002139 02-17
LEVINE RM 003245 04-03, 003489 04-04
LEVINSON AY 002640 03-08
LEVITAN DE 003081 04-03
LEVITON D 000463 01-05
LEVITT RA 002140 02-17
LEVY DL 001702 02-08
LEVY RH 001648 02-06
LEVY WB 003170 04-03
LEW JY 000155 01-03
LEWANDOWSKI G 002141 02-17
LEWI PJ 003009 03-17, 003010 03-17
LEWICKA-WYSOCKA H 002601 03-07
LEWINSKY L 001885 02-13
LEWINSKY M 001884 02-13
LEWIS D 003206 04-03
LEWIS DC 003751 04-14
LEWIS EG 000796 01-12
LEWIS JK 000145 01-03
LEWIS R 002776 03-11
LEWIS SA 000839 01-13
LEYBURN P 002646 03-08
LEYLAND M 001538 02-04
LEYSEN JEMF 002433 03-04
LHAMON WT 002901 03-15
LHERMITTE F 003631 04-11
LI CH 002298 03-03
LIBINZON RY 002295 03-03
LICATA SM 002066 02-15
LICHT B 000786 01-11
LICHTENSTEIGER W 001233 02-03, 001234 02-03, 001277 02-03
LIEBER CS 003321 04-03
LIEBOWITZ JH 001703 02-08
LIEBSCHUTZ J 003207 04-03
LIEBSON I 001046 01-17
LIEFKE T 002681 03-09
LIEN EL 001278 02-03
LIENERT GA 002093 02-16
LIENHART R 001234 02-03, 001277 02-03
LILJA GP 003759 04-15
LILJEQUIST S 001478 02-04, 002442 03-04
LIN JT 000962 01-15
LIN M 003343 04-04
LIN R 000014 01-01
LIND K 001633 02-05
LINDBERG D 001741 02-09
LINDENBAUM A 001181 02-03
LINDHOLM H 000553 01-08
LINDNER LA 002737 03-11
LINDQUIST TD 001247 02-03
LINDQVIST M 001174 02-03
LINDSAY S 003769 04-15
LINDSEY CJ 001300 02-03
LINDSTROM LH 003546 04-08
LINET OI 000878 01-14
LING N 003397 04-04
LINGETTI M 001837 02-11
LINGJAERDE O 000963 01-15
LINGSCH C 000964 01-15
LINK J 000586 01-09, 001745 02-09
LINKE H 002602 03-07
LINNOILA M 000458 01-05, 000755 01-11, 000835 01-13, 000840 01-13, 001838 02-11
LINSEMAN MA 000116 01-03, 001539 02-04
LINZMAYER L 002873 03-14
LION JR 003879 04-17
LIPINSKI JF 002884 03-15
LIPMAN RS 001755 02-09, 002982 03-17
LIPPER S 000904 01-14, 002054 02-15
LIPPMANN S 003802 04-15
LIPPMANN W 000205 01-03, 001279 02-03, 001335 02-03, 003243 04-03
LIPSITT LP 000834 01-13
LIPTON JM 001245 02-03
LIPTON M 000525 01-08, 000526 01-08, 000527 01-08, 000528 01-08, 000535 01-08
LIPTON MA 003885 04-17
LIS M 003875 04-17
LISCIANI R 001374 02-03
LISSAK K 000364 01-04, 002485 03-04, 003415 04-04
LITTLETON JM 003423 04-04
LIU S 001280 02-03
LIUZZI A 002943 03-15
LIVERMORE JD 003694 04-13
LIVINGSTON A 000367 01-04
LJUNGBERG S 000132 01-03
LJUNGBERG T 003087 04-03
LLEWELLYN ME 001454 02-04
LLOYD DSL 001920 02-13
LO CASCIO A 000604 01-09
LOCKARD JS 001648 02-06
LODGE D 002228 03-03
LOEW DM 001540 02-04, 001978 02-14, 002192 03-02, 003314 04-03
LOFSTRANDH S 000168 01-03
LOGAN JG 001281 02-03
LOH H 000447 01-04
LOH HH 000122 01-03, 000128 01-03, 000349 01-04, 000350 01-04, 000933 01-15, 001238 02-03, 001600 02-04, 001604 02-04, 002298 03-03, 002324 03-03, 003715 04-13
LOHAUS R 000473 01-06, 001645 02-06
LOKHANDWALA MF 003208 04-03
LOLORDO VM 000913 01-14
LOMAX P 003086 04-03
LOMBARDI F 001771 02-09
LOMBARDI M 000633 01-09
LOMHOLT BS 001839 02-11
LOMONTE A 000023 01-02
LONDON JW 003107 04-03
LONG JP 000068 01-03, 001104 02-02
LONG RS 003759 04-15
LONGCHAMPT J 002823 03-13
LONGDEN A 001685 02-08, 002624 03-08
LOO H 000815 01-13, 001032 01-17, 001756 02-09
LOOSE R 001759 02-09
LOOSEN PT 001757 02-09, 001840 02-11, 002682 03-09
LOPATKA JE 001282 02-03
LOPEZ-IBOR ALINO JJ 000627 01-09, 003011 03-17
LORCY Y 002081 02-15
LOREI TW 003896 04-17
LORENS SA 000335 01-04, 001283 02-03
LORENZ D 001182 02-03
LORENZINI R 000756 01-11
LOREZ H 000156 01-03
LOREZ HP 001629 02-05
LORINCZ P 001671 02-07
LOSEV NA 002299 03-03
LOTFY AO 000794 01-12
LOTTI VJ 001459 02-04, 003063 04-02
LOUDON JB 002055 02-15
LOVENBERG W 002217 03-03
LOVSTAD RA 000841 01-13
LOWE G 000201 01-03, 001541 02-04
LOWE WC 000368 01-04
LOWENTHAL DT 000860 01-13
LOWTHER WR 001542 02-04
LOZANO LO 000547 01-08
LUAUTE JP 000643 01-09
LUBA A 001918 02-13
LUBETKIN AI 000924 01-14
LUCAS LA 003421 04-04
LUCHINS D 000554 01-08, 000628 01-09, 003846 04-17
LUCIUS G 002801 03-13
LUCKE KH 001730 02-09
LUDERS H 003209 04-03
LUDIN HP 001671 02-07
LUGEZ-RENAN F 000504 01-07, 001758 02-09
LUJAN M 001180 02-03
LUKKARI I 000458 01-05
LULLMANN-RAUCH R 001284 02-03
LUND J 000629 01-09, 003521 04-07
LUND M 000969 01-15, 001861 02-11
LUNDBORG P 000459 01-05
LUNDH B 001933 02-13
LUNDIN G 003555 04-09, 003574 04-09
LUNDSTROM J 001082 02-01
LUNGWITZ J 002681 03-09
LUSCOMBE DK 000135 01-03, 000136 01-03, 003679 04-13, 003685 04-13, 003807 04-15, 003866 04-17
LUSTGARTEN JA 002083 02-15
LUTTGE WG 000369 01-04
LUTTGES MW 000359 01-04
LUTZ EG 002056 02-15, 002913 03-15
LUYTEN-KELLERMANN M 003682 04-13
LUZI T 000757 01-11
LWOFF JM 001474 02-04
LYNCH JJ 003422 04-04
LYNN RK 002041 02-15, 003694 04-13

M

MAAS JW 000630 01-09
MAASS CA 003260 04-03
MAC DOWALL V 001030 01-17
MACALUSO B 001697 02-08
MACCONAILL M 000455 01-05
MACCRIMMON D 002904 03-15
MACDONALD AJ 000994 01-15
MACDONALD E 001543 02-04
MACDONALD JS 003502 04-05
MACDONALD RL 003210 04-03
MACIAS QUINTANA MDC 001059 01-17
MACK G 002280 03-03, 002555 03-04
MACKAY AVP 001759 02-09, 002641 03-08
MACKERER CR 000157 01-03
MACKINNON AM 000158 01-03
MACKINNON DA 001593 02-04
MACLAUGHLIN DS 003675 04-13
MACLAY W 002822 03-13
MACLEAN A 000401 01-04
MACLEAN J 000196 01-03
MACLEAN KI 003423 04-04
MACLENNAN W 000965 01-15
MACLEOD R 000243 01-03
MACY L 003492 04-05
MACZYNSKA-RUSINIAK 8 002570 03-05
MADRONAL J 002231 03-03
MADSEN JA 001841 02-11
MADSEN SN 003114 04-03
MAEDA H 002493 03-04
MAENGWYN-DAVIES GD 001402 02-03
MAES RAA 002955 03-16
MAGGINI C 002106 02-17
MAGNUS RV 003564 04-09
MAGNUSON DJ 001285 02-03, 003373 04-04
MAGNUSSON G 000457 01-05
MAGNUSSON KE 001693 02-08
MAGOUR S 003211 04-03
MAGRAM G 003879 04-17
MAGRINAT G 003698 04-13
MAGRINI F 001917 02-13
MAGRO D 003025 03-17
MAGUIRE K 000655 01-09
MAGUIRE KP 003552 04-09
MAHADIK SP 001328 02-03
MAHAL AS 000694 01-10
MAHAUX J 000275 01-04, 000276 01-04
MAICKEL RP 003245 04-03, 003489 04-04
MAISEL AS 001599 02-04
MAITRE A 002652 03-08
MAITRE L 000665 01-09, 001228 02-03, 001412 02-03, 001413 02-03, 001602 02-04
MAITRE M 002501 03-04
MAJ J 001286 02-03, 001544 02-04, 002300 03-03
MAJCHROWICZ E 000370 01-04, 001287 02-03
MAJCZAK A 000631 01-09, 002645 03-08
MAJKOWSKI J 000159 01-03
MAJUMDAR SK 003803 04-15
MAKELA R 001818 02-11
MAKMAN MH 000261 01-03, 003881 04-17
MAKULOVA ID 002914 03-15
MALDOV DG 002295 03-03
MALEK-AHMADI P 001979 02-14
MALFROY-CAMINE B 003089 04-03
MALHOTRA HK 003739 04-14
MALICK JB 000371 01-04, 002494 03-04
MALIK K 002642 03-08
MALIK SC 000694 01-10
MALIN DH 003309 04-03
MALINEN L 001818 02-11
MALLACH HJ 002880 03-14
MALLARI CG 001264 02-03
MALLINGER AG 001936 02-13, 002829 03-13, 003700 04-13
MALLINGER J 001936 02-13, 002829 03-13, 003700 04-13
MALMFORS T 000457 01-05, 001011 01-17
MALMGREN H 002824 03-13
MALMNAS CO 000160 01-03
MALNOE A 003190 04-03
MALONE MJ 003258 04-03
MALOR R 000129 01-03
MALSEED RT 001438 02-04
MALTAVERNE S 000758 01-11
MALTEBIE AA 001822 02-11
MALVEAUX EJ 003138 04-03
MAMELAK M 002590 03-07, 003740 04-14
MAN NK 001001 01-15
MANABE R 002820 03-13
MANAKA S 002057 02-15
MANARA L 000161 01-03
MANDEL P 002280 03-03, 002555 03-04, 003259 04-03
MANDEL SPH 002142 02-17
MANDELL AJ 000143 01-03, 000162 01-03, 000632 01-09, 000842 01-13, 001505 02-04
MANDRACCHIA G 001663 02-07
MANESS DD 002258 03-03, 003165 04-03
MANGONI A 000488 01-07, 000759 01-11
MANIAN AA 001090 02-01, 001094 02-01, 001099 02-01, 001322 02-03, 003183 04-03
MANIGAULT I 003318 04-03
MANKU MS 000616 01-09, 003012 03-17
MANN HB 002143 02-17
MANN JI 000966 01-15
MANNING FJ 002495 03-04, 003424 04-04
MANNISTO PT 001288 02-03, 001350 02-03
MANOGUERRA AS 003759 04-15
MANTEGAZZA P 003109 04-03, 003241 04-03
MANTLE TJ 000163 01-03, 001289 02-03
MANZIN E 000905 01-14
MAO CC 002301 03-03, 002571 03-05
MAR JB 002298 03-03
MARCARIA V 001101 02-02
MARCER D 003724 04-14
MARCHESI GF 000760 01-11
MARCHIORI E 002117 02-17
MARCHOK PL 000417 01-04
MARCJAN K 002643 03-08
MARCO E 002301 03-03, 002571 03-05
MARCOS LR 003841 04-16
MARCUS J 001060 01-17
MARCUS R 000372 01-04, 000379 01-04
MARCY R 001290 02-03
MARCZYNSKI TJ 001291 02-03
MARDER SR 003857 04-17
MAREGA MG 000756 01-11
MARGOLIN DI 002058 02-15
MARGOTTA V 000467 01-06
MARHOLIN D 001008 01-16
MARIANI FHA 000967 01-15
MARIE C 000961 01-15
MARIE-CARDINE M 000505 01-07, 001672 02-07
MARIN A 000948 01-15
MARINI JL 001842 02-11, 001996 02-14, 003686 04-13, 003741 04-14
MARKIANOS ES 001927 02-13
MARKO M 002239 03-03
MARKS I 000695 01-10
MARKS N 000049 01-03, 002267 03-03
MARKS P 002059 02-15
MARKY M 001535 02-04
MARRIOTT P 000899 01-14, 002144 02-17, 002644 03-08, 002915 03-15
MARSDEN CA 001292 02-03, 001463 02-04
MARSDEN CD 000094 01-03, 000195 01-03, 000314 01-04, 001186 02-03, 002060 02-15, 002234 03-03, 002436 03-04, 002891 03-15, 002916 03-15, 003368 04-04, 003446 04-04
MARSELOS M 003212 04-03
MARSHALL AJ 003742 04-14
MARSHALL FD 000187 01-03
MARSHALL JF 000373 01-04, 000463 01-05, 003425 04-04
MARTELLI S 003048 04-01
MARTENS H 002793 03-11
MARTENSSON E 003655 04-13
MARTIN BR 002404 03-03, 003426 04-04
MARTIN IL 000002 01-01, 001135 02-03
MARTIN JB 002374 03-03
MARTIN JF 000194 01-03
MARTIN K 000964 01-15
MARTIN P 001649 02-06, 003366 04-04
MARTIN R 000495 01-07
MARTIN RA 002462 03-04
MARTIN WR 000164 01-03, 000761 01-11, 001928 02-13, 003093 04-03
MARTINEZ PINA A 002145 02-17
MARTINEZ TT 003213 04-03
MARTINI A 002061 02-15
MARTINI M 002061 02-15
MARTZ R 000889 01-14, 001902 02-13, 002032 02-15
MARUYAMA S 002302 03-03
MARUYAMA Y 003289 04-03
MARZO M 002610 03-08
MASEK K 000165 01-03, 000404 01-04
MASHITER K 000987 01-15
MASIAK M 000631 01-09, 002645 03-08
MASLINSKI C 002303 03-03
MASON AS 002943 03-15
MASSARI VJ 000843 01-13
MASSARINI M 000633 01-09
MASSERMAN JH 003013 03-17
MASSEY BH 001814 02-11
MASSON M 002752 03-11
MASSOULIE J 003110 04-03
MASTAGLIA FL 003773 04-15
MASTROSIMONE F 002683 03-09
MASTURZO P 000044 01-03
MASUDA K 000531 01-08, 002259 03-03
MASUMURA I 002700 03-09
MATCHETT JA 003214 04-03
MATEJCEK M 000915 01-14
MATHESON RT 000166 01-03
MATHEW NT 003632 04-11
MATHIAS CJ 003701 04-13
MATHIEU LF 000455 01-05, 003092 04-03
MATSUDA H 002365 03-03
MATSUDA K 002536 03-04
MATSUDA M 003297 04-03
MATSUDA T 002264 03-03
MATSUGUCHI Y 000562 01-08
MATSUI T 000644 01-09
MATSUI Y 003215 04-03, 003427 04-04
MATSUJIMA Y 000696 01-10
MATSUMOTO K 000552 01-08, 002569 03-05, 003056 04-01, 003069 04-02
MATSUMOTO M 001630 02-05
MATSUOKA M 000552 01-08, 000555 01-08
MATSUSHIMA E 002918 03-15
MATSUSHITA H 001372 02-03
MATSUYAMA SS 003216 04-03
MATSUZAKI M 000167 01-03
MATTEOLI E 000703 01-10
MATTES KD 001618 02-05
MATTHEWS HW 001844 02-11
MATTILA M 003014 03-17
MATTILA MJ 000458 01-05, 000835 01-13, 000840 01-13
MATTKE DJ 000556 01-08
MATTSSON B 001693 02-08, 002632 03-08, 003533 04-08
MATUK F 003804 04-15
MATUS S 003783 04-15
MATUSSEK N 000844 01-13, 001760 02-09, 001927 02-13, 002821 03-13
MATYUSHIN AI 002321 03-03, 002327 03-03
MAUGH TH 000795 01-12
MAULE WF 000377 01-04
MAURISSEN J 002555 03-04
MAY EL 002404 03-03
MAY J 003262 04-03
MAY JG 000376 01-04
MAY PRA 000506 01-07, 001704 02-08
MAYER DJ 002496 03-04, 003401 04-04, 003687 04-13
MAYER J 003751 04-14
MAYER K 000360 01-04, 000775 01-11
MAYEVSKY A 002304 03-03
MAYFIELD MA 000142 01-03, 003197 04-03
MAYO J 003854 04-17
MAYSKIY AI 001364 02-03, 002360 03-03
MAYSOV NI 002305 03-03
MAYZELIS MY 002306 03-03
MAZAUX J 002888 03-15
MAZUR M 001631 02-05
MAZZAGATTI NJ 001565 02-04
MAZZELLA GL 000633 01-09
MCAINSH J 002591 03-07
MCALLISTER HA 003810 04-15
MCALPINE CJ 002606 03-07
MCCABE MS 003565 04-09
MCCABE OL 001856 02-11, 003623 04-11
MCCANDLESS DW 002307 03-03
MCCARTY RC 000374 01-04
MCCAUGHRAN JA 003428 04-04
MCCLANE TK 000761 01-11
MCCLEARN GE 000095 01-03
MCCLELLAND HA 002646 03-08, 003644 04-11
MCCLURE RF 000567 01-08
MCCULLOCH J 003217 04-03
MCCURDY RL 000491 01-07
MCDEVITT D 000808 01-13
MCDEVITT DG 002591 03-07

MCDONALD LK 001564 02-04
MCELHATTON PR 003511 04-05
MCFARLAIN RA 001843 02-11
MCFARLAND D 002867 03-14
MCFARLAND DJ 003743 04-14
MCGAUGH JL 003400 04-04
MCGEER PL 003168 04-03
MCGINITY JW 003688 04-13
MCGLASHAN TH 003852 04-17
MCGOUGH WE 000997 01-15, 002005 02-14
MCGUFFIN JC 001459 02-04
MCGUIRE PS 000375 01-04
MCHALE CG 003111 04-03
MCINTYRE HB 003670 04-13
MCKEARNEY JW 002497 03-04, 003465 04-04
MCKENZIE CE 003445 04-04
MCKENZIE G 001578 02-04
MCKIM WA 000906 01-14
MCKINNEY WT 000145 01-03, 001530 02-04, 002511 03-04
MCLAREN AD 000752 01-11
MCLEAN JH 000319 01-04, 000376 01-04
MCLENDON DM 000377 01-04, 000490 01-07
MCLENNAN H 001293 02-03, 003250 04-03
MCLEOD MN 000592 01-09
MCMILLAN DE 000152 01-03, 001507 02-04, 001545 02-04, 003381 04-04
MCMILLAN JC 003270 04-03
MCMURRAY TM 001530 02-04
MCNAMEE H8 003805 04-15
MCNEIL HG 001844 02-11
MCNEILL JH 001337 02-03, 003213 04-03
MCNULTY H 003806 04-15
MCNUTT 8A 003633 04-11
MCQUILLEN J 003629 04-11
MEACHAM MP 001919 02-13
MEANS LW 001608 02-04
MEAUX J 000481 01-07
MEDDA L 000233 01-03
MEDINA JL 001034 01-17
MEDZIHRADSKY F 001160 02-03
MEEK JL 000168 01-03, 002185 03-01
MEGA A 002470 03-04
MEGENS A 003367 04-04
MEHENDALE HM 003218 04-03
MEHILANE L 000705 01-10
MEHTA VH 003195 04-03
MEIER M 000089 01-03
MEIER-RUGE W 002308 03-03
MEISTER RG 003056 04-01, 003069 04-02
MEIU G 002723 03-10
MELCHIOR CL 000378 01-04
MELCHIORRE C 000013 01-01
MELDRUM B 000273 01-04, 003304 04-03
MELDRUM BS 001294 02-03
MELGES FT 001980 02-14
MELIKIAN AP 003057 04-01
MELITO I 001556 02-04
MELLAN8Y H 003152 04-03
MELLANBY J 003152 04-03
MELLER E 001091 02-01, 003219 04-03
MELLERUP ET 000649 01-09, 001929 02-13, 002309 03-03, 002338 03-03
MELLINA S 000604 01-09
MELLO NK 000907 01-14
MELLOW AM 001611 02-04
MELTZER HL 000634 01-09
MELTZER HY 000557 01-08, 000558 01-08, 001129 02-03, 002310 03-03, 002445 03-04, 003085 04-03, 003220 04-03, 003221 04-03, 003222 04-03, 003288 04-03, 003689 04-13
MELZACK R 000845 01-13
MENDELL JR 001632 02-05
MENDELS J 000515 01-07, 001736 02-09, 001761 02-09, 003107 04-03, 003551 04-09, 003566 04-09, 003567 04-09, 003568 04-09
MENDELSON JH 000907 01-14, 001930 02-13, 001981 02-14, 002850 03-14, 003746 04-14
MENDELSON W8 000169 01-03, 000846 01-13, 000968 01-15, 002879 03-14, 003403 04-04, 003749 04-14
MENDLEWICZ J 001762 02-09, 001935 02-13, 002825 03-13, 003568 04-09
MENDYK A 002297 03-03
MENETREY D 001275 02-03
MENGHI P 002961 03-17
MENNINI T 000161 01-03
MENNUNI G 000801 01-13
MENON MK 002498 03-04
MENZL A 000676 01-10
MEREL J 000505 01-07
MEREL JP 001672 02-07
MEREU G 000099 01-03
MERKEL U 001757 02-09, 002682 03-09
MERKER J 001335 02-03
MERLIS S 002120 02-17, 002162 02-17, 002163 02-17
MESHALI MM 000170 01-03
MESSIHA FS 001763 02-09, 002684 03-09
MESSNER E 002903 03-15
METCALF G 000181 01-03, 003226 04-03
METSELAAR HJ 003123 04-03
MEWALDT SP 003725 04-14
MEYER DR 002311 03-03
MEYER E 003355 04-04
MEYER ER 001315 02-03, 003116 04-03
MEYER JK 002866 03-14
MEYER JS 003102 04-03, 003297 04-03
MEYER ME 000453 01-04
MEYER RE 000372 01-04, 000379 01-04, 001930 02-13
MEYER-PRO8ST B 002769 03-11
MEYERSON BJ 000294 01-04, 001475 02-04, 003429 04-04
MEZRITZ M 000982 01-15, 002174 02-17
MIALET JP 002752 03-11
MICELI G 003634 04-11
MICHAELIS EK 000328 01-04
MICHALSKA M 002669 03-09
MICHALUK J 001544 02-04
MICHAUD GM 001252 02-03
MICHEL IM 000254 01-03
MICHENFELDER JD 000380 01-04
MICHISHITA C 000552 01-08
MIDDAUGH LD 002312 03-03
MIDDAUGH SJ 000381 01-04
MIELKE DH 001843 02-11
MIEST P 003690 04-13
MIGLECZ E 003296 04-03
MIHARA M 002921 03-15
MIIKE A 002700 03-09
MIKESKA JA 001264 02-03
MIKHAIL AR 001764 02-09
MIKHALENKO IN 002313 03-03
MIKKELSEN B 000969 01-15
MIKKELSEN 80 002976 03-17
MIKSIC S 002292 03-03, 002499 03-04
MIKULKA PJ 003412 04-04, 003503 04-05
MIL8ERG L 001563 02-04
MILDE JH 000380 01-04
MILEY WM 001565 02-04
MILIARESSIS E 000382 01-04
MILLAR AY 003842 04-16
MILLER AA 000285 01-04
MILLER AL 002333 03-03
MILLER DE PAIVA L 000635 01-09
MILLER JC 003145 04-03
MILLER JJ 003250 04-03
MILLER L 002867 03-14
MILLER LL 003743 04-14
MILLER MA 002500 03-04
MILLER P 003807 04-15
MILLER PH 001796 02-10
MILLER R 000094 01-03, 000195 01-03
MILLER RE 000383 01-04
MILLER ST 003118 04-03
MILLOY S 000384 01-04
MILLS IH 001765 02-09, 001797 02-10
MILLS KC 003430 04-04
MILNER JS 000385 01-04
MILNER L 003808 04-15
MILSTEIN SL 002960 03-17
MILSTEIN V 003750 04-14
MINAMI K 000753 01-11
MINDUS P 000885 01-14, 001845 02-11
MINELLI A 003103 04-03
MINEYEVA-VYALYKH MF 002314 03-03
MINNEMAN KP 000171 01-03
MINZ M 002849 03-14
MIREYLEES SE 001393 02-03
MIRIN SM 001930 02-13
MIRMAN M 003597 04-10
MIRO QUINTANA L 000565 01-08
MIRSKY AF 003242 04-03
MISHRA RK 000261 01-03
MISIAK H 000518 01-07
MISKIN RC 003166 04-03
MISRA AL 000167 01-03, 001931 02-13
MISRA CH 001316 02-03
MISRA PC 003569 04-09
MISSLIN R 000386 01-04, 002501 03-04
MISUREC J 002647 03-08, 002724 03-10
MITCHELL D 001633 02-05
MITCHELL LK 001633 02-05
MITCHELL SC 002315 03-03
MITLER MM 002421 03-04
MITSCHER LA 001097 02-01, 001098 02-01
MIURA W 000636 01-09
MIYA TS 003505 04-05
MIYAGISHI T 000697 01-10, 002895 03-15
MIYAKAWA A 002586 03-06
MIYAKE H 002259 03-03
MIYAKE M 002358 03-03
MIYAKOSHI T 000762 01-11, 003015 03-17
MIYAMOTO T 000155 01-03
MIYASAKA M 002732 03-10
MIYAUCHI T 003438 04-04
MIYAZAKA M 002931 03-15
MIYAZAKI Y 000970 01-15
MIZUNO K 000545 01-08
MIZUNO T 002918 03-15
MJORNDAL T 002632 03-08, 003533 04-08
MODAK AT 003289 04-03
MODESTIN J 003016 03-17
MODIANOS DT 002502 03-04
MOEREELS H 002577 03-05
MOGENSON GJ 002420 03-04
MOGILNICKA E 002194 03-02, 002503 03-04
MOHAMEDI S 002062 02-15
MOHLER H 001295 02-03
MOHR C 002511 03-04
MOINET A 000643 01-09, 001705 02-08
MOIZESZOWICZ J 001785 02-10, 003570 04-09
MOJA EA 000387 01-04, 001994 02-14, 002504 03-04, 002505 03-04, 003431 04-04
MOLANDER L 002506 03-04
MOLDOFSKY H 003641 04-11
MOLEMAN P 000172 01-03
MOLEYRE J 002183 03-01
MOLINA VA 001214 02-03
MOLLA AL 001798 02-10
MOLLENAUER S 001546 02-04, 001563 02-04, 002316 03-03
MOLLER I 003070 04-02
MOLLER NIELSEN I 001547 02-04
MOLLER SE 000496 01-07, 000637 01-09
MOLLOY B8 000101 01-03, 003051 04-01, 00314 04-03
MOLTER DJ 003223 04-03
MOLTZ H 003453 04-04
MONASMITH 8 000388 01-04
MONFORT J 000643 01-09
MONIUSZKO-JAKONIUK J 000173 01-03, 00017 01-03, 002507 03-04
MONTAGUE AF 003542 04-08
MONTANARI C 001846 02-11
MONTANARO N 000238 01-03
MONTANES JM 001108 02-02
MONTEJO IGLESIAS ML 000627 01-09
MONTELLO M 001157 02-03
MONTGOMERY RL 000175 01-03
MONTGOMERY S 000589 01-09, 001740 02-09
MONTGOMERY SA 000590 01-09
MONTI JA 001320 02-03
MONTOYA GA 003224 04-03
MOODY JP 000638 01-09, 000994 01-15
MOODY RR 001611 02-04
MOORE 8W 003052 04-01, 003060 04-01
MOORE CL 000389 01-04
MOORE JD 002805 03-13
MOORE JW 002508 03-04
MOORE KE 000438 01-04, 001220 02-03, 00122 02-03, 002483 03-04
MOORE MR 000752 01-11
MOORE NC 003809 04-15
MOORE RA 002195 03-02
MOORHOUSE RA 003806 04-15
MORA F 001296 02-03, 003432 04-04
MORALI G 001444 02-04
MORAN E 002511 03-04
MORANDINI G 000507 01-07, 000508 01-07
MORASCO J 003874 04-17
MORCALDI L 000763 01-11
MOREL E 003383 04-04
MORETON JE 000390 01-04, 002559 03-04
MORGAN BA 002317 03-03
MORGAN JM 003433 04-04

MORGAN M 002440 03-04
MORGAN MY 003635 04-11
MORGAN WW 000176 01-03, 001297 02-03
MORI A 001630 02-05
MORI Y 000581 01-09, 001993 02-14
MORIFUJI T 000687 01-10
MORIHISA JM 003434 04-04
MORIN J 000639 01-09
MORIN LP 001548 02-04
MORINELLI JA 000547 01-08
MORITA M 002378 03-03
MORITA S 000745 01-11, 002077 02-15
MORIYA H 002732 03-10
MORLANO J 000812 01-13
MOROOER L 001428 02-03
MORRIS D 002943 03-15
MORRIS RJ 001805 02-10, 003600 04-10
MORRISON H 000145 01-03
MORSE WH 001495 02-04, 002482 03-04
MORSELLI PL 001331 02-03
MORTIAUX HJGM 003367 04-04
MORTON JJ 003696 04-13
MORZORATI SL 003225 04-03
MOSCI8ROOOWA 8 002108 02-17
MOSES F 002380 03-03
MOSKO SS 001298 02-03
MOSKOVITZ R 003802 04-15
MOSNAIM AO 001351 02-03
MOSTAFA M 000177 01-03
MOTOMATSU T 003875 04-17
MOTOVILOVA VG 002572 03-05
MOTTONEN M 000394 01-04
MOUNIE J 001192 02-03
MOUNT 8M 000845 01-13, 000847 01-13
MOUNTJOY CQ 000640 01-09
MOURIES MA 001474 02-04
MOUW OR 002222 03-03
MOUZIN G 000151 01-03
MOXLEY R 003629 04-11
MOYER CE 001944 02-13
MOYER OL 002817 03-13
MOYES ICA 000641 01-09
MOYES R8 000641 01-09
MOYLAN OS 001662 02-07
MOZHAYEVA GN 001299 02-03
MRONGOVIUS RI 000178 01-03
MTA8AJI JP 000616 01-09
MUCH OR 002562 03-05
MUELLER J 003645 04-11
MUELLER R 000145 01-03
MUFTIC R 000126 01-03
MUHLAU G 002826 03-13
MUKHERJEE 8P 000179 01-03, 001549 02-04, 003435 04-04
MUKHOPAOHYAY AK 003504 04-05
MUKHOPAOHYAY SN 000050 01-03, 001143 02-03
MULDER AH 000236 01-03, 003127 04-03
MULE SJ 000167 01-03, 001949 02-13
MULICK JA 000133 01-03
MULLEN A 003691 04-13
MULLER E 002806 03-13
MULLER K 002000 02-14
MULLER P 001481 02-04
MULLER V 002890 03-15
MULLER WE 003174 04-03
MULLER-LIMMROTH W 002000 02-14
MULLER-OERLINGHAUSEN 8 000532 01-08, 000663 01-09, 000971 01-15, 001653 02-07, 001766 02-09, 001772 02-09, 001879 02-13
MULLICK FG 003810 04-15
MUNOIM F 003606 04-10
MUNDIM FO 001806 02-10, 001810 02-10
MUNEKIYO K 003266 04-03
MUNIZ C 002063 02-15
MUNIZ CE 002917 03-15
MUNKVAD I 000391 01-04, 000858 01-13
MUNOZ MC 000414 01-04
MUNOZ RA 002064 02-15, 003811 04-15
MURAKI T 002384 03-03, 003472 04-04
MURAMATSU I 003233 04-03
MURAMATSU M 000180 01-03
MURASAKI M 001550 02-04
MURAWSKI 8J 002897 03-15
MURGUIA O 000642 01-09
MURKOFSKY CA 002765 03-11
MUROI K 002470 03-04
MURPHREE OD 001125 02-03
MURPHY CM 002894 03-15
MURPHY OL 000576 01-08, 000584 01-09, 001061 01-17, 001729 02-09, 001748 02-09, 002014 02-15, 002702 03-09, 002804 03-13, 003550 04-09, 003666 04-13, 003692 04-13
MURPHY OS 002217 03-03
MURPHY GM 000439 01-04
MURPHY JE 001798 02-10, 003636 04-11
MURPHY JM 001551 02-04
MURRAY GN 003443 04-04
MURRAY JN 000908 01-14
MURRAY TS 003837 04-15
MUSSARE F 001691 02-08
MUSSINI E 000190 01-03
MUSTY RE 001300 02-03
MYASNIKOVA YM 002299 03-03
MYCEK MJ 000062 01-03
MYERS DH 000930 01-15
MYERS EO 000972 01-15
MYERS RO 000181 01-03, 000378 01-04, 003226 04-03, 003432 04-04
MYERS RR 001390 02-03
MYRAN CS 002376 03-03
MYSLO8OOSKY M 003017 03-17

N

NA8ESHIMA T 001523 02-04, 002391 03-03, 002509 03-04
NADEL AM 002146 02-17
NADLER E 002827 03-13
NAESTOFT J 001908 02-13
NAFTOLIN F 001444 02-04
NAGAI K 002318 03-03
NAGAMATSU S 002930 03-15
NAGAO 8 003452 04-04
NAGAO S 002565 03-05
NAGASAKI N 000102 01-03, 002284 03-03, 002510 03-04
NAGAYAMA H 000182 01-03, 002381 03-03
NAGGAR AN 002525 03-04
NAGURSKA H 003018 03-17
NAGY A 002844 03-13, 003227 04-03
NAGY ZN 001551 02-04
NAHAS AO 003637 04-11
NAHAS GG 001183 02-03
NAHORSKI SR 000183 01-03, 001301 02-03, 001302 02-03
NAHUNEK K 002647 03-08, 002724 03-10
NAIK SR 001303 02-03, 003228 04-03
NAIMARK RS 001982 02-14
NAIR NPV 002648 03-08, 002770 03-11
NAITOH P 001941 02-13
NAKAGAWA F 001706 02-08
NAKAGAWA K 002319 03-03
NAKAGAWA T 000622 01-09, 000692 01-10
NAKAHAMA H 002281 03-03
NAKAHARA T 001251 02-03
NAKAMURA E 002381 03-03
NAKAMURA H 002918 03-15
NAKAMURA K 000184 01-03, 000184 01-03, 002320 03-03, 002320 03-03, 002407 03-03
NAKAMURA M 000392 01-04, 001552 02-04, 001553 02-04
NAKAMURA Y 002509 03-04
NAKANE K 002707 03-09
NAKANO K 002707 03-09
NAKANO T 000185 01-03
NAKANO U 002245 03-03
NAKAO T 001708 02-08
NAKAOSA T 002918 03-15
NAKAYA S 002567 03-05
NAKAYAMA I 003410 04-04
NALI8OFF 8D 001982 02-14
NAM8A T 000713 01-10
NANIA A 000679 01-10
NANNI S 001771 02-09
NAPIERALSKA M 002748 03-11
NAQUET R 002431 03-04
NAQUIRA C 001121 02-03
NARAGHI M 002007 02-15
NARASIMHACHARI N 000014 01-01
NARDINI M 000848 01-13
NARITA S 000559 01-08
NARVER EL 002421 03-04
NASH JL 003829 04-15
NASH RJ 001847 02-11, 002005 02-14, 003744 04-14
NASRALLAH H 000861 01-13
NASSAR 8A 000616 01-09
NASTUK WL 001304 02-03
NATELSON 8H 001554 02-04
NATHAN 8A 002549 03-04
NATHAN L 001792 02-10
NATHANSON J 001398 02-03
NATTERMANN RA 000181 01-03
NAUMENKO EV 000186 01-03
NAUMOV AP 001299 02-03
NAUMOV YI 002321 03-03
NAUSIEOA PA 003835 04-15
NAVA V 000560 01-08
NAVARRO G 001555 02-04
NAVAS GE 001081 02-01
NAWATA H 002057 02-15
NAYAK RK 001905 02-13
NAYLOR GJ 000849 01-13, 000994 01-15
NAYLOR H 002863 03-14
NAYLOR RJ 000068 01-03, 000301 01-04, 001105 02-02, 002189 03-02, 002436 03-04, 003368 04-04
NAZARETYAN RA 001305 02-03
NEAL MJ 001130 02-03
NEALE R 002065 02-15
NE8OTOV VA 002089 02-16
NECKERS LM 002185 03-01
NEOERGAARO OA 003229 04-03
NEEDLEMAN HL 001799 02-10
NEFF NH 003516 04-06
NEGISHI K 003232 04-03
NEGULYAYEV YA 001299 02-03
NEIL JF 002066 02-15, 002829 03-13, 003700 04-13, 003793 04-15
NEILL 08 001489 02-04
NEILL E 003701 04-13
NELSON O 003868 04-17
NESSE R 000973 01-15
NETO JP 001556 02-04
NEU8AUER H 001767 02-09
NEU8AUER HW 002890 03-15
NEUHOFF V 002223 03-03
NEUMANN F 001368 02-03
NEUMANN H 001766 02-09
NEUMEYER JL 000229 01-03
NEUSCH 8 000937 01-15
NEVES CAROOSO J 000645 01-09
NEVITT JR 003365 04-04
NEVSIMAL O 000870 01-13
NEWELL DJ 003644 04-11
NEWLON PG 003401 04-04
NEZIROGLU F 000523 01-07, 000721 01-10, 000872 01-13
NG RH 000187 01-03
NGAI SH 001139 02-03
NIAZI S 000850 01-13
NICHOLLS PJ 000030 01-03
NICHOLS OE 002186 03-01
NICHOLSON AN 000393 01-04, 001657 02-07
NICHOLSON C 001306 02-03
NICK J 000643 01-09
NICKOLSON VJ 001307 02-03, 001308 02-03, 001309 02-03
NICOLAIOIS S 001465 02-04
NIEOERER W 002239 03-03
NIEFORTH KA 002190 03-02
NIELSEN IM 000073 01-03, 001246 02-03
NIELSEN M 001650 02-06
NIELSEN NP 000764 01-11, 001707 02-08, 001800 02-10
NIELSON HC 001566 02-04
NIEMAN G 002940 03-15
NIEMEGEERS CJE 001118 02-02, 001414 02-03, 001460 02-04, 001461 02-04, 001462 02-04, 002433 03-04, 003364 04-04
NIEMINEN L 000394 01-04
NIETHARDT P 001918 02-13
NIGHTINGALE CH 000170 01-03
NIGRI A 001673 02-07
NIKIFOROV VA 001271 02-03
NIKITOPOULOU G 003693 04-13
NINO R 002725 03-10
NIREN8ERG M 003155 04-03
NIS8ET PA 003776 04-15
NISHIOA K 000713 01-10
NISHIKAWA T 002284 03-03, 002510 03-04
NISHIMOI T 002365 03-03
NISHIMORI T 002536 03-04
NISHIWAKI K 002381 03-03

NISHIZONO M 000561 01-08, 000562 01-08, 000765 01-11
NISKANEN P 000766 01-11
NISTICO G 001310 02-03, 003436 04-04
NITURA0 0 000538 01-08
NOBLE A8 002511 03-04
NO8LE EP 001311 02-03, 001954 02-14, 002069 02-15
NOEL BJ 003789 04-15
NOMOTO T 002389 03-03
NOMURA K 002365 03-03
NOMURA S 000563 01-08
NONAKA K 002390 03-03
NOONAN JPA 002649 03-08, 002738 03-11
NOONE JF 003887 04-17
NORAVYAN OS 002323 03-03
NOR08ERG A 003230 04-03
NORDGREN L 003849 04-17
NORDQVIST P 002736 03-11
NORING R 002291 03-03
NORRIS 8 003565 04-09
NORRIS FH 001209 02-03
NORSETH T 002198 03-03
NORTH RA 001634 02-05
NORTHUP LR 001312 02-03
NOTSU Y 002355 03-03
NOTTINGHAM J0 001701 02-08
NOUSIAINEN U 003212 04-03
NOVELLONE M 001768 02-09
NOWAK H 001367 02-03
NOWAK JZ 002303 03-03
NOYES R 001872 02-12
NOYES RW 002105 02-17
NOZAKI M 000472 01-06
NOZAWA A 000713 01-10
NUMAN R 001557 02-04, 002292 03-03
NUMATA Y 000851 01-13
NUNN AJ 002090 02-16
NUORTIO L 000032 01-03
NUROWSKA K 000724 01-11, 002570 03-05, 002650 03-08
NY8ERG G 000827 01-13
NYBERG J 000457 01-05
NYQUIST SE 003156 04-03
NYSTROM I 001927 02-13

O

OAKLEY NR 001189 02-03, 001190 02-03
OBERLANOER C 001448 02-04
O8ERMEIER F 003231 04-03
O8OYLE M 000368 01-04
OBRIEN JE 001009 01-16
OBRIEN JP 003813 04-15
OBRIST W0 002096 02-16
OCHI Y 002244 03-03
OCONNELL RA 003854 04-17
OCONNOR 0G 000514 01-07
OCONNOR J 001887 02-13
O0EA RF 001313 02-03, 002414 03-03
O0ONNELL JP 000068 01-03, 001104 02-02
O0ONOVAN 0J 001281 02-03
OEHLERT W 000937 01-15
OELSCHLAGER H 003714 04-13
OETTINGER B 002772 03-11
OFFERLIN MR 003483 04-04
OFFORO 0 002940 03-15
OFIESH JG 000845 01-13
OFLANAGAN PM 000586 01-09
OGATA H 002512 03-04
OGAWA H 002489 03-04, 002513 03-04
OGREN S 000212 01-03, 001571 02-04
OGUAKWA JU 001087 02-01
OGUCHI T 001550 02-04
OGURA C 001708 02-08, 002921 03-15
OGURI K 002324 03-03
OHARA K 000644 01-09
OHASHI K 001112 02-02, 002488 03-04
OHGA Y 002358 03-03
OHI M 002687 03-09, 002707 03-09
OHI S 002514 03-04
OHKUMA T 000696 01-10, 000909 01-14
OHLIN P 001933 02-13
OHLMAN T 002091 02-16
OHMAN R 001769 02-09, 001911 02-13, 003671 04-13
OHMIYA T 002356 03-03
OHMORI K 002399 03-03
OHMOTO T 000767 01-11
OHNO S 003073 04-02
OHTA M 002325 03-03
OHTAKA T 000395 01-04
OHTANI 0 003073 04-02
OHUCHI T 002326 03-03
OI S 001222 02-03
OISHI R 002399 03-03, 003450 04-04
OKA M 002515 03-04
OKA T 000188 01-03, 000396 01-04, 001358 02-03, 001558 02-04, 003232 04-03, 003437 04-04
OKA8E S 002547 03-04
OKA8E T 003066 04-02
OKA0A F 000581 01-09, 000654 01-09, 000697 01-10, 002356 03-03
OKADA M 002676 03-09
OKAMOTO K 001314 02-03
OKAMOTO M 002513 03-04, 002516 03-04
OKISHI K 000552 01-08
OKITA GT 000432 01-04
OKSENKRUG GF 001271 02-03
OKUIZUMI K 002489 03-04
OKUMA T 001709 02-08, 002921 03-15
OKUTA G 002938 03-15
OLAFSSON O 003865 04-17
OLEARY JF 000029 01-03
OLESEN OV 000189 01-03, 002383 03-03
OLESHANSKY MA 002385 03-03
OLESINSKI Z 002651 03-08
OLGIATI SG 003739 04-14
OLIVARI MT 001917 02-13
OLLEY JE 003480 04-04
OLLINO S 001771 02-09
OLNEY JW 000194 01-03, 001315 02-03, 001316 02-03
OLSEN G0 003694 04-13
OLSEN M 003738 04-14
OLSEN PZ 000969 01-15, 001861 02-11
OLSON L 001398 02-03
OLSON WH 001632 02-05
OLTON OS 000103 01-03
OMORI S 000668 01-09
OMORI Y 002565 03-05
ONORUSEK G 003348 04-04
OPICE B 000723 01-11, 002756 03-11
OPITZ K 001317 02-03
OPROIU L 000538 01-08
OR8ACH J 001580 02-04
ORBAN I 003201 04-03
OREG M 003349 04-04
ORELANO L 000823 01-13, 002632 03-08, 003076 04-02, 003533 04-08
ORGANISCIAK OT 001318 02-03
ORGURA C 000696 01-10
ORLIN L 001B53 02-11
ORSINGHER OA 001214 02-03
ORSULAK PJ 000218 01-03
ORTEGA E 001934 02-13
OS8ORN GG 003638 04-11
OS8ORNE ML 003534 04-08
OSBORNE NN 002223 03-03
OSNYACH VS 002327 03-03
OSORIO PLM 002B68 03-14
OST L 000768 01-11, 003546 04-08
OSTER JR 00369B 04-13
OSTFELO A 003595 04-10
OSTROVSKIY BI 001836 02-11
OSUMI Y 003233 04-03, 003266 04-03
OSWALO I 00284B 03-14
OTANI W 000551 01-08
OTHMER E 003890 04-17
OTSUKA R 000552 01-08
OTSUKI S 000608 01-09, 001661 02-07
OTT J 001063 01-17, 001088 02-01
OTTAVIO L 002746 03-11
OTTINGER E 000232 01-03
OTTO J 001110 02-02
OTUAMA L 003802 04-15
OUCHI T 002180 02-17
OULES J 000961 01-15
OVERALL J 001965 02-14
OVERALL JE 0035B8 04-10, 003596 04-10, 003888 04-17
OVERO KF 002813 03-13, 003695 04-13
OVERSTREET 0H 001580 02-04, 002541 03-04, 002554 03-04
OVERTON 0A 000397 01-04, 002517 03-04
OWEN CA 002388 03-03
OWEN F 002688 03-09, 003234 04-03
OWEN OE 002330 03-03
OWMAN C 002114 02-17
OZAWA H 001319 02-03, 003438 04-04

P

PA8LO G 003677 04-13
PACH J 000698 01-10, 001801 02-10
PACHA W 001878 02-13
PACHECKA J 000190 01-03
PACHECO H 000004 01-01, 003848 04-17
PACIFICI GM 001331 02-03, 001983 02-14
PA0EN C 002328 03-03
PA0FIELO A 003814 04-15
PA0FIELD PL 003696 04-13
PAES 0E SOUSA M 000645 01-09
PAESALU EI 002382 03-03
PAGE JG 000398 01-04, 002329 03-03
PAGEL J 001320 02-03
PAGOT R 000961 01-15
PAINTER MJ 003697 04-13
PALAIA R 000757 01-11
PALATNIKOV GM 002394 03-03
PALESTINE ML 001850 02-11
PALET J 002532 03-04
PALFAI T 000399 01-04, 001559 02-04, 003417 04-04
PALLA0INI G 000467 01-06
PALME G 003702 04-13
PALMER GC 001321 02-03, 001322 02-03, 001340 02-03
PALMER RF 003677 04-13
PALMGREN E 001030 01-17
PALUMBO E 000763 01-11
PANASYUK PV 002203 03-03
PAN0EY G 001895 02 13
PAN0EY GN 001665 02-07
PAN0EY V8 001446 02-04
PANTANO JA 002922 03-15
PANTAROTTO C 000046 01-03, 000190 01-03, 002240 03-03
PANZIK HL 000799 01-13
PAOLETTI R 002210 03-03
PAPAIOANNOU G 000027 01-02
PAPAVASILIOU PS 003118 04-03
PAPOUSEK M 001990 02-14
PAPPAS BA 001323 02-03
PAPPAS NJ 002083 02-15
PAR0ELL H 002145 02-17
PAR00 JV 003235 04-03
PARE CM8 000612 01-09, 001064 01-17
PARE WP 002773 03-11
PAREOES A 003530 04-08
PARENT M 000975 01-15, 001010 01-16, 001065 01-17, 001655 02-07
PARIANI HK 003208 04-03
PARIANTE F 000673 01-10
PARK C 001682 02-08
PARK SJ 003696 04-13
PARKER ES 001954 02-14, 002069 02-15
PARKER JM 001632 02-05
PARKER LF 000400 01-04
PARKER N 003022 03-17
PARKES J0 002869 03-14
PARMAR SS 000072 01-03, 003236 04-03
PARTON RV 000537 01-08
PARTYKA RA 001114 02-02
PARVATHY S 000109 01-03
PASCAL J 001710 02-08
PASCAU0 M 00106B 01-17
PASHINSKIY VG 002572 03-05
PASHUK LK 002286 03-03
PASQUALE SA 002105 02-17
PASSATORE M 00349B 04-05
PASSE 0H 003494 04-05
PASSERO S 002061 02-15
PASTAN S 001165 02-03
PASTERNAK V 003349 04-04
PASTERSKI J 002655 03-08
PASTRANA E 002726 03-10
PATAY M 000702 01-10
PATCHETT AA 003063 04-02
PATEL AJ 001295 02-03
PATEL BC 000082 01-03
PATEL MS 002330 03-03
PATIL P 001097 02-01
PATKINA NA 002331 03-03, 002518 03-04
PATON 0M 001282 02-03, 001324 02-03, 001325 02-03

ATRASCU F 002723 03-10
ATRICK TB 000191 01-03
ATRIZI C 000852 01-13
ATTEE CJ 000197 01-03
ATZOLD U 002153 02-17
AUL SM 001326 02-03, 003220 04-03, 003222 04-03
AULIN J 001121 02-03
AUNOVIC J 000133 01-03
AVESI V 002154 02-17
AVLIK A 002268 03-03
AYKEL ES 000646 01-09, 001770 02-09
EACHEY JE 000401 01-04, 003439 04-04
EARCE MJ 003074 04-02
EARL RG 002332 03-03
EARSON RE 003584 04-10
ECK AW 000910 01-14
ECK EJ 002333 03-03
ECKNOLD JC 002B51 03-14, 0035B0 04-10
EDEMONTE WA 001351 02-03
EDERSEN V 001466 02-04, 003070 04-02
EEKE SC 001873 02-12
EESKER SJ 000113 01-03
EGHINI R 002615 03-08
EGRAM GV 0019BB 02-14
EKKARINEN A 000517 01-07, 000B63 01-13, 000B64 01-13
EKKARINEN J 000B62 01-13
ELC I 003023 03-17
ELLENC M 001013 01-17
ELTON EW 000192 01-03, 000B53 01-13
ENA-RAMOS A 003639 04-11
ENATI G 001994 02-14
ENCE DH 003505 04-05
ENNELLI G 000B52 01-13
ENNING J 001BB4 02-13
ENNINGS EJM 000193 01-03
ENOVICH P 003640 04-11
ENRY JK 003643 04-11
EPE G 0026B3 03-09
EPPER CM 001236 02-03
EPPLINKHUIZEN L 002011 02-15
ERACCHI M 001900 02-13
ERBELLINI D 000BB1 01-14, 001670 02-07
ERCY VA 003237 04-03
EREIRA-OGAN J 001B05 02-10, 003600 04-10
EREL J 001749 02-09
EREL JM 001935 02-13, 003183 04-03, 003560 04-09, 003659 04-13, 003674 04-13, 003BB1 04-17
ERENYI G 001720 02-0B
EREZ DE FRANCISCO C 000699 01-10
EREZ GO 00369B 04-13
EREZ VJ 000194 01-03, 003052 04-01
EREZ-PALACIOS G 001444 02-04
ERI G 000149 01-03
ERINGER E 000195 01-03
ERINO-MARTEL M 001465 02-04
ERLICK O 003703 04-13
ERLMAN B 003B89 04-17
ERLMAN RL 001165 02-03
EROL Y 000771 01-11
ERON-MAGNAN P 001042 01-17
EROSINO N 002746 03-11
ERRIN JH 002B2B 03-13, 003053 04-01
ERRIS C 001066 01-17, 001693 02-0B, 002632 03-0B, 0029B1 03-17, 003533 04-08, 003555 04-09
ERRY KW 002242 03-03, 002243 03-03
ERRY TL 000196 01-03, 000196 01-03
ERSINGER MA 001560 02-04
ERSSON E 003546 04-0B
ERSSON G 001B02 02-10, 003699 04-13, 003774 04-15, 003B15 04-15
ERSSON S 003238 04-03, 003239 04-03
ERT A 002193 03-02, 002334 03-03, 003240 04-03
ERT CB 002193 03-02, 002335 03-03
ERTSCHUK LP 001327 02-03
ERUMAL AS 00132B 02-03
ERVOMAYSKIY BY 002155 02-17
ERZYNSKI J 000769 01-11
ETA G 000770 01-11
ETERFALVI M 001448 02-04
ETERFY G 000197 01-03
ETERMANN H 002612 03-08
ETEROVA E 002657 03-08
ETERS BA 000796 01-12
ETERS DAV 001323 02-03
PETERS G 002479 03-04
PETERS JR 002562 03-05
PETERSEN BH 000854 01-13
PETERSEN E 000025 01-02
PETERSEN KG 000833 01-13
PETERSEN KW 001610 02-04
PETERSON DW 00019B 01-03, 002519 03-04
PETERSON GR 002345 03-03
PETERSON JM 000133 01-03
PETERSON NA 000199 01-03
PETHO B 002B70 03-14
PETRALI EH 0000B6 01-03
PETRI-BOT A 002393 03-03
PETRICH C 001B51 02-11
PETRIE A 002B15 03-13
PETRIE WM 001733 02-09, 0029B7 03-17
PETROVICKY P 000130 01-03
PETRUCH F 001711 02-08, 001BB9 02-13
PETTUS C 001840 02-11
PETTY F 003057 04-01
PETURSSON H 001712 02-0B
PFAFF DW 002502 03-04
PFEFFERBAUM A 003B16 04-15
PFEIFER HJ 000976 01-15
PFEIFER Y 002B39 03-13
PFEIL KA 000176 01-03
PFLUG B 001BB9 02-13
PHELIPPEAU M 001969 02-14
PHILLIPS AG 000200 01-03, 001296 02-03, 00145B 02-04
PHILLIPS O 00100B 01-16
PHILLIPS JR 000460 01-05
PHILLIPS KG 000201 01-03
PHILLIPS ME 001329 02-03
PHILLIPS MI 000123 01-03, 003404 04-04
PHILLIPS PJ 002070 02-15
PHILLIPSON OT 000125 01-03
PHILLIS JW 001330 02-03, 002336 03-03
PIANTADOSI C 0012B7 02-03
PICCALUGA G 002923 03-15
PICKARO FJ 003303 04-03
PICKELMANN P 000033 01-03
PICKWORTH W8 003440 04-04
PICOTTI GB 003109 04-03, 003241 04-03
PIDEVICH IN 002203 03-03
PIECHOCKI T 0024B6 03-04
PIEPER WA 001561 02-04
PIERI L 00115B 02-03, 002215 03-03, 002337 03-03
PIERS DA 0017B1 02-09
PIETIKAINEN S 003212 04-03
PIETRUSZEWSKA I 002643 03-0B
PIGINI M 000013 01-01
PIJNEN8URG AJJ 001562 02-04
PIN M 000656 01-09
PINARO G 000693 01-10, 003523 04-07, 003594 04-10
PINCHARD A 001655 02-07
PINDER RM 001021 01-17, 001105 02-02, 0021B9 03-02
PINEAU R 002050 02-15
PINELLI P 000591 01-09
PINTA ER 003571 04-09
PINTER EJ 000197 01-03
PINTER S 000456 01-05
PINTO F 000B01 01-13
PINYAZHKO RM 000005 01-01
PIOTROWSKI Z 002601 03-07
PIPPENGER CE 003209 04-03
PIPPINGER C 003697 04-13
PIRES OE OLIVEIRA RS 002774 03-11
PIRES P 002092 02-16
PIRTTIPERA V 000542 01-0B
PISANA F 000700 01-10
PISARZ A 001013 01-17
PISHKIN V 003603 04-10
PITLICK W 003697 04-13
PIYAKALMALA S 0036B9 04-13
PLAA GL 002230 03-03
PLACHETA P 000202 01-03
PLACIDI GF 001331 02-03
PLANCHE R 000509 01-07, 000510 01-07, 001B03 02-10, 002603 03-07, 002689 03-09
PLANT RL 003333 04-03
PLATMAN SR 002156 02-17
PLENGE P 002309 03-03, 002338 03-03, 002339 03-03
PLETSCHER A 003264 04-03
PLOCHER D 001B08 02-10
PLOTCZYK J 0004B5 01-07
PLOTNIK R 001546 02-04, 001563 02-04, 002316 03-03
PLOTNIKOFF NP 000203 01-03, 000402 01-04
PLOTSKY P 0003B8 01-04
POCELINKO R 003B6B 04-17
POCHATOV YM 002248 03-03
POCOCK J 003742 04-14
PODDAR MK 000042 01-03
PODDUBIUK ZM 002340 03-03, 0024B4 03-04, 002520 03-04
POELDINGER WJ 002690 03-09
POFFEN8ARGER PL 0002B1 01-04
POHORECKY LA 000063 01-03, 000403 01-04
POIRIER LJ 003B55 04-17
POKOLY T 003B01 04-15
POKORNY AO 003B5B 04-17
POLAND RE 000514 01-07
POLC P 001332 02-03
POLDINGER W 000701 01-10, 003B25 04-15
POLESE A 001917 02-13
POLEVAYA OY 00162B 02-05
POLEWKA A 002710 03-10
POLICICCHIO D 001B37 02-11
POLING A 003441 04-04, 003442 04-04
POLITZER IR 001564 02-04
POLIVY J 0019B4 02-14
POLIZOS P 0029BB 03-17
POLK A 001905 02-13
POLLACK E 002B61 03-14
POLLARD GT 002468 03-04
POLLERI A 000044 01-03
POLLOCK B 000473 01-06, 001645 02-06
POLLOCK SH 000B55 01-13
POLONOWITA A 001713 02-0B
POLVAN N 003625 04-11
POMANOVA TV 002572 03-05
PONOMAREVA LV 002572 03-05
PONOMAREVA SI 002412 03-03
POOL M 001484 02-04
POOLE D 003745 04-14
POPOVA EN 002341 03-03
POPOVICI I 00053B 01-08
PORATH G 0004B2 01-07
PORCEDDU ML 0013BB 02-03, 00243B 03-04
PORCELLATI G 001127 02-03
PORFIRIEVA RP 001426 02-03
POROT MJ 000771 01-11
PORSOLT RD 003071 04-02
POSCHLOVA N 000165 01-03, 000404 01-04
POSEL Z 00274B 03-11
POSNER I 001565 02-04
POST R 003727 04-14
POST RM 000911 01-14, 001044 01-17, 001333 02-03, 001696 02-08, 00174B 02-09, 001962 02-14, 002673 03-09, 002B12 03-13, 003041 03-17
POSTMA E 002B05 03-13
POTEPAN P 000506 01-07
POUGET R 000977 01-15
POUPAERT J 0010B9 02-01
POUST RI 001936 02-13, 002829 03-13, 003700 04-13
POWELL BJ 001513 02-04, 002585 03-06, 003B90 04-17
POWELL JW 003090 04-03
POWELL RJ 001B27 02-11
POWERS JB 00154B 02-04
POYEN 8 002924 03-15
POYNTON C 000677 01-10
POZENEL H 000B56 01-13
PRADHAN SN 000179 01-03, 000204 01-03, 001549 02-04, 003435 04-04
PRADO BA 001004 01-16
PRADO DE CARVALHO L 0031B1 04-03
PRAGAY E8 003242 04-03
PRAGER RH 000140 01-03
PRAKASH R 003730 04-14
PRANGE AJ 000145 01-03, 000647 01-09, 001530 02-04, 001B40 02-11
PRASAD ALN 0015B5 02-04
PRATT CNFW 0001B3 01-03
PRATT OE 003120 04-03
PRATT P 000920 01-14
PREACHE MM 001635 02-05
PREAT S 001502 02-04
PREMONT J 001150 02-03, 001151 02-03, 002342 03-03
PRENTICE CRM 000092 01-03

PRESKORN SH 003817 04-15
PRESLEY AP 000978 01-15
PRESTON D 002940 03-15
PREZIOSI P 001310 02-03
PRIAM M 003133 04-03
PRICE DO 002496 03-04, 003676 04-13, 003687 04-13
PRICE MTC 001334 02-03, 003443 04-04
PRICHEP LS 002830 03-13
PRIEN RF 000772 01-11
PRIEST RG 001985 02-14
PRIMAVERA A 002694 03-09
PRING M 003107 04-03
PRIOR M 002904 03-15
PRIORA PM 001771 02-09
PROP-VAN DEN BERG CM 003444 04-04
PROTAIS P 002521 03-04
PROTIVA M 002577 03-05
PRUSEK W 000979 01-15
PRUSOFF B 000648 01-09, 002174 02-17
PRUSOFF BA 000646 01-09
PRYOR GT 003445 04-04
PRYOR TL 003484 04-04
PRZEGALINSKI E 002561 03-04, 002573 03-05
PSATTA DM 002343 03-03
PUDNEY H 001821 02-11
PUGH DD 002936 03-15
PUGSLEY TA 000205 01-03, 001279 02-03, 001335 02-03, 003243 04-03
PUHAKKA P 002704 03-09
PUHRINGER W 002705 03-09
PUJOL J 003190 04-03
PURCHATZKE G 003843 04-16
PURI SK 001336 02-03, 003244 04-03
PURVIS SR 000019 01-02
PUSAKULICH RL 001566 02-04
PUTNAM RW 001321 02-03
PUZYNSKI S 000511 01-07, 002618 03-08
PYCOCK C 000273 01-04, 000405 01-04, 002234 03-03
PYCOCK CJ 001519 02-04, 002436 03-04, 002522 03-04, 003368 04-04, 003446 04-04
PYLATUK KL 001337 02-03

Q

QUARRIE J 001947 02-13
QUARTEY GRC 000206 01-03
QUASTEL OMJ 001314 02-03
QUASTEL JH 001314 02-03
QUATTRINI A 000760 01-11
QUAYLE ES 001320 02-03
QUENZER LF 003516 04-06
QUERMONNE MA 001290 02-03
QUETIN A 000945 01-15
QUILLIEN R 000702 01-10
QUINN PO 002872 03-14
QUIRCE CM 003245 04-03
QUITKIN F 002157 02-17, 002927 03-15, 003547 04-08, 003818 04-15
QUOCK RM 002523 03-04

R

RAABE W 003246 04-03
RAAFLAUB J 000857 01-13
RABEY JM 002871 03-14
RABINOWITZ JL 003107 04-03
RACAGNI G 001430 02-03
RACKENSPERGER W 002691 03-09
RADA RT 001697 02-08
RADOING JA 001180 02-03
RADIVOJEVIC M 001594 02-04
RADMAYR E 002071 02-15
RADOMSKA G 000979 01-15
RADOMSKI T 003677 04-13
RADOW BL 000400 01-04
RADULOVACKI M 000065 01-03
RAEFSKY C 002330 03-03
RAFAELSEN OJ 000649 01-09, 001747 02-09, 001782 02-09, 001929 02-13, 003024 03-17
RAFAL RD 003524 04-07
RAFII A 003687 04-13
RAFT D 000592 01-09
RAGHUPATHY E 000199 01-03
RAIJOLA E 000517 01-07, 000863 01-13
RAINEY JM 003819 04-15
RAINFORD EA 001327 02-03
RAITERI M 000002 01-01, 000207 01-03, 001135 02-03, 003247 04-03
RAJAN KS 001090 02-01
RAKONCZAY Z 000177 01-03
RAKOW D 001896 02-13
RALEIGH FR 003572 04-09
RAMAEKERS F 003447 04-04
RAMIREZ A 000486 01-07
RAMPLING DJ 002925 03-15
RAMSAY A 003842 04-16
RAMSAY C 000054 01-03
RAMSAY LE 003837 04-15
RAMSAY RE 002063 02-15
RANDRUP A 000858 01-13, 002194 03-02, 002506 03-04
RANDT CT 000406 01-04
RANJE C 003448 04-04
RANNOU J 000639 01-09
RANSOM BR 001338 02-03
RAOTMA H 003555 04-09, 003574 04-09
RAPIN JR 001401 02-03, 003383 04-04
RAPOPORT JL 000912 01-14, 002775 03-11, 002872 03-14
RAPP DL 001567 02-04
RAPP W 001693 02-08, 003533 04-08
RAPPAPORT M 002817 03-13
RAPPOLT NR 001852 02-11
RAPPOLT RT 001852 02-11
RAPPORT MM 001260 02-03, 001328 02-03
RASKIN A 001986 02-14
RASMUSSEN PT 003537 04-08
RASTOGI RB 001120 02-03, 003248 04-03, 003249 04-03, 003449 04-04
RATCLIFFE F 001370 02-03
RATEL M 002652 03-08
RATNIKOVA LA 002295 03-03
RAVENNA M 000770 01-11
RAVINA E 001108 02-02
RAWLOW A 001286 02-03
RAWTICH AB 000924 01-14
RAY B 001446 02-04
RAYEVSKIY KS 002248 03-03, 002305 03-03, 002314 03-03
RAYNAL D 000741 01-11
RAYNAUD G 003190 04-03
RAZANI J 001865 02-11
RAZDAN RK 001339 02-03, 003061 04-01
RAZZAK A 003450 04-04
REALE A 001673 02-07
REAVEY-CANTWELL NH 001905 02-13
REBEC GV 000208 01-03, 002122 02-17, 002344 03-03
REBOUL J 003058 04-01, 003059 04-01
RECCHIA M 000536 01-08
RECH RH 001599 02-04
REDDY PKSP 001143 02-03
REDFERN PH 001188 02-03, 001468 02-04, 002111 02-17
REDGRAVE P 000181 01-03, 000209 01-03
REDMAN W 000884 01-14
REDMOND DE 001804 02-10
REOOS JO 003177 04-03
REES HD 000407 01-04
REES JA 001674 02-07
REES WL 000612 01-09, 001067 01-17
REFSUM H 000084 01-03
REGALADO RG 003891 04-17
REGARDH C 000828 01-13, 000859 01-13, 001011 01-17
REGGIANI G 003690 04-13
REHSE K 003255 04-03
REHULKA J 002268 03-03, 003135 04-03
REICH L 001055 01-17
REICHEL G 002826 03-13
REICHEL H 001927 02-13
REICHINGER M 001990 02-14
REICHMAN JD 000846 01-13
REICHOWA J 000751 01-11, 000802 01-13
REID AE 002768 03-11
REID JL 002815 03-13, 003701 04-13
REID L 003469 04-04
REID LD 001285 02-03, 002443 03-04, 002444 03-04, 002500 03-04, 002528 03-04, 003373 04-04
REID WH 000980 01-15, 002926 03-15
REIDENBERG MM 000860 01-13
REIGLE T 000218 01-03
REILLY PP 003892 04-17
REILLY TM 000981 01-15
REIM B 002821 03-13
REIMHERR FW 002794 03-11, 003820 04-15
REINHARD JFJ 002345 03-03
REINHARDT B 001918 02-13
REINHARDT G 001948 02-13
REIS DJ 000211 01-03
REISER DE 001714 02-08
REITANO S 001707 02-08, 001793 02-10, 001800 02-10
REITER H 001990 02-14
REITER LW 001485 02-04
REITER RJ 000176 01-03
REITH MEA 000112 01-03
REMEN D 000878 01-14
REMINGTON G 001435 02-04, 001568 02-04
REMY F 000650 01-09
RENARD P 000650 01-09, 001068 01-17, 002727 03-10
RENDUELES G 000605 01-09
RENFORDT E 000651 01-09, 001772 02-09, 002692 03-09
RENIS M 001221 02-03
RENNICK PM 002776 03-11
RENO H 003496 04-05
RENYI AL 000212 01-03, 000213 01-03, 000214 01-03
RESCHINI E 001900 02-13
RESNEKOV L 000890 01-14
RESNICK RB 000512 01-07, 001853 02-11, 001949 02-13, 001950 02-13, 003745 04-14
REVUELTA A 002301 03-03, 002571 03-05
REVZIN A 001384 02-03
REWERSKI W 002486 03-04
REY MOSQUERA JE 002831 03-13
REYES E 001340 02-03
REYNOLDS DJ 003535 04-08
REYNOLDS EH 000989 01-15, 002891 03-15
REYNOLDS I 003025 03-17
REYNOLDSON JA 001457 02-04
REZEK M 000408 01-04, 000409 01-04, 003451 04-04
RHEAD JC 001877 02-12
RHEE V 001316 02-03
RHO J 003517 04-06
RIAL W 003597 04-10
RIAL WY 002124 02-17
RIBORDY SC 003821 04-15
RICCA E 002162 02-17, 002163 02-17
RICCIO DC 000451 01-04
RICE JC 000181 01-03, 003226 04-03
RICE KC 003072 04-02
RICH ES 003711 04-13
RICHARDS DJ 003605 04-10
RICHARDS JG 000156 01-03, 001629 02-05
RICHAROS WA 001877 02-12
RICHARDSON JC 001904 02-13
RICHARDSON R 001555 02-04
RICHARDSON TL 003250 04-03
RICHMAN BW 000944 01-15, 001038 01-17
RICHTER D 003026 03-17
RICHTER JA 003251 04-03
RICHTER R 001987 02-14, 003690 04-13
RICHTER WR 001639 02-05
RICKELS K 001033 01-17, 001050 01-17, 002124 02-17, 003597 04-10, 003598 04-10, 003599 04-10, 003600 04-10
RICKLES K 001805 02-10
RICKLES WH 001982 02-14
RICKMAN EE 001787 02-10
RIDOLE KD 000912 01-14
RIDGES AP 000652 01-09
RIDOLO P 000941 01-15
RIEDERER P 002588 03-07
RIEGER H 000253 01-03, 003274 04-03
RIESENBERG RA 003768 04-15
RIFE SS 003770 04-15
RIFFEE WH 001341 02-03, 003252 04-03, 003253 04-03
RIFKIN A 002157 02-17, 002927 03-15, 003547 04-08, 003818 04-15
RIFKIN SI 003822 04-15
RIGGI F 000536 01-08, 001680 02-08, 001681 02-08
RIGTER H 002188 03-02, 003447 04-04
RIKER WK 003224 04-03
RILEY AL 000913 01-14
RILEY CC 001119 02-03
RILEY E 001157 02-03
RILEY GJ 002693 03-09

ILEY T 002072 02-15
IM CS 002776 03-11
IMON R 000519 01-07, 001687 02-08, 002014 02-15, 002209 03-03, 002800 03-13
ING8ERGER V 003654 04-13, 003709 04-13
INGWALD E 001671 02-07
IORDAN CE 000982 01-15
ISDALL PC 001674 02-07
ISNER ME 001342 02-03, 002524 03-04
ITSCHEL WA 002604 03-07
IVA D 000703 01-10
IVERA-CALIMLIM L 000861 01-13, 002346 03-03
IVERS W 002581 03-05
IZVI ZA 001985 02-14
IZZOLI G 000783 01-11
O8AGLIA J 002924 03-15
OBBINS T 001538 02-04
OBBINS TW 000412 01-04, 001113 02-02, 001567 02-04, 003454 04-04
O8ERGE AG 003254 04-03
O8ERGE C 000007 01-01
OBERT G 000773 01-11
OBERTS PJ 001237 02-03
O8ERTSON HA 001343 02-03
O8INS E 000883 01-14
O8INS RK 003066 04-02
O8INSON AM 003531 04-08
O8INSON CR 001988 02-14
O8INSON DS 002073 02-15
OBINSON FM 003063 04-02
OBINSON GMH 002784 03-11
O8INSON JS 000456 01-05
OBINSON SE 002347 03-03
OBINSON TE 002403 03-03
O8Y DM 001119 02-03
OCCATAGLIATA G 002694 03-09
OCCO G 000773 01-11
OCHA AV 001806 02-10, 001810 02-10
OOA G 003052 04-01, 003060 04-01
OOA 8E 000889 01-14, 001902 02-13, 002032 02-15
ODE A 002618 03-08
OOERO JM 000311 01-04
OOGERS RJ 000410 01-04, 002348 03-03
ODIN E 003452 04-04
ODIN EA 002776 03-11
OOIN M 003452 04-04
OOVA A 002647 03-08
ODRIGUEZ C 001934 02-13
ODRIGUEZ-SIERRA JF 002525 03-04
OEHRS T 000390 01-04
OESSLER RL 001787 02-10
OFFMAN M 000218 01-03
OFFWARG H 003660 04-13
OGAN F 003081 04-03
OGERS B 000401 01-04, 003439 04-04
OGERS D 000401 01-04
OGERS KJ 000183 01-03, 001301 02-03
OGERS MH 003535 04-08
OGERS MV 001844 02-11
OHMER F 002928 03-15
OHR8ACH KW 002468 03-04
OHR8ERG RG 001989 02-14
OIZIN L 002581 03-05
OLLANDI R 000044 01-03
OLLS ET 000422 01-04, 001296 02-03
OLSTEN C 001353 02-03
OMAN G 003555 04-09, 003574 04-09
OMANO D 000852 01-13
OMEU J 003027 03-17
OMI JC 000547 01-08, 002728 03-10
OMILDO 8UENO J 001806 02-10
OMMELSPACHER H 001569 02-04, 003255 04-03
ONAI AZ 001344 02-03, 003296 04-03
OOKE KC 001675 02-07
OOS B 001030 01-17, 002844 03-13
OOSDORP N 001942 02-13
OOTS I 003702 04-13
OPARTZ P 000386 01-04, 002555 03-04
OPER M 003539 04-08
OQUEFEUIL B 000914 01-14
OSA A 003631 04-11
OSE O 003256 04-03
OSECRANS JA 002526 03-04, 003401 04-04
OSEN 8 002116 02-17
OSEN M 002808 03-13
OSEN8ERG A 001311 02-03
OSEN8ERG HC 002516 03-04
OSEN8ERG L 000587 01-09
ROSENBERG P 003453 04-04
ROSENFELD H 001805 02-10, 003600 04-10
ROSENFELD JP 002527 03-04, 003257 04-03
ROSENGARTEN H 000564 01-08, 001091 02-01
ROSENTHAL E 000461 01-05
ROSENTHAL JH 002863 03-14
ROSENTHAL M 003203 04-03, 003294 04-03
ROSHCHINA LF 002349 03-03
ROSIN AJ 003893 04-17
ROSMAN NP 003258 04-03
ROSNER H 000210 01-03
ROSOFF CJ 000634 01-09
ROSS CA 001404 02-03, 001570 02-04
ROSS DH 000070 01-03
ROSS DM 001854 02-11
ROSS LL 001347 02-03
ROSS MS 003641 04-11
ROSS RA 000211 01-03
ROSS S 000450 01-04, 003044 03-17
ROSS SA 001854 02-11
ROSS SB 000212 01-03, 000213 01-03, 000214 01-03, 000513 01-07, 001345 02-03, 001571 02-04
ROSS WD 003601 04-10
ROSSER R 002074 02-15, 003028 03-17
ROSSI AM 003746 04-14
ROSSI NA 002528 03-04
ROSSI S 001101 02-02
ROSSNER M 002681 03-09
ROSZKOWSKI AP 001346 02-03
ROTH 8 000870 01-13
ROTH D 003349 04-04
ROTH JA 001937 02-13
ROTH RH 001910 02-13, 002587 03-06, 003154 04-03
ROTH WT 002001 02-14, 003894 04-17
ROTH-SCHECHTER 8F 003259 04-03
ROTHMAN TP 001347 02-03
ROTHWEILER R 002793 03-11
ROTIROTI D 001310 02-03
ROTROSEN J 000478 01-07, 002832 03-13
ROUFOGALIS 8D 001348 02-03
ROUGER E 001874 02-12
ROUSH BW 003148 04-03
ROUSSELLE JC 001201 02-03
ROUTTENBERG A 001262 02-03, 003433 04-04
ROUX J 002593 03-07
ROVEI V 000046 01-03
ROVERE C 000536 01-08, 001680 02-08, 001681 02-08
ROWAN J 000791 01-12
ROWE CE 000117 01-03
ROWLANO M 001138 02-03
ROWLEY VN 000330 01-04, 001491 02-04
ROY AC 002225 03-03
ROY EJ 002450 03-04, 003260 04-03
ROZOILSKY 8 000206 01-03
ROZITIS A 001152 02-03
ROZONOV Y8 001636 02-05
RUBIN RT 000514 01-07
RUBOVITS R 002675 03-09
RUCH W 001159 02-03, 001359 02-03
RUCH-MONACHON M 001230 02-03
RUCKE8USCH Y 000464 01-05
RUDOLPH M 001990 02-14
RUOY JW 003506 04-05
RUOY TA 001424 02-03, 003332 04-03, 003333 04-03
RUDY V 001703 02-08
RUELIUS HW 001914 02-13
RUGER U 001766 02-09, 002075 02-15
RUGGIERI GO 001092 02-01
RUH-BERNHARDT O 002928 03-15
RUIMY DD 003407 04-04
RUIZ E 003759 04-15
RUIZ OGARA C 002158 02-17
RUIZ PELAEZ JG 002831 03-13
RUIZ R 000565 01-08
RUMP S 001637 02-05
RUSOVA TV 002287 03-03
RUSSEK E 000748 01-11
RUSSELL GFM 001774 02-09
RUSSELL NJ 003224 04-03
RUSSFIELD A 003801 04-15
RUSTIA JK 003770 04-15
RUSZCZEWSKI P 001349 02-03
RUTANEN S 000454 01-05
RUTHER E 001990 02-14
RUTKOWSKI R 000774 01-11
RUTLEDGE CO 000064 01-03, 000935 01-15, 001831 02-11
RYAN JR 003400 04-04
RYBAKOWSKI J 000704 01-10, 002695 03-09, 002696 03-09
RYDZYNSKI Z 002777 03-11
RYZHOV IV 001271 02-03

S

SAAD SF 002350 03-03
SAARI M 001323 02-03
SAARIO I 002929 03-15
SAARMA J 000705 01-10
SAARMA M 000705 01-10
SAARNIVAARA L 001288 02-03, 001350 02-03
SAAVEDRA JMM 002254 03-03
SABAN R 003261 04-03
SA8ELLI HC 001351 02-03, 002833 03-13, 003262 04-03
SA8LE-AMPLIS R 001352 02-03
SA8LOSKY L 003597 04-10, 003600 04-10
SACCHETTI E 002834 03-13
SACHAR EJ 001916 02-13, 002159 02-17, 002832 03-13, 002897 03-15, 003684 04-13, 003881 04-17
SACHS 8D 001477 02-04
SAFER O 001855 02-11
SAFTA L 000411 01-04
SAGDUYU H 003198 04-03
SAHA S 000042 01-03
SAHAKIAN 8J 000412 01-04, 003454 04-04
SAHGAL A 003475 04-04
SAHN SA 000960 01-15
SAIOEL DR 001875 02-12
SAIER J 003350 04-04
SAITO M 000653 01-09, 000753 01-11, 001251 02-03
SAITO R 002586 03-06
SAITO S 000348 01-04, 002473 03-04
SAITO Y 000654 01-09, 000745 01-11, 002356 03-03, 002820 03-13, 002895 03-15
SAKAGUCHI N 000562 01-08
SAKAMOTO F 002930 03-15
SAKAMOTO M 002930 03-15
SAKURAOA O 002367 03-03
SAKURADA S 002281 03-03, 002539 03-04
SAKURAI M 000566 01-08
SALDANA H 000486 01-07
SALOANA HERNANOEZ OH 002697 03-09
SALES M 000961 01-15
SALETU 8 000915 01-14, 001773 02-09, 001991 02-14, 002873 03-14
SALIS PJ 001973 02-14, 003563 04-09
SALMAN KN 001097 02-01
SALMI T 000131 01-03
SALMONA M 000190 01-03, 002846 03-13
SALVAOORINI S 000018 01-01
SALVESEN C 001992 02-14
SAMAIN W 000816 01-13
SAMANIN R 001140 02-03, 003455 04-04
SAMANO AF 002083 02-15
SAMEC VV 002778 03-11
SAMET CM 003642 04-11
SAMJEE A 000650 01-09
SAMORAJSKI T 001353 02-03
SAMPATH-KHANNA S 002298 03-03
SAMPSON L 002351 03-03
SAMPSON SR 000215 01-03
SAMUEL O 003263 04-03
SAMUELS S 000406 01-04
SAMVELYAN VM 001354 02-03
SANAVIO C 000805 01-13
SAN8ORN CR 001322 02-03
SANCHEZ E 000414 01-04
SANDBERG D 003276 04-03
SANDGAROE 8 002094 02-16
SANDIFER MG 003823 04-15
SANDLER K 000515 01-07
SANDMAN CA 003319 04-03
SANOS JM 003029 03-17
SANDS R 003029 03-17
SANER A 000156 01-03, 003264 04-03
SANFORD CS 002222 03-03
SANGANI H 002738 03-11
SANGER DJ 000216 01-03, 000413 01-04, 001572 02-04, 001573 02-04, 002529 03-04
SANGUINETTI AM 003432 04-04
SANNERSTEDT R 000866 01-13

SANNITA WG 002874 03-14
SANO T 000102 01-03, 002284 03-03, 002S10 03-04
SANSONE G 00080S 01-13
SANTACANA MP 000414 01-04
SANTACROCE P 000679 01-10
SANTAGOSTINO A 000323 01-04, 000324 01-04
SANTALO R 0036S6 04-13
SANTEN R 000877 01-14
SANTOS MR 002728 03-10
SANYAL AK 0000S0 01-03
SAPIO M 00272S 03-10
SARACENI C 000673 01-10
SARAF K 002861 03-14
SARAF KR 000988 01-1S
SARAI K 000S63 01-08
SARAN BM 001774 02-09
SARANTAKIS D 001278 02-03, 003309 04-03
SARAU H 001S78 02-04
SARGENT T 0023S2 03-03
SARGES R 003075 04-02
SARNEK J 001286 02-03
SARNO M 001680 02-08
SARTESCHI P 000706 01-10, 002106 02-17
SASA M 002353 03-03, 003266 04-03
SASAKI K 001661 02-07
SASAKI T 000S63 01-08
SASSENRATH EN 001S74 02-04
SASTRY BSR 0013SS 02-03, 0023S4 03-03, 0034S6 04-04
SATHANANTHAN GL 00177S 02-09
SATHANANTHAN K 000S94 01-09
SATINOER KP 001S7S 02-04
SATO C 002931 03-1S
SATO K 00236S 03-03
SATO M 000788 01-11, 0013S6 02-03, 0022S2 03-03, 002277 03-03, 002474 03-04, 002S30 03-04
SATO S 003643 04-11
SATO T 001993 02-14, 002530 03-04
SATOH H 0023SS 03-03
SATOH M 001268 02-03, 0013S7 02-03
SATOH Y 0023SS 03-03
SATOMI R 000S81 01-09, 0006S4 01-09, 0023S6 03-03, 002820 03-13
SAVAGE C 001856 02-11, 003623 04-11
SAVERY F 001938 02-13
SAWA A 001358 02-03
SAWADA H 0023S7 03-03
SAXENA B 002904 03-15
SAYERS AC 0011S9 02-03, 001359 02-03, 001S76 02-04
SAYLE D 003030 03-17
SBOROONE RJ 002S31 03-04
SCARONE S 001994 02-14
SCARPINO O 000760 01-11
SCATTON B 000217 01-03
SCERNI RA 00004S 01-03
SCHACH S 00164S 02-06
SCHACHT U 003200 04-03
SCHACHTER S 003703 04-13, 003707 04-13
SCHACT J 000427 01-04
SCHAEFER A 003267 04-03
SCHAEFER CF 003824 04-1S
SCHAEFER GJ 002466 03-04, 0034S7 04-04
SCHAFER N 000916 01-14
SCHAFFNER R 0003S8 01-04, 001230 02-03
SCHAIN RJ 003747 04-14
SCHALLEK W 001360 02-03
SCHALLERT T 002403 03-03, 003324 04-03
SCHALLING D 00088S 01-14, 00184S 02-11
SCHALLY AV 000203 01-03, 002480 03-04, 003319 04-03
SCHANBERG SM 000343 01-04, 003299 04-03
SCHANOA H 001773 02-09
SCHAPIRA K 003644 04-11
SCHARBACH H 000S16 01-07, 001807 02-10
SCHARF MB 000748 01-11, 003737 04-14
SCHATZBERG AF 000218 01-03
SCHECHTER MD 002S26 03-04
SCHECTER C 001041 01-17
SCHEEL-KRUGER J 0011S4 02-03, 003268 04-03
SCHENKER S 003499 04-0S
SCHERMER M 002926 03-15
SCHERRER P 002779 03-11
SCHEULER W 001884 02-13, 001885 02-13
SCHIELE BC 000600 01-09
SCHIFF AA 001731 02-09, 001939 02-13, 002646 03-08, 003564 04-09
SCHIFF PL 001084 02-01
SCHIFFMAN HR 000997 01-15
SCHIFFTER R 002878 03-14
SCHILDKRAUT JJ 000218 01-03
SCHILLINGS RT 001914 02-13
SCHINDLER R 001069 01-17
SCHINK P 002754 03-11
SCHIPPER J 000236 01-03
SCHIRMER EW 000006 01-01
SCHLANT RC 003138 04-03
SCHLEMMER RF 00041S 01-04
SCHLESINGER J 000951 01-1S
SCHLESS A 003600 04-10
SCHLESS AP 003S66 04-09
SCHMELING WT 000219 01-03
SCHMIDT CW 003763 04-15
SCHMIDT D 001940 02-13, 003880 04-17
SCHMIOT H 003458 04-04
SCHMIDT HS 003748 04-14
SCHMIDT J 003S73 04-09
SCHMIDT RT 001070 01-17
SCHMIDT TH 000916 01-14
SCHMIDT W 0034S9 04-04
SCHMITS R 003492 04-0S
SCHMITT H 001469 02-04
SCHMITZ I 00077S 01-11
SCHNEEWINO U 00091S 01-14
SCHNEIOER C 000298 01-04
SCHNEIDER CW 000237 01-03
SCHNEIDER D 001361 02-03
SCHNEIDER H 001071 01-17
SCHNEIDER JF 002S81 03-05
SCHNEIDERMAN B 000220 01-03
SCHNELL RC 003S05 04-0S
SCHNEYER JJ 000707 01-10
SCHNIEDEN H 000443 01-04, 001S77 02-04
SCHOCKER W 003269 04-03
SCHOENFELD H 002209 03-03
SCHOENFELD WN 003270 04-03
SCHOEPF J 002797 03-12
SCHONECKE OW 000708 01-10, 000916 01-14
SCHONHOFER PS 002208 03-03, 0024S9 03-04
SCHOOLAR JC 00389S 04-17
SCHOOLER NR 000776 01-11, 003S39 04-08
SCHOONOVER SC 002103 02-17
SCHOOR M 001919 02-13
SCHOPF J 001867 02-12
SCHORDERET M 003271 04-03
SCHOTMAN P 000112 01-03
SCHOTT G 000777 01-11
SCHOTTOORF B 003667 04-13
SCHOU M 001072 01-17, 001857 02-11, 002160 02-17, 002383 03-03, 00266S 03-09, 002698 03-09, 002932 03-1S, 003031 03-17, 003864 04-17
SCHREIBER H 002532 03-04
SCHREIBER HL 000416 01-04, 003487 04-04, 003S07 04-0S
SCHROEDER DJ 0037S7 04-14
SCHROEDER JS 002840 03-13
SCHROEDER NH 003896 04-17
SCHROLD J 003229 04-03
SCHRYVER HF 0014S2 02-04
SCHUBERT H 001654 02-07
SCHUBRING G 002880 03-14
SCHUCKIT M 001941 02-13
SCHUEFFEL W 000708 01-10
SCHUENEMAN AL 001984 02-14
SCHULER ME 001346 02-03
SCHULTE AM ESCH J 000221 01-03
SCHULTE PW 000992 01-1S
SCHULTE W 001794 02-10
SCHULTES RE 001073 01-17, 001093 02-01
SCHULTZ R 001346 02-03
SCHULZ J 003269 04-03
SCHULZ R 000222 01-03, 003272 04-03
SCHULZE G 003273 04-03
SCHUMACHER GE 001079 01-17
SCHUMPELICK V 000223 01-03
SCHUPP RR 000917 01-14
SCHUPPEL R 001711 02-08
SCHUSTER CR 000890 01-14, 001639 02-05, 002533 03-04
SCHUSTER P 002671 03-09
SCHUTZ H 003274 04-03
SCHUTZ R 003181 04-03
SCHUURMAN T 003444 04-04
SCHUYTEN-RESNICK E 001853 02-11
SCHWABE U 0023S8 03-03
SCHWARTZ AS 000417 01-04
SCHWARTZ G 002648 03-08
SCHWARTZ J 000039 01-03
SCHWARTZ JC 002S21 03-04, 003089 04-03
SCHWARTZ LK 000S12 01-07
SCHWARTZ MA 000819 01-13, 002805 03-13
SCHWARZ D 002691 03-09
SCHWARZ E 003690 04-13
SCHWEITZER J 003116 04-03
SCHWEITZER JW 000793 01-12, 003219 04-03
SCHWERTNER HA 003100 04-03, 0033S5 04-04
SCHYVE P 003689 04-13
SCIANNANDRONE R 000848 01-13
SCOGGINS B 000S93 01-09
SCOGGINS BA 0006S5 01-09, 000880 01-14, 001193 02-03, 002023 02-1S, 003552 04-09
SCOLLAN EL 002480 03-04
SCOPPOLA L 0008S2 01-13
SCOTT DF 001961 02-14
SCOTT JF 000847 01-13
SCOTT JP 003421 04-04
SCOTTO J 0006S6 01-09
SCOTTO JC 002S89 03-07
SCRIABINE A 0014S9 02-04, 00327S 04-03
SCUVEE-MOREAU J 001191 02-03
SEALES DM 001941 02-13
SEARS RJ 002S34 03-04
SEBENS JB 001922 02-13
SECAREANU A 000411 01-04, 000711 01-10
SECHZER PH 001676 02-07
SEDOVA KS 002S72 03-0S
SEDRUP J 003866 04-17
SEDVALL G 001362 02-03, 002086 02-16, 0020 02-16, 00283S 03-13, 002836 03-13, 0036S3 04-13, 003704 04-13
SEEBER U 001363 02-03, 0023S9 03-03
SEEMAN P 000474 01-06, 001481 02-04
SEGAL A 001805 02-10, 002124 02-17
SEGAL D 003397 04-04
SEGAL DS 000418 01-04, 000842 01-13, 001S0 02-04, 002S3S 03-04
SEGAL M 003276 04-03
SEGAL R 0018S8 02-11
SEGELMAN AB 000983 01-1S
SEGELMAN FP 000983 01-1S
SEGRE E 001934 02-13
SEIOAH N 00387S 04-17
SEIOEN LS 002332 03-03
SEIOLER FJ 001377 02-03, 002370 03-03
SEIGER A 001398 02-03
SEIMEON J 00364S 04-11
SEITZ H 00260S 03-07
SEKI M 002S67 03-0S
SEKITA K 002S69 03-0S
SELBMANN H 000916 01-14
SELORUP J 000S86 01-09, 003807 04-1S, 0038 04-17
SELLAB 000419 01-04
SELLERS EM 000778 01-11, 000868 01-13, 001 02-11
SELLIN LC 001247 02-03
SELLMAN R 000S17 01-07, 000862 01-13, 000 01-13, 000864 01-13
SELMAN FB 000567 01-08
SELWYN A 001862 02-11
SEMPLE JM 002348 03-03
SEN AK 002837 03-13
SENAULT B 000420 01-04
SENAY EC 003898 04-17
SENEKOWITSCH R 001306 02-03
SENN H 003825 04-1S
SENON D 001469 02-04
SENTENAC-ROMANOU H 003139 04-03
SEP-KOWALIKOWA B 002608 03-08
SEPINWALL J 00243S 03-04
SEPPALA T 001995 02-14, 002933 03-1S
SERBAN G 002161 02-17
SEREGI A 003267 04-03
SERGEYEV PV 001364 02-03, 002360 03-03
SERLICK ER 003084 04-03
SERMAS CE 001701 02-08
SEROVA LI 000186 01-03
SETEKLEIV J 000812 01-13
SETHNA DM 000285 01-04
SETHY VH 00136S 02-03
SETLER P 001S78 02-04
SETYONEGORO RK 000743 01-11
SEVERS WB 001115 02-02
SEWELL J 0018S9 02-11

SEWELL RDE 001366 02-03
SEYAL M 002361 03-03
SEYFRIED C 001367 02-03
SHADER RI 000865 01-13, 001074 01-17, 001862 02-11, 001914 02-13, 002599 03-07, 003675 04-13, 003705 04-13, 003731 04-14, 003788 04-15, 003789 04-15, 003830 04-15
SHAFER G 001317 02-03
SHAGASS C 003710 04-13
SHAH BK 001651 02-06
SHAH NS 001229 02-03
SHAMMAS E 003602 04-10
SHANKS C 000778 01-11
SHANKS RG 002591 03-07
SHANLEY BC 003237 04-03
SHANNON HE 000421 01-04, 002362 03-03, 002466 03-04, 003460 04-04
SHAPIRO AK 000807 01-13
SHAPIRO BH 001368 02-03
SHAPIRO E 000807 01-13
SHAPIRO RW 000649 01-09
SHARMA HL 001534 02-04
SHARMA RP 001369 02-03
SHARMA VN 001534 02-04
SHARPLESS NS 002388 03-03
SHASKAN EG 000568 01-08, 003658 04-13
SHAW OM 000657 01-09, 002693 03-09
SHAW JP 001370 02-03
SHAW SG 000422 01-04
SHAYDROV VV 001628 02-05
SHEARD MH 000423 01-04, 001371 02-03, 001508 02-04, 001842 02-11, 001996 02-14, 003461 04-04, 003741 04-14
SHEARER DE 002563 03-05
SHEFFIELD BF 003592 04-10, 003840 04-16
SHELDRAKE P 002B75 03-14
SHELENKOVA SA 002363 03-03
SHELLENBERGER MK 001638 02-05, 003158 04-03
SHEN F 001604 02-04
SHEPPARD C 002162 02-17, 002163 02-17
SHERING A 001776 02-09
SHERLOCK S 003635 04-11
SHERMAN AD 000224 01-03, 002364 03-03, 002574 03-05
SHERMAN DG 000681 01-10, 002729 03-10
SHERMAN WR 001002 01-16
SHETH UK 003228 04-03
SHETTY T 001860 02-11
SHIBATA K 002366 03-03
SHIBUYA K 002536 03-04
SHIBUYA T 002365 03-03, 002467 03-04
SHICK JFE 000890 01-14
SHIFFMAN SM 000951 01-15
SHIGEHISA T 001523 02-04
SHIH JC 003517 04-06
SHIMA K 002281 03-03
SHIMADA A 002366 03-03
SHIMADA K 002575 03-05
SHIMAMOTO J 002378 03-03
SHIMAO S 002921 03-15
SHIMAZONO Y 002732 03-10
SHIMAZU T 001372 02-03
SHIMIZU H 001095 02-01
SHIMIZU J 000569 01-08
SHIMIZU M 000139 01-03, 001250 02-03, 001582 02-04, 002244 03-03, 002273 03-03, 002515 03-04, 003706 04-13
SHINODA A 002537 03-04
SHINOHARA M 002367 03-03
SHINTOMI K 002538 03-04
SHIRAZAWA H 003032 03-17
SHOHAM-MOSHONOV S 002845 03-13
SHOHAM-MOSHONOV SR 003277 04-03
SHOJI T 002539 03-04
SHOPSIN B 001211 02-03, 001777 02-09, 001876 02-12, 001955 02-14, 002076 02-15, 002164 02-17, 002876 03-14, 003861 04-17
SHORT PH 000225 01-03
SHORTLIDGE JS 000022 01-02
SHOSTAK M 001749 02-09, 001935 02-13, 003560 04-09, 003674 04-13
SHOULSON I 000501 01-07, 002592 03-07
SHULGIN AT 000226 01-03, 001114 02-02, 002186 03-01, 002352 03-03
SHUMILINA AI 002368 03-03
SHURLEY JT 003603 04-10
SHUSTER L 000225 01-03, 00327B 04-03
SHYBUT GT 001639 02-05
SIBLEY DH 001506 02-04
SIBONY O 002672 03-09
SIDOROWICZ S 002669 03-09
SIDOROWICZ W 002659 03-08
SIEGEL RK 000424 01-04, 000984 01-15, 001451 02-04, 002540 03-04, 003358 04-04
SIEGEL S 000227 01-03, 003462 04-04
SIEMENS AJ 001373 02-03
SIEMSEN FK 000415 01-04
SIEROSLAWSKI H 002873 03-14
SIGG EB 003194 04-03
SIGGINS GR 002369 03-03
SIGNORELLI A 000425 01-04
SIIRTOLA T 000832 01-13
SILBERFARB P 001972 02-14
SILBERMANN RM 000709 01-10
SILVERMAN AP 001579 02-04
SILVERMAN H 003597 04-10
SILVERMAN LM 001632 02-05
SILVERMAN M 003033 03-17
SILVERMAN PB 003034 03-17
SILVERSTEIN B 003703 04-13, 003707 04-13
SILVERSTONE JT 003604 04-10
SILVESTRINI B 001374 02-03
SIMANTOV R 000015 01-01, 003279 04-03
SIMARD N 002165 02-17
SIMINSKA W 002777 03-11
SIMON FR 000158 01-03
SIMON NM 002934 03-15
SIMON P 001589 02-04, 002427 03-04, 002544 03-04, 002653 03-08, 003035 03-17
SIMON RP 003826 04-15
SIMON SM 003407 04-04
SIMONOVICH M 003222 04-03
SIMONSEN N 001861 02-11
SIMONYAN IM 001305 02-03
SIMPSON CW 000181 01-03
SIMPSON DM 002877 03-14
SIMPSON GM 000985 01-15, 001715 02-08, 001746 02-09, 00177B 02-09, 001898 02-13, 001899 02-13, 002021 02-15, 002935 03-15, 003527 04-08, 003592 04-10, 003840 04-16
SIMPSON LL 000986 01-15, 001494 02-04, 002780 03-11
SINCLAIR JG 001355 02-03, 002354 03-03, 003456 04-04
SINCLAIR JM 000658 01-09
SINGER E 000202 01-03
SINGER G 002171 02-17
SINGER L 002928 03-15
SINGER R 003604 04-10
SINGH AN 000710 01-10
SINGH B 002720 03-10
SINGH JKG 001134 02-03
SINGH MM 001716 02-08, 001717 02-08, 002654 03-08
SINGH PP 000228 01-03
SINGHAL RL 001120 02-03, 00324B 04-03, 003249 04-03, 003449 04-04
SINKHORN C 003890 04-17
SINN M 002878 03-14
SIRBU A 000411 01-04, 000711 01-10
SIRIS S 003041 03-17
SIRIS SG 003857 04-17
SISENWINE SF 001914 02-13
SITARAM N 002879 03-14, 003708 04-13, 003749 04-14
SIUCHNINSKA H 000574 01-08, 002748 03-11
SIVIT C 003240 04-03
SIWERS B 003555 04-09, 003574 04-09, 003709 04-13
SJOBERG N 002114 02-17
SJODIN T 001942 02-13
SJOHOLM I 001942 02-13
SJOLUND B 001943 02-13
SJOQVIST F 003654 04-13, 003709 04-13
SJOSTROM R 000669 01-09, 000871 01-13
SKANBERG I 000054 01-03
SKARYSZEWSKA-SAWICKA J 002655 03-08
SKAUG OE 00091B 01-14
SKINNER DM 001580 02-04
SKLAR L 003481 04-04
SKLAR LA 003508 04-05
SKLAR LS 000271 01-04
SKOCZKOWSKI J 002664 03-08, 003036 03-17
SKOLNICK P 001375 02-03, 001376 02-03
SKOTT A 002B44 03-13
SLAMA B 002724 03-10
SLATER IH 002195 03-02
SLATER P 000290 01-04
SLATER S 003666 04-13
SLATKIN DJ 001084 02-01
SLEATOR EK 001814 02-11
SLIWINSKA-PRZYJEMSKA H 000548 01-08
SLOBETZ F 000982 01-15, 002174 02-17
SLOGGEM J 002059 02-15
SLOMAN JG 002023 02-15
SLOMINSKA-ZUREK J 002463 03-04
SLONIEC M 002561 03-04
SLOTKIN TA 000150 01-03, 001377 02-03, 001378 02-03, 002370 03-03, 003299 04-03
SLOTNICK RN 003144 04-03
SLOVITER HA 002371 03-03
SMALL IF 003750 04-14
SMALL JG 003750 04-14
SMEE ML 002541 03-04
SMERALDI E 002834 03-13
SMILEY KA 001379 02-03
SMIRNOVA YI 002251 03-03
SMITH A 000512 01-07
SMITH BM 001302 02-03
SMITH CFC 002317 03-03
SMITH CM 003595 04-10
SMITH DE 002947 03-15, 002985 03-17
SMITH DF 001380 02-03, 001581 02-04, 0015B2 02-04, 002542 03-04, 003706 04-13
SMITH F 003529 04-08
SMITH HH 003827 04-15
SMITH J 000518 01-07
SMITH JM 001718 02-08
SMITH JR 001997 02-14
SMITH LS 003827 04-15
SMITH M 003469 04-04
SMITH MC 003037 03-17, 003899 04-17
SMITH N 001557 02-04, 002292 03-03, 002499 03-04
SMITH P 003345 04-04
SMITH RC 001583 02-04, 002939 03-15
SMITH RV 000229 01-03
SMITH SG 000255 01-03, 002437 03-04, 002543 03-04
SMITH SH 001644 02-05
SMITH TC 001944 02-13
SMITH VK 002982 03-17
SMITS JF 000230 01-03
SMITS SE 001242 02-03, 001584 02-04
SMOKCUM RWJ 003322 04-03
SMOLNIKOVA NM 002341 03-03
SMOLYANIKOVA NM 002576 03-05
SMULEWICZ AB 002699 03-09
SMYTH DG 001147 02-03, 002453 03-04
SMYTH MR 001294 02-03
SMYTH RD 001905 02-13
SMYTH RG 003280 04-03
SMYTHIES JR 0019B8 02-14, 0032B1 04-03
SNAITH RP 000530 01-08
SNEAD OC 003282 04-03
SNELL CR 001147 02-03, 002453 03-04
SNELL JD 001503 02-04
SNIDER RS 0032B3 04-03
SNIDER SR 001585 02-04, 0032B3 04-03
SNODDY HD 000101 01-03
SNOW AE 001381 02-03
SNYDER BD 001808 02-10
SNYDER EW 0015B6 02-04, 003509 04-05
SNYDER S 000526 01-08
SNYDER SH 000015 01-01, 000071 01-03, 001406 02-03, 001909 02-13, 002253 03-03, 002997 03-17, 003134 04-03, 003235 04-03, 003279 04-03, 003284 04-03, 003493 04-05, 003510 04-05
SNYDER T 001033 01-17
SOBARI T 000743 01-11
SOBIESZEK A 000159 01-03
SOBRINO Z. A 002730 03-10
SOCZYNSKA J 002662 03-08
SODERHOLM S 000519 01-07
SOFIA D 000983 01-15
SOFIA RD 000426 01-04, 0032B5 04-03
SOKOLOFF L 002367 03-03
SOLDATOS CR 000877 01-14
SOLOMON GE 000807 01-13
SOLOMON J 000338 01-04
SOLOMON K 002166 02-17, 003828 04-15
SOLOMON PR 002508 03-04
SOLOMON T 001823 02-11
SOLOW RA 003038 03-17
SOLVELL L 000B27 01-13, 00082B 01-13, 000B59 01-13

SOLYOM L 000672 01-10
SOMERVILLE 8W 003039 03-17
SOMOHANO MOP 002730 03-10
SOMORI A 000668 01-09
SOMS AP 001618 02-05
SONTAG KH 002223 03-03
SORENSEN R 002665 03-09
SORENSON CA 001587 02-04
SORIMACHI M 002467 03-04
SOSKIN RA 001877 02-12
SOTHMAN A 000836 01-13
SOTZING JH 001588 02-04
SOU8RIE P 001589 02-04, 002427 03-04, 002544 03-04
SOULAIRAC AA 000919 01-14
SOULAIRAC ML 000919 01-14
SOURKES TL 001395 02-03, 003125 04-03, 003467 04-04, 003553 04-09
SOUSA-POZA JF 001989 02-14
SOUTHWICK P 001546 02-04
SOUTO LOPES J 000645 01-09
SOWELL JW 002196 03-02
SPADARO P 002610 03-08
SPALOING JC 003603 04-10
SPANO PF 000242 01-03, 001225 02-03, 001382 02-03, 001383 02-03, 002372 03-03
SPAR8ER S8 000198 01-03, 000461 01-05, 002311 03-03, 003388 04-04
SPAULOING JH 003489 04-04
SPECKEN8ACH W 002373 03-03
SPECTOR N 001775 02-09
SPECTOR S 001775 02-09, 002805 03-13, 003141 04-03
SPEHLMANN R 001070 01-17, 003286 04-03
SPEISER Z 000231 01-03, 003518 04-06
SPENCE MA 003627 04-11
SPENCER J 001384 02-03
SPENCER PSJ 001366 02-03, 003496 04-05, 003883 04-17
SPIEGEL AM 001748 02-09
SPIEGEL R 001978 02-14
SPIESS C 000069 01-03
SPIKER DG 002936 03-15
SPINGLER PJ 000167 01-03
SPINNLER H 000737 01-11
SPIRO HR 003236 04-03
SPIRTES MA 000203 01-03, 001945 02-13
SPOHN HE 002133 02-17
SPOTO G 001994 02-14
SPRAGUE G 001385 02-03
SPRAGUE GL 001386 02-03
SPRAGUE RL 001814 02-11
SPRING C 001998 02-14
SPRING GK 001779 02-09
SPRINGER AO 000427 01-04, 001590 02-04
SQUIRES R 000025 01-02
SQUIRES RF 001273 02-03, 003287 04-03
SRINIVASAMURTHY U 000694 01-10
STAAK M 002880 03-14
STAHL J 002826 03-13
STAHL SM 000558 01-08, 003288 04-03
STALLINGS MA 000935 01-15
STALLONE F 000601 01-09
STALVEY L 001591 02-04
STANCER HC 000252 01-03, 002672 03-09, 002837 03-13
STANORIDGE RT 001114 02-02
STANFIELO C 003712 04-13
STANG O 002374 03-03
STANGE G 000232 01-03
STANIKOWSKA I 002633 03-08
STANLEY M 003325 04-03, 003326 04-03
STANLEY ME 001592 02-04
STANSKI OR 001862 02-11
STANTON TL 001136 02-03
STARK P 003056 04-01, 003069 04-02
STARMER GA 000129 01-03, 002857 03-14, 002858 03-14
STARR OA 003900 04-17
STATON MA 003833 04-15
STAVINOHA W8 003050 04-01, 003289 04-03
STAVORSKI JM 003275 04-03
STAWARZ RJ 000053 01-03, 000250 01-03
STEEN8ERG ML 003067 04-02, 003183 04-03
STEFANINI E 000233 01-03, 001387 02-03, 001388 02-03
STFFANIS CN 001946 02-13
STEFANO G8 001389 02-03
STEIN 8 001585 02-04
STEIN J 003575 04-09
STEIN JM 003463 04-04
STEIN8ECK HF 001368 02-03
STEIN8ERG MS 002375 03-03
STEIN8ERG R 000033 01-03
STEINER A 002793 03-11
STEINER J 000987 01-15
STEINER M 003775 04-15
STEINFELS M 002167 02-17
STEINHAUSEN H 001863 02-11
STELLA VJ 003115 04-03
STEN8ERG J 000866 01-13
STENGER A 000151 01-03
STENGER RJ 001177 02-03
STENSON RL 002986 03-17
STEPANSKY P 001050 01-17
STEPANSKY W 001050 01-17
STEPHENS ON 000428 01-04
STERMAN M8 001640 02-05
STERN JM 001593 02-04
STERN P 000096 01-03, 001594 02-04
STEVENSON H 000677 01-10
STEVENSON J 002623 03-08, 003552 04-09
STEWART J 002440 03-04
STEWART JT 002376 03-03
STEWART MJ 003842 04-16
STEWART RM 000429 01-04, 000430 01-04
STEWART W 001596 02-04
STEWART WJ 001595 02-04, 003464 04-04
STICKGOLO A 002022 02-15
STIFF MP 000626 01-09
STILLMAN R 000022 01-02, 002838 03-13
STILLWELL WG 002376 03-03
STIMMEL GL 003760 04-15
STINUS L 000234 01-03
STITT FW 003525 04-07
STITZER M 003465 04-04
STOCK K 002459 03-04
STOCKARO JJ 001390 02-03
STOCKHAUS K 001111 02-02
STOFF OM 000022 01-02, 000235 01-03, 000387 01-04, 002504 03-04, 002505 03-04, 003431 04-04
STOKAN O 003740 04-14
STOKES PE 001999 02-14
STOLL K 002082 02-15
STONE 8M 001657 02-07
STONE CA 001459 02-04
STONE CJ 001391 02-03, 003290 04-03
STONE EA 002377 03-03
STONE GC 001873 02-12
STONE TW 001392 02-03
STOOF JC 000236 01-03
STORMS L 003733 04-14
STOTSKY 8A 003595 04-10
STRAIGHT RC 000796 01-12, 003509 04-05
STRAKER M 002168 02-17
STRAND LJ 001934 02-13
STRANDJORO RE 003664 04-13
STRANGE AW 000237 01-03
STRASSER H 002000 02-14
STRATTEN WP 003075 04-02
STRAUGHAN DW 002113 02-17
STRAUMANIS JJ 003710 04-13
STRAUSS J 000861 01-13
STRAUSS JS 003852 04-17
STRAUSS S 001569 02-04, 003255 04-03
STRAYHORN JM 003829 04-15
STREIFLER M 002871 03-14
STREKALOVA SN 002341 03-03, 002576 03-05
STRICHERZ ME 000920 01-14
STRICK PL 000431 01-04
STRICKER EM 000463 01-05
STRIPLING JS 003291 04-03
STROCCHI P 000238 01-03
STROLIN-8ENEOETTI M 003190 04-03
STROM8OM U 003466 04-04
STROMSAETHER CE 000812 01-13
STRU8ELT O 003231 04-03
STRUVE FA 000988 01-15
STRUYKER 8OUDIER HAJ 001562 02-04
STRUYKER-8OUOIER HA 000230 01-03
STRZYZEWSKI W 000704 01-10
STURTZ G 000011 01-01
STUTTE KH 002691 03-09
SU M 000432 01-04
SU PC 001304 02-03
SUAREZ EM 001597 02-04
SUAREZ RICHAROS M 002656 03-08
SU8IRA S 003570 04-09
SUCHENWIRTH R 000921 01-14
SUCHENWIRTH RMA 003755 04-14
SUEHIRO K 000692 01-10
SUENAGA N 003292 04-03
SUGANO K 002732 03-10, 002931 03-15
SUGAWARA M 002902 03-15
SUGIMOTO J 002378 03-03
SUGIURA S 003073 04-02
SUGRUE MF 001393 02-03
SUH M 002940 03-15
SUKYASYAN A 003526 04-07
SULKOWSKI A 003711 04-13
SULLIVAN FM 003511 04-05
SULLIVAN HR 002329 03-03
SULLIVAN JL 000944 01-15, 003712 04-13
SULMAN FG 002839 03-13
SULSER F 000053 01-03, 000250 01-03, 002347 03-03
SUMMER GK 001185 02-03
SUMMY-LONG JY 001115 02-02
SUN AY 001394 02-03, 003293 04-03
SUN GY 003293 04-03
SUN JY 000063 01-03
SUN S 003713 04-13
SUNDELL S 000935 01-15
SUNOT TM 000380 01-04
SUNKIN J 001647 02-06
SUTTER AR 003483 04-04
SUTTER JM 000520 01-07, 000656 01-09, 00258 03-07
SUTTON S 002830 03-13
SUWA N 000654 01-09, 000697 01-10, 000745 01-11, 002356 03-03, 002895 03-15
SUZMAN MM 002731 03-10
SUZUKI JK 001094 02-01, 001099 02-01
SUZUKI N 000581 01-09
SUZUKI S 000779 01-11, 002476 03-04, 002569 03-05
SUZUKI T 000712 01-10
SUZUKI Y 002077 02-15
SVENOSEN O 003070 04-02
SVENSSON TH 001223 02-03, 003466 04-04
SVESTKA J 002647 03-08
SWA8ACK DO 003534 04-08
SWAHN C 002094 02-16, 002835 03-13, 002836 03-13
SWAIN HH 003072 04-02
SWAIN T 001093 02-01
SWAMY VC 001361 02-03
SWANN A 001804 02-10
SWANSON JM 000922 01-14
SWEET R 000807 01-13
SWETT CP 003830 04-15
SWIRSKY SN 003604 04-10
SWISHER C 003835 04-15
SYAPIN PJ 001311 02-03
SYKES PA 001947 02-13
SYLVIA AL 003294 04-03
SYME GJ 003405 04-04
SYME LA 003405 04-04
SYMES AL 001395 02-03, 003467 04-04
SYNOER S 000527 01-08
SYVALAHTI E 000867 01-13
SZA8AOI E 001141 02-03, 001142 02-03, 00309 04-03, 003295 04-03
SZADOWASKA A 001641 02-05
SZAJNERMAN Z 002695 03-09
SZARVASI E 001116 02-02
SZASZ T 000521 01-07
SZE PY 000334 01-04, 002379 03-03
SZEKELY JI 000239 01-03, 001344 02-03, 00329 04-03
SZEMIS A 000659 01-09, 002655 03-08
SZILAGYI PIA 001227 02-03
SZKILNIK R 002463 03-04, 002578 03-05
SZLA8OWICZ JW 000660 01-09
SZMIGIELSKA H 001641 02-05, 001642 02-05
SZMIGIELSKI A 001631 02-05, 001641 02-05
SZPORNY L 000321 01-04
SZUCS VA 001106 02-02
SZULCZYNSKA K 002781 03-11
SZYOLIK H 002745 03-11
SZYMANSKA T 001637 02-05

T

TA8AKOFF 8 002380 03-03
TA8ERNER PV 003074 04-02

ACHI8ANA M 002937 03-15
ACHIKI KH 002381 03-03
ACKIE AN 001084 02-01
AOEUSIK CJ 001285 02-03
AOOKORO S 001112 02-02, 002488 03-04, 002489 03-04, 002490 03-04, 002513 03-04, 003416 04-04
AFUNAI SS 001780 02-09
AGASHIRA E 002545 03-04
AGASHIRA Y 003297 04-03
AGHAVY A 001948 02-13
AHEOL A 002945 03-15
AILLANOIER G 000433 01-04
AINER 8 003136 04-03
AIRA N 000121 01-03, 000185 01-03
AIT AC 000661 01-09
AKAOA K 002546 03-04
AKAGI A 000182 01-03
AKAGI H 001268 02-03, 002200 03-03, 003410 04-04
AKAGI K 002547 03-04
AKAHASHI K 000923 01-14
AKAHASHI KI 003734 04-14, 003736 04-14
AKAHASHI R 000182 01-03, 000566 01-08, 002381 03-03, 002700 03-09
AKAHASHI S 000551 01-08, 000570 01-08, 000741 01-11, 002700 03-09, 002782 03-11
AKAHASHI Y 000923 01-14
AKAHATA N 000697 01-10, 002895 03-15
AKAMURO M 001075 01-17
AKAORI S 000040 01-03, 003266 04-03
AKASHIMA S 002411 03-03
AKEICHI M 000465 01-05
AKEMORI AE 003204 04-03, 003334 04-03
AKENAGA J 003111 04-03
AKENAKA F 002326 03-03
AKEUCHI K 002547 03-04
AKEUCHI T 002938 03-15
AL E 002839 03-13
AMASY V 002485 03-04
AMMINGA C 002939 03-15
ANABE K 002410 03-03
ANAKA K 002937 03-15
ANAKA M 000902 01-14, 002510 03-04
ANAKA S 002326 03-03
ANG AH 003391 04-04
ANG 8K 003680 04-13
ANG LC 000023 01-02, 003118 04-03, 003473 04-04
ANJASIRI P 001396 02-03
ANNEN RH 003468 04-04
ANNER J 001770 02-09
ANSELLA M 000571 01-08, 000780 01-11, 002006 02-14
AO LC 001618 02-05
ARANSKAYA AD 002701 03-09
ARSY D 002883 03-15
ARVE US 002382 03-03
ASSIN JP 000240 01-03, 001150 02-03, 001151 02-03, 001397 02-03, 002342 03-03
ATARELLI R 002734 03-10
ATE OL 000781 01-11
ATEISHI M 001095 02-01
ATEISHI T 000182 01-03, 002381 03-03
ATSUYAMA T 002509 03-04
AUB A 003379 04-04
AUB J 003469 04-04
AVOLACCINI L 00262B 03-08
AYLOR D 00139B 02-03, 001399 02-03
AYLOR J8 003062 04-02
AYLOR JR 002708 03-09
AYLOR M 000434 01-04
AYLOR MA 001737 02-09
AYLOR O 003770 04-15
AYLOR P 003469 04-04
AYLOR SP 000924 01-14
ZIAUX P 002750 03-11
CCE JJ 003751 04-14
ETER RR 000600 01-09
GELER J 001744 02-09
JA JS 000572 01-08
LEGOY G 000364 01-04, 002487 03-04, 003415 04-04
LNER JI 000435 01-04
MPLE OJ 003714 04-13
MPLETON JL 000799 01-13
N 8ROEKE J 003063 04-02
N 8RUGGENCATE G 000033 01-03
NNANT FS 002783 03-11
TEO RKC 002857 03-14, 002858 03-14
TERASAWA E 001400 02-03
TERASHIMA M 002950 03-15
TERAVAINEN H 000782 01-11
TERENIUS L 003298 04-03, 003429 04-04
TERNAUX JP 000120 01-03
TERRI8ILI F 001786 02-10
TESCHENOORF HJ 001110 02-02
TETREAULT L 000693 01-10, 003594 04-10
TETZNER M 003273 04-03
THAOANI PV 003299 04-03
THAKUR R 001858 02-11
THEILGAARO A 003738 04-14
THEMEN JFA 002607 03-07, 002663 03-08
THENEN SW 003108 04-03
THIERCELIN JF 001401 02-03
THIERRY AM 000234 01-03, 000240 01-03, 001150 02-03, 001151 02-03, 001397 02-03, 002342 03-03
THIESSEN JJ 000868 01-13
THOA N8 001402 02-03
THOMAS A 003864 04-17
THOMAS OG 002087 02-16
THOMAS OJ 002051 02-15
THOMAS E 000357 01-04, 001525 02-04
THOMAS G 003868 04-17
THOMAS JR 000436 01-04
THOMPSON OM 000437 01-04
THOMPSON G 003492 04-05
THOMPSON H 001955 02-14
THOMPSON JA 000164 01-03
THOMPSON KS 001055 01-17
THOMPSON RW 003387 04-04
THOMPSON T 003441 04-04, 003442 04-04
THOMSEN K 000189 01-03, 001403 02-03, 002383 03-03, 003300 04-03
THONNARO-PHILLIPS I 002232 03-03
THOR DH 000325 01-04
THOREN P 003654 04-13
THORIN H 000804 01-13
THORN I 000969 01-15
THORN8URG JE 000438 01-04, 001220 02-03
THORNBY J 003519 04-07
THORNBY JI 001701 02-08, 001973 02-14
THORNER M 003693 04-13
THORNER MO 002943 03-15
THORNHILL JA 00159B 02-04
THORNTON EW 000337 01-04
THORNTON M 001348 02-03
THORNTON W 003898 04-17
THOROGOOO M 000966 01-15
THORSEN K 000820 01-13
THORUP M 003548 04-0B
THOUMAIAN AH 000317 01-04
THUNELL S 002018 02-15
THURGATE JK 003757 04-14
TIGNOL J 002888 03-15
TIGOLI F 0007B3 01-11
TILKIAN AG 002840 03-13
TILSON HA 001599 02-04, 003463 04-04, 003470 04-04, 003471 04-04
TIMBALOI A 000547 01-08
TINKLENBERG J 000022 01-02
TINKLEN8ERG JR 000439 01-04, 002001 02-14, 003894 04-17
TIPTON KF 000163 01-03, 0012B9 02-03
TISOALE SA 000784 01-11
TISLOW R 001033 01-17
TIZABI Y 001402 02-03
TO8E A 001117 02-02
TO8E M 002569 03-05
TO8IN JM 002784 03-11
TOBIS J 002078 02-15
TOOA N 000241 01-03
TODO MC 002169 02-17
TODRICK A 000661 01-09
TOFANETTI O 003301 04-03
TOGNETTI P 003350 04-04
TOGNONI G 001331 02-03
TOKUOA M 002566 03-05
TOKUNAGA Y 002384 03-03, 003472 04-04
TOLLENAERE JP 002577 03-05
TOLMACHEVA NS 002305 03-03
TOLMAN KG 000066 01-03, 000166 01-03
TOLONE SF 000757 01-11
TOLOSA E 000023 01-02
TOLOSA ES 003473 04-04
TOLPPANEN E 000131 01-03
TOMCZAK W 002748 03-11
TONG JH 003280 04 03
TONGE S 001204 02-03
TONGE SR 001203 02-03
TONON GC 000242 01-03, 001382 02-03
TOPOLINSKI H 003273 04-03
TORGOW JS 003903 04-17
TORRELIO M 000341 01-04, 003173 04-03
TORRY JM 002079 02-15
TORU M 002732 03-10
TOSCA P 000722 01-10
TOTMAN R 001864 02-11
TOURE MF 003350 04-04
TOURNOUX C 000484 01-07
TOUSSAINT C 001065 01-17, 001655 02-07
TOWER 8B 000514 01-07
TOYONAGA T 000562 01-08
TOZU A 002676 03-09
TRA8UCCHI M 000078 01-03, 000242 01-03, 001225 02-03, 001382 02-03, 001383 02-03, 002372 03-03
TRAFICANTE LJ 002385 03-03
TRAFTON CL 000243 01-03
TRAIN K 001965 02-14
TRANSBOL I 000585 01-09, 002026 02-15
TRASKMAN L 003654 04-13
TREEGOOB M 002170 02-17
TREMAIN JE 000440 01-04
TREMBLA K 002651 03-08
TREMBLAY O 001474 02-04
TRENCHARO A 000612 01-09
TRENDELENBURG U 003315 04-03
TRETOLA R 001903 02-13
TRICKLEBANK MD 003303 04-03
TRIMBLE M 003304 04-03
TRIMBLE MR 0009B9 01-15
TRITES RL 002940 03-15
TROLIN G 001223 02-03
TROUILLER G 000004 01-01
TROUPIN AS 000788 01-11
TROWLAND R 001516 02-04
TRUCHOT R 001192 02-03
TRULSON ME 000016 01-01, 000441 01-04, 001404 02-03, 001517 02-04, 001570 02-04, 003338 04-03, 003407 04-04
TRUMBO OA 001912 02-13
TRUNCER PC 001473 02-04
TRZECIAK HI 001509 02-04, 002578 03-05
TSANG D 003467 04-04
TSENG L 001600 02-04, 003715 04-13
TSETLIN MG 001B36 02-11
TSIKALOVA TS 002289 03-03
TSILLI EI 002287 03-03
TSUCHIYA T 002386 03-03, 002387 03-03, 003474 04-04
TSUJIMOTO A 000244 01-03, 002261 03-03
TSUKAMOTO M 000753 01-11
TSUKAMOTO R 000545 01-08, 002820 03-13
TSUKAMOTO T 002264 03-03
TSUKASAKI N 000522 01-07
TSUTSUI S 000713 01-10, 000869 01-13
TSUTSUMI S 000753 01-11
TUASON VB 000600 01-09, 003669 04-13
TUCHMAN MM 000904 01-14
TUCHMANN-OUPLESSIS H 000990 01-15
TUCK JR 003654 04-13, 003709 04-13
TUOBALL N 000115 01-03
TUDOR S 000076 01-03
TUOORACHE D 000538 01-08
TUMA AH 001B65 02-11
TUNKS ER 003646 04-11
TUOMISTO J 003305 04-03
TUREK 8 001877 02-12
TURKANIS SA 001379 02-03, 003306 04-03
TURNBULL MJ 000245 01-03
TURNER DA 003843 04-16
TURNER EG 000442 01-04
TURNER P 000612 01-09, 000714 01-10, 002674 03-09, 002733 03-10, 002822 03-13, 003520 04-07
TVERDOVA YB 002941 03-15
TWEEO JA 001666 02-07
TYAKHEPYLD LY 002382 03-03
TYCE GM 001405 02-03, 002388 03-03
TYE NC 003475 04-04
TYRER P 000715 01-10, 003040 03-17
TYSZKA E 003018 03-17
TZENG S 003307 04-03

U

UCHIDA Y 001709 02-08, 002389 03-03
UCHIMURA H 001251 02-03
UCHIYAMA T 000869 01-13
UDA8E RU 002770 03-11
UDANGIU 5N 000538 01-08
UEKI 5 002399 03-03, 003450 04-04
UENO A 002390 03-03
UENO T 000581 01-09, 002241 03-03, 002579 03-05
UETA H 002921 03-15
UHL GR 001406 02-03
UHLENHUTH EH 003843 04-16
UHLIG 8 002681 03-09
UHLIR V 001648 02-06
UKAI M 002391 03-03
UKIDA T 002536 03-04
ULI5S D8 003061 04-01
ULMAR G 002291 03-03
ULRICH G 002095 02-16
ULRICH RF 001691 02-08, 003541 04-08
ULYANOVA OV 002395 03-03
UMIO Y 000851 01-13
UNGAR AL 003309 04-03
UNGAR F 003308 04-03
UNGAR G 003309 04-03
UNGER HR 000582 01-09
UNGER5TEDT U 002369 03-03, 003087 04-03, 003425 04-04, 003448 04-04
UN50LD R 000937 01-15
UR8A-H0LMGREN R 000344 01-04, 002465 03-04
UR5TAD H 001171 02-03
U5DIN E 000246 01-03
USEMANN H 002631 03-08
USPEN5KIY AY 001407 02-03
U5UI S 003476 04-04
UVNAS 8 001362 02-03
UZAN A 002392 03-03
UZUN0V P 002227 03-03

V

VAAMONDE CA 003698 04-13
VACHON L 003711 04-13
VADLAMANI NL 001931 02-13
VAI5RU8 5 000785 01-11
VALDE5 M 000344 01-04, 002465 03-04
VALDES ME 002080 02-15
VALDMAN AV 002548 03-04
VALE HE 000335 01-04
VALE JA 003831 04-15
VALENTI P 000017 01-01, 000018 01-01, 000247 01-03
VALLECOR5I GF 001846 02-11
VALZELLI L 000475 01-06, 000706 01-10, 002989 03-17
VAN 8U5KIRK R 002455 03-04, 003400 04-04
VAN COLLER P 000716 01-10
VAN DE POLL NE 001443 02-04
VAN DEN 8ERG CJ 001719 02-08
VAN DEN 8URG W 001781 02-09
VAN DEN 5TEEN N 003579 04-10
VAN DER HEYDEN JAM 001562 02-04
VAN DI5 H 001443 02-04
VAN DORS5ER W 000476 01-06, 00140B 02-03
VAN KAMMEN D 003692 04-13
VAN KAMMEN DP 001696 02-08, 001729 02-09, 002702 03-09, 003041 03-17, 003550 04-09, 003727 04-14, 003857 04-17
VAN KEMPEN GMJ 000193 01-03
VAN NUFFEL D 001705 02-08
VAN ORDEN L5 001104 02-02
VAN PRAAG HM 000573 01-08, 001781 02-09, 001922 02-13, 002841 03-13, 003042 03-17, 003043 03-17, 003310 04-03, 003323 04-03, 003576 04-09, 003716 04-13, 003717 04-13, 003718 04-13, 003719 04-13, 003720 04-13, 003752 04-14, 003901 04-17, 003902 04-17
VAN PUTTEN T 000506 01-07, 002703 03-09, 002942 03-15, 003753 04-14
VAN REE JM 003311 04-03, 003477 04-04
VAN RIEZEN H 000443 01-04
VAN R055UM JM 000077 01-03, 000466 01-05, 001562 02-04
VAN WOERT MH 001910 02-13
VAN ZANTEN AK 001781 02-09
VAN ZWIETEN PA 000248 01-03, 003312 04-03
VAN ZWIETEN-BOOT 8J 002393 03-03
VANDER AJ 002222 03-03
VANGGAARD T 001809 02-10, 003583 04-10
VANOV SK 003605 04-10
VARDARI5 RM 000449 01-04, 000924 01-14
VARDI J 002871 03-14
VARGA E 001715 02-08
VARGAS F 001409 02-03
VARGIU L 002438 03-04
VARKONYI 8 001720 02-08
VARKONYI-WALLER5TEIN P 000786 01-11
VARTANIAN V 001677 02-07
VAUTERIN C 000961 01-15
VAYER JS 001587 02-04
VAYNTRU8 MY 002886 03-15
VAZQUEZ AJ 001351 02-03
VEDERNIKOVA NN 001364 02-03, 002360 03-03
VEHRE5CHILD T 002769 03-11
VELA-8UENO A 000877 01 14
VELA5CO F 003313 04-03
VELASCO M 003313 04-03
VELLA G 002734 03-10
VENALAINEN E 002704 03-09
VENCOVSKY E 002657 03-08, 002785 03-11
VENDSBORG P8 0017B2 02-09
VENEMA K 001922 02-13
VENKATAKRI5HNA-BHATT H 003399 04-04
VENN RD 002786 03-11
VER8ANCK P 003568 04-09
VERBRUGGEN F 000275 01-04, 000276 01-04
VERDEAU-PAILLES J 002787 03-11
VERE8EY K 001949 02-13
VEREECKEN JLTM 003549 04-09
VERGHE5E A 003721 04-13
VERHOEF J 000249 01-03
VERNIKO5-DANELLI5 J 002278 03-03
VERRILL HL 001632 02-05
VER5IANI CALDEIRA MV 001806 02-10
VER5IANI M 001810 02-10, 003606 04-10
VERVI5CH A 001013 01-17
VE5COVINI L 001811 02-10, 002923 03-15
VE5ELKIN NP 002394 03-03
VES5EY MP 000966 01-15
VE5TERMARK 5 000969 01-15
VETULANI J 000053 01-03, 000250 01-03, 002557 03-04
VEYN AM 001812 02-10
VIALA A 002842 03-13
VIANA P 001793 02-10
VICKERY JL 002527 03-04
VICTOR 5 003136 04-03
VIDAILLAC G 001181 02-03
VIDRUK EH 000215 01-03
VIGOURET JM 002192 03-02, 003314 04-03
VIGRAN R 001311 02-03
VIKBERG P 001257 02-03
VIKHLYAYEV YI 002187 03-02, 002395 03-03
VIKI5-FREI8ERG5 V 000435 01-04
VILLALOBO5 A 003577 04-09
VILLEMOES P 001693 02-08
VILLENEUVE A 002396 03-03
VILLENEUVE C 002658 03-08
VILLE5CA5 R 003487 04-04, 003507 04-05
VILLUM5EN D 002214 03-03
VINAR O 001076 01-17
VINCENT JH 000444 01-04
VIRC L 003544 04-08
VIRET J 002297 03-03
VIRION A 000039 01-03
VI5HNUVAJJALA 8R 003164 04-03
VIUKARI M 000755 01-11, 000766 01-11, 001838 02-11
VIUKARI NMA 000519 01-07, 000662 01-09
VIVIEN P 0020B1 02-15
VIZZIELLO GF 002670 03-09
VLA5OV NA 001812 02-10
VOGEL HP 000663 01-09
VOGEL JR 002549 03-04
VOGEL RA 002550 03-04
VOGEL W 003801 04-15
VOGEL WH 003315 04-03, 003478 04-04
VOHLAND H 002843 03-13
VOHRA J 001193 02-03, 002023 02-15
VOIGT R 000253 01-03
VOITA5HEV5KY A 000985 01-15
VOLAN5 GN 003B31 04-15
VOLAN5CHI D 000076 01-03
VOLAVKA J 001949 02-13, 001950 02-13
VOLDEN G 000991 01-15
VOLICER L 001336 02-03, 003244 04-03, 003316 04-03
VOLK W 002082 02-15
VOLKMAR F 002896 03-15
VOLLER GW 000787 01-11
VON EIFF AW 001077 01-17
VON HANXLEDEN V 002788 03-11
VON KNORRING L 000664 01-09, 001693 02-08, 002632 03-08, 003533 04-08
VON LIEVEN T 000992 01-15
VON 5CHEELE C 003849 04-17
VON STRALENDORFF 8 001410 02-03
VON WILD K 002789 03-11
VON ZER55EN D 002691 03-09, 002790 03-11
VO55 HV 001851 02-11
VRIELINK R 000193 01-03
VUILLAUME M 003083 04-03
VYBOROVA L 002647 03-08
VYMAZAL J 000870 01-13

W

WA8ER D 001799 02-10
WACHTEL H 003479 04-04
WADA JA 000788 01-11, 001171 02-03
WADDINGHAM S 003348 04-04
WADDINGTON JL 001601 02-04, 003480 04-04
WADE DN 001348 02-03
WADE GN 002450 03-04, 003260 04-03
WADKE D 001086 02-01
WAGATSUMA 5 002909 03-15
WAGNER E 001842 02-11, 001996 02-14
WAGNER HR 001321 02-03
WAGNER JG 003317 04-03
WAHA8ZADEH A 001865 02-11
WAHL G 000257 01-03
WAHL5TROM G 000445 01-04, 001411 02-03, 002551 03-04, 003076 04-02, 003512 04-05
WAIT J5 003757 04-14
WAJDA IJ 003176 04-03, 003318 04-03
WAKE A 000788 01-11, 001171 02-03
WALDECK 8 000251 01-03
WALDMANN E 003832 04-15
WALDMEIER PC 001228 02-03, 001412 02-03, 001413 02-03, 001602 02-04
WALDMEIR PC 000665 01-09
WALINDER J 001769 02-09, 002844 03-13, 003647 04-11
WALKER BR 003648 04-11
WALKER J 000792 01-12
WALKER JM 002424 03-04, 003319 04-03
WALKER KP 002170 02-17
WALKER MN 002217 03-03
WALLACE ER 003B33 04-15
WALLACE JE 003100 04-03, 003355 04-04, 003491 04-05
WALLACE M 002171 02-17
WALLACE P 000308 01-04
WALLACE 5J 000993 01-15
WALLBORG M 000056 01-03
WALLEN5TEIN MC 001603 02-04
WALLER M8 003251 04-03
WALLIN B 000804 01-13
WALLIN L 001769 02-09, 003647 04-11
WALLNAU L8 001506 02-04
WAL5ER A 001096 02-01
WAL5ER J 000069 01-03
WAL5H G0 001888 02-13
WAL5H MR 000658 01-09
WALTER M 002334 03-03
WALTER R 003065 04-02
WALTERS JR 002587 03-06
WALTHAM RD 002070 02-15
WALTON KG 000278 01-04, 001643 02-05
WALTREGNY A 0007B9 01-11
WANDER JD 003057 04-01
WANG HS 002096 02-16
WANG RIH 001280 02-03, 003607 04-10, 003 04-14
WANG RY 002580 03-05, 003320 04-03
WANG 5C 003113 04-03
WANG Y 000666 01-09
WANIEK W 000698 01-10, 001801 02-10
WANKE B 002843 03-13
WANNAG A 002198 03-03
WARBURTON DM 002002 02-14
WARD AD 000140 01-03
WARD JW 003747 04-14
WARD M 003790 04-15

VARD WG 001185 02-03
VARDASZKO-LSKOWSKA H 002172 02-17
VARDASZKO-LYSKOWSKA H 002601 03-07
VARING EM 000667 01-09
VARING H 002055 02-15
VARING RH 002315 03-03
VARNECKA-PRZYBYLSKA M 000548 01-08
VARREN C 000572 01-08
VARREN JW 000537 01-08
VARSH JJ 000252 01-03, 002672 03-09
VARTOESKY L 001890 02-13
VARWICK RO 002397 03-03
VASER PG 000069 01-03
VASHTON A 003745 04-14
VASIK A 000485 01-07, 002620 03-08, 002621 03-08, 002659 03-08, 002669 03-09, 002745 03-11
VASIR H 000866 01-13
VASS JAH 002943 03-15
VASTERLAIN CG 003321 04-03
VATANABE HY 002398 03-03
VATANABE K 001248 02-03, 002398 03-03
VATANABE M 000668 01-09
VATANABE S 002399 03-03
VATERFIELD AA 002317 03-03, 003322 04-03
VATERMAN AE 000367 01-04
VATERS HL 000259 01-03
VATERS WE 000966 01-15
VATKINS CJ 003330 04-03
VATKINS J 003814 04-15
VATKINS JC 001199 02-03, 003074 04-02
VATKINS JW 000245 01-03
VATSON BW 001920 02-13
VATSON JM 003834 04-15
VATSON PJ 002552 03-04
VATTS G 001721 02-08
VATTS RWE 001827 02-11
VAUQUIER A 001078 01-17, 001118 02-02, 001414 02-03
VAXMAN O 003608 04-10
VAY EL 000122 01-03, 000128 01-03, 000349 01-04, 000350 01-04, 001244 02-03, 001604 02-04, 002298 03-03
VAYNE AW 003509 04-05
VAYNE H 000807 01-13
VAYNER MJ 003463 04-04
VAZEK Y 002944 03-15
DOWIAK MW 000548 01-08
EBSTER MH 001044 01-17, 003863 04-17
EDER HG 002583 03-06
EDL W 003755 04-14
EHR T 002675 03-09
EI E 000446 01-04, 000447 01-04
EI ET 001605 02-04
EIDLER DJ 003317 04-03
EIDLEY E 000469 01-06
EIHRAUCH TR 000253 01-03
EIL AT 002173 02-17, 003756 04-14
EIL JV 000960 01-15
EINER H 003094 04-03
EINER J 001079 01-17
EINER M 003017 03-17
EINER WJ 000448 01-04, 002553 03-04, 003835 04-15
EINFELD RE 000819 01-13
EINGARTNER H 002838 03-13
EINHARDT F 002051 02-15
EINREB HJ 001702 02-08
EINRYB I 000254 01-03
EINSTOCK M 000097 01-03, 000231 01-03, 001415 02-03, 002224 03-03, 002400 03-03, 002419 03-04, 002845 03-13, 003277 04-03, 003518 04-06
EINTRAUB M 003868 04-17
EISBRODT N D03504 04-05
EISCHER M 001606 02-04
EISER G 002945 03-15
EISS B 001055 01-17, 002881 03-14
EISSMAN A 003075 04-02
EISSMAN BA D02401 03-03
EISSMAN MM 000646 01-09, 000648 01-09, 000925 01-14, 002174 02-17
EISZ DJ 000449 01-04
LBEL L 000724 01-11, 002650 03-08
LBURN PJ 000129 01-03
LCH KMA 003297 04-03
LCH RB 003757 04-14
LCH WM 003075 04-02
LDON DA 000317 01-04
WELIKY I 001086 02-01
WELLING EM 002791 03-11
WELLS C 001633 02-05
WENCELIS S 002946 03-15
WENDEL HA 003694 04-13
WENDELBOE J 001861 02-11
WENDER PH 002794 03-11
WENDT-SUHL G 000292 01-04
WENGER GR 000064 01-03
WENK RE 002083 02-15
WENTHOLD RJ 001085 02-01
WENZLIK R 001416 02-03
WERBENEC J 000275 01-04, 000276 01-04
WERBLOWSKY JH 003600 04-10
WERBOFF J 000450 01-04
WERKO L 000866 01-13
WERMUTH C 001109 02-02
WERNER I 000916 01-14
WERNER TE 000255 01-03, 002543 03-04
WERNER W 000732 01-11
WERNER WM 001682 02-08
WERRY JS 000926 01-14, 000927 01-14, 001859 02-11, 003649 04-11
WERTHESSEN N 000535 01-08
WESSEL HB 003618 04-11
WESSON DR 002947 03-15
WEST LE 000398 01-04
WESTBLOM U 003650 04-11
WESTERINK BHC 000256 01-03, 001417 02-03, 001418 02-03, 001419 02-03, 001420 02-03, 001722 02-08, 003323 04-03
WESTFALL TC 000257 01-03
WESTLING H 001933 02-13
WESTON PF 002554 03-04
WETTERBERG L 000513 01-07, 003044 03-17
WEVER K 002402 03-03
WHALEN CK 001866 02-11
WHARTON W 003381 04-04
WHEAL HV 001293 02-03
WHEATLEY O 000717 01-10, 000718 01-10, 000719 01-10, 003609 04-10
WHEATLEY PL 000285 01-04
WHEELER TJ 000337 01-04
WHELESS JC 001038 01-17, 003556 04-09
WHELPTON R 001951 02-13
WHETTON PS 001698 02-08
WHIGHAM KAE 000092 01-03
WHISHAW IQ 000258 01-03, 002403 03-03, 003324 04-03
WHITE FJ 003003 03-17
WHITE HL 000592 01-09
WHITE J 002003 02-14
WHITE JH 002175 02-17
WHITE M 001548 02-04
WHITE N 003481 04-04
WHITE RP 003440 04-04
WHITEHOUSE MJ 003090 04-03
WHITESIDES DB 001229 02-03
WHITESIDES GH 000374 01-04
WHITNEY G 003482 04-04
WHITTIER JR 001826 02-11
WHYMAN A 002948 03-15
WHYTE SF 000994 01-15
WIBERG A 000823 01-13, 003076 04-02
WIDELITZ H 001421 02-03
WIDELITZ MM 001421 02-03
WIDERLOV E 000669 01-09, 000871 01-13, 001678 02-07
WIEBEL FJ 000259 01-03
WIEGANT VM 000112 01-03, 002453 03-04
WIELOSZ M 001652 02-06, 002846 03-13
WIEPKEMA PR 003444 04-04
WIESEL F 001422 02-03, 002094 02-16, 002835 03-13, 002836 03-13, 003653 04-13
WIJEWICKRAMA HSDS D01789 02-10
WIKLER A 002867 03-14, 0D3743 04-14
WILBUR M 003754 04-14
WILCHEK M 003349 04-04
WILDER BJ 002063 02-15
WILK S D00260 01-03, DD3325 04-D3, D03326 04-03
WILKENING D 000261 01-D3
WILKINSON IMS 002D85 02-15
WILKINSON RT 000910 01-14
WILL B 002555 03-04
WILL BE 003483 04-04
WILLER J 000875 01-14
WILLETT AB 0D1714 02-08
WILLIAMS H 000030 01-03
WILLIAMS HE 000582 01-09
WILLIAMS JA 001202 02-03
WILLIAMS JG 001832 02-11
WILLIAMS JT 001634 02-05
WILLIAMS P 001745 02-09
WILLIAMS R 001745 02-09, 003234 04-03
WILLIAMS RJP 002810 03-13
WILLIAMS RL 001973 02-14, 002176 02-17, 003563 04-09, 003858 04-17
WILLIAMS SE 001698 02-08
WILLSON NJ 002581 03-05
WILNER M 003841 04-16
WILSON A 002003 02-14
WILSON BPM 003691 04-13
WILSON CB 002792 03-11
WILSON CJ 002328 03-03
WILSON CWM 003691 04-13
WILSON GT 002004 02-14
WILSON H 000266 01-03
WILSON IC 001840 02-11
WILSON JP 003138 04-03
WILSON JT 000995 01-15
WILSON LG 000742 01-11
WILSON LM 000451 01-04
WILSON MC 002556 03-04
WILSON PA 003120 04-03
WILSON RS 002404 03-03
WILSON TR 000452 01-04
WILSON WP 001733 02-09, 002146 02-17
WINBLAD B 000823 01-13
WING LMH 003701 04-13
WINGER G 001503 02-04
WINIEWICZ Z 000979 01-15
WINOKUR A 003722 04-13
WINOKUR G 001727 02-09
WINOUKUR A 002405 03-03
WINSBERG BG 003652 D4-11, 003758 04-14
WINSHIP-BALL A 001167 02-03
WINSLOW WW 003591 04-10
WINSTEAD OK 000720 01-10, 000996 01-15, 002177 02-17
WIRZ-JUSTICE A 001952 02-13, 002705 03-09
WISE DA 003484 04-04
WISE RA 000262 01-03, 000267 01-03, 001198 02-03
WISHART TB 000086 01-03, 000087 01-03
WISNIEWSKI K 000173 01-03, 000174 01-03, 002507 03-04, 003101 04-03
WISUSCHIL W 000556 01-08
WITIAK OT 003164 04-03
WITKIN JM 001607 02-04, 002422 03-04
WITTENBORN JR 000997 01-15, 002005 02-14, 003744 04-14
WITTER A 000249 01-03
WITTS O 003520 04-07
WLOSINSKA I 002655 03-08
WODE-HELGODT B 002086 02-16, 002835 03-13, 002836 03-13, 003704 04-13
WODKA L 002660 03-08
WOELK H 001127 02-03
WOERNER MG 003593 04-10
WOGGON B 001653 02-07, 001723 02-08, 002793 03-11, 002962 03-17
WOJCIK A 002573 03-05
WOJDYSLAWSKA I 000574 01-08, 002661 03-08, 002662 03-08, 002748 03-11, 003018 03-17
WOLAK E 002601 03-07, 002643 03-08
WOLF GL 000731 01-11
WOLF HP 001367 02-03
WOLF R 002652 03-08
WOLF S 000527 01-08, 000575 01-08
WOLF SM 003651 04-11
WOLFARTH S 002557 03-04, 003327 04-03, 003485 04-04
WOLFF A 002706 03-09
WOLLERT U 003174 04-03
WOLMAN B 002178 02-17
WOLPERT EA 003836 D4-15
WOLSTENHOLME GEW 002179 02-17
WOLTHUIS OL 000928 D1-14, 001307 02-03, 001308 02-03, DD1309 02-03
WONG DT 000263 01-03, 001242 02-03, 001423 02-03, 003328 04-03
WONG J 002030 02-15
WONG K 00D474 01-06
WONG KC 003820 04-15
WOOD CA 002949 D3-15
WOOD DR 002794 03-11
WOOD F 003530 04-08

WOOD JD 000113 01-03
WOOD K 003663 04-13
WOOD WG 000416 01-04, 003486 04-04, 003487 04-04
WOODRUFF GN 000264 01-03, 003128 04-03
WOODRUFF ML 000453 01-04
WOODS JH 001454 02-04
WOODS P 001596 02-04
WOODS SC 001633 02-05
WOODWARD DJ 001239 02-03
WOODWARD JA 003888 04-17
WOOLLARD KV 001666 02-07
WOOLLARD PM 001237 02-03
WORSTMANN W 001110 02-02
WREN A 000443 01-04
WREN J 000998 01-15
WRIGHT C 003692 04-13
WRIGHT CM 000393 01-04
WRIGHT FD 001890 02-13
WRIGHT J 001217 02-03, 003329 04-03
WRIGHT L 002532 03-04
WRIGHT PL 001644 02-05
WRIGHT S 001783 02-09
WRIGHT WA 003202 04-03
WROBLEWSKA J 002642 03-08
WU W 001097 02-01, 001098 02-01
WUENSCH KL 001608 02-04
WUNSCH E 001428 02-03
WURTMAN RJ 002219 03-03, 003207 04-03, 003330 04-03, 003624 04-11
WYATT R 000527 01-08
WYATT RJ 000022 01-02, 000235 01-03, 000387 01-04, 000439 01-04, 000576 01-08, 001080 01-17, 001500 02-04, 001501 02-04, 001696 02-08, 002014 02-15, 002504 03-04, 002505 03-04, 002629 03-08, 002838 03-13, 002879 03-14, 003431 04-04, 003749 04-14, 003903 04-17
WYNDOWE J 000672 01-10
WYPER DJ 002606 03-07
WYSS U 001869 02-12

Y

YAGI F 002406 03-03
YAGI K 000670 01-09
YAJIMA T 002407 03-03
YAKATAN GJ 002258 03-03, 003165 04-03
YAKSH TL 001424 02-03, 003331 04-03, 003332 04-03, 003333 04-03
YALE C 000506 01-07, 002942 03-15
YAMADA H 000577 01-08, 000636 01-09
YAMADA K 003292 04-03
YAMAMOTO I 000122 01-03, 002273 03-03
YAMAMOTO K 002676 03-09, 002732 03-10
YAMAMURA HI 000029 01-03, 003331 04-03, 003510 04-05
YAMAMURA M 002538 03-04
YAMANOUE S 000578 01-08
YAMASHITA K 000581 01-09, 000654 01-09, 000697 01-10, 002241 03-03, 002356 03-03
YAMATAKE Y 002180 02-17
YAMAUCHI M 002847 03-13
YAMAUCHI T 000745 01-11
YAMAZAKI M 002245 03-03
YAMAZAKI T 001993 02-14
YAMHURE A 003577 04-09
YANAGISAWA M 002408 03-03
YANAGITA T 002366 03-03, 002546 03-04, 002558 03-04
YANAI J 001609 02-04, 003488 04-04
YANAURA S 002180 02-17, 002545 03-04
YANG M 001997 02-14
YANKU I 002248 03-03
YANO I 003334 04-03
YAOUANC J 000011 01-01
YARBROUGH GG 001425 02-03
YARYURA-TOBIAS JA 000523 01-07, 000721 01-10, 000872 01-13
YASUNOBU KT 001222 02-03
YASUYAMA M 002384 03-03
YATES CA 000265 01-03
YATES CM 000266 01-03
YEHUDA S 002409 03-03, 003335 04-03
YELLIN AM 001998 02-14
YEN KOO HC 001610 02-04
YENSEN R 001877 02-12, 002735 03-10
YEPES LE 003652 04-11, 003758 04-14
YEUNG JC 001424 02-03
YEVTUSHENKO SK 002795 03-11
YIH TO 000466 01-05
YINGLING JE 001124 02-03
YOGI H 002410 03-03
YOKEL RA 000267 01-03
YOKOYAMA S 000668 01-09
YONEDA R 002460 03-04
YONEDA Y 002288 03-03, 002411 03-03, 003336 04-03
YONEKURA T 000562 01-08
YORK JL 003638 04-11
YORKSTON NJ 002607 03-07, 002663 03-08
YOSHIDA H 000037 01-03, 002263 03-03
YOSHIDA K 000139 01-03, 002244 03-03, 002273 03-03
YOSHIDA N 002707 03-09, 002950 03-15
YOSHIKAWA A 000010 01-01, 001216 02-03
YOSHIZAKI T 000268 01-03
YOUDIM MBH 002588 03-07, 003904 04-17
YOUNG GA 002559 03-04
YOUNG JPR 000671 01-09
YOUNG LD 003578 04-09
YOUNG RE 003837 04-15
YOUNG SN 003467 04-04, 003553 04-09
YOUNG WW 003770 04-15
YOUNG YK 000666 01-09
YOUNTS BW 003203 04-03
YU G 003278 04-03
YU M 001724 02-08
YURA R 000753 01-11
YURKEWICZ L 003137 04-03

Z

ZABEK DH 002798 03-12
ZABIK JE 003489 04-04
ZAHARIADE S 002723 03-10
ZAHN TP 000579 01-08
ZAJACZKOWSKA A 002601 03-07
ZAKI SA 002607 03-07, 002663 03-08
ZAKRZEWSKA F 000999 01-15, 001000 01-15
ZAKS AS 002412 03-03
ZAKUSOV VV 001426 02-03, 003046 03-17
ZALEJSKI S 000739 01-11
ZALEWSKI CJ 002560 03-04
ZAMBOTTI F 003109 04-03, 003241 04-03
ZAMIR N 002413 03-03
ZAMOSTIEN BB 002124 02-17
ZARIFIAN E 000815 01-13, 001032 01-17
ZARRINDAST MR 001267 02-03
ZARYCKI EP 000041 01-03
ZATZ M 001313 02-03, 002414 03-03
ZAVODNICK S 001725 02-08
ZOICHYNEC B 002951 03-15
ZEBROWSKA-LUPINA I 002561 03-04, 002573 03-05
ZELOMAN VL 001836 02-11
ZELASCHI NM 002656 03-08
ZELEWSKA M 002710 03-10
ZELLER EA 001611 02-04, 003337 04-03
ZEMAITIS MA 000269 01-03
ZEMLAN FP 003338 04-03
ZEMP JW 002312 03-03
ZENCHOFF G 001096 02-01
ZENTNER JL 002181 02-17
ZERBETTO R 002028 02-15
ZERBI F 000591 01-09, 000722 01-10
ZGIRSKI L 002608 03-08
ZIANCE RJ 001427 02-03
ZIEGLER D 000962 01-15
ZIEGLER MG 003666 04-13
ZIEGLER VE 002708 03-09, 003723 04-13, 003768 04-15
ZIEGLGANSBERGER W 001357 02-03, 001428 02-03, 001429 02-03
ZILM DH 000778 01-11
ZIMMER D 001867 02-12, 001869 02-12
ZIMMERMAN AM 003339 04-03
ZIMMERMAN S 003339 04-03
ZIMMERMANN E 003199 04-03
ZIMMERMANN J 001410 02-03
ZIMMERMANN RL 000580 01-09
ZIMMERMANN-TANSELLA C 002006 02-14
ZINBERG NE 000797 01-12, 002882 03-14
ZINGRAFF J 001001 01-15
ZIRNIS A 001094 02-01, 001099 02-01
ZITRIN CM 003593 04-10
ZIVANOVIC D 001438 02-04
ZLOTNIK G 002791 03-11
ZOHAR J 001687 02-08, 002800 03-13
ZOTTERMAN Y 001362 02-03
ZOUBOK B 000985 01-15
ZSILLA G 001430 02-03, 001431 02-03, 001432 02-03
ZUBAN AT 001555 02-04
ZUMOFF B 001887 02-13, 003660 04-13, 003838 04-15
ZURCHER G 000468 01-06
ZVARTAU EE 002548 03-04, 003490 04-04
ZWAS ST 002983 03-17
ZWEIG JS 003340 04-03
ZWIERS H 000112 01-03
ZWILLING G 001624 02-05
ZYG J 002664 03-08
ZYGALA P 002642 03-08

Z

SUBJECT INDEX

[The Subject Index is machine generated. Keywords in the titles of abstracts appear alphabetically in the left hand margin, under each keyword is a list of titles in which the keyword appears. The spelling of words in the titles of abstracts has not been changed, hence, two spellings of the same word may appear in this index -- for example, BEHAVIOR and BEHAVIOUR.]

A-101
CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
0DD697 01-1D
CLINICAL EXPERIENCE OF N-DESMETHYLDIAZEPAM (A-101) IN THE FIELD OF PSYCHIATRY.
0D0712 01-1D

ABDOMINAL
THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
00D129 D1-03
LEXOTANIL (RO-5-335D) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
D0D7D8 D1-1D

ABILITIES
A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
0D1494 D2-D4

ABILITY
TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
DD0321 D1-D4
MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
0D1231 D2-D3
MARIJUANA EFFECTS DN SIMULATED FLYING ABILITY.
DD1919 D2-13
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 4DB F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
DD215D D2-17
THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACRDMOLECULES IN THE RAT BRAIN.
DD3132 D4-D3
AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION DF PROBLEM-SOLVING ABILITY.
0D3513 D4-06
MEDAZEPAM AND THE DRIVING ABILITY OF ANXIOUS PATIENTS.
0D3B09 D4-15

ABLATION
EFFECTS OF AMPHETAMINE AND ILLUMINATION ON ACTIVITY FOLLOWING FRONTAL ABLATION.
DDD356 D1-04

ABNORMAL
USE DF PSYCHDPHARMACEUTICALS FOR THE TREATMENT OF ABNORMAL BEHAVIDR OF OLIGDPHRENIC EPILEPTICS.
DD2772 D3-11
REVERSE TOLERANCE TO STIMULANT-INDUCED ABNORMAL BEHAVIOR.
DD3196 D4-D3
ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DDPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
DD3631 D4-11
DRUG METABOLISM UNDER PATHDLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN.
0D387B D4-17

ABNORMALITIES
SLEEP AND SLEEP ABNDRMALITIES IN DEPRESSION.
DD3563 D4-D9
ABNDRMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
DD3631 D4-11

ABOLITION
ABOLITIDN OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION
DDD347 01-D4
ABDLITION OF NDMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
DD1334 D2-D3
SELECTIVE 6-OHDA INDUCED DESTRUCTION DF MESOLIMBIC DOPAMINE NEURDNS: ABDLITION DF PSYCHOSTIMULANT-INDUCED LOCOMDTOR ACTIVITY IN RATS.
DD1526 D2-D4

ABREACTION
TREATMENT OF VAGINISMUS BY I.V. DIAZEPAM (VALIUM) ABREACTIDN INTERVIEWS.
DD1764 D2-D9

ABRUPT
ACUTE HYPERTENSION AFTER ABRUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION
DD3B33 D4-15

ABSCESS
DECADRON IN THE TREATMENT OF CEREBRAL ABSCESS: AN EXPERIMENTAL STUDY.
000206 01-D3

ABSENCE
ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
DD1639 02-D5
ABSENCE DF AN ANTIDEPRESSIVE EFFECT OF LITHIUM IN THE CLINIC AND IN EXPERIMENTS.
DD2313 D3-D3
ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
DD2393 D3-D3
ABSENCE OF MORPHINE ANTAGDNISM DF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATIDN IN A RAT BRAIN MINCE SYSTEM.
DD3191 D4-D3
EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
DD3417 D4-D4
IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
DD361B D4-11
CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
DD3643 D4-11

ABSENCES
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATDNIC SEIZURES.
DDD969 D1-15

ABSOLUTE
THE ABSOLUTE CONFIGURATION OF SU-23397: A NOVEL NEUROLEPTIC AGENT.
D03D49 D4-D1
ABSOLUTE AVAILABILITY OF LITHIUM.
DD37DD D4-13

ABSORPTION
ABSDRPTIDN AND BIDTRANSFORMATION OF CHOLECALCIFEROL IN DRUG-INDUCED OSTEDMALACIA.
DDD166 D1-03
THE EFFECT OF DESMETHYLIMIPRAMINE DN THE ABSORPTION OF ALCOHOL AND PARACETAMDL.
0DDB24 D1-13
ABSORPTIDN, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
DD11B1 D2-03
INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSDRPTION OF NORADRENALINE BY SYNAPTIC VESICLES DF THE HYPOTHALAMUS.
DD1426 02-D3
CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF DRAL 14C-LORAZEPAM.
DD1914 D2-13
EFFECT OF LITHIUM DN GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE.
D02346 D3-D3
ABSORPTION, DISTRIBUTIDN AND ELIMINATION OF 1D-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
DD2392 D3-D3
ETHANOL AND DRAL DIAZEPAM ABSDRPTION.
DD3677 D4-13
ABSORPTION AND DISPDSITIDN OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPUBLISHED PAPER).
DD37D5 04-13
ABSORPTION RATE, BLODD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPDXIDE.
DD3731 D4-14

ABSTINENCE
ATTENUATIDN OF PRECIPITATED ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-TETRAHYDROCANNABINOL.
DDD31D D1-D4
RESPDNSE TD DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
D0D341 D1-D4
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
DD0349 01-D4

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE.
001445 02-04

SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION.
003172 04-03

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME.
003352 04-04

ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

ABSTINENCE-LIKE
PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE.
001604 02-04

ABUSE
ABUSE OF RITALIN BY TAFT CITY SCHOOL DISTRICT.
000B79 01-14

USE AND ABUSE OF PSYCHOTROPIC DRUGS.
001016 01-17

BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06

MONOAMINE-OXIDASE INHIBITORS: POTENTIAL FOR DRUG ABUSE.
001876 02-12

PROJECT SUMMARY: PSYCHOPHARMACOLOGY OF DRUG ABUSE.
002533 03-04

MAO INHIBITORS: POTENTIAL FOR DRUG ABUSE. (UNPUBLISHED PAPER).
002876 03-14

HEMINEURINE ABUSE BY A CHRONIC ALCOHOLIC.
002946 03-15

DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

AMPHETAMINE AND COCAINE ABUSE. (UNPUBLISHED PAPER).
0029B7 03-17

ABUSE OF SOLVENTS FOR KICKS.
003862 04-17

ABUSING
USING OR ABUSING? AN ANTHROPOLOGICAL APPROACH TO THE STUDY OF PSYCHOACTIVE DRUGS.
0029B5 03-17

ABUSIVE
AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002B6B 03-14

ACARICIDE
MUSCARINIC AGONISTS PROVIDE A NEW CLASS OF ACARICIDE.
000019 01-02

ACCELERATION
ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
000647 01-09

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-02

EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03

ACCEPTANCE
A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
000912 01-14

ACCESS
CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04

SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04-03

ACCIDENT
CORRELATION BETWEEN INJURIES DUE TO ACCIDENT AND USE OF ALCOHOL OR DRUGS.
002018 02-15

ACCIDENTAL
ACCIDENTAL BENALGIN POISONING.
000979 01-15

ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15

ACCIDENTS
CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
002928 03-15

ACCOMPANIED
ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

ACCUMULATION
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03

ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03

PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03

EFFECTS OF FENFLURAMINE ON ACCUMULATION OF 5-HYDROXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN.
001137 02-03

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION (UNPUBLISHED PAPER).
001313 02-03

BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
00312B 04-03

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
003239 04-03

LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03

SEROTONIN ACCUMULATION BY SKELETAL MUSCLE.
00328B 04-03

ACCUMULATIONS
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03

ACETALDEHYDE
ACETALDEHYDE AS A PSYCHOPHARMACOLOGICAL AGENT: TASK SPECIFICITY OF GENOTYPIC DIFFERENCES.
0033B0 04-0

ACETAMIDE
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-0

ACETAMINOPHEN
INHIBITION OF ACETAMINOPHEN GLUCURONIDATION BY OXAZEPAM.
000093 01-0

ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

ACETAZOLAMIDE
HEREDITARY PAROXYSMAL ATAXIA RESPONSIVE TO ACETAZOLAMIDE.
003629 04-11

ACETYLCHOLINE
REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
000008 01-01
HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02
EFFECT OF ORGANOPHOSPHORUS COMPOUNDS ON ACETYLCHOLINE SYNTHESIS IN BRAIN.
000180 01-03
POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
000209 01-03
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
0004B2 01-07
ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-03
INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03
EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION.
001365 02-03
TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-03
CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03
REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03
ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03
MODULATION OF ACETYLCHOLINE IN THE NEOSTRIATUM BY DOPAMINE AND 5-HYDROXYTRYPTAMINE.
002216 03-03
A NEW MICROMETHOD FOR DETERMINING THE EFFECTS OF DRUGS ON THE TURNOVER RATE OF ACETYLCHOLINE. (PH.D. DISSERTATION).
002274 03-03
THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05
THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLEI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
0025B4 03-06
EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
003251 04-03
REGIONAL ACETYLCHOLINE CONTENT IN MOUSE BRAIN AFTER MORPHINE TABLET IMPLANTATION.
0032B9 04-03
DEPRESSION BY MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-04
ANTIDEPRESSANTS AND THE MUSCARINIC ACETYLCHOLINE RECEPTOR.
003510 04-05

ACETYLCHOLINESTERASE
THE EFFECT OF MEMORY BLOCKING ANTIBIOTICS AND THEIR ANALOGS ON ACETYLCHOLINESTERASE.
000427 01-04
WHEN DOES INHIBITION OF BRAIN ACETYLCHOLINESTERASE CAUSE AMNESIA IN RATS?
003152 04-03

ACETYLMETHADOL
FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001B58 02-11

ACETYLPROMAZINE
OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

ACETYLSALICYLIC-ACID
EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN.
000266 01-03
SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04-03

ACHIEVEMENT
INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000B76 01-14

ACID
TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN.
000256 01-03
ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000B05 01-13
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15

ACIDIC
ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03

ACIDS
RESEARCH IN THE DIPROPYLACETIC SERIES. XII. EXTENDED ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

ACIPENSER-GULDENSTADTI
BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI.
002394 03-03

ACOUSTIC
EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04
EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04
TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-04

ACQUIRED
ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-04
ACQUIRED PREFERENCE FOR MORPHINE BUT NOT D-AMPHETAMINE AS A RESULT OF SACCHARINE ADULTERATION.
001513 02-04

ACQUISITION
EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
000365 01-04
CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
0003B5 01-04
REPEATED ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIDATE AND IMIPRAMINE.
000437 01-04
DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIDANCE IN RATS.
000469 01-06
OPERANT ACQUISITION OF MARIHUANA IN MAN.
000907 01-14
DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE-AVERSION.
000913 01-14
PHARMACOLOGICAL SUBSTANCES INFLUENCING ACQUISITION BEHAVIOR IN RATS.
000928 01-14
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03
PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03

EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
001507 02-04

ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-04

RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND IN THE EFFECTS OF DIAZEPAM.
00248B 03-04

ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING.
002495 03-04

EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
002501 03-04

EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-04

MORPHINE TOLERANCE ACQUISITION AS AN ASSOCIATIVE PROCESS.
003462 04-04

ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION.
003503 04-05

ACQUISITIONS

INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

ACRIDONE

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. INTRODUCTION TO PARTS X-XII, AND PART X. ACRIDONE DERIVATIVES.
000017 01-01

ACTH

BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN.
000407 01-04

EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

ACTH4-10

ACTH4-10 ON MEMORY DYSFUNCTION.
002771 03-11

ACTH4-10: COGNITIVE AND BEHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING-DISABLED CHILDREN.
002B72 03-14

EEG AND TASK PERFORMANCE AFTER ACTH4-10 IN MAN.
002B74 03-14

EFFECTS OF ACTH4-10 ON ECT-INDUCED MEMORY DYSFUNCTIONS.
00375D 04-14

ACTH4-9

IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION.
000249 01-03

ACTING

ANALGESIA PRODUCED BY MORPHINE WHEN ACTING FROM THE LIQUOR SPACE.
0011B4 02-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03

BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLOROPHENESIN CARBAMATE.
002467 03-04

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-03

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

ACTION

PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
000080 01-03

ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
000106 01-03

TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03

RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03

STUDIES ON THE SITE OF ACTION OF CLONIDINE UTILIZING A SYMPATHETIC CHOLINERGIC SYSTEM.
000144 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

INVESTIGATIONS OF THE MECHANISM OF CENTRAL ACTION OF KININS.
000174 01-03

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03

A POSSIBLE COMMON MECHANISM OF ACTION OF ANTIDEPRESSANT TREATMENTS.
000250 01-03

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION
000340 01-04

REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04

ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-04

THE MECHANISM OF ACTION OF PSYCHOPHARMACOLOGICAL AGENTS ON BEHAVIOUR.
000391 01-04

A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE).
000395 01-04

CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
000408 01-04

ANESTHETIC ACTION OF METHYLEUGENOL AND OTHER EUGENOL DERIVATIVES.
000419 01-04

ANTIANXIETY ACTION OF TRANZENE 50 MG.
000481 01-07

THERAPEUTIC ACTION OF D-PHENYLALANINE IN PARKINSONS DISEASE
000495 01-07

CLINICAL SPECTRUM OF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE.
000532 01-08

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08

NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
00D5B4 01-09

MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION.
000591 01-09

A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

CLINICAL STUDY OF A NEW FORM OF DIBENZEPINE, WITH PROTRACTED ACTION
000633 01-09

CLINICAL STUDIES ON THE ANTIDEPRESSANT ACTION OF LOPRAMINE
000660 01-09

CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
000683 01-10

CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION.
000700 01-10

COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11

ACTION OF TRAZODONE ON MENTAL FUNCTIONS OF THE AGED.
000770 01-11

MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000806 01-13

POSSIBLE ROLES OF CATECHOLAMINES IN THE ACTION OF NARCOTIC DRUGS.
000809 01-13

CURRENT VIEWS ON THE MECHANISM OF CHLORPROMAZINE ACTION.
000831 01-13

CENTRAL MECHANISMS OF ACTION OF P-CHLOROAMPHETAMINE: BIOCHEMICAL AND HISTOLOGICAL STUDIES. (PH.D. DISSERTATION).
000B43 01-13

THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15

BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE BIOCHEMICAL LITERATURE.
0010B0 01-17

NITROUS-OXIDE ANALGESIA: RESEMBLANCE TO OPIATE ACTION.
001139 02-03

THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03

REVERSAL OF THE ACTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-03

DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION.
0011B3 02-03

BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03

REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
001216 02-03

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03

POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 02-03

ON THE ANTICATALEPTIC ACTION OF CYPROHEPTADINE.
0012B6 02-03

THE SPECIFICITY OF ACTION OF THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-03

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION. (UNPUBLISHED PAPER).
001313 02-03

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN.
001349 02-03

COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04

SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION.
001493 02-04

CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04

CENTRAL ACTION OF NOMIFENSINE.
001544 02-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

ANTIAGGRESSIVE ACTION OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN MICE.
001571 02-04

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

THE EFFECT OF BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05

POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION.
001677 02-07

NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
001679 02-0B

ANTIDEPRESSANT ACTION OF CLOTHIAPINE.
0017B6 02-10

DOUBLE-BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI-6B20 BUFOXINE.
001B11 02-10

HYPERACTIVITY: RESEARCH, THEORY, AND ACTION
001B54 02-11

PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 02-13

BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13

ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 02-13

ACTION OF PSYCHOLEPTICS ON SOME PHYSIOLOGICAL INDICES IN STUTTERERS.
00195B 02-14

PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION.
002172 02-17

PHARMACOLOGICAL ACTION OF PYRIMIDOINDOLE DERIVATIVES.
0021B7 03-02

THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED BEHAVIOURAL RESPONSES IN MICE.
0021BB 03-02

SYMPATHOMIMETIC EFFECT OF SEROTONIN AND ACTION OF IMIPRAMINE AND PHTHORACIZINE ON THIS EFFECT.
002203 03-03

ACTION OF ANTIDEPRESSANTS ON CONVULSIVE EFFECT OF CORAZOL AND STRYCHNINE.
002220 03-03

EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS.
002224 03-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

ACTION OF DIAZEPAM, HALOPERIDOL, MORPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 03-03

PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03

ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
002323 03-03

STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-03

THE MECHANISM OF OPIATE AGONIST AND ANTAGONIST ACTION. (UNPUBLISHED PAPER).
002335 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN THE RETINA: A POINT OF ACTION FOR D-LSD.
002372 03-03

NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY.
002395 03-03

DOPAMINERGIC AND SEROTONERGIC ACTION OF ERGOMETRINE.
002418 03-04

A COMPARISON OF THE CENTRAL ACTION OF SOME PROSTAGLANDINS /PGS/ IN RATS.
002484 03-04

AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
002486 03-04

A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
002536 03-04

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
002548 03-04

DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04

CYTOTOXIC ACTION OF PSYCHOTROPIC DRUGS ON LEUKOCYTES IN VITRO.
002570 03-05

FIVE YEARS OF EXPERIENCE WITH PROLONGED ACTION FLUPHENAZINE.
002643 03-08

METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-0B

CLINICAL EVALUATION OF FLUPENTHIXOL WITH PROLONGED ACTION.
002655 03-0B

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZONE (FI-6654).
0026B3 03-09

EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
D02746 03-11

THE ACTION OF TRICYCLICS (ALONE OR IN COMBINATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY.
002782 03-11

TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENDED ACTION FORM OF BIPERIDEN HYDROCHLORIDE: 9 MONTH STUDY OF 55 HOSPITALIZED PATIENTS.
0027B7 03-11

THE MODE OF ACTION OF PSYCHOTROPIC DRUGS.
002B07 03-13

POSSIBLE MECHANISM FOR BIOLOGICAL ACTION OF LITHIUM.
002B10 03-13

POTENTIATION OF THE ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
002B44 03-13

LITHIUM: ITS MODE AND RANGE OF ACTION.
003024 D3-17

DIAZEPAM: RADIOPROTECTIVE ACTION AND EFFECT ON TOXICITY AND RADIOPROTECTIVE POWER OF CYSTEAMINE.
003139 04-03

THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-D3

ANTICONVULSANT ACTION OF DIAZEPAM: INCREASE OF CORTICAL POSTSYNAPTIC INHIBITION.
003246 04-03

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 D4-03

STUDIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE.
003333 04-03

SNAKE VENOM ACTION: ARE ENZYMES INVOLVED IN IT?
DD3337 D4-D3

PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
DD3343 04-04

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME.
DD3352 D4-D4

SITE OF ACTION OF DEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS.
D03367 D4-D4

ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE.
003383 04-04

DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04

THE ACTION OF LITHIUM-CARBONATE ON THE SLEEPWALKING CYCLE IN THE CAT.
003419 04-04

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTION IN MICE.
0D3427 04-04

THE REINFORCING ACTION OF MORPHINE AND ITS PARADOXICAL SIDE-EFFECT.
D034B1 04-04

CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
003505 04-05

FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-1

LITHIUM -- MECHANISM OF ACTION SIMILAR TO PHENYTOIN.
D03681 04-1

CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN
DD3704 04-1

IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-1

ACTIONS

ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RELEVANCE FOR PSYCHOMOTOR EFFECTS.
0D014B D1-0

DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
000198 01-0

NEUROPHARMACOLOGICAL ACTIONS OF ENKEPHALIN AFTER SYSTEMATIC ADMINISTRATION.
0D0203 01-0

BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
DD0204 01-0

DIFFERENCES BETWEEN THE ANOREXIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE -- POSSIBLE EFFECTS ON HUNGER AND SATIETY.
000291 01-0

SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
0D0413 01-0

CHLORIMIPRAMINE, ITS CLINICAL ACTIONS.
D00721 01-1

ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
D00B05 01-1

NEW TRENDS OF BETA-BLOCKERS IN ACTIONS AND APPLICATIONS.
DD0B69 01-1

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS O THE GAMMA-BUTYROLACTONE-INDUCED INCREASE IN MOUSE BRAIN DOPAMINE.
001220 02-

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-

ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, O NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
D01235 02-

SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE.
00124B 02-

BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA.
DD1254 D2-

PHARMACODYNAMIC ACTIONS OF DIHYDROPROPYLFURYLIDENECYCLOPENTANEDIONE (OUDENONE).
001319 D2-

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
D01357 D2-

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
DD1425 D2

STIMULANT ACTIONS OF DELTA9-TETRAHYDROCANNABINOL IN MICE.
0014B0 02-04
AN ANIMAL 8EHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-04
8IOCHEMISTRY AND 8EHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE AND ANTIPSYCHOTIC DRUGS.
002122 02-17
SPECTRUM OF PHARMACOLOGICAL ACTIONS ON 8RAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02
A CEREBELLAR MODEL TO STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINO8UTYRIC-ACID MEDIATED TRANSMISSION. (UNPU8LISHED PAPER).
002212 03-03
CENTRAL ACTIONS OF 8ENZODIAZEPINES.
002228 03-03
ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND 8RAINSTEM NEURONES.
002229 03-03
A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03
COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AND DIAZEPAM IN ISOLATED RAT HEART.
00237B 03-03
CENTRAL NERVOUS ACTIONS OF CAR8AMAZEPINE.
002410 03-03
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04
CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04
A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04
DIFFERENTIATION OF NEUROPHARMACOLOGICAL ACTIONS OF APOMORPHINE AND D-AMPHETAMINE.
002523 03-04
AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-G8-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09
THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA.
003011 03-17
ACTIONS OF FENFLURAMINE ON GLUCOSE UPTAKE IN VITRO AND IN VIVO.
003185 04-03
TRYPTAMINE: BIMODAL ACTIONS ON THE EEG AND 8EHAVIOR OF RA88ITS.
003440 04-04
ANTIDEPRESSANT EVALUATION AND THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN DEPRESSIVE PATIENTS.
003521 04-07

ACTIVATION

GA8A RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CERE8ELLAR C-GMP ELICITED 8Y DIAZEPAM. (UNPU8LISHED PAPER).
000051 01-03
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03
ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 01-05
SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
000783 01-11
CATECHOLAMINES IN ACTIVATION, STEREOTYPY, AND LEVEL OF MOOD.
00085B 01-13
CLIM8ING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03
INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03
NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHI8ITION 8Y EPINEPHRINE AND ACTIVATION 8Y THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-03
MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS.
001267 02-03
THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEM8RANE ATPASE 8Y 8IOGENIC AMINES.
001281 02-03
EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON 8EHAVIOUR IN CHICKENS.
001469 02-04
INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04
CLINICAL STUDIES OF ANESTHETIC CERE8RAL ACTIVATION.
001841 02-11
NEUROTRANSMITTER AND PSYCHOSTIMULANT-INDUCED PSYCHOSIS ACTIVATION.
001970 02-14
AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION: 8EHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY 8Y INJECTION OF CHOLERA ENTEROTOXIN INTO THE SU8STANTIA-NIGRA.
003516 04-06
THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13

ACTIVATOR

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03

ACTIVE

ON THE LONG-LASTING INHI8ITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-8ROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03
DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03
IN VIVO FATE OF A BEHAVIORALLY*ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION.
000249 01-03
5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04
ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-09
A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04
MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13
A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE META8OLITES IN HUMAN PLASMA AND CSF.
002086 02-16
INHIBITORY EFFECT OF MID8RAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
002487 03-04
MOOD ACTIVE AGENTS IN DEPRESSION.
003895 04-17

ACTIVELY

PHARMACOLOGIC RESPONSE TO PENTO8AR8ITAL IN ACTIVELY IMMUNIZED MICE.
003141 04-03

ACTIVITIES

REVERSI8LE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-8ETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECERE8RATE CAT.
001275 02-03
EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03
ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION.
001304 02-03

COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-04

CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
003056 04-01

EFFECT OF MORPHINE ON MOUSE BRAIN ATPASE ACTIVITIES.
003126 04-03

EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-03

DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
003480 04-04

ACTIVITY

POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01

STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

CYCLOPENTONE DERIVATIVES RELATED TO MEPROBAMATE: CONFORMATION ACTIVITY RELATIONSHIPS.
000013 01-01

DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01

F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON MONOAMINE-OXIDASE ACTIVITY OF RAT TISSUES IN VIVO.
000042 01-03

INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03

ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
000106 01-03

MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
00010B 01-03

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION.
000132 01-03

DIFFERENTIAL EFFECTS OF LOW DOSES OF ETHANOL ON THE IMPULSE ACTIVITY IN VARIOUS REGIONS OF THE LIMBIC SYSTEM.
000142 01-03

COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
000155 01-03

TRYPTOPHAN-HYDROXYLASE IN DISCRETE BRAIN NUCLEI: COMPARISON OF ACTIVITY IN VITRO AND IN VIVO.
00016B 01-03

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001BB 01-03

ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
000190 01-03

ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
00022B 01-03

SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
0002B9 01-04

NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04

THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

EFFECT OF METHAMPHETAMINE ON MOTOR ACTIVITY IN YOUNG AND OLD MICE.
000320 01-04

EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACID UPON BEHAVIORAL ACTIVITY IN THE RAT.
00032B 01-04

EFFECTS OF AMPHETAMINE AND ILLUMINATION ON ACTIVITY FOLLOWING FRONTAL ABLATION.
000356 01-04

DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-04

BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN.
000393 01-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIDINE OR METHADONE-INDUCED DECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-04

THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04

EFFECTS OF L-TRYPTOPHAN AND L-METHIONINE ON ACTIVITY IN THE RAT.
000434 01-04

ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
0004B4 01-07

BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS.
000568 01-08

LOW PLATELET MONOAMINE-OXIDASE ACTIVITY AND SCHIZOPHRENIA.
000576 01-08

A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-1

THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
0007B1 01-1

COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000B66 01-1

THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
000B7B 01-1

CLINICAL PARAMETERS OF ANTIDEPRESSANT ACTIVITY.
001010 01-1

EXPERIMENTAL STUDY OF THE PSYCHOSTIMULATING ACTIVITY OF AMANTADINE.
001025 01-1

PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
0010B6 02-0

DOPAMINERGIC ACTIVITY OF SOME APOMORPHINE ANALOGS.
001104 02-0

SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
00110B 02-0

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-0

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 02-03

PIPERIDINE: EFFECTS ON LOCOMOTOR ACTIVITY AND BRAIN MONOAMINE TURNOVER.
001122 02-03

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-03

ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-03

EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03

NORADRENALINE SYNTHESIS FROM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
001186 02-03

RECORDING OF THE ELECTROPHYSIOLOGICAL ACTIVITY OF THE LOCUS-COERULEUS IN THE RAT.
001191 02-03

EFFECT OF ETHANOL ON IMPULSE ACTIVITY IN ISOLATED CEREBELLUM.
001206 02-03

ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
00121B 02-03

EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-03

IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-03

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-03

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03

ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY.
001260 02-03

ETHANOL-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
001264 02-03

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-D3

EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTAB-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY.
001339 02-03

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-D3

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
D01366 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-D3

LOCOMOTOR ACTIVITY AND PLASMA, RED BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
0013B0 02-03

MODIFICATION OF ANESTHETIC INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02-03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03

APPETITE STIMULANT ACTIVITY OF CARBOXYDIHYDROXYPROHEPTADINE.
001459 02-04

ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
0D1474 02-04

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001500 02-04

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE ON REACTIONS TO NOVELTY AND ACTIVITY IN RATS.
001515 02-04

PHYSOSTIGMINE EFFECTS ON ACTIVITY AND REACTIONS TO NOVELTY.
001516 02-04

LITHIUM EFFECTS ON VERTICAL ACTIVITY IN RATS: A REPLY TO D. F. SMITH.
001520 D2-04

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04

LOCOMOTOR ACTIVITY AND EXPLORATION: THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT.
00153B D2-04

EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
00155B 02-04

GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
00156B 02-04

REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE.
0015B1 02-04

AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
0015B7 02-D4

BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE
001591 02-04

EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY.
001595 02-04

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
0016D2 D2-D4

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
0D1606 02-04

IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER.
00162B 02-05

EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMAL NA-K-ATPASE ACTIVITY.
001630 02-05

EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN
001723 D2-0B

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

CATECHOLAMINE ACTIVITY AND REPORTED MORBIDITY.
0D2123 02-17

NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY.
DD2196 03-02

EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
DD2222 03-03

FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
002223 03-03
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
002255 03-03
EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03
THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
0022B1 03-03
A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
002296 03-03
EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-03
MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN.
002319 03-03
APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03-03
SERUM DOPAMINE-BETA-HYDROXYLASE ACTIVITY (V): EFFECTS OF VARIOUS DRUGS ON THE ENZYME ACTIVITY.
002326 03-03
THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
002337 03-03
ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-03
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-03
CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03
COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON BRAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
0023B2 03-03
EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS.
002399 03-03
THE SEDATIVE EFFECTS OF NICOTINAMIDE ON GERBIL WHEEL-RUNNING ACTIVITY.
002423 03-04
DIAZEPAM MODIFICATION OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04
BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04
THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY.
002439 03-04
PIRACETAM: NOOTROPIC PHARMACOLOGY OF NEUROINTEGRATIVE ACTIVITY.
002454 03-04
SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04
THE EFFECT OF CHLORDIAZEPOXIDE ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS.
002476 03-04
EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04
EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-04
THE EFFECTS OF ANDROGEN ON WHEEL-SPINNING ACTIVITY IN INFANT RATS.
002537 03-04
INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04
ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT.
002541 03-04
EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04
DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04
ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002556 03-04
ACTIVITY OF PERIPHERAL BLOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA.
00261B 03-0B
MARIHUANA AND HUMAN PHYSICAL ACTIVITY.
002B50 03-14
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15
SPECTRUM OF ACTIVITY OF SOME DRUGS.
002974 03-17
INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYDRAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID.
00304B 04-01
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 04-02
AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02
SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIOIMIDAZOLINES.
003067 04-02
POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02
SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5-ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02
ANALGESIC AND TRANQUILIZING ACTIVITY OF 5,B DISUBSTITUTED 1-TETRALONE MANNICH-BASES.
003075 04-02
BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003076 04-02
9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03
EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE-OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-03
UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFECTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03
ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION.
003117 04-03
THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA
003137 04-03
FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03
EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03
CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

MORPHINE-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RA8BITS.
003197 04-03

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISU8STITUTED PIPERAZINES.
003236 04-03

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
003248 04-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-03

INHI8ITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION.
00326B 04-03

COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNA8INOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
0032B5 04-03

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

EFFECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS.
003350 04-04

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID-DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY.
003401 04-04

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-04

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04

EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

EFFECTS OF LITHIUM-CARBONATE ON MOTOR ACTIVITY IN MANIA AND DEPRESSION.
003561 04-09

PLATELET MONOAMINE-OXIDASE ACTIVITY IN SCHIZOPHRENIC PATIENTS.
00365B 04-13

IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
003B4B 04-17

A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003B76 04-17

FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

ACTUALITIES

THE ETHICS AND THE ACTUALITIES OF PHARMACOTHERAPY.
003015 03-17

ACUPUNCTURE

OUTPATIENT HEROIN DETOXIFICATION WITH ACUPUNCTURE AND STAPLEPUNCTURE.
0027B3 03-11

ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE.
003687 04 13

ACUTE

ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

MECHANISM OF THE EFFECT OF ACUTE ETHANOL ON HEXOBARBITAL METABOLISM.
000074 01-03

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
0000B6 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN
0000B7 01-03

A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN
000154 01-03

A DOSE-RESPONSE STUDY OF THE ACUTE EFFECTS OF ETHANOL ON THE SLEEP OF RATS.
000169 01-03

ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
000279 01-04

THE EFFECT OF ACUTE METHADONE ON FIXED-INTERVAL SCHEDULES OF REINFORCEMENT IN PIGEONS. (PH.D. DISSERTATION).
000375 01-04

ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
00039B 01-04

MEASUREMENT OF ACUTE AND CHRONIC BEHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-04

EVALUATION OF LENPERONE IN ACUTE SCHIZOPHRENIA.
000515 01-07

CLINICAL EXPERIENCE IN USING TLP-607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-0B

ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY.
000540 01-0B

LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-0B

ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
000777 01-11

EFFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHOLIC PATIENTS.
0007B2 01-11

EVIDENCE FOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION.
000B73 01-14

UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15

ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-15

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03

ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-03

ACUTE CENTRAL EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE IN FOWL.
001310 02-03

ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DIIN-PROPYLACETATE.
001533 02-04

ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05

EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE.
001637 02-05

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
001689 02-08

A DOUBLE-BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
001698 02-08

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-0B

RAPID TREATMENT OF ACUTE PSYCHOSIS.
001726 02-09

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION. REPORT OF A CONTROLLED CLINICAL TRIAL.
001B39 02-11

CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS: A COMPARATIVE STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE.
001B50 02-11

ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-13

NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
001949 02-13

RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14

ACUTE ORGANIC-BRAIN-SYNDROME PSYCHOSIS WITH METHYLDOPA THERAPY.
002046 02-15

PHENOTHIAZINE REACTION SIMULATING ACUTE CATATONIA.
002072 02-15

INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17

PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION.
00221B 03-03

THE MECHANISM OF THE EFFECT OF ACUTE STRESS ON HEXOBARBITAL METABOLISM.
002221 03-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
0022B0 03-03

EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE.
0022B5 03-03

EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
002287 03-03

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO.
002339 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03-03

ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04

ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002556 03-04

DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-0B

A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
002627 03-0B

ACUTE CATATONIAS WITH FAVORABLE OUTCOME: A REPORT OF TWO CASES.
002652 03-08

INTRAVENOUS LORAZEPAM IN ACUTE ANXIETY CRISES.
002718 03-10

ANTIDEPRESSANT BLOOD LEVELS IN ACUTE OVERDOSE.
002906 03-15

ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15

A SLEEP STUDY OF ACUTE PSYCHOTIC STATES DUE TO ALCOHOL AND MEPROBAMATE ADDICTION.
002937 03-15

NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION.
003172 04-03

ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTAB-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

NEUROPEPTIDES: INFLUENCE OF ACUTE AND CHRONIC EFFECTS OF OPIATES.
003199 04-03

THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

CHROMOSOME STUDIES BEFORE AND AFTER THE ACUTE ADMINISTRATION OF MORPHINE.
003216 04-03

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
003248 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE
003253 04-03

NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

EFFECTS OF ACUTE AND CONTINUOUS PENTOBARBITAL ADMINISTRATION ON THE GAMMA-AMINOBUTYRIC-ACID SYSTEM.
003307 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
0034B7 04-04

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
00353B 04-06

PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04-11

PROPRANOLOL EFFECTS ON ACUTE MARIHUANA INTOXICATION IN MAN.
003711 04-13

METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

DETERMINING OPTIMUM DOSE AND ACUTE TOLERANCE OF TRIAZOLAM.
003754 04-14

ACUTE ORGANIC-BRAIN-SYNDROME WITH PROPRANOLOL AND METHYLDOPA.
003779 04-15

ACUTE OVERDOSAGE WITH BENZODIAZEPINE DERIVATIVES.
0037B9 04-15

ACUTE HYPERTENSION AFTER ABRUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION.
003B33 04-15
THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003852 04-17

ACYLUREAS
STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
000178 01-03

ADAPTATION
NEUROBIOLOGICAL MECHANISMS OF ADAPTATION IN RELATION TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
000162 01-03
METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY.
000842 01-13

ADAPTATIONAL
ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03

ADAPTIVE
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17

ADDICT
NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11

ADDICTION
BEHAVIOR AND ADDICTION: EXPERIMENTAL STUDIES OF MORPHINE-DEPENDENCE. (PH. D. DISSERTATION).
000315 01-04
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-04
ELECTROACUPUNCTURE AND HEROIN ADDICTION, A CASE REPORT.
000744 01-11
AGONISTS AND ANTAGONISTS IN THE TREATMENT OF DRUG ADDICTION.
000773 01-11
A CONTROLLED STUDY OF THE TREATMENT OF NARCOTIC ADDICTION IN IRAN: A PRELIMINARY REPORT (UNPUBLISHED PAPER).
001B65 02-11
NALOXONE IN OPIATE ADDICTION.
002742 03-11
A SLEEP STUDY OF ACUTE PSYCHOTIC STATES DUE TO ALCOHOL AND MEPROBAMATE ADDICTION
002937 03-15
CLINICAL THERAPEUTIC REPORTS ON ADDICTION TO RARE DRUGS.
002969 03-17
DRUG ADDICTION: LIGHT AT THE END OF THE TUNNEL?
003422 04-04
PENTAZOCINE ADDICTION: A WARNING.
003B32 04-15

ADDICTIVE
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
0012B5 02-03
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION- DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION
003373 04-04

ADDICTS
POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSION IN ALCOHOL ADDICTS.
000742 01-11
FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001B5B 02-11
DIGIT SYMBOL PERFORMANCE IN METHADONE TREATED EX-HEROIN ADDICTS.
001956 02-14
EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS; COMPARISON WITH BLOOD LEVELS.
002041 02-15
PSYCHOTROPIC DRUGS IN OPIOID ADDICTS ON METHADONE TREATMENT.
002119 02-17
CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONE IN THE COMMUNITY
002174 02-17
SULPIRIDE IN WITHDRAWAL OF NONALCOHOLIC DRUG ADDICTS.
002593 03-07
THE USE OF METHADONE AS A TREATMENT TOOL FOR OPIATE ADDICTS: A TWO-YEAR FOLLOW-UP STUDY.
003025 03-17

ADDISONS
ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY
000947 01-15

ADDITION
ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING THE ADDITION OF THROMBIN AND A23187. (UNPUBLISHED PAPER).
002B04 03-13

ADDITIVE
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03

ADENOSINE
FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09
EFFECTS OF ADENOSINE ANALOGS ON RAT CEREBRAL CORTICAL NEURONS.
002336 03-03
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03
EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03
ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03
EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03
EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

ADENOSINE-TRIPHOSPHATASE
INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

ADENYL-CYCLASE
DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03
NO EFFECTS OF QUATERNARY NEUROLEPTICS ON HUMAN PROLACTIN AND ADENYL-CYCLASE.
003BB1 04-17

ADENYLATE-CYCLASE
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03
A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03
AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN- COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS.
001348 02-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03

A DOPAMINE-STIMULATED ADENYLATE-CYCLASE IN RAT SUBSTANTIA-NIGRA.
0013B2 02-03

EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

THE EFFECT OF HALOPERIDOL ON EPINEPHRINE-STIMULATED ADENYLATE-CYCLASE IN HUMANS.
002209 03-03

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03

EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN THE RETINA: A POINT OF ACTION FOR D-LSD.
002372 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
D02385 03-03

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL BETA-ADRENERGIC ADENYLATE-CYCLASE.
D0366B 04-13

ADENYLATE-CYCLASES

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

ADIPOSE

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE.
001202 02-03

ADJUNCT

THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

ADJUNCTIVE

SCOPOLAMINE AND ADJUNCTIVE DRINKING IN RATS.
000216 01-03

EFFECTS OF DIAZEPAM AND RIPAZEPAM ON TWO MEASURES OF ADJUNCTIVE DRINKING IN RATS.
001572 02-04

ADJUNCTS

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION.
003469 04-04

ADJUSTMENT

PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16

ADMINISTERED

DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000B59 01-13

DE PLANTIS TOXICARIIS E MUNDO NOVO TROPICALE COMMENTATIONES XIII. FURTHER NOTES ON VIROLA AS AN ORALLY ADMINISTERED HALLUCINOGEN.
001093 02-01

BEHAVIORAL EFFECTS OF INTRAVENTRICULARLY ADMINISTERED VASOPRESSIN AND VASOPRESSIN FRAGMENTS.
001107 02-02

ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
0011B1 02-03

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY.
001613 02-05

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-0B

INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04

CLINICAL EVALUATION OF A WEEKLY ADMINISTERED NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-07

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

ENHANCEMENT OF RETENTION WITH CENTRALLY ADMINISTERED CATECHOLAMINES.
003400 04-04

ANTRDEPRESSAMT EFFECTS OF DESIPRAMINE ADMINISTERED IN TWO DOSAGE SCHEDULES.
003566 04-09

AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT.
003657 04-13

ADMINISTERING

THE EFFECTS OF ADMINISTERING LITHIUM-CARBONATE ON THE BALANCE OF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
0D1774 02-09

ADMINISTRATION

EFFECTS OF PHOSPHOLIPID ADMINISTRATION ON ENDOGENOUS CEREBRAL PHOSPHOLIPID BIOSYNTHESIS.
000036 01-03

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
000075 01-03

INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 01-03

ENHANCEMENT OF PENTOBARBITAL EFFECT BY CONTINUOUS ADMINISTRATION OF MORPHINE IN THE MOUSE.
000122 01-03

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION.
000132 D1-03

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN
000136 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-03

BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN.
000184 01-03

NEUROPHARMACOLOGICAL ACTIONS OF ENKEPHALIN AFTER SYSTEMATIC ADMINISTRATION.
000203 01-03

EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN.
00021B 01-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
000238 01-03

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03

IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION.
000249 01-03

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
000269 01-03

THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04

CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONTAXIC DOSES OF ETHYLALCOHOL.
000305 01-04

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04

ENHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
00031B 01-04

CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04

HEART-RATE LEARNING AFTER D-TUBOCURARINE ADMINISTRATION IN ANIMALS.
000329 01-04

FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION.
000404 01-04

BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN.
000407 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04

EFFECTS OF THE ADMINISTRATION OF TWO DOSES OF SULPIRIDE ON THE BEHAVIOUR OF THE RAT.
000414 01-04

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04

EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

INTRAVENOUS ADMINISTRATION OF MAPROTYLIN IN DEPRESSION.
0004B5 01-07

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE.
0005B7 01-09

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
0007B3 01-11

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
000796 01-12

SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000835 01-13

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000B36 01-13

REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000B64 01-13

THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
000B67 01-13

CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COCAINE ADMINISTRATION IN HUMANS.
000B90 01-14

ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15

AN IRREVERSIBLE EFFECT OF LITHIUM ADMINISTRATION TO PATIENTS.
000964 01-15

CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15

ADMINISTRATION OF PSYCHOTROPIC DRUGS FROM THE STANDPOINT OF THE GENERAL PRACTITIONER.
001071 01-17

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03

EFFECTS OF AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM FROM RAT BRAIN.
001421 02-03

EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-04

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04

INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
001466 02-04

CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001500 02-04

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON.
001505 02-04

DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04

SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
0015B3 02-04

AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
0015B7 02-04

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN.
001631 02-05

TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
001641 02-05

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
001648 02-06

ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
001735 02-09

OBSERVATIONS OF THE INTRAVENOUS ADMINISTRATION OF SULPIRIDE (DOBREN).
00176B 02-09

SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN-ETHYL-ESTER.
001922 02-13

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-03

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03-03

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
002280 03-03

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION.
0022BB 03-03

NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
00231B 03-03

OXIDATIVE PHOSPHORYLATION IN VARIOUS PARTS OF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION.
002321 03-03

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03-03

MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
00236B 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03-03

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
002480 03-04

EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-04

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04

EFFECT OF UNIT DOSE AND ROUTE OF ADMINISTRATION ON SELF-ADMINISTRATION OF MORPHINE.
002543 03-04

DIFFERENCES IN CYTOCHROME-P-450 OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
002563 03-05

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05

CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002B06 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002820 03-13

DRUG INTERACTIONS OF THE COMPONENTS OF OPTALIDON AFTER ORAL ADMINISTRATION.
002B23 03-13

L-TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS.
002B71 03-14

BEHAVIORAL EFFECTS OF REPEATED PSYCHOACTIVE DRUG ADMINISTRATION. (PH.D. DISSERTATION).
002B77 03-14

A CASE WHERE ADMINISTRATION OF LITHIUM-CARBONATE CAUSED POLYURIA.
002938 03-15

EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE.
00310B 04-03

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE-OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-03

FENFLURAMINE LONG-TERM ADMINISTRATION AND BRAIN SEROTONIN
003130 04-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION.
003172 04-03

ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTAB-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
0031B2 04-03

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
003184 04-03

EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
0031B7 04-03

THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

CHROMOSOME STUDIES BEFORE AND AFTER THE ACUTE ADMINISTRATION OF MORPHINE.
003216 04-03

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION.
003217 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03

DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION
003293 04-03

EFFECTS OF ACUTE AND CONTINUOUS PENTOBARBITAL ADMINISTRATION ON THE GAMMA-AMINOBUTYRIC-ACID SYSTEM.
003307 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

BARBITURATE DEPENDENCE IN MICE: EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION.
003348 04-04

MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS: LACK OF TOLERANCE WITH LONG-TERM ADMINISTRATION.
003382 04-04

REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION
003573 04-09

ORAL CHOLINE ADMINISTRATION TO PATIENTS WITH TARDIVE-DYSKINESIA.
003624 04-11

POLYGRAPHIC SLEEP RECORDINGS BEFORE AND AFTER THE ADMINISTRATION OF FLUNITRAZEPAM.
003626 04-11

EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING.
003698 04-13

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14

DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003801 04-15

MINISTRATIONS

DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03

ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS.
002489 03-04

EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

MITTED

PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
001683 02-08

ADOLESCENT

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY IN THE MID-SEVENTIES: PROGRESS OR PLATEAU?.
003038 03-17

MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
003582 04-10

ADOLESCENTS

RESPONSE OF ADOLESCENTS WITH MINIMAL-BRAIN-DYSFUNCTION TO METHYLPHENIDATE.
003630 04-11

ADRENAL

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
000155 01-03

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-03

EFFECTS OF CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL.
000268 01-03

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION.
001934 02-13

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03-03

INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
0023B9 03-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

ADRENALECTOMIZED

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

ADRENALECTOMY

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

ADRENALINE

EFFECTS OF CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL.
000268 01-03

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
00046B 01-06

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
000491 01-07

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000B26 01-13

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN.
001197 02-03

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03

ADRENERGIC

AGENTS AFFECTING ADRENERGIC FUNCTION IN ANTIHYPERTENSIVE THERAPY -- II.
000731 01-11

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL.
00082B 01-13

COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000B66 01-13

CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-03

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE.
001202 02-03

REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
001216 02-03

EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS.
001527 02-04

THE EFFECT OF ALPHA AND BETA ADRENERGIC RECEPTOR BLOCKERS ON SLEEP IN THE RAT.
001624 02-05

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF ADRENERGIC SYSTEM.
002246 03-03

HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03

THE PSYCHOPHARMACOLOGY OF BETA ADRENERGIC BLOCKADE: PHARMACOKINETIC AND EPIDEMIOLOGIC ASPECTS.
002599 03-07

2-PHENYLETHYLAMINE AND OTHER ADRENERGIC MODULATORS.
002B33 03-13

NEUROPSYCHIATRIC EFFECTS OF ADRENERGIC BETA-RECEPTOR BLOCKING AGENTS.
002978 03-17

ADRENERGIC CHOLINERGIC IMBALANCE IN AFFECTIVE DISORDERS.
003021 03-17

TURNOVER OF 5-HYDROXYDOPAMINE IN ADRENERGIC NERVES.
003157 04-03

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03

THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-03

ADRENERGIC RESPONSES IN THE AFFECTIVE DISORDERS.
00355B 04-09

ADRENOCEPTOR

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03

ADRENOCORTICAL

5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04

NEUROENDOCRINE REGULATION IN DEPRESSION I. LIMBIC SYSTEM ADRENOCORTICAL DYSFUNCTION.
001736 02-09

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

ADRENOLYTICS

A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
00220B 03-03

ADRENOMEDULLARY

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-

ADRENORECEPTORS

FUNCTIONAL SIGNIFICANCE OF THE ALPHA AND BETA ADRENORECEPTORS IN THE STRUCTURES OF THE STRIOPALLIDAR SYSTEM.
002299 03-

ADULT

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-

5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-

SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-

THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-

EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-

THE IDENTIFICATION AND TREATMENT OF ADULT BRAIN DYSFUNCTION
002143 02-

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RA FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMI UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS
002343 03

INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY.
00276B 03

GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04

RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
00349B 04

LITHIUM IN ADULT ANOREXIA-NERVOSA: A PILOT REPORT ON TWO PATIENTS.
003610 04

ADULTERATION

ACQUIRED PREFERENCE FOR MORPHINE BUT NOT D-AMPHETAMINE AS RESULT OF SACCHARINE ADULTERATION
001513 02

ADULTS

DIAGNOSIS AND TREATMENT OF MINIMAL-BRAIN-DYSFUNCTION IN ADULTS.
002794 03

ADVANCE

THE ADVANCE OF DEPRESSIVE DISEASES.
001015 01

ADVANCED

PSYCHOLOGIC EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL IN ADVANCED CANCER PATIENTS.
001B72 02

ADVANTAGES

THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3 DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01

THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01

ADVERSE

ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01

SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORIN OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS
002142 02

ADVERSE REACTIONS IN TREATMENT WITH LITHIUM-CARBONATE AND HALOPERIDOL.
002665 03

ADVERSE REACTIONS TO MARIHUANA USE AMONG COLLEGE STUDENT
002B96 03

AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE
002897 03-15
ADVERSE EFFECTS OF PHARMACOTHERAPY IN CHILDHOOD PSYCHOSIS.
002988 03-17
RECENT ADVANCES IN THE TREATMENT AND PREVENTION OF ADVERSE REACTIONS TO LITHIUM.
003031 03-17
TOWARD THE OPERATIONAL IDENTIFICATION OF ADVERSE DRUG REACTIONS.
003800 04-15

VERSELY
A COMPARISON OF THE A8ILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
001494 02-04

VERTISEMENTS
APPEALS USED IN ADVERTISEMENTS FOR PSYCHOTROPIC DRUGS: AN EXPLORATORY STUDY.
003899 04-17

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIA8LES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08

ECT
EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUA8-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
000389 01-04
PHYSOSTIGMINE: EFFECTS ON COGNITION AND AFFECT IN NORMAL SU8JECTS.
001965 02-14
EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTONIC AFFECT.
002605 03-07
THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14

ECTIVE
PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION: COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES.
000197 01-03
NEURO8IOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CAR8ONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
000584 01-09
A DOU8LE-8LIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
000589 01-09
A DOUBLE-8LIND COMPARISON OF LITHIUM-CAR8ONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09
LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SU8TYPES OF PRIMARY AFFECTIVE DISORDER.
000601 01-09
HOW LONG SHOULD PROPHYLACTICS BE CONTINUED IN AFFECTIVE DISORDERS
000606 01-09
LONG-TERM THERAPY OF AFFECTIVE DISORDERS AND SCHIZOPHRENIA.
000620 01-09
THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09
CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01-09
A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09
THE POTENTIAL VALUE OF 8IOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
000652 01-09
TRICYCLIC ANTIDEPRESSANTS, TRYPTOPHAN AND AFFECTIVE DISORDER
000657 01-09
CEREBROSPINAL FLUID AMINE META8OLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17
EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04
AFFECTIVE PSYCHOSES FOLLOWING RENAL TRANSPLANT.
001733 02-09
THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, 8IOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09
NEUROPSYCHO8IOLOGY OF AFFECTIVE DISORDERS: SOME METHODOLOGICAL CONSIDERATIONS.
001751 02-09
THE CURRENT ROLE OF LITHIUM IN THE TREATMENT OF AFFECTIVE DISORDERS.
001779 02-09
LITHIUM CAR8ONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH 8IPOLAR AFFECTIVE DISEASE.
001813 02-11
CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPU8LISHED PAPER).
001962 02-14
ON PROPHYLAXIS IN UNIPOLAR AFFECTIVE DISORDER.
002157 02-17
CURRENT STATUS OF LITHIUM THERAPY IN AFFECTIVE DISORDERS.
002160 02-17
AFFECTIVE STATES ASSOCIATED WITH MORPHINE INJECTIONS.
002528 03-04
TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECAR8OXYLASE INHI8ITOR, M5T-1R8.
002672 03-09
ADVANCES IN THE DRUG THERAPY OF AFFECTIVE DISORDERS.
002680 03-09
A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09
AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12
STUDIES OF CSF AMINE META8OLITES IN AFFECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002812 03-13
MHPG, AMITRIPTYLINE AND AFFECTIVE DISORDERS: A LONGITUDINAL STUDY.
002834 03-13
PHARMACOLOGICAL TREATMENT OF AFFECTIVE DISORDERS.
002962 03-17
ADRENERGIC CHOLINERGIC IM8ALANCE IN AFFECTIVE DISORDERS.
003021 03-17
BIOGENIC AMINE PRECURSORS AND AFFECTIVE ILLNESSES.
003551 04-09
ADRENERGIC RESPONSES IN THE AFFECTIVE DISORDERS.
003558 04-09
BIOCHEMISTRY OF THE AFFECTIVE DISORDERS.
003562 04-09
PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
003863 04-17
A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

AFFERENT
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
001168 02-03

AFFINITIES
AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
003328 04-03

AFFINITY
5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOMAL MEM8RANES.
001201 02-03
INTERACTIONS 8ETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
001207 02-03
STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03
A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003876 04-17

AFTER-DISCHARGE
PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03
INFLUENCE OF DELTA9-TETRAHYDROCANNA8INOL AND CANNA8ID!OL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03

AFTERCARE
LONG-ACTING DRUGS WITH AFTERCARE OF SCHIZOPHRENICS.
000546 01-08
DRUG IN THE AFTERCARE TREATMENT OF SCHIZOPHRENIA.
000549 01-08

EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14

PHARMACOLOGICAL AFTERCARE FOR HOMOGENOUS GROUPS OF PATIENTS.
003890 04-17

AG-3-5

SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
000446 01-04

AGE

ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
000777 01-11

PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
001182 02-03

NOTE 2: DEPRESSION IN THE DEVELOPMENTAL AGE: CLINICOTHERAPEUTIC STUDY OF DEPRESSION IN THE DEVELOPMENTAL AGE.
002725 03-10

RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03-11

INCREASED SENSITIVITY TO NITRAZEPAM IN OLD AGE.
003724 04-14

AGED

ASTHE-CRINOL-12 IN THE ASTHENIA SYNDROME OF AGED SUBJECTS.
000497 01-07

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION.
000658 01-09

ACTION OF TRAZODONE ON MENTAL FUNCTIONS OF THE AGED.
000770 01-11

TREATING THE AGED WITH PSYCHOTROPIC DRUGS.
001038 01-17

PHARMACOKINETIC APPROACH TO DRUG DOSING IN THE AGED.
002604 03-07

EFFECTS OF DIMETHYLAMINOETHANOL UPON LIFE-SPAN AND BEHAVIOR OF AGED JAPANESE QUAIL.
003112 04-03

PSYCHOACTIVE DRUGS IN THE TREATMENT OF THE AGED.
00363B 04-11

AGES

MANS USE OF DRUGS THROUGH THE AGES.
001023 01-17

AGGRAVATION

AGGRAVATION OF DIABETIC HYPERGLYCEMIA BY CHLORDIAZEPOXIDE.
003B3B 04-15

AGGREGATE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE.
003491 04-05

AGGREGATION

EFFECT OF AGGREGATION ON MORPHINE LETHALITY IN RATS.
00350B 04-05

AGGRESSION

VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRESSION IN RATS.
000325 01-04

BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-D4

THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-D4

THE PAIN AGGRESSION INDUCED BY BRONOPOL IN THE RAT.
000394 01-04

FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION.
000404 01-04

AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK INDUCED AGGRESSION IN THE RAT.
00D410 D1-04

THE EFFECTS OF ALCOHOL AND DELTA9-TETRAHYDROCANNABINOL ON HUMAN PHYSICAL AGGRESSION.
000924 01-14

DIAZEPAM AND AGGRESSION.
000959 01-15

P CHLOROAMPHETAMINE: SHORT AND LONG-TERM EFFECTS UPON SHOCK ELICITED AGGRESSION
001371 02-03

SYNERGISTIC EFFECT OF ESTRADIOL-BENZOATE AND DIHYDROTESTOSTERONE ON AGGRESSION IN MICE.
0014B6 02-04

ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
001492 02-04

INCREASED AGGRESSION IN RATS AFTER WITHDRAWAL OF LONG-TERM USED OXAZEPAM.
001509 02-04

EFFECT OF ETHANOL ON AGGRESSION AND TIMIDITY IN MICE.
001532 02-04

DRUG-INDUCED AGGRESSION
002249 03-0

EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK.
0D2276 03-0

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
00234B 03-0

MECHANISM AND CHARACTERISTICS OF DRUG-INDUCED AGGRESSION. (PH.D. DISSERTATION).
002451 03-0

SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-0

ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH).
002494 03-0

IMIPRAMINE AND AGGRESSION.
002925 03-1

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-0

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-386, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-0

EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER.
003484 04-0

AGGRESSIVE

AGGRESSIVE BEHAVIOR INDUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-0

6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-0

EFFECTS OF LITHIUM ON FOOT-SHOCK-INDUCED AGGRESSIVE BEHAVIOR IN RATS.
001549 02-0

THE EFFECT OF LITHIUM ON IMPULSIVE AGGRESSIVE BEHAVIOR IN MAN
D01996 02-1

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-0

THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS AND RHESUS-MONKEYS.
003406 04-0

AGGRESSIVITY

AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
0024B6 03-0

AGING

CHLORPROMAZINE AND AGING IN THE BRAIN.
D01353 02-0

AGING AND DEPRESSION: SOME UNANSWERED QUESTIONS.
001752 02-0

PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001B45 D2-1

AGITANS

CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN PARALYSIS AGITANS.
001B46 02-1

AGITATION

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
D02095 02-1

FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION.
002597 03-0

GONIST
ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03
THE INTERACTION OF DELTA9-TETRAHYOROCANNABINOL WITH CHOLINOMIMETIC ORUGS IN AN AGONIST ANTAGONIST PARADIGM.
001521 02-04
CATECHOLAMINE AGONIST ANO RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL ORUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14
THE MECHANISM OF OPIATE AGONIST ANO ANTAGONIST ACTION. (UNPUBLISHED PAPER).
002335 03-03

GONISTIC
LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-04

GONISTS
MUSCARINIC AGONISTS PROVIOE A NEW CLASS OF ACARICIDE.
000019 01-02
OOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03
PHARMACOLOGICAL STUOIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03
A NORAORENALINE SENSITIVE AOENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES ANO THE EFFECTS OF AGONISTS, AORENOLYTICS ANO NEUROLEPTIC ORUGS.
000125 01-03
INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INOUCED BY MUSCARINIC CHOLINERGIC AGONISTS ANO PROSTAGLANOIN-F2ALPHA.
0001B3 01-03
ERGOT ALKALOIDS AS OOPAMINE AGONISTS: COMPARISON IN TWO ROOENT MOOELS.
000273 01-04
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS INDUCEO BY HALOPERIOOL.
00043B 01-04
AGONISTS ANO ANTAGONISTS IN THE TREATMENT OF DRUG AODICTION.
000773 01-11
NEURONAL RESPONSES TO AORENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIOENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS ANO INHIBITORY BETA-AORENOCEPTORS.
001141 02-03
DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS ANO ANTAGONISTS ON THE GAMMA-BUTYROLACTONE-INOUCED INCREASE IN MOUSE BRAIN DOPAMINE.
001220 02-03
RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS ANO ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03
CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
002255 03-03
ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUOATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-03
EFFECTS OF CHOLINERGIC AGONISTS AND ANTAGONISTS ON MORPHINE WITHORAWAL SYNDROME.
002469 03-04
ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT.
002541 03-04
ATTEMPT AT TREATING PARKINSONISM WITH AGONISTS OF THE DOPAMINERGIC SYSTEM.
002751 03-11
CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIOEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17
AFFINITIES OF OPIATE AGONISTS ANO ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
00332B 04-03
ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL OOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

RANULOCYTOSIS
CLOZAPINE ANO AGRANULOCYTOSIS.
003B25 04-15

AHR-1118
DOUBLE-BLINO EVALUATION OF AHR-111B AND AMITRIPTYLINE IN DEPRESSEO PATIENTS.
0004B6 01-07

AHR-6134
AHR-6134: A NEW ANTIANXIETY ORUG WITH UNEXPECTEO RESULTS.
002595 03-07

AID
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AIO OF ORUGS AND OTHER METHODS OF ANTIOEPRESSANT THERAPY. DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13
TESTING THE DA HYPOTHESIS WITH THE AID OF ORUGS.
003719 04-13
VERIFICATION OF THE MA HYPOTHESIS WITH THE AIO OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS
003752 04-14

AIDS
EFFICACY AND SIOE-EFFECTS OF NITRAZEPAM AND THIORIOAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS.
000755 01-11

AIR
INTERACTION BETWEEN HYPERBARIC AIR AND D-AMPHETAMINE EFFECTS ON PERFORMANCE.
000436 01-04

AKATHISIA
NEUROLEPTIC-INDUCED AKATHISIA ANO DYSTONIA TRIGGERED BY ALCOHOL.
002056 02-15

AKINESIA
BETA-ENOORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

ALBINO
ROLE OF 5-HYOROXYTRYPTAMINE IN PROSTAGLANOIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03
ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
00022B 01-03
THE EFFECTS OF CHRONIC LITHIUM-CHLORIOE AOMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04
ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
001143 02-03
RETINAL LIPIOOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIOEPRESSANTS.
0012B4 02-03
THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS.
002471 03-04
CATECHOLAMINES AND OPERANT RESPONSE RATES IN ALBINO RATS.
002555 03-04

ALBUM
THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY.
0021B2 03-01

ALBUMIN
STUDIES ON THE BINDING OF BENZOOIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13
THE BINDING OF PHENOTHIAZINES AND RELATED COMPOUNDS TO HUMAN SERUM ALBUMIN.
002B2B 03-13
QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003053 04-01

ALCOHOL
EFFECTS OF HALOPERIDOL ANO LITHIUM ON BLOOD ALCOHOL LEVEL IN RABBITS
000141 01-03
THE EFFECTS OF ALCOHOL ANO ATROPINE ON EEG ANO BEHAVIOR IN THE RABBIT.
00025B 01-03
RESIOUAL LEARNING OEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04
POST-OETOXIFICATION DRUG TREATMENT OF ANXIETY AND OEPRESSION IN ALCOHOL AOOICTS.
000742 01-11
THE EFFECT OF OESMETHYLIMIPRAMINE ON THE ABSORPTION OF ALCOHOL ANO PARACETAMOL.
000B24 01-13

HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AETER CHRONIC ALCOHOL INTAKE.
000B63 01-13
FVIDENCE EOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION.
000B73 01-14
THE EFFECTS OE ALCOHOL AND DELTA9-TETRAHYDROCANNABINOL ON HUMAN PHYSICAL AGGRESSION.
000924 01-14
ALCOHOL DRUG INTERACTIONS IN DAILY MEDICAL PRACTICE.
000974 01-15
ALCOHOL MEM8RANE INTERACTION IN THE BRAIN: NOREPINEPHRINE RELFASE.
001394 02-03
DRINKING PATTERNS AS PREDICTORS OE ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04
AMBULANT TRFATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
00181B 02-11
INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001B40 02-11
THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL.
001941 02-13
EFFFCTS OF ALCOHOL ON SPECIEIC AND ENVIRONMENTAL FEAR.
001966 02-14
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
0019B0 02-14
ALCOHOL AND TENSION REDUCTION: COGNITIVF AND PHYSIOLOGICAL EEEECTS.
0019B4 02-14
ALCOHOL, FIFLD DEPENDENCE, AND DYADIC SFLF-DISCLOSURE.
001989 02-14
FFFFCT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RFLATED TO DRIVING.
001995 02-14
EXPFCTANCIFS, ALCOHOL, AND SEXUAL AROUSAL IN MALF SOCIAL DRINKERS.
D02004 02-14
CORRFLATION BFTWFEN INJURIES DUE TO ACCIDENT AND USE OF ALCOHOL OR DRUGS.
00201B 02-15
NEUROLEPTIC-INDUCFD AKATHISIA AND DYSTONIA TRIGGFRFD BY ALCOHOL.
D02056 02-15
ALCOHOL AND MEMORY: STORAGE AND STATE-DEPFNDENCY.
002069 02-15
A CASE OF SUICIDE WITH NITRAZEPAM AND ALCOHOL.
002079 02-15
THF INFLUFNCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVFMENTS.
0020B5 02-15
PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTFRACTIONS OF ALCOHOL AND OXAZEPAM WITH RFGARD TO RFSPONSF BFHAVIOR.
002BB0 03-14
A SLFFP STUDY OF ACUTE PSYCHOTIC STATFS DUF TO ALCOHOL AND MEPROBAMATF ADDICTION.
002937 03-15
ALCOHOL, ANESTHFTICS, MFMBRANFS.
002963 03-17
DISCRIMINABLE STIMULI PRODUCED BY ALCOHOL AND OTHFR CNS DEPRESSANTS.
002964 03-17
INTERACTION OF ALCOHOL WITH PSYCHOTROPIC DRUGS.
D02973 03-17
MODERN PROBLEMS OE PHARMACOPSYCHIATRY. VOL. II: ALCOHOL, DRUGS AND DRIVING.
D03014 03-17
REVFRSAL OF DELAYFD MYFLINOGENESIS IN THE EETAL ALCOHOL SYNDROME.
00325B 04-03
DOPAMINE LFVELS IN THE STRIATUM AND THE FEEECT OF ALCOHOL AND RESERPINE.
0D331B 04-03
CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS
003321 04-03
THE EFFFCT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT
003499 D4-05
HYDROXYZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL.
D03614 04-11
THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003639 04-11
THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13

ALCOHOLIC

A TRIAL OF EFNFLURAMINE IN THE TREATMENT OE THE CHRONIC ALCOHOLIC PATIENT.
000752 01-11
USE OF DIBENZEPINE RETARD IN THE TREATMENT OE ALCOHOLIC DEPRESSION.
000764 01-11
LITHIUM TRFATMENT DURING ALCOHOLIC WITHDRAWAL.
00077B 01-11
EEFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHOLIC PATIENTS.
0007B2 01-11
LOWERFD MONOAMINE-OXIDASE IN CONNECTION WITH ALCOHOLIC SUICIDES.
000823 01-13
REGIONAL SEROTONIN LEVELS IN BRAIN: A COMPARISON OE DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000883 01-14
EXPERIENCE IN THE TRFATMFNT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
001815 02-11
COMPARISON OF MUSCLE RFLAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001B43 02-11
CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS: A COMPARATIVF STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE.
001850 02-11
REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVF PATIENTS: STUDIFS IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRFNIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002B21 03-13
HEMINEURINE ABUSF BY A CHRONIC ALCOHOLIC.
002946 03-15
PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-318B9) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-11
INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG MFTABOLISM IN PATIENTS WITH ALCOHOLIC LIVFR CIRRHOSIS.
003702 04-13
THF FFFFCT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUCED OCULOGYRAL ILLUSION.
003757 04-14

ALCOHOLICS

RFDUCED CONCFNTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZFPAM.
000B64 01-13
PLASMA PROTFIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
000B6B 01-13
IMPORTANCE OF PROMOTIL IN FOLLOW-UP TREATMENT OE ALCOHOLICS.
002740 03-11
DOUBLE-BLIND STUDY OF THE EFFFCT OF PROPRANOLOL AGAINST PLACEBO IN THF WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZFRS, ANALGETICS, AND OPIATES -- A PRFLIMINARY RFPORT.
002754 03-11
EFFICACY OF PIRACFTAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
00296B 03-17
WAIS FUNCTIONING OF CIRRHOTIC AND NON-CIRRHOTIC ALCOHOLICS.
003B27 04-15

ALCOHOLISM

ON THF THFRAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
00275B 03-11
PROPRANOLOL IN ALCOHOLISM.
002B55 03-14
SOBERING DATA ON LITHIUM IN ALCOHOLISM.
00357B 04-09

ALCOHOLS

SFLFCTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFFCTS ON OPEN-FIELD ACTIVITY.
000237 01-03
RESEARCH IN THE DIPROPYLACETIC SERIES. XII. FXTENDFD ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

ALDOSTERONE

EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVFLS OF ACTH, CORTICOSTFRONE, ALDOSTFRONF, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

ERTNESS
AMPHETAMINES AND ALERTNESS.
002869 03-14

IMENTARY
MAZINDOL (TERONAC) IN THE TREATMENT OF PREDOMINANTLY ALIMENTARY OBESITY.
002719 03-10

PHATIC
RESEARCH IN THE DIPROPYLACETIC SERIES. XII. EXTENDED ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

KALOID
ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
001082 02-01
REFLEXINE, A NEW INDOLE ALKALOID OF RAUWOLFIA-REFLEXA.
001083 02-01
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
001084 02-01
A NEW ALKALOID FROM ERYTHROPHLEUM-COUMINGA.
001087 02-01
AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001832 02-11

KALOIDS
EFFECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES.
000199 01-03
ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS.
000273 01-04
INDOLE ALKALOIDS IN PLANT HALLUCINOGENS.
001073 01-17
ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
001082 02-01
ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01
A NOTE ON THE ISOLATION AND IDENTIFICATION OF THE QUATERNARY ALKALOIDS OF PHELLODENDRON-WILSONII.
001098 02-01
EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA.
001324 02-03
EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04
NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02
EFFECTS OF ERGOT ALKALOIDS ON THE HYPOTHALAMIC PITUITARY AXIS.
002239 03-03
BIOCHEMICAL EFFECTS OF ERGOT ALKALOIDS WITH SPECIAL REFERENCE TO THE BRAIN.
002308 03-03
ELECTROENCEPHALOGRAM AND ERGOT ALKALOIDS.
002786 03-11
INTERACTION BETWEEN YOHIMBINE ALKALOIDS AND AMPHETAMINE IN MICE.
003501 04-05

YLTETRAHYDROCARBAZOLE-ETHANAMINES
EFFECTS OF ALKYLTETRAHYDROCARBAZOLE-ETHANAMINES AND RELATED COMPOUNDS, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-03

YLUREAS
STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
000178 01-03

-NIGHT
EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
000902 01-14

EGED
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 3.
002975 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 2.
003007 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 1.
003022 03-17

ERGY
ALLERGY TO DIAZEPAM.
003803 04-15
ALLERGY TO DIAZEPAM.
003808 04-15
ALLERGY TO DIAZEPAM.
003814 04-15

ALLEVIATION
ALLEVIATION OF NARCOTIC WITHDRAWAL BY CONDITIONAL STIMULI.
002292 03-03

ALLOCATION
EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK.
002276 03-03

ALLOPURINOL
TRYPTOPHAN AND ALLOPURINOL IN THE TREATMENT OF DEPRESSION
001777 02-09

ALLOXAN
REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04

ALLYPROPYMAL
TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL.
002976 03-17

ALPHA-ACETYLMETHADOL
THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

ALPHA-ACTIVITY
ALPHA-ACTIVITY AND BETA-ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE.
003315 04-03

ALPHA-ADRENERGIC
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03

ALPHA-ADRENOCEPTOR
SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE.
001248 02-03

ALPHA-ADRENOCEPTORS
NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03
PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
003142 04-03
INVOLVEMENT OF CENTRAL ALPHA-ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL.
003208 04-03

ALPHA-ANTAGONIST
NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-03

ALPHA-ETHYL-4-METHYL-M-TYRAMINE
DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS.
002242 03-03

ALPHA-FLUPENTHIXOL-INDUCED
ALPHA-FLUPENTHIXOL-INDUCED HYPERACTIVITY BY CHRONIC DOSING IN RATS.
000412 01-04

ALPHA-MELANOCYTE
NEUROPHARMACOLOGICAL TESTS WITH ALPHA-MELANOCYTE STIMULATING HORMONE.
000402 01-04

ALPHA-METHADOL
THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL
STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

ALPHA-METHYL-P-TYROSINE
APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
000346 01-04

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA
003875 04-17

ALPHA-METHYL-P-TYROSINE-METHYL-ESTER
STUDIES IN MICE ON THE ANTAGONISM OF DEXTROAMPHETAMINE ANOREXIA BY ALPHA-METHYL-P-TYROSINE-METHYL-ESTER HCL.
001471 02-04

ALPHA-METHYLDOPA
ALPHA-METHYLDOPA AND FORGETFULNESS.
000946 01-15

FACILITATION OF EFFECTS OF L-DOPA BY ALPHA-METHYLDOPA.
001407 02-03

ALPHA-METHYLTRYPTOPHAN
EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON RAT SOCIAL BEHAVIOUR.
001463 02-04

ALPHA-METHYLTYROSINE
COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
001215 02-03

EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-03

ALPHA-MMT
ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

ALPHA-MPT
ROLE OF BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR.
002252 03-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

ALPHA-NORADRENERGIC
ALPHA NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE
000346 01-04

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
002253 03-03

ALPHA-RECEPTOR
REVERSIBLE ADRENERGIC ALPHA RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL 3 PIPERIDINO PROPIOPHENONE (TOLPERISONE).
001216 02-03

ALPHA-RIGIDITY
EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE.
003314 04-03

ALPHA-TETRALONE
SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA TETRALONE AND N ARYLPIPERAZINES.
001108 02-02

ALPHA-TOCOPHEROL
THE EFFECT OF ALPHA TOCOPHEROL DEFICIENCY ON THE PHARMACOKINETICS AND PHARMACOLOGICAL EFFECT OF BARBITAL.
000170 01-03

ALPRAZOLAM
PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31889) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
000682 01-1

PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-31889) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-1

ALPRENOLOL
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-0

ALTERATION
BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-0

IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
001255 02-0

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-0

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-0

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-0

DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002832 03-

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVIT BY ADRENERGIC BLOCKERS IN MICE.
003214 04-

CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
003505 04-

ALTERATIONS
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRON MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL AND NEUROHUMORAL VARIABLES.
000355 01-

QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLI ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-

LITHIUM-INDUCED ALTERATIONS IN RAT GANGLIONIC LIPIDS.
001318 02-

MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02-

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-

PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-

HYPOTHYROID-LIKE ALTERATIONS IN TESTOSTERONE METABOLISM IN ANOREXIA-NERVOSA.
001887 02-

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION
002288 03-

BEHAVIORAL ALTERATIONS IN PATIENTS WITH BASAL GANGLIA LESIONS.
002430 03

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONI MORPHINE TREATMENT
002541 03

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING T ADDITION OF THROMBIN AND A23187. (UNPUBLISHED PAPER).
002804 03

ELECTROENCEPHALOGRAPHIC ALTERATIONS IN MARIHUANA USERS.
002831 03

INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX
003131 04

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

ALTERED

SYMPOSIUM ON ALTERED STATES OF CONSCIOUSNESS.
000791 01-12

EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02-03

COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
001B67 02-12

A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 02-12

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

ALTERING

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON.
001796 02-10

AN EXPERIMENTAL STUDY ON THE CONSCIOUSNESS ALTERING EFFECT OF N,N DIMETHYLTRYPTAMINE (DMT).
002797 03-12

ALTERNATION

INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANEOUS ALTERNATION TASK.
000361 01-04

EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT
002462 03-04

ALTERNATIONS

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

ALTERNATIVE

LONG-TERM TRANQUILIZERS: AN ALTERNATIVE FOR PRACTICE.
001B01 02-10

GLUTETHIMIDE -- AN UNSAFE ALTERNATIVE TO BARBITURATE HYPNOTICS.
002919 03-15

THE BEHAVIORAL TREATMENT OF INSOMNIA: AN ALTERNATIVE TO DRUG THERAPY.
003B21 04-15

ALTERNATIVES

ALTERNATIVES TO LEVODOPA.
001062 01-17

ALTERS

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04

MORPHINE ALTERS DISTRIBUTION OF GABA IN THALAMUS.
003336 04-03

ALUMINA

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

ALUMINA-INDUCED

EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-03

AMANTADINE

INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

AMANTADINE VERSUS TRIHEXYPHENIDYL IN THE TREATMENT OF NEUROLEPTIC INDUCED PARKINSONISM.
000B1B 01-13

EXPERIMENTAL STUDY OF THE PSYCHOSTIMULATING ACTIVITY OF AMANTADINE
001025 01-17

ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION.
001304 02-03

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN PARALYSIS AGITANS.
001B46 02-11

HALOPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT OF HUNTINGTONS CHOREA.
001B93 02-13

AMANTADINE REDUCES DRUG-INDUCED PARKINSONISM.
0019B3 02-14

AMANTADINE THERAPY FOR DRUG-INDUCED EXTRAPYRAMIDAL SIGNS AND DEPRESSION.
00273B 03-11

AMANTADINES

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

AMBULANT

AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
001B1B 02-11

AMBULATORY

PIMOZIDE VERSUS FLUPHENAZINE IN AMBULATORY SCHIZOPHRENICS: A 12-MONTH COMPARISON STUDY.
003534 04-0B

AMELIORATION

THERAPEUTIC AMELIORATION OF ANXIETY RELATED HYPERTENSION AND ANGINA-PECTORIS.
0006B6 01-10

AMENORRHOEA

DOPAMINE-INDUCED INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA.
001900 02-13

AMERICAS

THE DRUGGING OF THE AMERICAS.
003033 03-17

AMFERPRAMONE

ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04

AMIDES

INFLUENCE ON PSYCHOLEPTIC EFFECTS OF DIFFERENT TYPES OF SUBSTITUTIONS IN A SERIES OF CRESOTINIC AMIDES.
000151 01-03

AMINAZINE

EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
0022B6 03-03

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN.
002306 03-03

REGULARITIES IN PENETRATION OF THE PLACENTAL BARRIER BY AMINAZINE.
002576 03-05

AMINE

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

AMINE METABOLISM.
000555 01-0B

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

EFFECTS OF CLOMIPRAMINE AND OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
000665 01-09

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN
001135 02-03

EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03

PROGRESSIVE EFFECTS OE COCAINE ON BEHAVIOR ANO CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINOLING ANO PSYCHOSIS.
001333 02-03

AUTONOMIC NERVES, MAST CELLS, ANO AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OE RATS AETER ADMINISTRATION OE DISULEIRAM.
002241 03-03

DETERMINATION OE BIOGENIC AMINE METABOLITES IN CEREBROSPINAL ELUID BY MASS ERAGMENTOGRAPHY -- METHOOS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

STUDIES OF CSF AMINE METABOLITES IN AEEECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002B12 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OE CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATEO BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13

AMINE REPLETION IN THE RESERPINIZEO CAT: EEEECT UPON PGO WAVES AND REM SLEEP.
003106 04-03

EEFECTS OE ALKYLTETRAHYDROCARBAZOLE-ETHANAMINES AND RELATEO COMPOUNDS, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-03

EFFECTS OE ACUTE DIAZEPAM ANO CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
00324B 04-03

THE MEASUREMENT OF BIOGENIC AMINE TURNOVER USING OXYGEN-1B.
003263 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF EETAL ANO NEONATAL RAT BRAIN
003299 04-03

NOMIFENSINE AND ITS OERIVATIVES AS POSSIBLE TOOLS FOR STUDYING AMINE UPTAKE.
003305 04-03

IN VITRO O-DEMETHYLATION OF THE PSYCHOMIMETIC AMINE, DIMETHOXY-4-METHYLPHENYL-2-AMINOPROPANE.
003340 04-03

BIOGENIC AMINE PRECURSORS AND AEEECTIVE ILLNESSES.
003551 04-09

PLATELET AND PLASMA AMINE OXIOASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT
003692 04-13

AMINE-INDUCED

THE EFFECT OE THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC-AMP AND CARDIAC CONTRACTILE FORCE.
003213 04-03

AMINEPTIC

A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OE THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISOROERS
000736 01-11

AMINERGIC

HISTOCHEMICAL AND MICROPUNCH ANALYSIS OE AMINERGIC AND CHOLINERGIC PATHWAYS. (UNPUBLISHED PAPER).
002266 03-03

AMINERGIC EACTORS IN MENTAL ILLNESS.
002965 03-17

AMINES

THE IONIZATION OE PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OE ZWITTERION CONSTANTS.
000001 01-01

EFEECTS OE DRUGS AFFECTING ENOOGENOUS AMINES OR CYCLIC NUCLEOTIOES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE.
00029B 01-04

PAPAVERINE, DRUG-INDUCEO STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04

METABOLISM OE INOOLE AMINES IN DEPRESSION
000617 01-09

COMPARISON OF THE EFFECTIVENESS OF DESERPIOINE, RESERPINE, AND ALPHA METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
001215 02-03

THE EFFECTS OE OUABAIN ANO THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES.
0012B1 02-03

INHIBITION OF 3,5 NUCLEOTIOE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP EORMATION BY BIOGENIC AMINES IN VITRO ANO IN VIVO.
001301 02-03

ACUTE ANO CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIOOL, ANO SULPIRIOE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN
001410 02-03

EEEECTS OF DIHYOROGENATEO ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE ANO ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04

HEAO TWITCHES INDUCED BY BENZODIAZEPINES ANO THE ROLE OE BIOGENIC AMINES.
001552 02-04

SULEUR ANALOGS OE PSYCHOTOMIMETIC AMINES.
0021B6 03-01

THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN.
002271 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, ANO F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OE BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

PHARMACOCHEMICAL ANALYSIS OE RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
00305B 04-01

PHARMACOCHEMICAL ANALYSIS OE RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE EOR GLC RESOLUTION OE CHIRAL AMINES.
003064 04-02

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, OOPAMINE, AND 5-HYDROXYTRYPTAMINE.
003247 04-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

STUDIES ON THE DEPLETION OF BRAIN AMINES BY M-TYROSINE.
0032B0 04-03

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04

PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04-1

AMINO-ACID

AMINO-ACID TRANSPORT INHIBITION. BRAIN AND BEHAVIORAL CORRELATES.
000406 01-0

BARBITURATE REVERSAL OF AMINO-ACID ANTAGONISM PRODUCED BY CONVULSANT AGENTS.
001102 02-0

SUPPRESSION OF AMPHETAMINE-INOUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-0

AMINO-ACID-INDUCED

THE SPECIEICITY OF ACTION OE THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-0

AMINO-ACIDS

REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN.
000194 01-0

EFFECTS OE 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-0

EEEECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES.
000199 01-0

THE EFFECT OF PLASMA AMINO-ACIDS ON DEPRESSION
000637 01-0

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-0

ACTION OE AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-0

AMINOOXYACETIC-ACID

EFFECTS OE CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OE COBALT EPILEPTIC FOCI IN RATS
001196 02-0

EFFECTS OE AMINOOXYACETIC ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLICiACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-03

EFEECTS OE AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OE MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
002270 03-03

EEEECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V. EEEECTS OE PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-04

AMINOPHYLLINE

EEEECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03

AMINOPYRIDINE

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM
001306 02-03

AMIPHENAZOLE

SOME DERIVATIVES OF 2,4 DIAMINO-5-PHENYLTHIAZOLE (AMIPHENAZOLE).
000030 01-03

AMITRIPTYLINE

EFEECTS OE AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04

DOUBLE-BLIND EVALUATION OE AHR-111B AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
0004B6 01-07

A DOUBLE-BLIND STUDY OE THE ANTIDEPRESSANTS DIBENZEPIN (NOVERIL) AND AMITRIPTYLINE.
0005B2 01-09

MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION
000591 01-09

CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000604 01-09

CLINICAL ASPECTS OE ORGANON-GB-94 VS AMITRIPTYLINE.
00061B 01-09

AMITRIPTYLINE IN PSYCHIATRIC THERAPY: EIGHT YEARS OF USAGE IN HOSPITAL PRACTICE.
000656 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OE THE EFFECTS OE AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION
00065B 01-09

MIANSERIN VERSUS AMITRIPTYLINE: A DOUBLE-BLIND TRIAL EVALUATED BY THE AMP SYSTEM.
000663 01-09

A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000B29 01-13

DIBENZEPIN AND AMITRIPTYLINE IN DEPRESSIVE STATES: COMPARATIVE DOUBLE-BLIND TRIAL.
000B93 01-14

KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 02-03

A COMPARISON OF AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES.
001731 02-09

EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA.
001765 02-09

THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OE AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09

DOUBLE BLIND ATTEMPT AT COMPARISON OF EEFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION
0017B3 02-09

AMITRIPTYLINE THERAPY IN PATIENTS WITH ANOREXIA-NERVOSA.
001799 02-10

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001B9B 02-13

CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE
00207B 02-15

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16

ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OE AMITRIPTYLINE AND CLOZAPINE.
002671 03-09

AUTONOMIC ACTIONS AND INTERACTIONS OE MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09

AMITRIPTYLINE IN THE TREATMENT OE DEPRESSION
002697 03-09

CHLORIMIPRAMINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION.
002704 03-09

AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OE ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002709 03-10

CLINICAL EVALUATION OE AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF DEPRESSION.
002713 03-10

CLINICAL EVALUATION OE AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES.
002714 03-10

AMITRIPTYLINE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002716 03-10

EFFECTS OF AMITRIPTYLINE ON THE PROGRESS OF DEPRESSION
002726 03-10

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03-11

MHPG, AMITRIPTYLINE AND AFEECTIVE DISORDERS: A LONGITUDINAL STUDY.
002B34 03-13

QUANTITATIVE DETERMINATION OE AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09

AMOXAPINE: A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
003577 04-09

CLINICAL TRIAL COMPARISON OF TWO SUSTAINED-RELEASE FORMS OF AMITRIPTYLINE.
0035B6 04-10

CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10

A COMPARISON OF MAPROTILINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
003604 04-10

AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11

A STUDY OF LOW-DOSE AMITRIPTYLINE OVERDOSES.
003B13 04-15

AMITRIPTYLINE-N-OXIDE

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS BEFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N OXIDE.
001794 02-10

AMIZEPINE

OBSERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL-NERVOUS-SYSTEM DYSFUNCTIONS.
002762 03-11

AMNESIA

PENTYLENETETRAZOL-INDUCED AMNESIA: A CASE FOR OVERT SEIZURES.
000399 01-04

BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA.
001254 02-03

VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA. CONTINGENCY ON TASKS AND SPECIES.
001440 02-04

TIME DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?
001559 02-04

DELAY OF ONSET OE TRANSIENT AMNESIA AFTER HYPOXIA.
002416 03-04

WHEN DOES INHIBITION OF BRAIN ACETYLCHOLINESTERASE CAUSE AMNESIA IN RATS?
003152 04-03

AMNESIAS
DDC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OE DL-DOPS.
001232 02-03

AMOBARBITAL
DIEFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
000909 01-14

A CASE OF DEFICIENCY OF N-HYDROXYLATION OF AMOBARBITAL.
0036B0 04-13

AMOUNT
EEFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04

AMOXAPINE
AMOXAPINE: A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
003577 04-09

AMP
MIANSERIN VERSUS AMITRIPTYLINE: A DOUBLE-BLIND TRIAL EVALUATED BY THE AMP SYSTEM.
000663 01-09

AMPHEPRAMONE
EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

AMPHETAMINE
THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OE D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN
0000B6 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D AMPHETAMINE-SULFATE.
0000BB 01-03

BENZODIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03

EEFECTS OF AMYGDALA LESIONS ON TASTE-AVERSIONS PRODUCED BY AMPHETAMINE AND LICL.
000116 01-03

INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03

INHIBITION OF MONOAMINE-OXIDASE BY AMPHETAMINE AND RELATED COMPOUNDS
000163 01-03

NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS (PH D. DISSERTATION).
00020B 01-03

EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELE-STIMULATION AND INTRAVENOUS AMPHETAMINE SELE-ADMINISTRATION
000262 01-03

ATTENUATION OE INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03

THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHFTAMINE.
000274 01-04

DIFFERENCES BETWEEN THE ANOREXIC ACTIONS OE AMPHETAMINE AND FENFLURAMINE POSSIBLE EFFECTS ON HUNGER AND SATIETY.
000291 01-04

THF EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVFD AND SATIATED MICE.
000313 01-04

LITHIUM AND AMPHETAMINE HYPERACTIVITY IN RATS: DIFFERENTIAL EEFECT ON D AND L ISOMERS
000326 01-04

DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF STIMULATION.
000335 01-04

DIFFERENCES IN THF EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS
00034B 01-04

EFFECTS OE AMPHETAMINE AND ILLUMINATION ON ACTIVITY FOLLOWING FRONTAL ABLATION.
000356 01-04

CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
0003B5 01-04

THE EEEECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
0009B6 01-15

EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN
001204 02-03

IN VITRO METABOLISM OE AMPHETAMINE: AN APPARENT ENANTIOMERIC INTERACTION.
001217 02-03

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OE AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
0012B2 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELE-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
0012B5 02-03

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03

ROLE OF NORADRENERGIC AND DOPAMINERGIC PROCESSES IN AMPHETAMINE SELE-ADMINISTRATION.
001342 02-03

AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF-STIMULATION IN CAUDATE OR HYPOTHALAMUS OE THE SQUIRREL-MONKEY.
0013B4 02-03

EFEECTS OE AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM EROM RAT BRAIN
001421 02-03

AMPHETAMINE ATTENUATION OF TONIC IMMOBILITY IN CHICKENS.
001449 02-04

ON THE RELATION BETWEEN HYPODIPSIA AND ANOREXIA INDUCED BY (+) AMPHETAMINE IN THE MOUSE.
001472 02-04

ACTIVITY OE ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OE OBESITY IN ANIMALS.
001474 02-04

EFFECT OE NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE
001535 02-04

AMPHETAMINE REDUCTION OE MOTOR ACTIVITY IN RATS AETER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
0015B7 02-04

THE EEEECT OE BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05

URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM.
001729 02-09

BIOCHEMISTRY AND BEHAVIOR: SOME CENTRAL ACTIONS OE AMPHETAMINE AND ANTIPSYCHOTIC DRUGS
002122 02-1

SOME CHARACTERISTICS OF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OF PSYCHOPATHOLOGY
002204 03-0

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EEEECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
00220B 03-0

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE.
00223B 03-0

ROLE OE BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR
002252 03-0

SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFEECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY (PH.D. DISSERTATION).
002272 03-0

PECULIARITIES OF THE ACTION OE SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS
0022B9 03-0

EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN
002373 03-0

A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING· A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
002448 03-04

EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
002458 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION
002500 03-04

DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
002532 03-04

ANTIDEPRESSANT RESPONSE PREDICTION BY AMPHETAMINE. (UNPUBLISHED PAPER).
002702 03-09

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821 03-13

AMPHETAMINE AND COCAINE ABUSE. (UNPUBLISHED PAPER).
002987 03-17

BIOLOGICAL DISPOSITION OF RIGID ANALOGS OF AMPHETAMINE.
003147 04-03

CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003153 04-03

ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDRODIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
003184 04-03

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION.
003217 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

THE ROLE OF N-HYDROXYAMPHETAMINE IN THE METABOLIC DEAMINATION OF AMPHETAMINE.
003329 04-03

LACK OF STIMULATION BY HIGH AMPHETAMINE DOSES FOLLOWING A LOW-DOSE OF SPIPERONE.
003345 04-04

PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION.
003360 04-04

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
003368 04-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION
003373 04-04

EFFECTS OF P-CHLOROPHENYLALANINE AND AMPHETAMINE ON HABITUATION OF EXPLORATION.
003385 04-04

EFFECT OF TRYPTAMINE ANTAGONISTS ON SELF-STIMULATION: INTERACTION WITH AMPHETAMINE.
003386 04-04

TOLERANCE AND CROSS-TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003389 04-04

THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
003395 04-04

EFFFCTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

EARLY DEVELOPMENTAL CHANGFS IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RFLATION TO HIPPOCAMPAL FUNCTION
003418 04-04

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

FXAGGERATED RESPONSE TO (+)AMPHETAMINE IN GERIATRIC GERBILS.
003468 04-04

EFFECTS OF DELTA9 TETRAHYDROCANNABINOL (DELTA9 THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE
003491 04-05

INTERACTION BETWEEN YOHIMBINE ALKALOIDS AND AMPHETAMINE IN MICE.
003501 04-05

MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY IN RATS.
003507 04-05

AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDRFN.
003670 04-13

SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTFRACTION WITH AMPHETAMINE SULFATE.
003688 04-13

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

AMPHETAMINE-INDUCED

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-02

SUPPRESSION OF AMPHETAMINE-INDUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-03

AMPHETAMINE-INDUCED RELEASE OF DOPAMINE FROM THE SUBSTANTIA-NIGRA IN VITRO.
002328 03-03

SPONTANEOUS AND AMPHETAMINE-INDUCED HEAD-SHAKING IN INFANT RATS.
002465 03-04

DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON AMPHETAMINE-INDUCED LOCOMOTION AND STEREOTYPY.
002535 03-04

THE EFFECT OF DIMETHYLAMINOETHANOL (DEANOL) ON AMPHETAMINF-INDUCED STEREOTYPED BEHAVIOR (AISB).
002553 03-04

AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION: BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17

INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-04

AMPHETAMINE-INDUCED ANGIITIS LEADING TO RENAL FAILURE
003822 04-15

AMPHETAMINE-TYPE

EFFECT OF AMPHETAMINE-TYPE PSYCHOSTIMULANTS ON BRAIN METABOLISM.
000817 01-13

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT
001192 02-03

AMPHETAMINES

TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03

AMPHETAMINES: TIGHTER CONTROLS ON THE HORIZON.
002125 02-17

AMPHETAMINES AND ALERTNESS.
002B69 03-14

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

AMYGDALA

EFFECTS OF AMYGDALA LESIONS ON TASTE-AVERSIONS PRODUCED BY AMPHETAMINE AND LICL.
000116 01-03

INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04

CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
002348 03-03

EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS
002399 03-03

UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFFCTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03

INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

AMYGDALOID

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04

FAILURE OF ATROPINE TO RETARD AMYGDALOID KINDLING.
001171 02-03

AMYLOBARBITONE

A NEW METABOLITE OF AMYLOBARBITONE: CARBOXYBUTYLETHYLBARBITURIC-ACID.
003090 04-03

A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11

AMYLOPECTINE

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04

AMYTAL

EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES OF SNAIL GIANT NEURONS.
002201 03-03

THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS.
002471 03-04

THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003B41 04-16

ANAFRANIL

EVALUATION OF THE NEW DRUG - CLOMIPRAMINE (ANAFRANIL).
000522 01-07

THE EFFECT OF CLOMIPRAMINE (ANAFRANIL) ON CONTINUING PAIN
000636 01-09

ANAFRANIL IN OBSESSIVE-COMPULSIVE NEUROSIS.
000672 01-10

COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
001228 02-03

THE MANAGEMENT OF PHOBIC DISORDERS USING CLOMIPRAMINE (ANAFRANIL).
00360B 04-10

A COMPARISON OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003621 04-11

A COMPARATIVE TRIAL OF ANAFRANIL, PERTOFRAN AND AN ANAFRANIL/PERTOFRAN COMBINATION.
003636 04-11

AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT
003657 04-13

COMPARISONS OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003672 04-13

PLASMA LEVEL STUDIES WITH CLOMIPRAMINE (ANAFRANIL).
003679 04-13

PRACTICAL CONSIDERATIONS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE: AN UPDATED REVIEW.
003764 04-15

SEXUAL SIDE EFFECTS OF CLOMIPRAMINE (ANAFRANIL).
003765 04-15

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
003807 04-15

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY STATE PLASMA LEVEL MEASUREMENTS.
003B66 04-17

CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN
003B91 04-17

ANALEPTIC

ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION
003117 04-03

ANALEPTICS

EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE.
002285 03-03

ANALGESIA

SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT
000102 01-03

NITROUS-OXIDE ANALGESIA: RESEMBLANCE TO OPIATE ACTION
001139 02-03

ANALGESIA PRODUCED BY MORPHINE WHEN ACTING FROM THE LIQUOR SPACE
0011B4 02-03

CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-0

COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-0

POSSIBLE INVOLVEMENT OF GABA IN MORPHINE ANALGESIA.
002411 03-0

CENTRAL-NERVOUS-SYSTEM MECHANISMS OF ANALGESIA.
002496 03-0

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
003228 04-0

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF TH LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-0

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN
003276 04-0

ENHANCEMENT OF PROPOXYPHENE-INDUCED ANALGESIA BY DOXEPIN
003301 04-0

POTENTIATION OF MORPHINE ANALGESIA BY MUSCIMOL.
003354 04-0

REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY.
003401 04-0

ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE.
0036B7 04-1

PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSE IN MAN.
003708 04-1

ANALGESIC

MORPHINE ANALGESIC TOLERANCE: ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-0

ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-1

A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECT OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE
001100 02-0

MORPHINE-LIKE ANALGESIC EFFECT OF A PITUITARY HORMONE, BETA-LIPOTROPIN
001344 02-0

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
0021B0 02-1

D-ALA2-MET ENKEPHALINAMIDE A POTENT, LONG-LASTING SYNTHETIC PENTAPEPTIDE ANALGESIC.
002193 03-0

9-NOR-9-HYDROXYHEXAHYDROCANNABINOLS SYNTHESIS, SOME BEHAVIORAL AND ANALGESIC PROPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-0

MECHANISM OF ANALGESIC EFFECTS OF NARCOTICS.
00242B 03-0

COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-0

AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
0024B6 03-0

TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COMBINATION (MERSYNDOL).
003039 03-1

DIMETHYLBIS-PHENYLACETYL-DIAZATETRACYCLODODECANE, A POTENT, NOVEL ANALGESIC
003063 04-0

ANALGESIC AND TRANQUILIZING ACTIVITY OF 5,8 DISU8STITUTED 1 TETRALONE MANNICH 8ASES.
003075 04-02

ANALGESIC, HEART RATE, AND TEMPERAT''RE EFFECTS OF DELTA8 THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

DYSKINESIA AFTER DISCONTINUATION OF COMPOUND ANALGESIC CONTAINING OXYCODONE.
003784 04-15

ANALGESICS

THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT
000098 01-03

INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
001168 02-03

EFFECTS OF LITHIUM AND RU8IDIUM ON ANTINOCICEPTION AND 8EHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-03

EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN META8OLISM IN 8RAIN OF RATS AND MICE.
001358 02-03

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03

INTERACTIONS 8ETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 02-04

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
002180 02-17

INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03

8LOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESICS IN THE MOUSE.
002362 03-03

THE EFFECTS OF ANALGESICS ON THE CONDITIONED 8EHAVIOR OF RATS (II).
002509 03-04

DISCRIMINABLE STIMULI PRODUCED 8Y NARCOTIC ANALGESICS.
003005 03-17

NALGETICS

THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
D00867 01-13

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC 8RAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03

DOU8LE-8LIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACE8O IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11

NALOG

IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION.
000249 01-03

ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
002480 03-04

AN ANALOG OF ENKEPHALIN HAVING PROLONGED OPIATE-LIKE EFFECTS IN VIVO.
003319 04-03

NALOGS

THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THF MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

8EHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN.
000407 01-04

THE EFFECT OF MEMORY BLOCKING ANTIBIOTICS AND THEIR ANALOGS ON ACETYLCHOLINESTERASE.
000427 01-04

DOPAMINERGIC ACTIVITY OF SOME APOMORPHINE ANALOGS.
001104 02-02

EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC ACID AND ADENYL CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03

SULFUR ANALOGS OF PSYCHOTOMIMETIC AMINES
002186 03-01

EFFECTS OF ADENOSINE ANALOGS ON RAT CERE8RAL CORTICAL NEURONS.
002336 03-03

INHI8ITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE 8Y 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION
003051 04-01

CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01

8IOLOGICAL DISPOSITION OF RIGID ANALOGS OF AMPHETAMINE.
003147 04-03

ANALOGUE

COMPARISON 8ETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003897 04-17

ANALOGUES

HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNA8INOL WITH POTENT 8IOLOGICAL ACTIVITY.
001339 02-03

THE INHI8ITION OF MOUSE 8RAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
003074 04-02

THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
003395 04-04

ANALYSIS

ANALYSIS OF INHI8ITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
000215 01-03

ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04

THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A CRITICAL ANALYSIS.
000554 01-08

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

COST/PROFIT ANALYSIS OF ANTIDEPRESSANTS.
000676 01-10

THE GILLES-DE-LA-TOURETTE SYNDROME: AN ANALYSIS OF PU8LISHED CASES DEALING WITH THE COURSE OF THE DISEASE AND ITS PROGNOSIS.
000725 01-11

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 D2-03

ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
001218 02-03

SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND 8ENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY.
0D1360 02-03

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS 8Y MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

DATA ANALYSIS PROBLEMS IN THE AREA OF PHARMACOKINETICS RESEARCH.
001651 02-06

A DEPRESSIVE SYNDROME RESPONSIVE TO LITHIUM: AN ANALYSIS OF 20 CASES.
001767 02-09

STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
001772 02-09

PSYCHOSTIMULANTS AND CHILDREN: A REVIEW AND ANALYSIS.
D01866 02-11

SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001884 02-13

A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
0D1885 02-13

PSYCHOPHYSIOLOGICAL ASPECTS IN EEG ANALYSIS OF CEREBRAL DRUG EFFECTS.
00191B 02-13

EEG SPECTRAL ANALYSIS OF THE EFFECTS OF CAFFEINE.
001925 02-13

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16

HISTOCHEMICAL AND MICROPUNCH ANALYSIS OF AMINERGIC AND CHOLINFRGIC PATHWAYS. (UNPUBLISHED PAPER).
002266 03-03

ELECTROENCEPHALOGRAPHIC ANALYSIS OF THE CENTRAL EFFECT OF PIRASIDOL.
002349 03-03

A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHFR EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04

AN ANALYSIS OF BARBITURATE-INDUCED EATING AND DRINKING IN THE RAT.
002552 03-04

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
002586 03-06

TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFFCTS.
002692 03-09

RESULTS OF TREATING NERVOUS TICS IN CHILDREN. BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION. A COMPARATIVE KINETIC ANALYSIS.
002B46 03-13

AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002B6B 03-14

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
003058 04-01

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
003545 04-08

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED MFTABOLITE IN HUMAN PLASMA.
003653 04-13

ANAPHYLACTIC
INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASF FROM BOVINE GRANULOCYTES.
000124 01-03

ANATENSOL
EXPFRIFNCES WITH THE LONG-TFRM USE OF ANATENSOL DFPOT.
000779 01-11

ANATOMICAL
ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04

ANCIENT
PSYCHOMYOCOLOGICAL STUDIES OF AMANITA -- FROM ANCIENT SACRAMENT TO MODERN PHOBIA.
001063 01-17

THFRAPFUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIFNT USF OF VERATRUM (ALBUM) BY DISCOVERIES OF MODFRN PSYCHOPHARMACOLOGY.
0021B2 03-01

ANDEAN
ANDFAN COCA CHEWING: A METABOLIC PERSPECTIVE
002B02 03-13

ANDROGEN
MASCULINF SEXUAL BEHAVIOR IN MALF AND FEMALE RATS FOLLOWING PFRINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANFSTHETIZATION AND SEXUAL EXPERIFNCE.
001499 02-04

THF FFFFCTS OF ANDROGEN ON WHEEL-SPINNING ACTIVITY IN INFANT RATS
002537 03-04

NARCOTICS AND THF HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTF FFFECTS ON LUTEINIZING HORMONE, TESTOSTERONF AND ANDROGFN DFPFNDFNT SYSTFMS.
003116 04-03

NFONATAL ANDROGEN INJFCTION CHANGES OPFN-FIELD BEHAVIOR OF MICF
003402 04-04

ANDROGEN-INDUCED
EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCFD SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-0

ANDROGENS
PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-1

ANERGIC
BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS
000568 01-0

ANESTHESIA
VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRFSSION IN RATS.
000325 01-0

CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
000380 01-0

THE USE OF ANESTHESIA IN CHILDRFN
00206B 02-

SOLUBILIZATION OF BRAIN MITOCHONDRIAL HEXOKINASE IN ANESTHESIA.
002402 03-

EFFECT OF ISOLATION ON BARBITURATE ANESTHESIA IN THE RAT.
002440 03-

THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003860 04-

ANESTHESIOLOGICAL
PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS OXIDE USED IN THE TREATMENT OF BORDERLINE PSYCHOTIC STATES
001B36 02-

ANESTHETIC
ANESTHFTIC ACTION OF METHYLEUGENOL AND OTHER EUGENOL DERIVATIVES.
000419 01-

EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION.
001245 02

CLINICAL STUDIES OF ANESTHETIC CEREBRAL ACTIVATION
001B41 02

ANESTHETIC-INDUCED
MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02

PREVENTION OF LOCAL ANESTHETIC-INDUCED CONVULSIONS BY GAMMA-AMINOBUTYRIC-ACID.
002261 03

ANESTHETICS
EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION O 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
00003B 01

THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN
001349 02

ALCOHOL, ANESTHETICS, MEMBRANES.
002963 03

ANESTHETIZATION
MASCULINE SEXUAL BFHAVIOR IN MALE AND FEMALE RATS FOLLOW PERINATAL MANIPULATION OF ANDROGEN. EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02

ANESTHETIZED
EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPONSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
000028 0

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEAR AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 0

METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLET ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 0

INFLUFNCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CERFBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 0

EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHFTIZFD DOGS.
003183 0

ANGIITIS
AMPHETAMINE-INDUCED ANGIITIS LEADING TO RFNAL FAILURE.
003B22 0

ANGINA-PECTORIS
THERAPEUTIC AMFLIORATION OF ANXIFTY RELATFD HYPERTENSION A ANGINA-PECTORIS.
000686 0

ANGINAL
EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14

ANGIOTENSIN
ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
003433 04-04

ANGIOTENSIN-II
REGIONAL STUDY OF CEREBRAL VENTRICLE SENSITIVE SITES TO ANGIOTENSIN-II.
000123 01-03
EVIDENCE THAT THE PREOPTIC-REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04
INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

ANGIOTENSINS
DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-04

ANICOTINE
EFFECT OF ANICOTINE ON SOME PROPERTIES OF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE.
001299 02-03

ANIMAL
PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS.
000024 01-02
HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-13
TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
001111 02-02
MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-03
EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04
AN ANIMAL BEHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-04
ON THE RELEVANCE OF ANIMAL STUDIES ON LITHIUM TO THE UNDERSTANDING OF LITHIUM THERAPY.
002128 02-17
ANIMAL MODELS IN HUMAN PSYCHOBIOLOGY.
002161 02-17
BIOCHEMICAL BASIS OF AN ANIMAL MODEL OF DEPRESSIVE ILLNESS -- A PRELIMINARY REPORT.
002381 03-03
NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-04
ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04
EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-04
DEPRESSION: A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-02
NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03
BETA-PHENYLETHYLAMINE AND ANIMAL BEHAVIOR. (UNPUBLISHED PAPER).
003431 04-04
AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION OF PROBLEM-SOLVING ABILITY.
003513 04-06
BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AN ANIMAL MODEL OF HYPERACTIVITY STATES.
003518 04-06

ANIMALS
5 METHOXYDIMETHYLTRYPTAMINE: BEHAVIORAL AND TOXICOLOGICAL EFFECTS IN ANIMALS.
000022 01-02
ULTRASTRUCTURAL STUDIES OF CHLORAMPHENICOL-INDUCED NEUROPATHY IN EXPERIMENTAL ANIMALS.
000147 01-03
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
HEART RATE LEARNING AFTER D-TUBOCURARINE ADMINISTRATION IN ANIMALS
000329 01-04
A SURVEY OF THE PHARMACOLOGICAL PROPERTIES OF METOPROLOL IN ANIMALS AND MAN.
001011 01-17
ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04
CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE IN EXPERIMENTS WITH NONANESTHETIZED ANIMALS.
001636 02-05
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
002289 03-03
ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
002323 03-03
BEHAVIOURAL EFFECTS OF BETA-RECEPTOR BLOCKING AGENTS IN EXPERIMENTAL ANIMALS.
002442 03-04
EMOTIONAL AND MOTIVATIONAL ASPECTS OF DRUG TAKING BEHAVIOR OF ANIMALS.
002464 03-04
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V. EFFECTS OF PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-04
EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
002548 03-04
STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE IN LABORATORY ANIMALS.
003492 04-05
DRUG METABOLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN.
003878 04-17

ANOCOCCYGEUS
DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03
EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
003128 04-03

ANOMALOUS
ANOMALOUS EFFECT OF PROBENECID ON RAT BRAIN PHENOLSULPHOTRANSFERASE.
000193 01-03

ANORECTIC
ANORECTIC EFFECTIVENESS OF DIFFERING DOSAGE FORMS OF FENFLURAMINE.
000784 01-11
PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03
ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04
A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
001529 02-04
TOLERANCE TO THE INCREASE OF STRIATAL HOMOVANILLIC-ACID ELICITED BY SEVERAL ANORECTIC DRUGS.
003186 04-03
ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04

ANOREXIA
BENZODIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03
FACTORS INFLUENCING TOLERANCE TO D-AMPHETAMINE-INDUCED ANOREXIA IN RATS.
000384 01-04
MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS.
001267 02-03
STUDIES IN MICE ON THE ANTAGONISM OF DEXTROAMPHETAMINE ANOREXIA BY ALPHA-METHYL-P-TYROSINE-METHYL-ESTER HCL.
001471 02-04
ON THE RELATION BETWEEN HYPODIPSIA AND ANOREXIA INDUCED BY (+) AMPHETAMINE IN THE MOUSE.
001472 02-04

ANOREXIA-NERVOSA
AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA. 001765 02-09
AMITRIPTYLINE THERAPY IN PATIENTS WITH ANOREXIA-NERVOSA. 001799 02-10
PHENOXYBENZAMINE IN ANOREXIA-NERVOSA. 001B04 02-10
HYPOTHYROID-LIKE ALTERATIONS IN TESTOSTERONE METABOLISM IN ANOREXIA-NERVOSA. 001BB7 02-13
CYPROHEPTADINE IN ANOREXIA-NERVOSA. (UNPUBLISHED PAPER). 003590 04-10
LITHIUM IN ADULT ANOREXIA-NERVOSA: A PILOT REPORT ON TWO PATIENTS. 003610 04-11
CORTISOL SECRETION AND METABOLISM IN ANOREXIA-NERVOSA. 003660 04-13

ANOREXIANT
SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY. 002117 02-17

ANOREXIANTS
PRESCRIPTION AND NONPRESCRIPTION ANOREXIANTS. 001897 02-13

ANOREXIC
DIFFERENCES BETWEEN THE ANOREXIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE -- POSSIBLE EFFECTS ON HUNGER AND SATIETY. 000291 01-04
REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS. 000373 01-04
ON THE MECHANISM OF PULMONAL HYPERTENSION INDUCED BY ANOREXIC AGENTS. 003223 04-03
ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT. 003344 04-04

ANOREXIGENIC
TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS. 000109 01-03
ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE. D01119 02-03

ANTACIDS
A FIVE-YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS. 003B49 04-17

ANTAGONISM
ANTAGONISM OF GABA-MEDIATED INHIBITION IN THE CENTRAL-NERVOUS-SYSTEM BY CAPROLACTAM DERIVATIVES. 000140 01-03
THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBITAL NARCOSIS IN THE MONKEY. 00D14S 01-03
ANTAGONISM OF IMIPRAMINE POISONING BY ANTICONVULSANTS IN THE RAT. 0004SS 01-0S
BARBITURATE REVERSAL OF AMINO-ACID ANTAGONISM PRODUCED BY CONVULSANT AGENTS. 001102 02-02
CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL. 00120B 02-03
ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE. 001209 02-D3
KYNURENINES ANTAGONISM AGAINST S-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS. 001272 02-03
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL. 001376 02-03
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN. 001441 02-04
STUDIES IN MICE ON THE ANTAGONISM OF DEXTROAMPHETAMINE ANOREXIA BY ALPHA-METHYL-P-TYROSINE-METHYL-ESTER HCL. 001471 02-04
ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE. 0015B4 02-04
ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES. 002243 03-03
ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH). 002494 03-04
ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2. 0028B7 03-1S
ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION. 003117 04-03
ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDROBENZOTHIEPINE NEUROLEPTICS. 003164 04-03
ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM. 003191 04-03
STUDIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE. 003333 04-03
ANTICONVULSANT DRUG ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL-INDUCED SEIZURES IN RABBITS. 003366 04-04
ANTAGONISM OF ETONITAZENES EFFECTS IN RATS AND PIGEONS. 0D3381 04-04
MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE. 003434 04-04
ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS. 003466 D4-04
NALOXONE ANTAGONISM AS EVIDENCE FOR NARCOTIC MECHANISMS. 003676 04-13
ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE. 0036B7 04-13

ANTAGONIST
COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL. 0D0B2B 01-13
IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?. 001330 02-03
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM. D01S21 02-04
THE MECHANISM OF OPIATE AGONIST AND ANTAGONIST ACTION. (UNPUBLISHED PAPER). 002335 03-03
CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS. 0024S6 D3-D4
BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE. D03309 04-03
NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH. 003623 04-11
ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE. 003687 04-13

ANTAGONISTS
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS. D0005B 01-03
DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN. 000077 D1-03
SUBSTITUTED BENZAMIDES AS DOPAMINE ANTAGONISTS. D00094 01-03
A STUDY OF MUSCARINIC RECEPTOR HETEROGENEITY WITH WEAK ANTAGONISTS. D00D97 01-03
THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT. D00D9B 01-03
THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES. D00289 D1-D4

QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07

AGONISTS AND ANTAGONISTS IN THE TREATMENT OF DRUG ADDICTION
000773 01-11

TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
001111 02-02

REVERSAL OF THE ACTION OF GAMMA AMINOBUTYRIC ACID (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-03

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN
001197 02-03

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS ON THE GAMMA-BUTYROLACTONE-INDUCED INCREASE IN MOUSE BRAIN DOPAMINE.
001220 02-03

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03

THE SPECIFICITY OF ACTION OF THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-03

SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS.
001348 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-03

TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03

EVIDENCE FOR NALOXONE AND OPIATES AS GABA ANTAGONISTS.
001450 02-04

SYNTHESIS OF POTENTIAL MESCALINE ANTAGONISTS.
002190 03-02

POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-03

THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN.
002303 03-03

THE PRESYNAPTIC EFFECT OF BETA-ADRENOCEPTOR ANTAGONISTS ON NORADRENERGIC NEURONES.
002400 03-03

DISCRIMINATIVE PROPERTIES OF NARCOTIC ANTAGONISTS.
002466 03-04

EFFECTS OF CHOLINERGIC AGONISTS AND ANTAGONISTS ON MORPHINE WITHDRAWAL SYNDROME.
002469 03-04

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT.
002541 03-04

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17

POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02

THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
003328 04-03

EFFECT OF TRYPTAMINE ANTAGONISTS ON SELF-STIMULATION INTERACTION WITH AMPHETAMINE
003386 04-04

ANTAGONIZE

PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

ANTAGONIZES

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION
003268 04-03

ANTAGONIZING

ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03

DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04

ANTECEDENTS

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

ANTHRACENE

EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

ANTHROPOLOGICAL

USING OR ABUSING? AN ANTHROPOLOGICAL APPROACH TO THE STUDY OF PSYCHOACTIVE DRUGS.
002985 03-17

ANTIADRENERGIC

INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03

ANTIAGGRESSIVE

EFFECTS OF A NOVEL ANTIAGGRESSIVE AGENT UPON TWO TYPES OF BRAIN STIMULATED EMOTIONAL BEHAVIOR.
000357 01-04

ANTIAGGRESSIVE ACTION OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN MICE.
001571 02-04

ANTIAGGRESSIVE EFFECT OF LITHIUM ION IN MAN.
003741 04-14

ANTIAGGRESSIVES

ARYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIAGGRESSIVES.
000276 01-04

ANTIALLERGENIC

ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
002392 03-03

ANTIANXIETY

ANTIANXIETY ACTION OF TRANZENE 50 MG.
000481 01-07

STUDY IN A PEDIATRIC MILIEU OF AN ANTIANXIETY DRUG: CLOBAZAM.
000494 01-07

ANTIANXIETY EFFECTS OF TRAZODONE (A DOUBLE-BLIND STUDY WITH DIAZEPAM AND PLACEBO).
001806 02-10

EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04

AHR-6134: A NEW ANTIANXIETY DRUG WITH UNEXPECTED RESULTS.
002595 03-07

3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

ANTIANXIETY RECEPTORS IN THE BRAIN?.
003180 04-03

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-386, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
003588 04-10

IS THE DRUG EFFECT ANTIANXIETY OR ANTIDEPRESSANT?
003596 04-10

ANTIANXIETY DRUG TRIALS IN HYPERTENSION.
003609 04-10

ANTIBIOTICS

THE EFFECT OF MEMORY BLOCKING ANTIBIOTICS AND THEIR ANALOGS ON ACETYLCHOLINESTERASE.
000427 01-04

ANTIBODIES

ANTINUCLEAR ANTIBODIES IN PATIENTS ON LITHIUM-CARBONATE.
000978 01-15

BIONEUTRALIZING PROPERTIES OF SEROTONIN ANTIBODIES.
002412 03-03

ANTICATALEPTIC
ON THE ANTICATALEPTIC ACTION OF CYPROHEPTADINE.
0012B6 02-03

ANTICHOLINERGIC
SHORT-TERM MEMORY IN THE RHESUS-MONKEY: DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
0002B3 01-04

EFFECTS OF ANTICHOLINERGIC AGENTS ON CONDITIONED INHIBITION IN THE RAT. (PH.D. DISSERTATION).
000440 01-04

THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000B20 01-13

ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION.
001304 02-03

ANTICHOLINERGIC PROPERTIES OF ANTIPSYCHOTIC DRUGS AND THEIR RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS.
001359 02-03

CATALEPSY INDUCED BY MORPHINE OR HALOPERIDOL: EFFECTS OF APOMORPHINE AND ANTICHOLINERGIC DRUGS.
001481 02-04

ANTICHOLINERGIC EXACERBATION OF PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL SYNDROME.
002009 02-15

REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
00204B 02-15

EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS.
002224 03-03

COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11

OVERUSE OF SYNTHETIC ANTICHOLINERGIC DRUGS IN PSYCHIATRY.
002915 03-15

STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03

HEAT STROKE ASSOCIATED WITH MEDICATIONS HAVING ANTICHOLINERGIC EFFECTS.
003759 04-15

A FIVE-YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS.
003849 04-17

ANTICHOLINERGICS
INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03

EFFECTS OF ANTICHOLINERGICS ON THE HABITUATION OF TONIC IMMOBILITY IN CHICKENS.
001511 02-04

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04

ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY.
002035 02-15

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

PHYSOSTIGMINE TREATMENT OF DELIRIUM INDUCED BY ANTICHOLINERGICS.
002903 03-15

ANTICHOLINESTERASE
RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION.
000029 01-03

ANTICONVULSANT
ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION.
000132 01-03

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04

ANTICONVULSANT DRUGS AND MENTAL SYMPTOMS: A REVIEW.
0009B9 01-15

CLONAZEPAM: A REVIEW OF A NEW ANTICONVULSANT DRUG.
001022 01-17

ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
001143 02-03

THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC 13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03

SOME EFFECTS OF INTERACTION OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS.
002295 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS.
002755 03-11

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03

ANTICONVULSANT ACTION OF DIAZEPAM: INCREASE OF CORTICAL POSTSYNAPTIC INHIBITION.
003246 04-03

EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR.
003282 04-03

ANTICONVULSANT DRUG ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL-INDUCED SEIZURES IN RABBITS.
003366 04-04

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT DRUGS ON DIBUTYRYL-CYCLIC-AMP EVOKED SEIZURES.
003436 04-04

CARBAMAZEPINE AS AN ANTICONVULSANT IN CHILDREN.
003747 04-14

ANTICONVULSANT-INDUCED
ANTICONVULSANT-INDUCED DYSKINESIAS: A COMPARISON WITH DYSKINESIAS INDUCED BY NEUROLEPTICS.
002891 03-15

ANTICONVULSANTS
RESEARCH IN THE DIPROPYLACETIC SERIES. XII. EXTENDED ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

ANTAGONISM OF IMIPRAMINE POISONING BY ANTICONVULSANTS IN THE RAT.
000455 01-05

RICKETS AND ANTICONVULSANTS IN MENTALLY RETARDED PATIENTS.
0037B3 04-15

ANTIDEPRESSANT
A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03

COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03

A POSSIBLE COMMON MECHANISM OF ACTION OF ANTIDEPRESSANT TREATMENTS.
000250 01-03

NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

A NEW MEDICATION OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-07

THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.
000628 01-09

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS.
000655 01-09

CLINICAL STUDIES ON THE ANTIDEPRESSANT ACTION OF LOPRAMINE.
000660 01-09

WHAT ARE TRICYCLIC ANTIDEPRESSANT DRUGS?
000661 01-09

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA 34276 BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
000683 01-10

PRELIMINARY OPEN STUDY OF NOMIFENSIN: A NEW ANTIDEPRESSANT.
000699 01-10

METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY.
000842 01-13

MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
001002 01-16

CLINICAL PARAMETERS OF ANTIDEPRESSANT ACTIVITY.
001010 01-16

IS THE HYPOTHALAMIC HORMONE THYREOTROPE AN ANTIDEPRESSANT AGENT?
001032 01-17

PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
0010B6 02-01

METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-984).
001154 02-03

EFFECT OF TRICYCLIC ANTIDEPRESSANT DRUGS ON THE HEART.
001193 02-D3

EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03

TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03

TANDAMINE: A NEW ANTIDEPRESSANT.
001660 D2-07

POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION.
001677 02-07

CLINICAL AND PHARMACOLOGICAL EFFECTS OF TREATMENT WITH A NEW ANTIDEPRESSANT.
001739 D2-09

MIANSERIN HYDROCHLORIDE: A NOVEL ANTIDEPRESSANT.
001740 02-09

DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09

PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART.
001749 02-09

STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
001772 02-09

TRH BY SLOW, CONTINUOUS INFUSION: AN ANTIDEPRESSANT?.
0017B1 02-09

ANTIDEPRESSANT ACTION OF CLOTHIAPINE.
0D17B6 02-10

VAGRAN-50: A SITUATIONAL ANTIDEPRESSANT.
001790 02-10

SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001BB4 02-13

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0019B6 02-14

EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 02-14

CARDIAC EFFECTS OF DIFFERENT TRICYCLIC ANTIDEPRESSANT DRUGS.
002023 02-15

SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002039 02-15

CARDIOVASCULAR EFFECTS OF NEUROLEPTIC AND ANTIDEPRESSANT DRUGS. PRELIMINARY REPORT
002062 02-15

SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002067 02-15

TRICYCLIC ANTIDEPRESSANT CARDIOTOXICITY.
0D2073 02-15

CLINICAL USE OF ANTIDEPRESSANT DRUGS.
002129 02-17

PRESCRIPTION OF AN ANTIDEPRESSANT AND THE PHYSICIAN PATIENT RELATIONSHIP.
002154 02-17

DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-02

EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS
002224 03-03

DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN
002271 03-03

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04

METAPRAMINE AS ANTIDEPRESSANT AND PSYCHOSTIMULANT.
0025B9 03-07

PREDICTION OF TRICYCLIC ANTIDEPRESSANT RESPONSE: A CRITICAL REVIEW.
002667 03-09

VILOXAZIN (VIVALAN-ICI) -- A STRUCTURALLY NEW ANTIDEPRESSANT.
00267B 03-09

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZONE (FI-6654).
002683 03-09

ANTIDEPRESSANT RESPONSE PREDICTION BY AMPHETAMINE. (UNPUBLISHED PAPER).
002702 03-09

POTENTIATION OF THE ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
002B44 D3-13

TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS.
002BB4 D3-15

SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN.
002BB9 D3-15

ANTIDEPRESSANT BLOOD LEVELS IN ACUTE OVERDOSE.
0D2906 03-15

SEVERE NEUTROPENIA URTICARIA WITH ANTIDEPRESSANT THERAPY.
D02907 D3-15

MANAGEMENT OF TRICYCLIC ANTIDEPRESSANT TOXICITIES.
D02949 03-15

ON THE CLASSIFICATION OF ANTIDEPRESSANT DRUGS.
003010 03-17

DEPRESSION: A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
0D3071 04-02

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
00312B 04-03

ANTIDEPRESSANT DRUGS AND DOPAMINE UPTAKE IN DIFFERENT BRAIN REGIONS.
003146 04-D3

EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-03

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 D4-04

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
D034B9 04-04

ANTIDEPRESSANT EVALUATION AND THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN DEPRESSIVE PATIENTS.
003521 04-07

R-BD6, A TETRACYCLIC ANTIDEPRESSANT: AN EARLY PHASE-TWO STUDY.
003523 04-07

ANTIDEPRESSANT EFFECTS OF DESIPRAMINE ADMINISTERED IN TWO DOSAGE SCHEDULES.
003566 04-09

IS THE DRUG EFFECT ANTIANXIETY OR ANTIDEPRESSANT?
003596 04-10

IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-13

ANTIDEPRESSANT PLASMA LEVELS.
D03674 04-13

VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
DD3717 04-13

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

LITHIUM AS AN ANTIDEPRESSANT: DISCOVERIES THROUGH CLINICAL OBSERVATIONS.
003B92 04-17

ANTIDEPRESSANTS

STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01

PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
000107 01-03

EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN.
000218 01-03

RESEARCH IN THE BENZOFURAN SERIES LVII. BENZOFURYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIDEPRESSANTS.
000275 01-04

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
00045B 01-05

EVALUATION TECHNIQUES IN THE STUDY OF TRICYCLIC ANTIDEPRESSANTS.
000476 01-06

TRANQUILIZERS OR ANTIDEPRESSANTS FOR CHRONIC SCHIZOPHRENICS: A LONG-TERM STUDY.
000572 01-08

BLOOD SERUM DENSITIES OF TRICYCLIC ANTIDEPRESSANTS -- VIEWS GAINED THROUGH THERAPEUTIC USE.
0005B1 01-09

A DOUBLE-BLIND STUDY OF THE ANTIDEPRESSANTS DIBENZEPIN (NOVERIL) AND AMITRIPTYLINE.
0005B2 01-09

THE EFFECTIVE DOSAGE OF ANTIDEPRESSANTS.
0005BB 01-09

A COMPARATIVE STUDY OF ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIVE STATES.
00059B 01-09

PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
000610 01-09

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

ANTIDEPRESSANTS.
000621 01-09

SOME ASPECTS OF THE METABOLISM OF TRICYCLIC ANTIDEPRESSANTS.
00063B 01-09

ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
000647 01-09

PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09

TRICYCLIC ANTIDEPRESSANTS, TRYPTOPHAN AND AFFECTIVE DISORDER.
000657 01-09

DO TRICYCLIC ANTIDEPRESSANTS WORK?
000662 01-09

EFFECTS OF CLOMIPRAMINE AND OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
000665 01-09

COST/PROFIT ANALYSIS OF ANTIDEPRESSANTS.
000676 01-10

THEORETICAL BASIS OF THERAPY WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
000B44 01-13

RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
000BB0 01-14

EFFECTS OF ANTIDEPRESSANTS UPON SLEEP, ESPECIALLY ON REM SLEEP.
000923 01-14

CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15

DYSKINESIAS ASSOCIATED WITH TRICYCLIC ANTIDEPRESSANTS.
000944 01-15

SUICIDE WITH TRICYCLIC ANTIDEPRESSANTS.
001019 01-17

(SPIRO(PIPERIDINETHIAZOLE) 3,2-A)PYRIMIDINES): ANTIDEPRESSANTS AND PLATELET-AGGREGATION INHIBITORS.
001116 02-02

POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIDEPRESSANTS.
001284 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
001288 02-03

AUGMENTATION OF PENTYLENETETRAZOL-INDUCED SEIZURES BY TRICYCLIC ANTIDEPRESSANTS.
001346 02-03

INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
00140B 02-03

THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02-07

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS.
001727 02-09

DO TRICYCLIC ANTIDEPRESSANTS WORK?
001939 02-13

DO TRICYCLIC ANTIDEPRESSANTS WORK?.
002027 02-15

ACTION OF ANTIDEPRESSANTS ON CONVULSIVE EFFECT OF CORAZOL AND STRYCHNINE.
002220 03-0

NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
002283 03-0

THE BIOLOGICAL DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.
002356 03-0

TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES IN VENTRICULAR AUTOMATICITY.
002562 03-0

TRIAL OF ANTIDEPRESSANTS.
002799 03-1

THE EFFECT OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS ON THE HEART AND CIRCULATION.
002B90 03-1

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
00292B 03-1

COMBINING TRICYCLIC AND MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS.
002936 03-1

TRIALS WITH ANTIDEPRESSANTS REASSESSED.
0029B1 03-1

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-1

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-0

EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
0031B3 04-0

EFFECTS OF ALKYLTETRAHYDROCARBAZOLE-ETHANAMINES AND RELATED COMPOUNDS, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-0

ANTIDEPRESSANTS AND THE MUSCARINIC ACETYLCHOLINE RECEPTOR.
003510 04-0

SYSTEMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
003579 04-1

LACK OF EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON SERUM PROLACTIN LEVELS.
003689 04-1

IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
003883 04-17

RESERPINE: MIRROR IMAGE OF THE ANTIDEPRESSANTS.
003901 04-17

TRICYCLIC ANTIDEPRESSANTS AND CENTRAL MONOAMINE METABOLISM.
003902 04-17

ANTIDEPRESSIVE

A STUDY OF THE ANTIDEPRESSIVE EFFECT OF MAPROTILINE.
000668 01-09

INTERACTION OF SOME NEUROLEPTIC AND ANTIDEPRESSIVE AGENTS WITH HUMAN COERULOPLASMIN.
000841 01-13

ABSENCE OF AN ANTIDEPRESSIVE EFFECT OF LITHIUM IN THE CLINIC AND IN EXPERIMENTS.
002313 03-03

TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09

CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
003520 04-07

ANTIDEPRESSIVES

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION. REPORT OF A CONTROLLED CLINICAL TRIAL.
001B39 02-11

ANTIDIURETIC

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003804 04-15

ANTIDOPAMINERGIC

THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000B20 01-13

INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03

THE DOPAMINERGIC AND ANTIDOPAMINERGIC EFFECTS OF SOME APORPHINES.
003473 04-04

ANTIEPILEPTIC

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

MENTAL EFFECTS OF ANTIEPILEPTIC DRUGS.
000938 01-15

FETAL MALFORMATIONS AND ANTIEPILEPTIC DRUGS.
002047 02-15

APHASIA IN A CHILD WITH EPILEPSY: IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT.
002752 03-11

CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
0028B6 03-15

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

ANTIESTROGEN

INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

ANTIESTROGENS

EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-04

EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-62B, ON RAT AND HAMSTER LORDOSIS.
001548 02-04

ANTIHEMOLYTIC

HEMOLYTIC AND ANTIHEMOLYTIC EFFECTS OF ANTIPSYCHOTIC DRUGS.
002B27 03-13

ANTIHISTAMINIC

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM.
003206 04-03

ANTIHYPERTENSIVE

AGENTS AFFECTING ADRENERGIC FUNCTION IN ANTIHYPERTENSIVE THERAPY -- II.
000731 01-11

FURTHER HEMODYNAMIC INVESTIGATIONS OF THE ANTIHYPERTENSIVE EFFECT OF LEXOTAN (BROMAZEPAM).
000856 01-13

ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 02-13

ANTIINFLAMMATORY

SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5-ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02

ANTIMANIC

TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS.
0028B4 03-15

ANTIMETABOLITES

PATHOLOGIC EFFECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03

ANTIMIGRAINE

INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
001207 02-03

ANTIMUSCARINICS

BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-04

ANTINOCICEPTION

CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012B8 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-03

ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE.
001584 02-04

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
0031BB 04-03

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
0031B9 04-03

ANTINOCICEPTIVE

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
0002B9 01-04

DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03

STUDIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE.
003333 04-03

A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS
003426 04-04

A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003B76 04-17

ANTINUCLEAR
ANTINUCLEAR ANTIBODIES IN PATIENTS ON LITHIUM-CARBONATE.
000978 D1-15

ANTIPARKINSON
A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
DDD961 D1-15
USE OF SO-CALLED ANTIPARKINSON MEDICATIONS IN PSYCHIATRY.
D028B8 D3-15
INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
D03495 04-05
REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
DD3572 04-09

ANTIPARKINSONIAN
THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR
D00239 D1-D3
VITAMINS, NEUROLEPTICS, AND ANTIPARKINSONIAN DRUGS IN CATECHOLAMINE EXCRETION
0DDB72 01-13
ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002887 03-15
DISCONTINUANCE OF ASSOCIATED ANTIPARKINSONIAN DRUGS IN LONG-TERM NEUROLEPTIC TREATMENT.
D02923 D3-15
ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
D03537 D4-DB

ANTIPARKINSONS
ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L DOPA AND DOPA-DECARBOXYLASE INHIBITOR.
DD0745 01-11

ANTIPSORIATIC
A COMPARATIVE EVALUATION OF THE ANTIPSORIATIC EFFECT OF L-DDPA VERSUS PLACEBO IN PSORIASIS.
DD193B D2-13

ANTIPSYCHOTIC
ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
DD0474 01-06
DOSAGE FOR ANTIPSYCHOTIC DRUGS.
000529 D1-0B
DOSAGE FOR ANTIPSYCHOTIC DRUGS.
DD1060 D1-17
BRAIN HOMOVANILLIC-ACID: REGIONAL CHANGES OVER TIME WITH ANTIPSYCHOTIC DRUGS.
DD1152 D2-D3
THE DOPAMINE RECEPTOR AND ANTIPSYCHOTIC EFFECT.
DD1259 02-D3
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
0D1335 D2-D3
SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS.
00134B D2-03
ANTICHOLINERGIC PROPERTIES OF ANTIPSYCHOTIC DRUGS AND THEIR RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS.
DD1359 D2-D3
ANTIPSYCHOTIC DRUGS: PHARMACODYNAMICS AND PHARMACOKINETICS.
DD1362 D2-D3
ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
DD16D2 D2-D4
GENERIC AND TRADE NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE
DD16B2 D2-DB
ANTIPSYCHOTIC EFFECTIVENESS IN RELATION TO PLASMA LEVEL OF CLOZAPINE.
D01B7B D2-13
PROLACTIN SECRETION AND ANTIPSYCHOTIC EFFICACY.
DD1916 D2-13
COMPARATIVE DOSES AND COSTS OF ANTIPSYCHOTIC MEDICATION.
0D211D 02-17
BIOCHEMISTRY AND BEHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE AND ANTIPSYCHOTIC DRUGS.
DD2122 D2-17
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I ROLE OF ADRENERGIC SYSTEM
DD2246 D3-D3
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN.
D02247 03-D3
HEMOLYTIC AND ANTIHEMOLYTIC EFFECTS OF ANTIPSYCHOTIC DRUGS.
DD2827 03-13
TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS.
D02884 03-15
ANTIPSYCHOTIC AGENTS AND SERUM PROLACTIN LEVELS.
002900 03-15
POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
DD3079 04-03
INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
D03143 D4-D3
EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
0031B7 D4-D3
PERLAPINE AND DOPAMINE METABOLISM: PREDICTION OF ANTIPSYCHOTIC EFFICACY.
003325 04-D3
HYPOTHERMIC EFFECTS OF ANTIPSYCHOTIC PHENOTHIAZINES.
DD3335 D4-03
MORPHINE AS ANTIPSYCHOTIC DRUG.
003554 04-D9
REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
003572 04-D9
CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN.
D03704 04-13
THE EFFECTS OF SELECTED ANTIPSYCHOTIC DRUGS ON HUMAN JUDGMENT.
0D3728 04-14
ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15
MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION
0D3798 D4-15
ACUTE HYPERTENSION AFTER ABRUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION.
0D3B33 04-15
ANTIPSYCHOTIC DRUG USE: PHYSICIAN PRESCRIBING PRACTICES IN RELATION TO CURRENT RECOMMENDATIONS.
D03B96 04-17

ANTIPSYCHOTICS
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
0DDD53 01-D3
REPLY TO A LETTER CRITICIZING POINTS IN A LETTER ON THE NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
0D1BB2 D2-13
MORE ON NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
DD2040 02-15
METHODOLOGY OF CLINICAL TESTING OF ANTIPSYCHOTICS.
D0209B D2-17
REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
0D2226 D3-03
ANTIPSYCHOTICS AND GABA TURNOVER IN MAMMALIAN BRAIN NUCLEI. (UNPUBLISHED PAPER).
0023D1 03-D3
THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05

ANTIPSYCHOTOGEN
THE C-FRAGMENT OF BETA-LIPOTROPIN: AN ENDOGENOUS NEUROLEPTIC OR ANTIPSYCHOTOGEN?
0D2267 03-D3

ANTIPUNISHMENT
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
0034BD 04-04

ANTIPYRETIC
THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
0DDB67 01-13

ANTIPYRINE
COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN
002B13 03-13

ANTISCHIZOPHRENIC
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15
ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN.
003493 04-05
HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
0036B4 04-13

ANTISEIZURE
ON CHANGING BLOOD DENSITIES OF ANTISEIZURE DRUGS TAKEN IN LARGE VOLUMES.
002950 03-15

ANTISEROTONERGIC
SEROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
000448 01-04

ANTISERUM
ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY.
001260 02-03

ANTISOCIAL
A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR.
001703 02-0B

ANTISPASMODIC
ANTISPASMODIC EFFECTS OF ETPENAL.
001354 02-03

ANTITUMOR
POTENTIAL CENTRAL-NERVOUS-SYSTEM ANTITUMOR AGENTS. AZIRIDINYLBENZOQUINONES. 2.
001656 02-07

ANXIETY
ANXIETY DRUGS AND BABOON BEHAVIOUR.
0002B7 01-04
TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION
00065B 01-09
A PLACEBO CONTROLLED TRIAL OF DIAZEPAM AND OXPRENOLOL FOR ANXIETY.
000677 01-10
SOMATIC ANXIETY ATTACKS AND PROPRANOLOL.
0006B1 01-10
THERAPEUTIC AMELIORATION OF ANXIETY RELATED HYPERTENSION AND ANGINA-PECTORIS.
0006B6 01-10
THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY.
000693 01-10
CLINICOBIOLOGICAL OBSERVATIONS ON ANXIETY/.
000706 01-10
BETA-ADRENOCEPTOR BLOCKADE IN HYPERTHYROIDISM AND ANXIETY.
000714 01-10
ANXIETY AND TENSION AND BETA-BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 D1-10
EVALUATION OF TRAZODONE IN THE TREATMENT OF ANXIETY.
D00719 D1-10
POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSION IN ALCOHOL ADDICTS.
000742 01-11
LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
000BB6 D1-14
A COMPARISON OF AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES
001731 02-09
ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
001735 02-09
OXPRENOLOL AND PROPRANOLOL IN ANXIETY STATES.
0017B4 02-10
DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
D017B7 02-10
NONPHARMACOLOGICAL FACTORS IN DRUG TREATMENT OF ANXIETY STATES.
001B02 02-10
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY
001B10 02-10
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001B43 02-11
BETA-ADRENERGIC BLOCKADE AND ANXIETY
001B49 02-11
ANXIETY AND DEPRESSION: DIFFERENTIAL DIAGNOSIS AND TREATMENT IN DAILY PRACTICE.
002134 02-17
NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY.
00214B 02-17
BENZODIAZEPINES AND NEUROTIC ANXIETY: CRITIQUE.
002166 02-17
NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-04
AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002709 03-10
AMITRIPTYLINE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002716 03-10
INTRAVENOUS LORAZEPAM IN ACUTE ANXIETY CRISES.
002718 03-10
CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03-10
SOMATIC AND PSYCHIC SYMPTOMS IN ANXIETY.
002722 03-10
BETA-ADRENERGIC BLOCKADE AND ANXIETY.
002729 03-10
CLINICAL EVALUATION OF THE EFFECTS OF OXYPERTINE IN STATES OF ANXIETY.
002730 03-10
PROPRANOLOL IN THE TREATMENT OF ANXIETY.
002731 03-10
CLINICAL AND EXPERIMENTAL STUDIES ON THE EFFECTS OF PROPRANOLOL IN ANXIETY.
002733 03-10
ANXIETY, RESTLESSNESS AND ANXIOLYTICS.
002734 03-10
THE NEUROPSYCHOLOGY OF ANXIETY.
002B14 03-13
THE ROLE OF BODILY FEELINGS IN ANXIETY.
003040 03-17
ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-0B
ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09
A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
DD35B9 04-10
EFFECTS ON EMG FEEDBACK, DIAZEPAM AND THEIR COMBINATION ON CHRONIC ANXIETY.
003594 D4-10
PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
D03597 04-1D
PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003599 04-10
HALAZEPAM AND DIAZEPAM IN NEUROTIC ANXIETY: A DOUBLE-BLIND STUDY.
003600 D4-10
CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
DD3606 04-10
THE EFFICACY OF PERCOGESIC IN RELIEF OF MUSCULOSKELETAL PAIN ASSOCIATED WITH ANXIETY.
D03619 04-11
THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11
A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11

ANXIOLYTIC
EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE.
000694 01-10
DOUBLE-BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI-6B20 BUFOXINE.
001811 02-10
NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-04
TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-10
A CONTROLLED CLINICAL STUDY WITH CLOBAZAM -- A NEW ANXIOLYTIC AGENT.
0035B5 04-10
A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
003605 04-10
NEW ANXIOLYTIC RATING SCALE.
003607 04-10
INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
003843 04-16

ANXIOLYTICS
THE RATIONAL USE OF ANXIOLYTICS.
001886 02-13
ANXIETY, RESTLESSNESS AND ANXIOLYTICS.
002734 03-10

ANXIOUS
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
0004B4 01-07
RIPAZEPAM (CI-6B3) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10
A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN.
0017B5 02-10
HALOPERIDOL IN THE TREATMENT OF PSYCHONEUROTIC ANXIOUS OUTPATIENTS.
001792 02-10
LORAZEPAM AND DIAZEPAM IN ANXIOUS OUTPATIENTS: A CONTROLLED STUDY.
001805 02-10
PHARMACOLOGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
003556 04-09
BRIEF TREATMENT OF ANXIOUS PATIENTS WITH HALAZEPAM IN HIGH DOSES.
003591 04-10
PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-31B89) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-11
MEDAZEPAM AND THE DRIVING ABILITY OF ANXIOUS PATIENTS.
003B09 04-15

APALLIC
PATHOPHYSIOLOGICAL ASPECTS CONCERNING THE TREATMENT OF THE APALLIC SYNDROME.
0027B9 03-11

APES
GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
001561 02-04

APHASIA
APHASIA IN A CHILD WITH EPILEPSY: IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT.
002752 03-11

APIS-MELLIFICA-CARNICA
EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-04

APLYSIA
SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 02-03

APNEA
CAFFEINE IN THE PREVENTION OF APNEA OF PREMATURITY.
002B16 03-13
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

APOMORPHINE
THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01
CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02
CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03
APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03
METABOLISM IN VITRO OF POTENTIAL APOMORPHINE PRODRUGS.
000229 01-03
PROLONGED APOMORPHINE-LIKE BEHAVIOURAL EFFECTS OF APOMORPHINE ESTERS.
00027B 01-04
EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04
AGGRESSIVE BEHAVIOR INDUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-04
THERAPEUTICAL EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
0004BB 01-07
DOPAMINERGIC ACTIVITY OF SOME APOMORPHINE ANALOGS.
001104 02-02
PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-03
THE STRESS-DEPENDENT NATURE OF APOMORPHINE HYPERTHERMIA.
0013B1 02-03
TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION
001395 02-03
COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04
CATALEPSY INDUCED BY MORPHINE OR HALOPERIDOL: EFFECTS OF APOMORPHINE AND ANTICHOLINERGIC DRUGS.
0014B1 02-04
EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04
INFLUENCE OF 6-HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
002463 03-04
CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04
DIFFERENTIATION OF NEUROPHARMACOLOGICAL ACTIONS OF APOMORPHINE AND D-AMPHETAMINE
002523 03-04
PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03
POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03
THE EFFECT OF APOMORPHINE AND HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
003181 04-03
EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03
INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03
EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE
003314 04-03
STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04
SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

APOMORPHINE-INDUCED

ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
000279 01-04

INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04

BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-04

SEROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
000448 01-04

ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
001492 02-04

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
00220B 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 03-03

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE AND METHACHOLINE ON THE APOMORPHINE-INDUCED GNAWING IN THE RABBIT.
0034B5 04-04

APOMORPHINE-LIKE

PROLONGED APOMORPHINE-LIKE BEHAVIOURAL EFFECTS OF APOMORPHINE ESTERS.
000278 01-04

APOMORPHINES

BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

APONEURON

CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11

APORPHINES

COMPARISON OF THE DOPAMINERGIC EFFECTS OF N-SUBSTITUTED APORPHINES.
00249B 03-04

THE DOPAMINERGIC AND ANTIDOPAMINERGIC EFFECTS OF SOME APORPHINES.
003473 04-04

APPEALS

USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-17

APPEALS USED IN ADVERTISEMENTS FOR PSYCHOTROPIC DRUGS: AN EXPLORATORY STUDY.
003B99 04-17

APPEARANCE

EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04

EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03

APPETITE

APPETITE STIMULANT ACTIVITY OF CARBOXYDIHYDROXYPROHEPTADINE
001459 02-04

OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07

APPLICATIONS

NEW TRENDS OF BETA-BLOCKERS IN ACTIONS AND APPLICATIONS.
000B69 01-13

SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTERACTION WITH AMPHETAMINE SULFATE.
003688 04-13

APPROACH

PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE.
000492 01-07

CHLORIMIPRAMINE, FOR OBSESSIVE-COMPULSIVE NEUROSIS: AN ORGANIC APPROACH.
000523 01-07

BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH.
000710 01-10

SUGGESTIONS FOR A RATIONAL APPROACH TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001725 02-0B

PSYCHOPHARMACOLOGY -- A BIOLOGICAL APPROACH.
002140 02-17

PHARMACOKINETIC APPROACH TO DRUG DOSING IN THE AGED.
002604 03-07

USING OR ABUSING? AN ANTHROPOLOGICAL APPROACH TO THE STUDY OF PSYCHOACTIVE DRUGS.
0029B5 03-17

NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS: PHARMACOLOGICAL APPROACH.
003B45 04-17

PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
003B63 04-17

APPROACHES

SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03

TREATMENT APPROACHES TO MANIA.
002097 02-17

NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-04

RATIONAL APPROACHES TO THE PHARMACOTHERAPY OF CHOREA.
002B03 03-13

THERAPEUTIC APPROACHES IN NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIAS.
002910 03-15

INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
00300B 03-17

APPROXIMATION

AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
00161B 02-05

ARACHIDONYL

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION.
003293 04-03

ARECOLINE

EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK.
002276 03-03

ARIZONINE

ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
0010B2 02-01

AROMATASE

EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-04

AROMATIC

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
0031B4 04-03

AROUSAL
THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
000781 01-11
NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04
EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS.
002004 02-14
VIGILANCE AND AROUSAL IN DEPRESSIVE STATES.
002712 03-10
TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002879 03-14
THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

ARREST
EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE.
002008 02-15

ARRHYTHMIAS
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03
SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN.
002B89 03-15

ARTERIAL
THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
000107 01-03

ARTERIES
INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
000241 01-03

ARTERY
CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04
EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA-BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-07
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03

ARTIFICIAL
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
000265 01-03

ARYLACYLAMIDASE
RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03

ARYLALKYLAMINES
EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03

ARYLHYDROCARBON-HYDROXYLASE
INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
001212 02-03

ARYLOXYALKYLAMIDOXIMES
ARYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIAGGRESSIVES.
000276 01-04

ASCENDING
ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
001334 02-03
BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04
THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04
THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 04-03
SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

ASPARTATE
MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN.
000224 01-03
REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN.
003207 04-03

ASPARTIC-ACID
MUTUAL EFFECTS OF MORPHINE AND ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
00319B 04-03

ASPERMIA
CONCERNING ASPERMIA NOTED IN PERSONS TAKING THIORIDAZINE.
002049 02-15

ASPHYXIA
TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
003303 04-03

ASPIRIN
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15

ASSAY
PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
000610 01-09
A NOTE ON THE ASSAY OF CHLORPROMAZINE-N-OXIDE AND ITS SULPHOXIDE IN PLASMA AND URINE.
000B11 01-13

ASSAYED
CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04

ASSAYS
BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

ASSESSED
CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02-03

ASSESSING
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14
ASSESSING INTERACTIONS OF ENVIRONMENT X DRUG.
001596 02-04

ASSESSMENT
THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01
SYSTEMATIC ASSESSMENT OF TOLERANCE TO PENTOBARBITAL BY PELLET IMPLANTATION.
000342 01-04
ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06
ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
00121B 02-03
AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10
REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF PROPRANOLOL.
001954 02-14
INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16
PSYCHOTROPIC DRUG ASSESSMENT -- CURRENT STATUS, FUTURE PROSPECTS. (UNPUBLISHED PAPER)
002139 02-17
CLINICAL ASSESSMENT FOR PEDIATRIC PSYCHOPHARMACOLOGY (UNPUBLISHED PAPER).
002775 03-11

QUANTITATIVE ASSESSMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE IN MICE.
003140 04-03
NEUROPSYCHOPHARMACOLOGICAL MODELS FOR OBJECTIVE ASSESSMENT OF CENTRAL EFFECTS OF HORMONES.
003B70 04-17

ASSISTED
MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001B77 02-12

ASSOCIATION
PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04
A CONTROLLED STUDY OF THE ASSOCIATION OF CLOMIPRAMINE AND LITHIUM.
000643 01-09
CHEMOTHERAPY OF MELANCHOLIA BY SEQUENTIAL ASSOCIATION OF A NEUROLEPTIC AND VILOXAZINE.
00266B 03-09
HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002B49 03-14
ANNUAL MEETING OF THE SCANDINAVIAN ASSOCIATION OF PSYCHOPHARMACOLOGY.
002991 03-17

ASSOCIATIVE
MORPHINE TOLERANCE ACQUISITION AS AN ASSOCIATIVE PROCESS.
003462 04-04

ASSUMPTIONS
SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 01-0B
THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003B52 04-17

ASTHE-CRINOL-12
ASTHE-CRINOL-12 IN THE ASTHENIA SYNDROME OF AGED SUBJECTS.
000497 01-07

ASTHENIA
ASTHE-CRINOL-12 IN THE ASTHENIA SYNDROME OF AGED SUBJECTS.
000497 01-07

ASTHENIC
USE OF SIDNOCARB IN TREATING PATIENTS IN ASTHENIC OR DEPRESSIVE STATES.
002699 03-09

ASTHMA
SOME PROBLEMS OF THE TREATMENT OF BRONCHIAL ASTHMA.
0027B1 03-11

ASTROBLASTS
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

ASYLUM
THE PSYCHIATRIC SECTOR AND THE WALLS OF THE ASYLUM.
00263B 03-0B

ASYMMETRIES
THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-0B

ASYMMETRY
DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04
PHARMACOLOGIC IMPLICATIONS OF HEMISPHERIC ASYMMETRY.
003017 03-17

ATAXIA
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-DIBENZOTHIEPINS, ATAXIA IN MICE.
002577 03-05
HEREDITARY PAROXYSMAL ATAXIA RESPONSIVE TO ACETAZOLAMIDE.
003629 04-11

ATAXIAS
PHYSOSTIGMINE IN FAMILIAL ATAXIAS.
003627 04-11

ATENOLOL
A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION: SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-07
CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER.
002591 03-07

ATHEROSCLEROSIS
SIDE EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

ATHEROSCLEROTIC
EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001B29 02-11

ATONIC
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15

ATPASE
THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES.
0012B1 02-03
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-03
EFFECT OF MORPHINE ON MOUSE BRAIN ATPASE ACTIVITIES.
003126 04-03

ATRIA
EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
0000B4 01-03
EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA.
001324 02-03
EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

ATRIAL
EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03

ATRIOVENTRICULAR
FIRST-DEGREE ATRIOVENTRICULAR BLOCK DURING LITHIUM-CARBONATE TREATMENT.
003796 04-15

ATROPHY
CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.
002060 02-15

ATROPINE
THE EFFECTS OF ALCOHOL AND ATROPINE ON EEG AND BEHAVIOR IN THE RABBIT.
00025B 01-03
FAILURE OF ATROPINE TO RETARD AMYGDALOID KINDLING.
001171 02-03
THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03
EVALUATION OF ATROPINE THERAPY IN TREATING SCHIZOPHRENIA.
002630 03-0B
EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03
EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
0034B0 04-04
EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE AND METHACHOLINE ON THE APOMORPHINE-INDUCED GNAWING IN THE RABBIT.
0034B5 04-04

ATROPINE-BINDING
SOLUBILISATION OF ATROPINE-BINDING MATERIAL FROM BRAIN.
003110 04-03

ATTACHMENT
A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01

ATTACK
ALTERNATIONS OF MOUSF ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03
EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04
EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT.
002057 02-15
EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS INTERSPECIFIC ALLOCATION OF ATTACK.
002276 03-03
EFFECTS OF NICOTINIC AND MUSCARINIC COMPOUNDS ON BITING ATTACK IN THE CAT.
002424 03-04
A RAT MODEL OF VIOLENT ATTACK BEHAVIOR. (PH.D. DISSERTATION).
002531 03-04

ATTACKS
SOMATIC ANXIETY ATTACKS AND PROPRANOLOL.
0006B1 01-10
TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COMBINATION (MERSYNDOL).
003039 03-17

ATTAINED
PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04

ATTENDING
PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
002B54 03-14

ATTENTION
THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
0007B1 01-11
AN AUDIOVISUAL TEST OF DIVIDED ATTENTION.
000B74 01-14
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION.
000B75 01-14
DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03
A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION.
003525 04-07
BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04-14

ATTENUATE
NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-04

ATTENUATION
ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03
ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-TETRAHYDROCANNABINOL.
000310 01-04
RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
000341 01-04
AMPHETAMINE ATTENUATION OF TONIC IMMOBILITY IN CHICKENS.
001449 02-04
DIFFERENTIAL ATTENUATION OF SOME EFFECTS OF HALOPERIDOL IN RATS GIVEN SCOPOLAMINE.
00157B 02-04
HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION
003172 04-03
ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS
003266 04-03
TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-04

ATTITUDES
FREE LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN.
003B6B 04-17

ATTRIBUTABLE
THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003639 04-11

ATTRIBUTED
EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE.
002008 02-15

ATYPICAL
ATYPICAL ENDOGENOUS DEPRESSION: DIAGNOSTIC CRITERIA.
001B09 02-10

AUDIOGENIC
AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03
THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE
000076 01-03
SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION
000286 01-04
EFFECT OF MORPHINE AND NALOXONE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-04

AUDIOVISUAL
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09
AN AUDIOVISUAL TEST OF DIVIDED ATTENTION
000B74 01-14

AUDITORY
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRADIENTS IN RATS.
000449 01-04
EFFECTS OF IMIPRAMINE ON AUDITORY SENSITIVITY IN THE RAT IN RELATION TO INITIAL SENSITIVITY.
001523 02-04
OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS.
002546 03-04

AUGMENTATION
AUGMENTATION OF PENTYLENETETRAZOL-INDUCED SEIZURES BY TRICYCLIC ANTIDEPRESSANTS.
001346 02-03
AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

AUGMENTED
ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-04

AUTISM
CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11
THE THERAPY AND COURSE OF AUTISM.
002759 03-11

AUTOEROTIC
PSYCHODYNAMIC EVALUATION OF A CASE OF AUTOEROTIC FETISHISM.
000609 01-09

AUTOGENIC
AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10
ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10

AUTOMAINTAINED
THE EFFECTS OF D-AMPHETAMINE ON THE AUTOMAINTAINED KEY PECKING OF PIGEONS.
003441 04-04

AUTOMATED
AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14
AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL.
002106 02-17
AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS (PH.D. DISSERTATION).
002B6B 03-14

AUTOMATICITY
TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES IN VENTRICULAR AUTOMATICITY.
002562 03-05

AUTOMATISM
THE CONCEPT OF DRUG AUTOMATISM.
000950 01-15

AUTOMUTILATION
POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
003450 04-04

AUTONOMIC
AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17
AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09
AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
0031B2 04-03
IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03
PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04-15

AUTOOXIDATION
INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

AUTORADIOGRAPHIC
AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
0030BB 04-03

AUTORADIOGRAPHY
DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03
APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
0025B6 03-06
ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTAB-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE.
00316B 04-03

AUTORECEPTORS
DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
00307B 04-03

AVAILABILITY
INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 01-03
EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-04
ABSOLUTE AVAILABILITY OF LITHIUM.
003700 04-13

AVERAGE
INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09

AVERAGED
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002B63 03-14
CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-0B

AVERSION
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03
PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION.
003360 04-04

AVERSIVE
MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03
AVERSIVE SMOKING: CARBOXYHEMOGLOBIN LEVELS BEFORE AND AFTER RAPID SMOKING.
001903 02-13
DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04
SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05

AVOIDANCE
THE EFFECTS OF DIETHYLDITHIOCARBAMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
0002B4 01-04
5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04
CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
0003B5 01-04
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04
DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIDANCE IN RATS.
000469 01-06
CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-03
INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
001466 02-04
CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-04
A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04
CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04
DIFFERENTIAL EFFECTS OF MORPHINE ON TWO-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
001575 02-04
CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING.
0015BB 02-04
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
00160B 02-04
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04
THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
00247B 03-04
INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
0024B7 03-04
RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND IN THE EFFECTS OF DIAZEPAM.
0024BB 03-04
EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04
FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
003394 04-04
DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION.
003469 04-04

EFFECTS OF TRYPTAMINE ON THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
003478 04-04
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
003480 04-04

AVOIDING
AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-15

AWAKE
SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03
METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 03-03

AXIS
EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION
001934 02-13
EFFECTS OF ERGOT ALKALOIDS ON THE HYPOTHALAMIC PITUITARY AXIS.
002239 03-03
EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
0023B4 03-03
NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

AXONAL
SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

AXONS
ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

AXOTOMY
EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN
002373 03-03

AZABUTYRON
PHARMACOKINETIC STUDY OF THE NEUROLEPTIC AZABUTYRON
00224B 03-03

AZAFEN
DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN
002701 03-09

AZAPERONE
OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

AZIDOMORPHINE
CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03

AZIRIDINYLBENZOQUINONES
POTENTIAL CENTRAL-NERVOUS-SYSTEM ANTITUMOR AGENTS. AZIRIDINYLBENZOQUINONES. 2.
001656 02-07

A2-ACYLATION
PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NFUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03

A23187
ALTERATIONS IN HUMAN PLATELET SFROTONIN UPTAKE FOLLOWING THE ADDITION OF THROMBIN AND A231B7. (UNPUBLISHED PAPER).
002B04 03-13

B-RING
CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIFS OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RFLATFD LACTONES.
003056 04-01

BABIES
WHAT HAPPFNED LATFR TO THE LITHIUM BABIES? A FOLLOW-UP STUDY OF CHILDREN BORN WITHOUT MALFORMATIONS.
002932 03-15

BABOON
ANXIETY DRUGS AND BA8OON BEHAVIOUR.
0002B7 01-04
EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRAL HEMODYAMICS AND META8OLISM IN THE BABGON.
003297 04-03

BABOONS
THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03
COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001503 02-04
SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

BACKWARD
LONG-DELAY 8ACKWARD TASTE-AVERSION CONDITIONING WITH LITHIUM.
00337B 04-04

BACLOFEN
BACLOFEN AND GAMMA-HYDROXYBUTYRATE: SIMILAR EFFECTS ON CEREBRAL DOPAMINE NEURONES.
000083 01-03
BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA (UNPUBLISHED PAPER).
000534 01-08
BACLOFEN IN SCHIZOPHRENIA.
000539 01-08
EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-03
CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03
EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03
CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
0015B9 02-04
A DOUBLE-BLIND TRIAL OF BACLOFEN AGAINST PLACEBO IN THE TREATMENT OF SCHIZOPHRENIA.
001664 02-07
NEUROLEPTIC EFFECT OF BACLOFEN IN CHRONIC SCHIZOPHRENICS.
001700 02-08
BACLOFEN (LIORESAL) IN THE TREATMENT OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA.
001923 02-13
EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS
002270 03-03
CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04-03
EFFECT OF GAMMA-BUTYROLACTONE AND BACLOFEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03
EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACID.
003647 04-11

BALANCE
BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
000204 01-03
EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
001115 02-02
THE EFFECTS OF ADMINISTERING LITHIUM-CARBONATE ON THE BALANCE OF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
001774 02-09
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CERE8ROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15

BARBITAL
THE EFFECT OF ALPHA-TOCOPHEROL DEFICIENCY ON THE PHARMACOKINETICS AND PHARMACOLOGICAL EFFECT OF BARBITAL.
000170 01-03
THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS
001297 02-03

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL.
003261 04-03

ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

ARBITURATE

CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

BARBITURATE HYPNOTICS, A TOO-FREQUENT AND NONSOOTHING PRESCRIPTION.
001043 01-17

BARBITURATE REVERSAL OF AMINO-ACID ANTAGONISM PRODUCED BY CONVULSANT AGENTS.
001102 02-02

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
00123B 02-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03

BARBITURATE PRESCRIBING: PSYCHIATRISTS VIEWS.
002102 02-17

EFFECT OF ISOLATION ON BARBITURATE ANESTHESIA IN THE RAT.
002440 03-04

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-11

GLUTETHIMIDE -- AN UNSAFE ALTERNATIVE TO BARBITURATE HYPNOTICS.
002919 03-15

BARBITURATE DEPENDENCE IN MICE: EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION
00334B 04-04

BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04-14

NEONATAL BARBITURATE WITHDRAWAL.
003769 04-15

VERTICAL GAZE PALSY IN BARBITURATE INTOXICATION.
003773 04-15

THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003B60 04-17

ARBITURATE-INDUCED

AN ANALYSIS OF BARBITURATE-INDUCED EATING AND DRINKING IN THE RAT.
002552 03-04

ARBITURATES

PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04

REVERSAL OF THE ACTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-03

SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND BENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY
001360 02-03

IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 02-03

THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES?
002360 03-03

EFFECT OF ENZYME INDUCTION BY BARBITURATES ON NEUROHORMONE EXCRETION IN MAN.
002B39 03-13

3 HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 04-13

BARBITURATES AND SERUM CALCIUM IN THE ELDERLY
003837 04-15

BARIUM

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

BARORECEPTOR

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

BARRIER

REGULARITIES IN PENETRATION OF THE PLACENTAL BARRIER BY AMINAZINE.
002576 03-05

AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

BASAL

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-03

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION.
002260 03-03

BEHAVIORAL ALTERATIONS IN PATIENTS WITH BASAL GANGLIA LESIONS.
002430 03-04

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

BASE

CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15

BASELINE

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03

BASELINES

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04

BATTERER

LITHIUM-SALTS IN THE MANAGEMENT OF A CHILD BATTERER.
002679 03-09

BATTERY

FINDINGS WITH A CONDITIONING TEST BATTERY: DIFFERENTIAL RESPONSIVENESS TO DIAZEPAM AND DOXEPIN
0035B0 04-10

BEE

EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-04

BEEF

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-03

5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
0012B9 02-03

BEHAVIOR

HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02

NEUROPEPTIDES, BRAIN AND BEHAVIOR.
000112 01-03

SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES
000133 01-03

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT
000160 01-03

BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
000204 01-03

ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03

THE EFFECTS OF ALCOHOL AND ATROPINE ON EEG AND BEHAVIOR IN THE RABBIT.
00025B 01-03

EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
000279 01-04

EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
0002B1 01-04

BEHAVIOR AND DRUG EFFECTS DURING CHRONIC STRESS.
0002B2 01-04

THE EFFECTS OF MANIPULATIONS WITH THE DOPAMINERGIC SYSTEM ON SELF-STIMULATION BEHAVIOR.
000293 01-04

EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-04

INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04

BEHAVIOR AND ADDICTION: EXPERIMENTAL STUDIES OF MORPHINE-DEPENDENCE. (PH. D. DISSERTATION).
000315 01-04

SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT RAT.
000327 01-04

EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
00033B 01-04

THE EFFECTS OF CHLORPROMAZINE UPON FEAR MOTIVATED BEHAVIOR IN THE SQUIRREL-MONKEY.
000345 01-04

CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04

CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04

THE EFFECTS OF PERPHENAZINE ON SELF-ADMINISTRATION BEHAVIOR.
000353 01-04

EFFECTS OF A NOVEL ANTIAGGRESSIVE AGENT UPON TWO TYPES OF BRAIN STIMULATED EMOTIONAL BEHAVIOR.
000357 01-04

INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27-EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
0003B7 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04

EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04

AGGRESSIVE BEHAVIOR INDUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-04

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04

SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
000446 01-04

SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04

DISORDERED BEHAVIOR OF EPILEPTICS AND CURRENT THERAPEUTIC ORIENTATIONS.
000757 01-11

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11

A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
000912 01-14

PHARMACOLOGICAL SUBSTANCES INFLUENCING ACQUISITION BEHAVIOR IN RATS.
00092B 01-14

THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-1

MONOAMINE-OXIDASE, MONOAMINE-OXIDASE INHIBITING DRUGS AND HUMAN BEHAVIOR (UNPUBLISHED REPORT).
001061 01-1

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN
001224 02-0

MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-0

6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-0

PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AN PSYCHOSIS.
001333 02-0

CHOLINERGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT.
001434 02-0

EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-0

EFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY
001453 02-0

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-0

PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-0

THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS
001476 02-0

HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-0

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW LEVEL EXPOSURE TO LEAD AND TRITIUM.
0014B5 02-0

EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT. IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-0

BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-

MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWIN PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-

COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001503 02-

THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON
001505 02-

EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT.
001510 02-

AN ANIMAL BEHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-

EFFECTS OF LITHIUM ON FOOT-SHOCK-INDUCED AGGRESSIVE BEHAVIO IN RATS
001549 02-

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02

ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

SCOPOLAMINE AND FOOD-REINFORCED BEHAVIOR IN THE RAT
001563 02-04

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04

POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04

DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04

EFFECTS OF PENTOBARBITAL ON PUNISHED BEHAVIOR AT DIFFERENT SHOCK INTENSITIES.
001607 02-04

LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE.
001609 02-04

EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-0B

A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR.
001703 02-0B

PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON.
001796 02-10

PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
001B25 02-11

THE EFFECT OF LITHIUM ON IMPULSIVE AGGRESSIVE BEHAVIOR IN MAN
001996 02-14

EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 02-14

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16

BIOCHEMISTRY AND BEHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE AND ANTIPSYCHOTIC DRUGS.
002122 02-17

PHARMACOLOGY: DRUGS AFFECTING BEHAVIOR.
002132 02-17

HORMONES, BEHAVIOR, AND PSYCHOPATHOLOGY: PAPERS FROM A MEETING.
002159 02-17

SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03

INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-04

ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
002437 03-04

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
002446 03-04

SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION THE EFFECTS PRODUCED BY P CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL MONKEYS
002457 03-04

EMOTIONAL AND MOTIVATIONAL ASPECTS OF DRUG TAKING BEHAVIOR OF ANIMALS.
002464 03-04

EFFECTS OF L-5 HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
002470 03-04

EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V. EFFECTS OF PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-04

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
002478 03-04

EFFECTS OF DRUGS ON BEHAVIOR CONTROLLED BY NOXIOUS STIMULI.
0024B2 03-04

EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
002501 03-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-04

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

THE EFFECTS OF ANALGESICS ON THE CONDITIONED BEHAVIOR OF RATS (II).
002509 03-04

EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
002512 03-04

THE EFFECT OF OMETINE ON LEARNED BEHAVIOR IN THE WAKIN GOLDFISH.
002514 03-04

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04

MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

A RAT MODEL OF VIOLENT ATTACK BEHAVIOR. (PH.D. DISSERTATION).
002531 03-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
00253B 03-04

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
00254B 03-04

EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-04

THE EFFECT OF DIMETHYLAMINOETHANOL (DEANOL) ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR (AISB).
002553 03-04

NICOTINE AND BEHAVIOR.
00255B 03-04

USE OF PSYCHOPHARMACEUTICALS FOR THE TREATMENT OF ABNORMAL BEHAVIOR OF OLIGOPHRENIC EPILEPTICS.
002772 03-11

HALOPERIDOL IN THE THERAPY OF SEVERE BEHAVIOR DISORDERS.
002B51 03-14

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002B60 03-14

RELATIVE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN: AN INTERIM REPORT.
002B62 03-14

PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTERACTIONS OF ALCOHOL AND OXAZEPAM WITH REGARD TO RESPONSE BEHAVIOR.
002BB0 03-14

PHARMACOLOGY OF EMOTIVE BEHAVIOR.
003046 03-17

EFFECTS OF DIMETHYLAMINOETHANOL UPON LIFE-SPAN AND BEHAVIOR OF AGED JAPANESE QUAIL.
003112 04-03

ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDRODIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

REVERSE TOLERANCE TO STIMULANT-INOUCEO ABNORMAL BEHAVIOR.
003196 04-03

EFFECT OF OESGLYCINAMIOE LYSINE VASOPRESSIN (OG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-04

CHANGES IN ORUG-INDUCEO STEREOTYPEO BEHAVIOR AFTER 6-OHOA LESIONS IN NORAORENALINE NEURONS.
003357 04-04

PARGYLINE-INDUCEO INCREASES IN SENSITIVITY TO THE EFFECTS OF ORUGS ON OPERANT BEHAVIOR IN PIGEONS.
003361 04-04

EFFECTS OF OIAZEPAM ON EXPLORATORY BEHAVIOR OF PIGS.
003369 04-04

GONAOAL HORMONES ANO SEXUAL BEHAVIOR IN GROUPS OF AOULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-04

EFFECTS OF SCOPOLAMINE ANO METHSCOPOLAMINE ON ACQUISITION ANO RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR ANO TOTAL BRAIN ACETYLCHOLINE.
003377 04-04

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS ANO SUPPRESSION OF FIXEO-RATIO OPERANT BEHAVIOR IN MORPHINE-OEPENOENT RATS.
0033B8 04-04

BEHAVIOR MAINTAINED UNOER SECOND-OROER SCHEOULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

EFFECTS OF COCAINE AND O-AMPHETAMINE ON BEHAVIOR MAINTAINEO UNOER VARIOUS SCHEOULES OF FOOO PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-04

NEONATAL ANOROGEN INJECTION CHANGES OPEN-FIELO BEHAVIOR OF MICE.
003402 04-04

THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS ANO RHESUS-MONKEYS.
003406 04-04

PENTOBARBITAL, DIAZEPAM ANO BEMEGRIDE: THEIR EFFECTS ON OPEN-FIELO BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
00340B 04-04

PERSEVERATION ANO ROTATIONAL BEHAVIOR ELICITEO BY O-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR AOMINISTRATION.
003413 04-04

OOSE-DEPENDENT ACTION OF CORTICOSTEROIOS ON BRAIN SEROTONIN CONTENT ANO PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04

BETA-ENOORPHIN AND MALE SEXUAL BEHAVIOR.
003429 04-04

BETA-PHENYLETHYLAMINE ANO ANIMAL BEHAVIOR. (UNPUBLISHED PAPER).
003431 04-04

MORPHINE-INDUCEO ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCEO ROTATION ANO ANTAGONISM BY NALOXONE.
003434 04-04

TRYPTAMINE: BIMOOAL ACTIONS ON THE EEG ANO BEHAVIOR OF RABBITS.
003440 04-04

EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04

ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS
003454 04-04

PSYCHOPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

LONG TERM REOUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-04

MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY IN RATS.
003507 04-05

PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04-11

PRELIMINARY REPORT ON THE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MOOIFICATION IN HYPERKINETIC CHILDREN.
003620 04-11

HYPOTHALAMIC RELEASING HORMONES AND BEHAVIOR.
003722 04-13

EFFECTS OF 1694 AND OTHER DOPAMINERGIC AGENTS ON CIRCLING BEHAVIOR.
003855 04-17

BEHAVIORAL

5-METHOXYDIMETHYLTRYPTAMINE: BEHAVIORAL ANO TOXICOLOGICAL EFFECTS IN ANIMALS.
000022 01-02

BEHAVIORAL ANO NEUROCHEMICAL CHANGES FOLLOWING AOMINISTRATION OF 6-HYOROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIOBRAIN.
0001B4 01-03

COMPUTER USE IN BEHAVIORAL STUDY.
000272 01-04

NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INOUCEO BY CENTRAL CHOLINERGIC ORUGS.
0002BB 01-04

BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE OECARBOXYLASE INHIBITOR RO-4-4602.
000295 01-04

BEHAVIORAL OEPRESSION: THYROID INTERACTIONS WITH NOREPINEPHRINE OEPLETING ORUGS.
000307 01-04

EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACIO UPON BEHAVIORAL ACTIVITY IN THE RAT.
00032B 01-04

ORUG-INOUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL ANO NEUROCHEMICAL INOICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL ANO NEUROHUMORAL VARIABLES.
000355 01-04

BEHAVIORAL ANO BIOCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYOROXYOOPA.
000376 01-04

MEASUREMENT OF ACUTE ANO CHRONIC BEHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-04

WITHORAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION.
000403 01-04

AMINO-ACIO TRANSPORT INHIBITION: BRAIN ANO BEHAVIORAL CORRELATES.
000406 01-04

BEHAVIORAL ANO BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR AOMINISTRATION OF ACTH ANALOGS ANO LYSINE VASOPRESSIN
000407 01-04

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC AOMINISTRATION OF O-AMPHETAMINE.
000415 01-04

AGGRESSIVE BEHAVIOR INOUCEO BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-04

BEHAVIORAL EFFECTS ON THE PROGENY OF MICE TREATED WITH METHYLMERCURY.
000432 01-04

REPEATEO ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIOATE AND IMIPRAMINE.
000437 01-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-10

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON.
00076B 01-11

THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILOREN. (PH.D. DISSERTATION).
000917 01-14

THE EFFECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
0009B6 01-15

BEHAVIORAL EFFECTS OF INTRAVENTRICULARLY ADMINISTERED VASOPRESSIN AND VASOPRESSIN FRAGMENTS.
001107 02-02

SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 02-03

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03

EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION
001245 02-03

BEHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL
001385 02-03
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
001400 02-03
BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03
SOME BEHAVIORAL EFFECTS OF PRETHCAMIDE COMPARED WITH THOSE OF ITS TWO COMPONENTS.
001437 02-04
BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04
BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS.
001527 02-04
ISONIAZID: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN RHESUS-MONKEYS.
001530 02-04
NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
001583 02-04
BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04
COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04
PERIOD OF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLDEN HAMSTER
001616 02-05
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06
CANNABINOID-INDUCED BEHAVIORAL CONVULSIONS IN RABBITS.
001649 02-06
DEPRESSION: BEHAVIORAL, BIOCHEMICAL, DIAGNOSTIC AND TREATMENT CONCEPTS.
001746 02-09
THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS
002006 02-14
9-NOR-9-HYDROXYHEXAHYDROCANNABINOLS. SYNTHESIS, SOME BEHAVIORAL AND ANALGESIC PROPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-03
BEHAVIORAL EFFECTS OF P-METHOXYPHENYLETHYLAMINE A PHARMACOLOGICAL STUDY.
002419 03-04
BEHAVIORAL ALTERATIONS IN PATIENTS WITH BASAL GANGLIA LESIONS.
002430 03-04
EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN COMBINATION WITH STIMULANT DRUGS IN RABBITS.
002434 03-04
BEHAVIORAL DRUG EFFECTS UPON OPERANT RESPONSE FORCE.
002447 03-04
CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE DEPENDENT MONKEYS.
002456 03-04
INFLUENCE OF 6 HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
002463 03-04
BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04
CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04
SOCIAL ISOLATION INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM
002510 03-04
A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT
002520 03-04
OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS
002546 03-04
CORRELATION OF BEHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE (PH D DISSERTATION).
002560 03-04
EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE
002566 03-05
BEHAVIORAL EFFECTS OF WITHDRAWAL OF FLUPHENAZINE AFTER LONG TERM TREATMENT.
002578 03-05
ACTH4-10: COGNITIVE AND BEHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING-DISABLED CHILDREN.
002872 03-14
BEHAVIORAL EFFECTS OF REPEATED PSYCHOACTIVE DRUG ADMINISTRATION (PH D. DISSERTATION).
002877 03-14
BEHAVIORAL PHARMACOLOGY: THE CURRENT STATUS.
002881 03-14
BEHAVIORAL PHARMACOLOGY.
002990 03-17
AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION: BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17
LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03
AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03
THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION
003341 04-04
CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES
003397 04-04
THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04
BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL-3912A) WITH R-DOM AND S-AMPHETAMINE.
003470 04-04
BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04
EFFECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE
003483 04-04
MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-05
SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
003509 04-05
THE BEHAVIORAL TREATMENT OF INSOMNIA: AN ALTERNATIVE TO DRUG THERAPY
003821 04-15
AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

BEHAVIORALLY

IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION
000249 01-03
ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-04
AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11

BEHAVIORS

LOCOMOTOR ACTIVITY AND EXPLORATION THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT.
001538 02-04
THE EFFECTS OF D-AMPHETAMINE AND ILLUMINATION ON BEHAVIORS OF THE SQUIRREL-MONKEY.
001542 02-04

INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
002450 03-04

HALLUCINOGEN-INDUCED BEHAVIORS OF FREE-MOVING CHIMPANZEES.
00335B 04-04

BEHAVIOUR

THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03

THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR.
000239 01-03

ANXIETY DRUGS AND BABOON BEHAVIOUR.
0002B7 01-04

THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04

EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04

BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04

THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BFHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
00030B 01-04

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04

L-DOPA EFFECTS ON SEXUAL BEHAVIOUR: AN EXPERIMENTAL STUDY.
000360 01-04

5 HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCF BEHAVIOUR.
000364 01-04

ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-04

THE MECHANISM OF ACTION OF PSYCHOPHARMACOLOGICAL AGENTS ON BEHAVIOUR.
000391 01-04

NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS.
000405 01-04

SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04

EFFECTS OF THE ADMINISTRATION OF TWO DOSES OF SULPIRIDE ON THE BFHAVIOUR OF THE RAT.
000414 01-04

SFROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
00044B 01-04

PSYCHOTHFRAPY AND BEHAVIOUR THERAPY.
000925 01 14

EFFFCTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BFHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012BB 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS
001350 02-03

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DFRIVATIVES.
00144B 02-04

FFFECTS OF P CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON RAT SOCIAL BEHAVIOUR.
001463 02-04

CHANGFS IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04

EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02 04

EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE
001601 02 04

CHEMICAL STIMULANTS OF SHAKING BEHAVIOUR.
001605 02-04

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

EFFECT OF TRYPTAMINERGIC DRUGS ON ELECTROSHOCK FIGHTING BEHAVIOUR IN RATS.
002417 03-04

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-03

SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI
00336B 04-04

EFFECTS OF DIAZEPAM ON BEHAVIOUR SUPPRESSED BY EXTINCTION IN PIGS.
003370 04-04

OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN
003447 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

BENZODIAZEPINES AND DISCRIMINATION BEHAVIOUR: DISSOCIATION OF RESPONSE AND SENSORY FACTORS
003475 04-04

BEHAVIOURAL

PROLONGED APOMORPHINE-LIKE BEHAVIOURAL EFFECTS OF APOMORPHINE ESTERS.
00027B 01-04

SOME BEHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA-TRANSAMINASE.
0002B5 01-04

BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN.
000393 01-04

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06

THE BEHAVIOURAL EFFECTS OF EOS-INDUCED CHANGES IN SUBSTANTIA-NIGRA GABA LEVELS.
00152B 02-04

BFHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE
001579 02-04

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
0015B5 02-04

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE
001601 02-04

THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED BEHAVIOURAL RESPONSES IN MICE
0021BB 03-02

BEHAVIOURAL EFFECTS OF BETA-RECEPTOR BLOCKING AGENTS IN EXPERIMENTAL ANIMALS
002442 03-04

OPERANT BEHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6vHYDROXYDOPAMINE TREATMENT
002519 03-04
POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT.
002522 03-04
DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04
PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY.
002959 03-17
FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03
ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-04
INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04
EFFECTS OF N,N DIMETHYLTRYPTAMINE ON BEHAVIOURAL HABITUATION IN THE RAT.
003384 04-04
REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04
A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04
BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04
THE PHYSICAL AND BEHAVIOURAL COMPLEX OF DEMENTIA.
003893 04-17

BEHAVIOURS
INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOURS IN RODENTS.
001519 02-04

BELLERGAL
THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

BELLIGERENT
PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04-11

BEMEGRIDE
PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPEN-FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
003408 04-04

BENALGIN
ACCIDENTAL BENALGIN POISONING.
000979 01-15

BENDROFLUAZIDE
EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION.
003742 04-14

BENEFICIAL
BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13

BENIGN
EFFECT OF CORETAL-POLFA (OXPRENOLOL) ON PARKINSONIAN TREMOR AND BENIGN ESSENTIAL TRFMOR.
000734 01-11
PROPRANOLOL IN BENIGN ESSENTIAL TREMOR.
00287B 03-14

BENSERAZIDE
COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM.
002815 03-13
HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002849 03-14

BENZAMIDES
SUBSTITUTED BENZAMIDES AS DOPAMINE ANTAGONISTS
000094 01-03
THE BENZAMIDES IN PSYCHOPHARMACOLOGY: SULPIRIDE AND SULTOPRIDE.
000520 01-07

BENZOCHINOLIZIN
CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-08

BENZOCTAMINE
FAILURE OF BENZOCTAMINE TO INFLUENCE THF ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
002223 03-03

BENZODIAZEPINE
EFFECTS OF BENZODIAZEPINE TRANQUILLIZERS ON THE SOCIAL RESPONSES OF RATS.
000452 01-04
THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01-07
CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10
BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH.
000710 01-10
CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07
BENZODIAZEPINE DRUGS IN GENERAL MEDICAL PATIENTS.
001833 02-11
INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN
002320 03-03
BENZODIAZEPINE RECEPTORS IN RAT BRAIN.
003287 04-03
THE INTERACTION BETWEEN CLONIDINE AND VARIOUS NEUROLEPTIC AGENTS AND SOME BENZODIAZEPINE TRANQUILLIZERS.
003312 04-03
EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH.
003522 04-07
ACUTE OVERDOSAGE WITH BENZODIAZEPINE DERIVATIVES.
0037B9 04-15
WITHDRAWAL FROM BENZODIAZEPINE THERAPY.
003B72 04-17

BENZODIAZEPINE-INDUCED
BENZODIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03
BENZODIAZEPINE-INDUCED MODIFICATIONS OF DREAM CONTENT: THE EFFECT OF FLUNITRAZEPAM.
001969 02-14

BENZODIAZEPINE-2-ONE
THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01-07
POSSIBILITY OF USING 7-CHLORO-5-(2-CHLOROPHENYL) 1,3-DIHYDRO-2H-1,4 BENZODIAZEPINE-2-ONE. IN CASES OF PSYCHOTIC SYMPTOMATOLOGY.
000508 01-07

BENZODIAZEPINES
DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04
INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL DOPAMINE NEURONS.
000358 01-04
SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04
BENZODIAZEPINES AND HUMAN SLEEP.
000839 01-13
BENZODIAZEPINES AND HUMAN PERFORMANCE.
000900 01-14
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 75. 7-HYDROXYAMINOBENZODIAZEPINES AND DERIVATIVES.
001096 02-01
EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONF, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03
SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND BENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY.
001360 02-03

HEAD TWITCHES INDUCED BY BENZODIAZEPINES AND THE ROLE OF BIOGENIC AMINES.
001552 02-04

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

EFFECT OF THE 1,5 BENZODIAZEPINES, CLOBAZAM AND TRIFLUBAZAM, ON THE SLEEP OF MAN
001657 02-07

STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

BENZODIAZEPINES AND NEUROTIC ANXIETY: CRITIQUE.
002166 02-17

CENTRAL ACTIONS OF BENZODIAZEPINES.
00222B 03-03

KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES I: CHLORDIAZEPOXIDE AND DEMOXEPAM.
00225B 03-03

A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION (PH.D DISSERTATION).
002296 03-03

EFFECTS OF BENZODIAZEPINES ON BRAIN MONOAMINES.
002365 03-03

EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS IN THE CAT BRAIN.
0023B6 03-03

EFFECTS OF BENZODIAZEPINES AND PENTOBARBITAL ON THE EVOKED POTENTIALS IN THE CAT BRAIN
0023B7 03-03

DISCRIMINABLE EFFECTS OF BENZODIAZEPINES.
002517 03-04

UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFECTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03

KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES II: OXAZEPAM AND DIAZEPAM.
003165 04-03

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS
003474 04-04

BENZODIAZEPINES AND DISCRIMINATION BEHAVIOUR: DISSOCIATION OF RESPONSE AND SENSORY FACTORS.
003475 04-04

BENZODIAZEPINES AND WITHDRAWAL PSYCHOSIS: REPORT OF THREE CASES.
003B17 04-15

BENZODIAZEPINIC
2,3 BENZODIAZEPINIC SYSTEMS. PART II. OXODIHYDROBENZODIAZEPINES. SYNTHESIS AND PHARMACOLOGIC STUDY
001109 02-02

BENZOFLAVONE
EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03

BENZOFURAN
RESEARCH IN THE BENZOFURAN SERIES LVII. BENZOFURYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIDEPRESSANTS.
000275 01-04

BENZOFURYLOXYALKYLAMIDOXIMES
RESEARCH IN THE BENZOFURAN SERIES LVII. BENZOFURYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIDEPRESSANTS.
000275 01-04

BENZOTHIATRIAZEPINES
SYNTHESIS OF 2,1,4,5 BENZOTHIATRIAZEPINES 2,2 DIOXIDES AND OF 4 KETOBENZOTHIADIAZEPINES 2,2 DIOXIDES.
001101 02-02

BENZOXAZOLINONIC
CHEMICAL AND PHARMACODYNAMIC STUDY OF BETA-AMINOKETONES OF BENZOXAZOLINONIC STRUCTURE
001103 02-02

BEST
BIG BROTHER KNOWS BEST
001B23 02-11

BETA-ACTIVITY
ALPHA ACTIVITY AND BETA ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE
003315 04-03

BETA-ADRENERGIC
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03

AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-1

EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000833 01-1

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-0

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-0

ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-0

BETA-ADRENERGIC BLOCKADE AND ANXIETY.
001B49 02-1

BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-0

MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-

BETA-ADRENERGIC BLOCKADE AND ANXIETY
002729 03-

THE EFFECT OF BETA-ADRENERGIC BLOCKADE (PROPRANOLOL) ON DIFFERENT TREMORS.
002753 03-

BETA-ADRENERGIC BLOCKING AGENTS IN THE TREATMENT OF PSYCHOSES. A REPORT ON 17 CASES.
002790 03-

DIFFERENTIAL INTERACTIONS OF PHENOBARBITAL AND PENTOBARBITA WITH BETA-ADRENERGIC MECHANISMS IN VITRO AND VIVO.
003262 04-

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL BETA-ADRENERGIC ADENYLATE-CYCLASE.
003668 04-

BETA-ADRENOCEPTOR
BETA-ADRENOCEPTOR BLOCKADE IN HYPERTHYROIDISM AND ANXIETY
000714 01-

THE PRESYNAPTIC EFFECT OF BETA-ADRENOCEPTOR ANTAGONISTS ON NORADRENERGIC NEURONES.
002400 03-

CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER.
002591 03

CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03

BETA-ADRENOCEPTORS
NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRA CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA ADRENOCEPTORS.
001141 02

CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02

BETA-AMINOKETONES
CHEMICAL AND PHARMACODYNAMIC STUDY OF BETA-AMINOKETONE OF BENZOXAZOLINONIC STRUCTURE.
001103 02

BETA-ANTAGONIST
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL
001376 02

BETA-BLOCKADE
BETA BLOCKADE OF MORPHINE-INDUCED HYPERLACTACIDEMIA IN RABBITS
001352 02

EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE
001673 02-07
PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION
002218 03-03
THE USE OF BETA-BLOCKADE IN DEPENDENCE
002766 03-11

BETA-BLOCKERS
BETA-BLOCKERS AS PSYCHOTROPIC DRUGS.
000516 01-07
ANXIETY AND TENSION AND BETA BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 01-10
NEW TRENDS OF BETA-BLOCKERS IN ACTIONS AND APPLICATIONS.
000869 01-13

BETA-CARBOLINE
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
003192 04-03

BETA-CARBOLINES
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN
003255 04-03

BETA-ENDORPHIN
BETA-ENDORPHIN IN VITRO INHIBITION OF STRIATAL DOPAMINE RELEASE.
002298 03-03
CROSS-TOLERANCE BETWEEN MORPHINE AND BETA-ENDORPHIN IN VIVO.
003296 04-03
BETA-ENDORPHIN AND MALE SEXUAL BEHAVIOR.
003429 04-04

BETA-ENDORPHIN-INDUCED
BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003875 04-17

BETA-INTERCEPTOR
THE USE OF THE BETA-INTERCEPTOR PHENDORAL WITHIN THE FIELD OF PSYCHIATRY.
000749 01-11

BETA-LIPOTROPIN
INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA-LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
001147 02-03
MORPHINE-LIKE ANALGESIC EFFECT OF A PITUITARY HORMONE, BETA-LIPOTROPIN.
001344 02-03
THE C-FRAGMENT OF BETA-LIPOTROPIN: AN ENDOGENOUS NEUROLEPTIC OR ANTIPSYCHOTOGEN?
002267 03-03

BETA-N-OXALYL-L-DIAMINOPROPIONIC-ACID
BRAIN AND RETINAL DAMAGE FROM LATHYRUS-EXCITOTOXIN, BETA-N-OXALYL-L-DIAMINOPROPIONIC-ACID.
001316 02-03

BETA-PHENYLETHYLAMINE
INTERACTION OF BETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
000002 01-01
PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
00013B 01-03
DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
000387 01-04
EFFECT OF BETA-PHENYLETHYLAMINE AND D-AMPHETAMINE ON ELECTRICAL SELF-STIMULATION OF BRAIN
002468 03-04
DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04
NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-04
BETA-PHENYLETHYLAMINE AND ANIMAL BEHAVIOR (UNPUBLISHED PAPER).
003431 04-04

BETA-RECEPTOR
BEHAVIOURAL EFFECTS OF BETA-RECEPTOR BLOCKING AGENTS IN EXPERIMENTAL ANIMALS.
002442 03-04
EFFECT OF THE BETA-RECEPTOR BLOCKER PROPRANOLOL ON MANIA.
002691 03-09
APPLICATION OF BETA RECEPTOR BLOCKING AGENTS IN COMBINED THERAPY OF ENDOGENOUS PSYCHOSIS.
002972 03-17
NEUROPSYCHIATRIC EFFECTS OF ADRENERGIC BETA RECEPTOR BLOCKING AGENTS.
002978 03-17
BETA RECEPTOR BLOCKERS IN PSYCHIATRY
003016 03-17

BETA-STIMULANT
UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15

BETA1-RECEPTOR
COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1 RECEPTOR ANTAGONIST METOPROLOL.
000B2B 01-13
COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-87-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-13

BETEL
BETEL QUID AND REACTION TIME.
000920 01-14

BIASES
DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE AND D-AMPHETAMINE: EFFECTS ON HABITUATION
001435 02-04

BIBLIOGRAPHY
A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM - APPENDIX II (PART III).
001072 01-17
PSYCHOPHARMACOLOGY -- A RECURRING BIBLIOGRAPHY.
002147 02-17

BICARBONATE
SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN.
002889 03-15

BICUCULLINE
EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03
SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

BICYCLIC
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
000058 01-03

BIGUANIDES
EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

BILATERAL
THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15
CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
002446 03-04
THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-08

BILE
HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION
000316 01-04

BILIARY
BILIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN
000808 01-13
BILIARY EXCRETION OF DIAZEPAM AND ITS METABOLITES IN MAN
000862 01-13
THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
001134 02-03
EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN.
003218 04-03

BIMODAL
BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03
TRYPTAMINE: BIMODAL ACTIONS ON THE EEG AND BEHAVIOR OF RABBITS.
003440 04-04

BIMODALITY

DN THE BIMODALITY OE THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZDPHRENIC PATIENTS.
000579 01-08

BINDING

INDEPENDENT VARIATION DF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03

PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
00086B 01-13

DIHYDROERGDTAMINE BINDING TD RAT 8RAIN MEMBRANES.
001169 02-03

5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSDMAL MEMBRANES.
001201 02-03

CDMPARISON OF THE EFFECTS OE MAPROTILINE (LUDIOMIL R) AND CLDMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN 8INDING IN PLASMA.
001228 02-03

IDENTIFICATION OE OPIATE/RECEPTOR 8INDING IN VIVO.
D01240 02-03

THE BINDING DF THE DPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS DF RAT BRAIN
001242 02-03

IRREVERSIBLE PROTEIN BINDING DF 14C-IMIPRAMINE IN RATS IN VIVO.
001258 02-03

CHARACTERISTICS AND ALTERED SENSITIVITY DF CEREBRAL BETA-ADRENDCEPTORS ASSESSED BY 3H-PROPRANDLOL BINDING.
001302 02-03

MECHANISM OE INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN: METAL BINDING AND FLUDRESCENCE STUDIES.
001328 02-03

PHARMACDKINETICS AND PLASMA BINDING DF DIAZEPAM IN MAN, DOG, RABBIT, GUINEA-PIG AND RAT.
001921 D2-13

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONDAMINE-OXIDASE.
001937 02-13

STUDIES DN THE BINDING DF BENZDDIAZEPINES TD HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

PHARMACOLDGIC PRDPERTIES DF (3H)DIHYDROERGDKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTDRS IN RAT BRAIN MEMBRANES.
002253 03-03

THE BINDING OF PHENOTHIAZINES AND RELATED COMPOUNDS TO HUMAN SERUM ALBUMIN
00282B 03-13

QUANTITATIVE CDRRELATIDNS BETWEEN ALBUMIN BINDING CONSTANTS AND CHRDMATOGRAPHIC RM VALUES OF PHENDTHIAZINE DERIVATIVES.
003053 04-01

PDTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACDLOGICAL ACTIVITY, AND DPIATE RECEPTDR BINDING DF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMDRPHANS.
D03072 04-D2

BINDING DF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITIDN BY MDRPHINE OR NALOXONE.
0030B9 D4-03

STUDIES DN THE RELATIONSHIP DF BINDING AFFINITY TO PSYCHDACTIVE AND ANTICHDLINERGIC PDTENCY OF A GROUP OF PSYCHDTOMIMETIC GLYCOLATES
003091 04-03

THF INFLUENCE OF LITHIUM DN WATER BINDING ABILITY, CONSISTENCY AND MACRDMOLECULES IN THE RAT BRAIN
003132 04-03

STFREDSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS DF GABA RECEPTDR BINDING IN RAT BRAIN
003134 04-03

ONTDGENESIS OF DDPAMINE RECEPTOR BINDING IN THE CORPUS-STRIATUM OF THE RAT
003235 04-03

DPIATF RFCEPTOR BINDING IN THE PITUITARY GLAND.
003279 04-03

ANTISCHIZOPHRENIC DRUGS: CHRDNIC TREATMENT ELEVATES DOPAMINF RECEPTDR BINDING IN BRAIN.
003493 04-05

THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTDNIN BINDING PRDTFIN
003517 04-06

BIOAVAILABILITY

A SIMPLE METHDD FOR DETERMINING DIAZEPAM AND ITS MAJOR META8OLITES IN BIOLDGICAL ELUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
0004B0 01-07

POLYETHYLENE-GLYCOL AS A SOLVENT EDR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATIDN, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIDNS.
000B36 01-13

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000B59 D1-13

BIOAVAILABILITY OE TWO PREPARATIONS OF CHLDRDIAZEPOXIDE.
001944 02-13

DETERMINATION OE PSYCHOACTIVITY AND CEREBRAL BIDAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACD-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14

BIOAVAILABILITY AND SIDE-EFFECTS DE DIFEERENT LITHIUM-CARBDNATE PRDDUCTS.
D02904 03-15

STEADY-STATE BIDAVAILABILITY OF TWD CLORAZEPATE DIPOTASSIUM DDSAGE FORMS.
003662 04-13

BIOCHEMICAL

PHARMACDLOGICAL AND BIDCHEMICAL STUDIES OF INTRACRANIAL SELE-STIMULATION- ROLES DF DOPAMINERGIC AND NORADRENERGIC NEURDNAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
D00234 01-03

BEHAVIDRAL AND BIDCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYDRDXYDOPA.
000376 01-04

BEHAVIORAL AND BIDCHEMICAL RESPDNSES OE MICE TO THE INTRAVENTRICULAR ADMINISTRATIDN OF ACTH ANALOGS AND LYSINE VASDPRESSIN.
0D0407 01-0

PATHOPHYSIDLOGY -- BIDCHEMICAL CDNSIDERATIONS.
00D52B 01-0

THE POTENTIAL VALUE DF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATIDN OF AFFECTIVE DISDRDERS.
0D0652 01-0

L-DDPA TREATMENT IN PARKINSONISM. BIOCHEMICAL BASIS.
D00802 01-1

CENTRAL MECHANISMS OF ACTIDN OF P-CHLORDAMPHETAMINE: BIDCHEMICAL AND HISTDLOGICAL STUDIES. (PH.D. DISSERTATION).
000B43 01-1

CLINICAL AND BIOCHEMICAL CONSIDERATIONS DN THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L-DOPA.
0D094B 01-1

BIOCHEMISTRY AND SCHIZDPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM DE ACTION: A REVIEW OE THE BIOCHEMICAL LITERATURE.
001080 01-1

BIOCHEMICAL ACTIONS OF SYMPATHDMIMETIC DRUGS WHICH OVERCDME CYCLDHEXIMIDE-INDUCED AMNESIA.
001254 02-0

TAURINE AND CDBALT-INDUCED EPILEPSY IN THE RAT: A BIDCHEMICAL AND ELECTRDCORTICDGRAPHIC STUDY.
DD1256 D2-0

BIDCHEMICAL LOCALIZATION DF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS DF THE RAT CEREBRAL CORTEX.
0D1340 D2-0

BIDCHEMICAL PLASTICITY DF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001351 02-0

ISDNIAZID: BEHAVIORAL AND BIDCHEMICAL EFFECTS IN RHESUS-MONKEYS.
D01530 D2-0

INHIBITIDN DF MDNOAMINE-DXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLDGICAL AND BIDCHEMICAL PARAMETERS.
0D1569 02-0

DEPRESSIDN: BEHAVIORAL, BIDCHEMICAL, DIAGNOSTIC AND TREATMENT CONCEPTS.
D01746 02-0

BIDCHEMICAL EFFECTS OF ERGOT ALKALOIDS WITH SPECIAL REFERENC TO THE BRAIN.
002308 03-0

BIDCHEMICAL BASIS DF AN ANIMAL MDDEL DF DEPRESSIVE ILLNESS -- PRELIMINARY REPORT.
D023B1 03-0

BLOCKADE OF APOMORPHINES OISCRIMINATIVE STIMULUS PROPFRTIES. RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03 04

SOCIAL ISOLATION INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM
002510 03-04

CORRELATION OF BEHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE (PH D. OISSERTATION).
002560 03-04

OETERMINATION OF BIOGENIC AMINE METABOLITES IN CFREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHOOS ANO BIOCHEMICAL STUDIES OF OEPRESSIVE OISOROERS.
002666 03-09

VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIOATION
002811 03-13

GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 04-03

PHARMACOLOGICAL ANO BIOCHEMICAL STUOIES WITH THREE METABOLITES OF NOMIFENSINE.
003200 04-03

BIOCHEMICAL ANO PHARMACOLOGICAL STUOIES ON AN ANIMAL MOOEL OF HYPERACTIVITY STATES.
003518 04-06

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISOROERS.
003576 04-09

LITHIUM IN OEPRESSION: A BIOCHEMICAL STUDY
003584 04-10

CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC ORUG ACTION IN MAN.
003704 04-13

INITIAL CLINICAL TRIAL BASEO ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
003709 04-13

BIOCHEMISTRY

BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE BIOCHEMICAL LITERATURE.
001080 01-17

BIOCHEMISTRY ANO BEHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE AND ANTIPSYCHOTIC DRUGS.
002122 02-17

BIOCHEMISTRY OF THE AFFECTIVE DISORDERS.
003562 04-09

BIOELECTRIC

BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULOENSTADTI.
002394 03-03

BIOELECTRICAL

THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-0B

BIOGENIC

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

PAPAVERINE, ORUG-INDUCEO STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT
000362 01-04

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

EFFECTS OF CLOMIPRAMINE ANO OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
000665 01-09

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RFSERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
001215 02-03

EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03

THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES
001281 02-03

INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINF, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THF RAT
001540 02-04

HEAD TWITCHES INDUCED BY BENZODIAZFPINES AND THE ROLE OF BIOGENIC AMINES
001552 02-04

THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG GB 94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN
002271 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANOINS A1, F1, E2, F1ALPHA, ANO F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME ORUGS ANO ON THE LEVEL ANO TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUIO BY MASS FRAGMENTOGRAPHY -- METHODS ANO BIOCHEMICAL STUOIES OF OEPRESSIVE DISOROERS.
002666 03-09

EFFECTS OF ALKYLTETRAHYOROCARBAZOLE-ETHANAMINES AND RELATED COMPOUNOS, POTENTIAL ANTIOEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-03

LITHIUM: MOOIFICATION OF BEHAVIORAL ACTIVITY ANO BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROIO RATS.
003249 04-03

THE MEASUREMENT OF BIOGENIC AMINE TURNOVER USING OXYGEN-18.
003263 04-03

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC ANO BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04

BIOGENIC AMINE PRECURSORS AND AFFECTIVE ILLNESSES.
003551 04-09

FACTORS INFLUENCING THE OEAMINATION ANO FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

BIOLOGICAL

PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04

A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
0004B0 01-07

BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILOHOOD.
000730 01-11

HASHISH. UNSATURATEO SIOE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY.
001339 02-03

THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE OISORDERS (UNPUBLISHED PAPER).
001750 02-09

DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS.
001907 02-13

BIOLOGICAL SUBSTRATES OF MENTAL ILLNESS.
002130 02-17

PSYCHOPHARMACOLOGY -- A BIOLOGICAL APPROACH.
002140 02-17

INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUOY USING SPIN LABELS.
002297 03-03

THE BIOLOGICAL DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.
002356 03-03

MEPERIOINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY OERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

POSSIBLE MECHANISM FOR BIOLOGICAL ACTION OF LITHIUM.
002810 03-13

INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYORAZIOES OF INOOLIZINE-2-CARBOXYLIC-ACID.
003048 04-01

BIOLOGICAL DISPOSITION OF RIGID ANALOGS OF AMPHETAMINE.
003147 04-03

THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA.
003543 04-08

PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISOROERS, ANO NEUROSES.
0035B1 04-10

BIOLOGY

THE BIOLOGY OF THE SCHIZOPHRENIC PROCESS.
000575 01-0B

A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM -- APPENDIX II (PART III).
001072 01-17

BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03

BIONEUTRALIZING
BIONEUTRALIZING PROPERTIES OF SEROTONIN ANTIBODIES.
002412 03-03

BIOSYNTHESIS
EFFECTS OF PHOSPHOLIPID ADMINISTRATION ON ENDOGENOUS CEREBRAL PHOSPHOLIPID BIOSYNTHESIS.
000036 01-03

A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-0B

MAMMALIAN BIOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
000793 01-12

BIOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACEREBRALLY INJECTED CHOLINE.
001127 02-03

INHIBITION OF CATECHOLAMINE BIOSYNTHESIS AND MEMORY PROCESSES.
001214 02-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03

BIOTRANSFORMATION
THE INFLUENCE OF PHENOBARBITAL ON BIOTRANSFORMATION OF 25-HYDROXYCHOLECALCIFEROL.
000066 01-03

ABSORPTION AND BIOTRANSFORMATION OF CHOLECALCIFEROL IN DRUG-INDUCED OSTEOMALACIA.
000166 01-03

BIPERIDEN
TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENDED ACTION FORM OF BIPERIDEN HYDROCHLORIDE: 9 MONTH STUDY OF 55 HOSPITALIZED PATIENTS.
0027B7 03-11

MOOD ELFVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION
00379B 04-15

BIPHASIC
BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

BIPHENYL-DIBENZODIOXIN
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
0010B4 02-01

BIPHENYLS
EFFFCTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

BIPOLAR
A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001B13 02-11

BIPOLAR-I
LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01-09

BIPOLAR-II
LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS
000603 01-09

BISMUTH
DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
002051 02-15

BITING
EFFECTS OF NICOTINIC AND MUSCARINIC COMPOUNDS ON BITING ATTACK IN THE CAT.
002424 03-04

EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG TERM ISOLATION IN MICE.
002470 03-04

BL-3912A
BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL 3912A) WITH R-DOM AND S-AMPHETAMINE
003470 04-04

BLACK
PSYCHOTIC MASKED DEPRESSION OR BLACK MASK FOR DEPRESSION.
000613 01-09

BLADDER
PSYCHOTROPIC DRUG-INDUCED BLADDER DECOMPENSATION.
003797 04-15

BLASTOGENIC
EFFECT OF PSYCHOTROPIC AGENTS UPON THE BLASTOGENIC RESPONSE OF HUMAN T-LYMPHOCYTES.
003656 04-13

BLEEDING
GASTROINTESTINAL BLEEDING IN PATIENTS ON BROMOCRIPTINE.
002943 03-15

BLIND
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

THE EFFECTS OF HALLUCINOGENS ON BLIND MONKEYS.
002540 03-04

BLINDNESS
TASK-SPECIFIC EFFECTS OF D-AMPHETAMINE AND BLINDNESS ON BALB/CJ MICE
000317 01-04

BLOCK
MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-03

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

FIRST-DEGREE ATRIOVENTRICULAR BLOCK DURING LITHIUM-CARBONATE TREATMENT
003796 04-15

BLOCKADE
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03

COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03

METOCLOPRAMIDE AND DOPAMINE RECEPTOR BLOCKADE.
000195 01-03

ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03

BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE DECARBOXYLASE INHIBITOR RO-4-4602.
000295 01-0

BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-0

NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-0

BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
000421 01-0

BETA-ADRENOCEPTOR BLOCKADE IN HYPERTHYROIDISM AND ANXIETY.
000714 01-1

CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-0

NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-0

LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
00139B 02-0

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 02-0

RECEPTOR BLOCKADE AND RECEPTOR HYPERSENSITIVITY AFTER TREATMENT WITH NEUROLEPTICS.
001547 02-0

BETA-ADRENERGIC BLOCKADE AND ANXIETY.
001B49 02-

SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-

BLOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESIC IN THE MOUSE.
002362 03-

BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
002508 03-04

THE PSYCHOPHARMACOLOGY OF BETA ADRENERGIC BLOCKADE: PHARMACOKINETIC AND EPIDEMIOLOGIC ASPECTS.
002599 03-07

BETA-ADRENERGIC BLOCKADE AND ANXIETY.
002729 03-10

THE EFFECT OF BETA-ADRENERGIC BLOCKADE (PROPRANOLOL) ON DIFFERENT TREMORS.
002753 03-11

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
003087 04-03

BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
003109 04-03

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03

CHOLINERGIC BLOCKADE AND TONIC IMMOBILITY IN CHICKENS.
003387 04-04

EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION.
003742 04-14

BLOCKADES

PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04-15

BLOCKER

CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER.
002591 03-07

EFFECT OF THE BETA-RECEPTOR BLOCKER PROPRANOLOL ON MANIA.
002691 03-09

INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-04

BLOCKERS

EFFECTS OF CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL.
000268 01-03

INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
001213 02-03

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03

THE EFFECT OF ALPHA AND BETA ADRENERGIC RECEPTOR BLOCKERS ON SLEEP IN THE RAT.
001624 02-05

BETA-RECEPTOR BLOCKERS IN PSYCHIATRY.
003016 03-17

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03

LOCKING

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03

THE EFFECT OF MEMORY BLOCKING ANTIBIOTICS AND THEIR ANALOGS ON ACETYLCHOLINESTERASE.
000427 01-04

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000833 01-13

REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL 3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
001216 02-03

SELECTIVE ALPHA ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE
00124B 02-03

EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN
001423 02-03

BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-03

BEHAVIOURAL EFFECTS OF BETA-RECEPTOR BLOCKING AGENTS IN EXPERIMENTAL ANIMALS.
002442 03-04

MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-05

CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03-10

BETA-ADRENERGIC BLOCKING AGENTS IN THE TREATMENT OF PSYCHOSES. A REPORT ON 17 CASES.
002790 03-11

APPLICATION OF BETA-RECEPTOR BLOCKING AGENTS IN COMBINED THERAPY OF ENDOGENOUS PSYCHOSIS.
002972 03-17

NEUROPSYCHIATRIC EFFECTS OF ADRENERGIC BETA-RECEPTOR BLOCKING AGENTS.
002978 03-17

BLOCKS

HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03

HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION.
003364 04-04

BLOOD

EFFECTS OF HALOPERIDOL AND LITHIUM ON BLOOD ALCOHOL LEVEL IN RABBITS.
000141 01-03

DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE.
000513 01-07

BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS.
000568 01-08

BLOOD SERUM DENSITIES OF TRICYCLIC ANTIDEPRESSANTS -- VIEWS GAINED THROUGH THERAPEUTIC USE.
000581 01-09

PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09

BLOOD LEVELS AND ELECTROENCEPHALOGRAPHIC EFFECTS OF DIAZEPAM AND BROMAZEPAM.
000819 01-13

DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-15

THE EFFECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
000986 01-15

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
001188 02-03

EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-03

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03

BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-07

DETERMINATION OF MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHODOLOGICAL ASPECTS.
001896 02-13

BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13

CARBON-MONOXIDE BLOOD LEVELS AND REPORTED CESSATION OF SMOKING.
001933 02-13

HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13

INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
0019B2 02-14

EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS; COMPARISON WITH BLOOD LEVELS.
002041 02-15

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: BLOOD LEVELS AND CLINICAL RESPONSE.
002120 02-17

EFFECTS OF NEUROTROPIC SUBSTANCES ON SECRETION AND BLOOD SUPPLY OF THE PANCREAS.
002290 03-03

EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-03

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07

CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN.
002616 03-08

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-08

ACTIVITY OF PERIPHERAL BLOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA.
00261B 03-08

ANTIDEPRESSANT BLOOD LEVELS IN ACUTE OVERDOSE.
002906 03-15

ON CHANGING BLOOD DENSITIES OF ANTISEIZURE DRUGS TAKEN IN LARGE VOLUMES.
002950 03-15

AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
003241 04-03

THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 04-13

DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE TO TREATMENT.
003669 04-13

EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE OF (3H)5 HYDROXYTRYPTAMINE BY HUMAN BLOOD PLATELETS.
003715 04-13

ABSORPTION RATE, BLOOD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPOXIDE.
003731 04-14

BODILY
THE ROLE OF BODILY FEELINGS IN ANXIETY.
003040 03-17

BODY
ANALYSIS OF INHIBITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
000215 01-03

DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15

EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION.
001245 02-0

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-1

EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN.
002330 03-0

CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-0

DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE.
003245 04-0

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
00338B 04-

TOLERANCE TO THE EFFECTS OF DELTA9-THC ON SHUTTLE-BOX PERFORMANCE AND BODY TEMPERATURE
00339B 04-

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWT AND BODY COMPOSITION OF HYPERACTIVE CHILDREN
003633 04-

NEUROLEPTIC DRUG EFFECTS ON CHILDRENS BODY WEIGHT AND HEIGHT.
003645 04

BONDING
ENTHALPIES OF HYDROGEN BONDING IN PSYCHOTROPIC DRUGS.
000191 01

BORDERLINE
PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS OXIDE USED IN THE TREATMENT OF BORDERLINE PSYCHOTIC STATE
001836 02

BORN
WHAT HAPPENED LATER TO THE LITHIUM BABIES? A FOLLOW-UP STU OF CHILDREN BORN WITHOUT MALFORMATIONS.
002932 03

BOSTON
CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REP FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRA
000976 01

THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHT FROM A CONFERENCE IN BOSTON
003B73 04

BOUND
IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOU WITH THE PROTEIN CARRIER.
00162B 0

BOVINE
INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMI RELEASE FROM BOVINE GRANULOCYTES.
000124 0

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 0

THE EFFECT OF BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION O CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 0

THE SUBUNIT STRUCTURE OF BOVINE BRAIN PROTEIN-14-3-2.
003060 0

BOX
EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMI INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 0

BOYS
A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE
000912 0

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROO SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED A HYPERACTIVE BEFORE AND DURING MEDICATION. (ED.D. DISSERTATION).
002B60 0

BRADYCARDIA
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS O ATROPINE DURING UNDERWATER SWIMMING IN THE RAT
003324

BRADYCARDIC
INVOLVEMENT OF CENTRAL ALPHA ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL
00320B

BRADYKININ

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

INTERACTION OF BRADYKININ WITH DOPAMINERGIC RECEPTORS IN THE CNS.
002507 03-04

BRAIN

REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
00000B 01-01

AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03

F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03

CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE -- EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS.
000041 01-03

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03

INHIBITION OF RAT BRAIN MONOAMINE-OXIDASE BY FORMAMIDINES AND RELATED COMPOUNDS.
00004B 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS.
00007B 01-03

THE EFFECT OF METHYSERGIDE ON 5-HYDROXYTRYPTAMINE TURNOVER IN WHOLE BRAIN.
0000B2 01-03

THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
0000B5 01-03

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THF DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
0000B6 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03

SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03

NEUROPEPTIDES, BRAIN AND BEHAVIOR.
000112 01-03

OBSERVATIONS ON THE FATE OF CYSTATHIONINE IN RAT BRAIN.
000115 01-03

PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03

LITHIUM-CARBONATE DISTRIBUTION AND ITS EFFECTS ON THE OTHER IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 01-03

THE EFFECTS OF QUIPAZINE ON 5-HT METABOLISM IN THE RAT BRAIN
000120 01-03

PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
00013B 01-03

EFFECT OF THEOPHYLLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN.
000139 01-03

ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RFLEVANCE FOR PSYCHOMOTOR EFFECTS.
00014B 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03

A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

TRYPTOPHAN-HYDROXYLASE IN DISCRETE BRAIN NUCLEI: COMPARISON OF ACTIVITY IN VITRO AND IN VIVO.
00016B 01-03

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-03

TEMPORAL AND REGIONAL DIFFERENCES IN BRAIN CONCENTRATIONS OF LITHIUM IN RATS.
000179 01-03

EFFECT OF ORGANOPHOSPHORUS COMPOUNDS ON ACETYLCHOLINE SYNTHESIS IN BRAIN.
0001B0 01-03

THE EFFECTS OF VARIOUS AGENTS IN VITRO ON HOMOCARNOSINE CARNOSINE SYNTHETASE FROM RAT BRAIN.
0001B7 01-03

ANOMALOUS EFFECT OF PROBENECID ON RAT BRAIN PHENOLSULPHOTRANSFERASE.
000193 01-03

REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN.
000194 01-03

DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
00019B 01-03

EFFECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES.
000199 01-03

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

EFFECT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN BRAIN.
000210 01-03

EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN.
00021B 01-03

MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN.
000224 01-03

CHANGES IN BRAIN NOREPINEPHRINE ASSOCIATED WITH SENSITIZATION TO D-AMPHETAMINE.
000225 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

BRAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHIBITION
000252 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN.
000256 01-03

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN.
000263 01-03

EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN.
000266 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
0002B9 01-04

AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
000343 01-04

EFFECTS OF A NOVEL ANTIAGGRESSIVE AGENT UPON TWO TYPES OF BRAIN STIMULATED EMOTIONAL BEHAVIOR.
0D0357 01-04

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PRDTEIN SYNTHESIS IN VIVO.
00D359 D1-D4

PAPAVERINE, DRUG-INDUCED STEREOTYPY AND CATALEPSY AND BIDGENIC AMINES IN THE BRAIN OF THE RAT.
DD0362 01-D4

AMINO-ACID TRANSPORT INHIBITION· BRAIN AND BEHAVIORAL CDRRELATES.
D0D4D6 D1-D4

IS THE RELEASE OF NORADRENALINE NECESSARY FOR SELF-STIMULATION OF THE BRAIN?.
00D422 D1-D4

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
00D42B 01-04

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
D00444 01-04

ACTIVATION INDUCED RESTDRATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DDPAMINE DEPLETING BRAIN LESIONS.
DD0463 D1-05

EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
DD0465 01-D5

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
0DD473 01-D6

EFFECT OF AMPHETAMINE-TYPE PSYCHDSTIMULANTS ON BRAIN METABOLISM.
DD0B17 D1-13

REGIONAL SEROTONIN LEVELS IN BRAIN. A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
0D0BB3 D1-14

STUDY OF NOOANALEPTIC DRUG EFFECT ON BRAIN METABOLISM IN HUMANS.
00D914 D1-14

THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
DD1D78 D1-17

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMDNE.
D0112D D2-D3

PIPERIDINE: EFFECTS ON LOCOMOTDR ACTIVITY AND BRAIN MDNDAMINE TURNOVER.
DD1122 D2-D3

BIOSYNTHESIS OF RAT BRAIN PHDSPHATIDYLCHOLINES FRDM INTRACEREBRALLY INJECTED CHOLINE.
0D1127 D2-03

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPRDMAZINE AND IMIPRAMINE.
D01129 D2-D3

EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
DD1135 D2-D3

EFFECTS DF FENFLURAMINE ON ACCUMULATIDN OF 5-HYDRDXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES DF RAT BRAIN.
0D1137 D2-D3

THE EFFECT DF STERDID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
DD1140 D2-D3

RDLE DF BRAIN MONDAMINES IN THE ANTICDNVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
D01143 D2-D3

DECREASED GABA AND GLUTAMATE CONCENTRATIDN IN RAT BRAIN AFTER TREATMENT WITH 6-AMINDNICOTINAMIDE.
DD1144 D2-D3

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA-LIPDTRDPIN WITH BRAIN OPIATE RECEPTORS.
DD1147 D2-D3

BRAIN HOMOVANILLIC ACID: REGIONAL CHANGES OVER TIME WITH ANTIPSYCHOTIC DRUGS.
DD1152 D2-D3

EFFECTS OF TETRAHYDRO-BETA CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN.
D01156 D2-D3

DIHYDROERGOTAMINE BINDING TO RAT BRAIN MEMBRANES.
D01169 02-D3

EFFECT OF CARBAMAZEPINE ON CHOLINERGIC PARAMETERS IN RAT BRAIN AREAS.
0D1170 02-0

DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DDPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
DD1175 02-0

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-0

TRYPTOPHAN TRANSPORT IN BRAIN SYNAPTOSOMES: EFFECTS OF L-DOPA.
001185 D2-0

UPTAKE OF 5-HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION.
D011B7 D2-0

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
DD1196 D2-0

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN
DD1197 D2-

PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN.
DD120D D2-

5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOM MEMBRANES.
DD12D1 D2-

MDDIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NDRADRENALINE METABDLISM IN DISCRETE AREAS O RAT BRAIN.
DD12D3 D2-

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
DD12D4 D2

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
0D12D9 D2

EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTI WITH P-CPA DN RAT BRAIN 5-HT
001211 D2

INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYP MONDAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
DD1213 D2

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AN ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
DD1215 02

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS THE GAMMA-BUTYROLACTONE-INDUCED INCREASE IN MOUSE BRA DOPAMINE.
001220 D2

IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MA ACTIVITY IN RAT BRAIN.
0D1221 D2

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DO TO DOPAMINE IN THE BRAIN.
DD1224 D

ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
DD1227 0

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
DD1237 D

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONA BARBITURATE TOLERANCE.
DD123B D

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLAT DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN
DD1242 0

CHANGES IN CATECHOLAMINE CDNCENTRATIONS AND SYNTHESIS RA IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
DD1246 0

ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY.
DD126D 0

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 0

EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03

BRAIN AND RETINAL DAMAGE FROM LATHYRUS-EXCITOTOXIN, BETA-N-OXALYL-L-DIAMINOPROPIONIC-ACID.
001316 02-03

A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03

RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03

EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
001329 02-03

REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03

THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-03

OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE BRAIN OF THE LOCUST, SCHISTOCERCA-GREGARIA.
001343 02-03

LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART.
001345 02-03

CHLORPROMAZINE AND AGING IN THE BRAIN.
001353 02-03

EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
00135B 02-03

IS FEMININE DIFFERENTIATION OF THE BRAIN HORMONALLY DETERMINED?.
00136B 02-03

INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE BRAIN.
001369 02-03

EFFECT OF LITHIUM ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM IN MICE.
001370 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03

EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES.
0013B7 02-03

EFFECT OF TRAZODONE ON BRAIN DOPAMINE METABOLISM.
0013BB 02-03

ALCOHOL MEMBRANE INTERACTION IN THE BRAIN: NOREPINEPHRINE RELEASE.
001394 02-03

TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION.
001395 02-03

EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03

THE EFFECT OF L-DOPA AND AN INHIBITOR OF PERIPHERAL DECARBOXYLATION ON GLUCOSE METABOLISM IN BRAIN.
001405 02-03

REGIONAL AND SUBCELLULAR DISTRIBUTIONS OF BRAIN NEUROTENSIN.
001406 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03

COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN.
001419 02-03

REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03

EFFECTS OF AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM FROM RAT BRAIN
001421 02-03

THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

EFFECT OF PROPRANOLOL ON RAT BRAIN NOREPINEPHRINE IN VITRO.
001427 02-03

REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03

OPIOID PEPTIDES (ENDORPHINS) IN PITUITARY AND BRAIN.
001496 02-04

ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN.
001512 02-04

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 02-04

EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04

EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04

EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-04

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04

DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
0015B5 02-04

BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04

EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMAL NA-K-ATPASE ACTIVITY.
001630 02-05

THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN.
001631 02-05

UPTAKE AND METABOLISM OF 3-METHOXYTYRAMINE IN THE CAT BRAIN.
00163B 02-05

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
001641 02-05

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN.
001650 02-06

SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-0B

PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT.
001776 02-09

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

THE IDENTIFICATION AND TREATMENT OF ADULT BRAIN DYSFUNCTION.
002143 D2-17

MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN.
0021B5 03-01

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN
002202 03-03

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
00220B 03-03

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-03

L-DOPA: PLASMA PHARMACOKINETICS AND CONVERSION TO DOPAMINE IN BRAIN. (PH.D. DISSERTATION).
002233 03-03

REGIONAL DISTRIBUTION OF ETHANOL IN RAT BRAIN.
0D2236 03-03

DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS.
002242 03-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03

THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS.
002250 03-03

ROLE OF BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR.
D02252 03-D3

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
0D2253 03-D3

PHARMACOLOGICAL STUDIES ON DEVELOPMENT OF RESPONSE TO CATECHOLAMINE IN BRAIN.
D02263 03-D3

UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
D0226B D3-D3

THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN.
0D2271 D3-03

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
D02277 03-D3

EFFECT OF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
0D22B4 D3-03

ANTIPSYCHOTICS AND GABA TURNOVER IN MAMMALIAN BRAIN NUCLEI. (UNPUBLISHED PAPER).
DD2301 03-03

THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN.
D02303 03-D3

METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
0D2304 D3-03

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN
DD2306 D3-03

BIOCHEMICAL EFFECTS OF ERGOT ALKALOIDS WITH SPECIAL REFERENCE TO THE BRAIN
D023DB D3-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-03

NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
002318 03-03

MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN
002319 03-03

INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN
002320 03-03

OXIDATIVE PHOSPHORYLATION IN VARIOUS PARTS OF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION.
002321 03-03

HOW TRANQUILIZERS ACT ON THE BRAIN.
D02322 03-03

EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN.
002330 03-03

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO.
002339 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
D02345 03-03

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
00235B D3-D3

EFFECTS OF BENZODIAZEPINES ON BRAIN MONOAMINES.
D02365 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION
002370 03-03

EFFECTS OF PSYCHOACTIVE AGENTS ON THE BRAIN.
0D2371 03-03

STUDIES ON THE EFFECT OF 5,5 DIPHENYLHYDANTOIN ON IN VITRO PROTEIN SYNTHESIS IN RAT BRAIN.
D02375 D3-03

CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03

GLUCOCORTICOID REGULATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN.
DD2379 03-03

DIFFERENTIAL EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON INDOLEAMINES IN BRAIN.
DD23B0 D3-D3

COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON BRAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
D023B2 D3-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
D023B5 D3-03

EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS IN THE CAT BRAIN
DD23B6 03-03

EFFECTS OF BENZODIAZEPINES AND PENTOBARBITAL ON THE EVOKED POTENTIALS IN THE CAT BRAIN.
0D23B7 D3-D

BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI.
002394 D3-0

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
0D239B D3-0

SOLUBILIZATION OF BRAIN MITOCHONDRIAL HEXOKINASE IN ANESTHESIA.
0024D2 D3-D

THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE. (PH.D. DISSERTATION).
0D2405 D3-D

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
00240B 03-03

BRAIN DOPAMINE, D-AMPHETAMINE AND THERMOREGULATION IN RATS.
002409 03-03

HYPERTENSION AND CATECHOLAMINE DISTRIBUTION IN DIFFERENT PARTS OF THE RAT BRAIN
002413 03-03

EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
00243B 03-04

DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN.
002459 03-04

EFFECT OF BETA-PHENYLETHYLAMINE AND D-AMPHETAMINE ON ELECTRICAL SELF-STIMULATION OF BRAIN.
00246B 03-04

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05

THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLEI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
0025B4 03-06

SINGLE-AGENT CHEMOTHERAPY OF BRAIN TUMORS: A FIVE-YEAR REVIEW.
002792 03-11

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
002B1B 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13

PREPARATION AND PROPERTIES OF THE BRAIN SPECIFIC PROTEIN-14-3-2
003052 04-01

THE SUBUNIT STRUCTURE OF BOVINE BRAIN PROTEIN-14-3-2.
003060 04-01

THE INHIBITION OF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
003074 04-02

BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003076 04-02

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
0030BB 04-03

EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN.
003094 04-03

A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID.
003107 04-03

BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE
003109 04-03

SOLUBILISATION OF ATROPINE-BINDING MATERIAL FROM BRAIN.
003110 04-03

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-03

THE EXCLUSION OF L-ISOLEUCINE OR OF L LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME
003120 04-03

REGIONAL TRANSPORT OF TRYPTOPHAN IN RAT BRAIN
003125 04-03

EFFECT OF MORPHINE ON MOUSE BRAIN ATPASE ACTIVITIES.
003126 04-03

FENFLURAMINE LONG-TERM ADMINISTRATION AND BRAIN SEROTONIN.
003130 04-03

THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN.
003132 04-03

STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINDING IN RAT BRAIN.
003134 04-03

EFFECTS OF GAMMA-AMINOBUTYRIC-ACID ON 33PI INCORPORATION INTO RAT BRAIN PHOSPHOLIPIDS IN VIVO.
003144 04-03

IN VITRO AND IN VIVO STUDIES OF EXTRAPINEAL N-ACETYLTRANSFERASE OF RAT BRAIN.
003145 04-03

ANTIDEPRESSANT DRUGS AND DOPAMINE UPTAKE IN DIFFERENT BRAIN REGIONS.
003146 04-03

WHEN DOES INHIBITION OF BRAIN ACETYLCHOLINESTERASE CAUSE AMNESIA IN RATS?
003152 04-03

KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-ACID TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT BRAIN.
003154 04-03

IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES.
00315B 04-03

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTAB-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE.
00316B 04-03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT BRAIN.
003174 04-03

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RAT BRAIN 5-HT TURNOVER.
003179 04-03

ANTIANXIETY RECEPTORS IN THE BRAIN?.
003180 04-03

THE EFFECT OF APOMORPHINE AND HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
0031B1 04-03

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
0031BB 04-03

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
003193 04-03

PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-03

MUTUAL EFFECTS OF MORPHINE AND ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
00319B 04-03

EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN
003204 04-03

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM.
003206 04-03

REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN
003207 04-03

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-03

TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
003219 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04-03

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA-AMINOLAEVULINIC-ACID IN RATS.
003237 04-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
003251 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-03

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN
003255 04-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE ISOLATED PERFUSED RAT BRAIN.
003274 04-03

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN.
003276 04-03

STUDIES ON THE DEPLETION OF BRAIN AMINES BY M-TYROSINE.
0032B0 04-03

BENZODIAZEPINE RECEPTORS IN RAT BRAIN.
0032B7 04-03

REGIONAL ACETYLCHOLINE CONTENT IN MOUSE BRAIN AFTER MORPHINE TABLET IMPLANTATION
0032B9 04-03

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION.
003293 04-03

METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN.
003294 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN.
003299 04-03

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
003303 04-03

STUDIES ON MEMBRANE RECEPTOR SITES FOR SEROTONIN IN THE BRAIN.
00330B 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 04-03

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5 MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-0

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
00332B 04-0

INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
00333B 04-0

THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF-STIMULATION OF THE BRAIN DURING HYPOXIA.
003342 04-0

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-0

EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-0

DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-0

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAI CATECHOLAMINE METABOLISM TO DELTAB-TETRAHYDROCANNABINO
003423 04-0

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTIO IN MICE.
003427 04-0

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-0

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE I REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-

ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN
003493 04-

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: CLINICAL STUDIES.
003716 04

BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04

BRAIN-DAMAGE

EFFECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE.
0034B3 04

PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04

BRAIN-DAMAGED

PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRA DAMAGED RATS.
000220 01

BRAINS

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03

ENDORPHINS IN BRAINS OF DECAPITATED AND MICROWAVE-KILLED MICE.
003050 04

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERA RATS.
003211 04

EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE
003B74 04

BRAINSTEM

OBSERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT BRAINSTEM.
000059 0

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
000155 0

EFFECTS OF HALOTHANE ON CATECHOLAMINE METABOLISM IN THE BRAINSTEM OF RATS.
000221 01-03

EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION
001245 02-03

ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND BRAINSTEM NEURONES.
002229 03-03

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

BRALLOBARBITAL

PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION.
000466 01-05

BREAKDOWN

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN
001197 02-03

BREAST

PASSAGE OF DIAZEPAM AND DESMETHYLDIAZEPAM INTO BREAST MILK.
000932 01-15

RAUWOLFIA DERIVATIVES AND BREAST CANCER.
002050 02-15

BREAST-FEEDING

LITHIUM-CARBONATE AND BREAST-FEEDING.
001947 02-13

BREATHING

THE EFFECTS OF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05

BRED

DIFFERENTIAL EFFECTS OF MORPHINE ON TWO-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
001575 02-04

BREEDS

HYPERACTIVITY IN TWO DOG BREEDS AND THEIR HYBRIDS.
003421 04-04

BRIETAL

COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11

BRIGHTNESS

DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVE BRIGHTNESS DISCRIMINATION LEARNING IN RATS.
000351 01-04

EFFECTS OF P-CHLOROPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04

BROMAZEPAM

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-10

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

BROMAZEPAM IN PSYCHOSOMATIC MEDICINE.
000771 01-11

BLOOD LEVELS AND ELECTROENCEPHALOGRAPHIC EFFECTS OF DIAZEPAM AND BROMAZEPAM.
000B19 01-13

FURTHER HEMODYNAMIC INVESTIGATIONS OF THE ANTIHYPERTENSIVE EFFECT OF LEXOTAN (BROMAZEPAM).
000B56 01-13

THE PHARMACOKINETICS OF BROMAZEPAM IN MAN.
000B57 01-13

A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01

CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10

ROMIDE

CHRONIC BROMIDE INTOXICATION WITH A SEVERE NEUROLOGICAL DEFICIT.
002052 02-15

OMISM

THE CONTEMPORARY DIAGNOSIS OF BROMISM.
0020B3 02-15

BROMOCRIPTINE

EFFECTS OF BROMOCRIPTINE ON CENTRAL DOPAMINERGIC RECEPTORS.
000242 01-03

BROMOCRIPTINE IN HUNTINGTON CHOREA.
000500 01-07

STUDIES WITH BROMOCRIPTINE: PART 2. DOUBLE-BLIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07

TREATMENT OF MANIA WITH BROMOCRIPTINE.
000594 01-09

THE MANY FACES OF BROMOCRIPTINE.
0007B5 01-11

BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION.
001190 02-03

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
0015B5 02-04

CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR.
001671 02-07

PSYCHOSIS IN PATIENT ON BROMOCRIPTINE AND LEVODOPA WITH CARBIDOPA.
002054 02-15

NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02

STUDIES WITH BROMOCRIPTINE: PART 1. ON-OFF PHENOMENA.
002600 03-07

GASTROINTESTINAL BLEEDING IN PATIENTS ON BROMOCRIPTINE.
002943 03-15

EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE.
003314 04-03

SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY.
003635 04-11

BROMOERGOCRYPTINE

PRELIMINARY STUDY OF THE TREATMENT OF ENDOGENOUS DEPRESSION WITH BROMOERGOCRYPTINE.
002694 03-09

BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE

SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE.
00124B 02-03

BROMPERIDOL

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
00111B 02-02

BROMPTON

THE BROMPTON MIXTURE: EFFECTS ON PAIN IN CANCER PATIENTS.
000B45 01-13

USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000B47 01-13

BRONCHIAL

SOME PROBLEMS OF THE TREATMENT OF BRONCHIAL ASTHMA.
0027B1 03-11

BRONOPOL

THE PAIN AGGRESSION INDUCED BY BRONOPOL IN THE RAT.
000394 01-04

BROTHER

BIG BROTHER KNOWS BEST.
001B23 02-11

BROWN

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE.
001202 02-03

BUFOXINE

DOUBLE-BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI-6B20 BUFOXINE.
001B11 02-10

BULB

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS.
0014B9 02-04

PHARMACOLOGICAL STUDY OF EVOKED POTENTIALS IN THE OLFACTORY BULB.
002361 03-03

BULBAR

PHENOTHIAZINE-INDUCED BULBAR PALSY-LIKE SYNDROME AND SUDDEN DEATH.
003B2B 04-15

BULBECTOMY
BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBFCTOMY IN RATS: A POSSIBLE MODEL FOR THE DETFCTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

BULBOSPINAL
SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
0023S4 03-03

BULLFROG
A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RFLATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
002296 03-03

BUNDLE
DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLF: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-03
LORDOSIS IN FEMALE RATS FOLLOWING MFDIAL FORFBRAIN BUNDLE LFSIONS.
002S02 03-04

BUNDLES
THE EFFECTS OF DFSTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 04-03

BUNITROLOL
EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000B33 01 13

BUTACLAMOL
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NFW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
00133S 02-03
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-03
EFFECT OF FLUPFNTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SFCRETION IN RATS.
003220 04-03

BUTANEDIOL
SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS.
0012B7 02-03

BUTORPHANOL
INTRAMUSCULAR BUTORPHANOL AND MEPERIDINE IN POSTOPERATIVE PAIN.
001662 02-07

BUTRIPTYLINE
TREATMENT OF DEPRESSION WITH BUTRIPTYLINE.
001743 02-09

BUTYROLACTONE
TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

BUTYROPHENONE
BROMPFRIDOL, A NEW POTFNT NEUROLEPTIC OF THE BUTYROPHFNONF SERIES: A COMPARISON OF THF EFFECTS OF BROMPFRIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
00111B 02-02

BUTYROPHENONES
POTFNTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHFNONFS WITH AN IMIDAZOLIDINE CYCLF.
000004 01-01
BUTYROPHENONES FROM THF ISOMERIC 2-AMINO-S-PHFNYLBICYCLONONANFS.
00306B 04-02
POTENTIAL PSYCHOTROPICS. XII. SYNTHFSIS AND STRUCTURF OF NFW BUTYROPHENONFS WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLFPTIC ACTIVITY.
003B4B 04-17

BUZZER
A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THF SHUTTLE-SHOCK CONTINGFNCY AS FACTORS IN THE ELICITATION OF SHUTTLE RFSPONSES TO A BUZZER IN RATS.
002477 03-04

BUZZER-SHOCK
A PHARMACOLOGICAL SFPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RFSPONSES TO A BUZZFR IN RATS.
002477 03-04

C-AMP
DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-0
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASF IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN
0023BS 03-0
CHANGES OF THF FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-0

C-FIBER
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-0

C-FRAGMENT
INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
001147 02-
THE C-FRAGMENT OF BETA-LIPOTROPIN: AN ENDOGENOUS NEUROLEPTI OR ANTIPSYCHOTOGEN?
002267 03-

C-GMP
GABA RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CEREBELLA C-GMP ELICITED BY DIAZEPAM. (UNPUBLISHED PAPER).
0000S1 01-
CLIMBING FIBER ACTIVATION AND 3,S CYCLIC GUANOSINE MONOPHOSPHATF (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI CEREBELLUM.
00114S 02-
DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C GMP ELICITED BY HALOPERIDOL AND DIAZEPAM.
002211 03-
ACTION OF DIAZFPAM, HALOPERIDOL, MORPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
0022S6 03-
CEREBELLAR C-GMP LEVFLS RFDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
0024B1 03

CA + +
HYPOTHALAMIC NA + AND CA + + IONS AND TEMPERATURE SET-POINT. NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHER THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
0001B1 01

CA-ATPASE
EFFFCT OF LITHIUM ON CA-ATPASE.
001737 02

CADMIUM
CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
00350S 04

CAFFEINE
ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RFSPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
0002S1 01
EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATIO AND LEARNED BEHAVIOR IN MICE.
000296 01
METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT: NE MFTABOLIC PATHWAY OF CAFFEINF.
00112B 02
SFLF-ADMINISTRATION OF CAFFFINF BY THE RAT.
001436 02
EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE RFACTIONS TO NOVELTY AND ACTIVITY IN RATS.
001S1S 02
EFG SPECTRAL ANALYSIS OF THE EFFECTS OF CAFFEINE.
001925 02
DOSE-RELATED SLEFP DISTURBANCES INDUCED BY COFFEE AND CAFFEINE.
001973 02
CAFFEINE IN THE PREVENTION OF APNEA OF PREMATURITY.
002B16 03
EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS SIMULTANFOUS VISUAL DISCRIMINATION IN THREE INBRED STRAIN OF MICE.
003362 04

CAFFEINE-INDUCED
MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENFRGIC BLOCKING AGENTS
002S64 0

CALCIUM
CALCIUM DEPLETION OF SYNAPTOSOMES AFTER MORPHINE TREATME
000070 0

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

CALCIUM UPTAKE INTO RAT PHEOCHROMOCYTOMA CELLS.
001165 02-03

EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
001748 02-09

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13

LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS.
002309 03-03

LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS.
002338 03-03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

BARBITURATES AND SERUM CALCIUM IN THE ELDERLY.
003837 04-15

CALCULATION

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01

CALMATIVE

ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

CALORICALLY

THE EFFECT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUCED OCULOGYRAL ILLUSION.
003757 04-14

CANCER

THE BROMPTON MIXTURE: EFFECTS ON PAIN IN CANCER PATIENTS.
000B45 01-13

PSYCHOLOGIC EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL IN ADVANCED CANCER PATIENTS.
001872 02-12

RAUWOLFIA DERIVATIVES AND BREAST CANCER.
002050 D2-15

CANNABIDIOL

INFLUENCE OF CANNABIDIOL ON SECOBARBITAL EFFECTS AND PLASMA KINETICS.
001902 02-13

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
003285 04-D3

INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03

DELTA1-TETRAHYDROCANNABINOL, CANNABIDIOL AND CANNABINOL EFFECTS ON THE IMMUNE RESPONSE OF MICE.
DD3339 D4-D3

CANNABINOID

A NOVEL CANNABINOID CONTAINING A 1,8 CINEOL MOIETY.
003061 D4-D1

9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
0D3099 D4-03

A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS.
003426 04-D4

CANNABINOID-INDUCED

CANNABINOID-INDUCED BEHAVIORAL CONVULSIONS IN RABBITS.
D01649 02-06

CANNABINOIDS

COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS
DD0426 D1-D4

EFFECTS OF CANNABINOIDS ON THE PERFUSED RAT HEART.
D01379 D2-D3

EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE.
D01445 02-04

CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
D03056 04-01

CANNABINOIDS. 1. 1-AMINO- AND 1-MERCAPTO 7,8,9,10-TETRAHYDRO 6H DIBENZOPYRANS.
003069 04-02

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

CANNABINOL

COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
003285 04-03

DELTA1-TETRAHYDROCANNABINOL, CANNABIDIOL AND CANNABINOL EFFECTS ON THE IMMUNE RESPONSE OF MICE.
003339 04-03

CANNABINOLS

CANNABINOLS AND THE ROSETTE FORMING PROPERTIES OF LYMPHOCYTES IN VITRO.
001901 02-13

CANNABIS

ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
00022B 01-03

RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04

SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATION UPON RAT OFFSPRING.
001622 02-05

HUMAN EEG SPECTRA BEFORE AND DURING CANNABIS HALLUCINATIONS.
001924 02-13

CANNABIS PSYCHOSIS.
002920 03-15

CANNABIS AND HEALTH.
002992 03-17

CANNABIS-INDUCED

TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001B69 02-12

CAPACITY

THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN.
000BB7 01-14

PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03

EFFICACY OF PIRACETAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
00296B 03-17

CAPILLARY

THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 D4-13

CAPROLACTAM

ANTAGONISM OF GABA-MEDIATED INHIBITION IN THE CENTRAL-NERVOUS-SYSTEM BY CAPROLACTAM DERIVATIVES.
DDD140 01-03

CAPSULE

THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
DD1647 D2-06

CAPSULES

HERBAL INTOXICATION: PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
D0D9B4 D1-15

CAPTURE

DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
DD2955 D3-16

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
D03713 04-13

CARASSIUS-AURATUS

MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
D01611 02-D4

CARBACHOL

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
DD34D4 D4-D4

CARBAMATE
BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04

CARBAMAZEPINE
THE THERAPEUTIC AND PREVENTATIVE EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON DEPRESSION
000696 01-10
SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11
PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
0007BB 01-11
EFFECT OF CARBAMAZEPINE ON CHOLINERGIC PARAMETERS IN RAT BRAIN AREAS.
001170 02-03
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-03
TWO CASES OF MDI DEPRESSION WHERE CARBAMAZEPINE WAS ESPECIALLY EFFECTIVE.
001742 02-09
AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
001B1B 02-11
A COMPARATIVE CONTROLLED STUDY BETWEEN CARBAMAZEPINE AND DIPHENYLHYDANTOIN IN PSYCHOMOTOR EPILEPSY.
001B61 02-11
CENTRAL NERVOUS ACTIONS OF CARBAMAZEPINE.
002410 03-03
A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS.
002776 03-11
THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
003209 04-03
A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05
CARBAMAZEPINE IN THE DYSCONTROL SYNDROME ASSOCIATED WITH LIMBIC SYSTEM DYSFUNCTION.
003646 04-11
CARBAMAZEPINE AS AN ANTICONVULSANT IN CHILDREN.
003747 04-14

CARBAMOYL
SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5-ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02

CARBIDOPA
EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEY
000064 01-03
PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
000962 01-15
PSYCHOSIS IN PATIENT ON BROMOCRIPTINE AND LEVODOPA WITH CARBIDOPA.
002054 02-15
COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM.
002B15 03-13
SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
003330 04-03

CARBON-DISULFIDE
DISULFIRAM TOXICITY AND CARBON-DISULFIDE POISONING.
003B19 04-15

CARBON-MONOXIDE
CARBON-MONOXIDE BLOOD LEVELS AND REPORTED CESSATION OF SMOKING.
001933 02-13
EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-04

CARBONATE
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03
EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
0015B2 02-04
LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001B13 02-11
AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO.
001B42 02-11
EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
002415 03-04

CARBONIC-ANHYDRASE
EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07
THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF-STIMULATION OF THE BRAIN DURING HYPOXIA.
003342 04-04

CARBOXYBUTYLETHYLBARBITURIC-ACID
A NEW METABOLITE OF AMYLOBARBITONE: CARBOXYBUTYLETHYLBARBITURIC-ACID.
003090 04-03

CARBOXYDIHYDROXYPROHEPTADINE
APPETITE STIMULANT ACTIVITY OF CARBOXYDIHYDROXYPROHEPTADINE.
001459 02-04

CARBOXYHEMOGLOBIN
AVERSIVE SMOKING: CARBOXYHEMOGLOBIN LEVELS BEFORE AND AFTER RAPID SMOKING.
001903 02-13

CARBROMAL
ON THE TOXICOLOGY OF CARBROMAL.
002B43 03-13

CARCINOID
EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15

CARDERS
RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
000341 01-04

CARDIAC
SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS.
000377 01-04
CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10
PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION: EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000B52 01-13
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14
EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA-BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE
001673 02-07
EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE.
00200B 02-15
CARDIAC EFFECTS OF DIFFERENT TRICYCLIC ANTIDEPRESSANT DRUGS.
002023 02-15
CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE.
00207B 02-15
HYPOTHYROIDISM WITH EPISODIC PSYCHIATRIC AND CARDIAC MANIFESTATIONS.
002127 02-17
TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES IN VENTRICULAR AUTOMATICITY.
002562 03-05
EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03
THE EFFECT OF THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC-AMP AND CARDIAC CONTRACTILE FORCE.
003213 04-03
EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03
TREATING DEPRESSED CARDIAC PATIENTS.
003601 04-10
IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-13

CARDIAC SIDE EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
003830 04-15
MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION
003856 04-17

CARDIOPULMONARY
THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09

CARDIORESPIRATORY
COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03

CARDIOTONIC
MECHANISM OF NEUROTOXICITY OF CARDIOTONIC GLYCOSIDES.
003149 04-03

CARDIOTOXICITY
TRICYCLIC ANTIDEPRESSANT CARDIOTOXICITY.
002073 02-15

CARDIOVASCULAR
INTRAHYPOTHALAMIC SEROTONIN AND CARDIOVASCULAR CONTROL IN RATS.
000230 01-03
CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COCAINE ADMINISTRATION IN HUMANS.
000890 01-14
PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14
CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-03
EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04
CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE IN EXPERIMENTS WITH NONANESTHETIZED ANIMALS.
001636 02-05
CARDIOVASCULAR RESPONSES OF HYPERACTIVE CHILDREN TO METHYLPHENIDATE.
001814 02-11
CARDIOVASCULAR EFFECTS OF NEUROLEPTIC AND ANTIDEPRESSANT DRUGS. PRELIMINARY REPORT.
002062 02-15
DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03
THE CARDIOVASCULAR EFFECTS OF LITHIUM IN MAN: A REVIEW OF THE LITERATURE.
002840 03-13
AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
0031B2 04-03
EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14

CARE
CARE OF SCHIZOPHRENIC PATIENTS OUTSIDE THE HOSPITAL: RESEARCH RESULTS AND BASIC PRINCIPLES.
002631 03-08
GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11
LORAZEPAM IS A SATISFACTORY PREANESTHETIC SEDATIVE IF USED WITH CARE.
002743 03-11

CARNEGIEA-GIGANTEA
ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
0010B2 02-01

CARNOSINE
THE EFFECTS OF VARIOUS AGENTS IN VITRO ON HOMOCARNOSINE CARNOSINE SYNTHETASE FROM RAT BRAIN.
0001B7 01-03

CAROTID
ANALYSIS OF INHIBITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
000215 01-03

CAROXAZONE
CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZONE (FI-6654).
002683 03-09

CARPIPRAMINE
CLINICAL SPECTRUM OF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE
000532 01-08
A DOUBLE-BLIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-08
ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03
DOUBLE-BLIND CLINICAL STUDY OF CARPIPRAMINE/PLACEBO.
001688 02-08
ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN
001723 02-08

CARRIER
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000849 01-13
IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER.
001628 02-05

CARVISKEN
CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

CASTRATED
THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03
EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-04

CASTRATION
CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
000385 01-04

CAT
MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
000108 01-03
PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
000788 01-11
INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED BY THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
001235 02-03
DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION- RCPV) IN THE CAT.
001291 02-03
LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03
REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03
EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03
A STUDY ON PSYCHOMOTOR EPILEPSY WITH KINDLED CAT PREPARATIONS.
001356 02-03
THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03
THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04
LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
001508 02-04

EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04

UPTAKE AND METABOLISM OF 3-METHOXYTYRAMINE IN THE CAT BRAIN.
00163B 02-05

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF OROPERIOOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03

EFFECTS OF BENZOOIAZEPINES ON EVOKEO POTENTIALS INOUCEO IN THE LIMBIC SYSTEM ANO HYPOTHALAMUS IN THE CAT BRAIN.
0023B6 03-03

EFFECTS OF BENZOOIAZEPINES AND PENTOBARBITAL ON THE EVOKEO POTENTIALS IN THE CAT BRAIN.
0023B7 03-03

EFFECTS OF NICOTINIC AND MUSCARINIC COMPOUNOS ON BITING ATTACK IN THE CAT.
002424 03-04

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) ANO ANTIOEPRESSANT AGENTS ON BRAINSTEM ANO HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
002485 03-04

WITHORAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBITAL OOSING IN CAT.
002516 03-04

AMINE REPLETION IN THE RESERPINIZEO CAT: EFFECT UPON PGO WAVES ANO REM SLEEP.
003106 04-03

MORPHINE, NALOXONE ANO THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-03

EFFECTS OF LSO ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03

PHARMACOKINETICS OF PENTOBARBITAL IN THE CAT ANO COMPARISONS WITH THE RABBIT ANO MAN.
003317 04-03

OEPRESSION BY MORPHINE OF THE RESTING ANO EVOKEO RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUOATE NUCLEUS IN VIVO.
003331 04-03

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES ANO THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

THE ACTION OF LITHIUM-CARBONATE ON THE SLEEPWALKING CYCLE IN THE CAT.
003419 04-04

CATABOLISM

CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE.
001711 02-0B

CATALEPSY

PAPAVERINE, ORUG-INOUCED STEREOTYPY ANO CATALEPSY ANO BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04

CORRELATION BETWEEN CATALEPSY AND OOPAMINE OECREASE IN THE RAT STRIATUM INOUCEO BY NEUROLEPTICS.
001241 02-03

EFFECTS OF AMINOOXYACETIC-ACIO ANO BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACIO INCREASE AND ANTINOCICEPTION CAUSEO BY METHADONE IN RATS.
001257 02-03

CATALEPSY INOUCED BY MORPHINE OR HALOPERIOOL: EFFECTS OF APOMORPHINE AND ANTICHOLINERGIC ORUGS.
0014B1 02-04

INTERACTION OF DRUG EFFECTS WITH TESTING PROCEOURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04

EFFECT OF CHOLINERGIC DRUGS ON METHADONE-INOUCEO CATALEPSY AND STEREOTYPIES IN RATS TREATEO CHRONICALLY WITH METHAOONE.
002199 03-03

EFFECTS OF AMINOOXYACETIC-ACID ANO BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC ANO STRIATAL OOPAMINE TURNOVER INDUCEO BY HALOPERIOOL IN RATS.
002270 03-03

NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCEO CATALEPSY.
002395 03-03

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCEO CATALEPSY, ANTINOCICEPTION ANO CHANGES IN BRAIN OOPAMINE METABOLISM.
0031B8 04-03

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
003189 04-03

OOPAMINERGIC FUNCTION IN TWO PATIENTS WITH CATALEPSY.
003529 04-08

CATALEPTIC

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN OOPAMINE FUNCTION IN MICE.
003427 04-04

CATALEPTOGENIC

REGULATION OF CHOLINERGIC NEURONS BY OOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHEO PAPER).
002226 03-03

CATALYTIC

EVIDENCE FOR A SINGLE CATALYTIC BINOING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIOASE.
001937 02-13

CATAMNESTIC

CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUOY.
001B79 02-13

CATAPLEXY

EFFECTS OF IMIPRAMINE, CHLORIMIPRAMINE, AND FLUOXETINE ON CATAPLEXY IN OOGS.
002421 03-04

PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNOROME ANO HYPERSOMNIA.
00374B 04-14

CATATONIA

LITHIUM TREATMENT OF A PATIENT WITH PERIOOIC CATATONIA.
001712 02-08

PHENOTHIAZINE REACTION SIMULATING ACUTE CATATONIA.
002072 02-15

CATATONIA-LIKE

CATATONIA-LIKE SYMPTOMATOLOGY ANO WITHORAWAL OYSKINESIAS.
002043 02-15

CATATONIAS

ACUTE CATATONIAS WITH FAVORABLE OUTCOME: A REPORT OF TWO CASES.
002652 03-0B

CATCHING

PSYCHOPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

CATECHOL

SYNTHESIS ANO CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIOE (OORIDEN) IN HUMAN URINE
000799 01-13

CATECHOL-O-METHYLTRANSFERASE

REO-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE ANO RESPONSE TO IMIPRAMINE IN UNIPOLAR OEPRESSIVE WOMEN
000592 01-09

OETERMINATION OF MONOAMINE-OXIOASE ANO CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHOOOLOGICAL ASPECTS.
001B96 02-13

CATECHOLAMINE

CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE ANO TYROSINE -- EFFECTS OF PSYCHOTROPIC ORUGS AND OTHER AGENTS.
000041 01-03

EFFECTS OF CATECHOLAMINE DEPLETING ORUGS AND O-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS ANO REGION OF THE LOCUS-COERULEUS.
000061 01-03

SELECTIVE OEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03

PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE OEPLETION: COMPARATIVE STUOIES OF METABOLIC, ENOOCRINE ANO AFFECTIVE CHANGES.
000197 01-03

EFFECTS OF HALOTHANE ON CATECHOLAMINE METABOLISM IN THE BRAINSTEM OF RATS.
000221 01-03

CATECHOLAMINES ANO OEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE OISOROERS.
000630 01-09

VITAMINS, NEUROLEPTICS, ANO ANTIPARKINSONIAN ORUGS IN CATECHOLAMINE EXCRETION.
000B72 01-13

CENTRAL CATECHOLAMINE NEUROTRANSMITTERS ANO PSYCHOACTIVE ORUGS (UNPUBLISHED PAPER).
001014 01-17

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM
001188 02-03

INHIBITION OF CATECHOLAMINE BIOSYNTHESIS AND MEMORY PROCESSES.
001214 02-03

EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART RATE IN THE RAT
001223 02-03

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES
001377 02-03

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
001585 02-04

THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN
001631 02-05

CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14

CATECHOLAMINE ACTIVITY AND REPORTED MORBIDITY.
002123 02-17

DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03

PHARMACOLOGICAL STUDIES ON DEVELOPMENT OF RESPONSE TO CATECHOLAMINE IN BRAIN.
002263 03-03

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
002280 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03-03

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
002348 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03-03

HYPERTENSION AND CATECHOLAMINE DISTRIBUTION IN DIFFERENT PARTS OF THE RAT BRAIN.
002413 03-03

CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
002446 03-04

AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION: BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN
003276 04-03

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
003283 04-03

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTA8-TETRAHYDROCANNABINOL
003423 04-04

ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

CATECHOLAMINE-INDUCED

PERIPHERAL EFFECTS OF THE AMPHETAMINE TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT
001192 02-03

CATECHOLAMINE-STIMULATED

INDEPENDENT VARIATION OF BETA ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES
000071 01-03

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
001237 02-03

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION (UNPUBLISHED PAPER).
001313 02-03

CATECHOLAMINERGIC

INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANEOUS ALTERNATION TASK.
000361 01-04

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03

EFFECT OF CATECHOLAMINERGIC DRUGS ON EPILEPTOGENIC PROPERTIES OF THE CAUDATE NUCLEUS.
002206 03-03

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03

EFFECT OF CATECHOLAMINERGIC DRUGS ON SYSTEMS OF REWARD AND PUNISHMENT IN EXPERIMENTS ON CATS.
002518 03-04

CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003153 04-03

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: CLINICAL STUDIES.
003716 04-13

REDUCED CATECHOLAMINERGIC TRANSMISSION AND CLINICAL EFFECTS OF NEUROLEPTICS.
003718 04-13

CATECHOLAMINES

THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01

EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPONSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
000028 01-03

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03

ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
000228 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN.
000263 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
000289 01-04

RELATIVE ROLE OF CATECHOLAMINES IN HEAD-SHAKING OF INFANT RATS.
000344 01-04

CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01-09

POSSIBLE ROLES OF CATECHOLAMINES IN THE ACTION OF NARCOTIC DRUGS
000809 01-13

CATECHOLAMINES AND PSYCHOSIS.
000813 01-13

CATECHOLAMINES IN ACTIVATION, STEREOTYPY, AND LEVEL OF MOOD.
000858 01-13

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE
001120 02-03

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 02-03

NEURONAL LOCALIZATION OF THE ENHANCEO AOENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

ALTERNATIONS OF MOUSE ADRENAL MEOULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGEO VASOPRESSIN ADMINISTRATION ANO AFTER ITS WITHORAWAL.
001641 02-05

THE EFFECT OF PROLONGEO VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT 8RAIN AND KIDNEYS.
001642 02-05

LEVELS OF BRAIN O-METHYLATEO CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03

POTENTIATION OF EFFECTS OF CATECHOLAMINES ANO SYMPATHETIC STIMULATION BY TRIAZOLOBENZODIAZEPINE.
002245 03-03

EFFECTS OF DRUGS MOOIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCEO EPILEPSY IN PAPIO-PAPIO.
002431 03-04

CATECHOLAMINES ANO OPERANT RESPONSE RATES IN ALBINO RATS.
002555 03-04

CENTRAL CATECHOLAMINES.
002977 03-17

EFFECTS OF OISULFIRAM ANO CHLORAL HYORATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER ANO BRAIN
003094 04-03

PLASMA CORTICOSTERONE ANO BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC ORUGS.
003194 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE.
003383 04-04

ENHANCEMENT OF RETENTION WITH CENTRALLY ADMINISTEREO CATECHOLAMINES.
003400 04-04

EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE.
003B74 04-17

CATION

ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-OEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000B49 01-13

CATIONS

OSTEOPENIA ANO DYSREGULATION OF OIVALENT CATIONS IN LITHIUM TREATEO PATIENTS.
000585 01-09

EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON AOENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

CATS

EFFECTS OF GABA, GLYCINE, PICROTOXIN ANO BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

COMBINED PHARMACOKINETIC ANO PHARMACOOYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
000055 01-03

THE EFFECTS OF RESERPINE, L-OOPA AND 5-HYOROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID ANO HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUIO, BEHAVIOUR AND EEG IN CATS.
000065 01-03

BENZOOIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

ANALYSIS OF INHIBITORY EFFECT OF OOPAMINE ON CAROTIO BODY CHEMORECEPTORS IN CATS.
000215 01-03

EFFECT OF PSYCHOTROPIC ORUGS ON CAUDATE SPINOLE IN CATS.
001250 02-03

EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CAROIOVASCULAR STRUCTURES IN CATS ANO ON BEHAVIOUR IN CHICKENS.
001469 02-04

CHLORPROMAZINE AND HALOPERIOOL ACTION ON CAUOATE INHIBITION OF CONDITIONEO REFLEX AVOIOANCE REACTION IN CATS.
001524 02-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCEO BY HYPOTHALAMIC STIMULATION IN RATS ANO CATS.
001550 02-04

DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIOEPRESSANT ORUG.
002195 03-02

THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MID8RAIN OORSAL RAPHE IN CATS.
002281 03-03

METABOLISM OF 1,4 OIHYOROTRIFLUOROMETHYLQUINOXALINEOIONE (LILLY-72525) IN RATS AND CATS.
002329 03-03

STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-03

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMIO) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT OISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-0

EFFECTS OF PSYCHOTROPIC DRUGS UPON THE HYPOTHALAMIC RAGE RESPONSE IN CATS.
002493 03-0

EFFECT OF CATECHOLAMINERGIC ORUGS ON SYSTEMS OF REWARO ANO PUNISHMENT IN EXPERIMENTS ON CATS.
00251B 03-0

EFFECT OF INTRACAUOATE DRUG INJECTIONS ON THE STRIATAL SYNOROME IN RESERPINIZEO CATS.
003122 04-0

THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS ANO CATS.
003203 04-0

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEOIATE RESPIRATORY, TEMPERATURE ANO OTHER AUTONOMIC CHANGES.
003226 04-0

OIFFERENTIATION IN BRAIN ANO LIVER OOPA/5-HTP-OECARBOXYLASE ACTIVITY AFTER L-OOPA AOMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-0

EFFECT OF OIAZEPAM ON PYRAMIOAL TRACT ANO ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-0

SITE OF ACTION OF OEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS.
003367 04-0

THE RESULTS OF PENICILLIN-G AOMINISTRATION ON CHRONIC UNRESTRAINEO CATS: ELECTROGRAPHIC ANO BEHAVIORAL OBSERVATIONS.
003452 04-0

CAUDATE

EFFECT OF PSYCHOTROPIC ORUGS ON CAUOATE SPINOLE IN CATS.
001250 02-0

AMPHETAMINE, CHLORPROMAZINE ANO CLONIOINE EFFECTS ON SELF-STIMULATION IN CAUOATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
001384 02-0

CHLORPROMAZINE AND HALOPERIOOL ACTION ON CAUOATE INHIBITION OF CONOITIONEO REFLEX AVOIDANCE REACTION IN CATS.
001524 02-0

EFFECTS OF LESIONS OF THE CAUDATE NUCLEUS ON MORPHINE-DEPENOENCE IN THE RAT.
001539 02-0

EFFECT OF CATECHOLAMINERGIC ORUGS ON EPILEPTOGENIC PROPERTIES OF THE CAUOATE NUCLEUS.
002206 03-0

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INOUCED BY STIMULATION OF THE CAUOATE NUCLEUS
002235 03-0

STRUCTURAL CHANGES IN CAUOATE NUCLEUS IN THE PROGENY OF RAT SUBJECTED TO THE ACTION OF CHLORPROMAZINE
002341 03-0

CYTOCHEMICAL ANO ELECTROPHYSIOLOGICAL STUOIES OF DOPAMINE I THE CAUOATE NUCLEUS.
002369 03-0

THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTAC ANO THE DOPAMINE-DEPLETED CAUOATE NUCLEUS.
0032B6 04-0

THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRA CONTROL OF THE CAUDATE NUCLEUS.
003327 04-0

OEPRESSION BY MORPHINE OF THE RESTING ANO EVOKEO RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUOATE NUCLEUS IN VIVO.
003331 04-0

CAUDATE-PUTAMEN
ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION
002344 03-03

CAUSATIVE
IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 02-03

CAUTION
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

CD-1
EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE.
003B74 04-17

CELL
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03
FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS.
0017B2 02-09
NEUROTRANSMITTER METABOLISM IN CELL CULTURE.
002213 03-03
EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03
DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
00307B 04-03

CELLS
INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
000130 01-03
PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03
CALCIUM UPTAKE INTO RAT PHEOCHROMOCYTOMA CELLS.
001165 02-03
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03
DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03
HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13
AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF ADRENERGIC SYSTEM.
002246 03-03
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN.
002247 03-03
FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03
THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
002337 03-03
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03
PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03

ELLULAR
ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03
BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03
CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03-03
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION
003202 04-03
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9 TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON TOLERANT RATS.
003211 04-03

CENTRAL
RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION
000029 01-03
EFFECT OF SOME PHOSPHODIESTERASE INHIBITORS ON CENTRAL DOPAMINE MECHANISMS.
000100 01-03
MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03
INVESTIGATIONS OF THE MECHANISM OF CENTRAL ACTION OF KININS.
000174 01-03
STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
00017B 01-03
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03
BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
000204 01-03
POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
000209 01-03
ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03
ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03
EFFECTS OF BROMOCRIPTINE ON CENTRAL DOPAMINERGIC RECEPTORS.
000242 01-03
ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03
NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS.
0002BB 01-04
INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL DOPAMINE NEURONS.
00035B 01-04
A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE).
000395 01-04
CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
00040B 01-04
AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04
CENTRAL MECHANISMS OF ACTION OF P-CHLOROAMPHETAMINE: BIOCHEMICAL AND HISTOLOGICAL STUDIES. (PH.D. DISSERTATION).
000B43 01-13
CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS (UNPUBLISHED PAPER).
001014 01-17
THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
0011BB 02-03
EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-03
INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED BY THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03
MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-03
CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03

ACUTE CENTRAL EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE IN FOWL.
001310 02-03

PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03

EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04

CENTRAL ACTION OF NOMIFENSINE.
001544 02-04

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

THE EFFECT OF BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05

CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR.
001671 02-07

CENTRAL MONOAMINES AND HYPERKINESIS OF CHILDHOOD.
001B60 02-11

PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14

REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE
00204B 02-15

BIOCHEMISTRY AND BEHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE AND ANTIPSYCHOTIC DRUGS.
002122 02-17

CENTRAL ACTIONS OF BENZODIAZEPINES.
00222B 03-03

CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03-03

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

EFFECTS OF THEOPHYLLINE ON CENTRAL MONOAMINE NEURONS.
002273 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

ELECTROENCEPHALOGRAPHIC ANALYSIS OF THE CENTRAL EFFECT OF PIRASIDOL.
002349 03-03

CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03

CENTRAL NERVOUS ACTIONS OF CARBAMAZEPINE.
002410 03-03

BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04

A COMPARISON OF THE CENTRAL ACTION OF SOME PROSTAGLANDINS /PGS/ IN RATS.
002484 03-04

EFFECT OF NOMIFENSINE ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS.
002503 03-04

CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
00250B 03-04

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
002536 03-04

CENTRAL MONOAMINE METABOLISM IN DEPRESSION AND MANIA. (UNPUBLISHED PAPER).
002675 03-09

CENTRAL CATECHOLAMINES.
002977 03-17

POSSIBLE INVOLVEMENT OF CENTRAL FACTORS IN THE MEDIATION OF CONDITIONED TASTE-AVERSION.
0030B1 04-03

THE EFFECT OF PROSTAGLANDIN-E1 ON CENTRAL CHOLINERGIC MECHANISMS.
003101 04-03

POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03

INVOLVEMENT OF CENTRAL ALPHA-ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL.
00320B 04-03

SENSITIVITY OF COMPONENTS OF THE CENTRAL VESTIBULAR COMPLEX TO PENTOBARBITAL.
003225 04-03

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
00324B 04-03

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE.
0033B3 04-04

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFORMANCE IN MICE.
003416 04-04

CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE.
003446 04-04

POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
003450 04-04

EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04

ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE: STUDIES IN TETRAPLEGIC SUBJECTS.
003701 04-13

CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN.
003704 04-13

NEUROPSYCHOPHARMACOLOGICAL MODELS FOR OBJECTIVE ASSESSMENT OF CENTRAL EFFECTS OF HORMONES.
003B70 04-17

TRICYCLIC ANTIDEPRESSANTS AND CENTRAL MONOAMINE METABOLISM.
003902 04-17

CENTRAL-NERVOUS-SYSTEM

INTERACTION OF BETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT
000002 01-01

ANTAGONISM OF GABA-MEDIATED INHIBITION IN THE CENTRAL-NERVOUS-SYSTEM BY CAPROLACTAM DERIVATIVES.
000140 01-03

MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS OF INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04

PLACENTAL TRANSFER OF CENTRAL-NERVOUS-SYSTEM DEPRESSANTS IN SHEEP.
000464 01-05

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-03

INTERACTION OF CENTRAL-NERVOUS-SYSTEM DRUGS WITH SYNAPTOSOMAL TRANSPORT PROCESSES.
001160 02-03

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL
001194 02-03

LOCALIZATION OF PHENOBARBITAL IN MOUSE CENTRAL-NERVOUS-SYSTEM BY IMMUNOFLUORESCENCE.
001327 02-03

POTENTIAL CENTRAL-NERVOUS-SYSTEM ANTITUMOR AGENTS. AZIRIDINYLBENZOQUINONES. 2.
001656 02-03

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION.
002288 03-03

CENTRAL-NERVOUS-SYSTEM MECHANISMS OF ANALGESIA.
002496 03-04

EFFECT OF CHRONIC TREATMENT OF METHYLMERCURIC-CHLORIDE ON THE CENTRAL-NERVOUS-SYSTEM IN RATS.
002565 03-05

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
0025B6 03-06

OBSERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL-NERVOUS-SYSTEM DYSFUNCTIONS.
002762 03-11

CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
003056 04-01

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 04-02

AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 04-04

FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

CENTRALLY

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. INTRODUCTION TO PARTS X-XII, AND PART X. ACRIDONE DERIVATIVES.
000017 01-01

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XI. LENGTHENING OF THE BASIC CHAIN.
00001B 01-01

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-03

ENHANCEMENT OF RETENTION WITH CENTRALLY ADMINISTERED CATECHOLAMINES.
003400 04-04

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

CEREBELLAR

GABA RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CEREBELLAR C-GMP ELICITED BY DIAZEPAM. (UNPUBLISHED PAPER).
000051 01-03

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
00139B 02-03

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY
001613 02-05

DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C GMP ELICITED BY HALOPERIDOL AND DIAZEPAM.
002211 03-03

A CEREBELLAR MODEL TO STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSION. (UNPUBLISHED PAPER).
002212 03-03

CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03

CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS
002481 03-04

EFFECTS OF METHADONE HYDROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPARED FROM METHADONE-TOLERANT AND CONTROL RATS.
0025B1 03-05

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-03

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
0032B3 04-03

CEREBELLUM

EFFECTS OF 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-03

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03

IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
00115B 02-03

EFFECT OF ETHANOL ON IMPULSE ACTIVITY IN ISOLATED CEREBELLUM.
001206 02-03

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-03

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

ACTION OF DIAZEPAM, HALOPERIDOL, MORPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 03-03

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03

THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
002337 03-03

REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
003097 04-03

CEREBRAL

EFFECTS OF PHOSPHOLIPID ADMINISTRATION ON ENDOGENOUS CEREBRAL PHOSPHOLIPID BIOSYNTHESIS.
000036 01-03

STIMULATION OF CEREBRAL HISTAMINE H2-RECEPTORS BY CLONIDINE.
000039 01-03

STUDIES OF CONNECTIONS BETWEEN LOCUS-COERULEUS AND CEREBRAL CORTEX.
000040 01-03

BACLOFEN AND GAMMA-HYDROXYBUTYRATE: SIMILAR EFFECTS ON CEREBRAL DOPAMINE NEURONES.
0000B3 01-03

REGIONAL STUDY OF CEREBRAL VENTRICLE SENSITIVE SITES TO ANGIOTENSIN-II.
000123 01-03

INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN F2ALPHA.
0001B3 01-03

DECADRON IN THE TREATMENT OF CEREBRAL ABSCESS: AN EXPERIMENTAL STUDY.
000206 01-03

INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
000241 01-03

INFLUENCE OF DIAZEPAM AND PHENYTOIN ON PENICILLIN-INDUCED CEREBRAL CONVULSIONS.
000253 01-03

GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
00037B 01-04

CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

TREATMENT OF CEREBRAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
0007B6 01-11

EFFECT OF PAPAVERINE ON CEREBRAL ELECTROGENESIS.
000B10 01-13

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14

1035-MD (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY.
001013 01-17

CEREBRAL NEUROTRANSMISSION AND PSYCHOTROPIC DRUGS.
001065 01-17

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY
001249 02-03

INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02-03

CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02-03

DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
00130B 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE
001309 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

EFFECTS OF NEUROLEPTIC AGENTS ON CYCLIC-GMP IN RAT CEREBRAL CORTEX.
001322 02-03

IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?.
001330 02-03

BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03

ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03

LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE
0013B0 02-03

COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM.
001413 02-03

THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02-03

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-03

THERAPY OF CEREBRAL ISCHEMIA.
001B30 02-11

CLINICAL STUDIES OF ANESTHETIC CEREBRAL ACTIVATION.
001B41 02-11

PSYCHOPHYSIOLOGICAL ASPECTS IN EEG ANALYSIS OF CEREBRAL DRUG EFFECTS.
00191B 02-13

CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.
002060 02-15

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02 16

EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX
002264 03-03

EFFECTS OF ADENOSINE ANALOGS ON RAT CEREBRAL CORTICAL NEURONS.
002336 03-03

THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC-ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
002350 03-03

EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT. (UNPUBLISHED PAPER).
002367 03-03

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 03-05

EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY
002774 03-11

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
002B1B 03-13

DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14

INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03

THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION.
003217 04-03

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
0032B3 04-03

EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRAL HEMODYAMICS AND METABOLISM IN THE BABOON
003297 04-03

CEREBRAL APPLICATION OF ENKEPHALINS.
003349 04-04

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS
003720 04-1

CEREBROSPINAL

THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-0

CUMULATION IN CEREBROSPINAL FLUID OF THE N DESMETHYL METABOLITE AFTER LONG TERM TREATMENT WITH DIAZEPAM IN MAN
000B25 01-13

CEREBROSPINAL FLUID CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN MAN
000B32 01-13

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA. CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03

THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-0B

CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLIC PATIENTS.
001747 02-09

CORRELATION BETWEEN PLASMA AND CEREBROSPINAL LEVELS OF IMIPRAMINE.
001775 02-09

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001B62 02-11

14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B35 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-13

CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15

EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACID.
003647 04-11

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

REBROVASCULAR

DRUG THERAPY IN CHRONIC CEREBROVASCULAR INSUFFICIENCY IN THE ELDERLY.
001B37 02-11

RVICAL

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

SSATION

CARBON-MONOXIDE BLOOD LEVELS AND REPORTED CESSATION OF SMOKING.
001933 02-13

F

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
00051B 01-07

AIN

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XI. LENGTHENING OF THE BASIC CHAIN
00001B 01-01

AINS

REPEATED ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIDATE AND IMIPRAMINE.
000437 01-04

ANGE

OBSERVATIONS ON THE PHENOMENOLOGY OF CONSCIOUSNESS CHANGE.
000797 01-12

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG TERM TREATMENT WITH HALOPERIDOL.
001194 02-03

CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE.
001711 02-0B

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA
002617 03-0B

WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED.
0026B5 03-09

CHANGES

F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE
000075 01-03

BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN
0001B4 01-03

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001BB 01-03

PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION-COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES.
000197 01-03

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION
000211 01-03

PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRAIN-DAMAGED RATS.
000220 01-03

CHANGES IN BRAIN NOREPINEPHRINE ASSOCIATED WITH SENSITIZATION TO D-AMPHETAMINE.
000225 01-03

NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS.
0002BB 01-04

BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06

MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
00054B 01-0B

METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES: PSYCHOMETRIC CHANGES.
000740 01-11

MINIMAL-BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000B03 01-13

DRUG-INDUCED HANDWRITING CHANGES: AN EMPIRICAL REVIEW.
000B95 01-14

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM THERAPY.
00099B 01-15

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION
001055 01-17

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE
001120 02-03

CHANGES IN CNS RESPONSIVENESS DURING HIBERNATION
001136 02-03

BRAIN HOMOVANILLIC-ACID: REGIONAL CHANGES OVER TIME WITH ANTIPSYCHOTIC DRUGS.
001152 02-03

IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
00115B 02-03

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03

CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04

THE BEHAVIOURAL EFFECTS OF EOS-INDUCED CHANGES IN SUBSTANTIA-NIGRA GA8A LEVELS.
00152B 02-04

ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

BEHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE.
001579 02-04

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
001585 02-04

EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY.
001595 02-04

CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
00159B 02-04

THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05

ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-0B

EFFECTS OF PRACTICE ON MARIJUANA-INDUCED CHANGES IN REACTION TIME.
001873 02-12

HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
00220B 03-03

CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03-03

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVFN PATHOLOGY.
0022B6 03-03

MORPHINE INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN.
002319 03-03

STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03

DIFFERFNTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSFRTATION).
002351 03-03

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCFRATION FOLLOWING WATER IMMERSION STRESS.
00239B 03-03

CONDITIONFD BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJFCTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DFPFNDFNT MONKEYS.
002456 03-04

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-0

SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
002510 03-0

TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES I VENTRICULAR AUTOMATICITY.
002562 03-0

CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-0

CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN
002616 03-0

PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY
002632 03-0

CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002B06 03-

CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
002BB6 03-

CHANGES IN PRESCRIBING PATTERNS OF MINOR TRANQUILIZERS.
003037 03-

SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETIC IN RATS.
003092 04-

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTE DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
00317B 04-

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM
003188 04-

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT
003195 04-

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVIT BY ADRENERGIC BLOCKERS IN MICE.
003214 04-

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION
003217 04-

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSIN (ALPHA-MPT).
003269 04-

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS.
003357 04-

CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AN CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RAT
003390 04-

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AN NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY-EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-

NEONATAL ANDROGEN INJECTION CHANGES OPEN-FIELD BEHAVIOR OF MICE
003402 04-

EARLY DEVELOPMENTAL CHANGES IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RELATION TO HIPPOCAMPAL FUNCTION
00341B 04-

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION
003443 04-

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDF LYSINE VASOPRESSIN.
003447 04-

EFFFCTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04

ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM OF RABBITS POISONED WITH METHYLMERCURY
003500 04-05
CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE
003533 04-08
CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08
DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE TO TREATMENT.
003669 04-13
THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13
PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13
DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003824 04-15
EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE.
003889 04-17

ANGING
CHANGING THERAPY AND PROGNOSIS IN MANIC-DEPRESSIVES.
0006B7 01-10
ON CHANGING BLOOD DENSITIES OF ANTISEIZURE DRUGS TAKEN IN LARGE VOLUMES.
002950 03-15
PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE -- A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

ANNELS
EFFECT OF ANICOTINE ON SOME PROPERTIES OF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE.
001299 02-03

ARACTER
A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11

ARACTERISATION
CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

ARACTERISTIC
POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

ARACTERISTICS
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09
TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03
CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03
CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02-03
CHARACTERISTICS OF TETRAHYDROCANNABINOL (THC) PRODUCED DISCRIMINATION IN RATS.
001518 02-04
SOME CHARACTERISTICS OF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OE PSYCHOPATHOLOGY.
002204 03-03
MECHANISM AND CHARACTERISTICS OF DRUG-INDUCED AGGRESSION (PH.D. DISSERTATION).
002451 03-04
WITHDRAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBITAL DOSING IN CAT.
002516 03-04
CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04
CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
002886 03-15
GENERAL CHARACTERISTICS OF DISCRIMINATIVE STIMULI PRODUCED BY DRUGS
003004 03-17

CHARACTERIZATION
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03
SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13
PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC EORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
001086 02-01
IR SPECTROSCOPIC CHARACTERIZATION OF 2-THIOHYDANTOINS AND 2-THIOBARBITURATES.
001089 02-01
CHARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES AND RELATED DRUGS WITH LIPIDS BY UV-SPECTROPHOTOMETRY.
002583 03-06
NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01
DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
003078 04-03
CHARACTERIZATION OF RAT SKELETAL MUSCLE MONOAMINE-OXIDASE.
003085 04-03
CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

CHARACTEROLOGICAL
CHARACTEROLOGICAL SIGNIFICANCE OF MEDICATION.
002136 02-17

CHECKLIST
THE EFFECT OF SEQUENCE ON THE STABILITY OF THE HOPKINS SYMPTOM CHECKLIST (HSCL). (UNPUBLISHED PAPER).
0029B2 03-17

CHELATES
METAL CHELATES OF L-DOPA FOR IMPROVED REPLENISHMENT OF DOPAMINERGIC POOLS.
001090 02-01

CHEMICAL
CHEMICAL AND PHARMACODYNAMIC STUDY OF BETA-AMINOKETONES OF BENZOXAZOLINONIC STRUCTURE.
001103 02-02
CHEMICAL STIMULANTS OF SHAKING BEHAVIOUR.
001605 02-04
INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03
CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN.
002616 03-08
CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01
QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

CHEMICALLY
IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER.
001628 02-05

CHEMISTRY
COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
002183 03-01

CHEMORECEPTORS
ANALYSIS OF INHIBITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
000215 01-03

CHEMOTHERAPEUTIC
SEX AS A FACTOR IN METABOLISM, TOXICITY, AND EFFICACY OE PHARMACODYNAMIC AND CHEMOTHERAPEUTIC AGENTS.
000822 01-13
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 02-17

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND EOREIGN PSYCHIATRISTS PREFERENCES EOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17

PSYCHOTHERAPEUTIC AND CHEMOTHERAPEUTIC RELATIONS IN INSOMNIA.
002727 03-10

CHEMOTHERAPY

SUGGESTIONS FOR A RATIONAL APPROACH TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001725 02-08

RECENT DEVELOPMENTS IN THE CHEMOTHERAPY OE SCHIZOPHRENIC PSYCHOSES.
002625 03-08

CHEMOTHERAPY OF MELANCHOLIA 8Y SEQUENTIAL ASSOCIATION OE A NEUROLEPTIC AND VILOXAZINE.
002668 03-09

SINGLE-AGENT CHEMOTHERAPY OF BRAIN TUMORS: A FIVE-YEAR REVIEW.
002792 03-11

CHEWING

COCAINE SELF-ADMINISTRATION IN MONKEYS 8Y CHEWING AND SMOKING.
000424 01-04

ANDEAN COCA CHEWING: A META8OLIC PERSPECTIVE.
002802 03-13

HEN8ANE CHEWING.
003029 03-17

CHICK

F-INDUCED CHANGES AND ITS REVERSAL 8Y ITP IN MEMBRANE TUR8IDITY AND ADENYLATE-CYCLASE ACTIVITY OE CHICK 8RAIN MICROSOMES.
000037 01-03

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCU8ATION ON THE DEVELOPMENT OE TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 D4-03

CHICKEN

EFFFCT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN BRAIN.
000210 01-03

CHICKENS

DRUG EEFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS.
D00110 D1-03

AMPHETAMINE ATTENUATION OF TONIC IMMO8ILITY IN CHICKENS.
001449 02-04

EEEECTS OF ACTIVATION OE H1-RECEPTORS AND H2-RECEPTORS ON CFNTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04

EFFECTS OE INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMO8ILITY IN CHICKENS.
001506 02-04

EFFECTS OE ANTICHOLINERGICS ON THE HA8ITUATION OF TONIC IMMOBILITY IN CHICKENS.
001511 02-D4

POSTPONEMENT OE SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

CHOLINERGIC 8LOCKADE AND TONIC IMMO8ILITY IN CHICKENS.
003387 04-D4

CHICKS

THE EFFECTS OE DIETHYLDITHIOCAR8AMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03

TIME DEPENDENT EFFECTS PRODUCED IN CHICKS AFTER PRENATAL INJECTION OF METHYLMERCURY.
000461 01-05

CHILD

LITHIUM-SALTS IN THE MANAGEMENT OE A CHILD BATTERER.
002679 03-09

APHASIA IN A CHILD WITH EPILEPSY: IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT.
002752 03-11

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY IN THE MID-SFVENTIES: PROGRESS OR PLATEAU?.
00303B 03-17

THE VALUF OF PHENOBAR8ITAL IN THE CHILD WHO HAS HAD A SINGLE EE8RILF SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11

CHILDBIRTH

THE PLACENTAL TRANSFER OF DRUGS DURING CHILD8IRTH: A POSSI8LE INFLUENCE ON THE NEW8ORN
001892 02-13

CHILDHOOD

BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
000730 01-11

CENTRAL MONOAMINES AND HYPERKINESIS OF CHILDHOOD.
001860 02-11

ADVERSE EEFECTS OE PHARMACOTHERAPY IN CHILDHOOD PSYCHOSIS.
002988 03-1

CHILDREN

A DOU8LE-8LIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-1

TREATMENT OF CHILDREN WITH DIFEICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHA8OL) IN JAKARTA, INDONESIA.
000743 01-1

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CERE8RAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-1

DEANOL IN THE TREATMENT OE HYPERKINETIC CHILDREN.
000884 01-1

THE EFEECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-1

STIMULANT RELATED STATE-DEPENDENT LEARNING IN HYPERACTIVE CHILDREN.
000922 01-1

MEDICATION FOR HYPERKINETIC CHILDREN.
000926 01-1

HALOPERIDOL AND METHYLPHENIDATE IN HYPERACTIVE CHILDREN.
000927 01-1

TOXICOPATHIC HALLUCINATORY SYNDROMES IN CHILDREN.
000942 01-1

PHENO8AR8ITONE FOR CONVULSIONS IN CHILDREN.
000993 01-1

SPECIAL PRO8LEMS FOR DRUGS USED IN CHILDREN.
000995 01-1

CARDIOVASCULAR RESPONSES OF HYPERACTIVE CHILDREN TO METHYLPHENIDATE.
001814 02-

CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS AND HYPERACTIVITY IN CHILDREN.
001847 02-

HYPERACTIVE CHILDREN.
0D1855 02-

PSYCHOSTIMULANTS AND CHILDREN: A REVIEW AND ANALYSIS.
0D1866 02-

EFEECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN.
001998 02-

THE USE OF ANESTHESIA IN CHILDREN.
D02068 D2-

PRACTICAL USE OE PSYCHOTROPIC DRUGS IN CHILDREN.
002175 02-

CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF 8LOOD DURING PHARMACOLOGICAL TREATMENT OE SCHIZOPHRENIC CHILDREN.
D02616 03-

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF 8LOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN EOR SCHIZOPHRENIA.
0D2617 03-

O8SERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL-NERVOUS-SYSTEM DYSFUNCTIONS.
DD2762 03-

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
D02767 03-

RESULTS OF TREATING NERVOUS TICS IN CHILDREN: 8ASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
DD2777 03-

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACE8O AND METHYLPHENIDATE STUDY.
002830 D3-

PREDICTING THE RESPONSE OE HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002852 03-

COMPARATIVE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE IN HYPERKINETIC CHILDREN.
D02861 D3-

RELATIVE EEFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN: AN INTERIM REPORT.
0D2862 03-

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION
002863 D3-

ACTH4-10: COGNITIVE AND BEHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING-DISA8LED CHILDREN
D02872 03-

SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN
002889 03 15
WHAT HAPPENED LATER TO THE LITHIUM BABIES? A FOLLOW UP STUDY OF CHILDREN BORN WITHOUT MALFORMATIONS
002932 03 15
PRELIMINARY REPORT ON THE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN
003620 04-11
THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN
003633 04-11
EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11
AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11
AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN
003670 04-13
CARBAMAZEPINE AS AN ANTICONVULSANT IN CHILDREN.
003747 04-14
VOMITING DURING NEUROLEPTIC WITHDRAWAL IN CHILDREN
003758 04-14
THE USE OF METHYLPHENIDATE AND IMIPRAMINE IN GILLES-DE-LA-TOURETTES DISEASE IN CHILDREN
003782 04-15
IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-15

IILDRENS

CHILDRENS PSYCHOPHARMACOLOGY UNIT.
000729 01-11
NEUROLEPTIC DRUG EFFECTS ON CHILDRENS BODY WEIGHT AND HEIGHT.
003645 04-11

IIMPANZEES

HALLUCINOGEN-INDUCED BEHAVIORS OF FREE-MOVING CHIMPANZEES.
003358 04-04

IIRAL

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

LOPOXIDE

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
D00691 01-1D

LORACYZINE

EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
D01815 D2-11

LORAL

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04
EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN
003094 04-03

LORAMPHENICOL-INDUCED

ULTRASTRUCTURAL STUDIES OF CHLORAMPHENICOL-INDUCED NEUROPATHY IN EXPERIMENTAL ANIMALS.
D00147 01-03

LORAZEPATE

CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION
0D0700 01-10
VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE.
000702 01-1D
THE USE OF DIPOTASSIUM CHLORAZEPATE AT HIGH DOSAGE IN TRFATMENT OF OBESITY.
000738 01-11

ORDESMETHYLDIAZEPAM

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 D2-03
THE EFFFCTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS.
002006 02-14

ORDIAZEPOXIDE

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINF MFTABOLISM IN THE RAT BRAIN
000205 01-03
THE EFFECT OF CHLORDIAZEPOXIDE ON THE ANTICIPATION OF ELECTRIC SHOCKS.
000292 01 04
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVF BRIGHTNESS DISCRIMINATION LEARNING IN RATS
000351 01-04
EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE
000694 01 10
HICCUPS FOLLOWING INGESTION OF ORAL CHLORDIAZFPOXIDE
000996 01-15
A COMPARISON OF THE EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDF ON EXPLORATION AND ON ITS HABITUATION.
001483 02-04
EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON SOCIAL INTERACTION IN RATS.
0D1484 02-04
STATE-DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDF AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
0014B8 02-04
EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS
001573 02-04
A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE
001601 02-04
STUDIES ON THE INTERACTION OF CHLORDIAZEPOXIDE, DIAZEPAM, AND NITRAZEPAM WITH PHENPROCOUMON.
001627 02-05
CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE IN EXPERIMENTS WITH NONANESTHETIZED ANIMALS.
001636 02-05
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
0D1810 02-10
CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS: A COMPARATIVE STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE
001B50 D2-11
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001862 02-11
BIOAVAILABILITY OF TWO PREPARATIONS OF CHLORDIAZEPOXIDE.
001944 02-13
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES I: CHLORDIAZEPOXIDE AND DEMOXEPAM.
002258 03-03
INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 D3-04
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
DD2448 03-04
DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TRFATMENT OF CHLORDIAZEPOXIDE.
002475 03-04
THE EFFECT OF CHLORDIAZEPOXIDF ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS.
002476 03-04
A DOUBLE-BLIND COMPARISON OF SULPIRIDE WITH CHLORDIAZEPOXIDE IN NEUROSIS.
0D2732 03-10
N-DESMETHYLDIAZEPAM: A NEW METABOLITE OF CHLORDIAZEPOXIDE IN MAN.
002B05 03-13
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
003480 04 D4
A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
0D3603 04-10
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINF AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
003606 04-10
THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003639 04-11
IMIPRAMINE AND CHLORDIAZEPOXIDE IN ENURESIS
003649 04-11
ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPUBLISHFD PAPER).
003705 04-13

ABSORPTION RATE, BLOOD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPOXIDE.
003731 04-14

AGGRAVATION OF DIABETIC HYPERGLYCEMIA BY CHLORDIAZEPOXIDE.
003B3B 04-15

CHLORHYDRATE

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES.
001031 01-17

CHLORIDE

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

CHLORIMIPRAMINE

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
000075 01-03

CHLORIMIPRAMINE, FOR OBSESSIVE-COMPULSIVE NEUROSIS: AN ORGANIC APPROACH.
000523 01-07

INTRAVENOUS CHLORIMIPRAMINE AND DEPRESSIVE SUBTYPES.
000600 01-09

CHLORIMIPRAMINE, ITS CLINICAL ACTIONS.
000721 01-10

POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
001757 02-09

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

EFFECTS OF IMIPRAMINE, CHLORIMIPRAMINE, AND FLUOXETINE ON CATAPLEXY IN DOGS
002421 03-04

CHLORIMIPRAMINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION.
002704 03-09

EFEECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS
003350 04-04

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE
003654 04-13

CHLORMETHIAZOLE

COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11

ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15

PHYSIOLOGICAL DEPENDENCE ON, AND SYMPTOMS OF WITHDRAWAL FROM, CHLORMETHIAZOLE
0009B1 01-15

CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE

PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT
0010B6 02-01

CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

CHLOROPHENYL-GABA

IS CHLOROPHENYL GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?
001330 02-03

CHLOROQUINE

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17

CHLOROTHIAZIDE

EFFECT OF CHLOROTHIAZIDE ON THE PHARMACOKINETICS OF LITHIUM IN PLASMA AND ERYTHROCYTES.
002B29 03-13

CHLORPHENESIN

BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-0

CHLORPHENIRAMINE

INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-0

CHLORPHENTERMINE

RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIDEPRESSANTS.
0012B4 02-0

CHLORPROMAZINE

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT
000047 01-0

EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
0000B4 01-0

COMPARATIVE EFFECTS OF CHLORPROMAZINE AND ITS FREE-RADICAL ON MEMBRANE FUNCTIONS.
000153 01-0

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-0

EFFECT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN BRAIN.
000210 01-0

EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN
000266 01-0

THE EFFECTS OF CHLORPROMAZINE UPON FEAR MOTIVATED BEHAVIOR IN THE SQUIRREL-MONKEY
000345 01-0

DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
000348 01-0

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-0

EFFECTS OF LOW AND MODERATE DOSES OF CHLORPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT
000435 01-0

FOOD DOMINANCE IN DOGS: EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE.
000450 01-0

LOXAPINE SUCCINATE: A COMPARATIVE STUDY WITH CHLORPROMAZINE
000541 01-0

A DOUBLE-BLIND COMPARISON OF TPN-12 AND CHLORPROMAZINE ON SCHIZOPHRENIA.
000552 01-

CURRENT VIEWS ON THE MECHANISM OF CHLORPROMAZINE ACTION
000B31 01-

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000B61 01-

PSYCHIATRIC MEDICINE AND SLEEP -- CHLORPROMAZINE
000B97 01-

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
000909 01-

GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA.
001003 01-

METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH: CHLORPROMAZINE -- A CASE IN POINT.
00100B 01-

THE SYNTHESIS OF POSSIBLE DIHYDROXYLATED AND TRIHYDROXYLATED CHLORPROMAZINE METABOLITES.
001094 02-

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE
001129 02-

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
001285 02-

CHLORPROMAZINE AND AGING IN THE BRAIN
001353 02-03
AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF STIMULATION IN CAUDATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
001384 02-03
THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02-03
A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
001494 02-04
CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS
001608 02-04
THE EFFECT OF BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05
SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-08
EFFECT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
001995 02-14
PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15
POST-DOPAMINE ISCHEMIA TREATED WITH CHLORPROMAZINE.
002080 02-15
A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
002086 02-16
HOW LONG DOES CHLORPROMAZINE LAST?.
002133 02-17
THE INTRODUCTION OF CHLORPROMAZINE.
002151 02-17
ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
002184 03-01
EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX.
002264 03-03
INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
002297 03-03
THE METABOLISM OF CHLORPROMAZINE IN THE NEONATAL GUINEA-PIG.
002315 03-03
STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03
EFFECT OF LITHIUM ON GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE.
002346 03-03
MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
00236B 03-03
COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AND DIAZEPAM IN ISOLATED RAT HEART.
00237B 03-03
INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
002389 03-03
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
002448 03-04
EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE
002492 03-04
EFFECT OF CHLORPROMAZINE ON THE REPRODUCTION IN RATS.
002567 03-05
HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 03-08
DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-08
THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-08
EFFECTS OF CHLORPROMAZINE ON THE ISOLATED PERFUSED RAT HEART
003084 04-03
EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03
EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY
003242 04-03
IN VITRO STUDIES OF SOME CHLORPROMAZINE METABOLITES AS POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
003265 04-03
COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE ISOLATED PERFUSED RAT BRAIN.
003274 04-03
REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04
INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04
EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04
THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-08
ECT VERSUS CHLORPROMAZINE IN MANIA.
003565 04-09
PHARMACOKINETICS OF CHLORPROMAZINE AFTER SINGLE AND CHRONIC DOSAGE.
003664 04-13
BLUE SKIN PIGMENTATION AND CHLORPROMAZINE.
003792 04-15

CHLORPROMAZINE-INDUCED
THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR.
000239 01-03

CHLORPROMAZINE-N-OXIDE
A NOTE ON THE ASSAY OF CHLORPROMAZINE-N-OXIDE AND ITS SULPHOXIDE IN PLASMA AND URINE.
000B11 01-13

CHLORPROTHIXENE
EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03
AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
001182 02-03

CHOICE
EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
0003B9 01-04
THE CHOICE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW.
000571 01-08

CHOICES
LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
000886 01-14
CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17

CHOLECALCIFEROL
ABSORPTION AND BIOTRANSFORMATION OF CHOLECALCIFEROL IN DRUG-INDUCED OSTEOMALACIA.
000166 01-03

CHOLERA
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA
003516 04-06

CHOLESTEROL
EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

CHOLINE
CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03

VINYL ETHERS OF CHOLINE AND CONGENERS.
000067 01-03

8IOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACERE8RALLY INJECTED CHOLINE.
001127 02-03

DEPRESSION ASSOCIATED WITH ORAL CHOLINE.
002939 03-15

EFFECT OF OXOTREMORINE AND SODIUM PENTO8AR8ITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03

ORAL CHOLINE ADMINISTRATION TO PATIENTS WITH TARDIVE-DYSKINESIA.
003624 04-11

CHOLINE-ACETYLTRANSFERASE

CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECAR8OXYLASE AND TYROSINE-HYDROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG
001085 02-01

CHOLINERGIC

CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02

EFFECT OF P-NITROPHENYL-DIAZONIUM-FLUOROBORATE ON CHOLINERGIC MECHANISMS
000069 01-03

MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHI8ITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
000128 01-03

STUDIES ON THE SITE OF ACTION OF CLONIDINE UTILIZING A SYMPATHETIC CHOLINERGIC SYSTEM.
000144 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN
000149 01-03

INCREASED CERE8RAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN-F2ALPHA
000183 01-03

CHOLINERGIC MODIFICATION OF DRUG-INDUCED STEREOTYPY IN RATS.
000201 01-03

EFFECTS OF CHOLINERGIC DRUGS AND THEIR 8LOCKERS ON ADRENALINE RFLEASE FROM RAT ADRENAL
000268 01-03

NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED 8Y CENTRAL CHOLINERGIC DRUGS
000288 01-04

INTERACTION 8ETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANFOUS ALTERNATION TASK.
000361 01-04

AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT
000410 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-06

CHOLINERGIC SIDE-EFFECTS ASSOCIATED WITH DEANOL
000973 01-15

EFFECT OF CAR8AMAZFPINE ON CHOLINERGIC PARAMETERS IN RAT 8RAIN AREAS.
001170 02-03

INCRFASF IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDFNCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK
001269 02-03

DISORDFR OF CHOLINERGIC MFDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVFR GLYCOGEN SYNTHESIS
001372 02-03

CHOLINFRGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT
001434 02-04

FFFFCT OF CHOLINERGIC DRUGS ON METHADONE-INDUCED CATALEPSY AND STFREOTYPIES IN RATS TRFATED CHRONICALLY WITH MFTHADONF
002199 03-03

RFGULATION OF CHOLINERGIC NEURONS BY DOPAMINFRGIC TERMINALS: INFLUFNCF OF CATALFPTOGFNIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS (UNPU8LISHED PAPER)
002226 03-03

HISTOCHFMICAL AND MICROPUNCH ANALYSIS OF AMINERGIC AND CHOLINIRGIC PATHWAYS. (UNPUBLISHED PAPER).
002266 03-03

A8SENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEED8ACK INHI8ITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 03-0

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RA88IT OR RAT.
002403 03-0

PHENCYCLIDINE-INDUCED ROTATIONAL 8EHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION 8Y DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-0

EFFECTS OF CHOLINERGIC AGONISTS AND ANTAGONISTS ON MORPHINI WITHDRAWAL SYNDROME.
002469 03-0

CENTRAL CHOLINERGIC 8LOCKADE 8Y SCOPOLAMINE AND HA8ITUATION, CLASSICAL CONDITIONING, AND LATENT INHI8ITION OF THE RA8BITS NICTITATING MEM8RANE RESPONSE.
002508 03-

CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SU8STANTIA-NIGRA IN THE RA88IT.
002557 03-

CHOLINERGIC PROCESSES IN SCHIZOPHRENIA.
002654 03-

ADRENERGIC CHOLINERGIC IM8ALANCE IN AFFECTIVE DISORDERS.
003021 03-

THE EFFECT OF PROSTAGLANDIN-E1 ON CENTRAL CHOLINERGIC MECHANISMS.
003101 04

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN 8RAIN DOPAMINE META8OLISM
003188 04

CHOLINERGIC 8LOCKADE AND TONIC IMMO8ILITY IN CHICKENS.
003387 04

CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AN CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RA
003390 04

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGI AND CHOLINERGIC DYNAMICS.
003880 04

CHOLINESTERASE

ACTIVITY OF PERIPHERAL BLOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA.
002618 03

CHOLINOCEPTIVE

O8SERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT BRAINSTEM
000059 01

CHOLINOLYTIC

INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WIT NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
003495 04

CHOLINOMIMETIC

THE INTERACTION OF DELTA9-TETRAHYDROCANNA8INOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM
001521 02

EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK
002276 03

CHOREA

8ROMOCRIPTINE IN HUNTINGTON CHOREA.
000500 0

TRIAL OF A NEW THERAPY OF HUNTINGTONS CHOREA.
000733 0

MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SU8STRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 0

MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION
001826 0

HALOPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT OF HUNTINGTONS CHOREA.
001893 0

RATIONAL APPROACHES TO THE PHARMACOTHERAPY OF CHOREA
002803 0

METHYLPHENIDATE-INDUCED CHOREA
003835 0

CHOROID

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOR PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 0

CHROMATIC

LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY
000886 0

ROMATIN
APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT
002324 03 03

ROMATOGRAPHIC
A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000829 01 13
GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA.
001003 01-16
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS
001889 02-13
QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
0030S3 04-01

ROMATOGRAPHY
GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01
QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-06
MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02-13
SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY
0029S3 03-16
THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY
003667 04-13

OMOSOMAL
MINIMAL-BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000803 01-13

OMOSOME
CHROMOSOME STUDIES BEFORE AND AFTER THE ACUTE ADMINISTRATION OF MORPHINE.
003216 04-03

ONIC
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03
THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES-MODIFICATION BY CHLORIMIPRAMINE.
00007S 01-03
THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
000086 01-03
EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
000087 01-03
A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03
THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03
BEHAVIOR AND DRUG EFFECTS DURING CHRONIC STRESS.
000282 01-04
THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04
ENHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH D DISSERTATION).
000318 01-04
CHRONIC METHYLPHENIDATE EFFECTS ON LEARNING IN AN F2 GENERATION
000330 01-04
MEASUREMENT OF ACUTE AND CHRONIC BEHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-04
ALPHA FLUPENTHIXOL-INDUCED HYPERACTIVITY BY CHRONIC DOSING IN RATS.
000412 01-04
BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D AMPHETAMINE
00041S 01 04
THE INTERACTION BETWEEN ELECTRICALLY INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT
00044S 01-04
A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
000S30 01-08
BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA (UNPUBLISHED PAPER).
000S34 01 08
GROWTH HORMONE SECRETION IN CHRONIC SCHIZOPHRENIA.
000S36 01-08
DOUBLE-BLIND TRIAL OF L DOPA IN CHRONIC SCHIZOPHRENIA.
000537 01-08
ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY.
000540 01-08
INTRAMUSCULAR DOUBLE-BLIND STUDY OF DFPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000S42 01-08
CLINICAL STUDY OF PIMOZIDE WITH CHRONIC SCHIZOPHRENICS
00056S 01-08
CLINICAL EXPERIENCE IN USING TLP-607 FOR CHRONIC SCHIZOPHRENIA
000S69 01-08
TRANQUILIZERS OR ANTIDEPRESSANTS FOR CHRONIC SCHIZOPHRENICS: A LONG-TERM STUDY.
000S72 01-08
THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY.
000693 01-10
CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11
A TRIAL OF FENFLURAMINE IN THE TREATMENT OF THE CHRONIC ALCOHOLIC PATIENT.
000752 01-11
USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY.
000763 01-11
ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
000777 01-11
USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000847 01-13
HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000B63 01-13
REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000864 01-13
PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
000B68 01-13
TREATMENT OF CHRONIC POSTTRAUMATIC ORGANIC-BRAIN-SYNDROME WITH DEXTROAMPHETAMINE. FIRST REPORTED CASE.
000904 01-14
CHRONIC USE OF MARIJUANA
000967 01-15
PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15
INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03
BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
00119S 02-03
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS
001196 02-03
NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
001198 02-03
REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03
CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION.
001365 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04

THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-04

EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04

THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON
001505 02-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE
001583 02-04

CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING.
0015BB 02-04

ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05

PROLACTIN SECRETION IN CHRONIC SCHIZOPHRENIA.
0016B0 02-08

GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
0016B1 02-08

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-08

CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-0B

LONG-TERM STUDY OF MOLINDONE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENICS.
001697 02-08

A DOUBLE-BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
001698 02-0B

NEUROLEPTIC EFFECT OF BACLOFEN IN CHRONIC SCHIZOPHRENICS.
001700 02-08

STUDY OF THE USE OF MODITEN-RETARD (FLUPHENAZINE-ENANTHATE) AND OF MODECATE (FLUPHENAZINE-DECANOATE) IN 20 CHRONIC CASES.
001710 02-0B

THE USE OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF CHRONIC, SEVERE PAINS.
001B34 02-11

DRUG THERAPY IN CHRONIC CEREBROVASCULAR INSUFFICIENCY IN THE ELDERLY
001B37 02-11

BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13

THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
001920 02-13

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE
001945 02-13

NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
001949 02-13

THREE CASES OF CHRONIC PENTAZOCINE (SOSEGON, PENTAGIN) INTOXICATION
002045 02-15

CHRONIC BROMIDE INTOXICATION WITH A SEVERE NEUROLOGICAL DEFICIT
002052 02-15

CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA
002060 02-15

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-

APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03

WITHDRAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBIT DOSING IN CAT.
002516 03

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRON MORPHINE TREATMENT.
002541 03

DIFFERENCES IN CYTOCHROME-P-450 OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
002563 0

EFFECT OF CHRONIC TREATMENT OF METHYLMERCURIC-CHLORIDE ON THE CENTRAL-NERVOUS-SYSTEM IN RATS.
002565 0

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED B CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 0

FOLLOW-UP OF PATIENTS WITH CHRONIC SCHIZOPHRENIA -- WITH SPECIAL REFERENCE TO THE EFFECTS OF PHARMACOTHERAPY.
002609 0

FLUPHENAZINE-DECANOATE IN CHRONIC PSYCHOTIC SUBJECTS.
002610 0

PIPOTIAZINE-PALMITATE IN CHRONIC SCHIZOPHRENIA.
002615 0

CLINICAL EFFECTS OF TRYPTOPHAN IN CHRONIC SCHIZOPHRENIC PATIENTS.
002629 0

HYPORESPONSIVITY OF CHRONIC SCHIZOPHRENIC PATIENTS TO DEXTROAMPHETAMINE.
002635 0

A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHER STUDY OF CHRONIC SCHIZOPHRENICS.
002636 0

THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 0

CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT CHRONIC SCHIZOPHRENIA.
002645 0

LOXAPINE SUCCINATE IN THE TREATMENT OF CHRONIC SCHIZOPHRE
00264B 0

COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHR SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SL RELEASE FORM.
002650 0

RESULTS OF MODITEN-DEPOT TREATMENT IN CHRONIC SCHIZOPHRE
002660

ON THE THERAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
002758

URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHR SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS
00279B

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REAC AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHR EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETA PART 1: GROUP PROFILES.
002940

HEMINEURINE ABUSE BY A CHRONIC ALCOHOLIC
002946

EFFICACY OF PIRACETAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
002968 03 17

THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03 17

BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003076 04-02

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE-OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04 03

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTA8-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
003182 04-03

NEUROPEPTIDES: INFLUENCE OF ACUTE AND CHRONIC EFFECTS OF OPIATES.
003199 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION
003293 04-03

EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

THE RESULTS OF PENICILLIN G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
003487 04-04

HYPOTHALAMIC SELF-STIMULATION UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN
003493 04-05

PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003519 04-07

EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

PENFLURIDOL: A DOUBLE-BLIND TRIAL IN CHRONIC SCHIZOPHRENIA.
003542 04-08

THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA: A CONTROLLED STUDY
003546 04 08

EFFECTS ON EMG FEEDBACK, DIAZEPAM AND THEIR COMBINATION ON CHRONIC ANXIETY
003594 04 10

SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY.
003635 04 11

PHARMACOKINETICS OF CHLORPROMAZINE AFTER SINGLE AND CHRONIC DOSAGE.
003664 04-13

ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
003873 04-17

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN.
003883 04-17

CHRONICALLY

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY.
001613 02-05

EFFECT OF CHOLINERGIC DRUGS ON METHADONE-INDUCED CATALEPSY AND STEREOTYPIES IN RATS TREATED CHRONICALLY WITH METHADONE.
002199 03-03

INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE
003334 04-03

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-05

CI-628

EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-628, ON RAT AND HAMSTER LORDOSIS.
001548 02-04

CI-683

RIPAZEPAM (CI-683) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10

CIA

PSYCHIATRISTS, PHYSICIANS AND THE CIA DRUG PROGRAM.
000521 01-07

CIBA-34276-BA

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

CIGARETTE

3. SOCIAL LIFE, CIGARETTE SMOKING, AND URINARY PH.
003707 04-13

CIGARETTES

HERBAL INTOXICATION: PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
000984 01-15

CINEOL

A NOVEL CANNABINOID CONTAINING A 1,8 CINEOL MOIETY.
003061 04-01

CINGULATE

THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03

CIRCADIAN

DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
000265 01-03

EFFECT OF LITHIUM IONS ON CIRCADIAN RHYTHMS.
001479 02-04

CIRCLING

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
000128 01-03

CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04

CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 02-03

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS COERULEUS.
002234 03-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04

MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

EEFECTS OF 1694 AND OTHER DOPAMINERGIC AGENTS ON CIRCLING BEHAVIOR
003B55 04-17

CIRCUIT
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL UNITED STATES V SMITH, 521 F 2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-17

CIRCUITRY
INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS
003143 04-03

CIRCULAR
STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03

CIRCULARITY
FORMATION OF CIRCULARITY AS A MANIFESTATION OF PATHOMORPHOSIS IN SCHIZOPHRENIA
002640 03-08

CIRCULATION
EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000833 01-13

EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-03

THE EFFECT OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS ON THE HEART AND CIRCULATION.
002B90 03-15

SIDE EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME
D03120 04-03

CIRCULATORY
CIRCULATORY MANIFESTATIONS OF SOMA AND PSYCHE.
000717 01-10

SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS
001123 02-03

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF EI 121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY.
002774 03-11

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION
003217 04-03

CIRRHOSIS
INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

CIRRHOTIC
WAIS FUNCTIONING OF CIRRHOTIC AND NON-CIRRHOTIC ALCOHOLICS.
003827 04-1

CIS-CLOPENTHIXOL-DECANOATE
PHARMACOLOGY OF CIS-CLOPENTHIXOL-DECANOATE, A DEPOT NEUROLEPTIC.
003070 04-0

CISTERNAL
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-0

CLASS
MUSCARINIC AGONISTS PROVIDE A NEW CLASS OF ACARICIDE.
000019 01-0

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002B60 03-1

3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-0

CLASSICAL
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE
002508 03-

METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-

CLASSIFICATION
SURVEY AND CLASSIFICATION OF PSYCHOPHARMACOLOGICAL DRUGS.
001036 01-

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-

ON THE CLASSIFICATION OF ANTIDEPRESSANT DRUGS.
003010 03-

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS
003323 04

CLASSROOM
A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
000912 01

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION. (ED.D DISSERTATION).
002B60 03

CLEARANCE
THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES INSIPIDUS
D03300 04

SALIVARY AND URINARY LITHIUM CLEARANCE WHILE RECUMBENT AN UPRIGHT.
003706 04

CLIMBING
CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI CEREBELLUM.
001145 02

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
D02521 03

CLINIC
MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
D010D2 01

ABSENCE OF AN ANTIDEPRESSIVE EFFECT OF LITHIUM IN THE CLINIC AND IN EXPERIMENTS
002313 0

A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC
D02644 0

RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL
DD2777 0

PSYCHOTROPIC DRUGS IN THE CLINIC AND IN PRACTICE.
D02995 0

LITHIUM NONRESPONDERS IN A LITHIUM CLINIC.
DD3569 0

CLINICAL

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
000483 01-07

CLINICAL STUDY OF LIN-1418 (SULTOPRIDE).
000487 01-07

PATIENTS REACTIONS TO CLINICAL DRUG TESTING.
000489 01-07

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
000504 01-07

CLINICAL TRIAL OF SULTOPRIDE.
000505 01-07

STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07

CLINICAL EXPERIENCE IN USING TLP-607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-08

CLINICAL INVESTIGATIONS.
000527 01-08

CLINICAL SPECTRUM OF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE.
000532 01-08

DOUBLE-BLIND CLINICAL COMPARISON OF HF-1854 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
000538 01-08

CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-08

CLINICAL STUDY AND EVALUATION OF A NEW DERIVATIVE OF PHENOTHIAZINE.
000547 01-08

CLINICAL EXPERIENCE IN USING PENFLUPIDOL (TLP-607) FOR SCHIZOPHRENIA.
000559 01-08

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 01-08

CLINICAL STUDY OF PIMOZIDE WITH CHRONIC SCHIZOPHRENICS.
000565 01-08

CLINICAL EXPERIENCE IN USING TLP-607 FOR CHRONIC SCHIZOPHRENIA.
000569 01-08

CLINICAL EXPERIENCE OF THIOTHIXENE (NAVANE) FOR SCHIZOPHRENIA.
000577 01-08

CLINICAL EFFECT OF PENFLURIDOL FOR SCHIZOPHRENIA -- ESPECIALLY DELUSION.
000578 01-08

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
000593 01-09

CLINICAL ASPECTS OF ORGANON-G8-94 VS AMITRIPTYLINE.
000618 01-09

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 01-09

APPLICATION OF SINEQUAN IN THE TREATMENT OF VARIOUS CLINICAL FORMS OF DEPRESSION.
000631, 01-09

CLINICAL STUDY OF A NEW FORM OF DIBENZEPINE, WITH PROTRACTED ACTION.
000633 01-09

CLINICAL TRIAL OF 5-HTP.
000639 01-09

CLINICAL EXPERIENCE OF SEPAZON (CLOXAZOLAM) FOR DEPRESSIVE MANIC.
000644 01-09

CLINICAL PHYSIOLOGICAL STUDY OF DRUGS FOR THE TREATMENT OF PSYCHOSES.
000653 01-09

CLINICAL STUDIES ON THE ANTIDEPRESSANT ACTION OF LOPRAMINE.
000660 01-09

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

EXPERIMENTAL CLINICAL USE OF PINAZEPAM IN PSYCHOSOMATIC MEDICINE.
000673 01-10

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-10

EARLY CLINICAL DRUG EVALUATION UNIT.
000678 01-10

CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
000683 01-10

CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
000689 01-10

CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) - FOR NEUROSES
000697 01-10

CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION.
000700 01-10

CLINICAL AND EXPERIMENTAL STUDY ON TRAZODONE.
000705 01-10

CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CARBONATE.
000709 01-10

CLINICAL EXPERIENCE OF N-DESMETHYLDIAZEPAM (A 101) IN THE FIELD OF PSYCHIATRY.
000712 01-10

CHLORIMIPRAMINE, ITS CLINICAL ACTIONS.
000721 01-10

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11

TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 189 HOSPITALIZED PATIENTS.
000727 01-11

CLINICAL STUDY OF THE EFFECTS OF VINCAMIN IN SENILE DEMENTIA SYNDROME.
000735 01-11

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11

A CLINICAL TRIAL OF PERVINCAMINE-FORTE-RETARD IN NEUROPSYCHIATRY.
000758 01-11

THERAPEUTIC EFFECTS OF TAURINE IN EPILEPSY: A CLINICAL AND POLYPHYSIOGRAPHIC STUDY.
000760 01-11

USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY.
000763 01-11

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
000783 01-11

COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000800 01-13

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 01-13

CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
000881 01-14

EFFECTS IN CLINICAL NEUROLOGY OF THERAPY WITH NOOTROPIC AGENT.
000921 01-14

CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L-DOPA.
000948 01-15

CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSED WOMEN
000994 01-15

METHODOLOGICAL PROBLEMS IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
001005 01-16

CLINICAL PARAMETERS OF ANTIDEPRESSANT ACTIVITY
001010 01-16

PRESENT STATUS OF CLINICAL PSYCHOPHARMACOLOGY.
001017 01-17

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES.
001031 01-17

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

IMPROVED CLINICAL SCREENING OF PHENOTROPIC DRUGS.
001051 01-17

PROPOSED GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF PSYCHOTROPIC DRUGS (REPLICATED).
001053 01-17

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
001057 01-17

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

CLINICAL TRIALS: METHODOLOGY VERSUS PRACTICE -- ATTEMPT AT A COMPROMISE.
001653 02-07

COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07

CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07

BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-07

CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR
001671 02-07

CLINICAL TRIAL OF SULTOPRIDE.
001672 02-07

POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION
001677 02-07

GENERIC AND TRADE-NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE.
001682 02-08

DOUBLE-BLIND CLINICAL STUDY OF CARPIPRAMINE/PLACEBO.
001688 02-08

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
001689 02-08

CLINICAL EFFECT OF L-DOPA ON SCHIZOPHRENIA.
001708 02-08

USE OF DOXEPINE IN THE VARIOUS CLINICAL FORMS OF DEPRESSION
001738 02-09

CLINICAL AND PHARMACOLOGICAL EFFECTS OF TREATMENT WITH A NEW ANTIDEPRESSANT.
001739 02-09

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE ENANTHATE
001741 02-09

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
001758 02-09

DOUBLE BLIND ATTEMPT AT COMPARISON OF EFFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION.
001783 02-09

TREATMENT OF PHOBIC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL.
001791 02-10

PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEED TO BELONG IN THE LIGHT OF THREE CLINICAL CASES
001793 02-10

DOUBLE BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI 6820 BUFOXINE
001811 02-10

DOUBLE BLIND CLINICAL TRIAL OF 5 HYDROXYTRYPTOPHAN IN A CASE OF LESCH NYHAN SYNDROME.
001827 02-11

AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE
001832 02-11

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION REPORT OF A CONTROLLED CLINICAL TRIAL
001839 02-11

CLINICAL STUDIES OF ANESTHETIC CEREBRAL ACTIVATION
001841 02-11

CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN PARALYSIS AGITANS.
001846 02-1

CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS AND HYPERACTIVITY IN CHILDREN
001847 02-1

PREDICTION OF CLINICAL RESPONSE TO LITHIUM.
001870 02-1

CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUDY.
001879 02-1

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001889 02-1

INTRACELLULAR LITHIUM AND CLINICAL RESPONSE.
001895 02-1

CLINICAL ASPECTS OF KINETIC STUDIES ON PERPHENAZINE.
001908 02-1

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY
001909 02-1

CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM.
001914 02-1

CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULATIONS.
001955 02-1

SLEEP AND PSYCHOTROPIC DRUGS: CLINICAL ASPECTS.
001957 02-1

CLINICAL USE OF NARCOTICS.
002007 02-1

METHODOLOGY OF CLINICAL TESTING OF ANTIPSYCHOTICS.
002098 02-1

AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY- AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL.
002106 02-1

SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: BLOOD LEVELS AND CLINICAL RESPONSE.
002120 02-

CLINICAL USE OF ANTIDEPRESSANT DRUGS.
002129 02-

THE NEW DRUG STATUTE AND THE FUTURE OF CLINICAL PSYCHOPHARMACOLOGY
002141 02-

CLINICAL PSYCHIATRY AND PSYCHOPHARMACOLOGY -- A REVIEW.
002168 02-

CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONE IN THE COMMUNITY
002174 02-

CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER
002591 03-

THE CLINICAL EVALUATION OF NEW DRUGS.
002594 03-

CLINICAL EVALUATION OF A WEEKLY ADMINISTERED NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-

FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION
002597 03-

CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENI PSYCHOSIS.
002620 03-

CLINICAL INVESTIGATION OF CLOZAPINE IN SCHIZOPHRENIA
002621 03-

CLINICAL EFFECTS OF TRYPTOPHAN IN CHRONIC SCHIZOPHRENIC PATIENTS
002629 03

CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA
002645 03

RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVA NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN
002647 03

CLINICAL EVALUATION OF FLUPENTHIXOL WITH PROLONGED ACTION
002655 03

INITIAL CLINICAL EVALUATION OF MODITEN-DEPOT
002659 03

CLINICAL EVALUATION OF CLOZAPINE- A FOLLOW-UP STUDY.
002662 03

CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
002664 03

CLINICAL EXPERIENCES WITH NOXIPTILINE
0026B1 03-09

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZONE (F1-6654).
002683 03-09

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10

CLINICAL EVALUATION OF AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF DEPRESSION.
002713 03-10

CLINICAL EVALUATION OF AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES
002714 03-10

PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10

CLINICAL EVALUATION OF LORAZEPAM IN EMERGENCY PSYCHIATRY.
002728 03-10

CLINICAL EVALUATION OF THE EFFECTS OF OXYPERTINE IN STATES OF ANXIETY.
002730 03-10

CLINICAL AND EXPERIMENTAL STUDIES ON THE EFFECTS OF PROPRANOLOL IN ANXIETY.
002733 03-10

CLINICAL EVALUATION OF NITRAZEPAM-POLFA.
002745 03-11

CLINICAL EXPERIENCES WITH FLUPHENAZINE-DECANOATE (DF) IN 50 LONG-TERM PATIENTS.
002756 03-11

PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-11

CLINICAL ASSESSMENT FOR PEDIATRIC PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER).
002775 03-11

CLINICAL DOUBLE-BLIND STUDY WITH TWO DIFFERENT DOSAGES OF MAPROTILINE (150 AND 225MG PER DAY).
002793 03-11

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13

ON THE CLINICAL PHARMACOLOGY OF PENFLURIDOL.
002B24 03-13

IMPORTANCE OF THE DOPAMINE METABOLISM FOR THE CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
002B41 03-13

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002B63 03-14

THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
002B64 03-14

CLINICAL MANAGEMENT OF SEXUAL DISORDERS.
002B66 03-14

CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
002BB6 03-15

OROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY.
002911 03-15

A CASE PRESENTING SOME REACTIVE CLINICAL SIGNS DURING TREATMENT OF L-DOPA.
002930 03-15

STUDIES ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS
00295B 03-17

CLINICAL THERAPEUTIC REPORTS ON ADDICTION TO RARE DRUGS.
002969 03-17

DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE. CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT PART II.
002971 03-17

CLINICAL AND PHARMACOLOGICAL SPECTRAL MAPS OF THE NEUROLEPTICS.
003009 03-17

EXPERIMENTAL AND CLINICAL VECTORS IN PHARMACOLOGY.
003013 03-17

IMPORTANCE OF DOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE EFFECTS OF NEUROLEPTICS
003043 03-17

CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
003520 04-07

A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION
003525 04-07

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE - A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PSYCHIATRIC ASPECTS.
003555 04-09

CLINICAL IMPLICATIONS OF IMIPRAMINE PLASMA LEVELS FOR DEPRESSIVE ILLNESS.
003560 04-09

LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
00356B 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PHARMACOLOGICAL ASPECTS.
003574 04-09

AMOXAPINE: A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
003577 04-09

A CONTROLLED CLINICAL STUDY WITH CLOBAZAM -- A NEW ANXIOLYTIC AGENT.
0035B5 04-10

CLINICAL TRIAL COMPARISON OF TWO SUSTAINED-RELEASE FORMS OF AMITRIPTYLINE.
0035B6 04-10

PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003597 04-10

PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003599 04-10

A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
003603 04-10

FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-11

CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11

CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
003643 04-11

THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

CLINICAL PHARMACOKINETICS OF LORAZEPAM. II. INTRAMUSCULAR INJECTION
003675 04-13

CLINICAL EFFECTS AND PHARMACOKINETICS OF RACEMIC METHADONE AND ITS OPTICAL ISOMERS.
003694 04-13

INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
003709 04-13

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: CLINICAL STUDIES.
003716 04-13

REDUCED CATECHOLAMINERGIC TRANSMISSION AND CLINICAL EFFECTS OF NEUROLEPTICS.
00371B 04-13

LITHIUM TREATMENT IN THE ELDERLY. I. CLINICAL USAGE.
0037B1 04-15

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
003B07 04-15

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003B66 04-17

LITHIUM AS AN ANTIDEPRESSANT: DISCOVERIES THROUGH CLINICAL OBSERVATIONS.
003B92 04-17

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

CLINICOBIOLOGICAL

CLINICOBIOLOGICAL OBSERVATIONS ON ANXIETY/.
000706 01-10

CLINICOPATHOPHYSIOLOGICAL
DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN.
DD27D1 D3-D9

CLINICOTHERAPEUTIC
NOTE 2: DEPRESSION IN THE DEVELOPMENTAL AGE: CLINICOTHERAPEUTIC STUDY OF DEPRESSION IN THE DEVELOPMENTAL AGE.
DD2725 D3-1D

CLINICS
PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
DD2B54 D3-14

DRUG-DEPENDENCE CLINICS.
DD38D5 04-15

CLOBAZAM
STUDY IN A PEDIATRIC MILIEU OF AN ANTIANXIETY DRUG: CLOBAZAM.
0DD494 D1-07

EFFECT OF THE 1,5 BENZODIAZEPINES, CLOBAZAM AND TRIFLUBAZAM, ON THE SLEEP OF MAN.
DD1657 D2-07

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
D03248 04-D3

A CONTROLLED CLINICAL STUDY WITH CLOBAZAM -- A NEW ANXIOLYTIC AGENT.
DD3585 D4-10

CLOCKS
DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS.
DD1907 02-13

CLOMIPRAMINE
SINGLE-DOSE STUDIES WITH CLOMIPRAMINE IN NORMAL SUBJECTS.
DDD135 D1-D3

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN
DDD136 D1-D3

EVALUATION OF THE NEW DRUG -- CLOMIPRAMINE (ANAFRANIL).
DD0522 01-D7

PLASMA PROLACTIN CONCENTRATIONS IN PATIENTS ON CLOMIPRAMINE.
DDD586 D1-09

THE EFFECT OF CLOMIPRAMINE (ANAFRANIL) ON CONTINUING PAIN.
DDD636 D1-09

A CONTROLLED STUDY OF THE ASSOCIATION OF CLOMIPRAMINE AND LITHIUM.
0DD643 D1-D9

EFFECTS OF CLOMIPRAMINE AND OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
0DD665 D1-09

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
DD0741 D1-11

COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
D0122B D2-D3

THE EFFECT OF CLOMIPRAMINE ON PROLACTIN LEVELS -- PILOT STUDIES.
001745 D2-09

CLOMIPRAMINE IN PHOBIC AND OBSESSIONAL STATES: PRELIMINARY REPORT.
DD17B9 D2-10

TREATMENT OF PHOBIC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL.
DD1791 D2-1D

COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION
DD26B2 03-D9

SLEFP DEPRIVATION AND CLOMIPRAMINE IN ENDOGENOUS DEPRESSION.
DD27D5 D3-D9

POTFNTIATION OF THE ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN
DD2B44 D3-13

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS
D03227 D4-D3

THF MANAGEMENT OF PHOBIC DISORDERS USING CLOMIPRAMINE (ANAFRANIL).
DD36DB 04-10

A COMPARISON OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE RFGIMFS
D03621 D4-11

MASS FRAGMFNTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODFMETHYLATED METABOLITE IN HUMAN PLASMA.
DD3653 04-13

AN INVFSTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT.
DD3657 D4-13

COMPARISONS OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
DD3672 D4-1

PLASMA LEVEL STUDIES WITH CLOMIPRAMINE (ANAFRANIL).
0D3679 04-1

PRACTICAL CONSIDERATIONS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE: AN UPDATED REVIEW.
003764 04-1

SEXUAL SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL).
003765 04-1

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
D03BD7 D4-

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
DD3B66 D4-

CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERA PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
0D3891 D4-

CLONAZEPAM
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTI MYOCLONUS, AND ATONIC SEIZURES.
0DD969 D1-

CLONAZEPAM: A REVIEW OF A NEW ANTICONVULSANT DRUG.
0D1D22 D1-

CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
D01663 D2-

THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM (THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
D02337 D3

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTI DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
D03511 D4

CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
D03643 D4

STIFF-MAN SYNDROME AND CLONAZEPAM.
003650 D4

CLONIDINE
STIMULATION OF CEREBRAL HISTAMINE H2-RECEPTORS BY CLONIDINE
DD0D39 D1

STUDIES ON THE SITE OF ACTION OF CLONIDINE UTILIZING A SYMPATHETIC CHOLINERGIC SYSTEM.
DDD144 D1

ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
DD0346 D1

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
0D11BB 02

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
D01375 02

AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF STIMULATION IN CAUDATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
D01384 03

ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
0D1492 D3

INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOU IN RODENTS.
DD1519 0

INFLUENCE OF 6-HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
DD2463 0

PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXA BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE
DD3142 0

THE INTERACTION BETWEEN CLONIDINE AND VARIOUS NEUROLEPTIC AGENTS AND SOME BENZODIAZEPINE TRANQUILLIZERS.
DD3312 0

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS COERULEUS LESIONED RATS.
DD3371 0

POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE
0D3450 0

BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS
003471 04-04
THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE: STUDIES IN TETRAPLEGIC SUBJECTS.
003701 04-13

CLONIDINE-INDUCED
THE REVERSAL OF CLONIDINE-INDUCED HYPOTENSION BY PROTRIPTYLINE AND DESIPRAMINE.
00024B 01-03
CLONIDINE-INDUCED LOCOMOTOR HYPERACTIVITY IN RATS.
002561 03-04
EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03

CLOPIMOZIDE
LONG-ACTING NEUROLEPTICS: A PRELIMINARY STUDY OF CLOPIMOZIDE (R29764).
001655 02-07

CLOPREDNOL
EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION.
001934 02-13

CLORAZEPATE
EFFECTS OF DIKALIUM CLORAZEPATE ON SERUM LEVELS AND METABOLITES.
000766 01-11
AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14
STEADY-STATE BIOAVAILABILITY OF TWO CLORAZEPATE DIPOTASSIUM DOSAGE FORMS.
003662 04-13

CLORGYLINE
EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04

CLOTHIAPINE
CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11
ANTIDEPRESSANT ACTION OF CLOTHIAPINE.
0017B6 02-10

CLOUDS
PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON.
001796 02-10

CLOXAZOLAM
CLINICAL EXPERIENCE OF SEPAZON (CLOXAZOLAM) FOR DEPRESSIVE MANIC.
000644 01-09
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14
EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

CLOZAPINE
DOPAMINE METABOLISM IN THE NUCLEUS-ACCUMBENS: THE EFFECT OF CLOZAPINE.
000260 01-03
MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07
DOUBLE-BLIND CLINICAL COMPARISON OF HF-1B54 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
00053B 01-0B
INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03
ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03
CLOZAPINE: REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT.
001412 02-03
INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
0015B3 02-04
PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-08
ANTIPSYCHOTIC EFFECTIVENESS IN RELATION TO PLASMA LEVEL OF CLOZAPINE
001878 02-13
CLINICAL INVESTIGATION OF CLOZAPINE IN SCHIZOPHRENIA.
002621 03-0B
DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-08
ON THE PROBLEM OF SIDE-EFFECTS OF CLOZAPINE
002657 03-0B
CLINICAL EVALUATION OF CLOZAPINE: A FOLLOW-UP STUDY.
002662 03-08
ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OF AMITRIPTYLINE AND CLOZAPINE.
002671 03-09
CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
00354B 04-0B
CLOZAPINE AND AGRANULOCYTOSIS.
003B25 04-15

CLUBBING
CLUBBING -- A SIDE-EFFECT OF LONG-TERM PHENOTHIAZINES TREATMENT.
002905 03-15

CLUSTER
CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11

CMHC
PEER REVIEW OF PRESCRIBING PATTERNS IN A (CMHC).
001033 01-17

CN-69725-27
INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04

CNS
CNS DEPRESSANTS: EFFECTS ON POSTSYNAPTIC PHARMACOLOGY.
000043 01-03
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03
VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-03
EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04
CHANGES IN CNS RESPONSIVENESS DURING HIBERNATION.
001136 02-03
ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
00121B 02-03
EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03
THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03
BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06
DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS.
001907 02-13
INTERACTION OF BRADYKININ WITH DOPAMINERGIC RECEPTORS IN THE CNS.
002507 03-04
PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY.
002959 03-17
DISCRIMINABLE STIMULI PRODUCED BY ALCOHOL AND OTHER CNS DEPRESSANTS.
002964 03-17

CNV
BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04-14

COAGULATION
CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
003S4B 04-0B

COATED
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEOIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUOY.
003774 04-1S

COBALT
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

COBALT-INDUCED
TAURINE AND COBALT-INDUCED EPILEPSY IN THE RAT: A BIOCHEMICAL AND ELECTROCORTICOGRAPHIC STUDY.
0012S6 02-03

COCA
ANDEAN COCA CHEWING: A METABOLIC PERSPECTIVE.
002B02 03-13

DIFFERENCES IN THE EXPERIENCES OF USING COCA AND COCAINE.
0037S6 04-14

COCAINE
COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03

COCAINE SELF-ADMINISTRATION IN MONKEYS BY CHEWING ANO SMOKING
000424 01-04

TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-0S

CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COCAINE AOMINISTRATION IN HUMANS.
000B90 01-14

COCAINE, KINDLING, AND PSYCHOSIS.
000911 01-14

DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03

PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03

EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03

COCAINE CUE IN RATS AS IT RELATES TO SUBJECTIVE DRUG EFFECTS: A PRELIMINARY REPORT.
001462 02-04

BEHAVIOR MAINTAINED UNDER A SECOND-OROER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
00149S 02-04

PROPRANOLOL IN COCAINE TOXICITY.
001BS2 02-11

MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNOER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
0024S7 03-04

ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002SS6 03-04

COCAINE AND MORPHINE SELF-ADMINISTRATION: EFFECTS OF DIFFERENTIAL REARING.
002SB5 03-06

AMPHETAMINE AND COCAINE ABUSE. (UNPUBLISHED PAPER).
0029B7 03-17

COCAINE SNORTING FOR FUN
003020 03-17

POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03

SENSITIZATION TO COCAINE STIMULATION IN MICE.
00327B 04-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

EFFECTS OF COCAINE AND D-AMPHETAMINE ON BEHAVIOR MAINTAINED UNOER VARIOUS SCHEDULES OF FOOO PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-04

COCAINE EFFECTS ON SLEEP PARAMETERS IN THE RAT.
003403 04-04

THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS ANO RHESUS-MONKEYS.
003406 04-04

A KICK FROM COCAINE.
003732 04-14

DIFFERENCES IN THE EXPERIENCES OF USING COCA AND COCAINE.
0037S6 04-14

COCHLEA
CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-0ECARBOXYLASE AND TYROSINE-HYDROXYLASE IN THE COCHLEA ANO COCHLEAR NUCLEUS OF THE GUINEA-PIG.
0010BS 02-01

COCHLEAR
CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECARBOXYLASE AND TYROSINE-HYOROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG.
0010BS 02-01

CODEINE
TERATOLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-0S

A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-02

VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY.
0014S4 02-04

SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACIO IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04-03

COENZYMES
ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYOROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
0021B4 03-01

COERULOPLASMIN
INTERACTION OF SOME NEUROLEPTIC AND ANTIDEPRESSIVE AGENTS WITH HUMAN COERULOPLASMIN
000B41 01-1

COEXISTING
COEXISTING TARDIVE-DYSKINESIA AND PARKINSONISM: A CASE REPORT.
00366S 04-1

COFFEE
DOSE-RELATED SLEEP DISTURBANCES INDUCEO BY COFFEE AND CAFFEINE.
001973 02-1

COGNITION
PHYSOSTIGMINE: EFFECTS ON COGNITION AND AFFECT IN NORMAL SUBJECTS
00196S 02-1

COGNITIVE
SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9 TETRAHYDROCANNABINOL.
000796 01-1

THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-1

COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA -- PILOT EXPERIMENT.
001B64 02-1

EFFECTS OF MARIJUANA, EXPECTATION AND SUGGESTIBILITY ON COGNITIVE FUNCTIONING.
001963 02-1

ALCOHOL AND TENSION REDUCTION: COGNITIVE AND PHYSIOLOGICAL EFFECTS.
0019B4 02-1

CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.
002060 02-1

AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHOOYSLEPTICS.
002796 03-1

THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002BS7 03-1

ACTH4-10: COGNITIVE AND 8EHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING DISABLED CHILDREN
002872 D3-14
THE EFFECT OF LITHIUM-CAR8ONATE ON THE COGNITIVE FUNCTIONS OF NORMAL SU8JECTS.
003736 D4-14

COGWHEEL
COGWHEEL RIGIDITY EARLY IN LITHIUM THERAPY
002D15 02-15
REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY
0D2076 D2-15

COHESIVENESS
SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITA8ILITY INDUCED 8Y P-CPA IN THE RAT.
D01464 D2-D4

COINCIDENCE
COINCIDENCE OF 8LOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
0DD143 D1-03

COLITIS
COLITIS AND HEPATITIS CAUSED 8Y METHYLDOPA.
DD2D17 D2-15

COLLABORATIVE
NIMH-PR8 COLLA8ORATIVE STUDY OF LONG-ACTING FLUPHENAZINE.
0DD550 D1-08
CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE 8OSTON COLLA8ORATIVE DRUG SURVEILLANCE PROGRAM.
DD0976 D1-15

COLLATERAL
CLINICAL RESEARCH ON THE COLLATERAL DISINHI8ITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
DD1663 D2-D7

COLLEGE
ON THE TREATMENT OF MENTALLY DISTURBED COLLEGE STUDENTS.
DD1D47 D1-17
ADVERSE REACTIONS TO MARIHUANA USE AMONG COLLEGE STUDENTS.
DD2896 D3-15

COLLICULUS
SUPERIOR COLLICULUS LESIONS AND THE SU8SEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY. (PH.D. DISSERTATION).
0D2272 D3-D3

COLONY
BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
DDD415 D1-D4

COLOR
EVIDENCE FOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION.
DDD873 D1-14

COMA
DELAYED FORCED DOWN GAZE DURING OCULOVESTI8ULAR TESTING IN SEDATIVE DRUG-INDUCED COMA.
DD3826 D4-15

COMBINATION
THERAPEUTICAL EFFICACY OF A COM8INATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
DDD48B D1-D7
THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
DDD5D7 D1-D7
TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOU8LE-8LIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION.
DDD658 D1-D9
TREATMENT OF PARKINSONISM WITH A COM8INATION OF L-DOPA AND METHYLDOPA HYDRAZINE.
DDD87D D1-13
EFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY.
DD1453 02-D4
EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
DD1661 D2-D7
THF TRFATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-741D).
DD1773 D2-D9
EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
DD1815 D2-11
EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COM8INATION.
DD2D32 D2-15
EEG AND BEHAVIORAL EFFECTS OF DFLTA9 TETRAHYDROCANNA8INOL IN COM8INATION WITH STIMULANT DRUGS IN RA88ITS.
002434 D3-D4
THE ACTION OF TRICYCLICS (ALONE OR IN COMBINATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY
002782 03-11
THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANCE, ALONE AND IN COM8INATION WITH ETHANOL.
002858 03-14
TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COM8INATION (MERSYNDOL).
003039 03-17
TRYPTOPHAN NICOTINAMIDE COM8INATION IN DEPRESSION.
0D3553 04-09
EFFECTS ON EMG FEED8ACK, DIAZEPAM AND THEIR COM8INATION ON CHRONIC ANXIETY.
DD3594 04-10
A COMPARATIVE TRIAL OF ANAFRANIL, PERTOFRAN AND AN ANAFRANIL/PERTOFRAN COM8INATION.
DD3636 D4-11

COMBINATIONS
THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHI8ITOR COM8INATIONS: SUPPRESSION OF SELF-STIMULATION.
0D034D D1-D4
EFFECT OF NEUROLEPTICS AND OF COM8INATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
0D2231 D3-D3
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COM8INATIONS OF POSITIVE AND NEGATIVE ICS.
DD2444 D3-D4
EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
DD2458 D3-D4
WHOS GOT THE WRONG IDEA A8OUT TREATING DEPRESSION? ... A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COM8INATIONS IS O8VIOUSLY NEEDED.
DD2685 D3-D9

COMBINED
EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
DDDD52 01-D3
COM8INED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
DDDD55 D1-D3
EFFECTS OF COM8INED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT 8EHAVIOR AND MOTILITY OF RATS.
DDD277 D1-D4
COM8INED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHI8ITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
DDD359 D1-D4
STUDIES ON THE COMBINED USE OF DIAZEPAM WITH EXPOSURE IN VIVO.
DDD695 D1-10
ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECAR8OXYLASE INHIBITOR.
DDD745 D1-11
CLINICAL EXPERIENCES WITH THE COM8INED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
D0D756 D1-11
L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHI8ITOR (MK-486) IN PARKINSONISM.
D0D767 D1-11
COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL.
DDD828 D1-13
COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
DD1757 D2-D9
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENO8AR8ITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
DD2363 03-D3
COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION
DD2682 D3-D9
COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
DD2795 03-11
APPLICATION OF 8ETA-RECEPTOR BLOCKING AGENTS IN COM8INED THERAPY OF ENDOGENOUS PSYCHOSIS.
0D2972 D3-17

COM8INED USE OF NEUROLEPTIC DRUGS.
003414 04-04

A REVIEW OF COM8INED TRICYCLIC AND MAOI THERAPY.
003846 04-17

COMBINING

COM8INING TRICYCLIC AND MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS.
002936 03-15

COMMUNICATION

DELTA9-THC AND NONVER8AL COMMUNICATION IN MONKEYS.
0003B3 01-04

SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION. (UNPU8LISHED PAPER).
001173 02-03

COMMUNITY

HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-0B

M8D, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSI8ILITY AND COMMUNITY CONTROL/FE8RUARY 13-14, 1976.
002167 02-17

CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONF IN THE COMMUNITY.
002174 02-17

CASE STUDIES IN PSYCHIATRIC MANAGEMENT: HOSPITAL TO COMMUNITY.
002853 03-14

THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003841 04-16

THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
003873 04-17

COMPARED

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPFRIDOL 8Y A DOUBLE-8LIND TEST.
000562 01-08

SOME BEHAVIORAL EFFECTS OF PRETHCAMIDE COMPARED WITH THOSE OF ITS TWO COMPONENTS.
001437 02-04

A DOUBLE-8LIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARFD TO ITS RACEMIC FORM.
001670 02-07

EFFECTS OF TWO DIFFERFNT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING 8EHAVIOR IN HUMANS.
002000 02-14

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-0B

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LI8RIUM AND PLACF8O IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

COMPARING

AN EVALUATION OF THE DOU8LE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CAR8ONATE WITH PLACE8O.
001842 02-11

A MULTICENTRE STUDY COMPARING MAZINDOL AND PLACE8O IN OBESE PATIENTS.
003648 04-11

COMPARISON

HUMAN ENDORPHIN: COMPARISON WITH PORCINE ENDORPHIN, ENKFPHALIN AND NORMORPHINE.
000006 01-01

SOME NEUROTOXIC PROPERTIFS OF TRIETHYLENE-GLYCOL-DINITRATF: A COMPARISON WITH DFCAMETHONIUM.
000034 01-03

RESPONSES OF MID8RAIN NEURONES TO MICROIONTOPHORETICALLY APPLIFD 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

A COMPARISON OF THF ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDFPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03

TRYPTOPHAN-HYDROXYLASE IN DISCRETE BRAIN NUCLEI: COMPARISON OF ACTIVITY IN VITRO AND IN VIVO.
000168 01-03

A DOSF RESPONSE COMPARISON BETWEEN METHADONE AND MORPHINE SFLF ADMINISTRATION.
000255 01-03

ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS.
000273 01-04

SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNA8INOL: A COMPARISON WITH OTHER DRUGS.
000377 01-04

STUDIES WITH BROMOCRIPTINE: PART 2. DOU8LE-8LIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07

A DOU8LE-8LIND COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
000502 01-07

DOUBLE-8LIND CLINICAL COMPARISON OF HF-1B54 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
000538 01-0B

A DOUBLE-BLIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-08

A DOU8LE-BLIND COMPARISON OF TPN-12 AND CHLORPROMAZINE ON SCHIZOPHRENIA.
000552 01-08

COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOU8LE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-0B

LOXAPINE SUCCINATE: A DOU8LE-8LIND COMPARISON WITH HALOPERIDOL AND PLACE8O IN ACUTF SCHIZOPHRENICS.
000567 01-0B

A DOU8LE-8LIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
0005B9 01-09

A DOUBLE-8LIND COMPARISON OF LITHIUM-CAR8ONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09

CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000604 01-09

A DOU8LE-8LIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS DOU8LE-8LIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COM8INATION.
000658 01-09

A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOU8LE-8LIND COMPARISON WITH CHLOPOXIDE AND PLACE8O.
000691 01-10

EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE
000694 01-10

RIPAZEPAM (CI-683) DOU8LE-8LIND COMPARISON WITH PLACE8O IN ANXIOUS PATIENTS.
000707 01-10

COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-1

COMPARISON OF 8ROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM 8Y A DOU8LE-8LIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON
000768 01-11

COMPARISON OF FEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA
000800 01-1

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS
000836 01-1

COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS META8OLISM OF IMIPRAMINE IN HUMANS.
000B50 01-1

THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACE8O IN INPATIENT INSOMNIACS
00087B 01-1

REGIONAL SEROTONIN LEVELS IN BRAIN: A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000BB3 01-1

COMPARISON OF THE INHI8ITION OF 5-HYDROXYTRYPTAMINE UPTAKE 8Y METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
000933 01-1

A COMPARISON OF CONSUMPTION OF PSYCHOPHARMACOLOGICAL DRUGS.
001030 01-1

COMPARISON OF DANTROLENE SODIUM AND DIAZEPAM IN THE TREATMENT OF SPASTICITY.
001070 01-17

THE PLANNING OF A THERAPEUTIC COMPARISON IN PSYCHOPHARMACOLOGY
001077 01 17

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
00111B 02-02

ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE.
001119 02-03

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
001215 02-03

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 02-03

COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
00122B 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03

CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03

COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM.
001413 02-03

COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN.
001419 02-03

THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04

COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04

A COMPARISON OF THE EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON EXPLORATION AND ON ITS HABITUATION
0014B3 02-04

A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
001494 02-04

COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001503 02-04

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04

AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
00161B 02-05

COMPARISON OF LITHIUM SALTS.
00165B 02-07

COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-0B

EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 02-09

A COMPARISON OF AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES.
001731 02-09

EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA 335 BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

DOUBLE-BLIND ATTEMPT AT COMPARISON OF EFFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION
0017B3 02-09

A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
001B10 02 10

AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
001B18 02-11

COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001B43 02-11

METHADONE/LAAM MAINTENANCE: A COMPARISON STUDY.
001B56 02-11

COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
001B67 02-12

A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14

EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS; COMPARISON WITH BLOOD LEVELS.
002041 02-15

A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFERENT TYPES OF MORPHINE PELLETS.
002311 03-03

COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON
002334 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

9-NOR-9-HYDROXYHEXAHYDROCANNABINOLS. SYNTHESIS, SOME BEHAVIORAL AND ANALGESIC PROPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-03

COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-04

A COMPARISON OF THE CENTRAL ACTION OF SOME PROSTAGLANDINS /PGS/ IN RATS.
0024B4 03-04

COMPARISON OF THE DOPAMINERGIC EFFECTS OF N-SUBSTITUTED APORPHINES.
00249B 03-04

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-0B

A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
002627 03-0B

ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OF AMITRIPTYLINE AND CLOZAPINE.
002671 03-09

A DOUBLE-BLIND COMPARISON OF DOXEPIN AND NORTRIPTYLINE ON DEPRESSION
002676 03-09

DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
0026B9 03-09

A DOUBLE-BLIND COMPARISON OF SULPIRIDE WITH CHLORDIAZEPOXIDE IN NEUROSIS.
002732 03-10

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-11

A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS.
002776 03-11

COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002B13 03-13

COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM.
002B15 03-13

ANTICONVULSANT-INDUCED DYSKINESIAS: A COMPARISON WITH DYSKINESIAS INDUCED BY NEUROLEPTICS.
002B91 03-15

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
00305B 04-01

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE ISOLATED PERFUSED RAT BRAIN.
003274 04-03

EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND L-AMPHETAMINE.
003314 04-03

ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-04

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
003388 04-04

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

PIMOZIDE VERSUS FLUPHENAZINE IN AMBULATORY SCHIZOPHRENICS: A 12-MONTH COMPARISON STUDY.
003534 04-08

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09

CLINICAL TRIAL COMPARISON OF TWO SUSTAINED-RELEASE FORMS OF AMITRIPTYLINE.
0035B6 04-10

CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10

A COMPARISON OF MAPROTILINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
003604 04-10

A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
003606 04-10

A COMPARISON OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003621 04-11

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
003634 04-11

COMPARISON OF PIMOZIDE WITH HALOPERIDOL IN GILLES-DE-LA-TOURETTE SYNDROME.
003641 04-11

A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL BETA-ADRENERGIC ADENYLATE-CYCLASE.
00366B 04-13

COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003B97 04-17

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

COMPARISONS

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03

PHARMACOKINETICS OF PENTOBARBITAL IN THE CAT AND COMPARISONS WITH THE RABBIT AND MAN.
003317 04-03

BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL-3912A) WITH R-DOM AND S-AMPHETAMINE.
003470 04-04

COMPARISONS OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003672 04-13

COMPETENCY

USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-1

COMPLEMENTARY

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
00042B 01-0

COMPLETED

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
001986 02-1

COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003B97 04-1

COMPLEX

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
0000B1 01-0

THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-0

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-1

EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-0

SENSITIVITY OF COMPONENTS OF THE CENTRAL VESTIBULAR COMPLEX TO PENTOBARBITAL.
003225 04-0

THE PHYSICAL AND BEHAVIOURAL COMPLEX OF DEMENTIA.
003B93 04-1

COMPLEXES

MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-1

COMPLEXING

MOBILIZATION OF METHYLMERCURY IN VIVO AND IN VITRO USING N-ACETYL-DL-PENICILLAMINE AND OTHER COMPLEXING AGENTS.
002197 03-0

COMPLIANCE

A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION-SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-0

COMPLICATIONS

PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION
000466 01-0

COMPLICATIONS AND SIDE-EFFECTS IN LONG-TERM TREATMENT WITH PRACTOLOL.
000931 01-1

PSYCHOTHERAPEUTIC DRUGS: HOW TO MINIMISE COMPLICATIONS OF THERAPY.
002024 02-1

CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE.
00207B 02-1

COMPOSITION
THE EFFECTS OF LONG TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN.
003633 04-11

COMPREHENSIVE
PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
000610 01-09
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
001057 01-17
AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10

COMPROMISE
CLINICAL TRIALS- METHODOLOGY VERSUS PRACTICE -- ATTEMPT AT A COMPROMISE.
001653 02-07

COMPULSIVE
INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04
COMPULSIVE WATER DRINKING DURING DEPRESSIVE REACTION.
000688 01-10
WATER POISONING AND DIABETES-INSIPIDUS: A PROPOS COMPULSIVE WATER DRINKING AND DYSTHYMIA.
002717 03-10
LSD TREATMENT IN A SEVERE CASE OF COMPULSIVE NEUROSIS.
0035B3 04-10
PHENYTOIN AS A TREATMENT OF OBESITY ASSOCIATED WITH COMPULSIVE EATING.
003622 04-11

COMPUTER
COMPUTER USE IN BEHAVIORAL STUDY.
000272 01-04

COMT
IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-03

CONCENTRATION
INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN-F2ALPHA.
0001B3 01-03
CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
00045B 01-05
DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE.
001144 02-03
DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03
EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION
001365 02-03
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03
CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUDY.
001879 02-13
EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03
CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11
EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03
CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
003548 04-08
THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

CONCENTRATIONS
TEMPORAL AND REGIONAL DIFFERENCES IN BRAIN CONCENTRATIONS OF LITHIUM IN RATS.
000179 01-03
PLASMA PROLACTIN CONCENTRATIONS IN PATIENTS ON CLOMIPRAMINE
000586 01-09
THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09
PLASMA AND ERYTHROCYTE CONCENTRATIONS OF LITHIUM.
000722 01-10
CEREBROSPINAL FLUID CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN MAN
000832 01-13
MONITORING PLASMA CONCENTRATIONS OF NEUROLEPTICS.
000837 01-13
REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM
000B64 01-13
SERUM CONCENTRATIONS OF TRIIMIPRAMINE IN HEALTHY SUBJECTS.
000918 01-14
PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSED WOMEN.
000994 01-15
THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
001140 02-03
CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001B62 02-11
DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS.
002242 03-03
ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03
PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10
ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS.
002755 03-11
INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03
BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03
THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03
CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-04
EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04
FACTORS INFLUENCING PLASMA DRUG CONCENTRATIONS.
0036B5 04-13
ABSORPTION RATE, BLOOD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPOXIDE.
003731 04-14
ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

CONCEPT
THE CONCEPT OF DRUG AUTOMATISM.
000950 01-15
THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY.
002996 03-17

CONCEPTS
DEPRESSION: BEHAVIORAL, BIOCHEMICAL, DIAGNOSTIC AND TREATMENT CONCEPTS.
001746 02-09
NEWER CONCEPTS IN MANAGEMENT OF MIGRAINE HEADACHES.
003867 04-17

CONCEPTUAL
MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION.
000591 01-09
PSYCHOTHERAPY AND PHARMACOTHERAPY: CONCEPTUAL ISSUES.
003857 04-17

CONCLUSIVE
STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

CONCOMITANTS
THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION
003341 04-04

CONDITION
MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION.
003B56 04-17

CONDITIONAL
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03
INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPFATED ADMINISTRATION
001466 02-04
ALLEVIATION OF NARCOTIC WITHDRAWAL BY CONDITIONAL STIMULI.
002292 03-03

CONDITIONED
SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS.
000377 01-04
EFFECTS OF ANTICHOLINERGIC AGENTS ON CONDITIONED INHIBITION IN THE RAT. (PH.D. DISSERTATION).
000440 01-04
CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
000442 01-04
DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE-AVERSION.
000913 01-14
CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA.
00146B 02-04
CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04
EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04
CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
001589 02-04
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS
001610 02-04
UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
00226B 03-03
THE EFFFCT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-03
ROLE OF CONDITIONFD REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
002437 03-04
CONDITIONFD BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPFNDFNT MONKEYS.
002456 03-04
RAT STRAIN DIFFERFNCFS IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND IN THF EFFECTS OF DIAZEPAM
0024BB 03-04
ENHANCING EFFECTS INDUCED BY RFPEATED ADMINISTRATIONS OF DIAZFPAM ON CONDITIONED SUPPRESSION IN RATS.
0024B9 03-04
EFFECTS OF 2-PROPYL 2 PENTENOIC ACID ON THE ACQUISITION OF CONDITIONFD BEHAVIOR WITH NEGATIVE REINFORCEMFNT IN MICE.
002501 03-04
THE EFFECTS OF ANALGESICS ON THE CONDITIONED BEHAVIOR OF RATS (II).
002509 03-04
POSSIBLE INVOLVEMENT OF CENTRAL FACTORS IN THE MEDIATION OF CONDITIONED TASTE-AVERSION.
003081 04-03
PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION.
003360 04-04
ENDURING EFFECTS OF MORPHINE PELLETS REVEALED BY CONDITIONED TASTE-AVERSION.
003424 04-04
EFFECTS OF TRYPTAMINE ON THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
00347B 04-04

CONDITIONING
MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03
THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04
CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-03
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-04
A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04
EFFECTS OF WATER DEPRIVATION AND PRIOR LICL EXPOSURE IN CONDITIONING TASTE-AVERSIONS.
001597 02-04
EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05
CONDITIONING OF DISCRIMINABLE STIMULI PRODUCED BY MORPHINE.
002499 03-04
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
00250B 03-04
LONG-DELAY BACKWARD TASTE-AVERSION CONDITIONING WITH LITHIUM.
00337B 04-04
FINDINGS WITH A CONDITIONING TEST BATTERY: DIFFERENTIAL RESPONSIVENESS TO DIAZEPAM AND DOXEPIN.
003580 04-10

CONDITIONS
EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
0003B9 01-04
EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000B33 01-13
PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14
DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03
AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10
INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001840 02-11
INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17
TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
0022B2 03-03
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
002289 03-03
ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OF AMITRIPTYLINE AND CLOZAPINE.
002671 03-09

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

CONDUCTANCE
DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH
001290 02-03
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE
001982 02-14

CONDUCTING
PROPOSED GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF PSYCHOTROPIC DRUGS (REPLICATED).
0010S3 01 17

CONDUCTION
TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION. CHANGES IN VENTRICULAR AUTOMATICITY.
002562 03-0S
DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002826 03-13

CONFERENCE
CONFERENCE ON DEPRESSION IN RIO-DE-LA-PLATA.
000642 01-09
MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17
THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
003B73 04-17

CONFIGURATION
THE ABSOLUTE CONFIGURATION OF SU-23397: A NOVEL NEUROLEPTIC AGENT.
003049 04-01

CONFINEMENT
PHARMACOTHERAPY AND CONFINEMENT OF PATIENTS.
003032 03-17

CONFIRMED
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03

CONFLICT
EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

CONFORMATION
CYCLOPENTONE DERIVATIVES RELATED TO MEPROBAMATE: CONFORMATION ACTIVITY RELATIONSHIPS.
000013 01-01
INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION
003051 04-01

CONFORMATIONAL
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
0030S9 04-01

CONFORMATIONS
EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

CONFUSED
A DOUBLE-BLIND TRIAL OF NAFTIDROFURYL IN TREATING CONFUSED ELDERLY PATIENTS IN GENERAL PRACTICE.
003612 04-11

CONFUSIONAL
ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OF AMITRIPTYLINE AND CLOZAPINE.
002671 03-09

CONGENERS
VINYL ETHERS OF CHOLINE AND CONGENERS.
000067 01-03
COMPARISON OF THE INHIBITION OF S HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
000933 01-1S

CONGENITAL
A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
00162S 02-0S

CONGRESS
PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY
0029S9 03 17

CONJUGATED
THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3 METHOXY-4 HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-0B

CONNECTIONS
STUDIES OF CONNECTIONS BETWEEN LOCUS-COERULEUS AND CEREBRAL CORTEX.
000040 01-03

CONSCIOUS
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
THE INFLUENCE OF MEPROBAMATE ON HEART RATE IN THE CONSCIOUS DOG.
001615 02-0S
A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17
ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTAB-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

CONSCIOUSNESS
SYMPOSIUM ON ALTERED STATES OF CONSCIOUSNESS.
000791 01-12
OBSERVATIONS ON THE PHENOMENOLOGY OF CONSCIOUSNESS CHANGE.
000797 01-12
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
001B67 02-12
A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 02-12
AN EXPERIMENTAL STUDY ON THE CONSCIOUSNESS ALTERING EFFECT OF N,N DIMETHYLTRYPTAMINE (DMT).
002797 03-12
CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13
PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE -- ESPECIALLY LIGHT CONSCIOUSNESS IMPAIRMENTS.
002B9S 03-1S

CONSENSUS
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 02-17

CONSENT
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16

CONSERVATION
PSYCHOPHARMACOLOGY AND CONSERVATION.
002994 03-17

CONSISTENCY
THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN.
003132 04-03

CONSOLIDATION
EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-04
EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04
INFLUENCE OF PHYSOSTIGMINE UPON CONSOLIDATION OF MEMORY IN MICE.
000425 01-04

CONSTANTS
THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01

QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003053 04-01

CONSTITUENTS
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
0010B4 02-01
IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-D4
DISCRIMINABLE STIMULI PRODUCED BY MARIHUANA CONSTITUENTS.
003002 03-17

CONSTRICTION
THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
000129 01-03

CONSUMPTION
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-04
COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS.
000426 01-04
THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-08
A COMPARISON OF CONSUMPTION OF PSYCHOPHARMACOLOGICAL DRUGS.
001030 01-17
THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03
SHOCK-INDUCED ETHANOL CONSUMPTION IN RATS.
003430 04-04
INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
003489 04-04
THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
D03499 04-05

CONTINGENT
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
0D1291 02-03
THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
00192D 02-13
EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-04

CONTINUING
THE EFFECT OF CLOMIPRAMINE (ANAFRANIL) ON CONTINUING PAIN.
000636 01-09
ON DECISION MAKING SURROUNDING DRUG THERAPY: A CONTINUING DILEMMA.
003761 D4-15

CONTINUITY
THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY.
0021B2 03-01

CONTRACEPTION
INFLUENCE OF ORAL CONTRACEPTION ON SEXUAL RESPONSE.
002D2D D2-15

CONTRACEPTIVE
LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
0DD149 D1-D3
ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
DDD9BB D1-15
DREAM RECALL AND THE CONTRACEPTIVE PILL.
0D2B75 D3-14

CONTRACEPTIVES
THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
DD114D D2-03
DEPRESSIVE SYNDROME INDUCED BY ORAL CONTRACEPTIVES.
DD1979 02-14

CONTRACTILE
EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
003128 04-03
THE EFFECT OF THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC-AMP AND CARDIAC CONTRACTILE FORCE.
003213 04-03

CONTRACTILITY
EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
003183 04-03

CONTRACTIONS
BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
D02269 D3-03

CONTRADICTING
REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY.
0D2076 02-15

CONTRAINDICATED
EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE.
002008 02-15

CONTRASTING
THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-D3

CONTRAVERSIVE
THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

CONTROL
GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03
INTRAHYPOTHALAMIC SEROTONIN AND CARDIOVASCULAR CONTROL IN RATS.
000230 01-03
THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
001168 02-03
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS
DD1239 D2-03
SOMATOSTATIN IN THE PHYSIOLOGIC FEEDBACK CONTROL OF THYROTROPIN SECRETION
001396 02-03
A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001B21 D2-11
CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS: A COMPARATIVE STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE.
001B50 02-11
LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15
MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 D2-17
GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL
DD2191 D3-02
THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS (PH.D. DISSERTATION).
DD2257 D3-D3
POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT
DD2522 03-D4
THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
0D2529 D3-04
EFFECTS OF METHADONE HYDROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPARED FROM METHADONE-TOLERANT AND CONTROL RATS.
D025B1 D3-D5

PROPRANOLOL TO CONTROL SCHIZOPHRENIC SYMPTOMS:
55
PATIENTS.
002663 03-08
SOCIOPATHY: AN EXPERIMENT IN INTERNAL ENVIRONMENTAL CONTROL.
002737 03-11
GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11
DISCRIMINATIVE RESPONSE CONTROL BY PSYCHOMOTOR STIMULANTS.
003034 03-17
DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
003212 04-03
THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03
THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
003395 04-04
PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
00352B 04-0B
PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04-11

CONTROLLED

PATHOLOGIC EFFECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03
A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
000530 01-0B
A DOUBLE-BLIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-0B
CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000604 01-09
5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY.
000627 01-09
A CONTROLLED STUDY OF THE ASSOCIATION OF CLOMIPRAMINE AND LITHIUM.
000643 01-09
A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09
A PLACEBO CONTROLLED TRIAL OF DIAZEPAM AND OXPRENOLOL FOR ANXIETY.
000677 01-10
CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION.
000700 01-10
APPLICATION OF THE NEUROLEPTIC PIMOZIDE (ORAP-R-623B) FOR TRANQUILIZER INDICATIONS IN A CONTROLLED STUDY.
000701 01-10
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15
CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-0B
DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
0017B7 02-10
TREATMENT OF PHOBIC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL
001791 02-10
LORAZEPAM AND DIAZEPAM IN ANXIOUS OUTPATIENTS: A CONTROLLED STUDY.
001B05 02-10
TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION. REPORT OF A CONTROLLED CLINICAL TRIAL.
001B39 02-11
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001B45 02-11
A COMPARATIVE CONTROLLED STUDY BETWEEN CARBAMAZEPINE AND DIPHENYLHYDANTOIN IN PSYCHOMOTOR EPILEPSY
001B61 02-11
A CONTROLLED STUDY OF THE TREATMENT OF NARCOTIC ADDICTION IN IRAN: A PRELIMINARY REPORT (UNPUBLISHED PAPER).
001B65 02-11
FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS
002093 02-16
EFFECTS OF DRUGS ON BEHAVIOR CONTROLLED BY NOXIOUS STIMULI.
0024B2 03-04
PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE: A CONTROLLED DOUBLE BLIND STUDY
00259B 03-07
A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 03-08
CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03-10
THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA: A CONTROLLED STUDY.
003546 04-0B
SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09
CONTROLLED TRIAL OF NOMIFENSIN (HOE-9B4) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY.
003570 04-09
MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
0035B2 04-10
A CONTROLLED CLINICAL STUDY WITH CLOBAZAM -- A NEW ANXIOLYTIC AGENT.
0035B5 04-10
PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003597 04-10
PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003599 04-10
CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10
THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11

CONTROLLING

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-03
CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11
THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003639 04-11

CONTROLS

REGIONAL SEROTONIN LEVELS IN BRAIN. A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000BB3 01-14
AMPHETAMINES: TIGHTER CONTROLS ON THE HORIZON.
002125 02-17
DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13

CONVERSION

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 02-03
GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03
PROLONGED LSD FLASHBACKS AS CONVERSION REACTIONS.
001B75 02-12
L-DOPA: PLASMA PHARMACOKINETICS AND CONVERSION TO DOPAMINE IN BRAIN. (PH.D. DISSERTATION).
002233 03-03
MASS SPECTROGRAPHIC EVIDENCE OF THE CONVERSION OF P-CHLOROAMPHETAMINE TO 3,4 DIMETHOXYAMPHETAMINE.
002364 03-03
KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-ACID TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT BRAIN
003154 04-03

CONVULSANT

COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03
BARBITURATE REVERSAL OF AMINO-ACID ANTAGONISM PRODUCED BY CONVULSANT AGENTS.
001102 02-02

CONVULSANTS
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
000058 01-03
ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

CONVULSION
NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
00231B 03-03
CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

CONVULSIONS
INFLUENCE OF DIAZEPAM AND PHENYTOIN ON PENICILLIN-INDUCED CEREBRAL CONVULSIONS.
000253 01-03
THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04
PHENOBARBITONE FOR CONVULSIONS IN CHILDREN.
000993 01-15
EFFECT OF STRIATECTOMY ON THE COURSE OF PENTYLENETETRAZOL CONVULSIONS IN THE RAT.
001131 02-03
ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
001132 02-03
THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03
CANNABINOID-INDUCED BEHAVIORAL CONVULSIONS IN RABBITS.
001649 02-06
PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS.
002210 03-03
PREVENTION OF LOCAL ANESTHETIC-INDUCED CONVULSIONS BY GAMMA-AMINOBUTYRIC-ACID.
002261 03-03
THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA++ UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
003136 04-03
CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN
003205 04-03
EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-03
ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

CONVULSIVE
PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04
CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15
ACTION OF ANTIDEPRESSANTS ON CONVULSIVE EFFECT OF CORAZOL AND STRYCHNINE
002220 03-03
ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03
PSYCHOPHARMACOLOGY AND CONVULSIVE THERAPY.
002952 03-16

COORDINATION
COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
0021B3 03-01

COPING
THE DISEASE OF FAILURE OF COPING.
001797 02-10

COPPER
A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-05
USE OF RADIOACTIVE COPPER AND RADIOACTIVE ZINC IN PSYCHIATRIC DIAGNOSIS.
0029B3 03-17

COPULATION
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

COPULATORY
EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04
COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04
HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-04
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04
MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

CORAZOL
ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
001132 02-03
ACTION OF ANTIDEPRESSANTS ON CONVULSIVE EFFECT OF CORAZOL AND STRYCHNINE
002220 03-03

CORD
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT
001235 02-03
THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03
ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND BRAINSTEM NEURONES.
002229 03-03
AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
0030B8 04-03
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

CORDYCEPIN
THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03

CORETAL-POLFA
EFFECT OF CORETAL-POLFA (OXPRENOLOL) ON PARKINSONIAN TREMOR AND BENIGN ESSENTIAL TREMOR.
000734 01-11

CORNEAL
CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE.
000977 01-15

CORONARY
EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA-BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-07
EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-03
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03 15
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE
003138 04-03

CORPUS-STRIATUM
COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN
001419 02-03
EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
0023B5 03-03
EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-03

ONTOGENESIS OF DOPAMINE RECEPTOR BINDING IN THE CORPUS STRIATUM OF THE RAT.
003235 04-03

CORRECTIONAL

PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16

CORRECTIVE

NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY.
002395 03-03

CORRECTOR

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES
001031 01-17

CORRELATE

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
003684 04-13

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

CORRELATES

NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS. (PH. D. DISSERTATION).
000208 01-03

CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04

AMINO-ACID TRANSPORT INHIBITION: BRAIN AND BEHAVIORAL CORRELATES.
000406 01-04

ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
000988 01-15

DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03

DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM.
001831 02-11

GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 04-03

CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN.
003704 04-13

INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
003775 04-15

CORRELATION

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
000289 01-04

HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04

CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL.
001208 02-03

CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS.
001241 02-03

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03

CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03

INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
001585 02-04

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

CORRELATION BETWEEN PLASMA AND CEREBROSPINAL LEVELS OF IMIPRAMINE.
001775 02-09

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY.
001909 02-13

CORRELATION BETWEEN INJURIES DUE TO ACCIDENT AND USE OF ALCOHOL OR DRUGS.
002018 02-15

CORRELATION OF BEHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE. (PH.D. DISSERTATION).
002560 03-04

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-04

CORRELATIONS

STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
000178 01-03

QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003053 04-01

CORTEX

STUDIES OF CONNECTIONS BETWEEN LOCUS-COERULEUS AND CEREBRAL CORTEX.
000040 01-03

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03

THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03

THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
001283 02-03

PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-03

DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

EFFECTS OF NEUROLEPTIC AGENTS ON CYCLIC-GMP IN RAT CEREBRAL CORTEX.
001322 02-03
BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03
ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
0013S7 02-03
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03
CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03
EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX.
002264 03-03
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
00230S 03-03
PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:S CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03
INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX.
003131 04-03
THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF S HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03
EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03
SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

CORTICAL
CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
00003S 01-03
CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
00116B 02-03
IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?.
001330 02-03
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03
ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03
TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
00142S 02-03
ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
00142B 02-03
LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
001S0B 02-04
CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03-03
EFFECTS OF ADENOSINE ANALOGS ON RAT CEREBRAL CORTICAL NEURONS.
002336 03-03
CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03
THE EFFECT OF DESIPRAMINE ON THE UPTAKE OF MESCALINE BY CORTICAL SYNAPTOSOMES.
003095 04-03
EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
003242 04-03
ANTICONVULSANT ACTION OF DIAZEPAM: INCREASE OF CORTICAL POSTSYNAPTIC INHIBITION.
003246 04-03

CORTICOMEDIAL
SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
002348 03-03

CORTICOSTEROID
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT
002363 03-03

CORTICOSTEROIDS
EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION
001934 02-13
DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04

CORTICOSTERONE
INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT
00313S 04-03
EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03
PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-03
EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE.
003B74 04-17

CORTISOL
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001SS4 02-04
AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
001684 02-0B
CORTISOL SECRETION AND METABOLISM IN ANOREXIA-NERVOSA.
003660 04-13

CORTISONE
ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-1S

COST
COST/PROFIT ANALYSIS OF ANTIDEPRESSANTS.
000676 01-10

COSTS
COMPARATIVE DOSES AND COSTS OF ANTIPSYCHOTIC MEDICATION
002110 02-17

COUNTERACTING
EFFECTS OF FLUPENTHIXOL IN COUNTERACTING DEPRESSIVE STATES.
00060B 01-09

COUNTRIES
THE USE OF PSYCHOTROPIC DRUGS IN DEVELOPING COUNTRIES.
001048 01-17

COUPLED
POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03

COUPLING
PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

COURT
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 40B F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
0021S0 02-17
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 197S.
002152 02-17

CRAZY
DRUG REFUSAL IN SCHIZOPHRENIA AND THE WISH TO BE CRAZY
002942 03-15

CREAM
EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

CREAMS
DISTURBED OXIDATIVE METABOLISM IN ORGANIC BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
002051 02-15

CREATE
DRUGS WHICH CREATE PROBLEMS FOR THE ELDERLY.
000965 01-15

CREATIVE
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
002918 03-15

CRESOTINIC
INFLUENCE ON PSYCHOLEPTIC EFFECTS OF DIFFERENT TYPES OF SUBSTITUTIONS IN A SERIES OF CRESOTINIC AMIDES.
000151 01-03

CRICKET-KILLING
SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
000368 01-04

CRIME
AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002897 03-15

CRIMINAL
SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
000446 01-04

CRISES
INTRAVENOUS LORAZEPAM IN ACUTE ANXIETY CRISES.
002718 03-10

CRISIS
PSYCHOACTIVE DRUG CRISIS INTERVENTION.
0D2947 03-15

CRITERIA
MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION.
000591 01-09
ATYPICAL ENDOGENOUS DEPRESSION: DIAGNOSTIC CRITERIA.
001809 02-10

CRITICALLY
PSYCHIATRIC SYNDROMES IN CRITICALLY ILL PATIENTS.
000956 01-15

CRITICISM
GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11

CRITICIZING
REPLY TO A LETTER CRITICIZING POINTS IN A LETTER ON THE NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
0D1882 02-13

CRITIQUE
BENZODIAZEPINES AND NEUROTIC ANXIETY: CRITIQUE.
002166 02-17

CROMOGLYCATE
THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANCE, ALONE AND IN COMBINATION WITH ETHANOL.
00285B 03-14

CROSS-OVER
COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-04
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07
HYPNOTIC EFFECTS OF DIXYRAZINE IN A DOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
002736 03-11
COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

CROSS-TOLERANCE
CROSS TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC ACID DIETHYLAMIDE 25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT
000363 01-04
ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: MECHANISM FOR CROSS-TOLERANCE IN MICE.
001386 02-03
THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03
CROSS-TOLERANCE BETWEEN MORPHINE AND BETA ENDORPHIN IN VIVO.
003296 04-03
TOLERANCE AND CROSS-TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003389 04-04

CROWDED
A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

CRUDE
REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT.
001644 02-05

CRUZI
CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL.
D01121 02-03

CS-386
EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

CSF
CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER NEUROLEPTIC TREATMENT.
001687 02-D8
A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
DD2086 02-16
STUDIES OF CSF AMINE METABOLITES IN AFFECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002812 03-13
AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003D65 04-02

CUE
COCAINE CUE IN RATS AS IT RELATES TO SUBJECTIVE DRUG EFFECTS: A PRELIMINARY REPORT.
001462 02-D4
CUE USE IN STATE-DEPENDENT LEARNING.
DD1566 D2-04
NARCOTIC CUE AND NARCOTIC STATE.
DD3853 D4-17

CUES
MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002B67 03-14
PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
0035D6 04-D5

CULTURE
NEUROTRANSMITTER METABOLISM IN CELL CULTURE.
002213 03-D3
PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03

CULTURED
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03
PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
D0133B 02-03
PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
D03210 04-03

CULTURES
EFFECTS OF METHADONE HYDROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPARED FROM METHADONE-TOLERANT AND CONTROL RATS.
002581 03-D5

CUMULATION
CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN.
000B25 01-13

CUMULATIVE
CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04

CUNEATE
EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03

CURES
THE PLACE OF SULTOPRIDE AMONG NEUROLEPTIC CURES.
002603 03-07

CURVE
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15

CURVES
OBSERVATIONAL DETERMINATION OF DOSE-RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-04
PHENOBARBITAL DRINKING CURVES AFTER VARIED WATER DEPRIVATION.
00345B 04-04

CYCLE
POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01
LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN
000149 01-03
EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04
THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03
INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03
THE ACTION OF LITHIUM-CARBONATE ON THE SLEEPWALKING CYCLE IN THE CAT.
003419 04-04

CYCLIC
THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES
000257 01-03
EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE
000298 01-04
FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03
CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03
IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
00115B 02-03
EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-03
BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCED CHANGES.
002208 03-03
PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS.
002210 03-03
CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03
OPIATES, CYCLIC NUCLEOTIDES, AND XANTHINES.
002225 03-03
CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03-03
A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
002296 03-03
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03
DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN
002459 03-04
PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03
ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03
ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

CYCLIC-AMP
STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03
THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
000085 01-03
SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP
001155 02-03
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03
OPIATES AND CYCLIC-AMP. (UNPUBLISHED PAPER)
001263 02-03
INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO
001301 02-03
INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN. EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL
001376 02-03
BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE
001591 02-04
CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLIC PATIENTS.
001747 02-09
MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP.
002232 03-03
EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX.
002264 03-03
MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN
002319 03-03
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL
002347 03-03
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN
00235B 03-03
POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03
NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002B00 03-13
URINARY CYCLIC-AMP IN RELATION TO LITHIUM TREATMENT IN MANIC DEPRESSIVE ILLNESS.
002837 03-13

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS
003114 04-03

ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03

IN VITRO EFFECTS OF OPIATES ON CYCLIC-AMP IN RAT STRIATAL TISSUE.
003169 04-03

THE EFFECT OF THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC AMP AND CARDIAC CONTRACTILE FORCE
003213 04-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
00322B 04-03

LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT
003271 04-03

EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRAL HEMODYAMICS AND METABOLISM IN THE BABOON
003297 04-03

'CLIC-GMP

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN-F2ALPHA.
0001B3 01-03

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION. (UNPUBLISHED PAPER).
001313 02-03

EFFECTS OF NEUROLEPTIC AGENTS ON CYCLIC-GMP IN RAT CEREBRAL CORTEX.
001322 02-03

CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER NEUROLEPTIC TREATMENT.
0016B7 02-0B

MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP.
002232 03-03

REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
003097 04-03

'CLOBENZAPRINE

IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE
000046 01-03

'CLOHEXIMIDE

MODULATION OF CYCLOHEXIMIDE RESISTANT MEMORY BY SYMPATHOMIMETIC AGENTS.
000333 01-04

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
000359 01-04

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

'CLOHEXIMIDE-INDUCED

BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA.
001254 02-03

'CLOPENTONE

CYCLOPENTONE DERIVATIVES RELATED TO MEPROBAMATE: CONFORMATION ACTIVITY RELATIONSHIPS.
000013 01-01

CLOPHOSPHAMIDE

EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE
001635 02-05

PROHEPTADINE

ON THE ANTICATALEPTIC ACTION OF CYPROHEPTADINE.
0012B6 02-03

EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
00245B 03-04

CYPROHEPTADINE IN ANOREXIA-NERVOSA. (UNPUBLISHED PAPER).
003590 04-10

STATHIONINE

OBSERVATIONS ON THE FATE OF CYSTATHIONINE IN RAT BRAIN.
000115 01-03

CYSTEAMINE

DIAZEPAM: RADIOPROTECTIVE ACTION AND EFFECT ON TOXICITY AND RADIOPROTECTIVE POWER OF CYSTEAMINE.
003139 04-03

CYSTEINE

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE- EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY
001222 02-03

CYTOCHEMICAL

CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN THE CAUDATE NUCLEUS.
002369 03-03

CYTOCHROME-P-450

CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL.
001121 02-03

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03

DIFFERENCES IN CYTOCHROME-P-450 OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
002563 03-05

CYTOTOXIC

CYTOTOXIC ACTION OF PSYCHOTROPIC DRUGS ON LEUKOCYTES IN VITRO.
002570 03-05

CZECHOSLOVAK

RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN
002647 03-0B

C14-DOPAMINE

IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM ABOUT THE EFFECTS OF MORPHINE ON UPTAKE AND RELEASE OF C14-DOPAMINE.
003104 04-03

D-ALA2-MET-ENKEPHALINAMIDE

D-ALA2-MET-ENKEPHALINAMIDE: A POTENT, LONG-LASTING SYNTHETIC PENTAPEPTIDE ANALGESIC.
002193 03-02

D-AMPHETAMINE

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03

CHANGES IN BRAIN NOREPINEPHRINE ASSOCIATED WITH SENSITIZATION TO D-AMPHETAMINE.
000225 01-03

TASK-SPECIFIC EFFECTS OF D-AMPHETAMINE AND BLINDNESS ON BALB/CJ MICE.
000317 01-04

INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04

THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
000343 01-04

INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04

REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS
000373 01-04

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04

INTERACTION BETWEEN HYPERBARIC AIR AND D-AMPHETAMINE EFFECTS ON PERFORMANCE.
000436 01-04

CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
000442 01-04

FDOD DOMINANCE IN DDGS: EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE.
000450 01-04

TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-05

THE EFFFCTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE.
001119 02-03

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-03

MDDIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE DN NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001203 02-03

DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE AND D-AMPHETAMINE: EFFECTS ON HABITUATION.
001435 02-04

TREMOROGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE AND THFIR SUPPRESSION BY DDPAMINE.
00143B 02-04

FFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALDXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY.
001453 02-04

EFFFCTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPDTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS.
001489 02-04

EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04

EFFECTS DF PENTOBARBITAL AND D-AMPHETAMINE ON THE RFPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
001507 02-04

ACQUIRED PREFERFNCE FDR MORPHINE BUT NOT D-AMPHETAMINE AS A RFSULT OF SACCHARINE ADULTERATION.
001513 02-04

THF EFFECTS DF D-AMPHETAMINE AND ILLUMINATION DN BEHAVIORS DF THE SQUIRREL-MONKEY.
001542 02-04

EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04

THE EFFECTS OF D-AMPHETAMINE ON TEMPORAL DISCRIMINATION IN THE RAT.
001567 02-04

GFNETIC AND DNTOGENETIC VARIATIONS IN LOCOMDTOR ACTIVITY FDLLDWING TRFATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE
00156B 02-04

EFFECTS DF CHLORDIAZEPDXIDE, RIPAZEPAM AND D-AMPHETAMINE DN CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS DF RATS HAVING DIFFERENT BEHAVIORAL BASELINFS.
001599 02-04

D AMPHETAMINF IN THE MANIC SYNDRDME.
00172B 02-09

SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS: EFFECT OF D-AMPHETAMINE AND HALOPERIDOL.
001927 02-13

EFFFCT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03

THE FXISTFNCE OF TOLFRANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PFRFORMANCE IN THE RAT.
002332 03-03

FNHANCEMFNT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TFRM D AMPHETAMINE ADMINISTRATION.
002344 03-03

BRAIN DOPAMINE, D-AMPHETAMINE AND THERMOREGULATION IN RATS.
002409 03-03

INTFRACTION OF D-AMPHETAMINE WITH PENTDBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS DN PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-0

EFFECT OF BETA-PHENYLETHYLAMINE AND D-AMPHETAMINE ON ELECTRICAL SELF-STIMULATION OF BRAIN.
002468 03-0

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-0

PUNISHMENT DF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
002497 03-0

EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-0

DIFFERENTIATION OF NEUROPHARMACOLOGICAL ACTIONS OF APOMORPHINE AND D-AMPHETAMINE.
002523 03-0

THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-0

THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002529 03-0

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-0

EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
0031B7 04-0

EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDIT IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE
003314 04-0

ANDREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-0

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-0

EFFECTS OF COCAINE AND D-AMPHETAMINE ON BEHAVIOR MAINTAINED UNDER VARIOUS SCHEDULES OF FOOD PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-0

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION
003413 04-0

THE EFFECTS OF D-AMPHETAMINE ON THE AUTOMAINTAINED KEY PECKING OF PIGEONS
003441 04-0

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-0

INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM CARBONATE IN DEPRESSED PATIENTS.
003550 04-0

D-AMPHETAMINE-INDUCED

FACTORS INFLUENCING TOLERANCE TO D-AMPHETAMINE-INDUCED ANDREXIA IN RATS
0003B4 01-0

D-AMPHETAMINE-SULFATE

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
0000B6 01-0

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D-AMPHETAMINE-SULFATE.
0000BB 01-0

D-FENFLURAMINE

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
003241 04-0

D-GLUCARIC-ACID

PHENOBARBITONE-INDUCED URINARY EXCRETIONS OF D-GLUCARIC ACID AND 6BETA-HYDROXYCORTISOL IN MAN
002B22 03-1

D-LSD

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINFRGIC RECEPTORS IN THE RAT STRIATUM II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASF -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-0

DOPAMINE SENSITIVE ADENYLATE CYCLASE IN THE RETINA: A POINT OF ACTION FOR D-LSD.
002372 03-03

LYSERGIC-ACID-DIETHYLAMIDE
EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT (UNPUBLISHED PAPER).
002367 03-03
TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE
003372 04-04
THE EFFECT OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) UPON SHOCK-ELICITED FIGHTING IN RATS.
003461 04-04

OXAZEPAM
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO-DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

PHENYLALANINE
THERAPEUTIC ACTION OF D-PHENYLALANINE IN PARKINSONS DISEASE.
000495 01-07

TUBOCURARINE
HEART-RATE LEARNING AFTER D-TUBOCURARINE ADMINISTRATION IN ANIMALS.
000329 01-04

AILY
STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE.
000182 01-03
IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION
000269 01-03
ALCOHOL DRUG INTERACTIONS IN DAILY MEDICAL PRACTICE.
000974 01-15
A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-07
AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07
ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
001735 02-09
ANXIETY AND DEPRESSION: DIFFERENTIAL DIAGNOSIS AND TREATMENT IN DAILY PRACTICE.
002134 02-17
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
003373 04-04
A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
0035B9 04-10

ALES
BIOCHEMICAL PLASTICITY OF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001351 02-03

ALMANE
EFFECTS OF FLURAZEPAM (DALMANE) ON ANTERIOR PITUITARY SECRETION.
000877 01-14
THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

AMAGE
BRAIN AND RETINAL DAMAGE FROM LATHYRUS-EXCITOTOXIN, BETA-N-OXALYL L-DIAMINOPROPIONIC-ACID.
001316 02-03
ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS
0014B9 02-04
CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
002446 03-04
THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 03-04

DAMS
SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION
000286 01-04

DANGERS
DANGERS OF DEXTROPROPOXYPHENE
003812 04-15
DANGERS OF DEXTROPROPOXYPHENE
003831 04-15

DANITRACENE
EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09
DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002873 03-14

DANTROLENE
COMPARISON OF DANTROLENE SODIUM AND DIAZEPAM IN THE TREATMENT OF SPASTICITY.
001070 01-17

DARK
PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON
001796 02-10

DATA
LITHIUM TREATMENT. SOME DATA AND RECENT PERSPECTIVES.
001068 01-17
EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03
DATA ANALYSIS PROBLEMS IN THE AREA OF PHARMACOKINETICS RESEARCH.
001651 02-06
EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
001B12 02-10
A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
001885 02-13
SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17
RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
003058 04-01
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08
SOBERING DATA ON LITHIUM IN ALCOHOLISM.
003578 04-09
ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
003883 04-17

DATURA
DATURA POISONING.
003777 04-15

DATURA-SUAVEOLENS
INDUCED PSYCHOSIS FROM INGESTION OF DATURA-SUAVEOLENS.
001871 02-12

DDC-INDUCED
DDC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OF DL-DOPS.
001232 02-03

DEAMINATION
THE ROLE OF N-HYDROXYAMPHETAMINE IN THE METABOLIC DEAMINATION OF AMPHETAMINE.
003329 04-03
FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

DEANOL
DEANOL IN THE TREATMENT OF HYPERKINETIC CHILDREN
000884 01-14
CHOLINERGIC SIDE-EFFECTS ASSOCIATED WITH DEANOL.
000973 01-15
THE EFFECT OF DIMETHYLAMINOETHANOL (DEANOL) ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR (AISB).
002553 03-04

THERAPY WITH DIMETHYLAMINOETHANOL (DEANOL) IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL HYPERKINESIA.
002801 03-13

DEANOL IN GILLES-DE-LA-TOURETTE SYNDROME: A PRELIMINARY INVESTIGATION
003571 04-09

DEATH

PHENOTHIAZINE DEATH: AN UNUSUAL CASE REPORT.
002948 03-15

LSD TOXICITY: A SUSPECTED CAUSE OF DEATH.
003790 04-15

PHENOTHIAZINE-INDUCED BULBAR PALSY-LIKE SYNDROME AND SUDDEN DEATH.
003B28 04-15

CARDIAC SIDE-EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
003B30 04-15

DECADRON

DECADRON IN THE TREATMENT OF CEREBRAL ABSCESS: AN EXPERIMENTAL STUDY.
000206 01-03

DECAMETHONIUM

SOME NEUROTOXIC PROPERTIES OF TRIETHYLENE-GLYCOL-DINITRATE: A COMPARISON WITH DECAMETHONIUM.
000034 01-03

DECAPITATED

ENDORPHINS IN BRAINS OF DECAPITATED AND MICROWAVE-KILLED MICE.
003050 04-01

DECARBOXYLASE

BRAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHIBITION.
000252 01-03

BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE DECARBOXYLASE INHIBITOR RO-4-4602.
000295 01-04

L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-4B6) IN PARKINSONISM.
000767 01-11

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 D2-03

TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1RB
002672 03-09

THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
003239 04-03

DECARBOXYLATION

THE EFFECT OF L-DOPA AND AN INHIBITOR OF PERIPHERAL DECARBOXYLATION ON GLUCOSE METABOLISM IN BRAIN.
001405 02-03

DECEREBRATE

EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04

DECISION

ON DECISION MAKING SURROUNDING DRUG THERAPY: A CONTINUING DILEMMA.
003761 04-15

DECISIONAL

DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003B24 04-15

DECISIONS

DECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
D0388B 04-17

DECOMPENSATION

SULPIRIDE AND PSYCHIC DECOMPENSATION.
003023 03-17

PSYCHOTROPIC DRUG-INDUCED BLADDER DECOMPENSATION.
003797 04-15

DECOMPOSITION

THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
003047 04-01

DECONDITIONING

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION
003469 04-04

DECREASING

VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-0

DECREMENTAL

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-0

DEEP

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-0

DEFENDANT

DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 408 F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
D02150 02-1

DEFENSE

SCOPOLAMINE: EFFECTS ON FEAR OR DEFENSE RESPONSES IN THE RAT.
001546 02-0

DEFICIENCY

THE EFFECT OF ALPHA-TOCOPHEROL DEFICIENCY ON THE PHARMACOKINETICS AND PHARMACOLOGICAL EFFECT OF BARBITAL
000170 01-0

A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-0

THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-0

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY
002774 03-1

PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
D03581 04-1

A CASE OF DEFICIENCY OF N HYDROXYLATION OF AMOBARBITAL.
D03680 04-1

DEFICIENT

IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
00015B 01-0

DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-0

DEFICIT

DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-0

RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-0

PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-0

CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
00160B 02-0

CHRONIC BROMIDE INTOXICATION WITH A SEVERE NEUROLOGICAL DEFICIT.
002052 02-1

DEFICITS

MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-0

DEFINITION

EXPERIMENTAL PHARMACOLOGICAL DIFFERENTIAL DEFINITION OF NOOTROPIC DRUGS.
000B92 01-1

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-0

DEGENERATION

ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-0

DEGRADATION

DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-0

GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-0

DEHYDRATION
UNCONDITIONED TASTE AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION
003202 04 03

DEIKEL
RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
000341 01-04

DELAY
DELAY OF ONSET OF TRANSIENT AMNESIA AFTER HYPOXIA.
002416 03-04

DELAYED
CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION
000700 01-10
EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
0022B6 03-03
EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
002746 03-11
REVERSAL OF DELAYED MYELINOGENESIS IN THE FETAL ALCOHOL SYNDROME.
00325B 04-03
DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA
003826 04-15

DELAYING
EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-04
TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
003541 04-0B

DELIRIOUS
EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
002746 03-11

DELIRIUM
CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CARBONATE.
000709 01-10
ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-15
PHYSOSTIGMINE TREATMENT OF DELIRIUM INDUCED BY ANTICHOLINERGICS.
002903 03-15
DELIRIUM ASSOCIATED WITH LITHIUM THERAPY AND ELECTROCONVULSIVE THERAPY.
003794 04-15

DELTA-AMINOLAEVULINIC-ACID
LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA AMINOLAEVULINIC ACID IN RATS.
003237 04-03

DELTA1-TETRAHYDROCANNABINOL
DELTA1-TETRAHYDROCANNABINOL, CANNABIDIOL AND CANNABINOL EFFECTS ON THE IMMUNE RESPONSE OF MICE.
003339 04-03

DELTA8-TETRAHYDROCANNABINOL
HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTAB-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY.
001339 02-03
ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTAB-TETRAHYDROCANNABINOL.
003423 04-04

DELTA8-THC
ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTAB-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

DELTA8-3H-TETRAHYDROCANNABINOL
ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTAB-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE
00316B 04-03

DELTA9-TETRAHYDROCANNABINOL
EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON MONOAMINE-OXIDASE ACTIVITY OF RAT TISSUES IN VIVO.
000042 01-03
THE INTERACTION BETWEEN PROSTAGLANDIN E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE
000129 01-03
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01 03
HYPOTHERMIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION
000219 01 03
ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE DEPENDENT RATS BY DELTA9-TETRAHYDROCANNABINOL.
000310 01-04
SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9 TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS.
000377 01-04
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRADIENTS IN RATS.
000449 01-04
SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9 TETRAHYDROCANNABINOL.
000796 01-12
THE EFFECTS OF ALCOHOL AND DELTA9-TETRAHYDROCANNABINOL ON HUMAN PHYSICAL AGGRESSION
000924 01-14
DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION.
0011B3 02-03
INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
001212 02-03
IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
001255 02-03
BEHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
0013B5 02-03
ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: MECHANISM FOR CROSS-TOLERANCE IN MICE.
0013B6 02-03
THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04
STIMULANT ACTIONS OF DELTA9-TETRAHYDROCANNABINOL IN MICE.
0014B0 02-04
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM.
001521 02-04
REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT
001644 02-05
PSYCHOLOGIC EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL IN ADVANCED CANCER PATIENTS.
001B72 02-12
EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN COMBINATION WITH STIMULANT DRUGS IN RABBITS.
002434 03-04
THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002B57 03-14
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03
AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
0031B2 04-03
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03
COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
0032B5 04-03
INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03
INTERACTIONS BETWEEN DELTA9-TETRAHYDROCANNABINOL AND PHENCYCLIDINE HYDROCHLORIDE IN RATS.
003445 04-04
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL (DELTA9-THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE.
003491 04-05
PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04 15

DELTA9-TETRAHYDROCANNABINOL-INDUCED
ANTICDNVULSANT DRUG ANTAGONISM OE DELTA9-TETRAHYDROCANNABINDL-INDUCED SEIZURES IN RABBITS.
DD3366 D4-04

DELTA9-THC
RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
DD0341 D1-D4
DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
DDD3B3 01-D4
RDLE DF EXPERIFNCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EEFECT OE DFLTA9-THC DN SPACED RESPONDING.
0D2495 D3-D4
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OE DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
DD3211 D4-D3
TDLERANCE TO THE EEEECTS OF DELTA9-THC ON SHUTTLE-BOX PEREORMANCE AND BODY TEMPERATURF.
00339B D4-04
EFFECTS OE DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE.
DD3491 D4-05

DELTA9-TRANS-TETRAHYDROCANNABINOL
CDMPARISON OF ALTFRED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINF
DD1B67 D2-12
INVOLVEMENT DF CENTRAL ALPHA-ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OE (-) DELTA9-TRANS-TETRAHYDRDCANNABINOL.
DD3208 D4-D3

DELUSION
CLINICAL EFFECT OF PENFLURIDOL FOR SCHIZOPHRENIA - ESPECIALLY DELUSION.
00057B D1-D8

DEMAND
DEMAND METHDD EVALUATION OE HYPNOTICS.
001676 D2-07

DEMENTIA
CLINICAL STUDY OE THE EFFECTS OF VINCAMIN IN SENILE DEMENTIA SYNDROME.
DDD735 01-11
AN ERGOT ALKALOID PREPARATIDN (HYDERGINE) IN THE TREATMENT OE DEMFNTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
DD1B32 D2-11
TRANSIENT DEMENTIA SYMPTOMS CAUSED IN ONE CASE BY ETHOPRDPAZINE.
DD2931 03-15
LEVODOPA TREATMENT IN PRESENILE DEMENTIA.
DD3738 D4-14
THE PHYSICAL AND BEHAVIOURAL COMPLEX OF DEMENTIA.
DD3B93 D4-17

DEMETHYLATION
QUANTITATIVF MEASURFMENT DF DFMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
DD2352 D3-D3

DEMONSTRATED
A QUANTITATIVE CORRFLATION BETWFEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DDPAMINF NFURONS IN ZONA-COMPACTA DF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDFR THE INFLUENCE OF NICOTINE AND PHYSDSTIGMINE
DD1277 D2-D3

DEMONSTRATION
AMINE RESPONSIVE ADENYLATE-CYCLASF ACTIVITY FRDM BRAIN: COMPARISDNS BETWFEN RAT AND RHFSUS-MDNKEY AND DFMONSTRATION OF DDPAMINF STIMULATED ADFNYLATE-CYCLASF IN MONKEY NEDCORTEX.
ODD254 D1-D3
THF DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG TERM TREATMENT WITH HALOPERIDOL.
0D1194 D2-D3
THE INFLUENCF OE MFPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINF ACTIVITY
DD1367 D2-D3

DEMOXEPAM
KINITICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZFPINFS I. CHLORDIAZEPOXIDE AND DEMOXEPAM.
DD225B D3-D3

DENSITIES
BLOOD SFRUM DENSITIES OE TRICYCLIC ANTIDEPRESSANTS -- VIFWS GAINED THROUGH THERAPEUTIC USF
DDD5B1 D1-09
PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OE TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
D00654 D1-09
ON CHANGING BLDOD DENSITIES OE ANTISEIZURE DRUGS TAKEN IN LARGF VOLUMES.
00295D D3-15

DENSITY
DIFFERENTIAL EFFECTS OF CHLORPRDMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN
D00909 01-14
SPECTRAL DENSITY ANALYSIS OE THE EFEECTS OE BARBITURATES AND BENZODIAZEPINFS ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY
DD1360 02-D3

DEONTOLOGIC
PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION.
DD2172 D2-17

DEPENDENCE
INCREASED CNS SENSITIVITY TO FLURDTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
DDD114 01-03
ASPECTS DF OPIATE DEPFNDENCE IN THE MYENTERIC PLEXUS DF THE GUINEA-PIG
000222 01-03
TEMPORAL RFLATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DFPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
D0D37D D1-04
PHYSICAL DFPENDENCE ON OPIATE-LIKE PEPTIDES.
000447 D1-04
INDUCTION OF PHYSICAL DEPENDENCE IN RATS BY SHORT INTFRVAL MEDICATION
DD0471 D1-D6
ASSESSMENT OF MORPHINE-TYPE PHYSICAL DFPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 D1-D6
EVALUATION OF PROPRANOLOL IN OPIATE DEPENDENCE.
DDD512 D1-D7
PHYSIOLOGICAL DEPENDENCE ON, AND SYMPTOMS OF WITHDRAWAL FROM, CHLORMETHIAZOLE
DDD981 01-15
SLEEP DISTURBANCE AND HYPNOTIC DRUG DEPENDENCE.
DD1D27 D1-17
TOLERANCE AND DEPFNDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
DD114B 02-D3
AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OE CHLDRPRDTHIXENE AND NORTRIPTYLINE IN RATS.
DD11B2 D2-03
THE EFFFCT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
D01243 D2-03
DISCRIMINATIVF STIMULUS PROPERTIES OF FENTANYL AND MORPHINF: TOLERANCF AND DEPENDENCE.
DD1461 D2-D4
RELATIONSHIP BETWEEN PHYSICAL DEPENDENCE AND TOLERANCE OF MORPHINF IN THF RAT.
DD14B2 D2-D4
ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICFPTION IN MICE.
DD15B4 D2-04
ALCOHOL, FIELD DEPENDFNCE, AND DYADIC SELF-DISCLOSURE.
0019B9 D2-14
CORTICAL EVOKFD POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLFRANCE AND PHYSICAL DEPENDENCE.
DD2366 D3-D3
STUDIES ON DRUG DEPENDENCE (REPT. 19): DEPENDENCE ON PREFERENCE ON AND PREFERENCE FOR MORPHINE.
002545 D3-04
THE USF OF BETA-BLOCKADE IN DEPENDENCE.
002766 D3-11
NALOXONE-INDUCED INHIBITION OF ETHANOL DEPENDENCE IN MICE.
0D310D D4-03
QUANTITATIVE ASSESSMENT OF TOLERANCF TO AND DEPENDENCE ON MORPHINE IN MICE.
0D3140 04-D3
BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE
D03309 D4-D3
INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTFLY AND CHRONICALLY WITH MORPHINF.
0D3334 D4-03
BARBITURATE DEPENDENCE IN MICF: EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION
D03348 D4-D4

ENDENT

REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
000008 01-01

DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA ACETYLMETHADOL
000390 01-04

NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS.
000405 01-04

EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS.
001297 02-03

ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
001428 02-03

INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOURS IN RODENTS.
001519 02-04

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03-03

POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT.
002522 03-04

NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-04

LETED

THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-04

LETING

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03

SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03

BEHAVIORAL DEPRESSION: THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS.
000307 01-04

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS
000463 01-05

ETION

CALCIUM DEPLETION OF SYNAPTOSOMES AFTER MORPHINE TREATMENT.
000070 01-03

PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION: COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES.
000197 01-03

EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
000281 01-04

DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
003109 04-03

STUDIES ON THE DEPLETION OF BRAIN AMINES BY M-TYROSINE.
003280 04-03

EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04

ETIONS

EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03

DEPOLARIZATION

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE
001202 02-03

CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03-03

DEPOLARIZATION-INDUCED

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

DEPOT

INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA
000542 01-08

THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY
000553 01-08

DEPOT NEUROLEPTICS.
000583 01-09

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

EXPERIENCES WITH THE LONG-TERM USE OF ANATENSOL DEPOT.
000779 01-11

CRITICAL STUDY OF THE USE OF LONG-ACTING NEUROLEPTICS (DEPOT NEUROLEPTICS) IN FRANCE.
001042 01-17

EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14

PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT.
002619 03-08

A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC.
002644 03-08

TREATMENTS OF SCHIZOPHRENIA WITH TRIFLUPROMAZINE DEPOT.
002661 03-08

PHARMACOLOGY OF CIS-CLOPENTHIXOL-DECANOATE, A DEPOT NEUROLEPTIC.
003070 04-02

DEPRENIL

L-DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE: A LONG-TERM STUDY.
002588 03-07

DEPRENYL

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04

DEPRESSANT

STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
000178 01-03

OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07

3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE
003295 04-03

DEPRESSANTS

CNS DEPRESSANTS: EFFECTS ON POSTSYNAPTIC PHARMACOLOGY
000043 01-03

EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04

PLACENTAL TRANSFER OF CENTRAL-NERVOUS-SYSTEM DEPRESSANTS IN SHEEP.
000464 01-05

GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
001561 02-04

DISCRIMINABLE STIMULI PRODUCED BY ALCOHOL AND OTHER CNS DEPRESSANTS.
002964 03-17

EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFORMANCE IN MICE.
003416 04-04

DEPRESSED

DOUBLE-BLIND EVALUATION OF AHR-111B AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
0004B6 01-07

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE.
0005B7 01-09

CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000604 01-09

DRUG AND FAMILY THERAPY IN DEPRESSED OUTPATIENTS.
000607 01-09

DRUG RELATED TEST PATTERNS OF DEPRESSED PATIENTS.
000626 01-09

AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09

TRH EFFECTS ON ENDOGENOUSLY DEPRESSED MALES
000669 01-09

A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09

TREATMENT OF THE DEPRESSED PATIENT IN THE HOME
000718 01-10

PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSED WOMEN
000994 01-15

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS
001727 02-09

URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM.
001729 02-09

EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
001748 02-09

SOMATIC THERAPIES IN OLDER DEPRESSED PATIENTS
001753 02-09

PHARMACOTHERAPY IN OLDER DEPRESSED PATIENTS.
002033 02-15

P CHLOROPHENYLALANINE REVERSAL OF TRANYLCYPROMINE EFFECTS IN DEPRESSED PATIENTS.
002164 02-17

HOW TO TREAT THE PROFOUNDLY DEPRESSED PATIENT.
002686 03-09

MEASUREMENT OF 5-HYDROXYINDOLE COMPOUNDS DURING L-5-HTP TREATMENT IN DEPRESSED PATIENTS.
002700 03-09

PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10

INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM CARBONATE IN DEPRESSED PATIENTS.
003550 04-09

PHARMACOLOGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
003556 04-09

AMOXAPINE A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
003577 04-09

TREATING DEPRESSED CARDIAC PATIENTS.
003601 04-10

INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS
003709 04-13

DEPRESSION

THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR.
000239 01-03

SOME BEHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA TRANSAMINASE
0002B5 01-04

BEHAVIORAL DEPRESSION THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS.
000307 01-04

INTRAVENOUS ADMINISTRATION OF MAPROTYLIN IN DEPRESSION
0004B5 01-07

MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION- CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION
000591 01-09

LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYP OF PRIMARY AFFECTIVE DISORDER.
000601 01

LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01

PLATELET UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN DEPRESSION.
000612 01

PSYCHOTIC MASKED DEPRESSION OR BLACK MASK FOR DEPRESSION.
000613 01

DEPRESSION TREATED WITH FG-4963: RESULTS FROM AN INITIAL EXPERIMENT.
000614 01

METABOLISM OF INDOLE AMINES IN DEPRESSION.
000617 01

A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION.
000624 01

CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF T CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01

APPLICATION OF SINEQUAN IN THE TREATMENT OF VARIOUS CLINICA FORMS OF DEPRESSION
000631 01

PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION RESULTS OF THE GROUP THERAPY.
000635 01

THE EFFECT OF PLASMA AMINO-ACIDS ON DEPRESSION
000637 01

CONFERENCE ON DEPRESSION IN RIO-DE-LA-PLATA.
000642 01

MAINTENANCE THERAPY OF DEPRESSION.
000646 01

FOLLOW-UP OF MAINTENANCE TREATMENT FOR DEPRESSION
00064B 01

CONCERNING PROPIZEPINE-CHLORHYDRATE AND ITS INDICATIONS IN DEPRESSION.
000650 01

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE A A FLUPHENAZINE NORTRIPTYLINE COMBINATION
00065B 01

PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31B89) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
0006B2 01

THE THERAPEUTIC AND PREVENTATIVE EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON DEPRESSION.
000696 01

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTI PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTIS
000726 01

POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSI IN ALCOHOL ADDICTS.
000742 01

USE OF DIBENZEPINE RETARD IN THE TREATMENT OF ALCOHOLIC DEPRESSION
000764 01

THYROID HORMONE AND DEPRESSION
000B71 01

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION
001055 01

UNWANTED EFFECTS OF LONG-TERM MEDICATION IN SCHIZOPHRENIA AND DEPRESSION
001064 01

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE
001209 02

EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02

NEUROENDOCRINE REGULATION IN DEPRESSION I. LIMBIC SYSTEM ADRENOCORTICAL DYSFUNCTION
001736 02

USE OF DOXEPINE IN THE VARIOUS CLINICAL FORMS OF DEPRESSION
00173B 02

TWO CASES OF MDI DEPRESSION WHERE CARBAMAZEPINE WAS ESPECIALLY EFFECTIVE.
001742 02

TREATMENT OF DEPRESSION WITH BUTRIPTYLINE.
001743 02

DEPRESSION BEHAVIORAL, BIOCHEMICAL, DIAGNOSTIC AND TREATMENT CONCEPTS.
001746 02

AGING AND DEPRESSION SOME UNANSWERED QUESTIONS.
001752 02

OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION MEDICATION AND GROUP PSYCHOTHERAPY
001755 02 09

COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
001757 02-09

LITHIUM IN THE TREATMENT OF DEPRESSION
001761 02 09

THERAPEUTIC PROPOSAL FOR INVOLUTIONAL DEPRESSION
001771 02-09

TRYPTOPHAN AND ALLOPURINOL IN THE TREATMENT OF DEPRESSION
001777 02-09

MIANSERIN IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
00179B 02 10

ATYPICAL ENDOGENOUS DEPRESSION DIAGNOSTIC CRITERIA.
001B09 02-10

A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001B21 02-11

PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION. ENVIRONMENTAL AND GENETIC FACTORS.
001935 02 13

PSYCHOLOGICAL ASPECTS OF PHASIC DEPRESSION DURING LITHIUM PROPHYLAXIS.
002075 02-15

ANXIETY AND DEPRESSION DIFFERENTIAL DIAGNOSIS AND TREATMENT IN DAILY PRACTICE.
002134 02-17

CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONE IN THE COMMUNITY.
002174 02-17

DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-02

DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-0B

TREATMENT OF DEPRESSION WITH LUDIOMIL CIBA.
002669 03-09

CENTRAL MONOAMINE METABOLISM IN DEPRESSION AND MANIA. (UNPUBLISHED PAPER).
002675 03-09

A DOUBLE-BLIND COMPARISON OF DOXEPIN AND NORTRIPTYLINE ON DEPRESSION.
002676 03-09

COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION.
0026B2 03-09

WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? ... A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED.
0026B5 03-09

PREPUBESCENT DEPRESSION (4TH REPORT) -- EXPERIENCES WITH THE EFFICACY OF LITHIUM-CARBONATE.
0026B7 03-09

PRELIMINARY STUDY OF THE TREATMENT OF ENDOGENOUS DEPRESSION WITH BROMOERGOCRYPTINE.
002694 03-09

AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION
002697 03-09

CHLORIMIPRAMINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION.
002704 03-09

SLEEP DEPRIVATION AND CLOMIPRAMINE IN ENDOGENOUS DEPRESSION
002705 03-09

CLINICAL EVALUATION OF AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF DEPRESSION.
002713 03-10

NEUROTIC DEPRESSION: AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS.
002721 03-10

NOTE 2: DEPRESSION IN THE DEVELOPMENTAL AGE.
CLINICOTHERAPEUTIC STUDY OF DEPRESSION IN THE DEVELOPMENTAL AGE.
002725 03-10

EFFECTS OF AMITRIPTYLINE ON THE PROGRESS OF DEPRESSION
002726 03-10

AMANTADINE THERAPY FOR DRUG-INDUCED EXTRAPYRAMIDAL SIGNS AND DEPRESSION.
00273B 03-11

MENTAL DISORDERS OTHER THAN SCHIZOPHRENIA AND DEPRESSION.
002764 03-11

REVERSAL OF NARCOTIC DEPRESSION IN THE NEONATE BY NALOXONE.
002B0B 03-13

TRYPTOPHAN IN DEPRESSION
002B09 03-13

DEPRESSION ASSOCIATED WITH ORAL CHOLINE
002939 03-15

DEPRESSION DURING RENAL DIALYSIS AND FOLLOWING TRANSPLANTATION
00302B 03 17

AMPHETAMINE INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION. BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03 17

DEPRESSION- A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-02

PRESYNAPTIC ALPHA ADRENOCEPTORS: THE DEPRESSION OF SELF STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE
003142 04 03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE
003170 04-03

DEPRESSION BY MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY
003537 04-0B

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

TRYPTOPHAN NICOTINAMIDE COMBINATION IN DEPRESSION
003553 04-09

MAPROTILINE (LUDIOMIL) IN DEPRESSION- A REPORT OF A MONITORED RELEASE STUDY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09

EFFECTS OF LITHIUM-CARBONATE ON MOTOR ACTIVITY IN MANIA AND DEPRESSION
003561 04-09

SLEEP AND SLEEP ABNORMALITIES IN DEPRESSION.
003563 04-09

PSYCHOBIOLOGY OF DEPRESSION
003567 04-09

CONTROLLED TRIAL OF NOMIFENSIN (HOE-9B4) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY.
003570 04-09

LITHIUM IN DEPRESSION- A BIOCHEMICAL STUDY.
0035B4 04-10

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT. A CASE REPORT.
0035B7 04-10

A COMPARISON OF MAPROTILINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
003604 04-10

SOME PROBLEMS IN THE TREATMENT OF DEPRESSION WITH PHARMACOLOGICAL AGENTS.
00377B 04-15

PHENOMENOLOGY AND TREATMENT OF DEPRESSION
003B5B 04-17

GENERAL PRACTITIONERS PRESCRIBING HABITS FOR PATIENTS WITH DEPRESSION.
003BB6 04-17

MOOD ACTIVE AGENTS IN DEPRESSION.
003B95 04-17

DEPRESSIONS

5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY
000627 01-09

COMPARATIVE STUDY OF THREE PSYCHOTROPIC DRUGS IN THE TREATMENT OF DEPRESSIONS.
000645 01-09

THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION
003573 04-09

DEPRESSIVE

PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION
0004B4 01-07

RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE AND RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN
000592 01-09

A COMPARATIVE STUDY OF ANTIOEPRESSANTS IN THE TREATMENT OF OEPRESSIVE STATES.
00059B 01-09

INTRAVENOUS CHLORIMIPRAMINE AND DEPRESSIVE SUBTYPES.
000600 01-09

EFFECTS OF ELUPENTHIXOL IN COUNTERACTING DEPRESSIVE STATES.
000608 01-09

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 01-09

THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS.
000640 01-09

CLINICAL EXPERIFNCE OE SEPAZON (CLOXAZOLAM) EOR DEPRESSIVE MANIC.
000644 01-09

THE TREATMENT OE LIEE THREATENING CARDIOPULMONARY ILLNESS ANO LIFE THREATFNING DEPRFSSIVE ILLNESS: SUICIDE EQUIVALENTS?.
0D0667 01-09

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

COMPULSIVE WATER DRINKING OURING DEPRESSIVE REACTION
0006BB 01-10

PSYCHOPHARMACOLOGICAL STUDY ON THE DEPRESSIVE STATE IN MEDICAL PRACTICE.
000692 01-10

REGIONAL SFROTONIN LEVELS IN BRAIN: A COMPARISON OF DEPRESSIVE SUICIDFS AND ALCOHOLIC SUICIDES WITH CONTROLS.
0008B3 01-14

DIBENZEPIN AND AMITRIPTYLINE IN DEPRESSIVE STATES: COMPARATIVE DOUBLE-BLIND TRIAL.
000B93 01-14

CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATFS SUPERVENING DURING PARKINSONIAN SYNDROMES TREATEO BY L-DOPA.
00094B 01-15

THF ADVANCE OF DEPRESSIVE OISEASES.
0D1015 01-17

EFFECT OE THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
00173D 02-09

A COMPARISON OE AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES.
001731 02-09

ONCE DAILY AOMINISTRATION OE ELUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OE MIXED ANXIETY/DEPRESSIVE STATES.
001735 D2-09

EEFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN OEPRESSIVE PATIENTS.
001760 02-09

A DEPRESSIVE SYNOROMF RESPONSIVE TO LITHIUM: AN ANALYSIS OE 20 CASES.
001767 02-09

LIFE FVENTS, DFPRESSIVE RELAPSE AND MAINTENANCE TREATMENT
001770 02-09

DOUBLE BLINO ATTEMPT AT COMPARISON OE EFEECTS OE LOFEPRAMINE ANO AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION
001783 02-09

A NFW PSYCHOTROPIC EOR THF TREATMENT OF ANXIOUS AND DEPRFSSIVF NEUROSES: NOMIFENSIN.
0017B5 02-10

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS OEPRESSIVE PATIENTS BEEORE AND AETER TREATMENT WITH AMITRIPTYLINE-N-OXIDF
001794 D2-10

INFLUENCING OFPRFSSIVE CONDITIONS OF THE ALCOHOL WITHORAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001B40 02-11

ANTIHYPFRTENSIVE ACTION OF PROPRANOLOL IN MAN- LACK OF EVIOENCE FOR A NEURAL DEPRESSIVE EEFECT.
001917 02-13

EFFFCT OF S ADENOSYL L-MFTHIONINF (SAME) UPON OEPRESSIVE SYMPTOMS.
001953 02-14

DEPRESSIVF SYNDROMF INDUCED BY ORAL CONTRACEPTIVES.
001979 02-14

TARDIVF DYSKINESIA AND DFPRESSIVE ILLNESS.
002029 02-15

INVESTIGATIONS WITH A BEHAVIOR ORIENTEO ASSESSMENT SCALE EOR DEPRFSSIVE INHIBITION ANO AGITATION: RESULTS OE A VIDEO OOCUMENTEO AMITRIPTYLINE MIANSERIN STUOY
002095 02-16

BIOCHEMICAL BASIS OE AN ANIMAL MODEL OE DEPRESSIVE ILLNESS -- A PRELIMINARY RFPORT
0023B1 03-03

EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTONIC AFFECT.
002605 03

DETERMINATION OE BIOGENIC AMINE METABOLITES IN CEREBROSPINA ELUID BY MASS ERAGMENTOGRAPHY -- METHODS AND BIOCHEMIC STUOIES OE DFPRESSIVE OISORDERS.
002666 03

AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WI DEPRESSIVE ILLNESS.
002674 03

OESCRIPTION OE A SIMPLE GRAPHIC MODEL ENABLING COMPARISON THE DEVELOPMENT OE DEPRESSIVE STATES.
002689 03

DRUG THERAPY IN DEPRESSIVE STATES: FACTORS IN SUICIDE PREVENTION.
DD2690 03

USE OF SIDNOCAR8 IN TREATING PATIENTS IN ASTHENIC OR DEPRESS STATES.
002699 D3

VIGILANCE AND AROUSAL IN DEPRESSIVE STATES.
002712 03

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTI AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821 03

DEPRESSIVE STATES INDUCED BY DRUGS OE ABUSE: CLINICAL EVIDEN THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
D02971 03

ANTIDEPRESSANT EVALUATION AND THE PHARMACOLOGICAL ACTION OF EG-4963 IN DEPRESSIVE PATIENTS.
003521 04

CLINICAL IMPLICATIONS OE IMIPRAMINE PLASMA LEVELS EOR DEPRESSIVE ILLNESS.
D0356D 04

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OE SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZI WITH NORTRIPTYLINE.
D03564 04

SIGNIFICANCE OE BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OE DEPRESSIVE DISORDERS.
003576 04

CONTROLLED COMPARISON OE BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
D03602 04

TOTAL AND NONBOUND PLASMA-TRYPTOPHAN IN DEPRESSIVE ILLNE
003663 04

DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE T TREATMENT.
003669 0

DEPRESSIVES

TWO DOSAGES OE IMIPRAMINE IN HOSPITALIZED ENDOGENOUS ANO NEUROTIC DEPRESSIVES.
DD1778 0

DEPRESSOR

DEPRESSOR EFFECT OE KYNURENINE AND ITS METABOLITES IN RATS
002293 0

REDUCTION OE STIMULATION PRODUCED ANALGESIA BY LYSERGIC-A DIETHYLAMIDE, A DEPRESSOR OE SEROTONERGIC NEURAL ACTIVIT
D03401 0

DEPRIVATION

THE EFEECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, EOOO DEPRIVATION, AND CURRENT INTENSITY ON SELE-STIMULATION O THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEOIAL ERONTAL CORTEX OE THE RAT. (PH.D. DISSERTATION).
000336 0

PSYCHOACTIVE DRUG EEFECT ON BEHAVIOURAL CHANGES INDUCEO PROLONGEO SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
D0D475 0

COMPARATIVE EVALUATION OE SEIZURE PROVOCATION METHODS W SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 0

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OE MEGIM AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STU
D007B3 0

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EEFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
D01314 0

RFVERSAL OE THE MEMORY DISRUPTIVE EEFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
0015B0 0

EFEECTS OE WATER DEPRIVATION AND PRIOR LICL EXPOSURE IN CONOITIONING TASTE-AVERSIONS.
D01597 0

COMBINEO SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
D01757 0

LX THIRTY-FIVE YEARS OF PSYCHOSOCIAL DEPRIVATION
002101 02 17

COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION.
002682 03-09

SLEEP DEPRIVATION AND CLOMIPRAMINE IN ENDOGENOUS DEPRESSION
002705 03-09

PHENOBARBITAL DRINKING CURVES AFTER VARIED WATER DEPRIVATION
003458 04-04

EPRIVATION-INDUCED

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
003489 04-04

EPRIVED

6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-03

ERIVATE

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-08

ERIVATES

SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN-ETHYL-ESTER.
001922 02-13

ERIVATIVE

NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02

TERATOLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-05

A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
000478 01-07

CLINICAL STUDY AND EVALUATION OF A NEW DERIVATIVE OF PHENOTHIAZINE.
000547 01-08

A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION.
000624 01-09

EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
000902 01-14

ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
001235 02-03

SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE
001248 02-03

EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

AN ERGOT DERIVATIVE IN THE TREATMENT OF PARKINSONS DISEASE.
002592 03-07

THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
003047 04-01

ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-04

EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A DOUBLE-BLIND STUDY IN HEALTHY PROBANDS.
003755 04-14

VATIVES

STUDY OF THE STABILITY OF PHENOTHIAZINE DERIVATIVES.
000005 01-01

CYCLOPENTONE DERIVATIVES RELATED TO MEPROBAMATE: CONFORMATION ACTIVITY RELATIONSHIPS.
000013 01-01

STRUCTURE ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01

STRUCTURE ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. INTRODUCTION TO PARTS X-XII, AND PART X. ACRIDONE DERIVATIVES.
000017 01-01

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES PART XI LENGTHENING OF THE BASIC CHAIN
00001B 01 01

NEW MORPHINE DERIVATIVES.
000027 01 02

SOME DERIVATIVES OF 2,4 DIAMINO 5-PHENYLTHIAZOLE (AMIPHENAZOLE).
000030 01-03

N ISOPROPYL DERIVATIVES OF DOPAMINE AND 5,6 DIHYDROXY 2 AMINOTETRALIN.
000068 01 03

ANTAGONISM OF GABA MEDIATED INHIBITION IN THE CENTRAL NERVOUS-SYSTEM BY CAPROLACTAM DERIVATIVES
000140 01 03

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

ANESTHETIC ACTION OF METHYLEUGENOL AND OTHER EUGENOL DERIVATIVES.
000419 01-04

QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07

BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH.
000710 01 10

UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15

THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001004 01-16

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 75. 7-HYDROXYAMINOBENZODIAZEPINES AND DERIVATIVES.
001096 02-01

THE SYNTHESIS OF POSSIBLE HYDROXYLATED METABOLITES OF 2-CHLOROPHENOTHIAZINE DERIVATIVES. (UNPUBLISHED PAPER).
001099 02-01

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-02

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
001448 02-04

FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04

RAUWOLFIA DERIVATIVES AND BREAST CANCER.
002050 02-15

PHARMACOLOGICAL ACTION OF PYRIMIDOINDOLE DERIVATIVES.
0021B7 03-02

HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
002189 03-02

SELECTIVITY OF 4-METHOXYPHENETHYLAMINE DERIVATIVES AS INHIBITORS OF MONOAMINE-OXIDASE.
002279 03-03

INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03

EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03

INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I N-SUBSTITUTED HYDRAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID
00304B 04 01

QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
DD3053 04-D1

CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
003056 D4-D1

CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003D57 D4-D1

EEFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
DD3193 D4-03

NOMIFENSINE AND ITS DERIVATIVES AS POSSIBLE TOOLS FOR STUDYING AMINE UPTAKE.
DD3305 D4-D3

ALPHA-ACTIVITY AND BETA-ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE.
003315 D4-D3

EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH.
DD3522 D4-D7

ACUTE OVERDOSAGE WITH BENZODIAZEPINE DERIVATIVES.
DD37B9 D4 15

DERIVED

MAMMALIAN BIOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
DDD793 01 12

SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
DD11DB D2-02

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA-LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
D01147 D2-03

DECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
D03888 D4-17

DERMATOLOGICAL

DERMATOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS DURING PSYCHOPHARMACOTHERAPY
D02921 D3-15

DESERPIDINE

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
DD1215 02-D3

DESGLYCINAMIDE

EFFECT OE DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
0D3356 04-D4

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN
DD3447 D4-D4

DESIGN

USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
DD1491 D2-D4

AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO
001842 D2-11

EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OE MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN
DD3365 D4-D4

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
DD3B43 D4-16

DESIPRAMINE

EEFFCT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA PIGS.
DDDD32 D1-D3

THE REVERSAL OF CLONIDINE INDUCED HYPOTENSION BY PROTRIPTYLINE AND DESIPRAMINE.
DDD24B D1-D3

ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM.
DD12BD D2-D3

PFRSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OE THE RAT VAS DEFERENS BY DESIPRAMINE.
DD1361 D2-D3

THF FFFFCT OE DESIPRAMINE ON THE UPTAKE OF MESCALINE BY CORTICAL SYNAPTOSOMES.
DD3D95 D4-D3

EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
DD3275 D4-D3

ANTIDEPRESSANT EFFECTS OF DESIPRAMINE ADMINISTERED IN TWO DOSAGE SCHEDULES.
0D3566 D4-

DESMETHYL

STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVE OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-

DESMETHYLDIAZEPAM

PASSAGE OF DIAZEPAM AND DESMETHYLDIAZEPAM INTO BREAST MIL
000932 01-

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM O 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM
D01225 D2-

DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
DD36B3 D4-

DESMETHYLIMIPRAMINE

THE EFFECT OE DESMETHYLIMIPRAMINE ON THE ABSORPTION OF ALCOHOL AND PARACETAMOL.
D00824 D1-

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM
0D1188 02

DESTRUCTION

DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
D002DD D1

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-DIHYDROXYTRYPTAMINE
DDD441 D1

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS I CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMIN NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTO ACTIVITY IN RATS
DD1526 D2

THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRES INDUCED GASTRIC ULCER
003233 D4

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF T ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL
DD3425 D4

DESYNCHRONIZATION

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
DD24D3 D3

DETECTION

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSAN DRUGS.
DD0443 D1

DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AN PSATHYRELLA.
0D1DBB 02

PROBLEMS ON THE FORENSIC DETECTION OF DEXTROMORAMIDE OR I METABOLITES.
DD3714 D4

DETERIORATION

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
0D3634 D4

DETERMINANT

MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY RATS.
0035D7 D4

DETERMINANTS

SCHEDULE INDUCED BEHAVIOR. A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02

GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
DD3494 D4

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
D037D3 04

ETERMINATION

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
000468 01-06

QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-06

IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000B14 01-13

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000829 01-13

GLC DETERMINATION OF DOXEPIN PLASMA LEVELS.
001009 01-16

OBSERVATIONAL DETERMINATION OF DOSE-RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-04

ESSAY ON DETERMINATION OF PSYCHOLOGICAL EFFECTS OF LITHIUM.
001756 02-09

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13

DETERMINATION OF MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHODOLOGICAL ASPECTS.
001B96 02-13

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001B9B 02-13

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
0020B6 02-16

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS.
002755 03-11

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002B26 03-13

DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY.
002953 03-16

DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
002955 03-16

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 04-13

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
003713 04-13

RMINED

MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01

IS FEMININE DIFFERENTIATION OF THE BRAIN HORMONALLY DETERMINED?
00136B 02-03

DETERRENT

DISULFIRAM IMPLANTATION, PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS
002003 02-14

DETOXICATION

EXPERIMENTAL STUDIES ON INTOXICATION OR DETOXICATION OF METHYLMERCURIC-CHLORIDE.
002262 03-03

DETOXIFICATION

SUCCESSFUL DETOXIFICATION FROM METHADONE MAINTENANCE FOLLOW-UP STUDY OF 38 PATIENTS.
000982 01-15

OUTPATIENT HEROIN DETOXIFICATION WITH ACUPUNCTURE AND STAPLEPUNCTURE.
0027B3 03-11

DEVELOP

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04

DEVELOPED

STUDIES ON TOLERANCE DEVELOPED TO SINGLE-DOSES OF MORPHINE IN MICE.
001244 02-03

DEVELOPING

TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-05

THE USE OF PSYCHOTROPIC DRUGS IN DEVELOPING COUNTRIES.
00104B 01-17

SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03

DEVELOPING OPTIMUM DRUG REGIMENS.
002105 02-17

EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN.
002330 03-03

MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS.
0023B3 03-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

DEVELOPMENT

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

NEUROBIOLOGICAL MECHANISMS OF ADAPTATION IN RELATION TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
000162 01-03

DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04

PSYCHOACTIVE DRUGS IN MEDICAL PRACTICE: THE PRESENT STAGE OF DEVELOPMENT.
001049 01-17

TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
00105B 01-17

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-03

ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM.
0012B0 02-03

ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT.
0013B3 02-03

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT A MORPHOLOGICAL STUDY.
001613 02-05

EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05

PRODIGIOUS DEVELOPMENT OF PSYCHOPHARMACOLOGY.
00216S 02-17

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

PHARMACOLOGICAL STUDIES ON DEVELOPMENT OF RESPONSE TO CATECHOLAMINE IN BRAIN
002263 03-03

TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
002282 03-03

CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE
002366 03-03

DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
002689 03-09

SEASONAL VARIATION IN DEVELOPMENT OF TOLERANCE TO MORPHINE.
002B4S 03-13

THE EFFECTS OF NALOXONE AND NALORPHINE DURING THE DEVELOPMENT OF MORPHINE-DEPENDENCE IN RHESUS-MONKEYS.
003077 04-03

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
003212 04-03

NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

SITE OF ACTION OF DEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS.
003367 04-04

THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-05

FLUOTRACEN (SKF-2B17S), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B17S)).
003625 04-11

DEVELOPMENTAL

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

NOTE 2: DEPRESSION IN THE DEVELOPMENTAL AGE: CLINICOTHERAPEUTIC STUDY OF DEPRESSION IN THE DEVELOPMENTAL AGE.
00272S 03-10

EARLY DEVELOPMENTAL CHANGES IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RELATION TO HIPPOCAMPAL FUNCTION
003418 04-04

DEVELOPMENTS

FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09

RECENT DEVELOPMENTS IN THE CHEMOTHERAPY OF SCHIZOPHRENIC PSYCHOSES.
00262S 03-0B

CURRENT DEVELOPMENTS IN PSYCHOPHARMACOLOGY
002989 03-17

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY
003042 03-17

DEVICE

A DEVICE FOR THE EVALUATION OF MOTOR INCOORDINATION IN RATS.
001439 02-04

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04

THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
001647 02-06

DEVOID

3 HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL NERVOUS SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

DEXAMETHASONE

SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES
000133 01-03

FACILITATION BY DEXAMETHASONE OF TOLERANCE TO ETHANOL IN THE RAT
0034B6 04-04

DEXETIMIDE

USE OF DEXETIMIDE (R-16470) WITH EXTRAPYRAMIDAL SYNDROMES CAUSED BY NEUROLEPTICS.
002061 02-1

DEXTROAMPHETAMINE

EFFECTS OF DEXTROAMPHETAMINE ON PSYCHOMOTOR SKILLS.
000889 01-1

TREATMENT OF CHRONIC POSTTRAUMATIC ORGANIC-BRAIN-SYNDROME WITH DEXTROAMPHETAMINE: FIRST REPORTED CASE.
000904 01-1

STUDIES IN MICE ON THE ANTAGONISM OF DEXTROAMPHETAMINE ANOREXIA BY ALPHA-METHYL-P-TYROSINE-METHYL-ESTER HCL.
001471 02-0

EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION.
002032 02-1

HYPORESPONSIVITY OF CHRONIC SCHIZOPHRENIC PATIENTS TO DEXTROAMPHETAMINE.
00263S 03-0

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE
0032S2 04-0

DEXTROMORAMIDE

PROBLEMS ON THE FORENSIC DETECTION OF DEXTROMORAMIDE OR ITS METABOLITES
003714 04-1

DEXTROPROPOXYPHENE

DANGERS OF DEXTROPROPOXYPHENE.
003812 04-1

DANGERS OF DEXTROPROPOXYPHENE
003831 04-1

DG-LVP

EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-0

DI-N-PROPYLACETATE

ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRE BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-0

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DI-N-PROPYLACETATE.
001S33 02-0

DIABETES-INSIPIDUS

WATER POISONING AND DIABETES-INSIPIDUS: A PROPOS COMPULSIVE WATER DRINKING AND DYSTHYMIA
002717 03-

PERSISTENT NEPHROGENIC DIABETES-INSIPIDUS AFTER LITHIUM-CARBONATE.
002934 03-

THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-0

DIABETIC

REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-

AGGRAVATION OF DIABETIC HYPERGLYCEMIA BY CHLORDIAZEPOXIDE.
00383B 04-

DIAGNOSED

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002B60 03-

DIAGNOSIS

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
0006S1 01-

THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
0006S2 01-

ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
000777 01-

THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER
0017S0 02-

THE CONTEMPORARY DIAGNOSIS OF BROMISM.
002083 02-

DIAGNOSIS IN PLANNING PSYCHOPHARMACOLOGICAL THERAPY
002099 02-

ANXIETY AND DEPRESSION. DIFFERENTIAL DIAGNOSIS AND TREATMENT IN DAILY PRACTICE
002134 02-

OIAGNOSIS ANO TREATMENT OF MINIMAL BRAIN OYSFUNCTION IN ADULTS.
002794 03 11

USE OF RAOIOACTIVE COPPER ANO RAOIOACTIVE ZINC IN PSYCHIATRIC DIAGNOSIS.
002983 03 17

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE OIAGNOSIS, TREATMENT, ANO PREVENTION OF OEPRESSIVE OISORDERS
003576 04-09

GNOSTIC

DEPRESSION: BEHAVIORAL, BIOCHEMICAL, OIAGNOSTIC ANO TREATMENT CONCEPTS.
001746 02-09

ATYPICAL ENOOGENOUS OEPRESSION OIAGNOSTIC CRITERIA.
001809 02-10

AN AUTOMATEO OIAGNOSTIC PROCESS (POA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIOE VERSUS HALOPERIOOL COMPARATIVE TRIAL.
002106 02-17

INTRAVENOUS METHYLPHENIOATE AS A OIAGNOSTIC ANO PSYCHOTHERAPEUTIC INSTRUMENT IN AOULT PSYCHIATRY.
002768 03-11

OECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVEO FROM OIAGNOSTIC FREQUENCY PATTERNS.
003888 04-17

L-ACCESS

SASKATCHEWAN DIAL-ACCESS ORUG INFORMATION SERVICE.
002970 03-17

LKYLATED

CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE ANO OOPAMINERGIC EFFECTS OF N,N DIALKYLATEO DOPAMINES.
000023 01-02

LLEL

EFFECTS OF SCOPOLAMINE ANO D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A OIALLEL ANALYSIS IN MICE.
001126 02-03

LYSIS

OIALYSIS ENCEPHALOPATHY: A POSSIBLE SEIZURE DISORDER.
002146 02-17

OEPRESSION DURING RENAL DIALYSIS ANO FOLLOWING TRANSPLANTATION.
003028 03-17

MINO-5-PHENYLTHIAZOLE

SOME DERIVATIVES OF 2,4 DIAMINO-5-PHENYLTHIAZOLE (AMIPHENAZOLE).
000030 01-03

PHRAGM

ON THE SWELLING OF THE OIAPHRAGM AMONG PATIENTS TAKING PSYCHOTROPIC DRUGS (SECOND REPORT).
002077 02-15

INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON ORUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM
003495 04-05

STEREOISOMERIC

ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY OIASTEREOISOMERIC OIHYOROOIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

ZEPAM

GABA RECEPTOR ACTIVATION MEOIATES THE DECREASE OF CEREBELLAR C-GMP ELICITED BY OIAZEPAM. (UNPUBLISHED PAPER).
000051 01-03

INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS ANO OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF OIAZEPAM.
000130 01-03

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS AOMINISTRATION.
000132 01-03

INFLUENCE OF OIAZEPAM ANO PHENYTOIN ON PENICILLIN-INOUCEO CEREBRAL CONVULSIONS.
000253 01-03

EFFECTS OF OIAZEPAM RELATEO TO SOCIAL HIERARCHY IN RHESUS-MONKEYS.
000311 01-04

BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN
000393 01-04

A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS- APPLICATION IN BIOAVAILABILITY STUOIES.
000480 01-07

A DOUBLE-BLINO COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
000502 01-07

INDUCTION EFFECT OF DIAZEPAM ON ITS OWN METABOLISM.
000517 01-07

A PLACEBO CONTROLLEO TRIAL OF DIAZEPAM AND OXPRENOLOL FOR ANXIETY
000677 01-10

THERAPEUTIC EFFICACY OF EMG FEEOBACK ANO ITS INTERACTION WITH OIAZEPAM IN CHRONIC ANXIETY
000693 01 10

STUOIES ON THE COMBINEO USE OF OIAZEPAM WITH EXPOSURE IN VIVO
000695 01 10

COMPARATIVE STUOY OF THE TRANQUILIZER EFFECT OF FLUSPIRILENE ANO DIAZEPAM
000698 01 10

OIAZEPAM USE IN MILITARY SICK-CALL.
000720 01 10

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZFR FOR PSYCHOSIS WITH OIAZEPAM BY A OOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

EFFECTS OF OIAZEPAM ANO ETHANOL ON HEART-RATE ANO GALVANIC SKIN RESPONSES.
000812 01-13

BLOOO LEVELS AND ELECTROENCEPHALOGRAPHIC EFFECTS OF DIAZEPAM AND BROMAZEPAM.
000819 01-13

CUMULATION IN CEREBROSPINAL FLUID OF THE N-OESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN
000825 01-13

CEREBROSPINAL FLUIO CONCENTRATIONS OF DIAZEPAM ANO ITS METABOLITES IN MAN.
000832 01-13

SATURATION OF TISSUES WITH N-OESMETHYLOIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATEO AOMINISTRATION OF DIAZEPAM.
000835 01-13

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

EFFECT OF FOOD AND REPEATEO INJECTIONS ON SERUM DIAZEPAM LEVELS.
000840 01-13

BILIARY EXCRETION OF DIAZEPAM AND ITS METABOLITES IN MAN.
000862 01-13

HUMAN AND ANIMAL STUOY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-13

REOUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000864 01-13

PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIOE IN CHRONIC ALCOHOLICS.
000868 01-13

THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, ANO PLACEBO IN INPATIENT INSOMNIACS.
000878 01-14

NEUROPSYCHOLOGIC EFFECTS OF OIAZEPAM RELATED TO SINGLE-OOSE KINETICS AND LIVER FUNCTION.
000898 01-14

PASSAGE OF DIAZEPAM ANO OESMETHYLOIAZEPAM INTO BREAST MILK.
000932 01-15

DIAZEPAM ANO AGGRESSION.
000959 01-15

EFFECT OF DIAZEPAM ON VENTILATORY RESPONSES.
000960 01-15

COMPARISON OF DANTROLENE SODIUM ANO DIAZEPAM IN THE TREATMENT OF SPASTICITY.
001070 01-17

REGIONAL DISTRIBUTION OF OIAZEPAM ANO ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03

REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING OIAZEPAM OR MUSCIMOL.
001431 02-03

STIMULATION OF FOOO INTAKE IN HORSES BY OIAZEPAM ANO PROMAZINE.
001452 02-04

EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEOULE.
001467 02-04

EFFECTS OF DIAZEPAM ANO RIPAZEPAM ON TWO MEASURES OF AOJUNCTIVE DRINKING IN RATS.
001572 02-04

STUOIES ON THE INTERACTION OF CHLORDIAZEPOXIDE, DIAZEPAM, ANO NITRAZEPAM WITH PHENPROCOUMON.
001627 02-05

CARDIOVASCULAR EFFECTS OF DIAZEPAM ANO CHLORDIAZEPOXIOE IN EXPERIMENTS WITH NONANESTHETIZED ANIMALS.
001636 02-05

DIAZEPAM IN THE TREATMENT OF TARDIVE-DYSKINESIA: PRELIMINARY DBSERVATIONS.
001716 02-0B

TREATMENT OF VAGINISMUS BY I.V. DIAZEPAM (VALIUM) ABREACTION INTERVIEWS.
001764 02-09

DIAZEPAM AND PHENDBARBITAL IN THE TREATMENT OF ANXIETY: A CDNTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
0017B7 02-10

LORAZEPAM AND DIAZEPAM IN ANXIDUS OUTPATIENTS: A CDNTRDLLED STUDY.
001B05 02-10

ANTIANXIETY EFFECTS OF TRAZODDNE (A DOUBLE-BLIND STUDY WITH DIAZEPAM AND PLACEBD).
001806 02-10

ENHANCEMENT DF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY: A TRIAL DF DIAZEPAM.
001BBB 02-13

PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DDG, RABBIT, GUINEA-PIG AND RAT.
001921 02-13

EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14

COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14

DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C-GMP ELICITED BY HALOPERIDOL AND DIAZEPAM.
002211 03-03

A CEREBELLAR MODEL TD STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSION (UNPUBLISHED PAPER).
002212 03-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITIDN OF (14C)PENTDBARBITAL IN RATS.
002230 03-03

ACTION DF DIAZEPAM, HALDPERIDDL, MDRPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 03-03

UPTAKE DF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIDNED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
002268 03-03

THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
002337 03-03

COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AND DIAZEPAM IN ISOLATED RAT HEART.
00237B 03-03

DIAZEPAM MODIFICATIDN OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04

RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVDIDANCE RESPONSES AND IN THE EFFECTS OF DIAZEPAM.
0024BB 03-04

ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM DN CONDITIDNED SUPPRESSION IN RATS.
002489 03-04

DIAZEPAM TREATMENT DF SDCIALLY ISOLATED MDNKEYS.
002511 03-04

DDXEPIN AND DIAZEPAM IN THE TREATMENT OF HOSPITALIZED GERIATRIC PATIENTS.
002770 03-11

CDNTRIBUTION TO THE MANAGEMENT OF FDCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATIDN OF DIAZEPAM (FAUSTAN).
002B06 03-13

DETERMINATIDN OF VARIATION IN THE SPEED DF CDNDUCTION DF MOTOR FIBERS AND DF THE DIPHENYLHYDANTDIN (PHENYTDIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT
002B26 03-13

WITHDRAWAL REACTION TO DIAZEPAM.
002927 03-15

DIAZEPAM IMPAIRS DRIVING SKILLS LESS THAN THIORIDAZINE.
002929 03-15

DIAZEPAM RADIOPROTECTIVE ACTIDN AND EFFECT ON TDXICITY AND RADIOPROTECTIVE POWER DF CYSTEAMINE
003139 04-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHDLAMINE CONTENT AND CARDIAC FUNCTION DF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

KINETICS AND MECHANISMS DF HYDRDLYSIS DF 1,4 BENZODIAZEPINES II OXAZEPAM AND DIAZEPAM.
003165 04-03

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES DF DIFFERENT PARTS OF THE RAT BRAIN.
003174 04-

CDNVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITIDN BY PHENDBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04

ANTICONVULSANT ACTION DF DIAZEPAM: INCREASE OF CORTICAL PDSTSYNAPTIC INHIBITIDN
003246 04-

EFFECTS DF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LDCOMOTDR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS
003248 04

EFFECT DF DIAZEPAM DN PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04

EFFECTS OF DIAZEPAM ON EXPLORATORY BEHAVIOR OF PIGS.
003369 04

EFFECTS OF DIAZEPAM ON BEHAVIOUR SUPPRESSED BY EXTINCTION I PIGS.
003370 04

PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPE FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
00340B 04

A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION.
003525 04

FINDINGS WITH A CONDITIONING TEST BATTERY: DIFFERENTIAL RESPDNSIVENESS TO DIAZEPAM AND DOXEPIN
003580 04

EFFECTS DN EMG FEEDBACK, DIAZEPAM AND THEIR COMBINATION O CHRONIC ANXIETY.
003594 04

HALAZEPAM AND DIAZEPAM IN NEUROTIC ANXIETY: A DOUBLE-BLIN STUDY
003600 04

ETHANOL AND ORAL DIAZEPAM ABSORPTION
003677 04

DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
003683 0

STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE.
003725 0

HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES O DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 0

DIAZEPAM WITHDRAWAL PSYCHOSIS: A CASE REPORT.
003772 0

GLAUCOMA DUE TD DIAZEPAM.
003795 0

ALLERGY TO DIAZEPAM.
003B03 0

ALLERGY TO DIAZEPAM.
00380B 0

ALLERGY TO DIAZEPAM
003B14 0

DIAZOXIDE

ADVERSE NEONATAL REACTIDN TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 0

DIBENZEPIN

A DOUBLE-BLIND STUDY OF THE ANTIDEPRESSANTS DIBENZEPIN (NOVERIL) AND AMITRIPTYLINE.
0005B2 0

DIBENZEPIN AND AMITRIPTYLINE IN DEPRESSIVE STATES: COMPARA DOUBLE-BLIND TRIAL.
000B93 0

DIBENZEPINE

CLINICAL STUDY OF A NEW FORM OF DIBENZEPINE, WITH PROTRAC ACTION
000633 0

USE OF DIBENZEPINE RETARD IN THE TREATMENT OF ALCOHOLIC DEPRESSION
000764 0

DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREDUS BODY AND URINE FROM FATAL POISONING.
000934 0

DIBENZOPYRANS

CANNABINOIDS. 1. 1-AMINO- AND 1-MERCAPTO 7,8,9,10-TETRAHYD 6H DIBENZOPYRANS.
003069 0

DIBUTYRYL-CYCLIC-AMP

EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRA HEMODYAMICS AND METABOLISM IN THE BABOON
003297 0

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT DRUGS ON DIBUTYRYL-CYCLIC-AMP EVOKED SEIZURES.
003436

DICHROISM
STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

DIELDRIN
INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EEELUX IN MOUSE BRAIN.
001369 02-03

DIENCEPHALIC
DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
000186 01-03

DIENCEPHALON
THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

DIET
PATHOLOGIC EFEECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION. THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04
THE EFFECT OF DIET ON ETHANOL WITHDRAWAL SYMPTOMATOLOGY.
003346 04-04
MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION
003B56 04-17

DIETHYLDITHIOCARBAMATE
THE EFFECTS OF DIETHYLDITHIOCARBAMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03

DIETHYLPROPION
TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03
SCHIZOPHRENIA-LIKE REACTION TO DIETHYLPROPION.
002037 02-15

DIETHYLSTILBESTROL
DIETHYLSTILBESTROL IN THE TREATMENT OF RAPE VICTIMS.
002B99 03-15

DIFFER
OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03

DIFFERENCE
SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
000133 01-03
PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03

DIFFERENTIATION
PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
000418 01-04
IS FEMININE DIFFERENTIATION OF THE BRAIN HORMONALLY DETERMINED?.
00136B 02-03
DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE AND D-AMPHETAMINE: EFFECTS ON HABITUATION.
001435 02-04
DIFFERENTIATION OF NEUROPHARMACOLOGICAL ACTIONS OF APOMORPHINE AND D-AMPHETAMINE
002523 03-04
DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-03

IFFERING
DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
00042B 01-04
ANORECTIC EFFECTIVENESS OF DIFFERING DOSAGE FORMS OF FENFLURAMINE.
0007B4 01-11

IFFICULTIES
TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION
0019B0 02-14

DIGIT
DIGIT SYMBOL PERFORMANCE IN METHADONE TREATED EX HEROIN ADDICTS
001956 02-14

DIGITOXIN
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA PIG LIVER.
000118 01-03

DIGOXIN
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03

DIGOXIN-INDUCED
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03

DIHYDRODIBENZOTHIEPINE
ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDRODIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

DIHYDROERGOKRYPTINE
PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
002253 03-03

DIHYDROERGOTAMINE
DIHYDROERGOTAMINE BINDING TO RAT BRAIN MEMBRANES.
001169 02-03

DIHYDROGENATED
EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04

DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

DIHYDROPROPYLFURYLIDENECYCLOPENTANEDIONE
PHARMACODYNAMIC ACTIONS OF DIHYDROPROPYLFURYLIDENECYCLOPENTANEDIONE (OUDENONE).
001319 02-03

DIHYDROTESTOSTERONE
SYNERGISTIC EFFECT OF ESTRADIOL-BENZOATE AND DIHYDROTESTOSTERONE ON AGGRESSION IN MICE.
0014B6 02-04

DIHYDROTRIFLUOROMETHYLQUINOXALINEDIONE
METABOLISM OF 1,4 DIHYDROTRIFLUOROMETHYLQUINOXALINEDIONE (LILLY-72525) IN RATS AND CATS.
002329 03-03

DIHYDROXY-2-AMINOTETRALIN
N-ISOPROPYL DERIVATIVES OF DOPAMINE AND 5,6 DIHYDROXY-2-AMINOTETRALIN.
00006B 01-03

DIHYDROXYLATED
THE SYNTHESIS OF POSSIBLE DIHYDROXYLATED AND TRIHYDROXYLATED CHLORPROMAZINE METABOLITES.
001094 02-01

DIHYDROXYPHENYLACETIC-ACID
REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03
ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03
THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

DIHYDROXYPHENYLALANINE
THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03

DIHYDROXYTRYPTAMINE
ACUTE CENTRAL EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE IN FOWL.
001310 02-03
BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04
DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF 5,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
0D1629 D2-05

DIKALIUM
EFFECTS OF DIKALIUM CLORAZEPATE ON SERUM LEVELS AND METABOLITES.
000766 01-11

DILEMMA
ON DECISION MAKING SURROUNDING DRUG THERAPY: A CONTINUING DILEMMA.
0D3761 04-1S

NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
D03816 D4-15

DIMETHOXY-4-METHYLAMPHETAMINE
EFFECTS OF 2,S DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
00D444 D1-04

DIMETHOXY-4-METHYLPHENYL-2-AMINOPROPANE
IN VITRO O-DEMETHYLATION OF THE PSYCHOMIMETIC AMINE, DIMETHOXY-4-METHYLPHENYL-2-AMINOPROPANE.
DD334D D4-03

DIMETHOXY-4-METHYLPHENYLBUTANE
BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL-3912A) WITH R-DOM AND S-AMPHETAMINE.
D0347D 04-04

DIMETHOXYAMPHETAMINE
MASS SPECTROGRAPHIC EVIDENCE OF THE CONVERSION OF P-CHLOROAMPHETAMINE TO 3,4 DIMETHOXYAMPHETAMINE.
DD2364 D3-03

DIMETHOXYPHENYLETHYLAMINE
FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
0D3394 04-D4

DIMETHOXYPHENYLETHYLAMINE-1-14C
UPTAKE OF 3,4 DIMETHOXYPHENYLETHYLAMINE-1-14C (14C-DMPEA) BY RAT TISSUES IN VITRO.
DD1229 02-D3

DIMETHOXYPHENYLISOPROPYLAMINES
PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES. 5. 4-ALKYL-2,S DIMETHOXYPHENYLISOPROPYLAMINES.
00D226 01-03

DIMETHYL
THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
0D3D47 04-01

DIMETHYL-3-PIPERIDINO-PROPIOPHENONE
REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
DD1216 02-03

DIMETHYLAMINOETHANOL
THE EFFECT OF DIMETHYLAMINOETHANOL (DEANOL) ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR (AISB).
0D2S53 03-D4

THERAPY WITH DIMETHYLAMINOETHANOL (DEANOL) IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL HYPERKINESIA.
DD28D1 03-13

EFFECTS OF DIMETHYLAMINOETHANOL UPON LIFE-SPAN AND BEHAVIOR OF AGED JAPANESE QUAIL.
003112 D4-03

DIMETHYLATED
URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
0D279B 03-12

DIMETHYLBIS-PHENYLACETYL-DIAZATETRACYCLODODECANE
DIMETHYLBIS-PHENYLACETYL-DIAZATETRACYCLODODECANE, A POTENT, NOVEL ANALGESIC.
003063 D4-D2

DIMETHYLHEPTYL
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,B,1DA ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-1D9S14).
DDD39B D1-D4

DIMETHYLTRYPTAMINE
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-2S (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
0DD363 D1-D4

POSSIBLE SOURCE OF ERROR IN STUDIES OF ENZYMATIC FORMATION OF DIMETHYLTRYPTAMINE
0D1D91 02-D1

COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
001B67 02-12

AN EXPERIMENTAL STUDY ON THE CONSCIOUSNESS ALTERING EFFECT OF N,N DIMETHYLTRYPTAMINE (DMT).
002797 03-12

EFFECTS OF N,N DIMETHYLTRYPTAMINE ON BEHAVIOURAL HABITUATION IN THE RAT.
D03384 D4-D4

DIMINISHED
THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
0D2S32 D3-04

DINKLACORINE
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
D01084 D2-D1

DIOXAAZASPIROUNDECANE
POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
DD3B48 D4-17

DIOXIDES
SYNTHESIS OF 2,1,4,S BENZOTHIATRIAZEPINES 2,2 DIOXIDES AND OF 4 KETOBENZOTHIADIAZEPINES 2,2 DIOXIDES.
D011D1 02-D2

DIPHENHYDRAMINE
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN
001441 D2-04

THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
DD167S D2-D7

DIPHENYLHYDANTOIN
THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
00D076 D1-03

INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
DD011B 01-D3

A COMPARATIVE CONTROLLED STUDY BETWEEN CARBAMAZEPINE AND DIPHENYLHYDANTOIN IN PSYCHOMOTOR EPILEPSY.
0D1861 02-11

MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY
0D194D D2-13

EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT
D02DS7 02-15

THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
0D2337 D3-D3

STUDIES ON THE EFFECT OF S,5 DIPHENYLHYDANTOIN ON IN VITRO PROTEIN SYNTHESIS IN RAT BRAIN.
DD237S D3-03

TREATMENT OF DRUG-INDUCED PSYCHOSIS WITH DIPHENYLHYDANTOIN
D02761 03-11

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
0D2826 D3-13

THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
0D3379 D4-0

DIPIPERON
PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
DD182S 02 1

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
DD3S49 D4-0

DIPOTASSIUM
CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION
D007DD D1 1

THE USE OF DIPOTASSIUM CHLORAZEPATE AT HIGH DOSAGE IN TREATMENT OF OBESITY.
DDD738 01 1

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS. ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14
STEADY-STATE BIOAVAILABILITY OF TWO CLORAZEPATE DIPOTASSIUM DOSAGE FORMS.
003662 04-13

DIPROPYLACETATE
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS
001196 02-03

DIPROPYLACETIC
RESEARCH IN THE DIPROPYLACETIC SERIES. XII. EXTENDED ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

DIPROPYLACETIC-ACID
INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
000723 01-11

DIPSOGENIC
EVIDENCE THAT THE PREOPTIC REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04
DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-04

DIPYRIDAMOLE
RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03

DIRECT
INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03
GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03
SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03
DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002893 03-15
INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03
PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
003343 04-04
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13

DIRECTION
EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
0002B4 01-04

DISABILITIES
METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES: PSYCHOMETRIC CHANGES.
000740 01-11

DISADVANTAGES
THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01-17

DISAGREEMENT
PROFESSIONAL DISAGREEMENT IN DRUG EFFICACY STUDY
002135 02-17

DISCHARGES
EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS
002407 03-03

DISCONTINUANCE
THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE-EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN.
000972 01-15
DISCONTINUANCE OF ASSOCIATED ANTIPARKINSONIAN DRUGS IN LONG-TERM NEUROLEPTIC TREATMENT.
002923 03-15

DISCONTINUATION
DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS
001691 02-08
DYSKINESIA AFTER DISCONTINUATION OF COMPOUND ANALGESIC CONTAINING OXYCODONE
0037B4 04-15

DISCONTINUOUS
BARBITURATE DEPENDENCE IN MICE EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION
00334B 04-04

DISCOVERIES
THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY
002182 03-01
LITHIUM AS AN ANTIDEPRESSANT: DISCOVERIES THROUGH CLINICAL OBSERVATIONS
003892 04-17

DISCOVERY
DRUG DISCOVERY AND INTRODUCTION: REGULATION AND OVERREGULATION
001669 02-07
THE DISCOVERY OF DRUG-INDUCED ILLNESS.
003799 04-15

DISCRIMINABILITY
DISCRIMINABILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04

DISCRIMINABLE
SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION.
001493 02-04
CONDITIONING OF DISCRIMINABLE STIMULI PRODUCED BY MORPHINE.
002499 03-04
DISCRIMINABLE EFFECTS OF BENZODIAZEPINES.
002517 03-04
DISCRIMINABLE STIMULI PRODUCED BY ALCOHOL AND OTHER CNS DEPRESSANTS.
002964 03-17
DISCRIMINABLE STIMULI PRODUCED BY MARIHUANA CONSTITUENTS.
003002 03-17
DISCRIMINABLE STIMULI PRODUCED BY HALLUCINOGENS.
003003 03-17
DISCRIMINABLE STIMULI PRODUCED BY NARCOTIC ANALGESICS.
003005 03-17

DISCRIMINANT
CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

DISCRIMINATED
EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
000365 01-04

DISCRIMINATION
DRUG EFFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS
000110 01-03
THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY.
000270 01-04
EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-04
EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04
DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
00034B 01-04
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVE BRIGHTNESS DISCRIMINATION LEARNING IN RATS.
000351 01-04
INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04
EFFECTS OF LOW AND MODERATE DOSES OF CHLORPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT.
000435 01-04
EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04
EVIDENCE FOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION
000B73 01-14

THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SUBSEQUENT DRUG STATE DISCRIMINATION.
000906 01-14

CHARACTERISTICS OF TETRAHYDROCANNABINOL (THC) PRODUCED DISCRIMINATION IN RATS.
00151B 02-04

EFFECTS OF P-CHLOROPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04

THE EFFECTS OF D-AMPHETAMINE ON TEMPORAL DISCRIMINATION IN THE RAT.
001567 02-04

ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05

EFFECTS OF SCOPOLAMINE ON A DOUBLE STIMULUS DISCRIMINATION.
002002 02-14

EFFECTS OF SCOPOLAMINE ON SMELL DISCRIMINATION IN THE RAT.
002316 03-03

THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS.
002471 03-04

DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-04

EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

BENZODIAZEPINES AND DISCRIMINATION BEHAVIOUR: DISSOCIATION OF RESPONSE AND SENSORY FACTORS.
003475 04-04

DISCRIMINATIVE

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04

BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
000421 01-04

DISCRIMINATIVE STIMULUS PROPERTIES OF A LOW DL-AMPHETAMINE DOSE.
001460 02-04

DISCRIMINATIVE STIMULUS PROPERTIES OF FENTANYL AND MORPHINE: TOLERANCE AND DEPENDENCE.
001461 02-04

DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04

BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

DISCRIMINATIVE PROPERTIES OF NARCOTIC ANTAGONISTS.
002466 03-04

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 03-04

THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-04

DRUGS AS DISCRIMINATIVE EVENTS IN HUMANS.
002960 03-17

GENERAL CHARACTERISTICS OF DISCRIMINATIVE STIMULI PRODUCED BY DRUGS.
003004 03-17

DISCRIMINATIVE RESPONSE CONTROL BY PSYCHOMOTOR STIMULANTS.
003034 03-17

HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION.
003364 04-04

THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL
003395 04-04

DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
00344B 04-04

DISCRIMINATIVE EFFECTS OF MORPHINE IN THE SQUIRREL-MONKEY.
003457 04-04

FURTHER EVALUATION OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT.
003460 04-04

DISEASE

L DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000192 01-03

THERAPEUTIC ACTION OF D-PHENYLALANINE IN PARKINSONS DISEASE.
000495 01-07

EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
000498 01-07

ANXIETY AND TENSION AND BETA-BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 01-10

THE GILLES-DE-LA-TOURETTE SYNDROME: AN ANALYSIS OF PUBLISHED CASES DEALING WITH THE COURSE OF THE DISEASE AND ITS PROGNOSIS.
000725 01-11

ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECARBOXYLASE INHIBITOR.
000745 01-11

PARANOID PSYCHOSIS WITH ONEIROIDAL ELEMENTS DURING THE COURSE OF REDLICH-FLATAUS DISEASE.
000769 01-11

PHARMACOKINETICS OF SEDATIVES IN LIVER DISEASE.
00079B 01-13

USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000B47 01-13

PIRIBEDIL IN THE TREATMENT OF PARKINSONS DISEASE.
00084B 01-13

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000B53 01-13

ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-15

DISEASE CAUSED BY DRUG THERAPY IN NEWBORN INFANTS.
000953 01-15

ON THE EFFECT OF DOPA DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM
000970 01-15

EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA-BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-0

LITHIUM-CARBONATE IN GILLES-DE-LA-TOURETTES DISEASE.
001763 02-0

THE DISEASE OF FAILURE OF COPING.
001797 02-1

LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE
001813 02-1

THE EFFECT OF LITHIUM IN MENIERES DISEASE.
001B16 02-1

MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION
001826 02-1

SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001890 02 1

L-DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE A LONG-TERM STUDY.
00258B 03-0

AN ERGOT DERIVATIVE IN THE TREATMENT OF PARKINSONS DISEASE
002592 03-0

A STUDY OF ENDOGENOUS DOPAMINE METABOLISM IN GILLES-DE-LA-TOURETTES DISEASE.
0026B4 03-0

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03 1

REMARKABLE ETIOLOGY IN A CASE OF GILLES-DE-LA-TOURETTES DISEASE.
002B65 03-1

DYSTONIA: THE SPECTRUM OF THE DISEASE
002916 03-1

CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE.
003446 04-0

PARKINSONS DISEASE: A THERAPEUTIC MEMORANDUM.
003611 04 1

REMARKABLE ETIOLOGY IN GILLES-DE-LA-TOURETTES DISEASE.
00362B 04-1

DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WIT HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04 1

DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE
0036B3 04-1

THE USE OF METHYLPHENIDATE AND IMIPRAMINE IN GILLES-DE-LA TOURETTES DISEASE IN CHILDREN.
0037B2 04-1

DISEASES

CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11

ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
000777 01-11

THE ADVANCE OF DEPRESSIVE DISEASES.
001015 01-17

DISINHIBITING

CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07

DISODIUM

THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANCE, ALONE AND IN COMBINATION WITH ETHANOL.
00285B 03-14

DISOPYRAMIDE

MENTAL DISTRESS IN PATIENT ON DISOPYRAMIDE.
003776 04-15

DISORDER

LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYPES OF PRIMARY AFFECTIVE DISORDER
000601 01-09

A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

TRICYCLIC ANTIDEPRESSANTS, TRYPTOPHAN AND AFFECTIVE DISORDER.
000657 01-09

SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PROBLEM OF PARANOID PSYCHOSIS.
00083B 01-13

DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03

RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?
001704 02-08

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13

DIALYSIS ENCEPHALOPATHY: A POSSIBLE SEIZURE DISORDER.
002146 02-17

ON PROPHYLAXIS IN UNIPOLAR AFFECTIVE DISORDER
002157 02-17

DRUGS USED IN THE TREATMENT OF MENTAL DISORDER.
003030 03-17

DISORDERED

DISORDERED BEHAVIOR OF EPILEPTICS AND CURRENT THERAPEUTIC ORIENTATIONS.
000757 01-11

AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11

DISORDERS

SCHIZOPHRENIA AND SLEEP DISORDERS.
000570 01-08

NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
0005B4 01-09

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09

HOW LONG SHOULD PROPHYLACTICS BE CONTINUED IN AFFECTIVE DISORDERS
000606 01-09

LONG TERM THERAPY OF AFFECTIVE DISORDERS AND SCHIZOPHRENIA
000620 01-09

THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09

CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01-09

THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
000652 01-09

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY.
000674 01-10

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10

LEXOTANIL (RO 5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
00070B 01-10

BENZODIAZEPINE DERIVATIVES IN PSYCHOSOMATIC DISORDERS A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH
000710 01-10

A DOUBLE BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS
001035 01-17

NEUROLOGICAL AND SENSORY DISORDERS IN THE ELDERLY.
001039 01-17

TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
00105B 01-17

THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01-17

THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09

NEUROPSYCHOBIOLOGY OF AFFECTIVE DISORDERS: SOME METHODOLOGICAL CONSIDERATIONS.
001751 02-09

THE CURRENT ROLE OF LITHIUM IN THE TREATMENT OF AFFECTIVE DISORDERS.
001779 02-09

SEVERE MOOD DISORDERS: A REVIEW.
0017B0 02-09

EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
001B12 02-10

PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
001B25 02-11

DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION.
002034 02-15

NEUROCHEMICAL AND NEUROPHARMACOLOGICAL FOUNDATIONS OF THE SLEEP DISORDERS.
002112 02-17

CURRENT STATUS OF LITHIUM THERAPY IN AFFECTIVE DISORDERS.
002160 02-17

THE THERAPISTS HANDBOOK: TREATMENT METHODS OF MENTAL DISORDERS.
00217B 02-17

ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1RB.
002672 03-09

ADVANCES IN THE DRUG THERAPY OF AFFECTIVE DISORDERS.
0026B0 03-09

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

MENTAL DISORDERS OTHER THAN SCHIZOPHRENIA AND DEPRESSION.
002764 03-11

CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
00277B 03-11

DRUG TREATMENT OF MENTAL DISORDERS.
0027B0 03-11

MHPG, AMITRIPTYLINE AND AFFECTIVE DISORDERS: A LONGITUDINAL STUDY
002B34 03-13

HALOPERIDOL IN THE THERAPY OF SEVERE BEHAVIOR DISORDERS.
002B51 03-14

CLINICAL MANAGEMENT OF SEXUAL DISORDERS.
002B66 03-14

PHARMACOLOGICAL TREATMENT OF AFFECTIVE DISORDERS.
002962 03-17

ADRENERGIC CHOLINERGIC IMBALANCE IN AFFECTIVE DISORDERS
003021 03-17

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

ADRENERGIC RESPONSES IN THE AFFECTIVE DISORDERS.
00355B 04-09

THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS.
003559 04-09

BIOCHEMISTRY OF THE AFFECTIVE DISORDERS.
003562 04-09

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISORDERS.
003576 04-09

PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
0035B1 04-10

MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
0035B2 04-10

THE MANAGEMENT OF PHOBIC DISORDERS USING CLOMIPRAMINE (ANAFRANIL).
003608 04-10

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

LITHIUM-CARBONATE IN PERSONALITY DISORDERS: A CASE OF HYSTERIA.
003753 04-14

PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH (UNPUBLISHED PAPER).
003B63 04-17

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

DISORGANIZATION
EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH
003522 04-07

DISPERSION
APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
002586 03-06

DISPOSITION
CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM.
001914 02-13

NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
001949 02-13

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

BIOLOGICAL DISPOSITION OF RIGID ANALOGS OF AMPHETAMINE.
003147 04-03

DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
0036B3 04-13

ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPUBLISHED PAPER).
003705 04-13

DISRUPT
DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

DISRUPTION
SHORT TERM MEMORY IN THE RHESUS-MONKEY: DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
0002B3 01-04

RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03

TASTE AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIVE AND DRUG SPECIFIC EFFECTS.
003359 04-04

FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
003394 04-04

DISRUPTIVE
REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
0015B0 02-04

DISRUPTS
ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
003433 04-0

DISSOCIATE
LOCOMOTOR ACTIVITY AND EXPLORATION: THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT
00153B 02-0

DISSOCIATION
ABOLITION OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION.
000347 01-0

DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-

CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
0015B9 02-

UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTION OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-

BENZODIAZEPINES AND DISCRIMINATION BEHAVIOUR: DISSOCIATION RESPONSE AND SENSORY FACTORS.
003475 04

DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
0034B0 04

DISSOCIATIVE
TASTE-AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIV AND DRUG SPECIFIC EFFECTS.
003359 04

DISSONANCE
COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA - PILOT EXPERIMENT.
001864 02

DISTINCT
DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01

THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04

DISTINGUISH
PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 0

DISTRESS
MENTAL DISTRESS IN PATIENT ON DISOPYRAMIDE.
003776 0

DISTRIBUTION
PHYLOGENETIC DISTRIBUTION OF A MORPHINE-LIKE PEPTIDE ENKEPHALIN
000015 0

TISSUE DISTRIBUTION OF METOPROLOL-3H IN THE MOUSE AND THE
000054 0

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMIN SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN
0000B6 0

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION D-AMPHETAMINE-SULFATE.
0000BB 0

LITHIUM-CARBONATE DISTRIBUTION AND ITS EFFECTS ON THE OTHE IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 0

ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
000579 0

THE SUBCELLULAR DISTRIBUTION OF 14C-GABA AND 3H-DOPAMINE THE RETINA.
001130 0

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION A OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPT
001150 0

ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINIST DISULFIRAM IN THE RAT
0011B1 0

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABO OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
0011B2 0

DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03

IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
001255 02-03

REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02-03

DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS.
001907 02-13

DISTRIBUTION OF LITHIUM BETWEEN ERYTHROCYTES AND PLASMA: IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES.
001915 D2-13

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-03

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-03

REGIONAL DISTRIBUTION OF ETHANOL IN RAT BRAIN.
002236 D3-03

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION
0022BB 03-03

ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
002392 03-03

THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE. (PH.D. DISSERTATION).
002405 03-03

HYPERTENSION AND CATECHOLAMINE DISTRIBUTION IN DIFFERENT PARTS OF THE RAT BRAIN.
002413 D3-03

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
D025B6 03-06

REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN.
0032D7 D4-D3

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
D03211 04-03

MORPHINE ALTERS DISTRIBUTION OF GABA IN THALAMUS.
003336 D4-03

EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE.
003BB9 D4-17

DISTRIBUTIONS

REGIONAL AND SUBCELLULAR DISTRIBUTIONS OF BRAIN NEUROTENSIN.
0D1406 02-03

INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY
003775 04-15

DISTURBANCE

SLEEP DISTURBANCE AND HYPNOTIC DRUG DEPENDENCE.
DD1D27 01-17

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
0034B7 04-D4

DISTURBANCES

TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
00166B D2-D7

DOSE-RELATED SLEEP DISTURBANCES INDUCED BY COFFEE AND CAFFEINE.
001973 02-14

NEUROPSYCHOLOGICAL AND EEG DISTURBANCES IN POLYDRUG USERS
002044 02-15

MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP
002232 03-03

CLINICAL EVALUATION OF AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES.
002714 03-10

EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-15

TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL.
002976 03-17

METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
003044 03-17

DISTURBED

DISTURBED SLEEP.
000747 01-11

ON THE TREATMENT OF MENTALLY DISTURBED COLLEGE STUDENTS.
001047 01-17

DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
002051 02-15

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
00352B 04-0B

DISUBSTITUTED

COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
0021B3 03-01

ANALGESIC AND TRANQUILIZING ACTIVITY OF 5,8 DISUBSTITUTED 1-TETRALONE MANNICH-BASES.
003075 04-02

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03

DISULFIRAM

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
000269 01-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
0011B1 02-03

SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-03

DISULFIRAM IMPLANTATION: PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS.
002003 02-14

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
D02241 03-D3

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
D02579 D3-05

EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN.
DD3D94 04-D3

DISULFIRAM TOXICITY AND CARBON-DISULFIDE POISONING.
0D3B19 D4-15

DITA

ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE.
D01119 D2-D3

DIURETIC

COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
0D32B5 D4-D3

DIURETICS

LITHIUM AND DIURETICS.
DD3B23 D4-15

DIURNAL

CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
D0159B D2-04

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
DD1929 D2-13

DIVALENT
OSTEOPENIA AND DYSREGULATION OF DIVALENT CATIONS IN LITHIUM TREATED PATIENTS.
0005B5 01-09
EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

DIVIDED
AN AUDIOVISUAL TEST OF DIVIDED ATTENTION.
000874 01-14

DIXYRAZINE
HYPNOTIC EFFECTS OF DIXYRAZINE IN A DOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
002736 03-11

DL-AMPHETAMINE
DISCRIMINATIVE STIMULUS PROPERTIES OF A LOW DL-AMPHETAMINE DOSE.
001460 02-04

DL-DOPS
DOC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OF DL-DOPS.
001232 02-03

DL-HOMOCYSTEINE
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
002198 03-03

DL-NOREPHEDRINE
PHARMACOKINETICS OF DL-NOREPHEDRINE 14C IN THE RAT.
001401 02-03

DL-3-
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
00039B 01-04

DMPEA
QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03

DMT
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04
AN EXPERIMENTAL STUDY ON THE CONSCIOUSNESS ALTERING EFFECT OF N,N DIMETHYLTRYPTAMINE (DMT).
002797 03-12

DOBREN
OBSERVATIONS OF THE INTRAVENOUS ADMINISTRATION OF SULPIRIDE (DOBREN).
00176B 02-09

DOCUMENTED
INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION. RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY
002095 02-16

DOG
EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPONSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
00002B 01-D3
COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
000055 01-03
PHARMACOKINETIC STUDIES OF METOPROLOL-3H IN THE RAT AND THE DOG.
000056 01-03
THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03
INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
D00241 01-03
METABOLISM OF METOPROLOL-3H IN MAN, THE DOG AND THE RAT.
D0DB04 01-13
CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
D01124 02-03
PETHIDINE PHARMACOKINETICS IN DOG: DOSE AND TIME STUDIES.
00113B 02-03
SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-03
THE INFLUENCE OF MEPROBAMATE ON HEART-RATE IN THE CONSCIOUS DOG
001615 02-05
PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DOG, RABBIT, GUINEA-PIG AND RAT.
001921 02-13
EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03
HYPERACTIVITY IN TWO DOG BREEDS AND THEIR HYBRIDS.
003421 04-04

DOGS
INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 01-03
PHARMACOKINETIC STUDIES OF PENTYLENETETRAZOL IN DOGS.
000137 01-03
FOOD DOMINANCE IN DOGS: EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE.
000450 01-04
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03
MORPHINE OPPOSED EFFECTS OF NALOXONE IN UNANESTHETIZED DOGS.
001252 02-03
EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-D3
EFFECTS OF IMIPRAMINE, CHLORIMIPRAMINE, AND FLUOXETINE ON CATAPLEXY IN DOGS.
002421 03-04
CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03
INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03
AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
0031B2 D4-03
EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
0031B3 04-03
SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

DOMESTIC
PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
00013B 01-03

DOMINANCE
FOOD DOMINANCE IN DOGS: EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE.
000450 01-04

DOMINANT
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

DOPA
THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03
A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 02-03
AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA
001233 02-0
THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
DD3239 04-0
DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-0

DOPA-DECARBOXYLASE
ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECARBOXYLASE INHIBITOR.
000745 D1-1
L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT
000BD1 01-1

ON THE EFFECT OF DOPA-DECAR8OXYLASE INHI8ITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM
000970 01-15

SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES 8Y CARBIDOPA, AN INHI8ITOR OF PERIPHERAL DOPA-DECAR8OXYLASE
003330 04-03

DOPA-INDUCED

THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED 8EHAVIOURAL RESPONSES IN MICE.
002188 03-02

DOPAC

EFFECTS OF LSD AND 2-8ROMOLSD ON STRIATAL DOPAC LEVELS.
003238 04-03

DOPAMINE

THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01

INTERACTION OF 8ETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
000002 01-01

DIFFERENTIAL EFFECT OF NEUROLEPTIC DRUGS ON DOPAMINE TURNOVER IN THE EXTRAPYRAMIDAL AND LIM8IC SYSTEM.
000003 01-01

N-ISOPROPYL DERIVATIVES OF DOPAMINE AND 5,6 DIHYDROXY-2-AMINOTETRALIN.
000068 01-03

ON THE SUPERSENSITIVITY OF DOPAMINE RECEPTORS, INDUCED 8Y NEUROLEPTICS.
000073 01-03

DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS.
000078 01-03

8ACLOFEN AND GAMMA-HYDROXY8UTYRATE: SIMILAR EFFECTS ON CERE8RAL DOPAMINE NEURONES.
000D83 01-03

SU8STITUTED BENZAMIDES AS DOPAMINE ANTAGONISTS.
000094 01-03

EFFECT OF SOME PHOSPHODIESTERASE INHIBITORS ON CENTRAL DOPAMINE MECHANISMS.
000100 01-03

ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RELEVANCE FOR PSYCHOMOTOR EFFECTS.
000148 01-03

A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03

DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
000186 01-03

METOCLOPRAMIDE AND DOPAMINE RECEPTOR BLOCKADE.
000195 D1-03

ANALYSIS OF INHIBITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
000215 D1-03

DOPAMINE META8OLISM IN THE MESOLIM8IC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03

INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG
00D241 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN-COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT 8RAIN
000256 01-03

DOPAMINE METABOLISM IN THE NUCLEUS-ACCUMBENS: THE EFFECT OF CLOZAPINE.
DDD260 01-03

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE INDUCED LESIONS OF THE NUCLEUS ACCUM8ENS
000264 01-03

ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT 8Y CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03

ERGOT ALKALOIDS AS DOPAMINE AGONISTS COMPARISON IN TWO RODENT MODELS
000273 01-04

A ROLE FOR DOPAMINE IN THE PSYCHOPHARMACOLOGY OF ELECTRICAL SELF-STIMULATION
000300 01-04

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE
000314 01-04

INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL DOPAMINE NEURONS.
000358 01-04

NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS.
000405 01-04

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
000428 01-04

REDUCED TURNOVER IN MESOLIM8IC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 01-05

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
000468 01-06

ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
000474 01-06

THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A CRITICAL ANALYSIS
000554 01-08

THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A REVIEW
00D558 01-08

PLATELET UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN DEPRESSION.
000612 01-09

MAMMALIAN BIOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
000793 01-12

LOW URINARY DOPAMINE AND PREDICTION OF PHENOTHIAZINE-INDUCED PARKINSONISM: A PRELIMINARY REPORT.
D00935 01-15

ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE.
D01119 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
DD1151 02-03

DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CERE8ROSPINAL FLUID.
001175 02-03

BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION.
0D1190 D2-D3

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN.
001197 02-03

EFFECTS OF FENTANYL AND DROPERIDOL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
00121D 02-03

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS ON THE GAMMA-BUTYROLACTONE-INDUCED INCREASE IN MOUSE BRAIN DOPAMINE.
0D1220 D2-03

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHI8ITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN
001224 02-D3

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
0D1226 02-D3

AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA. 001233 02-03

CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS. 001241 02-03

THE DOPAMINE RECEPTOR AND ANTIPSYCHOTIC EFFECT. 001259 02-03

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM. 001261 02-03

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE. 001277 02-03

OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE BRAIN OF THE LOCUST, SCHISTOCERCA-GREGARIA. 001343 02-03

SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS. 00134B 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY. 001367 02-03

ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT. 0013B3 02-03

EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES. 0013B7 02-03

EFFECT OF TRAZODONE ON BRAIN DOPAMINE METABOLISM. 0013BB 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS. 001397 02-03

CLOZAPINE: REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT. 001412 02-03

COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM. 001413 02-03

ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS. 001417 D2-03

COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN. 001419 02-D3

TREMOROGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE AND THEIR SUPPRESSION BY DOPAMINE. 00143B 02-04

THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS. 001447 02-04

THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS. 00147B 02-04

INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOURS IN RODENTS. 0D1519 D2-04

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE. 0D1522 D2-D4

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS. D01526 02-D4

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS. DD1602 02-04

MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS) DD1611 D2-D4

DOPAMINE AND SCHIZOPHRENIA. DD16B5 D2-0B

DOPAMINF AND SCHIZOPHRENIA. 001722 D2-DB

DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM. DD1B31 D2-11

CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULATIONS. D01955 02-14

INTRACEREBRAL DOPAMINE METABOLISM STUDIED BY A NOVEL RADIOISOTOPE TECHNIQUE. 00196B 02-14

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS. 002194 03-02

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN. 002202 03-03

MODULATION OF ACETYLCHOLINE IN THE NEOSTRIATUM BY DOPAMINE AND 5-HYDROXYTRYPTAMINE. 002216 03-03

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER). 002227 03-03

L-DOPA: PLASMA PHARMACOKINETICS AND CONVERSION TO DOPAMINE IN BRAIN. (PH.D. DISSERTATION). 002233 03-03

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS. D02234 03-03

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE. 00223B 03-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES. 002243 D3-03

THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS 002250 03-03

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS. 002270 03-03

EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS. D02291 03-D3

BETA-ENDORPHIN IN VITRO INHIBITION OF STRIATAL DOPAMINE RELEASE. 00229B 03-03

NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3. 00231B 03-D3

AMPHETAMINE-INDUCED RELEASE OF DOPAMINE FROM THE SUBSTANTIA-NIGRA IN VITRO. 00232B 03-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES. 002342 03-03

CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN THE CAUDATE NUCLEUS. 002369 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM. 002393 D3-D3

POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS. 002401 D3-03

BRAIN DOPAMINE, D-AMPHETAMINE AND THERMOREGULATION IN RATS. D02409 D3-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN DD2436 03-D4

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN. D0243B D3-04

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE. DD25D6 D3-D4

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM. DD2521 03-D4

POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT DD2522 D3-D4

THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS. DD2526 D3-D4

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT
002541 03-04

DOPAMINE AND SCHIZOPHRENIA.
002624 03-08

A STUDY OF ENDOGENOUS DOPAMINE METABOLISM IN GILLES-DE-LA-TOURETTES DISEASE.
0026B4 03-09

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION - LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13

DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002B32 03-13

IMPORTANCE OF THE DOPAMINE METABOLISM FOR THE CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
002841 03-13

IMPORTANCE OF DOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
003043 03-17

DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
00307B 04-03

POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03

EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03

ANTIDEPRESSANT DRUGS AND DOPAMINE UPTAKE IN DIFFERENT BRAIN REGIONS.
003146 04-03

INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
00317B 04-03

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
0031BB 04-03

ONTOGENESIS OF DOPAMINE RECEPTOR BINDING IN THE CORPUS-STRIATUM OF THE RAT.
003235 04-03

EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE, AND 5-HYDROXYTRYPTAMINE.
003247 04-03

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03

DOPAMINE LEVELS IN THE STRIATUM AND THE EFFECT OF ALCOHOL AND RESERPINE.
00331B 04-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-03

PERLAPINE AND DOPAMINE METABOLISM: PREDICTION OF ANTIPSYCHOTIC EFFICACY.
003325 04-03

DOPAMINE AND SCHIZOPHRENIA.
003326 04-03

PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION
003343 04-04

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL
003425 04-04

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTION IN MICE
003427 04-04

DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
00344B 04-04

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES
003449 04-04

ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN
003493 04-05

EFFECT OF DOPAMINE ON ESOPHAGEAL MOTOR FUNCTION
003504 04-05

ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM
003631 04-11

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

DOPAMINE-BETA-HYDROXYLASE

EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS ON THERMOREGULATION IN RESERPINE-TREATED RATS.
000010 01-01

INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03

THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
000274 01-04

EFFECT OF TWO INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE ON MATURATION OF MEMORY IN MICE.
0014B7 02-04

ANTIAGGRESSIVE ACTION OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN MICE.
001571 02-04

SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS: EFFECT OF D-AMPHETAMINE AND HALOPERIDOL.
001927 02-13

DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03

SERUM DOPAMINE-BETA-HYDROXYLASE ACTIVITY (V): EFFECTS OF VARIOUS DRUGS ON THE ENZYME ACTIVITY.
002326 03-03

THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY.
002439 03-04

BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03

DOPAMINE-DEPLETED

THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTACT AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
0032B6 04-03

DOPAMINE-FREE

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

DOPAMINE-INDUCED

DOPAMINE-INDUCED INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA.
001900 02-13

DOPAMINE-SENSITIVE

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03

EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN THE RETINA: A POINT OF ACTION FOR D-LSD.
002372 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
002385 03-03

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

DOPAMINE-STIMULATED

A DOPAMINE-STIMULATED ADENYLATE-CYCLASE IN RAT SUBSTANTIA-NIGRA.
001382 02-03

DOPAMINERGIC

CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02

APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03

ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
000128 01-03

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03

DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

TOPOGRAPHIC AND PHARMACOLOGICAL STUDY OF THE MESOCORTICAL DOPAMINFRGIC SYSTEM.
000240 01-03

EFFECTS OF BROMOCRIPTINE ON CENTRAL DOPAMINERGIC RECEPTORS.
000242 01-03

EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION
000262 01-03

THF EFFECTS OF MANIPULATIONS WITH THE DOPAMINERGIC SYSTEM ON SELF-STIMULATION BEHAVIOR.
000293 01-04

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS INDUCED BY HALOPERIDOL.
000438 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-06

METAL CHELATFS OF L-DOPA FOR IMPROVED REPLENISHMENT OF DOPAMINFRGIC POOLS.
001090 02-01

DOPAMINERGIC ACTIVITY OF SOME APOMORPHINE ANALOGS.
001104 02-02

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

IN VIVO CHANGES OF GUANOSINF 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINFRGIC MECHANISMS.
001158 02-03

INFLUENCF OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCFD ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03

NONSFLECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
001198 02-03

TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS.
001267 02-03

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK
001269 02-03

ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
001334 02-03

ROLE OF NORADRENERGIC AND DOPAMINERGIC PROCESSES IN AMPHETAMINE SELF-ADMINISTRATION.
001342 02-03

DOPAMINERGIC AGENTS: INFLUENCE ON SEROTONIN IN THE MOLLUSCAN NERVOUS SYSTEM.
001389 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04

DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04

CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR.
001671 02-07

INTRODUCTORY REMARKS AT INTERNATIONAL SYMPOSIUM ON NON STRIATAL DOPAMINERGIC NEURONS. (UNPUBLISHED PAPFR).
001881 02-13

CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03

PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION
002218 03-03

REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS. INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 03-03

DOPAMINERGIC DRUG EFFECTS UPON SEROTONIN NEURONS.
002300 03-03

INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN.
002320 03-03

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION
002344 03-03

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

DOPAMINERGIC AND SEROTONERGIC ACTION OF ERGOMETRINE.
002418 03-04

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN.
002459 03-04

MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
002483 03-04

ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM
002491 03-04

COMPARISON OF THE DOPAMINERGIC EFFECTS OF N-SUBSTITUTED APORPHINES.
002498 03-04

INTERACTION OF BRADYKININ WITH DOPAMINERGIC RECEPTORS IN THE CNS.
002507 03-04

CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SUBSTANTIA-NIGRA IN THE RABBIT.
002557 03-04

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
002587 03-04

A DOPAMINERGIC MECHANISM IN MANIA.
002673 03-09
ATTEMPT AT TREATING PARKINSONISM WITH AGONISTS OF THE DOPAMINERGIC SYSTEM.
002751 03-11
DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
003086 04-03
REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
003097 04-03
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
003192 04-03
MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION
003268 04-03
CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AND CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RATS.
003390 04-04
CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE.
003446 04-04
THE DOPAMINERGIC AND ANTIDOPAMINERGIC EFFECTS OF SOME APORPHINES.
003473 04-04
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06
DOPAMINERGIC FUNCTION IN TWO PATIENTS WITH CATALEPSY.
003529 04-08
DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13
EFFECTS OF 1694 AND OTHER DOPAMINERGIC AGENTS ON CIRCLING BEHAVIOR.
003855 04-17
AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

DOPAMINES
CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02

DORIDEN
SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13

DORSAL
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15
DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE
001455 02-04
EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGATA ON THE SPINAL DORSAL HORN NEURON.
002200 03-03
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF ADRENERGIC SYSTEM.
002246 03-03
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN
002247 03-03
THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
002281 03-03
STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-05
ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03
INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03
THE EFFECT OF DIPHENYLHYDANTOIN ON SELF STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY
003379 04-04
SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION
003443 04-04

DORSOMEDIAL
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
001608 02-04

DOSAGE
DOSAGE FOR ANTIPSYCHOTIC DRUGS.
000529 01-08
THE EFFECTIVE DOSAGE OF ANTIDEPRESSANTS.
000588 01-09
THE USE OF DIPOTASSIUM CHLORAZEPATE AT HIGH DOSAGE IN TREATMENT OF OBESITY.
000738 01-11
THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11
ANORECTIC EFFECTIVENESS OF DIFFERING DOSAGE FORMS OF FENFLURAMINE.
000784 01-11
CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 01-13
DOSAGE FOR ANTIPSYCHOTIC DRUGS.
001060 01-17
BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-07
AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07
HIGH DOSAGE NEUROLEPTIC THERAPY: A REVIEW.
001686 02-08
THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY.
001899 02-13
LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13
PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08
USE OF HALOPERIDOL AT VERY HIGH DOSAGE.
002637 03-08
ANTIDEPRESSANT EFFECTS OF DESIPRAMINE ADMINISTERED IN TWO DOSAGE SCHEDULES.
003566 04-09
A COMPARISON OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003621 04-11
STEADY-STATE BIOAVAILABILITY OF TWO CLORAZEPATE DIPOTASSIUM DOSAGE FORMS.
003662 04-13
PHARMACOKINETICS OF CHLORPROMAZINE AFTER SINGLE AND CHRONIC DOSAGE.
003664 04-13
COMPARISONS OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003672 04-13
NEUROLEPTIC DOSAGE, DURATION, AND TARDIVE-DYSKINESIA.
003760 04-15

DOSAGES
CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-08
TWO DOSAGES OF IMIPRAMINE IN HOSPITALIZED ENDOGENOUS AND NEUROTIC DEPRESSIVES.
001778 02-09
CLINICAL DOUBLE-BLIND STUDY WITH TWO DIFFERENT DOSAGES OF MAPROTILINE (150 AND 225MG PER DAY).
002793 03-11

DOSE
DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE-AVERSIONS: EFFECTS OF DOSE AND DURATION OF PRETREATMENT.
000337 01-04
PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07
CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 01-13

EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15

HUMAN SEDATIVE SELF-ADMINISTRATION: EFFECTS OF INTERINGESTION INTERVAL AND DOSE.
001046 01-17

PETHIDINE PHARMACOKINETICS IN DOG: DOSE AND TIME STUDIES.
00113B 02-03

DISCRIMINATIVE STIMULUS PROPERTIES OF A LOW DL-AMPHETAMINE DOSE.
001460 02-04

STATE-DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDE AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
0014B8 02-04

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

DOSE EFFECT RELATIONSHIP IN TREATMENT WITH PIRACETAM.
001B35 02-11

RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14

PERSISTENT PSYCHOTIC PHENOMENA FOLLOWING ONE DOSE OF PENTAZOCINE.
002025 02-15

CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
002481 03-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

EFFECT OF UNIT DOSE AND ROUTE OF ADMINISTRATION ON SELF-ADMINISTRATION OF MORPHINE.
002543 03-04

VERY HIGH DOSE FLUPHENAZINE-DECANOATE.
002646 03-08

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

DETERMINING OPTIMUM DOSE AND ACUTE TOLERANCE OF TRIAZOLAM.
003754 04-14

DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003B01 04-15

LITHIUM SIDE-EFFECTS IN RELATION TO DOSE AND TO LEVELS AND GRADIENTS OF LITHIUM IN PLASMA.
003B15 04-15

DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003B24 04-15

DOSE-DEPENDENT

DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03

DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04

DOSE-RELATED

DOSE-RELATED SLEEP DISTURBANCES INDUCED BY COFFEE AND CAFFEINE.
001973 02-14

DOSE-RESPONSE

DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01

A DOSE-RESPONSE STUDY OF THE ACUTE EFFECTS OF ETHANOL ON THE SLEEP OF RATS.
000169 01-03

A DOSE-RESPONSE COMPARISON BETWEEN METHADONE AND MORPHINE SELF-ADMINISTRATION.
000255 01-03

DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
0003B7 01-04

ETHANOL INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
001264 02-03

OBSERVATIONAL DETERMINATION OF DOSE RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-04

A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
0D1529 02-04

MORPHINE-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
003197 04-03

DOSES

DIFFERENTIAL EFFECTS OF LOW DOSES OF ETHANOL ON THE IMPULSE ACTIVITY IN VARIOUS REGIONS OF THE LIMBIC SYSTEM.
000142 01-03

CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04

EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
000367 01-04

TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04

MORPHINE-BASED SECONDARY REINFORCEMENT: EFFECTS OF DIFFERENT DOSES OF NALOXONE.
000372 01-04

EFFECTS OF THE ADMINISTRATION OF TWO DOSES OF SULPIRIDE ON THE BEHAVIOUR OF THE RAT.
000414 01-04

EFFECTS OF LOW AND MODERATE DOSES OF CHLORPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT.
000435 01-04

ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
000474 01-06

CLINICAL SPECTRUM OF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE.
000532 01-08

VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE.
0D0702 01-10

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000B59 01-13

THE EFFECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
000986 01-15

BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03

HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-08

BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13

EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 02-14

COMPARATIVE DOSES AND COSTS OF ANTIPSYCHOTIC MEDICATION.
002110 02-17

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04

HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002849 03-14

EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
0D3230 04-03

LACK OF STIMULATION BY HIGH AMPHETAMINE DOSES FOLLOWING A LOW-DOSE OF SPIPERONE.
003345 04-04

ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
00349B 04-05

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
0035B9 04-10

BRIEF TREATMENT OF ANXIOUS PATIENTS WITH HALAZEPAM IN HIGH DOSES.
003591 04-10

AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT
003657 04-13

DOSING

ALPHA-FLUPENTHIXOL-INDUCED HYPERACTIVITY BY CHRONIC DOSING IN RATS.
000412 01-04

NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
001949 02-13

WITHDRAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBITAL DOSING IN CAT.
002516 03-04

PHARMACOKINETIC APPROACH TO DRUG DOSING IN THE AGED.
002604 03-07

DOTHIEPIN

THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE-EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN.
000972 01-15

AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07

DOUBLE

EFFECTS OF SCOPOLAMINE ON A DOUBLE STIMULUS DISCRIMINATION.
002002 02-14

DOUBLE-BLIND

DOUBLE-BLIND EVALUATION OF AHR-1118 AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
0004B6 01-07

STUDIES WITH BROMOCRIPTINE: PART 2. DOUBLE-BLIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07

A DOUBLE-BLIND COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
000502 01-07

STUDY ON THE EFFECTS OF SULPIRIDE AND PERPHENAZINE IN B2 SCHIZOPHRENICS USING THE DOUBLE-BLIND METHOD.
000531 01-08

DOUBLE-BLIND TRIAL OF L-DOPA IN CHRONIC SCHIZOPHRENIA.
000537 01-08

DOUBLE-BLIND CLINICAL COMPARISON OF HF-1B54 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
00053B 01-08

INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-08

A DOUBLE-BLIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-08

A DOUBLE-BLIND COMPARISON OF TPN-12 AND CHLORPROMAZINE ON SCHIZOPHRENIA.
000552 01-08

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 01-08

COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOUBLE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-08

LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08

A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
0005B0 01-09

A DOUBLE-BLIND STUDY OF THE ANTIDEPRESSANTS DIBENZEPIN (NOVERIL) AND AMITRIPTYLINE.
0005B2 01-09

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
0005B9 01-09

A DOUBLE BLIND COMPARISON OF LITHIUM-CARBONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 01-09

5 HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE BLIND CONTROLLED STUDY.
000627 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION.
00065B 01-09

MIANSERIN VERSUS AMITRIPTYLINE. A DOUBLE BLIND TRIAL EVALUATED BY THE AMP SYSTEM
000663 01-09

PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS. A DOUBLE BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10

RIPAZEPAM (CI-6B3) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10

A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

DOUBLE-BLIND COMPARATIVE TEST OF LORAZEPAM FOR PSYCHONEUROSIS.
000753 01-11

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

DIBENZEPIN AND AMITRIPTYLINE IN DEPRESSIVE STATES: COMPARATIVE DOUBLE-BLIND TRIAL.
000B93 01-14

A DOUBLE-BLIND TRIAL OF BACLOFEN AGAINST PLACEBO IN THE TREATMENT OF SCHIZOPHRENIA.
001664 02-07

A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

A COMPARATIVE DOUBLE-BLIND STUDY OF THE SIDE-EFFECTS OF LITAREX AND LITHIONIT DURETTES.
00167B 02-07

DOUBLE-BLIND CLINICAL STUDY OF CARPIPRAMINE/PLACEBO.
0016BB 02-08

A DOUBLE-BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
00169B 02-08

ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN.
001723 02-08

DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09

DOUBLE-BLIND ATTEMPT AT COMPARISON OF EFFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION.
0017B3 02-09

ANTIANXIETY EFFECTS OF TRAZODONE (A DOUBLE-BLIND STUDY WITH DIAZEPAM AND PLACEBO).
001B06 02-10

A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
001B10 02-10

DOUBLE-BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI-6B20 BUFOXINE.
001B11 02-10

AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
001B1B 02-11

DOUBLE-BLIND CLINICAL TRIAL OF 5-HYDROXYTRYPTOPHAN IN A CASE OF LESCH-NYHAN SYNDROME.
001B27 02-11

AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO.
001B42 02-11

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION.
0020B2 02-15

METHODOLOGY IN DOUBLE-BLIND DRUG TRIALS.
0020BB 02-16

MATCHING PROPERTIES IN DOUBLE-BLIND TRIALS.
002090 02-16

PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE: A CONTROLLED DOUBLE-BLIND STUDY.
00259B 03-07

DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-08

A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
DD2627 03-D8

A DOUBLE-BLIND COMPARISON OF DOXEPIN AND NORTRIPTYLINE ON DEPRESSION.
DD2676 03-D9

A DOUBLE-BLIND COMPARISON OF SULPIRIDE WITH CHLORDIAZEPOXIDE IN NEUROSIS.
0D2732 03-10

HYPNOTIC EFFECTS OF DIXYRAZINE IN A DOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
DD2736 03-11

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-42DD), WITH A BARBITURATE.
00275D D3-11

DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
D02754 D3-11

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
002778 03-11

CLINICAL DOUBLE-BLIND STUDY WITH TWO DIFFERENT DOSAGES OF MAPROTILINE (150 AND 225MG PER DAY).
DD2793 03-11

PENFLURIDOL: A DOUBLE-BLIND TRIAL IN CHRONIC SCHIZOPHRENIA.
DD3542 D4-DB

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

AMOXAPINE: A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
DD3577 04-D9

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
DD35B9 04-10

HALAZEPAM AND DIAZEPAM IN NEUROTIC ANXIETY: A DOUBLE-BLIND STUDY.
0D36DD D4-1D

A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
DD36D5 04-10

A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
DD36D6 04-1D

A DOUBLE-BLIND TRIAL OF NAFTIDROFURYL IN TREATING CONFUSED ELDERLY PATIENTS IN GENERAL PRACTICE.
003612 D4-11

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES. DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
0D361B D4-11

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
DD3634 D4-11

CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
D03643 D4-11

EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A DOUBLE-BLIND STUDY IN HEALTHY PROBANDS.
DD3755 D4-14

COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
DD3774 D4-15

DOVES

EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
DDD3B9 D1-D4

DOXEPIN

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
D0D622 D1-D9

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
DDD963 D1-15

GLC DETERMINATION OF DOXEPIN PLASMA LEVELS
DD1009 D1-16

ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN.
DD1723 D2-DB

A DOUBLE-BLIND COMPARISON OF DOXEPIN AND NORTRIPTYLINE ON DEPRESSION
DD2676 D3-D9

DOXEPIN AND DIAZEPAM IN THE TREATMENT OF HOSPITALIZED GERIATRIC PATIENTS.
D0277D D3-11

ENHANCEMENT OF PROPOXYPHENE-INDUCED ANALGESIA BY DOXEPIN
D03301 04-03

FINDINGS WITH A CONDITIONING TEST BATTERY: DIFFERENTIAL RESPONSIVENESS TO DIAZEPAM AND DOXEPIN
003580 04-10

A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
003603 04-10

DOXEPINE

USE OF DOXEPINE IN THE VARIOUS CLINICAL FORMS OF DEPRESSION.
00173B D2-D9

DPH

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11

DREAM

BENZODIAZEPINE-INDUCED MODIFICATIONS OF DREAM CONTENT: THE EFFECT OF FLUNITRAZEPAM.
DD1969 D2-14

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
0D1994 D2-14

DREAM RECALL AND THE CONTRACEPTIVE PILL.
DD2875 03-14

DREAMING

DREAMING, FENFLURAMINE, AND VITAMIN-C.
003691 04-13

DRINKERS

EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS.
DD20D4 02-14

DRINKING

SCOPOLAMINE AND ADJUNCTIVE DRINKING IN RATS.
0D0216 D1-D3

INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE KILLING, FEEDING, AND DRINKING IN RATS.
DDD331 D1-04

GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
D0D37B 01-04

COMPULSIVE WATER DRINKING DURING DEPRESSIVE REACTION.
DDD688 D1-10

DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 D2-D4

EFFECTS OF DIAZEPAM AND RIPAZEPAM ON TWO MEASURES OF ADJUNCTIVE DRINKING IN RATS.
0D1572 D2-D4

DRINKING INDUCED BY PARENTERAL INJECTIONS OF PILOCARPINE.
D02449 D3-04

AN ANALYSIS OF BARBITURATE-INDUCED EATING AND DRINKING IN THE RAT.
0D2552 03-D4

WATER POISONING AND DIABETES-INSIPIDUS: A PROPOS COMPULSIVE WATER DRINKING AND DYSTHYMIA.
0D2717 D3-10

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
DD34D4 D4-D4

PHENOBARBITAL DRINKING CURVES AFTER VARIED WATER DEPRIVATION.
0D3458 04-D4

SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
DD3497 04-D5

DRIVE

MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
00139D D2-D3

DRIVING

THE EFFECTS OF PSYCHOTROPIC DRUGS UPON DRIVING RELATED SKILLS.
0DDBB2 D1-14

EFFECT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING
0D1995 D2-14

DIAZEPAM IMPAIRS DRIVING SKILLS LESS THAN THIORIDAZINE.
0D2929 D3-15

LORAZEPAM IMPAIRS DRIVING SKILLS.
D02933 D3-15

MODERN PROBLEMS OF PHARMACOPSYCHIATRY. VOL II: ALCOHOL, DRUGS AND DRIVING.
003D14 03-17

MEDAZEPAM AND THE DRIVING ABILITY OF ANXIOUS PATIENTS.
0D3BD9 D4 15

OPERIDOL
EFFECTS OF FENTANYL AND DROPERIDOL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
001210 02-03
FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03

UG
DRUG EFFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS.
000110 01-03
MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03
IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION
000269 01-03
BEHAVIOR AND DRUG EFFECTS DURING CHRONIC STRESS.
000282 01-04
HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION
000316 01-04
DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE-AVERSIONS: EFFECTS OF DOSE AND DURATION OF PRETREATMENT.
000337 01-04
ABOLITION OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION.
000347 01-04
DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-04
ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
000474 01-06
PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06
PATIENTS REACTIONS TO CLINICAL DRUG TESTING.
0004B9 01-07
STUDY IN A PEDIATRIC MILIEU OF AN ANTIANXIETY DRUG: CLOBAZAM.
000494 01-07
PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07
PSYCHIATRISTS, PHYSICIANS AND THE CIA DRUG PROGRAM.
000521 01-07
EVALUATION OF THE NEW DRUG -- CLOMIPRAMINE (ANAFRANIL).
000522 01-07
DRUG IN THE AFTERCARE TREATMENT OF SCHIZOPHRENIA.
000549 01-08
DRUG AND FAMILY THERAPY IN DEPRESSED OUTPATIENTS.
000607 01-09
DRUG RELATED TEST PATTERNS OF DEPRESSED PATIENTS.
000626 01-09
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09
PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09
EARLY CLINICAL DRUG EVALUATION UNIT.
000678 01-10
DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10
POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSION IN ALCOHOL ADDICTS.
000742 01-11
PSYCHODYNAMICS OF PSYCHOTROPIC DRUG THERAPY.
000765 01-11
AGONISTS AND ANTAGONISTS IN THE TREATMENT OF DRUG ADDICTION
000773 01-11
PARKINSONS SYNDROME: DRUG THERAPY.
000787 01-11
CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 01-13
DRUG STUDIES WITH WOMEN, THE ELDERLY, AND GROUPS.
000865 01-13
THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SUBSEQUENT DRUG STATE DISCRIMINATION
000906 01-14
DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE AVERSION.
000913 01-14
STUDY OF NOOANALEPTIC DRUG EFFECT ON BRAIN METABOLISM IN HUMANS.
000914 01-14
THE CONCEPT OF DRUG AUTOMATISM.
000950 01-15
DISEASE CAUSED BY DRUG THERAPY IN NEWBORN INFANTS
000953 01-15
ALCOHOL DRUG INTERACTIONS IN DAILY MEDICAL PRACTICE
000974 01-15
CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM
000976 01-15
CLONAZEPAM: A REVIEW OF A NEW ANTICONVULSANT DRUG.
001022 01-17
SLEEP DISTURBANCE AND HYPNOTIC DRUG DEPENDENCE
001027 01-17
PSYCHOTROPIC DRUG USE IN FAMILY PRACTICE.
001050 01-17
PSYCHOTROPIC DRUG KNOWLEDGE
001079 01-17
CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL.
001121 02-03
METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-984).
001154 02-03
ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
001218 02-03
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03
PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03
EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03
COCAINE CUE IN RATS AS IT RELATES TO SUBJECTIVE DRUG EFFECTS: A PRELIMINARY REPORT.
001462 02-04
A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
001529 02-04
TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04
PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04
INTERACTION OF DRUG EFFECTS WITH TESTING PROCEDURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04
ASSESSING INTERACTIONS OF ENVIRONMENT X DRUG.
001596 02-04
THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
001647 02-06
COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07
CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07
BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-07
DRUG DISCOVERY AND INTRODUCTION REGULATION AND OVERREGULATION
001669 02-07
POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION
001677 02-07
DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS
001691 02-08
CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE
001711 02-08
DRUG RESEARCH ON TREATMENT OF SCHIZOPHRENIA
001721 02-08

PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART.
001749 02-09

THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09

NONPHARMACOLOGICAL FACTORS IN DRUG TREATMENT OF ANXIETY STATES.
001B02 02-10

DRUG THERAPY IN CHRONIC CEREBROVASCULAR INSUFFICIENCY IN THE ELDERLY
001B37 02-11

DRUG THERAPY IN THE HYPERKINETIC SYNDROME.
001B44 02-11

THE DRUG TREATMENT OF PARKINSONISM.
001B4B 02-11

MONOAMINE-OXIDASE INHIBITORS: POTENTIAL FOR DRUG ABUSE.
001B76 02-12

DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13

PSYCHOPHYSIOLOGICAL ASPECTS IN EEG ANALYSIS OF CEREBRAL DRUG EFFECTS.
001918 02-13

EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14

CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
001986 02-14

SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTROPIC DRUG USE DURING PREGNANCY.
002010 02-15

CAN PENTAZOCINE BE A DRUG? OBSERVATIONS ON THE PROBLEM OF TALWINISM.
002028 02-15

METHODOLOGY IN DOUBLE-BLIND DRUG TRIALS.
002088 02-16

DEVELOPING OPTIMUM DRUG REGIMENS
002105 02-17

UPDATING PSYCHOTROPIC DRUG THERAPY.
002109 02-17

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

IMPLICATIONS OF DRUG TREATMENT FOR THE SOCIAL REHABILITATION OF SCHIZOPHRENIC PATIENTS.
002116 02-17

PSYCHOTROPIC DRUG PRESCRIPTION IN FAMILY PRACTICE.
002124 02-17

HALOPERIDOL: A USEFUL PSYCHIATRIC DRUG.
002126 02-17

PROFESSIONAL DISAGREEMENT IN DRUG EFFICACY STUDY.
002135 02-17

PSYCHOTROPIC DRUG ASSESSMENT - CURRENT STATUS, FUTURE PROSPECTS. (UNPUBLISHED PAPER)
002139 02-17

THE NEW DRUG STATUTE AND THE FUTURE OF CLINICAL PSYCHOPHARMACOLOGY.
002141 02-17

MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

CAUTION. DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION
002172 02-17

PSYCHOTROPIC DRUG USE IN FIVE CITY HOSPITALS.
002177 02-17

THE RECREATIONAL USE OF LSD-25 AND DRUG PROHIBITION
002181 02-17

DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-02

SOME CHARACTERISTICS OF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OF PSYCHOPATHOLOGY
002204 03-03

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-03

EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK
002276 03-0

DOPAMINERGIC DRUG EFFECTS UPON SEROTONIN NEURONS.
002300 03-0

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-0

ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-0

BEHAVIORAL DRUG EFFECTS UPON OPERANT RESPONSE FORCE.
002447 03-0

EMOTIONAL AND MOTIVATIONAL ASPECTS OF DRUG TAKING BEHAVIOR OF ANIMALS.
002464 03-0

CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-0

PROJECT SUMMARY: PSYCHOPHARMACOLOGY OF DRUG ABUSE.
002533 03-0

STUDIES ON DRUG DEPENDENCE (REPT. 19): DEPENDENCE ON PREFERENCE ON AND PREFERENCE FOR MORPHINE.
002545 03-0

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
002587 03-0

SULPIRIDE IN WITHDRAWAL OF NONALCOHOLIC DRUG ADDICTS.
002593 03-0

AHR-6134- A NEW ANTIANXIETY DRUG WITH UNEXPECTED RESULTS.
002595 03-0

PHARMACOKINETIC APPROACH TO DRUG DOSING IN THE AGED.
002604 03-0

USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY.
00262B 03-0

ADVANCES IN THE DRUG THERAPY OF AFFECTIVE DISORDERS.
0026B0 03-0

DRUG THERAPY IN DEPRESSIVE STATES: FACTORS IN SUICIDE PREVENTION
002690 03-0

TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-0

CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY
002720 03-1

NEUROTIC DEPRESSION- AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS
002721 03-1

DRUG TREATMENT OF MENTAL DISORDERS.
0027B0 03-1

VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIDATION.
002811 03-1

EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002B17 03-1

DRUG INTERACTIONS OF THE COMPONENTS OF OPTALIDON AFTER ORAL ADMINISTRATION
002B23 03-1

MAO INHIBITORS: POTENTIAL FOR DRUG ABUSE. (UNPUBLISHED PAPER)
002B76 03-1

BEHAVIORAL EFFECTS OF REPEATED PSYCHOACTIVE DRUG ADMINISTRATION (PH.D. DISSERTATION).
002B77 03-1

INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTI PATIENTS
00290B 03-1

OROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY
002911 03-1

DRUG REFUSAL IN SCHIZOPHRENIA AND THE WISH TO BE CRAZY.
002942 03-1

EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-1

PSYCHOACTIVE DRUG CRISIS INTERVENTION
002947 03-1

DRUG THERAPY OF PARKINSONISM
002967 03-1

SASKATCHEWAN DIAL-ACCESS DRUG INFORMATION SERVICE
002970 03-1

ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 3
002975 03-1

PSYCHOTROPIC DRUG USE IN THE ELDERLY PUBLIC IGNORANCE OR INDIFFERENCE?.
002980 03-17
THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY
002996 03-17
ETHICS IN DRUG RESEARCH IN THE USA
003006 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY COMMENT 2
003007 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY COMMENT 1.
003022 03-17
ADVANCES IN THE DRUG THERAPY OF MENTAL ILLNESS
003045 03-17
EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS.
003122 04-03
EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE
003187 04-03
DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
003212 04-03
DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE.
003245 04-03
EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR
003282 04-03
BARBITURATE DEPENDENCE IN MICE: EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION
003348 04-04
TASTE-AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIVE AND DRUG SPECIFIC EFFECTS.
003359 04-04
ANTICONVULSANT DRUG ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL-INDUCED SEIZURES IN RABBITS.
003366 04-04
DRUG ADDICTION LIGHT AT THE END OF THE TUNNEL?
003422 04-04
DRUG EFFECTS ON FIXED-INTERVAL RESPONDING WITH PAUSE REQUIREMENTS FOR FOOD PRESENTATION
003465 04-04
SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05
CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
003520 04-07
A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION
003525 04-07
PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08
TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS
003541 04-08
MORPHINE AS ANTIPSYCHOTIC DRUG.
003554 04-09
COMPARATIVE VALUE OF RATING AND SELF-RATING SCALES IN DRUG TRIALS.
003592 04-10
IS THE DRUG EFFECT ANTIANXIETY OR ANTIDEPRESSANT?
003596 04-10
NONSPECIFIC FACTORS IN DRUG TREATMENT.
003598 04-10
ANTIANXIETY DRUG TRIALS IN HYPERTENSION
003609 04-10
NEUROLEPTIC DRUG EFFECTS ON CHILDRENS BODY WEIGHT AND HEIGHT.
003645 04-11
DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL
003673 04-13
SEX DIFFERENCES IN DRUG EVALUATIONS.
003678 04-13
PHENOBARBITAL-INDUCED DRUG METABOLISM IN MAN
003682 04-13
FACTORS INFLUENCING PLASMA DRUG CONCENTRATIONS
003685 04-13
INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13
CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN
003704 04-13
ON DECISION MAKING SURROUNDING DRUG THERAPY A CONTINUING DILEMMA
003761 04-15
DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY A PILOT STUDY
003770 04-15
PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS
003787 04-15
IMIPRAMINE AND CHLOREN A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION
003791 04-15
TOWARD THE OPERATIONAL IDENTIFICATION OF ADVERSE DRUG REACTIONS
003800 04-15
GUIDE TO DRUG INTERACTIONS.
003806 04-15
THE BEHAVIORAL TREATMENT OF INSOMNIA: AN ALTERNATIVE TO DRUG THERAPY
003821 04-15
THE VALUE OF SELF-RATING SCALES IN DRUG TRIALS.
003840 04-16
INDIVIDUAL DRUG SUPPLY IN A PSYCHOGERIATRIC WARD: AN EVALUATION OF THE SYSTEM.
003842 04-16
DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003851 04-17
PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
003863 04-17
DRUG PRESCRIPTION IN ICELAND.
003865 04-17
HELPING PSYCHIATRIC OUTPATIENTS ACCEPT DRUG THERAPY
003871 04-17
THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY: A WEB OF PARADOXES.
003877 04-17
DRUG METABOLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN.
003878 04-17
DECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
003888 04-17
EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE.
003889 04-17
ANTIPSYCHOTIC DRUG USE: PHYSICIAN PRESCRIBING PRACTICES IN RELATION TO CURRENT RECOMMENDATIONS.
003896 04-17

DRUG-DEPENDENCE

DRUG-DEPENDENCE CLINICS.
003805 04-15

DRUG-DEPENDENT

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 03-04
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN
003365 04-04

DRUG-FREE

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16
PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA: AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
002688 03-09

DRUG-INDUCED

ABSORPTION AND BIOTRANSFORMATION OF CHOLECALCIFEROL IN DRUG-INDUCED OSTEOMALACIA.
000166 01-03
CHOLINERGIC MODIFICATION OF DRUG-INDUCED STEREOTYPY IN RATS.
000201 01-03
DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE AVERSIONS: EFFECTS OF DOSE AND DURATION OF PRETREATMENT.
000337 01-04
DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION
000352 01-04
PAPAVERINE, DRUG-INDUCED STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04
DRUG-INDUCED HANDWRITING CHANGES: AN EMPIRICAL REVIEW
000895 01-14
MANGANESE AND NIACIN IN THE TREATMENT OF DRUG-INDUCED DYSKINESIAS.
000958 01-15

EEEECT OE TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY. 000999 01-15

CURVE OE EXCITABILITY OE ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE. 001000 01-15

BEHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE. 001579 02-04

AMANTADINE REDUCES DRUG-INDUCED PARKINSONISM. 0019B3 02-14

DRUG-INDUCED AGGRESSION. 002249 03-03

MECHANISM AND CHARACTERISTICS OF DRUG-INDUCED AGGRESSION. (PH.D. DISSERTATION). 002451 03-04

AMANTADINE THERAPY FOR DRUG-INDUCED EXTRAPYRAMIDAL SIGNS AND DEPRESSION 00273B 03-11

TREATMENT OF DRUG-INDUCED PSYCHOSIS WITH DIPHENYLHYDANTOIN. 002761 03-11

DRUG-INDUCED HYPONATREMIA IN PSYCHOGENIC POLYDIPSIA. 002902 03-15

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS. 003357 04-04

PSYCHOTROPIC DRUG-INDUCED BLADDER DECOMPENSATION 003797 04-15

THE DISCOVERY OE DRUG-INDUCED ILLNESS. 003799 04-15

DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA. 003826 04-15

DRUG-SEEKING

ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR. 002437 03-04

DRUG-WITHDRAWAL

DRUG-WITHDRAWAL SYNDROMES. 002070 02-15

DRUGGING

THE DRUGGING OF THE AMERICAS. 003033 03-17

DRUGS

DIFEERENTIAL EFFECT OF NEUROLEPTIC DRUGS ON DOPAMINE TURNOVER IN THE EXTRAPYRAMIDAL AND LIMBIC SYSTEM. 000003 01-01

PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS. 000024 01-02

CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE - EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS. 000041 01-03

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OE THE LOCUS-COERULEUS. 000061 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OE PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE. 000076 01-03

A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS. 000125 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN 000149 01-03

A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN. 000154 01-03

THE EFEECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG. 000164 01-03

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA. 000173 01-03

STUDIES ON THE SITUATIONAL FACTORS AFEECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE 0001B2 01-03

ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO. 000190 01-03

ENTHALPIES OF HYDROGEN BONDING IN PSYCHOTROPIC DRUGS. 000191 01-03

THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR. 000239 01-03

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFEECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS. 000245 01-03

EFFECTS OE CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL. 00026B 01-03

ANXIETY DRUGS AND BABOON BEHAVIOUR. 0002B7 01-04

NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS. 0002BB 01-04

EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE. 000298 01-04

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS. 000299 01-04

BEHAVIORAL DEPRESSION: THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS. 000307 01-04

THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST. 000308 01-04

CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS. 000349 01-04

SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS. 000377 01-04

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS. 000443 01-04

METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS. 0004B3 01-07

STANDARD METHOD OE EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS. 000511 01-07

BETA-BLOCKERS AS PSYCHOTROPIC DRUGS. 000516 01-07

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW. 00051B 01-07

DOSAGE FOR ANTIPSYCHOTIC DRUGS. 000529 01-08

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS. 000544 01-0

LONG-ACTING DRUGS WITH AFTERCARE OF SCHIZOPHRENICS. 000546 01-0

METABOLISM OF DRUGS IN SCHIZOPHRENIA. 000566 01-0

FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS. 000619 01-0

COMPARATIVE STUDY OF THREE PSYCHOTROPIC DRUGS IN THE TREATMENT OF DEPRESSIONS. 000645 01-0

CLINICAL PHYSIOLOGICAL STUDY OF DRUGS FOR THE TREATMENT OF PSYCHOSES. 000653 01-0

THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS. 000655 01-0

WHAT ARE TRICYCLIC ANTIDEPRESSANT DRUGS? 000661 01-0

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY. 000674 01-1

ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECARBOXYLASE INHIBITOR. 000745 01-1

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY. 000746 01-1

POSSIBLE ROLES OF CATECHOLAMINES IN THE ACTION OF NARCOTIC DRUGS.
000B09 01 13
METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY
000842 01 13
VITAMINS, NEUROLEPTICS, AND ANTIPARKINSONIAN DRUGS IN CATECHOLAMINE EXCRETION
000B72 01-13
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION
000875 01 14
INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUFNCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000876 01-14
THE EFFECTS OF PSYCHOTROPIC DRUGS UPON DRIVING RELATFD SKILLS
0008B2 01-14
PSYCHIATRY, MEDICINE, AND SLEEP -- SLFEPING DRUGS AND TRANQUILIZERS.
000B91 01 14
EXPERIMENTAL PHARMACOLOGICAL DIFFERENTIAL DEFINITION OF NOOTROPIC DRUGS.
000892 01-14
USE OF NOOANALEPTIC AND NOOTROPIC DRUGS IN RESUSCITATION
000905 01 14
RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
000910 01-14
SIDE-EFFECTS OF PSYCHOTROPIC DRUGS.
000929 01-15
MENTAL EFFECTS OF ANTIEPILEPTIC DRUGS.
00093B 01-15
DRUGS WHICH CREATE PROBLEMS FOR THE ELDERLY.
000965 01-15
AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-15
SECONDARY EFFECTS OF PSYCHOTROPIC DRUGS
000975 01-15
ANTICONVULSANT DRUGS AND MENTAL SYMPTOMS: A REVIEW
0009B9 01-15
MONOGRAPHS ON DRUGS. VOL. II.
000990 01-15
SPECIAL PROBLEMS FOR DRUGS USED IN CHILDREN
000995 01-15
METHODOLOGICAL PROBLEMS IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
001005 01-16
CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS (UNPUBLISHED PAPER).
001014 01-17
USE AND ABUSE OF PSYCHOTROPIC DRUGS.
001016 01-17
MANS USE OF DRUGS THROUGH THE AGES.
001023 01-17
EMERGENCY CASES AND PSYCHOTROPIC DRUGS.
001029 01-17
A COMPARISON OF CONSUMPTION OF PSYCHOPHARMACOLOGICAL DRUGS.
001030 01-17
PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001035 01-17
SURVEY AND CLASSIFICATION OF PSYCHOPHARMACOLOGICAL DRUGS.
001036 01-17
PRESENT AND FUTURE TRENDS IN PSYCHOTROPIC DRUGS.
001037 01-17
TREATING THE AGED WITH PSYCHOTROPIC DRUGS.
00103B 01-17
THE USE OF PSYCHOTROPIC DRUGS IN DEVELOPING COUNTRIES.
00104B 01-17
PSYCHOACTIVE DRUGS IN MEDICAL PRACTICE: THF PRESENT STAGE OF DEVELOPMENT.
001049 01-17
IMPROVED CLINICAL SCRFENING OF PHENOTROPIC DRUGS.
001051 01-17
PROPOSED GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF PSYCHOTROPIC DRUGS (REPLICATED).
001053 01-17
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
001057 01-17
TOXIOCOMANIA IN HALLUCINOGENIC DRUGS.
001059 01-17
DOSAGE FOR ANTIPSYCHOTIC DRUGS.
001060 01-17
MONOAMINE-OXIDASE, MONOAMINE-OXIDASE INHIBITING DRUGS AND HUMAN BEHAVIOR (UNPUBLISHED REPORT).
001061 01-17
CEREBRAL NEUROTRANSMISSION AND PSYCHOTROPIC DRUGS.
001065 01 17
THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS
001067 01 17
ADMINISTRATION OF PSYCHOTROPIC DRUGS FROM THE STANDPOINT OF THE GFNERAL PRACTITIONER.
001071 01 17
THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
00107B 01 17
DRUGS FROM THE SEA.
001092 02-01
RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02
BRAIN HOMOVANILLIC-ACID: REGIONAL CHANGES OVER TIMF WITH ANTIPSYCHOTIC DRUGS.
001152 02-03
INTERACTION OF CENTRAL-NERVOUS-SYSTEM DRUGS WITH SYNAPTOSOMAL TRANSPORT PROCESSES.
001160 02-03
SUPPRESSION OF ETHANOL-INDUCED STIMULATION BY GABA-LIKE DRUGS.
001174 02-03
PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03
EFFECT OF TRICYCLIC ANTIDEPRESSANT DRUGS ON THE HEART.
001193 02-03
PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN
001200 02-03
INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
001207 02-03
THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03
CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03
EFFECT OF PSYCHOTROPIC DRUGS ON CAUDATE SPINDLE IN CATS.
001250 02-03
BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA.
001254 02-03
THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASF OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES
001337 02-03
ANTICHOLINERGIC PROPERTIES OF ANTIPSYCHOTIC DRUGS AND THEIR RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS.
001359 02-03
ANTIPSYCHOTIC DRUGS: PHARMACODYNAMICS AND PHARMACOKINETICS.
001362 02-03
TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03
ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03
EFFECTS OF DRUGS ON THE FORMATION OF HOMOVANILLIC ACID IN THE RAT RETINA.
00141B 02-03
COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN
001419 02-03
REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC ACID AND HOMOVANILLIC ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03
CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGDALA
00146B 02-04
EFFECTS OF DRUGS ON SUPPRESSED RESPONDING.
001470 02-04
ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04
CATALEPSY INDUCED BY MORPHINE OR HALOPERIDOL: FFFECTS OF APOMORPHINE AND ANTICHOLINERGIC DRUGS.
0014B1 02-04
SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION
001493 02-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNA8INOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM. 001521 02-04

BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS. 001527 02-04

EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED 8Y L-DOPA IN AMPHETAMINE TREATED MICE. 001535 02-04

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIM8IC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS. 001602 02-04

CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS. 001610 02-04

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RA8BITS 8Y MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSI8LE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS. 001645 02-06

BEHAVIORAL PROCEOURES FOR EVALUATING THE RELATIVE A8USE POTENTIAL OF CNS DRUGS IN PRIMATES. 001646 02-06

NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS. 001679 02-08

GENERIC AND TRAOE-NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE 001682 02-08

ELECTROENCEPHALOGRAMS IN SCHIZOPHRENIA TREATEO WITH PSYCHOTROPIC DRUGS. 001706 02-08

AN EVALUATION OF DRUGS IN THE ELEMENTARY SCHOOLS: SOME GEOGRAPHIC CONSIDERATIONS. 001788 02-10

PRESCRI8ING BEHAVIOR ALTERING DRUGS: OARK CLOUOS ON THE HORIZON. 001796 02-10

OO GERIATRIC DRUGS WORK?. 001824 02-11

PSYCHOLOGICAL MEOICINE: DRUGS USEO IN PSYCHOLOGICAL MEDICINE: PHARMACOLOGICAL BASIS OF TREATMENT. 001828 02-11

8ENZODIAZEPINE DRUGS IN GENERAL MEOICAL PATIENTS. 001833 02-11

THE USE OF PSYCHOTROPIC ORUGS IN THE TREATMENT OF CHRONIC, SEVERE PAINS. 001834 02-11

CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS ANO HYPERACTIVITY IN CHILDREN 001847 02-11

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS. 001889 02-13

THE PLACENTAL TRANSFER OF DRUGS DURING CHILDBIRTH: A POSSIBLE INFLUENCE ON THE NEW8ORN 001892 02-13

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS ANO CORRELATION WITH CLINICAL POTENCY 001909 02-13

DRUGS FIVE YEARS LATER: NALOXONE 001928 02-13

SLEEP AND PSYCHOTROPIC DRUGS: CLINICAL ASPECTS. 001957 02-14

INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS. 001967 02-14

INTROOUCTION: IMPORTANCE OF PSYCHOTROPIC ORUGS IN SLEEP RESEARCH 001975 02-14

PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SU8JECTIVE PARAMETERS. 001991 02-14

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF ORUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE OIPOTASSIUM. 001997 02-14

CORRELATION 8ETWEEN INJURIES OUE TO ACCIDENT ANO USE OF ALCOHOL OR DRUGS. 002018 02-15

CARDIAC EFFECTS OF DIFFERENT TRICYCLIC ANTIDEPRESSANT DRUGS. 002023 02-15

PSYCHOTHERAPEUTIC DRUGS: HOW TO MINIMISE COMPLICATIONS OF THERAPY 002024 02-15

PSYCHOTROPIC ORUGS AND THE EYE 002036 02-15

FETAL MALFORMATIONS AND ANTIEPILEPTIC DRUGS. 002047 02-15

CARDIOVASCULAR EFFECTS OF NEUROLEPTIC AND ANTIDEPRESSANT DRUGS. PRELIMINARY REPORT. 002062 02-15

ON THE SWELLING OF THE DIAPHRAGM AMONG PATIENTS TAKING PSYCHOTROPIC DRUGS (SECOND REPORT). 002077 02-15

THE INFLUENCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVEMENTS. 002085 02-15

THE PRACTITIONERS GUIDE TO PSYCHOACTIVE DRUGS. 002103 02-17

PSYCHOTROPIC DRUGS IN OPIOID ADDICTS ON METHADONE TREATMENT 002119 02-17

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: 8LOOD LEVELS AND CLINICAL RESPONSE. 002120 02-17

DRUGS WHICH ALTER THE MIND. 002121 02-17

8IOCHEMISTRY ANO 8EHAVIOR: SOME CENTRAL ACTIONS OF AMPHETAMINE ANO ANTIPSYCHOTIC ORUGS. 002122 02-17

CLINICAL USE OF ANTIOEPRESSANT ORUGS. 002129 02-17

PHARMACOLOGY: ORUGS AFFECTING 8EHAVIOR. 002132 02-17

THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLO HEALTH ORGANIZATION (WHO). (SUMMARY) 002137 02-17

SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF AOVERSE REACTIONS TO THERAPEUTIC ORUGS. 002142 02-17

ORUGS REQUESTED BY DEFENOANT DIO NOT IMPAIR A8ILITY TO STAND TRIAL. UNITED-STATES V HATRACK, 408 F.SUPP. 476. U.S. OISTRICT COURT O. NEW-JERSEY. FE8RUARY 19, 1976. 002150 02-17

THE USE OF STIMULANT DRUGS IN THE TREATMENT OF HYPERACTIVITY 002170 02-17

PRACTICAL USE OF PSYCHOTROPIC ORUGS IN CHILOREN. 002175 02-17

THE ACTION OF PSYCHOTROPIC DRUGS ON OOPA-INOUCEO BEHAVIOURAL RESPONSES IN MICE. 002188 03-02

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON 8RAIN OOPAMINE. INOICATIONS FOR OEVELOPMENT OF NEW PSYCHOACTIVE ORUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW ORUGS WITH SPECIAL ACTIONS ON OOPAMINE SYSTEMS 002194 03-02

EFFECT OF CHOLINERGIC DRUGS ON METHAOONE-INDUCEO CATALEPSY ANO STEREOTYPIES IN RATS TREATEO CHRONICALLY WITH METHADONE. 002199 03-03

EFFECT OF CATECHOLAMINERGIC ORUGS ON EPILEPTOGENIC PROPERTIES OF THE CAUOATE NUCLEUS. 002206 03-03

EVIOENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIOEPRESSANT DRUGS. 002224 03-03

EPOXIDE-OIOL PATHWAY IN THE META8OLISM OF TRICYCLIC DRUGS. 002240 03-03

LEVELS OF BRAIN O-METHYLATEO CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES 8Y CENTRALLY ACTING ORUGS. 002244 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF AORENERGIC SYSTEM. 002246 03-03

EFFECT OF ANTIPSYCHOTIC ORUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN 002247 03-03

EFFECTS OF PSYCHOTROPIC ORUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCEO PGO WAVES. 002259 03-03

A NEW MICROMETHOO FOR DETERMINING THE EFFECTS OF ORUGS ON THE TURNOVER RATE OF ACETYLCHOLINE. (PH.D. DISSERTATION). 002274 03-03

INTERACTION OF 8ENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE 8RAIN. 002320 03-03

SERUM OOPAMINE-8ETA-HYDROXYLASE ACTIVITY (V): EFFECTS OF VARIOUS DRUGS ON THE ENZYME ACTIVITY 002326 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1 E2, F1ALPHA, ANO F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANOINS ON THE ACTION OF SOME

DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE
002350 03-03

COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON BRAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
0023B2 03-03

EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-03

EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03

EFFECT OF TRYPTAMINERGIC DRUGS ON ELECTROSHOCK FIGHTING BEHAVIOUR IN RATS.
002417 03-04

NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-04

EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04

THE INFLUENCE OF PSYCHOTROPIC DRUGS UPON EMOTIONS.
002432 03-04

EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN COMBINATION WITH STIMULANT DRUGS IN RABBITS.
002434 03-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V. EFFECTS OF PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-04

EFFECTS OF DRUGS ON BEHAVIOR CONTROLLED BY NOXIOUS STIMULI.
002482 03-04

EFFECTS OF PSYCHOTROPIC DRUGS UPON THE HYPOTHALAMIC RAGE RESPONSE IN CATS.
002493 03-04

EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
002512 03-04

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

EFFECT OF CATECHOLAMINERGIC DRUGS ON SYSTEMS OF REWARD AND PUNISHMENT IN EXPERIMENTS ON CATS.
002518 03-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
002538 03-04

EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04

OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS.
002546 03-04

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
002548 03-04

EDUCTION OF LEARNED TASTE-AVERSIONS BY PREEXPOSURE TO DRUGS.
002549 03-04

EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-04

YTOTOXIC ACTION OF PSYCHOTROPIC DRUGS ON LEUKOCYTES IN VITRO.
002570 03-05

HARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES AND RELATED DRUGS WITH LIPIDS BY UV-SPECTROPHOTOMETRY.
002583 03-06

PPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
002586 03-06

HE CLINICAL EVALUATION OF NEW DRUGS.
002594 03-07

EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
002746 03-11

GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM
002747 03-11

THE MODE OF ACTION OF PSYCHOTROPIC DRUGS.
002807 03-13

HEMOLYTIC AND ANTIHEMOLYTIC EFFECTS OF ANTIPSYCHOTIC DRUGS
002827 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-13

PREDICTING THE RESPONSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002852 03-14

EFFECTS OF SOME PSYCHOACTIVE DRUGS UPON THE TRAPEZOID ILLUSION PERCEPTION
002856 03-14

THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
002B64 03-14

THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15

ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002B87 03-15

OVERUSE OF SYNTHETIC ANTICHOLINERGIC DRUGS IN PSYCHIATRY.
002915 03-15

DISCONTINUANCE OF ASSOCIATED ANTIPARKINSONIAN DRUGS IN LONG-TERM NEUROLEPTIC TREATMENT.
002923 03-15

ON CHANGING BLOOD DENSITIES OF ANTISEIZURE DRUGS TAKEN IN LARGE VOLUMES.
002950 03-15

SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

STUDIES ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
002958 03-17

DRUGS AS DISCRIMINATIVE EVENTS IN HUMANS.
002960 03-17

CLINICAL THERAPEUTIC REPORTS ON ADDICTION TO RARE DRUGS.
002969 03-17

DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

INTERACTION OF ALCOHOL WITH PSYCHOTROPIC DRUGS.
002973 03-17

SPECTRUM OF ACTIVITY OF SOME DRUGS.
002974 03-17

FUNCTIONS OF LOUD SOUND, PERSONALITY, AND DRUGS.
0029B4 03-17

USING OR ABUSING? AN ANTHROPOLOGICAL APPROACH TO THE STUDY OF PSYCHOACTIVE DRUGS.
0029B5 03-17

PSYCHOTROPIC DRUGS IN THE CLINIC AND IN PRACTICE.
002995 03-17

GENERAL CHARACTERISTICS OF DISCRIMINATIVE STIMULI PRODUCED BY DRUGS.
003004 03-17

INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
00300B 03-17

ON THE CLASSIFICATION OF ANTIDEPRESSANT DRUGS.
003010 03-17

MODERN PROBLEMS OF PHARMACOPSYCHIATRY. VOL. II: ALCOHOL, DRUGS AND DRIVING.
003014 03-17

PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE.
003019 03-17

DRUGS USED IN THE TREATMENT OF MENTAL DISORDER
003030 03-17

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-03

EFFECT OF PROPRANOLOL AND RELATED DRUGS ON TRANSMEMBRANEOUS PH DIFFERENCES IN LIPOSOMES
003080 04-03.

EFFECTS OF SEROTONERGIC DRUGS ON METHAQUALONE-INDUCED HYPOTHERMIA.
003102 04-03

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
0D3128 D4-03

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 D4-03

ANTIDEPRESSANT DRUGS AND DOPAMINE UPTAKE IN DIFFERENT BRAIN REGIONS.
003146 D4-03

SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
0D3175 D4-03

TOLERANCE TO THE INCREASE OF STRIATAL HOMOVANILLIC-ACID ELICITED BY SEVERAL ANORECTIC DRUGS.
0D3186 D4-03

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
0031B8 D4-D3

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
003189 04-03

PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-D3

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM.
003206 04-03

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-D3

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
0D3304 04-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
0D3323 04-D3

PARGYLINE-INDUCED INCREASES IN SENSITIVITY TO THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR IN PIGEONS.
D03361 04-D4

TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
D03372 D4-04

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
0D3399 04-D4

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS
D0341D D4-D4

COMBINED USE OF NEUROLEPTIC DRUGS.
003414 D4-04

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT DRUGS ON DIBUTYRYL-CYCLIC AMP EVOKED SEIZURES.
0D3436 04-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION
D03469 D4-04

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 D4-D4

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
D03489 D4-D4

ANTISCHIZOPHRENIC DRUGS- CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN.
DD3493 D4-D5

INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM
DD3495 D4-D5

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS
0D3496 04-05

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE
003511 04-05

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
003545 04-0

VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
D03588 04-1

PSYCHOACTIVE DRUGS IN THE TREATMENT OF THE AGED.
00363B 04-

IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-1

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY
0036B4 04-

VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIREC INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04

TESTING THE DA HYPOTHESIS WITH THE AID OF DRUGS.
003719 04-

THE EFFECTS OF SELECTED ANTIPSYCHOTIC DRUGS ON HUMAN JUDGMENT.
00372B 04-

COMPARATIVE EFFECTIVENESS OF NINE HYPNOTIC DRUGS: SLEEP LABORATORY STUDIES.
0D3737 04-

VERIFICATION OF THE MA HYPOTHESIS WITH THE AID OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 04-

A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, DRUGS, AN THEIR INTERACTION
003766 04

PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS
0037B7 04-

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMON IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
D03804 04-

A FIVE YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS.
003849 04

THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003852 04

PSYCHOTROPIC DRUGS AND MIGRAINE.
003887 D4-

APPEALS USED IN ADVERTISEMENTS FOR PSYCHOTROPIC DRUGS: AN EXPLORATORY STUDY
003B99 04-

DSP-4

ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE
000214 01-

DUAL

DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOG CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-

DUCKS

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
DD0312 01-

EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON TONIC IMMOBILI IN DUCKS AND GUINEA-PIGS.
000453 D1-

DUCTS

HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WIT LIGATED BILE DUCTS -- A LACK OF CORRELATION
0D0316 D1-

DUODENAL

EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
000728 01-

ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION DUODENAL ULCER PATIENTS.
0008D5 01

DURATION

EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-

DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE-AVERSIONS. EFFECTS OF DOSE AND DURATION OF PRETREATMENT
000337 01-

DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS
002242 03-

OURATION OF ACTION OF NALOXONE SU8CUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT 8EHAVIOURAL EFFECTS OF MORPHINE IN THE RAT
002559 03-04

NEUROLEPTIC OOSAGE, DURATION, ANO TAROIVE-OYSKINESIA.
003760 04-15

ETTER

COMPARISON OF PLASMA LITHIUM LEVELS ANO THEIR INTERINDIVIDUAL VARIATIONS WITH COATEO LITHIUM-CAR8ONATE TABLETS ANO A MEOIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

ETTES

A COMPARATIVE DOUBLE-8LINO STUOY OF THE SIOE EFFECTS OF LITAREX AND LITHIONIT OURETTES.
001678 02-07

DIC

ALCOHOL, FIELD DEPENDENCE, ANO DYAOIC SELF-OISCLOSURE
001989 02-14

AMICS

NOTE ON THE DYNAMICS OF THE PSYCHOORGANIC PROCESS.
000774 01-11

DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION.
002034 02-15

THE BIOLOGICAL DYNAMICS OF TRICYCLIC ANTIOEPRESSANTS.
002356 03-03

DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN
002701 03-09

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003BB0 04-17

CONTROL

CARBAMAZEPINE IN THE DYSCONTROL SYNDROME ASSOCIATED WITH LIMBIC SYSTEM DYSFUNCTION.
003646 04-11

UNCTION

NEUROMUSCULAR DYSFUNCTION IN SCHIZOPHRENIA.
000557 01-0B

NEUROENDOCRINE REGULATION IN DEPRESSION. I. LIMBIC SYSTEM ADRENOCORTICAL DYSFUNCTION.
001736 02-09

THE IDENTIFICATION AND TREATMENT OF ADULT BRAIN DYSFUNCTION.
002143 02-17

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION
002260 03-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYOOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN
002436 03-04

ACTH4-10 ON MEMORY DYSFUNCTION
002771 03-11

CARBAMAZEPINE IN THE DYSCONTROL SYNDROME ASSOCIATED WITH LIMBIC SYSTEM DYSFUNCTION.
003646 04-11

UNCTIONS

OBSERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL-NERVOUS-SYSTEM DYSFUNCTIONS.
002762 03-11

FFECTS OF ACTH4-10 ON ECT-INDUCED MEMORY DYSFUNCTIONS.
003750 04-14

INESIA

REATMENT OF PHENOTHIAZINE-INDUCED DYSKINESIA.
000493 01-07

MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION.
001826 02-11

ROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY.
002911 03-15

YSKINESIA AFTER DISCONTINUATION OF COMPOUND ANALGESIC CONTAINING OXYCODONE.
003784 04-15

NESIAS

NHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
000318 01-04

YSKINESIAS ASSOCIATED WITH TRICYCLIC ANTIDEPRESSANTS.
000944 01-15

ANGANESE AND NIACIN IN THE TREATMENT OF DRUG-INDUCED DYSKINESIAS
00095B 01-15

OYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WITH PRIOR METHADONE TREATMENT
001619 02-05

CATATONIA-LIKE SYMPTOMATOLOGY AND WITHDRAWAL DYSKINESIAS
002043 02-15

ANTICONVULSANT INOUCEO DYSKINESIAS: A COMPARISON WITH DYSKINESIAS INOUCEO BY NEUROLEPTICS.
002891 03-15

DYSREGULATION

OSTEOPENIA ANO DYSREGULATION OF OIVALENT CATIONS IN LITHIUM TREATEO PATIENTS.
000585 01-09

DYSTHYMIA

WATER POISONING ANO DIA8ETES INSIPIDUS: A PROPOS COMPULSIVE WATER DRINKING AND OYSTHYMIA.
002717 03-10

DYSTONIA

NEUROLEPTIC-INOUCEO AKATHISIA ANO DYSTONIA TRIGGERED BY ALCOHOL.
002056 02-15

DYSTONIA. THE SPECTRUM OF THE DISEASE.
002916 03-15

DYSTONIC

DYSTONIC REACTIONS FOLLOWING NEUROLEPTICS: TIME COURSE AND PROPOSED MECHANISMS.
000543 01-08

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
001689 02-08

DYSTONIC REACTIONS TO METOCLOPRAMIDE.
00203B 02-15

EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTONIC AFFECT.
002605 03-07

DYSTROPHY

POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-05

HYPERSOMNIA IN MYOTONIC DYSTROPHY: TREATMENT WITH METHYLPHENIDATE.
003640 04-11

EAG

TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-10

EATING

SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
00036B 01-04

AN ANALYSIS OF BARBITURATE-INDUCED EATING AND DRINKING IN THE RAT.
002552 03-04

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

PHENYTOIN AS A TREATMENT OF OBESITY ASSOCIATED WITH COMPULSIVE EATING.
003622 04-11

ECG

PLASMA NORTRIPTYLINE LEVELS AND ECG FINDINGS.
003723 04-13

ECONOMICS

THE MEDICAL ECONOMICS OF LITHIUM TREATMENT FOR MANIC-DEPRESSIVES.
003B54 04-17

ECS

EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
000052 01-03

ECT

LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001813 02-11

ECT VERSUS CHLORPROMAZINE IN MANIA.
003565 04-09

ECT-INDUCED

EFFECTS OF ACTH4-10 ON ECT-INDUCED MEMORY DYSFUNCTIONS.
003750 04-14

EEG

THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS
000159 01-03

THE EFFECTS OF ALCOHOL AND ATROPINE ON EEG AND 8EHAVIOR IN THE RAB8IT.
00025B 01-03

SOME 8EHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GA8A-TRANSAMINASE.
000285 01-04

CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACERE8ROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RA88ITS, AND EEG CORRELATES.
000323 01-04

EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
000498 01-07

MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
000783 01-11

COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000800 01-13

HYPNOTICS AND ETHANOL: RESIDUAL EEG EFFECTS.
000846 01-13

ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14

CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
001055 01-17

EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
001178 02-03

ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
00121B 02-03

MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02-03

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-08

TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001869 02-12

SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001884 02-13

A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
001B85 02-13

ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY. A TRIAL OF DIAZEPAM.
00188B 02-13

PSYCHOPHYSIOLOGICAL ASPECTS IN EEG ANALYSIS OF CEREBRAL DRUG EFFECTS.
001918 02-13

HUMAN EEG SPECTRA BEFORE AND DURING CANNA8IS HALLUCINATIONS.
001924 02-13

EEG SPECTRAL ANALYSIS OF THE EFFECTS OF CAFFEINE.
001925 02-13

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14

NEUROPSYCHOLOGICAL AND EEG DISTURBANCES IN POLYDRUG USERS.
002044 02-15

EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT.
002057 02-15

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN COMBINATION WITH STIMULANT DRUGS IN RA8BITS.
002434 03-04

DURATION OF ACTION OF NALOXONE SU8CUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-0

PYRITHIOXINE (ENCEPHA8OL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-1

CONTRI8UTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002806 03-1

AUTOMATED ANALYSIS OF EEG PATTERNS IN SU8JECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002868 03-1

EEG AND TASK PERFORMANCE AFTER ACTH4-10 IN MAN.
002874 03-1

TRYPTAMINE: 8IMODAL ACTIONS ON THE EEG AND 8EHAVIOR OF RA88ITS.
003440 04-0

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE
003533 04-0

DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL.
003673 04-1

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPU8LISHED PAPER).
003727 04-1

EFFECTIVENESS

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTIN NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-0

A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SULPIRIDE AND OXAZOLAM IN THE FIELD OF PSYCHOSOMATIC MEDICINE.
000713 01-1

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LA8ORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
000748 01-1

ANORECTIC EFFECTIVENESS OF DIFFERING DOSAGE FORMS OF FENFLURAMINE.
000784 01-1

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN-BIOGENIC AMINES.
001215 02-0

AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-1

EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
001812 02-1

EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM
001829 02-1

ANTIPSYCHOTIC EFFECTIVENESS IN RELATION TO PLASMA LEVEL OF CLOZAPINE.
001B78 02-1

EFFECTIVENESS OF INTERMEDIATE TERM USE OF SECOBAR8ITAL.
001972 02-1

COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
002608 03-0

A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS.
002776 03-1

EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPIN AND PROPRANOLOL.
003270 04-0

COMPARATIVE EFFECTIVENESS OF NINE HYPNOTIC DRUGS: SLEEP LABORATORY STUDIES.
003737 04-1

EFFICIENCY

EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-0

EFFLUX

ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-0

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-1

EFFECT OF VERATRINE ALKALOIDS ON THE FFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RAB8IT ATRIA.
001324 02 03

EFFECT OF ADRENERGIC NEURON 8LOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RA88IT ATRIA.
001325 02-03

INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE 8RAIN
001369 02-03

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE
002238 03-03

JACULATION

THE MANAGEMENT OF PREMATURE EJACULATION.
003729 04-14

LDERLY

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

TREATMENT OF CERE8RAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
000786 01-11

DRUG STUDIES WITH WOMEN, THE ELDERLY, AND GROUPS.
000865 01-13

DRUGS WHICH CREATE PRO8LEMS FOR THE ELDERLY.
000965 01-15

NEUROLOGICAL AND SENSORY DISORDERS IN THE ELDERLY.
001039 01-17

DRUG THERAPY IN CHRONIC CERE8ROVASCULAR INSUFFICIENCY IN THE ELDERLY.
001B37 02-11

PSYCHOPHARMACOLOGY OF THE ELDERLY.
002765 03-11

HELPING TO MAKE THE FINAL YEARS MEANINGFUL FOR THE ELDERLY RESIDENTS OF NURSING HOMES.
002859 03-14

SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 3.
002975 03-17

PSYCHOTROPIC DRUG USE IN THE ELDERLY: PUBLIC IGNORANCE OR INDIFFERENCE?.
002980 03-17

ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 2.
003007 03-17

ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 1.
003022 03-17

CONTROLLED TRIAL OF NOMIFENSIN (HOE-984) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY.
003570 04-09

THE SYSTEMIC USE OF PROCAINE IN THE TREATMENT OF THE ELDERLY: A REVIEW.
003595 04-10

A DOUBLE-BLIND TRIAL OF NAFTIDROFURYL IN TREATING CONFUSED ELDERLY PATIENTS IN GENERAL PRACTICE.
003612 04-11

ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPU8LISHED PAPER).
003705 04-13

DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY: A PILOT STUDY.
003770 04-15

LITHIUM TREATMENT IN THE ELDERLY. I. CLINICAL USAGE.
003781 04-15

TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.
0037B8 04-15

BARBITURATES AND SERUM CALCIUM IN THE ELDERLY.
003837 04-15

DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003851 04-17

CTRIC

ETHANOL AND THE RESPONSE TO ELECTRIC SHOCK IN RATS.
000063 01-03

THE EFFECT OF CHLORDIAZEPOXIDE ON THE ANTICIPATION OF ELECTRIC SHOCKS.
000292 01-04

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING 8Y THE PIGEON.
000366 01-04

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-0B

ELECTRICAL

A ROLE FOR DOPAMINE IN THE PSYCHOPHARMACOLOGY OF ELECTRICAL SELF-STIMULATION
000300 01-04

THE EFFECTS OF 6-AMINODOPAMINE ON ELECTRICAL SELF STIMULATION IN RATS.
000388 01-04

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE 8RAIN REINFORCEMENT IN THE RAT.
000444 01-04

METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 03-03

COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03

EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS.
002399 03-03

EFFECT OF BETA-PHENYLETHYLAMINE AND D-AMPHETAMINE ON ELECTRICAL SELF-STIMULATION OF BRAIN.
00246B 03-04

THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN.
003276 04-03

THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF-STIMULATION OF THE BRAIN DURING HYPOXIA.
003342 04-04

EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04

ELECTRICALLY-INDUCED

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

ELECTROACUPUNCTURE

ELECTROACUPUNCTURE AND HEROIN ADDICTION, A CASE REPORT.
000744 01-11

ELECTROACUPUNCTURE AND ENDOGENOUS MORPHINES.
001943 02-13

ELECTROAFFECTROGRAM

TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-10

ELECTROCARDIOGRAPHIC

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-10

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM THERAPY.
00099B 01-15

ELECTROCHEMICAL

ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
002184 03-01

ELECTROCONVULSIVE

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
000359 01-04

DISCRIMINA8ILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS.
001727 02-09

PROLACTIN RESPONSE TO ELECTROCONVULSIVE THERAPY.
001769 02-09

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

DELIRIUM ASSOCIATED WITH LITHIUM THERAPY AND ELECTROCONVULSIVE THERAPY.
003794 04-15

ELECTROCORTICAL

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

ELECTROCORTICOGRAM
SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND BENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY.
001360 02-03

ELECTROCORTICOGRAPHIC
TAURINE AND CO8ALT-INDUCED EPILEPSY IN THE RAT: A BIOCHEMICAL AND ELECTROCORTICOGRAPHIC STUDY.
001256 02-03

ELECTRODE
DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RA8BIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03

ELECTRODERMAL
ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
000579 01-08

ELECTRODES
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SU8CORTICAL BRAIN STRUCTURES OF CONSCIOUS RA88ITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

ELECTROENCEPHALOGRAM
EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE 8EHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

ELECTROENCEPHALOGRAM AND ERGOT ALKALOIDS.
0027B6 03-11

ELECTROENCEPHALOGRAMS
ELECTROENCEPHALOGRAMS IN SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC DRUGS.
001706 02-08

EFFECTS OF L-DOPA AND VITAMIN-B6 ON ELECTROENCEPHALOGRAMS OF SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT.
002B47 03-13

ELECTROENCEPHALOGRAPHIC
EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
0D0792 01-12

BLOOD LEVELS AND ELECTROENCEPHALOGRAPHIC EFFECTS OF DIAZEPAM AND BROMAZEPAM.
00D819 01-13

CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
D008B1 01-14

ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
0D0988 01-15

ELECTROENCEPHALOGRAPHIC ANALYSIS OF THE CENTRAL EFFECT OF PIRASIDOL.
002349 03-D3

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY.
002774 D3-11

ELECTROENCEPHALOGRAPHIC ALTERATIONS IN MARIHUANA USERS.
002B31 03-13

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
DD3363 04-04

ELECTROGENESIS
EFFECT OF PAPAVERINE ON CERE8RAL ELECTROGENESIS.
00D810 01-13

ELECTROGRAPHIC
THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04

ELECTROLYTE
INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
DD3775 04-15

ELECTROLYTIC
HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
D00219 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING 8EHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIM8IC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04

ELECTROMYOGRAPHIC
EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-03

ELECTRON
DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX 8Y ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
002586 03-06

DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
002955 03-16

ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTA8-3H-TETRAHYDROCANNA8INOL LOCALIZATION IN 8RAIN TISSUE.
003168 04-03

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
003713 04-13

ELECTROPHORESIS
ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
0D2014 02-15

ELECTROPHYSIOLOGIC
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION- RCPV) IN THE CAT.
0D1291 02-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
D03291 04-03

ELECTROPHYSIOLOGICAL
RECORDING OF THE ELECTROPHYSIOLOGICAL ACTIVITY OF THE LOCUS-COERULEUS IN THE RAT.
001191 D2-03

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-0

AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
D016B4 02-0

EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES O SNAIL GIANT NEURONS.
D02201 03-0

FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 D3-0

CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN THE CAUDATE NUCLEUS.
0D2369 03-0

SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
D03509 04-0

ELECTROPOLYGRAPHIC
EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
0D1812 02-1

ELECTROSHOCK
EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
D00D52 01-0

EFFECT OF TRYPTAMINERGIC DRUGS ON ELECTROSHOCK FIGHTING BEHAVIOUR IN RATS.
002417 03-0

THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA++ UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
DD3136 04-0

LEVATED
SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000B35 01-13

LEVATES
ANTISCHIZOPHRENIC DRUGS. CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN.
003493 04-05

EVATING
MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION.
003798 04-15

EVATION
ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 C2-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

EVATIONS
ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03

CITATION
A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 03-04

CITING
A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 02-12

MINATION
PENTOBARBITAL ELIMINATION IN PATIENTS WITH POOR RENAL FUNCTION.
000B60 01-13

HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000B63 01-13

RENAL ELIMINATION OF LITHIUM IN RATS WITH LITHIUM INTOXICATION.
001403 02-03

ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
002392 03-03

CIDATION
VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIDATION.
002B11 03-13

BRYOTOXIC
DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

BRYOTOXICITY
TERATOGENICITY AND EMBRYOTOXICITY OF SOME MALEINIMIDES.
001620 02-05

D-16139
CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-0B

RGENCIES
TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC: SULTOPRIDE.
000510 01-07

TREATMENT OF PSYCHIATRIC EMERGENCIES.
001B03 02-10

THE MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
002107 02-17

PHARMACOLOGIC MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
003B44 04-17

RGENCY
THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001004 01-16

EMERGENCY CASES AND PSYCHOTROPIC DRUGS.
001029 01-17

CLINICAL EVALUATION OF LORAZEPAM IN EMERGENCY PSYCHIATRY.
00272B 03-10

EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15

EMG
THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY
000693 01-10

EFFECTS ON EMG FEEDBACK, DIAZEPAM AND THEIR COMBINATION ON CHRONIC ANXIETY.
003594 04-10

EMOTIONAL
PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

EFFECTS OF A NOVEL ANTIAGGRESSIVE AGENT UPON TWO TYPES OF BRAIN STIMULATED EMOTIONAL BEHAVIOR.
000357 01-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04

EMOTIONAL AND MOTIVATIONAL ASPECTS OF DRUG TAKING BEHAVIOR OF ANIMALS.
002464 03-04

EMOTIONALLY
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04

EMOTIONS
THE INFLUENCE OF PSYCHOTROPIC DRUGS UPON EMOTIONS.
002432 03-04

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
00254B 03-04

EMOTIVE
PHARMACOLOGY OF EMOTIVE BEHAVIOR.
003046 03-17

EMPIRICAL
DRUG-INDUCED HANDWRITING CHANGES: AN EMPIRICAL REVIEW.
000B95 01-14

NEUROTIC DEPRESSION: AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS.
002721 03-10

EMPLOYING
ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
000346 01-04

EMPTYING
EFFECT OF LITHIUM ON GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE.
002346 03-03

EMULSION
ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION
000132 01-03

ENABLING
DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
0026B9 03-09

ENANTIOMERIC
IN VITRO METABOLISM OF AMPHETAMINE: AN APPARENT ENANTIOMERIC INTERACTION.
001217 02-03

ENCEPHABOL
TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11

PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10

ENCEPHALOPATHY
THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
001920 02-13

DIALYSIS ENCEPHALOPATHY: A POSSIBLE SEIZURE DISORDER.
002146 02-17

METHYLMERCURY-INDUCED ENCEPHALOPATHY IN MICE.
003502 04-05

SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY
003635 04-11

ENDINGS
THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENDINGS.
001409 02-03

LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
002305 03-03

ENDOCRINE
PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION: COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES.
000197 01-03

ENDOGENOUS
EFFECTS OF PHOSPHOLIPID ADMINISTRATION ON ENDOGENOUS CEREBRAL PHOSPHOLIPID BIOSYNTHESIS.
000036 01-03

EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE.
00029B 01-04

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04

COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
001757 02-09

TWO DOSAGES OF IMIPRAMINE IN HOSPITALIZED ENDOGENOUS AND NEUROTIC DEPRESSIVES.
00177B 02-09

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS BEFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-OXIDE.
001794 02-10

ATYPICAL ENDOGENOUS DEPRESSION: DIAGNOSTIC CRITERIA.
001B09 02-10

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

ELECTROACUPUNCTURE AND ENDOGENOUS MORPHINES.
001943 02-13

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03

THE C-FRAGMENT OF BETA-LIPOTROPIN: AN ENDOGENOUS NEUROLEPTIC OR ANTIPSYCHOTOGEN?
002267 03-03

A STUDY OF ENDOGENOUS DOPAMINE METABOLISM IN GILLES-DE-LA-TOURETTES DISEASE.
0026B4 03-09

PRELIMINARY STUDY OF THE TREATMENT OF ENDOGENOUS DEPRESSION WITH BROMOERGOCRYPTINE.
002694 03-09

SLEEP DEPRIVATION AND CLOMIPRAMINE IN ENDOGENOUS DEPRESSION.
002705 03-09

ENDOGENOUS OPIATE PEPTIDES. (UNPUBLISHED PAPER).
002B19 03-13

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002B21 03-13

APPLICATION OF BETA-RECEPTOR BLOCKING AGENTS IN COMBINED THERAPY OF ENDOGENOUS PSYCHOSIS.
002972 03-17

REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN
0032D7 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
0D3252 04-03

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION.
003573 D4-09

ENDOGENOUSLY
TRH EFFECTS ON ENDOGENOUSLY DEPRESSED MALES.
D00669 01-09

ENDOMETRIAL
DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003B01 04-15

ENDOMORPHOUS
THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-D9

ENDORPHIN
HUMAN ENDORPHIN: COMPARISON WITH PORCINE ENDORPHIN, ENKEPHALIN AND NORMORPHINE.
000006 01-01

ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03

ENDORPHINS
OPIOID PEPTIDES (ENDORPHINS) IN PITUITARY AND BRAIN.
D01496 02-04

ENDORPHINS IN BRAINS OF DECAPITATED AND MICROWAVE-KILLED MICE.
D03050 04-01

IN VITRO PHARMACOLOGY OF THE OPIOID PEPTIDES, ENKEPHALINS AND ENDORPHINS.
003322 04-03

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

ENDOSULFAN
INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

ENDURING
ENDURING EFFECTS OF MORPHINE PELLETS REVEALED BY CONDITIONED TASTE-AVERSION.
003424 04-04

ENERGY
EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
0025B6 03-06

ENGAGED
HEALTH STATUS IN PERSONS ENGAGED IN THE PRODUCTION OF TRIFTAZINE
002914 03-15

ENHANCEMENT
ENHANCEMENT OF PENTOBARBITAL EFFECT BY CONTINUOUS ADMINISTRATION OF MORPHINE IN THE MOUSE.
00D122 01-03

NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03

PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 02-03

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS.
0014B9 02-04

ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
001492 02-04

ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY- A TRIAL OF DIAZEPAM.
001BBB 02-13

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION
002344 03-03

ENHANCEMENT OF PROPOXYPHENE-INDUCED ANALGESIA BY DOXEPIN.
003301 04-03

ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04

ENHANCEMENT OF RETENTION WITH CENTRALLY ADMINISTERED CATECHOLAMINES.
0D3400 04-04

ENHANCES
PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
00133B 02-03

ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04

ENHANCING
RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02

DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PRDLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRD.
0D1307 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE
001309 02-03

ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS
0024B9 03-04

ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY
003351 04-04

EPHALIN

HUMAN ENDORPHIN: COMPARISON WITH PORCINE ENDORPHIN, ENKEPHALIN AND NORMORPHINE
000006 01-01

PHYLOGENETIC DISTRIBUTION OF A MORPHINE-LIKE PEPTIDE ENKEPHALIN.
000015 01-01

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

NEUROPHARMACOLOGICAL ACTIONS OF ENKEPHALIN AFTER SYSTEMATIC ADMINISTRATION.
000203 01-03

MORPHINE, ENKEPHALIN, AND THE SUBSTANTIA-GELATINOSA.
001617 02-05

ENKEPHALIN INHIBITS FIRING OF MYENTERIC NEURONES.
001634 02-05

NACTIVITY OF ENKEPHALIN ON HUMAN SERUM ESTERASE
001913 02-13

ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND BRAINSTEM NEURONES.
002229 03-03

ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
0024B0 03-04

AN ANALOG OF ENKEPHALIN HAVING PROLONGED OPIATE-LIKE EFFECTS IN VIVO.
003319 04-03

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
00332B 04-03

PHALIN-INDUCED

NKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
001209 02-03

NKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
00142B 02-03

EUROANATOMICAL FOCUS FOR MORPHINE AND ENKEPHALIN-INDUCED HYPERMOTILITY.
003240 04-03

PHALIN-STIMULATED

NKEPHALIN-STIMULATED PROLACTIN RELEASE.
00127B 02-03

PHALINS

TRUCTURE-ACTIVITY RELATIONSHIPS OF ENKEPHALINS IN THE STIMULATED GUINEA-PIG ILEUM.
0011B0 02-03

I VITRO PHARMACOLOGY OF THE OPIOID PEPTIDES, ENKEPHALINS AND ENDORPHINS.
003322 04-03

EREBRAL APPLICATION OF ENKEPHALINS.
003349 04-04

RAZOLE

CTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

HED

FECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE.
0034B3 04-04

OHEPATIC

LIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN.
000B0B 01-13

OTOXIN

TIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY NJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06

PIES

THALPIES OF HYDROGEN BONDING IN PSYCHOTROPIC DRUGS.
000191 01-03

ENTRY

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO WAY AVOIDANCE SESSION.
00247B 03-04

ENUCLEATION

INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
0023B9 03-03

ENURESIS

ENURESIS.
001054 01-17

IMIPRAMINE AND CHLORDIAZEPOXIDE IN ENURESIS.
003649 04-11

ENVIRONMENT

ASSESSING INTERACTIONS OF ENVIRONMENT X DRUG.
001596 02-04

EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

ENVIRONMENTAL

THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH.D. DISSERTATION).
000339 01-04

PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION: ENVIRONMENTAL AND GENETIC FACTORS.
001935 02-13

EFFECTS OF ALCOHOL ON SPECIFIC AND ENVIRONMENTAL FEAR.
001966 02-14

SOCIOPATHY: AN EXPERIMENT IN INTERNAL ENVIRONMENTAL CONTROL.
002737 03-11

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTAB-TETRAHYDROCANNABINOL.
003423 04-04

ENZYMATIC

POSSIBLE SOURCE OF ERROR IN STUDIES OF ENZYMATIC FORMATION OF DIMETHYLTRYPTAMINE.
001091 02-01

AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03

ENZYMATICALLY

AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

ENZYME

STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
00054B 01-0B

MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02-13

SERUM DOPAMINE-BETA-HYDROXYLASE ACTIVITY (V): EFFECTS OF VARIOUS DRUGS ON THE ENZYME ACTIVITY.
002326 03-03

EFFECT OF ENZYME INDUCTION BY BARBITURATES ON NEUROHORMONE EXCRETION IN MAN.
002B39 03-13

ENZYMES

THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN.
000266 01-03

PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN.
001200 02-03

IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 02-03

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES. 001626 02-05

DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES? 002360 03-03

SNAKE VENOM ACTION: ARE ENZYMES INVOLVED IN IT? 003337 04-03

EOS-INDUCED

THE BEHAVIOURAL EFFECTS OF EOS-INDUCED CHANGES IN SUBSTANTIA-NIGRA GABA LEVELS. 001528 02-04

EPIDEMIOLOGIC

THE PSYCHOPHARMACOLOGY OF BETA ADRENERGIC BLOCKADE: PHARMACOKINETIC AND EPIDEMIOLOGIC ASPECTS. 002599 03-07

EPILEPSY

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE. 000076 01-03

THERAPEUTIC EFFECTS OF TAURINE IN EPILEPSY: A CLINICAL AND POLYPHYSIOGRAPHIC STUDY. 000760 01-11

NEGATIVE ASPECTS OF PHARMACOLOGICAL PREVENTION OF EPILEPSY. 000940 01-15

CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES. 000969 01-15

TAURINE AND COBALT-INDUCED EPILEPSY IN THE RAT: A BIOCHEMICAL AND ELECTROCORTICOGRAPHIC STUDY. 001256 02-03

THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY. 001294 02-03

A STUDY ON PSYCHOMOTOR EPILEPSY WITH KINDLED CAT PREPARATIONS 001356 02-03

A COMPARATIVE CONTROLLED STUDY BETWEEN CARBAMAZEPINE AND DIPHENYLHYDANTOIN IN PSYCHOMOTOR EPILEPSY. 001861 02-11

ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY: A TRIAL OF DIAZEPAM. 001BB8 02-13

EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO. 002431 03-04

APHASIA IN A CHILD WITH EPILEPSY: IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT. 002752 03-11

ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS. 002755 03-11

EPILEPTIC

EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS. 000159 01-03

CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES. 000969 01-15

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS. 001196 02-03

EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT. 002057 02-15

A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS. 002776 03-11

EPILEPTICS

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL). 000732 01-11

COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS. 0D0739 01-11

DISORDERED BEHAVIOR OF EPILEPTICS AND CURRENT THERAPEUTIC ORIENTATIONS. 00D757 D1-11

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH. 0DD775 01-11

USE OF PSYCHOPHARMACEUTICALS FOR THE TREATMENT OF ABNORMAL BEHAVIOR OF OLIGOPHRENIC EPILEPTICS. 002772 03-11

EPILEPTIFORM

ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY. 001260 02-03

MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE. 001390 02-03

EPILEPTOGENESIS

INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX. 003131 04-03

EPILEPTOGENIC

EFFECT OF CATECHOLAMINERGIC DRUGS ON EPILEPTOGENIC PROPERTIES OF THE CAUDATE NUCLEUS. 002206 03-0

EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI. 003313 04-0

EPILOGUE

TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER). 001D58 01-1

EPINEPHRINE

NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE. 001164 02-0

EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE. 002D08 02-1

ALPHA-ACTIVITY AND BETA-ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE. 003315 04-0

EPINEPHRINE-STIMULATED

THE EFFECT OF HALOPERIDOL ON EPINEPHRINE-STIMULATED ADENYLAT CYCLASE IN HUMANS. 002209 03-0

EPISODE

ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY. 0D0540 01-0

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRIST PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE. 002163 02-

EPISODIC

HYPOTHYROIDISM WITH EPISODIC PSYCHIATRIC AND CARDIAC MANIFESTATIONS. D02127 02-

EPOXIDE

IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE. 000046 01-

ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO. 000190 01-

EPOXIDE-DIOL

EPOXIDE-DIOL PATHWAY IN THE METABOLISM OF TRICYCLIC DRUGS. 002240 03-

EQUIPMENT

LITHIUM AND GENETIC EQUIPMENT. 001762 02-

EQUIVALENCE

GENERIC AND TRADE-NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE. 001682 02-

EQUIVALENT

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTIC AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS. D03903 04

EQUIVALENTS

THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS 000667 01

ERETHISMIC

LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50. 00278B 03

ERGOCORNINE

EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER. 0D3484 04

ERGOMETRINE
FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04
DOPAMINERGIC AND SEROTONERGIC ACTION OF ERGOMETRINE.
002418 03-04

ERGOMETRINE-INDUCED
MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION.
003268 04-03

ERGOT
ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS.
000273 01-04
EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04
FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04
AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001832 02-11
NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02
EFFECTS OF ERGOT ALKALOIDS ON THE HYPOTHALAMIC PITUITARY AXIS.
002239 03-03
BIOCHEMICAL EFFECTS OF ERGOT ALKALOIDS WITH SPECIAL REFERENCE TO THE BRAIN.
00230B 03-03
AN ERGOT DERIVATIVE IN THE TREATMENT OF PARKINSONS DISEASE.
002592 03-07
ELECTROENCEPHALOGRAM AND ERGOT ALKALOIDS.
002786 03-11
EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
003193 04-03

ERROR
POSSIBLE SOURCE OF ERROR IN STUDIES OF ENZYMATIC FORMATION OF DIMETHYLTRYPTAMINE.
001091 02-01
METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
003044 03-17

ERRORS
TEMPO ERRORS AND MANIA.
003575 04-09

ERYTHROCYTE
PLASMA AND ERYTHROCYTE CONCENTRATIONS OF LITHIUM.
000722 01-10
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000849 01-13
A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09
ON THE SIGNIFICANCE OF THE ERYTHROCYTE LITHIUM TO PLASMA LITHIUM RATIO.
003686 04-13

ERYTHROCYTES
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03
ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-09
IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13
DISTRIBUTION OF LITHIUM BETWEEN ERYTHROCYTES AND PLASMA: IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES.
001915 02-13
PHARMACOKINETICS OF LITHIUM IN HUMAN PLASMA AND ERYTHROCYTES.
001936 02-13
EFFECT OF CHLOROTHIAZIDE ON THE PHARMACOKINETICS OF LITHIUM IN PLASMA AND ERYTHROCYTES.
002829 03-13

ERYTHROPHLEUM-COUMINGA
A NEW ALKALOID FROM ERYTHROPHLEUM-COUMINGA.
0010B7 02-01

ESCAPE
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
000365 01-04
A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
001529 02-04
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04
ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04
EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 04-04

ESERINE
THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

ESOPHAGEAL
EFFECT OF DOPAMINE ON ESOPHAGEAL MOTOR FUNCTION.
003504 04-05

ESSAY
ESSAY ON DETERMINATION OF PSYCHOLOGICAL EFFECTS OF LITHIUM.
001756 02-09

ESSAYS
SELECTED ESSAYS ON SCHIZOPHRENIA.
000790 01-12

EST
EST: A SPECIAL CASE IN PHARMACOTHERAPY.
003859 04-17

ESTAZOLAM
EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
000902 01-14

ESTER
USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN: SUMMARY.
002626 03-0B

ESTERASE
INACTIVITY OF ENKEPHALIN ON HUMAN SERUM ESTERASE.
001913 02-13
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

ESTERS
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
00005B 01-03
PROLONGED APOMORPHINE-LIKE BEHAVIOURAL EFFECTS OF APOMORPHINE ESTERS.
00027B 01-04

ESTIMATION
THE EFFECT OF NITROUS-OXIDE ON TIME ESTIMATION IN RATS.
001603 02-04
ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN.
001650 02-06
USEFULNESS OF SALIVA LITHIUM ESTIMATION
003721 04-13

ESTRADIOL-BENZOATE
SYNERGISTIC EFFECT OF ESTRADIOL-BENZOATE AND DIHYDROTESTOSTERONE ON AGGRESSION IN MICE.
0014B6 02-04

ESTRADIOL-INDUCED
INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
002450 03-04

ESTROGEN
MODIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001203 02-03
DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003B01 04-15

ESTROGENIC
CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT. 003260 04-03

ESTROGENS
SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS. 001123 02-03

ESTRUS
LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN. 000149 01-03
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS. 001400 02-03
INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS. 003201 04-03

ETHANOL
REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT. 00000B 01-01
ETHANOL AND THE RESPONSE TO ELECTRIC SHOCK IN RATS. 000063 01-03
MECHANISM OF THE EFFECT OF ACUTE ETHANOL ON HEXOBARBITAL METABOLISM. 000074 01-03
EFFECT OF HYPNOTICS ON MICE GENETICALLY SELECTED FOR SENSITIVITY TO ETHANOL. 000095 01-03
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT. 000114 01-03
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER. D0011B 01-03
DIFFERENTIAL EFFECTS OF LOW DOSES OF ETHANOL ON THE IMPULSE ACTIVITY IN VARIOUS REGIONS OF THE LIMBIC SYSTEM. 000142 01-03
ETHANOL AND ISOPROPANOL EFFECTS ON SCHEDULE-CONTROLLED RESPONDING. D00152 01-03
A DOSE-RESPONSE STUDY OF THE ACUTE EFFECTS OF ETHANOL ON THE SLEEP OF RATS. 000169 01-03
SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY. 000237 01-03
EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE. 00029B 01-04
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS. 000370 01-04
GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES. 00037B 01-04
EFFECTS OF P-CHLOROPHENYLALANINE ON ETHANOL SELF-SELECTION IN THE RAT. 000400 01-04
WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION. 000403 01-04
EFFECTS OF DIAZEPAM AND ETHANOL ON HEART-RATE AND GALVANIC SKIN RESPONSES. 000B12 01-13
HYPNOTICS AND ETHANOL: RESIDUAL EEG EFFECTS. 000B46 01-13
GAMMA-AMINOBUTYRIC-ACID IN DIFFERENT STRAINS OF MICE. EFFECT OF ETHANOL. 001166 02-03
EFFECT OF ETHANOL ON IMPULSE ACTIVITY IN ISOLATED CEREBELLUM. 001206 D2-03
SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS. 0012B7 02-03
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL. 001311 02-D3
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE. 001312 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL. 001363 02-03
DIFFERENTIAL EFFECTS OF PENTOBARBITAL AND ETHANOL IN MICE. 001373 02-03
ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: MECHANISM FOR CROSS-TOLERANCE IN MICE. 0013B6 02-03
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN. 001441 02-04
VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY. 001454 02-04
THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS. 00147B 02-04
A COMPARISON OF THE EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON EXPLORATION AND ON ITS HABITUATION. 0014B3 02-04
EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON SOCIAL INTERACTION IN RATS. 0014B4 02-04
EFFECT OF ETHANOL ON AGGRESSION AND TIMIDITY IN MICE. 001532 02-04
ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT. 001537 02-04
LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE. 001609 02-04
THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY. 001613 02-05
THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN. 001631 02-05
EFFECTS OF ETHANOL ON SCALP VISUAL EVOKED POTENTIALS. 00194B 02-13
REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF PROPRANOLOL. 001954 02-14
MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE. 002001 02-14
REGIONAL DISTRIBUTION OF ETHANOL IN RAT BRAIN. 002236 03-03
THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. 002B57 03-14
THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANCE, ALONE AND IN COMBINATION WITH ETHANOL. 0D2B5B 03-14
3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES. 003066 04-02
BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS. 003076 04-02
NALOXONE-INDUCED INHIBITION OF ETHANOL DEPENDENCE IN MICE. 003100 04-03
ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL. D03177 04-03
THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS. 003203 04-03
STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION. 003224 04-03
ON THE MECHANISM OF ENHANCED SENSITIVITY TO HEPATOTOXIC AGENTS INDUCED BY ETHANOL. 003231 04-03
THE EFFECTS OF PHENCYCLIDINE ON ETHANOL AND SODIUM HEXOBARBITAL IN MICE. 003290 04-03
THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION. 0D3293 04-03
EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN 0D3299 04-03
EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN. D03316 04-03

THE EFFECT OF DIET ON ETHANOL WITHDRAWAL SYMPTOMATOLOGY.
003346 04-04
ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04
SHOCK-INDUCED ETHANOL CONSUMPTION IN RATS.
003430 04-04
EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-04
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE INTAKE OF ETHANOL AND SACCHARIN SOLUTIONS.
003463 04-04
FACILITATION BY DEXAMETHASONE OF TOLERANCE TO ETHANOL IN THE RAT.
003486 04-04
LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
003488 04-04
ETHANOL AND ORAL DIAZEPAM ABSORPTION.
003677 04-13
ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003894 04-17

ETHANOL-INDUCED
SUPPRESSION OF ETHANOL-INDUCED STIMULATION BY GABA-LIKE DRUGS.
001174 02-03
ETHANOL-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
001264 02-03
ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03
LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION.
003428 04-04
LITHIUM-CARBONATE AND ETHANOL-INDUCED HIGHS IN NORMAL SUBJECTS.
003734 04-14

ETHANOLAMINE-O-SULPHATE
SOME BEHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA-TRANSAMINASE.
000285 01-04

ETHANOLS
ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

ETHICS
ETHICS IN DRUG RESEARCH IN THE USA.
003006 03-17
THE ETHICS AND THE ACTUALITIES OF PHARMACOTHERAPY.
003015 03-17

ETHINAMATE
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
002918 03-15

ETHOPROPAZINE
TRANSIENT DEMENTIA SYMPTOMS CAUSED IN ONE CASE BY ETHOPROPAZINE.
002931 03-15

ETHOSUXIMIDE
A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

ETHYLALCOHOL
CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04
CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING.
001588 02-04

ETHYLBENZATROPINE
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15

ETIOLOGICAL
ETIOLOGICAL CONSIDERATIONS.
000535 01-08

ETIOLOGY
PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001817 02-11
REMARKABLE ETIOLOGY IN A CASE OF GILLES-DE-LA-TOURETTES DISEASE.
002865 03-14
TARDIVE DYSKINESIA: MANIFESTATIONS, INCIDENCE, ETIOLOGY, AND TREATMENT.
002935 03-15
REMARKABLE ETIOLOGY IN GILLES-DE-LA-TOURETTES DISEASE.
003628 04-11

ETONITAZENE
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-04

ETONITAZENES
ANTAGONISM OF ETONITAZENES EFFECTS IN RATS AND PIGEONS.
003381 04-04

ETPENAL
ANTISPASMODIC EFFECTS OF ETPENAL.
001354 02-03

EUGENOL
ANESTHETIC ACTION OF METHYLEUGENOL AND OTHER EUGENOL DERIVATIVES.
000419 01-04

EUPHORIA
PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001891 02-13

EVALUATE
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
002255 03-03

EVALUATED
MIANSERIN VERSUS AMITRIPTYLINE: A DOUBLE-BLIND TRIAL EVALUATED BY THE AMP SYSTEM.
000663 01-09

EVALUATING
STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06
IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-06
DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-08
INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
003843 04-16

EVALUATION
WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION.
000403 01-04
EVALUATION TECHNIQUES IN THE STUDY OF TRICYCLIC ANTIDEPRESSANTS.
000476 01-06
METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
000483 01-07
DOUBLE-BLIND EVALUATION OF AHR-1118 AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000486 01-07
EVALUATION OF PROPRANOLOL IN OPIATE DEPENDENCE.
000512 01-07
EVALUATION OF LENPERONE IN ACUTE SCHIZOPHRENIA.
000515 01-07
EVALUATION OF THE NEW DRUG -- CLOMIPRAMINE (ANAFRANIL).
000522 01-07
CLINICAL STUDY AND EVALUATION OF A NEW DERIVATIVE OF PHENOTHIAZINE.
000547 01-08
MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION.
000591 01-09
PSYCHODYNAMIC EVALUATION OF A CASE OF AUTOEROTIC FETISHISM.
000609 01-09
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09
AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09
EARLY CLINICAL DRUG EVALUATION UNIT.
000678 01-10
CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
000683 01-10

EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE.
000694 01-10

EVALUATION OF TRAZODONE IN THE TREATMENT OF ANXIETY.
000719 01-10

COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
000741 01-11

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
000748 01-11

STATISTICAL EVALUATION OF POLYGRAPHIC INVESTIGATIONS OF PENTOXIFYLLINE.
000830 01-13

A DEVICE FOR THE EVALUATION OF MOTOR INCOORDINATION IN RATS.
001439 02-04

A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07

DEMAND METHOD EVALUATION OF HYPNOTICS.
001676 02-07

THERAPEUTIC EVALUATION OF PIPOTIAZINE-PALMITATE IN A GROUP OF SCHIZOPHRENICS.
001707 02-08

AN EVALUATION OF DRUGS IN THE ELEMENTARY SCHOOLS: SOME GEOGRAPHIC CONSIDERATIONS.
00178B 02-10

PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION.
001825 02-11

AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO.
001842 02-11

A COMPARATIVE EVALUATION OF THE ANTIPSORIATIC EFFECT OF L-DOPA VERSUS PLACEBO IN PSORIASIS.
001938 02-13

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-17

COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
002582 03-06

THE CLINICAL EVALUATION OF NEW DRUGS.
002594 03-07

CLINICAL EVALUATION OF A WEEKLY ADMINISTERED NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-07

PHARMACOTHERAPY OF SCHIZOPHRENIA: A CRITICAL EVALUATION.
002614 03-08

CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENIC PSYCHOSIS.
002620 03-08

EVALUATION OF ATROPINE THERAPY IN TREATING SCHIZOPHRENIA.
002630 03-08

CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA.
002645 03-08

COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08

COMPARATIVE EVALUATION OF MODITEN-DEPOT AND CONVENTIONAL MAINTENANCE TREATMENT USING NEUROLEPTICS.
002651 03-08

CLINICAL EVALUATION OF FLUPENTHIXOL WITH PROLONGED ACTION.
002655 03-08

INITIAL CLINICAL EVALUATION OF MODITEN-DEPOT.
002659 03-08

CLINICAL EVALUATION OF CLOZAPINE: A FOLLOW-UP STUDY.
002662 03-08

CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
002664 03-08

CLINICAL EVALUATION OF AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF DEPRESSION.
002713 03-10

CLINICAL EVALUATION OF AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES.
002714 03-10

CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03-10

CLINICAL EVALUATION OF LORAZEPAM IN EMERGENCY PSYCHIATRY
002728 03-10

CLINICAL EVALUATION OF THE EFFECTS OF OXYPERTINE IN STATES OF ANXIETY.
002730 03-10

CLINICAL EVALUATION OF NITRAZEPAM-POLFA.
002745 03-11

RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03-11

STUDIES ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
002958 03-17

FURTHER EVALUATION OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT.
003460 04-04

ANTIDEPRESSANT EVALUATION AND THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN DEPRESSIVE PATIENTS.
003521 04-07

EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PSYCHIATRIC ASPECTS.
003555 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PHARMACOLOGICAL ASPECTS.
003574 04-09

A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
003603 04-10

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION.
003742 04-14

INDIVIDUAL DRUG SUPPLY IN A PSYCHOGERIATRIC WARD: AN EVALUATION OF THE SYSTEM.
003842 04-16

EVALUATIONS

SEX DIFFERENCES IN DRUG EVALUATIONS.
003678 04-13

EVENT

ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003B94 04-17

EVENTS

LIFE EVENTS, DEPRESSIVE RELAPSE AND MAINTENANCE TREATMENT
001770 02-09

DRUGS AS DISCRIMINATIVE EVENTS IN HUMANS.
002960 03-17

EVIDENCE

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-0

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-0

EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-0

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04

EVIDENCE FOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION.
000873 01-14

RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
000910 01-14

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CERE8RAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY 8ETA-ADRENOCEPTORS.
001141 02-03

EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTION TO THIS SU8STANTIA-NIGRA IN RAT.
001189 02-03

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
001298 02-03

BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03

EVIDENCE FOR NALOXONE AND OPIATES AS GABA ANTAGONISTS.
001450 02-04

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON.
001458 02-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
0015B3 02-04

EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER BETA-8LOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-07

ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 02-13

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
002184 03-01

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN.
002202 03-03

EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS.
002224 03-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03

MASS SPECTROGRAPHIC EVIDENCE OF THE CONVERSION OF P-CHLOROAMPHETAMINE TO 3,4 DIMETHOXYAMPHETAMINE.
002364 03-03

EVIDENCE THAT THE PREOPTIC REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
002438 03-04

DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002832 03-13

ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SU8JECTS.
002922 03-15

DEPRESSIVE STATES INDUCED 8Y DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUM8ENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION.
003268 04-03

PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
003343 04-04

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
003509 04-05

NALOXONE ANTAGONISM AS EVIDENCE FOR NARCOTIC MECHANISMS.
003676 04-13

EVOKED

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-03

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-03

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
00150B 02-04

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL.
001941 02-13

EFFECTS OF ETHANOL ON SCALP VISUAL EVOKED POTENTIALS.
001948 02-13

PHARMACOLOGICAL STUDY OF EVOKED POTENTIALS IN THE OLFACTORY 8ULB.
002361 03-03

CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03

MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
00236B 03-03

EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS IN THE CAT BRAIN.
002386 03-03

EFFECTS OF BENZODIAZEPINES AND PENTOBARBITAL ON THE EVOKED POTENTIALS IN THE CAT BRAIN.
0023B7 03-03

DIAZEPAM MODIFICATION OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04

EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002817 03-13

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002830 03-13

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002863 03-14

THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
003242 04-03

INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03

DEPRESSION BY MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT DRUGS ON DIBUTYRYL-CYCLIC-AMP EVOKED SEIZURES.
003436 04-04

EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
003474 04-04

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08

INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09

PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSES IN MAN.
003708 04-13

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

EX-ADDICTS
SHORT-TERM EFFECTS OF NALTREXONE IN 155 HEROIN EX-ADDICTS.
001950 02-13

EX-CONVICT
TESTIMONY BY AN EX-CONVICT AGAINST MEDICAL EXPERIMENTATION IN PRISONS.
003B82 04-17

EX-HEROIN
DIGIT SYMBOL PERFORMANCE IN METHADONE TREATED EX-HEROIN ADDICTS.
001956 02-14

EXACERBATION
ANTICHOLINERGIC EXACERBATION OF PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL SYNDROME.
002009 02-15

EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT.
002057 02-15

EXACERBATIONS
PSYCHOTIC EXACERBATIONS PRODUCED BY NEUROLEPTICS.
001715 02-08

EXACT
AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
00161B 02-05

EXAGGERATED
EXAGGERATED RESPONSE TO (+)AMPHETAMINE IN GERIATRIC GERBILS.
003468 04-04

EXAMINATION
COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOUBLE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-08

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

EXAMINATIONS
PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTERACTIONS OF ALCOHOL AND OXAZEPAM WITH REGARD TO RESPONSE BEHAVIOR.
002880 03-14

EXAMINED
PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
000788 01-11

EXAMPLES
SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-0

EXCESSIVE
TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM
002030 02-1

INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN.
002453 03-0

EXCITABILITY
EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY
000999 01-1

CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-1

EXCITATION
INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000089 01-0

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
001585 02-0

MECHANISMS OF EXCITATION AND INHIBITION IN THE NIGROSTRIATAL SYSTEM.
003250 04-0

THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION.
003341 04-0

INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-0

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-0

EXCITATIONS
THE SPECIFICITY OF ACTION OF THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-0

EXCITATORY
NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-

TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-

EXCLUSION
THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN O THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN B PARTIALLY OVERCOME.
003120 04-

EXCRETION
A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AN AFTER THE ADMINISTRATION OF METHIONINE.
000587 01-

BILIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN.
000808 01-

BILIARY EXCRETION OF DIAZEPAM AND ITS METABOLITES IN MAN.
000B62 01-

VITAMINS, NEUROLEPTICS, AND ANTIPARKINSONIAN DRUGS IN CATECHOLAMINE EXCRETION.
000B72 01-

THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
001134 02-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
001181 02-03

URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM.
001729 02-09

EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS; COMPARISON WITH BLOOD LEVELS.
002041 02-15

URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
002798 03-12

EFFECT OF ENZYME INDUCTION BY BARBITURATES ON NEUROHORMONE EXCRETION IN MAN
002B39 03-13

EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN.
00321B 04-03

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

EXCRETIONS

PHENOBARBITONE-INDUCED URINARY EXCRETIONS OF D-GLUCARIC-ACID AND 6BETA-HYDROXYCORTISOL IN MAN.
002B22 03-13

EXEMPLIFICATION

AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL.
002106 02-17

EXERCISE

HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 03-0B

EXISTENCE

EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTION TO THIS SUBSTANTIA-NIGRA IN RAT.
0011B9 02-03

THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

EXOGENOUS

EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15

EXPECTANCIES

EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS.
002004 02-14

EXPECTATION

EFFECTS OF MARIJUANA, EXPECTATION AND SUGGESTIBILITY ON COGNITIVE FUNCTIONING.
001963 02-14

THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17

WITHDRAWAL FROM METHADONE MAINTENANCE: RATE OF WITHDRAWAL AND EXPECTATION.
003B9B 04-17

EXPECTATIONS

GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11

EXPERIENCE

CLINICAL EXPERIENCE IN USING TLP-607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-08

CLINICAL EXPERIENCE IN USING PENFLURIDOL (TLP-607) FOR SCHIZOPHRENIA.
000559 01-0B

CLINICAL EXPERIENCE IN USING TLP-607 FOR CHRONIC SCHIZOPHRENIA.
000569 01-0B

CLINICAL EXPERIENCE OF THIOTHIXENE (NAVANE) FOR SCHIZOPHRENIA.
000577 01-0B

FIVE YEARS EXPERIENCE WITH LITHIUM-CARBONATE.
000595 01-09

CLINICAL EXPERIENCE OF SEPAZON (CLOXAZOLAM) FOR DEPRESSIVE MANIC.
000644 01-09

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
000697 01-10

CLINICAL EXPERIENCE OF N-DESMETHYLDIAZEPAM (A-101) IN THE FIELD OF PSYCHIATRY.
000712 01-10

PSYCHOPHARMACOLOGY RESEARCH WARD. TEN YEARS EXPERIENCE.
001076 01-17

MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-04

EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07

EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
001B15 02-11

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING.
002495 03-04

OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07

EXPERIENCE WITH THE USE OF SYDNOCARB, A NEW PSYCHOSTIMULANT.
002612 03-0B

PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT.
002619 03-0B

FIVE YEARS OF EXPERIENCE WITH PROLONGED ACTION FLUPHENAZINE.
002643 03-0B

EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
002746 03-11

AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12

ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002BB7 03-15

EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

EFFECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE.
0034B3 04-04

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
0034B7 04-04

GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
003494 04-05

EXPERIENCES

CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-0B

CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
0006B9 01-10

CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11

EXPERIENCES WITH THE LONG-TERM USE OF ANATENSOL DEPOT.
000779 01-11

PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION: EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000B52 01-13

CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR.
001671 02-07

EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14

EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTONIC AFFECT.
002605 03-07

CLINICAL EXPERIENCES WITH NOXIPTILINE.
002681 03-09

PREPUBESCENT DEPRESSION (4TH REPORT) -- EXPERIENCES WITH THE EFFICACY OF LITHIUM-CARBONATE.
002687 03-09

EXPERIENCES IN USING LITHIUM-CARBONATE -- ESPECIALLY WITH MANIA AND MANIC-DEPRESSIVE CASES.
002707 03-09

CLINICAL EXPERIENCES WITH FLUPHENAZINE-DECANOATE (DF) IN 50 LONG-TERM PATIENTS.
002756 03-11

ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002887 03-15

RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04-04

DIFFERENCES IN THE EXPERIENCES OF USING COCA AND COCAINE.
003756 04-14

EXPERIENCES WITH SOME NEW SCALES FOR USE IN GENERAL PRACTICE TRIALS.
003839 04-16

EXPERIENTIAL

EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUA8-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
000389 01-04

EXPERIMENT

DEPRESSION TREATED WITH FG-4963: RESULTS FROM AN INITIAL EXPERIMENT.
000614 01-09

CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION.
000700 01-10

COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA -- A PILOT EXPERIMENT.
0D1864 02-11

COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
0025B2 03-06

SOCIOPATHY: AN EXPERIMENT IN INTERNAL ENVIRONMENTAL CONTROL.
002737 03-11

EXPERIMENTAL

ULTRASTRUCTURAL STUDIES OF CHLORAMPHENICOL-INDUCED NEUROPATHY IN EXPERIMENTAL ANIMALS.
DD0147 01-03

DECADRON IN THE TREATMENT OF CEREBRAL ABSCESS: AN EXPERIMENTAL STUDY.
0002D6 D1-03

BEHAVIOR AND ADDICTION: EXPERIMENTAL STUDIES OF MORPHINE-DEPENDENCE. (PH. D. DISSERTATION).
D00315 D1-04

L-DOPA EFFECTS ON SEXUAL BEHAVIOUR: AN EXPERIMENTAL STUDY.
000360 01-04

EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
00D411 01-04

EXPERIMENTAL CLINICAL USE OF PINAZEPAM IN PSYCHOSOMATIC MEDICINE.
000673 01-10

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-1D

DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10

CLINICAL AND EXPERIMENTAL STUDY ON TRAZODONE.
0007D5 01-10

EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
00072B 01-11

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON
00D76B D1-11

EXPERIMENTAL PHARMACOLOGICAL DIFFERENTIAL DEFINITION OF NOOTROPIC DRUGS.
000892 01-14

EXPERIMENTAL STUDY OF THE PSYCHOSTIMULATING ACTIVITY OF AMANTADINE.
001D25 01-17

SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
DD1270 02-D3

DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03

EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03

MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02-03

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE.
001637 02-05

COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07

EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14

INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECO8ARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION.
001977 02-14

DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03

EXPERIMENTAL STUDIES ON INTOXICATION OR DETOXICATION OF METHYLMERCURIC-CHLORIDE.
002262 03-03

TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
002282 03-03

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

BEHAVIOURAL EFFECTS OF BETA-RECEPTOR BLOCKING AGENTS IN EXPERIMENTAL ANIMALS.
0D2442 03-04

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
002548 03-04

EXPERIMENTAL STUDY OF NOZEPAM TOXICITY.
0D2572 03-05

RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN
D02647 D3-08

PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION. CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
D02724 03-10

CLINICAL AND EXPERIMENTAL STUDIES ON THE EFFECTS OF PROPRANOLOL IN ANXIETY.
002733 D3-10

PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-11

AN EXPERIMENTAL STUDY ON THE CONSCIOUSNESS ALTERING EFFECT OF N,N DIMETHYLTRYPTAMINE (DMT).
002797 D3-12

EXPERIMENTAL AND CLINICAL VECTORS IN PHARMACOLOGY.
0D3D13 03-17

THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
0032D9 04-03

EXPERIMENTALLY

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
DD0664 01-09

EXPERIMENTATION

TESTIMONY BY AN EX-CONVICT AGAINST MEDICAL EXPERIMENTATION IN PRISONS.
DD3882 04-17

EXPERIMENTS

PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS.
00DD24 01-02

TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
DD1111 02-02

CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE IN EXPERIMENTS WITH NONANESTHETIZED ANIMALS.
001636 02-05

ABSENCE OF AN ANTIDEPRESSIVE EFFECT OF LITHIUM IN THE CLINIC AND IN EXPERIMENTS.
002313 03-03

STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-03

A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
002448 03-04

EFFECT OF CATECHOLAMINERGIC DRUGS ON SYSTEMS OF REWARD AND PUNISHMENT IN EXPERIMENTS ON CATS.
002518 03-04

TOXICITY OF TRICHLOROBUTADIENE IN SUBACUTE EXPERIMENTS.
002568 03-05

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03

EXPLANATIONS

NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS.
000288 01-04

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
003703 04-13

EXPLORATION

A COMPARISON OF THE EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON EXPLORATION AND ON ITS HABITUATION.
001483 02-04

LOCOMOTOR ACTIVITY AND EXPLORATION: THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT.
001538 02-04

EFFECTS OF P-CHLOROPHENYLALANINE AND AMPHETAMINE ON HABITUATION OF EXPLORATION.
003385 04-04

EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

EXPLORATORY

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04

EFFECTS OF DIAZEPAM ON EXPLORATORY BEHAVIOR OF PIGS.
003369 04-04

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

APPEALS USED IN ADVERTISEMENTS FOR PSYCHOTROPIC DRUGS: AN EXPLORATORY STUDY.
003899 04-17

EXPOSED

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09

NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

EXPOSURE

RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04

STUDIES ON THE COMBINED USE OF DIAZEPAM WITH EXPOSURE IN VIVO.
000695 01-10

DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE-AVERSION.
000913 01-14

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-04

EFFECTS OF WATER DEPRIVATION AND PRIOR LICL EXPOSURE IN CONDITIONING TASTE-AVERSIONS.
001597 02-04

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
002198 03-03

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION.
003360 04-04

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
003488 04-04

ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION
003503 04-05

EXPRESSION

ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION
000484 01-07

CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAM80A-DELTA9-TETRAHYDROCANNABINOL.
001208 02-03

ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY.
003351 04-04

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08

EXTENSOR

TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

EXTERNAL

INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION.
001977 02-14

EXTEROCEPTIVE

PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-05

EXTINCTION

5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04

ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
002437 03-04

RESISTANCE TO PUNISHMENT AND EXTINCTION FOLLOWING RESPONDING UNDER METHAMPHETAMINE OR SECOBARBITAL. (PH.D. DISSERTATION).
002534 03-04

EFFECTS OF DIAZEPAM ON BEHAVIOUR SUPPRESSED BY EXTINCTION IN PIGS.
003370 04-04

EXTRACT

ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03

THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY.
000270 01-04

EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
000792 01-12

REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT.
001644 02-05

EXTRACTS

EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
001115 02-02

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

EXTRAGRANULAR

EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA.
001324 02-03

EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

EXTRAPINEAL
IN VITRO AND IN VIVO STUDIES OF EXTRAPINEAL N-ACETYLTRANSFERASE OF RAT BRAIN.
003145 04-03

EXTRAPYRAMIDAL
DIFFERENTIAL EFFECT OF NEUROLEPTIC DRUGS ON DOPAMINE TURNOVER IN THE EXTRAPYRAMIDAL AND LIMBIC SYSTEM.
000003 01-01
L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000192 01-03
ENHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
000318 01-04
A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
000478 01-07
THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08
L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000853 01-13
EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15
A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
000961 01-15
ANTICHOLINERGIC PROPERTIES OF ANTIPSYCHOTIC DRUGS AND THEIR RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS.
001359 02-03
A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001821 02-11
ANTICHOLINERGIC EXACERBATION OF PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL SYNDROME.
D02009 02-15
EXTRAPYRAMIDAL SIDE-EFFECTS IN LITHIUM MAINTENANCE THERAPY.
002021 02-15
USE OF DEXETIMIDE (R-16470) WITH EXTRAPYRAMIDAL SYNDROMES CAUSED BY NEUROLEPTICS.
002061 02-15
AMANTADINE THERAPY FOR DRUG-INDUCED EXTRAPYRAMIDAL SIGNS AND DEPRESSION.
002738 03-11
THERAPY WITH DIMETHYLAMINOETHANOL (DEANOL) IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL HYPERKINESIA.
002B01 03-13
THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15
EXTRAPYRAMIDAL EFFECTS OF NEUROLEPTICS.
002912 03-15
EXTRAPYRAMIDAL SIDE-EFFECT OF CERTAIN TRANQUILIZERS.
002913 03-15
EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-15
NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
002986 03-17
STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
D03368 04-04

EYE
PSYCHOTROPIC DRUGS AND THE EYE.
0D2036 02-15
THE INFLUENCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVEMENTS.
002DB5 02-15

F-INDUCED
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
D00037 01-03

F-1983
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACE80, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07

FACES
THE MANY FACES OF BROMOCRIPTINE.
000785 01-11

FACETS
SOME FACETS OF THE SCREENING OF PSYCHOPHARMACOLOGICAL AGENTS.
002954 03-16

FACILITATE
ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
0024B0 D3-04

FACILITATED
FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION.
000404 01-04

FACILITATING
A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

FACILITATION
THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03
THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
000274 01-04
SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 02-03
FACILITATION OF EFFECTS OF L-DOPA BY ALPHA-METHYLDOPA.
001407 02-03
FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
003394 04-04
FACILITATION BY DEXAMETHASONE OF TOLERANCE TO ETHANOL IN THE RAT.
0034B6 D4-04

FACILITATORY
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03

FACTOR-I
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
003615 04-11

FAILS
DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

FAILURE
LITHIUM-CARBONATE PROPHYLAXIS FAILURE.
D0D596 01-09
FAILURE OF ATROPINE TO RETARD AMYGDALOID KINDLING.
001171 02-03
PSYCHOLOGICAL STRESS AS A CAUSE OF LITHIUM PROPHYLAXIS FAILURE, A REPORT OF THREE CASES.
001732 02-D9
THE DISEASE OF FAILURE OF COPING.
D01797 02-10
FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001858 02-11
FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
002223 03-03
NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11
AMPHETAMINE-INDUCED ANGIITIS LEADING TO RENAL FAILURE.
DD3B22 04-15
AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
00388D D4-17

FAILURES
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17
LITHIUM IN PREVIOUS TREATMENT FAILURES.
002703 03-D9

AIRY
LONG-ACTING NEUROLEPTICS -- A FAIRY STORY?
000899 01-14

AMILIAL
PHYSOSTIGMINE IN FAMILIAL ATAXIAS.
003627 04-11

AMILY
DRUG AND FAMILY THERAPY IN DEPRESSED OUTPATIENTS.
000607 01-09
PSYCHOTROPIC DRUG USE IN FAMILY PRACTICE.
001050 01-17
PSYCHOTROPIC DRUG PRESCRIPTION IN FAMILY PRACTICE
002124 02-17
PRESCRIPTION IN FAMILY THERAPY: PART 1.
002961 03-17

ANN
USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN: SUMMARY.
002626 03-08

AT
FAT CELL NUM8ER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS.
0017B2 02-09

ATAL
DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS 8ODY AND URINE FROM FATAL POISONING.
000934 01-15

ATE
OBSERVATIONS ON THE FATE OF CYSTATHIONINE IN RAT BRAIN.
000115 01-03
IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION
000249 01-03
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03

ATHER
A FAVORABLE RESPONSE TO LITHIUM-CARBONATE IN A SCHIZOAFFECTIVE FATHER AND SON.
001714 02-0B

AUSTAN
CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002B06 03-13
DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002826 03-13

AVOUR
EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

DA
FDA: A SLOW STARTER AND A SLOW RUNNER.
00299B 03-17

EAR
THE EFFECTS OF CHLORPROMAZINE UPON FEAR MOTIVATED BEHAVIOR IN THE SQUIRREL-MONKEY.
000345 01-04
SCOPOLAMINE: EFFECTS ON FEAR OR DEFENSE RESPONSES IN THE RAT.
001546 02-04
EFFECTS OF ALCOHOL ON SPECIFIC AND ENVIRONMENTAL FEAR.
001966 02-14

EASIBLE
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
000649 01-09

EBRILE
THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11

EDBACK
THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY.
000693 01-10
ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
001298 02-03
SOMATOSTATIN IN THE PHYSIOLOGIC FEEDBACK CONTROL OF THYROTROPIN SECRETION.
001396 02-03
ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 03-03
EFFECTS ON EMG FEED8ACK, DIAZEPAM AND THEIR COMBINATION ON CHRONIC ANXIETY.
003594 04-10

FEEDING
THE EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVED AND SATIATED MICE.
000313 01-04
INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04
CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
001598 02-04
NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

FEELINGS
THE ROLE OF BODILY FEELINGS IN ANXIETY.
003040 03-17

FELINE
DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03
EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM.
003206 04-03

FEMALE
EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04
INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04
THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04
COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04
HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-04
MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-04
EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT.
001510 02-04
DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04
LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
002502 03-04
MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04
INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
003338 04-03

FEMININE
IS FEMININE DIFFERENTIATION OF THE BRAIN HORMONALLY DETERMINED?.
001368 02-03
MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

FEMTOMOLE
SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
000468 01-06

FENFLURAMINE
TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03
COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03

DIFFERENCES BETWEEN THE ANDREXIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE -- POSSIBLE EFFECTS ON HUNGER AND SATIETY.
000291 01-04

THE EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVED AND SATIATED MICE.
000313 01-04

A TRIAL OF FENFLURAMINE IN THE TREATMENT OF THE CHRDNIC ALCOHOLIC PATIENT.
000752 01-11

ANORECTIC EFFECTIVENESS OF DIFFERING DOSAGE FORMS OF FENFLURAMINE.
000784 01-11

EFFECTS OF FENFLURAMINE ON ACCUMULATION DF 5-HYDROXYTRYPTAMINE AND OTHER NEURDTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN.
001137 02-03

EFFECTS OF SELECTIVE FDREBRAIN DEPLETIDNS OF NOREPINEPHRINE AND SERDTONIN DN THE ACTIVITY AND FDDD INTAKE EFFECTS DF AMPHETAMINE AND FENFLURAMINE.
001162 02-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATIDN OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE.
003108 04-03

FENFLURAMINE LONG-TERM ADMINISTRATION AND BRAIN SEROTONIN.
003130 04-03

ACTIDNS OF FENFLURAMINE ON GLUCOSE UPTAKE IN VITRO AND IN VIVD.
0031B5 04-03

REDUCTION IN PLASMA NDREPINEPHRINE DURING FENFLURAMINE TREATMENT.
003666 04-13

DREAMING, FENFLURAMINE, AND VITAMIN-C.
003691 04-13

FENTANYL

EFFECTS OF FENTANYL AND DROPERIDDL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
001210 02-03

DISCRIMINATIVE STIMULUS PROPERTIES OF FENTANYL AND MORPHINE: TDLERANCE AND DEPENDENCE.
001461 02-04

FERRETS

PSYCHDPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

FERTILITY

LEVODOPA, FERTILITY, AND LONGEVITY.
003118 04-03

FETAL

THE EFFECTS DF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05

SEPARATELY DEVELOPING AXONAL UPTAKE DF 5-HYDRDXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

FETAL MALFDRMATIONS AND ANTIEPILEPTIC DRUGS.
002047 02-15

REVERSAL DF DELAYED MYELINOGENESIS IN THE FETAL ALCOHOL SYNDROME.
003258 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTD SYNAPTOSDMES DF FETAL AND NEONATAL RAT BRAIN.
003299 04-03

FETISHISM

PSYCHODYNAMIC EVALUATION DF A CASE OF AUTOEROTIC FETISHISM.
000609 01-09

FETOPATHY

MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-05

FETUS

SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTRDPIC DRUG USE DURING PREGNANCY.
002010 02-15

FETUSES

THE EFFECT DF N-ACETYL-DL-PENICILLAMINE AND DL-HDMOCYSTEINE THIOLACTONE DN THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLDRIDE.
002198 03-03

FG-4963

NEURDCHEMICAL AND PHARMACOLOGICAL PRDPERTIES OF A NEW SEROTONIN PDTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02

DEPRESSION TREATED WITH FG-4963: RESULTS FROM AN INITIAL EXPERIMENT.
000614 01-09

PHARMACOKINETIC STUDIES OF FG-4963.
000629 01-09

POTENTIATION DF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

ANTIDEPRESSANT EVALUATION AND THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN DEPRESSIVE PATIENTS.
003521 04-07

FI-6654

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZDNE (FI-6654).
002683 03-09

FI-6B20

DDUBLE-BLIND CLINICAL STUDY OF THE ANXIDLYTIC ACTION OF A NEW AGENT: FI-6820 BUFOXINE.
001811 02-10

FIBER

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MDNDPHDSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03

FIBERS

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002826 03-13

FIBRE

DIFFERENTIAL EFFECTS DF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

FIBRINOPEPTIDES

THE EFFECT OF BDVINE FIBRINDPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05

FIGHTING

INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATIDN-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04

SHDCK-ELICITED FIGHTING IN RATS: IMPDRTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04

EFFECT OF TRYPTAMINERGIC DRUGS ON ELECTROSHOCK FIGHTING BEHAVIDUR IN RATS.
002417 03-04

THE EFFECT OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) UPON SHOCK-ELICITED FIGHTING IN RATS.
003461 04-04

FINE

EFFECT DF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE
000465 01-05

FIRING

ENKEPHALIN INHIBITS FIRING OF MYENTERIC NEURONES.
001634 02-05

EFFECT OF ANTIPSYCHDTIC DRUGS ON THE FIRING DF DORSAL RAPHE CELLS. I. RDLE OF ADRENERGIC SYSTEM.
002246 03-03

EFFECT DF ANTIPSYCHDTIC DRUGS DN THE FIRING DF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN.
002247 03-03

STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SERDTONERGIC NEURDNES IN THE DORSAL RAPHE
002580 03-05

STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANDL IN SYMPATHETIC GANGLIDN
003224 04-03

EXCITATDRY AND DEPRESSANT NEURONAL RESPONSES TO NDRADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE DF THE BASELINE FIRING RATE.
003295 04-03

FIRST-DEGREE

FIRST-DEGREE ATRIOVENTRICULAR BLOCK DURING LITHIUM-CARBDNATE TREATMENT.
003796 04-15

FIRST-PASS

CDMPARISON DF OBSERVED AND PREDICTED FIRST-PASS METABDLISM OF IMIPRAMINE IN HUMANS.
000B50 01-13

FIXED
THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09

FIXED-INTERVAL
THE EFFECT OF ACUTE METHADONE ON FIXED-INTERVAL SCHEDULES OF REINFORCEMENT IN PIGEONS. (PH.D. DISSERTATION).
000375 01-04
DRUG EFFECTS ON FIXED-INTERVAL RESPONDING WITH PAUSE REQUIREMENTS FOR FOOD PRESENTATION
003465 04-04

FIXED-RATIO
EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
002457 03-04
A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
003388 04-04

FL-121
A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY.
002774 03-11

FLASHBACK
MARIJUANA FLASHBACK PHENOMENA.
002022 02-15

FLASHBACKS
PROLONGED LSD FLASHBACKS AS CONVERSION REACTIONS.
001875 02-12

FLAVIN
THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01
ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
0021B4 03-01

FLAVOR
ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY.
003351 04-04

FLEXOR
EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY.
000999 01-15
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15

FLICKER
CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
00051B 01-07

FLINCH
EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-03

FLOW
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
001982 02-14
EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16
EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07
INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03
THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-03

FLUANXOL
PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT.
002619 03-08

FLUCTUATION
STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE.
000182 01-03

FLUID
THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03
CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN
000825 01-13
CEREBROSPINAL FLUID CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN MAN.
000B32 01-13
CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03
DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03
THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-08
CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLIC PATIENTS.
001747 02-09
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001B62 02-11
14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13
METHODOLOGICAL REVIEW OF FLUID THERAPY IN PSYCHIATRY.
002145 02-17
DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09
NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002800 03-13
CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 03-13
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-13
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15
A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID.
003107 04-03
INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
003489 04-04
EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACID.
003647 04-11
MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

FLUIDS
A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
0004B0 01-07
SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16
MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

FLUNITRAZEPAM
8ENZODIAZEPINE-INDUCED MODIFICATIONS OF DREAM CONTENT: THE EFFECT OF FLUNITRAZEPAM.
001969 02-14
A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-11
POLYGRAPHIC SLEEP RECORDINGS BEFORE AND AFTER THE ADMINISTRATION OF FLUNITRAZEPAM.
003626 04-11

FLUORESCENCE
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03
MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN: METAL BINDING AND FLUORESCENCE STUDIES.
001328 02-03
FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT 8RAIN.
002408 03-03

FLUORINATED
META8OLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
003083 04-03

FLUOROHISTOCHEMICAL
FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
002408 03-03

FLUOROMETHYLPIPERIDINOBUTYROPHENONE
PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

FLUOROMETRIC
REGIONAL RAT 8RAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03

FLUOSTIGMINE
EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE.
001637 02-05

FLUOTRACEN
FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-28175)).
003625 04-11

FLUOXETINE
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03
EFFECTS OF IMIPRAMINE, CHLORIMIPRAMINE, AND FLUOXETINE ON CATAPLEXY IN DOGS.
002421 03-04

FLUOXETINE-HCL
INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN
003411 04-04

FLUPENTHIXOL
EFFECTS OF FLUPENTHIXOL IN COUNTERACTING DEPRESSIVE STATES.
000608 01-09
A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09
EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02-07
THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09
COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08
CLINICAL EVALUATION OF FLUPENTHIXOL WITH PROLONGED ACTION.
002655 03-08
EFFECT OF FLUPENTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SECRETION IN RATS.
003220 04-03

FLUPHENAZINE
INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-08
CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-08
NIMH-PRB COLLABORATIVE STUDY OF LONG-ACTING FLUPHENAZINE.
000550 01-08
TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION
000658 01-09
THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS 8ETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11
SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08
A COMPARISON OF AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES.
001731 02-09
ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
001735 02-09
METHODS FOR STUDY OF FLUPHENAZINE KINETICS IN MAN.
001951 02-13
BEHAVIORAL EFFECTS OF WITHDRAWAL OF FLUPHENAZINE AFTER LONG-TERM TREATMENT.
002578 03-05
A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 03-08
FIVE YEARS OF EXPERIENCE WITH PROLONGED ACTION FLUPHENAZINE.
002643 03-08
COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08
PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003519 04-07
PIMOZIDE VERSUS FLUPHENAZINE IN AMBULATORY SCHIZOPHRENICS: A 12-MONTH COMPARISON STUDY.
003534 04-08
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08
ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09
FLUPHENAZINE THERAPY IN GROUPS.
003739 04-14

FLUPHENAZINE-DECANOATE
STUDY OF THE USE OF MODITEN-RETARD (FLUPHENAZINE-ENANTHATE) AND OF MODECATE (FLUPHENAZINE-DECANOATE) IN 20 CHRONIC CASES.
001710 02-08
FLUPHENAZINE-DECANOATE MAINTENANCE IN SCHIZOPHRENIA: A RETROSPECTIVE STUDY.
001713 02-08
A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001821 02-11
FLUPHENAZINE-DECANOATE IN CHRONIC PSYCHOTIC SUBJECTS.
002610 03-08
VERY HIGH DOSE FLUPHENAZINE-DECANOATE.
002646 03-08
CLINICAL EXPERIENCES WITH FLUPHENAZINE-DECANOATE (DF) IN 50 LONG-TERM PATIENTS.
002756 03-11
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08

FLUPHENAZINE-ENANTHATE
CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-08
STUDY OF THE USE OF MODITEN-RETARD (FLUPHENAZINE-ENANTHATE) AND OF MODECATE (FLUPHENAZINE-DECANOATE) IN 20 CHRONIC CASES.
001710 02-08

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

FLUPHENAZINES
THERAPY WITH INJECTABLE FLUPHENAZINES.
002611 03-08

FLURAZEPAM
EFFECTS OF FLURAZEPAM (DALMANE) ON ANTERIOR PITUITARY SECRETION.
000877 01-14

THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS.
002093 02-16

TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL.
002976 03-17

TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.
003788 04-15

FLUROTHYL
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03

FLUSH
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15

FLUSPIRILENE
INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-DB

COMPARATIVE STUDY OF THE TRANQUILIZER EFFECT OF FLUSPIRILENE AND DIAZEPAM.
00069B 01-1D

FLUXES
THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENDINGS.
001409 02-03

FLYING
MARIJUANA EFFECTS ON SIMULATED FLYING ABILITY.
001919 02-13

FOCAL
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-03

CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
0D2806 D3-13

FOCI
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B D2-03

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
DD3313 04-03

FOCUS
EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-D3

THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
D03209 D4-D3

NEUROANATOMICAL FOCUS FOR MORPHINE AND ENKEPHALIN-INDUCED HYPERMOTILITY.
0D3240 D4-03

FOLLOW-UP
FOLLOW-UP OF MAINTENANCE TREATMENT FOR DEPRESSION
D0064B D1-09

A FOLLOW-UP OF 7B PATIENTS WITH GILLES-DE-LA-TOURETTES SYNDROME.
000B07 D1-13

A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
D00912 01-14

SUCCESSFUL DETOXIFICATION FROM METHADONE MAINTENANCE: FOLLOW-UP STUDY OF 38 PATIENTS.
DD0982 01-15

THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY.
001B99 02-13

FOLLOW-UP OF PATIENTS WITH CHRONIC SCHIZOPHRENIA -- WITH SPECIAL REFERENCE TO THE EFFECTS OF PHARMACOTHERAPY.
002609 03-08

CLINICAL EVALUATION OF CLOZAPINE: A FOLLOW-UP STUDY.
002662 03-08

IMPORTANCE OF PROMOTIL IN FOLLOW-UP TREATMENT OF ALCOHOLICS.
002740 03-11

PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
002854 03-14

WHAT HAPPENED LATER TO THE LITHIUM BABIES? A FOLLOW-UP STUDY OF CHILDREN BORN WITHOUT MALFORMATIONS.
002932 03-15

THE USE OF METHADONE AS A TREATMENT TOOL FOR OPIATE ADDICTS: A TWO-YEAR FOLLOW-UP STUDY.
003025 03-17

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
003618 04-11

FOOD
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 D1-04

COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS.
000426 01-04

FOOD DOMINANCE IN DOGS: EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE.
00045D D1-04

EFFECT OF FOOD AND REPEATED INJECTIONS ON SERUM DIAZEPAM LEVELS.
00DB4D 01-13

EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
DD1162 D2-D3

THE EFFECT OF LITHIUM ON FOOD INTAKE IN RATS.
DD1317 D2-03

STIMULATION OF FOOD INTAKE IN HORSES BY DIAZEPAM AND PROMAZINE.
001452 02-04

A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
DD1529 D2-D4

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
002457 03-04

EFFECTS OF COCAINE AND D-AMPHETAMINE ON BEHAVIOR MAINTAINED UNDER VARIOUS SCHEDULES OF FOOD PRESENTATION IN SQUIRREL-MONKEYS.
DD3392 04-04

EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 D4-D4

DRUG EFFECTS ON FIXED-INTERVAL RESPONDING WITH PAUSE REQUIREMENTS FOR FOOD PRESENTATION.
003465 04-D4

FOOD-REINFORCED
SCOPOLAMINE AND FOOD-REINFORCED BEHAVIOR IN THE RAT.
001563 D2-04

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-D3

FOOT
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001D00 D1-15

FOOT-SHOCK
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
DD3365 D4-04

FOOT-SHOCK-INDUCED
EFFECTS OF LITHIUM ON FOOT-SHOCK-INDUCED AGGRESSIVE BEHAVIOR IN RATS.
0D1549 02-04

FORCE
BEHAVIORAL DRUG EFFECTS UPON OPERANT RESPONSE FORCE.
002447 03-04
THE EFFECT OF THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC-AMP AND CARDIAC CONTRACTILE FORCE.
003213 04-03

FORCED
DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA.
003826 04-15

FOREARM
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
0D1982 02-14

FOREBRAIN
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03
THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
00D075 01-03
A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
DD0125 01-03
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03
EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03
IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
D01255 02-03
ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
001298 02-D3
TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
DD2278 03-03
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-03
EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN.
DD2373 03-03
LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
002502 03-D4

FOREIGN
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 D2-17
CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 D2-17

FORENSIC
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 D1-D7
PSYCHOPHARMACOLOGY AND THE LAW: A FORENSIC PSYCHIATRISTS VIEWPOINT.
002118 D2-17
PROBLEMS ON THE FORENSIC DETECTION OF DEXTROMORAMIDE OR ITS METABOLITES.
DD3714 04-13

FOREWARNING
THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE-EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN.
D00972 01-15

FORGETFULNESS
ALPHA-METHYLDOPA AND FORGETFULNESS.
00D946 01-15

FORMAMIDINES
INHIBITION OF RAT BRAIN MONOAMINE-OXIDASE BY FORMAMIDINES AND RELATED COMPOUNDS.
D0004B 01-D3

FORMATION
EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
D00038 01-D3
CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE -- EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS.
0D0041 01-03
THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
000085 01-03
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03
POSSIBLE SOURCE OF ERROR IN STUDIES OF ENZYMATIC FORMATION OF DIMETHYLTRYPTAMINE.
001091 02-01
INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
DD13D1 02-D3
EFFECTS OF DRUGS ON THE FORMATION OF HOMOVANILLIC-ACID IN THE RAT RETINA.
0D1418 02-03
CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03
STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-05
FORMATION OF CIRCULARITY AS A MANIFESTATION OF PATHOMORPHOSIS IN SCHIZOPHRENIA.
002640 03-08
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03
THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 04-D3
CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

FORMING
ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
000190 01-D3
CANNABINOLS AND THE ROSETTE FORMING PROPERTIES OF LYMPHOCYTES IN VITRO.
001901 02-13

FORMULATION
ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION.
00D132 01-03
A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003866 04-17

FORTRAL
THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
002D87 02-16

FOUNDATIONS
NEUROCHEMICAL AND NEUROPHARMACOLOGICAL FOUNDATIONS OF THE SLEEP DISORDERS.
D02112 02-17
GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11

FOWL
PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
000138 01-03
ACUTE CENTRAL EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE IN FOWL
0D1310 02-D3

FRACTION
THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION.
0D3293 04-D3

FRACTIONS
ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
DDD232 01-D3

FRAGMENTOGRAPHIC
A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
0020B6 D2-16

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD
002094 02-16

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED METABOLITE IN HUMAN PLASMA
003653 04-13

AGMENTOGRAPHY

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

AGMENTS

BEHAVIORAL EFFECTS OF INTRAVENTRICULARLY ADMINISTERED VASOPRESSIN AND VASOPRESSIN FRAGMENTS.
001107 02-02

INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN.
002453 03-04

AMEWORK

A TIGHT PSYCHOTHERAPEUTICAL FRAMEWORK FOR THE DISCUSSION OF THE EFFECTS OF PSYCHOPHARMACA.
001007 01-16

ANCE

CRITICAL STUDY OF THE USE OF LONG-ACTING NEUROLEPTICS (DEPOT NEUROLEPTICS) IN FRANCE.
001042 01-17

EE

STUDY OF FREE AND TOTAL TRYPTOPHAN IN PLASMA. ITS INTEREST IN PSYCHIATRY.
000815 01-13

RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04

THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-08

FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS.
002093 02-16

TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, MST-1R8.
002672 03-09

MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002867 03-14

EE-LIVING

FREE-LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN.
003868 04-17

EE-MOVING

HALLUCINOGEN-INDUCED BEHAVIORS OF FREE-MOVING CHIMPANZEES.
003358 04-04

E-RADICAL

COMPARATIVE EFFECTS OF CHLORPROMAZINE AND ITS FREE-RADICAL ON MEMBRANE FUNCTIONS.
000153 01-03

QUENCY

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
000518 01-07

DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL.
003673 04-13

DECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
003888 04-17

CTION

PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15

OG

BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03

OGS

POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 02-03

NTAL

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03

DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF STIMULATION
000335 01-04

THE EFFECTS OF D-AMPHETAMINE VERSUS L AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

EFFECTS OF AMPHETAMINE AND ILLUMINATION ON ACTIVITY FOLLOWING FRONTAL ABLATION
000356 01-04

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
001283 02-03

FRUCTOSEDIPHOSPHATE

EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-04

FRUSTRATION

PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEED TO BELONG IN THE LIGHT OF THREE CLINICAL CASES.
001793 02-10

FUGUE-STATE

AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002897 03-15

FUN

COCAINE SNORTING FOR FUN.
003020 03-17

FUNCTION

RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION.
000029 01-03

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04

AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04

AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09

AGENTS AFFECTING ADRENERGIC FUNCTION IN ANTIHYPERTENSIVE THERAPY -- II.
000731 01-11

MARIHUANA, TETRAHYDROCANNABINOL AND T-CELL FUNCTION.
000854 01-13

PENTOBARBITAL ELIMINATION IN PATIENTS WITH POOR RENAL FUNCTION.
000860 01-13

NEUROPSYCHOLOGIC EFFECTS OF DIAZEPAM RELATED TO SINGLE-DOSE KINETICS AND LIVER FUNCTION
000898 01-14

PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04

SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-08

MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION
001826 02-11

DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS.
001907 02-13

EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION.
001934 02-13

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION
002260 03-03

DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03

MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
002483 03-04

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03

A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

EARLY DEVELOPMENTAL CHANGES IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RELATION TO HIPPOCAMPAL FUNCTION
003418 04-04

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTION IN MICE.
003427 04-04

EFFECT OF DOPAMINE ON ESOPHAGEAL MOTOR FUNCTION.
003504 04-05

DOPAMINERGIC FUNCTION IN TWO PATIENTS WITH CATALEPSY.
003529 04-08

DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL.
003673 04-13

INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN
003751 04-14

FUNCTIONAL

FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
000619 01-09

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10

LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
000708 01-10

SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PROBLEM OF PARANOID PSYCHOSIS.
000B38 01-13

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
001238 02-03

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DI-N-PROPYLACETATE.
001533 02-04

PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001B17 02-11

FUNCTIONAL SIGNIFICANCE OF THE ALPHA AND BETA ADRENORECEPTORS IN THE STRUCTURES OF THE STRIOPALLIDAR SYSTEM.
002299 03-03

EFFICACY OF PIRACETAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
00296B 03-17

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
003487 04-04

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

FUNCTIONALLY

DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03

FUNCTIONING

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA' TETRAHYDROCANNABINOL.
000796 01-1

THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-

EFFECTS OF MARIJUANA, EXPECTATION AND SUGGESTIBILITY ON COGNITIVE FUNCTIONING.
001963 02-

EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-

WAIS FUNCTIONING OF CIRRHOTIC AND NON-CIRRHOTIC ALCOHOLICS.
003827 04-

FUNCTIONS

COMPARATIVE EFFECTS OF CHLORPROMAZINE AND ITS FREE-RADICAL ON MEMBRANE FUNCTIONS.
000153 01-

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
000428 01-

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 01-

ACTION OF TRAZODONE ON MENTAL FUNCTIONS OF THE AGED.
000770 01-

THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002857 03-

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
002928 03-

FUNCTIONS OF LOUD SOUND, PERSONALITY, AND DRUGS.
0029B4 03-

THE EFFECT OF LITHIUM-CARBONATE ON THE COGNITIVE FUNCTIONS OF NORMAL SUBJECTS.
003736 04-

FUNDAMENTAL

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
002408 03-

G-31406

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY
003537 04-

GABA

EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-

GABA RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CEREBELLA C-GMP ELICITED BY DIAZEPAM. (UNPUBLISHED PAPER).
000051 01-

BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
00005B 01-

3-ISOXAZOLIDONE -- AN INHIBITOR OF GABA METABOLISM
000113 01-

VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVEL IN CNS
000126 01-

MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMA IN FOUR DISCRETE AREAS OF MOUSE BRAIN
000224 01-

EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACID UPON BEHAVIORAL ACTIVITY IN THE RAT.
000328 01-

DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE
001144 02-

REVERSAL OF THE ACTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-

SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION (UNPUBLISHED PAPER).
001173 02-

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC ACIO OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS ANO THE OEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

ACTIONS OF THE P-CHLOROPHENYL OERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORO OF THE CAT
001235 02-03

GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03

CENTRAL GABA RECEPTOR AGONISTS. COMPARISON OF MUSCIMOL ANO BACLOFEN.
001303 02-03

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTUREO MOUSE SPINAL NEURONS.
00133B 02-03

THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENOINGS.
001409 02-03

EVIDENCE FOR NALOXONE ANO OPIATES AS GABA ANTAGONISTS.
001450 02-04

THE BEHAVIOURAL EFFECTS OF EOS-INOUCEO CHANGES IN SUBSTANTIA-NIGRA GABA LEVELS.
00152B 02-04

A BEHAVIOURAL MOOEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIOE.
001601 02-04

GABA MEOIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALEO BY INTRANIGRAL MUSCIMOL.
002191 03-02

METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHEO PAPER).
002255 03-03

ALTERATIONS IN OISTRIBUTION ANO METABOLISM OF GAMMA-AMINOBUTYRIC-ACIO (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION.
0022BB 03-03

EFFECTS OF OPIATES ON GABA ANO OOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
002291 03-03

ANTIPSYCHOTICS ANO GABA TURNOVER IN MAMMALIAN BRAIN NUCLEI. (UNPUBLISHEO PAPER).
002301 03-03

EFFECTS OF VARIOUS ORUGS ON MORPHINE-INOUCEO STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES ANO TAIL RESPONSE.
002391 03-03

POSSIBLE INVOLVEMENT OF GABA IN MORPHINE ANALGESIA.
002411 03-03

POSSIBLE GABA MEOIATED CONTROL OF DOPAMINE OEPENOENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT.
002522 03-04

THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05

ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION.
003117 04-03

STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINOING IN RAT BRAIN.
003134 04-03

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INOUCEO LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIOENCE FOR A GABA OOPAMINERGIC INTERACTION.
00326B 04-03

MORPHINE ALTERS OISTRIBUTION OF GABA IN THALAMUS.
003336 04-03

EFFECTS OF GABA, GABOB ANO SOME ANTICONVULSANT ORUGS ON OIBUTYRYL-CYCLIC-AMP EVOKEO SEIZURES.
003436 04-04

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) ANO GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A OOUBLE-BLIND STUDY IN HEALTHY PROBANOS.
003755 04-14

ABA-INDUCED

SUPPRESSION OF GABA-INOUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

ABA-LIKE

SUPPRESSION OF ETHANOL-INOUCEO STIMULATION BY GABA-LIKE ORUGS.
001174 02-03

FURTHER ELECTROPHYSIOLOGICAL EVIOENCE FOR THE GABA-LIKE EFFECT OF OROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM
002302 03-03

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACIO (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

GABA-MEDIATED

GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYOROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03

ANTAGONISM OF GABA-MEDIATEO INHIBITION IN THE CENTRAL-NERVOUS-SYSTEM BY CAPROLACTAM OERIVATIVES.
000140 01-03

PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEOIATEO POSTSYNAPTIC INHIBITION OF CULTUREO MAMMALIAN NEURONS.
003210 04-03

GABA-TRANSAMINASE

SOME BEHAVIOURAL ANO EEG STUOIES ON THE BEHAVIOURAL OEPRESSION PROOUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA-TRANSAMINASE.
0002B5 01-04

GABACULINE

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT ANO CONVULSIONS IN MICE.
003215 04-03

GABERGIC

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIOENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

GABERGIC COMPOUNOS AND SCHIZOPHRENIA.
001719 02-0B

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACIO INCREASE AND ANTINOCICEPTION CAUSEO BY PILOCARPINE IN RATS.
0031B9 04-03

GABOB

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT ORUGS ON DIBUTYRYL-CYCLIC-AMP EVOKEO SEIZURES.
003436 04-04

GAIN

FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATEO PATIENTS.
0017B2 02-09

TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM.
002030 02-15

GALACTORRHOEA

OOPAMINE-INOUCEO INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA.
001900 02-13

GALLUS-DOMESTICUS

THE EFFECTS OF DIETHYLOITHIOCARBAMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03

GALVANIC

EFFECTS OF DIAZEPAM ANO ETHANOL ON HEART-RATE ANO GALVANIC SKIN RESPONSES.
000B12 01-13

GAMMA-AMINOBUTYRATE

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT ANO CONVULSIONS IN MICE.
003215 04-03

GAMMA-AMINOBUTYRIC-ACID

REVERSAL OF THE ACTION OF GAMMA-AMINOBUTYRIC-ACIO (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-03

GAMMA-AMINOBUTYRIC-ACIO IN OIFFERENT STRAINS OF MICE. EFFECT OF ETHANOL.
001166 02-03

A CEREBELLAR MOOEL TO STUOY THE ACTIONS OF OIAZEPAM ANO MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACIO MEOIATEO TRANSMISSION. (UNPUBLISHEO PAPER).
002212 03-03

PREVENTION OF LOCAL ANESTHETIC-INDUCED CONVULSIONS BY GAMMA-AMINOBUTYRIC-ACIO.
002261 03-03

ALTERATIONS IN OISTRIBUTION ANO METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE AOMINISTRATION.
0022BB 03-03

PENTOBARBITAL ANO SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC-ACIO.
002333 03-03

THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC ANO PARASYMPATHOLYTIC ORUGS ON THE GAMMA-AMINOBUTYRIC-ACIO CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
002350 03-03

EFFECTS OF GAMMA-AMINOBUTYRIC-ACID ON 33PI INCORPORATION INTO RAT BRAIN PHOSPHOLIPIDS IN VIVO.
003144 04-03

EFFECTS OF ACUTE AND CONTINUOUS PENTOBARBITAL ADMINISTRATION ON THE GAMMA-AMINOBUTYRIC-ACID SYSTEM.
003307 04-03

GAMMA-AMINOBUTYRICACID

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

GAMMA-BUTYROLACTONE

EFFECT OF GAMMA-BUTYROLACTONE AND BACLOFEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03

GAMMA-BUTYROLACTONE-INDUCED

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS ON THE GAMMA-BUTYROLACTONE-INDUCED INCREASE IN MOUSE BRAIN DOPAMINE.
001220 02-03

GAMMA-GLUTAMYL-TRANSPEPTIDASE

BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03

GAMMA-HYDROXYBUTYRATE

BACLOFEN AND GAMMA-HYDROXYBUTYRATE: SIMILAR EFFECTS ON CEREBRAL DOPAMINE NEURONES.
0000B3 01-03

GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03

GAMMA-HYDROXYBUTYRATE IN THE TREATMENT OF NARCOLEPSY: A PRELIMINARY REPORT.
002590 03-07

THE EFFECTS OF GAMMA-HYDROXYBUTYRATE ON SLEEP.
003740 04-14

GAMMA-HYDROXYBUTYRATE-INDUCED

EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR.
0032B2 04-03

GAMMA-RIGIDITY

EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE.
003314 04-03

GAMMA-3H-AMINOBUTYRIC-ACID

KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-ACID TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT BRAIN.
003154 04-03

GAMMA-3H-HYDROXYBUTYRIC-ACID

KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-ACID TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT BRAIN.
003154 04-03

GANGLIA

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-03

TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION.
002260 03-03

BEHAVIORAL ALTERATIONS IN PATIENTS WITH BASAL GANGLIA LESIONS.
002430 03-04

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

GANGLION

A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
002296 03-03

STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION.
003224 04-03

GANGLIONECTOMY

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

GANGLIONIC

THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT.
00009B 01-0

LITHIUM-INDUCED ALTERATIONS IN RAT GANGLIONIC LIPIDS.
00131B 02-0

GANGLIOSIDES

EFFECT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN BRAIN.
000210 01-0

ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY.
001260 02-0

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
003634 04-1

GAS

GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-0

QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-0

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000B29 01-1

GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA.
001003 01-1

MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02-1

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY
002953 03-1

THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 04-1

GASTRIC

EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
00072B 01-1

ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000B05 01-1

SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-0

EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-0

EFFECT OF LITHIUM ON GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE
002346 03-0

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
00239B 03-0

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-0

THE PHARMACEUTICAL MANAGEMENT OF GASTRIC ULCERATION. (PH.D. DISSERTATION).
002773 03-1

THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS INDUCED GASTRIC ULCER.
003233 04-0

GASTROINTESTINAL

CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
0006B9 01-1

GASTROINTESTINAL BLEEDING IN PATIENTS ON BROMOCRIPTINE.
002943 03-1

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-1

GAZE

VERTICAL GAZE PALSY IN BARBITURATE INTOXICATION.
003773 04-1

DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA.
003B26 04-1

GENERALITY
SCHEDULE INDUCED BEHAVIOR A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17

GENERALIZATION
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRADIENTS IN RATS
000449 01-04

GENERATING
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03
INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN. EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-03
POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03

GENERATION
CHRONIC METHYLPHENIDATE EFFECTS ON LEARNING IN AN F2 GENERATION
000330 01-04
PSYCHOPHARMACOLOGY IN ITS SECOND GENERATION.
001052 01-17

GENERIC
GENERIC AND TRADE-NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE.
0016B2 02-0B

GENETIC
GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
00037B 01-04
GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
00156B 02-04
LITHIUM AND GENETIC EQUIPMENT.
001762 02-09
PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION: ENVIRONMENTAL AND GENETIC FACTORS.
001935 02-13
LITHIUM-SALTS IN PSYCHIATRY: IMPORTANCE OF GENETIC FACTORS.
002B25 03-13
GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 04-03

GENETICALLY
EFFECT OF HYPNOTICS ON MICE GENETICALLY SELECTED FOR SENSITIVITY TO ETHANOL.
000095 01-03
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03

GENICULATE
PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03
DIAZEPAM MODIFICATION OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04

GENITAL
MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE
001499 02-04

GENOTYPE
GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
003494 04-05

GENOTYPIC
ACETALDEHYDE AS A PSYCHOPHARMACOLOGICAL AGENT. TASK SPECIFICITY OF GENOTYPIC DIFFERENCES
0033B0 04-04

GEOGRAPHIC
AN EVALUATION OF DRUGS IN THE ELEMENTARY SCHOOLS: SOME GEOGRAPHIC CONSIDERATIONS.
0017BB 02-10

GEOMETRY
MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN
001265 02-03

GERBIL
THE SEDATIVE EFFECTS OF NICOTINAMIDE ON GERBIL WHEEL-RUNNING ACTIVITY
002423 03-04
PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPEN FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
00340B 04-04

GERBILS
EXAGGERATED RESPONSE TO (+)AMPHETAMINE IN GERIATRIC GERBILS.
003468 04-04

GERIATRIC
TRIMETHOZINE IN A GERIATRIC MILIEU.
000479 01-07
LONG-TERM LITHIUM THERAPY OF GERIATRIC MANIC-DEPRESSIVES.
000599 01-09
COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11
DO GERIATRIC DRUGS WORK?.
001B24 02-11
EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07
HYPNOTIC EFFECTS OF DIXYRAZINE IN A DOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
002736 03-11
GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11
GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11
DOXEPIN AND DIAZEPAM IN THE TREATMENT OF HOSPITALIZED GERIATRIC PATIENTS.
002770 03-11
THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
00277B 03-11
PROCAINE HYDROCHLORIDE AS A MONOAMINE-OXIDASE INHIBITOR: IMPLICATIONS FOR GERIATRIC THERAPY.
00314B 04-03
EXAGGERATED RESPONSE TO (+)AMPHETAMINE IN GERIATRIC GERBILS.
00346B 04-04
TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT: A CASE REPORT.
0035B7 04-10

GERIATRICS
TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 1B9 HOSPITALIZED PATIENTS.
000727 01-11

GESTATION
SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION.
0002B6 01-04

GIANT
PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15
EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES OF SNAIL GIANT NEURONS.
002201 03-03

GILLES-DE-LA-TOURETTE
THE GILLES-DE-LA-TOURETTE SYNDROME: AN ANALYSIS OF PUBLISHED CASES DEALING WITH THE COURSE OF THE DISEASE AND ITS PROGNOSIS.
000725 01-11
DEANOL IN GILLES-DE-LA-TOURETTE SYNDROME: A PRELIMINARY INVESTIGATION
003571 04-09
COMPARISON OF PIMOZIDE WITH HALOPERIDOL IN GILLES-DE-LA-TOURETTE SYNDROME.
003641 04-11

GILLES-DE-LA-TOURETTES
A FOLLOW-UP OF 7B PATIENTS WITH GILLES-DE-LA-TOURETTES SYNDROME.
000807 01-13
LITHIUM-CARBONATE IN GILLES-DE-LA-TOURETTES DISEASE.
001763 02-09
GILLES-DE-LA-TOURETTES SYNDROME.
001B19 02-11
A STUDY OF ENDOGENOUS DOPAMINE METABOLISM IN GILLES-DE-LA-TOURETTES DISEASE.
0026B4 03-09

TREATMENT OF GILLES-DE-LA-TOURETTES SYNDROME WITH HALOPERIDOL.
002791 03-11

REMARKABLE ETIOLOGY IN A CASE OF GILLES-DE-LA-TOURETTES DISEASE.
002865 03-14

REMARKABLE ETIOLOGY IN GILLES-DE-LA-TOURETTES DISEASE.
00362B 04-11

THE USE OF METHYLPHENIDATE AND IMIPRAMINE IN GILLES-DE-LA-TOURETTES DISEASE IN CHILDREN
003782 04-15

GINGKO-BILOBA
ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03

GLAND
OPIATE RECEPTOR BINDING IN THE PITUITARY GLAND.
003279 04-03

GLANDS
INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
000155 01-03

EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03

REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

GLASS
THE DETERMINATION OF BARBITURATES IN BLOOD WITH GLASS CAPILLARY GAS CHROMATOGRAPHY.
003667 04-13

GLAUCOMA
OUTPATIENT PSYCHIATRIC MEDICATIONS AND GLAUCOMA.
000980 01-15

GLAUCOMA DUE TO DIAZEPAM.
003795 04-15

GLAUCOMAS
A REVIEW OF PSYCHOTROPIC MEDICATIONS AND THE GLAUCOMAS.
002926 03-15

GLC
IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000814 01-13

GLC DETERMINATION OF DOXEPIN PLASMA LEVELS.
001009 01-16

DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
002955 03-16

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
003713 04-13

GLIAL
PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03

GLIOMA
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03

GLUCOCORTICOID
GLUCOCORTICOID REGULATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN
002379 03-03

GLUCOSE
ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03

THE EFFECT OF L-DOPA AND AN INHIBITOR OF PERIPHERAL DECARBOXYLATION ON GLUCOSE METABOLISM IN BRAIN.
001405 02-03

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO.
002339 03-03

EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT. (UNPUBLISHED PAPER).
002367 03-03

EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03

ACTIONS OF FENFLURAMINE ON GLUCOSE UPTAKE IN VITRO AND IN VIVO.
003185 04-03

GLUCURONIDATION
INHIBITION OF ACETAMINOPHEN GLUCURONIDATION BY OXAZEPAM.
000093 01-03

GLUTAMATE
MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN
000224 01-03

DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE.
001144 02-03

REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN.
003207 04-03

GLUTAMATE-DECARBOXYLASE
CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECARBOXYLASE AND TYROSINE-HYDROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG.
001085 02-01

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03

THE INHIBITION OF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
003074 04-02

GLUTAMATE-INDUCED
ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03

GLUTAMIC-ACID
EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACID UPON BEHAVIORAL ACTIVITY IN THE RAT.
00032B 01-04

IS GLUTAMIC-ACID THE PYRAMIDAL TRACT NEUROTRANSMITTER?.
001392 02-03

GLUTAMINE
REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN
003207 04-03

GLUTEN
WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001702 02-0E

WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001717 02-0E

WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS
001718 02-0E

GLUTEN AND SCHIZOPHRENIA.
001932 02-13

GLUTETHIMIDE
SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13

GLUTETHIMIDE -- AN UNSAFE ALTERNATIVE TO BARBITURATE HYPNOTICS.
002919 03-15

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY
002953 03-16

GLYCEMIC
GLYCEMIC SIDE-EFFECTS IN PATIENTS DUE TO NEUROLEPTIC THERAPY.
002941 03-15

GLYCINE
EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03

GLYCOGEN
EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN.
001197 02-03

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVER GLYCOGEN SYNTHESIS.
001372 02-03

YCOL
8EHAVIORAL AND META8OLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
001385 02-03
CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE META8OLITES OF 8RAIN NOREPINEPHRINE.
002377 03-03

YCOLATES
STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03

YCOPROTEINS
EFFECT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN 8RAIN.
000210 01-03

YCOSIDES
MECHANISM OF NEUROTOXICITY OF CARDIOTONIC GLYCOSIDES.
003149 04-03

AWING
INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04
POSSI8LE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED 8Y APOMORPHINE GNAWING TEST IN MICE.
003119 04-03
EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE AND METHACHOLINE ON THE APOMORPHINE-INDUCED GNAWING IN THE RAB8IT.
003485 04-04

RH
GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
0016B1 02-0B

-NO-GO
DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-04

LDEN
PERIOD OF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLDEN HAMSTER.
001616 02-05
EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER.
003484 04-04

LDFISH
ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-04
THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03
PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04
MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
001611 02-04
THE EFFECT OF OMETINE ON LEARNED BEHAVIOR IN THE WAKIN GOLDFISH.
002514 03-04

NADAL
SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
000133 01-03
INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04
EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
0023B4 03-03
NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03
GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-04
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

NADOTROPIN
GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
001681 02-0B
ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY
001930 02-13

GRADIENTS
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRADIENTS IN RATS.
000449 01-04
VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA. CONTINGENCY ON TASKS AND SPECIES.
001440 02-04
LITHIUM SIDE-EFFECTS IN RELATION TO DOSE AND TO LEVELS AND GRADIENTS OF LITHIUM IN PLASMA
003815 04-15

GRADUALLY
MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS.
002383 03-03

GRANULAR
INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

GRANULOCYTES
INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASE FROM BOVINE GRANULOCYTES.
000124 01-03

GRAPHIC
DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
002689 03-09

GRASSHOPPER
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

GRAVES
SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001B90 02-13

GRAY
SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

GROOMING
INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN
002453 03-04

GROUP
A NEW MEDICATION OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-07
PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION. RESULTS OF THE GROUP THERAPY.
000635 01-09
A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01
CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-0B
THERAPEUTIC EVALUATION OF PIPOTIAZINE-PALMITATE IN A GROUP OF SCHIZOPHRENICS.
001707 02-0B
OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY.
001755 02-09
A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14
NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
0022B3 03-03
A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 03-0B
PSYCHODYNAMIC OBSERVATIONS OF A GROUP OF PATIENTS TREATED WITH LITHIUM-CARBONATE.
002670 03-09
NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE PART 1: GROUP PROFILES.
002940 03-15
STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03

GROUPS
ORUG STUOIES WITH WOMEN, THE ELOERLY, AND GROUPS.
000865 01-13
AN ELECTROPHYSIOLOGICAL STUOY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC ANO OTHER MENTALLY ILL PATIENT GROUPS ANO ON NORMAL SUBJECTS.
0016B4 02-0B
RETROSPECTIVE EVALUATION ANO MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLOER AGE GROUPS.
0027B4 03-11
GONAOAL HORMONES ANO SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-04
FLUPHENAZINE THERAPY IN GROUPS.
003739 04-14
PHARMACOLOGICAL AFTERCARE FOR HOMOGENOUS GROUPS OF PATIENTS.
003890 04-17

GROWTH
EFFECT OF POTASSIUM ON LITHIUM-INOUCEO GROWTH RETAROATION ANO POLYURIA IN RATS.
000189 01-03
GROWTH HORMONE SECRETION IN CHRONIC SCHIZOPHRENIA.
000536 01-08
THE LEVELS OF SERUM GROWTH HORMONE ANO IMMUNOREACTIVE INSULIN AFTER AOMINISTRATION OF ANTIPYRETIC ANALGETICS.
000867 01-13
EFFECT OF METHYLOOPA ON PROLACTIN ANO GROWTH HORMONE.
000987 01-15
EFFECTS OF METHAOONE HYOROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPAREO FROM METHADONE-TOLERANT ANO CONTROL RATS.
002581 03-05
REOUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENOOGENOUS OEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE ANO ENOOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002B21 03-13
THE EFFECTS OF LONG-TERM STIMULANT MEOICATION ON THE GROWTH ANO BODY COMPOSITION OF HYPERACTIVE CHILOREN
003633 04-11

GUANETHIDINE
A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE ANO MOLINOONE TO INTERACT ADVERSELY WITH GUANETHIDINE
001494 02-04

GUANIDINO
EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMAL NA-K-ATPASE ACTIVITY.
001630 02-05

GUANOSINE
CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03
IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY OOPAMINERGIC MECHANISMS.
001158 02-03
EFFECT OF DESMETHYLDIAZEPAM ANO CHLOROESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-03
CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY OOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03
PHARMACOLOGICALLY-INOUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX. DIFFERENCE BETWEEN APOMORPHINE, HALOPERIOOL ANO HARMALINE.
003096 04-03
ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE ANO CHRONIC TREATMENT WITH ETHANOL.
003177 04-03
EFFECTS OF ACUTE ANO CHRONIC ETHANOL AOMINISTRATION ANO WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE ANO GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

GUIDANCE
PRESCRIPTIVE GUIOANCE FOR USAGE OF PSYCHOPHARMACEUTICALS.
001020 01-17

GUIDE
THE PRACTITIONERS GUIOE TO PSYCHOACTIVE DRUGS.
002103 02-17
NEUROTIC OEPRESSION AN EMPIRICAL GUIOE TO TWO SPECIFIC DRUG TREATMENTS
002721 03-10
GUIOE TO ORUG INTERACTIONS
003806 04-15

GUIDELINES
PROPOSEO GUIOELINES FOR CONOUCTING CLINICAL TRIALS OF PSYCHOTROPIC DRUGS (REPLICATED).
001053 01-1

GUINEA-PIG
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXI WITH ETHANOL IN THE ISOLATEO PERFUSED GUINEA-PIG LIVER.
000118 01-0
ASPECTS OF OPIATE OEPENDENCE IN THE MYENTERIC PLEXUS OF THE GUINEA-PIG.
000222 01-0
ENHANCEO SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
000318 01-0
CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECARBOXYLASE AND TYROSINE-HYOROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG.
001085 02-0
STRUCTURE-ACTIVITY RELATIONSHIPS OF ENKEPHALINS IN THE STIMULATED GUINEA-PIG ILEUM.
001180 02-0
BEHAVIORAL EVIOENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-0
PHARMACOKINETICS ANO PLASMA BINDING OF DIAZEPAM IN MAN, OOG, RABBIT, GUINEA-PIG AND RAT.
001921 02-1
THE METABOLISM OF CHLORPROMAZINE IN THE NEONATAL GUINEA-PIG
002315 03-0

GUINEA-PIGS
EFFECT OF RESERPINE, DESIPRAMINE ANO PHENYTOIN ON DIGOXIN-INDUCEO ARRHYTHMIAS AND MYOCAROIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-0
AOAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES I GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-0
EFFECTS OF SCOPOLAMINE ANO PHYSOSTIGMINE ON TONIC IMMOBILIT IN OUCKS ANO GUINEA-PIGS.
000453 01-0
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
001400 02-0

GUNN
THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
001134 02-

GUSTATORY
DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-
PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE T AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION
003360 04-

GYNECOLOGY
PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY.
000674 01-

H-102-09
Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYOROXYTRYPTAMINE UPTAKE.
000212 01-

H-87-07
COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WIT (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY
000B66 01-

H-93-26
COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WIT (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-

HABITS
GENERAL PRACTITIONERS PRESCRIBING HABITS FOR PATIENTS WITH OEPRESSION
0038B6 04-

HABITUATION
DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE A D-AMPHETAMINE. EFFECTS ON HABITUATION
001435 02
A COMPARISON OF THE EFFECTS OF ETHANOL AND CHLORDIAZEPOXID ON EXPLORATION AND ON ITS HABITUATION.
0014B3 02

EFFECTS OF ANTICHOLINERGICS ON THE HABITUATION OF TONIC IMMOBILITY IN CHICKENS.
001511 02-04

CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
002508 03-04

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECERE8RATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04

EFFECTS OF N,N DIMETHYLTRYPTAMINE ON BEHAVIOURAL HABITUATION IN THE RAT.
003384 04-04

EFFECTS OF P-CHLOROPHENYLALANINE AND AMPHETAMINE ON HABITUATION OF EXPLORATION
003385 04-04

LAZEPAM

BRIEF TREATMENT OF ANXIOUS PATIENTS WITH HALAZEPAM IN HIGH DOSES.
003591 04-10

HALAZEPAM AND DIAZEPAM IN NEUROTIC ANXIETY: A DOUBLE-BLIND STUDY.
003600 04-10

LF-LIFE

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-03

LLUCINATIONS

TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001B69 02-12

HUMAN EEG SPECTRA BEFORE AND DURING CANNABIS HALLUCINATIONS.
001924 02-13

L-TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS.
002871 03-14

HALLUCINATIONS FOLLOWING WITHDRAWAL OF VALIUM.
002B94 03-15

LLUCINATORY

MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07

TOXICOPATHIC HALLUCINATORY SYNDROMES IN CHILDREN.
000942 01-15

AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12

LLUCINOGEN

DE PLANTIS TOXICARIIS E MUNDO NOVO TROPICALE COMMENTATIONES XIII. FURTHER NOTES ON VIROLA AS AN ORALLY ADMINISTERED HALLUCINOGEN.
001093 02-01

LLUCINOGEN-INDUCED

HALLUCINOGEN-INDUCED BEHAVIORS OF FREE-MOVING CHIMPANZEES.
003358 04-04

LLUCINOGEN-TREATED

OBSERVATIONAL DETERMINATION OF DOSE-RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-04

LLUCINOGENIC

HALLUCINOGENIC AGENTS.
001021 01-17

TOXIOCOMANIA IN HALLUCINOGENIC DRUGS.
001059 01-17

LLUCINOGENS

A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-08

INDOLE ALKALOIDS IN PLANT HALLUCINOGENS.
001073 01-17

AN ANIMAL BEHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-04

COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
001B67 02-12

THE EFFECTS OF HALLUCINOGENS ON BLIND MONKEYS.
002540 03-04

DISCRIMINABLE STIMULI PRODUCED BY HALLUCINOGENS.
003003 03-17

HALLUCINOSIS

PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01 15

HALOINDOLES

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 03-05

HALOPERIDOL

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE
000035 01-03

EFFECTS OF HALOPERIDOL AND LITHIUM ON BLOOD ALCOHOL LEVEL IN RABBITS.
000141 01-03

EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS INDUCED BY HALOPERIDOL.
000438 01-04

SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07

DOUBLE-BLIND CLINICAL COMPARISON OF HF-1854 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
00053B 01-08

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 01-08

COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOUBLE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-08

LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08

CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11

HALOPERIDOL AND METHYLPHENIDATE IN HYPERACTIVE CHILDREN.
000927 01-14

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION
00111B 02-02

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

CATALEPSY INDUCED BY MORPHINE OR HALOPERIDOL: EFFECTS OF APOMORPHINE AND ANTICHOLINERGIC DRUGS.
0014B1 02-04

CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04

HALOPERIDOL AND LIGHT REINFORCEMENT IN THE RAT.
001541 02-04

DIFFERENTIAL ATTENUATION OF SOME EFFECTS OF HALOPERIDOL IN RATS GIVEN SCOPOLAMINE.
001578 02-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
001583 02-04

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08

HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-08

HALOPERIDOL IN THE TREATMENT OF PSYCHONEUROTIC ANXIOUS OUTPATIENTS.
001792 02-10

ANOTHER INDICATION FOR HALOPERIDOL.
001B22 02-11

CONTROL OF ACUTE ALCOHOLIC WITHORAWAL SYMPTOMS: A COMPARATIVE STUOY OF HALOPERIDOL ANO CHLOROIAZEPOXIOE.
001850 02-11

HALOPERIOOL, RESERPINE, L-DOPA ANO AMANTAOINE IN THE TREATMENT OF HUNTINGTONS CHOREA.
001893 02-13

PHARMACOKINETIC STUOIES ON HALOPERIOOL IN MAN.
001911 02-13

SERUM OOPAMINE-BETA-HYOROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS: EFFECT OF O-AMPHETAMINE AND HALOPERIOOL.
001927 02-13

TOXIC REACTIONS TO LITHIUM AND HALOPERIDOL.
002055 02-15

AN AUTOMATEO DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL.
002106 02-17

HALOPERIDOL: A USEFUL PSYCHIATRIC DRUG.
002126 02-17

THE EFFECT OF HALOPERIOOL ON EPINEPHRINE-STIMULATEO ADENYLATE-CYCLASE IN HUMANS.
002209 03-03

DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C-GMP ELICITEO BY HALOPERIDOL ANO DIAZEPAM.
002211 03-03

ACTION OF DIAZEPAM, HALOPERIDOL, MORPHINE ANO MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 03-03

EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03

EFFECTS OF AMINOOXYACETIC-ACIO AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
002270 03-03

HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03

STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-D3

USE OF HALOPERIDOL AT VERY HIGH DOSAGE.
002637 03-08

ADVERSE REACTIONS IN TREATMENT WITH LITHIUM-CARBONATE AND HALOPERIDOL.
002665 03-09

TREATMENT OF GILLES-DE-LA-TOURETTES SYNDROME WITH HALOPERIDOL.
002791 03-11

HALOPERIDOL IN THE THERAPY OF SEVERE BEHAVIOR DISORDERS.
002B51 03-14

THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNDROME.
002901 03-15

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: OIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM AOMINISTRATION.
003172 04-03

THE EFFECT OF APOMORPHINE ANO HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
D031B1 04-03

HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION.
003364 04-04

SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
003528 04-08

COMPARISON OF PIMOZIDE WITH HALOPERIDOL IN GILLES-DE-LA-TOURETTE SYNDROME.
003641 04-11

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL BETA-ADRENERGIC ADENYLATE-CYCLASE.
003668 04-13

ON THE METABOLISM OF HALOPERIDOL IN MAN.
003671 04-13

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

HALOPERIDOL-INDUCED

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INOUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-(

HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN MONKEYS.
001504 02-(

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIOOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-(

HALOTHANE

EFFECTS OF HALOTHANE ON CATECHOLAMINE META8OLISM IN THE 8RAINSTEM OF RATS.
000221 01-(

HALOTHANE-INDUCED

OETERMINATION OF HALOTHANE-INOUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-

HAMSTER

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-

EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-628, ON RAT AND HAMSTER LORDOSIS.
001548 02-

PERIOD OF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLOEN HAMSTER.
001616 02-

EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER.
003484 04-

HANDBOOK

THE THERAPISTS HANDBOOK: TREATMENT METHODS OF MENTAL OISORDERS.
002178 02-

GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS ANO PRIMARY CARE PHYSICIANS.
002741 03-

HANDBOOK OF PSYCHOPHARMACOLOGY.
002997 03-

HANDLING

SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR OAMS DURING GESTATION
0D0286 01-

THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-

EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING.
00369B 04-

HANDWRITING

DRUG-INOUCED HANDWRITING CHANGES: AN EMPIRICAL REVIEW.
000895 01-

HARMALINE

THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENDINGS.
001409 02-

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTI DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL ANO HARMALINE.
003096 04-

HASHISH

HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY.
D01339 02-

TRACKING OIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
001980 02-

HATRACK

DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAN TRIAL. UNITED-STATES V. HATRACK, 40B F.SUPP. 476. U.S. DISTRIC COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
D02150 02-

HAZARD

A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, ORUGS, AN THEIR INTERACTION.
0D3766 04

HAZARDOUS

CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02

HAZARDS
MARIHUANA: NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
000795 01-12
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
000983 01-15

HAZARI
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001800 02-10

HEAD
EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE.
000298 01-04
EFFECTS OF AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04
HEAD TWITCHES INDUCED BY BENZODIAZEPINES AND THE ROLE OF BIOGENIC AMINES.
001552 02-04
5-METHOXYTRYPTAMINE-INDUCED HEAD TWITCHES IN RATS.
002573 03-05

HEAD-DIPPING
THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
000308 01-04

HEAD-SHAKING
RELATIVE ROLE OF CATECHOLAMINES IN HEAD-SHAKING OF INFANT RATS.
000344 01-04
SPONTANEOUS AND AMPHETAMINE-INDUCED HEAD-SHAKING IN INFANT RATS.
002465 03-04

HEADACHE
ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17
BEHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE.
001579 02-04
CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11

HEADACHES
NEWER CONCEPTS IN MANAGEMENT OF MIGRAINE HEADACHES.
003867 04-17

HEALTH
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
000983 01-15
THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17
HEALTH STATUS IN PERSONS ENGAGED IN THE PRODUCTION OF TRIFTAZINE.
002914 03-15
CANNABIS AND HEALTH.
002992 03-17
A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, DRUGS, AND THEIR INTERACTION.
003766 04-15

HEALTHY
SERUM CONCENTRATIONS OF TRIIMIPRAMINE IN HEALTHY SUBJECTS.
00091B 01-14
SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001B84 02-13
FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS.
002093 02-16
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15
SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15
EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A DOUBLE-BLIND STUDY IN HEALTHY PROBANDS.
003755 04-14

HEART
CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 01-05
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05
ANXIETY AND TENSION AND BETA-BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 01-10
EFFECT OF TRICYCLIC ANTIDEPRESSANT DRUGS ON THE HEART.
001193 02-03
5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA
001289 02-03
LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART
001345 02-03
EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03
EFFECTS OF CANNABINOIDS ON THE PERFUSED RAT HEART.
001379 02-03
DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13
EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03
COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AND DIAZEPAM IN ISOLATED RAT HEART.
00237B 03-03
THE EFFECT OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS ON THE HEART AND CIRCULATION.
002890 03-15
EFFECTS OF CHLORPROMAZINE ON THE ISOLATED PERFUSED RAT HEART.
003084 04-03

HEART-RATE
HEART-RATE LEARNING AFTER D-TUBOCURARINE ADMINISTRATION IN ANIMALS.
000329 01-04
EFFECTS OF DIAZEPAM AND ETHANOL ON HEART-RATE AND GALVANIC SKIN RESPONSES.
000B12 01-13
OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND.
000B34 01-13
EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-03
THE INFLUENCE OF MEPROBAMATE ON HEART-RATE IN THE CONSCIOUS DOG.
001615 02-05
DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
0019B2 02-14
MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14
EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-04
ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTA8-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03
THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13
DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003824 04-15

HEARTBEAT
THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-03

HEAT
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

HEAT STROKE ASSOCIATED WITH MEDICATIONS HAVING ANTICHOLINERGIC EFFECTS.
003759 04-15

HEAT-ESCAPE
HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02

HEIGHT
NEUROLEPTIC DRUG EFFECTS ON CHILDRENS BODY WEIGHT AND HEIGHT.
003645 04-11

HELPING
HELPING TO MAKE THE FINAL YEARS MEANINGFUL FOR THE ELDERLY RESIDENTS OF NURSING HOMES.
002859 03-14

HELPING PSYCHIATRIC OUTPATIENTS ACCEPT DRUG THERAPY.
003871 04-17

HEME
IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
000158 01-03

HEMICHOLINIUM-3
PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

HEMIDIAPHRAGMS
EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
001329 02-03

HEMINEURINE
HEMINEURINE ABUSE BY A CHRONIC ALCOHOLIC.
002946 03-15

HEMISPHERES
THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC-ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
002350 03-03

HEMISPHERIC
PHARMACOLOGIC IMPLICATIONS OF HEMISPHERIC ASYMMETRY.
003017 03-17

HEMISUCCINATE
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07

HEMOCOAGULATION
EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001829 02-11

HEMODIALYZED
ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15

HEMODYAMICS
EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRAL HEMODYAMICS AND METABOLISM IN THE BABOON.
003297 04-03

HEMODYNAMIC
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000B26 01-13

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
000B27 01-13

FURTHER HEMODYNAMIC INVESTIGATIONS OF THE ANTIHYPERTENSIVE EFFECT OF LEXOTAN (BROMAZEPAM).
000856 01-13

COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-13

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 03-08

HEMODYNAMICS
CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
002818 03-13

EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
0031B3 04-03

HEMOLYTIC
HEMOLYTIC AND ANTIHEMOLYTIC EFFECTS OF ANTIPSYCHOTIC DRUGS.
002827 03-13

HENBANE
HENBANE CHEWING.
003029 03-17

HEPATIC
IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
000158 01-03

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
000269 01-03

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
001920 02-13

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

HEPATITIS
COLITIS AND HEPATITIS CAUSED BY METHYLDOPA.
002017 02-15

EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
002287 03-03

HEPATOTOXIC
ON THE MECHANISM OF ENHANCED SENSITIVITY TO HEPATOTOXIC AGENTS INDUCED BY ETHANOL.
003231 04-03

HERB
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
0009B3 01-15

HERBAL
HERBAL INTOXICATION: PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
000984 01-15

HEREDITARY
POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

HEREDITARY PAROXYSMAL ATAXIA RESPONSIVE TO ACETAZOLAMIDE.
003629 04-1

HEROIN
ELECTROACUPUNCTURE AND HEROIN ADDICTION, A CASE REPORT.
000744 01-1

CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
00159B 02-0

HEROIN WITHDRAWAL SYNDROME IN NEWBORNS.
001B51 02-1

ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-1

SHORT-TERM EFFECTS OF NALTREXONE IN 155 HEROIN EX-ADDICTS.
001950 02-1

OUTPATIENT HEROIN DETOXIFICATION WITH ACUPUNCTURE AND STAPLEPUNCTURE.
002783 03-1

MODULATION OF HEROIN SELF-ADMINISTRATION BY NEUROHYPOPHYSEAL PRINCIPLES.
003477 04-0

HETEROGENEITY
A STUDY OF MUSCARINIC RECEPTOR HETEROGENEITY WITH WEAK ANTAGONISTS.
000097 01-0

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-0

THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04-0

HETEROGENEOUS
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
003480 04-0

HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
000398 01-0

EXOBARBITAL
MECHANISM OF THE EFFECT OF ACUTE ETHANOL ON HEXOBARBITAL METABOLISM.
000074 01-03
EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03
HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04
THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03
THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03
THE MECHANISM OF THE EFFECT OF ACUTE STRESS ON HEXOBARBITAL METABOLISM.
002221 03-03
THE INTERACTION BETWEEN PILOCARPINE AND HEXOBARBITAL IN MALE RATS.
002551 03-04
THE EFFECTS OF PHENCYCLIDINE ON ETHANOL AND SODIUM HEXOBARBITAL IN MICE.
003290 04-03
CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
003505 04-05

XOBARBITONE
ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

XOKINASE
SOLUBILIZATION OF BRAIN MITOCHONDRIAL HEXOKINASE IN ANESTHESIA.
002402 03-03

1854
DOUBLE-BLIND CLINICAL COMPARISON OF HF-1854 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
000538 01-08

ERNATION
CHANGES IN CNS RESPONSIVENESS DURING HIBERNATION.
001136 02-03

CUPS
HICCUPS FOLLOWING INGESTION OF ORAL CHLORDIAZEPOXIDE.
000996 01-15

RARCHY
EFFECTS OF DIAZEPAM RELATED TO SOCIAL HIERARCHY IN RHESUS-MONKEYS.
000311 01-04

H-AFFINITY
PENTOBARBITAL AND SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC-ACID.
002333 03-03

H-DOSAGE
SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11

H-DOSE
HIGH-DOSE TREATMENT OF RATS WITH PERPHENAZINE-ENANTHATE.
001205 02-03
A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11
TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.
003788 04-15

HLIGHTS
THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
003873 04-17

HS
LITHIUM-CARBONATE AND ETHANOL-INDUCED HIGHS IN NORMAL SUBJECTS.
003734 04-14

OCAMPAL
ABOLITION OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION.
000347 01-04
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
001178 02-03
INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03
CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION).
002446 03-04
UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFECTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03
EARLY DEVELOPMENTAL CHANGES IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RELATION TO HIPPOCAMPAL FUNCTION.
003418 04-04
PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN
003447 04-04
EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04

HIPPOCAMPUS
EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
00003B 01-03
PATHOLOGIC EFFECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03
CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
00040B 01-04
CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03
PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-04

HISTAMINE
STIMULATION OF CEREBRAL HISTAMINE H2-RECEPTORS BY CLONIDINE.
000039 01-03
INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASE FROM BOVINE GRANULOCYTES.
000124 01-03
SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-09
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN.
001441 02-04
THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN.
002303 03-03

HISTIDINE-DECARBOXYLASE
THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-03

HISTOCHEMICAL
HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13
AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17
HISTOCHEMICAL AND MICROPUNCH ANALYSIS OF AMINERGIC AND CHOLINERGIC PATHWAYS. (UNPUBLISHED PAPER).
002266 03-03

HISTOLOGICAL
CENTRAL MECHANISMS OF ACTION OF P-CHLOROAMPHETAMINE: BIOCHEMICAL AND HISTOLOGICAL STUDIES. (PH.D. DISSERTATION).
000B43 01-13

HISTORY
OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND.
000B34 01-13

HOE-9B4
METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-9B4).
001154 02-03
CONTROLLED TRIAL OF NOMIFENSIN (HOE-984) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY.
003570 04-09

HOME
TREATMENT OF THE DEPRESSED PATIENT IN THE HOME.
00071B 01-10

HOMEOSTATIS
PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

HOMES
HELPING TO MAKE THE FINAL YEARS MEANINGFUL FOR THE ELDERLY RESIDENTS OF NURSING HOMES.
002859 03-14

DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY: A PILOT STUDY.
003770 04-15

HOMOCANNABINOID
CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME 8-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
003056 04-01

HOMOCARNOSINE
THE EFFECTS OF VARIOUS AGENTS IN VITRO ON HOMOCARNOSINE CARNOSINE SYNTHETASE FROM RAT BRAIN.
000187 01-03

HOMOGENATES
THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03

EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03

TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
002278 03-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
002358 03-03

ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03

HOMOGENOUS
PHARMACOLOGICAL AFTERCARE FOR HOMOGENOUS GROUPS OF PATIENTS.
003890 04-17

HOMOVANILLIC-ACID
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03

BRAIN HOMOVANILLIC-ACID: REGIONAL CHANGES OVER TIME WITH ANTIPSYCHOTIC DRUGS.
001152 02-03

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-03

EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03

EFFECTS OF DRUGS ON THE FORMATION OF HOMOVANILLIC-ACID IN THE RAT RETINA.
001418 02-03

REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03

TOLERANCE TO THE INCREASE OF STRIATAL HOMOVANILLIC-ACID ELICITED BY SEVERAL ANORECTIC DRUGS.
003186 04-03

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
003189 04-03

EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACID.
003647 04-11

HOMOVANILLIC-ACIDS
THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-

HONEY
EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA
001442 02-

HOPKINS
THE EFFECT OF SEQUENCE ON THE STABILITY OF THE HOPKINS SYMPTOM CHECKLIST (HSCL). (UNPUBLISHED PAPER).
002982 03-

HORIZON
PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON.
001796 02-

AMPHETAMINES: TIGHTER CONTROLS ON THE HORIZON.
002125 02

HORMONAL
EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHO IN RING DOVES (STREPTOPELIA-RISORIA).
000389 01

HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02

POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02

HORMONALLY
IS FEMININE DIFFERENTIATION OF THE BRAIN HORMONALLY DETERMINED?.
001368 02

HORMONE
THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBIT NARCOSIS IN THE MONKEY.
000145 01

THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01

NEUROPHARMACOLOGICAL TESTS WITH ALPHA-MELANOCYTE STIMULATING HORMONE.
000402 0

GROWTH HORMONE SECRETION IN CHRONIC SCHIZOPHRENIA.
000536 0

ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
000647 0

THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
000867 0

THYROID HORMONE AND DEPRESSION.
000871 0

EFFECT OF METHYLDOPA ON PROLACTIN AND GROWTH HORMONE.
000987 0

IS THE HYPOTHALAMIC HORMONE THYREOTROPE AN ANTIDEPRESSA AGENT?
001032 0

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMO ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 0

ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 0

MORPHINE-LIKE ANALGESIC EFFECT OF A PITUITARY HORMONE, BETA LIPOTROPIN.
001344 0

GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMON RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
001681 0

EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 0

INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAW SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001840 0

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 0

THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE. (PH.D. DISSERTATION).
002405 0

EFFECTS OF POSTTRIAL HORMONE INJECTIONS ON MEMORY PROCES
002455 0

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT
002485 03-04

ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH)
002494 03-04

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS. STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821 03-13

NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION
003117 04-03

THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION.
003341 04-04

THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA: A CONTROLLED STUDY.
003546 04-08

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION
003573 04-09

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
003615 04-11

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003804 04-15

HORMONES

SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
000133 01-03

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04

5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04

THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS.
000640 01-09

HORMONES, BEHAVIOR, AND PSYCHOPATHOLOGY: PAPERS FROM A MEETING.
002159 02-17

EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03

EFFECT OF NEUROHYPOPHYSEAL HORMONES ON MORPHINE-DEPENDENCE.
003311 04-03

GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-04

HYPOTHALAMIC RELEASING HORMONES AND BEHAVIOR.
003722 04-13

NEUROPSYCHOPHARMACOLOGICAL MODELS FOR OBJECTIVE ASSESSMENT OF CENTRAL EFFECTS OF HORMONES.
003870 04-17

HORN

DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03

EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGATA ON THE SPINAL DORSAL HORN NEURON.
002200 03-03

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS
003399 04-04

HORSES

STIMULATION OF FOOD INTAKE IN HORSES BY DIAZEPAM AND PROMAZINE
001452 02-04

HOSPITAL

CONTRIBUTION OF SLOW-RELEASE NEUROLEPTICS ON OPENING UP THE MENTAL HOSPITAL
000605 01-09

AMITRIPTYLINE IN PSYCHIATRIC THERAPY EIGHT YEARS OF USAGE IN HOSPITAL PRACTICE.
000656 01-09

NEUROLEPTIC TARDIVE-DYSKINESIAS: STUDY OF 1660 PATIENTS IN A PSYCHIATRIC HOSPITAL.
002019 02-15

USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN: SUMMARY
002626 03-08

USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY.
002628 03-08

CARE OF SCHIZOPHRENIC PATIENTS OUTSIDE THE HOSPITAL: RESEARCH RESULTS AND BASIC PRINCIPLES.
002631 03-08

TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-08

CASE STUDIES IN PSYCHIATRIC MANAGEMENT: HOSPITAL TO COMMUNITY.
002853 03-14

PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
002854 03-14

HOSPITALIZATION

NOCTRAN AS A SLEEP INDUCER DURING HOSPITALIZATION (BASED ON 50 CASES).
000503 01-07

HOSPITALIZED

USE OF ST-1191 IN HOSPITALIZED PATIENTS.
000679 01-10

TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 189 HOSPITALIZED PATIENTS.
000727 01-11

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-08

DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09

TWO DOSAGES OF IMIPRAMINE IN HOSPITALIZED ENDOGENOUS AND NEUROTIC DEPRESSIVES.
001778 02-09

PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA: AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
002688 03-09

DOXEPIN AND DIAZEPAM IN THE TREATMENT OF HOSPITALIZED GERIATRIC PATIENTS.
002770 03-11

TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENDED ACTION FORM OF BIPERIDEN HYDROCHLORIDE: 9 MONTH STUDY OF 55 HOSPITALIZED PATIENTS.
002787 03-11

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08

AMOXAPINE: A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF AMOXAPINE AND AMITRIPTYLINE IN DEPRESSED HOSPITALIZED PATIENTS.
003577 04-09

CARDIAC SIDE-EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
003830 04-15

HOSPITALS

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

OBSERVATIONS ON THE USE OF PSYCHOPHARMACOLOGY IN PSYCHIATRIC HOSPITALS.
001012 01-17

PSYCHOTROPIC DRUG USE IN FIVE CITY HOSPITALS.
002177 02-17

HUMAN

HUMAN ENDORPHIN: COMPARISON WITH PORCINE ENDORPHIN, ENKEPHALIN AND NORMORPHINE.
000006 01-01

DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-03

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
000491 01-07

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
000518 01-07

SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13

IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000814 01-13

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000829 01-13

BENZODIAZEPINES AND HUMAN SLEEP.
000839 01-13

INTERACTION OF SOME NEUROLEPTIC AND ANTIDEPRESSIVE AGENTS WITH HUMAN COERULOPLASMIN.
000841 01-13

HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-13

BENZODIAZEPINES AND HUMAN PERFORMANCE.
000900 01-14

THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

THE EFFECTS OF ALCOHOL AND DELTA9-TETRAHYDROCANNABINOL ON HUMAN PHYSICAL AGGRESSION.
000924 01-14

COMPARISON OF THE INHIBITION OF 5-HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
000933 01-15

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-15

GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA
001003 01-16

HUMAN SEDATIVE SELF-ADMINISTRATION. EFFECTS OF INTERINGESTION INTERVAL AND DOSE.
001046 01-17

MONOAMINE-OXIDASE, MONOAMINE-OXIDASE INHIBITING DRUGS AND HUMAN BEHAVIOR (UNPUBLISHED REPORT).
001061 01-17

DETERMINATION OF MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHODOLOGICAL ASPECTS.
001B96 02-13

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001B98 02-13

INACTIVITY OF ENKEPHALIN ON HUMAN SERUM ESTERASE.
001913 02-13

DISTRIBUTION OF LITHIUM BETWEEN ERYTHROCYTES AND PLASMA: IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES.
001915 02-13

HUMAN EEG SPECTRA BEFORE AND DURING CANNABIS HALLUCINATIONS.
001924 02-13

PHARMACOKINETICS OF LITHIUM IN HUMAN PLASMA AND ERYTHROCYTES.
001936 02-13

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS.
001967 02-14

THE INFLUENCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVEMENTS.
0020B5 02-

A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMA PLASMA AND CSF.
002086 02-

AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAI BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUD
002114 02

ANIMAL MODELS IN HUMAN PSYCHOBIOLOGY.
002161 02

PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING T ADDITION OF THROMBIN AND A23187. (UNPUBLISHED PAPER).
002804 03

THE BINDING OF PHENOTHIAZINES AND RELATED COMPOUNDS TO HUMAN SERUM ALBUMIN.
002828 03

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION: A COMPARAT KINETIC ANALYSIS.
002B46 03

HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND D ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002849 03

MARIHUANA AND HUMAN PHYSICAL ACTIVITY.
002B50 03

THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANC ALONE AND IN COMBINATION WITH ETHANOL.
00285B 03

TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002B79 03

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
003042 03

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED METABOLITE IN HUMAN PLASMA.
003653 04

EFFECT OF PSYCHOTROPIC AGENTS UPON THE BLASTOGENIC RESPONS OF HUMAN T-LYMPHOCYTES.
003656 04

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL BETA-ADRENERGIC ADENYLATE-CYCLASE.
003668 04

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
003684 04

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 0

EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE (3H)5-HYDROXYTRYPTAMINE BY HUMAN BLOOD PLATELETS.
003715 0

STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE.
003725 0

THE EFFECTS OF SELECTED ANTIPSYCHOTIC DRUGS ON HUMAN JUDGMENT.
003728 0

EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 0

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 0

NO EFFECTS OF QUATERNARY NEUROLEPTICS ON HUMAN PROLACTIN AND ADENYL-CYCLASE.
003BB1 0

HUMANS

COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS METABOLIS OF IMIPRAMINE IN HUMANS.
000850 0

CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COC ADMINISTRATION IN HUMANS.
000890 0

STUDY OF NOOANALEPTIC DRUG EFFECT ON BRAIN METABOLISM IN HUMANS.
000914 0

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT THE EFFICACY OF PROPRANOLOL.
001954 0

POLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH
00197B 0

THE EFFECTS OF NICOTINAMIDE UPON SLEEP IN HUMANS.
001988 0

PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP
001990 02-14
EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 02-14
THE EFFECT OF HALOPERIDOL ON EPINEPHRINE-STIMULATED ADENYLATE-CYCLASE IN HUMANS.
002209 03-03
DRUGS AS DISCRIMINATIVE EVENTS IN HUMANS.
002960 03-17

HUMORAL
EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001B8 01-03
EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
001558 02-04
THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 D4-04

HUNGER
DIFFERENCES BETWEEN THE ANOREXIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE -- POSSIBLE EFFECTS ON HUNGER AND SATIETY.
0D0291 01-04
THE EFFECT OF CHLORDIAZEPOXIDE ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS.
002476 03-D4

HUNGRY
EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04

HUNTINGTON
BROMOCRIPTINE IN HUNTINGTON CHOREA.
00D500 01-07
DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13

HUNTINGTONS
TRIAL OF A NEW THERAPY OF HUNTINGTONS CHOREA.
00D733 01-11
MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SUBSTRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 01-11
MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION.
001826 02-11
HALOPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT OF HUNTINGTONS CHOREA.
001893 02-13

HYBERBARIC
CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04-03

HYBRID
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03

HYBRIDS
HYPERACTIVITY IN TWO DOG BREEDS AND THEIR HYBRIDS.
003421 04-04

HYDERGINE
AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001832 02-11
NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02

HYDRATE
IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04
EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN.
003094 04-03

HYDRAZIDES
INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYDRAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID.
DD304B 04-D1

HYDRAZINE
TREATMENT OF PARKINSONISM WITH A COMBINATION OF L-DOPA AND METHYLDOPA HYDRAZINE.
000870 01-13

HYDROCARBON
HYDROCARBON OR SOLVENT INHALATION.
0D3834 04-15

HYDROCHLOROTHIAZIDE
COMPARATIVE DIURETIC ACTIVITY OF DELTA9 TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT
003285 04-03

HYDROCORTISONE
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-03

HYDROGEN
ENTHALPIES OF HYDROGEN BONDING IN PSYCHOTROPIC DRUGS.
000191 01-03

HYDROLYSIS
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES I: CHLORDIAZEPOXIDE AND DEMOXEPAM.
0D2258 03-03
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES II: OXAZEPAM AND DIAZEPAM.
003165 04-03

HYDROXIDE
THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
0D3D47 04-01

HYDROXYETHYL
PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
DD1117 02-02

HYDROXYINDOLEACETIC-ACID
THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
DD3176 D4-D3

HYDROXYLATED
THE SYNTHESIS OF POSSIBLE HYDROXYLATED METABOLITES OF 2-CHLOROPHENOTHIAZINE DERIVATIVES. (UNPUBLISHED PAPER).
DD1099 02-01

HYDROXYLATION
ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
0031B4 04-D3

HYDROXYMETHOXY
MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
DD2376 D3-03

HYDROXYZINE
HYDROXYZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL.
003614 04-11

HYPERACTIVE
REDUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-03
A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
DDD912 01-14
THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-14
STIMULANT RELATED STATE-DEPENDENT LEARNING IN HYPERACTIVE CHILDREN
D00922 01-14
HALOPERIDOL AND METHYLPHENIDATE IN HYPERACTIVE CHILDREN.
000927 D1-14
CARDIOVASCULAR RESPONSES OF HYPERACTIVE CHILDREN TO METHYLPHENIDATE.
001814 02-11
HYPERACTIVE CHILDREN
001855 02-11
EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN.
0D199B 02-14
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION. (ED.D. DISSERTATION).
002B60 03-14
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002863 03-14
ACTH4-1D: COGNITIVE AND BEHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING-DISABLED CHILDREN.
0D2872 D3-14

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN.
003633 04-11

EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11

AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN.
003670 04-13

HYPERACTIVITY

LITHIUM AND AMPHETAMINE HYPERACTIVITY IN RATS: DIFFERENTIAL EFFECT ON D AND L ISOMERS
000326 01-04

ALPHA-FLUPENTHIXOL-INDUCED HYPERACTIVITY BY CHRONIC DOSING IN RATS.
000412 01-04

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS AND HYPERACTIVITY IN CHILDREN.
001B47 02-11

HYPERACTIVITY: RESEARCH, THEORY, AND ACTION.
001B54 02-11

THE USE OF STIMULANT DRUGS IN THE TREATMENT OF HYPERACTIVITY.
002170 02-17

HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
0021B9 03-02

SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY. (PH.D. DISSERTATION).
002272 03-03

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

CLONIDINE-INDUCED LOCOMOTOR HYPERACTIVITY IN RATS.
002561 03-04

THERAPY FOR HYPERACTIVITY SEEN IN MINIMAL-BRAIN-DYSFUNCTION.
002763 03-11

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04

HYPERACTIVITY IN TWO DOG BREEDS AND THEIR HYBRIDS.
003421 04-04

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 04-04

BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AN ANIMAL MODEL OF HYPERACTIVITY STATES.
00351B 04-06

HYPERBARIC

INTERACTION BETWEEN HYPERBARIC AIR AND D-AMPHETAMINE EFFECTS ON PERFORMANCE.
000436 01-04

THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN.
001349 02-03

HYPERCALCAEMIA

LITHIUM, HYPERCALCAEMIA, HYPERMAGNESAEMIA, AND HYPERPARATHYROIDISM.
002026 02-15

HYPERGLYCEMIA

AGGRAVATION OF DIABETIC HYPERGLYCEMIA BY CHLORDIAZEPOXIDE.
003B3B 04-15

HYPERINOTROPIC

ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15

HYPERKINESIA

THERAPY WITH DIMETHYLAMINOETHANOL (DEANOL) IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL HYPERKINESIA.
002B01 03-13

RELATIONSHIP BETWEEN TARDIVE-DYSKINESIA, L-DOPA-INDUCED HYPERKINESIA AND PARKINSONISM.
0037B5 04-15

HYPERKINESIS

CENTRAL MONOAMINES AND HYPERKINESIS OF CHILDHOOD.
001B60 02-11

EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002B17 03-13

HYPERKINETIC

DEANOL IN THE TREATMENT OF HYPERKINETIC CHILDREN.
000BB4 01-14

MEDICATION FOR HYPERKINETIC CHILDREN.
000926 01-14

DRUG THERAPY IN THE HYPERKINETIC SYNDROME.
001B44 02-11

HYPERKINETIC SYNDROME.
001B63 02-11

CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002B30 03-13

PREDICTING THE RESPONSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002B52 03-14

COMPARATIVE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE IN HYPERKINETIC CHILDREN.
002B61 03-14

RELATIVE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN: AN INTERIM REPORT.
002B62 03-14

PRELIMINARY REPORT ON THE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN.
003620 04-11

HYPERKINETICS

IS THERE A ROLE FOR THE TEACHER IN THE USE OF MEDICATIONS FOR HYPERKINETICS
00090B 01-14

HYPERLACTACIDEMIA

BETA-BLOCKADE OF MORPHINE-INDUCED HYPERLACTACIDEMIA IN RABBITS.
001352 02-03

HYPERLITHEMIA

NONTOXIC HYPERLITHEMIA IN IMPENDING MANIA.
003B36 04-15

HYPERMAGNESAEMIA

LITHIUM, HYPERCALCAEMIA, HYPERMAGNESAEMIA, AND HYPERPARATHYROIDISM.
002026 02-15

HYPERMOTILITY

POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

NEUROANATOMICAL FOCUS FOR MORPHINE AND ENKEPHALIN-INDUCED HYPERMOTILITY.
003240 04-0

INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-0

HYPERPARATHYROIDISM

LITHIUM, HYPERCALCAEMIA, HYPERMAGNESAEMIA, AND HYPERPARATHYROIDISM.
002026 02-1

HYPERPLASIA

DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003B01 04-1

HYPERREACTIVITY

L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
000103 01-0

HYPERSENSITIVITY

RECEPTOR BLOCKADE AND RECEPTOR HYPERSENSITIVITY AFTER TREATMENT WITH NEUROLEPTICS.
001547 02-0

EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
0022B6 03-0

HYPERSEXUALITY

SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
001464 02-0

HYPERSOMNIA

HYPERSOMNIA IN MYOTONIC DYSTROPHY: TREATMENT WITH METHYLPHENIDATE.
003640 04-1

PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNDROME AND HYPERSOMNIA.
00374B 04-1

HYPERTENSION

THERAPEUTIC AMELIORATION OF ANXIETY RELATED HYPERTENSION AN ANGINA-PECTORIS.
0006B6 01-1

A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-07

DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03

HYPERTENSION AND CATECHOLAMINE DISTRIBUTION IN DIFFERENT PARTS OF THE RAT BRAIN.
002413 03-03

PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
002854 03-14

ON THE MECHANISM OF PULMONAL HYPERTENSION INDUCED BY ANOREXIC AGENTS.
003223 04-03

ANTIANXIETY DRUG TRIALS IN HYPERTENSION.
003609 04-10

EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION.
003742 04-14

ACUTE HYPERTENSION AFTER ABRUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION.
003833 04-15

HYPERTENSIVE

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04

HYPERTHERMIA

HYPERTHERMIA FOLLOWING SELF-STIMULATION OF THE MEDIAN RAPHE IN THE RAT.
0003B2 01-04

THE EFFECT OF LITHIUM-CHLORIDE ON MORPHINE-INDUCED AND PYROGEN-INDUCED HYPERTHERMIA IN RATS.
001161 02-03

THE STRESS-DEPENDENT NATURE OF APOMORPHINE HYPERTHERMIA.
001381 02-03

EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUCED HYPERTHERMIA IN NON-TOLERANT RATS.
003232 04-03

HYPERTHERMIC

DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03

HYPERTHYROID

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

HYPERTHYROIDISM

BETA-ADRENOCEPTOR BLOCKADE IN HYPERTHYROIDISM AND ANXIETY.
000714 01-10

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04

HYPERVENTILATION

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION. REPORT OF A CONTROLLED CLINICAL TRIAL.
001B39 02-11

HYPNOSIS

ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03

HYPNOTIC

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
00074B 01-11

THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
00087B 01-14

CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
0008B1 01-14

RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
000910 01-14

SLEEP DISTURBANCE AND HYPNOTIC DRUG DEPENDENCE.
001027 01-17

HAS SODIUM VALPROATE HYPNOTIC EFFECTS?.
001961 02-14

TRIAZOLAM: AN EFFECTIVE HYPNOTIC IN GENERAL PRACTICE.
001964 02-14

DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION
002034 02-15

FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS.
002093 02-16

HYPNOTIC EFFECTS OF DIXYRAZINE IN A DOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
002736 03-11

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-11

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
002778 03-11

SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5-ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02

HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES OF DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 04-14

COMPARATIVE EFFECTIVENESS OF NINE HYPNOTIC DRUGS: SLEEP LABORATORY STUDIES.
003737 04-14

HYPNOTICS

EFFECT OF HYPNOTICS ON MICE GENETICALLY SELECTED FOR SENSITIVITY TO ETHANOL.
000095 01-03

PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07

HYPNOTICS AND ETHANOL: RESIDUAL EEG EFFECTS.
000846 01-13

BARBITURATE HYPNOTICS, A TOO-FREQUENT AND NONSOOTHING PRESCRIPTION.
001043 01-17

DEMAND METHOD EVALUATION OF HYPNOTICS.
001676 02-07

NITRAZEPAM AND TEMAZEPAM: A COMPARATIVE TRIAL OF TWO HYPNOTICS.
001985 02-14

DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11

AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002868 03-14

CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
00291B 03-15

GLUTETHIMIDE -- AN UNSAFE ALTERNATIVE TO BARBITURATE HYPNOTICS.
002919 03-15

EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15

HYPODIPSIA

ON THE RELATION BETWEEN HYPODIPSIA AND ANOREXIA INDUCED BY (+) AMPHETAMINE IN THE MOUSE.
001472 02-04

HYPONATREMIA

POLYDIPSIA, HYPONATREMIA, AND SEIZURES IN PSYCHOTIC PATIENTS.
000968 01-15

DRUG-INDUCED HYPONATREMIA IN PSYCHOGENIC POLYDIPSIA.
002902 03-15

HYPORESPONSIVITY

HYPORESPONSIVITY OF CHRONIC SCHIZOPHRENIC PATIENTS TO DEXTROAMPHETAMINE.
002635 03-08

HYPOTENSION

THE REVERSAL OF CLONIDINE-INDUCED HYPOTENSION BY PROTRIPTYLINE AND DESIPRAMINE.
00024B 01-03

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION.
0020B2 02-15

HYPOTENSIVE

ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01

INVOLVEMENT OF CENTRAL ALPHA-ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL.
003208 04-03

THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE: STUDIES IN TETRAPLEGIC SUBJECTS.
003701 04-13

HYPOTHALAMIC

EFFECT OF HYPOTHALAMIC PHOSPHOLIPIDS ON PROLACTIN INCRETION.
000044 01-03

DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-03

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
000265 01-03

THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
000274 01-04

DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF-STIMULATION.
000335 01-04

ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
000346 01-04

IS THE HYPOTHALAMIC HORMONE THYREOTROPE AN ANTIDEPRESSANT AGENT?
001032 01-17

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03

EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-03

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04

DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION.
001934 02-13

EFFECTS OF ERGOT ALKALOIDS ON THE HYPOTHALAMIC PITUITARY AXIS.
002239 03-03

THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE.
002294 03-03

EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03

EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
0023B4 03-03

THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE. (PH.D. DISSERTATION).
002405 03-03

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04

EFFECTS OF PSYCHOTROPIC DRUGS UPON THE HYPOTHALAMIC RAGE RESPONSE IN CATS.
002493 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
0030B7 04-03

NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION
003364 04-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
003373 04-04

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION.
00342B 04-04

EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

HYPOTHALAMIC SELF-STIMULATION UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

HYPOTHALAMIC RELEASING HORMONES AND BEHAVIOR.
003722 04-13

HYPOTHALAMICALLY

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04

HYPOTHALAMUS

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS; SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVER GLYCOGEN SYNTHESIS.
001372 02-03

AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF-STIMULATION IN CAUDATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
0013B4 02-03

INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001426 02-03

EFFECTS OF NEUROLEPTICS ON TYROSINE-HYDROXYLASE OF SYNAPTOSOMES OF THE RAT HYPOTHALAMUS.
002314 03-03

DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03

EFFECTS OF 8ENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIM8IC SYSTEM AND HYPOTHALAMUS IN THE CAT BRAIN.
002386 03-03
THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE 8Y SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
002397 03-03
POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03
EFFECTS OF 1,4 8ENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
003474 04-04

HYPOTHERMIA
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON 8LOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03
HYPOTHERMIA INDUCED 8Y DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
000219 01-03
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED 8Y DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DI8ENZOPYRAN-9-ONE (LILLY-109514).
000398 01-04
SUPPRESSION OF AMPHETAMINE-INDUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-03
EFFECTS OF SEROTONERGIC DRUGS ON METHAQUALONE-INDUCED HYPOTHERMIA.
003102 04-03

HYPOTHERMIC
ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
000228 01-03
HYPOTHERMIC EFFECTS OF ANTIPSYCHOTIC PHENOTHIAZINES.
003335 04-03

HYPOTHESIS
PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
0000B1 01-03
THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A CRITICAL ANALYSIS.
000554 01-0B
THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A REVIEW.
00055B 01-08
CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01-09
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
000649 01-09
PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 02-13
CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPU8LISHED PAPER).
001962 02-14
URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
002798 03-12
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13
TESTING THE DA HYPOTHESIS WITH THE AID OF DRUGS.
003719 04-13
VERIFICATION OF THE MA HYPOTHESIS WITH THE AID OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 04-14

YPOTHYROID-LIKE
HYPOTHYROID-LIKE ALTERATIONS IN TESTOSTERONE METABOLISM IN ANOREXIA-NERVOSA.
001887 02-13

YPOTHYROIDISM
HYPOTHYROIDISM WITH EPISODIC PSYCHIATRIC AND CARDIAC MANIFESTATIONS.
002127 02-17

YPOXIA
A STUDY OF THE PROTECTIVE PROPERTIES OF SEGOLAN IN HYPOXIA.
001024 01-17
DELAY OF ONSET OF TRANSIENT AMNESIA AFTER HYPOXIA.
002416 03-04
EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH D DISSERTATION).
0025S0 03-04
THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF STIMULATION OF THE BRAIN DURING HYPOXIA
003342 04-04

HYPOXIC
EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-04

HYSTERIA
LITHIUM-CARBONATE IN PERSONALITY DISORDERS: A CASE OF HYSTERIA.
003753 04-14

HYSTERIA-LIKE
HYSTERICAL AND HYSTERIA-LIKE REACTIONS DURING NEUROLEPTIC TREATMENT FOR SCHIZOPHRENIA.
003036 03-17

HYSTERICAL
HYSTERICAL AND HYSTERIA-LIKE REACTIONS DURING NEUROLEPTIC TREATMENT FOR SCHIZOPHRENIA.
003036 03-17

H1-RECEPTORS
EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04

H2-RECEPTORS
STIMULATION OF CEREBRAL HISTAMINE H2-RECEPTORS BY CLONIDINE.
000039 01-03
EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2-RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04

H3-DIMETACRINE
DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03

H75-12
DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS.
002242 03-03

IATROGENIC
MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION.
003B56 04-17

ICELAND
DRUG PRESCRIPTION IN ICELAND.
003865 04-17

ICS
EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04

IDEATION
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
001980 02-14

IDENTICAL
LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001B13 02-11
IDENTICAL PSYCHOSIS IN A PAIR OF MONOZYGOTIC TWINS.
002966 03-17

IDENTIFICATION
IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE.
000046 01-03
IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000814 01-13
ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01
A NOTE ON THE ISOLATION AND IDENTIFICATION OF THE QUATERNARY ALKALOIDS OF PHELLODENDRON-WILSONII.
001098 02-01
IDENTIFICATION OF OPIATE/RECEPTOR BINDING IN VIVO.
001240 02-03

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04

THE IDENTIFICATION AND TREATMENT OF ADULT BRAIN DYSFUNCTION.
002143 02-17

MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

TOWARD THE OPERATIONAL IDENTIFICATION OF ADVERSE DRUG REACTIONS.
003800 04-15

IDENTIFIED

ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

IDENTIFYING

THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001004 01-16

IDIOPATHIC

STUDIES WITH BROMOCRIPTINE: PART 2. DOUBLE-BLIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07

IDRACILAMIDE

SUICIDE ATTEMPT IN A SUBJECT TREATED WITH IDRACILAMIDE.
002924 03-15

IGNORANCE

PSYCHOTROPIC DRUG USE IN THE ELDERLY: PUBLIC IGNORANCE OR INDIFFERENCE?.
002980 03-17

ILEUM

STRUCTURE-ACTIVITY RELATIONSHIPS OF ENKEPHALINS IN THE STIMULATED GUINEA-PIG ILEUM.
0011B0 02-03

SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

ILL

PSYCHIATRIC SYNDROMES IN CRITICALLY ILL PATIENTS.
000956 01-15

AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
001684 02-08

INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
00300B 03-17

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT: A CASE REPORT.
0035B7 04-10

ILLNESS

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
000589 01-09

PROLACTIN AND MENTAL ILLNESS.
000616 01-09

FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
000619 01-09

THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS.
000640 01-09

FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09

THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09

ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000849 01-13

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14

ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
002014 02-15

TARDIVE-DYSKINESIA AND DEPRESSIVE ILLNESS.
002029 02-15

BIOLOGICAL SUBSTRATES OF MENTAL ILLNESS.
002130 02-17

BIOCHEMICAL BASIS OF AN ANIMAL MODEL OF DEPRESSIVE ILLNESS -- A PRELIMINARY REPORT.
002381 03-03

DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-08

AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09

TOTAL AND NONBOUND TRYPTOPHAN IN UNIPOLAR ILLNESS.
002693 03-09

STUDIES OF CSF AMINE METABOLITES IN AFFECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002B12 03-1

URINARY CYCLIC-AMP IN RELATION TO LITHIUM TREATMENT IN MANIC-DEPRESSIVE ILLNESS.
002837 03-1

AMINERGIC FACTORS IN MENTAL ILLNESS.
002965 03-1

ADVANCES IN THE DRUG THERAPY OF MENTAL ILLNESS.
003045 03-1

ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY.
003351 04-0

ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION.
003503 04-0

PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-0

CLINICAL IMPLICATIONS OF IMIPRAMINE PLASMA LEVELS FOR DEPRESSIVE ILLNESS.
003560 04-0

LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
00356B 04-0

TOTAL AND NONBOUND PLASMA-TRYPTOPHAN IN DEPRESSIVE ILLNESS.
003663 04-1

THE DISCOVERY OF DRUG-INDUCED ILLNESS.
003799 04-1

ILLNESS-INDUCED

PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-0

ILLNESSES

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES
000670 01-0

BIOGENIC AMINE PRECURSORS AND AFFECTIVE ILLNESSES.
003551 04-0

ILLUMINATION

EFFECTS OF AMPHETAMINE AND ILLUMINATION ON ACTIVITY FOLLOWING FRONTAL ABLATION.
000356 01-0

THE EFFECTS OF D-AMPHETAMINE AND ILLUMINATION ON BEHAVIORS OF THE SQUIRREL-MONKEY.
001542 02-0

ILLUSION

EFFECTS OF SOME PSYCHOACTIVE DRUGS UPON THE TRAPEZOID ILLUSION PERCEPTION.
002856 03-1

THE EFFECT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUCED OCULOGYRAL ILLUSION.
003757 04-1

ILLUSTRATION

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-1

IMAGE

A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC.
002644 03-0

RESERPINE: MIRROR IMAGE OF THE ANTIDEPRESSANTS.
003901 04-1

IMBALANCE

ADRENERGIC CHOLINERGIC IMBALANCE IN AFFECTIVE DISORDERS.
003021 03-1

IMI

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-0

IMIDAZOISOINDOLE
ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT
003344 04-04

IMIDAZOLE
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2 ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07

IMIDAZOLIDINE
POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01

IMIDAZOLIDINETHIONES
SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIOIMIDAZOLINES.
003067 04-02

IMIDAZOLOCARBAMIDES
ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03

IMIPRAMINE
COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

REPEATED ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIDATE AND IMIPRAMINE.
000437 01-04

ANTAGONISM OF IMIPRAMINE POISONING BY ANTICONVULSANTS IN THE RAT.
000455 01-05

RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE AND RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN.
000592 01-09

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 01-09

DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10

COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS METABOLISM OF IMIPRAMINE IN HUMANS.
000B50 01-13

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
000909 01-14

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 02-03

ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
001143 02-03

KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 02-03

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
001506 02-04

EFFECTS OF IMIPRAMINE ON AUDITORY SENSITIVITY IN THE RAT IN RELATION TO INITIAL SENSITIVITY.
001523 02-04

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

IMIPRAMINE SEROTONIN-INDUCED MYOPATHY.
001632 02-05

EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 02-09

DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09

CORRELATION BETWEEN PLASMA AND CEREBROSPINAL LEVELS OF IMIPRAMINE.
001775 02-09

TWO DOSAGES OF IMIPRAMINE IN HOSPITALIZED ENDOGENOUS AND NEUROTIC DEPRESSIVES.
00177B 02-09

PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION: ENVIRONMENTAL AND GENETIC FACTORS.
001935 02-13

COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14

EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN
00199B 02-14

A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

SYMPATHOMIMETIC EFFECT OF SEROTONIN AND ACTION OF IMIPRAMINE AND PHTHORACIZINE ON THIS EFFECT.
002203 03-03

NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
0022B3 03-03

EFFECTS OF IMIPRAMINE, CHLORIMIPRAMINE, AND FLUOXETINE ON CATAPLEXY IN DOGS.
002421 03-04

COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002B13 03-13

IMIPRAMINE AND AGGRESSION.
002925 03-15

SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETICS IN RATS.
003092 04-03

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT BRAIN.
003174 04-03

EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN.
00321B 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PSYCHIATRIC ASPECTS.
003555 04-09

CLINICAL IMPLICATIONS OF IMIPRAMINE PLASMA LEVELS FOR DEPRESSIVE ILLNESS.
003560 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PHARMACOLOGICAL ASPECTS.
003574 04-09

IMIPRAMINE AND PHOBIA.
003593 04-10

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
00361B 04-11

IMIPRAMINE AND CHLORDIAZEPOXIDE IN ENURESIS.
003649 04-11

THE USE OF METHYLPHENIDATE AND IMIPRAMINE IN GILLES-DE-LA-TOURETTES DISEASE IN CHILDREN.
0037B2 04-15

IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-15

IMIPRAMINE-HCL
PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

IMIPRAMINE-N-OXIDE
INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

IMMATURE
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04

TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION.
001395 02-03

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
003303 D4-03

IMMERSION
ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03

CHANGES IN SERDTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
002398 03-03

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04

IMMOBILITY
EFFECTS OF SCDPOLAMINE AND PHYSOSTIGMINE ON TONIC IMMOBILITY IN DUCKS AND GUINEA-PIGS.
000453 01-04

AMPHETAMINE ATTENUATION OF TDNIC IMMOBILITY IN CHICKENS.
001449 02-04

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
0D15D6 02-D4

EFFECTS OF ANTICHOLINERGICS ON THE HABITUATION OF TONIC IMMOBILITY IN CHICKENS.
001511 02-D4

CHOLINERGIC BLOCKADE AND TONIC IMMOBILITY IN CHICKENS.
003387 D4-04

IMMUNE
MARIHUANA: NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
0D0795 01-12

DELTA1-TETRAHYDROCANNABINDL, CANNABIDIOL AND CANNABINOL EFFECTS ON THE IMMUNE RESPONSE OF MICE.
D03339 D4-03

IMMUNIZED
PHARMACOLOGIC RESPONSE TO PENTOBARBITAL IN ACTIVELY IMMUNIZED MICE.
0D3141 04-03

IMMUNOASSAY
MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
D01940 02-13

IMMUNODEPRESSIVE
IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER.
001628 D2-05

IMMUNOFLUORESCENCE
LOCALIZATION OF PHENOBARBITAL IN MOUSE CENTRAL-NERVOUS-SYSTEM BY IMMUNOFLUORESCENCE.
0D1327 02-03

IMMUNOREACTIVE
THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
D00867 01-13

IMPACT
SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION. (UNPUBLISHED PAPER).
D01173 02-D3

PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION)
0D2956 D3-16

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
003545 04-08

THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS.
0D3559 D4-09

THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY: A WEB OF PARADOXES.
003877 04-17

IMPAIR
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 4DB F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
0D2150 D2-17

IMPAIRED
IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
DD0158 01-D3

IMPAIRMENT
IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
00D269 D1-D3

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DI-N-PROPYLACETATE.
001533 02-04

CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.
002060 02-15

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
00282D 03-13

MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002867 03-14

IMPAIRMENTS
TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04

PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE -- ESPECIALLY LIGHT CDNSCIOUSNESS IMPAIRMENTS.
0D2895 03-15

IMPAIRS
DIAZEPAM IMPAIRS DRIVING SKILLS LESS THAN THIORIDAZINE.
002929 03-1

LORAZEPAM IMPAIRS DRIVING SKILLS.
002933 03-1

IMPENDING
NONTOXIC HYPERLITHEMIA IN IMPENDING MANIA.
D03836 04-1

IMPLANTATION
SYSTEMATIC ASSESSMENT OF TOLERANCE TD PENTOBARBITAL BY PELLET IMPLANTATION.
0D0342 01-0

INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-0

DISULFIRAM IMPLANTATION. PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS.
0D2003 02-1

REGIONAL ACETYLCHOLINE CONTENT IN MOUSE BRAIN AFTER MORPHIN TABLET IMPLANTATION.
003289 04-0

RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION.
003353 04-0

IMPLANTED
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
D00473 01-0

A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFEREN TYPES OF MORPHINE PELLETS.
002311 D3-0

IMPORTANT
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVA IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-0

IMPRESSIONS
FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION
002597 03-0

IMPROVEMENT
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001845 02-1

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
0D1906 02-

APHASIA IN A CHILD WITH EPILEPSY: IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT.
002752 03-

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B2D 03-

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEME IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002B63 03-

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
0D3524 04-

IMPULSE
DIFFERENTIAL EFFECTS OF LOW DOSES OF ETHANOL ON THE IMPULSE ACTIVITY IN VARIOUS REGIONS OF THE LIMBIC SYSTEM.
000142 01-03
EFFECT OF ETHANOL ON IMPULSE ACTIVITY IN ISOLATED CEREBELLUM.
001206 02-03

IMPULSES
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
001168 02-03

IMPULSIVE
THE EFFECT OF LITHIUM ON IMPULSIVE AGGRESSIVE BEHAVIOR IN MAN
001996 02-14

INACTIVATION
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04

INACTIVITY
INACTIVITY OF ENKEPHALIN ON HUMAN SERUM ESTERASE.
001913 02-13

INBORN
METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
003044 03-17

INBRED
EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
0013B0 02-03
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04
LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE.
001609 02-04
EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

INCIDENCE
EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15
TARDIVE-DYSKINESIA: MANIFESTATIONS, INCIDENCE, ETIOLOGY, AND TREATMENT.
002935 03-15
DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003B01 04-15

INCOORDINATION
A DEVICE FOR THE EVALUATION OF MOTOR INCOORDINATION IN RATS.
001439 02-04

INCREASING
TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

INCRETION
EFFECT OF HYPOTHALAMIC PHOSPHOLIPIDS ON PROLACTIN INCRETION.
000044 01-03

INCUBATED
EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-03

INCUBATION
THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

INDEPENDENCE
DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION. INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04

INDEPENDENT
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03
PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-04
INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN II AND CARBACHOL
003404 04-04

INDICATED
TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001869 02-12

INDICATION
ANOTHER INDICATION FOR HALOPERIDOL
001822 02-11

INDICATOR
THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13

INDICES
DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION
000352 01-04
EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001B29 02-11
ACTION OF PSYCHOLEPTICS ON SOME PHYSIOLOGICAL INDICES IN STUTTERERS.
00195B 02-14

INDIFFERENCE
PSYCHOTROPIC DRUG USE IN THE ELDERLY: PUBLIC IGNORANCE OR INDIFFERENCE?.
002980 03-17

INDIRECT
INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03

INDIVIDUAL
PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07
RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
000910 01-14
INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
002450 03-04
INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09
INDIVIDUAL DRUG SUPPLY IN A PSYCHOGERIATRIC WARD: AN EVALUATION OF THE SYSTEM.
003842 04-16

INDIVIDUALS
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001845 02-11
REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001880 02-13
MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION
00379B 04-15

INDOLE
METABOLISM OF INDOLE AMINES IN DEPRESSION
000617 01-09
INDOLE ALKALOIDS IN PLANT HALLUCINOGENS.
001073 01-17
REFLEXINE, A NEW INDOLE ALKALOID OF RAUWOLFIA-REFLEXA.
0010B3 02-01
A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04

INDOLEAMINE
MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS OF INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04

INDOLEAMINES
DIFFERENTIAL EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON INDOLEAMINES IN BRAIN
0023B0 03-03

INDOLETHYLAMINE
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01

INDOLIZINE
INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYDRAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID.
00304B 04-01

INDOLIZINE-2-CARBOXYLIC-ACID
INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYORAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID.
00304B 04-01

INDONESIA
TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11

INDUCE
INTERACTIONS BETWEEN NALOXONE AN0 NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INOUCE POLYOIPSIA.
001545 02-04
CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INOUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

INDUCED
ON THE SUPERSENSITIVITY OF DOPAMINE RECEPTORS, INDUCE0 BY NEUROLEPTICS.
000073 01-03
INHIBITORY EFFECTS OF PROPRANOLOL AN0 OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
0000B9 01-03
L-00PA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
000103 01-03
INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANOIN-F2ALPHA.
0001B3 01-03
HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
000219 01-03
CHARACTERISTICS OF SUSTAINE0 TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIOOS OR MELATONIN.
000265 01-03
NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS.
0002BB 01-04
INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONA0AL HORMONES.
0D0312 01-04
THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH.D. DISSERTATION).
000339 01-04
THE PAIN AGGRESSION INDUCED BY BRONOPOL IN THE RAT.
00D394 01-04
AGGRESSIVE BEHAVIOR INOUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
00042D 01-D4
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS INDUCED BY HALOPERIDOL.
DD043B 01-04
SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
0D0446 01-04
TOXICITY AN0 TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
00D454 01-D5
ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
0D0463 01-05
PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
D00475 01-06
EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000B26 01-13
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
0DDB27 01-13
A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
D00961 01-15
TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
0D114B 02-03
CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS.
001241 02-03
6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-03
A COMPARISON OF CIRCLING BEHAVIOUR INOUCED IN NIGROSTRIATAL LESIONE0 RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04
SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
001464 02-04
ON THE RELATION BETWEEN HYPODIPSIA AND ANOREXIA INDUCED BY (+) AMPHETAMINE IN THE MOUSE.
001472 02-04
CATALEPSY INDUCED BY MORPHINE OR HALOPERIDOL: EFFECTS OF APOMORPHINE AND ANTICHOLINERGIC DRUGS.
0014B1 02-04
SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04
EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INOUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
001535 02-04
ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INOUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04
HEA0 TWITCHES INDUCE0 BY BENZODIAZEPINES AND THE ROLE OF BIOGENIC AMINES.
001552 02-04
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY THE HALLUCINOGENS (-) DELTA9-TRANS-TETRAHYDROCANNABINOL AND N,N DIMETHYLTRYPTAMINE.
D01B67 02-12
INDUCED PSYCHOSIS FROM INGESTION OF DATURA-SUAVEOLENS.
001B71 02-12
DOSE-RELATED SLEEP DISTURBANCES INDUCED BY COFFEE AND CAFFEINE.
001973 02-14
DEPRESSIVE SYNDROME INDUCE0 BY ORAL CONTRACEPTIVES.
001979 02-14
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE
0019B2 02-14
REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
002D4B 02-15
SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17
HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
002189 03-02
EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03
EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
0D2270 03-03
COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-D3
EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS IN THE CAT BRAIN
0023B6 D3-03
EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
DD2431 03-04
DRINKING INDUCED BY PARENTERAL INJECTIONS OF PILOCARPINE.
DD2449 03-04
INFLUENCE OF 6-HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCE0 BY APOMORPHINE OR CLONIDINE IN RATS.
D02463 D3-04
EFFECTS OF L-5-HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
00247D 03-D4
ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS.
DD24B9 03-04
NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
D02505 D3-D4

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05

ANTICONVULSANT-INDUCED DYSKINESIAS: A COMPARISON WITH DYSKINESIAS INDUCED BY NEUROLEPTICS.
002B91 03-15

PHYSOSTIGMINE TREATMENT OF DELIRIUM INDUCED BY ANTICHOLINERGICS.
002903 03-15

DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-03

BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
003109 04-03

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04-03

ON THE MECHANISM OF PULMONAL HYPERTENSION INDUCED BY ANOREXIC AGENTS.
003223 04-03

ON THE MECHANISM OF ENHANCED SENSITIVITY TO HEPATOTOXIC AGENTS INDUCED BY ETHANOL.
003231 04-03

LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION :N PAIRS OF MONKEYS.
003410 04-04

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
003450 04-04

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

THE HEART-RATE RESPONSE AS AN INDICATOR OF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13

THE EFFECT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUCED OCULOGYRAL ILLUSION.
003757 04-14

INDUCER

NOCTRAN AS A SLEEP INDUCER DURING HOSPITALIZATION (BASED ON 50 CASES).
000503 01-07

INDUCING

PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

INDUCTION

MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
00010B 01-03

TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS
000370 01-04

INDUCTION OF PHYSICAL DEPENDENCE IN RATS BY SHORT INTERVAL MEDICATION.
000471 01-06

INDUCTION EFFECT OF DIAZEPAM ON ITS OWN METABOLISM.
000517 01-07

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
001212 02-03

IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 02-03

RESERPINE INDUCTION OF MOUSE-KILLING IN NONKILLER RATS.
001443 02-04

POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04

DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES?
002360 03-03

INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN.
002453 03-04

EFFECT OF ENZYME INDUCTION BY BARBITURATES ON NEUROHORMONE EXCRETION IN MAN.
002B39 03-13

INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION.
003353 04-04

NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

INERTIA

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11

INEXPENSIVE

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

INFANT

REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN.
000194 01-03

RELATIVE ROLE OF CATECHOLAMINES IN HEAD-SHAKING OF INFANT RATS.
000344 01-04

SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTROPIC DRUG USE DURING PREGNANCY.
002010 02-15

SPONTANEOUS AND AMPHETAMINE-INDUCED HEAD-SHAKING IN INFANT RATS.
002465 03-04

THE EFFECTS OF ANDROGEN ON WHEEL-SPINNING ACTIVITY IN INFANT RATS.
002537 03-04

INFANTS

DISEASE CAUSED BY DRUG THERAPY IN NEWBORN INFANTS.
000953 01-15

INFARCTION

RISK FACTORS FOR MYOCARDIAL INFARCTION IN YOUNG WOMEN
000966 01-15

INFERIOR

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

INFERTILITY

PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001B17 02-11

INFLUENCE

AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03

THE INFLUENCE OF PHENOBARBITAL ON BIOTRANSFORMATION OF 25-HYDROXYCHOLECALCIFEROL.
000066 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN
000149 01-03

INFLUENCE ON PSYCHOLEPTIC EFFECTS OF DIFFERENT TYPES OF SUBSTITUTIONS IN A SERIES OF CRESOTINIC AMIDES.
000151 01-03

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
DD0173 01-03

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
0D0176 D1-03

ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
D0D232 D1-D3

INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
DD0241 01-03

INFLUENCE OF DIAZEPAM AND PHENYTOIN ON PENICILLIN-INDUCED CEREBRAL CONVULSIONS.
000253 01-03

INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04

THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH.D. DISSERTATION).
000339 01-04

INFLUENCE OF PHYSOSTIGMINE UPON CONSOLIDATION OF MEMORY IN MICE.
000425 01-04

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-D6

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000826 01-13

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
0DD827 D1-13

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 D1-14

THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
0D1D7B 01-17

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
0D1159 D2-D3

INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
DD1168 02-03

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 D2-03

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 D2-D3

TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX
001355 D2-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

INFLUENCE OF DIELORIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE BRAIN.
001369 02-03

DOPAMINERGIC AGENTS: INFLUENCE ON SEROTONIN IN THE MOLLUSCAN NERVOUS SYSTEM.
001389 02-03

REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03

INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001426 02-03

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04

DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04

THE INFLUENCE OF MEPROBAMATE ON HEART-RATE IN THE CONSCIOUS DOG.
001615 02-05

MEDICAL AND SOCIAL INFLUENCE OF PHARMACOTHERAPY AGAINST SCHIZOPHRENIA.
001699 02-08

THE PLACENTAL TRANSFER OF DRUGS DURING CHILDBIRTH. A POSSIBLE INFLUENCE ON THE NEWBORN.
001892 02-13

INFLUENCE OF CANNABIDIOL ON SECOBARBITAL EFFECTS AND PLASMA KINETICS.
001902 02-13

PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14

INFLUENCE OF ORAL CONTRACEPTION ON SEXUAL RESPONSE.
002020 02-15

THE INFLUENCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVEMENTS.
002085 02-15

INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
002223 D3-03

REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 D3-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE.
002294 03-03

THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN
D02303 D3-03

INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
002389 D3-03

THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
002397 03-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS UPON EMOTIONS.
002432 D3-04

INFLUENCE OF 6-HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
002463 03-04

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR
002530 D3-04

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
DD2547 03-04

DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN.
002701 D3-09

INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
00290B 03-15

THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA
003011 03-17

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN
003132 04-03

INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT.
003135 04-03

INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT BRAIN
003174 04-03

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

NEUROPEPTIDES: INFLUENCE OF ACUTE AND CHRONIC EFFECTS OF OPIATES.
003199 04-03

INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03

THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03

INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
00333B 04-03

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

PSYCHOPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003B60 04-17

INFLUENCES

NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS.
000405 01-04

SEROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
00044B 01-04

HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-04

INFLUENCING

FACTORS INFLUENCING TOLERANCE TO D-AMPHETAMINE-INDUCED ANOREXIA IN RATS.
0003B4 01-04

INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000B76 01-14

PHARMACOLOGICAL SUBSTANCES INFLUENCING ACQUISITION BEHAVIOR IN RATS.
00092B 01-14

INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001B40 02-11

FACTORS INFLUENCING PLASMA DRUG CONCENTRATIONS.
0036B5 04-13

VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13

FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM
003904 04-17

INFORMATION

THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17

THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNDROME
002901 03-15

SASKATCHEWAN DIAL-ACCESS DRUG INFORMATION SERVICE
002970 03-17

INFORMED

PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT (PH.D. DISSERTATION).
002956 03-16

INFUSION

ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
00045B 01-05

TRH BY SLOW, CONTINUOUS INFUSION: AN ANTIDEPRESSANT?.
0017B1 02-09

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

INFUSIONS

PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
00041B 01-04

COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001503 02-04

CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04

INGESTION

HICCUPS FOLLOWING INGESTION OF ORAL CHLORDIAZEPOXIDE.
000996 01-15

SUSTAINED INGESTION OF METHADONE AND THE SLEEP OF MONKEYS.
0015B6 02-04

INDUCED PSYCHOSIS FROM INGESTION OF DATURA-SUAVEOLENS.
001B71 02-12

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN.
003299 04-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY.
003351 04-04

PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04-15

INHALATION

CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING.
0015BB 02-04

SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATION UPON RAT OFFSPRING.
001622 02-05

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

HYDROCARBON OR SOLVENT INHALATION.
003B34 04-15

INHIBITED

RESTORATION OF SELF-STIMULATION INHIBITED BY NEUROLEPTICS.
001414 02-03

INHIBITING

MONOAMINE-OXIDASE, MONOAMINE-OXIDASE INHIBITING DRUGS AND HUMAN BEHAVIOR (UNPUBLISHED REPORT).
001061 01-17

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME
003352 04-04

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVEgDYSKINESIA.
003615 04-11

INHIBITION

THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

INHIBITION OF RAT BRAIN MONOAMINE-OXIDASE BY FORMAMIDINES AND RELATED COMPOUNDS.
000048 01-03

ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03

INHIBITION OF ACETAMINOPHEN GLUCURONIDATION BY OXAZEPAM.
000093 01-03

BENZODIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03

MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
000108 01-03

INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASE FROM BOVINE GRANULOCYTES.
000124 01-03

ANTAGONISM OF GABA-MEDIATED INHIBITION IN THE CENTRAL-NERVOUS-SYSTEM BY CAPROLACTAM DERIVATIVES.
000140 01-03

INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
000155 01-03

INHIBITION OF MONOAMINE-OXIDASE BY AMPHETAMINE AND RELATED COMPOUNDS.
000163 01-03

INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES.
D00213 01-03

SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03

BRAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHIBITION.
0D0252 01-D3

THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
D0D274 01-04

INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
DD0312 01-D4

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
D00359 01-04

AMINO-ACID TRANSPORT INHIBITION: BRAIN AND BEHAVIORAL CORRELATES.
00D406 01-D4

EFFECTS OF ANTICHOLINERGIC AGENTS ON CONDITIONED INHIBITION IN THE RAT. (PH.D. DISSERTATION).
00044D 01-04

COMPARISON OF THE INHIBITION OF 5-HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
00D933 01-15

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 D2-D3

NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-D3

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
D01192 02-D3

INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
001212 02-D3

INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
D01213 02-03

INHIBITION OF CATECHOLAMINE BIOSYNTHESIS AND MEMORY PROCESSES.
001214 D2-03

TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-03

ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM.
0012B0 02-03

INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02-03

RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03

TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03

ON THE SELECTIVE INHIBITION OF SEROTONIN UPTAKE IN VIVO BY ORG-6582.
001393 02-03

LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
001398 02-03

PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
001400 02-03

ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
00142B 02-03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 D2-03

INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
001466 02-04

CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
D01524 02-04

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
0D1551 02-04

INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-D4

CORRELATION OF BEHAVIOURAL INHIBITION OR EXCITATION PRODUCED BY BROMOCRIPTINE WITH CHANGES IN BRAIN CATECHOLAMINE TURNOVER.
0D1585 D2-04

INHIBITION OF MORPHINE EFFECTS BY SYNTHETIC SUBSTANCE-P.
001594 02-D4

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
DD1652 D2-06

DOPAMINE-INDUCED INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA.
0019DD D2-13

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
0D1952 02-13

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002D95 02-16

MONOAMINE-OXIDASE AND ITS INHIBITION.
002179 02-17

TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
0D2278 03-03

BETA-ENDORPHIN IN VITRO INHIBITION OF STRIATAL DOPAMINE RELEASE.
002298 D3-D3

SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
DD2354 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 D3-03

CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
DD250B D3-D4

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION A COMPARATIVE KINETIC ANALYSIS.
002846 03-13

INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION.
003051 04-01

THE INHIBITION OF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
003074 04-02

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
003087 04-03

BINDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITION BY MORPHINE OR NALOXONE.
003089 04-03

NALOXONE-INDUCED INHIBITION OF ETHANOL DEPENDENCE IN MICE.
003100 04-03

STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
003138 04-03

WHEN DOES INHIBITION OF BRAIN ACETYLCHOLINESTERASE CAUSE AMNESIA IN RATS?
003152 04-03

BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04-03

PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
003239 04-03

ANTICONVULSANT ACTION OF DIAZEPAM: INCREASE OF CORTICAL POSTSYNAPTIC INHIBITION.
003246 04-03

MECHANISMS OF EXCITATION AND INHIBITION IN THE NIGROSTRIATAL SYSTEM.
003250 04-03

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN.
003255 04-03

INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03

INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03

INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE.
003334 04-03

THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF-STIMULATION OF THE BRAIN DURING HYPOXIA.
003342 04-04

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04

INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE
003654 04 13

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

INHIBITOR

INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000089 01-03

3-ISOXAZOLIDONE -- AN INHIBITOR OF GABA METABOLISM.
000113 01-03

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03

SOME BEHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA-TRANSAMINASE.
0002B5 01-04

BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE DECARBOXYLASE INHIBITOR RO-4-4602.
000295 01-04

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION.
000340 01-04

ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECARBOXYLASE INHIBITOR.
000745 01-11

L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-486) IN PARKINSONISM.
000767 01-11

L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
000B01 01-13

ON THE EFFECT OF DOPA-DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM.
000970 01-15

THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-03

THE EFFECT OF L-DOPA AND AN INHIBITOR OF PERIPHERAL DECARBOXYLATION ON GLUCOSE METABOLISM IN BRAIN.
001405 02-03

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
00235B 03-03

EFFECTS OF A CARBONIC-ANHYDRASE INHIBITOR ON CEREBRAL BLOOD FLOW IN GERIATRIC PATIENTS.
002606 03-07

TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1RB.
002672 03-09

COMBINING TRICYCLIC AND MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS.
002936 03-15

NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01

PROCAINE HYDROCHLORIDE AS A MONOAMINE-OXIDASE INHIBITOR: IMPLICATIONS FOR GERIATRIC THERAPY.
00314B 04-03

EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RAT BRAIN 5-HT TURNOVER.
003179 04-03

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-03

SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
003330 04-03

INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
003709 04-13

INHIBITORS
EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS ON THERMOREGULATION IN RESERPINE-TREATED RATS.
000010 01-01
SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03
EFFECT OF SOME PHOSPHODIESTERASE INHIBITORS ON CENTRAL DOPAMINE MECHANISMS.
000100 01-03
DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE.
000513 01-07
TOWARDS RATIONAL THERAPY WITH MONOAMINE-OXIDASE INHIBITORS.
000715 01-10
(SPIRO(PIPERIDINETHIAZOLE) 3,2-A)PYRIMIDINES): ANTIDEPRESSANTS AND PLATELET-AGGREGATION INHIBITORS.
001116 02-02
A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIOR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN.
001224 02-03
MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 02-03
POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03
EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-04
EFFECT OF TWO INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE ON MATURATION OF MEMORY IN MICE.
001487 02-D4
ANTIAGGRESSIVE ACTION OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN MICE.
0D1571 02-04
MONOAMINE-OXIDASE INHIBITORS: POTENTIAL FOR DRUG ABUSE.
001B76 02-12
SELECTIVITY OF 4-METHOXYPHENETHYLAMINE DERIVATIVES AS INHIBITORS OF MONOAMINE-OXIDASE.
002279 03-03
THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY.
0D2439 D3-D4
MAO INHIBITORS: POTENTIAL FOR DRUG ABUSE. (UNPUBLISHED PAPER).
002B76 03-14
TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
D03219 04-03
IN VITRO STUDIES OF SOME CHLORPROMAZINE METABOLITES AS POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
D03265 04-03
VERIFICATION OF THE MA HYPOTHESIS WITH THE AID OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 D4-14

INHIBITORY
INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
DDD0B9 D1-03
MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03
ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03
ANALYSIS OF INHIBITORY EFFECT OF DOPAMINE ON CAROTID BODY CHEMORECEPTORS IN CATS.
DD0215 01-D3
AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
0D0343 01-04
NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS
001141 02-03
TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 D2-D3
THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 D2-D4
ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04
HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03
INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
0024B7 03-04
INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04
TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
0D3456 04-04

INHIBITS
ENKEPHALIN INHIBITS FIRING OF MYENTERIC NEURONES.
001634 D2-05
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03
CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 D4-03

INITIAL
DEPRESSION TREATED WITH FG-4963: RESULTS FROM AN INITIAL EXPERIMENT.
00D614 01-09
INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
0D0723 01-11
CLOZAPINE: REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT.
001412 02-03
EFFECTS OF IMIPRAMINE ON AUDITORY SENSITIVITY IN THE RAT IN RELATION TO INITIAL SENSITIVITY.
D01523 02-04
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13
INITIAL CLINICAL EVALUATION OF MODITEN-DEPOT.
002659 03-0B
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION
0D2B63 03-14
DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002B93 03-15
INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX.
003131 04-03
INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
D03709 04-13

INITIATION
THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
D00776 01-11
PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
D00962 01-15
ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
DD2437 03-D4
EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 D4-04

INJECTABLE
THERAPY WITH INJECTABLE FLUPHENAZINES.
0D2611 03-DB

INJECTED
BIOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACEREBRALLY INJECTED CHOLINE.
001127 D2-03
EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION.
D01245 02-03
HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
DD21B9 03-D2
SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
DD3399 D4-04

ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE
003433 04-04

JECTION

HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02

PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D-AMPHETAMINE-SULFATE.
000088 01-03

BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
000378 01-04

TIME-DEPENDENT EFFECTS PRODUCED IN CHICKS AFTER PRENATAL INJECTION OF METHYLMERCURY.
000461 01-05

UPTAKE OF 5-HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION.
001187 02-03

THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03

RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03

TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION.
001395 02-03

BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04

FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF 5,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
001629 02-05

MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP.
002232 03-03

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
002457 03-04

BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

NEONATAL ANDROGEN INJECTION CHANGES OPEN-FIELD BEHAVIOR OF MICE.
003402 04-04

ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06

CLINICAL PHARMACOKINETICS OF LORAZEPAM. II. INTRAMUSCULAR INJECTION.
003675 04-13

ECTIONS

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN
0000B6 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN
0000B7 01-03

SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
000368 01-04

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
000491 01-07

EFFECT OF FOOD AND REPEATED INJECTIONS ON SERUM DIAZEPAM LEVELS.
000B40 01-13

DDC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OF DL-DOPS
001232 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY
001454 02-04

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
001506 02-04

BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS.
001527 02-04

CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
001598 02-04

THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE.
002294 03-03

ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04

MORPHINE INJECTIONS IN THE TASTE-AVERSION PARADIGM.
002443 03-04

DRINKING INDUCED BY PARENTERAL INJECTIONS OF PILOCARPINE.
002449 03-04

SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

EFFECTS OF POSTTRIAL HORMONE INJECTIONS ON MEMORY PROCESSES.
002455 03-04

CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS.
002456 03-04

AFFECTIVE STATES ASSOCIATED WITH MORPHINE INJECTIONS.
002528 03-04

CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-05

EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS.
003122 04-03

RIGIDITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-03

UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE AND METHACHOLINE ON THE APOMORPHINE-INDUCED GNAWING IN THE RABBIT.
0034B5 04-04

INJURIES

CORRELATION BETWEEN INJURIES DUE TO ACCIDENT AND USE OF ALCOHOL OR DRUGS.
00201B 02-15

INNER

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 03-04

INNERVATION

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

INOTROPIC

RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03

INPATIENT
THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
D00553 D1-08
THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
D0DB7B 01-14
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003841 04-16

INPATIENTS
EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS.
00D755 01-11
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
D01843 D2-11
A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
DD36D3 D4-10

INPUT
ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04
HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03

INSECT
METABOLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
003083 04-03

INSIDE
PRISON RESEARCH: THE VIEW FROM INSIDE.
003869 04-17

INSOMNIA
TWO OCCULT CAUSES OF INSOMNIA AND THEIR THERAPEUTIC PROBLEMS.
000460 01-05
PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07
PHARMACOLOGICAL THERAPY OF INSOMNIA.
000780 D1-11
TREATMENT OF INSOMNIA.
000901 01-14
COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA -- A PILOT EXPERIMENT.
0D1864 02-11
INSOMNIA AND ITS TREATMENT.
001971 02-14
AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002709 03-10
AMITRIPTYLINE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002716 D3-1D
PSYCHOTHERAPEUTIC AND CHEMOTHERAPEUTIC RELATIONS IN INSOMNIA.
002727 03-1D
THE BEHAVIORAL TREATMENT OF INSOMNIA: AN ALTERNATIVE TO DRUG THERAPY.
DD3B21 D4-15

INSOMNIAC
CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
0DD8B1 01-14

INSOMNIACS
THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
0DD878 D1-14

INSTITUTION
SOME STUDIES IN AN INSTITUTION FOR THE MENTALLY RETARDED.
DD1B59 D2-11
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
DD2956 03-16

INSTITUTIONALIZED
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
0D1040 01-17

INSTRUMENT
INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY.
D02768 03-11

INSTRUMENTALLY
THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-0

INSUFFICIENCY
TREATMENT OF CEREBRAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
000786 D1-1
DRUG THERAPY IN CHRONIC CEREBROVASCULAR INSUFFICIENCY IN THE ELDERLY.
D01B37 D2-1
PSYCHIATRIC PHARMACOTHERAPY IN RENAL INSUFFICIENCY.
002016 02-1
THYROID INSUFFICIENCY IN THE COURSE OF LITHIUM THERAPY.
002081 02-1

INSUFFICIENT
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-1

INSULIN
THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
000867 01-1
EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
001329 02-0

INSURANCE
PHARMACOTHERAPY AND MEDICAL INSURANCE.
003000 03-1

INTACT
THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTAC AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
003286 04-0

INTAKE
THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
DDD3D4 D1-0
HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-1
EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AN SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
0D1162 D2-0
THE EFFECT OF LITHIUM ON FOOD INTAKE IN RATS.
D01317 02-0
STIMULATION OF FOOD INTAKE IN HORSES BY DIAZEPAM AND PROMAZINE
DD1452 02-0
A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
0D1529 02-D
EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE
002544 D3-0
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE INTAKE OF ETHANOL AND SACCHARIN SOLUTIONS.
003463 04-0

INTEGRATED
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
DD0649 01-D
PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
0D3B63 D4-1

INTENSE
SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
DD251D D3-0

INTENSIFICATION
INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-0

INTENSITIES
EFFECTS OF PENTOBARBITAL ON PUNISHED BEHAVIOR AT DIFFERENT SHOCK INTENSITIES.
001607 02-0

INTENSITY
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT (PH.D. DISSERTATION)
D00336 01-0
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-

COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE
001277 02-03

EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002B17 03-13

EFFECTIVENESS OF ATRIAL PACING IN MACACA MULATTA AS A FUNCTION OF PACING PULSE INTENSITY MODIFICATION 8Y ATROPINE AND PROPRANOLOL.
003270 04-03

EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN
003365 04-04

TENSIVE

THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
003843 04-16

TERACT

A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
001494 02-04

TERACTION

INTERACTION OF BETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
000002 01-01

INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
00011B 01-03

THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
000129 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL DOPAMINE NEURONS.
00035B 01-04

INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANEOUS ALTERNATION TASK.
000361 01-04

INTERACTION BETWEEN HYPERBARIC AIR AND D-AMPHETAMINE EFFECTS ON PERFORMANCE.
000436 01-04

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY.
000693 01-10

INTERACTION OF SOME NEUROLEPTIC AND ANTIDEPRESSIVE AGENTS WITH HUMAN COERULOPLASMIN.
000841 01-13

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

INTERACTION OF CENTRAL-NERVOUS-SYSTEM DRUGS WITH SYNAPTOSOMAL TRANSPORT PROCESSES.
001160 02-03

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
001188 02-03

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN
001204 02-03

EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTION WITH P-CPA ON RAT BRAIN 5-HT
001211 02-03

IN VITRO METABOLISM OF AMPHETAMINE: AN APPARENT ENANTIOMERIC INTERACTION.
001217 02-03

INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED 8Y THEIR EFFECTS ON PGO WAVES IN THE CAT
001230 02-03

MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN METAL BINDING AND FLUORESCENCE STUDIES.
00132B 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

8EHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
001385 02-03

ALCOHOL MEMBRANE INTERACTION IN THE BRAIN NOREPINEPHRINE RELEASE.
001394 02-03

INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
001408 02-03

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON SOCIAL INTERACTION IN RATS.
001484 02-04

SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION.
001493 02-04

INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOURS IN RODENTS.
001519 02-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM.
001521 02-04

INTERACTION OF DRUG EFFECTS WITH TESTING PROCEDURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04

DYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WITH PRIOR METHADONE TREATMENT.
001619 02-05

STUDIES ON THE INTERACTION OF CHLORDIAZEPOXIDE, DIAZEPAM, AND NITRAZEPAM WITH PHENPROCOUMON.
001627 02-05

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY.
001909 02-13

INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION.
001977 02-14

ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES.
002184 03-01

SOME EFFECTS OF INTERACTION OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS.
002295 03-03

INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
002297 03-03

INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN.
002320 03-03

INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-04

INTERACTION OF BRADYKININ WITH DOPAMINERGIC RECEPTORS IN THE CNS.
002507 03-04

THE INTERACTION BETWEEN PILOCARPINE AND HEXOBARBITAL IN MALE RATS.
002551 03-04

CURRENT STATE OF RESEARCH ON PROPRANOLOL OPIATE INTERACTION.
002757 03-11

THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002B57 03-14

INTERACTION OF ALCOHOL WITH PSYCHOTROPIC DRUGS.
002973 03-17

INTERACTION OF SERYLTRIHYDROXYBENZYLHYDRAZINE WITH L-DOPA-DECARBOXYLASE FROM PIG KIDNEY.
003103 04-03

THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DDPAMINERGIC INTERACTION.
003268 04-03

THE INTERACTIDN BETWEEN CLONIDINE AND VARIOUS NEUROLEPTIC AGENTS ANO SOME BENZOOIAZEPINE TRANQUILLIZERS.
003312 04-03

EFFECT OF TRYPTAMINE ANTAGONISTS ON SELF-STIMULATION: INTERACTION WITH AMPHETAMINE.
003386 04-04

INTERACTIDN BETWEEN YOHIMBINE ALKALOIDS AND AMPHETAMINE IN MICE.
003501 04-D5

THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTONIN BINDING PROTEIN
003517 04-D6

A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS DF MOOD AND ATTENTION.
DD3525 04-D7

SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTERACTION WITH AMPHETAMINE SULFATE.
003688 04-13

INTERACTION OF PERPHENAZINE WITH THE KINETICS OF NORTRIPTYLINE.
DD3695 04-13

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACDLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLDGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
003703 D4-13

A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, DRUGS, AND THEIR INTERACTION
003766 D4-15

INTERACTIONS

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
0DD12B 01-D3

BEHAVIORAL DEPRESSION: THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS.
000307 D1-04

INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
D00467 D1-D6

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 D1-13

ALCOHOL DRUG INTERACTIONS IN DAILY MEDICAL PRACTICE.
000974 D1-15

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA-LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
DD1147 D2-03

INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
0012D7 02-D3

INTERACTIONS BETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 02-04

ASSESSING INTERACTIONS OF ENVIRONMENT X DRUG.
001596 02-04

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
DD1648 02-D6

BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
0D1665 D2-07

INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART RATE, AND SKIN CONDUCTANCE.
0019B2 D2-14

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION
002260 03-D3

CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SUBSTANTIA-NIGRA IN THE RABBIT.
002557 03-D4

CHARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES AND RELATED DRUGS WITH LIPIDS BY UV-SPECTROPHOTOMETRY.
002583 03-06

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
0025B7 03-D6

AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
0D2674 03-09

DRUG INTERACTIONS OF THE COMPONENTS OF OPTALIDON AFTER ORAL ADMINISTRATION.
002B23 03-13

PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTERACTIONS OF ALCOHOL AND OXAZEPAM WITH REGARD TO RESPONSE BEHAVIOR.
002880 03-14

INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
003008 03-17

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-0

DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE.
003245 04-0

DIFFERENTIAL INTERACTIONS OF PHENDBARBITAL AND PENTOBARBITAL WITH BETA-ADRENERGIC MECHANISMS IN VITRO AND VIVD.
003262 04-0

INTERACTIONS BETWEEN DELTA9-TETRAHYDROCANNABINOL AND PHENCYCLIDINE HYDROCHLORIDE IN RATS.
DD3445 D4-0

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
0034B9 04-0

INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
0D3495 D4-0

STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE.
003725 04-1

DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY: A PILOT STUDY.
0D3770 04-1

GUIDE TO DRUG INTERACTIONS.
003806 D4-1

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-1

INTERCEPTORS

THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-0

INTERDEPENDENCE

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDE AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-0

INTERFERENCE

EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 D1-0

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENC WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-0

DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
D03448 D4-0

ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION
0D3503 D4-0

INTERFERON

ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
D001D6 01-0

INTERINDIVIDUAL

COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUA VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONI DURETTER).
003699 D4-1

INTERINGESTION

HUMAN SEDATIVE SELF-ADMINISTRATION: EFFECTS OF INTERINGESTION INTERVAL AND DOSE.
001D46 01-1

INTERMALE

FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION
00D404 D1-0

INTERMEDIATE

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
000748 D1-1

EFFECTIVENESS OF INTERMEDIATE TERM USE OF SECOBARBITAL.
D01972 D2-1

NTERMITTENT
CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING.
001588 02-04
EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS
002513 03-04
INTERMITTENT PSYCHOPHARMACOTHERAPY: REVIEW OF LITERATURE AND CRITICAL REMARKS.
00265B 03-08

NTERMITTENTLY
EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
002458 03-04

NTERNAL
PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000852 01-13
INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION.
001977 02-14
SOCIOPATHY: AN EXPERIMENT IN INTERNAL ENVIRONMENTAL CONTROL.
002737 03-11
OPIATE RECEPTORS AND INTERNAL OPIATES.
0032B4 04-03
RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04-04

NTERNATIONAL
INTRODUCTORY REMARKS AT INTERNATIONAL SYMPOSIUM ON NON-STRIATAL DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).
001BB1 02-13
THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17
SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS.
002142 02-17
PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY.
002959 03-17
THE LITHIUM LIBRARIAN: AN INTERNATIONAL INDEX.
003B64 04-17

NTERNEURONES
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

NTERNEURONS
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03

NTERPERSONAL
THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
00353B 04-0B

NTERPHASE
CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-0B

NTERSHOCK
SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04

NTERSPECIFIC
EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK.
002276 03-03

NTERSTIMULUS
DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL.
003673 04-13

NTERTRIAL
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04

NTERVAL
SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04
INDUCTION OF PHYSICAL DEPENDENCE IN RATS BY SHORT INTERVAL MEDICATION
000471 01-06
THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES (PH.D. DISSERTATION).
000903 01-14
HUMAN SEDATIVE SELF-ADMINISTRATION. EFFECTS OF INTERINGESTION INTERVAL AND DOSE.
001046 01-17
VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY.
001454 02-04
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04
DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL.
003673 04-13

INTERVENTION
PSYCHOACTIVE DRUG CRISIS INTERVENTION.
002947 03-15

INTERVENTIONS
BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
000730 01-11

INTERVIEWS
TREATMENT OF VAGINISMUS BY I.V. DIAZEPAM (VALIUM) ABREACTION INTERVIEWS.
001764 02-09
STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
001772 02-09
TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003841 04-16

INTESTINAL
THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
000129 01-03

INTOXICATION
RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION.
000029 01-03
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04
PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION
000466 01-05
HERBAL INTOXICATION: PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
0009B4 01-15
RENAL ELIMINATION OF LITHIUM IN RATS WITH LITHIUM INTOXICATION
001403 02-03
EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05
REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF PROPRANOLOL.
001954 02-14
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
001980 02-14
DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION.
002034 02-15
THREE CASES OF CHRONIC PENTAZOCINE (SOSEGON, PENTAGIN) INTOXICATION.
002045 02-15
CHRONIC BROMIDE INTOXICATION WITH A SEVERE NEUROLOGICAL DEFICIT.
002052 02-15
EXACERBATION OF EPILEPTIC ATTACK AND EEG DUE TO INTOXICATION OF DIPHENYLHYDANTOIN, A CASE REPORT.
002057 02-15
TREATMENT OF TRICYCLIC INTOXICATION.
002064 02-15
EXPERIMENTAL STUDIES ON INTOXICATION OR DETOXICATION OF METHYLMERCURIC-CHLORIDE.
002262 03-03
MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS.
0023B3 03-03
PROPRANOLOL EFFECTS ON ACUTE MARIHUANA INTOXICATION IN MAN
003711 04-13

THE EFFECT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUCED OCULOGYRAL ILLUSION.
003757 04-14

VERTICAL GAZE PALSY IN BARBITURATE INTOXICATION
003773 04-15

INTRA

INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
003775 04-15

INTRAARTERIAL

ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05

INTRACAUDATE

TREMOROGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE AND THEIR SUPPRESSION BY DOPAMINE.
001438 02-04

EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS.
003122 04-03

INTRACELLULAR

INTRACELLULAR LITHIUM AND CLINICAL RESPONSE.
001895 02-13

INTRACEREBRAL

INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04

INTRACEREBRAL DOPAMINE METABOLISM STUDIED BY A NOVEL RADIOISOTOPE TECHNIQUE.
00196B 02-14

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03

INTRACEREBRALLY

BIOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACEREBRALLY INJECTED CHOLINE.
001127 02-03

INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04

INTRACEREBROVENTRICULAR

CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04

EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF 5,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
001629 02-05

INTRACISTERNAL

EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-03

EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACID UPON BEHAVIORAL ACTIVITY IN THE RAT.
00032B 01-04

INTRACRANIAL

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
000087 01-03

DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
00111B 02-02

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE
001285 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04

DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04

EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
002512 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION
003373 04-04

INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN
003411 04-04

INTRAERYTHROCYTE

CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUDY.
001879 02-13

INTRAHYPOTHALAMIC

HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

INTRAHYPOTHALAMIC SEROTONIN AND CARDIOVASCULAR CONTROL IN RATS.
000230 01-03

INTRAMUSCULAR

INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-08

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04

INTRAMUSCULAR BUTORPHANOL AND MEPERIDINE IN POSTOPERATIVE PAIN
001662 02-07

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

CLINICAL PHARMACOKINETICS OF LORAZEPAM. II. INTRAMUSCULAR INJECTION.
003675 04-13

INTRAMUSCULARLY

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08

INTRANIGRAL

GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02

INTRAOCULAR

THE EFFECT OF DORYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

INTRAPERITONEAL

ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
0024B0 03-04

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION
003413 04-04

NTRASEPTAL

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS.
001527 02-04

NTRASPECIFIC

EFFECTS OF THE CHOLINOMIMETIC DRUG ARECOLINE UPON AGGRESSION: INTRASPECIFIC VS. INTERSPECIFIC ALLOCATION OF ATTACK.
002276 03-03

NTRASTRIATAL

MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP.
002232 03-03

EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE AND METHACHOLINE ON THE APOMORPHINE-INDUCED GNAWING IN THE RABBIT.
003485 04-04

NTRAVENOUS

ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION
000132 01-03

EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-03

ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 01-05

INTRAVENOUS ADMINISTRATION OF MAPROTYLIN IN DEPRESSION.
000485 01-07

INTRAVENOUS CHLORIMIPRAMINE AND DEPRESSIVE SUBTYPES.
000600 01-09

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
000783 01-11

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COCAINE ADMINISTRATION IN HUMANS.
000890 01-14

ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15

VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY.
001454 02-04

DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04

ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05

OBSERVATIONS OF THE INTRAVENOUS ADMINISTRATION OF SULPIRIDE (DOBREN).
00176B 02-09

14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002556 03-04

INTRAVENOUS LORAZEPAM IN ACUTE ANXIETY CRISES.
00271B 03-10

INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY
002768 03-11

CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002806 03-13

EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03

BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

INTRAVENOUSLY

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

INTRAVENTRICULAR

PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-04

INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04

BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN
000407 01-04

PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
00041B 01-04

UPTAKE OF 5-HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION.
001187 02-03

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001500 02-04

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
001506 02-04

DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

INTRAVENTRICULARLY

DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04

BEHAVIORAL EFFECTS OF INTRAVENTRICULARLY ADMINISTERED VASOPRESSIN AND VASOPRESSIN FRAGMENTS.
001107 02-02

INTRINSIC

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04

COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-87e07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-13

INTROSPECTIVE
A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001868 02-12

INTRUDER
VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRESSION IN RATS.
000325 01-04

INVESTIGATED
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04

INVESTIGATING
SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04

INVESTIGATION
INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
000580 01-09

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION
001977 02-14

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15

COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
002183 03-01

INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03

A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
002536 03-04

CLINICAL INVESTIGATION OF CLOZAPINE IN SCHIZOPHRENIA.
002621 03-08

PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA. AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
002688 03-09

DEANOL IN GILLES-DE-LA-TOURETTE SYNDROME: A PRELIMINARY INVESTIGATION
003571 04-09

VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
003588 04-10

AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT
003657 04-13

THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003852 04-17

INVESTIGATIONS
INVESTIGATIONS OF THE MECHANISM OF CENTRAL ACTION OF KININS.
000174 01-03

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-06

CLINICAL INVESTIGATIONS.
000527 01-08

EXPERIMENTAL AND CLINICAL INVESTIGATIONS ON THE BEHAVIORAL AND ELECTROCARDIOGRAPHIC EFFECTS OF BROMAZEPAM.
000675 01-10

STATISTICAL EVALUATION OF POLYGRAPHIC INVESTIGATIONS OF PENTOXIFYLLINE.
000830 01-13

FURTHER HEMODYNAMIC INVESTIGATIONS OF THE ANTIHYPERTENSIVE EFFECT OF LEXOTAN (BROMAZEPAM).
000856 01-13

PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY
002095 02-16

NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02

BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04

DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS
002873 03-14

PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION
003360 04-04

INVOLUNTARY
MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SUBSTRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 01-11

INVOLUTION
PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10

INVOLUTIONAL
THERAPEUTIC PROPOSAL FOR INVOLUTIONAL DEPRESSION
001771 02-09

INVOLVED
PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

SNAKE VENOM ACTION- ARE ENZYMES INVOLVED IN IT?
003337 04-03

INVOLVEMENT
EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
002348 03-03

SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-03

POSSIBLE INVOLVEMENT OF GABA IN MORPHINE ANALGESIA.
002411 03-03

POSSIBLE INVOLVEMENT OF CENTRAL FACTORS IN THE MEDIATION OF CONDITIONED TASTE-AVERSION
003081 04-03

CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003153 04-03

INVOLVEMENT OF CENTRAL ALPHA-ADRENOCEPTORS IN THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL.
003208 04-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE
003228 04-03

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04

POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
003450 04-04

ODINE
A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN BOUND IODINE IN MANIC DEPRESSIVE PATIENTS.
0005B0 01-09

ON
PSYCHOPHARMACOLOGY OF THE LITHIUM ION
000B21 01-13
EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE CYCLASE ACTIVITY IN RAT BRAIN
001643 02-05
ANTIAGGRESSIVE EFFECT OF LITHIUM ION IN MAN
003741 04-14

ONIZATION
THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01
CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01
QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

ONOPHORE-X-537A
ON THE EFFECT OF THE IONOPHORE-X-537A ON NEUROMUSCULAR TRANSMISSION IN THE RAT.
000131 01-03

ONS
LITHIUM-CARBONATE DISTRIBUTION AND ITS EFFECTS ON THE OTHER IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 01-03
HYPOTHALAMIC NA+ AND CA+ + IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
0001B1 01-03
EFFECT OF LITHIUM IONS ON CIRCADIAN RHYTHMS.
001479 02-04

ONTOPHORETIC
IONTOPHORETIC APPLICATION OF OPIATES TO THE LOCUS-COERULEUS.
00309B 04-03

OTHALAMATE
ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05

POTALAMINE
CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
0006B9 01-10

RONIAZID
IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000B14 01-13

AN
A CONTROLLED STUDY OF THE TREATMENT OF NARCOTIC ADDICTION IN IRAN: A PRELIMINARY REPORT (UNPUBLISHED PAPER).
001B65 02-11

RATIONAL
RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-0B
AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002B97 03-15

REVERSIBLE
AN IRREVERSIBLE EFFECT OF LITHIUM ADMINISTRATION TO PATIENTS.
000964 01-15
IRREVERSIBLE PROTEIN BINDING OF 14C-IMIPRAMINE IN RATS IN VIVO.
00125B 02-03

RIGATION
SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-03

RITABILITY
SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
001464 02-04

RITANT
THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY.
002439 03-04

ADRINE
ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
002323 03-03

ISCHEMIA
THERAPY OF CEREBRAL ISCHEMIA.
001B30 02-11
POST-DOPAMINE ISCHEMIA TREATED WITH CHLORPROMAZINE.
0020B0 02-15
METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 03-03

ISCHEMIC
ANXIETY AND TENSION AND BETA-BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 01-10

ISOCARBOXAZID
EFFECTS OF AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04

ISOLATED
IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE.
000046 01-03
EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
0000B4 01-03
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
00011B 01-03
INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
000241 01-03
EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN
000263 01-03
EFFECT OF ETHANOL ON IMPULSE ACTIVITY IN ISOLATED CEREBELLUM.
001206 02-03
ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-03
AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
002305 03-03
COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AND DIAZEPAM IN ISOLATED RAT HEART.
00237B 03-03
METABOLISM OF 3-O-METHYLDOPA BY THE ISOLATED PERFUSED RAT LIVER.
0023BB 03-03
DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
002511 03-04
EFFECTS OF CHLORPROMAZINE ON THE ISOLATED PERFUSED RAT HEART.
0030B4 04-03
LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03
COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE ISOLATED PERFUSED RAT BRAIN.
003274 04-03

ISOLATION
ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01
A NOTE ON THE ISOLATION AND IDENTIFICATION OF THE QUATERNARY ALKALOIDS OF PHELLODENDRON-WILSONII.
00109B 02-01
EFFECT OF ISOLATION ON BARBITURATE ANESTHESIA IN THE RAT.
002440 03-04
EFFECTS OF L-5-HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
002470 03-04
AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
0024B6 03-04
ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04

ISOLATION-INDUCED
INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04
THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-04
ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH).
002494 03-04

SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
002510 03-04

ISOMERIC
BUTYROPHENONES FROM THE ISOMERIC 2-AMINO-5-PHENYLBICYCLONONANES.
003068 04-02

ISOMERS
EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

LITHIUM AND AMPHETAMINE HYPERACTIVITY IN RATS: DIFFERENTIAL EFFECT ON D AND L ISOMERS
000326 01-04

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03

CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003153 04-03

EFFECT OF FLUPENTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SECRETION IN RATS.
003220 04-03

TOLERANCE AND CROSS-TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003389 04-04

CLINICAL EFFECTS AND PHARMACOKINETICS OF RACEMIC METHADONE AND ITS OPTICAL ISOMERS.
003694 04-13

ISONIAZID
ISONIAZID: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN RHESUS-MONKEYS.
001530 02-04

ISOPRENALINE
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE
000B27 01-13

ISOPROPANOL
ETHANOL AND ISOPROPANOL EFFECTS ON SCHEDULE-CONTROLLED RESPONDING.
000152 01-03

ISOTOPIC
AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03

ISOZYMES
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

ITERATIVE
DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

ITP
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03

JAKARTA
TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11

JAPANESE
EFFECTS OF DIMETHYLAMINOETHANOL UPON LIFE-SPAN AND BEHAVIOR OF AGED JAPANESE QUAIL
003112 04-03

JAROSLAW
TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-0B

JAVA
CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
000380 01-04

JEALOUSY
SUCCESSFUL USE OF THIOTHIXENE IN TWO CASES OF PATHOLOGICAL JEALOUSY
000690 01-10

JUDGMENT
THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS.
002006 02-14

THE EFFECTS OF SELECTED ANTIPSYCHOTIC DRUGS ON HUMAN JUDGMENT.
003728 04-14

JUMPING
THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS.
001447 02-04

EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
001535 02-04

DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04

JUSTIFICATION
THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY.
0021B2 03-01

JUSTON
EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTONIC AFFECT.
002605 03-07

JUVENILE
INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04

RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04-04

K+-ATPASE
COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON BRAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
002382 03-03

KANSAS
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-1

KEPONE
EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN.
003218 04-0

KETAMINE
EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
000367 01-0

A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE).
000395 01-0

PERSONALITY PREDISPOSITION AND EMERGENCE PHENOMENA WITH KETAMINE.
000794 01-1

THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS.
002250 03-0

KETOBENZOTHIADIAZEPINES
SYNTHESIS OF 2,1,4,5 BENZOTHIATRIAZEPINES 2,2 DIOXIDES AND OF 4 KETOBENZOTHIADIAZEPINES 2,2 DIOXIDES.
001101 02-0

KETONE
EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN
002330 03-0

KEY
THE EFFECTS OF D-AMPHETAMINE ON THE AUTOMAINTAINED KEY PECKING OF PIGEONS.
003441 04-0

KICK
A KICK FROM COCAINE.
003732 04-1

KICKS
ABUSE OF SOLVENTS FOR KICKS.
003862 04-1

KIDNEY
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-0

INTERACTION OF SERYLTRIHYDROXYBENZYLHYDRAZINE WITH L-DOPA-DECARBOXYLASE FROM PIG KIDNEY.
003103 04-0

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

KIDNEYS
THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

KILLS
IF SPEED KILLS, TRICYCLICS MASSACRE.
001734 02-09

KINASE
MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN
002319 03-03
APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03-03
REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

KINDLED
A STUDY ON PSYCHOMOTOR EPILEPSY WITH KINDLED CAT PREPARATIONS.
001356 02-03

KINDLING
PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
00078B 01-11
COCAINE, KINDLING, AND PSYCHOSIS.
000911 01-14
FAILURE OF ATROPINE TO RETARD AMYGDALOID KINDLING.
001171 02-03
PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03

KINETIC
CLINICAL ASPECTS OF KINETIC STUDIES ON PERPHENAZINE.
001908 02-13
UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION: A COMPARATIVE KINETIC ANALYSIS.
002B46 03-13

KINETICS
ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
000190 01-03
NEUROPSYCHOLOGIC EFFECTS OF DIAZEPAM RELATED TO SINGLE-DOSE KINETICS AND LIVER FUNCTION.
000B9B 01-14
INFLUENCE OF CANNABIDIOL ON SECOBARBITAL EFFECTS AND PLASMA KINETICS.
001902 02-13
METHODS FOR STUDY OF FLUPHENAZINE KINETICS IN MAN.
001951 02-13
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES I: CHLORDIAZEPOXIDE AND DEMOXEPAM.
002258 03-03
THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
002397 03-03
COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002813 03-13
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03
KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-ACID TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT BRAIN
003154 04-03
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES II: OXAZEPAM AND DIAZEPAM.
003165 04-03
INTERACTION OF PERPHENAZINE WITH THE KINETICS OF NORTRIPTYLINE.
003695 04-13

KININS
INVESTIGATIONS OF THE MECHANISM OF CENTRAL ACTION OF KININS.
000174 01-03

KNOWLEDGE
PSYCHOTROPIC DRUG KNOWLEDGE.
001079 01-17

KNOWS
BIG BROTHER KNOWS BEST.
001B23 02-11

KYNURENINE
DEPRESSOR EFFECT OF KYNURENINE AND ITS METABOLITES IN RATS
002293 03-03
THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03

KYNURENINES
KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS
001272 02-03

L-ALPHA-ACETYLMETHADOL
DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-04
L-ALPHA-ACETYLMETHADOL (LAAM): PROGNOSTIC CONSIDERATIONS.
001853 02-11

L-AMPHETAMINE
DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
00019B 01-03
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04
SLEEP: EFFECTS OF D- AND L-AMPHETAMINE IN MAN AND IN RAT.
000B96 01-14
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04
DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04
INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04
INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09

L-DOPA
EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEY.
000064 01-03
THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03
L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
000103 01-03
THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03
L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000192 01-03
L-DOPA EFFECTS ON SEXUAL BEHAVIOUR: AN EXPERIMENTAL STUDY.
000360 01-04
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05
EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
00049B 01-07
DOUBLE-BLIND TRIAL OF L-DOPA IN CHRONIC SCHIZOPHRENIA.
000537 01-0B
OUTCOME OF PARKINSONISM AFTER 2 YEARS OF L-DOPA PLUS RO-4-4602.
000737 01-11
ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA-DECARBOXYLASE INHIBITOR.
000745 01-11
RESULTS OF L-DOPA TREATMENT IN PARKINSONISM.
000751 01-11
L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-4B6) IN PARKINSONISM.
000767 01-11
COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000B00 01-13

L-DDPA PLUS DOPA-DECARBDXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
DDDBD1 D1-13

L-DOPA TREATMENT IN PARKINSONISM. BIDCHEMICAL BASIS.
DDDBD2 D1-13

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
DDDB53 01-13

TREATMENT OF PARKINSONISM WITH A COMBINATION OF L-DDPA AND METHYLDOPA HYDRAZINE.
DDDB70 01-13

CLINICAL AND BIDCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDRDMES TREATED BY L-DOPA.
D0D94B D1-15

ON THE EFFECT DF DOPA-DECARBOXYLASE INHIBITDR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FDR LONG-TERM.
DDD97D 01-15

THERAPEUTIC APPLICATION OF L-DDPA.
DD1056 01-17

METAL CHELATES OF L-DOPA FOR IMPROVED REPLENISHMENT DF DOPAMINERGIC PDOLS.
D0109D D2-01

DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CDNCENTRATION IN CEREBRDSPINAL FLUID.
D01175 02-D3

TRYPTOPHAN TRANSPORT IN BRAIN SYNAPTDSOMES: EFFECTS OF L-DOPA.
DD1185 02-03

NORADRENALINE SYNTHESIS FRDM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
DD1186 D2-D3

ALTERATIDN DF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DDPA.
001266 D2-03

THE EFFECT OF L-DOPA AND AN INHIBITOR DF PERIPHERAL DECARBOXYLATIDN ON GLUCDSE METABOLISM IN BRAIN.
DD14D5 D2-D3

FACILITATIDN DF EFFECTS OF L-DOPA BY ALPHA-METHYLDOPA.
0D14D7 02-D3

EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
0D1535 02-D4

EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERDRAL LDNG-TERM THERAPY OF PARKINSON SYNDROME.
DD1654 02-D7

CLINICAL EFFECT OF L-DOPA ON SCHIZDPHRENIA.
DD17DB 02-DB

HALDPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT DF HUNTINGTONS CHOREA.
DD1B93 D2-13

A COMPARATIVE EVALUATION OF THE ANTIPSDRIATIC EFFECT OF L-DOPA VERSUS PLACEBO IN PSORIASIS.
DD193B D2-13

EFFECTS OF L-DOPA ON SLEEP IN PARKINSONISM.
001993 D2-14

L-DOPA: PLASMA PHARMACOKINETICS AND CDNVERSION TO DDPAMINE IN BRAIN. (PH.D. DISSERTATIDN).
DD2233 D3-D3

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CDNTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS DF CHRONIC ADMINISTRATION DF L-DOPA AND SAFRAZINE.
DD2277 D3-D3

EFFECT DF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTDPHAN LEVELS IN VARIOUS TISSUES.
DD22B4 D3-D3

PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFDRMANCE CAPACITY DF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
DD22B9 03-D3

SINGLE AND REPEATED ADMINISTRATION DF NEURDLEPTIC DRUGS TO RATS: EFFECTS DN STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPRDMINE AND L-TRYPTOPHAN DR L-DOPA.
DD2461 03-04

ROLE OF BRAIN SERDTDNIN DN METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR --.
DD2474 D3-D4

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
DD253D D3-D4

L DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE: A LONG-TERM STUDY
DD25BB D3-D7

THE EFFECT OF L-DOPA AND VITAMIN-B6 IN SCHIZDPHRENIA.
D02634 D3-DB

CLINICAL RESEARCH INTD AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHDWED IMPRDVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
D0282D D3-13

EFFECTS OF L-DOPA AND VITAMIN B6 ON ELECTROENCEPHALOGRAMS OF SCHIZDPHRENIC PATIENTS: A PRELIMINARY REPORT.
D02B47 03-13

A CASE PRESENTING SOME REACTIVE CLINICAL SIGNS DURING TREATMENT OF L-DOPA
DD293D D3-15

DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
D03254 04-03

ABNORMAL MDVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNDRMALITIES IN THE DOPAMINE METABOLISM.
003631 D4-11

L-DOPA-DECARBOXYLASE

INTERACTION OF SERYLTRIHYDROXYBENZYLHYDRAZINE WITH L-DOPA-DECARBOXYLASE FROM PIG KIDNEY.
D03103 D4-03

L-DOPA-INDUCED

THE SIGNIFICANCE OF DOPAMINE, VERSUS DTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT
DD016D D1-03

A COMPARISON OF THE EFFECTS OF DECARBOXYLASE INHIBITORS ON L-DOPA-INDUCED CIRCLING BEHAVIDR AND THE CONVERSION OF DOPA TO DOPAMINE IN THE BRAIN
DD1224 D2-03

THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY
D02439 03-D4

L-TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS.
0D2B71 D3-14

RELATIONSHIP BETWEEN TARDIVE-DYSKINESIA, L-DOPA-INDUCED HYPERKINESIA AND PARKINSONISM.
DD3785 D4-15

L-GLUTAMIC-ACID

THE INHIBITION DF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
DD3074 D4-02

L-ISOLEUCINE

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME
DD3120 D4-D3

L-ISOPROTERENOL-SENSITIVE

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HDMOGENATES.
DD2342 D3-03

L-LEUCINE

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATIDN, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
DD312D D4-03

L-METHIONINE

EFFECTS OF L-TRYPTOPHAN AND L-METHIONINE ON ACTIVITY IN THE RAT.
DDD434 D1-04

L-PHENYLEPHRINE

ALPHA-NDRADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION. STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
D0D346 D1-04

L-TRYPTOPHAN

DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
DDDD16 D1-01

EFFECTS OF L-TRYPTOPHAN AND L-METHIONINE ON ACTIVITY IN THE RAT.
DDD434 D1-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
DD2461 D3-04

L-TRYPTOPHAN IN DEPRESSION.
0D2BD9 D3-13

L-TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS.
002871 03-14

VALINE
THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
003120 04-03

5-HTP
MEASUREMENT OF 5-HYDROXYINDOLE COMPOUNDS DURING L-5-HTP TREATMENT IN DEPRESSED PATIENTS.
002700 03-09

5-HYDROXYTRYPTOPHAN
DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01
EFFECTS OF L-5-HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
002470 03-04

5-HYDROXYTRYPTOPHAN-ETHYL-ESTER
SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN-ETHYL-ESTER.
001922 02-13

AAM
L-ALPHA-ACETYLMETHADOL (LAAM): PROGNOSTIC CONSIDERATIONS.
001B53 02-11
METHADONE/LAAM MAINTENANCE: A COMPARISON STUDY.
001B56 02-11

BEL
PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U318B9) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
0006B2 01-10

BELED
QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03

BELS
NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY.
00214B 02-17
INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
002297 03-03

BORATORY
INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-04
CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04
SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
00036B 01-04
HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
00074B 01-11
LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15
ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
002323 03-03
STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE IN LABORATORY ANIMALS.
003492 04-05
COMPARATIVE EFFECTIVENESS OF NINE HYPNOTIC DRUGS: SLEEP LABORATORY STUDIES.
003737 04-14
PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS.
0037B7 04-15

OUR
ATTEMPTED SUICIDE IN LABOUR.
002065 02-15

TATING
THE PASSAGE OF 14C-DELTA-9-TETRAHYDROCANNABINOL INTO THE MILK OF LACTATING SQUIRREL-MONKEYS.
001167 02-03

TONE
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
0004B2 01-07

TONES
CANNABINOIDS. 2. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOID DERIVATIVES AND RELATED LACTONES.
003056 04-01

LAMBDA-DELTA9-TETRAHYDROCANNABINOL
CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE- THFIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL.
00120B 02-03

LAMINA
DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03

LARGE-SCALE
PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
001B25 02-11

LATENCY
EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT
000294 01-04
EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

LATENT
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
00250B 03-04

LATERAL
EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03
THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
000274 01-04
DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF-STIMULATION
000335 01-04
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04
PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03
DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04
DIAZEPAM MODIFICATION OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04
HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION
003364 04-04
SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

LATERALIZING
ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY: A TRIAL OF DIAZEPAM.
001BBB 02-13

LATHYRUS-EXCITOTOXIN
BRAIN AND RETINAL DAMAGE FROM LATHYRUS-EXCITOTOXIN, BETA-N-OXALYL-L-DIAMINOPROPIONIC-ACID.
001316 02-03

LAW
PSYCHOPHARMACOLOGY AND THE LAW: A FORENSIC PSYCHIATRISTS VIEWPOINT.
00211B 02-17

LAYER
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13

LEAD
LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
00139B 02-03

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-04

LEARNED

EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-D4

EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04

THE EFFECT OF OMETINE ON LEARNED BEHAVIOR IN THE WAKIN GOLDFISH.
002514 03-04

REDUCTION OF LEARNED TASTE-AVERSIONS BY PREEXPOSURE TO DRUGS.
002549 03-04

EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF COMPLEX LEARNED BEHAVIOR. (PH.D DISSERTATION).
002550 03-04

LEARNING

DRUG EFFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS.
000110 01-03

THE EFFECTS OF DIETHYLDITHIOCARBAMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03

THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY
000270 01-04

EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-04

EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04

MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-D4

RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04

HEART-RATE LEARNING AFTER D-TUBOCURARINE ADMINISTRATION IN ANIMALS.
000329 01-04

CHRONIC METHYLPHENIDATE EFFECTS ON LEARNING IN AN F2 GENERATION
000330 01-04

ABOLITION OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION.
000347 01-04

DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
00034B 01-04

DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVE BRIGHTNESS DISCRIMINATION LEARNING IN RATS.
000351 01-D4

EFFECTS OF LOW AND MODERATE DOSES OF CHLORPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT.
000435 01-04

METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES: PSYCHOMETRIC CHANGES.
000740 01-11

TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11

THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN.
000BB7 01-14

STIMULANT RELATED STATE-DEPENDENT LEARNING IN HYPERACTIVE CHILDREN
00D922 01-14

EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA
001442 02-04

STATE DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDE AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
0014BB 02-04

EFFECTS OF P-CHLOROPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04

CUE USE IN STATE-DEPENDENT LEARNING.
001566 D2-04

CHRONIC INTERMITTENT ETHYLALCOHOL INHALATION AND AVOIDANCE LEARNING
0015BB D2-04

CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
0015B9 02-0

MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
001611 02-0

THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS
002471 03-0

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 03-0

EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V EFFECTS OF PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-0

DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-0

THE EFFECT OF CHLORDIAZEPOXIDE ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS.
002476 03-0

EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVA IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN
003365 04-0

EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 04-0

ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
003433 04-0

THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
00353B 04-0

LEARNING-DISABLED

ACTH4-10: COGNITIVE AND BEHAVIORAL EFFECTS IN HYPERACTIVE, LEARNING-DISABLED CHILDREN
002872 03-

LENGTH

NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-

LENGTHENING

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XI. LENGTHENING OF THE BASIC CHAIN
000018 01-

LENPERONE

EVALUATION OF LENPERONE IN ACUTE SCHIZOPHRENIA
000515 01-

LENS

CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE.
000977 01-

LEPIDOPTERA

METABOLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
0030B3 04-

LEPONEX

DOUBLE-BLIND CLINICAL COMPARISON OF HF-1B54 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
000538 01-

RESULTS OF LEPONEX TREATMENT IN SCHIZOPHRENIA.
000574 01-

USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY
000763 01-

RESULTS OF LEPONEX TREATMENT.
0D2601 03-

THE NEUROLEPTIC LEPONEX.
0D3027 03-

LESCH-NYHAN

DOUBLE-BLIND CLINICAL TRIAL OF 5-HYDROXYTRYPTOPHAN IN A CASE OF LESCH-NYHAN SYNDROME.
001B27 02-

LESIONED

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR O ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTI NIGRA.
002355 03-

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
D03371 04-

SIONS

EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS
00003B 01-03

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D AMPHETAMINE SULFATE AND SUBSTANTIA NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN
0000B6 01-03

L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS
000103 01-03

EFFECTS OF AMYGDALA LESIONS ON TASTE-AVERSIONS PRODUCED BY AMPHETAMINE AND LICL.
000116 01-03

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
00012B 01-03

HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION
000219 01-03

THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04

INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04

CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS
000349 01-04

CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04

DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04

MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS OF INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS
000463 01-05

CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE.
000977 01-15

ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
001334 02-03

EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT.
001510 02-04

BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04

DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04

EFFECTS OF LESIONS OF THE CAUDATE NUCLEUS ON MORPHINE-DEPENDENCE IN THE RAT
001539 02-04

CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
00160B 02-04

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY (PH.D. DISSERTATION).
002272 03-03

EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE
0022B5 03-03

BEHAVIORAL ALTERATIONS IN PATIENTS WITH BASAL GANGLIA LESIONS.
002430 03-04

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN
002436 03-04

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS
002445 03-04

LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
002502 03-04

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03

THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
0032B3 04-03

STUDIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE.
003333 04-03

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS.
003357 04-04

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-04

LETHAL

CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

BLOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESICS IN THE MOUSE.
002362 03-03

LETHALITY

EFFECT OF AGGREGATION ON MORPHINE LETHALITY IN RATS.
00350B 04-05

LEUKOCYTES

CYTOTOXIC ACTION OF PSYCHOTROPIC DRUGS ON LEUKOCYTES IN VITRO.
002570 03-05

LEVEL

EFFECTS OF HALOPERIDOL AND LITHIUM ON BLOOD ALCOHOL LEVEL IN RABBITS.
000141 01-03

DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE.
000513 01-07

CATECHOLAMINES IN ACTIVATION, STEREOTYPY, AND LEVEL OF MOOD.
000B58 01-13

PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART.
001749 02-09

ANTIPSYCHOTIC EFFECTIVENESS IN RELATION TO PLASMA LEVEL OF CLOZAPINE.
001B7B 02-13

THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY.
001B99 02-13

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
002340 03-03

CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SUBSTANTIA-NIGRA IN THE RABBIT.
002557 03-04

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

PLASMA LEVEL STUDIES WITH CLOMIPRAMINE (ANAFRANIL).
003679 04-13

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003B66 04-17

LEVELS

REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
00000B 01-01

SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT
000102 01-03

VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-03

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
000548 01-08

THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.
00062B 01-09

THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS.
000655 01-09

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11

EFFECTS OF DIKALIUM CLORAZEPATE ON SERUM LEVELS AND METABOLITES.
000766 01-11

BLOOD LEVELS AND ELECTROENCEPHALOGRAPHIC EFFECTS OF DIAZEPAM AND BROMAZEPAM.
000819 01-13

SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000B35 01-13

EFFECT OF FOOD AND REPEATED INJECTIONS ON SERUM DIAZEPAM LEVELS.
000B40 01-13

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000B61 01-13

THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
000B67 01-13

REGIONAL SEROTONIN LEVELS IN BRAIN: A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000BB3 01-14

MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
001002 01-16

GLC DETERMINATION OF DOXEPIN PLASMA LEVELS.
001009 01-16

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-0

ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-0

THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC 13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-0

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-0

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-0

REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-0

STATE-DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDE AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
00148B 02-0

THE BEHAVIOURAL EFFECTS OF EOS-INDUCED CHANGES IN SUBSTANTIA NIGRA GABA LEVELS.
001528 02-0

EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4 IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-0

RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-

A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-

BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-

THE EFFECT OF CLOMIPRAMINE ON PROLACTIN LEVELS -- PILOT STUDIE
001745 02-

CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLI PATIENTS
001747 02

CORRELATION BETWEEN PLASMA AND CEREBROSPINAL LEVELS OF IMIPRAMINE.
001775 02

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
0018B9 02-

AVERSIVE SMOKING: CARBOXYHEMOGLOBIN LEVELS BEFORE AND AFT RAPID SMOKING.
001903 02-

BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-

SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN-ETHYL-ESTER.
001922 02-

CARBON-MONOXIDE BLOOD LEVELS AND REPORTED CESSATION OF SMOKING
001933 02-

PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION: ENVIRONMENTAL AN GENETIC FACTORS.
001935 02-

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02

EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS, COMPARISON WITH BLOOD LEVELS.
002041 02

LITHIUM TOXICITY WITH LOW SERUM LEVELS: REPORT OF A CASE
002063 02

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: BLOOD LEVELS AND CLINICAL RESPONSE.
002120 02

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03

LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FO THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS
002244 03

THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS
002250 03

EFFECT OF L DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
0022B4 03-03

EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03-03

EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04

CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
0024B1 03-04

PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08

TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, MST-1RB.
002672 03-09

NORTRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.
002708 03-09

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 D3-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002836 03-13

AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002868 03-14

ANTIPSYCHOTIC AGENTS AND SERUM PROLACTIN LEVELS.
D02900 03-15

ANTIDEPRESSANT BLOOD LEVELS IN ACUTE OVERDOSE.
002906 03-15

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
003120 04-03

EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
003187 04-03

MUTUAL EFFECTS OF MORPHINE AND ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
003198 04-03

EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03

EFFECTS OF LSD AND 2-BROMOLSD ON STRIATAL DOPAC LEVELS.
003238 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
D03316 04-03

DOPAMINE LEVELS IN THE STRIATUM AND THE EFFECT OF ALCOHOL AND RESERPINE
003318 04-03

INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
00333B 04-03

EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE -- A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

CLINICAL IMPLICATIONS OF IMIPRAMINE PLASMA LEVELS FOR DEPRESSIVE ILLNESS.
DD3560 04-09

EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID.
003647 04-11

ANTIDEPRESSANT PLASMA LEVELS.
003674 04-13

LACK OF EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON SERUM PROLACTIN LEVELS
003689 04-13

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY
003696 04-13

COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

PLASMA NORTRIPTYLINE LEVELS AND ECG FINDINGS.
003723 04-13

DOSE LEVELS OF ESTROGEN ADMINISTRATION AND INCIDENCE OF ENDOMETRIAL HYPERPLASIA. (UNPUBLISHED PAPER).
003801 04-15

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
003807 04-15

LITHIUM SIDE-EFFECTS IN RELATION TO DOSE AND TO LEVELS AND GRADIENTS OF LITHIUM IN PLASMA.
003815 04-15

LEVER-PRESSING

EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
002458 03-04

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
0D3079 04-03

EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-D4

LEVODOPA

INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 D1-03

STUDIES WITH BROMOCRIPTINE: PART 2. DOUBLE-BLIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07

PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
000962 01-15

ALTERNATIVES TO LEVODOPA.
D01062 D1-17

PSYCHOSIS IN PATIENT ON BROMOCRIPTINE AND LEVODOPA WITH CARBIDOPA.
002054 02-15

COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM.
002815 03-13

LEVODOPA, FERTILITY, AND LONGEVITY.
00311B 04-D3

EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03

LEVODOPA TREATMENT IN PRESENILE DEMENTIA.
D03738 04-14

LEVOMEPROMAZINE

EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
000084 01-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-03

LEVOPA

COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11

LEXOTAN

TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
D00680 01-10

CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10

FURTHER HEMODYNAMIC INVESTIGATIONS OF THE ANTIHYPERTENSIVE EFFECT OF LEXOTAN (BROMAZEPAM).
000856 01-13

LEXOTANIL
LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
00070B 01-10

LIABILITY
ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06

LIBERATION
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
002305 03-03

LIBRARIAN
THE LITHIUM LIBRARIAN: AN INTERNATIONAL INDEX.
003B64 04-17

LIBRIUM
THE EVALUATION OF BELLERGAL TABLETS COMPAREO TO LIBRIUM ANO PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATEO WITH FUNCTIONAL GASTROINTESTINAL OISORDERS.
003642 04-11

LICL
EFFECTS OF AMYGDALA LESIONS ON TASTE-AVERSIONS PRODUCEO BY AMPHETAMINE ANO LICL.
000116 01-03

EFFECTS OF WATER OEPRIVATION ANO PRIOR LICL EXPOSURE IN CONDITIONING TASTE-AVERSIONS.
001597 02-04

UNCONOITIONEO TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: OISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

LIFE
THE TREATMENT OF LIFE THREATENING CAROIOPULMONARY ILLNESS AND LIFE THREATENING OEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09

PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15

LIFE EVENTS, OEPRESSIVE RELAPSE AND MAINTENANCE TREATMENT.
001770 02-09

INFLUENCE OF STRESS ANO PHENOBARBITAL ON CORTICOSTERONE METABOLISM OURING EARLY POSTNATAL LIFE OF RAT.
003135 04-03

3. SOCIAL LIFE, CIGARETTE SMOKING, ANO URINARY PH.
003707 04-13

LIFE-SPAN
EFFECTS OF OIMETHYLAMINOETHANOL UPON LIFE-SPAN ANO BEHAVIOR OF AGED JAPANESE QUAIL.
003112 04-03

LIGATED
HEXOBARBITAL SLEEPING TIME AND ORUG METABOLISM IN RATS WITH LIGATEO BILE OUCTS -- A LACK OF CORRELATION.
000316 01-04

LIGATION
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT ANO CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03

LIGHT
HALOPERIDOL ANO LIGHT REINFORCEMENT IN THE RAT.
001541 02-04

PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEEO TO BELONG IN THE LIGHT OF THREE CLINICAL CASES.
001793 02-10

MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT OURING CHLORPROMAZINE ADMINISTRATION.
00236B 03-03

PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE -- ESPECIALLY LIGHT CONSCIOUSNESS IMPAIRMENTS.
002B95 03-15

DRUG ADOICTION: LIGHT AT THE END OF THE TUNNEL?
003422 04-04

LIGHTING
HAMSTER PINEAL NORAORENALINE: LEVELS OVER A REGULATEO LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

LILLY-109514
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PROOUCEO BY OL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,B,10A ALPHA HEXAHYORO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
00039B 01-04

LILLY-110140
INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIOENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04

LILLY-72525
METABOLISM OF 1,4 DIHYDROTRIFLUOROMETHYLQUINOXALINEDIONE (LILLY-72525) IN RATS AND CATS.
002329 03-03

LIMBIC
DIFFERENTIAL EFFECT OF NEUROLEPTIC DRUGS ON DOPAMINE TURNOVER IN THE EXTRAPYRAMIDAL AND LIMBIC SYSTEM.
000003 01-01

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORAORENERGIC MECHANISMS IN THE MOOE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03

A NORAORENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES ANO THE EFFECTS OF AGONISTS, AORENOLYTICS ANO NEUROLEPTIC ORUGS.
000125 01-03

DIFFERENTIAL EFFECTS OF LOW OOSES OF ETHANOL ON THE IMPULSE ACTIVITY IN VARIOUS REGIONS OF THE LIMBIC SYSTEM.
000142 01-03

NEUROENOOCRINE REGULATION IN OEPRESSION I. LIMBIC SYSTEM AORENOCORTICAL OYSFUNCTION.
001736 02-09

THE NORAORENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN ANO ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-03

EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INOUCEO IN THE LIMBIC SYSTEM ANO HYPOTHALAMUS IN THE CAT BRAIN.
0023B6 03-03

EFFECTS OF 1,4 BENZOOIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECOROED IN THE LIMBIC SYSTEM ANO HYPOTHALAMUS.
003474 04-04

CARBAMAZEPINE IN THE OYSCONTROL SYNOROME ASSOCIATEO WITH LIMBIC SYSTEM DYSFUNCTION.
003646 04-11

LIN-1418
CLINICAL STUOY OF LIN-141B (SULTOPRIOE).
0004B7 01-07

LINK
INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT-EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEOBACK INHIBITION OF OOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 03-03

LINKED
THE ROLE OF N-ALLYL ANO N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-OIMETHYLGLYCINE-OXIOASE -- N-MONOAMINE-OXIOASE.
000011 01-01

LIORESAL
ACTIONS OF THE P-CHLOROPHENYL OERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE ANO NON-NOCICEPTIVE UNITS IN THE SPINAL CORO OF THE CAT.
001235 02-03

BACLOFEN (LIORESAL) IN THE TREATMENT OF NEUROLEPTIC-INOUCED TARDIVE-OYSKINESIA.
001923 02-13

LIPIDOSIS
RETINAL LIPIDOSIS IN ALBINO RATS TREATEO WITH CHLORPHENTERMINE ANO WITH TRICYCLIC ANTIOEPRESSANTS.
0012B4 02-03

LIPIDS
LITHIUM-INOUCEO ALTERATIONS IN RAT GANGLIONIC LIPIOS.
00131B 02-03

CHARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES ANO RELATED DRUGS WITH LIPIOS BY UV-SPECTROPHOTOMETRY.
0025B3 03-06

LIPOLYSIS
PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC ORJGS: INHIBITION OF CATECHOLAMINE-INOUCEO LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE AOIPOSE TISSUE OF MAN AND RAT
001192 02-03

LIPOPHILICITY
A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003B76 04-17

LIPOSOMES
EFFECT OF PROPRANOLOL AND RELATEO DRUGS ON TRANSMEMBRANEOUS PH DIFFERENCES IN LIPOSOMES.
0030B0 04-03

LIPOTROPIN
INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN
002453 03-04

LIQUID
GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01
MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02 13
SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY
002953 03-16

LIQUOR
ANALGESIA PRODUCED BY MORPHINE WHEN ACTING FROM THE LIQUOR SPACE.
0011B4 02-03

LISURIDE
EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
003193 04-03

LITAREX
A COMPARATIVE DOUBLE-BLIND STUDY OF THE SIDE-EFFECTS OF LITAREX AND LITHIONIT DURETTES.
001678 02-07

LITERATURE
BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE BIOCHEMICAL LITERATURE.
0010B0 01-17
AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001B32 02-11
INTERMITTENT PSYCHOPHARMACOTHERAPY: REVIEW OF LITERATURE AND CRITICAL REMARKS.
00265B 03-0B
THE CARDIOVASCULAR EFFECTS OF LITHIUM IN MAN: A REVIEW OF THE LITERATURE.
002B40 03-13

LITHIONIT
A COMPARATIVE DOUBLE-BLIND STUDY OF THE SIDE-EFFECTS OF LITAREX AND LITHIONIT DURETTES.
00167B 02-07
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

LITHIUM
THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
000075 01-03
EFFECTS OF HALOPERIDOL AND LITHIUM ON BLOOD ALCOHOL LEVEL IN RABBITS.
000141 01-03
TEMPORAL AND REGIONAL DIFFERENCES IN BRAIN CONCENTRATIONS OF LITHIUM IN RATS.
000179 01-03
EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN.
00021B 01-03
LITHIUM AND AMPHETAMINE HYPERACTIVITY IN RATS: DIFFERENTIAL EFFECT ON D AND L ISOMERS
000326 01-04
EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
00033B 01-04
FOUR METHODS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
000496 01-07
OSTEOPENIA AND DYSREGULATION OF DIVALENT CATIONS IN LITHIUM TREATED PATIENTS.
000585 01-09
LONG-TERM LITHIUM THERAPY OF GERIATRIC MANIC-DEPRESSIVES.
000599 01-09
LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01-09
LITHIUM MAINTENANCE THERAPY
000625 01-09
A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09
ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-09
A CONTROLLED STUDY OF THE ASSOCIATION OF CLOMIPRAMINE AND LITHIUM.
000643 01-09
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
000649 01-09
RED-BLOOD-CELL LITHIUM INDEX AND LONG-TERM MAINTENANCE TREATMENT.
000704 01-10
PLASMA AND ERYTHROCYTE CONCENTRATIONS OF LITHIUM.
000722 01-10
LITHIUM TREATMENT DURING ALCOHOLIC WITHDRAWAL.
00077B 01-11
MINIMAL BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000803 01-13
MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000806 01-13
PSYCHOPHARMACOLOGY OF THE LITHIUM ION.
000B21 01-13
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000B49 01-13
LITHIUM AND THYROTOXICOSIS.
000930 01-15
LITHIUM AND THYROTOXICOSIS.
000936 01-15
THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS AND LITHIUM.
000937 01-15
LITHIUM NEUROTOXICITY.
000954 01-15
AN IRREVERSIBLE EFFECT OF LITHIUM ADMINISTRATION TO PATIENTS.
000964 01-15
LITHIUM IN TARDIVE-DYSKINESIA.
0009B5 01-15
ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM THERAPY.
00099B 01-15
ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15
LITHIUM PROPHYLAXIS.
001045 01-17
LITHIUM TREATMENT. SOME DATA AND RECENT PERSPECTIVES.
001068 01-17
A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM -- APPENDIX II (PART III).
001072 01-17
POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03
EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012B8 02-03
THE EFFECT OF LITHIUM ON FOOD INTAKE IN RATS.
001317 02-03
EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-03
EFFECT OF LITHIUM ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM IN MICE.
001370 02-03
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE
0013B0 02-03
EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES.
0013B7 02-03
RENAL ELIMINATION OF LITHIUM IN RATS WITH LITHIUM INTOXICATION
001403 02-03
EFFECT OF LITHIUM IONS ON CIRCADIAN RHYTHMS.
001479 02-04
LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
00150B 02-04
LITHIUM EFFECTS ON VERTICAL ACTIVITY IN RATS: A REPLY TO D. F. SMITH.
001520 02-04
EFFECTS OF LITHIUM ON FOOT-SHOCK-INDUCED AGGRESSIVE BEHAVIOR IN RATS.
001549 02-04
EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04
COMPARISON OF LITHIUM SALTS.
00165B 02-07

A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR. 001703 02-08

LITHIUM TREATMENT OF A PATIENT WITH PERIODIC CATATONIA. 001712 02-08

URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM. 001729 02-09

PSYCHOLOGICAL STRESS AS A CAUSE OF LITHIUM PROPHYLAXIS FAILURE, A REPORT OF THREE CASES. 001732 02-09

EFFECT OF LITHIUM ON CA-ATPASE. 001737 02-09

EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS. 001748 02-09

ESSAY ON DETERMINATION OF PSYCHOLOGICAL EFFECTS OF LITHIUM. 001756 02-09

EFFECTS OF LITHIUM THERAPY DURING PREGNANCY. 001759 02-09

LITHIUM IN THE TREATMENT OF DEPRESSION. 001761 02-09

LITHIUM AND GENETIC EQUIPMENT. 001762 02-09

STUDY OF THE IMPORTANCE OF NEUROTIC PSYCHOLOGICAL FACTORS IN THE SUCCESS OF LONG-TERM LITHIUM TREATMENT. 001766 02-09

A DEPRESSIVE SYNDROME RESPONSIVE TO LITHIUM: AN ANALYSIS OF 20 CASES. 001767 02-09

THE CURRENT ROLE OF LITHIUM IN THE TREATMENT OF AFFECTIVE DISORDERS. 001779 02-09

FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS. 001782 02-09

LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE. 001813 02-11

THE EFFECT OF LITHIUM IN MENIERES DISEASE. 001816 02-11

AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO. 001842 02-11

INDICATIONS FOR LITHIUM SALT IN OTHER THAN MANIC-DEPRESSIVE PSYCHOSIS. 001857 02-11

PREDICTION OF CLINICAL RESPONSE TO LITHIUM. 001870 02-12

CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUDY. 001879 02-13

SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3. 001890 02-13

PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM. 001891 02-13

INTRACELLULAR LITHIUM AND CLINICAL RESPONSE. 001895 02-13

THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY. 001899 02-13

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES. 001906 02-13

DISTRIBUTION OF LITHIUM IN THE CNS AND THE FUNCTION OF BIOLOGICAL CLOCKS. 001907 02-13

DISTRIBUTION OF LITHIUM BETWEEN ERYTHROCYTES AND PLASMA: IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES. 001915 02-13

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER 001929 02-13

PHARMACOKINETICS OF LITHIUM IN HUMAN PLASMA AND ERYTHROCYTES. 001936 02-13

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE. 001945 02-13

THE EFFECT OF LITHIUM ON IMPULSIVE AGGRESSIVE BEHAVIOR IN MAN. 001996 02-14

MORE ABOUT THE RELATIONSHIP OF LITHIUM TO PSORIASIS. 002011 02-15

COGWHEEL RIGIDITY EARLY IN LITHIUM THERAPY. 002015 02-15

EXTRAPYRAMIDAL SIDE-EFFECTS IN LITHIUM MAINTENANCE THERAPY 002021 02-15

LITHIUM, HYPERCALCAEMIA, HYPERMAGNESAEMIA, AND HYPERPARATHYROIDISM. 002026 02-15

TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM. 002030 02-15

TOXIC REACTIONS TO LITHIUM AND HALOPERIDOL. 002055 02-15

LITHIUM TOXICITY WITH LOW SERUM LEVELS: REPORT OF A CASE. 002063 02-15

THYROTOXICOSIS AND LITHIUM. 002074 02-15

PSYCHOLOGICAL ASPECTS OF PHASIC DEPRESSION DURING LITHIUM PROPHYLAXIS. 002075 02-15

REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY. 002076 02-15

THYROID INSUFFICIENCY IN THE COURSE OF LITHIUM THERAPY. 002081 02-15

ON THE RELEVANCE OF ANIMAL STUDIES ON LITHIUM TO THE UNDERSTANDING OF LITHIUM THERAPY. 002128 02-17

CURRENT STATUS OF LITHIUM THERAPY IN AFFECTIVE DISORDERS. 002160 02-17

LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS. 002309 03-03

ABSENCE OF AN ANTIDEPRESSIVE EFFECT OF LITHIUM IN THE CLINIC AND IN EXPERIMENTS. 002313 03-03

LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS. 002338 03-03

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO. 002339 03-03

EFFECT OF LITHIUM ON GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE. 002346 03-03

MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS. 002383 03-03

LITHIUM IN PSYCHIATRY: A SYNOPSIS. 002396 03-03

EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7 002415 03-04

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS. 002542 03-04

LITHIUM MAGNESIUM RELATIONSHIP IN RED-BLOOD-CELLS DURING LITHIUM PROPHYLAXIS. 002695 03-09

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS. 002696 03-09

ADVANCES IN LITHIUM THERAPY 002698 03-09

LITHIUM IN PREVIOUS TREATMENT FAILURES. 002703 03-09

POSSIBLE MECHANISM FOR BIOLOGICAL ACTION OF LITHIUM. 002810 03-13

EFFECT OF CHLOROTHIAZIDE ON THE PHARMACOKINETICS OF LITHIUM IN PLASMA AND ERYTHROCYTES. 002829 03-13

URINARY CYCLIC-AMP IN RELATION TO LITHIUM TREATMENT IN MANIC-DEPRESSIVE ILLNESS. 002837 03-13

THE CARDIOVASCULAR EFFECTS OF LITHIUM IN MAN: A REVIEW OF THE LITERATURE. 002840 03-13

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT. 002893 03-15

LITHIUM THERAPY: A BRIEF REVIEW 002917 03-15

WHAT HAPPENED LATER TO THE LITHIUM BABIES? A FOLLOW-UP STUDY OF CHILDREN BORN WITHOUT MALFORMATIONS. 002932 03-15

LITHIUM: ITS MODE AND RANGE OF ACTION 003024 03-17

RECENT ADVANCES IN THE TREATMENT AND PREVENTION OF ADVERSE REACTIONS TO LITHIUM
003031 03-17

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

THE INFLUENCE OF LITHIUM ON WATER 8INDING A8ILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN
003132 04-03

EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION
003172 04-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND 8RAIN 8IOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS
003249 04-03

LITHIUM INHI8ITION OF CYCLIC-AMP ACCUMULATION INDUCED 8Y DOPAMINE IN ISOLATED RETINAE OF THE RA88IT.
003271 04-03

THE RENAL HANDLING OF LITHIUM. RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIA8ETES-INSIPIDUS.
003300 04-03

LONG-DELAY 8ACKWARD TASTE-AVERSION CONDITIONING WITH LITHIUM.
003378 04-04

LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION.
003428 04-04

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS 8RAIN CONCENTRATIONS IN RATS.
003435 04-04

THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS.
003559 04-09

LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
003568 04-09

LITHIUM NONRESPONDERS IN A LITHIUM CLINIC.
003569 04-09

SO8ERING DATA ON LITHIUM IN ALCOHOLISM.
003578 04-09

LITHIUM IN DEPRESSION- A 8IOCHEMICAL STUDY.
003584 04-10

LITHIUM IN ADULT ANOREXIA-NERVOSA: A PILOT REPORT ON TWO PATIENTS.
003610 04-11

CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11

A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL 8ETA-ADRENERGIC ADENYLATE-CYCLASE.
00366B 04-13

LITHIUM -- MECHANISM OF ACTION SIMILAR TO PHENYTOIN.
003681 04-13

ON THE SIGNIFICANCE OF THE ERYTHROCYTE LITHIUM TO PLASMA LITHIUM RATIO.
003686 04-13

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY
003696 04-13

EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING.
003698 04-13

COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

ABSOLUTE AVAILA8ILITY OF LITHIUM.
003700 04-13

SALIVARY AND URINARY LITHIUM CLEARANCE WHILE RECUM8ENT AND UPRIGHT.
003706 04-13

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

USEFULNESS OF SALIVA LITHIUM ESTIMATION.
003721 04-13

ANTIAGGRESSIVE EFFECT OF LITHIUM ION IN MAN.
003741 04-14

COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TA8LETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

INTRA/EXTRA RED 8LOOD-CELL LITHIUM AND ELECTROLYTE DISTRI8UTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY
003775 04-15

LITHIUM TREATMENT IN THE ELDERLY I CLINICAL USAGE
003781 04-15

THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS.
003793 04-15

DELIRIUM ASSOCIATED WITH LITHIUM THERAPY AND ELECTROCONVULSIVE THERAPY.
003794 04-15

LITHIUM SIDE-EFFECTS IN RELATION TO DOSE AND TO LEVELS AND GRADIENTS OF LITHIUM IN PLASMA.
003815 04-15

LITHIUM AND DIURETICS
003823 04-15

A REVIEW OF NEUROTOXICITY OF LITHIUM DURING THERAPEUTIC TREATMENT
003829 04-15

THE MEDICAL ECONOMICS OF LITHIUM TREATMENT FOR MANIC-DEPRESSIVES.
003854 04-17

THE LITHIUM LI8RARIAN: AN INTERNATIONAL INDEX.
003864 04-17

LITHIUM IN THE TREATMENT OF A MANIC PATIENT WITH MULTIPLE-SCLEROSIS: A CASE REPORT.
003879 04-17

LITHIUM AS AN ANTIDEPRESSANT: DISCOVERIES THROUGH CLINICAL O8SERVATIONS.
003892 04-17

LITHIUM-CARBONATE

LITHIUM-CAR8ONATE DISTRI8UTION AND ITS EFFECTS ON THE OTHER IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 01-03

A THREE YEAR DOUBLE-8LIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
000580 01-09

NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
000584 01-09

A DOU8LE-8LIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
000589 01-09

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09

FIVE YEARS EXPERIENCE WITH LITHIUM-CARBONATE.
000595 01-09

LITHIUM-CARBONATE PROPHYLAXIS FAILURE.
000596 01-09

LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYPES OF PRIMARY AFFECTIVE DISORDER.
000601 01-09

CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CAR8ONATE.
000709 01-10

ANTINUCLEAR ANTI8ODIES IN PATIENTS ON LITHIUM-CARBONATE.
000978 01-15

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CAR8ONATE AND CHLORAL HYDRATE.
001564 02-04

A FAVORABLE RESPONSE TO LITHIUM-CARBONATE IN A SCHIZOAFFECTIVE FATHER AND SON.
001714 02-08

LITHIUM-CAR8ONATE IN GILLES-DE-LA-TOURETTES DISEASE.
001763 02-09

THE EFFECTS OF ADMINISTERING LITHIUM-CARBONATE ON THE BALANCE OF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
001774 02-09

LITHIUM-CAR8ONATE AND BREAST-FEEDING.
001947 02-13

EMERGENCE OF MYASTHENIA-GRAVIS DURING TREATMENT WITH LITHIUM-CAR8ONATE.
002066 02-15

ADVERSE REACTIONS IN TREATMENT WITH LITHIUM-CAR8ONATE AND HALOPERIDOL.
002665 03-09

PSYCHODYNAMIC O8SERVATIONS OF A GROUP OF PATIENTS TREATED WITH LITHIUM-CARBONATE.
002670 03-09

PREPU8ESCENT DEPRESSION (4TH REPORT) -- EXPERIENCES WITH THE EFFICACY OF LITHIUM-CARBONATE.
002687 03-09

EXPERIENCES IN USING LITHIUM-CAR8ONATE -- ESPECIALLY WITH MANIA AND MANIC-DEPRESSIVE CASES.
002707 03-09

INDICATIONS FOR LITHIUM-CARBONATE PROPHYLAXIS.
002710 03-10
BIOAVAILABILITY AND SIDE-EFFECTS OF DIFFERENT LITHIUM-CARBONATE PRODUCTS.
002904 03-15
PERSISTENT NEPHROGENIC DIABETES-INSIPIDUS AFTER LITHIUM-CARBONATE.
002934 03-15
A CASE WHERE ADMINISTRATION OF LITHIUM-CARBONATE CAUSED POLYURIA.
002938 03-15
THE ACTION OF LITHIUM-CARBONATE ON THE SLEEPWALKING CYCLE IN THE CAT.
003419 04-04
INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09
EFFECTS OF LITHIUM-CARBONATE ON MOTOR ACTIVITY IN MANIA AND DEPRESSION
003561 04-09
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
D03699 04-13
LITHIUM-CARBONATE AND ETHANOL-INDUCED HIGHS IN NORMAL SUBJECTS.
003734 04-14
THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14
THE EFFECT OF LITHIUM-CARBONATE ON THE COGNITIVE FUNCTIONS OF NORMAL SUBJECTS.
003736 04-14
LITHIUM-CARBONATE IN PERSONALITY DISORDERS: A CASE OF HYSTERIA.
003753 04-14
COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15
FIRST-DEGREE ATRIOVENTRICULAR BLOCK DURING LITHIUM-CARBONATE TREATMENT.
003796 04-15
PROLONGATION OF MUSCLE RELAXANT EFFECTS BY LITHIUM-CARBONATE.
003B20 04-15

LITHIUM-CHLORIDE
THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04
SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
00036B 01-04
THE EFFECT OF LITHIUM-CHLORIDE ON MORPHINE-INDUCED AND PYROGEN-INDUCED HYPERTHERMIA IN RATS.
001161 02-03
EFFECTS OF LITHIUM-CHLORIDE ON SLEEP PATTERNS IN THE RAT.
001465 02-04
REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE.
0015B1 D2-04
RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14
POTENTIATING EFFECT OF LITHIUM-CHLORIDE ON METHAMPHETAMINE-INDUCED STEREOTYPY IN MICE.
00343B 04-04

LITHIUM-INDUCED
EFFECT OF POTASSIUM ON LITHIUM-INDUCED GROWTH RETARDATION AND POLYURIA IN RATS.
0001B9 01-03
LITHIUM-INDUCED ALTERATIONS IN RAT GANGLIONIC LIPIDS.
00131B 02-03

LITHIUM-SALTS
USE OF LITHIUM-SALTS IN PSYCHIATRIC THERAPEUTICS.
000611 01-09
LITHIUM-SALTS IN THE MANAGEMENT OF A CHILD BATTERER.
002679 D3-09
LITHIUM-SALTS IN PSYCHIATRY: IMPORTANCE OF GENETIC FACTORS.
0D2825 03-13

LIVER
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
00011B 01-03
ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
000190 01-03
PHARMACOKINETICS OF SEDATIVES IN LIVER DISEASE.
00079B 01-13
NEUROPSYCHOLOGIC EFFECTS OF DIAZEPAM RELATED TO SINGLE-DOSE KINETICS AND LIVER FUNCTION.
000898 01-14
DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15
IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 02-03
INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03
INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
D01212 02-03
IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 02-03
CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVER GLYCOGEN SYNTHESIS.
D01372 02-03
CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE.
001711 02-08
EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS
0022B7 03-03
DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES?
002360 03-03
METABOLISM OF 3-O-METHYLDOPA BY THE ISOLATED PERFUSED RAT LIVER.
002388 03-03
CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002B20 03-13
EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN.
003094 04-03
ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
0031B4 04-03
DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
D03254 04-03
DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
0036B3 04-13
INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

LIVING
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
000649 01-09

LI2CO3
NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
00231B 03-03

LM-209
ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
002392 03-03

LOAD
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03

LOBE
ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY: A TRIAL OF DIAZEPAM.
001BBB 02-13

LOCAL
PREVENTION OF LOCAL ANESTHETIC-INDUCED CONVULSIONS BY GAMMA-AMINOBUTYRIC-ACID.
002261 03-03

EFFECTS OF D-LYSERGIC-ACID DIETHYLAMIDE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT. (UNPUBLISHED PAPER).
002367 03-03

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

LOCALISED

POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
000209 01-03

LOCALIZATION

PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION: EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000852 01-13

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

LOCALIZATION OF PHENOBARBITAL IN MOUSE CENTRAL-NERVOUS-SYSTEM BY IMMUNOFLUORESCENCE.
001327 02-03

BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03

ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
0030BB 04-03

ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTAB-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE.
003168 04-03

LOCOMOTION

EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04

DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON AMPHETAMINE-INDUCED LOCOMOTION AND STEREOTYPY.
002535 03-04

LOCOMOTOR

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001B8 01-03

ON THE INTERACTION BETWEEN CAFFEINE AND BARBITURATES WITH RESPECT TO LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINES.
000251 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
000343 01-04

REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIDINE OR METHADONE-INDUCED DECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-04

THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-02

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 02-03

PIPERIDINE: EFFECTS ON LOCOMOTOR ACTIVITY AND BRAIN MONOAMINE TURNOVER.
001122 02-03

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-03

LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS.
001489 02-04

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04

LOCOMOTOR ACTIVITY AND EXPLORATION. THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT
001538 02-04

EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
00155B 02-04

GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
001568 02-04

THE IRRITANT PROPERTIES OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN RELATION TO THEIR EFFECTS ON L-DOPA-INDUCED LOCOMOTOR ACTIVITY.
002439 03-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-04

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04

CORRELATION OF BEHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE. (PH.D. DISSERTATION).
002560 03-04

CLONIDINE-INDUCED LOCOMOTOR HYPERACTIVITY IN RATS.
002561 03-04

ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
003248 04-03

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION.
003268 04-03

EARLY DEVELOPMENTAL CHANGES IN THE LOCOMOTOR RESPONSE TO AMPHETAMINE AND THEIR RELATION TO HIPPOCAMPAL FUNCTION.
00341B 04-04

LOCUS-COERULEUS

STUDIES OF CONNECTIONS BETWEEN LOCUS-COERULEUS AND CEREBRAL CORTEX.
000040 01-03

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
0000B1 01-03

INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
000130 01-03

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03

NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-03

RECORDING OF THE ELECTROPHYSIOLOGICAL ACTIVITY OF THE LOCUS-COERULEUS IN THE RAT.
001191 02-03

NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON.
00145B 02-04

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS.
002399 03-03

IONTOPHORETIC APPLICATION OF OPIATES TO THE LOCUS-COERULEUS.
00309B 04-03

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

LOCUST

OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE BRAIN OF THE LOCUST, SCHISTOCERCA-GREGARIA.
001343 02-03

LOFEPRAMINE

DOUBLE-BLIND ATTEMPT AT COMPARISON OF EFFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION.
0017B3 02-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PSYCHIATRIC ASPECTS.
003555 04-09

COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PHARMACOLOGICAL ASPECTS.
003574 04-09

LONG

HOW LONG SHOULD PROPHYLACTICS BE CONTINUED IN AFFECTIVE DISORDERS
000606 01-09

HOW LONG DOES CHLORPROMAZINE LAST?.
002133 02-17

EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
003474 04-04

LONG-ACTING

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08

LONG-ACTING DRUGS WITH AFTERCARE OF SCHIZOPHRENICS.
000546 01-08

NIMH-PRB COLLABORATIVE STUDY OF LONG-ACTING FLUPHENAZINE.
000550 01-08

LONG-ACTING NEUROLEPTICS -- A FAIRY STORY?
000B99 01-14

CRITICAL STUDY OF THE USE OF LONG-ACTING NEUROLEPTICS (DEPOT NEUROLEPTICS) IN FRANCE.
001042 01-17

PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17

LONG-ACTING NEUROLEPTICS: A PRELIMINARY STUDY OF CLOPIMOZIDE (R29764).
001655 02-07

TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
00166B 02-07

CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04

USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN-SUMMARY.
002626 03-08

USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY
00262B 03-08

POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-11

LONG-DELAY

LONG-DELAY BACKWARD TASTE-AVERSION CONDITIONING WITH LITHIUM.
003378 04-04

LONG-LASTING

ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03

COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM.
001413 02-03

D-ALA2-MET-ENKEPHALINAMIDE: A POTENT, LONG-LASTING SYNTHETIC PENTAPEPTIDE ANALGESIC.
002193 03-02

LONG-STANDING

CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN
003B91 04-17

LONG-TERM

NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS. (PH. D. DISSERTATION).
00020B 01-03

EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN
000218 01-03

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 01-08

TRANQUILIZERS OR ANTIDEPRESSANTS FOR CHRONIC SCHIZOPHRENICS: A LONG-TERM STUDY.
000572 01-08

LONG-TERM LITHIUM THERAPY OF GERIATRIC MANIC-DEPRESSIVES.
000599 01-09

LONG-TERM THERAPY OF AFFECTIVE DISORDERS AND SCHIZOPHRENIA.
000620 01-09

THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09

RED-BLOOD-CELL LITHIUM INDEX AND LONG-TERM MAINTENANCE TREATMENT.
000704 01-10

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
000741 01-11

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA. DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

EXPERIENCES WITH THE LONG-TERM USE OF ANATENSOL DEPOT.
000779 01-11

CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN.
000B25 01-13

COMPLICATIONS AND SIDE-EFFECTS IN LONG-TERM TREATMENT WITH PRACTOLOL.
000931 01-15

THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS AND LITHIUM.
000937 01-15

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

ON THE EFFECT OF DOPA-DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM.
000970 01-15

PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15

UNWANTED EFFECTS OF LONG-TERM MEDICATION IN SCHIZOPHRENIA AND DEPRESSION
001064 01-17

INDICATIONS FOR LONG-TERM PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC SYNDROMES.
001066 01-17

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL NERVOUS SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03

LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART
001345 02-03

P-CHLOROAMPHETAMINE: SHORT AND LONG-TERM EFFECTS UPON SHOCK-ELICITED AGGRESSION
001371 02-03

EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03

THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON 1HE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS.
00147B 02-04

INCREASED AGGRESSION IN RATS AFTER WITHDRAWAL OF LONG-TERM USED OXAZEPAM.
001509 02-04

LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE.
001609 02-04

SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATION UPON RAT OFFSPRING.
001622 02-05

EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07

DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS.
001691 02-0B

LONG-TERM STUDY OF MOLINDONE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENICS.
001697 02-0B

STUDY OF THE IMPORTANCE OF NEUROTIC PSYCHOLOGICAL FACTORS IN THE SUCCESS OF LONG-TERM LITHIUM TREATMENT.
001766 02-09

LONG-TERM TRANQUILIZERS: AN ALTERNATIVE FOR PRACTICE.
001B01 02-10

REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001BB0 02-13

ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY.
002035 02-15

LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15

REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY.
002076 02-15

SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-17

NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3
00231B 03-03

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-03

EFFECTS OF L-5-HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
002470 03-04

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04

LONG-TERM TOXICITY STUDY OF METHYLMERCURIC-CHLORIDE IN MONKEYS (REPORT V).
002569 03-05

BEHAVIORAL EFFECTS OF WITHDRAWAL OF FLUPHENAZINE AFTER LONG-TERM TREATMENT.
00257B 03-05

L-DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE: A LONG-TERM STUDY.
00258B 03-07

A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIDOL (R-16341).
002656 03-0B

CLINICAL EXPERIENCES WITH FLUPHENAZINE-DECANOATE (DF) IN 50 LONG-TERM PATIENTS.
002756 03-11

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
002778 03-11

LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50
0027B8 03-11

CLUBBING -- A SIDE EFFECT OF LONG-TERM PHENOTHIAZINES TREATMENT
002905 03-15

DISCONTINUANCE OF ASSOCIATED ANTIPARKINSONIAN DRUGS IN LONG TERM NEUROLEPTIC TREATMENT.
002923 03-15

PSEUDOPSYCHOTIC RELAPSES IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS
002945 03-15

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

FENFLURAMINE LONG-TERM ADMINISTRATION AND BRAIN SEROTONIN
003130 04-03

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
0031B4 04-03

MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS: LACK OF TOLERANCE WITH LONG-TERM ADMINISTRATION
0033B2 04-04

LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-04

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-0B

LONG-TERM TREATMENTS OF PSYCHOTIC STATES.
003613 04-11

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
00361B 04-11

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN
003633 04-11

EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING.
00369B 04-13

LONGEVITY

LEVODOPA, FERTILITY, AND LONGEVITY.
00311B 04-03

LONGITUDINAL

MHPG, AMITRIPTYLINE AND AFFECTIVE DISORDERS: A LONGITUDINAL STUDY.
002B34 03-13

LOPERAMIDE

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03

LOPRAMINE

CLINICAL STUDIES ON THE ANTIDEPRESSANT ACTION OF LOPRAMINE.
000660 01-09

LORAZEPAM

EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

A DOUBLE-BLIND COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
000502 01-07

STUDY OF THE PSYCHIATRIC INDICATIONS OF LORAZEPAM.
000509 01-07

DOUBLE-BLIND COMPARATIVE TEST OF LORAZEPAM FOR PSYCHONEUROSIS.
000753 01-11

PRELIMINARY STUDY OF PARENTERAL LORAZEPAM IN STATUS-EPILEPTICUS.
0007B9 01-11

LORAZEPAM AND DIAZEPAM IN ANXIOUS OUTPATIENTS: A CONTROLLED STUDY.
001B05 02-10

CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM.
001914 02-13

TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-10

INTRAVENOUS LORAZEPAM IN ACUTE ANXIETY CRISES.
00271B 03-10

CLINICAL EVALUATION OF LORAZEPAM IN EMERGENCY PSYCHIATRY.
002728 03-10

LORAZEPAM IS A SATISFACTORY PREANESTHETIC SEDATIVE IF USED WITH CARE.
002743 03-11

LORAZEPAM IMPAIRS DRIVING SKILLS.
002933 03-15
DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
002955 03-16
A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
003605 04-10
A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11
CLINICAL PHARMACOKINETICS OF LORAZEPAM. II. INTRAMUSCULAR INJECTION.
003675 04-13

LORDOSIS
EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-62B, ON RAT AND HAMSTER LORDOSIS.
001548 02-04
LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
002502 03-04

LOSS
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03
THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04
ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-04
ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING.
002495 03-04
A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
0033BB 04-04

LOUD
FUNCTIONS OF LOUD SOUND, PERSONALITY, AND DRUGS.
0029B4 03-17

LOW-COST
THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS.
003531 04-08

LOW-DOSE
SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07
LACK OF STIMULATION BY HIGH AMPHETAMINE DOSES FOLLOWING A LOW-DOSE OF SPIPERONE.
003345 04-04
A COMPARISON OF HIGH-DOSE AND LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11
A STUDY OF LOW-DOSE AMITRIPTYLINE OVERDOSES.
003813 04-15

LOW-LEVEL
ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
0014B5 02-04

LOWERED
LOWERED MONOAMINE-OXIDASE IN CONNECTION WITH ALCOHOLIC SUICIDES.
000B23 01-13

LOWERING
ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
000106 01-03
MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS: LACK OF TOLERANCE WITH LONG-TERM ADMINISTRATION.
003382 04-04

LOWERS
INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04

LOXAPINE
LOXAPINE SUCCINATE: A COMPARATIVE STUDY WITH CHLORPROMAZINE.
000541 01-08
LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08
EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE.
000694 01-10
THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02
A DOUBLE-BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
00169B 02-0B
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
001810 02-10
LOXAPINE SUCCINATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
00264B 03-0B
EFFICACY OF LOXAPINE IN THE TREATMENT OF PARANOID SCHIZOPHRENIA.
003527 04-08
EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-0B
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
003606 04-10

LSD
ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
0000B0 01-03
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL AND NEUROHUMORAL VARIABLES.
000355 01-04
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04
5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOMAL MEMBRANES.
001201 02-03
RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03
BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03
AN ANIMAL BEHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-04
PROLONGED LSD FLASHBACKS AS CONVERSION REACTIONS.
001B75 02-12
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04
EFFECTS OF LSD AND 2-BROMOLSD ON STRIATAL DOPAC LEVELS.
00323B 04-03
THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS
003239 04-03
EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03
TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-04
THE EFFECT OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) UPON SHOCK-ELICITED FIGHTING IN RATS.
003461 04-04
THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTONIN BINDING PROTEIN
003517 04-06
LSD TREATMENT IN A SEVERE CASE OF COMPULSIVE NEUROSIS.
0035B3 04-10
LSD TOXICITY: A SUSPECTED CAUSE OF DEATH.
003790 04-15

LSD-25
A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE).
000395 01-04
ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05
THE RECREATIONAL USE OF LSD-25 AND DRUG PROHIBITION.
0021B1 02-17
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04

U-10-171
NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171
003054 04-01
EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RAT BRAIN 5-HT TURNOVER
003179 04-03

U-7410
THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09

UDIOMIL
A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS
0005B9 01-09
COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA
00122B 02-03
TREATMENT OF DEPRESSION WITH LUDIOMIL CIBA.
002669 03-09
MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09

UMBAR
THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-0B
A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID.
003107 04-03

UNG
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01

UPUS-ERYTHEMATOSUS
SEX AND SYSTEMIC LUPUS-ERYTHEMATOSUS.
001959 02-14
THE PSYCHIATRY OF SYSTEMIC LUPUS-ERYTHEMATOSUS.
002149 02-17

USCHER
LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
000BB6 01-14

UTEINIZING
ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03
NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

UVATREN
COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOUBLE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-0B

X-101-129
DOUBLE-BLIND CLINICAL COMPARISON OF HF-1B54 (LX-101-129, CLOZAPINE, OR LEPONEX) WITH HALOPERIDOL.
00053B 01-0B

YMPHOCYTES
CANNABINOLS AND THE ROSETTE FORMING PROPERTIES OF LYMPHOCYTES IN VITRO.
001901 02-13

YSERGIC-ACID-DIETHYLAMIDE
RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03
THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
001134 02-03
COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
001475 02-04
COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04
REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC ACID DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY
003401 04-04

LYSERGIC-ACID-DIETHYLAMIDE-25
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT
000363 01-04

LYSINE
BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN
000407 01-04
EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT
003356 04-04
PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN.
003447 04-04

LYSOSOMAL
EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN
000266 01-03

LYSOSOMES
EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
0022B7 03-03

M-TYRAMINE
PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
00013B 01-03

M-TYROSINE
ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03
STUDIES ON THE DEPLETION OF BRAIN AMINES BY M-TYROSINE.
0032B0 04-03

MACACA
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-03

MACACA-MULATTA
BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN.
000393 01-04
EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03

MACROMOLECULAR
DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION.
0011B3 02-03

MACROMOLECULES
THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN
003132 04-03

MAGNESIUM
LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13
LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS.
002309 03-03
LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS.
00233B 03-03
LITHIUM MAGNESIUM RELATIONSHIP IN RED-BLOOD-CELLS DURING LITHIUM PROPHYLAXIS.
002695 03-09

MAINTAINED
EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04
VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY.
001454 02-04
BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04

COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001S03 02-04
DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS.
001691 02-08
CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONE IN THE COMMUNITY.
002174 02-17
EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
0024S7 03-04
BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04
EFFECTS OF COCAINE AND D-AMPHETAMINE ON BEHAVIOR MAINTAINED UNDER VARIOUS SCHEDULES OF FOOD PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-04
THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
00339S 04-04
EFFECTS OF DELAYING FOOD AVAILABILITY CONTINGENT ON ETHANOL MAINTAINED LEVER-PRESSING.
003442 04-04

MAINTENANCE

LITHIUM MAINTENANCE THERAPY.
00062S 01-09
MAINTENANCE THERAPY OF DEPRESSION.
000646 01-09
FOLLOW-UP OF MAINTENANCE TREATMENT FOR DEPRESSION
00064B 01-09
RED-BLOOD-CELL LITHIUM INDEX AND LONG-TERM MAINTENANCE TREATMENT.
000704 01-10
SUCCESSFUL DETOXIFICATION FROM METHADONE MAINTENANCE: FOLLOW-UP STUDY OF 3B PATIENTS.
000982 01-1S
CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08
FLUPHENAZINE-DECANOATE MAINTENANCE IN SCHIZOPHRENIA: A RETROSPECTIVE STUDY.
001713 02-08
LIFE EVENTS, DEPRESSIVE RELAPSE AND MAINTENANCE TREATMENT.
001770 02-09
METHADONE/LAAM MAINTENANCE: A COMPARISON STUDY.
001BS6 02-11
EXTRAPYRAMIDAL SIDE-EFFECTS IN LITHIUM MAINTENANCE THERAPY.
002021 02-1S
REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY.
002076 02-1S
ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
002437 03-04
INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
0024B7 03-04
THE MAINTENANCE AND MANAGEMENT OF SCHIZOPHRENIA.
002639 03-08
COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08
COMPARATIVE EVALUATION OF MODITEN-DEPOT AND CONVENTIONAL MAINTENANCE TREATMENT USING NEUROLEPTICS.
0026S1 03-08
THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17
DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE
00324S 04-03
EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
0034S3 04-04
PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003S19 04-07
THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS.
003S31 04-08
PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003S44 04-08
WITHDRAWAL FROM METHADONE MAINTENANCE: RATE OF WITHDRAWAL AND EXPECTATION.
003B9B 04-17

MAJEPTIL

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN
002306 03-03

MAJOR

A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
0004B0 01-07
ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN
0016S0 02-06
INDICATIONS FOR SULTOPRIDE, A MAJOR NEUROLEPTIC.
001B74 02-12
SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD
002094 02-16
DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
0036B3 04-13

MALE

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT
000160 01-03
INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04
CHOLINERGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT.
001434 02-04
EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS
001444 02-04
MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE
001499 02-04
EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS.
002004 02-14
EFFECT OF APOMORPHINE PLUS S-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03
POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03
THE INTFRACTION BETWEEN PILOCARPINE AND HEXOBARBITAL IN MALE RATS.
002SS1 03-04
PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10
INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03
EFFECT OF GAMMA-BUTYROLACTONE AND BACLOFEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03
EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03
EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT
0033S6 04-04
BETA-ENDORPHIN AND MALE SEXUAL BEHAVIOR
003429 04-04
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04
LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-04
ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPUBLISHED PAPER).
00370S 04-13

MALEINIMIDES
TERATOGENICITY AND EM8RYOTOXICITY OF SOME MALEINIMIDES
001620 02-05

MALES
TRH EFFECTS ON ENDOGENOUSLY DEPRESSED MALES
000669 01-09
A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES
002005 02-14
PSYCHOMOTOR PROCEDURES TO DISTINGUISH 8ETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACE8O ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

MALFORMATIONS
FETAL MALFORMATIONS AND ANTIEPILEPTIC DRUGS.
002047 02-15
WHAT HAPPENED LATER TO THE LITHIUM 8A8IES? A FOLLOW-UP STUDY OF CHILDREN 8ORN WITHOUT MALFORMATIONS.
002932 03-15

MALIGNANT
USE OF THE 8ROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000847 01-13

MAMMALIAN
MAMMALIAN 8IOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
000793 01-12
ANTIPSYCHOTICS AND GA8A TURNOVER IN MAMMALIAN BRAIN NUCLEI. (UNPUBLISHED PAPER).
002301 03-03
PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GA8A-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

MAN
PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL META8OLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03
BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE META8OLITES OF DIAZEPAM IN MAN
000393 01-04
META8OLISM OF METOPROLOL-3H IN MAN, THE DOG AND THE RAT.
000B04 01-13
8ILIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN.
000B08 01-13
CUMULATION IN CERE8ROSPINAL FLUID OF THE N-DESMETHYL META8OLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN.
000B25 01-13
COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL.
000B28 01-13
CERE8ROSPINAL FLUID CONCENTRATIONS OF DIAZEPAM AND ITS META8OLITES IN MAN.
000B32 01-13
THE PHARMACOKINETICS OF BROMAZEPAM IN MAN.
000857 01-13
8ILIARY EXCRETION OF DIAZEPAM AND ITS METABOLITES IN MAN
000862 01-13
COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-B7-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY
000866 01-13
THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN.
000887 01-14
SLEEP. EFFECTS OF D- AND L-AMPHETAMINE IN MAN AND IN RAT.
000896 01-14
OPERANT ACQUISITION OF MARIHUANA IN MAN
000907 01-14
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBAR8ITAL ON REM SLEEP AND REM DENSITY IN MAN
000909 01-14
A SURVEY OF THE PHARMACOLOGICAL PROPERTIES OF METOPROLOL IN ANIMALS AND MAN.
001011 01-17
PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHI8ITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN.
001441 02-04
EFFECT OF THE 1,5 BENZODIAZEPINES, CLO8AZAM AND TRIFLUBAZAM, ON THE SLEEP OF MAN
001657 02-07
BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13
PHARMACOKINETIC STUDIES ON HALOPERIDOL IN MAN
001911 02-13
ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 02-13
PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DOG, RA88IT, GUINEA-PIG AND RAT.
001921 02-13
METHODS FOR STUDY OF FLUPHENAZINE KINETICS IN MAN
001951 02-13
INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS.
001967 02-14
THE EFFECT OF LITHIUM ON IMPULSIVE AGGRESSIVE 8EHAVIOR IN MAN
001996 02-14
N-DESMETHYLDIAZEPAM: A NEW META8OLITE OF CHLORDIAZEPOXIDE IN MAN.
002805 03-13
COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002813 03-13
PHENO8AR8ITONE-INDUCED URINARY EXCRETIONS OF D-GLUCARIC-ACID AND 68ETA-HYDROXYCORTISOL IN MAN
002B22 03-13
EFFECT OF ENZYME INDUCTION 8Y 8AR8ITURATES ON NEUROHORMONE EXCRETION IN MAN.
002839 03-13
THE CARDIOVASCULAR EFFECTS OF LITHIUM IN MAN: A REVIEW OF THE LITERATURE.
002840 03-13
THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002857 03-14
EEG AND TASK PERFORMANCE AFTER ACTH4-10 IN MAN.
002874 03-14
PHARMACOKINETICS OF PENTO8ARBITAL IN THE CAT AND COMPARISONS WITH THE RABBIT AND MAN.
003317 04-03
ON THE METABOLISM OF HALOPERIDOL IN MAN.
003671 04-13
PHENOBAR8ITAL-INDUCED DRUG METABOLISM IN MAN.
003682 04-13
ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE.
0036B7 04-13
CENTRAL BIOCHEMICAL CORRELATES TO ANTIPSYCHOTIC DRUG ACTION IN MAN.
003704 04-13
PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSES IN MAN.
003708 04-13
PROPRANOLOL EFFECTS ON ACUTE MARIHUANA INTOXICATION IN MAN
003711 04-13
ANTIAGGRESSIVE EFFECT OF LITHIUM ION IN MAN.
003741 04-14
DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003824 04-15
FREE-LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN
003868 04-17
DRUG META8OLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN.
003B78 04-17

MANAGEMENT
EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15
THE MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
002107 02-17
THE MAINTENANCE AND MANAGEMENT OF SCHIZOPHRENIA.
002639 03-08
LITHIUM-SALTS IN THE MANAGEMENT OF A CHILD 8ATTERER.
002679 03-09
THE PHARMACEUTICAL MANAGEMENT OF GASTRIC ULCERATION (PH D DISSERTATION).
002773 03-11
RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03-11

CONTRIBUTION TO THE MANAGEMENT OF FOCAL EEG CHANGES WITH INTRAVENOUS ADMINISTRATION OF DIAZEPAM (FAUSTAN).
002B06 03-13
CASE STUDIES IN PSYCHIATRIC MANAGEMENT: HOSPITAL TO COMMUNITY.
002B53 03-14
CLINICAL MANAGEMENT OF SEXUAL DISORDERS.
002B66 03-14
MANAGEMENT OF TRICYCLIC ANTIDEPRESSANT TOXICITIES.
002949 03-15
THE MANAGEMENT OF PHOBIC DISORDERS USING CLOMIPRAMINE (ANAFRANIL).
00360B 04-10
THE MANAGEMENT OF PREMATURE EJACULATION.
003729 04-14
EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15
PHARMACOLOGIC MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
003B44 04-17
NEWER CONCEPTS IN MANAGEMENT OF MIGRAINE HEADACHES.
003B67 04-17

MANDRAX
THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

MANGANESE
MANGANESE AND NIACIN IN THE TREATMENT OF DRUG-INDUCED DYSKINESIAS.
000958 01-15

MANIA
TREATMENT OF MANIA WITH BROMOCRIPTINE.
000594 01-09
RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14
TREATMENT APPROACHES TO MANIA.
002097 02-17
A DOPAMINERGIC MECHANISM IN MANIA.
002673 03-09
CENTRAL MONOAMINE METABOLISM IN DEPRESSION AND MANIA (UNPUBLISHED PAPER).
002675 03-09
EFFECT OF THE BETA-RECEPTOR BLOCKER PROPRANOLOL ON MANIA.
002691 03-09
EXPERIENCES IN USING LITHIUM-CARBONATE -- ESPECIALLY WITH MANIA AND MANIC-DEPRESSIVE CASES.
002707 03-09
EFFECTS OF LITHIUM-CARBONATE ON MOTOR ACTIVITY IN MANIA AND DEPRESSION.
003561 04-09
ECT VERSUS CHLORPROMAZINE IN MANIA.
003565 04-09
TEMPO ERRORS AND MANIA.
003575 04-09
NONTOXIC HYPERLITHEMIA IN IMPENDING MANIA.
003B36 04-15

MANIC
CLINICAL EXPERIENCE OF SEPAZON (CLOXAZOLAM) FOR DEPRESSIVE MANIC.
000644 01-09
D-AMPHETAMINE IN THE MANIC SYNDROME.
00172B 02-09
CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09
CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLIC PATIENTS.
001747 02-09
LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001B13 02-11
LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13
FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION.
002597 03-07
LITHIUM IN THE TREATMENT OF A MANIC PATIENT WITH MULTIPLE-SCLEROSIS: A CASE REPORT.
003879 04-17

MANIC-DEPRESSIVE
A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
0005B0 01-09
FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
000619 01-09
ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-09
MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000B06 01-13
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000B49 01-13
PSYCHOANALYTIC ASPECTS OF THE TREATMENT OF MANIC-DEPRESSIVE PSYCHOSIS.
001754 02-09
THE EFFECTS OF ADMINISTERING LITHIUM-CARBONATE ON THE BALANCE OF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
001774 02-09
INDICATIONS FOR LITHIUM SALT IN OTHER THAN MANIC-DEPRESSIVE PSYCHOSIS.
001857 02-11
ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
002014 02-15
EXPERIENCES IN USING LITHIUM-CARBONATE -- ESPECIALLY WITH MANIA AND MANIC-DEPRESSIVE CASES.
002707 03-09
URINARY CYCLIC-AMP IN RELATION TO LITHIUM TREATMENT IN MANIC-DEPRESSIVE ILLNESS.
002B37 03-13
THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS.
003559 04-09
LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
00356B 04-09

MANIC-DEPRESSIVES
LONG-TERM LITHIUM THERAPY OF GERIATRIC MANIC-DEPRESSIVES.
000599 01-09
CHANGING THERAPY AND PROGNOSIS IN MANIC-DEPRESSIVES.
0006B7 01-10
THE MEDICAL ECONOMICS OF LITHIUM TREATMENT FOR MANIC-DEPRESSIVES.
003B54 04-17

MANIFESTATION
FORMATION OF CIRCULARITY AS A MANIFESTATION OF PATHOMORPHOSIS IN SCHIZOPHRENIA.
002640 03-08

MANIFESTATIONS
CIRCULATORY MANIFESTATIONS OF SOMA AND PSYCHE.
000717 01-10
HYPOTHYROIDISM WITH EPISODIC PSYCHIATRIC AND CARDIAC MANIFESTATIONS.
002127 02-17
THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03
TARDIVE-DYSKINESIA: MANIFESTATIONS, INCIDENCE, ETIOLOGY, AND TREATMENT.
002935 03-15

MANIFESTED
EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH.
003522 04-07

MANIPULATION
MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-04
AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION OF PROBLEM-SOLVING ABILITY
003513 04-06

MANIPULATIONS
THE EFFECTS OF MANIPULATIONS WITH THE DOPAMINERGIC SYSTEM ON SELF-STIMULATION BEHAVIOR.
000293 01-04

MANIPULATORS
LOCOMOTOR ACTIVITY AND EXPLORATION: THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT
001538 02-04

MANNER
THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
003120 04-03

MANNICH-BASES
SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
001108 02-02
ANALGESIC AND TRANQUILIZING ACTIVITY OF 5,B DISUBSTITUTED 1-TETRALONE MANNICH-BASES.
003075 04-02

MANS
MANS USE OF DRUGS THROUGH THE AGES.
001023 01-17

MANUAL
MANUAL OF PSYCHIATRIC THERAPEUTICS: PRACTICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY.
001074 01-17

MAO
INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000089 01-03
IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-03
MAO INHIBITORS: POTENTIAL FOR DRUG ABUSE. (UNPUBLISHED PAPER).
002B76 03-14
IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

MAOI
5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY.
000627 01-09
INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04
WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? ... A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED.
0026B5 03-09
A REVIEW OF COMBINED TRICYCLIC AND MAOI THERAPY.
003B46 04-17

MAPROTILINE
A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09
A STUDY OF THE ANTIDEPRESSIVE EFFECT OF MAPROTILINE.
00066B 01-09
CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09
COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
00122B 02-03
POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION.
001677 02-07
CLINICAL DOUBLE-BLIND STUDY WITH TWO DIFFERENT DOSAGES OF MAPROTILINE (150 AND 225MG PER DAY).
002793 03-11
MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09
A COMPARISON OF MAPROTILINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
003604 04-10

MAPROTYLIN
INTRAVENOUS ADMINISTRATION OF MAPROTYLIN IN DEPRESSION.
0004B5 01-07

MAPS
CLINICAL AND PHARMACOLOGICAL SPECTRAL MAPS OF THE NEUROLEPTICS.
003009 03-17

MARGINAL
ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10

MARIHUANA
MARIHUANA. NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
000795 01-12
MARIHUANA, TETRAHYDROCANNABINOL AND T-CELL FUNCTION.
000B54 01-13
OPERANT ACQUISITION OF MARIHUANA IN MAN.
000907 01-14
6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-03
MARIHUANA AND SEX
0019B1 02-14
EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION
002032 02-15
ELECTROENCEPHALOGRAPHIC ALTERATIONS IN MARIHUANA USERS.
002B31 03-13
MARIHUANA AND HUMAN PHYSICAL ACTIVITY
002850 03-14
ADVERSE REACTIONS TO MARIHUANA USE AMONG COLLEGE STUDENTS.
002B96 03-15
DISCRIMINABLE STIMULI PRODUCED BY MARIHUANA CONSTITUENTS.
003002 03-17
PROPRANOLOL EFFECTS ON ACUTE MARIHUANA INTOXICATION IN MAN.
003711 04-13
EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14
DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003824 04-15
ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003B94 04-17

MARIJUANA
THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY.
000270 01-04
EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
000792 01-12
EVIDENCE FOR ACUTE EFFECTS OF ALCOHOL AND MARIJUANA ON COLOR DISCRIMINATION.
000B73 01-14
CHRONIC USE OF MARIJUANA.
000967 01-15
REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT.
001644 02-05
MARIJUANA EFFECTS ON SIMULATED FLYING ABILITY.
001919 02-13
EFFECTS OF MARIJUANA, EXPECTATION AND SUGGESTIBILITY ON COGNITIVE FUNCTIONING.
001963 02-14
INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
0019B2 02-14
MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14
MARIJUANA FLASHBACK PHENOMENA.
002022 02-15
MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002B67 03-14
THE WAR OVER MARIJUANA.
002BB2 03-14
EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14
MARIJUANA: EFFECTS ON STORAGE AND RETRIEVAL OF PROSE MATERIAL.
003743 04-14

MARIJUANA-INDUCED
EFFECTS OF PRACTICE ON MARIJUANA-INDUCED CHANGES IN REACTION TIME.
001B73 02-12

MARKED
MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07

MASCULINE
HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-04
MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-04
MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

MASK
PSYCHOTIC MASKED DEPRESSION OR BLACK MASK FOR DEPRESSION.
000613 01-09

MASKED
PSYCHOTIC MASKED DEPRESSION OR BLACK MASK FOR DEPRESSION.
000613 01-09

MASSACRE
IF SPEED KILLS, TRICYCLICS MASSACRE.
001734 02-09

MASSIVE
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15

MAST
AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

MATCHING
MATCHING PROPERTIES IN DOUBLE-BLIND TRIALS.
002090 02-16

MATERNAL
ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15
EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04
NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY.
00214B 02-17
EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN.
003299 04-03
EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04
THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-05
MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY IN RATS.
003507 04-05

MATURATION
EFFECT OF TWO INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE ON MATURATION OF MEMORY IN MICE.
0014B7 02-04

MATURE
A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03

MAXIMAL
PERIOD OF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLDEN HAMSTER.
001616 02-05

MAXIMUM
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04
AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
00161B 02-05

MAZE
ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
0024B0 03-04

MAZINDOL
MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS.
001267 02-03
SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-17
OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07
MAZINDOL (TERONAC) IN THE TREATMENT OF PREDOMINANTLY ALIMENTARY OBESITY.
002719 03-10
BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
003109 04-03
EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
D03241 04-03
ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-04
ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04
A MULTICENTRE STUDY COMPARING MAZINDOL AND PLACEBO IN OBESE PATIENTS.
00364B 04-11

MBD
MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

MDA
THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE
0012B2 02-03
MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001877 02-12
THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

MDI
TWO CASES OF MDI DEPRESSION WHERE CARBAMAZEPINE WAS ESPECIALLY EFFECTIVE.
001742 02-09

MEASURE
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT
000114 01-03
THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL.
001941 02-13

MEASURED
THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
0002B9 01-04
THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03
POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE
003119 04-03
A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

MEASUREMENT
MEASUREMENT OF ACUTE AND CHRONIC BEHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-04
THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS.
000655 01-09
MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
001002 01-16
AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03
REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
001420 02-03
INTERACTION OF DRUG EFFECTS WITH TESTING PROCEDURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04
MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02-13
MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN.
0021B5 03-01
QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03
THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
D02641 03-DB
MEASUREMENT OF 5-HYDROXYINDOLE COMPOUNDS DURING L-5-HTP TREATMENT IN DEPRESSED PATIENTS.
002700 03-09

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC BRAIN-DISEASE, PHARMACOLOGY
002818 03 13

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002B93 03 15

THE MEASUREMENT OF BIOGENIC AMINE TURNOVER USING OXYGEN 1B.
003263 04-03

AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION OF PROBLEM-SOLVING ABILITY
003513 04-06

EASUREMENTS

STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003B66 04-17

EASURES

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
000491 01-07

EFFECTS OF DIAZEPAM AND RIPAZEPAM ON TWO MEASURES OF ADJUNCTIVE DRINKING IN RATS.
001572 02-04

A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

PROLACTIN AND PSYCHOPHYSIOLOGIC MEASURES AFTER SINGLE-DOSES OF THIORIDAZINE.
003693 04-13

EASURING

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
002587 03-06

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002B93 03-15

ECHANISM

THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

MECHANISM OF THE EFFECT OF ACUTE ETHANOL ON HEXOBARBITAL METABOLISM.
000074 01-03

RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03

INVESTIGATIONS OF THE MECHANISM OF CENTRAL ACTION OF KININS.
000174 01-03

ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03

A POSSIBLE COMMON MECHANISM OF ACTION OF ANTIDEPRESSANT TREATMENTS.
000250 01-03

THE MECHANISM OF ACTION OF PSYCHOPHARMACOLOGICAL AGENTS ON BEHAVIOUR.
000391 01-04

CURRENT VIEWS ON THE MECHANISM OF CHLORPROMAZINE ACTION
000831 01-13

BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION A REVIEW OF THE BIOCHEMICAL LITERATURE.
001080 01-17

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
001207 02-03

MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN: METAL BINDING AND FLUORESCENCE STUDIES.
001328 02-03

EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03

ETHANOL AND DELTA9 TETRAHYDROCANNABINOL MECHANISM FOR CROSS TOLERANCE IN MICE
001386 02 03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT
001429 02-03

THE MECHANISM OF THE EFFECT OF ACUTE STRESS ON HEXOBARBITAL METABOLISM.
002221 03-03

EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS.
002224 03-03

THE MECHANISM OF OPIATE AGONIST AND ANTAGONIST ACTION. (UNPUBLISHED PAPER).
002335 03-03

MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS
002383 03-03

MECHANISM OF ANALGESIC EFFECTS OF NARCOTICS.
002428 03-04

MECHANISM AND CHARACTERISTICS OF DRUG-INDUCED AGGRESSION (PH.D DISSERTATION).
002451 03-04

SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
002510 03-04

A DOPAMINERGIC MECHANISM IN MANIA.
002673 03-09

POSSIBLE MECHANISM FOR BIOLOGICAL ACTION OF LITHIUM
002810 03-13

REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
003097 04-03

MECHANISM OF NEUROTOXICITY OF CARDIOTONIC GLYCOSIDES.
003149 04-03

ON THE MECHANISM OF PULMONAL HYPERTENSION INDUCED BY ANOREXIC AGENTS.
003223 04-03

THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-03

ON THE MECHANISM OF ENHANCED SENSITIVITY TO HEPATOTOXIC AGENTS INDUCED BY ETHANOL.
003231 04-03

LITHIUM -- MECHANISM OF ACTION SIMILAR TO PHENYTOIN.
003681 04-13

IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-15

MECHANISMS

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03

EFFECT OF P-NITROPHENYL-DIAZONIUM-FLUOROBORATE ON CHOLINERGIC MECHANISMS.
000069 01-03

EFFECT OF SOME PHOSPHODIESTERASE INHIBITORS ON CENTRAL DOPAMINE MECHANISMS.
000100 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03

NEUROBIOLOGICAL MECHANISMS OF ADAPTATION IN RELATION TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
000162 01-03

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

DYSTONIC REACTIONS FOLLOWING NEUROLEPTICS: TIME COURSE AND PROPOSED MECHANISMS.
000543 01-08

CENTRAL MECHANISMS OF ACTION OF P-CHLOROAMPHETAMINE: BIOCHEMICAL AND HISTOLOGICAL STUDIES. (PH.D DISSERTATION).
000843 01-13

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES
001105 02-02

IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
00115B 02-03

SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION. (UNPUBLISHED PAPER).
001173 02-03
DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION.
001183 02-03
MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS.
001267 02-03
EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03
CHOLINERGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT.
001434 02-04
PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14
SYNAPTIC MECHANISMS IN THE SUBSTANTIA-NIGRA
002113 02-17
DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C-GMP ELICITED BY HALOPERIDOL AND DIAZEPAM.
002211 03-03
CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES I: CHLORDIAZEPOXIDE AND DEMOXEPAM.
00225B 03-03
NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
0022B3 03-03
THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03
STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-03
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04
CENTRAL-NERVOUS-SYSTEM MECHANISMS OF ANALGESIA.
002496 03-04
MECHANISMS UNDERLYING TARDIVE-DYSKINESIA.
002BB3 03-15
OROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY.
002911 03-15
DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17
DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
0030B6 04-03
THE EFFECT OF PROSTAGLANDIN-E1 ON CENTRAL CHOLINERGIC MECHANISMS.
003101 04-03
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES II: OXAZEPAM AND DIAZEPAM.
003165 04-03
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
003192 04-03
EFFECTS OF ALKYLTETRAHYDROCARBAZOLE-ETHANAMINES AND RELATEO COMPOUNDS, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-03
MECHANISMS OF EXCITATION AND INHIBITION IN THE NIGROSTRIATAL SYSTEM.
003250 04-03
DIFFERENTIAL INTERACTIONS OF PHENOBARBITAL AND PENTOBARBITAL WITH BETA-ADRENERGIC MECHANISMS IN VITRO AND VIVO.
003262 04-03
SFIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03
NALOXONE ANTAGONISM AS EVIDENCE FOR NARCOTIC MECHANISMS.
003676 04-13

MEDANTANE
COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11

MEDAZEPAM
MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01
MEDAZEPAM AND THE DRIVING ABILITY OF ANXIOUS PATIENTS.
003B09 04-15

MEDIAL
DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF-STIMULATION
000335 01-04
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04
COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03
LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
002502 03-04
MORPHINE, NALOXONE AND THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-03

MEDIAN
HYPERTHERMIA FOLLOWING SELF-STIMULATION OF THE MEDIAN RAPHE IN THE RAT
0003B2 01-04

MEDIATE
IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

MEDIATED
MAZINDOL ANOREXIA IS MEDIATED BY ACTIVATION OF DOPAMINERGIC MECHANISMS
001267 02-03
PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03
ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03
GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02
A CEREBELLAR MODEL TO STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSION (UNPUBLISHED PAPER).
002212 03-03
POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT
002522 03-04

MEDIATES
GABA RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CEREBELLAR C-GMP ELICITED BY DIAZEPAM. (UNPUBLISHED PAPER).
000051 01-03

MEDIATING
ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE
001202 02-03
DIFFERENT MECHANISMS MEDIATING THE DECREASE OF CEREBELLAR C-GMP ELICITED BY HALOPERIDOL AND DIAZEPAM.
002211 03-03
5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION
002429 03-04
EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
00243B 03-04

MEDIATION
5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR
000364 01-04
AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04
DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03
MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

POSSIBLE INVOLVEMENT OF CENTRAL FACTORS IN THE MEDIATION OF CONDITIONED TASTE-AVERSION
003081 04-03

INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03

MEDIATOR

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA NIGRA.
002355 03-03

MEDICAL

PSYCHOPHARMACOLOGICAL STUDY ON THE DEPRESSIVE STATE IN MEDICAL PRACTICE.
000692 01-10

ALCOHOL DRUG INTERACTIONS IN DAILY MEDICAL PRACTICE.
000974 01-15

PSYCHOACTIVE DRUGS IN MEDICAL PRACTICE: THE PRESENT STAGE OF DEVELOPMENT.
001049 01-17

MEDICAL AND SOCIAL INFLUENCE OF PHARMACOTHERAPY AGAINST SCHIZOPHRENIA
001699 02-08

BENZODIAZEPINE DRUGS IN GENERAL MEDICAL PATIENTS.
001833 02-11

MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

RESULTS OF TREATING NERVOUS TICS IN CHILDREN BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11

PHARMACOTHERAPY AND MEDICAL INSURANCE.
003000 03-17

THE MEDICAL ECONOMICS OF LITHIUM TREATMENT FOR MANIC-DEPRESSIVES.
003854 04-17

TESTIMONY BY AN EX-CONVICT AGAINST MEDICAL EXPERIMENTATION IN PRISONS.
003882 04-17

MEDICALLY

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT: A CASE REPORT.
003587 04-10

MEDICATION

INDUCTION OF PHYSICAL DEPENDENCE IN RATS BY SHORT INTERVAL MEDICATION.
000471 01-06

A NEW MEDICATION OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-07

THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
000652 01-09

MEDICATION FOR HYPERKINETIC CHILDREN.
000926 01-14

THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE-EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN
000972 01-15

UNWANTED EFFECTS OF LONG-TERM MEDICATION IN SCHIZOPHRENIA AND DEPRESSION.
001064 01-17

A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY
001755 02-09

COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001843 02-11

MEDICATION: INCREASED VIGILANCE NEEDED.
002053 02-15

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION
002082 02-15

COMPARATIVE DOSES AND COSTS OF ANTIPSYCHOTIC MEDICATION
002110 02-17

CHARACTEROLOGICAL SIGNIFICANCE OF MEDICATION.
002136 02-17

PSYCHIATRIC MEDICATION: THE ROLE OF THE NONPHYSICIAN
002156 02-17

SEX AND NEUROLEPTIC MEDICATION.
002649 03-08

THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D DISSERTATION).
002860 03-14

THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS
003531 04-08

REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
003572 04-09

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN.
003633 04-11

MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION.
003798 04-15

ACUTE HYPERTENSION AFTER ABRUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION.
003833 04-15

EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE.
003889 04-17

MEDICATIONS

IS THERE A ROLE FOR THE TEACHER IN THE USE OF MEDICATIONS FOR HYPERKINETICS
000908 01-14

OUTPATIENT PSYCHIATRIC MEDICATIONS AND GLAUCOMA.
000980 01-15

PSYCHOTROPIC MEDICATIONS.
001028 01-17

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS.
002884 03-15

USE OF SO-CALLED ANTIPARKINSON MEDICATIONS IN PSYCHIATRY.
002888 03-15

A REVIEW OF PSYCHOTROPIC MEDICATIONS AND THE GLAUCOMAS.
002926 03-15

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

HEAT STROKE ASSOCIATED WITH MEDICATIONS HAVING ANTICHOLINERGIC EFFECTS.
003759 04-15

MEDICINAL

CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
001084 02-01

MEDICINE

EXPERIMENTAL CLINICAL USE OF PINAZEPAM IN PSYCHOSOMATIC MEDICINE.
000673 01-10

A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SULPIRIDE AND OXAZOLAM IN THE FIELD OF PSYCHOSOMATIC MEDICINE.
000713 01-10

BROMAZEPAM IN PSYCHOSOMATIC MEDICINE
000771 01-11

RESEARCH ON THE USE OF SULPIRIDE IN PSYCHOSOMATIC MEDICINE: A STUDY OF 104 CASES.
000816 01-13

PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION: EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000852 01-13

PSYCHIATRY, MEDICINE, AND SLEEP -- SLEEPING DRUGS AND TRANQUILIZERS.
000891 01-14

PSYCHIATRIC MEDICINE AND SLEEP -- CHLORPROMAZINE.
000897 01-14

PSYCHOLOGICAL MEDICINE: DRUGS USED IN PSYCHOLOGICAL MEDICINE PHARMACOLOGICAL BASIS OF TREATMENT.
001828 02-11

MEDICINE FOR MELANCHOLY
002706 03-09

THE USE OF PROPRANOLOL IN SOMATIC MEDICINE.
002957 03-17

MEDITATION

MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION
003856 04-17

MEDIUM-SLOW
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 D4-13
COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
DD3774 D4-15

MEDULLA
EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
0D0177 01-D3
CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
DD237D D3-D3
AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
003DBB 04-03

MEDULLA-OBLONGATA
EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGATA ON THE SPINAL DORSAL HORN NEURON.
DD22D0 03-D3

MEDULLARY
ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
DD14D2 D2-D3
RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
DD3DB2 04-D3

MEGADOSE
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
DDD957 D1-15

MEGAVITAMINS
MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION
DD3B56 04-17

MEGIMIDE
SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
DDD7B3 D1-11

MEGLUMINE
ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
D01639 D2-05

MELANCHOLIA
CHEMOTHERAPY OF MELANCHOLIA BY SEQUENTIAL ASSOCIATION OF A NEUROLEPTIC AND VILOXAZINE.
DD266B D3-09

MELANCHOLIC
CYCLIC-AMP LEVELS IN CEREBROSPINAL FLUID IN MANIC MELANCHOLIC PATIENTS.
DD1747 D2-D9
LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
D01929 D2-13

MELANCHOLY
FOUR METHODS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
00D496 01-D7
MEDICINE FOR MELANCHOLY.
0027D6 03-09

MELANOCYTE
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
DD3615 D4-11

MELATONIN
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
DDD265 D1-D3
MELATONIN, MSH, AND PSYCHOSIS.
DD3B47 D4-17

MELITRACEN
CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
DDD604 D1-D9

MELLARIL
EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
DD22B7 D3-D3

MELPERONE
PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
D01110 02-D2
INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04

MEMBRANAL
DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE.
DDD513 D1-D7

MEMBRANE
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
DDDD37 D1-D3
COMPARATIVE EFFECTS OF CHLORPROMAZINE AND ITS FREE-RADICAL ON MEMBRANE FUNCTIONS.
D0D153 D1-03
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
D00B49 D1-13
THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES.
DD12B1 D2-D3
EFFECT OF ANICOTINE ON SOME PROPERTIES OF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE.
DD1299 02-03
ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION.
D013D4 D2-03
ALCOHOL MEMBRANE INTERACTION IN THE BRAIN: NOREPINEPHRINE RELEASE.
DD1394 D2-03
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
DD25DB D3-D4
STUDIES ON MEMBRANE RECEPTOR SITES FOR SEROTONIN IN THE BRAIN
DD33DB D4-D3

MEMBRANES
PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
D0D117 D1-D3
DIHYDROERGOTAMINE BINDING TO RAT BRAIN MEMBRANES.
D01169 D2-D3
5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOMAL MEMBRANES.
DD12D1 D2-D3
A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
DD132D D2-03
PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
DD2253 D3-D3
INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
DD2297 D3-D3
ALCOHOL, ANESTHETICS, MEMBRANES.
DD2963 03-17

MEMORIES
SIMILARITIES BETWEEN SHORT-TERM AND REACTIVATED MEMORIES.
DD149B D2-04

MEMORY
SHORT-TERM MEMORY IN THE RHESUS-MONKEY: DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
D0D2B3 D1-D4
MODULATION OF CYCLOHEXIMIDE RESISTANT MEMORY BY SYMPATHOMIMETIC AGENTS.
D00333 01-D4
INFLUENCE OF PHYSOSTIGMINE UPON CONSOLIDATION OF MEMORY IN MICE.
D00425 D1-D4
THE EFFECT OF MEMORY BLOCKING ANTIBIOTICS AND THEIR ANALOGS ON ACETYLCHOLINESTERASE.
000427 D1-04
THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN.
DDDBB7 01-14
INHIBITION OF CATECHOLAMINE BIOSYNTHESIS AND MEMORY PROCESSES.
DD1214 02-03
EFFECT OF TWO INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE ON MATURATION OF MEMORY IN MICE.
DD14B7 D2-04

REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE
0015B0 02-04
INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS
001967 02-14
ALCOHOL AND MEMORY: STORAGE AND STATE DEPENDENCY
002069 02-15
EFFECTS OF POSTTRIAL HORMONE INJECTIONS ON MEMORY PROCESSES.
002455 03-04
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04
ACTH4-10 ON MEMORY DYSFUNCTION.
002771 03-11
MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002B67 03-14
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN
003365 04-04
SUSCEPTIBILITY OF A REACTIVATED MEMORY TO THE EFFECTS OF STRYCHNINE: A TIME-DEPENDENT PHENOMENON
003393 04-04
STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE.
003725 04-14
EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14
EFFECTS OF ACTH4-10 ON ECT-INDUCED MEMORY DYSFUNCTIONS.
003750 04-14
ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003B94 04-17

MEN

SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07
BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03
BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04-14

MENIERES

THE EFFECT OF LITHIUM IN MENIERES DISEASE.
001B16 02-11

MENTAL

STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07
CONTRIBUTION OF SLOW-RELEASE NEUROLEPTICS ON OPENING UP THE MENTAL HOSPITAL.
000605 01-09
PROLACTIN AND MENTAL ILLNESS.
000616 01-09
CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11
ACTION OF TRAZODONE ON MENTAL FUNCTIONS OF THE AGED.
000770 01-11
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000BB5 01-14
MENTAL EFFECTS OF ANTIEPILEPTIC DRUGS
00093B 01-15
UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15
ANTICONVULSANT DRUGS AND MENTAL SYMPTOMS: A REVIEW.
0009B9 01-15
TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
00105B 01-17
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN.
001441 02-04
MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION
001B26 02-11
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001B45 02-11
DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION
002034 02-15
BIOLOGICAL SUBSTRATES OF MENTAL ILLNESS
002130 02-17
THE THERAPISTS HANDBOOK: TREATMENT METHODS OF MENTAL DISORDERS.
002178 02-17
ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04
MENTAL DISORDERS OTHER THAN SCHIZOPHRENIA AND DEPRESSION.
002764 03-11
DRUG TREATMENT OF MENTAL DISORDERS.
002780 03-11
LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50.
0027BB 03-11
AMINERGIC FACTORS IN MENTAL ILLNESS.
002965 03-17
EFFICACY OF PIRACETAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
00296B 03-17
DRUGS USED IN THE TREATMENT OF MENTAL DISORDER.
003030 03-17
ADVANCES IN THE DRUG THERAPY OF MENTAL ILLNESS.
003045 03-17
BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03
SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09
PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
0035B1 04-10
GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
003634 04-11
MENTAL DISTRESS IN PATIENT ON DISOPYRAMIDE.
003776 04-15

MENTALLY

THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
0007B1 01-11
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17
ON THE TREATMENT OF MENTALLY DISTURBED COLLEGE STUDENTS.
001047 01-17
AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
0016B4 02-08
SOME STUDIES IN AN INSTITUTION FOR THE MENTALLY RETARDED.
001B59 02-11
INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
00300B 03-17
RICKETS AND ANTICONVULSANTS IN MENTALLY RETARDED PATIENTS.
0037B3 04-15

MEPERIDINE

CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03
INTRAMUSCULAR BUTORPHANOL AND MEPERIDINE IN POSTOPERATIVE PAIN
001662 02-07
MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

MEPIPRAZOLE

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03
THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

MEPROBAMATE
CYCLOPENTONE DERIVATIVES RELATED TO MEPROBAMATE: CONFORMATION ACTIVITY RELATIONSHIPS.
000013 01-01
SUBJECTIVE AND PHYSIOLOGIC EFFECTS OF MORPHINE, PENTOBARBITAL, AND MEPROBAMATE.
000761 01-11
THE INFLUENCE OF MEPROBAMATE ON HEART-RATE IN THE CONSCIOUS DOG.
001615 02-05
A SLEEP STUDY OF ACUTE PSYCHOTIC STATES DUE TO ALCOHOL AND MEPROBAMATE ADDICTION.
002937 03-15

MER-25
EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-62B, ON RAT AND HAMSTER LORDOSIS.
001548 02-04

MERCURY
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-03

MERIONES-UNGUICULATUS
PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPEN-FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
00340B 04-04

MERSYNDOL
TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COMBINATION (MERSYNDOL).
003039 03-17

MESCALINE
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04
DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04
EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-03
THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON.
001505 02-04
MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
001611 02-04
SYNTHESIS OF POTENTIAL MESCALINE ANTAGONISTS.
002190 03-02
THE EFFECT OF DESIPRAMINE ON THE UPTAKE OF MESCALINE BY CORTICAL SYNAPTOSOMES.
003095 04-03
EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03
FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
003394 04-04

MESCALINE-INDUCED
BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-03

MESCALINS
METABOLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
0030B3 04-03

MESENCEPHALIC
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

MESENCEPHALON
COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON
002334 03-03

MESOCORTICAL
DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03
TOPOGRAPHIC AND PHARMACOLOGICAL STUDY OF THE MESOCORTICAL DOPAMINERGIC SYSTEM.
000240 01-03

MESOLIMBIC
DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03
TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN
000256 01-03
REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENELURIDOL.
000459 01-05
SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04
ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
001602 02-04
EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
002270 03-03
THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN
002436 03-04
MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
0024B3 03-04
STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04

MESORIDAZINE
MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION.
001B26 02-11
THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
00353B 04-08
MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
0035B2 04-10

METABOLIC
EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPONSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
00002B 01-03
PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION: COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES
000197 01-03
METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY
000B42 01-13
A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01
METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT. NEW METABOLIC PATHWAY OF CAFFEINE.
00112B 02-03
PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN.
001200 02-03
BEHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
0013B5 02-03
METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 03-03
ANDEAN COCA CHEWING: A METABOLIC PERSPECTIVE.
002B02 03-13
METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
003044 03-17
THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

THE ROLE OF N HYDROXYAMPHETAMINE IN THE METABOLIC DEAMINATION OF AMPHETAMINE.
003329 04-03

TABOLISM

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03

EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEY.
000064 01-03

MECHANISM OF THE EFFECT OF ACUTE ETHANOL ON HEXOBARBITAL METABOLISM.
000074 01-03

3-ISOXAZOLIDONE -- AN INHIBITOR OF GABA METABOLISM.
000113 01-03

THE EFFECTS OF QUIPAZINE ON 5-HT METABOLISM IN THE RAT BRAIN.
000120 01-03

PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
000138 01-03

EFFECT OF THEOPHYLLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN.
000139 01-03

ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RELEVANCE FOR PSYCHOMOTOR EFFECTS.
00014B 01-03

DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
000198 01-03

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03

EFFECTS OF HALOTHANE ON CATECHOLAMINE METABOLISM IN THE BRAINSTEM OF RATS.
000221 01-03

METABOLISM IN VITRO OF POTENTIAL APOMORPHINE PRODRUGS.
000229 01-03

BRAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHIBITION
000252 01-03

DOPAMINE METABOLISM IN THE NUCLEUS-ACCUMBENS: THE EFFECT OF CLOZAPINE.
000260 01-03

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
000269 01-03

HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04

INDUCTION EFFECT OF DIAZEPAM ON ITS OWN METABOLISM.
000517 01-07

AMINE METABOLISM.
000555 01-08

METABOLISM OF DRUGS IN SCHIZOPHRENIA
000566 01-08

METABOLISM OF INDOLE AMINES IN DEPRESSION.
000617 01-09

SOME ASPECTS OF THE METABOLISM OF TRICYCLIC ANTIDEPRESSANTS.
000638 01-09

METABOLISM OF METOPROLOL-3H IN MAN, THE DOG AND THE RAT.
000804 01-13

EFFECT OF AMPHETAMINE-TYPE PSYCHOSTIMULANTS ON BRAIN METABOLISM.
000817 01-13

SEX AS A FACTOR IN METABOLISM, TOXICITY, AND EFFICACY OF PHARMACODYNAMIC AND CHEMOTHERAPEUTIC AGENTS.
000822 01-13

EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS
000833 01-13

COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS METABOLISM OF IMIPRAMINE IN HUMANS.
000850 01-13

HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-13

STUDY OF NOOANALEPTIC DRUG EFFECT ON BRAIN METABOLISM IN HUMANS.
000914 01-14

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14

METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC ACID IN THE RAT NEW METABOLIC PATHWAY OF CAFFEINE.
001128 02-03

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
001182 02-03

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
001188 02-03

MODIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN
001203 02-03

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001204 02-03

EFFECTS OF FENTANYL AND DROPERIDOL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
001210 02-03

INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
001213 02-03

IN VITRO METABOLISM OF AMPHETAMINE: AN APPARENT ENANTIOMERIC INTERACTION.
001217 02-03

TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03

ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM.
001280 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03

PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03

EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
001358 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

EFFECT OF LITHIUM ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM IN MICE.
001370 02-03

EFFECT OF TRAZODONE ON BRAIN DOPAMINE METABOLISM.
001388 02-03

THE EFFECT OF L-DOPA AND AN INHIBITOR OF PERIPHERAL DECARBOXYLATION ON GLUCOSE METABOLISM IN BRAIN.
001405 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM.
001413 02-03

COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN
001419 02-03

THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02-03

MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
001611 02-04

UPTAKE AND METABOLISM OF 3-METHOXYTYRAMINE IN THE CAT BRAIN.
001638 02-05

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
D01642 02-D5

PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT.
D01776 D2-D9

HYPOTHYROID-LIKE ALTERATIONS IN TESTOSTERONE METABOLISM IN ANOREXIA-NERVOSA.
DD1BB7 D2-13

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
D01929 D2-13

NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
DD1949 D2-13

INTRACEREBRAL DOPAMINE METABOLISM STUDIED BY A NOVEL RADIOISOTOPE TECHNIQUE.
DD196B D2-14

DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
0D2051 02-15

NEUROTRANSMITTER METABOLISM IN CELL CULTURE.
0D2213 03-D3

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION (UNPUBLISHED PAPER).
D02217 D3-D3

THE MECHANISM OF THE EFFECT OF ACUTE STRESS ON HEXOBARBITAL METABOLISM.
D02221 03-D3

EPOXIDE-DIOL PATHWAY IN THE METABOLISM OF TRICYCLIC DRUGS.
DD224D D3-D3

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE
0022BD D3-03

EFFECT OF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
002284 D3-D3

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION
DD22BB D3-D3

EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
DD2291 D3-03

A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
DD2296 D3-D3

THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN
DD23D3 D3-03

LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS.
D02309 D3-D3

THE METABOLISM OF CHLORPROMAZINE IN THE NEONATAL GUINEA-PIG
0D2315 D3-03

MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN
DD2319 D3-03

METABOLISM OF 1,4 DIHYDROTRIFLUOROMETHYLQUINOXALINEDIONE (LILLY-72525) IN RATS AND CATS
0D2329 D3-D3

EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN
DD233D 03-D3

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO
DD2339 D3-D3

EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN.
D02373 D3-03

METABOLISM OF 3 O-METHYLDOPA BY THE ISOLATED PERFUSED RAT LIVER
0D23BB 03-D3

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
DD239B D3-D3

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SFROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
DD2574 D3-D5

THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLFI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
DD25B4 03-D6

CENTRAL MONOAMINE METABOLISM IN DEPRESSION AND MANIA (UNPUBLISHED PAPER)
DD2675 D3-D9

A STUDY OF ENDOGENOUS DOPAMINE METABOLISM IN GILLES-DE-LA-TOURETTES DISEASE
DD26B4 D3-09

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM. MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
DD2B1B 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM
DD2820 D3-13

TETRAHYDROCANNABINOL (THC): METABOLISM AND SUBJECTIVE EFFECTS.
D0283B D3-13

IMPORTANCE OF THE DOPAMINE METABOLISM FOR THE CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
DD2B41 D3-13

IMPORTANCE OF DOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
DD3D43 D3-1

METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
D03D44 D3-1

STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003D64 D4-0

METABOLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
DD3083 D4-0

EFFECTS OF DISULFIRAM AND CHLORAL HYDRATE ON THE METABOLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN
003D94 04-0

A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID
DD31D7 04-0

INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT
DD3135 D4-0

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
DD31BB D4-0

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM
DD32D6 D4-0

DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
DD3212 D4-0

CEREBRAL CIRCULATORY AND METABOLISM CHANGES FOLLOWING AMPHETAMINE ADMINISTRATION
0D3217 04-0

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA-AMINOLAEVULINIC-ACID IN RATS.
DD3237 D4-0

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
DD3241 D4-0

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS
0D324B D4-0

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
DD32B3 D4-0

EFFECTS OF CYCLIC-AMP AND DIBUTYRYL-CYCLIC-AMP ON CEREBRAL HEMODYAMICS AND METABOLISM IN THE BABOON.
DD3297 D4-0

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA
D033D3 D4-0

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS
DD3323 D4-0

PERLAPINE AND DOPAMINE METABOLISM: PREDICTION OF ANTIPSYCHOTIC EFFICACY.
DD3325 D4-0

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTAB-TETRAHYDROCANNABINOL
0D3423 04-0

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN
DD3447 D4-0

ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
003631 D4-1

CORTISOL SECRETION AND METABOLISM IN ANOREXIA NERVOSA.
003660 04-13

AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN
003670 04-13

ON THE METABOLISM OF HALOPERIDOL IN MAN
003671 04-13

PHENOBARBITAL-INDUCED DRUG METABOLISM IN MAN
0036B2 04-13

METABOLISM OF PHENOBARBITAL AND PHENYTOIN BY NEONATES WITH SEIZURES
003697 04-13

INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

DRUG METABOLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN
003B7B 04-17

TRICYCLIC ANTIDEPRESSANTS AND CENTRAL MONOAMINE METABOLISM.
003902 04-17

ETABOLISMS

CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL
001121 02-03

ETABOLITE

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03

SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13

CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN.
000B25 01-13

SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000B35 01-13

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-03

NOVEL METABOLITE OF NITRAZEPAM IN THE RABBIT URINE.
002357 03-03

N-DESMETHYLDIAZEPAM: A NEW METABOLITE OF CHLORDIAZEPOXIDE IN MAN.
002B05 03-13

A NEW METABOLITE OF AMYLOBARBITONE-CARBOXYBUTYLETHYLBARBITURIC-ACID.
003090 04-03

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN
003294 04-03

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED METABOLITE IN HUMAN PLASMA.
003653 04-13

DISPOSITION OF DIAZEPAM AND ITS MAJOR METABOLITE DESMETHYLDIAZEPAM IN PATIENTS WITH LIVER DISEASE.
0036B3 04-13

TABOLITES

IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE.
000046 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN
000256 01-03

BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN.
000393 01-04

A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
000480 01-07

EFFECTS OF DIKALIUM CLORAZEPATE ON SERUM LEVELS AND METABOLITES.
000766 01-11

CEREBROSPINAL FLUID CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN MAN
000B32 01-13

BILIARY EXCRETION OF DIAZEPAM AND ITS METABOLITES IN MAN
000B62 01-13

DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING
000934 01-15

GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA
001003 01-16

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

THE SYNTHESIS OF POSSIBLE DIHYDROXYLATED AND TRIHYDROXYLATED CHLORPROMAZINE METABOLITES.
001094 02-01

THE SYNTHESIS OF POSSIBLE HYDROXYLATED METABOLITES OF 2-CHLOROPHENOTHIAZINE DERIVATIVES. (UNPUBLISHED PAPER).
001099 02-01

REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03

ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03

ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN.
001650 02-06

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001B62 02-11

MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13

A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
0020B6 02-16

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

DEPRESSOR EFFECT OF KYNURENINE AND ITS METABOLITES IN RATS.
002293 03-03

MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03

THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-0B

DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09

STUDIES OF CSF AMINE METABOLITES IN AFFECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002B12 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B35 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-13

THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES WITH THREE METABOLITES OF NOMIFENSINE.
003200 04-03

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

IN VITRO STUDIES OF SOME CHLORPROMAZINE METABOLITES AS POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
003265 04-03

COMPARISON OE THE EEEECTS OF CHLORPROMAZINE ANO SOME OE ITS META8OLITES ON THE ISOLATEO PEREUSEO RAT 8RAIN.
003274 04-03

MONOAMINE META8OLITES IN CERE8ROSPINAL ELUIO ANO SEROTONIN UPTAKE INHI8ITION OURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

THE CONCENTRATION PATTERN OE NONCONJUGATEO THIORIOAZINE META8OLITES IN SERUM 8Y THIORIOAZINE TREATMENT ANO ITS RELATIONSHIP TO PHYSIOLOGICAL ANO CLINICAL VARIA8LES.
003655 04-13

PRO8LEMS ON THE FORENSIC OETECTION OF OEXTROMORAMIOE OR ITS METABOLITES.
003714 04-13

METAL

METAL CHELATES OF L-OOPA FOR IMPROVEO REPLENISHMENT OE DOPAMINERGIC POOLS.
001090 02-01

MECHANISM OE INTERACTION OF MYELIN 8ASIC PROTEIN ANO S-100 PROTEIN: METAL 8INOING ANO FLUORESCENCE STUOIES.
001328 02-03

METAPRAMINE

METAPRAMINE AS ANTIOEPRESSANT ANO PSYCHOSTIMULANT.
002589 03-07

METAPROLOL

COMPARATIVE HEMOOYNAMIC STUOIES IN MAN OE AORENERGIC 8ETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-87-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-13

METARAMINOL

INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACERE8RALLY AOMINISTEREO METARAMINOL IN MICE.
002539 03-04

METENKEPHALIN

THE EFFECTS OF MORPHINE ANO METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS.
001236 02-03

METHACHOLINE

EFFECTS OF INTRASTRIATAL INJECTIONS OF ATROPINE ANO METHACHOLINE ON THE APOMORPHINE-INOUCEO GNAWING IN THE RA88IT.
003485 04-04

METHADONE

A OOSE-RESPONSE COMPARISON 8ETWEEN METHAOONE ANO MORPHINE SELF-AOMINISTRATION.
000255 01-03

ENHANCEO SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC AOMINISTRATION OF METHAOONE IN THE RHESUS-MONKEY ANO GUINEA-PIG: IMPLICATIONS EOR EXTRAPYRAMIOAL OYSKINESIAS. (PH.D OISSERTATION).
000318 01-04

THE EEEECT OF ACUTE METHAOONE ON FIXEO-INTERVAL SCHEOULES OF REINFORCEMENT IN PIGEONS. (PH.O. OISSERTATION).
000375 01-04

ORUG SELF-AOMINISTRATION ANO SLEEP-AWAKE ACTIVITY IN RATS OEPENOENT ON MORPHINE, METHAOONE, OR L-ALPHA-ACETYLMETHAOOL.
000390 01-04

COMPARISON OF THE INHI8ITION OF 5-HYOROXYTRYPTAMINE UPTAKE BY METHADONE ANO ITS CONGENERS IN HUMAN PLATELETS.
000933 01-15

SUCCESSFUL OETOXIFICATION EROM METHADONE MAINTENANCE: FOLLOW-UP STUOY OF 38 PATIENTS.
000982 01-15

BEHAVIORAL EVIOENCE EOR OOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHAOONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03

THE BINOING OF THE OPTICAL ISOMERS OF METHAOONE, ALPHA-METHAOOL, ALPHA-ACETYLMETHAOOL ANO THEIR N-OEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT 8RAIN.
001242 02-03

EFFECTS OE AMINOOXYACETIC-ACIO ANO 8ACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACIO INCREASE ANO ANTINOCICEPTION CAUSEO BY METHAOONE IN RATS.
001257 02-03

ALTERATION 8Y METHAOONE OF CATECHOLAMINE UPTAKE ANO RELEASE IN ISOLATEO RAT AORENOMEOULLARY STORAGE VESICLES.
001377 02-03

EFFECTS OE NEONATAL OR MATERNAL METHAOONE AOMINISTRATION ON ORNITHINE-OECAR8OXYLASE ACTIVITY IN 8RAIN ANO HEART OF OEVELOPING RATS.
001378 02-03

SUSTAINEO INGESTION OF METHAOONE ANO THE SLEEP OF MONKEYS.
001586 02-04

DYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WITH PRIOR METHADONE TREATMENT.
001619 02-05

METHAOONE/LAAM MAINTENANCE: A COMPARISON STUDY.
001856 02-11

OIGIT SYM8OL PEREORMANCE IN METHAOONE TREATEO EX-HEROIN AOOICTS.
001956 02-14

EXCRETION OE METHAOONE IN SEMEN EROM METHAOONE AOOICTS; COMPARISON WITH 8LOOO LEVELS.
002041 02-15

PSYCHOTROPIC ORUGS IN OPIOIO AOOICTS ON METHAOONE TREATMENT.
002119 02-1

CLINICAL OEPRESSION AMONG NARCOTIC AOOICTS MAINTAINEO ON METHAOONE IN THE COMMUNITY.
002174 02-1

EFFECT OE CHOLINERGIC ORUGS ON METHAOONE-INOUCEO CATALEPSY ANO STEREOTYPIES IN RATS TREATEO CHRONICALLY WITH METHAOONE.
002199 03-0

EEFECTS OF METHADONE ON ACTIVITY ANO ON 8RAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-0

CATECHOLAMINE SYNTHESIS, STORAGE ANO RELEASE IN AORENAL MEOULLA ANO WHOLE BRAIN OURING ACUTE ANO CHRONIC METHAOONE AOMINISTRATION.
002370 03-0

EFFECTS OF METHAOONE HYOROCHLORIOE ON THE GROWTH OF ORGANOTYPIC CERE8ELLAR CULTURES PREPAREO FROM METHAOONE-TOLERANT ANO CONTROL RATS.
002581 03-0

THE USE OF METHAOONE AS A TREATMENT TOOL FOR OPIATE AOOICTS: A TWO-YEAR FOLLOW-UP STUOY.
003025 03-1

SUOOEN TOXICITY OF METHAOONE IN MONKEYS: 8EHAVIORAL ANO ELECTROPHYSIOLOGICAL EVIDENCE.
003509 04-0

CLINICAL EFFECTS ANO PHARMACOKINETICS OF RACEMIC METHAOONE ANO ITS OPTICAL ISOMERS.
003694 04-1

WITHORAWAL FROM METHAOONE MAINTENANCE: RATE OF WITHORAWAL ANO EXPECTATION.
003898 04-1

METHADONE-DEPENDENT

ATTENUATION OF PRECIPITATEO A8STINENCE IN METHAOONE-DEPENOENT RATS 8Y OELTA9-TETRAHYOROCANNA8INOL.
000310 01-0

RESPONSE TO OEIKEL ANO CAROERS ARTICLE ATTENUATION OF PRECIPITATE A8STINENCE IN METHAOONE-OEPENOENT RATS 8Y OELTA9-THC.
000341 01-0

METHADONE-HYDROCHLORIDE

INFLUENCE OF ACUTE ANO CHRONIC AOMINISTRATION OF METHAOONE HYOROCHLORIOE ON NAOPH-CYTOCHROME-C-REOUCTASE ANO CYTOCHROME-P-450 OE MOUSE LIVER MICROSOMES.
001177 02-0

METHADONE-INDUCED

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIOINE OR METHAOONE-INOUCEO OECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-0

EFFECT OF CHOLINERGIC ORUGS ON METHAOONE-INOUCEO CATALEPSY ANO STEREOTYPIES IN RATS TREATEO CHRONICALLY WITH METHAOONE.
002199 03-0

METHADONE-TOLERANT

EFFECTS OF METHADONE HYDROCHLORIOE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPAREO FROM METHAOONE TOLERANT AND CONTROL RATS.
002581 03-0

METHAMPHETAMINE

ENHANCEO SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC AOMINISTRATION OE METHAOONE IN THE RHESUS-MONKEY ANO GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIOAL OYSKINESIAS. (PH.O OISSERTATION).
000318 01-0

EFFECT OF METHAMPHETAMINE ON MOTOR ACTIVITY IN YOUNG ANO OLD MICE.
000320 01-0

MEASUREMENT OF ACUTE ANO CHRONIC 8EHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-0

EFFECT OF THE ACQUISITION ENHANCING ORUG PIRACETAM ON RAT CEREBRAL ENERGY META8OLISM. COMPARISON WITH NAFTIOROFURYL ANO METHAMPHETAMINE.
001309 02-0

EFEECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIOATE ON REACTIONS TO NOVELTY ANO ACTIVITY IN RATS.
001515 02-0

DYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WIT PRIOR METHAOONE TREATMENT.
001619 02-0

ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

RESISTANCE TO PUNISHMENT AND EXTINCTION FOLLOWING RESPONDING UNDER METHAMPHETAMINE OR SECOBARBITAL (PH D. DISSERTATION).
002534 03-04

EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
002566 03-05

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN
003294 04-03

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

EFFECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE
003483 04-04

METHAMPHETAMINE-INDUCED

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
00253B 03-04

POTENTIATING EFFECT OF LITHIUM-CHLORIDE ON METHAMPHETAMINE-INDUCED STEREOTYPY IN MICE.
00343B 04-04

METHAQUALONE

THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13

PERIPHERAL NEUROPATHY CAUSED BY METHAQUALONE.
002059 02-15

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY.
002953 03-16

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 04-02

METHAQUALONE-INDUCED

EFFECTS OF SEROTONERGIC DRUGS ON METHAQUALONE-INDUCED HYPOTHERMIA.
003102 04-03

METHIONINE

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE.
0005B7 01-09

METHIONINE-ENKEPHALIN

STRUCTURE-ACTIVITY RELATIONSHIPS OF METHIONINE-ENKEPHALIN
002317 03-03

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME.
003352 04-04

METHOCHLORIDE

EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

METHOD

TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06

A SIMPLE METHOD FOR DETERMINING DIAZEPAM AND ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUDIES.
0004B0 01-07

STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07

STUDY ON THE EFFECTS OF SULPIRIDE AND PERPHENAZINE IN B2 SCHIZOPHRENICS USING THE DOUBLE-BLIND METHOD
000531 01-0B

A METHOD FOR STUDYING PUPILLOMOTOR EFFECTS OF NEUROLEPTICS.
000556 01-08

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM
000B29 01-13

AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION. STUDIES WITH THC IN MONKEYS.
001574 02-04

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-06

DEMAND METHOD EVALUATION OF HYPNOTICS.
001676 02-07

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001B98 02-13

A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OF CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
002086 02-16

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION. I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
0021B0 02-17

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
00240B 03-03

TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09

NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14

METHODOLOGICAL

METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
0004B3 01-07

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09

METHODOLOGICAL PROBLEMS IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
001005 01-16

METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH: CHLORPROMAZINE -- A CASE IN POINT.
001008 01-16

NEUROPSYCHOBIOLOGY OF AFFECTIVE DISORDERS: SOME METHODOLOGICAL CONSIDERATIONS.
001751 02-09

DETERMINATION OF MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHODOLOGICAL ASPECTS.
001B96 02-13

METHODOLOGICAL REVIEW OF FLUID THERAPY IN PSYCHIATRY.
002145 02-17

METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-0B

METHODOLOGY

CLINICAL TRIALS: METHODOLOGY VERSUS PRACTICE -- ATTEMPT AT A COMPROMISE.
001653 02-07

METHODOLOGY IN DOUBLE-BLIND DRUG TRIALS.
0020BB 02-16

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

METHODOLOGY OF CLINICAL TESTING OF ANTIPSYCHOTICS.
00209B 02-17

INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
003709 04-13

METHODS
MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01
FOUR METHODS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
000496 01-07
COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11
MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000806 01-13
GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA.
001003 01-16
MEANS AND METHODS USED IN SUICIDE ATTEMPTS.
001018 01-17
EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
001812 02-10
EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001B29 02-11
METHODS FOR STUDY OF FLUPHENAZINE KINETICS IN MAN.
001951 02-13
THE THERAPISTS HANDBOOK: TREATMENT METHODS OF MENTAL DISORDERS.
002178 02-17
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
002255 03-03
COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
002582 03-06
DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY -- METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS.
002666 03-09
PLACEBO METHODS.
002993 03-17
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION.
003469 04-04
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13

METHOTRIMEPRAZINE
INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-03

METHOXAMINE
PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
00041B 01-04

METHOXYAMPHETAMINES
EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE OF (3H)5-HYDROXYTRYPTAMINE BY HUMAN BLOOD PLATELETS.
003715 04-13

METHSCOPOLAMINE
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-04

METHYL-TOLYLQUINAZOLONE
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 04-02

METHYLATION
A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-08

METHYLDOPA
TREATMENT OF PARKINSONISM WITH A COMBINATION OF L-DOPA AND METHYLDOPA HYDRAZINE.
000870 01-13
EFFECT OF METHYLDOPA ON PROLACTIN AND GROWTH HORMONE.
0009B7 01-15
COLITIS AND HEPATITIS CAUSED BY METHYLDOPA.
002017 02-15
ACUTE ORGANIC-BRAIN-SYNDROME PSYCHOSIS WITH METHYLDOPA THERAPY.
002046 02-15
ACUTE ORGANIC-BRAIN-SYNDROME WITH PROPRANOLOL AND METHYLDOPA.
003779 04-15
MYOCARDITIS ASSOCIATED WITH METHYLDOPA THERAPY.
003810 04-15

METHYLENEDIOXYAMPHETAMINE
3,4 METHYLENEDIOXYAMPHETAMINE AND ITS EFFECTS.
002173 02-17
THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

METHYLEUGENOL
ANESTHETIC ACTION OF METHYLEUGENOL AND OTHER EUGENOL DERIVATIVES.
000419 01-04

METHYLMALONATE
EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN.
002330 03-03

METHYLMERCURIC-CHLORIDE
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
002198 03-03
EXPERIMENTAL STUDIES ON INTOXICATION OR DETOXICATION OF METHYLMERCURIC-CHLORIDE.
002262 03-03
EFFECT OF CHRONIC TREATMENT OF METHYLMERCURIC-CHLORIDE ON THE CENTRAL-NERVOUS-SYSTEM IN RATS.
002565 03-05
LONG-TERM TOXICITY STUDY OF METHYLMERCURIC-CHLORIDE IN MONKEYS (REPORT V).
002569 03-05

METHYLMERCURY
BEHAVIORAL EFFECTS ON THE PROGENY OF MICE TREATED WITH METHYLMERCURY.
000432 01-04
TIME-DEPENDENT EFFECTS PRODUCED IN CHICKS AFTER PRENATAL INJECTION OF METHYLMERCURY.
000461 01-0
MOBILIZATION OF METHYLMERCURY IN VIVO AND IN VITRO USING N-ACETYL-DL-PENICILLAMINE AND OTHER COMPLEXING AGENTS.
002197 03-0
ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM OF RABBITS POISONED WITH METHYLMERCURY.
003500 04-0

METHYLMERCURY-INDUCED
METHYLMERCURY-INDUCED ENCEPHALOPATHY IN MICE.
003502 04-0

METHYLPERIDOL
COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) BY DOUBLE-BLIND EXAMINATION AND HALOPERIDOL.
000563 01-0

METHYLPHENIDATE
CHRONIC METHYLPHENIDATE EFFECTS ON LEARNING IN AN F2 GENERATION.
000330 01-0
REPEATED ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIDATE AND IMIPRAMINE.
000437 01-0
METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES: PSYCHOMETRIC CHANGES.
000740 01-1
THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
000781 01-1
THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN (PH.D. DISSERTATION).
000917 01-1
HALOPERIDOL AND METHYLPHENIDATE IN HYPERACTIVE CHILDREN.
000927 01-1
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-0
EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE ON REACTIONS TO NOVELTY AND ACTIVITY IN RATS.
001515 02-0
CARDIOVASCULAR RESPONSES OF HYPERACTIVE CHILDREN TO METHYLPHENIDATE.
001814 02-1

EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN
001998 02-14

THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03-11

INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY.
002768 03-11

THE ACTION OF TRICYCLICS (ALONE OR IN COMBINATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY.
002782 03-11

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002830 03-13

COMPARATIVE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE IN HYPERKINETIC CHILDREN.
002B61 03-14

RELATIVE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN: AN INTERIM REPORT.
002B62 03-14

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002863 03-14

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE.
0034B7 04-04

PRELIMINARY REPORT ON THE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN.
003620 04-11

RESPONSE OF ADOLESCENTS WITH MINIMAL-BRAIN-DYSFUNCTION TO METHYLPHENIDATE.
003630 04-11

EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11

HYPERSOMNIA IN MYOTONIC DYSTROPHY: TREATMENT WITH METHYLPHENIDATE.
003640 04-11

AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11

METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

THE USE OF METHYLPHENIDATE AND IMIPRAMINE IN GILLES-DE-LA-TOURETTES DISEASE IN CHILDREN.
003782 04-15

ETHYLPHENIDATE-INDUCED

THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04

METHYLPHENIDATE-INDUCED TICS.
00205B 02-15

SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY. (PH.D. DISSERTATION).
002272 03-03

METHYLPHENIDATE-INDUCED CHOREA.
003B35 04-15

ETHYLPHENIDATE-LIKE

METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-984).
001154 02-03

ETHYLTHIO

A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01

ETHYLXANTHINES

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17

ETHYPRYLON

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY.
002953 03-16

ETHYSERGIDE

THE EFFECT OF METHYSERGIDE ON 5-HYDROXYTRYPTAMINE TURNOVER IN WHOLE BRAIN.
0000B2 01-03

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE
0012B2 02-03

INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-04

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003524 04-07

METOCLOPRAMIDE

METOCLOPRAMIDE AND DOPAMINE RECEPTOR BLOCKADE.
000195 01-03

THERAPEUTICAL EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
00048B 01-07

DYSTONIC REACTIONS TO METOCLOPRAMIDE.
002038 02-15

METOPROLOL

EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPONSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
00002B 01-03

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
000055 01-03

TOXICOLOGICAL STUDIES ON METOPROLOL.
000457 01-05

QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-06

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000B26 01-13

INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
000B27 01-13

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL.
00082B 01-13

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000B59 01-13

A SURVEY OF THE PHARMACOLOGICAL PROPERTIES OF METOPROLOL IN ANIMALS AND MAN.
001011 01-17

METOPROLOL-3H

TISSUE DISTRIBUTION OF METOPROLOL-3H IN THE MOUSE AND THE RAT.
000054 01-03

PHARMACOKINETIC STUDIES OF METOPROLOL-3H IN THE RAT AND THE DOG.
000056 01-03

METABOLISM OF METOPROLOL-3H IN MAN, THE DOG AND THE RAT.
000804 01-13

METRAZOL

PRINCIPAL CELLS IN LATERAL GENICULATE: EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03

TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04

METRONIDAZOLE

SIDE-EFFECTS OF METRONIDAZOLE.
0037B6 04-15

MFB

SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

MHPG

REDUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-03

THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-08

MHPG, AMITRIPTYLINE AND AFFECTIVE DISORDERS: A LONGITUDINAL STUDY.
002B34 03-13

MIANSERIN

COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

MIANSERIN VERSUS AMITRIPTYLINE: A DOUBLE-BLIND TRIAL EVALUATED BY THE AMP SYSTEM.
000663 01-09

MIANSERIN HYDROCHLORIDE: A NOVEL ANTIDEPRESSANT.
001740 02-09

MIANSERIN IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
00179B 02-10

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16

AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09

MICE

AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03

EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
000052 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

EFFECT OF HYPNOTICS ON MICE GENETICALLY SELECTED FOR SENSITIVITY TO ETHANOL.
000095 01-03

EFFECTS OF SERINE ON MORPHINE-DEPENDENT MICE.
000096 01-03

INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03

ANTICONVULSANT ACTIVITY IN MICE OF DIAZEPAM IN AN EMULSION FORMULATION FOR INTRAVENOUS ADMINISTRATION.
000132 01-03

THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03

PATHOLOGIC EFFECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03

SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION.
000286 01-04

THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04

EFFECTS OF CAFFEINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN MICE.
000296 01-04

EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04

EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE.
000298 01-04

INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04

CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04

INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04

THE EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVED AND SATIATED MICE.
000313 01-04

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

TASK-SPECIFIC EFFECTS OF D-AMPHETAMINE AND BLINDNESS ON BALB/CJ MICE.
000317 01-04

EFFECT OF METHAMPHETAMINE ON MOTOR ACTIVITY IN YOUNG AND OLD MICE.
000320 01-04

PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04

THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH.D. DISSERTATION).
000339 01-04

SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
00036B 01-04

THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-04

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS
000386 01-04

EFFECTS OF AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04

BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN
000407 01-04

INFLUENCE OF PHYSOSTIGMINE UPON CONSOLIDATION OF MEMORY IN MICE.
000425 01-04

BEHAVIORAL EFFECTS ON THE PROGENY OF MICE TREATED WITH METHYLMERCURY.
000432 01-04

TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-0

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-0

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-0

THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
001140 02-0

GAMMA-AMINOBUTYRIC-ACID IN DIFFERENT STRAINS OF MICE. EFFECT OF ETHANOL.
001166 02-0

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-0

ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-0

THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-0

STUDIES ON TOLERANCE DEVELOPED TO SINGLE-DOSES OF MORPHINE IN MICE.
001244 02-0

POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-0

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
001282 02-0

EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE. II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012BB 02-0

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-0

ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-0

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-0

EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE. I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-0

EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
001358 02-0

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-0

EFFECT OF LITHIUM ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM IN MICE.
001370 02-0

DIFFERENTIAL EFFECTS OF PENTOBARBITAL AND ETHANOL IN MICE.
001373 02-03
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03
ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: MECHANISM FOR CROSS-TOLERANCE IN MICE
001386 02-03
TOXICOLOGY OF PHENCYCLIDINE IN MICE.
001391 02-03
EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE
001445 02-04
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04
EFFECT OF MORPHINE AND NALOXONE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-04
STUDIES IN MICE ON THE ANTAGONISM OF DEXTROAMPHETAMINE ANOREXIA BY ALPHA-METHYL-P-TYROSINE-METHYL-ESTER HCL.
001471 02-04
STIMULANT ACTIONS OF DELTA9-TETRAHYDROCANNABINOL IN MICE.
001480 02-04
SYNERGISTIC EFFECT OF ESTRADIOL-BENZOATE AND DIHYDROTESTOSTERONE ON AGGRESSION IN MICE.
001486 02-04
EFFECT OF TWO INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE ON MATURATION OF MEMORY IN MICE.
001487 02-04
DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04
EFFECT OF ETHANOL ON AGGRESSION AND TIMIDITY IN MICE.
001532 02-04
EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
001535 02-04
EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-04
THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04
EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
001558 02-04
ANTIAGGRESSIVE ACTION OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS IN MICE.
001571 02-04
ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE.
0015B4 02-04
BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04
DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04
PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE.
001604 02-04
A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04
LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE.
001609 02-04
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04
PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE
001621 02-05
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED BEHAVIOURAL RESPONSES IN MICE.
002188 03-02
AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03
EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
002280 03-03
EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE.
002285 03-03
EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-03
NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
002318 03-03
THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC-ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
002350 03-03
EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03
COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-04
EFFECTS OF L-5-HYDROXYTRYPTOPHAN ON BITING BEHAVIOR INDUCED BY LONG-TERM ISOLATION IN MICE.
002470 03-04
AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
002486 03-04
ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH).
002494 03-04
EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
002501 03-04
EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04
CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04
INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04
EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04
MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-05
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-DIBENZOTHIEPINS, ATAXIA IN MICE.
002577 03-05
ENDORPHINS IN BRAINS OF DECAPITATED AND MICROWAVE-KILLED MICE.
003050 04-01
NALOXONE-INDUCED INHIBITION OF ETHANOL DEPENDENCE IN MICE.
003100 04-03
EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE.
003108 04-03
POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03
EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03
GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 04-03
QUANTITATIVE ASSESSMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE IN MICE.
003140 04-03
PHARMACOLOGIC RESPONSE TO PENTOBARBITAL IN ACTIVELY IMMUNIZED MICE.
003141 04-03
MUTUAL EFFECTS OF MORPHINE AND ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
00319B 04-03
ALTERATION OF ETHANOL-INDUCED CHANGES IN LOCOMOTOR ACTIVITY BY ADRENERGIC BLOCKERS IN MICE.
003214 04-03

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 D4-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
003228 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIDSYNTHESIS IN MICE.
003252 04-D3

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-D3

SENSITIZATION TD COCAINE STIMULATION IN MICE.
00327B 04-03

THE EFFECTS OF PHENCYCLIDINE ON ETHANOL AND SODIUM HEXOBARBITAL IN MICE.
00329D 04-03

INHIBITION BY NALOXONE DF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE.
0D3334 04-03

DELTA1-TETRAHYDROCANNABINDL, CANNABIDIOL AND CANNA8INOL EFFECTS DN THE IMMUNE RESPONSE OF MICE.
D03339 04-03

BARBITURATE DEPENDENCE IN MICE: EFFECTS OF CONTINUOUS VS. DISCONTINUOUS DRUG ADMINISTRATION.
DD3348 04-D4

EFFECTS DF PRETRIAL AND POSTTRIAL CAFFEINE AOMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
D03362 04-04

NEONATAL ANDROGEN INJECTION CHANGES OPEN-FIELO 8EHAVIOR OF MICE.
003402 D4-04

THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS AND RHESUS-MDNKEYS.
D03406 04-D4

EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFDRMANCE IN MICE.
0D3416 04-D4

EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 D4-04

CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTION IN MICE.
D03427 04-04

MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATIDN AND ANTAGONISM BY NALOXONE.
DD3434 D4-D4

POTENTIATING EFFECT OF LITHIUM-CHLORIDE ON METHAMPHETAMINE-INDUCED STEREDTYPY IN MICE.
D03438 04-D4

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
0D3439 04-04

POSSIBLE INVOLVEMENT DF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
00345D D4-04

ANTAGONISM OF ETHANOLS CENTRAL STIMULATIDN IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
D03466 04-04

RELATIDNSHIP BETWEEN MORPHINE SELF-ADMINISTRATION AND THE EFFECT DF MORPHINE ACRDSS STRAINS OF MICE.
0D3482 04-04

LDNG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-D4

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE.
003491 04-05

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-D5

INTERACTION BETWEEN YOHIMBINE ALKALOIDS AND AMPHETAMINE IN MICE
D035D1 04-05

METHYLMERCURY-INDUCED ENCEPHALOPATHY IN MICE.
003502 D4-05

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
0D3511 D4-D5

EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE.
DD3874 D4-17

MICROCOSMAL

IS THE INOUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?.
001364 D2-0

MICRODISCS

TOPOGRAPHICAL OISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICRDESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
0D1397 02-

MICROELECTROPHORETICALLY

THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES
001142 02-

MICROESTIMATION

TOPDGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-

MICROINJECTION

EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGAT ON THE SPINAL DORSAL HORN NEURON
0D2200 03-

IDENTIFICATION BY MICRDINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
DD3226 D4-

SELF-STIMULATIDN OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
D03432 04

MICROIONTOPHORETIC

DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION 8Y MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
00307B 04

MICROIONTOPHORETICALLY

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYOROXYTRYPTAMINE: COMPARISON WITH THE RESPDN TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
0DDD60 01

MICROMETHOD

A NEW MICROMETHOD FOR DETERMINING THE EFFECTS OF DRUGS ON THE TURNOVER RATE OF ACETYLCHOLINE. (PH.D. DISSERTATION).
0D2274 03

MICROPUNCH

HISTOCHEMICAL AND MICROPUNCH ANALYSIS DF AMINERGIC AND CHOLINERGIC PATHWAYS. (UNPUBLISHED PAPER).
D02266 03

MICROQUANTITATIVE

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN
002408 03

MICROSCOPIC

DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRDN MICROSCOPIC AUTORADIOGRAPHY.
001249 02

APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTRDP DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
002586 03

ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTA8-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE.
003168 04

MICROSOMAL

ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
00D19D 01

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
00D269 01

EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMA NA-K-ATPASE ACTIVITY.
0D163D 02

DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES?
00236D 03

MICROSOMES

F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000D37 01

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADON HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 D2

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION
003184 04-03

MICROVASCULAR
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

MICROWAVE
EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE.
002285 03-03

MICROWAVE-KILLED
ENDORPHINS IN BRAINS OF DECAPITATED AND MICROWAVE-KILLED MICE.
003050 04-01

MIDBRAIN
RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 D1-03
BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN.
0001B4 01-03
ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
DD129B 02-03
EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT.
0D1510 02-D4
THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
002281 03-D3
INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
DD24B7 03-04

MIDDLE
CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

MIGRAINE
VASOACTIVE SUBSTANCES RELEVANT TO MIGRAINE.
001034 01-17
TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COMBINATION (MERSYNDOL).
003039 03-17
NEWER CONCEPTS IN MANAGEMENT OF MIGRAINE HEADACHES.
003B67 D4-17
PSYCHOTROPIC DRUGS AND MIGRAINE.
DD38B7 04-17

MILIEU
TRIMETHOZINE IN A GERIATRIC MILIEU.
0DD479 01-D7
STUDY IN A PEDIATRIC MILIEU OF AN ANTIANXIETY DRUG: CLOBAZAM.
D0D494 01-07
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07

MILITARY
DIAZEPAM USE IN MILITARY SICK-CALL.
D00720 01-10
RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 D3-11

MILK
PASSAGE OF DIAZEPAM AND DESMETHYLDIAZEPAM INTO BREAST MILK.
DD0932 D1-15
THE PASSAGE OF 14C-DELTA-9-TETRAHYDROCANNABINOL INTO THE MILK OF LACTATING SQUIRREL-MONKEYS.
DD1167 02-D3
THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03

MINCE
ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
DD3191 D4-D3

MIND
DRUGS WHICH ALTER THE MIND.
DD2121 02-17

MINIMAL
OBSERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL NERVOUS-SYSTEM DYSFUNCTIONS.
002762 03-11

MINIMAL-BRAIN-DAMAGE
MINIMAL-BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000803 01-13

MINIMAL-BRAIN-DYSFUNCTION
THERAPY FOR HYPERACTIVITY SEEN IN MINIMAL-BRAIN-DYSFUNCTION.
002763 03-11
DIAGNOSIS AND TREATMENT OF MINIMAL-BRAIN-DYSFUNCTION IN ADULTS.
002794 03-11
RESPONSE OF ADOLESCENTS WITH MINIMAL-BRAIN-DYSFUNCTION TO METHYLPHENIDATE.
003630 04-11

MINIMISE
PSYCHOTHERAPEUTIC DRUGS: HOW TO MINIMISE COMPLICATIONS OF THERAPY.
002D24 02-15

MINIREVIEW
MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
DD1253 D2-03

MINOR
THE EFFECT OF MINOR TRANQUILIZERS ON PSYCHOMOTOR PERFORMANCE.
D00997 01-15
CHANGES IN PRESCRIBING PATTERNS OF MINOR TRANQUILIZERS.
DD3037 03-17
IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
0D3618 04-11

MIOPITHECUS-TALAPOIN
GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-D4

MIRENIL-POLFA
CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENIC PSYCHOSIS.
002620 03-D8

MIRENIL-PROLONGATUM
COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL-PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
DD26DB D3-D8

MIRROR
THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
00D553 D1-0B
A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC.
002644 D3-08
RESERPINE: MIRROR IMAGE OF THE ANTIDEPRESSANTS.
0D39D1 04-17

MITIGATION
MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-D5

MITOCHONDRIA
5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
DD12B9 D2-D3
THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
0D3234 04-D3

MITOCHONDRIAL
SOLUBILIZATION OF BRAIN MITOCHONDRIAL HEXOKINASE IN ANESTHESIA.
0024D2 03-D3
METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN
D03294 04-03

MIXED
ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
D01735 D2-D9
ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
D03564 D4-09

MIXTURE
THE BROMPTON MIXTURE: EFFECTS ON PAIN IN CANCER PATIENTS.
DD0B45 D1-13
USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000847 01-13

MK-486
L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-4B6) IN PARKINSONISM.
000767 01-11

MN2
EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

MOBILIZATION
MOBILIZATION OF METHYLMERCURY IN VIVO AND IN VITRO USING N-ACETYL-DL-PENICILLAMINE AND OTHER COMPLEXING AGENTS.
002197 03-03

MODE
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE DF ACTION OF ANTIPSYCHOTICS.
000053 01-03

NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
0005B4 01-09

MODE DF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FDR EVALUATION.
000591 01-09

MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000B06 01-13

THE MODE OF ACTION DF PSYCHOTROPIC DRUGS.
002B07 03-13

LITHIUM: ITS MODE AND RANGE OF ACTION.
003024 03-17

MODECATE
STUDY OF THE USE OF MDDITEN-RETARD (FLUPHENAZINE-ENANTHATE) AND DF MODECATE (FLUPHENAZINE-DECANDATE) IN 20 CHRONIC CASES.
001710 02-0B

REMARKS ON THE EFFECTS OF MODITEN-RETARD AND MODECATE: NOTES ON 65 CASES.
002779 03-11

MODEL
MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MDDEL.
000227 01-03

BEHAVIDURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
0D0467 01-06

PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07

A NEUROBIOLOGICAL MODEL FDR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-03

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHDTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MDDEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

EFFECTS OF CHRDNIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04

A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04

AN ANIMAL BEHAVIOR MODEL FDR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINDGENS.
001517 02-D4

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZDDIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES DF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 02-12

SDME CHARACTERISTICS DF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OF PSYCHDPATHDLOGY.
002204 03-03

A CEREBELLAR MODEL TO STUDY THE ACTIDNS OF DIAZEPAM AND MUSCIMDL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSIDN (UNPUBLISHED PAPER).
002212 03-03

BIOCHEMICAL BASIS OF AN ANIMAL MODEL OF DEPRESSIVE ILLNESS -- A PRELIMINARY REPORT.
0023B1 03-03

MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
0024B3 03-04

A RAT MODEL OF VIOLENT ATTACK BEHAVIOR. (PH.D. DISSERTATION).
002531 03-04

DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
0026B9 03-09

DEPRESSIDN: A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-02

A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION DF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION OF PROBLEM-SOLVING ABILITY.
003513 04-06

BIOCHEMICAL AND PHARMACDLOGICAL STUDIES ON AN ANIMAL MDDEL OF HYPERACTIVITY STATES.
00351B 04-06

MODELS
NEUROBIOLOGICAL MECHANISMS DF ADAPTATION IN RELATIDN TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
000162 01-0

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-0

ERGOT ALKALOIDS AS DOPAMINE AGDNISTS: COMPARISON IN TWO RDDENT MODELS.
000273 01-0

ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AN UP-507-04) ON TWO MODELS OF DBESITY IN ANIMALS.
001474 02-0

ANIMAL MDDELS IN HUMAN PSYCHDBIOLOGY.
D02161 02-1

EFFECTS OF CARBON-MONOXIDE, HYPOXIC HYPOXIA, AND DRUGS ON ANIMAL MODELS OF CDMPLEX LEARNED BEHAVIOR. (PH.D. DISSERTATION).
002550 03-0

NEUROPSYCHDPHARMACOLOGICAL MDDELS FOR OBJECTIVE ASSESSMENT DF CENTRAL EFFECTS OF HORMONES.
0D3B70 D4-1

DECISIONS ABDUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
003BBB 04-1

MODERATE
EFFECTS OF LOW AND MODERATE DOSES OF CHLDRPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT.
000435 01-0

CLINICAL SPECTRUM DF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE.
000532 01-0

MODERATELY
PHARMACOLDGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
D03556 04-0

MODIFICATION
THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLDRIMIPRAMINE.
000075 01-

CHDLINERGIC MDDIFICATION OF DRUG-INDUCED STEREOTYPY IN RATS.
000201 01-

MDDIFICATION BY ESTRDGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS O RAT BRAIN.
001203 02-

INHIBITIDN OF THALAMIC AND HYPDTHALAMIC SDMATOSENSDRY EVDKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATIDN BY MDRPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-

MDDIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS DF RETICULOCORTICAL DRIVE.
001390 02-

PERIOD DF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MDDIFICATIDN BY TESTDSTERONE IN THE GDLDEN HAMSTER.
001616 02-

DIAZEPAM MODIFICATION OF EVOKED AND SPDNTANEDUS LATERAL GENICULATE ACTIVITY
002425 03-

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

RELATIVE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN: AN INTERIM REPORT.
002862 03-14

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03

PRELIMINARY REPORT ON THE EFFICACY OF METHYLPHENIDATE AND BEHAVIOR MODIFICATION IN HYPERKINETIC CHILDREN.
003620 04-11

MODIFICATIONS

CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
000881 01-14

CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15

URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM.
001729 02-09

BENZODIAZEPINE-INDUCED MODIFICATIONS OF DREAM CONTENT: THE EFFECT OF FLUNITRAZEPAM.
001969 02-14

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
002818 03-13

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003875 04-17

MODIFIED

THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
000308 01-04

MODIFYING

EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04

MODITEN-DEPOT

COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL-PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
002608 03-08

COMPARATIVE EVALUATION OF MODITEN-DEPOT AND CONVENTIONAL MAINTENANCE TREATMENT USING NEUROLEPTICS.
002651 03-08

INITIAL CLINICAL EVALUATION OF MODITEN-DEPOT.
002659 03-08

RESULTS OF MODITEN-DEPOT TREATMENT IN CHRONIC SCHIZOPHRENIA.
002660 03-08

CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
002664 03-08

MODITEN-RETARD

STUDY OF THE USE OF MODITEN-RETARD (FLUPHENAZINE-ENANTHATE) AND OF MODECATE (FLUPHENAZINE-DECANOATE) IN 20 CHRONIC CASES.
001710 02-08

REMARKS ON THE EFFECTS OF MODITEN-RETARD AND MODECATE: NOTES ON 65 CASES.
002779 03-11

MODULATION

MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03

MODULATION OF CYCLOHEXIMIDE RESISTANT MEMORY BY SYMPATHOMIMETIC AGENTS.
000333 01-04

ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
000346 01-04

MODULATION OF ACETYLCHOLINE IN THE NEOSTRIATUM BY DOPAMINE AND 5-HYDROXYTRYPTAMINE.
002216 03-03

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

CATECHOLAMINE MODULATION OF BEHAVIOR FOLLOWING BILATERAL HIPPOCAMPAL DAMAGE. (PH D. DISSERTATION).
002446 03-04

MODULATION OF HEROIN SELF-ADMINISTRATION BY NEUROHYPOPHYSEAL PRINCIPLES.
003477 04-04

MODULATORS

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
000188 01-03

EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
001558 02-04

2-PHENYLETHYLAMINE AND OTHER ADRENERGIC MODULATORS.
002833 03-13

EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUCED HYPERTHERMIA IN NON-TOLERANT RATS.
003232 04-03

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 04-04

MODULUS

AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
001618 02-05

MOIETIES

QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07

MOIETY

A NOVEL CANNABINOID CONTAINING A 1,8 CINEOL MOIETY.
003061 04-01

MOLECULAR

CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 02-03

MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13

COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
002183 03-01

ON THE MOLECULAR STRUCTURE OF THE OPIATE RECEPTOR.
003281 04-03

MOLECULE

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

MOLINDONE

A COMPARISON OF THE ABILITIES OF CHLORPROMAZINE AND MOLINDONE TO INTERACT ADVERSELY WITH GUANETHIDINE.
001494 02-04

LONG-TERM STUDY OF MOLINDONE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENICS.
001697 02-08

WEIGHT REDUCTION IN SCHIZOPHRENICS BY MOLINDONE.
003536 04-08

MOLLUSCAN

DOPAMINERGIC AGENTS: INFLUENCE ON SEROTONIN IN THE MOLLUSCAN NERVOUS SYSTEM.
001389 02-03

MONGREL

AUTONOMIC AND CARDIOVASCULAR EFFECTS OF CHRONIC DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION IN MONGREL DOGS.
003182 04-03

MONITORED

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09

MONITORING

MONITORING PLASMA CONCENTRATIONS OF NEUROLEPTICS.
000837 01-13

SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS.
002142 02-17

PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS.
003787 04-15

MONKEY

EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEY.
000064 01-03

THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBITAL NARCOSIS IN THE MONKEY.
000145 01-03

COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

BEHAVIOURAL ACTIVITY IN THE MONKEY (MACACA-MULATTA) OF THE METABOLITES OF DIAZEPAM IN MAN.
000393 01-04

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13

EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
003242 04-03

MONKEYS

CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
000383 01-04

COCAINE SELF-ADMINISTRATION IN MONKEYS BY CHEWING AND SMOKING.
000424 01-04

EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
001178 02-03

OBSERVATIONAL DETERMINATION OF DOSE-RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-D4

HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN MONKEYS.
001504 02-04

RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04

SUSTAINED INGESTION OF METHADONE AND THE SLEEP OF MONKEYS.
001586 02-04

DYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WITH PRIOR METHADONE TREATMENT.
001619 02-05

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
001648 02-06

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
002198 03-03

CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS.
002456 03-04

DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
002511 03-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
002538 03-04

THE EFFECTS OF HALLUCINOGENS ON BLIND MONKEYS.
002540 03-04

LONG-TERM TOXICITY STUDY OF METHYLMERCURIC-CHLORIDE IN MONKEYS (REPORT V).
002569 03-05

GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-D4

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-386, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
0D3410 D4-04

A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS.
DD3426 D4-04

SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
D03509 D4-05

MONOAMINE

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

EFFECT OF THEOPHYLLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN.
000139 01-03

BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS.
000568 01-08

PIPERIDINE: EFFECTS ON LOCOMOTOR ACTIVITY AND BRAIN MONOAMINE TURNOVER.
001122 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02-03

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

EFFECTS OF THEOPHYLLINE ON CENTRAL MONOAMINE NEURONS.
002273 03-03

EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN.
0D2373 03-03

CENTRAL MONOAMINE METABOLISM IN DEPRESSION AND MANIA. (UNPUBLISHED PAPER).
002675 03-09

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002836 03-13

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE METABOLISM.
003206 04-03

INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
003338 04-03

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY- DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13

TRICYCLIC ANTIDEPRESSANTS AND CENTRAL MONOAMINE METABOLISM.
003902 04-17

MONOAMINE-OXIDASE

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON MONOAMINE-OXIDASE ACTIVITY OF RAT TISSUES IN VIVO.
000042 01-03

INHIBITION OF RAT BRAIN MONOAMINE-OXIDASE BY FORMAMIDINES AND RELATED COMPOUNDS.
000048 01-03

MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
000108 01-03

INHIBITION OF MONOAMINE-OXIDASE BY AMPHETAMINE AND RELATED COMPOUNDS.
D00163 01-03

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION.
00034D 01-04

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
D00491 D1-01

LOW PLATELET MONOAMINE-OXIDASE ACTIVITY AND SCHIZOPHRENIA.
00D576 01-08

TOWARDS RATIONAL THERAPY WITH MONOAMINE-OXIDASE INHIBITORS.
0D0715 D1-1

LOWERED MONOAMINE-OXIDASE IN CONNECTION WITH ALCOHOLIC SUICIDES.
000823 01-13

MONOAMINE-OXIDASE, MONOAMINE-OXIDASE INHIBITING DRUGS AND HUMAN BEHAVIOR (UNPUBLISHED REPORT).
001061 01-17

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 02-03

EFFECTS OF TETRAHYDRO-BETA-CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN.
001156 02-03

INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
001213 02-03

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
001289 02-03

INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04

MONOAMINE-OXIDASE INHIBITORS: POTENTIAL FOR DRUG ABUSE.
001876 02-12

DETERMINATION OF MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN HUMAN BLOOD COMPONENTS: METHODOLOGICAL ASPECTS.
001896 02-13

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
002014 02-15

MONOAMINE-OXIDASE AND ITS INHIBITION.
002179 02-17

SELECTIVITY OF 4-METHOXYPHENETHYLAMINE DERIVATIVES AS INHIBITORS OF MONOAMINE-OXIDASE.
002279 03-03

PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA: AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
002688 03-09

COMBINING TRICYCLIC AND MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS.
002936 03-15

BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003076 04-02

CHARACTERIZATION OF RAT SKELETAL MUSCLE MONOAMINE-OXIDASE.
003085 04-03

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE-OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-03

STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
003138 04-03

PROCAINE HYDROCHLORIDE AS A MONOAMINE-OXIDASE INHIBITOR: IMPLICATIONS FOR GERIATRIC THERAPY.
003148 04-03

TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
003219 04-03

THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04-03

PLATELET MONOAMINE-OXIDASE ACTIVITY IN SCHIZOPHRENIC PATIENTS.
003658 04-13

MONOAMINERGIC

TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03

HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
001477 02-04

STUDY OF MONOAMINERGIC MECHANISMS OF HALOPERIDOL ACTION IN EXPERIMENTS WITH CATS.
002331 03-03

MONOAMINERGIC SENSORY REGULATION AND THE ROLE OF MORPHINE.
002353 03-03

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
00240B 03-03

MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-04

EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
003193 04-03

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

MONOAMINES

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
001140 02-03

ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
001143 02-03

CENTRAL MONOAMINES AND HYPERKINESIS OF CHILOHOOD.
001860 02-11

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-03

EFFECTS OF BENZODIAZEPINES ON BRAIN MONOAMINES.
002365 03-03

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04

FACTORS INFLUENCING THE DEAMINATION AND FUNCTIONAL ACTIVITY OF BIOGENIC MONOAMINES IN THE CENTRAL-NERVOUS-SYSTEM.
003904 04-17

MONODEMETHYLATED

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED METABOLITE IN HUMAN PLASMA.
003653 04-13

MONOGRAPHS

MONOGRAPHS ON DRUGS. VOL. II.
000990 01-15

MONOMETHYLATED

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

MONOMETHYLHYDRAZINE

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

MONOOXYGENASES

ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
000190 01-03

MONOPHOSPHATE

FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI OF CEREBELLUM.
001145 02-03

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-03

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03

MONOSYNAPTIC
TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03
SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-03
TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

MONOZYGOTIC
IDENTICAL PSYCHOSIS IN A PAIR OF MONOZYGOTIC TWINS.
002966 03-17

MONTMORILLONITE
SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTERACTION WITH AMPHETAMINE SULFATE.
00368B 04-13

MOOD
CATECHOLAMINES IN ACTIVATION, STEREOTYPY, AND LEVEL OF MOOD.
000858 01-13
EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
001748 02-09
THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09
SEVERE MOOD DISORDERS: A REVIEW.
001780 02-09
A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION
003525 04-07
THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14
THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS.
003793 04-15
MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION.
003798 04-15
MOOD ACTIVE AGENTS IN DEPRESSION.
003895 04-17

MOODSWING
MOODSWING: THE THIRD REVOLUTION IN PSYCHIATRY.
000602 01-09

MORBIDITY
CATECHOLAMINE ACTIVITY AND REPORTED MORBIDITY.
002123 02-17

MORNING
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

MORPHANTHRIDINE
A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
00047B 01-07

MORPHINE
NEW MORPHINE DERIVATIVES.
000027 01-02
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03
CALCIUM DEPLETION OF SYNAPTOSOMES AFTER MORPHINE TREATMENT.
000070 01-03
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03
SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03
ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
000106 01-03
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03
ENHANCEMENT OF PENTOBARBITAL EFFECT BY CONTINUOUS ADMINISTRATION OF MORPHINE IN THE MOUSE.
000122 01-03
DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03
MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN.
000224 01-03
MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03
THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03
A DOSE-RESPONSE COMPARISON BETWEEN METHADONE AND MORPHINE SELF-ADMINISTRATION.
000255 01-03
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03
INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-04
THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04
BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04
CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF MESCALINE AND MORPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04
BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-04
DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF-STIMULATION.
000335 01-04
DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-0
PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-0
BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
000421 01-0
TERATOLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-0
SUBJECTIVE AND PHYSIOLOGIC EFFECTS OF MORPHINE, PENTOBARBITAL AND MEPROBAMATE.
000761 01-1
A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-0
TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
001111 02-0
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-0
ANALGESIA PRODUCED BY MORPHINE WHEN ACTING FROM THE LIQUOR SPACE.
0011B4 02-0
EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN
001197 02-0
EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-0
ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-0
MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-0
THE EFFECTS OF MORPHINE AND METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS.
001236 02-0
THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-0
STUDIES ON TOLERANCE DEVELOPED TO SINGLE-DOSES OF MORPHINE IN MICE.
001244 02-0

MORPHINE OPPOSED EFFECTS OF NALOXONE IN UNANESTHETIZED DOGS.
001252 02-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-03

DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
0012B5 02-03

DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLDGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FDLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

SYSTEMATIC EXAMINATIDN IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

ENKEPHALIN-INDUCED INHIBITIDN OF CORTICAL NEURONES AND THE LACK DF THIS EFFECT IN MDRPHINE TDLERANT/DEPENDENT RATS.
00142B 02-03

CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNDVER RATE IN CORTEX AND HIPPDCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDDMDRPHINE.
D0143D 02-03

EFFECTS OF MDRPHINE ALONE AND IN COMBINATIDN WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MDNKEY.
001453 02-04

EFFECT OF MORPHINE AND NALOXDNE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-D4

DISCRIMINATIVE STIMULUS PRDPERTIES OF FENTANYL AND MORPHINE: TOLERANCE AND DEPENDENCE.
DD1461 02-04

CATALEPSY INDUCED BY MORPHINE DR HALOPERIDOL: EFFECTS OF APOMDRPHINE AND ANTICHOLINERGIC DRUGS.
0014B1 D2-04

RELATIDNSHIP BETWEEN PHYSICAL DEPENDENCE AND TOLERANCE OF MORPHINE IN THE RAT.
0014B2 D2-04

ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
D01492 02-D4

BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION DF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04

ACQUIRED PREFERENCE FOR MDRPHINE BUT NOT D-AMPHETAMINE AS A RESULT OF SACCHARINE ADULTERATION.
001513 02-04

PROPRANOLDL AND MORPHINE.
001555 02-04

SECONDARY REINFDRCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-04

DIFFERENTIAL EFFECTS DF MDRPHINE DN TWD-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
001575 02-04

INHIBITIDN OF MORPHINE EFFECTS BY SYNTHETIC SUBSTANCE-P.
001594 02-04

MDRPHINE, ENKEPHALIN, AND THE SUBSTANTIA-GELATINOSA.
DD1617 02-05

EFFECT OF MDRPHINE MICRDINJECTION INTO THE MEDULLA-OBLONGATA DN THE SPINAL DORSAL HORN NEURON.
002200 D3-03

ACTIDNS OF ENKEPHALIN AND MORPHINE DN SPINAL CORD AND BRAINSTEM NEURDNES.
002229 03-03

ACTION OF DIAZEPAM, HALOPERIDDL, MDRPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 D3-D3

EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
0022B0 03-03

THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
0022B1 03-03

ALTERATIONS IN DISTRIBUTION AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CENTRAL-NERVOUS-SYSTEM FOLLOWING MORPHINE ADMINISTRATION.
0022BB 03-03

A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFERENT TYPES OF MORPHINE PELLETS.
002311 03-03

OXIDATIVE PHDSPHORYLATION IN VARIOUS PARTS DF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION.
002321 03-D3

APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDRDGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03-03

COMPARISON BETWEEN NALDXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATIDN OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHDLAMINE LEVELS IN
002345 03-03

MONOAMINERGIC SENSORY REGULATION AND THE ROLE OF MDRPHINE.
002353 D3-03

EFFECT OF MDRPHINE ON THE HYPDTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TDLERANT RATS.
D023B4 D3-D3

THE INFLUENCE DF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTDSOMES PREPARED FRDM RAT HYPDTHALAMUS. (PH.D. DISSERTATIDN).
0D2397 03-03

POSSIBLE INVDLVEMENT OF GABA IN MORPHINE ANALGESIA.
D02411 03-03

NIGRDSTRIATAL EFFECTS OF MDRPHINE IN TWD MOUSE STRAINS.
002426 D3-04

MORPHINE INJECTIONS IN THE TASTE-AVERSION PARADIGM.
002443 D3-D4

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATIDN (ICS): DAILY MDRPHINE AND PRESSING FOR COMBINATIDNS OF PDSITIVE AND NEGATIVE ICS.
002444 03-04

EFFECTS OF CHDLINERGIC AGDNISTS AND ANTAGDNISTS ON MORPHINE WITHDRAWAL SYNDRDME.
DD2469 D3-04

CEREBELLAR C-GMP LEVELS REDUCED BY MDRPHINE AND PENTOBARBITAL DN A DOSE AND TIME-DEPENDENT BASIS.
0D24B1 D3-04

AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION DF MORPHINE IN RATS AND MICE
DD24B6 D3-04

ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATIDN OF THE STRIATUM.
002491 03-04

CONDITIDNING DF DISCRIMINABLE STIMULI PRODUCED BY MDRPHINE.
002499 03-04

THE DISCRIMINATIVE STIMULUS PRDPERTIES DF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-04

DIFFERENTIAL EFFECT OF MORPHINE DN TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATIDN: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
DD2527 03-04

AFFECTIVE STATES ASSDCIATED WITH MDRPHINE INJECTIONS.
00252B 03-04

ALTERATIONS IN THE EFFECTS DF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLDWING CHRONIC MORPHINE TREATMENT.
002541 D3-04

EFFECT OF UNIT DDSE AND RDUTE DF ADMINISTRATIDN ON SELF-ADMINISTRATION OF MORPHINE.
002543 D3-04

STUDIES ON DRUG DEPENDENCE (REPT. 19): DEPENDENCE ON PREFERENCE DN AND PREFERENCE FOR MORPHINE.
002545 03-04

DURATIDN DF ACTION DF NALOXDNE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04

CHANGES IN THE BDOY WEIGHT OF RAT ON CONTINUDUS INJECTIONS OF MORPHINE, PETHIOINE, OR PENTAZOCINE.
002575 03-05

COCAINE ANO MORPHINE SELF-AOMINISTRATION: EFFECTS OF DIFFERENTIAL REARING.
002585 03-06

SEASONAL VARIATIDN IN OEVELOPMENT OF TOLERANCE TD MORPHINE.
002845 03-13

BINOING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITIDN BY MORPHINE OR NALOXONE.
0030B9 04-03

9-NOR-9BETA-HYORDXYHEXAHYORDCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03

IN VITRO STUOIES IN SYNAPTOSOMES OF RAT STRIATUM ABOUT THE EFFECTS OF MORPHINE ON UPTAKE ANO RELEASE OF C14-ODPAMINE.
003104 04-03

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE-OXIOASE ACTIVITY IN OISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-03

UNIT ACTIVITY OF AMYGOALA ANO HIPPOCAMPAL NEURDNS: EFFECTS OF MORPHINE ANO BENZODIAZEPINES.
003113 04-03

SUPPRESSIDN OF GABA-INOUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

EFFECT OF MDRPHINE ON MOUSE BRAIN ATPASE ACTIVITIES.
003126 04-03

MORPHINE, NALOXONE AND THE RESPDNSES DF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-03

QUANTITATIVE ASSESSMENT OF TOLERANCE TO AND DEPENDENCE ON MDRPHINE IN MICE.
003140 04-03

HALDPERIOOL ATTENUATION OF MORPHINE ABSTINENCE: SYNERGISTIC EFFECT DF ACUTE LITHIUM AOMINISTRATION.
003172 04-03

ABSENCE OF MDRPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATEO 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATIDN IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

MUTUAL EFFECTS OF MORPHINE ANO ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
00319B 04-03

CHROMOSDME STUDIES BEFORE ANO AFTER THE ACUTE ADMINISTRATION OF MORPHINE.
003216 04-03

NEURDANATOMICAL FOCUS FDR MORPHINE AND ENKEPHALIN-INDUCED HYPERMDTILITY.
003240 04-03

DIFFERENTIAL EFFECT DF MORPHINE ON STIMULATIDN OF PRIMARY VERSUS HIGHER DROER TRIGEMINAL TERMINALS.
003257 04-03

ATTENUATION OF MDRPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-CDERULEUS ANO DORSAL RAPHE NUCLEUS.
003266 04-03

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEURDTRANSMITTERS OURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

NATURE DF SEASONAL VARIATION IN DEVELOPMENT DF ACUTE TOLERANCE TD MORPHINE.
003277 04-03

REGIONAL ACETYLCHOLINE CDNTENT IN MDUSE BRAIN AFTER MORPHINE TABLET IMPLANTATIDN.
003289 04-03

CRDSS-TOLERANCE BETWEEN MORPHINE AND BETA-ENDORPHIN IN VIVO.
003296 04-03

DEPRESSION BY MDRPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FRDM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-D3

INDUCTION DF TOLERANCE AND WITHORAWAL IN RATS RECEIVING MDRPHINE IN THE SPINAL SUBARACHNDIO SPACE.
003332 04-03

STUDIES ON THE ANTAGDNISM BY RAPHE LESIDNS DF THE ANTINDCICEPTIVE ACTIDN DF SYSTEMIC MORPHINE.
003333 04-03

INHIBITIDN BY NALOXONE DF TDLERANCE ANO DEPENOENCE IN MICE TREATED ACUTELY AND CHRDNICALLY WITH MORPHINE.
003334 04-03

MDRPHINE ALTERS DISTRIBUTIDN DF GABA IN THALAMUS.
003336 04-03

OPIATE-LIKE ACTIDN OF METHIONINE-ENKEPHALIN IN INHIBITING MDRPHINE ABSTINENCE SYNDRDME.
003352 04-04

POTENTIATIDN DF MDRPHINE ANALGESIA BY MUSCIMOL.
003354 04-04

PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE ANO MORPHINE ON CONOITIONEO GUSTATORY AVERSION.
003360 04-04

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALDGRAPHIC ANO BEHAVIOURAL EFFECTS OF MORPHINE IN POST-AOOICT RATS.
003363 04-04

SITE OF ACTION OF OEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS.
003367 04-04

EFFECT OF MORPHINE ON RESPONSE TO PAIN: A TWIN STUOY.
003374 04-04

MORPHINE LDWERING OF SELF-STIMULATIDN THRESHOLOS: LACK OF TOLERANCE WITH LONG TERM AOMINISTRATION.
0033B2 04-04

CHANGES IN SENSITIVITY TO DPERANT EFFECTS OF OOPAMINERGIC ANO CHOLINERGIC AGENTS FDLLDWING MORPHINE WITHORAWAL IN RATS.
003390 04-04

BEHAVIOR MAINTAINEO UNOER SECDNO-OROER SCHEOULES DF INTRAVENOUS MDRPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MDNKEYS.
003391 04-04

ENOURING EFFECTS OF MDRPHINE PELLETS REVEALEO BY CONOITIONEO TASTE-AVERSION.
003424 04-04

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVDUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY DF RATS.
003437 04-04

DISCRIMINATIVE EFFECTS OF MDRPHINE IN THE SQUIRREL-MONKEY.
003457 04-04

FURTHER EVALUATION DF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT.
003460 04-04

MORPHINE TOLERANCE ACQUISITIDN AS AN ASSDCIATIVE PROCESS.
003462 04-04

EFFECTS OF REPEATED MDRPHINE ADMINISTRATION DN COPULATIDN AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

THE REINFDRCING ACTION OF MDRPHINE AND ITS PARAODXICAL SIDE-EFFECT.
0D3481 04-04

RELATIDNSHIP BETWEEN MORPHINE SELF-ADMINISTRATION AND THE EFFECT OF MDRPHINE ACROSS STRAINS OF MICE.
003482 04-04

HYPOTHALAMIC SELF-STIMULATIDN UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

GENDTYPE AND TEST EXPERIENCE AS DETERMINANTS DF SENSITIVITY ANO TDLERANCE TO MORPHINE.
003494 04-05

EFFECT OF AGGREGATION DN MORPHINE LETHALITY IN RATS.
D03508 04-05

MORPHINE AS ANTIPSYCHDTIC DRUG.
003554 04-09

MORPHINE-BASED

MDRPHINE-BASED SECDNDARY REINFDRCEMENT: EFFECTS DF DIFFERENT ODSES DF NALOXONE.
0D0372 01-04

MORPHINE-DEPENDENCE

BEHAVIOR AND AODICTIDN: EXPERIMENTAL STUDIES DF MDRPHINE-DEPENDENCE. (PH. D. DISSERTATION).
000315 01-04

EFFECTS OF LESIONS DF THE CAUDATE NUCLEUS ON MORPHINE-OEPENOENCE IN THE RAT.
D01539 02-04

THE EFFECTS OF NALDXONE AND NALDRPHINE DURING THE DEVELOPMENT OF MDRPHINE-DEPENDENCE IN RHESUS-MONKEYS.
003077 04-03

EFFECT DF NEURDHYPOPHYSEAL HORMDNES ON MDRPHINE-DEPENDENCE.
003311 04-03

RAPID INDUCTIDN AND QUANTITATIDN OF MDRPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATIDN
003353 04-04

MORPHINE-DEPENDENT

EFFECTS OF SERINE ON MDRPHINE-DEPENDENT MICE.
0D0096 01-03

ODPAMINERGIC CHDLINERGIC INTERACTIONS IN NALDXONE-INDUCED CIRCLING IN MDRPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
000128 01-03

THE EFFECTS OF MDRPHINE-LIKE ANO NALORPHINE-LIKE DRUGS IN THE NONOEPENDENT AND MDRPHINE-DEPENDENT CHRDNIC SPINAL DDG
D00164 01-03

SCHEDULE-CDNTROLLED BEHAVIDR IN THE MORPHINE-DEPENDENT RAT.
D00327 01-04

EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE.
001445 02-04

THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS.
001447 02-04

DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04

PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE.
001604 02-04

CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS.
002456 03-04

DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
003086 04-03

EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
003388 04-04

MORPHINE-INDUCED

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
000188 01-03

POTENTIATION OF MORPHINE-INDUCED SEIZURE BY 6-HYDROXYDOPAMINE.
001133 02-03

THE EFFECT OF LITHIUM-CHLORIDE ON MORPHINE-INDUCED AND PYROGEN-INDUCED HYPERTHERMIA IN RATS.
001161 02-03

BETA-BLOCKADE OF MORPHINE-INDUCED HYPERLACTACIDEMIA IN RABBITS.
001352 02-03

EFFECT OF HUMORAL MODULATORS ON MORPHINE-INDUCED INCREASE IN LOCOMOTOR ACTIVITY OF MICE.
00155B 02-04

ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE.
0015B4 02-04

MORPHINE-INDUCED CHANGES OF CYCLIC-AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN.
002319 03-03

EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03

EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
003188 04-03

MORPHINE-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
003197 04-03

EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUCED HYPERTHERMIA IN NON-TOLERANT RATS.
003232 04-03

MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

MORPHINE-LIKE

PHYLOGENETIC DISTRIBUTION OF A MORPHINE-LIKE PEPTIDE ENKEPHALIN.
000015 01-01

THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03

TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
001148 02-03

MORPHINE-LIKE ANALGESIC EFFECT OF A PITUITARY HORMONE, BETA-LIPOTROPIN.
001344 02-03

MORPHINE-TOLERANT

EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
0023B4 03-03

MORPHINE-TYPE

ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06

MORPHINES

ELECTROACUPUNCTURE AND ENDOGENOUS MORPHINES
001943 02-13

MORPHOLOGICAL

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY.
001613 02-05

MORTALITY

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS.
001727 02-09

MOTHERS

REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05

MOTILITY

THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE
000129 01-03

EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000805 01-13

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04

MOTIVATED

THE EFFECTS OF CHLORPROMAZINE UPON FEAR MOTIVATED BEHAVIOR IN THE SQUIRREL-MONKEY.
000345 01-04

EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-04

MOTIVATION

INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000B76 01-14

MOTIVATIONAL

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL AND NEUROHUMORAL VARIABLES.
000355 01-04

EMOTIONAL AND MOTIVATIONAL ASPECTS OF DRUG TAKING BEHAVIOR OF ANIMALS.
002464 03-04

MOTIVATIONS

EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
00254B 03-04

FREE-LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN.
003B6B 04-17

MOTONEURONES

BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03

MOTOR

BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-04

EFFECT OF METHAMPHETAMINE ON MOTOR ACTIVITY IN YOUNG AND OLD MICE.
000320 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR
000409 01-04

ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
000796 01-12

EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY.
000999 01-15

CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15

EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-03

NORADRENALINE SYNTHESIS FROM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
0011B6 02-03

A DEVICE FOR THE EVALUATION OF MOTOR INCOORDINATION IN RATS.
001439 02-04

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001500 02-04

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DI-N-PROPYLACETATE.
001533 02-04

AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
0015B7 02-04

EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN.
00199B D2-14

MOTOR DISTURBANCES PRODUCED BY INTRASTRIATAL INJECTION OF CYCLIC-AMP AND CYCLIC-GMP.
002232 03-03

INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002B26 D3-13

THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002B57 03-14

EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-15

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-04

DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
00344B D4-04

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
D03451 04-04

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-D4

EFFECT OF DOPAMINE ON ESOPHAGEAL MOTOR FUNCTION.
DD3504 D4-05

EFFECTS OF LITHIUM-CARBONATE ON MOTOR ACTIVITY IN MANIA AND DEPRESSION.
003561 04-D9

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
00361B D4-11

MOTTLED

A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
D01625 02-05

MOUSE

TISSUE DISTRIBUTION OF METOPROLOL-3H IN THE MOUSE AND THE RAT.
0D0054 01-03

INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000DB9 01-03

ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
DD0106 01-03

ENHANCEMENT OF PENTOBARBITAL EFFECT BY CONTINUOUS ADMINISTRATION OF MORPHINE IN THE MOUSE.
000122 D1-03

THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
000129 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03

REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN.
000194 01-03

INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES.
000213 01-03

MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN.
000224 D1-03

SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
D002B9 01-04

THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
00030B 01-04

MEASUREMENT OF ACUTE AND CHRONIC BEHAVIORAL EFFECTS OF METHAMPHETAMINE IN THE MOUSE.
000401 01-04

FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION
D00404 01-04

EFFECTS OF TETRAHYDRO-BETA-CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN.
001156 02-03

INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN.
001197 02-03

INHIBITION OF ARYLHYDROCARBON-HYDROXYLASE INDUCTION IN BALB/C MOUSE LIVER BY DELTA9-TETRAHYDROCANNABINOL.
001212 02-03

DIFFERENTIAL ACTIONS OF DOPAMINE AGONISTS AND ANTAGONISTS ON THE GAMMA-BUTYROLACTONE-INDUCEO INCREASE IN MOUSE BRAIN DOPAMINE.
D01220 D2-03

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
DD1246 02-03

LOCALIZATION OF PHENOBARBITAL IN MOUSE CENTRAL-NERVOUS-SYSTEM BY IMMUNOFLUORESCENCE.
001327 D2-03

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
DD133B 02-D3

INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE BRAIN
001369 D2-03

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
0D14D2 D2-03

ON THE RELATION BETWEEN HYPODIPSIA AND ANOREXIA INDUCED BY (+) AMPHETAMINE IN THE MOUSE.
001472 D2-04

EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
0D1535 02-D4

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04

BLOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESICS IN THE MOUSE.
0D2362 03-D3

NIGROSTRIATAL EFFECTS OF MORPHINE IN TWO MOUSE STRAINS.
0D2426 D3-04

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
0D243B D3-D4

DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN.
002459 D3-04

CORRELATION OF BEHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE. (PH.D. DISSERTATION).
00256D D3-04

THE INHIBITION OF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC-ACID.
003074 04-02
EFFECT OF MORPHINE ON MOUSE BRAIN ATPASE ACTIVITIES.
003126 04-03
EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
003187 04-03
DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE.
003245 04-03
REGIONAL ACETYLCHOLINE CONTENT IN MOUSE BRAIN AFTER MORPHINE TABLET IMPLANTATION.
003289 04-03

MOUSE-KILLING
NEUROPHARMACOLOGICAL REGULATION OF MOUSE-KILLING BY RATS.
000280 01-04
INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04
RESERPINE INDUCTION OF MOUSE-KILLING IN NONKILLER RATS.
001443 02-04
EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

MOVE
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 02-17

MOVEMENT
THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000B20 01-13
EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-03

MOVEMENTS
THE EFFECTS OF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05
MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SUBSTRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 01-11
THE INFLUENCE OF DRUGS AND ALCOHOL UPON HUMAN EYE MOVEMENTS.
002085 02-15
ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
003631 04-11

MOVING
ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

MRC
PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT.
001776 02-09

MSH
MELATONIN, MSH, AND PSYCHOSIS.
003B47 04-17

MT-14-411
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14

MUCO-CUTANEOUS
SURMONTIL AND MUCO-CUTANEOUS PIGMENTATION.
002B9B 03-15

MUCOSA
SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-03
INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04

MULTICENTER
DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
0017B7 02-10

MULTICENTRE
AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
001818 02-11
PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
001825 02-11
A MULTICENTRE STUDY COMPARING MAZINDOL AND PLACEBO IN OBESE PATIENTS.
003648 04-11

MULTICLINIC
A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
003605 04-10

MULTIPLE
COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000859 01-13
CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03
EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
002415 03-04
THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
003379 04-04

MULTIPLE-SCLEROSIS
LITHIUM IN THE TREATMENT OF A MANIC PATIENT WITH MULTIPLE-SCLEROSIS: A CASE REPORT.
003879 04-17

MULTIPLE-UNIT
ETHANOL-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
001264 02-03
EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03
EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04
MORPHINE-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
003197 04-03
EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-03

MULTIPLICATION
MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
002368 03-03

MURINE
A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-05

MUSCARINIC
MUSCARINIC AGONISTS PROVIDE A NEW CLASS OF ACARICIDE.
000019 01-02
A STUDY OF MUSCARINIC RECEPTOR HETEROGENEITY WITH WEAK ANTAGONISTS.
000097 01-03
INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN-F2ALPHA
0001B3 01-03
TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03
ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN.
001512 02-04
EFFECTS OF NICOTINIC AND MUSCARINIC COMPOUNDS ON BITING ATTACK IN THE CAT.
002424 03-04
EFFECT OF MUSCARINIC CHOLINERGIC DRUGS ON MORPHINE-INDUCED CATALEPSY, ANTINOCICEPTION AND CHANGES IN BRAIN DOPAMINE METABOLISM.
0031B8 04-03
ANTIDEPRESSANTS AND THE MUSCARINIC ACETYLCHOLINE RECEPTOR.
003510 04-05

MUSCIMOL
GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03
CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03
REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03
GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02
A CEREBELLAR MODEL TO STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSION. (UNPUBLISHED PAPER).
002212 03-03
ACTION OF DIAZEPAM, HALOPERIDOL, MORPHINE AND MUSCIMOL ON THE C-GMP CONTENT OF CEREBELLUM. (UNPUBLISHED PAPER).
002256 03-03
MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS: EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION.
003268 04-03
POTENTIATION OF MORPHINE ANALGESIA BY MUSCIMOL.
003354 04-04

MUSCLE
CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 01-05
DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15
IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 02-03
DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001B43 02-11
BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04
CHARACTERIZATION OF RAT SKELETAL MUSCLE MONOAMINE-OXIDASE.
0030B5 04-03
EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
00312B 04-03
SEROTONIN ACCUMULATION BY SKELETAL MUSCLE.
0032BB 04-03
PROLONGATION OF MUSCLE RELAXANT EFFECTS BY LITHIUM-CARBONATE.
003820 04-15

MUSCULAR
POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03
MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-05

MUSCULOSKELETAL
THE EFFICACY OF PERCOGESIC IN RELIEF OF MUSCULOSKELETAL PAIN ASSOCIATED WITH ANXIETY.
003619 04-11
CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
003B91 04-17

MUTUAL
MUTUAL EFFECTS OF MORPHINE AND ASPARTIC-ACID ON BRAIN LEVELS IN MICE.
00319B 04-03

MYASTHENIA-GRAVIS
EMERGENCE OF MYASTHENIA-GRAVIS DURING TREATMENT WITH LITHIUM-CARBONATE.
002066 02-15

MYELIN
MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN. METAL BINDING AND FLUORESCENCE STUDIES.
001328 02-03

MYELINOGENESIS
REVERSAL OF DELAYED MYELINOGENESIS IN THE FETAL ALCOHOL SYNDROME
003258 04-03

MYENTERIC
LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03
ASPECTS OF OPIATE DEPENDENCE IN THE MYENTERIC PLEXUS OF THE GUINEA-PIG.
000222 01-03
ENKEPHALIN INHIBITS FIRING OF MYENTERIC NEURONES.
001634 02-05

MYOCARDIAL
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03
RISK FACTORS FOR MYOCARDIAL INFARCTION IN YOUNG WOMEN.
000966 01-15
EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
0031B3 04-03

MYOCARDITIS
MYOCARDITIS ASSOCIATED WITH METHYLDOPA THERAPY.
003810 04-15

MYOCLONUS
5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04
MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS OF INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15
BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13
RIGIDITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-03
MYOCLONUS IN THE YOUNG AFTER 5-HYDROXYTRYPTOPHAN.
003771 04-15
TRICYCLIC-INDUCED MYOCLONUS.
003B02 04-15

MYOPATHY
IMIPRAMINE SEROTONIN-INDUCED MYOPATHY.
001632 02-05

MYOTONIC
HYPERSOMNIA IN MYOTONIC DYSTROPHY: TREATMENT WITH METHYLPHENIDATE.
003640 04-11

M5T-1R8
TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1R8.
002672 03-09

N-ACETYL-DL-PENICILLAMINE
MOBILIZATION OF METHYLMERCURY IN VIVO AND IN VITRO USING N-ACETYL-DL-PENICILLAMINE AND OTHER COMPLEXING AGENTS.
002197 03-03
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-03

N-ACETYLTRANSFERASE
IN VITRO AND IN VIVO STUDIES OF EXTRAPINEAL N-ACETYLTRANSFERASE OF RAT BRAIN
003145 04-03

N-ALLYL
THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

N-ALLYLNORCODEINE
A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-02

N-ARYLPIPERAZINES
SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
00110B 02-02

N-DEMETHYLATED
THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN
001242 02-03

N-DEMETHYLATION
INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

N-DESMETHYL
PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03
CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN.
000825 01-13

N-DESMETHYLDIAZEPAM
CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
000697 01-10
CLINICAL EXPERIENCE OF N-DESMETHYLDIAZEPAM (A-101) IN THE FIELD OF PSYCHIATRY.
000712 01-10
SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000835 01-13
CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
000BB1 01-14
N-DESMETHYLDIAZEPAM: A NEW METABOLITE OF CHLORDIAZEPOXIDE IN MAN.
002B05 03-13

N-DIMETHYLGLYCINE-OXIDASE
THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

N-ETHYL-2-BROMOBENZYLAMINE
ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03

N-HYDROXYAMPHETAMINE
THE ROLE OF N-HYDROXYAMPHETAMINE IN THE METABOLIC DEAMINATION OF AMPHETAMINE.
003329 04-03

N-HYDROXYLATION
A CASE OF DEFICIENCY OF N-HYDROXYLATION OF AMOBARBITAL.
0036B0 04-13

N-HYDROXYNORMEPERIDINE
MEPERIDINE METABOLITES: IDENTIFICATION OF N-HYDROXYNORMEPERIDINE AND A HYDROXYMETHOXY DERIVATIVE OF MEPERIDINE IN BIOLOGICAL FLUIDS.
002376 03-03

N-ISOPROPYL
N-ISOPROPYL DERIVATIVES OF DOPAMINE AND 5,6 DIHYDROXY-2-AMINOTETRALIN.
00006B 01-03

N-METHYLTRANSFERASE
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01
SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03
INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION.
003051 04-01
IN VITRO STUDIES OF SOME CHLORPROMAZINE METABOLITES AS POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
003265 04-03

N-MONOAMINE-OXIDASE
THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

N-PROPARGYL
THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

N-SUBSTITUTED
COMPARISON OF THE DOPAMINERGIC EFFECTS OF N-SUBSTITUTED APORPHINES.
002498 03-04
INDOLIZINE DERIVATIVES WITH BIOLOGICAL ACTIVITY I: N-SUBSTITUTED HYDRAZIDES OF INDOLIZINE-2-CARBOXYLIC-ACID.
00304B 04-01
POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02
SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5-ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02

N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE
LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART.
001345 02-03

NA +
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

NA +-
COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON BRAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
0023B2 03-03

NA-K-ATPASE
EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMAL NA-K-ATPASE ACTIVITY.
001630 02-05

NACL
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

NAD-DEPENDENT
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03

NADPH-CYTOCHROME-C-REDUCTASE
INFLUENCE OF ACUTE AND CHRONIC ADMINISTRATION OF METHADONE-HYDROCHLORIDE ON NADPH-CYTOCHROME-C-REDUCTASE AND CYTOCHROME-P-450 OF MOUSE LIVER MICROSOMES.
001177 02-03

NAFTIDROFURYL
EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03
A DOUBLE-BLIND TRIAL OF NAFTIDROFURYL IN TREATING CONFUSED ELDERLY PATIENTS IN GENERAL PRACTICE.
003612 04-11

NAIVE
INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-04
ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-03
SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

NALODEINE
A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-02

NALORPHINE
A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-02
THE EFFECTS OF NALOXONE AND NALORPHINE DURING THE DEVELOPMENT OF MORPHINE-DEPENDENCE IN RHESUS-MONKEYS.
003077 04-03
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

NALORPHINE-LIKE
THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03

NALOXONE
ACTION OF NALOXONE ON THE INTERFERON LOWERING ACTIVITY OF MORPHINE IN THE MOUSE.
000106 01-03
EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001BB 01-03

BLOCKADE OF APOMORPHINE-INDUCED AGGRESSION BY MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-D4
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04
MORPHINE-BASED SECONDARY REINFORCEMENT: EFFECTS OF DIFFERENT DOSES OF NALOXONE.
000372 01-04
BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
000421 01-04
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03
CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL.
00120B 02-03
ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
0D12D9 02-03
MORPHINE OPPOSED EFFECTS OF NALOXONE IN UNANESTHETIZED DOGS.
D01252 02-03
EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE.
001445 02-04
EVIDENCE FOR NALOXONE AND OPIATES AS GABA ANTAGONISTS.
001450 02-D4
EFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY.
DD1453 D2-04
EFFECT OF MORPHINE AND NALOXONE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-04
INTERACTIONS BETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 D2-04
ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE.
0015B4 02-04
DRUGS FIVE YEARS LATER: NALOXONE.
00192B D2-13
COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03
DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04
NALOXONE IN OPIATE ADDICTION.
002742 03-11
REVERSAL OF NARCOTIC DEPRESSION IN THE NEONATE BY NALOXONE.
DD2B0B D3-13
THE EFFECTS OF NALOXONE AND NALORPHINE DURING THE DEVELOPMENT OF MORPHINE-DEPENDENCE IN RHESUS-MONKEYS.
003077 04-03
BINDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITION BY MORPHINE OR NALOXONE.
0D3DB9 D4-D3
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
DD3D93 D4-D3
MORPHINE, NALOXONE AND THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
DD3129 D4-D3
INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE.
003334 D4-D3
A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
0033BB D4-D4
MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
DD3434 D4-D4
NALOXONE ANTAGONISM AS EVIDENCE FOR NARCOTIC MECHANISMS.
003676 04-13
ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE.
0036B7 D4-13
NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14
THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003B60 04-17

NALOXONE-INDUCED
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
00012B 01-03
NALOXONE-INDUCED INHIBITION OF ETHANOL DEPENDENCE IN MICE.
003100 04-03

NALTREXONE
BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
000421 01-04
NALTREXONE: PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF SINGLE-DOSES.
000951 01-15
ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-13
NALTREXONE: DISPOSITION, METABOLISM, AND EFFECTS AFTER ACUTE AND CHRONIC DOSING.
001949 02-13
SHORT-TERM EFFECTS OF NALTREXONE IN 155 HEROIN EX-ADDICTS.
001950 02-13
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-D3
NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14

NAPROXEN
A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION.
003525 D4-07

NARCOLEPSY
EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
000741 01-11
GAMMA-HYDROXYBUTYRATE IN THE TREATMENT OF NARCOLEPSY: A PRELIMINARY REPORT.
0D259D 03-07
THE ACTION OF TRICYCLICS (ALONE OR IN COMBINATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY.
0027B2 03-11
PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNDROME AND HYPERSOMNIA.
D0374B 04-14
NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
DD3B16 04-15

NARCOSIS
THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBITAL NARCOSIS IN THE MONKEY.
0DD145 D1-D3

NARCOTIC
THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT.
0DD09B 01-03
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
D00349 01-04
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-D4
POSSIBLE ROLES OF CATECHOLAMINES IN THE ACTION OF NARCOTIC DRUGS.
000B09 01-13
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
D0116B 02-03
EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
D0135D D2-03
EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
DD135B D2-03
ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 D2-03

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03

SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION
001493 02-04

INTERACTIONS BETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 02-04

FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001858 02-11

A CONTROLLED STUDY OF THE TREATMENT OF NARCOTIC ADDICTION IN IRAN: A PRELIMINARY REPORT (UNPUBLISHED PAPER).
001865 02-11

CLINICAL DEPRESSION AMONG NARCOTIC ADDICTS MAINTAINED ON METHADONE IN THE COMMUNITY.
002174 02-17

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION: I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
002180 02-17

ALLEVIATION OF NARCOTIC WITHDRAWAL BY CONDITIONAL STIMULI.
002292 03-03

INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03

BLOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESICS IN THE MOUSE.
002362 03-03

CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS.
002456 03-04

DISCRIMINATIVE PROPERTIES OF NARCOTIC ANTAGONISTS.
002466 03-04

REVERSAL OF NARCOTIC DEPRESSION IN THE NEONATE BY NALOXONE.
002B08 03-13

DISCRIMINABLE STIMULI PRODUCED BY NARCOTIC ANALGESICS.
003005 03-17

THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11

NALOXONE ANTAGONISM AS EVIDENCE FOR NARCOTIC MECHANISMS.
003676 04-13

ANTAGONISM OF ACUPUNCTURE ANALGESIA IN MAN BY THE NARCOTIC ANTAGONIST NALOXONE.
0036B7 04-13

NARCOTIC CUE AND NARCOTIC STATE.
003B53 04-17

NARCOTICS

ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RELEVANCE FOR PSYCHOMOTOR EFFECTS.
000148 01-03

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
000289 01-04

CLINICAL USE OF NARCOTICS.
002007 02-15

MECHANISM OF ANALGESIC EFFECTS OF NARCOTICS.
00242B 03-04

NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN.
003204 04-03

NATIONAL

PRISON RESEARCH: NATIONAL COMMISSION SAYS NO, UNLESS....
003B50 04-17

NATIVE

CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 02-17

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17

NATRIURESIS

PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION.
002218 03-03

NATURE

THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
000085 01-03

THE NATURE OF SCHIZOPHRENIA.
000525 01-08

THE STRESS-DEPENDENT NATURE OF APOMORPHINE HYPERTHERMIA.
001381 02-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04

NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

NAVANE

CLINICAL EXPERIENCE OF THIOTHIXENE (NAVANE) FOR SCHIZOPHRENIA.
000577 01-08

NEED

RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-0B

PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEED TO BELONG IN THE LIGHT OF THREE CLINICAL CASES.
001793 02-10

NEGATIVE

NEGATIVE ASPECTS OF PHARMACOLOGICAL PREVENTION OF EPILEPSY.
000940 01-15

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-03

THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
001920 02-13

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04

EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
002501 03-04

DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04

NEGLIGIBLE

GAMMA-HYDROXYBUTYRATE DEGRADATION IN THE BRAIN IN VIVO: NEGLIGIBLE DIRECT CONVERSION TO GABA.
001295 02-03

NEMBUTAL

NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

NEOCORTEX

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

NEOCORTICAL

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

NEONATAL

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYDROXYDOPA.
000376 01-04

ADVERSE NEONATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03

NEONATAL HYPERTHYROIDISM ALTERS THE DEVELOPMENT OF BEHAVIORAL AROUSAL AND INHIBITION IN THE MOUSE.
001551 02-04

AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
001587 02-04
THE METABOLISM OF CHLORPROMAZINE IN THE NEONATAL GUINEA-PIG.
0D2315 D3-03
OPERANT BEHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6-HYDROXYDOPAMINE TREATMENT.
D02519 03-04
EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN.
0D3299 D4-03
NEONATAL ANDROGEN INJECTION CHANGES OPEN-FIELD BEHAVIOR OF MICE.
003402 04-04
NEONATAL BARBITURATE WITHDRAWAL.
003769 04-15

NEONATALLY
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

NEONATE
REVERSAL OF NARCOTIC DEPRESSION IN THE NEONATE BY NALOXONE.
0D280B 03-13

NEONATES
METABOLISM OF PHENOBARBITAL AND PHENYTOIN BY NEONATES WITH SEIZURES.
D03697 04-13

NEOPHOBIA
ENHANCING THE EXPRESSION OF FLAVOR NEOPHOBIA: SOME EFFECTS OF THE INGESTION ILLNESS CONTINGENCY.
DD3351 04-04

NEOSTRIATAL
GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
DDD1D4 01-03
ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT.
DD1383 02-03
GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02

NEOSTRIATUM
ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-D3
PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-D3
MODULATION OF ACETYLCHOLINE IN THE NEOSTRIATUM BY DOPAMINE AND 5-HYDROXYTRYPTAMINE.
0D2216 03-03
ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
DD3433 04-04

NEPHROGENIC
PERSISTENT NEPHROGENIC DIABETES-INSIPIDUS AFTER LITHIUM-CARBONATE.
D02934 03-15

NERVE
INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
00013D 01-D3
ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 D1-03
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-D4
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
DD1168 02-D3
THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENDINGS.
0014D9 D2-03
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
0023D5 D3-D3
PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
DD3259 D4-03

NERVES
EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03
EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF 5,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
001629 02-05
AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 D2-17
TURNOVER OF 5-HYDROXYDOPAMINE IN ADRENERGIC NERVES.
0D3157 04-03
SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
0D333D D4-03

NERVOUS
ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
0D1125 02-03
DOPAMINERGIC AGENTS: INFLUENCE ON SEROTONIN IN THE MOLLUSCAN NERVOUS SYSTEM.
001389 02-03
CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03-03
CENTRAL NERVOUS ACTIONS OF CARBAMAZEPINE.
0D2410 03-03
A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
002536 03-D4
RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11
ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM OF RABBITS POISONED WITH METHYLMERCURY.
00350D D4-05

NEURAL
PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
0DD1D1 01-03
ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 02-13
A NEURAL SYSTEMS THEORY OF SCHIZOPHRENIA AND TARDIVE-DYSKINESIA.
002D42 02-15
INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
0D2450 03-04
REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID-DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY
0034D1 D4-04

NEURAMINIDASE
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

NEUROANATOMICAL
NEUROANATOMICAL FOCUS FOR MORPHINE AND ENKEPHALIN-INDUCED HYPERMOTILITY.
0D3240 04-03

NEUROBIOLOGICAL
NEUROBIOLOGICAL MECHANISMS OF ADAPTATION IN RELATION TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
0DD162 01-03
NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
0005B4 D1-09
A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-D9

NEUROBLASTOMA
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
0D3155 04-D3

NEUROCHEMICAL
NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
D0D025 01-02

8EHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MID8RAIN.
000184 01-03

DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION
000352 01-04

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03

NEUROCHEMICAL AND NEUROPHARMACOLOGICAL FOUNDATIONS OF THE SLEEP DISORDERS.
002112 02-17

NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
002283 03-03

NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY.
002395 03-03

OPERANT BEHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6-HYDROXYDOPAMINE TREATMENT.
002519 03-04

NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01

EUROEFFECTOR

THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-03

EUROENDOCRINE

SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07

SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PROBLEM OF PARANOID PSYCHOSIS.
00083B 01-13

NEUROENDOCRINE REGULATION IN DEPRESSION. I. LIMBIC SYSTEM ADRENOCORTICAL DYSFUNCTION
001736 02-09

DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002832 03-13

EUROHORMONE

EFFECT OF ENZYME INDUCTION BY BARBITURATES ON NEUROHORMONE EXCRETION IN MAN.
002B39 03-13

EUROHUMORAL

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL AND NEUROHUMORAL VARIABLES.
000355 01-04

NEUROHUMORAL INTERACTIONS AND BASAL GANGLIA FUNCTION AND DYSFUNCTION.
002260 03-03

EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUCED HYPERTHERMIA IN NON-TOLERANT RATS.
003232 04-03

EUROHYPOPHYSEAL

EFFECT OF NEUROHYPOPHYSEAL HORMONES ON MORPHINE-DEPENDENCE.
003311 04-03

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

MODULATION OF HEROIN SELF-ADMINISTRATION BY NEUROHYPOPHYSEAL PRINCIPLES.
003477 04-04

EUROINTEGRATIVE

PIRACETAM: NOOTROPIC PHARMACOLOGY OF NEUROINTEGRATIVE ACTIVITY.
002454 03-04

EUROLEPTIC

DIFFERENTIAL EFFECT OF NEUROLEPTIC DRUGS ON DOPAMINE TURNOVER IN THE EXTRAPYRAMIDAL AND LIMBIC SYSTEM.
000003 01-01

A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03

DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIDANCE IN RATS.
000469 01-06

ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
000474 01-06

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC SULTOPRIDE.
000504 01-07

TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC: SULTOPRIDE.
000510 01-07

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08

THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-08

APPLICATION OF THE NEUROLEPTIC PIMOZIDE (ORAP-R-6238) FOR TRANQUILIZER INDICATIONS IN A CONTROLLED STUDY.
000701 01-10

INTERACTION OF SOME NEUROLEPTIC AND ANTIDEPRESSIVE AGENTS WITH HUMAN COERULOPLASMIN.
000B41 01-13

EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15

SOME NOTES ON THE PATIENT WITH NEUROLEPTIC SYNDROME.
000941 01-15

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES.
001031 01-17

SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
001108 02-02

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-02

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
00111B 02-02

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

EFFECTS OF NEUROLEPTIC AGENTS ON CYCLIC-GMP IN RAT CEREBRAL CORTEX.
001322 02-03

EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE.
001535 02-04

CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
001679 02-0B

HIGH DOSAGE NEUROLEPTIC THERAPY: A REVIEW
0016B6 02-0B

CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER NEUROLEPTIC TREATMENT.
0016B7 02-08

NEUROLEPTIC EFFECT OF BACLOFEN IN CHRONIC SCHIZOPHRENICS.
001700 02-0B

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
00175B 02-09

INDICATIONS FOR SULTOPRIDE, A MAJOR NEUROLEPTIC.
001B74 02-12

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY.
001909 02-13

NEUROLEPTIC TARDIVE-DYSKINESIAS: STUDY OF 1660 PATIENTS IN A PSYCHIATRIC HOSPITAL.
002019 02-15

CARDIOVASCULAR EFFECTS OF NEUROLEPTIC AND ANTIDEPRESSANT DRUGS. PRELIMINARY REPORT.
002062 02-15

PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION
002172 02-17

PHARMACOKINETIC STUDY OF THE NEUROLEPTIC AZABUTYRON.
00224B 03-03

THE C-FRAGMENT OF BETA-LIPOTROPIN: AN ENDOGENOUS NEUROLEPTIC OR ANTIPSYCHOTOGEN?
002267 03-03

BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-OOPA.
002461 03-04

CUMULATIVE EFFECTS OF PENFLURIOOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED 8Y ITS BEHAVIORAL ACTIONS.
002490 03-04

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-OIBENZOTHIEPINS, ATAXIA IN MICE.
002577 03-05

CLINICAL EVALUATION OF A WEEKLY AOMINISTEREO NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-07

THE PLACE OF SULTOPRIOE AMONG NEUROLEPTIC CURES.
002603 03-07

USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN: SUMMARY.
002626 03-08

DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-08

SEX AND NEUROLEPTIC MEDICATION.
002649 03-08

A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIOOL (R-16341).
002656 03-08

CHEMOTHERAPY OF MELANCHOLIA BY SEQUENTIAL ASSOCIATION OF A NEUROLEPTIC AND VILOXAZINE.
002668 03-09

TREATMENT OF NEUROLEPTIC SYNOROME WITH AN EXTENDEO ACTION FORM OF BIPERIOEN HYOROCHLORIOE: 9 MONTH STUOY OF 55 HOSPITALIZED PATIENTS.
002787 03-11

OISCONTINUANCE OF ASSOCIATEO ANTIPARKINSONIAN ORUGS IN LONG-TERM NEUROLEPTIC TREATMENT.
002923 03-15

GLYCEMIC SIDE-EFFECTS IN PATIENTS OUE TO NEUROLEPTIC THERAPY.
002941 03-15

THE NEUROLEPTIC LEPONEX.
003027 03-17

HYSTERICAL AND HYSTERIA-LIKE REACTIONS OURING NEUROLEPTIC TREATMENT FOR SCHIZOPHRENIA.
003036 03-17

THE ABSOLUTE CONFIGURATION OF SU-23397: A NOVEL NEUROLEPTIC AGENT.
003049 04-01

PHARMACOLOGY OF CIS-CLOPENTHIXOL-DECANOATE, A DEPOT NEUROLEPTIC.
003070 04-02

THE INTERACTION BETWEEN CLONIDINE AND VARIOUS NEUROLEPTIC AGENTS AND SOME BENZODIAZEPINE TRANQUILLIZERS.
003312 04-03

COMBINEO USE OF NEUROLEPTIC DRUGS.
003414 04-04

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENAORINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-08

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE
003544 04-08

NEUROLEPTIC DRUG EFFECTS ON CHILORENS BOOY WEIGHT AND HEIGHT.
003645 04-11

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC ORUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
0036B4 04-13

VOMITING DURING NEUROLEPTIC WITHORAWAL IN CHILDREN.
00375B 04-14

NEUROLEPTIC OOSAGE, OURATION, AND TARDIVE-DYSKINESIA
003760 04-15

POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A OIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY
003B48 04-17

NEUROLEPTIC-INDUCED

AMANTADINE VERSUS TRIHEXYPHENIDYL IN THE TREATMENT OF NEUROLEPTIC-INDUCED PARKINSONISM.
000818 01-1

BACLOFEN (LIORESAL) IN THE TREATMENT OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA.
001923 02-1

ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INOUCED PARKINSON SYNDROME? A WITHDRAWAL STUOY.
002035 02-1

NEUROLEPTIC-INDUCEO AKATHISIA ANO DYSTONIA TRIGGEREO BY ALCOHOL.
002056 02-1

THERAPY WITH OIMETHYLAMINOETHANOL (OEANOL) IN NEUROLEPTIC-INOUCEO EXTRAPYRAMIDAL HYPERKINESIA.
002801 03-1

THERAPEUTIC APPROACHES IN NEUROLEPTIC-INOUCEO TAROIVE-DYSKINESIAS.
002910 03-1

NEUROLEPTIC-INOUCEO EXTRAPYRAMIDAL SYMPTOMS.
002986 03-1

NEUROLEPTICS

STRUCTURE-ACTIVITY RELATIONSHIPS AMONG OESMETHYL OERIVATIVE OF NEUROLEPTICS AND ANTIOEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INOOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-0

ON THE SUPERSENSITIVITY OF OOPAMINE RECEPTORS, INOUCEO BY NEUROLEPTICS.
000073 01-0

OECREASEO INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS O OESTRUCTION OF THE NIGRONEOSTRIATAL 8UNDLE: PERFORMANCE OR REINFORCEMENT OEFICIT
000200 01-0

OOPAMINE METABOLISM IN THE MESOLIMBIC ANO MESOCORTICAL OOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATEO AOMINISTRATIONS OF NEUROLEPTICS.
000217 01-0

BLOCKAOE OF APOMORPHINE-INOUCEO AGGRESSION 8Y MORPHINE OR NEUROLEPTICS: DIFFERENTIAL ALTERATION BY ANTIMUSCARINICS AND NALOXONE.
000332 01-0

INTERACTION OF 8ENZOOIAZEPINES WITH NEUROLEPTICS AT CENTRAL OOPAMINE NEURONS.
00035B 01-0

THERAPEUTIC AOVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZOOIAZEPINE 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-OIHYORO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01-0

OYSTONIC REACTIONS FOLLOWING NEUROLEPTICS: TIME COURSE AND PROPOSEO MECHANISMS.
000543 01-0

CHANGES IN SERUM ENZYME LEVELS OURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
00054B 01-0

A METHOD FOR STUOYING PUPILLOMOTOR EFFECTS OF NEUROLEPTICS.
000556 01-0

THE CHOICE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW.
000571 01-0

OEPOT NEUROLEPTICS.
000583 01-0

CONTRIBUTION OF SLOW-RELEASE NEUROLEPTICS ON OPENING UP THE MENTAL HOSPITAL
000605 01-0

VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE.
000702 01-1

CLINICAL EXPERIENCES WITH THE COMBINEO USE OF TWO NEUROLEPTICS, CLOTHIAPINE ANO HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-1

MONITORING PLASMA CONCENTRATIONS OF NEUROLEPTICS.
000B37 01-1

THEORETICAL BASIS OF THERAPY WITH NEUROLEPTICS ANO ANTIOEPRESSANTS.
000844 01-1

VITAMINS, NEUROLEPTICS, AND ANTIPARKINSONIAN DRUGS IN CATECHOLAMINE EXCRETION
000B72 01-1

LONG-ACTING NEUROLEPTICS -- A FAIRY STORY?
000899 01-1

THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS ANO LITHIUM.
000937 01-1

A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
000961 01 15

CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE
000977 01-15

CRITICAL STUDY OF THE USE OF LONG-ACTING NEUROLEPTICS (DEPOT NEUROLEPTICS) IN FRANCE.
001042 01-17

PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17

BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE BIOCHEMICAL LITERATURE.
001080 01-17

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS.
001241 02-03

EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION.
001365 02-03

RESTORATION OF SELF-STIMULATION INHIBITED BY NEUROLEPTICS.
001414 02-03

INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
001466 02-04

RECEPTOR BLOCKADE AND RECEPTOR HYPERSENSITIVITY AFTER TREATMENT WITH NEUROLEPTICS.
001547 02-04

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

LONG-ACTING NEUROLEPTICS: A PRELIMINARY STUDY OF CLOPIMOZIDE (R29764).
001655 02-07

PSYCHOTIC EXACERBATIONS PRODUCED BY NEUROLEPTICS.
001715 02-0B

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13

EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14

USE OF DEXETIMIDE (R-16470) WITH EXTRAPYRAMIDAL SYNDROMES CAUSED BY NEUROLEPTICS.
002061 02-15

INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03

EFFECTS OF NEUROLEPTICS ON TYROSINE-HYDROXYLASE OF SYNAPTOSOMES OF THE RAT HYPOTHALAMUS.
002314 03-03

NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-04

RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN.
002647 03-0B

COMPARATIVE EVALUATION OF MODITEN-DEPOT AND CONVENTIONAL MAINTENANCE TREATMENT USING NEUROLEPTICS.
002651 03-0B

METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-0B

NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002B00 03-13

IMPORTANCE OF THE DOPAMINE METABOLISM FOR THE CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
002841 03-13

ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002887 03-15

ANTICONVULSANT INDUCED DYSKINESIAS: A COMPARISON WITH DYSKINESIAS INDUCED BY NEUROLEPTICS.
002B91 03-15

PARADOXIC EFFECTS OF NEUROLEPTICS?
002892 03-15

EXTRAPYRAMIDAL EFFECTS OF NEUROLEPTICS.
002912 03-15

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
002928 03-15

PSEUDOPSYCHOTIC RELAPSES IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
002945 03-15

CLINICAL AND PHARMACOLOGICAL SPECTRAL MAPS OF THE NEUROLEPTICS.
003009 03-17

THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA.
003011 03-17

IMPORTANCE OF DOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
003043 03-17

EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-03

ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDRODIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
003178 04-03

INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03

OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: CLINICAL STUDIES.
003716 04-13

REDUCED CATECHOLAMINERGIC TRANSMISSION AND CLINICAL EFFECTS OF NEUROLEPTICS.
00371B 04-13

NO EFFECTS OF QUATERNARY NEUROLEPTICS ON HUMAN PROLACTIN AND ADENYL-CYCLASE.
003881 04-17

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

NEUROLOGIC

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY.
002774 03-11

NEUROLOGICAL

NEUROLOGICAL AND SENSORY DISORDERS IN THE ELDERLY.
001039 01-17

DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM.
001B31 02-11

CHRONIC BROMIDE INTOXICATION WITH A SEVERE NEUROLOGICAL DEFICIT.
002052 02-15

NEUROLOGY

EFFECTS IN CLINICAL NEUROLOGY OF THERAPY WITH NOOTROPIC AGENT.
000921 01-14

NEUROMUSCULAR

ON THE EFFECT OF THE IONOPHORE-X-537A ON NEUROMUSCULAR TRANSMISSION IN THE RAT.
000131 01-03

NEUROMUSCULAR DYSFUNCTION IN SCHIZOPHRENIA.
000557 01-08

ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION
001304 02-03

REPLY TO A LETTER CRITICIZING POINTS IN A LETTER ON THE NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
001BB2 02-13

MORE ON NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
002040 02-15

NEURON

EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03

EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGATA ON THE SPINAL DORSAL HORN NEURON.
002200 03-03

NEURONAL

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI OR IN LATERAL HYPOTHALAMUS.
000234 01-03

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03

SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION (UNPUBLISHED PAPER).
001173 02-03

MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-03

THE SPECIFICITY OF ACTION OF THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-03

ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
001298 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03

A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION. (PH.D. DISSERTATION).
002296 03-03

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-03

INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX.
003131 04-03

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03

NEURONES

EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

OBSERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT BRAINSTEM.
000059 01-03

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

BACLOFEN AND GAMMA-HYDROXYBUTYRATE: SIMILAR EFFECTS ON CEREBRAL DOPAMINE NEURONES.
000083 01-03

THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03

TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

THE EFFECTS OF MORPHINE AND METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS.
001236 02-0

LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART.
001345 02-0

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-0

ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
001428 02-0

ENKEPHALIN INHIBITS FIRING OF MYENTERIC NEURONES.
001634 02-0

ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND BRAINSTEM NEURONES.
002229 03-0

THE PRESYNAPTIC EFFECT OF BETA-ADRENOCEPTOR ANTAGONISTS ON NORADRENERGIC NEURONES.
002400 03-0

MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL O NIGROSTRIATAL FUNCTION.
002483 03-0

STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-0

MORPHINE, NALOXONE AND THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-0

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF TH ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-0

NEURONS

ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
000080 01-0

INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
000130 01-0

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-0

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-0

INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL DOPAMINE NEURONS.
000358 01-0

MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS O INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-0

REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL
000459 01-0

EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY
000999 01-1

CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-1

ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-0

NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-0

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
001209 02-0

EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-0

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-0

IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?.
001330 02-0

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03

LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
001398 02-03

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04

INTRODUCTORY REMARKS AT INTERNATIONAL SYMPOSIUM ON NON-STRIATAL DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).
0018B1 02-13

EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES OF SNAIL GIANT NEURONS.
002201 03-03

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN
002202 03-03

REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 03-03

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03

EFFECTS OF THEOPHYLLINE ON CENTRAL MONOAMINE NEURONS.
002273 03-03

DOPAMINERGIC DRUG EFFECTS UPON SEROTONIN NEURONS.
002300 03-03

INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN.
002320 03-03

EFFECTS OF ADENOSINE ANALOGS ON RAT CEREBRAL CORTICAL NEURONS.
002336 03-03

FUNDAMENTAL MICROQUANTITATIVE STUDIES BY FLUOROHISTOCHEMICAL METHOD ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
002408 03-03

EFFECT OF NOMIFENSINE ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS.
002503 03-04

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
0025B7 03-06

RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
0030B2 04-03

UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFECTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03

PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS
003357 04-04

EUROPATHWAYS
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03

EUROPATHY
ULTRASTRUCTURAL STUDIES OF CHLORAMPHENICOL-INDUCED NEUROPATHY IN EXPERIMENTAL ANIMALS
000147 01-03

PERIPHERAL NEUROPATHY CAUSED BY METHAQUALONE.
002059 02-15

EUROPEPTIDES
NEUROPEPTIDES, BRAIN AND BEHAVIOR
000112 01-03

NEUROPEPTIDES: INFLUENCE OF ACUTE AND CHRONIC EFFECTS OF OPIATES.
003199 04-03

NEUROPHARMACOLOGICAL
NEUROPHARMACOLOGICAL ACTIONS OF ENKEPHALIN AFTER SYSTEMATIC ADMINISTRATION.
000203 01-03

NEUROPHARMACOLOGICAL REGULATION OF MOUSE-KILLING BY RATS.
000280 01-04

NEUROPHARMACOLOGICAL TESTS WITH ALPHA-MELANOCYTE STIMULATING HORMONE.
000402 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-06

NEUROCHEMICAL AND NEUROPHARMACOLOGICAL FOUNDATIONS OF THE SLEEP DISORDERS.
002112 02-17

NEUROPHARMACOLOGICAL INVESTIGATIONS WITH TWO ERGOT ALKALOIDS, HYDERGINE AND BROMOCRIPTINE.
002192 03-02

BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04

BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04

DIFFERENTIATION OF NEUROPHARMACOLOGICAL ACTIONS OF APOMORPHINE AND D-AMPHETAMINE.
002523 03-04

NEUROPHARMACOLOGY
SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION (UNPUBLISHED PAPER).
001173 02-03

NEUROPHYSIOLOGICAL
NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS. (PH. D. DISSERTATION).
00020B 01-03

A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE).
000395 01-04

PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
001991 02-14

NEUROPHYSIOLOGY
NEUROPHYSIOLOGY -- PART IV.
002104 02-17

NEUROPSYCHIATRIC
DERMATOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS DURING PSYCHOPHARMACOTHERAPY.
002921 03-15

NEUROPSYCHIATRIC EFFECTS OF ADRENERGIC BETA-RECEPTOR BLOCKING AGENTS.
00297B 03-17

NEUROPSYCHIATRY
A CLINICAL TRIAL OF PERVINCAMINE-FORTE-RETARD IN NEUROPSYCHIATRY.
00075B 01-11

NEUROPSYCHOBIOLOGY
NEUROPSYCHOBIOLOGY OF AFFECTIVE DISORDERS: SOME METHODOLOGICAL CONSIDERATIONS.
001751 02-09

NEUROPSYCHOLOGIC
NEUROPSYCHOLOGIC EFFECTS OF DIAZEPAM RELATED TO SINGLE-DOSE KINETICS AND LIVER FUNCTION
000B9B 01-14

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003524 04-07

NEUROPSYCHOLOGICAL
A NEUROPSYCHOLOGICAL STUDY OF POLYDRUG USERS.
000B94 01-14

NEUROPSYCHOLOGICAL AND EEG DISTURBANCES IN POLYDRUG USERS.
002044 02-15

NEUROPSYCHOLOGY
THE NEUROPSYCHOLOGY OF ANXIETY.
002B14 03-13

NEUROPSYCHOPHARMACOLOGICAL
NEUROPSYCHOPHARMACOLOGICAL STUDIES WITH (--) TETRAHYDROCOPTISINE.
001446 02-04

NEUROPSYCHOPHARMACOLOGICAL MODELS FOR OBJECTIVE ASSESSMENT OF CENTRAL EFFECTS OF HORMONES.
003870 04-17

NEUROPSYCHOTROPIC
1035-MD (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY.
001013 01-17

NEUROSCIENCE
REVIEWS OF NEUROSCIENCE. VOL. 2.
002115 02-17

NEUROSES
TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
0006B0 01-10
CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
000697 01-10
A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN.
001785 02-10
PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
003581 04-10

NEUROSIS
CHLORIMIPRAMINE, FOR OBSESSIVE-COMPULSIVE NEUROSIS: AN ORGANIC APPROACH.
000523 01-07
ANAFRANIL IN OBSESSIVE-COMPULSIVE NEUROSIS.
000672 01-10
CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10
SOME THERAPEUTIC ASPECTS OF OBSESSIVE-PHOBIC NEUROSIS.
000711 01-10
COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11
TREATMENT OF PHOBIC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL.
001791 02-10
THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03
A DOUBLE-BLIND COMPARISON OF SULPIRIDE WITH CHLORDIAZEPOXIDE IN NEUROSIS.
002732 03-10
SYSTEMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
003579 04-10
LSD TREATMENT IN A SEVERE CASE OF COMPULSIVE NEUROSIS.
0035B3 04-10
CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS: PHARMACOLOGICAL APPROACH.
003B45 04-17

NEUROTENSIN
REGIONAL AND SUBCELLULAR DISTRIBUTIONS OF BRAIN NEUROTENSIN
001406 02-03

NEUROTIC
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
0004B4 01-07
A DOUBLE-BLIND COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
000502 01-07
PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION. RESULTS OF THE GROUP THERAPY.
000635 01-09
PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31889) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
000682 01-10
OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY.
001755 02-09
STUDY OF THE IMPORTANCE OF NEUROTIC PSYCHOLOGICAL FACTORS IN THE SUCCESS OF LONG TERM LITHIUM TREATMENT.
001766 02-09
TWO DOSAGES OF IMIPRAMINE IN HOSPITALIZED ENDOGENOUS AND NEUROTIC DEPRESSIVES.
001778 02-09
AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10
A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
001810 02-10
MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001877 02-12
BENZODIAZEPINES AND NEUROTIC ANXIETY: CRITIQUE.
002166 02-17
NEUROTIC DEPRESSION: AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS.
002721 03-10
THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10
HALAZEPAM AND DIAZEPAM IN NEUROTIC ANXIETY: A DOUBLE-BLIND STUDY.
003600 04-10

NEUROTOXIC
SOME NEUROTOXIC PROPERTIES OF TRIETHYLENE-GLYCOL-DINITRATE: A COMPARISON WITH DECAMETHONIUM.
000034 01-03
REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN.
000194 01-03
INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
003775 04-15

NEUROTOXICITY
LITHIUM NEUROTOXICITY.
000954 01-15
NEUROTOXICITY ASSOCIATED WITH SULPHONES.
000991 01-15
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN
001423 02-03
MECHANISM OF NEUROTOXICITY OF CARDIOTONIC GLYCOSIDES.
003149 04-03
PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03
A REVIEW OF NEUROTOXICITY OF LITHIUM DURING THERAPEUTIC TREATMENT.
003829 04-15

NEUROTRANSMISSION
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03
CEREBRAL NEUROTRANSMISSION AND PSYCHOTROPIC DRUGS.
001065 01-17
EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN
003193 04-03
DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
00344B 04-04

NEUROTRANSMITTER
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03
EFFECTS OF 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-03
BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
000204 01-03
IS GLUTAMIC-ACID THE PYRAMIDAL TRACT NEUROTRANSMITTER?.
001392 02-03
NEUROTRANSMITTER AND PSYCHOSTIMULANT-INDUCED PSYCHOSIS ACTIVATION.
001970 02-14
NEUROTRANSMITTER METABOLISM IN CELL CULTURE.
002213 03-03

NEUROTRANSMITTERS
PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03
COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-0B

CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS (UNPUBLISHED PAPER).
001014 01-17

EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
001135 02-03

EFFECTS OF FENFLURAMINE ON ACCUMULATION OF 5-HYDROXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN.
001137 02-03

EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-03

INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED BY THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03

STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY.
001909 02-13

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

UROTROPIC

EFFECTS OF NEUROTROPIC SUBSTANCES ON SECRETION AND BLOOD SUPPLY OF THE PANCREAS.
002290 03-03

UTRAL

THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES.
001281 02-03

SUPPRESSION OF AMPHETAMINE-INDUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-03

UTROPENIA

SEVERE NEUTROPENIA URTICARIA WITH ANTIDEPRESSANT THERAPY.
002907 03-15

W

POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01

GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01

MUSCARINIC AGONISTS PROVIDE A NEW CLASS OF ACARICIDE.
000019 01-02

PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS.
000024 01-02

NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02

NEW MORPHINE DERIVATIVES.
000027 01-02

SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03

VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-03

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN
000181 01-03

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03

SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03

NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04

TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

PROPOSAL OF A NEW MODEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-06

A NEW MEDICATION OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-07

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
000504 01-07

THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01-07

TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC SULTOPRIDE.
000510 01-07

EVALUATION OF THE NEW DRUG -- CLOMIPRAMINE (ANAFRANIL).
000522 01-07

CLINICAL STUDY AND EVALUATION OF A NEW DERIVATIVE OF PHENOTHIAZINE.
000547 01-0B

CLINICAL STUDY OF A NEW FORM OF DIBENZEPINE, WITH PROTRACTED ACTION.
000633 01-09

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

CLINICAL EXPERIENCE IN USING NEW ANTIDEPRESSANT MAPROTILINE (CIBA-34276-BA) AGAINST VARIOUS KINDS OF DEPRESSIVE ILLNESSES.
000670 01-09

CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
000697 01-10

PRELIMINARY OPEN STUDY OF NOMIFENSIN: A NEW ANTIDEPRESSANT.
000699 01-10

CONTROLLED CLINICAL EXPERIMENT WITH A NEW PREPARATION OF DIPOTASSIUM CHLORAZEPATE WITH DELAYED ACTION.
000700 01-10

CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10

TRIAL OF A NEW THERAPY OF HUNTINGTONS CHOREA.
000733 01-11

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

MARIHUANA: NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
000795 01-12

EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000833 01-13

NEW TRENDS OF BETA-BLOCKERS IN ACTIONS AND APPLICATIONS.
000869 01-13

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000885 01-14

THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN
000BB7 01-14

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14

A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
000961 01-15

CLONAZEPAM: A REVIEW OF A NEW ANTICONVULSANT DRUG.
001022 01-17

ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
001082 02-01

REFLEXINE, A NEW INDOLE ALKALOID OF RAUWOLFIA-REFLEXA.
001083 02-01

CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
001084 02-01

A NEW ALKALOID FROM ERYTHROPHLEUM-COUMINGA
001087 02-01

A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01

SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
001108 02-02

TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
001111 02-02

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
001118 02-02

METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT: NEW METABOLIC PATHWAY OF CAFFEINE.
001128 02-03

METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-984).
001154 02-03

SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION. (UNPUBLISHED PAPER).
001173 02-03

SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDROOIBENZAZOCINE.
00124B 02-03

EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03

A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04

EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04

CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

TANDAMINE: A NEW ANTIDEPRESSANT.
001660 02-07

CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07

TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
001668 02-07

POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION.
001677 02-07

CLINICAL AND PHARMACOLOGICAL EFFECTS OF TREATMENT WITH A NEW ANTIDEPRESSANT.
001739 02-09

DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
001758 02-09

STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
001772 02-09

A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN.
0017B5 02-10

DOUBLE-BLIND CLINICAL STUDY OF THE ANXIOLYTIC ACTION OF A NEW AGENT: FI-6820 BUFOXINE
001B11 02-10

STUDY OF THE ACTIVITY OF CEREBRAL MEDICATIONS. A NEW METHODOLOGY: LEVEL OF COMPARATIVE TRIALS.
002091 02-16

THE NEW DRUG STATUTE AND THE FUTURE OF CLINICAL PSYCHOPHARMACOLOGY
002141 02-17

NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY.
00214B 02-17

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
002180 02-17

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY.
002196 03-02

DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

A NEW MICROMETHOD FOR DETERMINING THE EFFECTS OF DRUGS ON THE TURNOVER RATE OF ACETYLCHOLINE. (PH.D. DISSERTATION).
002274 03-0

ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC.
002392 03-0

NEW APPROACHES TO THE STUDY OF ANXIETY AND ANXIOLYTIC DRUGS IN ANIMAL.
002427 03-0

THE CLINICAL EVALUATION OF NEW DRUGS.
002594 03-0

AHR-6134: A NEW ANTIANXIETY DRUG WITH UNEXPECTED RESULTS.
002595 03-0

EXPERIENCE WITH THE USE OF SYDNOCARB, A NEW PSYCHOSTIMULANT
002612 03-0

A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIDOL (R-16341).
002656 03-0

VILOXAZIN (VIVALAN-ICI) -- A STRUCTURALLY NEW ANTIDEPRESSANT.
002678 03-0

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CARDXAZONE (FI-6654).
002683 03-0

TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-1

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-1

PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-1

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY
002778 03-1

AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-1

N-DESMETHYLDIAZEPAM: A NEW METABOLITE OF CHLORDIAZEPOXIDE I MAN
002805 03-1

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS O A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002893 03-1

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY
003042 03-1

NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR. LU-10-171.
003054 04-0

NEW COMPOUNDS: SYNTHESIS OF 2-AMINO-5H 1,3,4-BENZOTRIAZEPIN-5 ONES.
003055 04-0

DEPRESSION A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-0

A NEW METABOLITE OF AMYLOBARBITONE: CARBOXYBUTYLETHYLBARBITURIC-ACID.
003090 04-0

EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-0

EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-0

ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-0

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIET DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-0

A CONTROLLED CLINICAL STUDY WITH CLOBAZAM -- A NEW ANXIOLYTIC AGENT.
003585 04-1

NEW ANXIOLYTIC RATING SCALE.
003607 04-1

FLUOTRACEN (SKF-28175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-1

EXPERIENCES WITH SOME NEW SCALES FOR USE IN GENERAL PRACTICE TRIALS
003839 04-16
POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
003848 04-17

EW-JERSEY
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 408 F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY FEBRUARY 19, 1976.
002150 02-17

EWBORN
DISEASE CAUSED BY DRUG THERAPY IN NEWBORN INFANTS.
000953 01-15
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
THE PLACENTAL TRANSFER OF DRUGS DURING CHILDBIRTH: A POSSIBLE INFLUENCE ON THE NEWBORN.
001892 02-13
THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-05

EWBORNS
OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND.
000834 01-13
HEROIN WITHDRAWAL SYNDROME IN NEWBORNS.
001B51 02-11

ACIN
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15
MANGANESE AND NIACIN IN THE TREATMENT OF DRUG-INDUCED DYSKINESIAS.
00095B 01-15

ALAMIDE
THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03
5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY.
000627 01-09

ALAMIDE-INDUCED
POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

AMID
THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

COTINAMIDE
THE EFFECTS OF NICOTINAMIDE UPON SLEEP IN HUMANS
0019B8 02-14
THE SEDATIVE EFFECTS OF NICOTINAMIDE ON GERBIL WHEEL-RUNNING ACTIVITY.
002423 03-04
TRYPTOPHAN NICOTINAMIDE COMBINATION IN DEPRESSION
003553 04-09

COTINE
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03
NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
00231B 03-03
THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-04
NICOTINE AND BEHAVIOR
00255B 03-04
THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION
003229 04-03
INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
003495 04-05

NICOTINIC
EFFECTS OF NICOTINIC AND MUSCARINIC COMPOUNDS ON BITING ATTACK IN THE CAT.
002424 03-04

NICTITATING
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
002508 03-04

NIGHT
INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

NIGHTMARES
TREATMENT OF NIGHTMARES.
000684 01-10
TREATMENT OF NIGHTMARES.
002744 03-11

NIGRAL
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
00012B 01-03
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04
CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04
THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03

NIGRONEOSTRIATAL
DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-03

NIGROSTRIATAL
DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04
A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
00144B 02-04
EFFECT OF MORPHINE AND HALOPERIDOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03
EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
002291 03-03
NIGROSTRIATAL EFFECTS OF MORPHINE IN TWO MOUSE STRAINS.
002426 03-04
PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04
MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
0024B3 03-04
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04
MECHANISMS OF EXCITATION AND INHIBITION IN THE NIGROSTRIATAL SYSTEM.
003250 04-03
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06

NIGROTHALAMIC
THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03

NIMH
IN THE SERVICE OF PSYCHOPHARMACOLOGY RESEARCH: THE PSC-PRB, NIMH PROGRAM 1956-1976. (UNPUBLISHED PAPER).
00213B 02-17

NIMH-PRB
NIMH-PRB COLLA8ORATIVE STUDY OF LONG-ACTING FLUPHENAZINE. 000550 01-08

NISOXETINE
EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN. 000263 01-03
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN. 001423 02-03
DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG. 002195 03-02

NITRAZEPAM
EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS. 000755 01-11
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMO8ARBITAL ON REM SLEEP AND REM DENSITY IN MAN. 000909 01-14
STUDIES ON THE INTERACTION OF CHLORDIAZEPOXIDE, DIAZEPAM, AND NITRAZEPAM WITH PHENPROCOUMON. 001627 02-05
NITRAZEPAM AND TEMAZEPAM: A COMPARATIVE TRIAL OF TWO HYPNOTICS. 001985 02-14
A CASE OF SUICIDE WITH NITRAZEPAM AND ALCOHOL. 002079 02-15
TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS. 002282 03-03
NOVEL META8OLITE OF NITRAZEPAM IN THE RABBIT URINE. 002357 03-03
NITRAZEPAM: LASTINGLY EFFECTIVE BUT TROUBLE ON WITHDRAWAL. 00284B 03-14
TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL. 002976 03-17
CATALEPTIC ACTION OF NITRAZEPAM AND BRAIN DOPAMINE FUNCTION IN MICE. 003427 04-04
INCREASED SENSITIVITY TO NITRAZEPAM IN OLD AGE. 003724 04-14

NITRAZEPAM-POLFA
CLINICAL EVALUATION OF NITRAZEPAM-POLFA. 002745 03-11

NITROUS-OXIDE
NITROUS-OXIDE ANALGESIA: RESEMBLANCE TO OPIATE ACTION 001139 02-03
THE EFFECT OF NITROUS-OXIDE ON TIME ESTIMATION IN RATS. 001603 02-04
PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS-OXIDE USED IN THE TREATMENT OF BORDERLINE PSYCHOTIC STATES. 001836 02-11

NO-GO
THE EFFECT OF CHLORDIAZEPOXIDE ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS. 002476 03-04

NOCICEPTIVE
MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS. 001231 02-03
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT. 001235 02-03
THE EFFECTS OF MORPHINE AND METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS. 001236 02-03

NOCICEPTORS
5-HYDROXYTRYPTAMINE AS A SENSITIZER OF SOMATIC NOCICEPTORS FOR PAIN-PRODUCING SUBSTANCES. 0001B5 01-03

NOCTRAN
NOCTRAN AS A SLEEP INDUCER DURING HOSPITALIZATION (BASED ON 50 CASES). 000503 01-07

NODE
EFFECT OF ANICOTINE ON SOME PROPERTIES OF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE. 001299 02-03

NOISE
NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS. 000302 01-04

NOMIFENSIN
PRELIMINARY OPEN STUDY OF NOMIFENSIN: A NEW ANTIDEPRESSANT 000699 01-
A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN. 001785 02
CONTROLLED TRIAL OF NOMIFENSIN (HOE-984) AND VILOXAZINE IN TH TREATMENT OF DEPRESSION IN THE ELDERLY. 003570 04

NOMIFENSINE
METHYLPHENIDATE-LIKE EFFECTS OF THE NEW ANTIDEPRESSANT DRUG NOMIFENSINE (HOE-984). 001154 02
CENTRAL ACTION OF NOMIFENSINE. 001544 02
SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS. 001884 02
A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALI 002005 02
EFFECT OF NOMIFENSINE ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS. 002503 03
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES WITH THREE METABOLITES OF NOMIFENSINE. 003200 04
NOMIFENSINE AND ITS DERIVATIVES AS POSSIBLE TOOLS FOR STUDYI AMINE UPTAKE. 003305 04

NOMIFENSINE-INDUCED
ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS. 001334 02

NOMIFENSINE-MALEATE
PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES. 003744 04

NON-AMPHETAMINIC
SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY. 002117 02

NON-CIRRHOTIC
WAIS FUNCTIONING OF CIRRHOTIC AND NON-CIRRHOTIC ALCOHOLICS 003827 04

NON-NOCICEPTIVE
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD O THE CAT. 001235 02

NON-STRIATAL
INTRODUCTORY REMARKS AT INTERNATIONAL SYMPOSIUM ON NON-STRIATAL DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER). 0018B1 02

NON-TOLERANT
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERA RATS. 003211 04
EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUC HYPERTHERMIA IN NON-TOLERANT RATS. 003232 04

NONALCOHOLIC
SULPIRIDE IN WITHDRAWAL OF NONALCOHOLIC DRUG ADDICTS. 002593 03

NONANESTHETIZED
CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE I EXPERIMENTS WITH NONANESTHETIZED ANIMALS. 001636 02

NONAQUEOUS
STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE LABORATORY ANIMALS. 003492 04

NONASSOCIATIVE
NONASSOCIATIVE EXPLANATIONS OF BEHAVIORAL CHANGES INDUCED BY CENTRAL CHOLINERGIC DRUGS. 00028B 01

NONATAXIC
CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSE OF ETHYLALCOHOL. 000305 01

NONBENZODIAZEPINOID
3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

NONBIOLOGICAL
CERTAIN NONBIOLOGICAL ASPECTS OF THE PHARMACOTHERAPY OF SCHIZOPHRENIA.
002108 02-17

NONBOUND
TOTAL AND NONBOUND TRYPTOPHAN IN UNIPOLAR ILLNESS.
002693 03-09
TOTAL AND NONBOUND PLASMA-TRYPTOPHAN IN DEPRESSIVE ILLNESS.
003663 04-13

NONCATALEPTOGENIC
REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 03-03

NONCOMPARATIVE
CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
003891 04-17

NONCONJUGATED
THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

NONDEPENDENT
THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

NONEPILEPTIC
INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
002908 03-15

NONHORMONAL
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04

NONKILLER
RESERPINE INDUCTION OF MOUSE-KILLING IN NONKILLER RATS.
001443 02-04

NONNARCOTIC
A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION: I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
0021B0 02-17

NONOBESE
EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE.
003108 04-03

NONPHARMACOLOGIC
FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001B58 02-11

NONPHARMACOLOGICAL
NONPHARMACOLOGICAL FACTORS IN DRUG TREATMENT OF ANXIETY STATES.
001802 02-10
INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

NONPHYSICIAN
PSYCHIATRIC MEDICATION: THE ROLE OF THE NONPHYSICIAN
002156 02-17

NONPRESCRIPTION
PRESCRIPTION AND NONPRESCRIPTION ANOREXIANTS.
001B97 02-13

NONPSYCHOTIC
METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

NONRESPONDERS
LITHIUM NONRESPONDERS IN A LITHIUM CLINIC
003569 04-09

NONSELECTIVE
NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03

NONSOOTHING
BARBITURATE HYPNOTICS, A TOO FREQUENT AND NONSOOTHING PRESCRIPTION.
001043 01-17

NONSPECIFIC
TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04
NONSPECIFIC FACTORS IN DRUG TREATMENT
003598 04-10

NONTERMINAL
ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

NONTOXIC
REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN
000194 01-03
NONTOXIC HYPERLITHEMIA IN IMPENDING MANIA.
003836 04-15

NONVERBAL
DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
000383 01-04

NOOANALEPTIC
USE OF NOOANALEPTIC AND NOOTROPIC DRUGS IN RESUSCITATION
000905 01-14
STUDY OF NOOANALEPTIC DRUG EFFECT ON BRAIN METABOLISM IN HUMANS.
000914 01-14

NOOTROPIC
NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000885 01-14
THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN.
000BB7 01-14
EXPERIMENTAL PHARMACOLOGICAL DIFFERENTIAL DEFINITION OF NOOTROPIC DRUGS.
000B92 01-14
USE OF NOOANALEPTIC AND NOOTROPIC DRUGS IN RESUSCITATION.
000905 01-14
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14
EFFECTS IN CLINICAL NEUROLOGY OF THERAPY WITH NOOTROPIC AGENT.
000921 01-14
PIRACETAM: NOOTROPIC PHARMACOLOGY OF NEUROINTEGRATIVE ACTIVITY.
002454 03-04

NORADRENALINE
INTERACTION OF BETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
000002 01-01
THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
000107 01-03
RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03
A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03
A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
000154 01-03
PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03
HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03
ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03
INFLUENCE OF DOPAMINE AND NORADRENALINE ON ISOLATED CEREBRAL ARTERIES OF THE DOG.
000241 01-03

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

IS THE RELEASE OF NORADRENALINE NECESSARY FOR SELF-STIMULATION OF THE BRAIN?.
000422 01-04

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION.
00042B 01-04

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
00046B 01-06

NORADRENALINE SYNTHESIS FROM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
0011B6 02-03

MODIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001203 02-03

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001204 02-03

EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA.
001324 02-03

EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 D2-03

THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-D3

OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE BRAIN OF THE LOCUST, SCHISTOCERCA-GREGARIA.
001343 D2-D3

INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
00140B 02-03

INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001426 D2-D3

EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 D2-D4

ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN
001650 02-06

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN.
DD22D2 03-03

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 D3-D3

ROLE OF BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR.
002252 03-03

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
0030B7 04-03

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
D0312B 04-03

INFLUENCE OF DOPAMINE AND NORADRENALINE ON THE TOTAL CEREBRAL BLOOD FLOW OF ANESTHETIZED DOGS.
003159 04-03

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE, AND 5-HYDROXYTRYPTAMINE.
DD3247 D4-D3

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-0

SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
003330 04-0

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS.
003357 04-0

NORADRENERGIC

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-0

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
0000B1 01-0

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-0

NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS
000405 01-0

NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE
001164 02-0

ROLE OF NORADRENERGIC AND DOPAMINERGIC PROCESSES IN AMPHETAMINE SELF-ADMINISTRATION
001342 02-0

LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART.
D01345 D2-0

LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS (UNPUBLISHED PAPER).
00139B 02-0

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON
00145B 02-0

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH D DISSERTATION)
0D2257 D3-0

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-0

CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-0

THE PRESYNAPTIC EFFECT OF BETA-ADRENOCEPTOR ANTAGONISTS ON NORADRENERGIC NEURONES.
002400 03-0

THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 D4-0

NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL
003261 04-0

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION
003443 04-0

POSSIBLE INVOLVEMENT OF A CENTRAL NORADRENERGIC SYSTEM IN AUTOMUTILATION INDUCED BY CLONIDINE IN MICE.
003450 04-0

NOREPINEPHRINE

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
0001B1 01-0

EFFECTS OF SHORT TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN
00021B 01-0

CHANGES IN BRAIN NOREPINEPHRINE ASSOCIATED WITH SENSITIZATION TO D-AMPHETAMINE
000225 D1-0

BEHAVIORAL DEPRESSION: THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS.
000307 01-04

PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
000418 01-04

EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03

SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

ALCOHOL MEMBRANE INTERACTION IN THE BRAIN: NOREPINEPHRINE RELEASE.
001394 02-03

EFFECT OF PROPRANOLOL ON RAT BRAIN NOREPINEPHRINE IN VITRO.
001427 02-03

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-03

THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS.
002250 03-03

THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE.
002294 03-03

CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03

INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION.
003051 04-01

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-03

ALPHA-ACTIVITY AND BETA-ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE.
003315 04-03

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04

REDUCTION IN PLASMA NOREPINEPHRINE DURING FENFLURAMINE TREATMENT.
003666 04-13

RMAL

SINGLE-DOSE STUDIES WITH CLOMIPRAMINE IN NORMAL SUBJECTS.
♂00135 01-03

PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRAIN-DAMAGED RATS.
000220 01-03

DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
00051B 01-07

THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN
000887 01-14

THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
001684 02-08

REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001880 02-13

PHYSOSTIGMINE: EFFECTS ON COGNITION AND AFFECT IN NORMAL SUBJECTS.
001965 02-14

INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS.
001967 02-14

COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14

A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14

THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS.
002006 02-14

COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-04

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002B21 03-13

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002830 03-13

THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
002B64 03-14

TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002B79 03-14

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04

DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13

LITHIUM-CARBONATE AND ETHANOL-INDUCED HIGHS IN NORMAL SUBJECTS.
003734 04-14

THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14

THE EFFECT OF LITHIUM-CARBONATE ON THE COGNITIVE FUNCTIONS OF NORMAL SUBJECTS.
003736 04-14

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

BARBITURATE EFFECTS ON BRAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN
003751 04-14

NORMALS

SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-08

SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS: EFFECT OF D-AMPHETAMINE AND HALOPERIDOL.
001927 02-13

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

NORMORPHINE
HUMAN ENDORPHIN: COMPARISON WITH PORCINE ENDORPHIN, ENKEPHALIN AND NORMORPHINE.
000006 01-01

NORMOTENSIVE
BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04

NORTRIPTYLINE
EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
000593 01-09

THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION.
000658 01-09

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000829 01-13

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
001182 02-03

A COMPARISON OF AMITRIPTYLINE AND A FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN ANXIETY DEPRESSIVE STATES.
001731 02-09

ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES
001735 02-09

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001898 02-13

A DOUBLE-BLIND COMPARISON OF DOXEPIN AND NORTRIPTYLINE ON DEPRESSION.
002676 03-09

NORTRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.
002708 03-09

THERAPEUTIC POSSIBILITIES OF NORTRIPTYLINE AND TORECAN.
002785 03-11

COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002B13 03-13

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE -- A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09

INTERACTION OF PERPHENAZINE WITH THE KINETICS OF NORTRIPTYLINE
003695 04-13

PLASMA NORTRIPTYLINE LEVELS AND ECG FINDINGS.
003723 04-13

NOSOLOGY
CURRENT PROBLEMS OF PSYCHIATRIC NOSOLOGY
002155 02-17

NOSOTROPIC
NOSOTROPIC EFFECTS OF PSYCHOPHARMACEUTICALS.
002B70 03-14

NOVELTY
THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE (PH.D. DISSERTATION).
000339 01-04

EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE ON REACTIONS TO NOVELTY AND ACTIVITY IN RATS.
001515 02-04

PHYSOSTIGMINE EFFECTS ON ACTIVITY AND REACTIONS TO NOVELTY.
001516 02-04

NOVERIL
A DOUBLE-BLIND STUDY OF THE ANTIDEPRESSANTS DIBENZEPIN (NOVERIL) AND AMITRIPTYLINE.
0005B2 01-09

NOXIOUS
EFFECTS OF ORUGS ON BEHAVIOR CONTROLLED BY NOXIOUS STIMULI.
0024B2 03-04

NOXIPTILINE
CLINICAL EXPERIENCES WITH NOXIPTILINE.
002681 03-

NOZEPAM
EXPERIMENTAL STUDY OF NOZEPAM TOXICITY.
002572 03-

NUCLEI
TRYPTOPHAN-HYDROXYLASE IN DISCRETE 8RAIN NUCLEI: COMPARISO OF ACTIVITY IN VITRO AND IN VIVO
000168 01-

CLIMBING FIBER ACTIVATION AND 3,5 CYCLIC GUANOSINE MONOPHOSPHATE (C-GMP) CONTENT IN CORTEX AND DEEP NUCLEI CEREBELLUM
001145 02-

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-

MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN
0021B5 03

ANTIPSYCHOTICS AND GABA TURNOVER IN MAMMALIAN BRAIN NUCLEI. (UNPUBLISHED PAPER).
002301 03

THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03

THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM NUCLEI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
002584 03

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN.
003276 04

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED B AMPHETAMINE ANO APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIME NUCLEI
003368 04

NUCLEIC-ACIDS
INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIE OF NUCLEIC-ACIDS.
002327 03

NUCLEOTIDE
INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02

CELLULAR DEPOLARIZATION AND CYCLIC NUCLEOTIDE CONTENT IN CENTRAL NERVOUS SYSTEM.
002237 03

A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTID METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFR SYMPATHETIC GANGLION (PH.D. DISSERTATION).
002296 03

NUCLEOTIDES
THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-OOPAMI FROM RAT STRIATAL SLICES.
000257 01

EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE
000298 01

PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02

BRAIN CYCLIC NUCLEOTIDES AND ADRENOLYTICS: EFFECTS ON AMPHETAMINE AND APOMORPHINE-INDUCEO CHANGES.
002208 03

PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS
002210 03

OPIATES, CYCLIC NUCLEOTIDES, AND XANTHINES.
002225 03

DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN
002459 03

NUCLEUS
REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRAD REACTION.
000211 01

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECARBOXYLASE AND TYROSINE-HYDROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG.
0010B5 02-01

EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03

EFFECTS OF LESIONS OF THE CAUDATE NUCLEUS ON MORPHINE-DEPENDENCE IN THE RAT.
001539 02-04

EFFECT OF CATECHOLAMINERGIC DRUGS ON EPILEPTOGENIC PROPERTIES OF THE CAUDATE NUCLEUS.
002206 03-03

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03

STRUCTURAL CHANGES IN CAUDATE NUCLFUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03

CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN THE CAUDATE NUCLEUS.
002369 03-03

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03

THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTACT AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
0032B6 04-03

THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03

DEPRESSION BY MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03

CLEUS-ACCUMBENS

DOPAMINE METABOLISM IN THE NUCLEUS-ACCUMBENS: THE EFFECT OF CLOZAPINE.
000260 01-03

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

BIPHASIC CHANGES IN MOTOR BEHAVIOUR FOLLOWING MORPHINE INJECTION INTO THE NUCLEUS-ACCUMBENS.
000301 01-04

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS.
00147B 02-04

FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-04

HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
0021B9 03-02

POSSIBLE GABA MEDIATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUMBENS OF THE RAT.
002522 03-04

MUSCIMOL ANTAGONIZES THE ERGOMETRINE-INDUCED LOCOMOTOR ACTIVITY IN NUCLEUS-ACCUMBENS. EVIDENCE FOR A GABA DOPAMINERGIC INTERACTION
00326B 04-03

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

NURSES

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0019B6 02-14

NURSING

REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05

HELPING TO MAKE THE FINAL YEARS MEANINGFUL FOR THE ELDERLY RESIDENTS OF NURSING HOMES.
002B59 03-14

O-DEMETHYLATION

IN VITRO O-DEMETHYLATION OF THE PSYCHOMIMETIC AMINE, DIMETHOXY-4-METHYLPHENYL-2-AMINOPROPANE.
003340 04-03

O-METHYLATED

LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03

ALPHA-ACTIVITY AND BETA-ACTIVITY OR O-METHYLATED DERIVATIVES OF NOREPINEPHRINE AND EPINEPHRINE.
003315 04-03

OBESE

EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE.
00310B 04-03

A MULTICENTRE STUDY COMPARING MAZINDOL AND PLACEBO IN OBESE PATIENTS.
00364B 04-11

OBESITY

THE USE OF DIPOTASSIUM CHLORAZEPATE AT HIGH DOSAGE IN TREATMENT OF OBESITY.
00073B 01-11

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON.
00076B 01-11

ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04

SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-17

OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07

MAZINDOL (TERONAC) IN THE TREATMENT OF PREDOMINANTLY ALIMENTARY OBESITY.
002719 03-10

PHENYTOIN AS A TREATMENT OF OBESITY ASSOCIATED WITH COMPULSIVE EATING.
003622 04-11

OBJECTIVE

TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09

NEUROPSYCHOPHARMACOLOGICAL MODELS FOR OBJECTIVE ASSESSMENT OF CENTRAL EFFECTS OF HORMONES.
003B70 04-17

OBSERVATION

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS.
002546 03-04

OBSERVATIONAL

OBSERVATIONAL DETERMINATION OF DOSE-RESPONSE CURVES IN HALLUCINOGEN-TREATED MONKEYS.
001451 02-04

OBSERVATIONS

OBSERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT BRAINSTEM.
000059 01-03

OBSERVATIONS ON THE FATE OF CYSTATHIONINE IN RAT BRAIN.
000115 01-03

EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
0006B3 01-10

CLINICOBIOLOGICAL OBSERVATIONS ON ANXIETY/.
000706 01-10

INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
000723 01-11

OBSERVATIONS ON THE PHENOMENOLOGY OF CONSCIOUSNESS CHANGE.
000797 01-12
OBSERVATIONS ON THE USE OF PSYCHOPHARMACOLOGY IN PSYCHIATRIC HOSPITALS.
001012 01-17
DIAZEPAM IN THE TREATMENT OF TARDIVE-DYSKINESIA: PRELIMINARY OBSERVATIONS.
001716 02-08
OBSERVATIONS OF THE INTRAVENOUS ADMINISTRATION OF SULPIRIDE (DOBREN).
001768 02-09
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001800 02-10
CAN PENTAZOCINE BE A DRUG? OBSERVATIONS ON THE PROBLEM OF TALWINISM.
002028 02-15
CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER.
002591 03-07
PSYCHODYNAMIC OBSERVATIONS OF A GROUP OF PATIENTS TREATED WITH LITHIUM-CARBONATE.
002670 03-09
EARLY OBSERVATIONS OF THE EFFECT OF PROPRANOLOL ON PSYCHOTIC PATIENTS.
002739 03-11
PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-11
OBSERVATIONS ON THE USE OF AMIZEPINE ON CHILDREN WITH MINIMAL CENTRAL-NERVOUS-SYSTEM DYSFUNCTIONS.
002762 03-11
FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE
003160 04-03
THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04
LITHIUM AS AN ANTIDEPRESSANT: DISCOVERIES THROUGH CLINICAL OBSERVATIONS.
003892 04-17

OBSERVED
COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS METABOLISM OF IMIPRAMINE IN HUMANS.
000850 01-13

OBSESSIONAL
TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
000680 01-10
CLOMIPRAMINE IN PHOBIC AND OBSESSIONAL STATES: PRELIMINARY REPORT.
001789 02-10
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001800 02-10

OBSESSIVE-COMPULSIVE
CHLORIMIPRAMINE, FOR OBSESSIVE-COMPULSIVE NEUROSIS: AN ORGANIC APPROACH.
000523 01-07
ANAFRANIL IN OBSESSIVE-COMPULSIVE NEUROSIS.
000672 01-10
SYSTEMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
003579 04-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS: PHARMACOLOGICAL APPROACH
003845 04-17

OBSESSIVE-PHOBIC
SOME THERAPEUTIC ASPECTS OF OBSESSIVE-PHOBIC NEUROSIS.
000711 01-10

OBSTETRIC
OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND
000B34 01-13

OCCLUSION
CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

OCCULT
TWO OCCULT CAUSES OF INSOMNIA AND THEIR THERAPEUTIC PROBLEMS.
000460 01-05

OCTOCLOTHEPIN
RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN
002647 03-08

OCTOPAMINE
OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE BR OF THE LOCUST, SCHISTOCERCA-GREGARIA.
001343 02

OCULOGYRAL
THE EFFECT OF ALCOHOLIC INTOXICATION UPON CALORICALLY INDUC OCULOGYRAL ILLUSION
003757 04

OCULOVESTIBULAR
DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING I SEDATIVE DRUG-INDUCED COMA.
003B26 04

OFFENDERS
DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
000685 01

OFFSPRING
REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURID
000459 01
SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATI UPON RAT OFFSPRING.
001622 02

OLDER
SOMATIC THERAPIES IN OLDER DEPRESSED PATIENTS.
001753 02
PUBLIC INTEREST REPORT NO. 19 -- THE OVERUSE OF TRANQUILIZERS OLDER PATIENTS.
001820 02
PHARMACOTHERAPY IN OLDER DEPRESSED PATIENTS.
002033 02
RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03

OLFACTORY
8EHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSAN DRUGS.
000443 01
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02
ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE OLFACTORY BULB DAMAGE IN RATS.
0014B9 02
PHARMACOLOGICAL STUDY OF EVOKED POTENTIALS IN THE OLFACT BULB.
002361 03

OLIGODENDROGLIAL
APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03

OLIGOPHRENIC
USE OF PSYCHOPHARMACEUTICALS FOR THE TREATMENT OF ABNOR BEHAVIOR OF OLIGOPHRENIC EPILEPTICS.
002772 03

OLIGOPHRENICS
TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH N PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
001668 02

OMETINE
THE EFFECT OF OMETINE ON LEARNED BEHAVIOR IN THE WAKIN GOLDFISH.
002514 03

ON-OFF
STUDIES WITH BROMOCRIPTINE: PART 1. ON-OFF PHENOMENA.
002600 03

ONCE-DAILY
ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZI WITH NORTRIPTYLINE.
003564 04

ONE-WAY
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04

ONEIROIDAL
PARANOID PSYCHOSIS WITH ONEIROIDAL ELEMENTS DURING THE COURSE OF REDLICH-FLATAUS DISEASE.
000769 01

ONTOGENESIS
ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN
001512 02

ONTOGENESIS OF DOPAMINE RECEPTOR BINDING IN THE CORPUS-STRIATUM OF THE RAT.
003235 04-03

ONTOGENETIC

ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT.
001383 02-03

GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
001568 02-04

ONYCHOMYS-TORRIDUS

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

OPAR

THE ROLE OF OPAR IN THE RESOCIALIZATION OF SCHIZOPHRENICS.
001720 02-08

OPEN

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31889) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
000682 01-10

PRELIMINARY OPEN STUDY OF NOMIFENSIN: A NEW ANTIDEPRESSANT.
000699 01-10

ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN.
D01723 02-DB

CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
0D3B91 D4-17

OPEN-FIELD

SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
000133 01-D3

SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 D1-03

NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
0003D2 01-04

EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
D0033B 01-04

EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
D015B2 02-D4

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-D4

NEONATAL ANDROGEN INJECTION CHANGES OPEN-FIELD BEHAVIOR OF MICE.
003402 04-04

OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
0034D5 04-04

PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPEN-FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
0034D8 04-D4

OPEN-LABEL

PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-318B9) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-11

OPERANT

THE EFFECT OF ANTIPARKINSONIAN DRUGS ON CHLORPROMAZINE-INDUCED DEPRESSION OF OPERANT BEHAVIOUR.
000239 D1-03

CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
DD0442 01-D4

OPERANT ACQUISITION OF MARIHUANA IN MAN
D0D907 01-14

THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS MONKEYS.
001476 02-04

THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON.
0D1505 D2-04

RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 D2-D4

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

BEHAVIORAL DRUG EFFECTS UPON OPERANT RESPONSE FORCE
002447 03-04

OPERANT BEHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6-HYDROXYDOPAMINE TREATMENT.
002519 03-04

THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002529 03-04

OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS.
002546 03-04

CATECHOLAMINES AND OPERANT RESPONSE RATES IN ALBINO RATS.
002555 03-04

DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04

PARGYLINE-INDUCED INCREASES IN SENSITIVITY TO THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR IN PIGEONS.
003361 04-04

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
003388 04-04

CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AND CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RATS.
00339D 04-04

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-04

OPERATION

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
002478 D3-04

OPERATIONAL

TOWARD THE OPERATIONAL IDENTIFICATION OF ADVERSE DRUG REACTIONS.
003B0D 04-15

OPHTHALMOLOGIC

PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE.
00D492 D1-07

OPIATE

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
0DD157 01-03

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
0DD171 D1-D3

ASPECTS OF OPIATE DEPENDENCE IN THE MYENTERIC PLEXUS OF THE GUINEA-PIG.
D00222 01-03

EVALUATION OF PROPRANOLOL IN OPIATE DEPENDENCE.
0D0512 01-D7

NITROUS-OXIDE ANALGESIA: RESEMBLANCE TO OPIATE ACTION.
D01139 D2-03

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA-LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
001147 02-03

CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL.
0D1208 D2-03

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
001209 02-03

IDENTIFICATION OF OPIATE/RECEPTOR BINDING IN VIVO.
001240 02-D3

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

THE MECHANISM OF OPIATE AGONIST AND ANTAGONIST ACTION. (UNPUBLISHED PAPER).
D02335 03-03

NALOXONE IN OPIATE ADDICTION
002742 03-11

CURRENT STATE OF RESEARCH ON PROPRANOLOL OPIATE INTERACTION.
002757 03-11

ENDOGENOUS OPIATE PEPTIDES. (UNPUBLISHED PAPER).
002B19 03-13

THE USE OF METHADONE AS A TREATMENT TOOL FOR OPIATE ADDICTS: A TWO-YEAR FOLLOW-UP STUDY
DD3025 03-17

POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
0030B8 04-03

OPIATE RECEPTOR BINDING IN THE PITUITARY GLAND.
003279 04-03

ON THE MOLECULAR STRUCTURE OF THE OPIATE RECEPTOR.
0032B1 04-03

OPIATE RECEPTORS AND INTERNAL OPIATES.
0032B4 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 04-03

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
00332B 04-03

A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS.
003426 04-04

A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003B76 04-17

OPIATE-LIKE

PHYSICAL DEPENDENCE ON OPIATE-LIKE PEPTIDES.
000447 01-04

AN ANALOG OF ENKEPHALIN HAVING PROLONGED OPIATE-LIKE EFFECTS IN VIVO.
003319 04-03

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME.
003352 04-04

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

OPIATES

OPIATES AND CYCLIC-AMP. (UNPUBLISHED PAPER)
001263 02-03

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03

EVIDENCE FOR NALOXONE AND OPIATES AS GABA ANTAGONISTS.
001450 02-04

OPIATES, CYCLIC NUCLEOTIDES, AND XANTHINES.
002225 03-03

EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
002291 03-03

DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11

RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
0030B2 04-03

IONTOPHORETIC APPLICATION OF OPIATES TO THE LOCUS-COERULEUS.
00309B 04-03

IN VITRO EFFECTS OF OPIATES ON CYCLIC-AMP IN RAT STRIATAL TISSUE.
003169 04-03

NEUROPEPTIDES: INFLUENCE OF ACUTE AND CHRONIC EFFECTS OF OPIATES.
003199 04-03

OPIATE RECEPTORS AND INTERNAL OPIATES.
0032B4 04-03

OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03

OPIOID

OPIOID PEPTIDES (ENDORPHINS) IN PITUITARY AND BRAIN.
001496 02-04

PSYCHOTROPIC DRUGS IN OPIOID ADDICTS ON METHADONE TREATMENT.
002119 02-17

OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03

IN VITRO PHARMACOLOGY OF THE OPIOID PEPTIDES, ENKEPHALINS AND ENDORPHINS.
003322 04-03

OPPOSED

MORPHINE OPPOSED EFFECTS OF NALOXONE IN UNANESTHETIZED DOGS.
001252 02-03

OPTALIDON

DRUG INTERACTIONS OF THE COMPONENTS OF OPTALIDON AFTER ORAL ADMINISTRATION.
002B23 03-13

OPTIC

THE EFFECT OF DIDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRADUCULAR INJECTION OF (3H)URIDINE.
001247 02-03

OPTICAL

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

CLINICAL EFFECTS AND PHARMACOKINETICS OF RACEMIC METHADONE AND ITS OPTICAL ISOMERS.
003694 04-13

OPTIMUM

DEVELOPING OPTIMUM DRUG REGIMENS.
002105 02-17

DETERMINING OPTIMUM DOSE AND ACUTE TOLERANCE OF TRIAZOLAM.
003754 04-14

ORAL

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
000796 01-12

THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000B20 01-13

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000B36 01-13

REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000B64 01-13

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
0009BB 01-15

HICCUPS FOLLOWING INGESTION OF ORAL CHLORDIAZEPOXIDE.
000996 01-15

ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

PSYCHOLOGIC EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL IN ADVANCED CANCER PATIENTS.
001B72 02-12

CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM.
001914 02-13

LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13

DEPRESSIVE SYNDROME INDUCED BY ORAL CONTRACEPTIVES
001979 02-14

INFLUENCE OF ORAL CONTRACEPTION ON SEXUAL RESPONSE.
002020 02-15

EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

EFFECT OF LITHIUM ON GASTRIC EMPTYING AND ABSORPTION OF ORAL CHLORPROMAZINE.
002346 03-03

DRUG INTERACTIONS OF THE COMPONENTS OF OPTALIDON AFTER ORAL ADMINISTRATION.
002B23 03-13

DEPRESSION ASSOCIATED WITH ORAL CHOLINE.
002939 03-15

ACUTE DOSE RESPONSE OF INTRADUCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04
PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS
003519 04-07
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08
TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION.
003573 04-09
ORAL CHOLINE ADMINISTRATION TO PATIENTS WITH TARDIVE-DYSKINESIA.
003624 04-11
ETHANOL AND ORAL DIAZEPAM ABSORPTION.
003677 04-13
ABSORPTION RATE, BLOOD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPOXIDE.
003731 04-14

ORALLY
DE PLANTIS TOXICARIIS E MUNDO NOVO TROPICALE COMMENTATIONES XIII. FURTHER NOTES ON VIROLA AS AN ORALLY ADMINISTERED HALLUCINOGEN.
001093 02-01
ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
001181 02-03

ORAP-R-6238
APPLICATION OF THE NEUROLEPTIC PIMOZIDE (ORAP-R-623B) FOR TRANQUILIZER INDICATIONS IN A CONTROLLED STUDY.
000701 01-10

ORDER
INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
00164B 02-06
DIFFERENTIAL EFFECT OF MORPHINE ON STIMULATION OF PRIMARY VERSUS HIGHER ORDER TRIGEMINAL TERMINALS.
0D3257 04-03

ORDINARY
COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
00D859 01-13

ORG-GB-94
THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN.
0D2271 03-03
AUTONOMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDROCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
D02674 03-09

ORG-6582
ON THE SELECTIVE INHIBITION OF SEROTONIN UPTAKE IN VIVO BY ORG-6582.
0D1393 02-03

ORGAN
EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
D01115 02-02
AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
0D11B2 02-D3

ORGANIC
CHLORIMIPRAMINE, FOR OBSESSIVE-COMPULSIVE NEUROSIS: AN ORGANIC APPROACH.
000523 01-07
PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-1D

ORGANIC-BRAIN-DISEASE
PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE: A CONTROLLED DOUBLE-BLIND STUDY.
002598 03-07
CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
002818 03-13

ORGANIC-BRAIN-SYNDROME
TREATMENT OF CHRONIC POSTTRAUMATIC ORGANIC-BRAIN-SYNDROME WITH DEXTROAMPHETAMINE: FIRST REPORTED CASE.
000904 D1-14
ACUTE ORGANIC-BRAIN-SYNDROME PSYCHOSIS WITH METHYLDOPA THERAPY.
002D46 02-15
DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
002051 D2-15
ACUTE ORGANIC-BRAIN-SYNDROME WITH PROPRANOLOL AND METHYLDOPA.
003779 04-15

ORGANIC-BRAIN-SYNDROMES
PSYCHOPATHOLOGY, PSYCHOPHARMACOLOGY AND THE ORGANIC-BRAIN-SYNDROMES: PART II.
002100 02-17
EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15

ORGANISM
LITHIUM IN THE LIVING ORGANISM: IS AN INTEGRATED HYPOTHESIS FEASIBLE
000649 01-09

ORGANIZATION
L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
000B01 01-13
EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
D01992 02-14
THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17

ORGANON-GB-94
CLINICAL ASPECTS OF ORGANON-GB-94 VS AMITRIPTYLINE.
000618 01-09

ORGANOPHOSPHORUS
EFFECT OF ORGANOPHOSPHORUS COMPOUNDS ON ACETYLCHOLINE SYNTHESIS IN BRAIN.
000180 01-03

ORGANOTYPIC
EFFECTS OF METHADONE HYDROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPARED FROM METHADONE-TOLERANT AND CONTROL RATS.
0025B1 03-D5

ORGANS
UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
002268 D3-D3

ORIENTATION
COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
0025B2 03-06

ORIENTATIONS
DISORDERED BEHAVIOR OF EPILEPTICS AND CURRENT THERAPEUTIC ORIENTATIONS.
DD0757 01-11

ORIENTED
A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
0D1885 02-13
INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
DD3841 04-16

ORIENTING
ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
0DD579 01-D8

ORIGIN
ON THE ORIGIN OF SCHIZOPHRENIC PSYCHOSES.
D00573 01-08

ORNITHINE-DECARBOXYLASE
EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN BRAIN AND HEART OF DEVELOPING RATS.
00137B 02-03

OROFACIAL
OROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY.
002911 03-15

ORPHENADRINE
ORPHENADRINE OVERDOSE TREATED WITH PHYSOSTIGMINE.
0D180B 02-1D
A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
D01B21 02-11
ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON

PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-08

ORTHOSTATIC
INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION.
002082 02-15

OSTEOMALACIA
ABSORPTION AND BIOTRANSFORMATION OF CHOLECALCIFEROL IN DRUG-INDUCED OSTEOMALACIA.
000166 01-03

OSTEOPENIA
OSTEOPENIA AND DYSREGULATION OF DIVALENT CATIONS IN LITHIUM TREATED PATIENTS.
000585 01-09

OUABAIN
THE EFFECTS OF OUABAIN AND THE ACTIVATION OF NEUTRAL MEMBRANE ATPASE BY BIOGENIC AMINES.
001281 02-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

OUDENONE
PHARMACODYNAMIC ACTIONS OF DIHYDROPROPYLFURYLIDENECYCLOPENTANEDIONE (OUDENONE).
001319 02-03

OUTCOME
OUTCOME OF PARKINSONISM AFTER 2 YEARS OF L-DOPA PLUS RO-4-4602.
000737 01-11

PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART
001749 02-09

EFFECT OF SOME ANALEPTICS ON THE OUTCOME OF ACUTE MICROWAVE LESIONS IN MICE.
002285 03-03

ACUTE CATATONIAS WITH FAVORABLE OUTCOME: A REPORT OF TWO CASES.
002652 03-08

THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17

OUTPATIENT
A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION.
000624 01-09

OUTPATIENT PSYCHIATRIC MEDICATIONS AND GLAUCOMA.
000980 01-15

MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
001002 01-16

OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY.
001755 02-09

USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY.
002628 03-08

A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC.
002644 03-08

OUTPATIENT HEROIN DETOXIFICATION WITH ACUPUNCTURE AND STAPLEPUNCTURE.
002783 03-11

A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
003605 04-10

OUTPATIENTS
PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07

DRUG AND FAMILY THERAPY IN DEPRESSED OUTPATIENTS.
000607 01-09

A CONTROLLED COMPARISON OF FLUPENTHIXOL AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS.
000671 01-09

PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31889) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
000682 01-10

DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS.
001691 02-08

DOUBLE-BLIND ATTEMPT AT COMPARISON OF EFFECTS OF LOFEPRAMINE AND AMITRIPTYLINE IN OUTPATIENTS WITH DEPRESSIVE CLINICAL PRESENTATION.
001783 02-09

HALOPERIDOL IN THE TREATMENT OF PSYCHONEUROTIC ANXIOUS OUTPATIENTS.
001792 02-10

LORAZEPAM AND DIAZEPAM IN ANXIOUS OUTPATIENTS: A CONTROLLED STUDY.
001805 02-10

MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001877 02-12

THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS.
002776 03-11

THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS.
003531 04-08

PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08

TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
003541 04-08

PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-31889) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-11

HELPING PSYCHIATRIC OUTPATIENTS ACCEPT DRUG THERAPY
003871 04-17

OUTPUT
REDUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-03

OVARIECTOMIZED
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
001400 02-03

OVER-THE-COUNTER
EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15

OVERCOME
BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA.
001254 02-03

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
003120 04-03

OVERDOSAGE
REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
002048 02-15

ACUTE OVERDOSAGE WITH BENZODIAZEPINE DERIVATIVES.
003789 04-15

OVERDOSE
ORPHENADRINE OVERDOSE TREATED WITH PHYSOSTIGMINE.
001808 02-10

ANTIDEPRESSANT BLOOD LEVELS IN ACUTE OVERDOSE.
002906 03-15

OVERDOSING THE TRICYCLIC OVERDOSE PATIENT.
003768 04-15

TREATMENT OF TRICYCLIC OVERDOSE PATIENTS.
003811 04-15

OVERDOSES
A STUDY OF LOW-DOSE AMITRIPTYLINE OVERDOSES.
003813 04-15

OVERDOSING
OVERDOSING THE TRICYCLIC OVERDOSE PATIENT.
003768 04-15

OVERREGULATION
DRUG DISCOVERY AND INTRODUCTION: REGULATION AND OVERREGULATION.
001669 02-07

OVERT
PENTYLENETETRAZOL-INDUCED AMNESIA: A CASE FOR OVERT SEIZURES.
000399 01-04

OVERUSE
PUBLIC INTEREST REPORT NO. 19 -- THE OVERUSE OF TRANQUILIZERS IN OLDER PATIENTS.
001820 02-11

OVERUSE OF SYNTHETIC ANTICHOLINERGIC DRUGS IN PSYCHIATRY.
002915 03-15

OVERVIEW
PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW
003885 04-17

OXAZEPAM
INHIBITION OF ACETAMINOPHEN GLUCURONIDATION BY OXAZEPAM.
000093 01-03
INCREASED AGGRESSION IN RATS AFTER WITHDRAWAL OF LONG-TERM USED OXAZEPAM.
001509 02-04
ON THE THERAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
002758 03-11
LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50.
002788 03-11
PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTERACTIONS OF ALCOHOL AND OXAZEPAM WITH REGARD TO RESPONSE BEHAVIOR.
002880 03-14
KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES II: OXAZEPAM AND DIAZEPAM.
003165 04-03

OXAZOLAM
A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SULPIRIDE AND OXAZOLAM IN THE FIELD OF PSYCHOSOMATIC MEDICINE.
000713 01-10
EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

OXIDASE
PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

OXIDATION
SOME OXIDATION PRODUCTS OF 2-SUBSTITUTED PHENOTHIAZINES.
001081 02-01

OXIDATIONS
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03

OXIDATIVE
DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS.
002051 02-15
OXIDATIVE PHOSPHORYLATION IN VARIOUS PARTS OF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION.
002321 03-03
THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

OXODIHYDROBENZODIAZEPINES
2,3 BENZODIAZEPINIC SYSTEMS. PART II. OXODIHYDROBENZODIAZEPINES. SYNTHESIS AND PHARMACOLOGIC STUDY.
001109 02-02

OXOTREMORINE
THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03
EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03
INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
003495 04-05

OXPRENOLOL
INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000089 01-03
A PLACEBO CONTROLLED TRIAL OF DIAZEPAM AND OXPRENOLOL FOR ANXIETY.
000677 01-10
EFFECT OF CORETAL-POLFA (OXPRENOLOL) ON PARKINSONIAN TREMOR AND BENIGN ESSENTIAL TREMOR.
000734 01-11
OXPRENOLOL AND PROPRANOLOL IN ANXIETY STATES.
0017B4 02-10
CONTROLLED EVALUATION OF THE BETA-ADRENOCEPTOR BLOCKING DRUG OXPRENOLOL IN ANXIETY.
002720 03-10

OXYCODONE
DYSKINESIA AFTER DISCONTINUATION OF COMPOUND ANALGESIC CONTAINING OXYCODONE.
003784 04-15

OXYGEN
THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN
001349 02-03
CONVULSIONS INDUCED BY HYBERBARIC OXYGEN INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN
003205 04-03

OXYGEN-18
THE MEASUREMENT OF BIOGENIC AMINE TURNOVER USING OXYGEN-18.
003263 04-03

OXYGENATED
CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01

OXYPERTINE
THE EFFECT OF OXYPERTINE ON TARDIVE-DYSKINESIA.
000851 01-13
CLINICAL EVALUATION OF THE EFFECTS OF OXYPERTINE IN STATES OF ANXIETY.
002730 03-10

OXYPROTHEPIN
RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN.
002647 03-0B

P-CHLORO-BETA-PHENYLETHYLAMINE
EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
001135 02-03

P-CHLORO-N-METHYLAMPHETAMINE
ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

P-CHLOROAMPHETAMINE
WORKSHOP ON P-CHLOROAMPHETAMINE.
000246 01-03
CENTRAL MECHANISMS OF ACTION OF P-CHLOROAMPHETAMINE: BIOCHEMICAL AND HISTOLOGICAL STUDIES. (PH.D. DISSERTATION).
000843 01-13
P-CHLOROAMPHETAMINE: SHORT AND LONG-TERM EFFECTS UPON SHOCK-ELICITED AGGRESSION.
001371 02-03
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03
MASS SPECTROGRAPHIC EVIDENCE OF THE CONVERSION OF P-CHLOROAMPHETAMINE TO 3,4 DIMETHOXYAMPHETAMINE.
002364 03-03
RIGIDITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-03
INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
00333B 04-03

P-CHLOROMETHAMPHETAMINE
BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
003109 04-03

P-CHLOROPHENYL
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
001235 02-03

P-CHLOROPHENYLALANINE
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
000279 01-04
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIDINE OR METHADONE-INDUCED DECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-04
EFFECTS OF P-CHLOROPHENYLALANINE ON ETHANOL SELF-SELECTION IN THE RAT.
000400 01-04
SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04
EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15
EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON RAT SOCIAL BEHAVIOUR.
001463 02-04

EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04

EFFECTS OF P-CHLOROPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04

EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04

P-CHLOROPHENYLALANINE REVERSAL OF TRANYLCYPROMINE EFFECTS IN DEPRESSED PATIENTS.
002164 02-17

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON AMPHETAMINE-INDUCED LOCOMOTION AND STEREOTYPY.
002535 03-04

EFFECTS OF P-CHLOROPHENYLALANINE AND AMPHETAMINE ON HABITUATION OF EXPLORATION.
003385 04-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE INTAKE OF ETHANOL AND SACCHARIN SOLUTIONS.
003463 04-04

P-CPA

SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04

EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTION WITH P-CPA ON RAT BRAIN 5-HT.
001211 02-03

SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
001464 02-04

SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-D4

P-HYDROXYAMPHETAMINE

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
0000B6 01-03

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D-AMPHETAMINE-SULFATE.
000088 01-03

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE.
00223B 03-03

P-METHOXYPHENYLETHYLAMINE

BEHAVIORAL EFFECTS OF P-METHOXYPHENYLETHYLAMINE: A PHARMACOLOGICAL STUDY.
002419 03-04

P-NITROPHENYL-DIAZONIUM-FLUOROBORATE

EFFECT OF P-NITROPHENYL-DIAZONIUM-FLUOROBORATE ON CHOLINERGIC MECHANISMS.
000069 01-03

P-TYRAMINE

PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE, M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
000138 01-03

P-WAVES

PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15

PACEMAKER

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000BB5 01-14

PACING

EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
D03270 D4-03

PAIN

MORPHINE AND PAIN: EFFECTS ON ASPARTATE, GABA AND GLUTAMATE IN FOUR DISCRETE AREAS OF MOUSE BRAIN
DD0224 D1-03

THE PAIN AGGRESSION INDUCED BY BRONOPOL IN THE RAT.
00D394 D1-04

THE EFFECT OF CLOMIPRAMINE (ANAFRANIL) ON CONTINUING PAIN.
000636 01-09

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09

THE BROMPTON MIXTURE: EFFECTS ON PAIN IN CANCER PATIENTS.
000845 01-13

USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000847 01-13

INTRAMUSCULAR BUTORPHANOL AND MEPERIDINE IN POSTOPERATIVE PAIN.
001662 02-07

THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
002087 02-1

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
002348 03-0

EFFECT OF MORPHINE ON RESPONSE TO PAIN: A TWIN STUDY.
003374 04-0

THE EFFICACY OF PERCOGESIC IN RELIEF OF MUSCULOSKELETAL PAIN ASSOCIATED WITH ANXIETY.
0D3619 04-1

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN.
003883 04-1

CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERA PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
003891 04-1

PAIN-PRODUCING

5-HYDROXYTRYPTAMINE AS A SENSITIZER OF SOMATIC NOCICEPTORS FOR PAIN-PRODUCING SUBSTANCES.
000185 01-0

PAINFUL

UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
00226B 03-0

PAINS

THE USE OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF CHRONIC, SEVERE PAINS.
001834 02-1

PAIR

IDENTICAL PSYCHOSIS IN A PAIR OF MONOZYGOTIC TWINS.
002966 03-1

PAIRED

SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-0

PAIRING

A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND O THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
D02477 03-0

PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-0

PAIRS

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-386, NEW ANTIANXIET DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
D0341D 04-0

PALSY

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
D03524 04-0

VERTICAL GAZE PALSY IN BARBITURATE INTOXICATION
0D3773 04-1

PALSY-LIKE

PHENOTHIAZINE-INDUCED BULBAR PALSY-LIKE SYNDROME AND SUDDEN DEATH.
003B28 04-1

PANAEOLUS

PSILOCYBIAN-MYCETISMUS WITH SPECIAL REFERENCE TO PANAEOLUS.
D00B55 01-1

DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AND PSATHYRELLA.
0D108B 02-0

PANCREAS

EFFECTS OF NEUROTROPIC SUBSTANCES ON SECRETION AND BLOOD SUPPLY OF THE PANCREAS.
D02290 03-0

PANIC

THE TREATMENT OF PATHOLOGICAL PANIC STATES WITH PROPRANOLO
D02677 03-0

PAPAVERINE
PAPAVERINE, DRUG-INDUCED STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04
EFFECT OF PAPAVERINE ON CEREBRAL ELECTROGENESIS.
000810 01-13
EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS: EVALUATION BY THE XENON-133 INHALATION METHOD.
002096 02-16

PAPIO-HAMADRYAS
EFFECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS.
003350 04-04

PAPIO-PAPIO
EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04

PARACETAMOL
THE EFFECT OF DESMETHYLIMIPRAMINE ON THE ABSORPTION OF ALCOHOL AND PARACETAMOL.
000824 01-13

PARADIGM
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL WITH CHOLINOMIMETIC DRUGS IN AN AGONIST ANTAGONIST PARADIGM.
001521 02-04
MORPHINE INJECTIONS IN THE TASTE-AVERSION PARADIGM.
002443 03-04
ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003B94 04-17

PARADOXES
THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY: A WEB OF PARADOXES.
003877 04-17

PARADOXIC
PARADOXIC EFFECTS OF NEUROLEPTICS?
002892 03-15

PARADOXICAL
CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14
EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04
THE REINFORCING ACTION OF MORPHINE AND ITS PARADOXICAL SIDE-EFFECT.
003481 04-04

PARALLEL
PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-04
IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13
PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN.
003447 04-04

PARALYSIS
EFFECT OF 7,B BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03
CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN PARALYSIS AGITANS.
001846 02-11

PARAMETER
CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03

PARAMETERS
LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03
THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
000308 01-04
THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
0D0652 01-09
PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
D00916 01-14
CLINICAL PARAMETERS OF ANTIDEPRESSANT ACTIVITY.
001010 01-16
EFFECT OF CARBAMAZEPINE ON CHOLINERGIC PARAMETERS IN RAT BRAIN AREAS.
001170 02-03
INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04
PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
001991 02-14
DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01
COCAINE EFFECTS ON SLEEP PARAMETERS IN THE RAT.
003403 04-04
SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISORDERS.
003576 04-09

PARAMETRIC
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
00305B 04-01
PARAMETRIC INVESTIGATIONS OF THE EFFECTS OF PRIOR EXPOSURE TO AMPHETAMINE AND MORPHINE ON CONDITIONED GUSTATORY AVERSION.
003360 04-04

PARANOID
MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07
ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY.
000540 01-0B
PARANOID PSYCHOSIS WITH ONEIROIDAL ELEMENTS DURING THE COURSE OF REDLICH-FLATAUS DISEASE.
000769 01-11
SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PROBLEM OF PARANOID PSYCHOSIS.
00083B 01-13
EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
0019B0 02-14
EFFICACY OF LOXAPINE IN THE TREATMENT OF PARANOID SCHIZOPHRENIA.
003527 04-08
NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
003B16 04-15

PARAQUAT
PARAQUAT POISONING.
002012 02-15

PARASYMPATHETIC
THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-03

PARASYMPATHOLYTIC
THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC-ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
002350 03-03

PARASYMPATHOMIMETIC
THE EFFECT OF CERTAIN PARASYMPATHOMIMETIC AND PARASYMPATHOLYTIC DRUGS ON THE GAMMA-AMINOBUTYRIC-ACID CONTENT IN THE CEREBRAL HEMISPHERES OF MICE.
0D2350 03-03

PARATHORMONE
EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
D01748 02-09

PARENTERAL
PRELIMINARY STUDY OF PARENTERAL LORAZEPAM IN STATUS-EPILEPTICUS.
0D0789 01-11
DRINKING INDUCED BY PARENTERAL INJECTIONS OF PILOCARPINE.
002449 03-04
REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN.
003207 D4-D3

PARGYLINE
DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
000387 01-04
EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03
COMPARISON OF SHORT AND LONG-LASTING EFFECTS OF PARGYLINE ON CEREBRAL DOPAMINE METABOLISM.
001413 02-03
PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE.
001604 02-04
DIFFERENTIAL EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON INDOLEAMINES IN BRAIN.
002380 03-03
DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

PARGYLINE-INDUCED
PARGYLINE-INDUCED INCREASES IN SENSITIVITY TO THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR IN PIGEONS.
003361 04-04

PARIETAL
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PARKINSON
COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000800 01-13
EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07
ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY.
002035 02-15

PARKINSONIAN
EFFECT OF CORETAL-POLFA (OXPRENOLOL) ON PARKINSONIAN TREMOR AND BENIGN ESSENTIAL TREMOR.
000734 01-11
CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L-DOPA.
00094B 01-15
EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY.
000999 01-15
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15
EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03
14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13

PARKINSONIANS
ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
003631 04-11

PARKINSONIGENIC
THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15

PARKINSONISM
THERAPEUTICAL EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
0004BB 01-07
STUDIES WITH BROMOCRIPTINE: PART 2. DOUBLE-BLIND COMPARISON WITH LEVODOPA IN IDIOPATHIC PARKINSONISM.
000501 01-07
OUTCOME OF PARKINSONISM AFTER 2 YEARS OF L-DOPA PLUS RO-4-4602.
000737 01-11
RESULTS OF L-DOPA TREATMENT IN PARKINSONISM.
000751 01-11
L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-4B6) IN PARKINSONISM.
000767 01-11
L-DOPA TREATMENT IN PARKINSONISM. BIOCHEMICAL BASIS.
000B02 01-13
AMANTADINE VERSUS TRIHEXYPHENIDYL IN THE TREATMENT OF NEUROLEPTIC-INDUCED PARKINSONISM.
000B18 01-13
TREATMENT OF PARKINSONISM WITH A COMBINATION OF L-DOPA AND METHYLDOPA HYDRAZINE.
000870 01-13
LOW URINARY DOPAMINE AND PREDICTION OF PHENOTHIAZINE-INDUCED PARKINSONISM: A PRELIMINARY REPORT.
000935 01-15
DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM.
001831 02-11
THE DRUG TREATMENT OF PARKINSONISM.
001848 02-11
AMANTADINE REDUCES DRUG-INDUCED PARKINSONISM.
0019B3 02-14
EFFECTS OF L-DOPA ON SLEEP IN PARKINSONISM.
001993 02-14
ATTEMPT AT TREATING PARKINSONISM WITH AGONISTS OF THE DOPAMINERGIC SYSTEM.
002751 03-11
COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11
COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM.
002B15 03-13
DRUG THERAPY OF PARKINSONISM.
002967 03-17
ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-08
COEXISTING TARDIVE-DYSKINESIA AND PARKINSONISM: A CASE REPORT.
003665 04-13
RELATIONSHIP BETWEEN TARDIVE-DYSKINESIA, L-DOPA-INDUCED HYPERKINESIA AND PARKINSONISM.
003785 04-15

PARKINSONS
THERAPEUTIC ACTION OF D-PHENYLALANINE IN PARKINSONS DISEASE.
000495 01-07
EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
000498 01-07
PARKINSONS SYNDROME: DRUG THERAPY
000787 01-11
L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
000B01 01-13
PIRIBEDIL IN THE TREATMENT OF PARKINSONS DISEASE.
000848 01-13
ON THE EFFECT OF DOPA-DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM.
000970 01-15
L-DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE: A LONG-TERM STUDY.
0025BB 03-07
AN ERGOT DERIVATIVE IN THE TREATMENT OF PARKINSONS DISEASE.
002592 03-07
CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE.
003446 04-04
PARKINSONS DISEASE: A THERAPEUTIC MEMORANDUM.
003611 04-11

PAROLEES
NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11

PAROXYSMAL
HEREDITARY PAROXYSMAL ATAXIA RESPONSIVE TO ACETAZOLAMIDE
003629 04-11

PARTIAL
ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03
BINDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITION BY MORPHINE OR NALOXONE.
003089 04-03
SITE OF ACTION OF DEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS.
003367 04-04

PARTIALLY
THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN OF THE RAT, CAUSED BY RAISED LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN BE PARTIALLY OVERCOME.
003120 04-03

PARTICIPATION
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17
THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03

PARTNERS
EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY
001595 02-04

PASSAGE
PASSAGE OF DIAZEPAM AND DESMETHYLDIAZEPAM INTO BREAST MILK.
000932 01-15
THE PASSAGE OF 14C-DELTA-9-TETRAHYDROCANNABINOL INTO THE MILK OF LACTATING SQUIRREL-MONKEYS.
001167 02-03

PASSIVE
THE EFFECTS OF DIETHYLDITHIOCARBAMATE ON PASSIVE AVOIDANCE LEARNING BY CHICKS (GALLUS-DOMESTICUS).
000111 01-03
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04
DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
0034B0 04-04

PATHOGENESIS
THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

PATHOLOGIC
PATHOLOGIC EFFECTS OF ANTIMETABOLITES ON THE HIPPOCAMPUS OF DIET CONTROLLED MICE.
000175 01-03

PATHOLOGICAL
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05
SUCCESSFUL USE OF THIOTHIXENE IN TWO CASES OF PATHOLOGICAL JEALOUSY.
000690 01-10
ABSENCE OF PATHOLOGICAL CHANGES FOLLOWING INTRAVENOUS METHAMPHETAMINE AND INTRAARTERIAL IOTHALAMATE MEGLUMINE.
001639 02-05
PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-0B
PERIODIC STRUCTURE OF PHYSIOLOGICAL AND PATHOLOGICAL TREMOR.
0020B9 02-16
PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05
THE TREATMENT OF PATHOLOGICAL PANIC STATES WITH PROPRANOLOL.
002677 03-09
DRUG METABOLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN.
003B7B 04-17

PATHOLOGY
EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
0022B6 03-03

PATHOMORPHOSIS
FORMATION OF CIRCULARITY AS A MANIFESTATION OF PATHOMORPHOSIS IN SCHIZOPHRENIA.
002640 03-0B

PATHOPHYSIOLOGICAL
MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SUBSTRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 01-11
PATHOPHYSIOLOGICAL ASPECTS CONCERNING THE TREATMENT OF THE APALLIC SYNDROME.
0027B9 03-11

PATHOPHYSIOLOGY
PATHOPHYSIOLOGY -- BIOCHEMICAL CONSIDERATIONS.
00052B 01-0B
METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY
000B42 01-13
CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY
002B1B 03-13
THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
003026 03-17

PATHS
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
00116B 02-03

PATHWAY
PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03
A NEW METABOLIC PATHWAY OF BROMAZEPAM INVOLVING ATTACHMENT OF A METHYLTHIO GROUP.
001095 02-01
METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT: NEW METABOLIC PATHWAY OF CAFFEINE.
00112B 02-03
EPOXIDE-DIOL PATHWAY IN THE METABOLISM OF TRICYCLIC DRUGS.
002240 03-03
THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03
INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03
THE PARTICIPATION OF THE NIGROTHALAMIC PATHWAY IN THE NIGRAL CONTROL OF THE CAUDATE NUCLEUS.
003327 04-03
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06

PATHWAYS
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
0000B1 01-03
THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-04
BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04
HISTOCHEMICAL AND MICROPUNCH ANALYSIS OF AMINERGIC AND CHOLINERGIC PATHWAYS. (UNPUBLISHED PAPER).
002266 03-03
EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
002291 03-03
EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-03

PATIENT
TREATMENT OF THE DEPRESSED PATIENT IN THE HOME.
00071B 01-10
A TRIAL OF FENFLURAMINE IN THE TREATMENT OF THE CHRONIC ALCOHOLIC PATIENT.
000752 01-11
SOME NOTES ON THE PATIENT WITH NEUROLEPTIC SYNDROME.
000941 01-15
EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15
ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15
A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION-SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-07
AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
0016B4 02-0B
RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-0B
LITHIUM TREATMENT OF A PATIENT WITH PERIODIC CATATONIA.
001712 02-0B

DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
001787 02-10

PSYCHOSIS IN PATIENT ON BROMOCRIPTINE AND LEVODOPA WITH CARBIDOPA.
002054 02-15

PRESCRIPTION OF AN ANTIDEPRESSANT AND THE PHYSICIAN PATIENT RELATIONSHIP.
002154 02-17

CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

HOW TO TREAT THE PROFOUNDLY DEPRESSED PATIENT.
002686 03-09

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
003528 04-08

PHARMACOLOGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
003556 04-09

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT: A CASE REPORT.
003587 04-10

SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY.
003635 04-11

OVERDOSING THE TRICYCLIC OVERDOSE PATIENT.
D0376B 04-15

MENTAL DISTRESS IN PATIENT ON DISOPYRAMIDE.
003776 04-15

PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS.
003787 04-15

THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY: HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
003B73 04-17

LITHIUM IN THE TREATMENT OF A MANIC PATIENT WITH MULTIPLE-SCLEROSIS: A CASE REPORT.
003879 04-17

COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003B97 04-17

PATIENTS

A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
000478 01-07

DOUBLE-BLIND EVALUATION OF AHR-1118 AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000486 01-07

PATIENTS REACTIONS TO CLINICAL DRUG TESTING.
000489 01-07

PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE.
000492 01-07

A DOUBLE-BLIND COMPARISON OF LORAZEPAM WITH DIAZEPAM IN NEUROTIC PATIENTS.
00D502 D1-07

PSYCHOTROPIC EFFECT OF PYROVALERONE (F-19B3), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07

A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
000530 01-0B

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 D1-08

ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
000579 01-08

A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
000580 D1-09

OSTEOPENIA AND DYSREGULATION OF DIVALENT CATIONS IN LITHIUM TREATED PATIENTS.
D00585 01-09

PLASMA PROLACTIN CONCENTRATIONS IN PATIENTS ON CLOMIPRAMINE.
000586 01-09

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE.
000587 01-09

LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01-09

CONTROLLED COMPARISON OF MELITRACEN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
000604 01-09

A DOUBLE-BLIND COMPARISON OF CLINICAL EFFICACY OF DOXEPIN AND IMIPRAMINE IN DEPRESSIVE PATIENTS.
000622 D1-09

DRUG RELATED TEST PATTERNS OF DEPRESSED PATIENTS.
000626 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION
000658 01-09

SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-09

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09

AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09

USE OF ST-1191 IN HOSPITALIZED PATIENTS.
000679 01-10

RIPAZEPAM (CI-6B3) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10

LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
000708 01-10

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM
000726 01-11

TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 189 HOSPITALIZED PATIENTS.
0D0727 01-11

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

EFFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHOLIC PATIENTS.
D00782 01-11

COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000B00 01-13

ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000805 01-13

A FOLLOW-UP OF 78 PATIENTS WITH GILLES-DE-LA-TOURETTES SYNDROME.
000807 01-13

THE BROMPTON MIXTURE: EFFECTS ON PAIN IN CANCER PATIENTS.
000B45 01-13

PENTOBARBITAL ELIMINATION IN PATIENTS WITH POOR RENAL FUNCTION.
D00B60 01-13

CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS
0DDB81 01-14

STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000885 01-14

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01 15

PSYCHIATRIC SYNDROMES IN CRITICALLY ILL PATIENTS.
DD0956 01-15

AN IRREVERSIBLE EFFECT OF LITHIUM ADMINISTRATION TO PATIENTS.
D00964 01-15

POLYDIPSIA, HYPONATREMIA, AND SEIZURES IN PSYCHOTIC PATIENTS.
000968 01-15

ON THE EFFECT OF DOPA-DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM.
D00970 01-15

THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN
000972 01-15

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE 8OSTON COLLA8ORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

ANTINUCLEAR ANTIBODIES IN PATIENTS ON LITHIUM-CAR8ONATE.
000978 01-15

SUCCESSFUL DETOXIFICATION FROM METHADONE MAINTENANCE. FOLLOW-UP STUDY OF 38 PATIENTS.
000982 01 15

ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
0009B8 01-15

EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILDT STUDY WITH 45 PATIENTS.
001661 02-07

EVIDENCE FOR IMPRDVED CARDIAC PERFDRMANCE AFTER BETA-BLOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-07

PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
001683 02-08

CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA 8EFORE AND AFTER NEURDLEPTIC TREATMENT.
001687 02-08

PATHOLDGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLDGY.
001692 02-0B

A DOUBLE-8LIND COMPARATIVE TRIAL OF LDXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
00169B 02-0B

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS.
001727 02-09

URINARY EXCRETIDN OF 3-METHOXY-4-HYDRDXYPHENYLGLYCDL IN DEPRESSED PATIENTS: MDDIFICATIONS BY AMPHETAMINE AND LITHIUM.
001729 02-09

EFFECT OF THYRDTRDPIN-RELEASING HDRMDNE IN CDMPARISDN TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 02-09

DDUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILDXAZINE AND IMIPRAMINE IN 50 HDSPITALIZED FEMALE PATIENTS.
001744 02-09

CYCLIC-AMP LEVELS IN CEREBRDSPINAL FLUID IN MANIC MELANCHDLIC PATIENTS.
001747 02-09

EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
00174B 02-09

SOMATIC THERAPIES IN DLDER DEPRESSED PATIENTS.
001753 02-09

EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN CDMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

THE EFFECTS OF ADMINISTERING LITHIUM-CARBDNATE DN THE BALANCE DF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
001774 02-09

FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS.
001782 02-09

PDLYGRAPHIC RECDRDING OF SLEEP IN ENDDGENDUS DEPRESSIVE PATIENTS BEFDRE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-DXIDE.
001794 02-10

AMITRIPTYLINE THERAPY IN PATIENTS WITH ANOREXIA-NERVDSA.
001799 02-10

EXPERIENCE IN THE TREATMENT DF ALCDHDLIC PATIENTS WITH CHLORACYZINE IN CDMBINATION WITH RATIONAL PSYCHDTHERAPY.
001B15 02-11

PUBLIC INTEREST REPDRT ND. 19 -- THE DVERUSE DF TRANQUILIZERS IN OLDER PATIENTS.
001820 02-11

BENZODIAZEPINE DRUGS IN GENERAL MEDICAL PATIENTS.
001B33 02-11

PLASMA AND CEREBRDSPINAL FLUID CDNCENTRATIDNS DF CHLORDIAZEPDXIDE AND ITS METABDLITES IN SURGICAL PATIENTS.
001862 02-11

PSYCHDLOGIC EFFECTS OF DRAL DELTA9-TETRAHYDROCANNABINDL IN ADVANCED CANCER PATIENTS.
001872 02-12

14C-HOMOVANILLIC-ACID IN THE CEREBRDSPINAL FLUID DF PARKINSDNIAN PATIENTS AFTER INTRAVENOUS 14C-L-DDPA.
001910 02-13

SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NDRMALS: EFFECT OF D-AMPHETAMINE AND HALDPERIDOL.
001927 02-13

HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT
001946 02-13

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0019B6 02 14

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

NEUROLEPTIC TARDIVE-DYSKINESIAS: STUDY OF 1660 PATIENTS IN A PSYCHIATRIC HOSPITAL.
002019 02-15

TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM.
002030 02-15

PHARMACDTHERAPY IN DLDER DEPRESSED PATIENTS.
002033 02-15

ON THE SWELLING OF THE DIAPHRAGM AMONG PATIENTS TAKING PSYCHOTROPIC DRUGS (SECDND REPORT).
002077 02-15

THE RELATION 8ETWEEN PAIN AND PERSDNALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
002087 02-16

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16

IMPLICATIDNS DF DRUG TREATMENT FDR THE SDCIAL REHABILITATIDN DF SCHIZDPHRENIC PATIENTS.
002116 02-17

P-CHLDRDPHENYLALANINE REVERSAL OF TRANYLCYPRDMINE EFFECTS IN DEPRESSED PATIENTS.
002164 02-17

BEHAVIDRAL ALTERATIDNS IN PATIENTS WITH BASAL GANGLIA LESIDNS.
002430 03-04

EXPERIENCES WITH JUSTON IN PATIENTS WITH DEPRESSIVE AND DYSTDNIC AFFECT.
002605 03-07

EFFECTS OF A CARBDNIC-ANHYDRASE INHIBITOR DN CEREBRAL BLDOD FLDW IN GERIATRIC PATIENTS.
002606 03-07

FOLLDW-UP DF PATIENTS WITH CHRDNIC SCHIZOPHRENIA -- WITH SPECIAL REFERENCE TD THE EFFECTS OF PHARMACDTHERAPY.
002609 03-08

HEMODYNAMIC EFFECTS OF THIDTHIXENE AND CHLDRPROMAZINE IN SCHIZDPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 03-0B

USE DF NEURDLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HDSPITAL CENTER DF FANN: SUMMARY.
002626 03-08

A DOUBLE-BLIND CDMPARISDN STUDY BETWEEN PENFLURIDDL AND PERPHENAZINE IN ACUTE SCHIZDPHRENIC PATIENTS.
002627 03-0B

CLINICAL EFFECTS OF TRYPTOPHAN IN CHRDNIC SCHIZDPHRENIC PATIENTS.
002629 03-08

CARE OF SCHIZDPHRENIC PATIENTS OUTSIDE THE HDSPITAL: RESEARCH RESULTS AND BASIC PRINCIPLES.
002631 03-08

HYPORESPDNSIVITY DF CHRDNIC SCHIZDPHRENIC PATIENTS TD DEXTRDAMPHETAMINE.
002635 03-0B

PRDPRANDLDL TD CONTRDL SCHIZOPHRENIC SYMPTOMS.
55

PATIENTS.
002663 03-08

PSYCHDDYNAMIC DBSERVATIDNS DF A GRDUP DF PATIENTS TREATED WITH LITHIUM-CARBDNATE.
002670 03-09

TDTAL AND FREE PLASMA TRYPTDPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS DF A PERIPHERAL DECARBDXYLASE INHIBITDR, M5T-1RB.
002672 03-09

AUTDNDMIC ACTIONS AND INTERACTIONS OF MIANSERIN HYDRDCHLORIDE (ORG-GB-94) AND AMITRIPTYLINE IN PATIENTS WITH DEPRESSIVE ILLNESS.
002674 03-09

PLATELET MONOAMINE-OXIDASE IN SCHIZDPHRENIA: AN INVESTIGATION IN DRUG-FREE HDSPITALIZED PATIENTS.
002688 03-09

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE DF PATIENTS WITH AFFECTIVE OISORDERS TREATED PRDPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

USE OF SIDNDCARB IN TREATING PATIENTS IN ASTHENIC OR DEPRESSIVE STATES.
002699 03-09

MEASUREMENT OF 5-HYDROXYINOOLE COMPOUNOS OURING L-5-HTP TREATMENT IN OEPRESSEO PATIENTS.
002700 03-09

PROTRIPTYLINE: THE RELATIONSHIP 8ETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON OEPRESSEO MALE PATIENTS.
002711 03-10

PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG ANO EXPERIMENTAL PSYCHOLOGICAL STUOY.
002724 03-10

HYPNOTIC EFFECTS OF DIXYRAZINE IN A OOUBLE-BLIND CROSS-OVER STUDY ON GERIATRIC PATIENTS.
002736 03-11

EARLY OBSERVATIONS OF THE EFFECT OF PROPRANOLOL ON PSYCHOTIC PATIENTS.
002739 03-11

CLINICAL EXPERIENCES WITH FLUPHENAZINE-DECANOATE (OF) IN 50 LONG-TERM PATIENTS.
002756 03-11

OOXEPIN ANO OIAZEPAM IN THE TREATMENT OF HOSPITALIZEO GERIATRIC PATIENTS.
002770 03-11

A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC ANO PSYCHOLOGIC STUOY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY OEFICIENCY.
002774 03-11

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP OISOROERS IN GERIATRIC PATIENTS: DOUBLE-BLINO TRIALS ANO LONG-TERM STUOY.
002778 03-11

RETROSPECTIVE EVALUATION ANO MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03-11

TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENOEO ACTION FORM OF BIPERIOEN HYOROCHLORIDE: 9 MONTH STUOY OF 55 HOSPITALIZED PATIENTS.
002787 03-11

COMBINEO TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEOANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11

NEUROLEPTICS REOUCE SPINAL FLUIO CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002B00 03-13

REOUCEO GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENOOGENOUS OEPRESSIVE PATIENTS: STUOIES IN NORMAL, REACTIVE ANO ENOOGENOUS OEPRESSIVE, SCHIZOPHRENIC, ANO CHRONIC ALCOHOLIC SUBJECTS.
002821 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE ORUGS ON LEVELS OF MONOAMINE METABOLITES ANO PROLACTIN IN CEREBROSPINAL FLUIO OF PSYCHIATRIC PATIENTS.
002835 03-13

SELECTIVE EFFECTS OF PSYCHOACTIVE ORUGS ON LEVELS OF MONOAMINE METABOLITES ANO PROLACTIN IN CEREBROSPINAL FLUIO OF PSYCHIATRIC PATIENTS.
002B36 03-13

EFFECTS OF L-OOPA ANO VITAMIN-B6 ON ELECTROENCEPHALOGRAMS OF SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT.
002B47 03-13

PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENOING HOSPITAL FOLLOW-UP CLINICS.
002B54 03-14

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEOURE IN PATIENTS UNOER LITHIUM TREATMENT.
002B93 03-15

THE EFFECTS OF HALOPERIOOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNOROME.
002901 03-15

INFLUENCE OF PSYCHOTROPIC ORUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLO IN NONEPILEPTIC PSYCHOTIC PATIENTS.
002908 03-15

OERMATOLOGICAL FINOINGS ON NEUROPSYCHIATRIC PATIENTS OURING PSYCHOPHARMACOTHERAPY.
002921 03-15

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS ANO ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIOENTS OCCURRING IN PATIENTS TREATEO WITH NEUROLEPTICS ANO ANTIDEPRESSANTS.
002928 03-15

GLYCEMIC SIOE-EFFECTS IN PATIENTS OUE TO NEUROLEPTIC THERAPY.
002941 03-15

GASTROINTESTINAL BLEEOING IN PATIENTS ON BROMOCRIPTINE.
002943 03-15

THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17

PHARMACOTHERAPY AND CONFINEMENT OF PATIENTS.
003032 03-17

ANTIOEPRESSANT EVALUATION ANO THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN OEPRESSIVE PATIENTS.
003521 04-07

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIOE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003524 04-07

OOPAMINERGIC FUNCTION IN TWO PATIENTS WITH CATALEPSY.
003529 04-08

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGEO EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATEO WITH PENFLURIOOL OR THIOTHIXENE.
003533 04-08

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION ANO COAGULATION FACTORS.
003548 04-08

SLEEP OISOROERS IN PATIENTS WITH SEVERE MENTAL OEPRESSION· OOUBLE-8LIND PLACE8O CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (OIPIPERON).
003549 04-09

INOIVIOUAL OIFFERENCES IN AVERAGE EVOKED RESPONSES TO O-AMPHETAMINE ANO L-AMPHETAMINE WITH ANO WITHOUT LITHIUM-CARBONATE IN OEPRESSEO PATIENTS.
003550 04-09

MAPROTILINE (LUDIOMIL) IN OEPRESSION: A REPORT OF A MONITOREO RELEASE STUOY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09

AMOXAPINE· A OOUBLE-BLIND COMPARATIVE CLINICAL STUOY OF AMOXAPINE ANO AMITRIPTYLINE IN OEPRESSEO HOSPITALIZEO PATIENTS.
003577 04-09

MESORIDAZINE (SERENTIL) IN PERSONALITY OISORDERS -- A CONTROLLED TRIAL IN AOOLESCENT PATIENTS.
003582 04-10

BRIEF TREATMENT OF ANXIOUS PATIENTS WITH HALAZEPAM IN HIGH OOSES.
003591 04-10

TREATING OEPRESSED CAROIAC PATIENTS.
003601 04-10

LITHIUM IN AOULT ANOREXIA-NERVOSA: A PILOT REPORT ON TWO PATIENTS.
003610 04-11

A DOUBLE-BLINO TRIAL OF NAFTIOROFURYL IN TREATING CONFUSEO ELOERLY PATIENTS IN GENERAL PRACTICE.
003612 04-11

ORAL CHOLINE AOMINISTRATION TO PATIENTS WITH TAROIVE-OYSKINESIA.
003624 04-11

A COMPARISON OF HIGH-OOSE ANO LOW-DOSE LORAZEPAM WITH AMYLOBARBITONE IN PATIENTS WITH ANXIETY STATES.
003644 04-11

A MULTICENTRE STUOY COMPARING MAZINOOL ANO PLACEBO IN OBESE PATIENTS.
003648 04-11

PLATELET MONOAMINE-OXIOASE ACTIVITY IN SCHIZOPHRENIC PATIENTS.
003658 04-13

OOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE ANO NORMAL CONTROLS.
003661 04-13

OISPOSITION OF OIAZEPAM ANO ITS MAJOR METABOLITE OESMETHYLOIAZEPAM IN PATIENTS WITH LIVER OISEASE.
003683 04-13

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION ANO ORUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
003702 04-13

INITIAL CLINICAL TRIAL BASEO ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN OEPRESSEO PATIENTS.
003709 04-13

EFFECTS OF PROLONGEO AOMINISTRATION OF PIMOZIOE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHEO PAPER).
003727 04-14

EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE ANO ON PSYCHOPHYSIOLOGICAL CAROIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14

METHYLPHENIDATE HYOROCHLORIOE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC ANO NONPSYCHOTIC PATIENTS
003733 04-14

ON THE SERUM CONCENTRATIONS ANO ANTIPSYCHOTIC EFFECTS OF THIORIOAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE ANO

THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15
RICKETS AND ANTICONVULSANTS IN MENTALLY RETARDED PATIENTS.
003783 04-15
SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003804 04-15
MEDAZEPAM AND THE DRIVING ABILITY OF ANXIOUS PATIENTS.
003809 04-15
TREATMENT OF TRICYCLIC OVERDOSE PATIENTS.
003811 04-15
CARDIAC SIDE-EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
003830 04-15
GENERAL PRACTITIONERS PRESCRIBING HABITS FOR PATIENTS WITH DEPRESSION
003886 04-17
PHARMACOLOGICAL AFTERCARE FOR HOMOGENOUS GROUPS OF PATIENTS.
003890 04-17

PATTERN
TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03
EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
00049B 01-07
THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000820 01-13
CLINICAL ELECTROENCEPHALOGRAPHIC MODIFICATIONS OF THE HYPNOTIC PATTERN OBTAINED WITH THE USE OF N-DESMETHYLDIAZEPAM IN 25 INSOMNIAC PATIENTS.
000881 01-14
EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
000902 01-14
A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
001885 02-13
ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05
THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

PATTERNS
DRUG RELATED TEST PATTERNS OF DEPRESSED PATIENTS.
000626 01-09
EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
000792 01-12
PEER REVIEW OF PRESCRIBING PATTERNS IN A (CMHC).
001033 01-17
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-03
EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04
EFFECTS OF LITHIUM-CHLORIDE ON SLEEP PATTERNS IN THE RAT.
001465 02-04
DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04
CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
00159B 02-04
A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14
AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002B6B 03-14
CHANGES IN PRESCRIBING PATTERNS OF MINOR TRANQUILIZERS.
003037 03-17
STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
003368 04-04
EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14
DECISIONS ABOUT DRUG THERAPY -- V. MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
003888 04-17

PAUSE
DRUG EFFECTS ON FIXED-INTERVAL RESPONDING WITH PAUSE REQUIREMENTS FOR FOOD PRESENTATION
003465 04-04

PAVLOVIAN
MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03

PDA
AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL.
002106 02-17

PECKING
THE EFFECTS OF D-AMPHETAMINE ON THE AUTOMAINTAINED KEY PECKING OF PIGEONS.
003441 04-04

PECULIARITIES
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03

PEDIATRIC
STUDY IN A PEDIATRIC MILIEU OF AN ANTIANXIETY DRUG: CLOBAZAM.
000494 01-07
CLINICAL ASSESSMENT FOR PEDIATRIC PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER).
002775 03-11

PEER
A 2-YEAR FOLLOW-UP OF 72 HYPERACTIVE BOYS: CLASSROOM BEHAVIOR AND PEER ACCEPTANCE.
000912 01-14
PEER REVIEW OF PRESCRIBING PATTERNS IN A (CMHC).
001033 01-17

PELLET
SYSTEMATIC ASSESSMENT OF TOLERANCE TO PENTOBARBITAL BY PELLET IMPLANTATION.
000342 01-04
RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION.
003353 04-04

PELLETS
A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFERENT TYPES OF MORPHINE PELLETS.
002311 03-03
DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04
ENDURING EFFECTS OF MORPHINE PELLETS REVEALED BY CONDITIONED TASTE-AVERSION.
003424 04-04

PEMOLINE
CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN PARALYSIS AGITANS.
001B46 02-11

PENETRATION
REGULARITIES IN PENETRATION OF THE PLACENTAL BARRIER BY AMINAZINE.
002576 03-05
AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

PENFLURIDOL
REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05
CLINICAL EXPERIENCE IN USING TLP-607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-08
A DOUBLE-BLIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-08
CLINICAL EXPERIENCE IN USING PENFLURIDOL (TLP-607) FOR SCHIZOPHRENIA.
000559 01-0B
CLINICAL EFFECT OF PENFLURIDOL FOR SCHIZOPHRENIA -- ESPECIALLY DELUSION.
000578 01-0B
PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
001683 02-08

CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08
EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03
CUMULATIVE EFFECTS OF PENFLURIDOL, A LONG-ACTING NEUROLEPTIC DRUG, AS ASSAYED BY ITS BEHAVIORAL ACTIONS.
002490 03-04
EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
00253B 03-04
CLINICAL EVALUATION OF A WEEKLY ADMINISTERED NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-07
A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
002627 03-08
PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08
A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIDOL (R-16341).
002656 03-08
ON THE CLINICAL PHARMACOLOGY OF PENFLURIDOL.
002824 03-13
PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003519 04-07
CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
D03533 04-08
PENFLURIDOL: A DOUBLE-BLIND TRIAL IN CHRONIC SCHIZOPHRENIA.
003542 04-08
PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-0B

PENICILLIN
PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

PENICILLIN-G
THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04

PENICILLIN-INDUCED
INFLUENCE OF DIAZEPAM AND PHENYTOIN ON PENICILLIN-INDUCED CEREBRAL CONVULSIONS.
D0D253 01-03

PENTAGIN
THREE CASES OF CHRONIC PENTAZOCINE (SOSEGON, PENTAGIN) INTOXICATION.
002D45 02-15

PENTAMETHYLENETETRAZOL
INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
002908 03-15

PENTAPEPTIDE
D-ALA2-MET-ENKEPHALINAMIDE: A POTENT, LONG-LASTING SYNTHETIC PENTAPEPTIDE ANALGESIC.
0D2193 D3-02

PENTAZOCINE
PERSISTENT PSYCHOTIC PHENOMENA FOLLOWING ONE DOSE OF PENTAZOCINE.
002025 02-15
CAN PENTAZOCINE BE A DRUG? OBSERVATIONS ON THE PROBLEM OF TALWINISM.
DD2028 02-15
THREE CASES OF CHRONIC PENTAZOCINE (SOSEGON, PENTAGIN) INTOXICATION.
D02045 02-15
THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
0D2087 02-16
CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE
002575 03-D5
PENTAZOCINE ADDICTION: A WARNING.
003832 04-15

PENTETRAZOL
EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04
ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

PENTOBARBITAL
INTERACTION OF PENTOBARBITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
000118 01-03
ENHANCEMENT OF PENTOBARBITAL EFFECT BY CONTINUOUS ADMINISTRATION OF MORPHINE IN THE MOUSE.
000122 01-03
THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBITAL NARCOSIS IN THE MONKEY.
000145 01-03
SYSTEMATIC ASSESSMENT OF TOLERANCE TO PENTOBARBITAL BY PELLET IMPLANTATION.
000342 01-04
EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04
SUBJECTIVE AND PHYSIOLOGIC EFFECTS OF MORPHINE, PENTOBARBITAL, AND MEPROBAMATE.
000761 01-11
PENTOBARBITAL ELIMINATION IN PATIENTS WITH POOR RENAL FUNCTION.
000860 01-13
ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM.
0012BD D2-03
PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03
DIFFERENTIAL EFFECTS OF PENTOBARBITAL AND ETHANOL IN MICE.
001373 02-03
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
0014DD D2-D3
EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04
PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-D4
EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
001507 02-D4
DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04
EFFECTS OF PENTOBARBITAL ON PUNISHED BEHAVIOR AT DIFFERENT SHOCK INTENSITIES.
0D16D7 D2-04
THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03
PENTOBARBITAL AND SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC-ACID.
D02333 D3-03
EFFECTS OF BENZODIAZEPINES AND PENTOBARBITAL ON THE EVOKED POTENTIALS IN THE CAT BRAIN.
DD23B7 03-03
INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
D02422 03-D4
CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
D02481 03-04
EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-D4
PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION: EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
DD2497 03-D4
WITHDRAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBITAL DOSING IN CAT.
D02516 03-04
DIFFERENCES IN CYTOCHROME-P-450 OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
D02563 D3-05

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

PHARMACOLOGIC RESPONSE TO PENTOBARBITAL IN ACTIVELY IMMUNIZED MICE.
003141 04-03

PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

SENSITIVITY OF COMPONENTS OF THE CENTRAL VESTIBULAR COMPLEX TO PENTOBARBITAL.
003225 04-03

EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
003251 04-03

PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03

DIFFERENTIAL INTERACTIONS OF PHENOBARBITAL AND PENTOBARBITAL WITH BETA-ADRENERGIC MECHANISMS IN VITRO AND VIVO.
003262 04-03

EFFECTS OF ACUTE AND CONTINUOUS PENTOBARBITAL ADMINISTRATION ON THE GAMMA-AMINOBUTYRIC-ACID SYSTEM.
003307 04-03

PHARMACOKINETICS OF PENTOBARBITAL IN THE CAT AND COMPARISONS WITH THE RABBIT AND MAN.
003317 04-03

PENTOBARBITAL, DIAZEPAM AND BEMEGRIDE: THEIR EFFECTS ON OPEN-FIELD BEHAVIOR IN THE GERBIL (MERIONES-UNGUICULATUS).
00340B 04-04

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
003713 04-13

PENTOBARBITAL-SODIUM

STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE IN LABORATORY ANIMALS.
003492 04-05

PENTOBARBITONE

THE EFFECTS OF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03

PENTOSE

THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03

PENTOXIFYLLINE

STATISTICAL EVALUATION OF POLYGRAPHIC INVESTIGATIONS OF PENTOXIFYLLINE.
000B30 01-13

PENTYLENETETRAZOL

PHARMACOKINETIC STUDIES OF PENTYLENETETRAZOL IN DOGS.
000137 01-03

EFFECT OF STRIATECTOMY ON THE COURSE OF PENTYLENETETRAZOL CONVULSIONS IN THE RAT.
001131 02-03

PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03

PENTYLENETETRAZOL-INDUCED

PENTYLENETETRAZOL-INDUCED AMNESIA: A CASE FOR OVERT SEIZURES.
000399 01-04

AUGMENTATION OF PENTYLENETETRAZOL-INDUCED SEIZURES BY TRICYCLIC ANTIDEPRESSANTS.
001346 02-03

PEOPLE

EFFECT OF PIRACETAM ON PSYCHOORGANIC SYNDROMES OF OLD PEOPLE.
003526 04-07

PEPTIC

PSYCHOPHARMACOLOGY OF THE PEPTIC ULCER.
000759 01-11

PEPTIDE

PHYLOGENETIC DISTRIBUTION OF A MORPHINE-LIKE PEPTIDE ENKEPHALIN.
000015 01-01

PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 02-13

AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

PEPTIDES

PHYSICAL DEPENDENCE ON OPIATE-LIKE PEPTIDES.
000447 01-04

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF BETA LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
001147 02-03

TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
00114B 02-03

OPIOID PEPTIDES (ENDORPHINS) IN PITUITARY AND BRAIN.
001496 02-04

ENDOGENOUS OPIATE PEPTIDES. (UNPUBLISHED PAPER).
002B19 03-13

OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 04-03

IN VITRO PHARMACOLOGY OF THE OPIOID PEPTIDES, ENKEPHALINS AND ENDORPHINS.
003322 04-03

CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

PERAZINE

CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE.
001711 02-0B

PERCEPTION

MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14

EFFECTS OF SOME PSYCHOACTIVE DRUGS UPON THE TRAPEZOID ILLUSION PERCEPTION.
002B56 03-14

PERCEPTUAL

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
000796 01-12

EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN.
00199B 02-14

THE INTERACTION OF ETHANOL AND DELTA9-TETRAHYDROCANNABINOL IN MAN: EFFECTS ON PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS.
002B57 03-14

DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES IN MAN FOLLOWING MARIHUANA SMOKING.
003B24 04-15

PERCOGESIC

THE EFFICACY OF PERCOGESIC IN RELIEF OF MUSCULOSKELETAL PAIN ASSOCIATED WITH ANXIETY.
003619 04-11

PERFENAZINE

CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CARBONATE.
000709 01-10

PERFORMANCE

DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-03

PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRAIN-DAMAGED RATS.
000220 01-03

THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04

INTERACTION BETWEEN HYPERBARIC AIR AND D-AMPHETAMINE EFFECTS ON PERFORMANCE.
000436 01-04

BENZODIAZEPINES AND HUMAN PERFORMANCE.
000900 01-14

THE EFFECT OF MINOR TRANQUILIZERS ON PSYCHOMOTOR PERFORMANCE.
000997 01-15

THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN.
001441 02-04

EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEDULE.
001467 02-04

TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED 8Y METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04
PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
001608 02-04
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEW8ORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX 8EHAVIOR AND ON ADULT 8EHAVIORAL PERFORMANCE.
001635 02-05
A SU8CHRONIC STUDY OF THE SU8JECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07
EVIDENCE FOR IMPROVED CARDIAC PERFORMANCE AFTER 8ETA-8LOCKADE IN PATIENTS WITH CORONARY ARTERY DISEASE.
001673 02-07
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001845 02-11
DIGIT SYM8OL PERFORMANCE IN METHADONE TREATED EX-HEROIN ADDICTS.
001956 02-14
EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON PERCEPTUAL MOTOR PERFORMANCE OF HYPERACTIVE CHILDREN.
001998 02-14
A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACE8O ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14
THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON 8EHAVIORAL PERFORMANCE AND SU8JECTIVE JUDGMENT IN NORMAL SU8JECTS.
002006 02-14
PECULIARITIES OF THE ACTION OF SODIUM-OXY8UTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
002289 03-03
THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE 8ETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03
EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
002415 03-04
ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
002480 03-04
ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03-11
THE EFFECT OF DISODIUM CROMOGLYCATE ON HUMAN PERFORMANCE, ALONE AND IN COMBINATION WITH ETHANOL.
002858 03-14
EEG AND TASK PERFORMANCE AFTER ACTH4-10 IN MAN.
002874 03-14
TOLERANCE TO THE EFFECTS OF DELTA9-THC ON SHUTTLE-BOX PERFORMANCE AND 8ODY TEMPERATURE.
003398 04-04
EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFORMANCE IN MICE.
003416 04-04
ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
003433 04-04
DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
003448 04-04
PSYCHOMOTOR PROCEDURES TO DISTINGUISH 8ETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACE8O ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14
BAR8ITURATE EFFECTS ON 8RAIN FUNCTION (CNV) AND ATTENTION PERFORMANCE IN NORMAL MEN.
003751 04-14

PERFORMANCES
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SU8STANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000885 01-14

PERFORMING
RELATIONS 8ETWEEN 8EHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04

PERFUSED
INTERACTION OF PENTO8AR8ITAL, DIPHENYLHYDANTOIN AND DIGITOXIN WITH ETHANOL IN THE ISOLATED PERFUSED GUINEA-PIG LIVER.
000118 01-03
EFFECTS OF CANNA8INOIDS ON THE PERFUSED RAT HEART.
001379 02-03
META8OLISM OF 3-O-METHYLDOPA 8Y THE ISOLATED PERFUSED RAT LIVER.
002388 03-03
EFFECTS OF CHLORPROMAZINE ON THE ISOLATED PERFUSED RAT HEART.
003084 04-03
ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
003184 04-03
COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS META8OLITES ON THE ISOLATED PERFUSED RAT 8RAIN
003274 04-03

PERFUSION
POTENTIATION OF CENTRAL REWARD 8Y LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
000209 01-03
CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED 8Y THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

PERIAQUEDUCTAL
SYSTEMATIC EXAMINATION IN THE RAT OF 8RAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: O8SERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

PERICARDIAL
PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RU8 FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15

PERINATAL
MASCULINE SEXUAL 8EHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE
001499 02-04

PERIODIC
LITHIUM TREATMENT OF A PATIENT WITH PERIODIC CATATONIA.
001712 02-08
PERIODIC STRUCTURE OF PHYSIOLOGICAL AND PATHOLOGICAL TREMOR.
002089 02-16

PERIPHERAL
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN
000181 01-03
ADAPTATIONAL 8EHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-8IL08A.
000232 01-03
8RAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHI8ITION.
000252 01-03
L-DOPA THERAPY COMBINED WITH PERIPHERAL DECAR8OXYLASE INHIBITOR (MK-486) IN PARKINSONISM.
000767 01-11
PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT
001192 02-03
THE EFFECT OF L-DOPA AND AN INHI8ITOR OF PERIPHERAL DECAR8OXYLATION ON GLUCOSE METABOLISM IN 8RAIN.
001405 02-03
INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
001408 02-03
A COMPARISON OF CIRCLING 8EHAVIOUR INDUCED IN NIGROSTRIATAL LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
001448 02-04
THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04
PERIPHERAL NEUROPATHY CAUSED 8Y METHAQUALONE
002059 02-15

ACTIVITY OF PERIPHERAL 8LOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA
002618 03-08
TOTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHI8ITOR, M5T-1R8.
002672 03-09
RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
003082 04-03
SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES 8Y CAR8IDOPA, AN INHI8ITOR OF PERIPHERAL DOPA-DECAR8OXYLASE.
003330 04-03
A COMPARISON OF THE EFFECT OF LITHIUM AND HALOPERIDOL ON HUMAN PERIPHERAL 8ETA-ADRENERGIC ADENYLATE-CYCLASE.
003668 04-13

RLAPINE
PERLAPINE AND DOPAMINE METABOLISM: PREDICTION OF ANTIPSYCHOTIC EFFICACY.
003325 04-03

RORAL
EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07
PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

PHENAZINE
THE EFFECTS OF PERPHENAZINE ON SELF-ADMINISTRATION BEHAVIOR.
000353 01-04
STUDY ON THE EFFECTS OF SULPIRIDE AND PERPHENAZINE IN 82 SCHIZOPHRENICS USING THE DOUBLE-BLIND METHOD.
000531 01-0B
CLINICAL ASPECTS OF KINETIC STUDIES ON PERPHENAZINE.
00190B 02-13
A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
002627 03-0B
INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04
INTERACTION OF PERPHENAZINE WITH THE KINETICS OF NORTRIPTYLINE.
003695 04-13

PHENAZINE-ENANTHATE
THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-0B
HIGH-DOSE TREATMENT OF RATS WITH PERPHENAZINE-ENANTHATE.
001205 02-03
PHARMACOKINETIC PROFILE OF PERPHENAZINE-ENANTHATE.
002B42 03-13

SEVERATION
PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

SISTENCE
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-04
PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04
MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

SISTENT
PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 02-03
PERSISTENT PSYCHOTIC PHENOMENA FOLLOWING ONE DOSE OF PENTAZOCINE.
002025 02-15
PERSISTENT NEPHROGENIC DIABETES-INSIPIDUS AFTER LITHIUM-CARBONATE.
002934 03-15

SISTING
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION.
003469 04-04

SONAL
PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT
002619 03-0B
ANTAGONISM 8ETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE PART 2.
002BB7 03-15

PERSONALITY
ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY.
000540 01-0B
PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH
000775 01-11
PERSONALITY PREDISPOSITION AND EMERGENCE PHENOMENA WITH KETAMINE.
000794 01-12
EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14
PERSONALITY SPECIFIC EFFECT OF A TRANQUILIZER
001987 02-14
THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
0020B7 02-16
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16
FUNCTIONS OF LOUD SOUND, PERSONALITY, AND DRUGS.
0029B4 03-17
PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
0035B1 04-10
MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
003582 04-10
HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES OF DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 04-14
THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14
LITHIUM-CARBONATE IN PERSONALITY DISORDERS: A CASE OF HYSTERIA.
003753 04-14

PERSONS
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17
CONCERNING ASPERMIA NOTED IN PERSONS TAKING THIORIDAZINE
002049 02-15
HEALTH STATUS IN PERSONS ENGAGED IN THE PRODUCTION OF TRIFTAZINE.
002914 03-15
SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

PERSPECTIVE
ANDEAN COCA CHEWING: A METABOLIC PERSPECTIVE.
002B02 03-13

PERSPECTIVES
LITHIUM TREATMENT. SOME DATA AND RECENT PERSPECTIVES.
00106B 01-17
AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12
PERSPECTIVES IN BIOLOGICAL PSYCHIATRY: PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
0035B1 04-10

PERTOFRAN
A COMPARATIVE TRIAL OF ANAFRANIL, PERTOFRAN AND AN ANAFRANIL/PERTOFRAN COMBINATION.
003636 04-11

PERVINCAMINE-FORTE-RETARD
A CLINICAL TRIAL OF PERVINCAMINE-FORTE-RETARD IN NEUROPSYCHIATRY
00075B 01-11

PETHIDINE
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIDINE OR METHADONE-INDUCED DECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-04
THE EFFECTS OF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05
PETHIDINE PHARMACOKINETICS IN DOG: DOSE AND TIME STUDIES.
00113B 02-03

CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-05

PGE1

HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
0001B1 01-03

PGO

INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED BY THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03

AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP.
003106 04-03

EFFECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS.
003350 04-04

PHARMACEUTICAL

THE PHARMACEUTICAL MANAGEMENT OF GASTRIC ULCERATION. (PH.D. DISSERTATION).
002773 03-11

PHARMACO-EEG

DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14

FLUOTRACEN (SKF-28175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-11

PHARMACOCHEMICAL

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
003058 04-01

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01

PHARMACODYNAMIC

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
000055 01-03

SEX AS A FACTOR IN METABOLISM, TOXICITY, AND EFFICACY OF PHARMACODYNAMIC AND CHEMOTHERAPEUTIC AGENTS.
000B22 01-13

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1-RECEPTOR ANTAGONIST METOPROLOL.
000828 01-13

CHEMICAL AND PHARMACODYNAMIC STUDY OF BETA-AMINOKETONES OF BENZOXAZOLINONIC STRUCTURE.
001103 02-02

PHARMACODYNAMIC ACTIONS OF DIHYDROPROPYLFURYLIDENECYCLOPENTANEDIONE (OUDENONE).
001319 02-03

EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
002286 03-03

PHARMACODYNAMICS

ANTIPSYCHOTIC DRUGS: PHARMACODYNAMICS AND PHARMACOKINETICS.
001362 02-03

PHARMACOELECTROENCEPHALOGRAPHY

A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY.
001885 02-13

PHARMACOGENETIC

PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04

A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR.
001703 02-0B

PHARMACOGENIC

PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15

ON THE CONDITIONS UNDERLYING PARTICULAR PHARMACOGENIC CONFUSIONAL STATES: A COMPARISON OF AMITRIPTYLINE AND CLOZAPINE.
002671 03-09

PHARMACOKINETIC

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF METOPROLOL IN THE CATS AND THE DOG.
000055 01-03

PHARMACOKINETIC STUDIES OF METOPROLOL-3H IN THE RAT AND THE DOG.
000056 01-03

PHARMACOKINETIC STUDIES OF PENTYLENETETRAZOL IN DOGS.
000137 01-03

PHARMACOKINETIC STUDIES OF FG-4963.
000629 01-09

COMBINED PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES IN MAN OF THE ADRENERGIC BETA1 RECEPTOR ANTAGONIST METOPROLOL.
000828 01-13

PHARMACOKINETIC STUDIES ON HALOPERIDOL IN MAN
001911 02-13

PHARMACOKINETIC STUDY OF THE NEUROLEPTIC AZABUTYRON.
002248 03-03

THE PSYCHOPHARMACOLOGY OF BETA ADRENERGIC BLOCKADE: PHARMACOKINETIC AND EPIDEMIOLOGIC ASPECTS.
002599 03-07

PHARMACOKINETIC APPROACH TO DRUG DOSING IN THE AGED.
002604 03-07

PHARMACOKINETIC PROFILE OF PERPHENAZINE-ENANTHATE.
002842 03-13

PHARMACOKINETICS

THE EFFECT OF ALPHA-TOCOPHEROL DEFICIENCY ON THE PHARMACOKINETICS AND PHARMACOLOGICAL EFFECT OF BARBITAL.
000170 01-03

PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION.
000466 01-05

PHARMACOKINETICS OF SEDATIVES IN LIVER DISEASE.
000798 01-13

THE PHARMACOKINETICS OF BROMAZEPAM IN MAN
000857 01-13

PETHIDINE PHARMACOKINETICS IN DOG: DOSE AND TIME STUDIES.
001138 02-03

ANTIPSYCHOTIC DRUGS: PHARMACODYNAMICS AND PHARMACOKINETICS.
001362 02-03

PHARMACOKINETICS OF DL-NOREPHEDRINE 14C IN THE RAT.
001401 02-03

DATA ANALYSIS PROBLEMS IN THE AREA OF PHARMACOKINETICS RESEARCH.
001651 02-06

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
0016B9 02-08

CLINICAL PHARMACOKINETICS OF LORAZEPAM: 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM.
001914 02-13

PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DOG, RABBIT, GUINEA-PIG AND RAT.
001921 02-13

PHARMACOKINETICS OF LITHIUM IN HUMAN PLASMA AND ERYTHROCYTES.
001936 02-13

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: BLOOD LEVELS AND CLINICAL RESPONSE.
002120 02-17

L-DOPA: PLASMA PHARMACOKINETICS AND CONVERSION TO DOPAMINE IN BRAIN (PH.D. DISSERTATION).
002233 03-03

EFFECT OF CHLOROTHIAZIDE ON THE PHARMACOKINETICS OF LITHIUM IN PLASMA AND ERYTHROCYTES.
002829 03-13

SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETICS IN RATS.
003092 04-03

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03

PHARMACOKINETICS OF PENTOBARBITAL IN THE CAT AND COMPARISONS WITH THE RABBIT AND MAN.
003317 04-03

PHARMACOKINETICS OF CHLORPROMAZINE AFTER SINGLE AND CHRONIC DOSAGE.
003664 04-13

CLINICAL PHARMACOKINETICS OF LORAZEPAM. II. INTRAMUSCULAR INJECTION
003675 04-13

CLINICAL EFFECTS AND PHARMACOKINETICS OF RACEMIC METHADONE AND ITS OPTICAL ISOMERS.
003694 04-13

ARMACOLOGIC

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRAIN-DAMAGED RATS.
000220 01-03

PHARMACOLOGIC THERAPY FOR SCHIZOPHRENIA.
000526 01-08

2,3 BENZODIAZEPINIC SYSTEMS. PART II. OXODIHYDROBENZODIAZEPINES SYNTHESIS AND PHARMACOLOGIC STUDY.
001109 02-02

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 02-04

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
002253 03-03

CLINICAL PHARMACOLOGIC OBSERVATIONS ON ATENOLOL, A BETA-ADRENOCEPTOR BLOCKER.
002591 03-07

PHARMACOLOGIC IMPLICATIONS OF HEMISPHERIC ASYMMETRY.
003017 03-17

PHARMACOLOGIC RESPONSE TO PENTOBARBITAL IN ACTIVELY IMMUNIZED MICE.
003141 04-03

PHARMACOLOGIC MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
003B44 04-17

FREE-LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN.
003B6B 04-17

ARMACOLOGICAL

POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01

NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS.
000078 01-03

EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03

PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03

THE EFFECT OF ALPHA-TOCOPHEROL DEFICIENCY ON THE PHARMACOKINETICS AND PHARMACOLOGICAL EFFECT OF BARBITAL.
000170 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

TOPOGRAPHIC AND PHARMACOLOGICAL STUDY OF THE MESOCORTICAL DOPAMINERGIC SYSTEM.
000240 01-03

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09

BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH
000710 01-10

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON.
000768 01-11

PHARMACOLOGICAL THERAPY OF INSOMNIA
0007B0 01-11

EXPERIMENTAL PHARMACOLOGICAL DIFFERENTIAL DEFINITION OF NOOTROPIC DRUGS
000892 01-14

PHARMACOLOGICAL SUBSTANCES INFLUENCING ACQUISITION BEHAVIOR IN RATS.
000928 01-14

NEGATIVE ASPECTS OF PHARMACOLOGICAL PREVENTION OF EPILEPSY.
000940 01-15

A SURVEY OF THE PHARMACOLOGICAL PROPERTIES OF METOPROLOL IN ANIMALS AND MAN
001011 01-17

CEREBROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPUBLISHED PAPER).
001044 01-17

INDICATIONS FOR LONG-TERM PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC SYNDROMES.
001066 01-17

PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-02

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY DESTRUCTION OF INTERNEURONS.
001239 02-03

A NEW MODEL OF ACTIVE AVOIDANCE CONDITIONING ADEQUATE FOR PHARMACOLOGICAL STUDIES.
001502 02-04

CLINICAL AND PHARMACOLOGICAL EFFECTS OF TREATMENT WITH A NEW ANTIDEPRESSANT.
001739 02-09

PSYCHOLOGICAL MEDICINE: DRUGS USED IN PSYCHOLOGICAL MEDICINE: PHARMACOLOGICAL BASIS OF TREATMENT.
001B2B 02-11

PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14

DISULFIRAM IMPLANTATION: PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS.
002003 02-14

AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17

PHARMACOLOGICAL ACTION OF PYRIMIDOINDOLE DERIVATIVES.
002187 03-02

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY
002196 03-02

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN
002202 03-03

PHARMACOLOGICAL STUDIES ON DEVELOPMENT OF RESPONSE TO CATECHOLAMINE IN BRAIN.
002263 03-03

PHARMACOLOGICAL STUDY OF EVOKED POTENTIALS IN THE OLFACTORY BULB.
002361 03-03

BEHAVIORAL EFFECTS OF P-METHOXYPHENYLETHYLAMINE: A PHARMACOLOGICAL STUDY.
002419 03-04

A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04

A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 03-04

A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
002536 03-04

ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002556 03-04

THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLEI DF RAT 8RAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
002584 03-06

CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN.
002616 03-08

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF 8LOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-08

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION: A COMPARATIVE KINETIC ANALYSIS.
002846 03-13

CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
D02B86 D3-15

PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSDNALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16

PHARMACOLOGICAL TREATMENT OF AFFECTIVE DISORDERS.
002962 03-17

CLINICAL AND PHARMACOLOGICAL SPECTRAL MAPS OF THE NEUROLEPTICS.
003009 03-17

TRANQUILIZERS: PHARMACOLOGICAL ASPECTS.
003035 03-17

SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIDIMIDAZOLINES.
003D67 D4-D2

POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZDMORPHANS.
DD3D72 D4-02

DDPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
D03078 04-03

GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
0D3124 04-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES WITH THREE METABOLITES OF NOMIFENSINE.
003200 04-03

BIOCHEMICAL AND PHARMACDLOGICAL STUDIES ON AN ANIMAL MODEL OF HYPERACTIVITY STATES.
0D3518 04-06

CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
DD3520 04-07

ANTIDEPRESSANT EVALUATIDN AND THE PHARMACOLOGICAL ACTIONS OF FG-4963 IN DEPRESSIVE PATIENTS.
003521 04-07

PHARMACOLOGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
DD3556 D4-09

CDMPARATIVE CLINICAL EVALUATIDN DF LOFEPRAMINE AND IMIPRAMINE: PHARMACOLOGICAL ASPECTS.
DD3574 04-09

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
0037D3 04-13

SOME PROBLEMS IN THE TREATMENT OF DEPRESSION WITH PHARMACOLOGICAL AGENTS.
0D3778 04-15

NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
003816 04-15

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS: PHARMACOLOGICAL APPROACH.
D03845 D4-17

PHARMACOLOGICAL AGENTS AS TOOLS IN PSYCHIATRIC RESEARCH.
003861 04-17

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
0D3BB3 D4-17

PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW.
D03885 04-17

PHARMACOLOGICAL AFTERCARE FOR HOMOGENOUS GROUPS OF PATIENTS.
D03890 D4-17

PHARMACOLOGICALLY

DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04

PHARMACOLOGICALLY-INDUCED

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CEREBELLAR CORTEX: DIFFERENCE BETWEEN APOMORPHINE, HALOPERIDOL AND HARMALINE.
003096 04-03

PHARMACOLOGY

CNS DEPRESSANTS: EFFECTS ON POSTSYNAPTIC PHARMACOLOGY.
000043 01-03

OBSERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT 8RAINSTEM.
DDDD59 01-03

A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM -- APPENDIX II (PART III).
001072 01-17

BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
001665 02-07

PHARMACOLOGY: DRUGS AFFECTING BEHAVIOR.
002132 02-17

PHARMACOLOGY OF SLEEP.
002176 02-17

COORDINATIDN OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
0021B3 03-01

PIRACETAM: NOOTROPIC PHARMACOLOGY OF NEUROINTEGRATIVE ACTIVITY.
002454 03-04

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
D02478 03-04

VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIDATION.
002811 D3-13

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
00281B 03-13

ON THE CLINICAL PHARMACOLOGY OF PENFLURIDOL.
D02824 03-13

BEHAVIORAL PHARMACOLOGY: THE CURRENT STATUS.
0D2881 03-14

PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY.
002959 D3-17

BEHAVIORAL PHARMACOLOGY.
0D2990 03-17

EXPERIMENTAL AND CLINICAL VECTORS IN PHARMACOLOGY.
0D3013 03-17

PHARMACOLOGY OF EMOTIVE BEHAVIOR.
0D3D46 03-17

PHARMACOLOGY OF CIS-CLOPENTHIXOL-DECANOATE, A DEPOT NEUROLEPTIC.
003070 D4-02

IN VITRO PHARMACOLOGY OF THE OPIOID PEPTIDES, ENKEPHALINS AND ENDORPHINS.
003322 04-03

PHARMACOPSYCHIATRY

MODERN PROBLEMS OF PHARMACOPSYCHIATRY. VOL. II: ALCOHOL, DRUGS AND DRIVING.
D03014 D3-17

PHARMACOPSYCHOLOGICAL

PHARMACOPSYCHOLOGICAL EXAMINATIONS CONCERNING INTERACTIONS OF ALCOHOL AND OXAZEPAM WITH REGARD TO RESPONSE BEHAVIOR.
002BB0 03-14

PHARMACOPSYCHOTHERAPY

PHARMACOPSYCHOTHERAPY OF SCHIZOPHRENIA.
0DO561 01-08

PHARMACOTHERAPEUTIC

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
00056D 01-08

PHARMACOTHERAPY

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

PHARMACOTHERAPY.
001006 01-16

TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS - PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
001058 01-17

THEORY OF TREATMENT -- PHARMACOTHERAPY
001075 01-17

DISORDER OF CHOLINERGIC MEDIATION UNDER HYPERTHERMIC CONDITIONS AND ITS EXPERIMENTAL PHARMACOTHERAPY.
001305 02-03

EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE
001637 02-05

INDICATIONS FOR PHARMACOTHERAPY OF SCHIZOPHRENIA
001694 02-08

PHARMACOTHERAPY OF SCHIZOPHRENIA
001695 02-08

MEDICAL AND SOCIAL INFLUENCE OF PHARMACOTHERAPY AGAINST SCHIZOPHRENIA.
001699 02-08

THOUGHTS ON PHARMACOTHERAPY FOR SCHIZOPHRENIA
001724 02-08

PSYCHIATRIC PHARMACOTHERAPY IN RENAL INSUFFICIENCY.
002016 02-15

PHARMACOTHERAPY IN OLDER DEPRESSED PATIENTS
002033 02-15

CERTAIN NONBIOLOGICAL ASPECTS OF THE PHARMACOTHERAPY OF SCHIZOPHRENIA.
002108 02-17

FOLLOW-UP OF PATIENTS WITH CHRONIC SCHIZOPHRENIA -- WITH SPECIAL REFERENCE TO THE EFFECTS OF PHARMACOTHERAPY.
002609 03-08

PHARMACOTHERAPY OF SCHIZOPHRENIA.
002613 03-08

PHARMACOTHERAPY OF SCHIZOPHRENIA: A CRITICAL EVALUATION.
002614 03-08

ACTIVITY OF PERIPHERAL BLOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA.
002618 03-08

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03-11

RATIONAL APPROACHES TO THE PHARMACOTHERAPY OF CHOREA.
002803 03-13

TWO CASES OF SERIOUS SIDE-EFFECTS DURING PHARMACOTHERAPY.
002909 03-15

ADVERSE EFFECTS OF PHARMACOTHERAPY IN CHILDHOOD PSYCHOSIS.
002988 03-17

PHARMACOTHERAPY AND MEDICAL INSURANCE
003000 03-17

THE PRESENT STATE OF PHARMACOTHERAPY
003001 03-17

THE ETHICS AND THE ACTUALITIES OF PHARMACOTHERAPY.
003015 03-17

PHARMACOTHERAPY AND CONFINEMENT OF PATIENTS
003032 03-17

PHARMACOTHERAPY HERE AND ABROAD: DIFFERENCES IN SIDE-EFFECTS.
003780 04-15

PSYCHOTHERAPY AND PHARMACOTHERAPY: CONCEPTUAL ISSUES.
003857 04-17

EST: A SPECIAL CASE IN PHARMACOTHERAPY
003859 04-17

HARMACY

PSYCHIATRIC PHARMACY RESIDENCY AND SERVICES.
001026 01-17

HASE-TWO

R-806, A TETRACYCLIC ANTIDEPRESSANT. AN EARLY PHASE-TWO STUDY.
003523 04-07

HASIC

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

PSYCHOLOGICAL ASPECTS OF PHASIC DEPRESSION DURING LITHIUM PROPHYLAXIS.
002075 02-15

HELLODENDRON-WILSONII

A NOTE ON THE ISOLATION AND IDENTIFICATION OF THE QUATERNARY ALKALOIDS OF PHELLODENDRON-WILSONII.
001098 02-01

HENANTHRENE

INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS
002327 03-03

PHENCYCLIDINE

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

TOXICOLOGY OF PHENCYCLIDINE IN MICE.
001391 02-03

THE EFFECTS OF PHENCYCLIDINE ON ETHANOL AND SODIUM HEXOBARBITAL IN MICE.
003290 04-03

INTERACTIONS BETWEEN DELTA9-TETRAHYDROCANNABINOL AND PHENCYCLIDINE HYDROCHLORIDE IN RATS.
003445 04-04

PHENCYCLIDINE-INDUCED

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

PHENDORAL

THE USE OF THE BETA-INTERCEPTOR PHENDORAL WITHIN THE FIELD OF PSYCHIATRY.
000749 01-11

PHENELZINE

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-03

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

PHENETHYLAMINE

PHENETHYLAMINE HYPOTHESIS FOR EMOTIONAL HOMEOSTATIS. DEPRESSIVE STATES AND THE ACTION MECHANISM OF ANTIDEPRESSANTS.
000021 01-02

PHENIRAMINE

INFLUENCE OF PHENIRAMINE AND CHLORPHENIRAMINE ON APOMORPHINE-INDUCED COMPULSIVE GNAWING IN MICE.
000306 01-04

PHENMETRAZINE

TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03

PHENOBARBITAL

THE INFLUENCE OF PHENOBARBITAL ON BIOTRANSFORMATION OF 25-HYDROXYCHOLECALCIFEROL.
000066 01-03

THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY. NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE.
000076 01-03

INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03

IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
000158 01-03

PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
000788 01-11

CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL.
001121 02-03

LOCALIZATION OF PHENOBARBITAL IN MOUSE CENTRAL-NERVOUS-SYSTEM BY IMMUNOFLUORESCENCE.
001327 02-03

EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
001329 02-03

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE.
001621 02-05

IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER.
001628 02-05

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
001648 02-06

DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY. A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
001787 02-10

MEASUREMENT OF DIPHENYLHYDANTOIN AND PHENOBARBITAL BY ENZYME IMMUNOASSAY AND GAS LIQUID CHROMATOGRAPHY.
001940 02-13

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
002282 03-03

EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-D3

THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
003047 04-01

INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT.
003135 04-03

CONVULSIONS INDUCED BY HYBERBARIC OXYGEN: INHIBITION BY PHENOBARBITAL, DIAZEPAM AND BACLOFEN.
003205 04-03

THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
D03209 D4-D3

DIFFERENTIAL INTERACTIONS OF PHENOBARBITAL AND PENTOBARBITAL WITH BETA-ADRENERGIC MECHANISMS IN VITRO AND VIVO.
003262 D4-03

PHENOBARBITAL DRINKING CURVES AFTER VARIED WATER DEPRIVATION
D0345B 04-04

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 D4-05

THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
DD3651 04-11

METABOLISM OF PHENOBARBITAL AND PHENYTOIN BY NEONATES WITH SEIZURES.
003697 04-13

INFLUENCE OF PHENOBARBITAL ON LIVER FUNCTION AND DRUG METABOLISM IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS.
D037D2 04-13

PHENOBARBITAL-INDUCED

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-D3

PHENOBARBITAL-INDUCED DRUG METABOLISM IN MAN.
DD3682 04-13

PHENOBARBITONE

PHENOBARBITONE FOR CONVULSIONS IN CHILDREN
DD0993 01-15

EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 D2-D3

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA-AMINOLAEVULINIC-ACID IN RATS.
003237 D4-03

PHENOBARBITONE-INDUCED

PHENOBARBITONE-INDUCED URINARY EXCRETIONS OF D-GLUCARIC-ACID AND 6BETA-HYDROXYCORTISOL IN MAN.
002822 03-13

PHENOLIC

THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE AND CATECHOLAMINES AND AN ASSESSMENT OF ZWITTERION CONSTANTS.
DD0001 D1-D1

PHENOLSULPHOTRANSFERASE

ANOMALOUS EFFECT OF PROBENECID ON RAT BRAIN PHENOLSULPHOTRANSFERASE.
00D193 01-03

PHENOMENA

PERSONALITY PREDISPOSITION AND EMERGENCE PHENOMENA WITH KETAMINE.
D00794 D1-12

MARIJUANA FLASHBACK PHENOMENA.
002D22 02-15

PERSISTENT PSYCHOTIC PHENOMENA FOLLOWING ONE DOSE OF PENTAZOCINE.
0D2D25 02-15

STUDIES WITH BROMOCRIPTINE: PART 1. ON-OFF PHENOMENA.
0026D0 03-D7

PHENOMENOLOGY

OBSERVATIONS ON THE PHENOMENOLOGY OF CONSCIOUSNESS CHANGE.
000797 01-12

PHENOMENOLOGY AND TREATMENT OF DEPRESSION.
003858 04-17

PHENOTHIAZINE

STUDY OF THE STABILITY OF PHENOTHIAZINE DERIVATIVES.
000005 01-01

A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
0DD530 01-08

CLINICAL STUDY AND EVALUATION OF A NEW DERIVATIVE OF PHENOTHIAZINE.
0D0547 01-08

CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE.
000977 01-15

THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001D04 01-16

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
0D1689 02-08

EPINEPHRINE NOT CONTRAINDICATED IN CARDIAC ARREST ATTRIBUTED TO PHENOTHIAZINE.
002008 02-15

PHENOTHIAZINE REACTION SIMULATING ACUTE CATATONIA.
D02072 02-15

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
0D2214 03-03

A MIRROR IMAGE OUTPATIENT STUDY AT A DEPOT PHENOTHIAZINE CLINIC.
002644 D3-08

PHENOTHIAZINE DEATH: AN UNUSUAL CASE REPORT.
00294B D3-15

QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003D53 04-01

CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01

PHENOTHIAZINE-INDUCED

TREATMENT OF PHENOTHIAZINE-INDUCED DYSKINESIA.
000493 D1-07

LOW URINARY DOPAMINE AND PREDICTION OF PHENOTHIAZINE-INDUCED PARKINSONISM: A PRELIMINARY REPORT.
DD0935 01-15

ANTICHOLINERGIC EXACERBATION OF PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL SYNDROME.
0D20D9 D2-15

PHENOTHIAZINE-INDUCED BULBAR PALSY-LIKE SYNDROME AND SUDDEN DEATH.
003B28 04-15

PHENOTHIAZINES

SOME OXIDATION PRODUCTS OF 2-SUBSTITUTED PHENOTHIAZINES.
001DB1 02-01

CHARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES AND RELATED DRUGS WITH LIPIDS BY UV-SPECTROPHOTOMETRY.
0025B3 03-06

THE BINDING OF PHENOTHIAZINES AND RELATED COMPOUNDS TO HUMAN SERUM ALBUMIN.
D02B2B 03-13

CLUBBING -- A SIDE-EFFECT OF LONG-TERM PHENOTHIAZINES TREATMENT.
0029D5 03-15

HYPOTHERMIC EFFECTS OF ANTIPSYCHOTIC PHENOTHIAZINES.
003335 04-03

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
0D3535 04-08

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
DD3545 D4-08

PHENOTROPIC

IMPROVED CLINICAL SCREENING OF PHENOTROPIC DRUGS.
0D1051 01-17

PHENOXYBENZAMINE

PHENOXYBENZAMINE IN ANOREXIA-NERVOSA.
0D1B04 02-10

PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
DD3142 D4-03

EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG
003275 04-03

ENPROCOUMON
STUDIES ON THE INTERACTION OF CHLORDIAZEPOXIDE, DIAZEPAM, AND NITRAZEPAM WITH PHENPROCOUMON.
001627 02-05

ENTERMINE
THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
001282 02-03

ENTOLAMINE
PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
003142 04-03

EFFECTS OF PHENTOLAMINE, PHENOXYBENZAMINE AND DESIPRAMINE ON CLONIDINE-INDUCED BLOCKADE OF CARDIAC ACCELERATION IN THE DOG.
003275 04-03

ENYLALANINE
CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE -- EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS.
000041 01-03

EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
000281 01-04

NYLALKYLAMINES
PHENYLALKYLAMINES WITH POTENTIAL PSYCHOTHERAPEUTIC UTILITY: 1. 2-AMINODIMETHOXYMETHPHENYLBUTANE.
001114 02-02

NYLETHYLAMINE
PHENYLETHYLAMINE EFFECTS IN RHESUS-MONKEYS (UNPUBLISHED PAPER).
000439 01-04

CHARACTERISATION OF THE MECHANISMS FOR HYPERACTIVITY INDUCTION FROM THE NUCLEUS-ACCUMBENS BY PHENYLETHYLAMINE DERIVATIVES.
001105 02-02

PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
003343 04-04

NYLETHYLAMINES
COMPARISON OF BEHAVIOR MAINTAINED BY INFUSIONS OF EIGHT PHENYLETHYLAMINES IN BABOONS.
001503 02-04

INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION.
003051 04-01

NYLISOPROPYLAMINES
PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES. 5. 4-ALKYL-2,5 DIMETHOXYPHENYLISOPROPYLAMINES.
000226 01-03

NYLPIPERIDINE
NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02

NYLTOLOXAMINE
ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

NYTOIN
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN-INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03

INFLUENCE OF DIAZEPAM AND PHENYTOIN ON PENICILLIN-INDUCED CEREBRAL CONVULSIONS.
000253 01-03

PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
000788 01-11

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
001648 02-06

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002826 03-13

THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
003209 04-03

PHENYTOIN AND CEREBELLAR LESIONS: SIMILAR EFFECTS ON CEREBRAL CATECHOLAMINE METABOLISM.
003283 04-03

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

PHENYTOIN AS A TREATMENT OF OBESITY ASSOCIATED WITH COMPULSIVE EATING.
003622 04-11

LITHIUM -- MECHANISM OF ACTION SIMILAR TO PHENYTOIN
003681 04-13

METABOLISM OF PHENOBARBITAL AND PHENYTOIN BY NEONATES WITH SEIZURES.
003697 04-13

PHEOCHROMOCYTOMA
CALCIUM UPTAKE INTO RAT PHEOCHROMOCYTOMA CELLS.
001165 02-03

PHOBIA
PSYCHOMYOCOLOGICAL STUDIES OF AMANITA -- FROM ANCIENT SACRAMENT TO MODERN PHOBIA.
001063 01-17

IMIPRAMINE AND PHOBIA.
003593 04-10

PHOBIC
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
000484 01-07

TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
000680 01-10

CLOMIPRAMINE IN PHOBIC AND OBSESSIONAL STATES: PRELIMINARY REPORT.
001789 02-10

TREATMENT OF PHOBIC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL.
001791 02-10

THE MANAGEMENT OF PHOBIC DISORDERS USING CLOMIPRAMINE (ANAFRANIL).
003608 04-10

PHOSPHATE
IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
001158 02-03

LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13

CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
002215 03-03

THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03

LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS.
002309 03-03

LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS.
002338 03-03

PHOSPHATIDYLCHOLINES
BIOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACEREBRALLY INJECTED CHOLINE.
001127 02-03

PHOSPHODIESTERASE
EFFECT OF SOME PHOSPHODIESTERASE INHIBITORS ON CENTRAL DOPAMINE MECHANISMS.
000100 01-03

INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02-03

EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX.
002264 03-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
002385 03-03

PHOSPHODIESTERASES
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
002358 03-03

PHOSPHOKINASE
CREATIVE PHOSPHOKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
002918 03-15

PHOSPHOLIPASE
PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03

PHOSPHOLIPID
EFFECTS OF PHOSPHOLIPID ADMINISTRATION ON ENDOGENOUS CEREBRAL PHOSPHOLIPID BIOSYNTHESIS.
000036 01-03

PHOSPHOLIPIDS
EFFECT OF HYPOTHALAMIC PHOSPHOLIPIDS ON PROLACTIN INCRETION.
0DD044 D1-03
EFFECTS OF GAMMA-AMINOBUTYRIC-ACID ON 33PI INCORPORATION INTO RAT BRAIN PHOSPHOLIPIDS IN VIVO.
003144 04-03

PHOSPHORUS
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
000058 01-03
EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING
003698 04-13

PHOSPHORYLATION
OXIDATIVE PHOSPHORYLATION IN VARIOUS PARTS OF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION
002321 03-03

PHOTICALLY
EFFECTS OF DRUGS MODIFYING BRAIN LEVELS OF CATECHOLAMINES ON PHOTICALLY INDUCED EPILEPSY IN PAPIO-PAPIO.
002431 03-04
INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
003306 04-03

PHOTOCHEMICAL
INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
002297 03-D3

PHOTOPERIODS
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN
000265 D1-03

PHOTOSENSITIVE
THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
D01294 D2-03
SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
0033D4 D4-03

PHOTOSTIMULATION
DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
00129D D2-D3

PHTHORACIZINE
SYMPATHOMIMETIC EFFECT OF SEROTONIN AND ACTION OF IMIPRAMINE AND PHTHORACIZINE ON THIS EFFECT.
0022D3 03-03
NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY.
DD2395 03-D3

PHYLOGENETIC
PHYLOGENETIC DISTRIBUTION OF A MORPHINE-LIKE PEPTIDE ENKEPHALIN
00DD15 01-01

PHYSICAL
INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
00D114 D1-D3
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
D0037D D1-D4
PHYSICAL DEPENDENCE ON OPIATE-LIKE PEPTIDES.
DDD447 D1-04
INDUCTION OF PHYSICAL DEPENDENCE IN RATS BY SHORT INTERVAL MEDICATION.
D0D471 01-D6
ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
DDD472 01-D6
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
00D826 D1-13
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
000827 01-13
THE EFFECTS OF ALCOHOL AND DELTA9-TETRAHYDROCANNABINOL ON HUMAN PHYSICAL AGGRESSION.
000924 01-14
AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-15
PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
001086 02-01
THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
0D1243 02-03
RELATIONSHIP BETWEEN PHYSICAL DEPENDENCE AND TOLERANCE OF MORPHINE IN THE RAT.
001482 02-04
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
002289 03-03
INVESTIGATION OF THE EFFECT OF NARCOTIC ANALGESICS (PHENANTHRENE DERIVATIVES) ON PHYSICAL CHEMICAL PROPERTIES OF NUCLEIC-ACIDS.
002327 03-03
CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03
CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN
0D2616 03-08
MARIHUANA AND HUMAN PHYSICAL ACTIVITY.
002850 D3-14
THE PHYSICAL AND BEHAVIOURAL COMPLEX OF DEMENTIA
003893 04-17

PHYSICIAN
DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
001787 D2-10
PRESCRIPTION OF AN ANTIDEPRESSANT AND THE PHYSICIAN PATIENT RELATIONSHIP.
002154 02-17
VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
0D3588 04-10
ANTIPSYCHOTIC DRUG USE: PHYSICIAN PRESCRIBING PRACTICES IN RELATION TO CURRENT RECOMMENDATIONS.
003896 04-17
COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003897 D4-17

PHYSICIANS
PSYCHIATRISTS, PHYSICIANS AND THE CIA DRUG PROGRAM.
00D521 01-07
GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11
PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE
0D3D19 03-17

PHYSIOLOGIC
SUBJECTIVE AND PHYSIOLOGIC EFFECTS OF MORPHINE, PENTOBARBITAL, AND MEPROBAMATE.
000761 D1-11
SOMATOSTATIN IN THE PHYSIOLOGIC FEEDBACK CONTROL OF THYROTROPIN SECRETION
001396 02-03

PHYSIOLOGICAL
INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
00DD79 01-03
CLINICAL PHYSIOLOGICAL STUDY OF DRUGS FOR THE TREATMENT OF PSYCHOSES
DD0653 01-09
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION.
DD0875 01-14
NALTREXONE: PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF SINGLE DOSES.
000951 01-15
PHYSIOLOGICAL DEPENDENCE ON, AND SYMPTOMS OF WITHDRAWAL FROM, CHLORMETHIAZOLE.
DDD981 01-15

INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04

ACTION OF PSYCHOLEPTICS ON SOME PHYSIOLOGICAL INDICES IN STUTTERERS.
001958 02-14

ALCOHOL AND TENSION REDUCTION COGNITIVE AND PHYSIOLOGICAL EFFECTS.
001984 02-14

PERIODIC STRUCTURE OF PHYSIOLOGICAL AND PATHOLOGICAL TREMOR
002089 02-16

CONDITIONED BEHAVIORAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INJECTIONS OF A NARCOTIC ANTAGONIST IN MORPHINE-DEPENDENT MONKEYS.
002456 03-04

AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17

THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION
003341 04-04

THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

DRUG METABOLISM UNDER PATHOLOGICAL AND ABNORMAL PHYSIOLOGICAL STATES IN ANIMALS AND MAN
003878 04-17

YSIOLOGY

CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
00281B 03-13

YSOSTIGMINE

INFLUENCE OF PHYSOSTIGMINE UPON CONSOLIDATION OF MEMORY IN MICE.
000425 01-04

EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON TONIC IMMOBILITY IN DUCKS AND GUINEA-PIGS.
000453 01-04

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03

PHYSOSTIGMINE EFFECTS ON ACTIVITY AND REACTIONS TO NOVELTY.
001516 02-04

REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
0015B0 02-04

ORPHENADRINE OVERDOSE TREATED WITH PHYSOSTIGMINE.
001B0B 02-10

PHYSOSTIGMINE: EFFECTS ON COGNITION AND AFFECT IN NORMAL SUBJECTS.
001965 02-14

REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
00204B 02-15

CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE.
002078 02-15

A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04

TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002879 03-14

PHYSOSTIGMINE TREATMENT OF DELIRIUM INDUCED BY ANTICHOLINERGICS.
002903 03-15

PHYSOSTIGMINE IN FAMILIAL ATAXIAS.
003627 04-11

IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-13

PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSES IN MAN.
003708 04-13

STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE
003725 04-14

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

PICA

POISON-INDUCED PICA IN RATS.
001633 02-05

PICROTOXIN

EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN.
002247 03-03

EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS: V. EFFECTS OF PICROTOXIN AND AMINOOXYACETIC-ACID.
002473 03-04

PICTURES

INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000876 01-14

PIERIS-BRASSICAE

METABOLISM OF FLUORINATED MESCALINS BY PIERIS-BRASSICAE (INSECT, LEPIDOPTERA).
0030B3 04-03

PIF

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-03

PIG

INTERACTION OF SERYLTRIHYDROXYBENZYLHYDRAZINE WITH L-DOPA-DECARBOXYLASE FROM PIG KIDNEY.
003103 04-03

PIGEON

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04

THE EFFECTS OF CHRONIC MESCALINE ADMINISTRATION ON OPERANT BEHAVIOR IN THE PIGEON.
001505 02-04

PIGEONS

THE EFFECT OF ACUTE METHADONE ON FIXED-INTERVAL SCHEDULES OF REINFORCEMENT IN PIGEONS. (PH.D. DISSERTATION).
000375 01-04

EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
001507 02-04

INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-04

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

PARGYLINE-INDUCED INCREASES IN SENSITIVITY TO THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR IN PIGEONS.
003361 04-04

ANTAGONISM OF ETONITAZENES EFFECTS IN RATS AND PIGEONS.
0033B1 04-04

THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS AND RHESUS-MONKEYS.
003406 04-04

THE EFFECTS OF D-AMPHETAMINE ON THE AUTOMAINTAINED KEY PECKING OF PIGEONS.
003441 04-04

PIGMENTATION

SURMONTIL AND MUCO-CUTANEOUS PIGMENTATION.
002B9B 03-15

BLUE SKIN PIGMENTATION AND CHLORPROMAZINE.
003792 04-15

PIGS

EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEDULE.
001467 02-04

EFFECTS OF DIAZEPAM ON EXPLORATORY BEHAVIOR OF PIGS.
003369 04-04

EFFECTS OF DIAZEPAM ON BEHAVIOUR SUPPRESSED BY EXTINCTION IN PIGS.
003370 04-04

PIGTAIL

EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEY.
000064 01-03

PILL
THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
001647 D2-06
DREAM RECALL AND THE CONTRACEPTIVE PILL.
002875 03-14

PILOCARPINE
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
D00482 01-D7
EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04
DRINKING INDUCED BY PARENTERAL INJECTIONS OF PILOCARPINE.
002449 03-04
THE INTERACTION BETWEEN PILOCARPINE AND HEXOBARBITAL IN MALE RATS.
002551 03-04
EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
0031B9 04-03

PILOT
PILOT OPEN LABEL STUDY WITH ALPRAZOLAM (U31889) IN OUTPATIENTS WITH NEUROTIC DEPRESSION.
000682 01-10
EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02-07
THE EFFECT OF CLOMIPRAMINE ON PROLACTIN LEVELS -- PILOT STUDIES.
001745 02-D9
COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA -- A PILOT EXPERIMENT.
001864 02-11
MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001877 02-12
ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-13
LITHIUM IN ADULT ANOREXIA-NERVOSA: A PILOT REPORT ON TWO PATIENTS.
0D3610 04-11
PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-318B9) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
D03617 04-11
DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY: A PILOT STUDY.
00377D 04-15
CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
D03891 04-17

PIMOZIDE
CLINICAL STUDY OF PIMOZIDE WITH CHRONIC SCHIZOPHRENICS.
D00565 01-08
PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 D1-10
APPLICATION OF THE NEUROLEPTIC PIMOZIDE (ORAP-R-6238) FOR TRANQUILIZER INDICATIONS IN A CONTROLLED STUDY.
DD0701 01-1D
NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
001198 D2-03
EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012BB D2-03
HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
DD1946 D2-13
A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 D3-08
CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA.
DD2645 D3-08
PIMOZIDE VERSUS FLUPHENAZINE IN AMBULATORY SCHIZOPHRENICS: A 12-MONTH COMPARISON STUDY.
003534 04-08
COMPARISON OF PIMOZIDE WITH HALOPERIDOL IN GILLES-DE-LA-TOURETTE SYNDROME.
003641 04-11
EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14

PINAZEPAM
EXPERIMENTAL CLINICAL USE OF PINAZEPAM IN PSYCHOSOMATIC MEDICINE.
D00673 01-1C

PINCH-INDUCED
ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
DD3454 D4-04

PINCHED-OFF
THE EFFECTS OF HARMALINE ON GABA FLUXES IN PINCHED-OFF NERVE ENDINGS.
001409 02-03

PINDOLOL
CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
00D746 01-1

PINEAL
HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
0D0176 01-0
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
000265 01-0
CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION. (UNPUBLISHED PAPER).
001313 02-0
EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-0
REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-0

PIPAMPERONE
PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION.
001825 02-1
SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
D03549 04-0

PIPERACETAZINE
PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE: A CONTROLLED DOUBLE-BLIND STUDY.
00259B 03-0

PIPERAZINES
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-0

PIPERIDINE
PIPERIDINE: EFFECTS ON LOCOMOTOR ACTIVITY AND BRAIN MONOAMINE TURNOVER.
001122 02-0

PIPERIDINETHIAZOLE
(SPIRO(PIPERIDINETHIAZOLE) 3,2-A)PYRIMIDINES): ANTIDEPRESSANTS AND PLATELET-AGGREGATION INHIBITORS.
0D1116 02-0

PIPEROXANE
NORADRENERGIC NEURONS OF THE LOCUS-COERULEUS: INHIBITION BY EPINEPHRINE AND ACTIVATION BY THE ALPHA-ANTAGONIST PIPEROXANE.
001164 02-0
PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
D03142 04-0

PIPORTIL
CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA.
D02645 03-0

PIPORTYL-PALMITATE
TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
D01668 02-0

PIPOTIAZINE-PALMITATE
THERAPEUTIC EVALUATION OF PIPOTIAZINE PALMITATE IN A GROUP OF SCHIZOPHRENICS.
001707 02-08
EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14
PIPOTIAZINE-PALMITATE IN CHRONIC SCHIZOPHRENIA.
002615 03-08
USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY.
002628 03-08

PIRACETAM
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03
PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
001308 02-03
EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03
DOSE EFFECT RELATIONSHIP IN TREATMENT WITH PIRACETAM.
001835 02-11
PIRACETAM: NOOTROPIC PHARMACOLOGY OF NEUROINTEGRATIVE ACTIVITY.
002454 03-04
EFFICACY OF PIRACETAM ON MENTAL FUNCTIONAL CAPACITY OF CHRONIC ALCOHOLICS.
002968 03-17
EFFECT OF PIRACETAM ON PSYCHOORGANIC SYNDROMES OF OLD PEOPLE.
003526 04-07
EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A DOUBLE-BLIND STUDY IN HEALTHY PROBANDS.
003755 04-14

PIRACETAM-INDUCED
PIRACETAM-INDUCED IMPROVEMENT OF MENTAL PERFORMANCE: A CONTROLLED STUDY ON NORMALLY AGING INDIVIDUALS.
001845 02-11

PIRASIDOL
ELECTROENCEPHALOGRAPHIC ANALYSIS OF THE CENTRAL EFFECT OF PIRASIDOL.
002349 03-03

PIRIBEDIL
PIRIBEDIL IN THE TREATMENT OF PARKINSONS DISEASE.
000848 01-13
DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03

PITUITARY
PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03
DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
000186 01-03
5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04
EFFECTS OF FLURAZEPAM (DALMANE) ON ANTERIOR PITUITARY SECRETION.
000877 01-14
TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
001148 02-03
MORPHINE-LIKE ANALGESIC EFFECT OF A PITUITARY HORMONE, BETA-LIPOTROPIN.
001344 02-03
OPIOID PEPTIDES (ENDORPHINS) IN PITUITARY AND BRAIN.
001496 02-04
EFFECTS OF CLOPREDNOL AND OTHER CORTICOSTEROIDS ON HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION.
001934 02-13
EFFECTS OF ERGOT ALKALOIDS ON THE HYPOTHALAMIC PITUITARY AXIS.
002239 03-03
THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03
EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
002384 03-03
NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS-ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03
ENDORPHIN FROM PITUITARY INHIBITS CYCLIC-AMP FORMATION IN HOMOGENATES OF NEUROBLASTOMA X GLIOMA HYBRID CELLS.
003155 04-03
OPIATE RECEPTOR BINDING IN THE PITUITARY GLAND.
003279 04-03
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

PKA
MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01

PLACEBO
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07
LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08
A PLACEBO CONTROLLED TRIAL OF DIAZEPAM AND OXPRENOLOL FOR ANXIETY.
000677 01-10
PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10
RIPAZEPAM (CI-6B3) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10
THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
00087B 01-14
A DOUBLE-BLIND TRIAL OF BACLOFEN AGAINST PLACEBO IN THE TREATMENT OF SCHIZOPHRENIA.
001664 02-07
DOUBLE-BLIND CLINICAL STUDY OF CARPIPRAMINE/PLACEBO.
001688 02-08
EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 02-09
ANTIANXIETY EFFECTS OF TRAZODONE (A DOUBLE-BLIND STUDY WITH DIAZEPAM AND PLACEBO).
001B06 02-10
AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE: A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO.
00181B 02-11
AN EVALUATION OF THE DOUBLE-BLIND DESIGN IN A STUDY COMPARING LITHIUM CARBONATE WITH PLACEBO.
001842 02-11
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001843 02-11
COGNITIVE DISSONANCE IN THE PLACEBO TREATMENT OF INSOMNIA -- A PILOT EXPERIMENT.
001864 02-11
A COMPARATIVE EVALUATION OF THE ANTIPSORIATIC EFFECT OF L-DOPA VERSUS PLACEBO IN PSORIASIS.
001938 02-13
EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 02-14
DISULFIRAM IMPLANTATION: PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS.
002003 02-14
A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14
DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11
EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002B30 03-13
PLACEBO METHODS.
002993 03-17

DIFFERENCES IN PLACEBO EFFECTS.
003515 04-06

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-08

TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
003541 04-08

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
003589 04-10

CONTROLLED COMPARISON OF BROMAZEPAM, AMITRIPTYLINE, AND PLACEBO IN ANXIETY DEPRESSIVE NEUROSIS.
003602 04-10

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
003634 04-11

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

A MULTICENTRE STUDY COMPARING MAZINDOL AND PLACEBO IN OBESE PATIENTS.
003648 04-11

EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

PLACENTAL

PLACENTAL TRANSFER OF CENTRAL-NERVOUS-SYSTEM DEPRESSANTS IN SHEEP.
000464 01-05

THE PLACENTAL TRANSFER OF DRUGS DURING CHILDBIRTH: A POSSIBLE INFLUENCE ON THE NEWBORN.
001892 02-13

REGULARITIES IN PENETRATION OF THE PLACENTAL BARRIER BY AMINAZINE.
002576 03-05

PLANNING

THE PLANNING OF A THERAPEUTIC COMPARISON IN PSYCHOPHARMACOLOGY.
001077 01-17

DIAGNOSIS IN PLANNING PSYCHOPHARMACOLOGICAL THERAPY.
002099 02-17

PLANT

INDOLE ALKALOIDS IN PLANT HALLUCINOGENS.
001073 01-17

PLANTAR

EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY.
000999 01-15

PLANTS

CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
001084 02-01

PLASMA

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03

PLASMA LEVELS OF CLOMIPRAMINE AND ITS N-DESMETHYL METABOLITE FOLLOWING ORAL ADMINISTRATION OF CLOMIPRAMINE IN MAN.
000136 01-03

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 01-05

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
000468 01-06

QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-06

PLASMA PROLACTIN CONCENTRATIONS IN PATIENTS ON CLOMIPRAMINE.
000586 01-09

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
000593 01-09

PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS
000610 01-09

THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09

THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS
000628 01-09

THE EFFECT OF PLASMA AMINO-ACIDS ON DEPRESSION
000637 01-09

THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS.
000655 01-09

PLASMA AND ERYTHROCYTE CONCENTRATIONS OF LITHIUM.
000722 01-10

A NOTE ON THE ASSAY OF CHLORPROMAZINE-N-OXIDE AND ITS SULPHOXIDE IN PLASMA AND URINE.
000811 01-13

STUDY OF FREE AND TOTAL TRYPTOPHAN IN PLASMA. ITS INTEREST IN PSYCHIATRY
000815 01-13

MONITORING PLASMA CONCENTRATIONS OF NEUROLEPTICS.
000837 01-13

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS
000861 01-13

HUMAN AND ANIMAL STUDY ON ELIMINATION FROM PLASMA AND METABOLISM OF DIAZEPAM AFTER CHRONIC ALCOHOL INTAKE.
000863 01-13

REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000864 01-13

PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
000868 01-13

PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSED WOMEN
000994 01-15

GAS CHROMATOGRAPHIC METHODS FOR THE STUDY OF CHLORPROMAZINE AND SOME OF ITS METABOLITES IN HUMAN PLASMA.
001003 01-16

GLC DETERMINATION OF DOXEPIN PLASMA LEVELS.
001009 01-16

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03

COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
00122B 02-03

THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03

LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03

RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART.
001749 02-09

CORRELATION BETWEEN PLASMA AND CEREBROSPINAL LEVELS OF IMIPRAMINE
001775 02-09

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS
001862 02-11

ANTIPSYCHOTIC EFFECTIVENESS IN RELATION TO PLASMA LEVEL OF CLOZAPINE
001878 02-13

THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001889 02-13

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001898 02-13

INFLUENCE OF CANNA8IDIOL ON SECO8AR8ITAL EFFECTS AND PLASMA KINETICS.
001902 02-13

DISTRIBUTION OF LITHIUM 8ETWEEN ERYTHROCYTES AND PLASMA: IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES.
001915 02-13

PHARMACOKINETICS AND PLASMA 8INDING OF DIAZEPAM IN MAN, DOG, RAB8IT, GUINEA-PIG AND RAT.
001921 02-13

PLASMA LEVELS OF IMIPRAMINE IN DEPRESSION: ENVIRONMENTAL AND GENETIC FACTORS.
001935 02-13

PHARMACOKINETICS OF LITHIUM IN HUMAN PLASMA AND ERYTHROCYTES.
001936 02-13

A MASS FRAGMENTOGRAPHIC METHOD FOR THE DETERMINATION OE CHLORPROMAZINE AND TWO OF ITS ACTIVE METABOLITES IN HUMAN PLASMA AND CSF.
002086 02-16

EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
002222 03-03

L-DOPA: PLASMA PHARMACOKINETICS AND CONVERSION TO DOPAMINE IN BRAIN. (PH.D. DISSERTATION).
002233 03-03

DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATIONS IN PLASMA: EXPERIMENTAL AND ESSENTIAL HYPERTENSION. (UNPUBLISHED PAPER
002254 03-03

EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03

PENELURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08

THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OE RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-0B

TOTAL AND EREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AEFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1R8.
002672 03-09

NORTRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.
002708 03-09

PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10

ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS.
002755 03-11

EFFECT OF CHLOROTHIAZIDE ON THE PHARMACOKINETICS OF LITHIUM IN PLASMA AND ERYTHROCYTES.
002B29 03-13

DETERMINATION OF LORAZEPAM IN PLASMA BY ELECTRON CAPTURE GLC.
002955 03-16

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

EFFECTS OF LEVODOPA AND DOPAMINE ON PLASMA GLUCOSE CONCENTRATION IN MICE.
003121 04-03

EFEECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-03

EFFECT OF GAMMA-BUTYROLACTONE AND BACLOEEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03

EEFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03

CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
00354B 04-0B

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

CLINICAL IMPLICATIONS OF IMIPRAMINE PLASMA LEVELS FOR DEPRESSIVE ILLNESS.
003560 04-09

MASS FRAGMENTOGRAPHIC ANALYSIS OF CLOMIPRAMINE AND ITS MONODEMETHYLATED METABOLITE IN HUMAN PLASMA.
003653 04-13

REDUCTION IN PLASMA NOREPINEPHRINE DURING FENFLURAMINE TREATMENT.
003666 04-13

ANTIDEPRESSANT PLASMA LEVELS.
003674 04-13

PLASMA LEVEL STUDIES WITH CLOMIPRAMINE (ANAFRANIL).
003679 04-13

FACTORS INELUENCING PLASMA DRUG CONCENTRATIONS.
003685 04-13

ON THE SIGNIFICANCE OF THE ERYTHROCYTE LITHIUM TO PLASMA LITHIUM RATIO.
003686 04-13

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

PLASMA NORTRIPTYLINE LEVELS AND ECG FINDINGS.
003723 04-13

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
003807 04-15

LITHIUM SIDE-EFFECTS IN RELATION TO DOSE AND TO LEVELS AND GRADIENTS OF LITHIUM IN PLASMA.
003B15 04-15

A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003B66 04-17

PLASMA-TRYPTOPHAN

TOTAL AND NONBOUND PLASMA-TRYPTOPHAN IN DEPRESSIVE ILLNESS.
003663 04-13

PLASTICITY

BIOCHEMICAL PLASTICITY OF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001351 02-03

PLATEAU

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY IN THE MID-SEVENTIES: PROGRESS OR PLATEAU?.
00303B 03-17

PLATELET

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

THE EFFECTS OF ADRENALINE INJECTIONS ON HUMAN PLATELET MONOAMINE-OXIDASE AND RELATED MEASURES.
000491 01-07

BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS.
000568 01-0B

LOW PLATELET MONOAMINE-OXIDASE ACTIVITY AND SCHIZOPHRENIA.
000576 01-08

PLATELET UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN DEPRESSION.
000612 01-09

ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
002014 02-15

PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA: AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
0026B8 03-09

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING THE ADDITION OE THROMBIN AND A23187. (UNPUBLISHED PAPER).
002B04 03-13

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
00292B 03-15

PLATELET MONOAMINE-OXIDASE ACTIVITY IN SCHIZOPHRENIC PATIENTS.
00365B 04-13

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

PLATELET-AGGREGATION

(SPIRO(PIPERIDINETHIAZOLE) 3,2-A)PYRIMIDINES): ANTIDEPRESSANTS AND PLATELET-AGGREGATION INHIBITORS.
001116 02-02

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLODD PLATELET-AGGREGATION.
002429 03-04

PLATELETS

COMPARISON OF THE INHIBITION OF 5-HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
000933 01-15

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-15

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-06

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITIDN DF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE 8Y HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION. A COMPARATIVE KINETIC ANALYSIS.
002846 03-13

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
003241 04-03

EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE OF (3H)5-HYDROXYTRYPTAMINE 8Y HUMAN 8LDOD PLATELETS.
003715 04-13

PLEXUS

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03

ASPECTS OF OPIATE DEPENDENCE IN THE MYENTERIC PLEXUS OF THE GUINEA-PIG.
000222 01-03

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

PMA

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
0012B2 02-03

PNMT

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND 8RAINSTEM DF RATS.
000155 01-03

POISON-INDUCED

POISON-INDUCED PICA IN RATS.
001633 02-05

POISONED

ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM OF RABBITS PDISONED WITH METHYLMERCURY.
003500 04-05

POISONING

ANTAGONISM OF IMIPRAMINE POISONING BY ANTICONVULSANTS IN THE RAT.
000455 01-05

DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15

ACCIDENTAL BENALGIN POISONING.
000979 01-15

ACCIDENTAL LITHIUM POISONING IN A CHRONICALLY HEMODIALYZED PATIENT.
001001 01-15

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATIDN. REPORT OF A CONTROLLED CLINICAL TRIAL.
001839 02-11

PARAQUAT POISONING.
002012 02-15

SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002039 02-15

SDDIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002067 02-15

CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE.
00207B 02-15

WATER POISONING AND DIA8ETES-INSIPIDUS: A PROPDS COMPULSIVE WATER DRINKING AND DYSTHYMIA.
002717 03-10

CREATIVE PHOSPHDKINASE ACTIVITY AND ACID BASE BALANCE IN CEREBROSPINAL FLUID AFTER POISONING WITH HYPNOTICS (ETHINAMATE).
002918 03-15

DATURA POISONING.
003777 04-15

DISULFIRAM TOXICITY AND CARBON-DISULFIDE PDISONING.
003819 04-15

POISONINGS

EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE.
001637 02-05

POLAROGRAPHY

THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BA8OONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03

POLYCHLORINATED

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

POLYCYCLIC

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
003058 04-01

PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITIDN AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01

POLYDIPSIA

POLYDIPSIA, HYPONATREMIA, AND SEIZURES IN PSYCHOTIC PATIENTS.
000968 01-15

INTERACTIONS BETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 02-04

DRUG-INDUCED HYPONATREMIA IN PSYCHOGENIC POLYDIPSIA.
002902 03-15

POLYDRUG

A NEUROPSYCHOLOGICAL STUDY OF POLYDRUG USERS.
000894 01-14

NEUROPSYCHOLOGICAL AND EEG DISTURBANCES IN POLYDRUG USERS.
002044 02-15

POLYETHYLENE-GLYCOL

POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

POLYGRAPHIC

STATISTICAL EVALUATION OF POLYGRAPHIC INVESTIGATIONS OF PENTOXIFYLLINE.
000830 01-13

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS BEFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-OXIDE.
001794 02-10

PDLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH.
00197B 02-14

POLYGRAPHIC SLEEP RECORDINGS BEFORE AND AFTER THE ADMINISTRATION OF FLUNITRAZEPAM.
003626 04-11

POLYMORPHIC

PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBDXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
001086 02-01

POLYPHARMACY

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATIDN HOSPITALS.
000772 01-11

POLYPHYSIOGRAPHIC

THERAPEUTIC EFFECTS OF TAURINE IN EPILEPSY: A CLINICAL AND PDLYPHYSIOGRAPHIC STUDY.
000760 01-11

POLYURIA

EFFECT OF POTASSIUM ON LITHIUM-INDUCED GROWTH RETARDATION AND POLYURIA IN RATS.
000189 01-03

A CASE WHERE ADMINISTRATION OF LITHIUM CARBONATE CAUSED POLYURIA.
002938 03-15

ONTINE
STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE
002580 03-05

ONTO-GENICULO-OCCIPITAL
MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
000108 01-03
EFFECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS.
003350 04-04

OLS
METAL CHELATES OF L-DOPA FOR IMPROVED REPLENISHMENT OF DOPAMINERGIC POOLS.
001090 02-01

PPER
THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
001647 02-06

PULATION
A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION.
000624 01-09
THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-14

PULATIONS
THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04-03

RCINE
HUMAN ENDORPHIN. COMPARISON WITH PORCINE ENDORPHIN, ENKEPHALIN AND NORMORPHINE.
000006 01-01

RTAFEMORAL
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
003138 04-03

RTASYSTEMIC
SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY.
003635 04-11

SITION
EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
003474 04-04

SITIVE
RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002B60 03-14
A POSITIVE RESPONSE TO RAPID TREATMENT.
003532 04-08

OLOGICAL
POSOLOGICAL AND CLINICAL STUDY OF MAPROTILINE, A NEW DRUG WITH ANTIDEPRESSANT ACTION
001677 02-07

T-ADDICT
INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04

T-DECAPITATION
CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

T-DETOXIFICATION
POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSION IN ALCOHOL ADDICTS.
000742 01-11

POST-DOPAMINE
POST-DOPAMINE ISCHEMIA TREATED WITH CHLORPROMAZINE
002080 02-15

POSTANOXIC
BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13

POSTERIOR
EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

POSTICTAL
DISCRIMINABILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04

POSTJUNCTIONAL
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03
PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
000418 01-04

POSTNATAL
INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT.
003135 04-03

POSTOPERATIVE
INTRAMUSCULAR BUTORPHANOL AND MEPERIDINE IN POSTOPERATIVE PAIN.
001662 02-07

POSTPARTUM
CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CARBONATE.
000709 01-10
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04
EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER.
003484 04-04

POSTPONEMENT
EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04
POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03
EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

POSTPSYCHOTIC
A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR.
001703 02-08

POSTSYNAPTIC
CNS DEPRESSANTS: EFFECTS ON POSTSYNAPTIC PHARMACOLOGY.
000043 01-03
DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03
PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
00133B 02-03
INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03
PENICILLIN AND PENTYLENETETRAZOL SELECTIVELY ANTAGONIZE GABA-MEDIATED POSTSYNAPTIC INHIBITION OF CULTURED MAMMALIAN NEURONS.
003210 04-03
ANTICONVULSANT ACTION OF DIAZEPAM: INCREASE OF CORTICAL POSTSYNAPTIC INHIBITION.
003246 04-03
PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION
003343 04-04

POSTTRAUMATIC
TREATMENT OF CHRONIC POSTTRAUMATIC ORGANIC-BRAIN-SYNDROME WITH DEXTROAMPHETAMINE: FIRST REPORTED CASE.
000904 01-14

POSTTREATMENT
ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

POSTTRIAL
DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
000348 01-04
RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03
EFFECTS OF POSTTRIAL HORMONE INJECTIONS ON MEMORY PROCESSES.
002455 03-04
EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

POTASSIUM
EFFECT OF POTASSIUM ON LITHIUM-INDUCED GROWTH RETARDATION AND POLYURIA IN RATS.
000189 01-03
VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE.
000702 01-10
LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03
ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03
INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

POTASSIUM-INDUCED
PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 02-03

POTENCIES
A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

POTENCY
STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY
001909 02-13
STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03
HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
003684 04-13

POTENT
BICYCLIC PHOSPHORUS ESTERS THAT ARE POTENT CONVULSANTS AND GABA ANTAGONISTS.
000058 01-03
BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION.
001118 02-02
HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY
001339 02-03
D-ALA2-MET-ENKEPHALINAMIDE: A POTENT, LONG-LASTING SYNTHETIC PENTAPEPTIDE ANALGESIC.
002193 03-02
BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-03
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN
00235B 03-03
ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
002480 03-04
NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01
DIMETHYLBIS PHENYLACETYL-DIAZATETRACYCLODODECANE, A POTENT, NOVEL ANALGESIC.
003063 04-02
9 NOR 9BETA HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03
EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-03
A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS.
003426 04-04

POTENTIAL
POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01
SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03
METABOLISM IN VITRO OF POTENTIAL APOMORPHINE PRODRUGS.
000229 01-03
RESEARCH IN THE BENZOFURAN SERIES LVII. BENZOFURYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIDEPRESSANTS.
000275 01-04
ARYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIAGGRESSIVES.
000276 01-04
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07
THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
000652 01-09
MAMMALIAN BIOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
000793 01-1
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
0009B3 01-1
PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
001086 02-0
SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
001108 02-0
PHENYLALKYLAMINES WITH POTENTIAL PSYCHOTHERAPEUTIC UTILITY: 1. 2-AMINODIMETHOXYMETHPHENYLBUTANE.
001114 02-0
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-0
POTENTIAL CENTRAL-NERVOUS-SYSTEM ANTITUMOR AGENTS. AZIRIDINYLBENZOQUINONES. 2.
001656 02-0
MONOAMINE-OXIDASE INHIBITORS: POTENTIAL FOR DRUG ABUSE.
001B76 02-1
THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL.
001941 02-1
SYNTHESIS OF POTENTIAL MESCALINE ANTAGONISTS.
002190 03-0
DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-0
MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
002368 03-0
CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA
002617 03-0
EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002817 03-1
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMEN IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002B63 03-1
MAO INHIBITORS: POTENTIAL FOR DRUG ABUSE. (UNPUBLISHED PAPER)
002876 03-1
POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-0
EFFECTS OF ALKYLTETRAHYDROCARBAZOLE-ETHANAMINES AND RELATED COMPOUNDS, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-0
IN VITRO STUDIES OF SOME CHLORPROMAZINE METABOLITES AS POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
003265 04-0

CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
003520 04-07

POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW 8UTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
003848 04-17

POTENTIALS

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SU8CORTICAL 8RAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

INHI8ITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-03

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CERE8ELLUM.
001306 02-03

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

CLASSIFICATION OF PSYCHOACTIVE DRUGS 8Y VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

EFFECTS OF ETHANOL ON SCALP VISUAL EVOKED POTENTIALS.
D01948 D2-13

PHARMACOLOGICAL STUDY OF EVOKED POTENTIALS IN THE OLFACTORY BULB.
002361 03-03

CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
0D2366 03-D3

EFFECTS OF BENZODIAZEPINES ON EVOKED POTENTIALS INDUCED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS IN THE CAT 8RAIN.
002386 03-D3

EFFECTS OF BENZODIAZEPINES AND PENTOBARBITAL ON THE EVOKED POTENTIALS IN THE CAT BRAIN.
002387 03-D3

EVOKED POTENTIALS IN HYPERKINETIC AND NORMAL CHILDREN UNDER CERTAINTY AND UNCERTAINTY: A PLACEBO AND METHYLPHENIDATE STUDY.
002B30 D3-13

EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
003242 04-03

INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON PHOTICALLY EVOKED AFTER-DISCHARGE POTENTIALS.
0033D6 04-03

EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
D03474 04-04

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
DD3894 04-17

OTENTIATED

KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 D2-03

OTENTIATES

P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 D1-03

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-D3

OTENTIATING

NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 D1-D2

POTENTIATING EFFECT OF LITHIUM-CHLORIDE ON METHAMPHETAMINE-INDUCED STEREOTYPY IN MICE.
003438 04-04

OTENTIATION

ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 D1-03

POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
D00209 D1-03

POTENTIATION OF MORPHINE-INDUCED SEIZURE BY 6-HYDROXYDOPAMINE.
001133 02-03

POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE 8Y LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

POTENTIATION OF EFFECTS OF CATECHOLAMINES AND SYMPATHETIC STIMULATION BY TRIAZOLO8ENZODIAZEPINE.
002245 03-03

POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

POTENTIATION OF THE ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
002844 03-13

3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
0D3079 D4-03

POTENTIATION OF MORPHINE ANALGESIA BY MUSCIMOL.
DD3354 D4-04

POWER

INCREASE IN THE POWER OF HUMAN MEMORY IN NORMAL MAN THROUGH THE USE OF DRUGS.
001967 02-14

DIAZEPAM: RADIOPROTECTIVE ACTION AND EFFECT ON TOXICITY AND RADIOPROTECTIVE POWER OF CYSTEAMINE.
D03139 04-D3

PRACTITIONER

ADMINISTRATION OF PSYCHOTROPIC DRUGS FROM THE STANDPOINT OF THE GENERAL PRACTITIONER.
D01071 01-17

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
0D3B07 04-15

PRACTITIONERS

THE PRACTITIONERS GUIDE TO PSYCHOACTIVE DRUGS.
0021D3 D2-17

GENERAL PRACTITIONERS PRESCRIBING HABITS FOR PATIENTS WITH DEPRESSION
003B86 04-17

PRACTOLOL

BILIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN
0DD80B 01-13

COMPLICATIONS AND SIDE-EFFECTS IN LONG-TERM TREATMENT WITH PRACTOLOL.
0D0931 D1-15

ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
002323 03-03

PRAZEPAM

A PHARMACOLOGICAL INVESTIGATION INTO THE CENTRAL NERVOUS ACTION OF PRAZEPAM.
0D2536 03-04

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
0035B9 04-1D

PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003597 04-10

PRAZEPAM IN ANXIETY: A CONTROLLED CLINICAL TRIAL.
003599 04-10

PRAZOSIN

EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION
003742 04-14

PREANESTHETIC

LORAZEPAM IS A SATISFACTORY PREANESTHETIC SEDATIVE IF USED WITH CARE.
002743 03-11

PRECIPITATE

RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
0D0341 01-D4

PRECIPITATED
ATTENUATION OF PRECIPITATED A8STINENCE IN METHADONE-DEPENDENT RATS 8Y DELTA9-TETRAHYDROCANNA8INOL.
000310 01-04
CIRCLING 8EHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04
CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNA8INOL.
001208 02-03
EFFECT OF SOME CANNABINOIDS ON NALOXONE PRECIPITATED ABSTINENCE IN MORPHINE-DEPENDENT MICE.
001445 02-04
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04
DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
003086 04-03
ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03
NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14

PRECIPITATION
POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13
PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE.
001604 02-04

PRECURSOR
EFFECT OF L-DOPA ON SEROTONIN META8OLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
002284 03-03
DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-04

PRECURSORS
BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13
EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN.
003204 04-03
BIOGENIC AMINE PRECURSORS AND AFFECTIVE ILLNESSES.
003551 04-09
VERIFICATION OF THE MA HYPOTHESIS WITH THE AID OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 04-14

PREDATORY
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04
LONG-TERM EFFECTS OF EARLY ETHANOL ON PREDATORY BEHAVIOR IN INBRED MICE.
001609 02-04
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04
INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04

PREDICTED
COMPARISON OF OBSERVED AND PREDICTED FIRST-PASS METABOLISM OF IMIPRAMINE IN HUMANS.
000850 01-13

PREDICTING
PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS.
000024 01-02
PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07
CLASSIFICATION OF PSYCHOACTIVE DRUGS 8Y VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSI8LE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06
PREDICTING THE RESPONSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002852 03-14

PREDICTION
LOW URINARY DOPAMINE AND PREDICTION OF PHENOTHIAZINE-INDUCED PARKINSONISM: A PRELIMINARY REPORT.
000935 01-15
ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIM8IC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
001602 02-04
PREDICTION OF CLINICAL RESPONSE TO LITHIUM.
001870 02-12
PREDICTION OF TRICYCLIC ANTIDEPRESSANT RESPONSE: A CRITICAL REVIEW.
002667 03-09
ANTIDEPRESSANT RESPONSE PREDICTION BY AMPHETAMINE. (UNPUBLISHED PAPER).
002702 03-09
THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
002864 03-14
PERLAPINE AND DOPAMINE METABOLISM: PREDICTION OF ANTIPSYCHOTIC EFFICACY.
003325 04-03
PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08

PREDICTIVE
ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04

PREDICTOR
THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-08

PREDICTORS
RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
000880 01-14
EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION
001055 01-17
DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002863 03-14
PREDICTORS OF DRUG RESPONSE IN THE AFFECTIVE DISORDERS: TOWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
003863 04-17

PREDISPOSITION
PERSONALITY PREDISPOSITION AND EMERGENCE PHENOMENA WITH KETAMINE.
000794 01-12

PREDNISONE
AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002897 03-15

PREDRUG
TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001869 02-12

PREEXPOSURE
THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SU8SEQUENT DRUG STATE DISCRIMINATION.
000906 01-14
REDUCTION OF LEARNED TASTE-AVERSIONS BY PREEXPOSURE TO DRUGS
002549 03-04
EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN.
003218 04-03

PREFERENCE
PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07
ACQUIRED PREFERENCE FOR MORPHINE BUT NOT D-AMPHETAMINE AS A RESULT OF SACCHARINE ADULTERATION
001513 02-04
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS: A MOVE TOWARD CONSENSUS.
002162 02-17

STUDIES ON DRUG DEPENDENCE (REPT. 19): DEPENDENCE ON PREFERENCE ON AND PREFERENCE FOR MORPHINE.
002545 03-04

LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION
003428 04-04

PREFERENCES

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17

PREFERENTIAL

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
001602 02-04

PREFERENTIAL NEUROTOXICITY OF PENTOBARBITAL ON NERVE AND GLIAL CELLS IN CULTURE.
003259 04-03

PREFRONTAL

PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-03

SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

PREGNANCY

EFFECTS OF LITHIUM THERAPY DURING PREGNANCY.
001759 02-09

SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTROPIC DRUG USE DURING PREGNANCY.
002010 02-15

PREJUNCTIONAL

PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
00041B 01-04

PREMATURE

THE MANAGEMENT OF PREMATURE EJACULATION.
003729 04-14

PREMATURITY

CAFFEINE IN THE PREVENTION OF APNEA OF PREMATURITY.
002816 03-13

PREMENSTRUAL

PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001817 02-11

PREMISES

MODE OF ACTION OF AMITRIPTYLINE IN DEPRESSION: CONCEPTUAL PREMISES AND CRITERIA FOR EVALUATION.
000591 01-09

PRENATAL

TIME-DEPENDENT EFFECTS PRODUCED IN CHICKS AFTER PRENATAL INJECTION OF METHYLMERCURY.
000461 01-05

SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATION UPON RAT OFFSPRING.
001622 02-05

PREOPTIC

HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
000219 01-03

EVIDENCE THAT THE PREOPTIC REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04

PREPUBESCENT

PREPUBESCENT DEPRESSION (4TH REPORT) -- EXPERIENCES WITH THE EFFICACY OF LITHIUM-CARBONATE.
0026B7 03-09

PRESCRIBING

PEER REVIEW OF PRESCRIBING PATTERNS IN A (CMHC).
001033 01-17

PRESCRIBING BEHAVIOR ALTERING DRUGS: DARK CLOUDS ON THE HORIZON.
001796 02-10

BARBITURATE PRESCRIBING: PSYCHIATRISTS VIEWS.
002102 02-17

PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE.
003019 03-17

CHANGES IN PRESCRIBING PATTERNS OF MINOR TRANQUILIZERS.
003037 03-17

DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003B51 04-17

GENERAL PRACTITIONERS PRESCRIBING HABITS FOR PATIENTS WITH DEPRESSION
0038B6 04-17

ANTIPSYCHOTIC DRUG USE: PHYSICIAN PRESCRIBING PRACTICES IN RELATION TO CURRENT RECOMMENDATIONS.
003B96 04-17

PRESCRIPTION

BARBITURATE HYPNOTICS, A TOO-FREQUENT AND NONSOOTHING PRESCRIPTION
001043 01-17

PRESCRIPTION AND NONPRESCRIPTION ANOREXIANTS.
001897 02-13

PSYCHOTROPIC DRUG PRESCRIPTION IN FAMILY PRACTICE.
002124 02-17

PRESCRIPTION OF AN ANTIDEPRESSANT AND THE PHYSICIAN PATIENT RELATIONSHIP.
002154 02-17

PRESCRIPTION IN FAMILY THERAPY: PART 1.
002961 03-17

DRUG PRESCRIPTION IN ICELAND.
003865 04-17

PRESCRIPTIVE

PRESCRIPTIVE GUIDANCE FOR USAGE OF PSYCHOPHARMACEUTICALS.
001020 01-17

PRESENILE

LEVODOPA TREATMENT IN PRESENILE DEMENTIA.
003738 04-14

PRESHOCK

THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002529 03-04

PRESSING

TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

PRESSOR

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

PRESSURE

GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01

THE EFFECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
0009B6 01-15

THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE: EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM.
001188 02-03

EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-03

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE TO TREATMENT
003669 04-13

PRESUMED

ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
0000B0 01-03

PRESYNAPTIC

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION. (UNPUBLISHED PAPER).
001313 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

THE PRESYNAPTIC EFFECT OF BETA-ADRENOCEPTOR ANTAGONISTS ON NORADRENERGIC NEURONES.
002400 03-03

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
0025B7 03-06

PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
003142 04-03

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

PRETHCAMIDE
SOME BEHAVIORAL EFFECTS OF PRETHCAMIDE COMPARED WITH THOSE OF ITS TWO COMPONENTS.
001437 02-04

PRETREATED
THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
000387 01-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

PRETREATMENT
DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE-AVERSIONS: EFFECTS OF DOSE AND DURATION OF PRETREATMENT.
000337 01-04

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
001402 02-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

MITIGATION OF CAFFEINE-INDUCED FETOPATHY IN MICE BY PRETREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
002564 03-05

TASTE-AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIVE AND DRUG SPECIFIC EFFECTS.
003359 04-04

PRETRIAL
EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

PREVENTATIVE
THE THERAPEUTIC AND PREVENTATIVE EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON DEPRESSION
000696 01-10

PREVENTED
DDC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OF DL-DOPS.
001232 02-03

PREVENTING
THE ACTION OF ASPIRIN IN PREVENTING THE NIACIN FLUSH AND ITS RELEVANCE TO THE ANTISCHIZOPHRENIC ACTION OF MEGADOSE NIACIN.
000957 01-15

PREVENTION
PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

NEGATIVE ASPECTS OF PHARMACOLOGICAL PREVENTION OF EPILEPSY.
000940 01-15

PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17

PREVENTION OF LOCAL ANESTHETIC-INDUCED CONVULSIONS BY GAMMA-AMINOBUTYRIC-ACID.
002261 03-03

DRUG THERAPY IN DEPRESSIVE STATES: FACTORS IN SUICIDE PREVENTION.
002690 03-09

EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIOUS PSYCHOSES.
002746 03-11

CAFFEINE IN THE PREVENTION OF APNEA OF PREMATURITY.
002816 03-13

RECENT ADVANCES IN THE TREATMENT AND PREVENTION OF ADVERSE REACTIONS TO LITHIUM
003031 03-17

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: DRUGS AS ADJUNCTS TO RESPONSE PREVENTION.
003469 04-04

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISORDERS.
003576 04-09

PREWEANLING
THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY.
001613 02-05

PREY
PSYCHOPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

PRIMARY
LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYPES OF PRIMARY AFFECTIVE DISORDER.
000601 01-09

COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION.
002682 03-09

GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11

PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE.
003019 03-17

DIFFERENTIAL EFFECT OF MORPHINE ON STIMULATION OF PRIMARY VERSUS HIGHER ORDER TRIGEMINAL TERMINALS.
003257 04-03

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08

PRIMATE
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04

ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-04

PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION STUDIES WITH THC IN MONKEYS.
001574 02-04

EFFECT OF CHLORIMIPRAMINE ON THE SO CALLED PONTO-GENICULO-OCCIPITAL ACTIVITY (PGO) IN A PRIMATE, PAPIO-HAMADRYAS.
003350 04-04

PRIMATES
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06

THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATION BY PRIMATES.
001647 02-06

PRIMIDONE
THE INFLUENCE OF ANTIEPILEPTIC DRUGS ON SOME ENZYMES ACTIVITY IN THE BRAIN OF MICE WITH AUDIOGENIC EPILEPSY NOTE I. THE ACTION OF PHENOBARBITAL, DIPHENYLHYDANTOIN AND PRIMIDONE
000076 01-03

A COMPARISON OF THE EFFECTIVENESS OF PRIMIDONE VERSUS CARBAMAZEPINE IN EPILEPTIC OUTPATIENTS.
002776 03-11

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE
003511 04-05

PRIMING
GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 04-03

PRIMING-INDUCED
EFFECT OF MORPHINE AND NALOXONE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-04

PRINCIPAL
PRINCIPAL CELLS IN LATERAL GENICULATE. EFFECTS OF METRAZOL ON CAPACITY TO AFTER-DISCHARGE.
001146 02-03

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

PRISON
PRISON RESEARCH: NATIONAL COMMISSION SAYS NO, UNLESS.
003850 04-17

PRISON RESEARCH THE VIEW FROM INSIDE
003869 04-17

PRISONS
TESTIMONY BY AN EX-CONVICT AGAINST MEDICAL EXPERIMENTATION IN PRISONS
003882 04-17

PRN
EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE
003889 04-17

PROBANDS
SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001884 02-13
EFFECTS OF THE GABA DERIVATIVE PIRACETAM: A DOUBLE-BLIND STUDY IN HEALTHY PROBANDS.
003755 04-14

PROBENECID
ANOMALOUS EFFECT OF PROBENECID ON RAT BRAIN PHENOLSULPHOTRANSFERASE.
000193 01-03
INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS.
001297 02-03
THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-08

PROBENECID-INDUCED
PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03

PROBLEM
SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PROBLEM OF PARANOID PSYCHOSIS.
000B3B 01-13
PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEED TO BELONG IN THE LIGHT OF THREE CLINICAL CASES.
001793 02-10
CAN PENTAZOCINE BE A DRUG? OBSERVATIONS ON THE PROBLEM OF TALWINISM.
00202B 02-15
OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07
ON THE PROBLEM OF SIDE-EFFECTS OF CLOZAPINE.
002657 03-08

PROBLEM-SOLVING
TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04
AN ANIMAL MODEL FOR THE MEASUREMENT AND MANIPULATION OF PROBLEM-SOLVING ABILITY.
003513 04-06

PROBLEMS
TWO OCCULT CAUSES OF INSOMNIA AND THEIR THERAPEUTIC PROBLEMS.
000460 01-05
METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
000483 01-07
USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY
000763 01-11
DRUGS WHICH CREATE PROBLEMS FOR THE ELDERLY.
000965 01-15
SPECIAL PROBLEMS FOR DRUGS USED IN CHILDREN.
000995 01-15
METHODOLOGICAL PROBLEMS IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
001005 01-16
DATA ANALYSIS PROBLEMS IN THE AREA OF PHARMACOKINETICS RESEARCH.
001651 02-06
CURRENT PROBLEMS OF PSYCHIATRIC NOSOLOGY.
002155 02-17
PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION
002172 02-17
METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-08
SOME PROBLEMS OF THE TREATMENT OF BRONCHIAL ASTHMA
0027B1 03-11
MODERN PROBLEMS OF PHARMACOPSYCHIATRY VOL. II: ALCOHOL, DRUGS AND DRIVING.
003014 03-17
PROBLEMS ON THE FORENSIC DETECTION OF DEXTROMORAMIDE OR ITS METABOLITES.
003714 04-13
SOME PROBLEMS IN THE TREATMENT OF DEPRESSION WITH PHARMACOLOGICAL AGENTS.
003778 04-15
DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003851 04-17

PROCAINE
A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION.
000624 01-09
CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17
PROCAINE HYDROCHLORIDE AS A MONOAMINE-OXIDASE INHIBITOR: IMPLICATIONS FOR GERIATRIC THERAPY.
00314B 04-03
THE SYSTEMIC USE OF PROCAINE IN THE TREATMENT OF THE ELDERLY: A REVIEW.
003595 04-10

PROCEDURE
DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002893 03-15

PROCEDURES
INTERACTION OF DRUG EFFECTS WITH TESTING PROCEDURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04
BEHAVIORAL PROCEDURES FOR EVALUATING THE RELATIVE ABUSE POTENTIAL OF CNS DRUGS IN PRIMATES.
001646 02-06
ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04
CEREBRAL HEMODYNAMICS AND BRAIN METABOLISM: MEASUREMENT PROCEDURES, PHYSIOLOGY, PATHOPHYSIOLOGY, MODIFICATIONS IN ORGANIC-BRAIN-DISEASE, PHARMACOLOGY.
00281B 03-13
PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE-MALEATE, IMIPRAMINE-HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

PROCEEDINGS
PROCEEDINGS OF THE SIXTH INTERNATIONAL CONGRESS OF PHARMACOLOGY VOLUME 3: CNS AND BEHAVIOURAL PHARMACOLOGY.
002959 03-17

PROCESSING
THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNDROME.
002901 03-15

PRODIGIOUS
PRODIGIOUS DEVELOPMENT OF PSYCHOPHARMACOLOGY.
002165 02-17

PRODRUGS
METABOLISM IN VITRO OF POTENTIAL APOMORPHINE PRODRUGS.
000229 01-03

PRODUCTION
INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000B76 01-14
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03
EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03
HEALTH STATUS IN PERSONS ENGAGED IN THE PRODUCTION OF TRIFTAZINE.
002914 03-15

PRODUCTIVE
INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001426 02-03

PRODUCTS
SOME OXIDATION PRODUCTS OF 2-SUBSTITUTED PHENOTHIAZINES.
0010B1 02-01
CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002820 03-13

BIOAVAILABILITY AND SIDE-EFFECTS OF DIFFERENT LITHIUM-CARBONATE PRODUCTS.
002904 03-15

PROFESSIONAL
PROFESSIONAL DISAGREEMENT IN DRUG EFFICACY STUDY.
002135 02-17

PROFILE
AGGRESSIVE BEHAVIOR INDUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-04

ACTIVITY PROFILE OF CARPIPRAMINE: RESULTS OF AN OPEN TRIAL AND A DOUBLE-BLIND TRIAL VERSUS DOXEPIN.
001723 02-08

PHARMACOKINETIC PROFILE OF PERPHENAZINE-ENANTHATE.
002842 03-13

PROFILES
NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

PROFIT
COST/PROFIT ANALYSIS OF ANTIDEPRESSANTS.
000676 01-10

PROFOUND
CHARACTERIZATION OF THE ENDORPHINS, NOVEL HYPOTHALAMIC AND NEUROHYPOPHYSEAL PEPTIDES WITH OPIATE-LIKE ACTIVITY: EVIDENCE THAT THEY INDUCE PROFOUND BEHAVIORAL CHANGES.
003397 04-04

PROFOUNDLY
HOW TO TREAT THE PROFOUNDLY DEPRESSED PATIENT.
002686 03-09

PROGENY
BEHAVIORAL EFFECTS ON THE PROGENY OF MICE TREATED WITH METHYLMERCURY.
000432 01-04

STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03

PROGESTERONE
INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001204 02-03

PROGESTERONE-INDUCED
PENTOBARBITAL INHIBITION OF PROGESTERONE-INDUCED BEHAVIORAL ESTRUS IN OVARIECTOMIZED GUINEA-PIGS.
001400 02-03

PROGNOSIS
CHANGING THERAPY AND PROGNOSIS IN MANIC-DEPRESSIVES.
000687 01-10

THE GILLES-DE-LA-TOURETTE SYNDROME: AN ANALYSIS OF PUBLISHED CASES DEALING WITH THE COURSE OF THE DISEASE AND ITS PROGNOSIS.
000725 01-11

PROGNOSTIC
L-ALPHA-ACETYLMETHADOL (LAAM): PROGNOSTIC CONSIDERATIONS.
001853 02-11

PROGNOSTICATOR
THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY.
001899 02-13

PROGRAM
PSYCHIATRISTS, PHYSICIANS AND THE CIA DRUG PROGRAM
000521 01-07

DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17

IN THE SERVICE OF PSYCHOPHARMACOLOGY RESEARCH: THE PSC-PRB, NIMH PROGRAM 1956-1976 (UNPUBLISHED PAPER).
002138 02-17

EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
002415 03-04

PROGRESS
PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
000610 01-09

EFFECTS OF AMITRIPTYLINE ON THE PROGRESS OF DEPRESSION.
002726 03-10

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY IN THE MID-SEVENTIES: PROGRESS OR PLATEAU?.
003038 03-17

PROGRESSIVE
PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03

EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEDULE.
001467 02-04

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003524 04-07

MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION
003856 04-17

PROHIBITION
THE RECREATIONAL USE OF LSD-25 AND DRUG PROHIBITION.
002181 02-17

PROJECTION
EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTION TO THIS SUBSTANTIA-NIGRA IN RAT.
001189 02-03

SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-04

PROJECTIONS
ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
001334 02-03

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON
001458 02-04

PROJECTIVE
CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08

PROLACTIN
EFFECT OF HYPOTHALAMIC PHOSPHOLIPIDS ON PROLACTIN INCRETION.
000044 01-03

PLASMA PROLACTIN CONCENTRATIONS IN PATIENTS ON CLOMIPRAMINE.
0005B6 01-09

PROLACTIN AND MENTAL ILLNESS.
000616 01-09

EFFECT OF METHYLDOPA ON PROLACTIN AND GROWTH HORMONE.
0009B7 01-1

ENKEPHALIN-STIMULATED PROLACTIN RELEASE.
001278 02-0

PROLACTIN SECRETION IN CHRONIC SCHIZOPHRENIA.
0016B0 02-0

THE EFFECT OF CLOMIPRAMINE ON PROLACTIN LEVELS -- PILOT STUDIES
001745 02-0

PROLACTIN RESPONSE TO ELECTROCONVULSIVE THERAPY.
001769 02-0

DOPAMINE-INDUCED INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA
001900 02-1

PROLACTIN SECRETION AND ANTIPSYCHOTIC EFFICACY.
001916 02-1

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE. EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-0

EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-0

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B35 03-1

SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-1

ANTIPSYCHOTIC AGENTS AND SERUM PROLACTIN LEVELS.
002900 03-1

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-0

EFFECT OF FLUPENTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SECRETION IN RATS.
003220 04-03

EFFECT OF GAMMA-BUTYROLACTONE AND BACLOFEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03

EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03

EFFECTS OF ERGOCORNINE AND PROLACTIN ON AGGRESSION IN THE POSTPARTUM GOLDEN HAMSTER.
003484 04-04

DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
003684 04-13

LACK OF EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON SERUM PROLACTIN LEVELS.
003689 04-13

PROLACTIN AND PSYCHOPHYSIOLOGIC MEASURES AFTER SINGLE-DOSES OF THIORIDAZINE.
003693 04-13

NO EFFECTS OF QUATERNARY NEUROLEPTICS ON HUMAN PROLACTIN AND ADENYL-CYCLASE.
003881 04-17

PROLINE

DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PROLOGUE

TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
001058 01-17

PROLONGATION

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-03

PROLONGATION OF MUSCLE RELAXANT EFFECTS BY LITHIUM-CARBONATE.
003820 04-15

PROLONGED

PROLONGED APOMORPHINE-LIKE BEHAVIOURAL EFFECTS OF APOMORPHINE ESTERS.
00027B 01-04

PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN.
001631 02-05

TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
001641 02-05

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

PROLONGED LSD FLASHBACKS AS CONVERSION REACTIONS.
001875 02-12

DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13

PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION.
002172 02-17

FIVE YEARS OF EXPERIENCE WITH PROLONGED ACTION FLUPHENAZINE.
002643 03-08

METHODOLOGICAL PROBLEMS OF A COMPARATIVE STUDY OF PROLONGED ACTION NEUROLEPTICS AND CLASSICAL NEUROLEPTICS.
002653 03-08

CLINICAL EVALUATION OF FLUPENTHIXOL WITH PROLONGED ACTION.
002655 03-08

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

EFFECTS OF PROLONGED FENFLURAMINE ADMINISTRATION IN OBESE AND NONOBESE MICE
003108 04-03

AN ANALOG OF ENKEPHALIN HAVING PROLONGED OPIATE-LIKE EFFECTS IN VIVO.
003319 04-03

PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14

PROLONGED DELTA9-TETRAHYDROCANNABINOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC BLOCKADES.
003767 04-15

PROMAZINE

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04

COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11

STIMULATION OF FOOD INTAKE IN HORSES BY DIAZEPAM AND PROMAZINE.
001452 02-04

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

PROMEDOL

EFFECT OF AMINAZINE AND PROMEDOL ON DELAYED HYPERSENSITIVITY AND PHARMACODYNAMIC CHANGES IN THESE SUBSTANCES IN THE GIVEN PATHOLOGY.
002286 03-03

PROMOTIL

IMPORTANCE OF PROMOTIL IN FOLLOW-UP TREATMENT OF ALCOHOLICS.
002740 03-11

PROPENE

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03

PROPERTY

SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-04

PROPHYLACTIC

A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

PROPHYLACTIC EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE EXAMINED IN KINDLING CAT PREPARATIONS.
0007BB 01-11

PROPHYLACTICALLY

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

PROPHYLACTICS

HOW LONG SHOULD PROPHYLACTICS BE CONTINUED IN AFFECTIVE DISORDERS
000606 01-09

PROPHYLAXIS

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
0005B9 01-09

A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND MAPROTILINE IN THE PROPHYLAXIS OF THE AFFECTIVE DISORDERS.
000590 01-09

LITHIUM-CARBONATE PROPHYLAXIS FAILURE.
000596 01-09

LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYPES OF PRIMARY AFFECTIVE DISORDER.
000601 01-09

LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01-09

LITHIUM PROPHYLAXIS.
001045 01-17

PSYCHOLOGICAL STRESS AS A CAUSE OF LITHIUM PROPHYLAXIS FAILURE, A REPORT OF THREE CASES.
001732 02-09

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

PSYCHOLOGICAL ASPECTS OF PHASIC DEPRESSION DURING LITHIUM PROPHYLAXIS.
DD2D75 02-15

ON PROPHYLAXIS IN UNIPOLAR AFFECTIVE DISORDER.
002157 02-17

LITHIUM MAGNESIUM RELATIONSHIP IN RED-BLOOD-CELLS DURING LITHIUM PROPHYLAXIS.
002695 03-09

INDICATIONS FOR LITHIUM-CARBONATE PROPHYLAXIS.
002710 03-10

PROPIZEPINE-CHLORHYDRATE

CONCERNING PROPIZEPINE-CHLORHYDRATE AND ITS INDICATIONS IN DEPRESSION.
000650 01-D9

PROPIZEPINE-HYDROCHLORIDE

A NEW MEDICATIDN OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-D7

PROPOSAL

PROPDSAL OF A NEW MDDEL WITH DOPAMINERGIC CHOLINERGIC INTERACTIONS FOR NEUROPHARMACOLOGICAL INVESTIGATIONS.
000467 01-D6

THERAPEUTIC PRDPOSAL FOR INVOLUTIONAL DEPRESSION.
D01771 02-09

PROPOXYPHENE-INDUCED

ENHANCEMENT OF PROPOXYPHENE-INDUCED ANALGESIA BY DOXEPIN.
003301 04-03

PROPRANOLOL

EFFECTS OF METOPROLOL AND PROPRANOLOL ON SOME METABOLIC RESPDNSES TO CATECHOLAMINES IN THE ANESTHETIZED DOG.
00002B D1-03

INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
D0DDB9 D1-03

REDUCTION BY PROPRANDLOL DF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
D0D231 01-03

EVALUATION OF PROPRANOLOL IN OPIATE DEPENDENCE.
DDD512 01-07

SOMATIC ANXIETY ATTACKS AND PROPRANOLOL.
000681 01-1D

EFFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHDLIC PATIENTS.
0007B2 01-11

INFLUENCE OF METOPROLOL AND PROPRANDLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK.
000826 01-13

INFLUENCE OF METOPRDLOL AND PRDPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY PHYSICAL WORK AND ISOPRENALINE.
DD0827 01-13

PSYCHDPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PRDPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

EFFECT DF PROPRANOLOL ON RAT BRAIN NDREPINEPHRINE IN VITRO.
001427 02-D3

PROPRANOLOL AND MORPHINE.
DD1555 02-04

OXPRENOLOL AND PROPRANOLOL IN ANXIETY STATES.
0D1784 02-10

PROPRANOLOL IN COCAINE TOXICITY.
0D1852 02-11

ANTIHYPERTENSIVE ACTION OF PROPRANOLOL IN MAN: LACK OF EVIDENCE FOR A NEURAL DEPRESSIVE EFFECT.
001917 D2-13

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF PROPRANOLOL.
DD1954 02-14

ACTION OF PRACTOLOL AND PROPRANOLOL ON THE EFFECTS OF ISADRINE IN LABORATORY ANIMALS.
D02323 D3-D3

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
DD2457 03-04

SAFEGUARDS IN THE TREATMENT OF SCHIZOPHRENIA WITH PROPRANOLOL.
DD2607 03-07

PROPRANOLOL TO CONTROL SCHIZOPHRENIC SYMPTOMS:
55

PATIENTS.
0D2663 03-DB

THE TREATMENT OF PATHOLOGICAL PANIC STATES WITH PROPRANOLOL.
0D2677 D3-09

EFFECT OF THE BETA-RECEPTOR BLOCKER PROPRANOLOL ON MANIA.
0D2691 D3-09

PROPRANOLOL IN THE TREATMENT OF ANXIETY.
DD2731 D3-1D

CLINICAL AND EXPERIMENTAL STUDIES ON THE EFFECTS OF PROPRANOLOL IN ANXIETY.
D02733 03-10

EARLY OBSERVATIONS OF THE EFFECT OF PROPRANOLOL ON PSYCHDTIC PATIENTS.
002739 03-11

THE EFFECT OF PROPRANOLOL IN STAMMERING.
002749 03-11

THE EFFECT OF BETA-ADRENERGIC BLOCKADE (PROPRANOLOL) ON DIFFERENT TREMORS.
002753 03-11

DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
0D2754 03-11

CURRENT STATE OF RESEARCH ON PROPRANOLOL OPIATE INTERACTION.
002757 03-11

PROPRANOLOL IN ALCOHOLISM.
002B55 03-14

PROPRANOLOL IN BENIGN ESSENTIAL TREMOR.
00287B 03-14

THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15

ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
0D2922 03-15

THE USE OF PROPRANOLOL IN SOMATIC MEDICINE.
0D2957 03-17

EFFECT OF PROPRANOLOL AND RELATED DRUGS ON TRANSMEMBRANEOUS PH DIFFERENCES IN LIPOSOMES.
003080 04-03

EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
00327D D4-03

PROPRANOLOL FOR THE CONTROL OF BELLIGERENT BEHAVIOR FOLLOWING ACUTE BRAIN-DAMAGE.
003616 04-11

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

PROPRANOLOL EFFECTS ON ACUTE MARIHUANA INTOXICATION IN MAN.
D03711 04-13

ACUTE ORGANIC-BRAIN-SYNDROME WITH PROPRANOLOL AND METHYLDOPA.
D03779 D4-15

PROPRANOLOL-INDUCED

PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION.
0D2218 03-03

PROPYLENE

BEHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
0013B5 02-03

PROSE

MARIJUANA: EFFECTS ON STORAGE AND RETRIEVAL OF PROSE MATERIAL.
003743 D4-14

PROSPECTIVE

THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11

PROSPECTS

PSYCHOTROPIC DRUG ASSESSMENT -- CURRENT STATUS, FUTURE PROSPECTS. (UNPUBLISHED PAPER)
D02139 D2-17

PROSTAGLANDIN

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
0D1237 02-03

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 D3-17

PROSTAGLANDIN-E1

THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
D00129 D1-03

EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-D3

THE EFFECT OF PROSTAGLANDIN-E1 ON CENTRAL CHOLINERGIC MECHANISMS.
003101 04-D3

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

PROSTAGLANDIN-E1-INDUCED
ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

PROSTAGLANDIN-E2
PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS.
002210 03-03

PROSTAGLANDIN-F2ALPHA
INCREASED CEREBRAL CYCLIC-GMP CONCENTRATION INDUCED BY MUSCARINIC CHOLINERGIC AGONISTS AND PROSTAGLANDIN-F2ALPHA.
000183 01-03

PROSTAGLANDINS
A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN
002340 03-03

A COMPARISON OF THE CENTRAL ACTION OF SOME PROSTAGLANDINS /PGS/ IN RATS.
002484 03-04

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

PROTECTION
CEREBRAL PROTECTION BY BARBITURATE ANESTHESIA: USE AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN JAVA MONKEYS.
0003B0 01-04

SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS.
001123 02-03

CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

PROTECTIVE
STUDY OF THE PROTECTIVE EFFECT OF VITAMIN-A ON STRESS ULCER IN THE RAT.
000223 01-03

A STUDY OF THE PROTECTIVE PROPERTIES OF SEGOLAN IN HYPOXIA.
001024 01-17

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
0012B2 02-03

THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN.
001349 02-03

PROTEIN
COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
000359 01-04

PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
000B6B 01-13

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
00123B 02-03

IRREVERSIBLE PROTEIN BINDING OF 14C-IMIPRAMINE IN RATS IN VIVO.
00125B 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
00130B 02-03

MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN: METAL BINDING AND FLUORESCENCE STUDIES.
00132B 02-03

EFFECTS OF AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM FROM RAT BRAIN
001421 02-03

IMMUNODEPRESSIVE ACTIVITY OF PHENOBARBITAL CHEMICALLY BOUND WITH THE PROTEIN CARRIER
00162B 02-05

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN.
002306 03-03

MORPHINE INDUCED CHANGES OF CYCLIC AMP METABOLISM AND PROTEIN KINASE ACTIVITY IN BRAIN
002319 03-03

APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03-03

STUDIES ON THE EFFECT OF 5,5 DIPHENYLHYDANTOIN ON IN VITRO PROTEIN SYNTHESIS IN RAT BRAIN
002375 03-03

REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTONIN BINDING PROTEIN.
003517 04-06

MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION.
003856 04-17

PROTEIN-BOUND
A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
000580 01-09

PROTEIN-14-3-2
PREPARATION AND PROPERTIES OF THE BRAIN SPECIFIC PROTEIN-14-3-2.
003052 04-01

THE SUBUNIT STRUCTURE OF BOVINE BRAIN PROTEIN-14-3-2.
003060 04-01

PROTHIADEN
AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07

PROTRACTED
CLINICAL STUDY OF A NEW FORM OF DIBENZEPINE, WITH PROTRACTED ACTION.
000633 01-09

PROTRIPTYLINE
THE REVERSAL OF CLONIDINE-INDUCED HYPOTENSION BY PROTRIPTYLINE AND DESIPRAMINE.
000248 01-03

PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSED WOMEN.
000994 01-15

PROTRIPTYLINE: THE RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS AND THE CLINICAL EFFECT ON DEPRESSED MALE PATIENTS.
002711 03-10

PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNDROME AND HYPERSOMNIA.
003748 04-14

PROVOCATION
COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11

PSATHYRELLA
DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AND PSATHYRELLA.
0010BB 02-01

PSC-PRB
IN THE SERVICE OF PSYCHOPHARMACOLOGY RESEARCH: THE PSC-PRB, NIMH PROGRAM 1956-1976. (UNPUBLISHED PAPER).
00213B 02-17

PSEUDO
PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15

PSEUDOCONDITIONING
ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04

PSEUDOPSYCHOTIC
PSEUDOPSYCHOTIC RELAPSES IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
002945 03-15

PSILOCYBE
DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AND PSATHYRELLA.
0010BB 02-01

PSILOCYBIAN-MYCETISMUS
PSILOCYBIAN-MYCETISMUS WITH SPECIAL REFERENCE TO PANAEOLUS.
000B55 01-13

PSILOCYBIN
DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AND PSATHYRELLA.
0010BB 02-01

PSORIASIS
A COMPARATIVE EVALUATION OF THE ANTIPSORIATIC EFFECT OF L-DOPA VERSUS PLACEBO IN PSORIASIS.
001938 02-13
MORE ABOUT THE RELATIONSHIP OF LITHIUM TO PSORIASIS.
002011 02-15

PSYCHASTHENIC
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
000484 01-07

PSYCHE
CIRCULATORY MANIFESTATIONS OF SOMA AND PSYCHE.
D00717 01-10

PSYCHEDELIC
A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001868 02-12

PSYCHEDELICS
THE USE OF PSYCHEDELICS IN PSYCHOTHERAPY.
003514 04-06

PSYCHIATRIC
STUDY OF THE PSYCHIATRIC INDICATIONS OF LORAZEPAM.
000509 01-07
TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC: SULTOPRIDE.
000510 01-07
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07
THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-08
USE OF LITHIUM-SALTS IN PSYCHIATRIC THERAPEUTICS.
000611 01-09
FURTHER DEVELOPMENTS IN THE STUDY OF 3,5 CYCLIC ADENOSINE MONOPHOSPHATE IN RELATION TO PSYCHIATRIC ILLNESS.
000641 01-09
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09
AMITRIPTYLINE IN PSYCHIATRIC THERAPY: EIGHT YEARS OF USAGE IN HOSPITAL PRACTICE.
000656 01-09
SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-09
USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY.
000763 01-11
POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
D00772 01-11
ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT.
D0D777 D1-11
PSYCHIATRIC MEDICINE AND SLEEP -- CHLORPROMAZINE.
0DD897 D1-14
UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
0DD945 D1-15
PSYCHIATRIC SYNDROMES IN CRITICALLY ILL PATIENTS.
0D0956 D1-15
PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
D0D962 01-15
OUTPATIENT PSYCHIATRIC MEDICATIONS AND GLAUCOMA.
0DD980 D1-15
ELECTROENCEPHALOGRAPHIC CORRELATES OF ORAL CONTRACEPTIVE USE IN PSYCHIATRIC PATIENTS.
0DD988 D1-15
OBSERVATIONS ON THE USE OF PSYCHOPHARMACOLOGY IN PSYCHIATRIC HOSPITALS.
0D1D12 01-17
PSYCHIATRIC PHARMACY RESIDENCY AND SERVICES.
001026 01-17
MANUAL OF PSYCHIATRIC THERAPEUTICS: PRACTICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY.
D01074 01-17
BLOOD LEVELS, DRUG INTERACTIONS AND DOSAGE IN PSYCHIATRIC CLINICAL PHARMACOLOGY.
0D1665 02-D7
PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT.
001776 02-09
TREATMENT OF PSYCHIATRIC EMERGENCIES.
001803 02-10
SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS: EFFECT OF D-AMPHETAMINE AND HALOPERIDOL.
001927 02-13
EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14
PSYCHIATRIC PHARMACOTHERAPY IN RENAL INSUFFICIENCY.
002016 02-15
NEUROLEPTIC TARDIVE-DYSKINESIAS: STUDY OF 1660 PATIENTS IN A PSYCHIATRIC HOSPITAL.
002019 02-15
THE MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
002107 02-17
HALOPERIDOL: A USEFUL PSYCHIATRIC DRUG.
002126 02-17
HYPOTHYROIDISM WITH EPISODIC PSYCHIATRIC AND CARDIAC MANIFESTATIONS.
002127 02-17
ONE HUNDRED FIFTY YEARS OF PSYCHIATRIC THERAPY.
002131 02-17
INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17
CURRENT PROBLEMS OF PSYCHIATRIC NOSOLOGY
002155 02-17
PSYCHIATRIC MEDICATION: THE ROLE OF THE NONPHYSICIAN
002156 02-17
THE PSYCHIATRIC SECTOR AND THE WALLS OF THE ASYLUM.
002638 03-08
USE OF THIORIDAZINE-RETARD IN PSYCHIATRIC TREATMENT.
002748 D3-11
RESULTS OF TREATING NERVOUS TICS IN CHILDREN BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11
RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
0D2784 03-11
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 03-13
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002836 03-13
CASE STUDIES IN PSYCHIATRIC MANAGEMENT: HOSPITAL TO COMMUNITY.
D02853 03-14
USE OF RADIOACTIVE COPPER AND RADIOACTIVE ZINC IN PSYCHIATRIC DIAGNOSIS.
002983 03-17
COMPARATIVE CLINICAL EVALUATION OF LOFEPRAMINE AND IMIPRAMINE: PSYCHIATRIC ASPECTS.
003555 04-09
A MULTICLINIC DOUBLE-BLIND TRIAL OF THE ANXIOLYTIC PROPERTIES OF LORAZEPAM IN PSYCHIATRIC OUTPATIENT PRACTICE.
DD3605 04-1D
EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14
CARDIAC SIDE-EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
DD3830 D4-15
PHARMACOLOGIC MANAGEMENT OF PSYCHIATRIC EMERGENCIES.
003844 04-17
PHARMACOLOGICAL AGENTS AS TOOLS IN PSYCHIATRIC RESEARCH.
DD3861 04-17
HELPING PSYCHIATRIC OUTPATIENTS ACCEPT DRUG THERAPY.
DD3871 04-17
THE CHRONIC PSYCHIATRIC PATIENT IN THE COMMUNITY. HIGHLIGHTS FROM A CONFERENCE IN BOSTON.
DD3873 04-17

PSYCHIATRISTS
PSYCHIATRISTS, PHYSICIANS AND THE CIA DRUG PROGRAM
D0D521 01-D7
SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
DD1986 D2-14
BARBITURATE PRESCRIBING: PSYCHIATRISTS VIEWS.
002102 D2-17

PSYCHOPHARMACOLOGY AND THE LAW: A FORENSIC PSYCHIATRISTS VIEWPOINT.
002118 02-17
CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 02-17
GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11

PSYCHIATRY
MOODSWING: THE THIRD REVOLUTION IN PSYCHIATRY.
000602 01-09
CLINICAL EXPERIENCE OF N-DESMETHYLDIAZEPAM (A-101) IN THE FIELD OF PSYCHIATRY.
000712 01-10
THE USE OF THE BETA-INTERCEPTOR PHENDORAL WITHIN THE FIELD OF PSYCHIATRY.
000749 01-11
STUDY OF FREE AND TOTAL TRYPTOPHAN IN PLASMA. ITS INTEREST IN PSYCHIATRY.
000815 01-13
METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY.
000842 01-13
PSYCHIATRY, MEDICINE, AND SLEEP -- SLEEPING DRUGS AND TRANQUILIZERS.
000891 01-14
1035-MD (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY.
001013 01-17
PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17
MANUAL OF PSYCHIATRIC THERAPEUTICS: PRACTICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY.
001074 01-17
TRASICOR IN PSYCHIATRY.
001B07 02-10
METHODOLOGICAL REVIEW OF FLUID THERAPY IN PSYCHIATRY.
002145 02-17
THE PSYCHIATRY OF SYSTEMIC LUPUS-ERYTHEMATOSUS.
002149 02-17
CLINICAL PSYCHIATRY AND PSYCHOPHARMACOLOGY -- A REVIEW.
00216B 02-17
LITHIUM IN PSYCHIATRY: A SYNOPSIS.
002396 03-03
ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10
CLINICAL EVALUATION OF LORAZEPAM IN EMERGENCY PSYCHIATRY.
00272B 03-10
GERIATRIC PSYCHIATRY: A HANDBOOK FOR PSYCHIATRISTS AND PRIMARY CARE PHYSICIANS.
002741 03-11
INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY.
00276B 03-11
LITHIUM-SALTS IN PSYCHIATRY: IMPORTANCE OF GENETIC FACTORS.
002B25 03-13
USE OF SO-CALLED ANTIPARKINSON MEDICATIONS IN PSYCHIATRY.
002BBB 03-15
OVERUSE OF SYNTHETIC ANTICHOLINERGIC DRUGS IN PSYCHIATRY.
002915 03-15
THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY.
002996 03-17
BETA-RECEPTOR BLOCKERS IN PSYCHIATRY.
003016 03-17
PERSPECTIVES IN BIOLOGICAL PSYCHIATRY- PART I. MENTAL DEFICIENCY, PERSONALITY DISORDERS, AND NEUROSES.
003581 04-10
THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY: A WEB OF PARADOXES.
003B77 04-17

PSYCHIC
PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10
TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
001668 02-07
SOMATIC AND PSYCHIC SYMPTOMS IN ANXIETY.
002722 03-10
SULPIRIDE AND PSYCHIC DECOMPENSATION
003023 03-17

PSYCHOACTIVE
PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS
000475 01-06
PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY.
000674 01-10
HERBAL INTOXICATION: PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
000984 01-15
CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS (UNPUBLISHED PAPER).
001014 01-17
PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001035 01-17
PSYCHOACTIVE DRUGS IN MEDICAL PRACTICE: THE PRESENT STAGE OF DEVELOPMENT.
001049 01-17
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
001057 01-17
THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
00107B 01-17
CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06
TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
00166B 02-07
THE PRACTITIONERS GUIDE TO PSYCHOACTIVE DRUGS.
002103 02-17
PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: BLOOD LEVELS AND CLINICAL RESPONSE.
002120 02-17
SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02
EFFECTS OF PSYCHOACTIVE AGENTS ON THE BRAIN.
002371 03-03
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B35 03-13
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002B36 03-13
EFFECTS OF SOME PSYCHOACTIVE DRUGS UPON THE TRAPEZOID ILLUSION PERCEPTION.
002B56 03-14
BEHAVIORAL EFFECTS OF REPEATED PSYCHOACTIVE DRUG ADMINISTRATION. (PH.D. DISSERTATION).
002B77 03-14
PSYCHOACTIVE DRUG CRISIS INTERVENTION
002947 03-15
USING OR ABUSING? AN ANTHROPOLOGICAL APPROACH TO THE STUDY OF PSYCHOACTIVE DRUGS.
0029B5 03-17
STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03
PSYCHOACTIVE DRUGS IN THE TREATMENT OF THE AGED.
00363B 04-11

PSYCHOACTIVITY
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14
DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002873 03-14

PSYCHOANALEPTIC
A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11

PSYCHOANALYTIC
PSYCHOANALYTIC ASPECTS OF THE TREATMENT OF MANIC-DEPRESSIVE PSYCHOSIS.
001754 02-09

PSYCHOBIOLOGICAL
NEUROBIOLOGICAL MECHANISMS OF ADAPTATION IN RELATION TO MODELS OF PSYCHOBIOLOGICAL DEVELOPMENT.
000162 01-03

PSYCHOBIOLOGY
ANIMAL MODELS IN HUMAN PSYCHOBIOLOGY.
002161 02-17
INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-03
PSYCHOBIOLOGY OF DEPRESSION.
003567 04-09

PSYCHOCHEMOTHERAPEUTIC
SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

PSYCHODYNAMIC
PSYCHODYNAMIC EVALUATION OF A CASE OF AUTOEROTIC FETISHISM.
000609 01-09
PSYCHODYNAMIC OBSERVATIONS OF A GROUP OF PATIENTS TREATED WITH LITHIUM-CARBONATE.
002670 03-09

PSYCHODYNAMICS
PSYCHODYNAMICS OF PSYCHOTROPIC DRUG THERAPY.
000765 01-11

PSYCHODYSLEPTICS
AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12

PSYCHOGENIC
THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COMBINATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09
CLINICAL EVALUATION OF AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES.
002714 03-10
DRUG-INDUCED HYPONATREMIA IN PSYCHOGENIC POLYDIPSIA.
002902 03-15

PSYCHOGERIATRIC
EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS.
000755 01-11
INDIVIDUAL DRUG SUPPLY IN A PSYCHOGERIATRIC WARD: AN EVALUATION OF THE SYSTEM.
003B42 04-16

PSYCHOGERIATRICS
CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE: OBSERVATIONS IN PSYCHOGERIATRICS.
0006B3 01-10

PSYCHOLEPTIC
INFLUENCE ON PSYCHOLEPTIC EFFECTS OF DIFFERENT TYPES OF SUBSTITUTIONS IN A SERIES OF CRESOTINIC AMIDES.
000151 01-03

PSYCHOLEPTICS
PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15
ACTION OF PSYCHOLEPTICS ON SOME PHYSIOLOGICAL INDICES IN STUTTERERS.
00195B 02-14

PSYCHOLOGIC
PSYCHOLOGIC EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL IN ADVANCED CANCER PATIENTS.
001872 02-12
A NEUROLOGIC, ELECTROENCEPHALOGRAPHIC AND PSYCHOLOGIC STUDY OF FL-121 IN PATIENTS WITH CEREBRAL CIRCULATORY DEFICIENCY.
002774 03-11

PSYCHOLOGICAL
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14
PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14
NALTREXONE: PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF SINGLE-DOSES
000951 01-15
COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07
PSYCHOLOGICAL STRESS AS A CAUSE OF LITHIUM PROPHYLAXIS FAILURE, A REPORT OF THREE CASES.
001732 02-09
ESSAY ON DETERMINATION OF PSYCHOLOGICAL EFFECTS OF LITHIUM.
001756 02-09
STUDY OF THE IMPORTANCE OF NEUROTIC PSYCHOLOGICAL FACTORS IN THE SUCCESS OF LONG-TERM LITHIUM TREATMENT.
001766 02-09
PSYCHOLOGICAL MEDICINE: DRUGS USED IN PSYCHOLOGICAL MEDICINE: PHARMACOLOGICAL BASIS OF TREATMENT.
001B2B 02-11
DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM.
001831 02-11
THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY
001920 02-13
EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14
DISULFIRAM IMPLANTATION. PLACEBO, PSYCHOLOGICAL DETERRENT, AND PHARMACOLOGICAL DETERRENT EFFECTS.
002003 02-14
PSYCHOLOGICAL ASPECTS OF PHASIC DEPRESSION DURING LITHIUM PROPHYLAXIS.
002075 02-15
PSYCHOLOGICAL AND DEONTOLOGIC PROBLEMS IN RELATION TO PROLONGED NEUROLEPTIC DRUG ACTION
002172 02-17
PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10
PSYCHOLOGICAL FEATURES OF PATIENTS WITH HYPERTENSION ATTENDING HOSPITAL FOLLOW-UP CLINICS.
002854 03-14
STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5 PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
003703 04-13
EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14
METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

PSYCHOMETRIC
TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 1B9 HOSPITALIZED PATIENTS.
000727 01-11
SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11
METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES: PSYCHOMETRIC CHANGES.
000740 01-11
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION
000B75 01-14
DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14

PSYCHOMIMETIC
IN VITRO O-DEMETHYLATION OF THE PSYCHOMIMETIC AMINE DIMETHOXY-4-METHYLPHENYL-2-AMINOPROPANE
003340 04-03

PSYCHOMOTOR
ACTIONS OF NARCOTICS ON BRAIN DOPAMINE METABOLISM AND THEIR RELEVANCE FOR PSYCHOMOTOR EFFECTS.
000148 01-03
VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE
000702 01-10
CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

EFFECTS OF DEXTROAMPHETAMINE ON PSYCHOMOTOR SKILLS
000889 01-14

THE EFFECT OF MINOR TRANQUILIZERS ON PSYCHOMOTOR PERFORMANCE
000997 01-15

RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02

A STUDY ON PSYCHOMOTOR EPILEPSY WITH KINDLED CAT PREPARATIONS.
001356 02-03

A COMPARATIVE CONTROLLED STUDY BETWEEN CARBAMAZEPINE AND DIPHENYLHYDANTOIN IN PSYCHOMOTOR EPILEPSY.
001861 02-11

EFFECT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
001995 02-14

A COMPARISON OF THE EFFECT OF IMIPRAMINE, NOMIFENSINE AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
002005 02-14

DISCRIMINATIVE RESPONSE CONTROL BY PSYCHOMOTOR STIMULANTS.
003034 03-17

PSYCHOMOTOR PROCEDURES TO DISTINGUISH BETWEEN ANTIDEPRESSANT MEDICATIONS: A COMPARISON OF THE EFFECTS OF NOMIFENSINE MALEATE, IMIPRAMINE HCL, AND PLACEBO ON THE PSYCHOMOTOR PERFORMANCE OF NORMAL MALES.
003744 04-14

PSYCHOMYOCOLOGICAL

PSYCHOMYOCOLOGICAL STUDIES OF AMANITA -- FROM ANCIENT SACRAMENT TO MODERN PHOBIA.
001063 01-17

PSYCHONEUROSIS

DOUBLE-BLIND COMPARATIVE TEST OF LORAZEPAM FOR PSYCHONEUROSIS.
000753 01-11

PSYCHONEUROTIC

HALOPERIDOL IN THE TREATMENT OF PSYCHONEUROTIC ANXIOUS OUTPATIENTS.
001792 02-10

A CLINICAL COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN PSYCHONEUROTIC INPATIENTS.
003603 04-10

PSYCHOORGANIC

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09

NOTE ON THE DYNAMICS OF THE PSYCHOORGANIC PROCESS.
000774 01-11

EFFECT OF PIRACETAM ON PSYCHOORGANIC SYNDROMES OF OLD PEOPLE.
003526 04-07

PSYCHOPATHIC

AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10

PSYCHOPATHOLOGICAL

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11

PSYCHOPATHOLOGICAL PROBLEM OF FRUSTRATION OF THE NEED TO BELONG IN THE LIGHT OF THREE CLINICAL CASES.
001793 02-10

CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY
002B86 03-15

PSYCHOPATHOLOGY

PSYCHOPATHOLOGY, PSYCHOPHARMACOLOGY AND THE ORGANIC BRAIN SYNDROMES. PART II.
002100 02-17

HORMONES, BEHAVIOR, AND PSYCHOPATHOLOGY: PAPERS FROM A MEETING.
002159 02-17

SOME CHARACTERISTICS OF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OF PSYCHOPATHOLOGY.
002204 03-03

PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08

THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA
003011 03-17

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE
003533 04-08

PSYCHOPHARMACA

A TIGHT PSYCHOTHERAPEUTICAL FRAMEWORK FOR THE DISCUSSION OF THE EFFECTS OF PSYCHOPHARMACA
001007 01-16

PSYCHOPHARMACEUTICALS

PRESCRIPTIVE GUIDANCE FOR USAGE OF PSYCHOPHARMACEUTICALS
001020 01-17

USE OF PSYCHOPHARMACEUTICALS FOR THE TREATMENT OF ABNORMAL BEHAVIOR OF OLIGOPHRENIC EPILEPTICS.
002772 03-11

NOSOTROPIC EFFECTS OF PSYCHOPHARMACEUTICALS.
002B70 03-14

PSYCHOPHARMACOGENETICS

PSYCHOPHARMACOGENETICS.
000BB8 01-14

PSYCHOPHARMACOLOGICAL

GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01

THE MECHANISM OF ACTION OF PSYCHOPHARMACOLOGICAL AGENTS ON BEHAVIOUR.
000391 01-04

VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09

PSYCHOPHARMACOLOGICAL STUDY ON THE DEPRESSIVE STATE IN MEDICAL PRACTICE.
000692 01-10

METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH: CHLORPROMAZINE -- A CASE IN POINT.
001008 01-16

A COMPARISON OF CONSUMPTION OF PSYCHOPHARMACOLOGICAL DRUGS.
001030 01-17

SURVEY AND CLASSIFICATION OF PSYCHOPHARMACOLOGICAL DRUGS.
001036 01-17

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
001561 02-04

POLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH.
00197B 02-14

DIAGNOSIS IN PLANNING PSYCHOPHARMACOLOGICAL THERAPY.
002099 02-17

ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04

SOME FACETS OF THE SCREENING OF PSYCHOPHARMACOLOGICAL AGENTS.
002954 03-16

PSYCHOPHARMACOLOGICAL RESEARCH
002979 03-17

ACETALDEHYDE AS A PSYCHOPHARMACOLOGICAL AGENT: TASK SPECIFICITY OF GENOTYPIC DIFFERENCES.
0033B0 04-04

PSYCHOPHARMACOLOGICAL INFLUENCE ON THE PREY CATCHING BEHAVIOR OF FERRETS.
003459 04-04

PSYCHOPHARMACOLOGY

A ROLE FOR DOPAMINE IN THE PSYCHOPHARMACOLOGY OF ELECTRICAL SELF-STIMULATION.
000300 01-04

THE BENZAMIDES IN PSYCHOPHARMACOLOGY SULPIRIDE AND SULTOPRIDE.
000520 01-07

CHILDRENS PSYCHOPHARMACOLOGY UNIT.
000729 01-11

PSYCHOPHARMACOLOGY OF THE PEPTIC ULCER
000759 01-11

PSYCHOPHARMACOLOGY OF THE LITHIUM ION
000B21 01-13

OBSERVATIONS ON THE USE OF PSYCHOPHARMACOLOGY IN PSYCHIATRIC HOSPITALS.
001012 01-17

PRESENT STATUS OF CLINICAL PSYCHOPHARMACOLOGY.
001017 01-17

PSYCHOPHARMACOLOGY IN ITS SECOND GENERATION.
001052 01-17

MANUAL OF PSYCHIATRIC THERAPEUTICS: PRACTICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY.
D01D74 01-17

PSYCHOPHARMACOLOGY RESEARCH WARD. TEN YEARS EXPERIENCE.
001076 01-17

THE PLANNING OF A THERAPEUTIC COMPARISON IN PSYCHOPHARMACOLOGY.
001077 01-17

SUMMARY ON PSYCHOPHARMACOLOGY IN SLEEP RESEARCH
DD1976 D2-14

PSYCHOPATHOLOGY, PSYCHOPHARMACOLOGY AND THE ORGANIC-BRAIN-SYNDROMES: PART II.
002100 02-17

AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDDL COMPARATIVE TRIAL.
002106 02-17

PSYCHOPHARMACOLOGY AND THE LAW: A FORENSIC PSYCHIATRISTS VIEWPOINT.
002118 D2-17

IN THE SERVICE OF PSYCHOPHARMACOLOGY RESEARCH: THE PSC-PRB, NIMH PROGRAM 1956-1976. (UNPUBLISHED PAPER).
00213B D2-17

PSYCHOPHARMACOLOGY -- A BIOLOGICAL APPROACH.
DD214D D2-17

THE NEW DRUG STATUTE AND THE FUTURE DF CLINICAL PSYCHOPHARMACOLOGY.
002141 02-17

PSYCHOPHARMACOLOGY -- A RECURRING BIBLIOGRAPHY.
002147 D2-17

PRODIGIOUS DEVELOPMENT OF PSYCHOPHARMACOLOGY.
002165 D2-17

CLINICAL PSYCHIATRY AND PSYCHDPHARMACOLOGY -- A REVIEW.
0D2168 02-17

THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY.
DD21B2 D3-D1

PROJECT SUMMARY: PSYCHDPHARMACOLOGY OF DRUG ABUSE.
002533 03-D4

THE PSYCHOPHARMACOLOGY OF BETA ADRENERGIC BLOCKADE: PHARMACDKINETIC AND EPIDEMIOLOGIC ASPECTS.
002599 D3-07

PSYCHOPHARMACOLOGY OF THE ELDERLY.
002765 03-11

CLINICAL ASSESSMENT FOR PEDIATRIC PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER).
DD2775 D3-11

PSYCHDPHARMACDLDGY AND CONVULSIVE THERAPY.
DD2952 D3-16

CURRENT DEVELOPMENTS IN PSYCHOPHARMACOLOGY.
DD29B9 D3-17

ANNUAL MEETING OF THE SCANDINAVIAN ASSOCIATION OF PSYCHOPHARMACOLOGY.
DD2991 D3-17

PSYCHOPHARMACOLOGY AND CONSERVATIDN.
0D2994 D3-17

HANDBOOK OF PSYCHOPHARMACOLOGY.
DD2997 03-17

CHILD AND ADDLESCENT PSYCHDPHARMACDLOGY IN THE MID-SEVENTIES: PROGRESS OR PLATEAU?.
0D3D3B D3-17

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
003042 03-17

PSYCHOPHARMACOLOGY AND SOCIAL WORK SKILLS.
0038B4 D4-17

PSYCHOPHARMACOLOGY.
0D39DD D4-17

PSYCHOPHARMACOTHERAPY

INTERMITTENT PSYCHOPHARMACOTHERAPY- REVIEW OF LITERATURE AND CRITICAL REMARKS.
DD2658 03-DB

DERMATOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS DURING PSYCHOPHARMACOTHERAPY.
002921 03-15

PSYCHOPHYSIOLOGIC

PROLACTIN AND PSYCHOPHYSIOLOGIC MEASURES AFTER SINGLE-DOSES OF THIORIDAZINE
003693 D4-13

PSYCHOPHYSIOLOGICAL

BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH.
000710 01-1D

PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE INFLUENCE OF VARIOUS PSYCHOLOGICAL CONDITIONS AND PROPRANOLOL ON HEMODYNAMIC CARDIOVASCULAR PARAMETERS IN HYPERTENSIVE PATIENTS.
000916 01-14

PSYCHOPHYSIOLOGICAL ASPECTS IN EEG ANALYSIS OF CEREBRAL DRUG EFFECTS.
001918 02-13

EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14

PSYCHOSES

MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
00D499 01-07

ON THE ORIGIN OF SCHIZOPHRENIC PSYCHOSES.
0DD573 01-08

CLINICAL PHYSIOLOGICAL STUDY OF DRUGS FOR THE TREATMENT OF PSYCHOSES.
000653 01-09

COMPARISDN OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11

BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
DD0730 01-11

AFFECTIVE PSYCHOSES FOLLDWING RENAL TRANSPLANT.
001733 D2-09

EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001829 02-11

RECENT DEVELOPMENTS IN THE CHEMOTHERAPY OF SCHIZOPHRENIC PSYCHOSES.
002625 D3-08

EXPERIENCE IN THE USE OF DELAYED ACTION DRUGS IN THE PREVENTION OF DELIRIDUS PSYCHOSES.
DD2746 03-11

BETA-ADRENERGIC BLOCKING AGENTS IN THE TREATMENT OF PSYCHOSES. A REPORT ON 17 CASES.
DD2790 03-11

AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
DD2796 03-12

PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW.
D03885 D4-17

PSYCHOSIS

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
0D0762 D1-11

PARANOID PSYCHOSIS WITH ONEIROIDAL ELEMENTS DURING THE COURSE OF REDLICH-FLATAUS DISEASE.
D00769 01-11

MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
00D806 D1-13

CATECHDLAMINES AND PSYCHOSIS.
DDD813 01-13

SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY DN THE PROBLEM OF PARANOID PSYCHOSIS.
00DB38 01-13

COCAINE, KINDLING, AND PSYCHOSIS.
000911 D1-14

EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
0D0952 01-15

PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
D01333 02-D3

NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
D01679 02-0B

RAPID TREATMENT OF ACUTE PSYCHOSIS.
D01726 02-D9

PSYCHOANALYTIC ASPECTS OF THE TREATMENT OF MANIC-DEPRESSIVE PSYCHOSIS.
0D1754 D2-09

INDICATIONS FOR LITHIUM SALT IN OTHER THAN MANIC-DEPRESSIVE PSYCHOSIS.
001857 D2-11

INDUCED PSYCHOSIS FROM INGESTION OF DATURA-SUAVEOLENS.
001871 02-12

NEUROTRANSMITTER AND PSYCHOSTIMULANT-INDUCED PSYCHOSIS ACTIVATION.
D0197D 02-14

ACUTE ORGANIC-BRAIN-SYNDROME PSYCHOSIS WITH METHYLDOPA THERAPY.
002D46 02-15

PSYCHOSIS IN PATIENT ON BROMOCRIPTINE AND LEVODOPA WITH CARBIDOPA.
002054 02-15

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05

PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT.
002619 03-08

CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENIC PSYCHOSIS.
002620 03-0B

TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-0B

DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN.
002701 03-09

TREATMENT OF DRUG-INDUCED PSYCHOSIS WITH DIPHENYLHYDANTOIN.
002761 03-11

CANNABIS PSYCHOSIS.
002920 03-15

EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-15

IDENTICAL PSYCHOSIS IN A PAIR OF MONOZYGOTIC TWINS.
002966 03-17

APPLICATION OF BETA-RECEPTOR BLOCKING AGENTS IN COMBINED THERAPY OF ENDOGENOUS PSYCHOSIS.
002972 03-17

ADVERSE EFFECTS OF PHARMACOTHERAPY IN CHILDHOOD PSYCHOSIS.
002988 03-17

INTERACTIONS OF ANTIPSYCHOTIC DRUGS WITH NOREPINEPHRINE AND CEREBELLAR NEURONAL CIRCUITRY: IMPLICATIONS FOR THE PSYCHOBIOLOGY OF PSYCHOSIS.
003143 04-03

DIAZEPAM WITHDRAWAL PSYCHOSIS: A CASE REPORT.
003772 04-15

NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
003816 04-15

BENZODIAZEPINES AND WITHDRAWAL PSYCHOSIS: REPORT OF THREE CASES.
003B17 04-15

MELATONIN, MSH, AND PSYCHOSIS.
003B47 04-17

PSYCHOSOCIAL

LX -- THIRTY-FIVE YEARS OF PSYCHOSOCIAL DEPRIVATION.
002101 02-17

EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
002222 03-03

ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10

NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1: GROUP PROFILES.
002940 03-15

PSYCHOSOMATIC

PSYCHOSOMATIC ASPECTS OF CATECHOLAMINE DEPLETION: COMPARATIVE STUDIES OF METABOLIC, ENDOCRINE AND AFFECTIVE CHANGES.
000197 01-03

PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE.
000492 01-07

PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION. RESULTS OF THE GROUP THERAPY.
000635 01-09

EXPERIMENTAL CLINICAL USE OF PINAZEPAM IN PSYCHOSOMATIC MEDICINE.
000673 01-10

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY.
000674 01-10

CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
000689 01-10

LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
00070B 01-10

BENZODIAZEPINE -- DERIVATIVES IN PSYCHOSOMATIC DISORDERS: A PHARMACOLOGICAL RELATED PSYCHOPHYSIOLOGICAL APPROACH.
000710 01-10

A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SULPIRIDE AND OXAZOLAM IN THE FIELD OF PSYCHOSOMATIC MEDICINE.
000713 01-10

BROMAZEPAM IN PSYCHOSOMATIC MEDICINE.
000771 01-11

RESEARCH ON THE USE OF SULPIRIDE IN PSYCHOSOMATIC MEDICINE: A STUDY OF 104 CASES.
000816 01-13

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001035 01-17

THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01-17

PSYCHOSOMATOSIS

PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION: EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000B52 01-13

PSYCHOSTIMULANT

METAPRAMINE AS ANTIDEPRESSANT AND PSYCHOSTIMULANT.
002589 03-07

EXPERIENCE WITH THE USE OF SYDNOCARB, A NEW PSYCHOSTIMULANT.
002612 03-0B

ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE.
0033B3 04-04

PSYCHOSTIMULANT-INDUCED

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04

NEUROTRANSMITTER AND PSYCHOSTIMULANT-INDUCED PSYCHOSIS ACTIVATION.
001970 02-14

PSYCHOSTIMULANTS

EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
0002B4 01-04

EFFECT OF AMPHETAMINE-TYPE PSYCHOSTIMULANTS ON BRAIN METABOLISM.
000817 01-13

PSYCHOSTIMULANTS AND CHILDREN: A REVIEW AND ANALYSIS.
001B66 02-11

PSYCHOSTIMULATING

EXPERIMENTAL STUDY OF THE PSYCHOSTIMULATING ACTIVITY OF AMANTADINE.
001025 01-17

PSYCHOSYNDROME

PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10

PSYCHOTHERAPEUTIC

PHENYLALKYLAMINES WITH POTENTIAL PSYCHOTHERAPEUTIC UTILITY: 1. 2-AMINODIMETHOXYMETHPHENYLBUTANE.
001114 02-02

PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS-OXIDE USED IN THE TREATMENT OF BORDERLINE PSYCHOTIC STATES.
001836 02-11

PSYCHOTHERAPEUTIC DRUGS: HOW TO MINIMISE COMPLICATIONS OF THERAPY.
002024 02-15

PSYCHOTHERAPEUTIC AND CHEMOTHERAPEUTIC RELATIONS IN INSOMNIA.
002727 03-10

INTRAVENOUS METHYLPHENIDATE AS A DIAGNOSTIC AND PSYCHOTHERAPEUTIC INSTRUMENT IN ADULT PSYCHIATRY.
002768 03-11

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003B04 04-15

PSYCHOTHERAPEUTICAL

A TIGHT PSYCHOTHERAPEUTICAL FRAMEWORK FOR THE DISCUSSION OF THE EFFECTS OF PSYCHOPHARMACA.
001007 01-16

PSYCHOTHERAPY

PSYCHOTHERAPY AND BEHAVIOUR THERAPY.
000925 01-14

OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY.
001755 02-09

EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
001815 02-11

MDA ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY.
001877 02-12

A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 03-08

THE USE OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) AS AN ADJUNCT TO BRIEF INTENSIVE PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS. (PH.D. DISSERTATION).
002735 03-10

THE USE OF PSYCHEDELICS IN PSYCHOTHERAPY
0D3514 04-06

PSYCHOTHERAPY AND PHARMACOTHERAPY: CONCEPTUAL ISSUES.
003857 04-17

PSYCHOTIC

POSSIBILITY OF USING 7-CHLORO-5-(2-CHLOROPHENYL) 1,3-DIHYDRO-2H-1,4 BENZODIAZEPINE-2-ONE. IN CASES OF PSYCHOTIC SYMPTOMATOLOGY.
0D05DB 01-D7

ACUTE PSYCHOTIC EPISODE IN A CHRONIC PARANOID PERSONALITY.
000540 01-08

PSYCHOTIC MASKED DEPRESSION OR BLACK MASK FOR DEPRESSION.
000613 01-D9

PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION. RESULTS OF THE GROUP THERAPY.
000635 01-09

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11

POLYDIPSIA, HYPONATREMIA, AND SEIZURES IN PSYCHOTIC PATIENTS.
000968 01-15

PSYCHOTIC EXACERBATIONS PRODUCED BY NEUROLEPTICS.
001715 02-08

PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS-OXIDE USED IN THE TREATMENT OF BORDERLINE PSYCHOTIC STATES.
001836 02-11

PERSISTENT PSYCHOTIC PHENOMENA FOLLOWING ONE DOSE OF PENTAZOCINE.
002025 02-15

CHEMOTHERAPEUTIC CHOICES OF NATIVE AND FOREIGN PSYCHIATRISTS PREFERENCES FOR AN ACUTE PSYCHOTIC EPISODE.
002163 D2-17

FLUPHENAZINE-DECANOATE IN CHRONIC PSYCHOTIC SUBJECTS.
002610 03-DB

EARLY OBSERVATIONS OF THE EFFECT OF PROPRANOLOL ON PSYCHOTIC PATIENTS.
002739 03-11

PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE -- ESPECIALLY LIGHT CONSCIOUSNESS IMPAIRMENTS.
002B95 D3-15

INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
0D29DB D3-15

A SLEEP STUDY OF ACUTE PSYCHOTIC STATES DUE TO ALCOHOL AND MEPROBAMATE ADDICTION.
DD2937 D3-15

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
00352B 04-DB

LONG-TERM TREATMENTS OF PSYCHOTIC STATES.
DD3613 D4-11

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
DD372D D4-13

ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
DD3762 04-15

MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION.
0D3856 D4-17

PSYCHOTICS

CORRELATION BETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
DD1741 D2-09

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION
DD2DB2 D2-15

PSYCHOTOGENS

MAMMALIAN BIOSYNTHESIS OF POTENTIAL PSYCHOTOGENS DERIVED FROM DOPAMINE.
DDD793 D1-12

PSYCHOTOLYSIS

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
00352B D4-D8

PSYCHOTOMIMETIC

PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES. 5. 4-ALKYL-2,5 DIMETHOXYPHENYLISOPROPYLAMINES.
0D0226 01-03

SULFUR ANALOGS OF PSYCHOTOMIMETIC AMINES.
002186 03-01

STUDIES ON THE RELATIONSHIP OF BINDING AFFINITY TO PSYCHOACTIVE AND ANTICHOLINERGIC POTENCY OF A GROUP OF PSYCHOTOMIMETIC GLYCOLATES.
003091 04-03

PSYCHOTOMIMETICS

A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF PSYCHOTOMIMETICS (LSD-25, OOM AND KETAMINE).
000395 01-04

PSYCHOTROPIC

PREDICTING PSYCHOTROPIC PROPERTIES OF NEW DRUGS ON THE BASIS OF ANIMAL EXPERIMENTS.
000024 D1-02

CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE -- EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS.
000041 01-D3

STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE.
0DD1B2 01-03

ENTHALPIES OF HYDROGEN BONDING IN PSYCHOTROPIC DRUGS.
000191 D1-D3

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIDANCE IN RATS.
000469 01-06

METHODOLOGICAL PROBLEMS IN CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
00D4B3 D1-07

STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07

BETA-BLOCKERS AS PSYCHOTROPIC DRUGS.
000516 01-D7

CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
000518 D1-D7

PSYCHOTROPIC EFFECT OF PYROVALERONE (F-1983), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
0DD519 D1-07

COMPARATIVE STUDY OF THREE PSYCHOTROPIC DRUGS IN THE TREATMENT OF DEPRESSIONS.
D00645 01-D9

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
DD0746 01-11

PSYCHODYNAMICS OF PSYCHOTROPIC DRUG THERAPY
D00765 D1-11

EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION.
000875 01-14

INFLUENCING ACHIEVEMENT MOTIVATION THROUGH PSYCHOTROPIC DRUGS: 2. DIFFERENTIAL INFLUENCING OF MOTIVATION PRODUCTION WITH 6 ACHIEVEMENT MOTIVATION PICTURES.
000876 D1-14

THE EFFECTS OF PSYCHOTROPIC DRUGS UPON DRIVING RELATED SKILLS.
0DDBB2 01-14

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS.
000929 D1-15

AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
00D971 D1-15

SECONDARY EFFECTS OF PSYCHOTROPIC DRUGS.
000975 D1-15

METHODOLOGICAL PROBLEMS IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
0010D5 D1-16

USE AND ABUSE OF PSYCHOTROPIC DRUGS.
001D16 D1-17

PSYCHOTROPIC MEDICATIONS.
001D2B D1-17

EMERGENCY CASES AND PSYCHOTROPIC DRUGS.
001D29 D1-17

PRESENT AND FUTURE TRENDS IN PSYCHOTROPIC DRUGS
001D37 D1-17

TREATING THE AGED WITH PSYCHOTROPIC DRUGS
D0103B D1-17

THE USE OF PSYCHOTROPIC DRUGS IN DEVELOPING COUNTRIES
001D4B D1-17

PSYCHOTROPIC DRUG USE IN FAMILY PRACTICE
001050 01-17
PROPOSED GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF PSYCHOTROPIC DRUGS (REPLICATED).
001053 01-17
CERE8RAL NEUROTRANSMISSION AND PSYCHOTROPIC DRUGS.
001065 01-17
THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01-17
ADMINISTRATION OF PSYCHOTROPIC DRUGS FROM THE STANDPOINT OF THE GENERAL PRACTITIONER.
001071 01-17
PSYCHOTROPIC DRUG KNOWLEDGE.
001079 01-17
PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN
001200 02-03
INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED 8Y THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03
EFFECT OF PSYCHOTROPIC DRUGS ON CAUDATE SPINDLE IN CATS.
001250 02-03
ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
001602 02-04
ELECTROENCEPHALOGRAMS IN SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC DRUGS.
001706 02-08
A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN.
0017B5 02-10
THE USE OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF CHRONIC, SEVERE PAINS.
001834 02-11
CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS AND HYPERACTIVITY IN CHILDREN.
001B47 02-11
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13
SLEEP AND PSYCHOTROPIC DRUGS: CLINICAL ASPECTS.
001957 02-14
COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14
INTRODUCTION- IMPORTANCE OF PSYCHOTROPIC DRUGS IN SLEEP RESEARCH.
001975 02-14
PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
001991 02-14
SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTROPIC DRUG USE DURING PREGNANCY.
002010 02-15
PSYCHOTROPIC DRUGS AND THE EYE.
002036 02-15
ON THE SWELLING OF THE DIAPHRAGM AMONG PATIENTS TAKING PSYCHOTROPIC DRUGS (SECOND REPORT).
002077 02-15
DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION.
0020B2 02-15
UPDATING PSYCHOTROPIC DRUG THERAPY.
002109 02-17
PSYCHOTROPIC DRUGS IN OPIOID ADDICTS ON METHADONE TREATMENT.
002119 02-17
PSYCHOTROPIC DRUG PRESCRIPTION IN FAMILY PRACTICE.
002124 02-17
THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17
PSYCHOTROPIC DRUG ASSESSMENT -- CURRENT STATUS, FUTURE PROSPECTS. (UNPUBLISHED PAPER)
002139 02-17
PRACTICAL USE OF PSYCHOTROPIC DRUGS IN CHILDREN
002175 02-17
PSYCHOTROPIC DRUG USE IN FIVE CITY HOSPITALS.
002177 02-17
THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED BEHAVIOURAL RESPONSES IN MICE
0021BB 03-02
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03
SOME EFFECTS OF INTERACTION OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS.
002295 03-03
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
002305 03-03
COMPARATIVE STUDY OF THE EFFECT OF CERTAIN PSYCHOTROPIC DRUGS ON 8RAIN NA+-, K+-ATPASE ACTIVITY IN VITRO.
002382 03-03
THE INFLUENCE OF PSYCHOTROPIC DRUGS UPON EMOTIONS.
002432 03-04
EFFECTS OF PSYCHOTROPIC DRUGS UPON THE HYPOTHALAMIC RAGE RESPONSE IN CATS.
002493 03-04
EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
002512 03-04
EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
002548 03-04
CORRELATION OF 8EHAVIORAL, BIOCHEMICAL, AND LOCOMOTOR EFFECTS OF SELECT PSYCHOTROPIC AGENTS IN THE MOUSE. (PH.D DISSERTATION).
002560 03-04
CYTOTOXIC ACTION OF PSYCHOTROPIC DRUGS ON LEUKOCYTES IN VITRO.
002570 03-05
APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY: DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM
0025B6 03-06
PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
002760 03-11
THE MODE OF ACTION OF PSYCHOTROPIC DRUGS.
002807 03-13
VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIDATION
002B11 03-13
THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
002864 03-14
THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15
INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
00290B 03-15
A REVIEW OF PSYCHOTROPIC MEDICATIONS AND THE GLAUCOMAS.
002926 03-15
EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
00292B 03-15
STUDIES ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS.
002958 03-17
INTERACTION OF ALCOHOL WITH PSYCHOTROPIC DRUGS.
002973 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 3.
002975 03-17
PSYCHOTROPIC DRUG USE IN THE ELDERLY: PUBLIC IGNORANCE OR INDIFFERENCE?.
0029B0 03-17
PSYCHOTROPIC DRUGS IN THE CLINIC AND IN PRACTICE.
002995 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY COMMENT 2.
003007 03-17
PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE.
003019 03-17
ALLEGED PSYCHOTROPIC DRUG USE IN THE ELDERLY. COMMENT 1.
003022 03-17
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
00305B 04-01
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITION AND CALCULATION OF CONFORMATIONAL PARAMETERS.
003059 04-01
PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-03
EFFECT OF PSYCHOTROPIC AGENTS UPON THE BLASTOGENIC RESPONSE OF HUMAN T-LYMPHOCYTES.
003656 04-13

PATIENT DRUG MONITORING: LABORATORY STUDIES FOR PSYCHOTROPIC DRUGS.
003787 04-15
PSYCHOTROPIC DRUG-INDUCED BLADDER DECOMPENSATION.
003797 04-15
A FIVE-YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS.
003849 04-17
PSYCHOTROPIC DRUGS AND MIGRAINE.
003887 04-17
APPEALS USED IN ADVERTISEMENTS FOR PSYCHOTROPIC DRUGS: AN EXPLORATORY STUDY.
003899 04-17

PSYCHOTROPICS
POTENTIAL PSYCHOTROPICS XI. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE.
000004 01-01
POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
003848 04-17

PUBLIC
PUBLIC INTEREST REPORT NO. 19 -- THE OVERUSE OF TRANQUILIZERS IN OLDER PATIENTS.
001B20 02-11
PSYCHOTROPIC DRUG USE IN THE ELDERLY: PUBLIC IGNORANCE OR INDIFFERENCE?.
002980 03-17

PULMONAL
ON THE MECHANISM OF PULMONAL HYPERTENSION INDUCED BY ANOREXIC AGENTS.
003223 04-03

PULSE
EFFECTIVENESS OF ATRIAL PACING IN MACACA-MULATTA AS A FUNCTION OF PACING PULSE INTENSITY: MODIFICATION BY ATROPINE AND PROPRANOLOL.
003270 04-03

PUNISHED
EFFECTS OF PENTOBARBITAL ON PUNISHED BEHAVIOR AT DIFFERENT SHOCK INTENSITIES.
001607 02-04
INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-04

PUNISHMENT
PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION: EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
002497 03-04
EFFECT OF CATECHOLAMINERGIC DRUGS ON SYSTEMS OF REWARD AND PUNISHMENT IN EXPERIMENTS ON CATS.
002518 03-04
RESISTANCE TO PUNISHMENT AND EXTINCTION FOLLOWING RESPONDING UNDER METHAMPHETAMINE OR SECOBARBITAL. (PH.D. DISSERTATION).
002534 03-04

PUPILLOMOTOR
A METHOD FOR STUDYING PUPILLOMOTOR EFFECTS OF NEUROLEPTICS.
000556 01-0B

PUPS
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04

PURCHASES
A FIVE-YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS.
003849 04-17

PURKINJE
ADDITIVE EFFECTS OF ETHANOL AND PURKINJE CELL LOSS IN THE PRODUCTION OF ATAXIA IN MICE.
001312 02-03
LEAD BLOCKADE OF NORADRENERGIC INHIBITION IN CEREBELLAR PURKINJE NEURONS. (UNPUBLISHED PAPER).
001398 02-03
FURTHER ELECTROPHYSIOLOGICAL EVIDENCE FOR THE GABA-LIKE EFFECT OF DROPERIDOL IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
002302 03-03
THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
002337 03-03

PUROMYCIN-INDUCED
PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04

PUTATIVE
EFFECTS OF 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-03
EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
001135 02-03
EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-03
THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05

PYRAMIDAL
IS GLUTAMIC-ACID THE PYRAMIDAL TRACT NEUROTRANSMITTER?.
001392 02-03
EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
003313 04-03

PYRASIDOL
DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

PYRAZIDOL
EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

PYRAZOLE
EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-04

PYRIDOXINE
DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
003254 04-03

PYRIMIDINES
(SPIRO(PIPERIDINETHIAZOLE) 3,2-A)PYRIMIDINES): ANTIDEPRESSANTS AND PLATELET-AGGREGATION INHIBITORS.
001116 02-02

PYRIMIDOINDOLE
PHARMACOLOGICAL ACTION OF PYRIMIDOINDOLE DERIVATIVES.
002187 03-02

PYRITHIOXINE
TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA
000743 01-11
PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION: CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10

PYROGEN
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT. NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
000181 01-03

PYROGEN-INDUCED
THE EFFECT OF LITHIUM-CHLORIDE ON MORPHINE-INDUCED AND PYROGEN-INDUCED HYPERTHERMIA IN RATS.
001161 02-03

PYROVALERONE
PSYCHOTROPIC EFFECT OF PYROVALERONE (F-19B3), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07
ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE
003383 04-04

PYRROLIDONE
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PYRROLODIAZEPINE
NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY.
002196 03-02

PYRROXAN
EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

PYSCHOSES
IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

UAIL
EFFECTS OF DIMETHYLAMINOETHANOL UPON LIFE-SPAN AND BEHAVIOR OF AGED JAPANESE QUAIL.
003112 04-03

UALITIES
MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT
000127 01-03

ANTIFICATION
SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

ANTITATION
RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION.
003353 04-04

ANTITATIVE
WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION
000403 01-04
QUANTITATIVE DETERMINATION OF METOPROLOL IN PLASMA AND URINE BY GAS CHROMATOGRAPHY.
000470 01-06
IDENTIFICATION AND QUANTITATIVE GLC DETERMINATION OF IPRONIAZID IN HUMAN URINE.
000B14 01-13
ASSESSING THE PSYCHOACTIVITY OF CLOXAZOLAM (MT-14-411) BY QUANTITATIVE EEG AND PSYCHOLOGICAL STUDIES.
000915 01-14
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03
PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
001991 02-14
QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-DIBENZOTHIEPINS, ATAXIA IN MICE.
002577 03-05
DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002B73 03-14
DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002893 03-15
QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003053 04-01
QUANTITATIVE ASSESSMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE IN MICE.
003140 04-03
QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03
A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04
FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-28175)).
003625 04-11
A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003876 04-17

ANTUM
COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
0021B3 03-01

ATERNARY
QUATERNARY PILOCARPINE DERIVATIVES AS POTENTIAL ACETYLCHOLINE ANTAGONISTS. 2. ALTERATIONS IN THE LACTONE AND IMIDAZOLE MOIETIES.
000482 01-07
A NOTE ON THE ISOLATION AND IDENTIFICATION OF THE QUATERNARY ALKALOIDS OF PHELLODENDRON-WILSONII.
001098 02-01
NO EFFECTS OF QUATERNARY NEUROLEPTICS ON HUMAN PROLACTIN AND ADENYL-CYCLASE.
003BB1 04-17

QUESTIONNAIRE
FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) 8Y HEALTHY SUBJECTS.
002093 02-16

QUID
BETEL QUID AND REACTION TIME.
000920 01-14

QUINAZOLINES
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 75. 7-HYDROXYAMINOBENZODIAZEPINES AND DERIVATIVES.
001096 02-01

QUINAZOLONES
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 04-02

QUINIDINE
CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17

QUININE
DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04
CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

QUIPAZINE
THE EFFECTS OF QUIPAZINE ON 5-HT METABOLISM IN THE RAT BRAIN.
000120 01-03

R-DOM
BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL-3912A) WITH R-DOM AND S-AMPHETAMINE.
003470 04-04

R-16341
A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIDOL (R-16341).
002656 03-08

R-16470
USE OF DEXETIMIDE (R-16470) WITH EXTRAPYRAMIDAL SYNDROMES CAUSED BY NEUROLEPTICS.
002061 02-15

R-806
R-806, A TETRACYCLIC ANTIDEPRESSANT: AN EARLY PHASE-TWO STUDY.
003523 04-07

RABBIT
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01
THE EFFECTS OF ALCOHOL AND ATROPINE ON EEG AND BEHAVIOR IN THE RABBIT.
000258 01-03
UPTAKE OF 5-HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION.
0011B7 02-03
EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA.
001324 02-03
EFFECT OF ADRENERGIC NEURON BLOCKING AGENTS AND BIGUANIDES ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
001325 02-03
SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03
CHOLINERGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT.
001434 02-04
EFFECTS OF GUANIDINO COMPOUNDS ON RABBIT BRAIN MICROSOMAL NA-K-ATPASE ACTIVITY.
001630 02-05
PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DOG, RABBIT, GUINEA-PIG AND RAT.
001921 02-13
THE EFFECT OF KETAMINE UPON NOREPINEPHRINE AND DOPAMINE LEVELS IN RABBIT BRAIN PARTS.
002250 03-03

DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTIDN OF STIMULATION ELECTRDDE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03
NOVEL METABOLITE OF NITRAZEPAM IN THE RABBIT URINE.
002357 03-03
INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA DR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03
CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SUBSTANTIA-NIGRA IN THE RABBIT.
002557 03-04
LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03
PHARMACOKINETICS OF PENTOBARBITAL IN THE CAT AND CDMPARISONS WITH THE RABBIT AND MAN.
003317 04-03
EFFECTS OF INTRASTRIATAL INJECTIONS OF ATRDPINE AND METHACHOLINE DN THE APDMORPHINE-INDUCED GNAWING IN THE RABBIT.
0D34B5 04-D4

RABBITS
EFFECTS DF HALOPERIDOL AND LITHIUM DN BLDDD ALCDHOL LEVEL IN RABBITS.
000141 01-03
CROSS-TOLERANCE TO ANTINOCICEPTION ELICITED BY INTRACEREBRDVENTRICULAR ADMINISTRATION OF MESCALINE AND MDRPHINE TO RABBITS, AND EEG CORRELATES.
000323 01-04
DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-D4
CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENDUS INFUSION TO ANESTHETIZED RABBITS.
00045B 01-05
TERATDLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CDDEINE.
000462 01-05
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCDRTICAL BRAIN STRUCTURES DF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NDRMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS DN THEM.
000473 01-06
ETHANDL-INDUCED REGIONAL AND DOSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
001264 02-03
BETA-BLDCKADE DF MDRPHINE-INDUCED HYPERLACTACIDEMIA IN RABBITS.
001352 02-03
EFFECT DF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATIDN ON SERUM CHDLESTERDL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05
CLASSIFICATIDN OF PSYCHDACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06
CANNABINDID-INDUCED BEHAVIORAL CONVULSIONS IN RABBITS.
001649 02-06
EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINDL IN CDMBINATIDN WITH STIMULANT DRUGS IN RABBITS.
002434 D3-D4
CENTRAL CHDLINERGIC BLOCKADE BY SCDPDLAMINE AND HABITUATIDN, CLASSICAL CDNDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
00250B 03-04
MORPHINE-INDUCED REGIONAL AND DDSE-RESPONSE DIFFERENCES IN MULTIPLE-UNIT ACTIVITY IN RABBITS.
003197 04-03
ANTICONVULSANT DRUG ANTAGDNISM DF DELTA9-TETRAHYDRDCANNABINDL-INDUCED SEIZURES IN RABBITS.
003366 04-04
TRYPTAMINE: BIMDDAL ACTIONS ON THE EEG AND BEHAVIDR OF RABBITS.
003440 04-04
ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM DF RABBITS POISONED WITH METHYLMERCURY.
003500 04-D5

RACEMIC
A DOUBLE-BLIND CRDSS-DVER EVALUATIDN DF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLDRD DIHYDROHEMISUCCINYLOXYPHENYLBENZDDIAZEPINDNE) COMPARED TO ITS RACEMIC FDRM.
001670 02-07
CLINICAL EFFECTS AND PHARMACOKINETICS OF RACEMIC METHADONE AND ITS DPTICAL ISDMERS.
003694 04-1

RADIANT
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-0

RADIOACTIVE
USE OF RADIOACTIVE COPPER AND RADIOACTIVE ZINC IN PSYCHIATRIC DIAGNOSIS.
0029B3 03-1
EFFECT OF DXOTREMORINE AND SODIUM PENTDBARBITONE ON THE PHARMACOKINETICS DF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHDLINE.
003230 04-0

RADIOCRYSTALLOGRAPHIC
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLDGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISDN DF THE PARAMETRIC VALUES.
0D305B 04-0
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA OF POLYCYCLIC PSYCHOTROPIC AMINES. I. DEFINITIDN AND CALCULATION OF CONFDRMATIONAL PARAMETERS.
003059 04-0

RADIOENZYMATIC
SIMULTANEOUS RADIOENZYMATIC DETERMINATIDN OF PLASMA AND TISSUE ADRENALINE, NDRADRENALINE AND DDPAMINE WITHIN THE FEMTOMOLE RANGE.
D0046B 01-0

RADIOISOTOPE
INTRACEREBRAL DOPAMINE METABOLISM STUDIED BY A NOVEL RADIOISOTOPE TECHNIQUE.
00196B D2-1

RADIOPROTECTIVE
DIAZEPAM: RADIDPRDTECTIVE ACTION AND EFFECT ON TOXICITY AND RADIDPRDTECTIVE PDWER OF CYSTEAMINE.
003139 04-0

RAGE
EFFECTS OF PSYCHOTROPIC DRUGS UPON THE HYPDTHALAMIC RAGE RESPONSE IN CATS.
002493 03-0

RAISED
REDUCTIDN BY PROPRANOLOL DF RAISED URINARY DUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-0
THE EXCLUSION DF L-ISOLEUCINE DR DF L-LEUCINE FROM THE BRAIN DF THE RAT, CAUSED BY RAISED LEVELS DF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSIDN CAN BE PARTIALLY DVERCOME.
003120 04-0

RANDOMIZED
TREATMENT OF CEREBRAL INSUFFICIENCY SYMPTDMS IN THE ELDERLY. RANDDMIZED COMPARATIVE STUDY OF TRIVASTAL.
0007B6 01-1

RANGE
SIMULTANEOUS RADIDENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NDRADRENALINE AND DDPAMINE WITHIN THE FEMTDMOLE RANGE.
00046B 01-0
LITHIUM: ITS MODE AND RANGE OF ACTIDN.
003024 03-1

RANVIER
EFFECT OF ANICOTINE DN SOME PRDPERTIES DF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE.
001299 02-0

RAPE
DIETHYLSTILBESTROL IN THE TREATMENT OF RAPE VICTIMS.
002B99 03-1

RAPHE
DOSE-RESPDNSE RELATIDNSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN DR L-5-HYDRDXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
D00016 01-0
ACTIDN DF LSD ON RAPHE NEURONS AND EFFECT DN PRESUMED SEROTDNERGIC RAPHE SYNAPSES.
0000B0 01-0
HYPERTHERMIA FOLLOWING SELF-STIMULATIDN OF THE MEDIAN RAPHE IN THE RAT.
0003B2 01-0
EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTIDN TD THIS SUBSTANTIA-NIGRA IN RAT.
0011B9 02-0
ELECTRDPHYSIDLDGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CDNTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-0

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF ADRENERGIC SYSTEM
002246 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN
002247 03-03

THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
002281 03-03

INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
002487 03-04

STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-05

RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
0030B2 04-03

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03

INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03

STUDIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE.
003333 04-03

RAPID

EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
000281 01-04

RAPID TREATMENT OF ACUTE PSYCHOSIS.
001726 02-09

AVERSIVE SMOKING: CARBOXYHEMOGLOBIN LEVELS BEFORE AND AFTER RAPID SMOKING.
001903 02-13

RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION.
003353 04-04

PSYCHOTOLYSIS WITH HALOPERIDOL: RAPID CONTROL OF THE ACUTELY DISTURBED PSYCHOTIC PATIENT.
003528 04-0B

A POSITIVE RESPONSE TO RAPID TREATMENT.
003532 04-0B

FLUOTRACEN (SKF-2B175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-11

NALOXONE PRECIPITATED WITHDRAWAL: A METHOD FOR RAPID INDUCTION ONTO NALTREXONE.
003745 04-14

RARE

CLINICAL THERAPEUTIC REPORTS ON ADDICTION TO RARE DRUGS.
002969 03-17

RAT

INTERACTION OF BETA-PHENYLETHYLAMINE WITH DOPAMINE AND NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.
000002 01-01

DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01

HEAT-ESCAPE BEHAVIOR IN THE RAT FOLLOWING INTRAHYPOTHALAMIC INJECTION OF ACETYLCHOLINE.
000026 01-02

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03

EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
00003B 01-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON MONOAMINE-OXIDASE ACTIVITY OF RAT TISSUES IN VIVO.
000042 01-03

IDENTIFICATION OF 10,11 EPOXIDE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATED FROM RAT URINE.
000046 01-03

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03

INHIBITION OF RAT BRAIN MONOAMINE-OXIDASE BY FORMAMIDINES AND RELATED COMPOUNDS.
000048 01-03

DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-03

TISSUE DISTRIBUTION OF METOPROLOL-3H IN THE MOUSE AND THE RAT
000054 01-03

PHARMACOKINETIC STUDIES OF METOPROLOL-3H IN THE RAT AND THE DOG.
000056 01-03

OBSERVATIONS ON THE PHARMACOLOGY OF CHOLINOCEPTIVE NEURONES IN THE RAT BRAINSTEM.
000059 01-03

INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03

EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
000084 01-03

THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN.
0000B6 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D-AMPHETAMINE-SULFATE.
000088 01-03

THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT.
000098 01-03

SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03

GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

OBSERVATIONS ON THE FATE OF CYSTATHIONINE IN RAT BRAIN.
000115 01-03

THE EFFECTS OF QUIPAZINE ON 5-HT METABOLISM IN THE RAT BRAIN.
000120 01-03

A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03

MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03

ON THE EFFECT OF THE IONOPHORE-X-537A ON NEUROMUSCULAR TRANSMISSION IN THE RAT.
000131 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03

EFFECT OF THEOPHYLLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN.
000139 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03

A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN
000154 01-03

IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
00015B 01-03

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-03

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-03

THE EFFECTS OF VARIOUS AGENTS IN VITRO ON HOMOCARNOSINE CARNOSINE SYNTHETASE FROM RAT BRAIN.
0001B7 01-03

EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001BB 01-03

ANOMALOUS EFFECT OF PROBENECID ON RAT BRAIN PHENOLSULPHOTRANSFERASE.
000193 01-03

EFFECTS OF 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-03

DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
00019B 01-03

EFFECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES.
000199 01-03

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

EFFECTS OF PYRROXAN AND CHLORDIAZEPOXIDE ON BIOGENIC AMINE METABOLISM IN THE RAT BRAIN.
000205 01-03

STUDY OF THE PROTECTIVE EFFECT OF VITAMIN-A ON STRESS ULCER IN THE RAT.
000223 01-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
00023B 01-03

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN.
000256 01-03

THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES.
000257 D1-03

EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN
000263 01-03

EFFECT OF CHLORPROMAZINE AND ACETYLSALICYLIC-ACID IN VIVO ON LYSOSOMAL ENZYMES IN RAT BRAIN.
000266 01-03

EFFECTS OF CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL.
00026B 01-03

IMPAIRMENT OF HEPATIC MICROSOMAL DRUG METABOLISM IN THE RAT DURING DAILY DISULFIRAM ADMINISTRATION.
0D0269 D1-D3

ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
0DD279 01-04

SOME BEHAVIOURAL AND EEG STUDIES ON THE BEHAVIOURAL DEPRESSION PRODUCED IN THE RAT BY ETHANOLAMINE-O-SULPHATE, AN INHIBITOR OF GABA-TRANSAMINASE.
DDD2B5 01-04

EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
0DD294 D1-04

THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
D00304 D1-D4

TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
DDD321 01-04

SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT RAT.
0DD327 01-04

EFFECTS OF INTRACISTERNAL GABA OR GLUTAMIC-ACID UPON BEHAVIORAL ACTIVITY IN THE RAT.
00D32B D1-04

THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
D00336 01-D4

PAPAVERINE, DRUG-INDUCED STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04

TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04

GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
00037B 01-04

HYPERTHERMIA FOLLOWING SELF-STIMULATION OF THE MEDIAN RAPHE IN THE RAT.
0003B2 01-04

THE PAIN AGGRESSION INDUCED BY BRONOPOL IN THE RAT.
000394 01-04

EFFECTS OF P-CHLOROPHENYLALANINE ON ETHANOL SELF-SELECTION IN THE RAT.
000400 01-04

AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04

EFFECTS OF THE ADMINISTRATION OF TWO DOSES OF SULPIRIDE ON THE BEHAVIOUR OF THE RAT.
000414 01-04

BLOCKADE OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT BY NALTREXONE AND NALOXONE.
0D0421 01-04

5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 D1-04

EFFECTS OF L-TRYPTOPHAN AND L-METHIONINE ON ACTIVITY IN THE RAT
000434 01-04

EFFECTS OF LOW AND MODERATE DOSES OF CHLORPROMAZINE ON DISCRIMINATION LEARNING IN THE RAT.
000435 01-04

EFFECTS OF ANTICHOLINERGIC AGENTS ON CONDITIONED INHIBITION IN THE RAT. (PH.D. DISSERTATION).
0D0440 01-04

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

ANTAGONISM OF IMIPRAMINE POISONING BY ANTICONVULSANTS IN THE RAT
D00455 01-05

ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06

METABOLISM OF METOPROLOL-3H IN MAN, THE DOG AND THE RAT.
D00B04 D1-13

SLEEP: EFFECTS OF D- AND L-AMPHETAMINE IN MAN AND IN RAT.
0D0B96 01-14

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
DD1106 02-02

EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
DD1115 02-02

BIOSYNTHESIS OF RAT BRAIN PHOSPHATIDYLCHOLINES FROM INTRACEREBRALLY INJECTED CHOLINE.
DD1127 02-03

METABOLISM OF 1,3,7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT: NEW METABOLIC PATHWAY OF CAFFEINE.
00112B D2-03

IN VITRO AND IN VIVO INHIBITION OF RAT LIVER, BRAIN AND MUSCLE MONOAMINE-OXIDASE BY CHLORPROMAZINE AND IMIPRAMINE.
001129 02-03

EFFECT OF STRIATECTOMY ON THE COURSE OF PENTYLENETETRAZOL CONVULSIONS IN THE RAT.
001131 02-03

EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
D01135 02-03

EFFECTS OF FENFLURAMINE ON ACCUMULATION OF 5-HYDROXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN.
001137 D2-03

DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE.
001144 02-D3

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

IN VIVO CHANGES OF GUANOSINE 3,5 CYCLIC PHOSPHATE IN RAT CEREBELLUM BY DOPAMINERGIC MECHANISMS.
001158 02-03

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: NEUROCHEMICAL RESULTS.
001159 02-03

DOES COCAINE HAVE A POSTSYNAPTIC ACTION ON RAT ANOCOCCYGEUS MUSCLE?.
001163 02-03

CALCIUM UPTAKE INTO RAT PHEOCHROMOCYTOMA CELLS.
001165 02-03

DIHYDROERGOTAMINE BINDING TO RAT BRAIN MEMBRANES.
001169 02-03

EFFECT OF CARBAMAZEPINE ON CHOLINERGIC PARAMETERS IN RAT BRAIN AREAS.
001170 02-03

ON THE MECHANISM OF THE HYPERTENSIVE ACTION OF INTRASEPTAL BRADYKININ IN THE RAT.
001172 02-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ORALLY ADMINISTERED DISULFIRAM IN THE RAT.
0011B1 02-03

EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTION TO THIS SUBSTANTIA-NIGRA IN RAT.
0011B9 02-03

RECORDING OF THE ELECTROPHYSIOLOGICAL ACTIVITY OF THE LOCUS-COERULEUS IN THE RAT.
001191 02-03

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03

PSYCHOTROPIC DRUGS AND METABOLIC ENZYMES IN RAT BRAIN.
001200 02-03

MODIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001203 02-03

INTERACTION BETWEEN AMPHETAMINE AND PROGESTERONE: EFFECTS ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001204 02-03

EFFECTS OF FENTANYL AND DROPERIDOL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
001210 02-03

EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTION WITH P-CPA ON RAT BRAIN 5-HT.
001211 02-03

IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-03

EFFECTS OF MORPHINE ON CENTRAL CATECHOLAMINE TURNOVER, BLOOD PRESSURE AND HEART-RATE IN THE RAT.
001223 02-03

EFFECT OF DESMETHYLDIAZEPAM AND CHLORDESMETHYLDIAZEPAM ON 3,5 CYCLIC GUANOSINE MONOPHOSPHATE LEVELS IN RAT CEREBELLUM.
001225 02-03

UPTAKE OF 3,4 DIMETHOXYPHENYLETHYLAMINE-1-14C (14C-DMPEA) BY RAT TISSUES IN VITRO.
001229 02-03

AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03

THE EFFECTS OF MORPHINE AND METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS.
001236 02-03

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
001237 02-03

CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS.
001241 02-03

THE BINDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

DISTRIBUTION OF H3-DIMETACRINE IN RAT CEREBRAL CORTEX BY ELECTRON MICROSCOPIC AUTORADIOGRAPHY.
001249 02-03

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03

IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
001255 02-03

TAURINE AND COBALT-INDUCED EPILEPSY IN THE RAT: A BIOCHEMICAL AND ELECTROCORTICOGRAPHIC STUDY.
001256 02-03

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 02-03

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03

PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-03

DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03

PROTEIN METABOLISM IN THE RAT CEREBRAL CORTEX IN VIVO AND IN VITRO AS AFFECTED BY THE ACQUISITION ENHANCING DRUG PIRACETAM.
00130B 02-03

EFFECT OF THE ACQUISITION ENHANCING DRUG PIRACETAM ON RAT CEREBRAL ENERGY METABOLISM. COMPARISON WITH NAFTIDROFURYL AND METHAMPHETAMINE.
001309 02-03

CATECHOLAMINE-STIMULATED CYCLIC-GMP ACCUMULATION IN THE RAT PINEAL: PRESYNAPTIC SITE OF ACTION. (UNPUBLISHED PAPER).
001313 02-03

LITHIUM-INDUCED ALTERATIONS IN RAT GANGLIONIC LIPIDS.
00131B 02-03

A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

EFFECTS OF NEUROLEPTIC AGENTS ON CYCLIC-GMP IN RAT CEREBRAL CORTEX.
001322 02-03

REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03

RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03

THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-03

BIOCHEMICAL LOCALIZATION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITHIN CELLULAR ELEMENTS OF THE RAT CEREBRAL CORTEX.
001340 02-03

LONG-TERM EFFECTS OF N-2-CHLOROETHYL-N-ETHYL-2-BROMOBENZYLAMINE HYDROCHLORIDE ON NORADRENERGIC NEURONES IN THE RAT BRAIN AND HEART.
001345 02-03

PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 02-03

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVER GLYCOGEN SYNTHESIS.
001372 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-03

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-03

EFFECTS OF CANNABINOIDS ON THE PERFUSED RAT HEART.
001379 02-03

A DOPAMINE-STIMULATED ADENYLATE-CYCLASE IN RAT SUBSTANTIA-NIGRA.
001382 02-03

ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT.
001383 02-03

TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION.
001395 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03

PHARMACOKINETICS OF DL-NOREPHEDRINE 14C IN THE RAT.
001401 02-03

INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
001408 02-03

ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03

ACIDIC DOPAMINE METABOLITES IN CORTICAL AREAS OF THE RAT BRAIN: LOCALIZATION AND EFFECTS OF DRUGS.
001417 02-03

EFFECTS OF DRUGS ON THE FORMATION OF HOMOVANILLIC-ACID IN THE RAT RETINA.
001418 02-03

COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN.
001419 02-03

REGIONAL RAT BRAIN LEVELS OF 3,4 DIHYDROXYPHENYLACETIC-ACID AND HOMOVANILLIC-ACID: CONCURRENT FLUOROMETRIC MEASUREMENT AND INFLUENCE OF DRUGS.
00142D 02-D3

EFFECTS OF AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM FROM RAT BRAIN.
001421 02-D3

THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN.
001423 02-03

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
0D1424 D2-D3

EFFECT OF PROPRANOLOL ON RAT BRAIN NOREPINEPHRINE IN VITRO.
DD1427 02-03

REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03

SELF-ADMINISTRATION OF CAFFEINE BY THE RAT.
DD1436 D2-04

EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON RAT SOCIAL BEHAVIOUR.
DD1463 02-04

SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
D01464 02-04

EFFECTS OF LITHIUM-CHLORIDE ON SLEEP PATTERNS IN THE RAT.
D01465 02-D4

COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
DD1475 D2-D4

HORMONAL AND MONOAMINERGIC INFLUENCES ON MASCULINE COPULATORY BEHAVIOR IN THE FEMALE RAT.
D01477 02-04

RELATIONSHIP BETWEEN PHYSICAL DEPENDENCE AND TOLERANCE OF MORPHINE IN THE RAT.
001482 02-0

ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-0

EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-0

LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
001508 02-0

EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT.
001510 02-0

ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN.
001512 02-0

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 02-0

EFFECTS OF IMIPRAMINE ON AUDITORY SENSITIVITY IN THE RAT IN RELATION TO INITIAL SENSITIVITY.
001523 02-0

ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-0

LOCOMOTOR ACTIVITY AND EXPLORATION. THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT
001538 02-0

EFFECTS OF LESIONS OF THE CAUDATE NUCLEUS ON MORPHINE-DEPENDENCE IN THE RAT.
001539 02-0

EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT
001540 02-0

HALOPERIDOL AND LIGHT REINFORCEMENT IN THE RAT.
001541 02-0

SCOPOLAMINE: EFFECTS ON FEAR OR DEFENSE RESPONSES IN THE RAT.
001546 02-0

EFFECTS OF THE ANTIESTROGENS, MER-25 AND CI-628, ON RAT AND HAMSTER LORDOSIS.
001548 02-0

SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
0D1557 02-0

FURTHER INVESTIGATIONS ON THE EFFECTS OF ERGOMETRINE AND OTHER ERGOT DERIVATIVES FOLLOWING INJECTION INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
001562 02-0

SCOPOLAMINE AND FOOD-REINFORCED BEHAVIOR IN THE RAT.
001563 D2-0

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-0

THE EFFECTS OF D-AMPHETAMINE ON TEMPORAL DISCRIMINATION IN THE RAT.
001567 02-0

DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
0D157D 02-0

DIFFERENTIAL EFFECTS OF MORPHINE ON TWO-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
0D1575 D2-0

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT: PHARMACOLOGIC RESULTS.
001576 D2-0

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
D01577 02-0

SHORT AND LONG-TERM EFFECTS OF PRENATAL CANNABIS INHALATION UPON RAT OFFSPRING.
DD1622 02-0

THE EFFECT OF ALPHA AND BETA ADRENERGIC RECEPTOR BLOCKERS ON SLEEP IN THE RAT.
DD1624 02-0

THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
DD1626 02-0

THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN
001631 02-0

TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
D01641 02-0

THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS.
001642 02-05

EFFECTS OF MN2 ION AND OTHER DIVALENT CATIONS ON ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.
001643 02-05

ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN
001650 02-06

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-D6

PHARMACOKINETICS AND PLASMA BINDING OF DIAZEPAM IN MAN, DOG, RABBIT, GUINEA-PIG AND RAT.
001921 02-13

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN.
D021B5 03-01

GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-D3

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 D3-D3

PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS.
002210 03-D3

PHENOBARBITAL-INDUCED PROLONGATION OF HALF-LIFE AND ALTERATION OF DISTRIBUTION OF A PHENOTHIAZINE DRUG METABOLITE IN THE RAT.
002214 03-D3

CHANGES OF RAT CEREBELLAR GUANOSINE 3,5 CYCLIC PHOSPHATE BY DOPAMINERGIC MECHANISMS IN VIVO.
DD2215 03-03

NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-D3

FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
DD2223 03-03

EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
D02231 03-D3

REGIONAL DISTRIBUTION OF ETHANOL IN RAT BRAIN.
002236 03-D3

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE.
00223B 03-D3

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
DD2243 03-03

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
DD2253 D3-03

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
DD2257 D3-03

EFFECT OF CHLORPROMAZINE ON CYCLIC-AMP PHOSPHODIESTERASE IN RAT CEREBRAL CORTEX.
002264 D3-D3

BETA-ADRENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INDUCED CONTRACTIONS IN THE RAT UTERUS.
0D2269 03-D3

THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN.
002271 03-D3

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
DD2275 03-03

TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
002278 03-03

EFFECT OF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
0022B4 03-03

THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN.
002303 03-03

METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
002304 03-03

LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
002305 03-03

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN.
DD2306 03-D3

EFFECTS OF NEUROLEPTICS ON TYROSINE-HYDROXYLASE OF SYNAPTOSOMES OF THE RAT HYPOTHALAMUS.
002314 03-03

EFFECTS OF SCOPOLAMINE ON SMELL DISCRIMINATION IN THE RAT.
DD2316 D3-D3

OXIDATIVE PHOSPHORYLATION IN VARIOUS PARTS OF THE RAT BRAIN FOLLOWING MORPHINE ADMINISTRATION.
002321 03-D3

EFFECT OF METHYLMALONATE ON KETONE BODY METABOLISM IN DEVELOPING RAT BRAIN.
002330 03-03

THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
DD2332 03-03

COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03

EFFECTS OF ADENOSINE ANALOGS ON RAT CEREBRAL CORTICAL NEURONS.
0D2336 03-03

THE EFFECT OF DIPHENYLHYDANTOIN, DIAZEPAM AND CLONAZEPAM ON THE ACTIVITY OF PURKINJE CELLS IN THE RAT CEREBELLUM.
0D2337 03-D3

ACUTE LITHIUM AFFECTS ON RAT BRAIN GLUCOSE METABOLISM -- IN VIVO.
002339 03-D3

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: II. THE EFFECT OF INTRAVENTRICULAR PROSTAGLANDINS ON THE ACTION OF SOME DRUGS AND ON THE LEVEL AND TURNOVER OF BIOGENIC AMINES IN THE RAT BRAIN.
DD2340 03-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

ENHANCEMENT OF EFFECTS OF DOPAMINERGIC AGONISTS ON NEURONAL ACTIVITY IN THE CAUDATE-PUTAMEN OF THE RAT FOLLOWING LONG-TERM D-AMPHETAMINE ADMINISTRATION.
002344 03-D3

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
DD2347 03-D3

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
00234B 03-D3

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
DD235B D3-D3

EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
DD2363 D3-D3

EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT. (UNPUBLISHED PAPER).
DD2367 D3-D3

EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN.
D02373 D3-D3

EFFECT OF HYPOTHALAMIC HORMONES ON THE CONCENTRATION OF ADENOSINE 3,5-MONOPHOSPHATE IN INCUBATED RAT PINEAL GLANDS.
002374 03-D3

STUDIES ON THE EFFECT OF 5,5 DIPHENYLHYDANTOIN ON IN VITRO PROTEIN SYNTHESIS IN RAT 8RAIN.
002375 03-03

COMPARATIVE STUDIES ON THE ACTIONS OF CHLORPROMAZINE AN0 DIAZEPAM IN ISOLATE0 RAT HEART.
002378 03-03

DOPAMINE-SENSITIVE A0ENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
002385 03-03

METABOLISM OF 3-0-METHYL0OPA 8Y THE ISOLATE0 PERFUSE0 RAT LIVER.
002388 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 03-03

THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARE0 FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
002397 03-03

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AN0 GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
002398 03-03

POTENTIATION OF DOPAMINE COUPLED CYCLIC-AMP GENERATING SYSTEM IN THE MALE RAT HYPOTHALAMUS.
002401 03-03

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

FUNDAMENTAL MICROQUANTITATIVE STUDIES 8Y FLUOROHISTOCHEMICAL METHO0 ON FLUORESCENCE OF THE MONOAMINERGIC NEURONS IN RAT BRAIN.
00240B 03-03

HYPERTENSION AND CATECHOLAMINE 0ISTRIBUTION IN DIFFERENT PARTS OF THE RAT 8RAIN
002413 03-03

REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC 0OPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT 8RAIN
002436 03-04

EFFECT OF ISOLATION ON BAR8ITURATE ANESTHESIA IN THE RAT.
002440 03-04

INDUCTION OF EXCESSIVE GROOMING IN THE RAT BY FRAGMENTS OF LIPOTROPIN
002453 03-04

EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
00247B 03-04

DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTI0E PRECURSOR IN THE RAT.
002479 03-04

RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AN0 IN THE EFFECTS OF DIAZEPAM.
0024BB 03-04

A COMPARISON OF THE CENTRAL ACTIONS OF PROSTAGLANDINS A1, E1, E2, F1ALPHA, AND F2ALPHA IN THE RAT: I. BEHAVIORAL, ANTINOCICEPTIVE AND ANTICONVULSANT ACTIONS OF INTRAVENTRICULAR PROSTAGLANDINS IN THE RAT.
002520 03-04

POSSIBLE GABA ME0IATED CONTROL OF DOPAMINE DEPENDENT BEHAVIOURAL EFFECTS FROM THE NUCLEUS-ACCUM8ENS OF THE RAT.
002522 03-04

A RAT MODEL OF VIOLENT ATTACK BEHAVIOR. (PH.0. 0ISSERTATION).
002531 03-04

AN ANALYSIS OF BARBITURATE-INDUCED EATING AND DRINKING IN THE RAT.
002552 03-04

DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
002559 03-04

THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05

CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-0

THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE META8OLISM IN NUCLEI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
002584 03-0

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AN0 ITS PHARMACOLOGICAL INHI8ITION: A COMPARATIV KINETIC ANALYSIS.
002846 03-

EFFECTS OF CHLORPROMAZINE ON THE ISOLATED PERFUSED RAT HEAR
0030B4 04-

CHARACTERIZATION OF RAT SKELETAL MUSCLE MONOAMINE-OXIDASE
003085 04-

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
003088 04-

8INDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM: PARTIAL INHIBITION BY MORPHINE OR NALOXONE.
003089 04-

EFFECTS OF DISULFIRAM AND CHLORAL HYORATE ON THE META8OLISM OF CATECHOLAMINES IN RAT LIVER AND BRAIN.
003094 04-

PHARMACOLOGICALLY-INDUCED CHANGES IN THE 3:5 CYCLIC GUANOSINE MONOPHOSPHATE CONTENT OF RAT CERE8ELLAR CORTE DIFFERENCE BETWEEN APOMORPHINE, HALOPERI0OL AND HARMALINE.
003096 04-

IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM A8OUT THE EFFECTS OF MORPHINE ON UPTAKE AN0 RELEASE OF C14-0OPAMINE
003104 04-

THE EXCLUSION OF L-ISOLEUCINE OR OF L-LEUCINE FROM THE BRAIN O THE RAT, CAUSED BY RAISE0 LEVELS OF L-VALINE IN THE CIRCULATION, AND THE MANNER IN WHICH THIS EXCLUSION CAN B PARTIALLY OVERCOME.
003120 04-

REGIONAL TRANSPORT OF TRYPTOPHAN IN RAT BRAIN.
003125 04-

EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
003128 04-

THE INFLUENCE OF LITHIUM ON WATER BIN0ING ABILITY, CONSISTENC AND MACROMOLECULES IN THE RAT BRAIN.
003132 04-

EVIDENCE IN FAVOUR OF THE EXISTENCE OF A DOPAMINE-FREE PROLACTIN INHIBITING FACTOR (PIF) IN RAT HYPOTHALAMIC EXTRACTS.
003133 04-

STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GAB RECEPTOR BINDING IN RAT BRAIN.
003134 04-

INFLUENCE OF STRESS AN0 PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT.
003135 04-

EFFECTS OF GAMMA-AMINOBUTYRIC-ACI0 ON 33PI INCORPORATION INTO RAT BRAIN PHOSPHOLIPIDS IN VIVO.
003144 04-

IN VITRO AND IN VIVO STUDIES OF EXTRAPINEAL N-ACETYLTRANSFERASE OF RAT BRAIN.
003145 04-

KINETICS OF IN VIVO CONVERSION OF GAMMA-3H-AMINOBUTYRIC-AC TO GAMMA-3H-HYDROXYBUTYRIC-ACID BY RAT 8RAIN.
003154 04-

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNA8INOL AND CANNABI0IOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-

IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES.
00315B 04-

RIGI0ITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-

IN VITRO EFFECTS OF OPIATES ON CYCLIC-AMP IN RAT STRIATAL TISSUE.
003169 04-

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT 8RAIN.
003174 04-

EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RA BRAIN 5-HT TURNOVER.
003179 04-

THE EFFECT OF APOMORPHINE AND HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
003181 04-03

ON THE AROMATIC HYDROXYLATION OF AMPHETAMINE IN RAT LIVER MICROSOMES AND PERFUSED LIVER PREPARATIONS: EFFECTS OF LONG-TERM ADMINISTRATION.
003184 04-03

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES ON MONOAMINERGIC NEUROTRANSMISSION IN RAT BRAIN.
003193 04-03

EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN.
003204 04-03

REGIONAL DISTRIBUTION OF ENDOGENOUS AND PARENTERAL GLUTAMATE, ASPARTATE AND GLUTAMINE IN RAT BRAIN.
003207 04-03

DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
003212 04-03

TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
003219 04-03

THE HETEROGENEITY OF MONOAMINE-OXIDASE IN DISTINCT POPULATIONS OF RAT BRAIN MITOCHONDRIA.
003234 04-03

ONTOGENESIS OF DOPAMINE RECEPTOR BINDING IN THE CORPUS-STRIATUM OF THE RAT.
003235 04-03

EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
003251 04-03

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN.
003255 04-03

NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL.
003261 04-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

COMPARISON OF THE EFFECTS OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE ISOLATED PERFUSED RAT BRAIN
003274 04-03

ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN.
003276 04-03

COMPARATIVE DIURETIC ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, CANNABINOL AND HYDROCHLOROTHIAZIDE IN THE RAT.
003285 04-03

BENZODIAZEPINE RECEPTORS IN RAT BRAIN.
003287 04-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION.
003293 04-03

METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN.
003294 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN.
003299 04-03

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
003303 04-03

EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN.
003316 04-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-03

HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
003328 04-03

ANOREXIC AND BEHAVIOURAL EFFECTS OF A NEW IMIDAZOISOINDOLE DERIVATIVE (MAZINDOL) IN COMPARISON WITH D-AMPHETAMINE IN THE RAT.
003344 04-04

INHIBITION OF RAT PREDATORY AGGRESSION BY ACUTE AND CHRONIC D-AMPHETAMINE AND L-AMPHETAMINE.
003347 04-04

RAPID INDUCTION AND QUANTITATION OF MORPHINE-DEPENDENCE IN THE RAT BY PELLET IMPLANTATION
003353 04-04

EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-04

EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-04

EFFECTS OF N,N DIMETHYLTRYPTAMINE ON BEHAVIOURAL HABITUATION IN THE RAT.
003384 04-04

COCAINE EFFECTS ON SLEEP PARAMETERS IN THE RAT.
003403 04-04

A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTA8-TETRAHYDROCANNABINOL.
003423 04-04

SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

EFFECTS OF CENTRAL NOREPINEPHRINE DEPLETION ON THE INITIATION AND MAINTENANCE OF MATERNAL BEHAVIOR IN THE RAT.
003453 04-04

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04

FURTHER EVALUATION OF THE DISCRIMINATIVE EFFECTS OF MORPHINE IN THE RAT.
003460 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

EFFECTS ON MOTOR ACTIVITY FOLLOWING LOCAL APPLICATION OF GAMMA-AMINOBUTYRICACID (GABA) AND GABA-LIKE DRUGS INTO THE RAT NUCLEUS-ACCUMBENS.
003479 04-04

FACILITATION BY DEXAMETHASONE OF TOLERANCE TO ETHANOL IN THE RAT.
003486 04-04

HYPOTHALAMIC SELF-STIMULATION UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

INTERACTIONS OF SOME CHOLINOLYTIC ANTIPARKINSON DRUGS WITH NICOTINE AND OXOTREMORINE ON RAT DIAPHRAGM.
003495 04-05

THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-05

CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
003505 04-05

ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003860 04-17

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM: FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
003880 04-17

RATE

REGULATION OF BRAIN DOPAMINE TURNOVER RATE-PHARMACOLOGICAL IMPLICATIONS.
000078 01-03

THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE.
0005B7 01-09

ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000B49 01-13

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS.
001297 02-03

CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-D3

REGIONAL CHANGES IN THE RATE OF TURNOVER OF ACETYLCHOLINE IN RAT BRAIN FOLLOWING DIAZEPAM OR MUSCIMOL.
001431 02-03

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03

MESCALINE: ITS EFFECTS ON LEARNING RATE AND DOPAMINE METABOLISM IN GOLDFISH (CARASSIUS-AURATUS)
001611 02-04

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-0B

DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13

MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN.
D021B5 03-01

A NEW MICROMETHOD FOR DETERMINING THE EFFECTS OF DRUGS ON THE TURNOVER RATE OF ACETYLCHOLINE. (PH.D. DISSERTATION).
002274 03-03

THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03

THE EFFECTS OF ANTIPSYCHOTICS ON THE TURNOVER RATE OF GABA AND ACETYLCHOLINE IN RAT BRAIN NUCLEI.
002571 03-05

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
00317B 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
0D3295 04-03

ABSORPTION RATE, BLOOD CONCENTRATIONS, AND EARLY RESPONSE TO ORAL CHLORDIAZEPOXIDE.
D03731 D4-14

WITHDRAWAL FROM METHADONE MAINTENANCE: RATE OF WITHDRAWAL AND EXPECTATION.
0D3B9B 04-17

RATES

CATECHOLAMINES AND OPERANT RESPONSE RATES IN ALBINO RATS.
002555 03-04

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
DD3252 04-D3

RATING

RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
0DDBB0 01-14

DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
0017B7 D2-10

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0D19B6 02-14

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
D03547 D4-0B

VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
0035BB 04-10

COMPARATIVE VALUE OF RATING AND SELF-RATING SCALES IN DRUG TRIALS.
003592 04-10

NEW ANXIOLYTIC RATING SCALE.
003607 04-10

RATIO

THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEDULE.
001467 02-04

LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
00356B 04-09

ON THE SIGNIFICANCE OF THE ERYTHROCYTE LITHIUM TO PLASMA LITHIUM RATIO.
0036B6 04-13

RATIONAL

TOWARDS RATIONAL THERAPY WITH MONOAMINE-OXIDASE INHIBITORS.
000715 01-10

RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-08

SUGGESTIONS FOR A RATIONAL APPROACH TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001725 02-08

EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COMBINATION WITH RATIONAL PSYCHOTHERAPY.
001B15 02-11

THE RATIONAL USE OF ANXIOLYTICS.
001BB6 02-13

RATIONAL APPROACHES TO THE PHARMACOTHERAPY OF CHOREA.
002B03 03-13

RATS

REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
000D0B 01-01

EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS ON THERMOREGULATION IN RESERPINE-TREATED RATS.
000010 01-01

ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

ETHANOL AND THE RESPONSE TO ELECTRIC SHOCK IN RATS.
000063 01-03

PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03

L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
0001D3 01-03

TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
0D0109 01-03

LITHIUM-CARBONATE DISTRIBUTION AND ITS EFFECTS ON THE OTHER IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 01-03

DOPAMINERGIC CHOLINERGIC INTERACTIONS IN NALOXONE-INDUCED CIRCLING IN MORPHINE-DEPENDENT RATS WITH NIGRAL LESIONS.
00012B 01-03

INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
00013D 01-03

SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
DDD133 01-03

INHIBITION OF PNMT ACTIVITY IN THE ADRENAL GLANDS AND BRAINSTEM OF RATS.
D00155 01-03

A DOSE-RESPONSE STUDY OF THE ACUTE EFFECTS OF ETHANOL ON THE SLEEP OF RATS.
0D0169 D1-03

TEMPORAL AND REGIONAL DIFFERENCES IN BRAIN CONCENTRATIONS OF LITHIUM IN RATS.
000179 01-03

EFFECT OF POTASSIUM ON LITHIUM-INDUCED GROWTH RETARDATION AND POLYURIA IN RATS.
0001B9 01-03

CHOLINERGIC MODIFICATION OF DRUG-INDUCED STEREOTYPY IN RATS.
DD0201 01-03

NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS. (PH D. DISSERTATION).
00020B 01-03

SCOPOLAMINE AND ADJUNCTIVE DRINKING IN RATS.
000216 01-03
HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
000219 01-03
PHARMACOLOGIC CHANGES IN PERFORMANCE OF NORMAL AND BRAIN-DAMAGED RATS.
000220 01-03
EFFECTS OF HALOTHANE ON CATECHOLAMINE METABOLISM IN THE BRAINSTEM OF RATS.
000221 01-03
ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
000228 01-03
INTRAHYPOTHALAMIC SEROTONIN AND CARDIOVASCULAR CONTROL IN RATS.
000230 01-03
REDUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-03
P-CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03
THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03
IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTEMIC ADMINISTRATION.
000249 01-03
EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS AND HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03
EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03
ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03
INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-04
EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04
NEUROPHARMACOLOGICAL REGULATION OF MOUSE-KILLING BY RATS.
000280 01-04
EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
000284 01-04
THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04
NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04
EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04
ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-TETRAHYDROCANNABINOL.
000310 01-04
HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04
MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-04
RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04
VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRESSION IN RATS.
000325 01-04
LITHIUM AND AMPHETAMINE HYPERACTIVITY IN RATS: DIFFERENTIAL EFFECT ON D AND L ISOMERS
000326 01-04
INTERACTIONS OF AMYGDALA LESIONS WITH EFFECTS OF PILOCARPINE AND D-AMPHETAMINE ON MOUSE-KILLING, FEEDING, AND DRINKING IN RATS.
000331 01-04
EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
000338 01-04
RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
000341 01-04
RELATIVE ROLE OF CATECHOLAMINES IN HEAD-SHAKING OF INFANT RATS.
000344 01-04
DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
000348 01-04
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04
CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS.
000350 01-04
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVE BRIGHTNESS DISCRIMINATION LEARNING IN RATS.
000351 01-04
DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION.
000352 01-04
EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
000367 01-04
INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04
REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04
BEHAVIORAL AND BIOCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYDROXYDOPA.
000376 01-04
NARCOTIC BLOCKADE, LENGTH OF ADDICTION AND PERSISTENCE OF ETONITAZENE CONSUMPTION IN RATS.
000379 01-04
FACTORS INFLUENCING TOLERANCE TO D-AMPHETAMINE-INDUCED ANOREXIA IN RATS.
000384 01-04
CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
000385 01-04
ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
000386 01-04
DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
000387 01-04
THE EFFECTS OF 6-AMINODOPAMINE ON ELECTRICAL SELF-STIMULATION IN RATS.
000388 01-04
DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-04
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE PETHIDINE OR METHADONE-INDUCED DECREASE IN LOCOMOTOR ACTIVITY OF RATS.
000396 01-04
DISCRIMINABILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04
ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
000398 01-04
NORADRENERGIC INFLUENCES ON DOPAMINE DEPENDENT BEHAVIOUR IN RATS.
000405 01-04
ALPHA-FLUPENTHIXOL-INDUCED HYPERACTIVITY BY CHRONIC DOSING IN RATS.
000412 01-04
SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04
PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04
SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA).
000423 01-04

COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS.
000426 01-04

MYOCLONUS AFTER 5-HYOROXYTRYPTOPHAN IN RATS WITH LESIONS OF INOOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04

BEHAVIOURAL CHANGES FOLLOWING OLFACTORY BULBECTOMY IN RATS: A POSSIBLE MODEL FOR THE DETECTION OF ANTIDEPRESSANT DRUGS.
000443 01-04

EFFECTS OF OELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRAOIENTS IN RATS.
000449 01-04

SCOPOLAMINES EFFECT ON PASSIVE AVOIOANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04

EFFECTS OF BENZODIAZEPINE TRANQUILLIZERS ON THE SOCIAL RESPONSES OF RATS.
000452 01-04

TERATOLOGICAL STUDIES OF RA88ITS ANO RATS TREATEO WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-05

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 01-05

EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE 8RAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIOANCE IN RATS.
000469 01-06

INDUCTION OF PHYSICAL OEPENOENCE IN RATS 8Y SHORT INTERVAL MEDICATION.
000471 01-06

PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGEO SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06

PHARMACOLOGICAL SUBSTANCES INFLUENCING ACQUISITION BEHAVIOR IN RATS.
000928 01-14

THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
0D1078 01-17

ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
001132 02-D3

THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
0D1134 D2-03

THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
D01140 D2-D3

ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
D01143 D2-03

TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
0D1148 02-03

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-D3

THE EFFECT OF LITHIUM-CHLORIDE ON MORPHINE-INDUCED AND PYROGEN-INDUCED HYPERTHERMIA IN RATS.
0D1161 02-03

EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
0D1182 02-03

EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
001198 02-03

HIGH-DOSE TREATMENT OF RATS WITH PERPHENAZINE-ENANTHATE.
D01205 D2-03

ACUTE EFFECTS OF MORPHINE ON REGIONAL BRAIN LEVELS OF ACETYLCHOLINE IN MICE AND RATS.
001227 02-D3

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-0

IRREVERSIBLE PROTEIN BINOING OF 14C-IMIPRAMINE IN RATS IN VIVO.
001258 02-0

EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-0

RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMI AND WITH TRICYCLIC ANTIDEPRESSANTS.
001284 02-0

SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHORAWAL SYNOROME IN RATS.
001287 D2-0

INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS.
001297 02-

6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-

THE EFFECT OF LITHIUM ON FOOD INTAKE IN RATS.
001317 02-

EFFECT OF STRUCTURAL ANALOGS OF 8UTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-

EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
001358 02-

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS ANO OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-

EFFECTS OF NEONATAL OR MATERNAL METHADONE ADMINISTRATION ON ORNITHINE-DECARBOXYLASE ACTIVITY IN 8RAIN AND HEART OF DEVELOPING RATS.
001378 02-

RENAL ELIMINATION OF LITHIUM IN RATS WITH LITHIUM INTOXICATION.
001403 02-

THE DISTRIBUTION AND METABOLISM OF CHLORPROMAZINE IN RATS AND THE RELATIONSHIP TO EFFECTS ON CEREBRAL MONOAMINE METABOLISM.
001422 02

ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
001428 02

A DEVICE FOR THE EVALUATION OF MOTOR INCOORDINATION IN RAT
001439 02

RESERPINE INDUCTION OF MOUSE-KILLING IN NONKILLER RATS.
001443 02

EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS
0D1444 02

THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS.
D01447 02

A COMPARISON OF CIRCLING BEHAVIOUR INDUCED IN NIGROSTRIATA LESIONED RATS AFTER PERIPHERAL ADMINISTRATION OF INDOLE DERIVATIVES.
001448 02

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON
00145B 02

COCAINE CUE IN RATS AS IT RELATES TO SUBJECTIVE DRUG EFFECTS: PRELIMINARY REPORT.
001462 02

CHANGES IN THE CONDITIONED AVOIDANCE BEHAVIOUR OF RATS FOLLOWING THE ADMINISTRATION OF DRUGS TO THE AMYGOALA.
0D1468 02

EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON SOCIAL INTERACTI IN RATS.
001484 02

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE OLFACTORY BULB DAMAGE IN RATS.
D014B9 02

MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWI PERINATAL MANIPULATION OF ANDROGEN: EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
0D1499 02

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION SPONTANEOUS MOTOR ACTIVITY OF RATS.
D01500 D2

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

INCREASED AGGRESSION IN RATS AFTER WITHDRAWAL OF LONG-TERM USED OXAZEPAM.
001509 02-04

EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE ON REACTIONS TO NOVELTY AND ACTIVITY IN RATS.
001515 02-04

CHARACTERISTICS OF TETRAHYDROCANNABINOL (THC) PRODUCED DISCRIMINATION IN RATS.
001518 02-04

LITHIUM EFFECTS ON VERTICAL ACTIVITY IN RATS: A REPLY TO D. F. SMITH.
001520 02-04

SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04

BEHAVIORAL EFFECTS OF INTRASEPTAL INJECTIONS OF ADRENERGIC DRUGS IN RATS.
001527 02-04

DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04

EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04

EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-04

EFFECTS OF LITHIUM ON FOOT-SHOCK-INDUCED AGGRESSIVE BEHAVIOR IN RATS.
001549 02-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

EFFECTS OF P-CHLOROPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04

EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04

EFFECTS OF DIAZEPAM AND RIPAZEPAM ON TWO MEASURES OF ADJUNCTIVE DRINKING IN RATS.
001572 02-04

EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

DIFFERENTIAL ATTENUATION OF SOME EFFECTS OF HALOPERIDOL IN RATS GIVEN SCOPOLAMINE.
00157B 02-04

BEHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE.
001579 02-04

REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE.
001581 02-04

EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04

AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
0015B7 02-04

CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
0015B9 02-04

POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04

CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
00159B 02-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04

THE EFFECT OF NITROUS-OXIDE ON TIME ESTIMATION IN RATS.
001603 02-04

CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
00160B 02-04

THE EFFECT OF ETHANOL CHRONICALLY ADMINISTERED TO PREWEANLING RATS ON CEREBELLAR DEVELOPMENT: A MORPHOLOGICAL STUDY.
001613 02-05

THE EFFECT OF BOVINE FIBRINOPEPTIDES ON THE CENTRAL ACTION OF CHLORPROMAZINE AND AMPHETAMINE IN RATS.
001614 02-05

ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05

POISON-INDUCED PICA IN RATS.
001633 02-05

POLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH.
001978 02-14

THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL-HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC-CHLORIDE.
00219B 03-03

EFFECT OF CHOLINERGIC DRUGS ON METHADONE-INDUCED CATALEPSY AND STEREOTYPIES IN RATS TREATED CHRONICALLY WITH METHADONE.
002199 03-03

EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
002222 03-03

THE INFLUENCE OF ACUTE DIAZEPAM PRETREATMENT ON THE ACTION AND DISPOSITION OF (14C)PENTOBARBITAL IN RATS.
002230 03-03

CHANGES IN THE AMINE AND ADRENAL CORTICAL HORMONE LEVELS WITHIN THE BRAINS OF RATS AFTER ADMINISTRATION OF DISULFIRAM.
002241 03-03

DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS.
002242 03-03

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
002270 03-03

EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
0022B7 03-03

EFFECTS OF OPIATES ON GABA AND DOPAMINE METABOLISM IN THE NIGROSTRIATAL PATHWAYS OF RATS.
002291 03-03

DEPRESSOR EFFECT OF KYNURENINE AND ITS METABOLITES IN RATS.
002293 03-03

THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS: INTRACEREBRAL MECHANISMS.
002307 03-03

LITHIUM EFFECTS ON MAGNESIUM, CALCIUM, AND PHOSPHATE METABOLISM IN RATS.
002309 03-03

EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03

A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFERENT TYPES OF MORPHINE PELLETS.
002311 03-03

NICOTINE CONVULSION AND BRAIN DOPAMINE CONTENTS IN RATS AND MICE AFTER LONG-TERM ADMINISTRATION OF LI2CO3.
002318 03-03

METABOLISM OF 1,4 DIHYDROTRIFLUOROMETHYLQUINOXALINEDIONE (LILLY-72525) IN RATS AND CATS.
002329 03-03

LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS.
00233B 03-03

STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03

QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03

MECHANISM OF GRADUALLY DEVELOPING LITHIUM INTOXICATION IN RATS.
002383 03-03

EFFECT OF MORPHINE ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MORPHINE-TOLERANT RATS.
0023B4 03-03

INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
0023B9 03-03

NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY.
002395 03-03

EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS.
002399 03-03

THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-03

BRAIN DOPAMINE, D-AMPHETAMINE AND THERMOREGULATION IN RATS.
002409 03-03

EFFECT OF TRYPTAMINERGIC DRUGS ON ELECTROSHOCK FIGHTING BEHAVIOUR IN RATS.
002417 03-04

ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
D02450 03-04

SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
00245B 03-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

INFLUENCE OF 6-HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
002463 03-04

SPONTANEOUS AND AMPHETAMINE-INDUCED HEAD-SHAKING IN INFANT RATS.
002465 03-04

THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS.
002471 03-04

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDENT DISCRIMINATIVE LEARNING.
002472 D3-04

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-D4

THE EFFECT OF CHLORDIAZEPOXIDE ON GO/NO-GO LEARNING RELATED TO HUNGER ACTIVITY IN RATS.
0D2476 03-D4

A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 D3-04

ENKEPHALIN AND A POTENT ANALOG FACILITATE MAZE PERFORMANCE AFTER INTRAPERITONEAL ADMINISTRATION IN RATS.
0024BD 03-04

A COMPARISON OF THE CENTRAL ACTION OF SOME PROSTAGLANDINS /PGS/ IN RATS.
0024B4 D3-04

AGGRESSIVITY, ISOLATION AND ANALGESIC ACTION OF MORPHINE IN RATS AND MICE
0024B6 03-D4

ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS.
0024B9 03-04

ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
D02491 D3-04

LORDOSIS IN FEMALE RATS FOLLOWING MEDIAL FOREBRAIN BUNDLE LESIONS.
0D25D2 03-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-D4

NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-0

THE EFFECTS OF ANALGESICS ON THE CONDITIONED BEHAVIOR OF RATS (II).
002509 03-0

EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
0D2512 03-0

EFFECTS OF INTERMITTENT ADMINISTRATION OF D-AMPHETAMINE ON LOCOMOTOR ACTIVITY AND HEART-RATE IN RATS.
002513 03-0

MONOAMINERGIC MEDIATION OF MASCULINE AND FEMININE COPULATORY BEHAVIOR IN FEMALE RATS.
002525 03-0

THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-0

THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002529 D3-0

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMIN UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-0

DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
002532 03-0

THE EFFECTS OF ANDROGEN ON WHEEL-SPINNING ACTIVITY IN INFANT RATS.
002537 03-0

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT.
002541 03-

EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-

EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
0D2547 03-

THE INTERACTION BETWEEN PILOCARPINE AND HEXOBARBITAL IN MAL RATS.
002551 03-

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
0D2554 03-

CATECHOLAMINES AND OPERANT RESPONSE RATES IN ALBINO RATS.
D02555 03-

CLONIDINE-INDUCED LOCOMOTOR HYPERACTIVITY IN RATS.
0D2561 03-

DIFFERENCES IN CYTOCHROME-P-45D OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
0D2563 03-

EFFECT OF CHRONIC TREATMENT OF METHYLMERCURIC-CHLORIDE ON THE CENTRAL-NERVOUS-SYSTEM IN RATS.
D02565 03-

EFFECT OF CHLORPROMAZINE ON THE REPRODUCTION IN RATS.
0D2567 03-

5-METHOXYTRYPTAMINE-INDUCED HEAD TWITCHES IN RATS.
0D2573 03-

PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
D02579 03-

EFFECTS OF METHADONE HYDROCHLORIDE ON THE GROWTH OF ORGANOTYPIC CEREBELLAR CULTURES PREPARED FROM METHADON TOLERANT AND CONTROL RATS.
0025B1 03-

COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT
0025B2 03-

BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003D76 04-

DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
DD30B6 04-

SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETI IN RATS.
D03092 04-

EFFECT OF CHRONIC ADMINISTRATION OF MORPHINE ON MONOAMINE OXIDASE ACTIVITY IN DISCRETE REGIONS OF THE BRAIN OF RATS.
003111 04-

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

EFFECTS OF LONG-TERM EXPOSURE TO ENVIRONMENTAL LEVELS OF POLYCHLORINATED BIPHENYLS ON PHARMACOKINETICS OF PENTOBARBITAL IN RATS.
003115 04-03

SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

WHEN DOES INHIBITION OF BRAIN ACETYLCHOLINESTERASE CAUSE AMNESIA IN RATS?
003152 04-03

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03

ANALGESIC, HEART-RATE, AND TEMPERATURE EFFECTS OF DELTAB-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-03

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
003189 04-03

INFLUENCE OF PREDOMINANTLY ANTIADRENERGIC AND ANTIDOPAMINERGIC NEUROLEPTICS ON THE ESTRUS CYCLE IN RATS.
003201 04-03

THE CEREBRAL OXIDATIVE METABOLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

EFFECT OF FLUPENTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SECRETION IN RATS.
003220 04-03

EFFECT OF GAMMA-BUTYROLACTONE AND BACLOFEN ON PLASMA PROLACTIN IN MALE RATS.
003221 04-03

EFFECT OF METABOLITES OF CHLORPROMAZINE ON PLASMA PROLACTIN LEVELS IN MALE RATS.
003222 04-03

BLOOD AND BRAIN CONCENTRATIONS OF IMIPRAMINE, CLOMIPRAMINE AND THEIR MONOMETHYLATED METABOLITES AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN RATS.
003227 04-03

EFFECT OF NEUROHUMORAL MODULATORS ON THE MORPHINE-INDUCED HYPERTHERMIA IN NON-TOLERANT RATS.
003232 04-03

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA-AMINOLAEVULINIC-ACID IN RATS.
003237 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
003239 04-03

EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE-DEPENDENT RATS.
003244 04-03

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
00324B 04-03

LITHIUM: MODIFICATION OF BEHAVIORAL ACTIVITY AND BRAIN BIOGENIC AMINES IN DEVELOPING HYPERTHYROID RATS.
003249 04-03

ATTENUATION OF MORPHINE ANALGESIA IN RATS WITH LESIONS OF THE LOCUS-COERULEUS AND DORSAL RAPHE NUCLEUS.
003266 04-03

THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-03

EFFECTS OF BROMOCRIPTINE ON ALPHA-RIGIDITY AND GAMMA-RIGIDITY IN RATS IN COMPARISON TO APOMORPHINE AND D-AMPHETAMINE.
003314 04-03

INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

INVOLVEMENT OF BRAIN BIOGENIC AMINES IN THE ELECTROENCEPHALOGRAPHIC AND BEHAVIOURAL EFFECTS OF MORPHINE IN POST-ADDICT RATS.
003363 04-04

EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04

THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
003379 04-04

ANTAGONISM OF ETONITAZENES EFFECTS IN RATS AND PIGEONS.
0033B1 04-04

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
0033B8 04-04

CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AND CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RATS.
003390 04-04

FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS.
003394 04-04

THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
003395 04-04

REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04

RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04-04

INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04

SHOCK-INDUCED ETHANOL CONSUMPTION IN RATS.
003430 04-04

MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

CORRELATION OF LITHIUM EFFECTS ON MOTOR ACTIVITY WITH ITS BRAIN CONCENTRATIONS IN RATS.
003435 04-04

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 04-04

INTERACTIONS BETWEEN DELTA9-TETRAHYDROCANNABINOL AND PHENCYCLIDINE HYDROCHLORIDE IN RATS.
003445 04-04

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN.
003447 04-04

DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
00344B 04-04

ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04

THE EFFECT OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) UPON SHOCK-ELICITED FIGHTING IN RATS.
003461 04-04

BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04

EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04

EFFECTS OF TRYPTAMINE ON THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
00347B 04-04

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS.
003489 04-04

SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05

MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY IN RATS.
003507 04-05

EFFECT OF AGGREGATION ON MORPHINE LETHALITY IN RATS.
00350B 04-05

BETA-ENDORPHIN-INDUCED AKINESIA IN RATS: EFFECT OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE AND RELATED MODIFICATIONS OF DOPAMINE TURNOVER IN THE BASAL GANGLIA.
003B75 04-17

RAUWOLFIA

RAUWOLFIA DERIVATIVES AND BREAST CANCER.
002050 02-15

RAUWOLFIA-REFLEXA

REFLEXINE, A NEW INDOLE ALKALOID OF RAUWOLFIA-REFLEXA.
0010B3 02-01

RCPV

DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03

REACTION

REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03

COMPULSIVE WATER DRINKING DURING DEPRESSIVE REACTION.
000688 01-10

BETEL QUID AND REACTION TIME.
000920 01-14

ADVERSE NEDNATAL REACTION TO MATERNAL ADMINISTRATION OF INTRAVENOUS CHLORMETHIAZOLE AND DIAZOXIDE.
000955 01-15

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04

EFFECTS OF PRACTICE DN MARIJUANA-INDUCED CHANGES IN REACTION TIME.
001873 02-12

REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001BB0 02-13

DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13

INVESTIGATION OF THE ORTHOSTATIC REACTION AFTER INTRAVENOUS ADMINISTRATION OF IMIPRAMINE, CHLORIMIPRAMINE, AND IMIPRAMINE-N-OXIDE.
002031 02-15

SCHIZOPHRENIA-LIKE REACTION TO DIETHYLPROPION.
002037 02-15

PHENOTHIAZINE REACTION SIMULATING ACUTE CATATONIA.
002072 02-15

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03

UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
002268 03-03

DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
002532 03-04

COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
002582 03-06

AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002897 03-15

WITHDRAWAL REACTION TO DIAZEPAM.
002927 03-15

EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14

REACTIONS

PATIENTS REACTIONS TO CLINICAL DRUG TESTING.
0004B9 01-07

DYSTONIC REACTIONS FOLLOWING NEUROLEPTICS: TIME COURSE AND PROPDSED MECHANISMS.
000543 01-08

SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS.
001123 02-03

DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04

EFFECTS OF CAFFEINE, METHAMPHETAMINE AND METHYLPHENIDATE ON REACTIONS TO NDVELTY AND ACTIVITY IN RATS.
001515 02-04

PHYSOSTIGMINE EFFECTS ON ACTIVITY AND REACTIONS TO NOVELTY.
001516 02-04

PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
0016B9 02-08

PROLONGED LSD FLASHBACKS AS CONVERSION REACTIONS.
001875 02-12

DYSTONIC REACTIONS TO METOCLOPRAMIDE.
00203B 02-15

TOXIC REACTIONS TO LITHIUM AND HALOPERIDOL.
002055 02-15

SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TD THERAPEUTIC DRUGS.
002142 02-17

BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI.
002394 03-03

ADVERSE REACTIONS IN TREATMENT WITH LITHIUM-CARBONATE AND HALOPERIDOL.
002665 03-09

ADVERSE REACTIONS TD MARIHUANA USE AMONG COLLEGE STUDENTS.
002896 03-15

RECENT ADVANCES IN THE TREATMENT AND PREVENTION OF ADVERSE REACTIONS TO LITHIUM.
003031 03-17

HYSTERICAL AND HYSTERIA-LIKE REACTIDNS DURING NEUROLEPTIC TREATMENT FDR SCHIZOPHRENIA.
003036 03-17

INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES DF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
003775 04-15

TOWARD THE OPERATIONAL IDENTIFICATION OF ADVERSE DRUG REACTIONS.
003B00 04-15

REACTIVATED

SIMILARITIES BETWEEN SHORT-TERM AND REACTIVATED MEMORIES.
00149B 02-04

SUSCEPTIBILITY OF A REACTIVATED MEMORY TO THE EFFECTS OF STRYCHNINE: A TIME-DEPENDENT PHENOMENON.
003393 04-04

REACTIVE

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRDNIC ALCOHOLIC SUBJECTS.
002821 03-13

A CASE PRESENTING SOME REACTIVE CLINICAL SIGNS DURING TREATMENT OF L-DOPA.
002930 03-15

REACTIVITY

SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-09

THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-08

READING

THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

REAGENTS
THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

REAPPRAISAL
PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

REARING
COCAINE AND MORPHINE SELF-ADMINISTRATION: EFFECTS OF DIFFERENTIAL REARING.
0025B5 03-06
ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04

REASSESSED
TRIALS WITH ANTIDEPRESSANTS REASSESSED.
0029B1 03-17

REBOUND
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15
EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

RECALL
MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002B67 03-14
DREAM RECALL AND THE CONTRACEPTIVE PILL.
002B75 03-14

RECEIVING
COMPARISON OF EEG AND CLINICAL FINDINGS IN PARKINSON PATIENTS RECEIVING L-DOPA.
000B00 01-13
THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY.
0020B7 02-16
ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY.
002767 03-11
INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03
PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY.
003696 04-13

RECEPTIVE
PENTOBARBITAL AND SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC-ACID.
002333 03-03
EVIDENCE THAT THE PREOPTIC REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04

RECEPTOR
GABA RECEPTOR ACTIVATION MEDIATES THE DECREASE OF CEREBELLAR C-GMP ELICITED BY DIAZEPAM. (UNPUBLISHED PAPER).
000051 01-03
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03
A STUDY OF MUSCARINIC RECEPTOR HETEROGENEITY WITH WEAK ANTAGONISTS.
000097 01-03
LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS.
000157 01-03
THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03
METOCLOPRAMIDE AND DOPAMINE RECEPTOR BLOCKADE.
000195 01-03
EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03
THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04
AN EVALUATION OF BETA-ADRENERGIC RECEPTOR FUNCTION IN DEPRESSED PATIENTS.
000666 01-09
EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000B33 01-13
BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION.
001190 02-03
THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03
NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03
IDENTIFICATION OF OPIATE/RECEPTOR BINDING IN VIVO.
001240 02-03
THE DOPAMINE RECEPTOR AND ANTIPSYCHOTIC EFFECT.
001259 02-03
RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03
CENTRAL GABA RECEPTOR AGONISTS: COMPARISON OF MUSCIMOL AND BACLOFEN.
001303 02-03
ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN.
001512 02-04
RECEPTOR BLOCKADE AND RECEPTOR HYPERSENSITIVITY AFTER TREATMENT WITH NEUROLEPTICS.
001547 02-04
THE EFFECT OF ALPHA AND BETA ADRENERGIC RECEPTOR BLOCKERS ON SLEEP IN THE RAT.
001624 02-05
CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULATIONS.
001955 02-14
CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS (PARADOXICAL DRUG EFFECTS). (UNPUBLISHED PAPER).
001962 02-14
REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03
ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
002255 03-03
THE INFLUENCE OF H1 AND H2 HISTAMINE RECEPTOR ANTAGONISTS ON HISTAMINE METABOLISM IN RAT BRAIN.
002303 03-03
HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03
DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002B32 03-13
POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N-SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS.
003072 04-02
STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINDING IN RAT BRAIN.
003134 04-03
ONTOGENESIS OF DOPAMINE RECEPTOR BINDING IN THE CORPUS-STRIATUM OF THE RAT.
003235 04-03
INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03
OPIATE RECEPTOR BINDING IN THE PITUITARY GLAND.
003279 04-03
ON THE MOLECULAR STRUCTURE OF THE OPIATE RECEPTOR.
0032B1 04-03
OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03
STUDIES ON MEMBRANE RECEPTOR SITES FOR SEROTONIN IN THE BRAIN.
00330B 04-03
PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
003343 04-04

INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION 8Y METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-04

REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04

CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE.
003446 04-04

ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR 8INDING IN 8RAIN.
003493 04-05

ANTIDEPRESSANTS AND THE MUSCARINIC ACETYLCHOLINE RECEPTOR.
003510 04-05

A QUANTITATIVE RELATIONSHIP BETWEEN ANTINOCICEPTIVE ACTIVITY, OPIATE RECEPTOR AFFINITY AND LIPOPHILICITY.
003876 04-17

RECEPTORS

ON THE SUPERSENSITIVITY OF DOPAMINE RECEPTORS, INDUCED BY NEUROLEPTICS.
000073 01-03

DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE 8RAIN.
000D77 01-03

THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
0000B5 01-03

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
000186 01-03

EFFECTS OF BROMOCRIPTINE ON CENTRAL DOPAMINERGIC RECEPTORS.
000242 01-03

ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC/DOPAMINE RECEPTORS.
000474 01-06

INTERACTIONS OF PEPTIDES DERIVED FROM THE C-FRAGMENT OF 8ETA-LIPOTROPIN WITH BRAIN OPIATE RECEPTORS.
001147 02-03

TOPOGRAPHICAL DISTRI8UTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN 8REAKDOWN IN MOUSE 8RAIN.
001197 02-03

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE.
0012D2 02-03

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
001209 02-03

THE 8INDING OF THE OPTICAL ISOMERS OF METHADONE, ALPHA-METHADOL, ALPHA-ACETYLMETHADOL AND THEIR N-DEMETHYLATED DERIVATIVES TO THE OPIATE RECEPTORS OF RAT BRAIN.
001242 02-03

INTERACTION OF CLONIDINE WITH PRESYNAPTIC AND POSTSYNAPTIC ADRENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
001375 02-03

ONTOGENETIC DEVELOPMENT OF NEOSTRIATAL DOPAMINE RECEPTORS IN THE RAT.
001383 02-03

TOPOGRAPHICAL DISTRI8UTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

8EHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03

TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
001415 02-03

THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS.
D01478 D2-04

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 D2-04

AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN 8RAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE 8INDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT 8RAIN MEMBRANES.
002253 03-03

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
002438 03-04

INTERACTION OF BRADYKININ WITH DOPAMINERGIC RECEPTORS IN THE CNS.
002507 03-04

CLIM8ING 8EHAVIOR INDUCED 8Y APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04

DOPAMINERGIC NEURONS: AN IN VIVO SYSTEM FOR MEASURING DRUG INTERACTIONS WITH PRESYNAPTIC RECEPTORS.
002587 03-06

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
00308B 04-03

ANTIANXIETY RECEPTORS IN THE BRAIN?.
003180 04-03

OPIATE RECEPTORS AND INTERNAL OPIATES.
003284 04-03

BENZODIAZEPINE RECEPTORS IN RAT BRAIN.
003287 04-03

AFFINITIES OF OPIATE AGONISTS AND ANTAGONISTS FOR THE ENKEPHALIN RECEPTORS OF RAT BRAIN.
00332B 04-03

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

RECIDIVISM

PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17

RECIPROCAL

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03

RECIRCULATION

8ILIARY EXCRETION AND ENTEROHEPATIC RECIRCULATION OF PRACTOLOL IN MAN.
00D808 01-13

RECORDED

EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIM8IC SYSTEM AND HYPOTHALAMUS.
003474 04-04

RECORDING

RECORDING OF THE ELECTROPHYSIOLOGICAL ACTIVITY OF THE LOCUS-COERULEUS IN THE RAT.
001191 02-03

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS BEFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-OXIDE.
001794 02-10

DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
003078 04-03

RECORDINGS

POLYGRAPHIC SLEEP RECORDINGS BEFORE AND AFTER THE ADMINISTRATION OF FLUNITRAZEPAM.
0D3626 04-11

RECOVERY

RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION.
00D029 01-03

ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
0D3303 04-03

EFFECTS OF METHAMPHETAMINE AND ENRICHED EXPERIENCE ON BEHAVIORAL RECOVERY AFTER BRAIN-DAMAGE.
0034B3 04-04

RECREATIONAL

THE RECREATIONAL USE OF LSD-25 AND DRUG PROHI8ITION.
002181 02-17

RECTAL
POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

RECUMBENT
SALIVARY AND URINARY LITHIUM CLEARANCE WHILE RECUMBENT AND UPRIGHT.
003706 04-13

RECURRENT
THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09
ANTISERUM TO BRAIN GANGLIOSIDES PRODUCED RECURRENT EPILEPTIFORM ACTIVITY.
001260 02-03
TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03

RECURRING
PSYCHOPHARMACOLOGY -- A RECURRING BIBLIOGRAPHY.
002147 02-17

RED-BLOOD-CELL
RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE AND RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN.
000592 01-09
RED-BLOOD-CELL LITHIUM INDEX AND LONG-TERM MAINTENANCE TREATMENT.
000704 01-10
LOCOMOTOR ACTIVITY AND PLASMA, RED-BLOOD-CELL AND CEREBRAL CORTEX LITHIUM CONCENTRATION IN INBRED MICE GIVEN LITHIUM CARBONATE.
001380 02-03
PHARMACOKINETICS OF RED-BLOOD-CELL PHENOTHIAZINE AND CLINICAL EFFECTS: ACUTE DYSTONIC REACTIONS.
001689 02-08
INTRA/EXTRA RED-BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY.
003775 04-15

RED-BLOOD-CELLS
LITHIUM MAGNESIUM RELATIONSHIP IN RED-BLOOD-CELLS DURING LITHIUM PROPHYLAXIS.
002695 03-09

REDLICH-FLATAUS
PARANOID PSYCHOSIS WITH ONEIROIDAL ELEMENTS DURING THE COURSE OF REDLICH-FLATAUS DISEASE.
000769 01-11

REDUCE
NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002B00 03-13

REDUCED
REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF D-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04
REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK-OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05
REDUCED CONCENTRATIONS OF PLASMA DIAZEPAM IN CHRONIC ALCOHOLICS FOLLOWING AN ORAL ADMINISTRATION OF DIAZEPAM.
000B64 01-13
CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
002481 03-04
REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821 03-13
REDUCED CATECHOLAMINERGIC TRANSMISSION AND CLINICAL EFFECTS OF NEUROLEPTICS.
003718 04-13

REDUCES
L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
000103 01-03
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
00160B 02-04
AMANTADINE REDUCES DRUG-INDUCED PARKINSONISM.
001983 02-14
LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION.
003428 04-04
PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-05

REDUCING
REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
003572 04-09

REDUCTION
REDUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS.
000231 01-03
CLOZAPINE: REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT.
001412 02-03
AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
001587 02-04
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001B43 02-11
ALCOHOL AND TENSION REDUCTION: COGNITIVE AND PHYSIOLOGICAL EFFECTS.
001984 02-14
REDUCTION OF LEARNED TASTE-AVERSIONS BY PREEXPOSURE TO DRUGS.
002549 03-04
REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID-DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY.
003401 04-04
LONG-TERM REDUCTION OF MALE AGONISTIC BEHAVIOR IN MICE FOLLOWING EARLY EXPOSURE TO ETHANOL.
0034BB 04-04
WEIGHT REDUCTION IN SCHIZOPHRENICS BY MOLINDONE.
003536 04-08
REDUCTION IN PLASMA NOREPINEPHRINE DURING FENFLURAMINE TREATMENT.
003666 04-13

REEXAMINATION
REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE.
001581 02-04

REFLEX
TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03
CHLORPROMAZINE AND HALOPERIDOL ACTION ON CAUDATE INHIBITION OF CONDITIONED REFLEX AVOIDANCE REACTION IN CATS.
001524 02-04
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-03
INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
002487 03-04
TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

REFLEXES
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03
INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
003338 04-03

REFLEXINE
REFLEXINE, A NEW INDOLE ALKALOID OF RAUWOLFIA-REFLEXA.
001083 02-01

REFRACTORY
THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS.
003793 04-15

REFUSAL
DRUG REFUSAL IN SCHIZOPHRENIA AND THE WISH TO BE CRAZY.
002942 03-15

REGIME
AN EVALUATION OF A ONCE DAILY DOSAGE REGIME OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).
001674 02-07

REGIMENS
DEVELOPING OPTIMUM DRUG REGIMENS.
002105 02-17

REGIMES
A COMPARISON OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003621 04-11
COMPARISONS OF VARIOUS CLOMIPRAMINE (ANAFRANIL) DOSAGE REGIMES.
003672 04-13

REGION
EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMINE ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01-03
HYPOTHERMIA INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN RATS WITH ELECTROLYTIC LESIONS OF PREOPTIC REGION.
000219 01-03
EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON.
001458 02-04
EVIDENCE THAT THE PREOPTIC REGION IS A RECEPTIVE SITE FOR THE DIPSOGENIC EFFECTS OF ANGIOTENSIN-II.
002420 03-04

REGRESSION
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03

REGULARITIES
REGULARITIES IN PENETRATION OF THE PLACENTAL BARRIER BY AMINAZINE.
002576 03-05

REGULATED
HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

REGULATING
THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
000085 01-03

REGULATION
REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS.
000078 01-03
DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
00D186 01-03
NEUROPHARMACOLOGICAL REGULATION OF MOUSE-KILLING BY RATS.
000280 01-04
DRUG DISCOVERY AND INTRODUCTION: REGULATION AND OVERREGULATION.
001669 02-07
NEUROENDOCRINE REGULATION IN DEPRESSION. I. LIMBIC SYSTEM ADRENOCORTICAL DYSFUNCTION.
001736 02-09
REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 03-03
REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
0D2227 03-03
MONOAMINERGIC SENSORY REGULATION AND THE ROLE OF MORPHINE.
002353 03-03
GLUCOCORTICOID REGULATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN.
002379 D3-03
REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03
THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLEI OF RAT BRAIN: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
DD25B4 03-06
REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
0D3097 04-03
EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
D03251 04-03
DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13

REGULATORY
DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04

REHABILITATION
IMPLICATIONS OF DRUG TREATMENT FOR THE SOCIAL REHABILITATION OF SCHIZOPHRENIC PATIENTS.
D02116 02-17

REHOSPITALIZATION
THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS.
003531 04-08

REINFORCED
EFFECT OF CYPROHEPTADINE AND COMBINATIONS OF CYPROHEPTADINE AND AMPHETAMINE ON INTERMITTENTLY REINFORCED LEVER-PRESSING IN RATS.
002458 03-04

REINFORCEMENT
DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
DD0200 01-03
ATTENUATION OF INTRAVENOUS AMPHETAMINE REINFORCEMENT BY CENTRAL DOPAMINE BLOCKADE IN RATS.
000267 01-03
MORPHINE-BASED SECONDARY REINFORCEMENT: EFFECTS OF DIFFERENT DOSES OF NALOXONE.
000372 01-04
THE EFFECT OF ACUTE METHADONE ON FIXED-INTERVAL SCHEDULES OF REINFORCEMENT IN PIGEONS. (PH.D. DISSERTATION).
000375 01-04
EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
D00444 01-04
THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
0D0903 01-14
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03
THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04
HALOPERIDOL AND LIGHT REINFORCEMENT IN THE RAT.
001541 02-04
SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
D01557 02-04
THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
0D2332 D3-03
EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
0D2415 03-04
EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
D02501 03-04
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION. (ED.D. DISSERTATION).
DD2860 03-14

REINFORCERS
ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
DD2437 03-04

REINFORCING
THE REINFORCING ACTION OF MORPHINE AND ITS PARADOXICAL SIDE-EFFECT.
003481 04-04

RELAPSE
PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
DOD417 01-04
ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
000849 01-13
LIFE EVENTS, DEPRESSIVE RELAPSE AND MAINTENANCE TREATMENT.
D01770 02-09
PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08
TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
0D3541 04-08

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

RELAPSES
PSEUDOPSYCHOTIC RELAPSES IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
002945 03-15

RELAXANT
ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
002723 03-10
PROLONGATION OF MUSCLE RELAXANT EFFECTS BY LITHIUM-CARBONATE.
003820 04-15

RELAXANTS
BEHAVIORAL AND NEUROPHARMACOLOGICAL INVESTIGATIONS CONCERNING ONE OF NEWER CENTRAL ACTING MUSCLE RELAXANTS, CHLORPHENESIN CARBAMATE.
002467 03-04

RELAXATION
COMPARISON OF MUSCLE RELAXATION WITH PLACEBO MEDICATION FOR ANXIETY REDUCTION IN ALCOHOLIC INPATIENTS.
001843 02-11

RELEARNING
EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
0002B4 01-04

RELEASABLE
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

RELEASE
RELEASE OF NORADRENALINE PROPOSED AS A MECHANISM FOR THE POSITIVE INOTROPIC ACTION OF DIPYRIDAMOLE.
000121 01-03
INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASE FROM BOVINE GRANULOCYTES.
000124 01-03
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03
COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03
THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES.
000257 01-03
EFFECTS OF CHOLINERGIC DRUGS AND THEIR BLOCKERS ON ADRENALINE RELEASE FROM RAT ADRENAL.
00026B 01-03
IS THE RELEASE OF NORADRENALINE NECESSARY FOR SELF-STIMULATION OF THE BRAIN?.
000422 01-04
EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN.
001135 02-03
ENKEPHALIN-STIMULATED PROLACTIN RELEASE.
00127B 02-03
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO.
001307 02-03
THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-03
ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-03
ALCOHOL MEMBRANE INTERACTION IN THE BRAIN: NOREPINEPHRINE RELEASE.
001394 02-03
NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
001679 02-08
LEVELS OF BRAIN O-METHYLATED CATECHOLAMINES AS AN INDEX FOR THE RELEASE OF CATECHOLAMINES BY CENTRALLY ACTING DRUGS.
002244 03-03
BETA-ENDORPHIN IN VITRO INHIBITION OF STRIATAL DOPAMINE RELEASE.
002298 03-03
AMPHETAMINE-INDUCED RELEASE OF DOPAMINE FROM THE SUBSTANTIA-NIGRA IN VITRO.
00232B 03-03
CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION.
002370 03-03
IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM ABOUT THE EFFECTS OF MORPHINE ON UPTAKE AND RELEASE OF C14-DOPAMINE
003104 04-03
EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-03
THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA++ UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
003136 04-03
PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03
EFFECTS OF PENTOBARBITAL ON THE REGULATION OF ACETYLCHOLINE CONTENT AND RELEASE IN DIFFERENT REGIONS OF RAT BRAIN.
003251 04-03
DEPRESSION BY MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03
MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY OF 10,000 PATIENTS IN GENERAL PRACTICE.
003557 04-09
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
003615 04-11
DOPAMINERGIC REGULATION OF PROLACTIN RELEASE IN PATIENTS WITH HUNTINGTON DISEASE AND NORMAL CONTROLS.
003661 04-13
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13
EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE OF (3H)5-HYDROXYTRYPTAMINE BY HUMAN BLOOD PLATELETS.
003715 04-13

RELEASING
DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-03
GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
0016B1 02-0B
HYPOTHALAMIC RELEASING HORMONES AND BEHAVIOR.
003722 04-13

RELIEF
THE EFFICACY OF PERCOGESIC IN RELIEF OF MUSCULOSKELETAL PAIN ASSOCIATED WITH ANXIETY.
003619 04-11

REM
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
000909 01-14
EFFECTS OF ANTIDEPRESSANTS UPON SLEEP, ESPECIALLY ON REM SLEEP.
000923 01-14
6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-03
REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
0015B0 02-04
DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-02
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03
AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP.
003106 04-03
THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

REMISSION
SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-0B

REMITTED
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-0B

RENAL
PENTOBARBITAL ELIMINATION IN PATIENTS WITH POOR RENAL FUNCTION.
000860 01-13
RENAL ELIMINATION OF LITHIUM IN RATS WITH LITHIUM INTOXICATION.
001403 02-03
AFFECTIVE PSYCHOSES FOLLOWING RENAL TRANSPLANT.
001733 02-09
PSYCHIATRIC PHARMACOTHERAPY IN RENAL INSUFFICIENCY.
002D16 02-15
DEPRESSION DURING RENAL DIALYSIS AND FOLLOWING TRANSPLANTATION.
003028 03-17
THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-03
EFFECT OF LONG-TERM LITHIUM ADMINISTRATION ON RENAL PHOSPHORUS HANDLING.
003698 04-13
AMPHETAMINE-INDUCED ANGIITIS LEADING TO RENAL FAILURE.
003822 04-15

RENDERED
REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT.
000008 01-01

RENIN
EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
002222 03-03
DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-04
EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 D4-03

RENSHAW
EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

REPARTITION
REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

REPEAL
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

REPEATED
DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03
EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
000238 01-03
INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-D4
EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
DDD367 D1-D4
REPEATED ACQUISITION OF BEHAVIORAL CHAINS: EFFECTS OF METHYLPHENIDATE AND IMIPRAMINE.
00D437 01-D4
SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000835 01-13
EFFECT OF FOOD AND REPEATED INJECTIONS ON SERUM DIAZEPAM LEVELS.
DD0840 01-13
CLOZAPINE: REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT.
001412 02-D3
INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
D01466 02-04
EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
0D1507 02-D4
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS.
001554 02-04
CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
001598 02-04
EFFICACY OF REPEATED PHARMACOTHERAPY IN EXPERIMENTAL ACUTE POISONINGS WITH FLUOSTIGMINE.
001637 02-05
EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN.
002306 03-03
ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE ON THE COPULATORY RESPONSE OF FEMALE RATS.
D02441 03-04
SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04
ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS.
002489 03-04
HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002849 03-14
BEHAVIORAL EFFECTS OF REPEATED PSYCHOACTIVE DRUG ADMINISTRATION. (PH.D. DISSERTATION).
002B77 03-14
FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03
REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04
EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04
EFFECTS OF REPEATED MORPHINE ADMINISTRATION ON COPULATION AND ON THE HYPOTHALAMIC PITUITARY GONADAL AXIS OF MALE RATS.
003472 04-04

REPETITIVE
STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION.
D03224 04-03

REPLENISHMENT
METAL CHELATES OF L-DOPA FOR IMPROVED REPLENISHMENT OF DOPAMINERGIC POOLS.
DD1090 02-01

REPLETION
AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP.
0D3106 D4-03

REPLICATION
AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION.
002B63 03-14

REPORTING
SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS.
002142 02-17

REPRODUCTION
EFFECT OF CHLORPROMAZINE ON THE REPRODUCTION IN RATS.
002567 03-05

REPRODUCTIVE
MARIHUANA: NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
0DD795 01-12
REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT.
D01644 02-05

REQUESTED
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 408 F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
DD215D 02-17

REQUIREMENTS
THE 24-HOUR LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS: A 2-YEAR FOLLOW-UP STUDY.
001B99 02-13

STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINDING IN RAT BRAIN
003134 04-03

DRUG EFFECTS ON FIXED-INTERVAL RESPONDING WITH PAUSE REQUIREMENTS FOR FOOD PRESENTATION
003465 04-04

RESEARCH

GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01

RESEARCH IN THE BENZOFURAN SERIES LVII. BENZOFURYLOXYALKYLAMIDOXIMES: POTENTIAL ANTIDEPRESSANTS.
000275 01-04

RESEARCH IN THE DIPROPYLACETIC SERIES. XII. EXTENDED ALIPHATIC ACIDS AND ALCOHOLS AS ANTICONVULSANTS.
000433 01-04

MODE OF ACTION OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS: A FEW PRESENT DAY METHODS OF RESEARCH.
000806 01-13

RESEARCH ON THE USE OF SULPIRIDE IN PSYCHOSOMATIC MEDICINE: A STUDY OF 104 CASES.
000816 01-13

METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH: CHLORPROMAZINE -- A CASE IN POINT.
001008 01-16

PSYCHOPHARMACOLOGY RESEARCH WARD. TEN YEARS EXPERIENCE.
001076 01-17

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

DATA ANALYSIS PROBLEMS IN THE AREA OF PHARMACOKINETICS RESEARCH.
001651 02-06

CLINICAL RESEARCH ON THE COLLATERAL DISINHIBITING EFFECTS OF A NEW KIND OF BENZODIAZEPINE DRUG CLONAZEPAM.
001663 02-07

DRUG RESEARCH ON TREATMENT OF SCHIZOPHRENIA.
001721 02-08

PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT.
001776 02-09

CLINICAL RESEARCH ON PSYCHOTROPIC DRUGS AND HYPERACTIVITY IN CHILDREN.
001847 02-11

HYPERACTIVITY: RESEARCH, THEORY, AND ACTION.
001854 02-11

INTRODUCTION: IMPORTANCE OF PSYCHOTROPIC DRUGS IN SLEEP RESEARCH.
001975 02-14

SUMMARY ON PSYCHOPHARMACOLOGY IN SLEEP RESEARCH.
001976 02-14

POLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH.
001978 02-14

IN THE SERVICE OF PSYCHOPHARMACOLOGY RESEARCH: THE PSC-PRB, NIMH PROGRAM 1956-1976. (UNPUBLISHED PAPER).
00213B 02-17

MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

CARE OF SCHIZOPHRENIC PATIENTS OUTSIDE THE HOSPITAL: RESEARCH RESULTS AND BASIC PRINCIPLES.
002631 03-08

CURRENT STATE OF RESEARCH ON PROPRANOLOL OPIATE INTERACTION.
002757 03-11

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002820 03-13

PSYCHOPHARMACOLOGICAL RESEARCH.
002979 03-17

ETHICS IN DRUG RESEARCH IN THE USA.
003006 03-17

PRISON RESEARCH: NATIONAL COMMISSION SAYS NO, UNLESS....
003850 04-17

PHARMACOLOGICAL AGENTS AS TOOLS IN PSYCHIATRIC RESEARCH.
003861 04-17

PRISON RESEARCH: THE VIEW FROM INSIDE.
003869 04-17

PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW.
003885 04-17

RESEMBLANCE

NITROUS-OXIDE ANALGESIA: RESEMBLANCE TO OPIATE ACTION.
001139 02-03

RESERPINE

EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA PIGS.
000032 01-03

EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
000052 01-03

THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03

INHIBITORY EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON EXCITATION INDUCED BY A MAO INHIBITOR AND RESERPINE IN THE MOUSE.
000089 01-03

MONOAMINE-OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
00010B 01-03

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

DIFFERENCES IN THE EFFECTS OF POSTTRIAL CHLORPROMAZINE, RESERPINE, AND AMPHETAMINE ON DISCRIMINATION LEARNING IN RATS.
00034B 01-04

EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
000365 01-04

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-03

COMPARISON OF THE EFFECTIVENESS OF DESERPIDINE, RESERPINE, AND ALPHA-METHYLTYROSINE ON BRAIN BIOGENIC AMINES.
001215 02-03

EFFECTS OF RESERPINE AND PARGYLINE ON GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT HYPOTHALAMIC NUCLEI.
001251 02-03

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-03

POTENTIATION OF RESERPINE ACTION IN FROGS AS A CHARACTERISTIC EFFECT OF ANTIDEPRESSANTS.
001271 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
001321 02-03

RESERPINE INDUCTION OF MOUSE-KILLING IN NONKILLER RATS.
001443 02-04

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04

THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04

HALOPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT OF HUNTINGTONS CHOREA.
001B93 02-13

THE EFFECTS OF SOME DRUGS (ESERINE, ATROPINE, RESERPINE, NIAMID) UPON THE EEG MANIFESTATIONS OF EXPERIMENTAL NEUROSIS IN ADULT CATS.
002343 03-03

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

DOPAMINE LEVELS IN THE STRIATUM AND THE EFFECT OF ALCOHOL AND RESERPINE.
003318 04-03

EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

RESERPINE: MIRROR IMAGE OF THE ANTIDEPRESSANTS.
003901 04-17

RESERPINE-INDUCED

EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03

RESERPINE-TREATED

EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS ON THERMOREGULATION IN RESERPINE-TREATED RATS.
000010 01-01

MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-04

RESERPINIZED

AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP.
003106 04-03

EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS.
003122 04-03

RESIDENCY

PSYCHIATRIC PHARMACY RESIDENCY AND SERVICES.
001026 01-17

RESIDENTS

HELPING TO MAKE THE FINAL YEARS MEANINGFUL FOR THE ELDERLY RESIDENTS OF NURSING HOMES.
002B59 03-14

DRUG DRUG INTERACTIONS AMONG RESIDENTS IN HOMES FOR THE ELDERLY: A PILOT STUDY.
003770 04-15

RESIDUAL

RESIDUAL LEARNING DEFICIT AFTER HEAVY EXPOSURE TO CANNABIS OR ALCOHOL IN RATS.
000322 01-04

HYPNOTICS AND ETHANOL: RESIDUAL EEG EFFECTS.
0DDB46 01-13

RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
DDD910 01-14

RESIDUES

THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

RESISTANCE

RESISTANCE TO PUNISHMENT AND EXTINCTION FOLLOWING RESPONDING UNDER METHAMPHETAMINE OR SECOBARBITAL. (PH.D. DISSERTATION).
002534 03-04

RESISTANT

MODULATION OF CYCLOHEXIMIDE RESISTANT MEMORY BY SYMPATHOMIMETIC AGENTS.
D0D333 01-D4

RESOCIALIZATION

THE ROLE OF OPAR IN THE RESOCIALIZATION OF SCHIZOPHRENICS.
D0172D 02-DB

RESOURCES

THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-0B

RESPIRATION

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
0D1192 02-D3

PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 D2-13

RESPIRATORY

RECOVERY OF CENTRAL RESPIRATORY FUNCTION FOLLOWING ANTICHOLINESTERASE INTOXICATION.
DD0D29 01-03

ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03

A COMPARATIVE STUDY OF THE ANALGESIC AND RESPIRATORY EFFECTS OF N-ALLYLNORCODEINE (NALODEINE), NALORPHINE, CODEINE AND MORPHINE.
001100 02-02

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN.
003294 04-03

RESPONSE

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

ETHANOL AND THE RESPONSE TO ELECTRIC SHOCK IN RATS.
000063 01-03

THE INTERACTION BETWEEN PROSTAGLANDIN-E1 AND DELTA9-TETRAHYDROCANNABINOL ON INTESTINAL MOTILITY AND ON THE ABDOMINAL CONSTRICTION RESPONSE IN THE MOUSE.
000129 01-03

EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04

EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04

RESPONSE TO DEIKEL AND CARDERS ARTICLE ATTENUATION OF PRECIPITATE ABSTINENCE IN METHADONE-DEPENDENT RATS BY DELTA9-THC.
000341 01-04

SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS.
00D377 01-04

CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
000442 01-04

RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE AND RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN.
000592 01-09

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
000593 01-09

OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND.
000B34 01-13

ERYTHROCYTE MEMBRANE CATION CARRIER, RELAPSE RATE OF MANIC-DEPRESSIVE ILLNESS AND RESPONSE TO LITHIUM.
D00B49 01-13

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
DDDB61 D1-13

RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
000BB0 01-14

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 D2-D3

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
D01290 D2-D3

ALTERNATIONS OF MOUSE ADRENAL MEDULLARY CATECHOLAMINES AND ENZYMES IN RESPONSE TO ATTACK: EFFECT OF PRETREATMENT AND POSTTREATMENT WITH PHENOBARBITAL.
DD14D2 D2-03

DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE AND D-AMPHETAMINE: EFFECTS ON HABITUATION.
001435 02-04

INHIBITION OF CONDITIONAL AVOIDANCE RESPONSE BY NEUROLEPTICS UPON REPEATED ADMINISTRATION.
001466 02-04

COMPARISON OF THE ACTION OF LYSERGIC-ACID-DIETHYLAMIDE AND APOMORPHINE ON THE COPULATORY RESPONSE IN THE FEMALE RAT.
D01475 02-04

ENHANCEMENT OF THE LOCOMOTOR RESPONSE TO D-AMPHETAMINE BY OLFACTORY BULB DAMAGE IN RATS.
0014B9 02-04

EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATED ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
DD15D7 D2-D4

LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT.
D0150B 02-D4

ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
0D1565 D2-04

A COMPARISON 8ETWEEN AMANTADINE AND 8ROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
001681 02-08

A FAVORA8LE RESPONSE TO LITHIUM-CARBONATE IN A SCHIZOAFFECTIVE FATHER AND SON.
001714 02-08

CORRELATION 8ETWEEN PLASMA LEVEL AND CLINICAL RESPONSE IN MANIC PSYCHOTICS GIVEN HIGH DOSE FLUPHENAZINE-ENANTHATE.
001741 02-09

PROLACTIN RESPONSE TO ELECTROCONVULSIVE THERAPY.
001769 02-09

PREDICTION OF CLINICAL RESPONSE TO LITHIUM.
001B70 02-12

INTRACELLULAR LITHIUM AND CLINICAL RESPDNSE.
001895 02-13

RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14

MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS DN TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14

INFLUENCE OF ORAL CONTRACEPTION ON SEXUAL RESPONSE.
002020 02-15

PHARMACOKINETICS OF PSYCHOACTIVE DRUGS: 8LDDD LEVELS AND CLINICAL RESPONSE.
002120 02-17

PHARMACOLOGICAL STUDIES ON DEVELDPMENT OF RESPONSE TD CATECHOLAMINE IN BRAIN.
002263 03-03

INFLUENCE OF ADRENAL ENUCLEATION DN THERMAL RESPDNSE TO CHLORPROMAZINE IN RATS.
0023B9 03-03

EFFECTS OF VARIOUS DRUGS ON MDRPHINE-INDUCED STRAUB RESPDNSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03

ACTIONS OF REPEATED INJECTIONS OF LSD AND APOMORPHINE DN THE COPULATORY RESPONSE OF FEMALE RATS.
002441 03-04

BEHAVIORAL DRUG EFFECTS UPDN OPERANT RESPONSE FDRCE.
002447 03-04

EFFECTS OF PSYCHOTROPIC DRUGS UPDN THE HYPDTHALAMIC RAGE RESPONSE IN CATS.
002493 03-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

CENTRAL CHOLINERGIC BLOCKADE 8Y SCOPOLAMINE AND HA8ITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RA8BITS NICTITATING MEMBRANE RESPONSE.
00250B 03-04

EFFECTS OF NEUROLEPTIC DRUGS ON THE AVOIDANCE RESPONSE AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
002515 03-04

CATECHOLAMINES AND OPERANT RESPONSE RATES IN AL8INO RATS.
002555 03-04

THE MEASUREMENT OF PLASMA CHLDRPROMAZINE AND ITS META8OLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-08

PREDICTION OF TRICYCLIC ANTIDEPRESSANT RESPONSE: A CRITICAL REVIEW.
002667 03-09

ANTIDEPRESSANT RESPONSE PREDICTIDN BY AMPHETAMINE. (UNPU8LISHED PAPER).
002702 03-09

NDRTRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.
002708 03-09

VARIABILITY OF PSYCHDTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TD ITS ELUCIDATIDN.
002B11 03-13

PREDICTING THE RESPDNSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002852 03-14

PHARMACOPSYCHOLOGICAL EXAMINATIDNS CONCERNING INTERACTIDNS OF ALCOHDL AND OXAZEPAM WITH REGARD TD RESPDNSE BEHAVIOR.
002880 03-14

DISCRIMINATIVE RESPONSE CDNTRDL BY PSYCHDMDTDR STIMULANTS.
003034 03-17

RESPDNSE OF MEDULLARY RAPHE NEURDNS TO PERIPHERAL STIMULATION AND TO SYSTEMIC DPIATES.
003082 04-03

PHARMACOLOGIC RESPONSE TO PENTDBARBITAL IN ACTIVELY IMMUNIZED MICE.
003141 04-03

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

THE CEREBRAL OXIDATIVE METABDLIC RESPONSE TO ACUTE ETHANOL ADMINISTRATION IN RATS AND CATS.
003203 04-03

AUGMENTATION OF THE BEHAVIORAL AND ELECTROPHYSIOLOGIC RESPONSE TO COCAINE 8Y CHRONIC ADMINISTRATION IN THE RAT.
003291 04-03

DELTA1-TETRAHYDROCANNABINOL, CANNABIDIOL AND CANNABINDL EFFECTS ON THE IMMUNE RESPONSE OF MICE.
003339 04-03

TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) DN ACDUSTIC STARTLE RESPONSE.
003372 04-04

EFFECT OF MORPHINE ON RESPDNSE TO PAIN: A TWIN STUDY.
003374 04-04

REPEATED CHLORPROMAZINE ADMINISTRATIDN INCREASES A BEHAVIOURAL RESPONSE OF RATS TD 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04

EFFECTS DF LDCUS-CDERULEUS LESIDNS UPDN CEREBRAL MDNDAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPDNSE TD AMPHETAMINE IN THE CAT.
003409 04-04

EARLY DEVELOPMENTAL CHANGES IN THE LDCDMDTOR RESPDNSE TO AMPHETAMINE AND THEIR RELATION TO HIPPDCAMPAL FUNCTION.
003418 04-04

ENVIRDNMENTAL STRESS AS A FACTDR IN THE RESPDNSE DF RAT BRAIN CATECHOLAMINE METABDLISM TO DELTA8-TETRAHYDRDCANNABINDL.
003423 04-04

EXAGGERATED RESPDNSE TO (+)AMPHETAMINE IN GERIATRIC GERBILS.
00346B 04-04

METHODS DF DECDNDITIDNING PERSISTING AVDIDANCE: DRUGS AS ADJUNCTS TD RESPDNSE PREVENTION.
003469 04-04

BENZDDIAZEPINES AND DISCRIMINATIDN BEHAVIDUR: DISSDCIATIDN DF RESPONSE AND SENSDRY FACTORS.
003475 04-04

EFFECTS DF TRYPTAMINE ON THE CDNDITIONED AVDIDANCE RESPDNSE IN RATS.
003478 04-04

A POSITIVE RESPONSE TD RAPID TREATMENT.
003532 04-08

PLASMA NDRTRIPTYLINE AND CLINICAL RESPDNSE -- A STUDY USING CHANGING PLASMA LEVELS.
003552 04-09

LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS.
003568 04-09

RESPONSE OF ADDLESCENTS WITH MINIMAL-BRAIN-DYSFUNCTION TO METHYLPHENIDATE.
003630 04-11

CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TD LITHIUM THERAPY.
003632 04-11

EFFECT OF PSYCHOTROPIC AGENTS UPDN THE BLASTOGENIC RESPONSE OF HUMAN T-LYMPHOCYTES.
003656 04-13

DEPRESSIVE SUBTYPES, BLODD PRESSURE CHANGES AND RESPDNSE TO TREATMENT.
003669 04-13

THE HEART-RATE RESPONSE AS AN INDICATOR DF CHANGES IN ACTIVATION INDUCED BY ALCOHOL.
003690 04-13

ABSORPTION RATE, BLDDD CDNCENTRATIDNS, AND EARLY RESPDNSE TO DRAL CHLORDIAZEPDXIDE.
003731 04-14

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIDNER TRIALS.
003B07 04-15

PREDICTDRS DF DRUG RESPDNSE IN THE AFFECTIVE DISDRDERS: TDWARD AN INTEGRATED APPROACH. (UNPUBLISHED PAPER).
003863 04-17

RESPONSES

EFFECTS DF METDPRDLDL AND PROPRANDLDL DN SDME METABDLIC RESPONSES TD CATECHDLAMINES IN THE ANESTHETIZED DOG.
00002B 01-03

RESPDNSES OF MIDBRAIN NEURDNES TD MICRDIDNTOPHDRETICALLY APPLIED 5-HYDRDXYTRYPTAMINE: CDMPARISDN WITH THE RESPDNSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

ADAPTATIONAL BEHAVIOR OF PERIPHERAL AND CENTRAL RESPONSES IN GUINEA-PIGS UNDER THE INFLUENCE OF VARIOUS FRACTIONS OF AN EXTRACT FROM GINGKO-BILOBA.
000232 01-03

BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN.
000407 01-04

EFFECTS OF BENZODIAZEPINE TRANQUILLIZERS ON THE SOCIAL RESPONSES OF RATS.
000452 01-04

TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-05

PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 D1-07

ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
000579 01-08

EFFECTS OF DIAZEPAM AND ETHANOL ON HEART-RATE AND GALVANIC SKIN RESPONSES.
000812 01-13

EFFECT OF DIAZEPAM ON VENTILATORY RESPONSES.
000960 01-15

CARDIOVASCULAR RESPONSES TO AVOIDANCE CONDITIONING IN THE DOG: EFFECTS OF ALPHA ADRENERGIC BLOCKADE.
001124 02-03

NEURONAL RESPONSES TO ADRENOCEPTOR AGONISTS IN THE CEREBRAL CORTEX: EVIDENCE FOR EXCITATORY ALPHA-ADRENOCEPTORS AND INHIBITORY BETA-ADRENOCEPTORS.
001141 02-03

ALTERATION OF BASAL GANGLIA EVOKED RESPONSES BY RESERPINE AND L-DOPA.
001266 02-03

DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 D2-D3

DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-D4

SCOPOLAMINE: EFFECTS ON FEAR OR DEFENSE RESPONSES IN THE RAT.
001546 02-04

CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
D01610 02-04

CARDIOVASCULAR RESPONSES OF HYPERACTIVE CHILDREN TO METHYLPHENIDATE.
DD1814 02-11

THE ACTION OF PSYCHOTROPIC DRUGS ON DOPA-INDUCED BEHAVIOURAL RESPONSES IN MICE.
002188 03-02

METABOLIC AND ELECTRICAL RESPONSES OF THE BRAIN TO COMPLETE ISCHEMIA IN THE AWAKE AND ANESTHETIZED RAT.
D02304 03-03

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 D3-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-D4

A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
D02477 D3-D4

RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND IN THE EFFECTS OF DIAZEPAM.
0024BB D3-D4

EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
002566 03-05

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
0D2B21 03-13

GENETIC, BIOCHEMICAL, AND PHARMACOLOGICAL CORRELATES OF RESPONSES TO PRIMING IN MICE.
003124 D4-03

EFFECTS OF ANTIDEPRESSANT DRUGS ON NORADRENALINE ACCUMULATION AND CONTRACTILE RESPONSES IN THE RAT ANOCOCCYGEUS MUSCLE.
003128 04-03

MORPHINE, NALOXONE AND THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-03

INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX.
003131 04-03

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03

THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTACT AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
003286 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03

INDEPENDENT RECEPTORS FOR PRESSOR AND DRINKING RESPONSES TO CENTRAL INJECTIONS OF ANGIOTENSIN-II AND CARBACHOL.
003404 04-04

A COMPARATIVE STUDY OF THE BEHAVIOURAL RESPONSES INDUCED BY CHRONIC ADMINISTRATION OF METHAMPHETAMINE AND AMPHETAMINE IN MICE.
003439 04-04

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08

INDIVIDUAL DIFFERENCES IN AVERAGE EVOKED RESPONSES TO D-AMPHETAMINE AND L-AMPHETAMINE WITH AND WITHOUT LITHIUM-CARBONATE IN DEPRESSED PATIENTS.
003550 04-09

ADRENERGIC RESPONSES IN THE AFFECTIVE DISORDERS.
0D3558 04-09

HUMAN PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS CORRELATE WITH ANTISCHIZOPHRENIC POTENCY.
0036B4 04-13

PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSES IN MAN.
0D3708 04-13

RESPONSIBILITY

MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

RESPONSIVE

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
0DD254 01-03

A PHARMACOGENETIC CASE REPORT: LITHIUM RESPONSIVE POSTPSYCHOTIC ANTISOCIAL BEHAVIOR.
001703 D2-08

A DEPRESSIVE SYNDROME RESPONSIVE TO LITHIUM: AN ANALYSIS OF 20 CASES.
D01767 D2-09

HEREDITARY PAROXYSMAL ATAXIA RESPONSIVE TO ACETAZOLAMIDE.
D03629 04-11

RESPONSIVENESS

THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
000107 D1-03

CHANGES IN CNS RESPONSIVENESS DURING HIBERNATION
001136 02-03

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
D01157 02-03

NEURONAL LOCALIZATION OF THE ENHANCED ADENYLATE-CYCLASE RESPONSIVENESS TO CATECHOLAMINES IN THE RAT CEREBRAL CORTEX FOLLOWING RESERPINE INJECTIONS.
D01321 02-03

FINDINGS WITH A CONDITIONING TEST BATTERY: DIFFERENTIAL RESPONSIVENESS TO DIAZEPAM AND DOXEPIN.
00358D D4-10

REST

HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 D3-08

RESTING
DEPRESSION 8Y MORPHINE OF THE RESTING AND EVOKED RELEASE OF (3H) ACETYLCHOLINE FROM THE CAT CAUDATE NUCLEUS IN VIVO.
003331 04-03

RESTLESSNESS
ANXIETY, RESTLESSNESS AND ANXIOLYTICS.
002734 03-10

RESTORATION
THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03
THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04
ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS IN RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 01-05
RESTORATION OF SELF-STIMULATION INHIBITED BY NEUROLEPTICS.
001414 02-03
PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE 8UT NOT 8Y PHENTOLAMINE OR PHENOXY8ENZAMINE.
003142 04-03

RESTRAINT
EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
000238 01-03

RESULTED
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

RESUSCITATION
USE OF NOOANALEPTIC AND NOOTROPIC DRUGS IN RESUSCITATION.
000905 01-14

RETARD
USE OF DIBENZEPINE RETARD IN THE TREATMENT OF ALCOHOLIC DEPRESSION.
000764 01-11
FAILURE OF ATROPINE TO RETARD AMYGDALOID KINDLING.
001171 02-03
EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07

RETARDATION
EFFECT OF POTASSIUM ON LITHIUM-INDUCED GROWTH RETARDATION AND POLYURIA IN RATS.
0001B9 01-03
LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50.
002788 03-11
ENHANCEMENT OF PSEUDOCONDITIONING AND RETARDATION OF ESCAPE BY LOW DOSES OF ETHANOL.
003375 04-04

RETARDED
A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11
THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
0007B1 01-11
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17
SOME STUDIES IN AN INSTITUTION FOR THE MENTALLY RETARDED.
001B59 02-11
RICKETS AND ANTICONVULSANTS IN MENTALLY RETARDED PATIENTS.
003783 04-15

RETENTION
MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03
EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
000365 01-04
DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE-AVERSION.
000913 01-14
RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03
PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
001590 02-04
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE 8OX BEHAVIOR AND TOTAL 8RAIN ACETYLCHOLINE
003377 04-04
ENHANCEMENT OF RETENTION WITH CENTRALLY ADMINISTERED CATECHOLAMINES.
003400 04-04
RETENTION OF INTERNAL EXPERIENCES IN JUVENILE AND ADULT RATS.
003412 04-04
EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 04-04
ANGIOTENSIN INJECTED INTO THE NEOSTRIATUM AFTER LEARNING DISRUPTS RETENTION PERFORMANCE.
003433 04-04
ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION.
003503 04-05

RETICULAR
DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04
STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-05

RETICULOCORTICAL
MODIFICATION OF ANESTHETIC-INDUCED EPILEPTIFORM EEG ACTIVITY BY EXPERIMENTAL ALTERATIONS OF RETICULOCORTICAL DRIVE.
001390 02-03
HALOPERIDOL BLOCKS AN ALPHA ADRENERGIC RECEPTOR IN THE RETICULOCORTICAL INHIBITORY INPUT.
002325 03-03

RETINA
THE SUBCELLULAR DISTRIBUTION OF 14C-GABA AND 3H-DOPAMINE IN THE RETINA.
001130 02-03
EFFECTS OF DRUGS ON THE FORMATION OF HOMOVANILLIC-ACID IN THE RAT RETINA.
001418 02-03
THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN THE RETINA: A POINT OF ACTION FOR D-LSD.
002372 03-03

RETINAE
LITHIUM INHIBITION OF CYCLIC-AMP ACCUMULATION INDUCED BY DOPAMINE IN ISOLATED RETINAE OF THE RABBIT.
003271 04-03

RETINAL
RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIDEPRESSANTS.
001284 02-03
BRAIN AND RETINAL DAMAGE FROM LATHYRUS-EXCITOTOXIN, BETA-N-OXALYL-L-DIAMINOPROPIONIC-ACID.
001316 02-03

RETRIEVAL
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04
MARIJUANA AND MEMORY IMPAIRMENT: THE EFFECT OF RETRIEVAL CUES ON FREE RECALL.
002B67 03-14
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04
MARIJUANA: EFFECTS ON STORAGE AND RETRIEVAL OF PROSE MATERIAL.
003743 04-14
ETHANOL AND MARIHUANA EFFECTS ON EVENT RELATED POTENTIALS IN A MEMORY RETRIEVAL PARADIGM.
003B94 04-17

RETROGRADE
REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03
DDC-INDUCED RETROGRADE AMNESIAS PREVENTED BY INJECTIONS OF DL-DOPS.
001232 02-03
VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA: CONTINGENCY ON TASKS AND SPECIES.
001440 02-04

RETROSPECTIVE
FLUPHENAZINE-DECANOATE MAINTENANCE IN SCHIZOPHRENIA: A RETROSPECTIVE STUDY.
001713 02-08
RETROSPECTIVE EVALUATION AND MANAGEMENT OF PSYCHIATRIC PATIENTS IN OLDER AGE GROUPS.
002784 03-11

REUPTAKE
SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
003087 04-03

REVERSAL
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03
PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03
THE REVERSAL OF CLONIDINE-INDUCED HYPOTENSION BY PROTRIPTYLINE AND DESIPRAMINE.
000248 01-03
INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
00D354 01-04
BARBITURATE REVERSAL OF AMINO-ACID ANTAGONISM PRODUCED BY CONVULSANT AGENTS.
001102 02-02
REVERSAL OF THE ACTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ANTAGONISTS BY BARBITURATES.
001153 02-03
REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
001580 02-04
REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF PROPRANOLOL.
001954 02-14
REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
002048 02-15
P-CHLOROPHENYLALANINE REVERSAL OF TRANYLCYPROMINE EFFECTS IN DEPRESSED PATIENTS.
DD2164 02-17
EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. II. REVERSAL BY PICROTOXIN.
002247 D3-D3
COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03
REVERSAL OF NARCOTIC DEPRESSION IN THE NEONATE BY NALOXONE.
002808 03-13
REVERSAL OF DELAYED MYELINOGENESIS IN THE FETAL ALCOHOL SYNDROME.
003258 04-03
EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 D4-04

REVERSE
SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001890 02-13
REVERSE TOLERANCE TO STIMULANT-INDUCED ABNORMAL BEHAVIOR.
003196 04-03

REVERSIBLE
REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION.
000211 01-03
REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
DD1216 D2-D3
TARDIVE-DYSKINESIA: ARE FIRST SIGNS REVERSIBLE?.
003818 04-15

REVIEW
CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
00051B D1-07
THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A REVIEW.
DDD558 01-08
A REVIEW OF RECENT STUDIES OF THE BIOSYNTHESIS AND EXCRETION OF HALLUCINOGENS FORMED BY METHYLATION OF NEUROTRANSMITTERS OR RELATED SUBSTANCES.
000564 01-08
THE CHOICE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW.
000571 01-08
DRUG-INDUCED HANDWRITING CHANGES: AN EMPIRICAL REVIEW.
000895 01-14
ANTICONVULSANT DRUGS AND MENTAL SYMPTOMS: A REVIEW.
000989 01-15
CLONAZEPAM: A REVIEW OF A NEW ANTICONVULSANT DRUG.
001022 01-17
PEER REVIEW OF PRESCRIBING PATTERNS IN A (CMHC).
001033 01-17
THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
00107B 01-17
BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE BIOCHEMICAL LITERATURE.
001080 01-17
BIOCHEMICAL PLASTICITY OF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001351 02-03
HIGH DOSAGE NEUROLEPTIC THERAPY: A REVIEW.
001686 02-08
SEVERE MOOD DISORDERS: A REVIEW.
001780 02-09
AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA: CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001832 02-11
PSYCHOSTIMULANTS AND CHILDREN: A REVIEW AND ANALYSIS.
D01B66 02-11
METHODOLOGICAL REVIEW OF FLUID THERAPY IN PSYCHIATRY.
002145 02-17
CLINICAL PSYCHIATRY AND PSYCHOPHARMACOLOGY -- A REVIEW.
002168 02-17
SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
0D2448 D3-D4
INTERMITTENT PSYCHOPHARMACOTHERAPY: REVIEW OF LITERATURE AND CRITICAL REMARKS.
0D265B D3-DB
PREDICTION OF TRICYCLIC ANTIDEPRESSANT RESPONSE: A CRITICAL REVIEW.
002667 03-09
PSYCHOTROPIC EFFECTS OF ANDROGENS: A REVIEW OF CLINICAL OBSERVATIONS AND NEW HUMAN EXPERIMENTAL FINDINGS.
DD2760 D3-11
SINGLE-AGENT CHEMOTHERAPY OF BRAIN TUMORS: A FIVE-YEAR REVIEW.
002792 03-11
URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
002798 03-12
THE CARDIOVASCULAR EFFECTS OF LITHIUM IN MAN: A REVIEW OF THE LITERATURE.
002840 03-13
PREDICTING THE RESPONSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
DD2B52 D3-14
LITHIUM THERAPY: A BRIEF REVIEW.
002917 03-15
A REVIEW OF PSYCHOTROPIC MEDICATIONS AND THE GLAUCOMAS.
002926 03-15
THE SYSTEMIC USE OF PROCAINE IN THE TREATMENT OF THE ELDERLY: A REVIEW.
DD3595 04-10
PRACTICAL CONSIDERATIONS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE: AN UPDATED REVIEW.
0D3764 04-15
A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, DRUGS, AND THEIR INTERACTION.
DD3766 D4-15
IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-15
A REVIEW OF NEUROTOXICITY OF LITHIUM DURING THERAPEUTIC TREATMENT.
DD3B29 04-15
A REVIEW OF COMBINED TRICYCLIC AND MAOI THERAPY.
003846 04-17

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
003883 04-17

REVOLUTION
MOODSWING: THE THIRD REVOLUTION IN PSYCHIATRY.
000602 01-09

REWARD
APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03
POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE.
000209 01-03
RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03
EFFECT OF CATECHOLAMINERGIC DRUGS ON SYSTEMS OF REWARD AND PUNISHMENT IN EXPERIMENTS ON CATS.
002518 03-04
INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04

REWARDED
TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04

RHESUS-MONKEY
AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03
SHORT-TERM MEMORY IN THE RHESUS-MONKEY: DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
000283 01-04
ENHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
000318 01-04
VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS-MONKEY.
001454 02-04
ACUTE PHARMACOLOGICAL ACTIVITY OF INTRAVENOUS COCAINE IN THE RHESUS-MONKEY.
002556 03-04

RHESUS-MONKEYS
EFFECTS OF DIAZEPAM RELATED TO SOCIAL HIERARCHY IN RHESUS-MONKEYS.
000311 01-04
PHENYLETHYLAMINE EFFECTS IN RHESUS-MONKEYS (UNPUBLISHED PAPER).
000439 01-04
ASSESSMENT OF CNS DRUG ACTIVITY IN RHESUS-MONKEYS BY ANALYSIS OF THE EEG.
001218 02-03
PROGRESSIVE EFFECTS OF COCAINE ON BEHAVIOR AND CENTRAL AMINE METABOLISM IN RHESUS-MONKEYS: RELATIONSHIP TO KINDLING AND PSYCHOSIS.
001333 02-03
THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04
BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04
ISONIAZID: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN RHESUS-MONKEYS.
001530 02-04
GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
001561 02-04
THE EFFECTS OF NALOXONE AND NALORPHINE DURING THE DEVELOPMENT OF MORPHINE-DEPENDENCE IN RHESUS-MONKEYS.
003077 04-03
SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04-03
BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04
THE EFFECTS OF COCAINE ON THE AGGRESSIVE BEHAVIOR OF MICE, PIGEONS AND RHESUS-MONKEYS.
003406 04-04

RHEUMATIC
CLOMIPRAMINE (ANAFRANIL) AND MUSCULOSKELETAL PAIN IN GENERAL PRACTICE: A PILOT, OPEN, NONCOMPARATIVE STUDY OF LONG-STANDING, RHEUMATIC PAIN.
003891 04-17

RHIZOTOMY
THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
003379 04-04

RHYTHM
INHIBITION OF MONOAMINE-OXIDASE AND DAY/NIGHT RHYTHM: CORRELATION BETWEEN PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS.
001569 02-04
LITHIUM EFFECTS ON DIURNAL RHYTHM OF CALCIUM, MAGNESIUM, AND PHOSPHATE METABOLISM IN MANIC MELANCHOLIC DISORDER.
001929 02-13

RHYTHMS
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN
000265 01-03
EFFECT OF LITHIUM IONS ON CIRCADIAN RHYTHMS.
001479 02-04
EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11

RICKETS
RICKETS AND ANTICONVULSANTS IN MENTALLY RETARDED PATIENTS.
0037B3 04-15

RIGID
INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION.
003051 04-01
BIOLOGICAL DISPOSITION OF RIGID ANALOGS OF AMPHETAMINE.
003147 04-03

RIGIDITY
EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG-INDUCED PARKINSONIAN RIGIDITY.
000999 01-15
CURVE OF EXCITABILITY OF ALPHA MOTOR NEURONS OF THE DORSAL FLEXOR OF THE FOOT IN DRUG-INDUCED PARKINSONIAN RIGIDITY BEFORE AND AFTER ADMINISTRATION OF ETHYLBENZATROPINE.
001000 01-15
COGWHEEL RIGIDITY EARLY IN LITHIUM THERAPY.
002015 02-15
REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY.
002076 02-15
RIGIDITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-03

RIO-DE-LA-PLATA
CONFERENCE ON DEPRESSION IN RIO-DE-LA-PLATA.
000642 01-09

RIPAZEPAM
RIPAZEPAM (CI-683) DOUBLE-BLIND COMPARISON WITH PLACEBO IN ANXIOUS PATIENTS.
000707 01-10
EFFECTS OF DIAZEPAM AND RIPAZEPAM ON TWO MEASURES OF ADJUNCTIVE DRINKING IN RATS.
001572 02-04
EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

RISK
RISK FACTORS FOR MYOCARDIAL INFARCTION IN YOUNG WOMEN.
000966 01-15

RISKS
THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS AND LITHIUM.
000937 01-15

RITALIN
ABUSE OF RITALIN BY TAFT CITY SCHOOL DISTRICT.
000879 01-14

RNA

THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE.
001247 02-03

THE EFFECT OF APOMORPHINE AND HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
003181 04-03

RO-4-4602

BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE DECARBOXYLASE INHIBITOR RO-4-4602.
000295 01-04

OUTCOME OF PARKINSONISM AFTER 2 YEARS OF L-DOPA PLUS RO-4-4602.
000737 01-11

HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002849 03-14

RO-5-3350

TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
000680 01-10

LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
000708 01-10

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

RO-5-4200

A DOUBLE-BLIND COMPARISON OF A NEW HYPNOTIC, FLUNITRAZEPAM (RO-5-4200), WITH A BARBITURATE.
002750 03-11

RODENT

ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS.
000273 01-04

RODENTS

NORADRENALINE SYNTHESIS FROM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
001186 02-03

INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOURS IN RODENTS.
001519 02-04

ROLE

THE ROLE OF N-ALLYL AND N-PROPARGYL ANALOGS IN THE MECHANISM OF INHIBITION OF FLAVIN LINKED ENZYMES: -- N-DIMETHYLGLYCINE-OXIDASE -- N-MONOAMINE-OXIDASE.
000011 01-01

ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: PHARMACOLOGICAL CHARACTERIZATION IN VITRO AND POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
000053 01-03

ROLE OF CATECHOLAMINES IN THE HYPOTHERMIC ACTIVITY OF CANNABIS IN ALBINO RATS.
00022B 01-03

A ROLE FOR DOPAMINE IN THE PSYCHOPHARMACOLOGY OF ELECTRICAL SELF-STIMULATION.
000300 01-04

AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
000343 01-04

RELATIVE ROLE OF CATECHOLAMINES IN HEAD-SHAKING OF INFANT RATS.
000344 01-04

THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-04

CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
00040B 01-04

THE ROLE OF LOCOMOTION IN CONDITIONING METHYLPHENIDATE-INDUCED LOCOMOTOR ACTIVITY.
000416 01-04

PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 01-08

THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS.
000640 01-09

IS THERE A ROLE FOR THE TEACHER IN THE USE OF MEDICATIONS FOR HYPERKINETICS
000908 01-14

ROLE OF DOPAMINE IN THE ANOREXIGENIC EFFECT OF DITA; COMPARISON WITH D-AMPHETAMINE.
001119 02-03

ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
001132 02-03

ROLE OF BRAIN MONOAMINES IN THE ANTICONVULSANT EFFECT OF IMIPRAMINE IN ALBINO RATS.
001143 02-03

ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-03

SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 02-03

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
001238 02-03

ROLE OF NORADRENERGIC AND DOPAMINERGIC PROCESSES IN AMPHETAMINE SELF-ADMINISTRATION.
001342 02-03

THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS.
001447 02-04

THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04

HEAD TWITCHES INDUCED BY BENZODIAZEPINES AND THE ROLE OF BIOGENIC AMINES.
001552 02-04

THE ROLE OF DPAR IN THE RESOCIALIZATION OF SCHIZOPHRENICS.
001720 02-08

THE CURRENT ROLE OF LITHIUM IN THE TREATMENT OF AFFECTIVE DISORDERS.
001779 02-09

A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001868 02-12

PSYCHIATRIC MEDICATION: THE ROLE OF THE NONPHYSICIAN
002156 02-17

EFFECT OF ANTIPSYCHOTIC DRUGS ON THE FIRING OF DORSAL RAPHE CELLS. I. ROLE OF ADRENERGIC SYSTEM.
002246 03-03

ROLE OF BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR.
002252 03-03

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

MONOAMINERGIC SENSORY REGULATION AND THE ROLE OF MORPHINE.
002353 03-03

ROLE OF CONDITIONED REINFORCERS IN THE INITIATION, MAINTENANCE AND EXTINCTION OF DRUG-SEEKING BEHAVIOR.
002437 03-04

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING.
002495 03-04

PRESCRIBING PSYCHOTROPIC DRUGS: THE PRIMARY PHYSICIANS ROLE.
003019 03-17

THE ROLE OF BODILY FEELINGS IN ANXIETY.
003040 03-17

POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE: THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 04-03

THE ROLE OF N-HYDROXYAMPHETAMINE IN THE METABOLIC DEAMINATION OF AMPHETAMINE.
003329 04-03

ROLE OF CENTRAL CATECHOLAMINES IN THE PSYCHOSTIMULANT ACTION OF PYROVALERONE.
003383 04-04

INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04

EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES.
003449 04-04

ROLE OF BRAIN MONOAMINES IN THE ANORECTIC ACTIVITY OF MAZINDOL AND D-AMPHETAMINE IN THE RAT.
003455 04-04

ROLES

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

POSSIBLE ROLES OF CATECHOLAMINES IN THE ACTION OF NARCOTIC DRUGS.
000B09 01-13

THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03

ROOM

EMERGENCY ROOM MANAGEMENT OF ORGANIC-BRAIN-SYNDROMES CAUSED BY OVER-THE-COUNTER HYPNOTICS.
003763 04-15

ROOT

ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01

ROSETTE

CANNABINOLS AND THE ROSETTE FORMING PROPERTIES OF LYMPHOCYTES IN VITRO.
001901 02-13

ROTA-ROD

EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFORMANCE IN MICE.
003416 04-04

ROTATION

DRUG-INDUCED ROTATION IN RATS WITHOUT LESIONS: BEHAVIORAL AND NEUROCHEMICAL INDICES OF A NORMAL ASYMMETRY IN NIGROSTRIATAL FUNCTION
000352 01-04

MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

ROTATIONAL

A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

PHENCYCLIDINE-INDUCED ROTATIONAL BEHAVIOR IN RATS WITH NIGROSTRIATAL LESIONS AND ITS MODULATION BY DOPAMINERGIC AND CHOLINERGIC AGENTS.
002445 03-04

MESOLIMBIC DOPAMINERGIC NEURONES IN THE ROTATIONAL MODEL OF NIGROSTRIATAL FUNCTION.
0024B3 03-04

A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

ROUTE

INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS.
000079 01-03

EFFECT OF UNIT DOSE AND ROUTE OF ADMINISTRATION ON SELF-ADMINISTRATION OF MORPHINE.
002543 03-04

RP-19552

TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL PALMITATE).
001668 02-07

RSA

INTRAVENTRICULAR ANTICHOLINERGICS DO NOT BLOCK CHOLINERGIC HIPPOCAMPAL RSA OR NEOCORTICAL DESYNCHRONIZATION IN THE RABBIT OR RAT.
002403 03-03

HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

RUB

PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY.
002013 02-15

RUBIDIUM

EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
0012BB 02-03

EFFECTS OF LITHIUM AND RUBIDIUM ON ANTINOCICEPTION AND BEHAVIOUR IN MICE: I. STUDIES ON NARCOTIC ANALGESICS AND ANTAGONISTS.
001350 02-03

EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
002566 03-05

RUBROSPINAL

EFFECTS OF GABA, GLYCINE, PICROTOXIN AND BICUCULLINE METHOCHLORIDE ON RUBROSPINAL NEURONES IN CATS.
000033 01-03

RULES

DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003B51 04-17

RUNNER

FDA: A SLOW STARTER AND A SLOW RUNNER.
00299B 03-17

RV7

EFFECTS OF CARBONATE OF LITHIUM ON PERFORMANCE UNDER A PROGRAM OF MULTIPLE REINFORCEMENT IV 1900 RV7.
002415 03-04

R16341

CLINICAL EVALUATION OF A WEEKLY ADMINISTERED NEUROLEPTIC: PENFLURIDOL (R16341).
002596 03-07

R29764

LONG-ACTING NEUROLEPTICS: A PRELIMINARY STUDY OF CLOPIMOZIDE (R29764).
001655 02-07

S-ADENOSYL-L-METHIONINE

EFFECT OF S-ADENOSYL-L-METHIONINE (SAME) UPON DEPRESSIVE SYMPTOMS.
001953 02-14

S-AMPHETAMINE

BEHAVIORAL COMPARISONS OF R-2-AMINO-1 2,5 DIMETHOXY-4-METHYLPHENYLBUTANE (BL-3912A) WITH R-DOM AND S-AMPHETAMINE.
003470 04-04

S-100

MECHANISM OF INTERACTION OF MYELIN BASIC PROTEIN AND S-100 PROTEIN: METAL BINDING AND FLUORESCENCE STUDIES.
00132B 02-03

SACCHARIN

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE INTAKE OF ETHANOL AND SACCHARIN SOLUTIONS.
003463 04-04

SACCHARINE

ACQUIRED PREFERENCE FOR MORPHINE BUT NOT D-AMPHETAMINE AS A RESULT OF SACCHARINE ADULTERATION.
001513 02-04

SACRAMENT

PSYCHOMYOCOLOGICAL STUDIES OF AMANITA -- FROM ANCIENT SACRAMENT TO MODERN PHOBIA.
001063 01-17

SAFEGUARDS

SAFEGUARDS IN THE TREATMENT OF SCHIZOPHRENIA WITH PROPRANOLOL.
002607 03-07

SAFETY

A REVIEW OF THE SAFETY HAZARD DUE TO POOR HEALTH, DRUGS, AND THEIR INTERACTION.
003766 04-15

SAFRAZINE
AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03

SAGITTAL
ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES.
000020 01-02

SALIVA
USEFULNESS OF SALIVA LITHIUM ESTIMATION.
003721 04-13

SALIVARY
SALIVARY AND URINARY LITHIUM CLEARANCE WHILE RECUMBENT AND UPRIGHT.
003706 04-13

SALSOLINOL
IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-03

SALT
INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
000723 01-11
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF D-OXAZEPAM HEMISUCCINATE SODIUM SALT (D-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07
INDICATIONS FOR LITHIUM SALT IN OTHER THAN MANIC-DEPRESSIVE PSYCHOSIS.
001B57 02-11

SALT-WATER
EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
001115 02-02

SALTS
COMPARISON OF LITHIUM SALTS.
00165B 02-07
A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

SANDLER
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001B00 02-10

SART-STRESS
COMPARISON BETWEEN ANALGESIC ACTIVITIES IN SART-STRESS MICE AND IN NORMAL MICE.
002460 03-04

SAS
EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04

SASKATCHEWAN
SASKATCHEWAN DIAL-ACCESS DRUG INFORMATION SERVICE.
002970 03-17

SASSAFRAS
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
0009B3 01-15

SATIATED
THE EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVED AND SATIATED MICE.
000313 01-04
EFFECTS OF D-AMPHETAMINE AND PILOCARPINE ON THE MOUSE-KILLING RESPONSE OF HUNGRY AND SATIATED RATS.
001565 02-04

SATIETY
DIFFERENCES BETWEEN THE ANOREXIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE -- POSSIBLE EFFECTS ON HUNGER AND SATIETY.
000291 01-04

SATURATION
SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000B35 01-13

SBR
A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

SC-13504
THE RELATIONSHIP BETWEEN THE ANTICONVULSANT PROPERTIES OF SC-13504 AND ITS PLASMA LEVELS, MEASURED BY POLAROGRAPHY, IN BABOONS WITH PHOTOSENSITIVE EPILEPSY.
001294 02-03

SCALE
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001B00 02-10
INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
002095 02-16
DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-0B
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-0B
VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
0035BB 04-10
NEW ANXIOLYTIC RATING SCALE.
003607 04-10

SCALES
RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
000BB0 01-14
DIAZEPAM AND PHENOBARBITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
0017B7 02-10
SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0019B6 02-14
COMPARATIVE VALUE OF RATING AND SELF-RATING SCALES IN DRUG TRIALS.
003592 04-10
EXPERIENCES WITH SOME NEW SCALES FOR USE IN GENERAL PRACTICE TRIALS.
003B39 04-16
THE VALUE OF SELF-RATING SCALES IN DRUG TRIALS.
003B40 04-16
COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003B97 04-17

SCALP
EFFECTS OF ETHANOL ON SCALP VISUAL EVOKED POTENTIALS.
00194B 02-13

SCANDINAVIAN
ANNUAL MEETING OF THE SCANDINAVIAN ASSOCIATION OF PSYCHOPHARMACOLOGY.
002991 03-17

SCHEDULE
THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04
EFFECT OF DIAZEPAM ON PERFORMANCE OF PIGS IN A PROGRESSIVE RATIO SCHEDULE
001467 02-04
BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04
ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04
SCHEDULE INDUCED BEHAVIOR: A REVIEW OF ITS GENERALITY, DETERMINANTS AND PHARMACOLOGICAL DATA.
002171 02-17
EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04
SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-04

SCHEDULE-CONTROLLED
ETHANOL AND ISOPROPANOL EFFECTS ON SCHEDULE-CONTROLLED RESPONDING.
000152 01-03
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT RAT.
000327 01-04
SCHEDULE-CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04

SCHEDULES
THE EFFECT OF ACUTE METHADONE ON FIXED-INTERVAL SCHEDULES OF REINFORCEMENT IN PIGEONS. (PH.D. DISSERTATION).
000375 01-04

CLINICAL RESPONSE AND PLASMA LEVELS: EFFECT OF DOSE, DOSAGE SCHEDULES, AND DRUG INTERACTIONS ON PLASMA CHLORPROMAZINE LEVELS.
000861 01-13

THE EFFECTS OF D-AMPHETAMINE ON READING 8Y NORMAL ADULT HUMAN SU8JECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14

INTERACTIONS 8ETWEEN NALOXONE AND NARCOTIC ANALGESICS UNDER THREE SCHEDULES THAT INDUCE POLYDIPSIA.
001545 02-04

EFFECTS OF PROPRANOLOL ON 8EHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
002457 03-04

PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION: EFFECTS OF D-AMPHETAMINE AND PENTO8AR8ITAL.
002497 03-04

8EHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

EFFECTS OF COCAINE AND D-AMPHETAMINE ON 8EHAVIOR MAINTAINED UNDER VARIOUS SCHEDULES OF FOOD PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-04

ANTIDEPRESSANT EFFECTS OF DESIPRAMINE ADMINISTERED IN TWO DOSAGE SCHEDULES.
003566 04-09

CHISTOCERCA-GREGARIA

OCTOPAMINE, DOPAMINE AND NORADRENALINE CONTENT OF THE 8RAIN OF THE LOCUST, SCHISTOCERCA-GREGARIA.
001343 02-03

CHIZOAFFECTIVE

A FAVORABLE RESPONSE TO LITHIUM-CARBONATE IN A SCHIZOAFFECTIVE FATHER AND SON.
001714 02-08

CHIZOPHRENIA

SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHI8ITORS.
000090 01-03

PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07

EVALUATION OF LENPERONE IN ACUTE SCHIZOPHRENIA.
000515 01-07

CLINICAL EXPERIENCE IN USING TLP-607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-08

THE NATURE OF SCHIZOPHRENIA.
000525 01-08

PHARMACOLOGIC THERAPY FOR SCHIZOPHRENIA.
000526 01-08

8ACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA (UNPU8LISHED PAPER).
000534 01-08

GROWTH HORMONE SECRETION IN CHRONIC SCHIZOPHRENIA.
000536 01-08

DOU8LE-8LIND TRIAL OF L-DOPA IN CHRONIC SCHIZOPHRENIA.
000537 01-08

8ACLOFEN IN SCHIZOPHRENIA.
000539 01-08

INTRAMUSCULAR DOU8LE-8LIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-08

CLINICAL EXPERIENCES IN USING HIGH DOSAGES OF FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE ON SCHIZOPHRENIA.
000545 01-08

DRUG IN THE AFTERCARE TREATMENT OF SCHIZOPHRENIA.
000549 01-08

A DOU8LE-8LIND CONTROLLED COMPARISON OF PENFLURIDOL AND CARPIPRAMINE ON SCHIZOPHRENIA.
000551 01-08

A DOU8LE-8LIND COMPARISON OF TPN-12 AND CHLORPROMAZINE ON SCHIZOPHRENIA.
000552 01-08

THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A CRITICAL ANALYSIS.
000554 01-08

NEUROMUSCULAR DYSFUNCTION IN SCHIZOPHRENIA.
000557 01-08

THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA: A REVIEW.
000558 01-08

CLINICAL EXPERIENCE IN USING PENFLURIDOL (TLP-607) FOR SCHIZOPHRENIA.
000559 01-08

PHARMACOPSYCHOTHERAPY OF SCHIZOPHRENIA.
000561 01-08

COMPARISON OF EFFECTS UPON SCHIZOPHRENIA OF METHYLPERIDOL (LUVATREN) 8Y DOU8LE-8LIND EXAMINATION AND HALOPERIDOL.
000563 01-08

META8OLISM OF DRUGS IN SCHIZOPHRENIA.
000566 01-08

CLINICAL EXPERIENCE IN USING TLP-607 FOR CHRONIC SCHIZOPHRENIA.
000569 01-08

SCHIZOPHRENIA AND SLEEP DISORDERS.
000570 01-08

THE CHOICE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW.
000571 01-08

RESULTS OF LEPONEX TREATMENT IN SCHIZOPHRENIA.
000574 01-08

LOW PLATELET MONOAMINE-OXIDASE ACTIVITY AND SCHIZOPHRENIA.
000576 01-08

CLINICAL EXPERIENCE OF THIOTHIXENE (NAVANE) FOR SCHIZOPHRENIA.
000577 01-08

CLINICAL EFFECT OF PENFLURIDOL FOR SCHIZOPHRENIA -- ESPECIALLY DELUSION
000578 01-08

LONG-TERM THERAPY OF AFFECTIVE DISORDERS AND SCHIZOPHRENIA.
000620 01-09

THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA: DOSAGE AND SIDE-EFFECT COMPARISONS 8ETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-11

SELECTED ESSAYS ON SCHIZOPHRENIA.
000790 01-12

SCHIZOPHRENIA AND NEUROENDOCRINE FUNCTIONAL DISORDER: A CASE STUDY ON THE PRO8LEM OF PARANOID PSYCHOSIS.
000838 01-13

CERE8ROSPINAL FLUID AMINE METABOLITES IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA: CLINICAL AND PHARMACOLOGICAL STUDIES (UNPU8LISHED PAPER).
001044 01-17

UNWANTED EFFECTS OF LONG-TERM MEDICATION IN SCHIZOPHRENIA AND DEPRESSION.
001064 01-17

BIOCHEMISTRY AND SCHIZOPHRENIA (PART IV): THE NEUROLEPTICS -- THEIR MECHANISM OF ACTION: A REVIEW OF THE 8IOCHEMICAL LITERATURE.
001080 01-17

EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL 8EHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04

A DOU8LE-BLIND TRIAL OF 8ACLOFEN AGAINST PLACE8O IN THE TREATMENT OF SCHIZOPHRENIA.
001664 02-07

PROLACTIN SECRETION IN CHRONIC SCHIZOPHRENIA.
001680 02-08

GONADOTROPIN RESPONSE TO SYNTHETIC GONADOTROPIN HORMONE RELEASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
001681 02-08

DOPAMINE AND SCHIZOPHRENIA.
001685 02-08

CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA 8EFORE AND AFTER NEUROLEPTIC TREATMENT.
001687 02-08

INDICATIONS FOR PHARMACOTHERAPY OF SCHIZOPHRENIA.
001694 02-08

PHARMACOTHERAPY OF SCHIZOPHRENIA.
001695 02-08

MEDICAL AND SOCIAL INFLUENCE OF PHARMACOTHERAPY AGAINST SCHIZOPHRENIA.
001699 02-08

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08

WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001702 02-08

ELECTROENCEPHALOGRAMS IN SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC DRUGS.
001706 02-08

CLINICAL EFFECT OF L-DOPA ON SCHIZOPHRENIA.
001708 02-08

FLUPHENAZINE-DECANOATE MAINTENANCE IN SCHIZOPHRENIA: A RETROSPECTIVE STUDY.
001713 02-08

WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001717 02-08

WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001718 02-08

GA8ERGIC COMPOUNDS AND SCHIZOPHRENIA.
001719 02-08

DRUG RESEARCH ON TREATMENT OF SCHIZOPHRENIA.
001721 02-08

DOPAMINE AND SCHIZOPHRENIA.
001722 02-08

THOUGHTS ON PHARMACOTHERAPY FOR SCHIZOPHRENIA.
001724 02-08

SUGGESTIONS FOR A RATIONAL APPROACH TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001725 02-08

TRYPTOPHAN AND SEROTONIN IN SCHIZOPHRENIA.
001883 02-13

GLUTEN AND SCHIZOPHRENIA.
001932 02-13

ELECTROPHORESIS OF PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA AND MANIC-DEPRESSIVE ILLNESS.
002014 02-15

A NEURAL SYSTEMS THEORY OF SCHIZOPHRENIA AND TARDIVE-DYSKINESIA.
002042 02-15

CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.
002060 02-15

CERTAIN NONBIOLOGICAL ASPECTS OF THE PHARMACOTHERAPY OF SCHIZOPHRENIA.
002108 02-17

SAFEGUARDS IN THE TREATMENT OF SCHIZOPHRENIA WITH PROPRANOLOL.
002607 03-07

COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL-PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
002608 03-08

FOLLOW-UP OF PATIENTS WITH CHRONIC SCHIZOPHRENIA -- WITH SPECIAL REFERENCE TO THE EFFECTS OF PHARMACOTHERAPY.
002609 03-08

PHARMACOTHERAPY OF SCHIZOPHRENIA.
002613 03-08

PHARMACOTHERAPY OF SCHIZOPHRENIA: A CRITICAL EVALUATION.
002614 03-08

PIPOTIAZINE-PALMITATE IN CHRONIC SCHIZOPHRENIA.
002615 03-08

CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-08

ACTIVITY OF PERIPHERAL BLOOD CHOLINESTERASE DURING PHARMACOTHERAPY OF SCHIZOPHRENIA.
002618 03-08

CLINICAL INVESTIGATION OF CLOZAPINE IN SCHIZOPHRENIA.
002621 03-08

DOPAMINE AND SCHIZOPHRENIA.
002624 03-08

EVALUATION OF ATROPINE THERAPY IN TREATING SCHIZOPHRENIA.
002630 03-08

THE EFFECT OF L-DOPA AND VITAMIN-B6 IN SCHIZOPHRENIA.
002634 03-08

THE MAINTENANCE AND MANAGEMENT OF SCHIZOPHRENIA.
002639 03-08

FORMATION OF CIRCULARITY AS A MANIFESTATION OF PATHOMORPHOSIS IN SCHIZOPHRENIA.
002640 03-08

TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-08

CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA.
002645 03-08

LOXAPINE SUCCINATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
00264B 03-08

COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08

CHOLINERGIC PROCESSES IN SCHIZOPHRENIA.
002654 03-08

RESULTS OF MODITEN-DEPOT TREATMENT IN CHRONIC SCHIZOPHRENIA.
002660 03-08

TREATMENTS OF SCHIZOPHRENIA WITH TRIFLUPROMAZINE DEPOT.
002661 03-08

CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
0D2664 03-08

PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIA: AN INVESTIGATION IN DRUG-FREE HOSPITALIZED PATIENTS.
D0268B 03-09

MENTAL DISORDERS OTHER THAN SCHIZOPHRENIA AND DEPRESSION.
002764 03-11

URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
0D2798 03-12

STUDIES OF CSF AMINE METABOLITES IN AFFECTIVE ILLNESS AND IN SCHIZOPHRENIA.
002812 03-13

DOPAMINE RECEPTOR ALTERATION IN SCHIZOPHRENIA: NEUROENDOCRINE EVIDENCE.
002832 03-13

DRUG REFUSAL IN SCHIZOPHRENIA AND THE WISH TO BE CRAZY.
002942 03-15

THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA.
003011 03-17

RESULTS OF SCHIZOPHRENIA TREATMENT OVER A FIVE-YEAR PERIOD.
003018 03-17

THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA.
003026 03-17

HYSTERICAL AND HYSTERIA-LIKE REACTIONS DURING NEUROLEPTIC TREATMENT FOR SCHIZOPHRENIA.
003036 D3-17

AMPHETAMINE-INDUCED CATECHOLAMINE ACTIVATION IN SCHIZOPHRENIA AND DEPRESSION: BEHAVIORAL AND PHYSIOLOGICAL EFFECTS (PRELIMINARY REPORT). (UNPUBLISHED REPORT).
003041 03-17

METABOLIC DISTURBANCES IN SCHIZOPHRENIA: SCHIZOPHRENIA AS AN INBORN ERROR OF METABOLISM.
D03044 03-17

BIOLOGY OF SCHIZOPHRENIA: MENTAL EFFECTS OF DOPAMINE-BETA-HYDROXYLASE INHIBITION IN NORMAL MEN.
003167 04-03

DOPAMINE AND SCHIZOPHRENIA.
003326 04-03

EFFICACY OF LOXAPINE IN THE TREATMENT OF PARANOID SCHIZOPHRENIA.
003527 04-08

EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

PENFLURIDOL: A DOUBLE-BLIND TRIAL IN CHRONIC SCHIZOPHRENIA.
003542 04-08

THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA.
003543 04-08

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
003545 04-08

THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA: A CONTROLLED STUDY.
003546 04-08

THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003852 04-17

A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

SCHIZOPHRENIA-LIKE

SCHIZOPHRENIA-LIKE REACTION TO DIETHYLPROPION.
002037 02-15

SCHIZOPHRENIC

A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
000478 01-07

A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
000530 01-08

A POSSIBLE SUBGROUP OF THE SCHIZOPHRENIC SYNDROME AND IMPLICATIONS FOR TREATMENT.
000533 01-08

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-08

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 01-08

ON THE ORIGIN OF SCHIZOPHRENIC PSYCHOSES.
0D0573 01-08

THE BIOLOGY OF THE SCHIZOPHRENIC PROCESS.
000575 01-08

ON THE BIMODALITY OF THE DISTRIBUTION OF ELECTRODERMAL ORIENTING RESPONSES IN SCHIZOPHRENIC PATIENTS.
DDD579 01-08

INDICATIONS FOR LONG-TERM PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC SYNDROMES.
001066 01-17

NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
D01679 02-08

PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
001683 02-08

AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
001684 02-08

DRUG DISCONTINUATION AMONG LONG-TERM, SUCCESSFULLY MAINTAINED SCHIZOPHRENIC OUTPATIENTS.
001691 02-08

PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-08

CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08

A DOUBLE-BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
00169B 02-0B

RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-08

HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16

IMPLICATIONS OF DRUG TREATMENT FOR THE SOCIAL REHABILITATION OF SCHIZOPHRENIC PATIENTS.
002116 02-17

CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN.
002616 03-08

PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT.
002619 03-08

CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENIC PSYCHOSIS.
002620 03-0B

HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE.
002622 03-0B

DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC ILLNESS.
002623 03-0B

RECENT DEVELOPMENTS IN THE CHEMOTHERAPY OF SCHIZOPHRENIC PSYCHOSES.
002625 03-0B

A DOUBLE-BLIND COMPARISON STUDY BETWEEN PENFLURIDOL AND PERPHENAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
002627 03-0B

CLINICAL EFFECTS OF TRYPTOPHAN IN CHRONIC SCHIZOPHRENIC PATIENTS.
002629 03-0B

CARE OF SCHIZOPHRENIC PATIENTS OUTSIDE THE HOSPITAL: RESEARCH RESULTS AND BASIC PRINCIPLES.
002631 03-08

HYPORESPONSIVITY OF CHRONIC SCHIZOPHRENIC PATIENTS TO DEXTROAMPHETAMINE.
002635 03-08

TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-08

PROPRANOLOL TO CONTROL SCHIZOPHRENIC SYMPTOMS:
55
PATIENTS.
002663 03-08

NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002800 03-13

REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002B21 03-13

EFFECTS OF L-DOPA AND VITAMIN-B6 ON ELECTROENCEPHALOGRAMS OF SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT.
002847 03-13

THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17

THE EFFECT OF LOW-COST MAINTENANCE MEDICATION ON THE REHOSPITALIZATION OF SCHIZOPHRENIC OUTPATIENTS.
003531 04-08

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-08

PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08

TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
003541 04-08

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
003548 04-08

PLATELET MONOAMINE-OXIDASE ACTIVITY IN SCHIZOPHRENIC PATIENTS.
003658 04-13

METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

SCHIZOPHRENICS

STUDY ON THE EFFECTS OF SULPIRIDE AND PERPHENAZINE IN B2 SCHIZOPHRENICS USING THE DOUBLE-BLIND METHOD.
000531 01-08

LONG-ACTING DRUGS WITH AFTERCARE OF SCHIZOPHRENICS.
000546 01-08

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 01-0B

CLINICAL STUDY OF PIMOZIDE WITH CHRONIC SCHIZOPHRENICS.
000565 01-0B

LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08

BLOOD PLATELET MONOAMINE ACTIVITY IN ANERGIC SCHIZOPHRENICS.
00056B 01-0B

TRANQUILIZERS OR ANTIDEPRESSANTS FOR CHRONIC SCHIZOPHRENICS: A LONG-TERM STUDY.
000572 01-0B

SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-09

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE.
001690 02-0B

LONG-TERM STUDY OF MOLINDONE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENICS.
001697 02-0B

NEUROLEPTIC EFFECT OF BACLOFEN IN CHRONIC SCHIZOPHRENICS.
001700 02-0B

HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-0B

THERAPEUTIC EVALUATION OF PIPOTIAZINE-PALMITATE IN A GROUP OF SCHIZOPHRENICS.
001707 02-0B

SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-0B

THE ROLE OF OPAR IN THE RESOCIALIZATION OF SCHIZOPHRENICS.
001720 02-08

A CONTROLLED PIMOZIDE, FLUPHENAZINE AND GROUP PSYCHOTHERAPY STUDY OF CHRONIC SCHIZOPHRENICS.
002636 03-0B

THE MEASUREMENT OF PLASMA CHLORPROMAZINE AND ITS METABOLITES AS A PREDICTOR OF RESPONSE IN CHRONIC SCHIZOPHRENICS.
002641 03-0B

PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003519 04-07

PIMOZIDE VERSUS FLUPHENAZINE IN AMBULATORY SCHIZOPHRENICS: A 12-MONTH COMPARISON STUDY.
003534 04-0B

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-0B

WEIGHT REDUCTION IN SCHIZOPHRENICS BY MOLINDONE.
003536 04-08
THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
003538 04-08
THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-08
FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08

SCHOOL
ABUSE OF RITALIN BY TAFT CITY SCHOOL DISTRICT.
000879 01-14
RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11

SCHOOLCHILDREN
CONTROLLING CONCENTRATION DISORDERS IN HYPERKINETIC SCHOOLCHILDREN WITH APONEURON.
002769 03-11

SCHOOLS
AN EVALUATION OF DRUGS IN THE ELEMENTARY SCHOOLS: SOME GEOGRAPHIC CONSIDERATIONS.
001788 02-10
MBD, DRUG RESEARCH AND THE SCHOOLS: A CONFERENCE ON MEDICAL RESPONSIBILITY AND COMMUNITY CONTROL/FEBRUARY 13-14, 1976.
002167 02-17

SCIATIC
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
00116B 02-03

SCOPOLAMINE
SCOPOLAMINE AND ADJUNCTIVE DRINKING IN RATS.
000216 01-03
SHORT-TERM MEMORY IN THE RHESUS-MONKEY: DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
000283 01-04
EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON TONIC IMMOBILITY IN DUCKS AND GUINEA-PIGS.
000453 01-04
THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SUBSEQUENT DRUG STATE DISCRIMINATION.
000906 01-14
EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-03
DIFFERENTIATION OF RESPONSE BIASES ELICITED BY SCOPOLAMINE AND D-AMPHETAMINE: EFFECTS ON HABITUATION.
001435 02-04
PARALLEL BUT INDEPENDENT EFFECTS OF PENTOBARBITAL AND SCOPOLAMINE ON HIPPOCAMPUS RELATED BEHAVIOR.
001473 02-04
SCOPOLAMINE: EFFECTS ON FEAR OR DEFENSE RESPONSES IN THE RAT.
001546 02-04
SCOPOLAMINE AND FOOD-REINFORCED BEHAVIOR IN THE RAT.
001563 02-04
GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
001568 02-04
DIFFERENTIAL ATTENUATION OF SOME EFFECTS OF HALOPERIDOL IN RATS GIVEN SCOPOLAMINE.
001578 02-04
EFFECTS OF SCOPOLAMINE ON A DOUBLE STIMULUS DISCRIMINATION.
002002 02-14
EFFECTS OF SCOPOLAMINE ON SMELL DISCRIMINATION IN THE RAT.
002316 03-03
A PHARMACOLOGICAL ANALYSIS OF PROCESSES UNDERLYING DIFFERENTIAL RESPONDING: A REVIEW AND FURTHER EXPERIMENTS WITH SCOPOLAMINE, AMPHETAMINE, LYSERGIC-ACID-DIETHYLAMIDE (LSD-25), CHLORDIAZEPOXIDE, PHYSOSTIGMINE, AND CHLORPROMAZINE.
00244B 03-04
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04
CENTRAL CHOLINERGIC BLOCKADE BY SCOPOLAMINE AND HABITUATION, CLASSICAL CONDITIONING, AND LATENT INHIBITION OF THE RABBITS NICTITATING MEMBRANE RESPONSE.
0025D8 03-04
THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTACT AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
D03286 D4-D3
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
0D3377 04-04
STUDIES ON HUMAN MEMORY: THE INTERACTIONS OF DIAZEPAM, SCOPOLAMINE, AND PHYSOSTIGMINE.
003725 04-14

SCOPOLAMINE-INDUCED
EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY.
001595 02-04
EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

SCOPOLAMINES
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE BEHAVIOR IN IMMATURE RATS.
000451 01-04

SCORES
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION.
000875 01-14

SCREENING
ASSESSMENT OF MORPHINE-TYPE PHYSICAL DEPENDENCE LIABILITY: A SCREENING METHOD USING THE RAT.
000472 01-06
IMPROVED CLINICAL SCREENING OF PHENOTROPIC DRUGS.
001051 01-17
SOME FACETS OF THE SCREENING OF PSYCHOPHARMACOLOGICAL AGENTS.
002954 03-16

SEA
DRUGS FROM THE SEA.
001092 02-01

SEARCH
SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03

SEASONAL
SEASONAL VARIATION IN DEVELOPMENT OF TOLERANCE TO MORPHINE.
002845 03-13
NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

SECOBARBITAL
INFLUENCE OF CANNABIDIOL ON SECOBARBITAL EFFECTS AND PLASMA KINETICS.
0019D2 02-13
EFFECTIVENESS OF INTERMEDIATE TERM USE OF SECOBARBITAL.
D01972 02-14
INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION.
001977 02-14
RESISTANCE TO PUNISHMENT AND EXTINCTION FOLLOWING RESPONDING UNDER METHAMPHETAMINE OR SECOBARBITAL. (PH.D. DISSERTATION).
002534 03-04
EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
003242 04-03

SECOND-ORDER
BEHAVIOR MAINTAINED UNDER A SECOND-ORDER SCHEDULE BY INTRAMUSCULAR INJECTION OF MORPHINE OR COCAINE IN RHESUS-MONKEYS.
001495 02-04
BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

SECONDARY
MORPHINE-BASED SECONDARY REINFORCEMENT: EFFECTS OF DIFFERENT DOSES OF NALOXONE.
000372 01-04
SECONDARY EFFECTS OF PSYCHOTROPIC DRUGS.
000975 01-15
A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES.
001031 01-17
SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-04

SECRETION
GROWTH HORMONE SECRETION IN CHRONIC SCHIZOPHRENIA.
00D536 01-08
ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
0DDBD5 01-13
EFFECTS OF FLURAZEPAM (DALMANE) ON ANTERIOR PITUITARY SECRETION.
000877 01-14
SECRETION AND IRRIGATION OF GASTRIC MUCOSA DURING DISULFIRAM EFFECT: EXPERIMENTAL STUDY IN THE DOG.
001270 02-03

SOMATOSTATIN IN THE PHYSIOLOGIC FEED8ACK CONTROL OF THYROTROPIN SECRETION.
001396 02-03

EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04

PROLACTIN SECRETION IN CHRONIC SCHIZOPHRENIA.
001680 02-08

DOPAMINE-INDUCED INHIBITION OF PROLACTIN SECRETION IN AMENORRHOEA GALACTORRHOEA.
001900 02-13

PROLACTIN SECRETION AND ANTIPSYCHOTIC EFFICACY.
001916 02-13

ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-13

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT 8RAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

EFFECTS OF NEUROTROPIC SUBSTANCES ON SECRETION AND BLOOD SUPPLY OF THE PANCREAS.
002290 03-03

PENTO8AR8ITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03

EFFECT OF FLUPENTHIXOL AND BUTACLAMOL ISOMERS ON PROLACTIN SECRETION IN RATS.
003220 04-03

CORTISOL SECRETION AND METABOLISM IN ANOREXIA-NERVOSA.
003660 04-13

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003804 04-15

OR

THE PSYCHIATRIC SECTOR AND THE WALLS OF THE ASYLUM.
002638 03-08

ATION

EVIDENCE FOR DOPAMINE RECEPTORS MEDIATING SEDATION IN THE MOUSE BRAIN.
002438 03-04

ATIVE

STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE.
000182 01-03

HUMAN SEDATIVE SELF-ADMINISTRATION: EFFECTS OF INTERINGESTION INTERVAL AND DOSE.
001046 01-17

PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-02

DYNAMICS OF MENTAL DISORDERS DUE TO HYPNOTIC AND SEDATIVE INTOXICATION.
002034 02-15

THE SEDATIVE EFFECTS OF NICOTINAMIDE ON GERBIL WHEEL-RUNNING ACTIVITY.
002423 03-04

LORAZEPAM IS A SATISFACTORY PREANESTHETIC SEDATIVE IF USED WITH CARE.
002743 03-11

AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002B68 03-14

DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA.
003826 04-15

TIVES

PHARMACOKINETICS OF SEDATIVES IN LIVER DISEASE.
00079B 01-13

ENTS

CHOLINERGIC EFFECTS OF MOLECULAR SEGMENTS OF APOMORPHINE AND DOPAMINERGIC EFFECTS OF N,N DIALKYLATED DOPAMINES.
000023 01-02

LAN

A STUDY OF THE PROTECTIVE PROPERTIES OF SEGOLAN IN HYPOXIA.
001024 01-17

RE

EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE.
000052 01-03

COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11

POTENTIATION OF MORPHINE-INDUCED SEIZURE BY 6-HYDROXYDOPAMINE.
001133 02-03

EFFECT OF CAR8AMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERNS IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
001178 02-03

EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05

DIALYSIS ENCEPHALOPATHY: A POSSIBLE SEIZURE DISORDER.
002146 02-17

CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003153 04-03

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF 8IOSYNTHESIS IN MICE.
003252 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

TOLERANCE AND CROSS-TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003389 04-04

THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11

SEIZURES

AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03

SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION.
0002B6 01-04

PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04

PENTYLENETETRAZOL-INDUCED AMNESIA: A CASE FOR OVERT SEIZURES.
000399 01-04

EXPERIMENTAL OBSERVATIONS ON THE EFFECT OF AMPHEPRAMONE ON THE BEHAVIOR, LOCOMOTION, PENTETRAZOL SEIZURES AND ELECTROENCEPHALOGRAM.
000411 01-04

POLYDIPSIA, HYPONATREMIA, AND SEIZURES IN PSYCHOTIC PATIENTS.
00096B 01-15

CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15

EFFECTS OF AMPHETAMINE ISOMERS AND CNS CATECHOLAMINERGIC BLOCKERS ON SEIZURES IN MICE.
001341 02-03

AUGMENTATION OF PENTYLENETETRAZOL-INDUCED SEIZURES BY TRICYCLIC ANTIDEPRESSANTS.
001346 02-03

EFFECT OF MORPHINE AND NALOXONE ON PRIMING-INDUCED AUDIOGENIC SEIZURES IN BALB/C MICE.
001457 02-04

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

ANTICONVULSANT DRUG ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL-INDUCED SEIZURES IN RABBITS.
003366 04-04

EFFECTS OF GABA, GABOB AND SOME ANTICONVULSANT DRUGS ON DIBUTYRYL-CYCLIC-AMP EVOKED SEIZURES.
003436 04-04

IMIPRAMINE IN ABSENCE AND MINOR MOTOR SEIZURES: DOUBLE-BLIND STUDY AND LONG-TERM FOLLOW-UP.
003618 04-11

CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
003643 04-11

METABOLISM OF PHENOBARBITAL AND PHENYTOIN BY NEONATES WITH SEIZURES.
003697 04-13

SELECTING
SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 01-03

SELECTION
SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 01-03

SELECTIVE
DOPAMINE RECEPTORS: SELECTIVE AGONISTS AND ANTAGONISTS OF FUNCTIONALLY DISTINCT TYPES WITHIN THE FELINE BRAIN.
000077 01-03
SELECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATECHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
000102 01-03
Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03
SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03
SELECTIVE NEUROENDOCRINE EFFECTS OF LOW-DOSE HALOPERIDOL IN NORMAL ADULT MEN.
000514 01-07
THE EFFECT OF METHYLPHENIDATE ON COGNITIVE AND BEHAVIORAL FUNCTIONING IN A SELECTIVE POPULATION OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
000917 01-14
EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03
SELECTIVE ALPHA-ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDRODIBENZAZOCINE.
001248 02-03
ON THE SELECTIVE INHIBITION OF SEROTONIN UPTAKE IN VIVO BY ORG-6582.
001393 02-03
SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION.
001493 02-04
SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS: ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS.
001526 02-04
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002835 03-13
SELECTIVE EFFECTS OF PSYCHOACTIVE DRUGS ON LEVELS OF MONOAMINE METABOLITES AND PROLACTIN IN CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
002836 03-13
NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01
SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
003087 04-03
PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03
EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RAT BRAIN 5-HT TURNOVER.
003179 04-03
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF NAD-DEPENDENT OXIDATIONS BY 1,4 DISUBSTITUTED PIPERAZINES.
003236 04-03
SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05

SELECTIVITY
SELECTIVITY OF 4-METHOXYPHENETHYLAMINE DERIVATIVES AS INHIBITORS OF MONOAMINE-OXIDASE.
002279 03-03
OPIOID PEPTIDES AND OPIATES DIFFER IN RECEPTOR SELECTIVITY.
00329B 04-03

SELENIUM
IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
000158 01-03

SELF-ADMINISTERED
CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-

SELF-ADMINISTERING
THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULU CONTROL.
003395 04-

SELF-ADMINISTRATION
A DOSE-RESPONSE COMPARISON BETWEEN METHADONE AND MORPHIN SELF-ADMINISTRATION.
000255 01-
EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SEL STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-
INTRAVENTRICULAR SELF-ADMINISTRATION OF MORPHINE IN NAIVE LABORATORY RATS.
000271 01-
THE EFFECTS OF PERPHENAZINE ON SELF-ADMINISTRATION BEHAVIOR.
000353 01-
DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-
COCAINE SELF-ADMINISTRATION IN MONKEYS BY CHEWING AND SMOKING.
000424 01-
HUMAN SEDATIVE SELF-ADMINISTRATION: EFFECTS OF INTERINGESTIO INTERVAL AND DOSE.
001046 01
ROLE OF NORADRENERGIC AND DOPAMINERGIC PROCESSES IN AMPHETAMINE SELF-ADMINISTRATION
001342 02
SELF-ADMINISTRATION OF CAFFEINE BY THE RAT.
001436 02
THE PILL POPPER: A DEVICE FOR DRUG CAPSULE SELF-ADMINISTRATIO 8Y PRIMATES.
001647 02
EFFECT OF UNIT DOSE AND ROUTE OF ADMINISTRATION ON SELF-ADMINISTRATION OF MORPHINE.
002543 03
COCAINE AND MORPHINE SELF-ADMINISTRATION: EFFECTS OF DIFFERENTIAL REARING.
0025B5 03
SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04
MODULATION OF HEROIN SELF-ADMINISTRATION BY NEUROHYPOPHYSEAL PRINCIPLES.
003477 04
RELATIONSHIP BETWEEN MORPHINE SELF-ADMINISTRATION AND THE EFFECT OF MORPHINE ACROSS STRAINS OF MICE.
0034B2 04

SELF-DISCLOSURE
ALCOHOL, FIELD DEPENDENCE, AND DYADIC SELF-DISCLOSURE.
001989 02

SELF-INJECTION
APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01

SELF-MEDICATION
AN UNUSUAL ADVERSE REACTION TO SELF-MEDICATION WITH PREDNISONE: AN IRRATIONAL CRIME DURING A FUGUE-STATE.
002897 03

SELF-RATING
SELF-RATING OBSESSIONAL SCALE OF SANDLER AND HAZARI: PRELIMINARY OBSERVATIONS.
001800 02
COMPARATIVE VALUE OF RATING AND SELF-RATING SCALES IN DRUG TRIALS.
003592 04
THE VALUE OF SELF-RATING SCALES IN DRUG TRIALS.
003840 04

SELF-SELECTION
EFFECTS OF P-CHLOROPHENYLALANINE ON ETHANOL SELF-SELECTION I THE RAT.
000400 01

SELF-STIMULATION
EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D-AMPHETAMIN ON SELF-STIMULATION OBTAINED FROM LATERAL HYPOTHALAMUS AND REGION OF THE LOCUS-COERULEUS.
000061 01
SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC

NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING
0000B1 01-03

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION (ICS) AND SOME ARYLALKYLAMINES IN THE RAT BRAIN.
0000B7 01-03

DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR DESTRUCTION OF THE NIGRONEOSTRIATAL BUNDLE: PERFORMANCE OR REINFORCEMENT DEFICIT
000200 01-03

BALANCE OF CENTRAL NEUROTRANSMITTER ACTIONS IN SELF-STIMULATION BEHAVIOR.
000204 01-03

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION. ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-03

EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-03

THE EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITION ON LATERAL HYPOTHALAMIC SELF-STIMULATION AND ITS FACILITATION BY AMPHETAMINE.
000274 01-04

THE EFFECTS OF MANIPULATIONS WITH THE DOPAMINERGIC SYSTEM ON SELF-STIMULATION BEHAVIOR.
000293 01-04

A ROLE FOR DOPAMINE IN THE PSYCHOPHARMACOLOGY OF ELECTRICAL SELF-STIMULATION.
000300 01-04

DIFFERENTIAL EFFECTS OF MORPHINE AND AMPHETAMINE ON MEDIAL FRONTAL AND LATERAL HYPOTHALAMIC SELF-STIMULATION.
000335 01-04

THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION.
000340 01-04

ALPHA-NORADRENERGIC MODULATION OF HYPOTHALAMIC SELF-STIMULATION: STUDIES EMPLOYING CLONIDINE, L-PHENYLEPHRINE AND ALPHA-METHYL-P-TYROSINE.
000346 01-04

HYPERTHERMIA FOLLOWING SELF-STIMULATION OF THE MEDIAN RAPHE IN THE RAT.
0003B2 01-04

THE EFFECTS OF 6-AMINODOPAMINE ON ELECTRICAL SELF-STIMULATION IN RATS.
0003BB 01-04

IS THE RELEASE OF NORADRENALINE NECESSARY FOR SELF-STIMULATION OF THE BRAIN?.
000422 01-04

DIFFERING BUT COMPLEMENTARY FUNCTIONS OF BRAIN NORADRENALINE AND DOPAMINE IN SELF-STIMULATION
00042B 01-04

THE INFLUENCE OF PSYCHOACTIVE DRUGS ON BRAIN SELF-STIMULATION IN RATS: A REVIEW.
00107B 01-17

BROMPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES: A COMPARISON OF THE EFFECTS OF BROMPERIDOL AND HALOPERIDOL IN INTRACRANIAL SELF-STIMULATION
00111B 02-02

NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03

COMPARISON OF THE EFFECTS OF MORPHINE ON HYPOTHALAMIC AND MEDIAL FRONTAL CORTEX SELF-STIMULATION IN THE RAT.
0012B3 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
0012B5 02-03

PREFRONTAL CORTEX AND NEOSTRIATUM SELF-STIMULATION IN THE RAT: DIFFERENTIAL EFFECTS PRODUCED BY APOMORPHINE.
001296 02-03

AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF-STIMULATION IN CAUDATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
0013B4 02-03

RESTORATION OF SELF-STIMULATION INHIBITED BY NEUROLEPTICS.
001414 02-03

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04

EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON.
00145B 02-04

A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
001529 02-04

EFFECT OF BETA-PHENYLETHYLAMINE AND D-AMPHETAMINE ON ELECTRICAL SELF-STIMULATION OF BRAIN.
00246B 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04

EFFECTS OF VARIOUS PSYCHOTROPIC DRUGS ON INTRACRANIAL SELF-STIMULATION BEHAVIOR IN RATS.
002512 03-04

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
0030B7 04-03

PRESYNAPTIC ALPHA-ADRENOCEPTORS: THE DEPRESSION OF SELF-STIMULATION BY CLONIDINE AND ITS RESTORATION BY PIPEROXANE BUT NOT BY PHENTOLAMINE OR PHENOXYBENZAMINE.
003142 04-03

THE EFFECT OF CARBONIC-ANHYDRASE INHIBITION ON ELECTRICAL SELF-STIMULATION OF THE BRAIN DURING HYPOXIA.
003342 04-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
003373 04-04

THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
003379 04-04

MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS: LACK OF TOLERANCE WITH LONG-TERM ADMINISTRATION.
0033B2 04-04

EFFECT OF TRYPTAMINE ANTAGONISTS ON SELF-STIMULATION: INTERACTION WITH AMPHETAMINE.
0033B6 04-04

SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

HYPOTHALAMIC SELF-STIMULATION UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

SEMEN

EXCRETION OF METHADONE IN SEMEN FROM METHADONE ADDICTS; COMPARISON WITH BLOOD LEVELS.
002041 02-15

SENILE

FOUR METHODS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
000496 01-07

CLINICAL STUDY OF THE EFFECTS OF VINCAMIN IN SENILE DEMENTIA SYNDROME.
000735 01-11

DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN.
002701 03-09

SENILITY

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE-BLIND METHOD.
000597 01-09

SENSITIVE

REGIONAL STUDY OF CEREBRAL VENTRICLE SENSITIVE SITES TO ANGIOTENSIN-II.
000123 01-03

A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT LIMBIC FOREBRAIN: PREPARATION, PROPERTIES AND THE EFFECTS OF AGONISTS, ADRENOLYTICS AND NEUROLEPTIC DRUGS.
000125 01-03

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

DOPAMINE SENSITIVE ADENYL-CYCLASE OF THE BRAIN: EFFECT OF L-DOPA AND PIRIBEDIL ON C-AMP CONCENTRATION IN CEREBROSPINAL FLUID.
001175 02-03

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03

SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS.
001348 02-03

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

A SENSITIVE METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA.
001B9B 02-13

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

DEPRESSION: A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-02

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

SENSITIVITY

EFFECT OF HYPNOTICS ON MICE GENETICALLY SELECTED FOR SENSITIVITY TO ETHANOL.
000095 01-03

INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03

ENHANCED SENSITIVITY TO METHAMPHETAMINE FOLLOWING CHRONIC ADMINISTRATION OF METHADONE IN THE RHESUS-MONKEY AND GUINEA-PIG: IMPLICATIONS FOR EXTRAPYRAMIDAL DYSKINESIAS. (PH.D DISSERTATION).
000318 01-04

AGGRESSIVE BEHAVIOR INDUCED BY APOMORPHINE: RELATIONS WITH SOME ELEMENTS OF THE BEHAVIORAL PROFILE AND WITH THE SENSITIVITY TO APOMORPHINE.
000420 01-04

5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04

THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03

CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
001302 02-03

THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS.
00147B 02-04

EFFECTS OF IMIPRAMINE ON AUDITORY SENSITIVITY IN THE RAT IN RELATION TO INITIAL SENSITIVITY.
001523 02-04

SENSITIVITY TO CHLORPROMAZINE EFFECTS ON BRAIN FUNCTION OF SCHIZOPHRENICS AND NORMALS.
001709 02-0B

SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001890 02-13

SENSITIVITY OF RATING SCALES COMPLETED BY PSYCHIATRISTS, NURSES AND PATIENTS TO ANTIDEPRESSANT DRUG EFFECTS.
0019B6 02-14

REGULATION OF DOPAMINE RECEPTOR SENSITIVITY BY AN ENDOGENOUS PROTEIN ACTIVATOR OF ADENYLATE-CYCLASE. (UNPUBLISHED PAPER).
002227 03-03

REPARTITION AND DRUG SENSITIVITY OF DOPAMINE AND L-ISOPROTERENOL-SENSITIVE ADENYLATE-CYCLASES IN RAT BRAIN HOMOGENATES.
002342 03-03

SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
00234B 03-03

SENSITIVITY OF COMPONENTS OF THE CENTRAL VESTIBULAR COMPLEX TO PENTOBARBITAL.
003225 04-03

ON THE MECHANISM OF ENHANCED SENSITIVITY TO HEPATOTOXIC AGENTS INDUCED BY ETHANOL.
003231 04-03

ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL.
003272 04-03

PARGYLINE-INDUCED INCREASES IN SENSITIVITY TO THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR IN PIGEONS.
003361 04

CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC A CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RA
003390 04

GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
003494 04

INCREASED SENSITIVITY TO NITRAZEPAM IN OLD AGE.
003724 04

SENSITIZATION

CHANGES IN BRAIN NOREPINEPHRINE ASSOCIATED WITH SENSITIZATI TO D-AMPHETAMINE.
000225 0

SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYS POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 0

A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 0

SENSITIZATION TO COCAINE STIMULATION IN MICE.
00327B 0

EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 0

SENSITIZER

5-HYDROXYTRYPTAMINE AS A SENSITIZER OF SOMATIC NOCICEPTOR FOR PAIN-PRODUCING SUBSTANCES.
0001B5 0

SENSORIMOTOR

ACTIVATION INDUCED RESTORATION OF SENSORIMOTOR FUNCTIONS RATS WITH DOPAMINE DEPLETING BRAIN LESIONS.
000463 0

SENSORY

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED B ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 0

SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DEL TETRAHYDROCANNABINOL.
000796 0

NEUROLOGICAL AND SENSORY DISORDERS IN THE ELDERLY.
001039 0

MONOAMINERGIC SENSORY REGULATION AND THE ROLE OF MORPHI
002353 0

BENZODIAZEPINES AND DISCRIMINATION BEHAVIOUR: DISSOCIATION RESPONSE AND SENSORY FACTORS.
003475 0

SEPARATION

A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AN THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITAT OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 0

SEPAZON

CLINICAL EXPERIENCE OF SEPAZON (CLOXAZOLAM) FOR DEPRESSIVE MANIC.
000644 0

SEPTAL

EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
000038 0

L-DOPA REDUCES HYPERREACTIVITY INDUCED BY SEPTAL LESIONS IN RATS.
000103 0

SEPTUM

THE EFFECT OF INNER SEPTUM DAMAGE (RATS) ON DRUG-DEPENDEN DISCRIMINATIVE LEARNING.
002472 0

SEQUENCE

THE EFFECT OF SEQUENCE ON THE STABILITY OF THE HOPKINS SYMPTOM CHECKLIST (HSCL). (UNPUBLISHED PAPER).
0029B2 0

SEQUENCES

EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON THE REPEATE ACQUISITION OF RESPONSE SEQUENCES BY PIGEONS.
001507 0

SEQUENTIAL

THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING TWO-WAY AVOIDANCE SESSION.
002478 0

CHEMOTHERAPY OF MELANCHOLIA BY SEQUENTIAL ASSOCIATION O NEUROLEPTIC AND VILOXAZINE.
00266B 0

SERENTIL
MESORIDAZINE (SERENTIL) IN PERSONALITY DISORDERS -- A CONTROLLED TRIAL IN ADOLESCENT PATIENTS.
003582 04-10

SERIAL
INVESTIGATION OF THE INTERACTION OF D-AMPHETAMINE AND AMANTADINE HYDROCHLORIDE USING REPEATED ACQUISITIONS WITH SERIAL REVERSAL DISCRIMINATION. (PH.D. DISSERTATION).
000354 01-04

SERINE
EFFECTS OF SERINE ON MORPHINE-DEPENDENT MICE.
000096 01-03

SERIOUS
TWO CASES OF SERIOUS SIDE-EFFECTS DURING PHARMACOTHERAPY.
002909 03-15

SEROTONERGIC
ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
000080 01-03
PHARMACOGENETIC STUDIES OF THE SEROTONERGIC SYSTEM IN ASSOCIATION WITH CONVULSIVE SEIZURES IN MICE.
000334 01-04
THE ROLE OF SEROTONERGIC PATHWAYS IN ISOLATION-INDUCED AGGRESSION IN MICE.
000371 01-04
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04
SEROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
00044B 01-04
ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
001132 02-03
MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-03
PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14
GLUCOCORTICOID REGULATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN.
002379 03-03
DOPAMINERGIC AND SEROTONERGIC ACTION OF ERGOMETRINE.
002418 03-04
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04
STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
0025B0 03-05
EFFECTS OF SEROTONERGIC DRUGS ON METHAQUALONE-INDUCED HYPOTHERMIA.
003102 04-03
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
003192 04-03
INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
003320 04-03
INTENSIFICATION OF AMPHETAMINE-INDUCED EXCITATION BY METHYSERGIDE, A SEROTONERGIC RECEPTOR BLOCKER.
003355 04-04
REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID-DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY.
003401 04-04
A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

EROTONIN
NEUROCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF A NEW SEROTONIN POTENTIATING PHENYLPIPERIDINE DERIVATIVE FG-4963.
000025 01-02
AUDIOGENIC SEIZURES IN MICE: INFLUENCE OF AGENTS AFFECTING BRAIN SEROTONIN.
000031 01-03
THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03
PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS PITUITARY ADRENAL FUNCTION IN RATS.
000101 01-03
A COMPARISON OF THE ACUTE AND CHRONIC EFFECTS OF FOUR ANTIDEPRESSANT DRUGS ON THE TURNOVER OF SEROTONIN, DOPAMINE AND NORADRENALINE IN THE RAT BRAIN
000154 01-03
INTRAHYPOTHALAMIC SEROTONIN AND CARDIOVASCULAR CONTROL IN RATS.
000230 01-03
SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03
AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF D-AMPHETAMINE.
000343 01-04
5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04
REGIONAL SEROTONIN LEVELS IN BRAIN: A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000883 01-14
EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-15
SYNAPTIC FACILITATION AND BEHAVIORAL SENSITIZATION IN APLYSIA: POSSIBLE ROLE OF SEROTONIN AND CYCLIC-AMP.
001155 02-03
EFFECTS OF TETRAHYDRO-BETA-CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN.
001156 02-03
EFFECTS OF SELECTIVE FOREBRAIN DEPLETIONS OF NOREPINEPHRINE AND SEROTONIN ON THE ACTIVITY AND FOOD INTAKE EFFECTS OF AMPHETAMINE AND FENFLURAMINE.
001162 02-03
COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
00122B 02-03
MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN.
001265 02-03
A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES.
001320 02-03
RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03
EFFECTS OF NARCOTIC ANALGESICS ON SEROTONIN METABOLISM IN BRAIN OF RATS AND MICE.
001358 02-03
THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03
INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE BRAIN.
001369 02-03
DOPAMINERGIC AGENTS: INFLUENCE ON SEROTONIN IN THE MOLLUSCAN NERVOUS SYSTEM.
001389 02-03
ON THE SELECTIVE INHIBITION OF SEROTONIN UPTAKE IN VIVO BY ORG-65B2.
001393 02-03
BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03
THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04
DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04
TRYPTOPHAN AND SEROTONIN IN SCHIZOPHRENIA.
001B83 02-13
BENEFICIAL EFFECTS OF SEROTONIN PRECURSORS IN POSTANOXIC ACTION MYOCLONUS.
001904 02-13
SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13
SYMPATHOMIMETIC EFFECT OF SEROTONIN AND ACTION OF IMIPRAMINE AND PHTHORACIZINE ON THIS EFFECT.
002203 03-03
NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. (UNPUBLISHED PAPER).
002217 03-03

TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
002278 03-03

EFFECT OF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
002284 03-03

DOPAMINERGIC DRUG EFFECTS UPON SEROTONIN NEURONS.
002300 03-03

SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-03

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
002398 03-03

BIONEUTRALIZING PROPERTIES OF SEROTONIN ANTIBODIES.
002412 03-03

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 03-05

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING THE ADDITION OF THROMBIN AND A23187. (UNPUBLISHED PAPER).
002804 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002820 03-13

NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR: LU-10-171.
003054 04-01

A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID.
003107 04-03

FENFLURAMINE LONG-TERM ADMINISTRATION AND BRAIN SEROTONIN.
003130 04-03

EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN.
003204 04-03

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN.
003255 04-03

SEROTONIN ACCUMULATION BY SKELETAL MUSCLE.
0032B8 04-03

STUDIES ON MEMBRANE RECEPTOR SITES FOR SEROTONIN IN THE BRAIN.
00330B 04-03

INTRACRANIAL REWARD AFTER LILLY-110140 (FLUOXETINE-HCL): EVIDENCE FOR AN INHIBITORY ROLE FOR SEROTONIN.
003411 04-04

DOSE-DEPENDENT ACTION OF CORTICOSTEROIDS ON BRAIN SEROTONIN CONTENT AND PASSIVE AVOIDANCE BEHAVIOR.
003415 04-04

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN.
003447 04-04

THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTONIN BINDING PROTEIN.
003517 04-06

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSED PATIENTS.
003709 04-13

SEROTONIN-INDUCED

IMIPRAMINE SEROTONIN-INDUCED MYOPATHY.
001632 02-05

SEROTONINERGIC

SEIZURE ACTIVITY IN PHOTOSENSITIVE BABOONS FOLLOWING ANTIDEPRESSANT DRUGS AND THE ROLE OF SEROTONINERGIC MECHANISMS.
003304 04-03

SERUM

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03

DIFFERENCES IN THE DEGRADATION OF HYPOTHALAMIC RELEASING FACTORS BY RAT AND HUMAN SERUM.
000049 01-03

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
000548 01-08

A THREE YEAR DOUBLE-BLIND INVESTIGATION OF THE EFFECTS OF LITHIUM-CARBONATE ON SERUM PROTEIN-BOUND IODINE IN MANIC-DEPRESSIVE PATIENTS.
000580 01-09

BLOOD SERUM DENSITIES OF TRICYCLIC ANTIDEPRESSANTS -- VIEWS GAINED THROUGH THERAPEUTIC USE.
000581 01-09

PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11

EFFECTS OF DIKALIUM CLORAZEPATE ON SERUM LEVELS AND METABOLITES.
000766 01-11

A GAS CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN SERUM.
000829 01-13

SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000835 01-13

EFFECT OF FOOD AND REPEATED INJECTIONS ON SERUM DIAZEPAM LEVELS
000840 01-13

THE LEVELS OF SERUM GROWTH HORMONE AND IMMUNOREACTIVE INSULIN AFTER ADMINISTRATION OF ANTIPYRETIC ANALGETICS.
000867 01-13

SERUM CONCENTRATIONS OF TRIIMIPRAMINE IN HEALTHY SUBJECTS.
000918 01-14

INCREASED RATE OF DISAPPEARANCE OF SERUM PROBENECID IN BARBITAL DEPENDENT RATS.
001297 02-03

ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03

EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL: AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE: EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001890 02-13

IMPROVEMENT OF LITHIUM PROPHYLAXIS OF ENDOGENOUS PHASIC PYSCHOSES: ASPECTS OF PARALLEL LITHIUM DETERMINATION IN SERUM AND IN ERYTHROCYTES.
001906 02-13

INACTIVITY OF ENKEPHALIN ON HUMAN SERUM ESTERASE.
001913 02-13

SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN-ETHYL-ESTER.
001922 02-13

SERUM DOPAMINE-BETA-HYDROXYLASE IN PSYCHIATRIC PATIENTS AND NORMALS EFFECT OF D-AMPHETAMINE AND HALOPERIDOL.
001927 02-13

STUDIES ON THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN BY CIRCULAR DICHROISM MEASUREMENTS.
001942 02-13

LITHIUM TOXICITY WITH LOW SERUM LEVELS: REPORT OF A CASE.
002063 02-15

SERUM DOPAMINE-BETA-HYDROXYLASE ACTIVITY (V): EFFECTS OF VARIOUS DRUGS ON THE ENZYME ACTIVITY.
002326 03-03

LITHIUM EFFECTS ON SERUM CALCIUM, MAGNESIUM AND PHOSPHATE, IN RATS.
002338 03-03

THE BINDING OF PHENOTHIAZINES AND RELATED COMPOUNDS TO HUMAN SERUM ALBUMIN.
002828 03-13

ANTIPSYCHOTIC AGENTS AND SERUM PROLACTIN LEVELS.
002900 03-15

SIMULTANEOUS DETERMINATION OF GLUTETHIMIDE, METHYPRYLON, AND METHAQUALONE IN SERUM BY GAS LIQUID CHROMATOGRAPHY.
002953 03-16

THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

LACK OF EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON SERUM PROLACTIN LEVELS.
0036B9 04-13

DETERMINATION OF PENTOBARBITAL IN SERUM BY ELECTRON CAPTURE GLC.
003713 04-13

ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

BARBITURATES AND SERUM CALCIUM IN THE ELDERLY
003837 04-15

SERVICES
PSYCHIATRIC PHARMACY RESIDENCY AND SERVICES.
001026 01-17

SERYLTRIHYDROXYBENZYLHYDRAZINE
INTERACTION OF SERYLTRIHYDROXYBENZYLHYDRAZINE WITH L-DOPA-DECARBOXYLASE FROM PIG KIDNEY
003103 04-03

SESSIONS
RELATIONS BETWEEN BEHAVIORAL AROUSAL AND PLASMA CORTISOL LEVELS IN MONKEYS PERFORMING REPEATED FREE OPERANT AVOIDANCE SESSIONS
001554 02-04

SET-POINT
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN.
0001B1 01-03

SEX
SEX DIFFERENCE IN THE EFFECT OF DEXAMETHASONE ON OPEN-FIELD BEHAVIOR IN RATS: GONADAL HORMONES.
000133 01-03

SEX AS A FACTOR IN METABOLISM, TOXICITY, AND EFFICACY OF PHARMACODYNAMIC AND CHEMOTHERAPEUTIC AGENTS.
000B22 01-13

SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS.
001123 02-03

AGE AND SEX DEPENDENCE OF ORGAN DISTRIBUTION AND METABOLISM OF CHLORPROTHIXENE AND NORTRIPTYLINE IN RATS.
0011B2 02-03

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

SEX AND SYSTEMIC LUPUS-ERYTHEMATOSUS.
001959 02-14

MARIHUANA AND SEX.
0019B1 02-14

SEX AND NEUROLEPTIC MEDICATION.
002649 03-0B

SEX DIFFERENCES IN DRUG EVALUATIONS.
00367B 04-13

HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES OF DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 04-14

SEX-RELATED
CADMIUM ALTERATION OF HEXOBARBITAL ACTION: SEX-RELATED DIFFERENCES IN THE RAT.
003505 04-05

SEXUAL
THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03

L-DOPA EFFECTS ON SEXUAL BEHAVIOUR: AN EXPERIMENTAL STUDY.
000360 01-04

INTRACEREBRAL IMPLANTATION OF THE ANTIESTROGEN CN-69725-27: EFFECTS ON FEMALE SEXUAL BEHAVIOR IN RATS.
000369 01-04

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11

CHOLINERGIC MECHANISMS AND SEXUAL BEHAVIOR IN THE MALE RABBIT.
001434 02-04

EFFECT OF SOME ANTIESTROGENS AND AROMATASE INHIBITORS ON ANDROGEN-INDUCED SEXUAL BEHAVIOR IN CASTRATED MALE RATS.
001444 02-04

THE INFLUENCE OF HYPOTHALAMICALLY ADMINISTERED RESERPINE ON THE SEXUAL BEHAVIOR OF THE FEMALE CAT.
001456 02-04

MASCULINE SEXUAL BEHAVIOR IN MALE AND FEMALE RATS FOLLOWING PERINATAL MANIPULATION OF ANDROGEN. EFFECTS OF GENITAL ANESTHETIZATION AND SEXUAL EXPERIENCE.
001499 02-04

EFFECTS OF MIDBRAIN LESIONS ON FEMALE SEXUAL BEHAVIOR IN THE RAT
001510 02-04

EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS
002004 02-14

INFLUENCE OF ORAL CONTRACEPTION ON SEXUAL RESPONSE
D02020 02-15

CLINICAL MANAGEMENT OF SEXUAL DISORDERS
002B66 03-14

INFLUENCE OF P-CHLOROAMPHETAMINE ON FEMALE SEXUAL REFLEXES AND BRAIN MONOAMINE LEVELS.
00333B 04-03

GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-D4

BETA-ENDORPHIN AND MALE SEXUAL BEHAVIOR
003429 04-04

NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

SEXUAL SIDE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL).
003765 04-15

SEXUALLY
EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT
003356 04-04

SHAKING
SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
000446 01-04

CHEMICAL STIMULANTS OF SHAKING BEHAVIOUR
001605 02-04

SHAM-OPERATED
ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR --
002474 03-04

SHEEP
THE EFFECTS OF PENTOBARBITONE AND PETHIDINE ON FETAL BREATHING MOVEMENTS IN SHEEP.
000456 01-05

PLACENTAL TRANSFER OF CENTRAL-NERVOUS-SYSTEM DEPRESSANTS IN SHEEP.
000464 01-05

OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

SHOCK
ETHANOL AND THE RESPONSE TO ELECTRIC SHOCK IN RATS.
000063 01-03

MODULATION OF THE AVERSIVE QUALITIES OF SHOCK THROUGH A CENTRAL INHIBITORY CHOLINERGIC SYSTEM IN THE RAT.
000127 01-03

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
000359 01-04

EFFECTS OF D-AMPHETAMINE, PENTOBARBITAL, CHLORPROMAZINE AND PROMAZINE ON ELECTRIC SHOCK POSTPONEMENT RESPONDING BY THE PIGEON.
000366 01-04

DISCRIMINABILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04

EFFECTS OF SCOPOLAMINE AND D-AMPHETAMINE ON LOCOMOTOR ACTIVITY BEFORE AND AFTER SHOCK: A DIALLEL ANALYSIS IN MICE.
001126 02-03

EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-03

EFFECTS OF PENTOBARBITAL ON PUNISHED BEHAVIOR AT DIFFERENT SHOCK INTENSITIES.
001607 02-04

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION. EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
002497 03-04

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE.
003160 04-03

FACILITATION AND DISRUPTION BY MESCALINE AND 3,4 DIMETHOXYPHENYLETHYLAMINE OF SHOCK AVOIDANCE IN RATS
003394 04-04

SHOCK-ELICITED
SHOCK-ELICITED FIGHTING IN RATS: IMPORTANCE OF INTERSHOCK INTERVAL UPON THE EFFECT OF P-CHLOROPHENYLALANINE (P-CPA)
000423 01-04

P-CHLOROAMPHETAMINE: SHORT AND LONG-TERM EFFECTS UPON SHOCK-ELICITED AGGRESSION
001371 02-03

THE EFFECT OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) UPON SHOCK-ELICITED FIGHTING IN RATS.
003461 04-04

SHOCK-INDUCED
AMYGDALOID FUNCTION IN THE CENTRAL CHOLINERGIC MEDIATION OF SHOCK-INDUCED AGGRESSION IN THE RAT.
000410 01-04
SHOCK-INDUCED AGGRESSION AND PAIN SENSITIVITY IN THE RAT: CATECHOLAMINE INVOLVEMENT IN THE CORTICOMEDIAL AMYGDALA.
00234B 03-03
SHOCK-INDUCED ETHANOL CONSUMPTION IN RATS.
003430 04-04

SHOCK-MAINTAINED
EFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY.
001453 02-04

SHOCKS
THE EFFECT OF CHLORDIAZEPOXIDE ON THE ANTICIPATION OF ELECTRIC SHOCKS.
000292 01-04

SHORT-TERM
EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN
000218 01-03
SHORT-TERM MEMORY IN THE RHESUS-MONKEY. DISRUPTION FROM THE ANTICHOLINERGIC SCOPOLAMINE.
000283 01-04
EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE
000741 01-11
EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-04
SIMILARITIES BETWEEN SHORT-TERM AND REACTIVATED MEMORIES.
001498 02-04
SHORT-TERM EFFECTS OF NALTREXONE IN 155 HEROIN EX-ADDICTS.
001950 02-13
SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF OBESITY.
002117 02-17
AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT.
003657 04-13
EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003841 04-16

SHUNT
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE
003138 04-03

SHUTTLE
A PHARMACOLOGICAL SEPARATION OF BUZZER-SHOCK PAIRING AND OF THE SHUTTLE-SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 03-04
THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN OPERATION DURING A TWO-WAY AVOIDANCE SESSION.
002478 03-04

SHUTTLE-BOX
P CHLOROPHENYLALANINE POTENTIATES FACILITATORY EFFECTS OF MESCALINE SHUTTLE-BOX ESCAPE/AVOIDANCE IN RATS.
000235 01-03
EFFECTS OF SCOPOLAMINE AND METHSCOPOLAMINE ON ACQUISITION AND RETENTION OF RAT ONE-WAY SHUTTLE-BOX BEHAVIOR AND TOTAL BRAIN ACETYLCHOLINE.
003377 04-04
TOLERANCE TO THE EFFECTS OF DELTA9-THC ON SHUTTLE-BOX PERFORMANCE AND BODY TEMPERATURE
003398 04-04

SHUTTLE-SHOCK
A PHARMACOLOGICAL SEPARATION OF BUZZER SHOCK PAIRING AND OF THE SHUTTLE SHOCK CONTINGENCY AS FACTORS IN THE ELICITATION OF SHUTTLE RESPONSES TO A BUZZER IN RATS.
002477 03-04

SIALIC-ACID
EFFECT OF CHLORPROMAZINE ON THE INCORPORATION OF SIALIC-ACID INTO GANGLIOSIDES AND GLYCOPROTEINS OF THE CHICKEN BRAIN.
000210 01-03
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

SICK-CALL
DIAZEPAM USE IN MILITARY SICK-CALL.
000720 01-10

SIDE-CHAIN
HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY.
001339 02-03
EFFECTS OF 1,4 BENZODIAZEPINES WITH A LONG SIDE-CHAIN IN POSITION 1 ON THE EVOKED POTENTIALS RECORDED IN THE LIMBIC SYSTEM AND HYPOTHALAMUS.
003474 04-0
ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-1

SIDE-EFFECT
THE INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA. DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE.
000776 01-1
CLUBBING -- A SIDE-EFFECT OF LONG-TERM PHENOTHIAZINES TREATMENT.
002905 03-1
EXTRAPYRAMIDAL SIDE-EFFECT OF CERTAIN TRANQUILIZERS.
002913 03-1
THE REINFORCING ACTION OF MORPHINE AND ITS PARADOXICAL SIDE-EFFECT
003481 04-0

SIDE-EFFECTS
EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS.
000755 01-1
SIDE-EFFECTS OF PSYCHOTROPIC DRUGS
000929 01-1
COMPLICATIONS AND SIDE-EFFECTS IN LONG-TERM TREATMENT WITH PRACTOLOL
000931 01-1
AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-1
THE EFFECT OF FOREWARNING ON THE OCCURRENCE OF SIDE-EFFECTS AND DISCONTINUANCE OF MEDICATION IN PATIENTS ON DOTHIEPIN
000972 01-1
CHOLINERGIC SIDE-EFFECTS ASSOCIATED WITH DEANOL.
000973 01-1
ANTICHOLINERGIC PROPERTIES OF ANTIPSYCHOTIC DRUGS AND THEIR RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS.
001359 02-0
A COMPARATIVE DOUBLE-BLIND STUDY OF THE SIDE-EFFECTS OF LITAREX AND LITHIONIT DURETTES.
00167B 02-0
A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001821 02-1
REPLY TO A LETTER CRITICIZING POINTS IN A LETTER ON THE NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
001BB2 02-1
SIDE-EFFECTS ON FETUS AND INFANT OF PSYCHOTROPIC DRUG USE DURING PREGNANCY
002010 02-1
EXTRAPYRAMIDAL SIDE-EFFECTS IN LITHIUM MAINTENANCE THERAPY.
002021 02-1
MORE ON NEUROMUSCULAR SIDE-EFFECTS OF ANTIPSYCHOTICS.
002040 02-1
ON THE PROBLEM OF SIDE-EFFECTS OF CLOZAPINE.
002657 03-0
IMPORTANCE OF THE DOPAMINE METABOLISM FOR THE CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
002841 03-1
TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS
002884 03-1
BIOAVAILABILITY AND SIDE-EFFECTS OF DIFFERENT LITHIUM-CARBONAT PRODUCTS
002904 03-1
TWO CASES OF SERIOUS SIDE-EFFECTS DURING PHARMACOTHERAPY.
002909 03-1
GLYCEMIC SIDE-EFFECTS IN PATIENTS DUE TO NEUROLEPTIC THERAPY
002941 03-1
SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-1

IMPORTANCE OF OOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS.
003043 03-17

SEXUAL SIOE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL).
003765 04-15

COMPARISON OF SIOE-EFFECTS WITH COATED LITHIUM CARBONATE TABLETS ANO LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE A OOU8LE-8LINO CROSS-OVER STUOY
003774 04-15

PHARMACOTHERAPY HERE AND ABROAO: DIFFERENCES IN SIOE EFFECTS.
003780 04-15

SIOE-EFFECTS OF METRONIOAZOLE.
003786 04-15

RELATIONSHIPS BETWEEN CLINICAL RESPONSE, PLASMA LEVELS AND SIOE-EFFECTS OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTITIONER TRIALS.
003807 04-15

LITHIUM SIDE-EFFECTS IN RELATION TO DOSE ANO TO LEVELS ANO GRAOIENTS OF LITHIUM IN PLASMA.
003815 04-15

CARDIAC SIDE-EFFECTS AND SUODEN DEATH IN HOSPITALIZEO PSYCHIATRIC PATIENTS.
003830 04-15

SIDMAN

CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
000385 01-04

SIDNOCARB

USE OF SIDNOCARB IN TREATING PATIENTS IN ASTHENIC OR DEPRESSIVE STATES.
002699 03-09

SIGNAL

SIGNAL ANALYSIS STUDY OF THE EFFECT OF THE ANTIDEPRESSANT NOMIFENSINE ON THE EEG OF HEALTHY PROBANDS.
001884 02-13

SIGNALLED

EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEOULE.
002492 03-04

SIGNALLING

SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS.
002142 02-17

SIGNALS

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIOINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

SIGNIFICANCE

THE SIGNIFICANCE OF DOPAMINE, VERSUS OTHER CATECHOLAMINES, FOR L-DOPA-INDUCED FACILITATION OF SEXUAL BEHAVIOR IN THE CASTRATED MALE RAT.
000160 01-03

EFFECT OF L-OOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

CLINICAL SIGNIFICANCE OF INTRAERYTHROCYTE LITHIUM CONCENTRATION: RESULTS OF A CATAMNESTIC STUDY.
001879 02-13

CHARACTEROLOGICAL SIGNIFICANCE OF MEDICATION.
002136 02-17

FUNCTIONAL SIGNIFICANCE OF THE ALPHA AND BETA ADRENORECEPTORS IN THE STRUCTURES OF THE STRIOPALLIDAR SYSTEM.
002299 03-03

ON THE SIGNIFICANCE OF REGIONAL DOPAMINE METABOLISM IN THE RAT BRAIN FOR THE CLASSIFICATION OF CENTRALLY ACTING DRUGS.
003323 04-03

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISORDERS.
003576 04-09

ON THE SIGNIFICANCE OF THE ERYTHROCYTE LITHIUM TO PLASMA LITHIUM RATIO.
003686 04-13

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

GNS

ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY: A TRIAL OF DIAZEPAM.
001888 02-13

AMANTADINE THERAPY FOR DRUG-INOUCED EXTRAPYRAMIDAL SIGNS AND OEPRESSION
002738 03-11

A CASE PRESENTING SOME REACTIVE CLINICAL SIGNS DURING TREATMENT OF L DOPA.
002930 03-15

TAROIVE-OYSKINESIA: ARE FIRST SIGNS REVERSIBLE?.
003818 04-15

SIMILARITIES

SIMILARITIES BETWEEN SHORT-TERM ANO REACTIVATED MEMORIES.
001498 02-04

SIMPLE

TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUOY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION.
000403 01-04

A SIMPLE METHOD FOR OETERMINING DIAZEPAM ANO ITS MAJOR METABOLITES IN BIOLOGICAL FLUIDS: APPLICATION IN BIOAVAILABILITY STUOIES.
0004B0 01-07

CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15

ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN ANO PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

A SIMPLE DEVICE FOR MEASURING EXPLORATORY ACTIVITY AND MOTILITY IN MICE.
001606 02-04

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04

DESCRIPTION OF A SIMPLE GRAPHIC MODEL ENABLING COMPARISON OF THE DEVELOPMENT OF DEPRESSIVE STATES.
0026B9 03-09

SIMULATED

MARIJUANA EFFECTS ON SIMULATED FLYING ABILITY.
001919 02-13

SIMULATING

PHENOTHIAZINE REACTION SIMULATING ACUTE CATATONIA.
002072 02-15

SIMULTANEOUSLY

THE INFLUENCE OF MEPIPRAZOLE ON MONOAMINE METABOLISM IN THE CNS OF THE RAT: DEMONSTRATION OF DIMINISHED NOREPINEPHRINE ACTIVITY UNDER SIMULTANEOUSLY INCREASED SEROTONIN AND DOPAMINE ACTIVITY.
001367 02-03

SINEQUAN

APPLICATION OF SINEQUAN IN THE TREATMENT OF VARIOUS CLINICAL FORMS OF DEPRESSION.
000631 01-09

SINGLE

DOPAMINE METABOLISM IN THE MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATED ADMINISTRATIONS OF NEUROLEPTICS.
000217 01-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
00023B 01-03

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000859 01-13

THE ACTION OF MICROELECTROPHORETICALLY APPLIED L-3,4 DIHYDROXYPHENYLALANINE (DOPA) ON SINGLE CORTICAL NEURONES.
001142 02-03

ENKEPHALIN-INDUCED DEPRESSION OF SINGLE NEURONS IN BRAIN AREAS WITH OPIATE RECEPTORS -- ANTAGONISM BY NALOXONE.
001209 02-03

A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-03

EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

EFFECT OF MORPHINE AND HALOPERIOOL ON SINGLE CELL ACTIVITY OF NIGROSTRIATAL NEURONS.
002265 03-03

THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
002281 03-03

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

DOPAMINE AUTORECEPTORS: PHARMACOLOGICAL CHARACTERIZATION BY MICROIONTOPHORETIC SINGLE CELL RECORDING STUDIES.
003078 04-03

EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY.
003589 04-10

THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY
003651 04-11

PHARMACOKINETICS OF CHLORPROMAZINE AFTER SINGLE AND CHRONIC DOSAGE.
003664 04-13

SINGLE-AGENT

SINGLE-AGENT CHEMOTHERAPY OF BRAIN TUMORS: A FIVE-YEAR REVIEW.
002792 03-11

SINGLE-DOSE

SINGLE-DOSE STUDIES WITH CLOMIPRAMINE IN NORMAL SUBJECTS.
000135 01-03

NEUROPSYCHOLOGIC EFFECTS OF DIAZEPAM RELATED TO SINGLE-DOSE KINETICS AND LIVER FUNCTION
000898 01-14

ANTAGONISM BY NALOXONE OF MORPHINE-INDUCED SINGLE-DOSE DEPENDENCE AND ANTINOCICEPTION IN MICE
0015B4 02-04

ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS.
001623 02-05

COMPARISON OF SINGLE-DOSE KINETICS OF IMIPRAMINE, NORTRIPTYLINE AND ANTIPYRINE IN MAN.
002813 03-13

SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETICS IN RATS.
003092 04-03

THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
003178 04-03

SINGLE-DOSES

NALTREXONE: PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF SINGLE-DOSES.
000951 01-15

STUDIES ON TOLERANCE DEVELOPED TO SINGLE-DOSES OF MORPHINE IN MICE.
001244 02-03

PROLACTIN AND PSYCHOPHYSIOLOGIC MEASURES AFTER SINGLE-DOSES OF THIORIDAZINE
003693 04-13

SINQUAN

LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15

SINUS

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY
000746 01-11

SINUSES

ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES
000020 01-02

SITES

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

REGIONAL STUDY OF CEREBRAL VENTRICLE SENSITIVE SITES TO ANGIOTENSIN II
000123 01-03

LOPERAMIDE BINDING TO OPIATE RECEPTOR SITES OF BRAIN AND MYENTERIC PLEXUS
000157 01-03

5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOMAL MEMBRANES
001201 02-03

EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION
001245 02-03

SYSTEMATIC EXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRECT APPLICATION OF MORPHINE: OBSERVATION OF DIFFERENTIAL EFFECTS WITHIN THE PERIAQUEDUCTAL GRAY.
001424 02-03

ONTOGENESIS OF MUSCARINIC RECEPTOR SITES IN RAT BRAIN.
001512 02-04

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

PHARMACOLOGIC PROPERTIES OF (3H)DIHYDROERGOKRYPTINE BINDING SITES ASSOCIATED WITH ALPHA-NORADRENERGIC RECEPTORS IN RAT BRAIN MEMBRANES.
002253 03-03

PENTOBARBITAL AND SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC-ACID.
002333 03-03

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

STUDIES ON MEMBRANE RECEPTOR SITES FOR SEROTONIN IN THE BRAIN.
003308 04-03

SITUATION

MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL
000227 01-03

SITUATIONAL

STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS -- I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE
0001B2 01-0

VAGRAN-50: A SITUATIONAL ANTIDEPRESSANT
001790 02-1

SKELETAL

CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
000458 01-0

CHARACTERIZATION OF RAT SKELETAL MUSCLE MONOAMINE-OXIDASE
003085 04-0

SEROTONIN ACCUMULATION BY SKELETAL MUSCLE
003288 04-0

SKF-28175

FLUOTRACEN (SKF-28175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-2B175)).
003625 04-1

SKF-525-A

PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE
001621 02-0

SKILLS

THE EFFECTS OF PSYCHOTROPIC DRUGS UPON DRIVING RELATED SKILLS
000BB2 01-1

EFFECTS OF DEXTROAMPHETAMINE ON PSYCHOMOTOR SKILLS.
000889 01-1

EFFECT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
001995 02-1

DIAZEPAM IMPAIRS DRIVING SKILLS LESS THAN THIORIDAZINE
002929 03-1

LORAZEPAM IMPAIRS DRIVING SKILLS.
002933 03-1

PSYCHOPHARMACOLOGY AND SOCIAL WORK SKILLS.
003884 04-1

SKIN

SKIN REACTIVITY TO HISTAMINE IN SCHIZOPHRENICS AND OTHER PSYCHIATRIC PATIENTS.
000659 01-0

EFFECTS OF DIAZEPAM AND ETHANOL ON HEART-RATE AND GALVANIC SKIN RESPONSES.
000B12 01-1

DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION, AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-0

INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART RATE, AND SKIN CONDUCTANCE
0019B2 02-1

DISTURBED OXIDATIVE METABOLISM IN ORGANIC-BRAIN-SYNDROME CAUSED BY BISMUTH IN SKIN CREAMS
002051 02-1

THE EFFECT OF CHLORPROMAZINE UPON BILATERAL ASYMMETRIES IN BIOELECTRICAL SKIN REACTIVITY OF SCHIZOPHRENICS.
003540 04-08

BLUE SKIN PIGMENTATION AND CHLORPROMAZINE.
003792 04-15

SLEEP

EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-03

A DOSE-RESPONSE STUDY OF THE ACUTE EFFECTS OF ETHANOL ON THE SLEEP OF RATS.
000169 01-03

EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
000281 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04

NOCTRAN AS A SLEEP INDUCER DURING HOSPITALIZATION (BASED ON 50 CASES).
000503 01-07

SCHIZOPHRENIA AND SLEEP DISORDERS.
000570 01-08

COMPARATIVE EVALUATION OF SEIZURE PROVOCATION METHODS WITH SLEEP DEPRIVATION AND BRIETAL IN EPILEPTICS.
000739 01-11

DISTURBED SLEEP.
000747 01-11

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
000748 01-11

SLEEP DEPRIVATION AND INTRAVENOUS ADMINISTRATION OF MEGIMIDE AS A MEANS OF EEG ACTIVATION: A COMPARATIVE CLINICAL STUDY.
0007B3 01-11

EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
000792 01-12

L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
000801 01-13

BENZODIAZEPINES AND HUMAN SLEEP.
000839 01-13

PSYCHIATRY, MEDICINE, AND SLEEP -- SLEEPING DRUGS AND TRANQUILIZERS.
000891 01-14

SLEEP: EFFECTS OF D- AND L-AMPHETAMINE IN MAN AND IN RAT.
000B96 01-14

PSYCHIATRIC MEDICINE AND SLEEP -- CHLORPROMAZINE.
000B97 01-14

EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
000902 01-14

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM, AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN
000909 01-14

EFFECTS OF ANTIDEPRESSANTS UPON SLEEP, ESPECIALLY ON REM SLEEP.
000923 01-14

SLEEP DISTURBANCE AND HYPNOTIC DRUG DEPENDENCE.
001027 01-17

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
001055 01-17

PHARMACOLOGICAL INVESTIGATIONS OF THE SEDATIVE AND SLEEP INDUCING EFFECT OF FLUOROMETHYLPIPERIDINOBUTYROPHENONE (MELPERONE).
001110 02-02

6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
001300 02-03

EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04

EFFECTS OF LITHIUM-CHLORIDE ON SLEEP PATTERNS IN THE RAT.
001465 02-04

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 02-04

DEPLETION OF BRAIN SEROTONIN FOLLOWING INTRAVENTRICULAR 5,7 DIHYDROXYTRYPTAMINE FAILS TO DISRUPT SLEEP IN THE RAT.
001570 02-04

REVERSAL OF THE MEMORY DISRUPTIVE EFFECTS OF REM SLEEP DEPRIVATION BY PHYSOSTIGMINE.
0015B0 02-04

SUSTAINED INGESTION OF METHADONE AND THE SLEEP OF MONKEYS.
0015B6 02-04

THE EFFECT OF ALPHA AND BETA ADRENERGIC RECEPTOR BLOCKERS ON SLEEP IN THE RAT
001624 02-05

EFFECT OF THE 1,5 BENZODIAZEPINES, CLOBAZAM AND TRIFLUBAZAM, ON THE SLEEP OF MAN
001657 02-07

A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
001757 02-09

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS BEFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-OXIDE.
001794 02-10

EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, BASED ON ELECTROPOLYGRAPHIC DATA.
001B12 02-10

PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001891 02-13

SLEEP AND PSYCHOTROPIC DRUGS: CLINICAL ASPECTS.
001957 02-14

DOSE-RELATED SLEEP DISTURBANCES INDUCED BY COFFEE AND CAFFEINE.
001973 02-14

INTRODUCTION: IMPORTANCE OF PSYCHOTROPIC DRUGS IN SLEEP RESEARCH.
001975 02-14

SUMMARY ON PSYCHOPHARMACOLOGY IN SLEEP RESEARCH.
001976 02-14

POLYGRAPHIC SLEEP STUDIES IN RATS AND HUMANS: THEIR USE IN PSYCHOPHARMACOLOGICAL RESEARCH.
001978 02-14

THE EFFECTS OF NICOTINAMIDE UPON SLEEP IN HUMANS.
0019BB 02-14

PHARMACOLOGICAL INFLUENCE OF CENTRAL SEROTONERGIC MECHANISMS ON HUMANS AND EFFECTS ON SLEEP.
001990 02-14

PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
001991 02-14

EFFECTS OF L-DOPA ON SLEEP IN PARKINSONISM.
001993 02-14

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

AUTOMATED SLEEP EEG ANALYSIS APPLIED TO THE EVALUATION OF DRUGS: ILLUSTRATION BY STUDY OF CLORAZEPATE DIPOTASSIUM.
001997 02-14

SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16

NEUROCHEMICAL AND NEUROPHARMACOLOGICAL FOUNDATIONS OF THE SLEEP DISORDERS.
002112 02-17

PHARMACOLOGY OF SLEEP.
002176 02-17

DEPRESSION OF REM SLEEP IN CATS BY NISOXETINE, A POTENTIAL ANTIDEPRESSANT DRUG.
002195 03-02

EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03

COMBINED SLEEP DEPRIVATION AND CLOMIPRAMINE IN PRIMARY DEPRESSION.
0026B2 03-09

SLEEP DEPRIVATION AND CLOMIPRAMINE IN ENDOGENOUS DEPRESSION.
002705 03-09

THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
00277B 03-11

HUMAN SLEEP AND 5-HTP: EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-4602).
002B49 03-14

TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002B79 03-14

A SLEEP STUDY OF ACUTE PSYCHOTIC STATES DUE TO ALCOHOL AND MEPROBAMATE ADDICTION.
002937 03-15

TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL.
002976 03-17

AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP
003106 04-03

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-04

COCAINE EFFECTS ON SLEEP PARAMETERS IN THE RAT.
003403 04-04

EFFECTS OF ATROPINE UPON THE HIPPOCAMPAL ELECTRICAL ACTIVITY IN RATS WITH SPECIAL REFERENCE TO PARADOXICAL SLEEP.
003476 04-04

SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09

SLEEP AND SLEEP ABNORMALITIES IN DEPRESSION.
003563 04-09

POLYGRAPHIC SLEEP RECORDINGS BEFORE AND AFTER THE ADMINISTRATION OF FLUNITRAZEPAM.
003626 04-11

EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
003727 04-14

COMPARATIVE EFFECTIVENESS OF NINE HYPNOTIC DRUGS: SLEEP LABORATORY STUDIES.
003737 04-14

THE EFFECTS OF GAMMA-HYDROXYBUTYRATE ON SLEEP.
003740 04-14

THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

SLEEP-AWAKE

DRUG SELF-ADMINISTRATION AND SLEEP-AWAKE ACTIVITY IN RATS DEPENDENT ON MORPHINE, METHADONE, OR L-ALPHA-ACETYLMETHADOL.
000390 01-04

SLEEP-WAKEFULNESS

EFFECTS OF DIHYDROGENATED ERGOT ALKALOIDS ON THE SLEEP-WAKEFULNESS CYCLE AND ON BRAIN BIOGENIC AMINES IN THE RAT.
001540 02-04

EFFECTS OF LOCUS-COERULEUS LESIONS UPON CEREBRAL MONOAMINE CONTENT, SLEEP-WAKEFULNESS STATES AND THE RESPONSE TO AMPHETAMINE IN THE CAT.
003409 04-04

SLEEPING

DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
00D245 01-03

HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04

EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
000367 01-04

EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS.
00D755 01-11

PSYCHIATRY, MEDICINE, AND SLEEP -- SLEEPING DRUGS AND TRANQUILIZERS.
000891 01-14

THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT.
001416 02-03

INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03

SLEEPWALKING

THE ACTION OF LITHIUM-CARBONATE ON THE SLEEPWALKING CYCLE IN THE CAT.
003419 04-04

SLICES

ENKEPHALIN AND OPIATE NARCOTICS INCREASE CYCLIC-GMP ACCUMULATION IN SLICES OF RAT NEOSTRIATUM.
000171 01-03

INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES.
000213 01-03

THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES.
000257 01-03

EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
D01329 02-D3

ANTAGONISM OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC MEDIATED ACCUMULATIONS OF CYCLIC-AMP IN RAT CEREBRAL CORTICAL SLICES BY THE BETA-ANTAGONIST (-)ALPRENOLOL.
001376 02-D3

BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN.
002358 03-03

EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-03

IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES.
003158 04-03

INFLUENCE OF DIAZEPAM AND IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT BRAIN.
003174 04-03

THE INFLUENCE OF 3,4 DIHYDROXYPHENYLACETIC-ACID ON THE ACCUMULATION OF 5 HYDROXYINDOLEACETIC-ACID IN THE CHOROID PLEXUS AND KIDNEY CORTEX SLICES OF RATS.
003176 04-03

SLOPE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE SLOPE OF AUDITORY GENERALIZATION GRADIENTS IN RATS.
000449 01-04

SLOW

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

TRH BY SLOW, CONTINUOUS INFUSION: AN ANTIDEPRESSANT?.
0017B1 02-09

MULTIPLICATION OF THE LATE SLOW COMPONENT OF THE EVOKED POTENTIAL TO LIGHT DURING CHLORPROMAZINE ADMINISTRATION.
00236B 03-03

FDA: A SLOW STARTER AND A SLOW RUNNER.
002998 D3-17

SLOW-RELEASE

CONTRIBUTION OF SLOW-RELEASE NEUROLEPTICS ON OPENING UP THE MENTAL HOSPITAL.
000605 01-09

COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000859 01-13

COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09

COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

SMELL

EFFECTS OF SCOPOLAMINE ON SMELL DISCRIMINATION IN THE RAT.
0D2316 03-03

THE EFFECT OF AMYTAL ON SMELL DISCRIMINATION LEARNING IN ALBINO RATS.
0D2471 03-04

SMOKING

COCAINE SELF-ADMINISTRATION IN MONKEYS BY CHEWING AND SMOKING.
000424 01-04

AVERSIVE SMOKING: CARBOXYHEMOGLOBIN LEVELS BEFORE AND AFTER RAPID SMOKING.
0D1903 02-1

CARBON-MONOXIDE BLOOD LEVELS AND REPORTED CESSATION OF SMOKING.
001933 D2-1

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
003703 04-1

3. SOCIAL LIFE, CIGARETTE SMOKING, AND URINARY PH.
003707 D4-1

EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
0D373D 04-1

DOSE RELATED HEART-RATE, PERCEPTUAL, AND DECISIONAL CHANGES I MAN FOLLOWING MARIHUANA SMOKING.
D03824 D4-1

SNAIL

EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES O SNAIL GIANT NEURONS.
002201 03-0

SNAKE
SNAKE VENOM ACTION: ARE ENZYMES INVOLVED IN IT?
003337 04-03

SNORTING
COCAINE SNORTING FOR FUN
003020 03-17

SOBERING
SOBERING DATA ON LITHIUM IN ALCOHOLISM.
003578 04-09

SOCIABILITY
EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY.
001595 02-04

SOCIAL
CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04
EFFECTS OF DIAZEPAM RELATED TO SOCIAL HIERARCHY IN RHESUS-MONKEYS.
000311 01-04
INHIBITION OF ADULT SOCIAL BEHAVIOUR IN DUCKS INDUCED BY JUVENILE ADMINISTRATION OF GONADAL HORMONES.
000312 01-04
BEHAVIORAL CHANGES IN A JUVENILE PRIMATE SOCIAL COLONY WITH CHRONIC ADMINISTRATION OF D-AMPHETAMINE.
000415 01-04
EFFECTS OF BENZODIAZEPINE TRANQUILLIZERS ON THE SOCIAL RESPONSES OF RATS.
000452 01-04
PREVENTION OF RECIDIVISM IN THE AGE OF LONG-ACTING NEUROLEPTICS AND SOCIAL PSYCHIATRY.
001069 01-17
EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON RAT SOCIAL BEHAVIOUR.
001463 02-04
SOCIAL COHESIVENESS, HYPERSEXUALITY AND IRRITABILITY INDUCED BY P-CPA IN THE RAT.
001464 02-04
EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE ON SOCIAL INTERACTION IN RATS.
0014B4 02-04
ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
0014B5 02-04
EFFECTS OF CHRONIC D-AMPHETAMINE ON SOCIAL BEHAVIOR OF THE RAT: IMPLICATIONS FOR AN ANIMAL MODEL OF PARANOID SCHIZOPHRENIA.
001490 02-04
PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04
MEDICAL AND SOCIAL INFLUENCE OF PHARMACOTHERAPY AGAINST SCHIZOPHRENIA.
001699 02-08
EXPECTANCIES, ALCOHOL, AND SEXUAL AROUSAL IN MALE SOCIAL DRINKERS.
002004 02-14
IMPLICATIONS OF DRUG TREATMENT FOR THE SOCIAL REHABILITATION OF SCHIZOPHRENIC PATIENTS.
002116 02-17
SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
002510 03-04
EXPERIMENTAL STUDY OF THE ACTION OF PSYCHOTROPIC DRUGS ON EMOTIONS, MOTIVATIONS AND SOCIAL BEHAVIOR OF ANIMALS.
00254B 03-04
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION. (ED.D. DISSERTATION).
002860 03-14
3. SOCIAL LIFE, CIGARETTE SMOKING, AND URINARY PH.
003707 04-13
PSYCHOPHARMACOLOGY AND SOCIAL WORK SKILLS.
003BB4 04-17

SOCIALIZATION
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS. (PH.D. DISSERTATION).
001040 01-17

SOCIALLY
DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
002511 03-04
EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-386, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

SOCIOENVIRONMENTAL
PSYCHOACTIVE DRUG EFFECT ON BEHAVIOURAL CHANGES INDUCED BY PROLONGED SOCIOENVIRONMENTAL DEPRIVATION IN RATS.
000475 01-06

SOCIOPATHIC
DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE (PH.D. DISSERTATION).
000685 01-10

SOCIOPATHY
SOCIOPATHY AN EXPERIMENT IN INTERNAL ENVIRONMENTAL CONTROL.
002737 03-11

SOCIOTHERAPY
PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-08

SODIUM
INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
000723 01-11
COMPARISON OF DANTROLENE SODIUM AND DIAZEPAM IN THE TREATMENT OF SPASTICITY.
001070 01-17
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03
EFFECT OF ANICOTINE ON SOME PROPERTIES OF SODIUM CHANNELS IN THE RANVIER NODE MEMBRANE.
001299 02-03
ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03
A DOUBLE-BLIND CROSS-OVER EVALUATION OF THE ACTIVITY OF O-OXAZEPAM HEMISUCCINATE SODIUM SALT (O-7-CHLORO DIHYDROHEMISUCCINYLOXYPHENYLBENZODIAZEPINONE) COMPARED TO ITS RACEMIC FORM.
001670 02-07
EFFECT OF SODIUM VALPROATE ON TARDIVE-DYSKINESIA.
001B38 02-11
HAS SODIUM VALPROATE HYPNOTIC EFFECTS?.
001961 02-14
EFFECT OF SODIUM AMYTAL ON ELECTROPHYSIOLOGICAL PROPERTIES OF SNAIL GIANT NEURONS.
002201 03-03
SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN.
002BB9 03-15
EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 04-03
INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03
THE EFFECTS OF PHENCYCLIDINE ON ETHANOL AND SODIUM HEXOBARBITAL IN MICE.
003290 04-03
THE RENAL HANDLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SODIUM CLEARANCE AND URINE FLOW IN RATS WITH DIABETES-INSIPIDUS.
003300 04-03
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT.
003B41 04-16

SODIUM-BICARBONATE
SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002039 02-15
SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002067 02-15

SODIUM-GLUTAMATE
THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05

SODIUM-OXYBUTYRATE
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
0022B9 03-03

SOLITARIUS
EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

SOLITARY
CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5tHYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

SOLUBILISATION
SOLUBILISATION OF ATROPINE-BINDING MATERIAL FROM BRAIN.
003110 04-03

SOLUBILITY
MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01

SOLUBILIZATION
SOLUBILIZATION OF BRAIN MITOCHONDRIAL HEXOKINASE IN ANESTHESIA
002402 03-03

SOLUBLE
STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

SOLUTIONS
POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

A SIMPLE AND INEXPENSIVE METHOD FOR THE INTRACEREBRAL ADMINISTRATION OF DRUG SOLUTIONS TO THE CONSCIOUS RAT.
002111 02-17

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE INTAKE OF ETHANOL AND SACCHARIN SOLUTIONS.
003463 04-04

STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE IN LABORATORY ANIMALS.
003492 04-05

SOLVENT
POLYETHYLENE-GLYCOL AS A SOLVENT FOR DIAZEPAM: BIOAVAILABILITY AND CLINICAL EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION, COMPARISON OF ORAL, INTRAMUSCULAR AND RECTAL ADMINISTRATION, AND PRECIPITATION FROM INTRAVENOUS SOLUTIONS.
000836 01-13

HYDROCARBON OR SOLVENT INHALATION.
003834 04-15

SOLVENTS
NEUROPSYCHOLOGIC AND PSYCHOSOCIAL ANTECEDENTS AND CHRONIC EFFECTS OF PROLONGED USE OF SOLVENTS AND METHAMPHETAMINE. PART 1 GROUP PROFILES
002940 03-15

ABUSE OF SOLVENTS FOR KICKS.
003B62 04-17

SOMA
CIRCULATORY MANIFESTATIONS OF SOMA AND PSYCHE.
000717 01-10

SOMATIC
5-HYDROXYTRYPTAMINE AS A SENSITIZER OF SOMATIC NOCICEPTORS FOR PAIN-PRODUCING SUBSTANCES.
000185 01-03

SOMATIC ANXIETY ATTACKS AND PROPRANOLOL.
0006B1 01-10

SOMATIC THERAPIES IN OLDER DEPRESSED PATIENTS.
001753 02-09

SOMATIC AND PSYCHIC SYMPTOMS IN ANXIETY
002722 03-10

THE USE OF PROPRANOLOL IN SOMATIC MEDICINE.
002957 03-17

SOMATICALLY
SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC DRUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS AND IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 03-15

SOMATOSENSORY
INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-03

LITHIUM EFFECTS ON THE SOMATOSENSORY CORTICAL EVOKED RESPONSE IN THE RAT AND CAT
00150B 02-04

THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL.
001941 02-13

PHYSOSTIGMINE ANALGESIA AND SOMATOSENSORY EVOKED RESPONSES IN MAN
003708 04-13

EFFECTS OF LITHIUM, TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

SOMATOSTATIN
CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
000408 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04

SOMATOSTATIN IN THE PHYSIOLOGIC FEEDBACK CONTROL OF THYROTROPIN SECRETION.
001396 02-03

BEHAVIOURAL AND MOTOR EXCITATION AND INHIBITION INDUCED BY THE ADMINISTRATION OF SMALL AND LARGE DOSES OF SOMATOSTATIN INTO THE AMYGDALA.
003451 04-04

SON
A FAVORABLE RESPONSE TO LITHIUM-CARBONATE IN A SCHIZOAFFECTIVE FATHER AND SON.
001714 02-08

SOSEGON
THREE CASES OF CHRONIC PENTAZOCINE (SOSEGON, PENTAGIN) INTOXICATION.
002045 02-15

SOUND
OBSTETRIC HISTORY AND THE HEART-RATE RESPONSE OF NEWBORNS TO SOUND.
000B34 01-13

FUNCTIONS OF LOUD SOUND, PERSONALITY, AND DRUGS.
002984 03-17

SOURCE
PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION.
000466 01-05

POSSIBLE SOURCE OF ERROR IN STUDIES OF ENZYMATIC FORMATION OF DIMETHYLTRYPTAMINE.
001091 02-01

ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION
003503 04-05

SOUTHERN
EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON THE PREDATORY BEHAVIOR OF SOUTHERN GRASSHOPPER MICE, ONYCHOMYS-TORRIDUS.
000374 01-04

SPACE
ANALGESIA PRODUCED BY MORPHINE WHEN ACTING FROM THE LIQUOR SPACE.
001184 02-03

INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

SPACED
ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING
002495 03-04

SPACING
INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS
001648 02-06

SPASTICITY
COMPARISON OF DANTROLENE SODIUM AND DIAZEPAM IN THE TREATMENT OF SPASTICITY
001070 01 17

SPATIAL
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT
002462 03-04

SPECIALISTS
CHEMOTHERAPEUTIC PREFERENCE OF NATIVE AND FOREIGN SPECIALISTS A MOVE TOWARD CONSENSUS.
002162 02-17

SPECIES
SHAKING BEHAVIOR INDUCED BY AG-3-5 IN SEVERAL CRIMINAL SPECIES.
000446 01-04

DETECTION OF PSILOCYBIN IN SPECIES OF PSILOCYBE, PANAEOLUS AND PSATHYRELLA.
001088 02-01

5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
001289 02-03

VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA CONTINGENCY ON TASKS AND SPECIES
001440 02-04

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 03-05

CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03

MORPHINE INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INDUCED ROTATION AND ANTAGONISM BY NALOXONE.
003434 04-04

SPECIFIC

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-03

IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?.
001330 02-03

ACETYLCHOLINE TURNOVER RATE IN SPECIFIC BRAIN NUCLEI: EFFECTS OF NARCOTIC ANALGETICS.
001432 02-03

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

EFFECTS OF ALCOHOL ON SPECIFIC AND ENVIRONMENTAL FEAR.
001966 02-14

PERSONALITY SPECIFIC EFFECT OF A TRANQUILIZER.
001987 02-14

BLOCKADE OF THE SPECIFIC LETHAL EFFECTS OF NARCOTIC ANALGESICS IN THE MOUSE
002362 03-03

NEUROTIC DEPRESSION: AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS.
002721 03-10

PREPARATION AND PROPERTIES OF THE BRAIN SPECIFIC PROTEIN-14-3-2.
003052 04-01

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
0030B7 04-03

TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
003219 04-03

TASTE-AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIVE AND DRUG SPECIFIC EFFECTS.
003359 04-04

THE SPECIFIC INTERACTION BETWEEN LSD AND SEROTONIN BINDING PROTEIN.
003517 04-06

SPECIFICATION

CATECHOLAMINES AND DEPRESSION: A FURTHER SPECIFICATION OF THE CATECHOLAMINE HYPOTHESIS OF THE AFFECTIVE DISORDERS.
000630 01-09

SPECIFICITY

STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01

MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03

ON THE SPECIFICITY AND MECHANISM OF ACTION OF M-TYROSINE IN ANTAGONIZING THE CENTRAL EFFECTS OF RESERPINE IN RATS.
000236 01-03

THE SPECIFICITY OF ACTION OF THREE POSSIBLE ANTAGONISTS OF AMINO-ACID-INDUCED NEURONAL EXCITATIONS.
001293 02-03

SPECIFICITY OF THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE FOR ANTIPSYCHOTIC ANTAGONISTS.
00134B 02-03

ACETALDEHYDE AS A PSYCHOPHARMACOLOGICAL AGENT: TASK SPECIFICITY OF GENOTYPIC DIFFERENCES.
0033B0 04-04

SPECTRA

HUMAN EEG SPECTRA BEFORE AND DURING CANNABIS HALLUCINATIONS.
001924 02-13

CHEMICAL IONIZATION MASS SPECTRA OF PHENOTHIAZINE DERIVATIVES AND THEIR OXYGENATED ANALOGS.
003057 04-01

DRUG EFFECTS ON EEG FREQUENCY SPECTRA AS A FUNCTION OF INTERSTIMULUS INTERVAL
003673 04-13

SPECTRAL

SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND BENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY
001360 02-03

A SYSTEM FOR PATTERN ORIENTED SPECTRAL ANALYSIS OF EEG DATA AND ITS APPLICATION IN PHARMACOELECTROENCEPHALOGRAPHY
001885 02-13

EEG SPECTRAL ANALYSIS OF THE EFFECTS OF CAFFEINE
001925 02-13

CLINICAL AND PHARMACOLOGICAL SPECTRAL MAPS OF THE NEUROLEPTICS.
003009 03-17

SPECTROGRAPHIC

MASS SPECTROGRAPHIC EVIDENCE OF THE CONVERSION OF P-CHLOROAMPHETAMINE TO 3,4 DIMETHOXYAMPHETAMINE.
002364 03-03

SPECTROMETRY

QUANTITATIVE DETERMINATION OF AMITRIPTYLINE AND ITS PRINCIPAL METABOLITE, NORTRIPTYLINE, BY GLC CHEMICAL IONIZATION MASS SPECTROMETRY.
003150 04-03

SPECTROPHOTOMETRIC

MEDAZEPAM PKA DETERMINED BY SPECTROPHOTOMETRIC AND SOLUBILITY METHODS.
000012 01-01

SPECTROSCOPIC

IR SPECTROSCOPIC CHARACTERIZATION OF 2-THIOHYDANTOINS AND 2-THIOBARBITURATES.
0010B9 02-01

SPECTRUM

CLINICAL SPECTRUM OF ACTION OF MODERATE AND HIGH DOSES OF CARPIPRAMINE.
000532 01-08

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTADINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS.
002194 03-02

DYSTONIA: THE SPECTRUM OF THE DISEASE.
002916 03-15

SPECTRUM OF ACTIVITY OF SOME DRUGS.
002974 03-17

SPECULATIONS

IMIPRAMINE AND CHILDREN: A REVIEW AND SOME SPECULATIONS ABOUT THE MECHANISM OF DRUG ACTION.
003791 04-15

SPEECH

EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH.
003522 04-07

SPEED

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA: A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08

IF SPEED KILLS, TRICYCLICS MASSACRE.
001734 02-09

DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002B26 03-13

SPIKE

THE EFFECTS OF PHENYTOIN, PHENOBARBITAL, AND CARBAMAZEPINE ON THE EXPERIMENTAL SPIKE FOCUS.
003209 04-03

SPIKE-WAVE

EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR.
003282 04-03

SPIN

INTERACTION OF CHLORPROMAZINE WITH BIOLOGICAL MEMBRANES: A PHOTOCHEMICAL STUDY USING SPIN LABELS.
002297 03-03

SPINAL

THE EFFECTS OF MORPHINE-LIKE AND NALORPHINE-LIKE DRUGS IN THE NONDEPENDENT AND MORPHINE-DEPENDENT CHRONIC SPINAL DOG.
000164 01-03

PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS.
001125 02-03

EFFECTS OF MORPHINE AND NALOXONE ON RENSHAW CELLS AND SPINAL INTERNEURONES IN MORPHINE DEPENDENT AND NONDEPENDENT RATS.
001179 02-03

BIMODAL ACTION OF GLYCINE ON FROG SPINAL MOTONEURONES.
001199 02-03

ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
001235 02-03

DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03

THE MECHANISM OF INHIBITION OF NEURONAL ACTIVITY BY OPIATES IN THE SPINAL CORD OF CAT.
001429 02-03

EFFECT OF MORPHINE MICROINJECTION INTO THE MEDULLA-OBLONGATA ON THE SPINAL DORSAL HORN NEURON.
002200 03-03

ACTIONS OF ENKEPHALIN AND MORPHINE ON SPINAL CORD AND BRAINSTEM NEURONES.
002229 03-03

SEROTONIN INVOLVEMENT IN THE BLOCKADE OF BULBOSPINAL INHIBITION OF THE SPINAL MONOSYNAPTIC REFLEX.
002354 03-03

NEUROLEPTICS REDUCE SPINAL FLUID CYCLIC-AMP IN SCHIZOPHRENIC PATIENTS.
002800 03-13

CLINICAL RESEARCH INTO AMINE METABOLISM PRODUCTS IN THE SPINAL FLUID (II) -- THREE CASES OF CONSCIOUSNESS IMPAIRMENT THAT SHOWED IMPROVEMENT AFTER L-DOPA ADMINISTRATION -- LIVER RELATED BRAIN DISEASE AND DOPAMINE AND SEROTONIN METABOLISM.
002820 03-13

AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. I. SPINAL CORD AND LOWER MEDULLA.
00308B 04-03

THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03

INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

SPINDLE
EFFECT OF PSYCHOTROPIC DRUGS ON CAUDATE SPINDLE IN CATS.
001250 02-03

SPIPERONE
LACK OF STIMULATION BY HIGH AMPHETAMINE DOSES FOLLOWING A LOW-DOSE OF SPIPERONE.
003345 04-04

SPIROPERIDOL
DISCRIMINATIVE AND MOTOR PERFORMANCE IN RATS AFTER INTERFERENCE WITH DOPAMINE NEUROTRANSMISSION WITH SPIROPERIDOL.
003448 04-04

SPLIT-BRAIN
EEG AND CLINICAL STUDIES OF THE DEVELOPMENT OF ALUMINA CREAM EPILEPTIC FOCUS IN SPLIT-BRAIN CATS.
000159 01-03

SPONTANEOUS
EFFECTS OF HUMORAL MODULATORS AND NALOXONE ON MORPHINE-INDUCED CHANGES IN THE SPONTANEOUS LOCOMOTOR ACTIVITY OF THE RAT.
0001B8 01-03

INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANEOUS ALTERNATION TASK.
000361 01-04

ACTION OF DI-N-PROPYLACETATE ON THE SPONTANEOUS AND ACQUIRED BEHAVIOUR IN GOLDFISH, MICE AND RATS.
0003B6 01-04

SPONTANEOUS ASSUMPTIONS OF A PHARMACOTHERAPEUTIC ROLE BY TWO LONG-TERM SCHIZOPHRENIC PATIENTS.
000560 01-0B

CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 02-03

ACTION OF AMINO-ACIDS AND CONVULSANTS ON CEREBELLAR SPONTANEOUS ACTION POTENTIALS IN VITRO: EFFECTS OF DEPRIVATION OF CHLORIDE, POTASSIUM OR SODIUM.
001314 02-03

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001500 02-04

THE INHIBITORY EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS.
001501 02-04

DIAZEPAM MODIFICATION OF EVOKED AND SPONTANEOUS LATERAL GENICULATE ACTIVITY.
002425 03-04

SPONTANEOUS AND AMPHETAMINE-INDUCED HEAD-SHAKING IN INFANT RATS.
002465 03-04

INCREASE IN SPONTANEOUS MOTOR ACTIVITY OF INTRACEREBRALLY ADMINISTERED METARAMINOL IN MICE.
002539 03-04

EFFECTS OF ACUTE DIAZEPAM AND CLOBAZAM ON SPONTANEOUS LOCOMOTOR ACTIVITY AND CENTRAL AMINE METABOLISM IN RATS.
003248 04-03

SPOT
THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001004 01-16

SQUAB-EGG
EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
000389 01-04

SQUIRREL-MONKEY
THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY.
000270 01-04

THE EFFECTS OF CHLORPROMAZINE UPON FEAR MOTIVATED BEHAVIOR IN THE SQUIRREL-MONKEY.
000345 01-04

SPECTRAL DENSITY ANALYSIS OF THE EFFECTS OF BARBITURATES AND BENZODIAZEPINES ON THE ELECTROCORTICOGRAM OF THE SQUIRREL-MONKEY.
001360 02-03

AMPHETAMINE, CHLORPROMAZINE AND CLONIDINE EFFECTS ON SELF-STIMULATION IN CAUDATE OR HYPOTHALAMUS OF THE SQUIRREL-MONKEY.
001384 02-03

EFFECTS OF MORPHINE ALONE AND IN COMBINATION WITH NALOXONE OR D-AMPHETAMINE ON SHOCK-MAINTAINED BEHAVIOR IN THE SQUIRREL-MONKEY.
001453 02-04

THE EFFECTS OF D-AMPHETAMINE AND ILLUMINATION ON BEHAVIORS OF THE SQUIRREL-MONKEY.
001542 02-04

BEHAVIOR MAINTAINED UNDER SECOND-ORDER SCHEDULES OF INTRAVENOUS MORPHINE INJECTION IN SQUIRREL-MONKEY AND RHESUS-MONKEYS.
003391 04-04

DISCRIMINATIVE EFFECTS OF MORPHINE IN THE SQUIRREL-MONKEY.
003457 04-04

SQUIRREL-MONKEYS
THE PASSAGE OF 14C-DELTA-9-TETRAHYDROCANNABINOL INTO THE MILK OF LACTATING SQUIRREL-MONKEYS.
001167 02-03

EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04

EFFECTS OF PROPRANOLOL ON BEHAVIOR MAINTAINED UNDER FIXED-RATIO SCHEDULES OF COCAINE INJECTION OR FOOD PRESENTATION IN SQUIRREL-MONKEYS.
002457 03-04

EFFECTS OF COCAINE AND D-AMPHETAMINE ON BEHAVIOR MAINTAINED UNDER VARIOUS SCHEDULES OF FOOD PRESENTATION IN SQUIRREL-MONKEYS.
003392 04-04

SRIF
CENTRAL SITE OF ACTION OF SOMATOSTATIN (SRIF): ROLE OF HIPPOCAMPUS.
000408 01-04

CORTICAL ADMINISTRATION OF SOMATOSTATIN (SRIF): EFFECT ON SLEEP AND MOTOR BEHAVIOR.
000409 01-04

ST-1191
USE OF ST-1191 IN HOSPITALIZED PATIENTS.
000679 01-10

STABILITY
STUDY OF THE STABILITY OF PHENOTHIAZINE DERIVATIVES.
000005 01-01

THE EFFECT OF SEQUENCE ON THE STABILITY OF THE HOPKINS SYMPTOM CHECKLIST (HSCL). (UNPUBLISHED PAPER).
002982 03-17

STABLE
AN ENZYMATICALLY STABLE PEPTIDE WITH ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM: ITS PENETRATION THROUGH THE BLOOD CSF BARRIER.
003065 04-02

STABLE NONAQUEOUS PENTOBARBITAL-SODIUM SOLUTIONS FOR USE IN LABORATORY ANIMALS.
003492 04-05

STAGE
PSYCHOACTIVE DRUGS IN MEDICAL PRACTICE: THE PRESENT STAGE OF DEVELOPMENT.
001049 01-17

STAGES
EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN.
003637 04-11

STAMMERING
THE EFFECT OF PROPRANOLOL IN STAMMERING.
002749 03-11

STANDARD
PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07
STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07

STANDARDIZED
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06

STANDARDS
TOWARD THE DEVELOPMENT OF CONTEMPORARY STANDARDS FOR THE PHARMACOTHERAPY OF MENTAL DISORDERS -- PROLOGUE AND EPILOGUE. (UNPUBLISHED PAPER).
001058 01-17

STAPLEPUNCTURE
OUTPATIENT HEROIN DETOXIFICATION WITH ACUPUNCTURE AND STAPLEPUNCTURE.
002783 03-11

STARTER
FDA: A SLOW STARTER AND A SLOW RUNNER.
002998 03-17

STARTLE
EFFECTS OF APOMORPHINE AND HALOPERIDOL ON THE ACOUSTIC STARTLE RESPONSE IN RATS.
000309 01-04
EFFECTS OF CLONIDINE ON HABITUATION AND SENSITIZATION OF ACOUSTIC STARTLE IN NORMAL, DECEREBRATE AND LOCUS-COERULEUS LESIONED RATS.
003371 04-04
TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-04

STARVED
THE EFFECTS OF (+) AMPHETAMINE AND FENFLURAMINE ON FEEDING IN STARVED AND SATIATED MICE.
000313 01-04

STATE
DISCRIMINABILITY OF THE POSTICTAL STATE PRODUCED BY ELECTROCONVULSIVE SHOCK IN RATS.
000397 01-04
STANDARD METHOD OF EVALUATING MENTAL STATE IN CLINICAL TRIALS OF PSYCHOTROPIC DRUGS.
000511 01-07
PSYCHOPHARMACOLOGICAL STUDY ON THE DEPRESSIVE STATE IN MEDICAL PRACTICE.
000692 01-10
LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
000886 01-14
THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SUBSEQUENT DRUG STATE DISCRIMINATION.
000906 01-14
PLASMA LEVEL OF ANTIDEPRESSANT DRUG AND OUTCOME: THE STATE OF THE ART.
001749 02-09
LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001813 02-11
A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09
CURRENT STATE OF RESEARCH ON PROPRANOLOL OPIATE INTERACTION.
002757 03-11
THE PRESENT STATE OF PHARMACOTHERAPY.
003001 03-17
METABOLITE STUDIES OF METHAMPHETAMINE EFFECTS BASED UPON MITOCHONDRIAL RESPIRATORY STATE IN RAT BRAIN.
003294 04-03
EFFECT OF MARIJUANA AND PLACEBO MARIJUANA SMOKING ON PSYCHOLOGICAL STATE AND ON PSYCHOPHYSIOLOGICAL CARDIOVASCULAR FUNCTIONING IN ANGINAL PATIENTS.
003730 04-14
NARCOTIC CUE AND NARCOTIC STATE.
003853 04-17

STATE-DEPENDENCY
ALCOHOL AND MEMORY: STORAGE AND STATE-DEPENDENCY.
002069 02-15

STATE-DEPENDENT
STIMULANT RELATED STATE-DEPENDENT LEARNING IN HYPERACTIVE CHILDREN.
000922 01-14
STATE-DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDE AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
001488 02-04
CUE USE IN STATE-DEPENDENT LEARNING.
001566 02-04
EFFECTS OF RESERPINE ON RETENTION OF ESCAPE REVERSAL IN MICE: ABSENCE OF STATE-DEPENDENT LEARNING.
003417 04-04

STATIONARY
INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

STATISTICAL
STATISTICAL EVALUATION OF POLYGRAPHIC INVESTIGATIONS OF PENTOXIFYLLINE.
000B30 01-13

STATUS-EPILEPTICUS
PRELIMINARY STUDY OF PARENTERAL LORAZEPAM IN STATUS-EPILEPTICUS.
0007B9 01-11

STATUTE
THE NEW DRUG STATUTE AND THE FUTURE OF CLINICAL PSYCHOPHARMACOLOGY.
002141 02-17

STATUTES
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17

STEADY-STATE
STEADY-STATE BIOAVAILABILITY OF TWO CLORAZEPATE DIPOTASSIUM DOSAGE FORMS.
003662 04-13
A CLINICAL TRIAL OF A 50MG FORMULATION OF CLOMIPRAMINE (ANAFRANIL) WITH STEADY-STATE PLASMA LEVEL MEASUREMENTS.
003866 04-17

STEP-LIKE
ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

STEREOCHEMISTRY
STEREOCHEMISTRY OF METABOLISM OF AMPHETAMINES: USE OF (-) ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYL-PHENYLACETYL CHLORIDE FOR GLC RESOLUTION OF CHIRAL AMINES.
003064 04-02

STEREOISOMERS
EFFECTS OF ALPHA-METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN-FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE.
001582 02-04
EFFECTS OF TRANYLCYPROMINE STEREOISOMERS, CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG-TERM LITHIUM ADMINISTRATION IN RATS.
002542 03-04

STEREOSPECIFIC
RAT BRAIN ARYLACYLAMIDASE: STEREOSPECIFIC INHIBITION BY LSD AND SEROTONIN RELATED COMPOUNDS.
001326 02-03

STEREOSPECIFICITY
STEREOSPECIFICITY OF INTERACTION OF NEUROLEPTIC DRUGS WITH NEUROTRANSMITTERS AND CORRELATION WITH CLINICAL POTENCY.
001909 02-13
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN AND ITS STEREOSPECIFICITY FOR BUTACLAMOL.
002347 03-03
STEREOSPECIFICITY AND STRUCTURE-ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINDING IN RAT BRAIN.
003134 04-03

STEREOTYPED
ACUTE INCREASES BY P-CHLOROPHENYLALANINE OF APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
000279 01-04
DOSE-RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
0003B7 01-04
SEROTONERGIC AND ANTISEROTONERGIC INFLUENCES ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
000448 01-04
A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

DOSE RESPONSE EFFECTS OF BETA-PHENYLETHYLAMINE ON STEREOTYPED BEHAVIOR IN PARGYLINE PRETREATED RATS.
002504 03-04

NEUROLEPTICS ATTENUATE STEREOTYPED BEHAVIOR INDUCED BY BETA-PHENYLETHYLAMINE IN RATS. (UNPUBLISHED PAPER).
002505 03-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON METHAMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
00253B 03-04

THE EFFECT OF DIMETHYLAMINOETHANOL (DEANOL) ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR (AISB).
002553 03-04

ANTAGONISM OF AMPHETAMINE STEREOTYPED BEHAVIOR BY DIASTEREOISOMERIC DIHYDRODIBENZOTHIEPINE NEUROLEPTICS.
003164 04-03

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS.
003357 04-04

STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI.
00336B 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

STEREOTYPICAL

RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02

STEREOTYPIES

EFFECT OF CHOLINERGIC DRUGS ON METHADONE-INDUCED CATALEPSY AND STEREOTYPIES IN RATS TREATED CHRONICALLY WITH METHADONE.
002199 03-03

STEREOTYPY

CHOLINERGIC MODIFICATION OF DRUG-INDUCED STEREOTYPY IN RATS.
000201 01-03

PAPAVERINE, DRUG-INDUCED STEREOTYPY AND CATALEPSY AND BIOGENIC AMINES IN THE BRAIN OF THE RAT.
000362 01-04

CATECHOLAMINES IN ACTIVATION, STEREOTYPY, AND LEVEL OF MOOD.
000B5B 01-13

ABOLITION OF NOMIFENSINE-INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS.
001334 02-03

SOME CHARACTERISTICS OF AMPHETAMINE STEREOTYPY AS A DRUG MODEL OF PSYCHOPATHOLOGY.
002204 03-03

ROLE OF BRAIN NORADRENALINE ON AMPHETAMINE STEREOTYPY -- EFFECTS OF ALPHA-MPT, IN PARTICULAR.
002252 03-03

ROLE OF BRAIN SEROTONIN ON METHAMPHETAMINE-INDUCED STEREOTYPY IN SHAM-OPERATED OR ADRENALECTOMIZED RATS. EFFECTS OF ALPHA-MMT, P-CPA OR L-DOPA, IN PARTICULAR -- .
002474 03-04

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON AMPHETAMINE-INDUCED LOCOMOTION AND STEREOTYPY.
002535 03-04

POTENTIATING EFFECT OF LITHIUM-CHLORIDE ON METHAMPHETAMINE-INDUCED STEREOTYPY IN MICE.
00343B 04-04

STEROID

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03

THE EFFECT OF STEROID CONTRACEPTIVES ON THE CONCENTRATIONS OF BRAIN MONOAMINES IN RATS AND MICE.
001140 02-03

PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE -- ESPECIALLY LIGHT CONSCIOUSNESS IMPAIRMENTS.
002B95 03-15

STEROIDS

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

STIFF-MAN

STIFF-MAN SYNDROME AND CLONAZEPAM.
003650 04-11

STIMULANT

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION.
000340 01-04

REDUCED ANOREXIC AND LOCOMOTOR STIMULANT ACTION OF O-AMPHETAMINE IN ALLOXAN DIABETIC RATS.
000373 01-04

STIMULANT RELATED STATE-DEPENDENT LEARNING IN HYPERACTIVE CHILDREN.
000922 01-14

THE EFFECT OF BEHAVIORAL STIMULANT DOSES OF AMPHETAMINE ON BLOOD PRESSURE.
0009B6 01-15

RELATIONSHIP BETWEEN REWARD ENHANCING AND STEREOTYPICAL EFFECTS OF PSYCHOMOTOR STIMULANT DRUGS.
001113 02-02

APPETITE STIMULANT ACTIVITY OF CARBOXYDIHYDROXYPROHEPTADINE.
001459 02-04

STIMULANT ACTIONS OF DELTA9-TETRAHYDROCANNABINOL IN MICE.
0014B0 02-04

THE USE OF STIMULANT DRUGS IN THE TREATMENT OF HYPERACTIVITY.
002170 02-17

EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN COMBINATION WITH STIMULANT DRUGS IN RABBITS.
002434 03-04

CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04

PREDICTING THE RESPONSE OF HYPERKINETIC CHILDREN TO STIMULANT DRUGS: A REVIEW.
002B52 03-14

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON THE GROWTH AND BODY COMPOSITION OF HYPERACTIVE CHILDREN.
003633 04-11

STIMULANT-INDUCED

REVERSE TOLERANCE TO STIMULANT-INDUCED ABNORMAL BEHAVIOR
003196 04-03

THE DIFFERENT EFFECT OF HUMORAL MODULATORS ON THE MORPHINE AND CENTRAL-NERVOUS-SYSTEM STIMULANT-INDUCED HYPERACTIVITY OF RATS.
003437 04-04

STIMULANTS

EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS.
000264 01-03

EFFECT OF CNS DEPRESSANTS AND STIMULANTS ON LATENCY FOR APPEARANCE OF COPULATORY RESPONSE IN THE FEMALE RAT.
000294 01-04

GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
001561 02-04

CHEMICAL STIMULANTS OF SHAKING BEHAVIOUR.
001605 02-04

MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13

DOPAMINERGIC STIMULANTS AND CYCLIC NUCLEOTIDES IN MOUSE BRAIN
002459 03-04

DISCRIMINATIVE RESPONSE CONTROL BY PSYCHOMOTOR STIMULANTS.
003034 03-17

STIMULATED

IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
00015B 01-03

AMINE RESPONSIVE ADENYLATE-CYCLASE ACTIVITY FROM BRAIN: COMPARISONS BETWEEN RAT AND RHESUS-MONKEY AND DEMONSTRATION OF DOPAMINE STIMULATED ADENYLATE-CYCLASE IN MONKEY NEOCORTEX.
000254 01-03

EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE-CYCLASE AND ON CYCLIC-GMP FORMATION IN PRIMATE BRAIN AMYGDALOID NUCLEUS.
000261 01-03

EFFECTS OF A NOVEL ANTIAGGRESSIVE AGENT UPON TWO TYPES OF BRAIN STIMULATED EMOTIONAL BEHAVIOR.
000357 01-04

STRUCTURE-ACTIVITY RELATIONSHIPS OF ENKEPHALINS IN THE STIMULATED GUINEA-PIG ILEUM.
0011B0 02-03

EFFECTS OF ANTAGONISTS OF ADRENALINE RECEPTORS AND DOPAMINE RECEPTORS ON MORPHINE STIMULATED GLYCOGEN BREAKDOWN IN MOUSE BRAIN.
001197 02-03

EFFECTS OF P-CHLOROPHENYLALANINE UPON BRAIN STIMULATED AFFECTIVE ATTACK IN THE CAT.
001525 02-04

ABSENCE OF MORPHINE ANTAGONISM OF PROSTAGLANDIN-E1 STIMULATED 3H-3,5 CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION IN A RAT BRAIN MINCE SYSTEM.
003191 04-03

INHIBITION OF THE SODIUM AND POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE ACTIVITY DURING AUTOOXIDATION OF APOMORPHINE.
003267 04-03

STIMULATING

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. INTRODUCTION TO PARTS X-XII, AND PART X ACRIDONE DERIVATIVES.
000017 01-01

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XI. LENGTHENING OF THE BASIC CHAIN.
000018 01-01

COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03

THE INFLUENCE OF BRADYKININ AND DRUGS BLOCKING ALPHA AND BETA-ADRENERGIC RECEPTOR ON THE STIMULATING EFFECT OF NIALAMIDE AND L-DOPA.
000173 01-03

STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

NEUROPHARMACOLOGICAL TESTS WITH ALPHA-MELANOCYTE STIMULATING HORMONE.
000402 01-04

PHENYLETHYLAMINE: EVIDENCE FOR A DIRECT, POSTSYNAPTIC DOPAMINE RECEPTOR STIMULATING ACTION.
003343 04-04

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
003615 04-11

STIMULATION

STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
000038 01-03

STIMULATION OF CEREBRAL HISTAMINE H2-RECEPTORS BY CLONIDINE.
000039 01-03

PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEMBRANES OF BRAIN, BY NEUROTRANSMITTERS AND OTHER AGONISTS.
000117 01-03

THE RELATIVE IMPORTANCE OF DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION FOR THE RESTORATION OF MOTOR ACTIVITY IN RESERPINE OR ALPHA-METHYL-P-TYROSINE PRETREATED MICE.
000314 01-04

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04

FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
000619 01-09

SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03

SUPPRESSION OF ETHANOL-INDUCED STIMULATION BY GABA-LIKE DRUGS.
001174 02-03

BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION.
001190 02-03

INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-03

DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT.
001274 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: SELF-STIMULATION UNDER MORPHINE, AMPHETAMINE, AND CHLORPROMAZINE.
001285 02-03

INHIBITION OF 3,5 NUCLEOTIDE PHOSPHODIESTERASE AND THE STIMULATION OF CEREBRAL CYCLIC-AMP FORMATION BY BIOGENIC AMINES IN VITRO AND IN VIVO.
001301 02-03

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS EFFECTS ON LIVER GLYCOGEN SYNTHESIS
001372 02-03

BEHAVIORAL EVIDENCE FOR THE STIMULATION OF CNS SEROTONIN RECEPTORS BY HIGH DOSES OF LSD.
001404 02-03

STIMULATION OF FOOD INTAKE IN HORSES BY DIAZEPAM AND PROMAZINE
001452 02-04

BRAIN DOPAMINE RECEPTORS AND SLEEP IN THE RAT: EFFECTS OF STIMULATION AND BLOCKADE.
001522 02-04

A DOSE-RESPONSE STUDY OF ANORECTIC DRUG EFFECTS ON FOOD INTAKE, SELF-STIMULATION, AND STIMULATION ESCAPE.
001529 02-04

ACTION OF ENPIPRAZOLE ON EMOTIONAL BEHAVIOR INDUCED BY HYPOTHALAMIC STIMULATION IN RATS AND CATS.
001550 02-04

A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION: I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
002180 02-17

PHARMACOLOGICAL EVIDENCE FOR A STIMULATION OF DOPAMINE NEURONS BY NORADRENALINE NEURONS IN THE BRAIN
002202 03-03

PROPRANOLOL-INDUCED ACUTE NATRIURESIS BY BETA-BLOCKADE AND DOPAMINERGIC STIMULATION
002218 03-03

EFFECT OF CATECHOLAMINERGIC AGENTS ON THE CIRCULAR REACTION INDUCED BY STIMULATION OF THE CAUDATE NUCLEUS.
002235 03-03

ELEVATION OF 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATIONS IN RAT BRAIN AND STIMULATION OF PROLACTIN SECRETION BY FENFLURAMINE: EVIDENCE FOR ANTAGONISM AT DOPAMINE RECEPTOR SITES.
002243 03-03

POTENTIATION OF EFFECTS OF CATECHOLAMINES AND SYMPATHETIC STIMULATION BY TRIAZOLOBENZODIAZEPINE.
002245 03-03

UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
002268 03-03

COMPARISON BETWEEN NALOXONE REVERSAL OF MORPHINE AND ELECTRICAL STIMULATION INDUCED ANALGESIA IN THE RAT MESENCEPHALON.
002334 03-03

DIFFERENTIAL CARDIOVASCULAR CHANGES AS A FUNCTION OF STIMULATION ELECTRODE SITE IN RABBIT HYPOTHALAMUS. (PH.D. DISSERTATION).
002351 03-03

ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

EFFECT OF STIMULATION OF LOCUS-COERULEUS ON ELECTRICAL ACTIVITY OF THE AMYGDALA IN RATS.
002399 03-03

EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-03

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION
002429 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE AND PRESSING FOR COMBINATIONS OF POSITIVE AND NEGATIVE ICS.
002444 03-04

INHIBITORY EFFECT OF MIDBRAIN RAPHE STIMULATION ON THE MAINTENANCE OF AN ACTIVE AVOIDANCE REFLEX.
002487 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
002500 03-04

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE. II. MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION: INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04

STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
002580 03-05

RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
0030B2 04-03
THE EFFECT OF THE NARCOTIC ANTAGONISTS NALOXONE, NALTREXONE AND NALORPHINE ON SPINAL CORD C-FIBER REFLEXES EVOKED BY ELECTRICAL STIMULATION OR RADIANT HEAT.
003093 04-03
DIFFERENTIAL EFFECT OF MORPHINE ON STIMULATION OF PRIMARY VERSUS HIGHER ORDER TRIGEMINAL TERMINALS.
003257 04-03
ANALGESIA PRODUCED BY ELECTRICAL STIMULATION OF CATECHOLAMINE NUCLEI IN THE RAT BRAIN.
003276 D4-03
SENSITIZATION TO COCAINE STIMULATION IN MICE.
00327B 04-03
INHIBITION OF NEURONS IN THE AMYGDALA BY DORSAL RAPHE STIMULATION: MEDIATION THROUGH A DIRECT SEROTONERGIC PATHWAY.
0D3320 04-03
LACK OF STIMULATION BY HIGH AMPHETAMINE DOSES FOLLOWING A LOW-DOSE OF SPIPERONE.
003345 04-04
HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION.
003364 04-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY AMPHETAMINE AND HYPOTHALAMIC SELF-STIMULATION.
003373 04-04
REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04
REDUCTION OF STIMULATION PRODUCED ANALGESIA BY LYSERGIC-ACID-DIETHYLAMIDE, A DEPRESSOR OF SEROTONERGIC NEURAL ACTIVITY.
003401 04-04
LITHIUM REDUCES PREFERENCE FOR ETHANOL-INDUCED BY HYPOTHALAMIC STIMULATION.
00342B 04-04
ANTAGONISM OF ETHANOLS CENTRAL STIMULATION IN MICE BY SMALL DOSES OF CATECHOLAMINE RECEPTOR AGONISTS.
003466 04-04

STIMULATION-INDUCED
THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
000075 01-03

STIMULATIONS
CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULATIONS.
0019S5 02-14

STIMULATOR
CLINICAL EXPERIENCES WITH BROMOCRIPTINE, A CENTRAL DOPAMINERGIC STIMULATOR.
001671 02-07

STIMULATORY
EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT S-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

STIMULI
EFFECTS OF PSYCHOSOCIAL STIMULI ON PLASMA RENIN ACTIVITY IN RATS.
002222 03-03
ALLEVIATION OF NARCOTIC WITHDRAWAL BY CONDITIONAL STIMULI.
002292 03-03
BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI.
DD2394 03-03
EFFECTS OF DRUGS ON BEHAVIOR CONTROLLED BY NOXIOUS STIMULI.
0024B2 03-04
CONDITIONING OF DISCRIMINABLE STIMULI PRODUCED BY MORPHINE.
002499 03-04
SOCIAL ISOLATION-INDUCED BEHAVIORAL CHANGES UNDER INTENSE STIMULI AND THE BIOCHEMICAL MECHANISM.
002510 03-D4
DISCRIMINABLE STIMULI PRODUCED BY ALCOHOL AND OTHER CNS DEPRESSANTS.
002964 03-17
DISCRIMINABLE STIMULI PRODUCED BY MARIHUANA CONSTITUENTS.
DD30D2 03-17
DISCRIMINABLE STIMULI PRODUCED BY HALLUCINOGENS.
DD3D03 03-17
GENERAL CHARACTERISTICS OF DISCRIMINATIVE STIMULI PRODUCED BY DRUGS.
003004 03-17
DISCRIMINABLE STIMULI PRODUCED BY NARCOTIC ANALGESICS.
DD3D0S 03-17
EFFECT OF FOOT-SHOCK INTENSITY ON AMOUNT OF MEMORY RETRIEVAL IN RATS BY EMOTIONALLY IMPORTANT STIMULI IN A DRUG-DEPENDENT LEARNING ESCAPE DESIGN.
003365 04-04

STIMULUS
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03
DISCRIMINATIVE STIMULUS PROPERTIES OF BENZODIAZEPINES, BARBITURATES AND PHARMACOLOGICALLY RELATED DRUGS; RELATION TO SOME INTRINSIC AND ANTICONVULSANT EFFECTS.
000299 01-04
CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
000442 01-04
MORPHINE: ABILITY TO BLOCK NEURONAL ACTIVITY EVOKED BY A NOCICEPTIVE STIMULUS.
001231 02-03
DISCRIMINATIVE STIMULUS PROPERTIES OF A LOW DL-AMPHETAMINE DOSE.
001460 02-04
DISCRIMINATIVE STIMULUS PROPERTIES OF FENTANYL AND MORPHINE: TOLERANCE AND DEPENDENCE.
001461 02-04
SELECTIVE INTERACTION OF DRUGS WITH A DISCRIMINABLE STIMULUS ASSOCIATED WITH NARCOTIC ACTION.
001493 02-04
DISCRIMINATIVE PENTOBARBITAL STIMULUS IN RATS IMMEDIATELY AFTER INTRAVENOUS ADMINISTRATION.
001531 02-04
SECONDARY REINFORCEMENT PROPERTY OF A STIMULUS PAIRED WITH MORPHINE ADMINISTRATION IN THE RAT.
001557 02-04
EFFECTS OF SCOPOLAMINE ON A DOUBLE STIMULUS DISCRIMINATION
002D02 02-14
BLOCKADE OF APOMORPHINES DISCRIMINATIVE STIMULUS PROPERTIES: RELATION TO NEUROLEPTIC ACTIVITY IN NEUROPHARMACOLOGICAL AND BIOCHEMICAL ASSAYS.
002433 03-04
PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION: EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
002497 03-04
THE DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE, D-AMPHETAMINE AND MORPHINE IN DOPAMINE DEPLETED RATS.
002526 03-04
THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002S29 03-04
DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
002532 03-04
EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002B17 03-13
PENTOBARBITAL DEPRESSION OF STIMULUS SECRETION COUPLING IN BRAIN -- SELECTIVE INHIBITION OF DEPOLARIZATION-INDUCED CALCIUM DEPENDENT RELEASE.
003170 04-03
HALOPERIDOL BLOCKS THE DISCRIMINATIVE STIMULUS PROPERTIES OF LATERAL HYPOTHALAMIC STIMULATION.
003364 D4-D4
THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
00339S 04-04

STIMULUS-BOUND
STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION.
003224 04-03

STIR
NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY
00214B 02-17

STORAGE
INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
DDD1SD D1-03
INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR S-HYDROXYTRYPTAMINE
001207 D2-03
ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
D01377 D2-03
ALCOHOL AND MEMORY: STORAGE AND STATE-DEPENDENCY.
D02D69 02-1S
CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION
00237D 03-D3

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
003241 04-03

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS: INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

MARIJUANA: EFFECTS ON STORAGE AND RETRIEVAL OF PROSE MATERIAL.
003743 04-14

STORES

PREVENTION BY CALCIUM ADMINISTRATION OF RESERPINE ACTION ON RAT BRAIN NORADRENALINE STORES: A REAPPRAISAL.
000161 01-03

STORY

LONG-ACTING NEUROLEPTICS -- A FAIRY STORY?
000B99 01-14

STP

EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
0012B2 02-03

STRAIN

STRAIN DEPENDENT DIFFERENCES IN RESPONSES TO CHRONIC ADMINISTRATION OF MORPHINE: LACK OF RELATIONSHIP TO BRAIN CATECHOLAMINE LEVELS IN
002345 03-03

RAT STRAIN DIFFERENCES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND IN THE EFFECTS OF DIAZEPAM.
0024B8 03-04

STRAINS

SELECTION OF C3 ALCOHOLS BY HIGH AND LOW ETHANOL SELECTING MOUSE STRAINS AND THE EFFECTS ON OPEN-FIELD ACTIVITY.
000237 01-03

EFFECTS OF NICOTINE ON DISCRIMINATION LEARNING, CONSOLIDATION AND LEARNED BEHAVIOUR IN TWO INBRED STRAINS OF MICE.
000297 01-04

GAMMA-AMINOBUTYRIC-ACID IN DIFFERENT STRAINS OF MICE. EFFECT OF ETHANOL.
001166 02-03

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-04

DIFFERENTIAL EFFECTS OF MORPHINE ON TWO-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
001575 02-04

BEHAVIORAL ACTIVITY AND ACCUMULATION OF CYCLIC-AMP IN BRAIN SLICES OF STRAINS OF MICE.
001591 02-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND LYSERGIC-ACID-DIETHYLAMIDE IN TWO STRAINS OF RATS HAVING DIFFERENT BEHAVIORAL BASELINES.
001599 02-04

EFFECTS OF ACUTE MORPHINE ADMINISTRATION ON THE CATECHOLAMINE METABOLISM OF THREE STRAINS OF MICE.
0022B0 03-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO STRAINS OF MICE.
002312 03-03

NIGROSTRIATAL EFFECTS OF MORPHINE IN TWO MOUSE STRAINS.
002426 03-04

DIFFERENCES IN CYTOCHROME-P-450 OF VARIOUS STRAINS OF RATS FOLLOWING CHRONIC ADMINISTRATION OF PENTOBARBITAL.
002563 03-05

EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04

BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04

RELATIONSHIP BETWEEN MORPHINE SELF-ADMINISTRATION AND THE EFFECT OF MORPHINE ACROSS STRAINS OF MICE.
003482 04-04

STRATEGIES

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

STRAUB

EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03

STREPTOPELIA-RISORIA

EXPERIENTIAL AND HORMONAL CONDITIONS AFFECT SQUAB-EGG CHOICE IN RING DOVES (STREPTOPELIA-RISORIA).
000389 01-04

STRESS

STUDY OF THE PROTECTIVE EFFECT OF VITAMIN-A ON STRESS ULCER IN THE RAT.
000223 01-03

BEHAVIOR AND DRUG EFFECTS DURING CHRONIC STRESS.
000282 01-04

NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04

EFFECT OF NEW BETA-ADRENERGIC RECEPTOR BLOCKING AGENT (BUNITROLOL) ON CIRCULATION AND METABOLISM UNDER CONDITIONS OF EXTREME STRESS.
000B33 01-13

SEX AND ESTROGENS IN PROTECTION AGAINST CIRCULATORY STRESS REACTIONS.
001123 02-03

PSYCHOLOGICAL STRESS AS A CAUSE OF LITHIUM PROPHYLAXIS FAILURE, A REPORT OF THREE CASES.
001732 02-09

INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTION
001977 02-14

INTERACTIONS OF MARIJUANA AND INDUCED STRESS: FOREARM BLOOD FLOW, HEART-RATE, AND SKIN CONDUCTANCE.
0019B2 02-14

THE MECHANISM OF THE EFFECT OF ACUTE STRESS ON HEXOBARBITAL METABOLISM.
002221 03-03

CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
002398 03-03

INFLUENCE OF STRESS AND PHENOBARBITAL ON CORTICOSTERONE METABOLISM DURING EARLY POSTNATAL LIFE OF RAT.
003135 04-03

EFFECT OF ACUTE STRESS AND OUABAIN ADMINISTRATION ON ADRENAL CATECHOLAMINE CONTENT AND CARDIAC FUNCTION OF RATS PRETREATED WITH DIAZEPAM.
003151 04-03

PLASMA CORTICOSTERONE AND BRAIN CATECHOLAMINES IN STRESS: EFFECT OF PSYCHOTROPIC DRUGS.
003194 04-03

ENVIRONMENTAL STRESS AS A FACTOR IN THE RESPONSE OF RAT BRAIN CATECHOLAMINE METABOLISM TO DELTAB-TETRAHYDROCANNABINOL.
003423 04-04

STUDIES OF THE INTERACTION OF PSYCHOLOGICAL AND PHARMACOLOGICAL DETERMINANTS OF SMOKING: 5. PSYCHOLOGICAL AND PHARMACOLOGICAL EXPLANATIONS OF SMOKING UNDER STRESS.
003703 04-13

STRESS-DEPENDENT

THE STRESS-DEPENDENT NATURE OF APOMORPHINE HYPERTHERMIA.
0013B1 02-03

STRESS-INDUCED

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10

THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 04-03

STRESSED

INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
000130 01-03

EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
000338 01-04

INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04

STRIATA

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL
001363 02-03

STRIATAL

STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT: EFFECTS OF HALOPERIDOL AND APOMORPHINE.
000035 01-03

ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN.
000256 01-03

THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES.
000257 01-03

THE EFFECTS OF CHLOROMETHYLPIPERAZINYLDIBENZOXAZEPINE (LOXAPINE) AND ITS DERIVATIVES ON THE DOPAMINE-SENSITIVE ADENYLATE-CYCLASE OF RAT STRIATAL HOMOGENATES.
001106 02-02

CHARACTERISTICS OF DOPAMINE AND BETA-ADRENERGIC SENSITIVE ADENYLATE-CYCLASES IN THE FRONTAL CEREBRAL CORTEX OF THE RAT. COMPARATIVE EFFECTS OF NEUROLEPTICS ON FRONTAL CORTEX AND STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASES.
001151 02-03

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY METHADONE IN RATS.
001257 02-03

INCREASE IN STRIATAL ACETYLCHOLINE BY PICROTOXIN IN THE RAT: EVIDENCE FOR A GABERGIC DOPAMINERGIC CHOLINERGIC LINK.
001269 02-03

EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03

CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03

EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION.
001365 02-03

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS.
001602 02-04

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE.
00223B 03-03

EFFECTS OF AMINOOXYACETIC-ACID AND BACLOFEN ON THE CATALEPSY AND ON THE INCREASE OF MESOLIMBIC AND STRIATAL DOPAMINE TURNOVER INDUCED BY HALOPERIDOL IN RATS.
002270 03-03

BETA-ENDORPHIN IN VITRO INHIBITION OF STRIATAL DOPAMINE RELEASE
00229B 03-03

INTERACTION OF BENZODIAZEPINE DRUGS WITH STRIATAL DOPAMINERGIC NEURONS IN THE BRAIN.
002320 03-03

THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN.
002436 03-04

SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS. EFFECTS ON STRIATAL DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L-TRYPTOPHAN OR L-DOPA.
002461 03-04

REGULATION OF CYCLIC-GMP IN CEREBELLUM BY A STRIATAL DOPAMINERGIC MECHANISM.
003097 04-03

EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS
003122 04-03

IN VITRO EFFECTS OF OPIATES ON CYCLIC-AMP IN RAT STRIATAL TISSUE
003169 04-03

TOLERANCE TO THE INCREASE OF STRIATAL HOMOVANILLIC-ACID ELICITED BY SEVERAL ANORECTIC DRUGS.
0031B6 D4-03

EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
DD31B7 04-D3

EFFECTS OF GABERGIC DRUGS ON THE CATALEPSY, STRIATAL HOMOVANILLIC-ACID INCREASE AND ANTINOCICEPTION CAUSED BY PILOCARPINE IN RATS.
003189 04-03

EFFECTS OF LSD AND 2-BROMOLSD ON STRIATAL DOPAC LEVELS.
003238 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS.
003239 04-03

INCREASE OF STRIATAL DOPAMINE TURNOVER BY DRUGS. INTERFERENCE WITH GRANULAR STORAGE OR RECEPTOR BLOCKADE
003264 04-03

STRIATECTOMY

EFFECT OF STRIATECTOMY ON THE COURSE OF PENTYLENETETRAZOL CONVULSIONS IN THE RAT.
001131 02-03

STRIATUM

DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL CORTEX AND STRIATUM OF THE RAT.
000172 01-03

EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
D00177 01-03

INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES
000213 01-03

ROLE OF STRIATUM IN THE EFFECT OF SEROTONERGIC AGENTS ON CORAZOL CONVULSIONS IN RATS.
0D1132 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS
001150 02-03

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT. NEUROCHEMICAL RESULTS.
D01159 02-03

EFFECTS OF FENTANYL AND DROPERIDOL ON THE DOPAMINE METABOLISM OF THE RAT STRIATUM.
001210 02-03

CORRELATION BETWEEN CATALEPSY AND DOPAMINE DECREASE IN THE RAT STRIATUM INDUCED BY NEUROLEPTICS.
001241 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

INFLUENCE OF ANTICHOLINERGICS AND CLOZAPINE ON THE HALOPERIDOL-INDUCED ACTIVATION OF THE DOPAMINERGIC SYSTEM IN THE STRIATUM OF THE RAT. PHARMACOLOGIC RESULTS.
001576 02-04

FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE
002223 03-03

EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCED FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM
002393 D3-03

ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 D3-04

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE. A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM
002521 03-04

BINDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM PARTIAL INHIBITION BY MORPHINE OR NALOXONE
D030B9 04-03

IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM ABOUT THE EFFECTS OF MORPHINE ON UPTAKE AND RELEASE OF C14-DOPAMINE
D03104 04-03

EFFECT OF APOMORPHINE ON DOPAMINE TURNOVER AND ADENOSINE 3,5 MONOPHOSPHATE CONTENT IN STRIATUM OF MORPHINE DEPENDENT RATS.
003244 04-03

DOPAMINE LEVELS IN THE STRIATUM AND THE EFFECT OF ALCOHOL AND RESERPINE.
00331B D4-D3

AMPHETAMINE HALOPERIDOL INTERACTIONS IN RAT STRIATUM-FAILURE TO CORRELATE BEHAVIORAL EFFECTS WITH DOPAMINERGIC AND CHOLINERGIC DYNAMICS.
DD3BBD D4 17

STRIOPALLIDAR
FUNCTIONAL SIGNIFICANCE OF THE ALPHA AND BETA ADRENORECEPTORS IN THE STRUCTURES OF THE STRIOPALLIDAR SYSTEM.
002299 03-03

STROKE
HEAT STROKE ASSOCIATED WITH MEDICATIONS HAVING ANTICHOLINERGIC EFFECTS.
003759 04-15

STRUCTURAL
EFFECT OF STRUCTURAL ANALOGS OF BUTACLAMOL (A NEW ANTIPSYCHOTIC DRUG) ON STRIATAL HOMOVANILLIC-ACID AND ADENYL-CYCLASE OF OLFACTORY TUBERCLE IN RATS.
001335 02-03
STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
002341 03-03
THE INHIBITION OF MOUSE BRAIN GLUTAMATE-DECARBOXYLASE BY SOME STRUCTURAL ANALOGUES OF L-GLUTAMIC ACID.
003074 04-02

STRUCTURALLY
VILOXAZIN (VIVALAN-ICI) -- A STRUCTURALLY NEW ANTIDEPRESSANT.
002678 03-09

STRUCTURE
PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11
CHEMICAL AND PHARMACODYNAMIC STUDY OF BETA-AMINOKETONES OF BENZOXAZOLINONIC STRUCTURE.
001103 02-02
PERIODIC STRUCTURE OF PHYSIOLOGICAL AND PATHOLOGICAL TREMOR.
002089 02-16
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002860 03-14
THE SUBUNIT STRUCTURE OF BOVINE BRAIN PROTEIN-14-3-2.
003060 04-01
ON THE MOLECULAR STRUCTURE OF THE OPIATE RECEPTOR.
003281 04-03
POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS AND STRUCTURE OF NEW BUTYROPHENONES WITH A DIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
003848 04-17

STRUCTURE-ACTIVITY
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01
STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. INTRODUCTION TO PARTS X-XII, AND PART X. ACRIDONE DERIVATIVES.
000017 01-01
STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XI. LENGTHENING OF THE BASIC CHAIN
000018 01-01
STRUCTURE-ACTIVITY CORRELATIONS FOR CENTRAL DEPRESSANT ACYLUREAS AND ALKYLUREAS.
000178 01-03
STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES. PART XII. SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03
STRUCTURE-ACTIVITY RELATIONSHIPS OF ENKEPHALINS IN THE STIMULATED GUINEA-PIG ILEUM.
001180 02-03
STRUCTURE ACTIVITY RELATIONSHIPS OF METHIONINE-ENKEPHALIN
002317 03-03
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-DIBENZOTHIEPINS, ATAXIA IN MICE.
002577 03-05
STEREOSPECIFICITY AND STRUCTURE ACTIVITY REQUIREMENTS OF GABA RECEPTOR BINDING IN RAT BRAIN
003134 04-03
STRUCTURE ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN
003255 04-03

STRUCTURED
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION
000484 01-07

STRUCTURES
EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE
000465 01-05
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
EFFECTS OF ACTIVATION OF H1-RECEPTORS AND H2 RECEPTORS ON CENTRAL CARDIOVASCULAR STRUCTURES IN CATS AND ON BEHAVIOUR IN CHICKENS.
001469 02-04
FUNCTIONAL SIGNIFICANCE OF THE ALPHA AND BETA ADRENORECEPTORS IN THE STRUCTURES OF THE STRIOPALLIDAR SYSTEM.
002299 03-03
EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN.
002306 03-03
AFFECTIVE COGNITIVE STRUCTURES AND PSYCHOSES: NEW PERSPECTIVES OF THE STUDY OF THE HALLUCINATORY EXPERIENCE USING PSYCHODYSLEPTICS.
002796 03-12
THE EFFECT OF APOMORPHINE AND HALOPERIDOL ON THE RNA CONTENT OF BRAIN STRUCTURES OF THE RAT.
003181 04-03

STRYCHNINE
ACTION OF ANTIDEPRESSANTS ON CONVULSIVE EFFECT OF CORAZOL AND STRYCHNINE.
002220 03-03
INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX.
003131 04-03
SUSCEPTIBILITY OF A REACTIVATED MEMORY TO THE EFFECTS OF STRYCHNINE: A TIME-DEPENDENT PHENOMENON.
003393 04-04

STUDENTS
ON THE TREATMENT OF MENTALLY DISTURBED COLLEGE STUDENTS.
001047 01-17
ADVERSE REACTIONS TO MARIHUANA USE AMONG COLLEGE STUDENTS.
002896 03-15

STUDYING
A METHOD FOR STUDYING PUPILLOMOTOR EFFECTS OF NEUROLEPTICS.
000556 01-08
MINIREVIEW: AN ANIMAL BEHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
001253 02-03
AN ANIMAL BEHAVIOR MODEL FOR STUDYING THE ACTIONS OF LSD AND RELATED HALLUCINOGENS.
001517 02-04
NOMIFENSINE AND ITS DERIVATIVES AS POSSIBLE TOOLS FOR STUDYING AMINE UPTAKE.
003305 04-03
A QUANTITATIVE ROTATIONAL MODEL FOR STUDYING SEROTONERGIC FUNCTION IN THE RAT.
003407 04-04

STUPOR
EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR
003282 04-03

STURGEON
BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI.
002394 03-03

STUTTERERS
ACTION OF PSYCHOLEPTICS ON SOME PHYSIOLOGICAL INDICES IN STUTTERERS.
001958 02-14

SU-23397
THE ABSOLUTE CONFIGURATION OF SU-23397: A NOVEL NEUROLEPTIC AGENT
003049 04-01

SUBACUTE
TOXICITY OF TRICHLOROBUTADIENE IN SUBACUTE EXPERIMENTS
002568 03-05
SUBACUTE IMIPRAMINE: CHANGES IN SINGLE-DOSE PHARMACOKINETICS IN RATS
003092 04-03

SUBARACHNOID
INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

SUBCELLULAR
THE SUBCELLULAR DISTRIBUTION OF 14C-GABA AND 3H-DOPAMINE IN THE RETINA.
001130 D2-D3
IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
001255 02-D3
REGIONAL AND SUBCELLULAR DISTRIBUTIONS OF BRAIN NEUROTENSIN.
0D14D6 D2-03
IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

SUBCHRONIC
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07

SUBCORTICAL
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY.
D03242 04-D3

SUBCUTANEOUS
DURATION OF ACTION OF NALOXONE SUBCUTANEOUS PELLETS IN ANTAGONIZING THE EEG AND OPERANT BEHAVIOURAL EFFECTS OF MORPHINE IN THE RAT.
0D2559 03-D4

SUBFORNICAL
EFFECTS OF SUBFORNICAL ORGAN EXTRACTS ON SALT-WATER BALANCE IN THE RAT.
001115 02-02

SUBGROUP
A POSSIBLE SUBGROUP OF THE SCHIZOPHRENIC SYNDROME AND IMPLICATIONS FOR TREATMENT.
000533 01-08

SUBJECT
THE EFFECT OF PSYCHOTROPIC DRUGS ON THE NORMAL SUBJECT AND THEIR IMPORTANCE FOR THE PREDICTION OF CLINICAL EFFECTS.
0D2B64 03-14
SUICIDE ATTEMPT IN A SUBJECT TREATED WITH IDRACILAMIDE.
0D2924 03-15

SUBJECTED
STRUCTURAL CHANGES IN CAUDATE NUCLEUS IN THE PROGENY OF RATS SUBJECTED TO THE ACTION OF CHLORPROMAZINE.
0D2341 D3-03

SUBJECTIVE
SUBJECTIVE AND PHYSIOLOGIC EFFECTS OF MORPHINE, PENTOBARBITAL, AND MEPROBAMATE.
D00761 D1-11
SENSORY, PERCEPTUAL, MOTOR AND COGNITIVE FUNCTIONING AND SUBJECTIVE REPORTS FOLLOWING ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
000796 01-12
CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF INTRAVENOUS COCAINE ADMINISTRATION IN HUMANS.
000890 01-14
COCAINE CUE IN RATS AS IT RELATES TO SUBJECTIVE DRUG EFFECTS: A PRELIMINARY REPORT.
0D1462 02-04
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07
A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
D01868 02-12
PSYCHOTROPIC DRUGS AND THE QUALITY OF SLEEP: QUANTITATIVE NEUROPHYSIOLOGICAL AND SUBJECTIVE PARAMETERS.
DD1991 02-14
MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14
THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS.
0020D6 02-14
TETRAHYDROCANNABINOL (THC): METABOLISM AND SUBJECTIVE EFFECTS.
002B3B 03-13

SUBJECTS
SINGLE-DOSE STUDIES WITH CLOMIPRAMINE IN NORMAL SUBJECTS.
DD0135 D1-03
ASTHE-CRINOL-12 IN THE ASTHENIA SYNDROME OF AGED SUBJECTS.
000497 01-07
CRITICAL FLICKER FREQUENCY (CFF) AND PSYCHOTROPIC DRUGS IN NORMAL HUMAN SUBJECTS -- A REVIEW.
0D0518 01-07
ACTIVE EFFLUX OF LITHIUM FROM ERYTHROCYTES OF MANIC-DEPRESSIVE SUBJECTS.
000634 01-09
THE EFFECTS OF D-AMPHETAMINE ON READING BY NORMAL ADULT HUMAN SUBJECTS UNDER RATIO AND INTERVAL REINFORCEMENT SCHEDULES. (PH.D. DISSERTATION).
000903 01-14
SERUM CONCENTRATIONS OF TRIIMIPRAMINE IN HEALTHY SUBJECTS.
000918 01-14
GREAT APES AND RHESUS-MONKEYS AS SUBJECTS FOR PSYCHOPHARMACOLOGICAL STUDIES OF STIMULANTS AND DEPRESSANTS.
0D1561 02-04
AN ELECTROPHYSIOLOGICAL STUDY ON THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZOPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
001684 02-08
PHYSOSTIGMINE: EFFECTS ON COGNITION AND AFFECT IN NORMAL SUBJECTS.
001965 02-14
COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14
THE EFFECTS OF CHLORDESMETHYLDIAZEPAM ON BEHAVIORAL PERFORMANCE AND SUBJECTIVE JUDGMENT IN NORMAL SUBJECTS.
002006 D2-14
FREE AND QUESTIONNAIRE CONTROLLED DESCRIPTION OF THE EFFECT OF A HYPNOTIC (FLURAZEPAM) BY HEALTHY SUBJECTS.
002093 02-16
FLUPHENAZINE-DECANOATE IN CHRONIC PSYCHOTIC SUBJECTS.
002610 03-08
REDUCED GROWTH HORMONE RESPONSES TO AMPHETAMINE IN ENDOGENOUS DEPRESSIVE PATIENTS: STUDIES IN NORMAL, REACTIVE AND ENDOGENOUS DEPRESSIVE, SCHIZOPHRENIC, AND CHRONIC ALCOHOLIC SUBJECTS.
002821 03-13
AUTOMATED ANALYSIS OF EEG PATTERNS IN SUBJECTS UNDER ABUSIVE LEVELS OF SEDATIVE HYPNOTICS. (PH.D. DISSERTATION).
002868 03-14
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
D02922 D3-15
THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE: STUDIES IN TETRAPLEGIC SUBJECTS.
003701 04-13
HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES OF DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 04-14
LITHIUM-CARBONATE AND ETHANOL-INDUCED HIGHS IN NORMAL SUBJECTS.
003734 04-14
THE EFFECT OF LITHIUM-CARBONATE ON AFFECT, MOOD, AND PERSONALITY OF NORMAL SUBJECTS.
003735 04-14
THE EFFECT OF LITHIUM-CARBONATE ON THE COGNITIVE FUNCTIONS OF NORMAL SUBJECTS.
003736 04-14

SUBSEQUENT
THE EFFECTS OF PREEXPOSURE TO SCOPOLAMINE ON SUBSEQUENT DRUG STATE DISCRIMINATION
000906 01-14
SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY. (PH.D. DISSERTATION).
002272 03-03

SUBSTANCE
VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-03
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON MENTAL PERFORMANCES (PACEMAKER PATIENTS).
000BB5 01-14
THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN
000BB7 01-14
STUDY OF THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON CARDIAC AND CEREBRAL METABOLISM.
000919 01-14

SUBSTANCE-P
IS CHLOROPHENYL-GABA A SPECIFIC ANTAGONIST OF SUBSTANCE-P ON CEREBRAL CORTICAL NEURONS?.
001330 02-03

INHIBITION OF MORPHINE EFFECTS BY SYNTHETIC SUBSTANCE-P
001594 02-04

SUBSTANTIA-GELATINOSA
MORPHINE, ENKEPHALIN, AND THE SUBSTANTIA-GELATINOSA
001617 02-05

SUBSTANTIA-NIGRA
THE EFFECT OF ACUTE AND CHRONIC INJECTIONS OF D-AMPHETAMINE-SULFATE AND SUBSTANTIA-NIGRA LESIONS ON THE DISTRIBUTION OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN THE RAT BRAIN
000086 01-03
THE EFFECTS OF D-AMPHETAMINE VERSUS L-AMPHETAMINE, FOOD DEPRIVATION, AND CURRENT INTENSITY ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND MEDIAL FRONTAL CORTEX OF THE RAT. (PH.D. DISSERTATION).
000336 01-04
EVIDENCE FOR THE EXISTENCE OF A RAPHE PROJECTION TO THIS SUBSTANTIA-NIGRA IN RAT.
0011B9 02-03
NONSELECTIVE ENHANCEMENT OF LOCUS-COERULEUS AND SUBSTANTIA-NIGRA SELF-STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03
AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA.
001233 02-03
TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03
RETENTION DISRUPTION FOLLOWING POSTTRIAL PICROTOXIN INJECTION INTO THE SUBSTANTIA-NIGRA.
001262 02-03
INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
00126B 02-03
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03
A DOPAMINE-STIMULATED ADENYLATE-CYCLASE IN RAT SUBSTANTIA-NIGRA.
0013B2 02-03
COMPARISON OF EFFECTS OF DRUGS ON DOPAMINE METABOLISM IN THE SUBSTANTIA-NIGRA AND THE CORPUS-STRIATUM OF RAT BRAIN.
001419 02-03
THE BEHAVIOURAL EFFECTS OF EOS-INDUCED CHANGES IN SUBSTANTIA-NIGRA GABA LEVELS.
00152B 02-04
SYNAPTIC MECHANISMS IN THE SUBSTANTIA-NIGRA.
002113 02-17
AMPHETAMINE-INDUCED RELEASE OF DOPAMINE FROM THE SUBSTANTIA-NIGRA IN VITRO.
00232B 03-03
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03
EFFECTS OF PENFLURIDOL ON DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF RATS.
002359 03-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND C-AMP PHOSPHODIESTERASE IN SUBSTANTIA-NIGRA AND CORPUS-STRIATUM OF RAT BRAIN.
0023B5 03-03
CHOLINERGIC DOPAMINERGIC INTERACTIONS AT THE LEVEL OF SUBSTANTIA-NIGRA IN THE RABBIT.
002557 03-04
ACTIVATION OF THE NIGROSTRIATAL DOPAMINERGIC PATHWAY BY INJECTION OF CHOLERA ENTEROTOXIN INTO THE SUBSTANTIA-NIGRA.
003516 04-06

SUBSTITUTE
THE USE OF FLURAZEPAM (DALMANE) AS A SUBSTITUTE FOR BARBITURATES AND METHAQUALONE/DIPHENHYDRAMINE (MANDRAX) IN GENERAL PRACTICE.
001675 02-07

SUBSTITUTED
ANTICONVULSANT ACTIVITY AND INHIBITION OF CELLULAR RESPIRATORY ACTIVITY BY SUBSTITUTED IMIDAZOLOCARBAMIDES.
000072 01-03
SUBSTITUTED BENZAMIDES AS DOPAMINE ANTAGONISTS.
000094 01-03
NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY.
002196 03-02
SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIOIMIDAZOLINES
003067 04-02

SUBSTITUTION
ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-15
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17
A POTENT ANTINOCICEPTIVE CANNABINOID WHICH LACKS OPIATE SUBSTITUTION PROPERTIES IN MONKEYS.
003426 04-04

SUBSTITUTIONS
INFLUENCE ON PSYCHOLEPTIC EFFECTS OF DIFFERENT TYPES OF SUBSTITUTIONS IN A SERIES OF CRESOTINIC AMIDES.
000151 01-03

SUBSTRAINS
DEVELOPMENT OF RAT SUBSTRAINS FOR STUDIES ON THE CONTROL OF DRUG METABOLISM.
003212 04-03

SUBSTRATE
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG DESMETHYL DERIVATIVES OF NEUROLEPTICS AND ANTIDEPRESSANTS FOR SUBSTRATE SPECIFICITY TO INDOLETHYLAMINE N-METHYLTRANSFERASE FROM RABBIT LUNG.
000014 01-01
EVIDENCE FOR INVOLVEMENT OF A DOPAMINERGIC SUBSTRATE IN SELF-STIMULATION AND INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION.
000262 01-03
MODERN VIEWS ON THE PATHOPHYSIOLOGICAL SUBSTRATE OF INVOLUNTARY MOVEMENTS IN HUNTINGTONS CHOREA.
000754 01-11
5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
0012B9 02-03

SUBSTRATES
BIOLOGICAL SUBSTRATES OF MENTAL ILLNESS.
002130 02-17
THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA.
003543 04-08

SUBTYPES
INTRAVENOUS CHLORIMIPRAMINE AND DEPRESSIVE SUBTYPES.
000600 01-09
LITHIUM-CARBONATE PROPHYLAXIS OF DEPRESSION IN THREE SUBTYPES OF PRIMARY AFFECTIVE DISORDER.
000601 01-09
TARDIVE-DYSKINESIA: ARE THERE SUBTYPES?.
001B94 02-13
CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11
DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE TO TREATMENT.
003669 04-13

SUBUNIT
THE SUBUNIT STRUCTURE OF BOVINE BRAIN PROTEIN-14-3-2.
003060 04-01

SUCCESSIVE
DRUG EFFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS.
000110 01-03
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE ON SIMULTANEOUS AND SUCCESSIVE BRIGHTNESS DISCRIMINATION LEARNING IN RATS.
000351 01-04
EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) ON SUCCESSIVE SENSORY DISCRIMINATION BEHAVIOR MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN REINFORCEMENT IN THE RAT.
000444 01-04

SUCCINATE
LOXAPINE SUCCINATE: A COMPARATIVE STUDY WITH CHLORPROMAZINE.
000541 01-08
LOXAPINE SUCCINATE: A DOUBLE-BLIND COMPARISON WITH HALOPERIDOL AND PLACEBO IN ACUTE SCHIZOPHRENICS.
000567 01-08
EVALUATION OF LOXAPINE SUCCINATE AS AN ANXIOLYTIC IN COMPARISON WITH CHLORDIAZEPOXIDE.
000694 01-10
LOXAPINE SUCCINATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
00264B 03-08
EVALUATION OF TWO DOSE LEVELS OF LOXAPINE SUCCINATE IN CHRONIC SCHIZOPHRENIA.
003530 04-08

SUCROSE
COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS.
000426 01-04

SUDDEN
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15
SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
003509 04-05
PHENOTHIAZINE-INDUCED BULBAR PALSY-LIKE SYNDROME AND SUDDEN DEATH.
003828 04-15
CARDIAC SIDE-EFFECTS AND SUDDEN DEATH IN HOSPITALIZED PSYCHIATRIC PATIENTS.
003830 04-15

SUGGESTIBILITY
EFFECTS OF MARIJUANA, EXPECTATION AND SUGGESTIBILITY ON COGNITIVE FUNCTIONING.
001963 02-14

SUGGESTING
EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03
BEHAVIOURAL CHANGES IN RATS SUGGESTING DRUG-INDUCED HEADACHE.
001579 02-04

SUGGESTIONS
SUGGESTIONS FOR A RATIONAL APPROACH TO THE CHEMOTHERAPY OF SCHIZOPHRENIA.
001725 02-08

SUICIDE
THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09
MEANS AND METHODS USED IN SUICIDE ATTEMPTS
001018 01-17
SUICIDE WITH TRICYCLIC ANTIDEPRESSANTS.
001019 01-17
ATTEMPTED SUICIDE IN LABOUR.
002065 02-15
A CASE OF SUICIDE WITH NITRAZEPAM AND ALCOHOL.
002079 02-15
DRUG THERAPY IN DEPRESSIVE STATES: FACTORS IN SUICIDE PREVENTION.
002690 03-09
SUICIDE ATTEMPT IN A SUBJECT TREATED WITH IDRACILAMIDE.
002924 03-15

SUICIDES
LOWERED MONOAMINE-OXIDASE IN CONNECTION WITH ALCOHOLIC SUICIDES.
000823 01-13
REGIONAL SEROTONIN LEVELS IN BRAIN: A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS.
000883 01-14

SULFATE
CENTRAL NORADRENERGIC ACTIVITY AND THE FORMATION OF GLYCOL SULFATE METABOLITES OF BRAIN NOREPINEPHRINE.
002377 03-03
INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04
SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTERACTION WITH AMPHETAMINE SULFATE.
003688 04-13

SULFHYDRYL
THE REACTION OF SULFHYDRYL REAGENTS WITH BOVINE HEPATIC MONOAMINE-OXIDASE: EVIDENCE FOR THE PRESENCE OF TWO CYSTEINE RESIDUES ESSENTIAL FOR ACTIVITY.
001222 02-03

SULFOBROMOPHTHALEIN
EFFECT OF PREEXPOSURE TO KEPONE ON THE BILIARY EXCRETION OF IMIPRAMINE AND SULFOBROMOPHTHALEIN
003218 04-03

SULFONE
ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

SULFOXIDE
ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

SULFOXIDES
EFFECTS OF LEVOMEPROMAZINE, CHLORPROMAZINE AND THEIR SULFOXIDES ON ISOLATED RAT ATRIA.
000084 01-03

SULFUR
SULFUR ANALOGS OF PSYCHOTOMIMETIC AMINES.
002186 03-01

SULPHATE
MODIFICATION BY ESTROGEN OF THE EFFECTS OF D-AMPHETAMINE SULPHATE ON NORADRENALINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN.
001203 02-03
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13
COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

SULPHONES
NEUROTOXICITY ASSOCIATED WITH SULPHONES.
000991 01-15

SULPHOXIDE
A NOTE ON THE ASSAY OF CHLORPROMAZINE-N-OXIDE AND ITS SULPHOXIDE IN PLASMA AND URINE.
000811 01-13

SULPIRIDE
EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT.
000238 01-03
EFFECTS OF THE ADMINISTRATION OF TWO DOSES OF SULPIRIDE ON THE BEHAVIOUR OF THE RAT.
000414 01-04
THERAPEUTICAL EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
000488 01-07
THE BENZAMIDES IN PSYCHOPHARMACOLOGY: SULPIRIDE AND SULTOPRIDE.
000520 01-07
STUDY ON THE EFFECTS OF SULPIRIDE AND PERPHENAZINE IN 82 SCHIZOPHRENICS USING THE DOUBLE-BLIND METHOD.
000531 01-08
A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SULPIRIDE AND OXAZOLAM IN THE FIELD OF PSYCHOSOMATIC MEDICINE.
000713 01-10
EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
000728 01-11
ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000805 01-13
RESEARCH ON THE USE OF SULPIRIDE IN PSYCHOSOMATIC MEDICINE: A STUDY OF 104 CASES.
000816 01-13
PSYCHOSOMATOSIS WITH COMMON CARDIAC LOCALIZATION-EXPERIENCES WITH SULPIRIDE IN INTERNAL MEDICINE.
000852 01-13
ACUTE AND CHRONIC EFFECT OF CARPIPRAMINE, CLOZAPINE, HALOPERIDOL, AND SULPIRIDE ON METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
001410 02-03
OBSERVATIONS OF THE INTRAVENOUS ADMINISTRATION OF SULPIRIDE (DOBREN).
001768 02-09
A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14
EFFECT OF CHLORPROMAZINE OR SULPIRIDE AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
001995 02-14
AN AUTOMATED DIAGNOSTIC PROCESS (PDA) IN CLINICAL PSYCHOPHARMACOLOGY: AN EXEMPLIFICATION OF ITS USE IN A SULPIRIDE VERSUS HALOPERIDOL COMPARATIVE TRIAL
002106 02-17
SULPIRIDE IN WITHDRAWAL OF NONALCOHOLIC DRUG ADDICTS
002593 03-07
A DOUBLE-BLIND COMPARISON OF SULPIRIDE WITH CHLORDIAZEPOXIDE IN NEUROSIS.
002732 03-10
SULPIRIDE AND PSYCHIC DECOMPENSATION
003023 03-17

SULTOPRIDE
CLINICAL STUDY OF LIN-1418 (SULTOPRIDE).
000487 01-07

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC SULTOPRIDE
000504 01-07

CLINICAL TRIAL OF SULTOPRIDE.
000505 01-07

TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC: SULTOPRIDE
000510 01-07

THE BENZAMIDES IN PSYCHOPHARMACOLOGY SULPIRIDE AND SULTOPRIDE.
000520 01-07

CLINICAL TRIAL OF SULTOPRIDE.
001672 02-07

CONTRIBUTION TO THE CLINICAL STUDY OF A NEW NEUROLEPTIC: SULTOPRIDE.
001758 02-09

INDICATIONS FOR SULTOPRIDE, A MAJOR NEUROLEPTIC.
001874 02-12

FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION
002597 03-07

THE PLACE OF SULTOPRIDE AMONG NEUROLEPTIC CURES.
002603 03-07

UPERFUSION

LARGE POTASSIUM SIGNALS AND SLOW POTENTIALS EVOKED DURING AMINOPYRIDINE OR BARIUM SUPERFUSION IN CAT CEREBELLUM.
001306 02-03

UPERIOR

HAMSTER PINEAL NORADRENALINE: LEVELS OVER A REGULATED LIGHTING PERIOD AND THE INFLUENCE OF SUPERIOR CERVICAL GANGLIONECTOMY.
000176 01-03

SUPERIOR COLLICULUS LESIONS AND THE SUBSEQUENT EFFECT ON AMPHETAMINE AND METHYLPHENIDATE-INDUCED HYPERACTIVITY. (PH.D. DISSERTATION).
002272 03-03

UPERSENSITIVE

REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

UPERSENSITIVITY

ON THE SUPERSENSITIVITY OF DOPAMINE RECEPTORS, INDUCED BY NEUROLEPTICS.
000073 01-03

PREJUNCTIONAL AND POSTJUNCTIONAL SUPERSENSITIVITY: DIFFERENTIATION BY INTRAVENTRICULAR INFUSIONS OF NOREPINEPHRINE AND METHOXAMINE.
00041B 01-04

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS INDUCED BY HALOPERIDOL.
00043B 01-04

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
0015B3 02-04

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
00317B 04-03

NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL.
003261 04-03

SUPERSENSITIVITY TO APOMORPHINE FOLLOWING DESTRUCTION OF THE ASCENDING DOPAMINE NEURONES: QUANTIFICATION USING THE ROTATIONAL MODEL.
003425 04-04

CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS DISEASE
003446 04-04

UPERVENING

CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L DOPA
00094B 01-15

UPPORT

APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF STIMULATION RESPONDING
000081 01-03

MARIHUANA: NEW SUPPORT FOR IMMUNE AND REPRODUCTIVE HAZARDS.
000795 01-12

SUPPORTING

ANTIDEPRESSANTS AND PAIN A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
003BB3 04-17

SUPPORTS

MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03

SUPPRESSANT

BEHAVIORAL SUPPRESSANT EFFECTS OF CLONIDINE IN STRAINS OF NORMOTENSIVE AND HYPERTENSIVE RATS.
003471 04-04

SUPPRESSED

EFFECTS OF DRUGS ON SUPPRESSED RESPONDING.
001470 02-04

EFFECTS OF DIAZEPAM ON BEHAVIOUR SUPPRESSED BY EXTINCTION IN PIGS.
003370 04-04

SUPPRESSES

STIMULATION OF PONTINE RETICULAR FORMATION SUPPRESSES FIRING OF SEROTONERGIC NEURONES IN THE DORSAL RAPHE.
0025B0 03-05

SUPPRESSION

VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRESSION IN RATS.
000325 01-04

THE STIMULANT ACTION OF TRYPTOPHAN MONOAMINE-OXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATION.
000340 01-04

SUPPRESSION OF CRICKET-KILLING AND EATING IN LABORATORY MICE FOLLOWING LITHIUM-CHLORIDE INJECTIONS.
000368 01-04

SUPPRESSION OF THE CARDIAC CONDITIONED RESPONSE BY DELTA9-TETRAHYDROCANNABINOL: A COMPARISON WITH OTHER DRUGS.
000377 01-04

CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING D-AMPHETAMINE AS THE CONDITIONED STIMULUS.
000442 01-04

SUPPRESSION OF ETHANOL-INDUCED STIMULATION BY GABA-LIKE DRUGS.
001174 02-03

SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS.
0012B7 02-03

TREMOROGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE AND THEIR SUPPRESSION BY DOPAMINE.
00143B 02-04

CONDITIONED SUPPRESSION DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS.
0015B9 02-04

SUPPRESSION OF AMPHETAMINE-INDUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-03

ENHANCING EFFECTS INDUCED BY REPEATED ADMINISTRATIONS OF DIAZEPAM ON CONDITIONED SUPPRESSION IN RATS.
0024B9 03-04

POTENTIATION BY ALPHA-METHYLTYROSINE OF THE SUPPRESSION OF FOOD-REINFORCED LEVER-PRESSING BEHAVIOUR INDUCED BY ANTIPSYCHOTIC DRUGS.
003079 04-03

SUPPRESSION OF GABA-INDUCED ABSTINENCE BEHAVIOUR IN NAIVE RATS BY MORPHINE AND BICUCULLINE.
003123 04-03

SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
003330 04-03

A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
0033BB 04-04

EFFECTS OF OXAZOLAM, CLOXAZOLAM, AND CS-3B6, NEW ANTIANXIETY DRUGS, ON SOCIALLY INDUCED SUPPRESSION AND AGGRESSION IN PAIRS OF MONKEYS.
003410 04-04

SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05

SUPRAEPENDYMAL
EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF S,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
001629 02-05

SUPRANUCLEAR
TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003S24 04-07

SUPRASPINAL
TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
0013SS 02-03
TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
0034S6 04-04

SUREPTIL
1035-MD (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY.
001013 01 17

SURFACE
NEURAMINIDASE RELEASABLE SURFACE SIALIC-ACID OF CULTURED ASTROBLASTS EXPOSED TO ETHANOL.
001311 02-03

SURGERY
EFFECTS OF BRAIN SURGERY AND EEG OPERANT CONDITIONING ON SEIZURE LATENCY FOLLOWING MONOMETHYLHYDRAZINE INTOXICATION IN THE CAT.
001640 02-05
THE RELATION BETWEEN PAIN AND PERSONALITY IN PATIENTS RECEIVING PENTAZOCINE (FORTRAL) AFTER SURGERY
002087 02-16

SURGICAL
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
001862 02-11

SURMONTIL
SURMONTIL AND MUCO-CUTANEOUS PIGMENTATION.
00289B 03-15

SURROUNDING
ON DECISION MAKING SURROUNDING DRUG THERAPY- A CONTINUING DILEMMA.
003761 04-15

SURVEILLANCE
CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM
000976 01-1S

SURVEY
POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11
A SURVEY OF THE PHARMACOLOGICAL PROPERTIES OF METOPROLOL IN ANIMALS AND MAN
001011 01-17
SURVEY AND CLASSIFICATION OF PSYCHOPHARMACOLOGICAL DRUGS.
001036 01-17
A FIVE YEAR SURVEY OF PURCHASES OF ANTACIDS, ANTICHOLINERGIC AND PSYCHOTROPIC DRUGS.
003B49 04-17

SURVIVING
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

SUSCEPTIBILITY
SUSCEPTIBILITY OF MICE TO AUDIOGENIC SEIZURES IS INCREASED BY HANDLING THEIR DAMS DURING GESTATION
000286 01-04
PERIOD OE MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLDEN HAMSTER.
001616 02-0S
CATECHOLAMINERGIC INVOLVEMENT IN THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
0031S3 04-03
TOLERANCE AND CROSS TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
003389 04 04
SUSCEPTIBILITY OF A REACTIVATED MEMORY TO THE EFFECTS OF STRYCHNINE A TIME-DEPENDENT PHENOMENON.
003393 04 04
HYPNOTIC SUSCEPTIBILITY AND PERSONALITY: THE CONSEQUENCES OF DIAZEPAM AND THE SEX OF THE SUBJECTS.
003726 04-14

SUSPECTED
LSD TOXICITY: A SUSPECTED CAUSE OF DEATH.
003790 04-15

SUSTAINED
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03
SUSTAINED PRESSOR RESPONSIVENESS TO PROLONGED HYPOTHALAMIC STIMULATION IN AWAKE RATS.
001157 02-03
SUSTAINED INGESTION OF METHADONE AND THE SLEEP OF MONKEYS.
001586 02-04

SUSTAINED-RELEASE
CLINICAL TRIAL COMPARISON OF TWO SUSTAINED-RELEASE FORMS OF AMITRIPTYLINE.
003586 04-10
SUSTAINED-RELEASE APPLICATIONS OF MONTMORILLONITE INTERACTION WITH AMPHETAMINE SULFATE.
003688 04-13

SUSTAINING
DECREMENTAL SKIN CONDUCTANCE RESPONSE IN MICE, DURING ITERATIVE PHOTOSTIMULATION; AN ATTENTION SUSTAINING CAPACITY MODEL FOR PSYCHOPHARMACOLOGICAL RESEARCH.
001290 02-03

SWELLING
ON THE SWELLING OF THE DIAPHRAGM AMONG PATIENTS TAKING PSYCHOTROPIC DRUGS (SECOND REPORT).
002077 02-1S

SWIMMING
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

SWINGS
THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS.
003793 04-1S

SYDNOCARB
EXPERIENCE WITH THE USE OF SYDNOCARB, A NEW PSYCHOSTIMULANT.
002612 03-08

SYMBOL
DIGIT SYMBOL PERFORMANCE IN METHADONE TREATED EX-HEROIN ADDICTS.
0019S6 02-14

SYMMETRICAL
A NEUROBIOLOGICAL MODEL FOR THE SYMMETRICAL PROPHYLACTIC ACTION OF LITHIUM IN BIPOLAR AFFECTIVE DISORDER.
000632 01-09

SYMPATHETIC
STUDIES ON THE SITE OF ACTION OF CLONIDINE UTILIZING A SYMPATHETIC CHOLINERGIC SYSTEM.
000144 01-03
ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE. THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM
001149 02-03
TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA
00141S 02-03
POTENTIATION OF EFFECTS OF CATECHOLAMINES AND SYMPATHETIC STIMULATION BY TRIAZOLOBENZODIAZEPINE.
00224S 03-03
A STUDY OF THE EFFECT OF BENZODIAZEPINES ON CYCLIC NUCLEOTIDE METABOLISM AS RELATED TO NEURONAL ACTIVITY IN THE BULLFROG SYMPATHETIC GANGLION (PH.D. DISSERTATION).
002296 03-03
THE EFFECT OF PARASYMPATHETIC AND SYMPATHETIC INTERCEPTORS ON INSTRUMENTALLY CONDITIONED HEARTBEAT (WHITE RATS).
002406 03-03
THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03
STIMULUS BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION
003224 04-03
SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIDOPA, AN INHIBITOR OF PERIPHERAL DOPA-DECARBOXYLASE.
003330 04-03

SYMPATHICOMIMETIC
COMPARATIVE HEMODYNAMIC STUDIES IN MAN OF ADRENERGIC BETA1-RECEPTOR AGENTS WITHOUT (H-93-26 METAPROLOL) OR WITH (H-87-07) INTRINSIC SYMPATHICOMIMETIC ACTIVITY.
000866 01-13

YMPATHOMIMETIC

MODULATION OF CYCLOHEXIMIDE RESISTANT MEMORY BY SYMPATHOMIMETIC AGENTS.
000333 01-04

BIOCHEMICAL ACTIONS OF SYMPATHOMIMETIC DRUGS WHICH OVERCOME CYCLOHEXIMIDE-INDUCED AMNESIA
001254 02-03

SYMPATHOMIMETIC EFFECT OF SEROTONIN AND ACTION OF IMIPRAMINE AND PHTHORACIZINE ON THIS EFFECT
002203 03-03

THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH.D. DISSERTATION).
002257 03-03

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE, AND 5-HYDROXYTRYPTAMINE.
003247 04-03

PROLONGED DELTA9-TETRAHYDROCANNA8INOL INGESTION: EFFECTS OF SYMPATHOMIMETIC AMINES AND AUTONOMIC 8LOCKADES.
003767 04-15

MPTOM

DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-08

THE EFFECT OF SEQUENCE ON THE STABILITY OF THE HOPKINS SYMPTOM CHECKLIST (HSCL). (UNPU8LISHED PAPER).
002982 03-17

MPTOMATOLOGY

POSSI8ILITY OF USING 7-CHLORO-5-(2-CHLOROPHENYL) 1,3-DIHYDRO-2H-1,4 8ENZODIAZEPINE-2-ONE. IN CASES OF PSYCHOTIC SYMPTOMATOLOGY.
000508 01-07

UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15

PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-08

CATATONIA-LIKE SYMPTOMATOLOGY AND WITHDRAWAL DYSKINESIAS.
002043 02-15

THE EFFECT OF DIET ON ETHANOL WITHDRAWAL SYMPTOMATOLOGY.
003346 04-04

MPTOMS

THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03

A MORPHANTHRIDINE DERIVATIVE IN SCHIZOPHRENIC PATIENTS -- LACK OF EXTRAPYRAMIDAL SYMPTOMS.
000478 01-07

TREATMENT OF CERE8RAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
000786 01-11

EXTRAPYRAMIDAL SYMPTOMS WITH HIGH DOSE NEUROLEPTIC AGENTS. INCIDENCE AND MANAGEMENT.
000939 01-15

PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
000962 01-15

PHYSIOLOGICAL DEPENDENCE ON, AND SYMPTOMS OF WITHDRAWAL FROM, CHLORMETHIAZOLE.
000981 01-15

ANTICONVULSANT DRUGS AND MENTAL SYMPTOMS: A REVIEW.
000989 01-15

EXPERIMENTAL DATA SUGGESTING AN ADRENERGIC MECHANISM IN THE PRODUCTION OF PARKINSONIAN SYMPTOMS.
001374 02-03

AM8ULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CAR8AMAZEPINE: A FORMAL MULTICENTRE DOU8LE-BLIND COMPARISON WITH PLACE8O.
001818 02-11

CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS: A COMPARATIVE STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE.
001850 02-11

EFFECT OF S-ADENOSYL-L-METHIONINE (SAME) UPON DEPRESSIVE SYMPTOMS.
001953 02-14

POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS 8Y 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

PROPRANOLOL TO CONTROL SCHIZOPHRENIC SYMPTOMS.

PATIENTS.
55

SOMATIC AND PSYCHIC SYMPTOMS IN ANXIETY.
002663 03-08

ON THE THERAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
002722 03-10

THE ACTION OF TRICYCLICS (ALONE OR IN COM8INATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY.
002758 03-11

PSYCHOTIC SYMPTOMS RESULTING FROM STEROID USE - ESPECIALLY LIGHT CONSCIOUSNESS IMPAIRMENTS.
002782 03-11

TRANSIENT DEMENTIA SYMPTOMS CAUSED IN ONE CASE BY ETHOPROPAZINE.
002895 03-15

NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
002931 03-15

THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY.
002986 03-17

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACE8O ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
002996 03-17

THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003537 04-08

THE EVALUATION OF BELLERGAL TA8LETS COMPARED TO LI8RIUM AND PLACE8O IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003639 04-11

SYNAPSES

ACTION OF LSD ON RAPHE NEURONS AND EFFECT ON PRESUMED SEROTONERGIC RAPHE SYNAPSES.
003642 04-11

MINIREVIEW: AN ANIMAL 8EHAVIOR MODEL FOR STUDYING CENTRAL SEROTONERGIC SYNAPSES.
000080 01-03

SYNAPTIC

PHARMACOLOGICAL STUDIES ON THE STIMULATION OF THE PHOSPHOLIPASE A2-ACYLATION SYSTEM OF SYNAPTIC MEM8RANES OF 8RAIN, 8Y NEUROTRANSMITTERS AND OTHER AGONISTS.
001253 02-03

SYNAPTIC FACILITATION AND 8EHAVIORAL SENSITIZATION IN APLYSIA: POSSI8LE ROLE OF SEROTONIN AND CYCLIC-AMP.
000117 01-03

A SEROTONIN SENSITIVE ADENYLATE-CYCLASE IN MATURE RAT BRAIN SYNAPTIC MEMBRANES
001155 02-03

EFFECTS OF TWO BENZODIAZEPINES, PHENO8ARBITONE, AND 8ACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001320 02-03

8IOCHEMICAL PLASTICITY OF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001332 02-03

INFLUENCE OF SOME PRODUCTIVE TROPINES ON A8SORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001351 02-03

SYNAPTIC MECHANISMS IN THE SUBSTANTIA-NIGRA.
001426 02-03

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBAR8ITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002113 02-17

PENTOBARBITAL AND SYNAPTIC HIGH-AFFINITY RECEPTIVE SITES FOR GAMMA-AMINOBUTYRIC ACID.
002275 03-03

THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA + + UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
002333 03-03

STIMULUS-BOUND REPETITIVE SYNAPTIC FIRING CAUSED BY ETHANOL IN SYMPATHETIC GANGLION.
003136 04-03

THE EFFECTS OF SCOPOLAMINE ON SYNAPTIC RESPONSES IN THE INTACT AND THE DOPAMINE-DEPLETED CAUDATE NUCLEUS.
003224 04-03

SYNAPTOSOMAL

COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY. EFFECTS OF FENFLURAMINE.
003286 04-03

INTERACTION OF CENTRAL-NERVOUS-SYSTEM DRUGS WITH SYNAPTOSOMAL TRANSPORT PROCESSES.
000143 01-03

5-HT AND LSD HIGH AFFINITY 8INDING SITES TO BRAIN SYNAPTOSOMAL MEMBRANES.
001160 02-03

001201 02-03

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN
001265 02-03

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE, AND 5-HYDROXYTRYPTAMINE.
003247 04-03

THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION.
003293 04-03

SYNAPTOSOMES

STIMULATION OF TYROSINE HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01

CALCIUM DEPLETION OF SYNAPTOSOMES AFTER MORPHINE TREATMENT.
000070 01-03

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON NEUROTRANSMITTER ACCUMULATION AND RELEASE MECHANISMS IN RAT FOREBRAIN SYNAPTOSOMES.
000134 01-03

INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-03

EFFECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES
000199 01-03

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES
000202 01-03

COMPARATIVE STUDY OE THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN.
000263 01-03

EFFECTS OF FENFLURAMINE ON ACCUMULATION OF 5-HYDROXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN
001137 02-03

TRYPTOPHAN TRANSPORT IN BRAIN SYNAPTOSOMES: EFFECTS OF L-DOPA.
0011B5 02-03

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
001237 02-03

EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES.
001387 02-03

EFFECTS OF NEUROLEPTICS ON TYROSINE-HYDROXYLASE OF SYNAPTOSOMES OE THE RAT HYPOTHALAMUS.
002314 03-03

THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH D DISSERTATION).
002397 03-03

THE EFFECT OF DESIPRAMINE ON THE UPTAKE OF MESCALINE BY CORTICAL SYNAPTOSOMES
003095 04-03

IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM ABOUT THE EFFECTS OF MORPHINE ON UPTAKE AND RELEASE OF C14-DOPAMINE.
003104 04-03

STRUCTURE ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN
003255 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL AND NEONATAL RAT BRAIN
003299 04-03

SYNDROME

ASTHENORINOL 12 IN THE ASTHENIA SYNDROME OF AGED SUBJECTS.
000497 01-07

A POSSIBLE SUBGROUP OF THE SCHIZOPHRENIC SYNDROME AND IMPLICATIONS FOR TREATMENT.
000533 01-08

NOOTROPIC CHARACTERISTICS IN PSYCHOORGANIC SENILITY SYNDROME EXPOSED BY THE DOUBLE BLIND METHOD.
000597 01-09

THE GILLES DE LA TOURETTE SYNDROME AN ANALYSIS OF PUBLISHED CASES DEALING WITH THE COURSE OF THE DISEASE AND ITS PROGNOSIS
000725 01-11

CLINICAL STUDY OF THE EFFECTS OF VINCAMIN IN SENILE DEMENTIA SYNDROME.
000735 01-11

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
000741 01-11

PARKINSONS SYNDROME: DRUG THERAPY.
000787 01-11

L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT
000801 01-13

MINIMAL-BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000803 01-13

A FOLLOW-UP OF 78 PATIENTS WITH GILLES-DE-LA-TOURETTES SYNDROME.
000B07 01-13

SOME NOTES ON THE PATIENT WITH NEUROLEPTIC SYNDROME.
000941 01-15

ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY.
000947 01-15

EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15

SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS.
001287 02-03

PRECIPITATION OF ABSTINENCE-LIKE SYNDROME IN MORPHINE-DEPENDENT MICE BY PARGYLINE
001604 02-04

EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07

D-AMPHETAMINE IN THE MANIC SYNDROME.
001728 02-09

A DEPRESSIVE SYNDROME RESPONSIVE TO LITHIUM: AN ANALYSIS OF 20 CASES.
001767 02-09

GILLES-DE-LA-TOURETTES SYNDROME.
001B19 02-11

DOUBLE-BLIND CLINICAL TRIAL OF 5-HYDROXYTRYPTOPHAN IN A CASE OF LESCH-NYHAN SYNDROME.
001827 02-11

INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001B40 02-11

DRUG THERAPY IN THE HYPERKINETIC SYNDROME.
001844 02-11

HEROIN WITHDRAWAL SYNDROME IN NEWBORNS.
001B51 02-11

HYPERKINETIC SYNDROME.
001B63 02-11

DEPRESSIVE SYNDROME INDUCED BY ORAL CONTRACEPTIVES.
001979 02-14

ANTICHOLINERGIC EXACERBATION OF PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL SYNDROME.
002009 02-15

ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY.
002035 02-15

REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE
00204B 02-15

5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

EFFECTS OF CHOLINERGIC AGONISTS AND ANTAGONISTS ON MORPHINE WITHDRAWAL SYNDROME.
002469 03-04

DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11

TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENDED ACTION FORM OF BIPERIDEN HYDROCHLORIDE: 9 MONTH STUDY OF 55 HOSPITALIZED PATIENTS.
0027B7 03-11

PATHOPHYSIOLOGICAL ASPECTS CONCERNING THE TREATMENT OF THE APALLIC SYNDROME.
0027B9 03-11

TREATMENT OF GILLES-DE-LA-TOURETTES SYNDROME WITH HALOPERIDOL.
002791 03-11

THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING 8Y PATIENTS WITH TOURETTES SYNDROME.
002901 03 15

EFFECT OF INTRACAUDATE DRUG INJECTIONS ON THE STRIATAL SYNDROME IN RESERPINIZED CATS.
003122 04-03

REVERSAL OF DELAYED MYELINOGENESIS IN THE FETAL ALCOHOL SYNDROME.
003258 04-03

OPIATE-LIKE ACTION OF METHIONINE-ENKEPHALIN IN INHIBITING MORPHINE ABSTINENCE SYNDROME
003352 04-04

DEANOL IN GILLES-DE-LA-TOURETTE SYNDROME: A PRELIMINARY INVESTIGATION
003571 04-09

COMPARISON OF PIMOZIDE WITH HALOPERIDOL IN GILLES-DE-LA-TOURETTE SYNDROME
003641 04-11

CARBAMAZEPINE IN THE DYSCONTROL SYNDROME ASSOCIATED WITH LIMBIC SYSTEM DYSFUNCTION
003646 04-11

STIFF-MAN SYNDROME AND CLONAZEPAM
003650 04-11

PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNDROME AND HYPERSOMNIA.
003748 04-14

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003804 04-15

PHENOTHIAZINE-INDUCED BULBAR PALSY LIKE SYNDROME AND SUDDEN DEATH.
003828 04-15

YNDROMES

CLINICAL EXPERIENCES WITH IPOTALAMINE IN PSYCHOSOMATIC GASTROINTESTINAL SYNDROMES.
000689 01-10

TOXICOPATHIC HALLUCINATORY SYNDROMES IN CHILDREN.
000942 01-15

CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L-DOPA.
000948 01-15

PSYCHIATRIC SYNDROMES IN CRITICALLY ILL PATIENTS.
000956 01-15

A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
000961 01-15

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES.
001031 01-17

INDICATIONS FOR LONG-TERM PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC SYNDROMES.
001066 01-17

CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08

USE OF DEXETIMIDE (R-16470) WITH EXTRAPYRAMIDAL SYNDROMES CAUSED BY NEUROLEPTICS.
002061 02-15

DRUG-WITHDRAWAL SYNDROMES.
002070 02-15

ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03 15

EFFECT OF PIRACETAM ON PSYCHOORGANIC SYNDROMES OF OLD PEOPLE.
003526 04-07

YNERGISTIC

SYNERGISTIC EFFECT OF ESTRADIOL BENZOATE AND DIHYDROTESTOSTERONE ON AGGRESSION IN MICE
001486 02-04

HALOPERIDOL ATTENUATION OF MORPHINE ABSTINENCE SYNERGISTIC EFFECT OF ACUTE LITHIUM ADMINISTRATION
003172 04-03

YNERGY

THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS
003793 04 15

YNOPSIS

LITHIUM IN PSYCHIATRY A SYNOPSIS
002396 03-03

YNTHESES

SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIOIMIDAZOLINES
003067 04 02

SYNTHESES AND ANTIINFLAMMATORY AND HYPNOTIC ACTIVITY OF 5 ALKOXY 3 (N-SUBSTITUTED CARBAMOYL) 1-PHENYLPYRAZOLES.
003073 04-02

SYNTHESIS

POTENTIAL PSYCHOTROPICS XI SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF NEW BUTYROPHENONES WITH AN IMIDAZOLIDINE CYCLE
000004 01 01

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03

IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442).
000158 01-03

EFFECT OF ORGANOPHOSPHORUS COMPOUNDS ON ACETYLCHOLINE SYNTHESIS IN BRAIN
000180 01-03

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
000289 01-04

COMBINED ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE INHIBITION OF BRAIN PROTEIN SYNTHESIS IN VIVO.
000359 01-04

SYNTHESIS AND CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIDE (DORIDEN) IN HUMAN URINE.
000799 01-13

THE SYNTHESIS OF POSSIBLE DIHYDROXYLATED AND TRIHYDROXYLATED CHLORPROMAZINE METABOLITES.
001094 02-01

THE SYNTHESIS OF POSSIBLE HYDROXYLATED METABOLITES OF 2-CHLOROPHENOTHIAZINE DERIVATIVES. (UNPUBLISHED PAPER).
001099 02-01

SYNTHESIS OF 2,1,4,5 BENZOTHIATRIAZEPINES 2,2 DIOXIDES AND OF 4 KETOBENZOTHIADIAZEPINES 2,2 DIOXIDES.
001101 02-02

SYNTHESIS AND POTENTIAL NEUROLEPTIC ACTIVITY OF NEW MANNICH-BASES DERIVED FROM ALPHA-TETRALONE AND N-ARYLPIPERAZINES.
001108 02-02

2,3 BENZODIAZEPINIC SYSTEMS. PART II. OXODIHYDROBENZODIAZEPINES. SYNTHESIS AND PHARMACOLOGIC STUDY.
001109 02-02

DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION
001183 02-03

NORADRENALINE SYNTHESIS FROM L-DOPA IN RODENTS AND ITS RELATIONSHIP TO MOTOR ACTIVITY.
001186 02-03

AN ENZYMATIC ISOTOPIC METHOD FOR DOPA AND ITS USE FOR THE MEASUREMENT OF DOPAMINE SYNTHESIS IN RAT SUBSTANTIA-NIGRA
001233 02-03

CATECHOLAMINE-STIMULATED PROSTAGLANDIN SYNTHESIS IN RAT BRAIN SYNAPTOSOMES.
001237 02-03

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
001238 02-03

CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03

RECIPROCAL ACTION OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH REGARD TO DOPAMINE SYNTHESIS AND METABOLISM.
001261 02-03

CHOLINERGIC STIMULATION OF THE RAT HYPOTHALAMUS: EFFECTS ON LIVER GLYCOGEN SYNTHESIS.
001372 02-03

SYNTHESIS OF POTENTIAL MESCALINE ANTAGONISTS.
002190 03-02

NEW SYNTHESIS OF SUBSTITUTED PYRROLODIAZEPINE AND ITS PHARMACOLOGICAL ACTIVITY.
002196 03-02

EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN
002306 03-03

CATECHOLAMINE SYNTHESIS, STORAGE AND RELEASE IN ADRENAL MEDULLA AND WHOLE BRAIN DURING ACUTE AND CHRONIC METHADONE ADMINISTRATION
002370 03-03

EFFECT OF AMPHETAMINE ON MONOAMINE SYNTHESIS AND METABOLISM AFTER AXOTOMY IN RAT FOREBRAIN
002373 03-03

STUDIES ON THE EFFECT OF 5,5 DIPHENYLHYDANTOIN ON IN VITRO PROTEIN SYNTHESIS IN RAT BRAIN
002375 03-03

ABSENCE OF A CHOLINERGIC LINK IN THE APOMORPHINE-INDUCFD FEEDBACK INHIBITION OF DOPAMINE SYNTHESIS IN RAT STRIATUM.
002393 D3-D3

9-NDR-9-HYDRDXYHEXAHYDROCANNABINOLS. SYNTHESIS, SOME BEHAVIDRAL AND ANALGESIC PRDPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-03

NEW COMPOUNDS: SYNTHESIS OF 2-AMINO-5H 1,3,4-BENZOTRIAZEPIN-5-ONES.
003055 D4-01

CANNABINOIOS. 2. SYNTHESIS ANO CENTRAL-NERVOUS-SYSTEM ACTIVITIES OF SOME B-RING HOMOCANNABINOIO DERIVATIVES AND RELATEO LACTONES.
003056 04-01

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF QUINAZOLONES RELATED TO METHYL-TOLYLQUINAZOLONE (METHAQUALONE).
003062 D4-D2

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-OOSE OF NEUROLEPTICS.
003178 04-03

CHRONIC ALCOHOL INGESTION INHIBITS RAT BRAIN PROTEIN SYNTHESIS.
003321 04-03

SUPPRESSION OF NORADRENALINE SYNTHESIS IN SYMPATHETIC NERVES BY CARBIOOPA, AN INHIBITOR OF PERIPHERAL OOPA-DECARBOXYLASE.
D0333D D4-D3

VFRIFICATION OF THE MA HYPOTHESIS WITH THE AIO OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 04-14

POTENTIAL PSYCHOTROPICS. XII. SYNTHESIS ANO STRUCTURE OF NEW BUTYROPHENONES WITH A OIOXAAZASPIROUNDECANE RING, HAVING NEUROLEPTIC ACTIVITY.
DD3B4B 04-17

EFFECT OF CORTICOSTERONE ON THE SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF CD-1 MICE.
003874 04-17

SYNTHESIZED

ESTIMATION OF NORADRENALINE ANO ITS MAJOR METABOLITES SYNTHESIZED FROM 3H-TYROSINE IN THE RAT BRAIN
001650 02-06

SYNTHESIZING

EFFECTS OF AMPHETAMINE ADMINISTRATION IN VIVO ON IN VITRO PROTEIN SYNTHESIZING SYSTEM FROM RAT BRAIN.
001421 02-D3

SYNTHETASE

THE EFFECTS OF VARIOUS AGENTS IN VITRO ON HOMOCARNOSINE CARNOSINE SYNTHETASE FROM RAT BRAIN.
DDD1B7 D1-D3

SYNTHETIC

A NEW SYNTHETIC ANTIPARKINSON AGENT, TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INOUCED BY NEUROLEPTICS.
DDD961 D1-15

INHIBITION OF MORPHINE EFFECTS BY SYNTHETIC SUBSTANCE-P.
DD1594 02-D4

GONADOTROPIN RESPONSE TO SYNTHETIC GONAOOTROPIN HORMONE RFLFASING HORMONE (GNRH) IN CHRONIC SCHIZOPHRENIA.
0D1681 D2-DB

D-ALA2-MET-FNKEPHALINAMIDE: A POTENT, LONG-LASTING SYNTHETIC PFNTAPEPTIDE ANALGESIC.
D02193 D3-02

OVERUSE OF SYNTHFTIC ANTICHOLINERGIC DRUGS IN PSYCHIATRY.
DD2915 03-15

SYROSINGOPINE

SFLECTIVE DEPLETING EFFECT OF SYROSINGOPINE ON BRAIN CATFCHOLAMINE LEVELS WITH RELATION TO MORPHINE ANALGESIA IN THE RAT.
DDD1D2 01-03

SYSTEMATIC

NFUROPHARMACOLOGICAL ACTIONS OF ENKEPHALIN AFTER SYSTFMATIC ADMINISTRATION
DDD2D3 01-03

SYSTFMATIC ASSESSMENT OF TOLERANCE TO PENTOBARBITAL BY PFLLFT IMPLANTATION.
DDD342 01-D4

SYSTEMATIC FXAMINATION IN THE RAT OF BRAIN SITES SENSITIVE TO THE DIRFCT APPLICATION OF MORPHINE: OBSERVATION OF DIFFFRENTIAL EFFECTS WITHIN THF PERIAQUEDUCTAL GRAY.
DD1424 D2-D3

LONG TFRM THFRAPY WITH SINQUAN- INVFSTIGATION OF TOLERANCE WITH SYSTFMATIC LABORATORY CONTROL.
DD2D71 D2-15

SYSTFMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NFUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
DD3579 04-10

SYSTEMIC

IN VIVO FATE OF A BEHAVIORALLY ACTIVE ACTH4-9 ANALOG IN RATS AFTER SYSTFMIC ADMINISTRATION.
DDD249 01-03

SEX ANO SYSTEMIC LUPUS-ERYTHEMATOSUS.
001959 02-14

THE PSYCHIATRY OF SYSTEMIC LUPUS-ERYTHEMATOSUS.
002149 02-17

SIDE-EFFECTS OF SOME PSYCHOCHEMOTHERAPEUTIC ORUGS ON SYSTEMIC CIRCULATION IN ATHEROSCLEROSIS ANO IN SOMATICALLY HEALTHY, ELDERLY PERSONS.
002951 D3-15

RESPONSE OF MEDULLARY RAPHE NEURONS TO PERIPHERAL STIMULATION AND TO SYSTEMIC OPIATES.
D03082 04-03

STUOIES ON THE ANTAGONISM BY RAPHE LESIONS OF THE ANTINOCICEPTIVE ACTION OF SYSTEMIC MORPHINE.
DD3333 D4-03

THE SYSTEMIC USE OF PROCAINE IN THE TREATMENT OF THE ELDERLY: A REVIEW.
0D3595 04-10

SYSTEMICALLY

OOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYOROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
0DD016 D1-D1

SYSTEMS

SPECIFIC MONOAMINE SYSTEMS AS REWARO PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC OOPAMINERGIC NEURONES ANO NORAORENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONOING.
000081 01-03

OOPAMINE METABOLISM IN THE MESOLIMBIC ANO MESOCORTICAL OOPAMINERGIC SYSTEMS AFTER SINGLE OR REPEATEO AOMINISTRATIONS OF NEUROLEPTICS.
000217 01-D3

PHARMACOLOGICAL AND BIOCHEMICAL STUOIES OF INTRACRANIAL SELF-STIMULATION ROLES OF OOPAMINERGIC ANO NORAORENERGIC NEURONAL SYSTEMS WITH ELECTROOES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 01-D3

AN INHIBITORY ROLE FOR BRAIN SEROTONIN CONTAINING SYSTEMS IN THE LOCOMOTOR EFFECTS OF O-AMPHETAMINE.
000343 D1-D4

THE INTERACTION OF TRICYCLIC ANTIOEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
D00615 01-09

2,3 BENZODIAZEPINIC SYSTEMS. PART II. OXOOIHYDROBENZOOIAZEPINES. SYNTHESIS AND PHARMACOLOGIC STUDY.
D01109 02-02

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN CEREBELLUM- PHARMACOLOGICAL HETEROGENEITY CONFIRMEO BY DESTRUCTION OF INTERNEURONS.
0D1239 02-03

INTERACTION OF CLONIOINE WITH PRESYNAPTIC ANO POSTSYNAPTIC AORENERGIC RECEPTORS OF RAT BRAIN: EFFECTS ON CYCLIC-AMP GENERATING SYSTEMS.
D01375 02-03

A NEURAL SYSTEMS THEORY OF SCHIZOPHRENIA ANO TAROIVE-OYSKINESIA.
002042 02-15

SPECTRUM OF PHARMACOLOGICAL ACTIONS ON BRAIN DOPAMINE. INDICATIONS FOR DEVELOPMENT OF NEW PSYCHOACTIVE DRUGS: DISCUSSION OF AMANTAOINES AS EXAMPLES OF NEW DRUGS WITH SPECIAL ACTIONS ON DOPAMINE SYSTEMS
002194 03-02

THE RELATIONSHIP BETWEEN STRIATAL ANO MESOLIMBIC OOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYOOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING OOPAMINE SYSTEMS OF RAT BRAIN.
DD2436 D3-04

EFFFCT OF CATECHOLAMINERGIC ORUGS ON SYSTEMS OF REWARO ANO PUNISHMENT IN EXPERIMENTS ON CATS.
0D2518 03-04

NARCOTICS ANO THE HYPOTHALAMIC PITUITARY GONAOAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE ANO ANDROGEN DEPENDENT SYSTEMS.
0D3116 04-D3

T-CELL

MARIHUANA, TETRAHYDROCANNABINOL ANO T-CELL FUNCTION.
0DDB54 01-13

T-LYMPHOCYTES

EFFECT OF PSYCHOTROPIC AGENTS UPON THE BLASTOGENIC RESPONSE OF HUMAN T-LYMPHOCYTES.
0D3656 04-13

-MAZE
POSTPARTUM, HORMONAL, AND NONHORMONAL INDUCTION OF MATERNAL BEHAVIOR IN RATS: EFFECTS ON T-MAZE RETRIEVAL OF PUPS.
001593 02-04
EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-04

ABLET
REGIONAL ACETYLCHOLINE CONTENT IN MOUSE BRAIN AFTER MORPHINE TABLET IMPLANTATION
003289 04-03

ABLETS
COMPARATIVE BIOAVAILABILITY AND EFFECT STUDIES ON METOPROLOL ADMINISTERED AS ORDINARY AND SLOW-RELEASE TABLETS IN SINGLE AND MULTIPLE DOSES.
000859 01-13
THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13
COMPARISON OF SIDE-EFFECTS WITH COATED LITHIUM-CARBONATE TABLETS AND LITHIUM SULPHATE PREPARATIONS GIVING MEDIUM-SLOW AND SLOW-RELEASE. A DOUBLE-BLIND CROSS-OVER STUDY.
003774 04-15

ACHYCARDIA
CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

AFT
ABUSE OF RITALIN BY TAFT CITY SCHOOL DISTRICT.
000879 01-14

AIL
ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03
EFFECTS OF VARIOUS DRUGS ON MORPHINE-INDUCED STRAUB RESPONSE IN MICE (II): THE RELATIONSHIP BETWEEN GABA DERIVATIVES AND TAIL RESPONSE.
002391 03-03
ISOLATION REARING ENHANCES TAIL PINCH-INDUCED ORAL BEHAVIOR IN RATS.
003454 04-04

AIL-FLICK
THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES.
000289 01-04

ALAPOIN
GONADAL HORMONES AND SEXUAL BEHAVIOR IN GROUPS OF ADULT TALAPOIN MONKEYS (MIOPITHECUS-TALAPOIN).
003376 04-04

ALWINISM
CAN PENTAZOCINE BE A DRUG? OBSERVATIONS ON THE PROBLEM OF TALWINISM.
002028 02-15

ANAKAN
TANAKAN IN GERIATRICS: CLINICAL AND PSYCHOMETRIC STUDY IN 189 HOSPITALIZED PATIENTS.
000727 01-11

ANDAMINE
TANDAMINE: A NEW ANTIDEPRESSANT.
001660 02-07
CLINICAL PHARMACOLOGICAL STUDIES OF TANDAMINE, A POTENTIAL ANTIDEPRESSIVE DRUG.
003520 04-07

APE
TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

ARDIVE-DYSKINESIA
THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000820 01-13
THE EFFECT OF OXYPERTINE ON TARDIVE-DYSKINESIA.
000851 01-13
LITHIUM IN TARDIVE-DYSKINESIA
000985 01-15
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN MONKEYS.
001504 02-04
DIAZEPAM IN THE TREATMENT OF TARDIVE DYSKINESIA: PRELIMINARY OBSERVATIONS.
001716 02-08
EFFECT OF SODIUM VALPROATE ON TARDIVE-DYSKINESIA
001838 02-11
TARDIVE-DYSKINESIA: ARE THERE SUBTYPES?.
001894 02-13
BACLOFEN (LIORESAL) IN THE TREATMENT OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA.
001923 02-13
TARDIVE-DYSKINESIA AND DEPRESSIVE ILLNESS.
002029 02-15
A NEURAL SYSTEMS THEORY OF SCHIZOPHRENIA AND TARDIVE-DYSKINESIA.
002042 02-15
MECHANISMS UNDERLYING TARDIVE-DYSKINESIA.
002883 03-15
TARDIVE-DYSKINESIA: MANIFESTATIONS, INCIDENCE, ETIOLOGY, AND TREATMENT.
002935 03-15
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING FACTOR-I AND TARDIVE-DYSKINESIA.
003615 04-11
ORAL CHOLINE ADMINISTRATION TO PATIENTS WITH TARDIVE-DYSKINESIA.
003624 04-11
COEXISTING TARDIVE-DYSKINESIA AND PARKINSONISM: A CASE REPORT.
003665 04-13
NEUROLEPTIC DOSAGE, DURATION, AND TARDIVE-DYSKINESIA
003760 04-15
RELATIONSHIP BETWEEN TARDIVE-DYSKINESIA, L-DOPA-INDUCED HYPERKINESIA AND PARKINSONISM.
003785 04-15
NARCOLEPSY, PARANOID PSYCHOSIS, AND TARDIVE-DYSKINESIA: A PHARMACOLOGICAL DILEMMA.
003816 04-15
TARDIVE-DYSKINESIA: ARE FIRST SIGNS REVERSIBLE?.
003818 04-15

TARDIVE-DYSKINESIAS
NEUROLEPTIC TARDIVE-DYSKINESIAS: STUDY OF 1660 PATIENTS IN A PSYCHIATRIC HOSPITAL.
002019 02-15
THERAPEUTIC APPROACHES IN NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIAS.
002910 03-15

TARGET
THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY.
002996 03-17

TASK
INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC AGENTS IN A SPONTANEOUS ALTERNATION TASK.
000361 01-04
CASTRATION AND AMPHETAMINE EFFECTS ON ACQUISITION OF A SIDMAN AVOIDANCE TASK IN RATS.
000385 01-04
DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13
EEG AND TASK PERFORMANCE AFTER ACTH4-10 IN MAN
002874 03-14
ACETALDEHYDE AS A PSYCHOPHARMACOLOGICAL AGENT. TASK SPECIFICITY OF GENOTYPIC DIFFERENCES.
003380 04-04
PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION.
003413 04-04

TASK-SPECIFIC
TASK-SPECIFIC EFFECTS OF D-AMPHETAMINE AND BLINDNESS ON BALB/CJ MICE.
000317 01-04

TASKS
VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA CONTINGENCY ON TASKS AND SPECIES.
001440 02-04
DISSOCIATION OF THE ANTIPUNISHMENT ACTIVITIES OF CHLORDIAZEPOXIDE AND ATROPINE USING TWO HETEROGENEOUS PASSIVE AVOIDANCE TASKS.
003480 04-04
CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-08

TASTE-AVERSION
DRUG EXPOSURE AND THE ACQUISITION AND RETENTION OF A CONDITIONED TASTE-AVERSION.
000913 01-14
MORPHINE INJECTIONS IN THE TASTE-AVERSION PARADIGM.
002443 03-04
POSSIBLE INVOLVEMENT OF CENTRAL FACTORS IN THE MEDIATION OF CONDITIONED TASTE-AVERSION.
003081 04-03
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03
TASTE-AVERSION DISRUPTION BY DRUG PRETREATMENT: DISSOCIATIVE AND DRUG SPECIFIC EFFECTS.
003359 04-04
LONG-DELAY BACKWARD TASTE-AVERSION CONDITIONING WITH LITHIUM.
00337B 04-04
ENDURING EFFECTS OF MORPHINE PELLETS REVEALED BY CONDITIONED TASTE-AVERSION
003424 04-04
ILLNESS ALONE EXPOSURE AS A SOURCE OF INTERFERENCE WITH THE ACQUISITION AND RETENTION OF A TASTE-AVERSION
003503 04-05

TASTE-AVERSIONS
EFFECTS OF AMYGDALA LESIONS ON TASTE-AVERSIONS PRODUCED BY AMPHETAMINE AND LICL.
000116 01-03
DRUG PRETREATMENT EFFECTS IN DRUG-INDUCED TASTE-AVERSIONS: EFFECTS OF DOSE AND DURATION OF PRETREATMENT.
000337 01-04
EFFECTS OF WATER DEPRIVATION AND PRIOR LICL EXPOSURE IN CONDITIONING TASTE-AVERSIONS.
001597 02-04
REDUCTION OF LEARNED TASTE-AVERSIONS BY PREEXPOSURE TO DRUGS.
002549 03-04
PAIRING NOVEL EXTEROCEPTIVE CUES AND ILLNESS REDUCES ILLNESS-INDUCED TASTE-AVERSIONS.
003506 04-05

TAURINE
THERAPEUTIC EFFECTS OF TAURINE IN EPILEPSY: A CLINICAL AND POLYPHYSIOGRAPHIC STUDY.
000760 01-11
TAURINE AND COBALT-INDUCED EPILEPSY IN THE RAT. A BIOCHEMICAL AND ELECTROCORTICOGRAPHIC STUDY.
001256 02-03
ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

TEA
SASSAFRAS AND HERB TEA: POTENTIAL HEALTH HAZARDS.
0009B3 01-15
HERBAL INTOXICATION. PSYCHOACTIVE EFFECTS FROM HERBAL CIGARETTES, TEA, AND CAPSULES.
000984 01-15

TEACHER
IS THERE A ROLE FOR THE TEACHER IN THE USE OF MEDICATIONS FOR HYPERKINETICS
000908 01-14
THE EFFECT OF POSITIVE TEACHER REINFORCEMENT AND CLASSROOM SOCIAL STRUCTURE ON CLASS BEHAVIOR OF BOYS DIAGNOSED AS HYPERACTIVE BEFORE AND DURING MEDICATION (ED.D. DISSERTATION).
002860 03-14

TECHNIQUE
SCHEDULE CONTROLLED BEHAVIOUR OF RATS AS A TECHNIQUE FOR INVESTIGATING THE ACTIONS OF BENZODIAZEPINES.
000413 01-04
INTRACEREBRAL DOPAMINE METABOLISM STUDIED BY A NOVEL RADIOISOTOPE TECHNIQUE.
00196B 02-14

TECHNIQUES
GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH
000009 01-01
EVALUATION TECHNIQUES IN THE STUDY OF TRICYCLIC ANTIDEPRESSANTS.
000476 01-06
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES 1 USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
000651 01-09

TECTUM
THE EFFECT OF CORDYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLDFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIDINE
001247 02-03

TEGMENTAL
BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN.
000184 01-0
SCHEDULE DEPENDENT CHANGES IN OPERANT RESPONDING AFTER LESIONS OF THE DORSAL TEGMENTAL NORADRENERGIC PROJECTION.
003443 04-0

TEGRETOL
THE THERAPEUTIC AND PREVENTATIVE EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON DEPRESSION.
000696 01-1
SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-1
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON SEIZURE AND EEG PATTERN IN MONKEYS WITH ALUMINA-INDUCED FOCAL MOTOR AND HIPPOCAMPAL FOCI.
00117B 02-0

TELENCEPHALON
EVIDENCE THAT SELF-STIMULATION OF THE REGION OF THE LOCUS-COERULEUS IN RATS DOES NOT DEPEND UPON NORADRENERGIC PROJECTIONS TO TELENCEPHALON
00145B 02-0

TEMAZEPAM
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-0
NITRAZEPAM AND TEMAZEPAM: A COMPARATIVE TRIAL OF TWO HYPNOTICS.
001985 02-

TEMPERATURE
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERA THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN
0001B1 01-0
TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMIN AND COCAINE IN DEVELOPING MICE
000454 01-0
EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION
001245 02-0
CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
001598 02-0
THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE
002294 03-0
ANALGESIC, HEART RATE, AND TEMPERATURE EFFECTS OF DELTA8-THC DURING ACUTE AND CHRONIC ADMINISTRATION TO CONSCIOUS RATS.
003173 04-0
IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04
DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE IN THE MOUSE
003245 04
TOLERANCE TO THE EFFECTS OF DELTA9-THC ON SHUTTLE-BOX PERFORMANCE AND BODY TEMPERATURE.
00339B 04-

TEMPO
TEMPO ERRORS AND MANIA.
003575 04-

TEMPORAL
TEMPORAL AND REGIONAL DIFFERENCES IN BRAIN CONCENTRATIONS O LITHIUM IN RATS.
000179 01-
TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-
VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA: CONTINGENCY ON TASKS AND SPECIES.
001440 02-
THE EFFECTS OF D-AMPHETAMINE ON TEMPORAL DISCRIMINATION IN THE RAT.
001567 02-
INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS
00164B 02-
ENHANCEMENT OF EEG LATERALIZING SIGNS IN TEMPORAL LOBE EPILEPSY. A TRIAL OF DIAZEPAM.
00188B 02

THE EFFECTS OF D-AMPHETAMINE ON THE TEMPORAL CONTROL OF OPERANT RESPONDING IN RATS DURING A PRESHOCK STIMULUS.
002529 03-04

THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNDROME
002901 03-15

TEMPORAL EFFECTS OF DRUG AND PLACEBO IN DELAYING RELAPSE IN SCHIZOPHRENIC OUTPATIENTS.
003541 04-08

TENDENCY

TENDENCY TO CANNABIS-INDUCED HALLUCINATIONS INDICATED BY PREDRUG EEG.
001869 02-12

TENORMIN

A STUDY OF ONCE DAILY TENORMIN (ATENOLOL) IN HYPERTENSION SOME IMPLICATIONS IN PATIENT COMPLIANCE.
001666 02-07

TENSION

ANXIETY AND TENSION AND BETA-BLOCKERS IN ISCHEMIC HEART DISEASE.
000716 01-10

ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17

PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001817 02-11

ALCOHOL AND TENSION REDUCTION: COGNITIVE AND PHYSIOLOGICAL EFFECTS.
0019B4 02-14

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

TERATOGENIC

DETERMINATION OF THE EMBRYOTOXIC AND TERATOGENIC EFFECTS OF THE NEW ANTIDEPRESSANT PYRASIDOL.
002251 03-03

A COMPARISON OF THE TERATOGENIC ACTIVITY OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE, CLONAZEPAM, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN MICE.
003511 04-05

TERATOGENICITY

TERATOGENICITY AND EMBRYOTOXICITY OF SOME MALEINIMIDES.
001620 02-05

TERATOLOGIC

REPRODUCTIVE AND TERATOLOGIC STUDIES WITH DELTA9-TETRAHYDROCANNABINOL AND CRUDE MARIJUANA EXTRACT.
001644 02-05

TERATOLOGICAL

TERATOLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-05

TERM

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
00074B 01-11

EFFECTIVENESS OF INTERMEDIATE TERM USE OF SECOBARBITAL.
001972 02-14

TERMINALS

ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 01-03

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE
000441 01-04

REGULATION OF CHOLINERGIC NEURONS BY DOPAMINERGIC TERMINALS: INFLUENCE OF CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. (UNPUBLISHED PAPER).
002226 03-03

THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA++ UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
003136 04-03

DIFFERENTIAL EFFECT OF MORPHINE ON STIMULATION OF PRIMARY VERSUS HIGHER ORDER TRIGEMINAL TERMINALS.
003257 04-03

TERMINATION

NONSELECTIVE ENHANCEMENT OF LOCUS COERULEUS AND SUBSTANTIA-NIGRA SELF STIMULATION AFTER TERMINATION OF CHRONIC DOPAMINERGIC RECEPTOR BLOCKADE WITH PIMOZIDE IN RATS.
00119B 02-03

PUNISHMENT OF RESPONDING UNDER SCHEDULES OF STIMULUS SHOCK TERMINATION EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL.
002497 03-04

TERMS

INTERACTIONS OF PHENYTOIN AND PHENOBARBITAL IN TERMS OF ORDER AND TEMPORAL SPACING OF ADMINISTRATION IN MONKEYS.
001648 02-06

TERONAC

MAZINDOL (TERONAC) IN THE TREATMENT OF PREDOMINANTLY ALIMENTARY OBESITY.
002719 03-10

TEST

THE CORRELATION BETWEEN ANTINOCICEPTIVE ACTIVITY OF NARCOTICS AND THEIR ANTAGONISTS AS MEASURED IN THE MOUSE TAIL-FLICK TEST AND INCREASED SYNTHESIS OF BRAIN CATECHOLAMINES
0002B9 01-04

THE EFFECT OF DRUGS ON VARIOUS PARAMETERS OF MOUSE BEHAVIOUR IN A MODIFIED HEAD-DIPPING TEST.
000308 01-04

TAPE TEST AS A SIMPLE NEW METHOD FOR THE STUDY OF COMPOUNDS INCREASING THE PROBLEM-SOLVING ABILITY OF THE RAT.
000321 01-04

PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA: A TEST DOSE MODEL.
000506 01-07

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 01-08

DRUG RELATED TEST PATTERNS OF DEPRESSED PATIENTS.
000626 01-09

DOUBLE-BLIND COMPARATIVE TEST OF LORAZEPAM FOR PSYCHONEUROSIS.
000753 01-11

AN AUDIOVISUAL TEST OF DIVIDED ATTENTION.
000B74 01-14

LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
0008B6 01-14

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15

TEST OF A FEW NEW MORPHINE ANTAGONISTS IN ANIMAL EXPERIMENTS.
001111 02-02

ANTINOCICEPTIVE ACTIVITY OF NARCOTIC AGONIST AND PARTIAL AGONIST ANALGESICS AND OTHER AGENTS IN THE TAIL IMMERSION TEST IN MICE AND RATS.
001366 02-03

A COMPARISON BETWEEN AMANTADINE AND BROMOCRIPTINE USING THE STEREOTYPED BEHAVIOR RESPONSE TEST (SBR) IN THE RAT.
001577 02-04

CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS.
001610 02-04

COMPARISON OF EXPERIMENTAL PSYCHOLOGICAL AND CLINICAL FINDINGS ON THE EFFECT OF A TEST DRUG.
001659 02-07

A TEST OF THE PSYCHEDELIC MODEL OF ALTERED STATES OF CONSCIOUSNESS: THE ROLE OF INTROSPECTIVE SENSITIZATION IN ELICITING UNUSUAL SUBJECTIVE REPORTS.
001B6B 02-12

EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14

CLIMBING BEHAVIOR INDUCED BY APOMORPHINE IN MICE: A SIMPLE TEST FOR THE STUDY OF DOPAMINE RECEPTORS IN STRIATUM.
002521 03-04

TEST OF A NEW ANXIOLYTIC, LORAZEPAM, WITH THE USE OF THE ELECTROAFFECTROGRAM (EAG).
002715 03-10

POSSIBLE ROLE OF DOPAMINE IN CENTRAL EFFECTS OF COCAINE AS MEASURED BY APOMORPHINE GNAWING TEST IN MICE.
003119 04-03

EFFECTS OF EXPERIENCE IN THE TEST ENVIRONMENT ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY IN AN EXPLORATION BOX.
003464 04-04

GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
003494 04-05

FINDINGS WITH A CONDITIONING TEST BATTERY. DIFFERENTIAL RESPONSIVENESS TO DIAZEPAM AND DOXEPIN
0035B0 04-10

TESTED

THE DISCRIMINATIVE PROPERTIES OF AMPHETAMINE ANALOGUES TESTED IN SELF-ADMINISTERING RATS UNDER MAINTAINED STIMULUS CONTROL.
003395 04-04

TESTICULAR
DIENCEPHALIC DOPAMINE RECEPTORS AND REGULATION OF PITUITARY TESTICULAR SYSTEM.
000186 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON RAT TESTICULAR ESTERASE ISOZYMES.
003156 04-03

TESTIMONY
TESTIMONY BY AN EX-CONVICT AGAINST MEDICAL EXPERIMENTATION IN PRISONS.
003882 04-17

TESTING
PATIENTS REACTIONS TO CLINICAL DRUG TESTING.
000489 01-07
USE OF A CROSS-OVER DESIGN IN TESTING SHORT-TERM METHYLPHENIDATE EFFECTS ON AVOIDANCE CONDITIONING.
001491 02-04
INTERACTION OF DRUG EFFECTS WITH TESTING PROCEDURES IN THE MEASUREMENT OF CATALEPSY.
001592 02-04
METHODOLOGY OF CLINICAL TESTING OF ANTIPSYCHOTICS.
002098 02-17
A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION: I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
002180 02-17
RESULTS OF CLINICAL AND EXPERIMENTAL TESTING OF CZECHOSLOVAK NEUROLEPTICS OCTOCLOTHEPIN AND OXYPROTHEPIN.
002647 03-08
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16
TESTING THE DA HYPOTHESIS WITH THE AID OF DRUGS.
003719 04-13
DELAYED FORCED DOWN GAZE DURING OCULOVESTIBULAR TESTING IN SEDATIVE DRUG-INDUCED COMA.
003826 04-15

TESTOSTERONE
ACUTE GLUTAMATE-INDUCED ELEVATIONS IN SERUM TESTOSTERONE AND LUTEINIZING HORMONE.
001315 02-03
PERIOD OF MAXIMAL SUSCEPTIBILITY TO BEHAVIORAL MODIFICATION BY TESTOSTERONE IN THE GOLDEN HAMSTER.
001616 02-05
HYPOTHYROID-LIKE ALTERATIONS IN TESTOSTERONE METABOLISM IN ANOREXIA-NERVOSA.
001B87 02-13
ACUTE EFFECTS OF HEROIN AND NALTREXONE ON TESTOSTERONE AND GONADOTROPIN SECRETION: A PILOT STUDY.
001930 02-13
NARCOTICS AND THE HYPOTHALAMIC PITUITARY GONADAL AXIS: ACUTE EFFECTS ON LUTEINIZING HORMONE, TESTOSTERONE AND ANDROGEN DEPENDENT SYSTEMS.
003116 04-03

TESTS
NEUROPHARMACOLOGICAL TESTS WITH ALPHA-MELANOCYTE STIMULATING HORMONE.
000402 01-04
WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION.
000403 01-04
THE USE OF SPOT TESTS AS A MEANS OF IDENTIFYING PHENOTHIAZINE DERIVATIVES IN EMERGENCY CASES.
001004 01-16
THE EFFECT OF ETHANOL AND DIPHENHYDRAMINE ON HISTAMINE ANTAGONISM AND MENTAL PERFORMANCE TESTS IN MAN.
001441 02-04
A CLINICAL STUDY OF NAPROXEN DIAZEPAM DRUG INTERACTION ON TESTS OF MOOD AND ATTENTION.
003525 04-07
METHYLPHENIDATE HYDROCHLORIDE EFFECTS ON PSYCHOLOGICAL TESTS IN ACUTE SCHIZOPHRENIC AND NONPSYCHOTIC PATIENTS.
003733 04-14

TETRABENAZINE
STUDIES ON THE SITUATIONAL FACTORS AFFECTING THE EFFECT OF PSYCHOTROPIC DRUGS - I. DAILY FLUCTUATION OF SEDATIVE EFFECT OF TETRABENAZINE
000182 01-03
EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
002566 03-05
THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER
003233 04-03

TETRACYCLIC
COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-0
PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
000610 01-0
THE EFFECT OF A TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-G8-94, ON THE TURNOVER OF BIOGENIC AMINES IN RAT BRAIN.
002271 03-0
THE EFFECT OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS ON THE HEART AND CIRCULATION
002B90 03-1
R-B06, A TETRACYCLIC ANTIDEPRESSANT: AN EARLY PHASE-TWO STUDY
003523 04-0

TETRADECAPEPTIDE
DIPSOGENIC EFFECTS OF INTRACRANIAL RENIN, THE ANGIOTENSINS AND THEIR TETRADECAPEPTIDE PRECURSOR IN THE RAT.
002479 03-0

TETRAHYDRO-BETA-CARBOLINES
EFFECTS OF TETRAHYDRO-BETA-CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN.
001156 02-0
TETRAHYDRO-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN.
003219 04-0

TETRAHYDRO-OXAZINES
COORDINATION OF QUANTUM CHEMISTRY AND MOLECULAR PHARMACOLOGY STUDIES IN THE INVESTIGATION OF A SERIES OF DISUBSTITUTED 1,4 TETRAHYDRO-OXAZINES.
002183 03-0

TETRAHYDROCANNABINOL
EFFECTS OF MARIJUANA EXTRACT AND TETRAHYDROCANNABINOL ON ELECTROENCEPHALOGRAPHIC SLEEP PATTERNS.
000792 01-1
MARIHUANA, TETRAHYDROCANNABINOL AND T-CELL FUNCTION
000854 01-1
CHARACTERISTICS OF TETRAHYDROCANNABINOL (THC) PRODUCED DISCRIMINATION IN RATS.
001518 02-0
TETRAHYDROCANNABINOL (THC): METABOLISM AND SUBJECTIVE EFFECTS.
002838 03-1

TETRAHYDROCANNABINOLS
9-NOR-9-HYDROXYHEXAHYDROCANNABINOLS. SYNTHESIS, SOME BEHAVIORAL AND ANALGESIC PROPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-0

TETRAHYDROCOPTISINE
NEUROPSYCHOPHARMACOLOGICAL STUDIES WITH (--) TETRAHYDROCOPTISINE.
001446 02-0

TETRAHYDROISOQUINOLINE
ALKALOIDS OF CARNEGIEA-GIGANTEA. ARIZONINE, A NEW TETRAHYDROISOQUINOLINE ALKALOID.
001082 02-0
HYPERACTIVITY INDUCED BY TETRAHYDROISOQUINOLINE DERIVATIVES INJECTED INTO THE NUCLEUS-ACCUMBENS.
002189 03-0

TETRAHYDROPAPAVEROLINE
IN VIVO AND IN VITRO STUDIES ON THE EFFECT OF TETRAHYDROPAPAVEROLINE AND SALSOLINOL ON COMT AND MAO ACTIVITY IN RAT BRAIN.
001221 02-0

TETRAPLEGIC
THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE: STUDIES IN TETRAPLEGIC SUBJECTS.
003701 04-

THALAMIC
ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX.
000431 01-0
INHIBITION OF THALAMIC AND HYPOTHALAMIC SOMATOSENSORY EVOKED POTENTIALS BY STIMULATION OF SUBSTANTIA-NIGRA AND ITS MODIFICATION BY MORPHINE AND METHOTRIMEPRAZINE (LEVOMEPROMAZINE).
001268 02-0
CHLORPROMAZINE REDUCES AVOIDANCE PERFORMANCE DEFICIT IN RATS WITH DORSOMEDIAL THALAMIC LESIONS.
001608 02-0
MORPHINE, NALOXONE AND THE RESPONSES OF MEDIAL THALAMIC NEURONES OF THE CAT.
003129 04-0

THALAMUS
THE EFFECTS OF MORPHINE AND METENKEPHALIN ON NOCICEPTIVE NEURONES IN THE RAT THALAMUS.
001236 02-0

MORPHINE ALTERS DISTRIBUTION OF GABA IN THALAMUS.
003336 04-03

THALICTRUM
ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01

THALICTRUM-LUCIDUM
ALKALOIDS OF THALICTRUM. XV. ISOLATION AND IDENTIFICATION OF THE HYPOTENSIVE ALKALOIDS OF THE ROOT OF THALICTRUM-LUCIDUM.
001097 02-01

THC
DELTA9-TETRAHYDROCANNABINOL (THC) AND MACROMOLECULAR SYNTHESIS: MECHANISMS OF ACTION
0011B3 02-03
CHARACTERISTICS OF TETRAHYDROCANNABINOL (THC) PRODUCED DISCRIMINATION IN RATS.
00151B 02-04
PRIMATE SOCIAL BEHAVIOR AS A METHOD OF ANALYSIS OF DRUG ACTION: STUDIES WITH THC IN MONKEYS.
001574 02-04
TETRAHYDROCANNABINOL (THC): METABOLISM AND SUBJECTIVE EFFECTS.
002B3B 03-13

THEOPHYLLINE
EFFECT OF THEOPHYLLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN.
000139 01-03
EFFECTS OF THEOPHYLLINE ON CENTRAL MONOAMINE NEURONS.
002273 03-03
THE EFFECT OF THEOPHYLLINE ON AMINE-INDUCED CARDIAC CYCLIC-AMP AND CARDIAC CONTRACTILE FORCE.
003213 04-03

THEORETICAL
THEORETICAL BASIS OF THERAPY WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
000B44 01-13
GERIATRIC DRUGS: THEORETICAL FOUNDATIONS, EXPECTATIONS, CONTROL, AND CRITICISM.
002747 03-11
DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

THEORY
THEORY OF TREATMENT -- PHARMACOTHERAPY.
001075 01-17
HYPERACTIVITY: RESEARCH, THEORY, AND ACTION.
001B54 02-11
A NEURAL SYSTEMS THEORY OF SCHIZOPHRENIA AND TARDIVE-DYSKINESIA.
002042 02-15

THERAPEUTIC
TWO OCCULT CAUSES OF INSOMNIA AND THEIR THERAPEUTIC PROBLEMS.
000460 01-05
THERAPEUTIC ACTION OF D-PHENYLALANINE IN PARKINSONS DISEASE.
000495 01-07
THERAPEUTIC ADVANTAGES OF A COMBINATION OF NEUROLEPTICS WITH A NEW BENZODIAZEPINE: 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H 1,4 BENZODIAZEPINE-2-ONE.
000507 01-07
BLOOD SERUM DENSITIES OF TRICYCLIC ANTIDEPRESSANTS -- VIEWS GAINED THROUGH THERAPEUTIC USE.
0005B1 01-09
THERAPEUTIC CONTROL OF PLASMA CONCENTRATIONS AND LONG-TERM EFFECT OF NORTRIPTYLINE IN RECURRENT AFFECTIVE DISORDERS.
000623 01-09
THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.
00062B 01-09
THERAPEUTIC AMELIORATION OF ANXIETY RELATED HYPERTENSION AND ANGINA-PECTORIS.
0006B6 01-10
THERAPEUTIC EFFICACY OF EMG FEEDBACK AND ITS INTERACTION WITH DIAZEPAM IN CHRONIC ANXIETY.
000693 01-10
THE THERAPEUTIC AND PREVENTATIVE EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON DEPRESSION.
000696 01-10
SOME THERAPEUTIC ASPECTS OF OBSESSIVE-PHOBIC NEUROSIS.
000711 01-10
INITIAL OBSERVATIONS OF THERAPEUTIC EFFECTS OF THE SODIUM SALT OF N DIPROPYLACETIC-ACID.
000723 01-11
COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11
ON APPLYING THE COMBINED THERAPEUTIC EFFECTS OF THE ANTIPARKINSONS DISEASE DRUGS L-DOPA AND DOPA DECARBOXYLASE INHIBITOR
000745 01-11
DISORDERED BEHAVIOR OF EPILEPTICS AND CURRENT THERAPEUTIC ORIENTATIONS.
000757 01-11
THERAPEUTIC EFFECTS OF TAURINE IN EPILEPSY: A CLINICAL AND POLYPHYSIOGRAPHIC STUDY.
000760 01-11
THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS AND LITHIUM.
000937 01-15
THERAPEUTIC APPLICATION OF L-DOPA
001056 01-17
THE PLANNING OF A THERAPEUTIC COMPARISON IN PSYCHOPHARMACOLOGY.
001077 01-17
HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-0B
THERAPEUTIC EVALUATION OF PIPOTIAZINE-PALMITATE IN A GROUP OF SCHIZOPHRENICS.
001707 02-0B
THERAPEUTIC PROPOSAL FOR INVOLUTIONAL DEPRESSION.
001771 02-09
EFFECTIVENESS OF THERAPEUTIC METHODS IN ATHEROSCLEROTIC PSYCHOSES AND SOME INDICES IN THE HEMOCOAGULATION SYSTEM.
001B29 02-11
BLOOD LEVELS OF METHAQUALONE IN MAN FOLLOWING CHRONIC THERAPEUTIC DOSES.
001905 02-13
LITHIUM LEVELS IN MONKEY AND HUMAN BRAIN AFTER CHRONIC, THERAPEUTIC, ORAL DOSAGE.
001945 02-13
SIGNALLING INCREASES IN REPORTING IN INTERNATIONAL MONITORING OF ADVERSE REACTIONS TO THERAPEUTIC DRUGS.
002142 02-17
CAUTION: DRUG SUBSTITUTION CAN BE HAZARDOUS TO PATIENT HEALTH. REPEAL OF PATIENT PROTECTION STATUTES HAS RESULTED IN THERAPEUTIC FAILURES.
002169 02-17
THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY.
0021B2 03-01
OBESITY AS A THERAPEUTIC PROBLEM: EXPERIENCE WITH THE APPETITE DEPRESSANT MAZINDOL.
002602 03-07
COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL-PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
00260B 03-0B
NORTRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.
00270B 03-09
THERAPEUTIC EFFECT OF A NEW HYPNOTIC ON SLEEP DISORDERS IN GERIATRIC PATIENTS: DOUBLE-BLIND TRIALS AND LONG-TERM STUDY.
00277B 03-11
THERAPEUTIC POSSIBILITIES OF NORTRIPTYLINE AND TORECAN.
0027B5 03-11
THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002BB5 03-15
THERAPEUTIC APPROACHES IN NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIAS.
002910 03-15
CLINICAL THERAPEUTIC REPORTS ON ADDICTION TO RARE DRUGS
002969 03-17
THERAPEUTIC ACTIONS OF THE NEUROLEPTICS AND THEIR INFLUENCE IN THE PSYCHOPATHOLOGY OF SCHIZOPHRENIA.
003011 03-17
PARKINSONS DISEASE: A THERAPEUTIC MEMORANDUM.
003611 04-11
A REVIEW OF NEUROTOXICITY OF LITHIUM DURING THERAPEUTIC TREATMENT.
003B29 04-15

THERAPEUTICAL
THERAPEUTICAL EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM.
0004BB 01-07
EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
00072B 01-11

THERAPEUTICS
USE OF LITHIUM-SALTS IN PSYCHIATRIC THERAPEUTICS.
000611 01-09

MANUAL OF PSYCHIATRIC THERAPEUTICS: PRACTICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY.
001074 01-17

THERAPIES
SOMATIC THERAPIES IN OLDER DEPRESSED PATIENTS.
001753 02-09

THERAPISTS
THE THERAPISTS HANDBOOK: TREATMENT METHODS OF MENTAL DISORDERS.
00217B 02-17

THERAPY
GAS AND HIGH PRESSURE LIQUID CHROMATOGRAPHY: NEW TECHNIQUES FOR PSYCHOPHARMACOLOGICAL THERAPY AND RESEARCH.
000009 01-01

PSYCHOTROPIC EFFECT OF PYROVALERONE (F-19B3), PLACEBO, AND MILIEU THERAPY AND THE PSYCHOLOGICAL STATUS OF FORENSIC PSYCHIATRIC PATIENTS.
000519 01-07

PHARMACOLOGIC THERAPY FOR SCHIZOPHRENIA.
000526 01-08

LONG-TERM LITHIUM THERAPY OF GERIATRIC MANIC-DEPRESSIVES.
000599 01-09

DRUG AND FAMILY THERAPY IN DEPRESSED OUTPATIENTS.
000607 01-09

LONG-TERM THERAPY OF AFFECTIVE DISORDERS AND SCHIZOPHRENIA
000620 01-09

LITHIUM MAINTENANCE THERAPY.
000625 01-09

PSYCHOSOMATIC STUDY OF NEUROTIC AND PSYCHOTIC DEPRESSION RESULTS OF THE GROUP THERAPY.
000635 01-09

MAINTENANCE THERAPY OF DEPRESSION.
000646 01-09

AMITRIPTYLINE IN PSYCHIATRIC THERAPY: EIGHT YEARS OF USAGE IN HOSPITAL PRACTICE.
000656 01-09

DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10

CHANGING THERAPY AND PROGNOSIS IN MANIC-DEPRESSIVES
0006B7 01-10

TOWARDS RATIONAL THERAPY WITH MONOAMINE-OXIDASE INHIBITORS.
000715 01-10

AGENTS AFFECTING ADRENERGIC FUNCTION IN ANTIHYPERTENSIVE THERAPY -- II.
000731 01-11

SERUM LEVELS, PSYCHOMETRIC AND PSYCHOPATHOLOGICAL FINDINGS IN COMPLEX EPILEPTICS ON HIGH-DOSAGE THERAPY WITH CARBAMAZEPINE (TEGRETOL).
000732 01-11

TRIAL OF A NEW THERAPY OF HUNTINGTONS CHOREA.
000733 01-11

PSYCHODYNAMICS OF PSYCHOTROPIC DRUG THERAPY.
000765 01-11

L-DOPA THERAPY COMBINED WITH PERIPHERAL DECARBOXYLASE INHIBITOR (MK-4B6) IN PARKINSONISM.
000767 01-11

PHARMACOLOGICAL THERAPY OF INSOMNIA.
0007B0 01-11

PARKINSONS SYNDROME. DRUG THERAPY
0007B7 01-11

THEORETICAL BASIS OF THERAPY WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
000B44 01-13

EFFECTS IN CLINICAL NEUROLOGY OF THERAPY WITH NOOTROPIC AGENT
000921 01-14

PSYCHOTHERAPY AND BEHAVIOUR THERAPY
000925 01-14

ACUTE DELIRIUM SYNDROME IN ADDISONS DISEASE UNDER CORTISONE SUBSTITUTION THERAPY
000947 01-15

DISEASE CAUSED BY DRUG THERAPY IN NEWBORN INFANTS.
000953 01-15

AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-15

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM THERAPY
00099B 01-15

EXPERIENCE WITH AN L-DOPA RETARD PREPARATION IN PERORAL LONG-TERM THERAPY OF PARKINSON SYNDROME.
001654 02-07

PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
0016B3 02-08

HIGH DOSAGE NEUROLEPTIC THERAPY: A REVIEW.
0016B6 02-08

MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS.
001727 02-09

THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09

EFFECTS OF LITHIUM THERAPY DURING PREGNANCY.
001759 02-09

AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA.
001765 02-09

PROLACTIN RESPONSE TO ELECTROCONVULSIVE THERAPY.
001769 02-09

AMITRIPTYLINE THERAPY IN PATIENTS WITH ANOREXIA-NERVOSA.
001799 02-10

A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY.
001B21 02-11

THERAPY OF CEREBRAL ISCHEMIA
001B30 02-11

DRUG THERAPY IN CHRONIC CEREBROVASCULAR INSUFFICIENCY IN THE ELDERLY
001B37 02-11

DRUG THERAPY IN THE HYPERKINETIC SYNDROME.
001B44 02-11

PSEUDO GIANT P-WAVES AND PERICARDIAL FRICTION RUB FOLLOWING CHLORPROMAZINE THERAPY
002013 02-15

COGWHEEL RIGIDITY EARLY IN LITHIUM THERAPY.
002015 02-15

EXTRAPYRAMIDAL SIDE-EFFECTS IN LITHIUM MAINTENANCE THERAPY.
002021 02-15

PSYCHOTHERAPEUTIC DRUGS: HOW TO MINIMISE COMPLICATIONS OF THERAPY
002024 02-15

ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY
002035 02-15

ACUTE ORGANIC-BRAIN-SYNDROME PSYCHOSIS WITH METHYLDOPA THERAPY
002046 02-15

LONG-TERM THERAPY WITH SINQUAN. INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15

REPLY TO A LETTER CONTRADICTING THE STATEMENT THAT COGWHEEL RIGIDITY IS RELATED TO LONG-TERM LITHIUM MAINTENANCE THERAPY
002076 02-15

THYROID INSUFFICIENCY IN THE COURSE OF LITHIUM THERAPY.
0020B1 02-15

DOUBLE-BLIND TRIAL OF THERAPY OF ORTHOSTATIC HYPOTENSION IN PSYCHOTICS UNDER PSYCHOTROPIC MEDICATION
0020B2 02-15

DIAGNOSIS IN PLANNING PSYCHOPHARMACOLOGICAL THERAPY
002099 02-17

UPDATING PSYCHOTROPIC DRUG THERAPY.
002109 02-17

ON THE RELEVANCE OF ANIMAL STUDIES ON LITHIUM TO THE UNDERSTANDING OF LITHIUM THERAPY.
00212B 02-17

ONE HUNDRED FIFTY YEARS OF PSYCHIATRIC THERAPY.
002131 02-17

METHODOLOGICAL REVIEW OF FLUID THERAPY IN PSYCHIATRY.
002145 02-17

CURRENT STATUS OF LITHIUM THERAPY IN AFFECTIVE DISORDERS.
002160 02-17

THERAPY WITH INJECTABLE FLUPHENAZINES.
002611 03-08

USE OF A LONG-ACTING DRUG (PIPOTIAZINE-PALMITATE) IN HOSPITAL AND OUTPATIENT THERAPY
00262B 03-08

EVALUATION OF ATROPINE THERAPY IN TREATING SCHIZOPHRENIA.
002630 03-08

A NEW NEUROLEPTIC FOR LONG-TERM THERAPY: PENFLURIDOL (R-16341).
002656 03-08

ADVANCES IN THE DRUG THERAPY OF AFFECTIVE DISORDERS.
0026B0 03-09

DRUG THERAPY IN DEPRESSIVE STATES: FACTORS IN SUICIDE PREVENTION
002690 03-09

ADVANCES IN LITHIUM THERAPY
00269B 03-09

ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY
002723 03-10
AMANTADINE THERAPY FOR DRUG-INDUCED EXTRAPYRAMIDAL SIGNS AND DEPRESSION
002738 03-11
ANTICONVULSANT THERAPY FOR EPILEPSY BY DETERMINATION OF PLASMA CONCENTRATIONS.
002755 03-11
ON THE THERAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
002758 03-11
THE THERAPY AND COURSE OF AUTISM.
002759 03-11
THERAPY FOR HYPERACTIVITY SEEN IN MINIMAL-BRAIN-DYSFUNCTION.
002763 03-11
THERAPY WITH DIMETHYLAMINOETHANOL (DEANOL) IN NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL HYPERKINESIA.
002801 03-13
HALOPERIDOL IN THE THERAPY OF SEVERE BEHAVIOR DISORDERS.
002851 03-14
CLINICAL CHARACTERISTICS OF PSYCHOPATHOLOGICAL CHANGES PRODUCED BY PHARMACOLOGICAL ANTIEPILEPTIC THERAPY.
002886 03-15
SEVERE NEUTROPENIA URTICARIA WITH ANTIDEPRESSANT THERAPY.
002907 03-15
OROFACIAL DYSKINESIA -- CLINICAL FEATURES, MECHANISMS AND DRUG THERAPY.
002911 03-15
LITHIUM THERAPY: A BRIEF REVIEW.
002917 03-15
EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
002928 03-15
GLYCEMIC SIDE-EFFECTS IN PATIENTS DUE TO NEUROLEPTIC THERAPY.
002941 03-15
EXTRAPYRAMIDAL MOTOR DISTURBANCES DUE TO DRUG THERAPY OF PSYCHOSIS.
002944 03-15
PSYCHOPHARMACOLOGY AND CONVULSIVE THERAPY.
002952 03-16
PRESCRIPTION IN FAMILY THERAPY: PART 1.
002961 03-17
DRUG THERAPY OF PARKINSONISM.
002967 03-17
APPLICATION OF BETA-RECEPTOR BLOCKING AGENTS IN COMBINED THERAPY OF ENDOGENOUS PSYCHOSIS.
002972 03-17
THE EXPECTATION OF OUTCOME FROM MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
002999 03-17
ADVANCES IN THE DRUG THERAPY OF MENTAL ILLNESS.
003045 03-17
PROCAINE HYDROCHLORIDE AS A MONOAMINE-OXIDASE INHIBITOR: IMPLICATIONS FOR GERIATRIC THERAPY.
003148 04-03
EFFECT OF ANTICONVULSANT DRUG THERAPY ON GAMMA-HYDROXYBUTYRATE-INDUCED SPIKE-WAVE STUPOR.
003282 04-03
REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
003572 04-09
CLINICAL SUBTYPES OF CLUSTER HEADACHE AND THEIR RESPONSE TO LITHIUM THERAPY.
003632 04-11
PLASMA LEVELS OF ANTIDIURETIC HORMONE IN PATIENTS RECEIVING PROLONGED LITHIUM THERAPY
003696 04-13
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13
FLUPHENAZINE THERAPY IN GROUPS.
003739 04-14
ON DECISION MAKING SURROUNDING DRUG THERAPY: A CONTINUING DILEMMA.
003761 04-15
INTRA/EXTRA RED BLOOD-CELL LITHIUM AND ELECTROLYTE DISTRIBUTIONS AS CORRELATES OF NEUROTOXIC REACTIONS DURING LITHIUM THERAPY
003775 04-15
DELIRIUM ASSOCIATED WITH LITHIUM THERAPY AND ELECTROCONVULSIVE THERAPY
003794 04-15
MYOCARDITIS ASSOCIATED WITH METHYLDOPA THERAPY.
003810 04-15
THE BEHAVIORAL TREATMENT OF INSOMNIA AN ALTERNATIVE TO DRUG THERAPY
003821 04-15
A REVIEW OF COMBINED TRICYCLIC AND MAOI THERAPY
003846 04-17
HELPING PSYCHIATRIC OUTPATIENTS ACCEPT DRUG THERAPY
003871 04-17
WITHDRAWAL FROM BENZODIAZEPINE THERAPY
003872 04-17
THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY A WEB OF PARADOXES.
003877 04-17
DECISIONS ABOUT DRUG THERAPY -- V MODELS DERIVED FROM DIAGNOSTIC FREQUENCY PATTERNS.
003888 04-17

THERMAL
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN
000181 01-03
INFLUENCE OF ADRENAL ENUCLEATION ON THERMAL RESPONSE TO CHLORPROMAZINE IN RATS.
002389 03-03
THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
003047 04-01

THERMOREGULATION
EFFECT OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS ON THERMOREGULATION IN RESERPINE-TREATED RATS.
000010 01-01
EFFECTS OF ANESTHETIC INJECTED INTO BRAINSTEM SITES ON BODY TEMPERATURE AND BEHAVIORAL THERMOREGULATION.
001245 02-03
BRAIN DOPAMINE, D-AMPHETAMINE AND THERMOREGULATION IN RATS.
002409 03-03

THERMOREGULATORY
THE INFLUENCE OF HYPOTHALAMIC TEMPERATURE ON SOME THERMOREGULATORY EFFECTS OF HYPOTHALAMIC INJECTIONS OF NOREPINEPHRINE.
002294 03-03
THE INFLUENCE OF LESIONS IN THE DIENCEPHALON AND OF DRUGS ON THE THERMOREGULATORY BEHAVIOUR OF RATS.
003273 04-03

THETA
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

THETA-ACTIVITY
ABOLITION OF THE HIPPOCAMPAL THETA-ACTIVITY AND DRUG LEARNING DISSOCIATION.
000347 01-04

THIAMIN
THIAMIN DEFICIENCY AND THE PENTOSE PHOSPHATE CYCLE IN RATS INTRACEREBRAL MECHANISMS.
002307 03-03

THIAMINE
MOLECULAR COMPLEXES OF COCAINE, ITS ACTIVE METABOLITES AND SOME OTHER STIMULANTS WITH THIAMINE.
001931 02-13

THIAZIDE
THIAZIDE LITHIUM SYNERGY IN REFRACTORY MOOD SWINGS.
003793 04-15

THIAZOL-4-YLMETHOXYAMINE
THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE
001243 02-03

THIN
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001889 02-13

THIOIMIDAZOLINES
SYNTHESES AND PHARMACOLOGICAL ACTIVITY OF SUBSTITUTED IMIDAZOLIDINETHIONES AND THIOIMIDAZOLINES
003067 04-02

THIOLACTONE
THE EFFECT OF N-ACETYL-DL-PENICILLAMINE AND DL HOMOCYSTEINE THIOLACTONE ON THE MERCURY DISTRIBUTION IN ADULT RATS, RAT FETUSES AND MACACA MONKEYS AFTER EXPOSURE TO METHYLMERCURIC CHLORIDE
002198 03-03

THIORIDAZINE
EFFICACY AND SIDE-EFFECTS OF NITRAZEPAM AND THIORIDAZINE AS SLEEPING AIDS IN PSYCHOGERIATRIC INPATIENTS
000755 01-11

THE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
000781 01-11

BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, CLOZAPINE, AND THIORIDAZINE.
001583 02-04

CONCERNING ASPERMIA NOTED IN PERSONS TAKING THIORIDAZINE.
002049 02-15

PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE: A CONTROLLED DOUBLE-BLIND STUDY.
002598 03-07

COMPARATIVE EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE IN HYPERKINETIC CHILDREN.
002861 03-14

DIAZEPAM IMPAIRS DRIVING SKILLS LESS THAN THIORIDAZINE.
002929 03-15

INHIBITION OF APOMORPHINE-INDUCED HYPERMOTILITY IN RATS BY CHLORPROMAZINE, PERPHENAZINE, THIORIDAZINE AND MELPERONE.
003420 04-04

THE EFFECTS OF THIORIDAZINE AND MESORIDAZINE ON THE INTERPERSONAL LEARNING OF ACUTE SCHIZOPHRENICS.
003538 04-08

THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL.
003639 04-11

THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

PROLACTIN AND PSYCHOPHYSIOLOGIC MEASURES AFTER SINGLE-DOSES OF THIORIDAZINE.
003693 04-13

ON THE SERUM CONCENTRATIONS AND ANTIPSYCHOTIC EFFECTS OF THIORIDAZINE, THIORIDAZINE SIDE-CHAIN SULFOXIDE AND THIORIDAZINE SIDE-CHAIN SULFONE, IN CHRONIC PSYCHOTIC PATIENTS.
003762 04-15

THIORIDAZINE-PROLONGATUM

CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
002664 03-08

THIORIDAZINE-RETARD

USE OF THIORIDAZINE-RETARD IN PSYCHIATRIC TREATMENT.
00274B 03-11

THIOTHIXENE

CLINICAL EXPERIENCE OF THIOTHIXENE (NAVANE) FOR SCHIZOPHRENIA.
000577 01-08

SUCCESSFUL USE OF THIOTHIXENE IN TWO CASES OF PATHOLOGICAL JEALOUSY.
000690 01-10

CLINICAL STUDY OF THE USE OF THIOTHIXENE IN CHRONIC PSYCHOTIC PATIENTS WITH PSYCHOMOTOR INERTIA, DEPRESSION, AND AUTISM.
000726 01-11

CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08

SPEED AND RATE OF REMISSION IN ACUTE SCHIZOPHRENIA. A COMPARISON OF INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE HCL WITH THIOTHIXENE AND HALOPERIDOL.
001701 02-08

HEMODYNAMIC EFFECTS OF THIOTHIXENE AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS AT REST AND DURING EXERCISE
002622 03-08

PENFLURIDOL AND THIOTHIXENE: DOSAGE, PLASMA LEVELS AND CHANGES IN PSYCHOPATHOLOGY.
002632 03-08

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08

THOUGHT

EFFECTS OF CERTAIN BENZODIAZEPINE DERIVATIVES ON DISORGANIZATION OF THOUGHT AS MANIFESTED IN SPEECH
003522 04-07

THOUGHTS

THOUGHTS ON PHARMACOTHERAPY FOR SCHIZOPHRENIA
001724 02-08

THREATENING

THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09

THRESHOLD

INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
002908 03-15

THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE
003252 04-03

ACUTE AND CHRONIC EFFECTS OF (-) AMPHETAMINE ON SEIZURE THRESHOLD AND BRAIN CATECHOLAMINES IN MICE.
003253 04-03

THRESHOLDS

EFFECT OF COMBINED RESERPINE AND ECS ON ELECTROSHOCK SEIZURE THRESHOLDS IN MICE
000052 01-03

EFFECTS OF MESCALINE ON FLINCH AND MOVEMENT SHOCK THRESHOLDS IN RATS.
001276 02-03

MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS: LACK OF TOLERANCE WITH LONG-TERM ADMINISTRATION.
003382 04-04

THROMBIN

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING THE ADDITION OF THROMBIN AND A231B7. (UNPUBLISHED PAPER).
002804 03-13

THROMBOEMBOLIC

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
00292B 03-15

THROMBOGENESIS

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
002928 03-15

THROMBOSIS

EFFECT OF L-DOPA ADMINISTRATION TO FINE STRUCTURES OF THE BRAIN, HEART, AND KIDNEY IN RATS, WITH SPECIAL REFERENCE TO THE APPEARANCE OF MICROVASCULAR THROMBOSIS AND ITS PATHOLOGICAL SIGNIFICANCE.
000465 01-05

THYMOANALEPTIC

CLINICAL CONTRIBUTION ON THE THYMOANALEPTIC ACTION OF THE NEW ANTIDEPRESSANT CAROXAZONE (FI-6654).
002683 03-09

THYMOLEPTICS

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
000548 01-08

EFFECTS OF THYMOLEPTICS ON BEHAVIOR ASSOCIATED WITH CHANGES IN BRAIN DOPAMINE II MODIFICATION AND POTENTIATION OF APOMORPHINE-INDUCED STIMULATION OF MICE.
002506 03-04

THYMONEUROLEPTIC

FLUOTRACEN (SKF-28175), A NEW THYMONEUROLEPTIC WITH RAPID ACTION AND LONG-ACTING PROPERTIES (QUANTITATIVE PHARMACO-EEG AND CLINICAL TRIALS IN THE DEVELOPMENT OF FLUOTRACEN (SKF-28175)).
003625 04-11

THYREOTROPE

IS THE HYPOTHALAMIC HORMONE THYREOTROPE AN ANTIDEPRESSANT AGENT?
001032 01-17

THYROID

BEHAVIORAL DEPRESSION THYROID INTERACTIONS WITH NOREPINEPHRINE DEPLETING DRUGS.
000307 01-04

THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS
000640 01-09

ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
000647 01-09

THYROID HORMONE AND DEPRESSION.
000871 01-13

THYROID INSUFFICIENCY IN THE COURSE OF LITHIUM THERAPY.
002081 02-15

THYROIDECTOMY

EFFECTS OF THYROIDECTOMY ON AMPHETAMINE-INDUCED ACCELERATION OF LOCOMOTOR ACTIVITY IN MICE.
001112 02-02

THYROTOXICOSIS

LITHIUM AND THYROTOXICOSIS.
000930 01-15

LITHIUM AND THYROTOXICOSIS.
000936 01-15

THYROTOXICOSIS AND LITHIUM
002074 02-15

THYROTROPHIC
THE POSSIBLE ROLE OF THYROID AND THYROTROPHIC HORMONES IN DEPRESSIVE ILLNESS.
000640 01-09

THYROTROPIN
SOMATOSTATIN IN THE PHYSIOLOGIC FEEDBACK CONTROL OF THYROTROPIN SECRETION
001396 02-03

THYROTROPIN-RELEASING
THYROTROPIN-RELEASING HORMONE: ANTAGONISM OF PENTOBARBITAL NARCOSIS IN THE MONKEY.
000145 01-03
THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03
CHANGES IN BRAIN CATECHOLAMINES AND SPONTANEOUS LOCOMOTOR ACTIVITY IN RESPONSE TO THYROTROPIN-RELEASING HORMONE.
001120 02-03
EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE.
001730 02-09
INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001840 02-11
THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE. (PH.D. DISSERTATION).
002405 03-03
EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
0024B5 03-04
ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH).
002494 03-04
ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION.
003117 04-03
THYROTROPIN-RELEASING HORMONE : PHYSIOLOGICAL CONCOMITANTS OF BEHAVIORAL EXCITATION.
003341 04-04
THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA- A CONTROLLED STUDY.
003546 04-08
TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION.
003573 04-09

TICS
METHYLPHENIDATE-INDUCED TICS.
00205B 02-15
RESULTS OF TREATING NERVOUS TICS IN CHILDREN. BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11

TIGHT
A TIGHT PSYCHOTHERAPEUTICAL FRAMEWORK FOR THE DISCUSSION OF THE EFFECTS OF PSYCHOPHARMACA.
001007 01-16

TIGHTER
AMPHETAMINES: TIGHTER CONTROLS ON THE HORIZON.
002125 02-17

TILIACORA-DINKLAGEI
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI
0010B4 02-01

TIME
DETERMINATION OF HALOTHANE-INDUCED SLEEPING TIME IN THE RAT: EFFECT OF PRIOR ADMINISTRATION OF CENTRALLY ACTIVE DRUGS.
000245 01-03
HEXOBARBITAL SLEEPING TIME AND DRUG METABOLISM IN RATS WITH LIGATED BILE DUCTS -- A LACK OF CORRELATION.
000316 01-04
THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH.D DISSERTATION).
000339 01-04
DYSTONIC REACTIONS FOLLOWING NEUROLEPTICS TIME COURSE AND PROPOSED MECHANISMS.
000543 01-0B
NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS
000651 01-09
BETEL QUID AND REACTION TIME
000920 01-14
PETHIDINE PHARMACOKINETICS IN DOG: DOSE AND TIME STUDIES.
00113B 02-03
BRAIN HOMOVANILLIC-ACID: REGIONAL CHANGES OVER TIME WITH ANTIPSYCHOTIC DRUGS.
001152 02 03
TIME COURSE OF APOMORPHINE IN THE BRAIN OF THE IMMATURE RAT AFTER APOMORPHINE INJECTION
001395 02-03
THE EFFECTS OF ADRENALINE AND GLUCOSE ON HEXOBARBITAL SLEEPING TIME AND ON HEXOBARBITAL BLOOD LEVELS IN THE RAT
001416 02-03
EFFECTS OF FRUCTOSEDIPHOSPHATE ADMINISTRATION ON LEARNING EFFICIENCY AND TIME SENSE OF THE HONEY BEE, APIS-MELLIFICA-CARNICA.
001442 02-04
THE EFFECT OF NITROUS-OXIDE ON TIME ESTIMATION IN RATS.
001603 02-04
A SUBCHRONIC STUDY OF THE SUBJECTIVE QUALITY OF SLEEP AND PSYCHOLOGICAL MEASURES OF PERFORMANCE ON THE MORNING FOLLOWING NIGHT TIME MEDICATION WITH TEMAZEPAM.
001667 02-07
NEUROLEPTIC DRUGS WITH TIME RELEASE ACTION FOR USE IN SCHIZOPHRENIC PSYCHOSIS.
001679 02-0B
STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
001772 02-09
EFFECTS OF PRACTICE ON MARIJUANA-INDUCED CHANGES IN REACTION TIME.
001B73 02 12
REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001BB0 02-13
MARIJUANA AND ETHANOL: DIFFERENTIAL EFFECTS ON TIME PERCEPTION, HEART-RATE, AND SUBJECTIVE RESPONSE.
002001 02-14
INFLUENCE OF ENDOSULFAN ON PENTOBARBITONE SLEEPING TIME AND BLOOD AND BRAIN CONCENTRATIONS IN MALE RATS.
003163 04-03
EFFECT OF LITHIUM ON THE TIME COURSE OF PLASMA LEVELS OF ACTH, CORTICOSTERONE, ALDOSTERONE, AND ON PLASMA RENIN ACTIVITY IN RATS.
003171 04-03
EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14

TIME-BLIND
TIME-BLIND ANALYSIS OF TV-STORED INTERVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09

TIME-DEPENDENT
TIME-DEPENDENT EFFECTS PRODUCED IN CHICKS AFTER PRENATAL INJECTION OF METHYLMERCURY.
000461 01-05
TIME-DEPENDENT PERFORMANCE IMPAIRMENTS PRODUCED BY METRAZOL: AMNESIA OR NONSPECIFIC DRUG EFFECT?.
001559 02-04
CEREBELLAR C-GMP LEVELS REDUCED BY MORPHINE AND PENTOBARBITAL ON A DOSE AND TIME-DEPENDENT BASIS.
002481 03-04
TIME-DEPENDENT EFFECTS OF PHYSOSTIGMINE ON NORMAL HUMAN SLEEP AND AROUSAL. (UNPUBLISHED PAPER).
002879 03-14
SUSCEPTIBILITY OF A REACTIVATED MEMORY TO THE EFFECTS OF STRYCHNINE: A TIME-DEPENDENT PHENOMENON.
003393 04-04
THE TIME-DEPENDENT INDUCTION OF REM SLEEP AND AROUSAL BY PHYSOSTIGMINE INFUSION DURING NORMAL HUMAN SLEEP.
003749 04-14

TIMES
EFFECTS OF REPEATED DOSES OF KETAMINE ON SLEEPING TIMES IN RATS.
000367 01-04
EFFECTS OF CHANGES IN STANDING MEDICATION DISTRIBUTION TIMES ON PRN DRUG USE.
003889 04-17

TIMIDITY
EFFECT OF ETHANOL ON AGGRESSION AND TIMIDITY IN MICE.
001532 02-04

TIMING
EFFECTS OF CHLORDIAZEPOXIDE, RIPAZEPAM AND D-AMPHETAMINE ON CONDITIONED ACCELERATION OF TIMING BEHAVIOUR IN RATS.
001573 02-04

TISSUE
TISSUE DISTRIBUTION OF METOPROLOL-3H IN THE MOUSE AND THE RAT.
000054 01-03
ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03

THE NATURE OF RECEPTORS REGULATING THE FORMATION OF CYCLIC-AMP IN BRAIN TISSUE.
000085 01-03

TURNOVER OF ACID DOPAMINE METABOLITES IN STRIATAL AND MESOLIMBIC TISSUE OF THE RAT BRAIN.
000256 01-03

SIMULTANEOUS RADIOENZYMATIC DETERMINATION OF PLASMA AND TISSUE ADRENALINE, NORADRENALINE AND DOPAMINE WITHIN THE FEMTOMOLE RANGE.
000468 01-06

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC DRUGS: INHIBITION OF CATECHOLAMINE-INDUCED LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN AND RAT.
001192 02-03

ADRENERGIC RECEPTORS MEDIATING DEPOLARIZATION IN BROWN ADIPOSE TISSUE.
001202 02-03

PENTOBARBITAL SELECTIVELY ENHANCES GABA MEDIATED POSTSYNAPTIC INHIBITION IN TISSUE CULTURED MOUSE SPINAL NEURONS.
001338 02-03

IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04

A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-05

SIMULTANEOUS DETERMINATION OF THE THREE MAJOR MONOAMINE METABOLITES IN BRAIN TISSUE AND BODY FLUIDS BY A MASS FRAGMENTOGRAPHIC METHOD.
002094 02-16

EFFECT OF PYRAZIDOL ON THE ENDOGENOUS NOREPINEPHRINE LEVEL IN RAT BRAIN AND HEART TISSUE.
002205 03-03

PROPERTIES OF DOPAMINE EFFLUX FROM RAT STRIATAL TISSUE CAUSED BY AMPHETAMINE AND P-HYDROXYAMPHETAMINE.
00223B 03-03

4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN
002358 03-03

CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03

THE DISTRIBUTION AND PROPERTIES OF THYROTROPIN-RELEASING HORMONE IN HYPOTHALAMIC AND BRAIN TISSUE (PH D. DISSERTATION).
002405 03-03

IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES.
00315B 04-03

ELECTRON MICROSCOPIC AUTORADIOGRAPHY ON DELTA8-3H-TETRAHYDROCANNABINOL LOCALIZATION IN BRAIN TISSUE.
003168 04-03

IN VITRO EFFECTS OF OPIATES ON CYCLIC-AMP IN RAT STRIATAL TISSUE.
003169 04-03

TISSUES

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON MONOAMINE-OXIDASE ACTIVITY OF RAT TISSUES IN VIVO.
000042 01-03

DISTRIBUTION AND OCCURRENCE OF AMPHETAMINE AND P-HYDROXYAMPHETAMINE IN TISSUES OF THE RAT AFTER INJECTION OF D-AMPHETAMINE-SULFATE.
000088 01-03

LITHIUM-CARBONATE DISTRIBUTION AND ITS EFFECTS ON THE OTHER IONS IN THE BRAIN AND THE OTHER TISSUES OF RATS.
000119 01-03

SATURATION OF TISSUES WITH N-DESMETHYLDIAZEPAM AS A CAUSE FOR ELEVATED SERUM LEVELS OF THIS METABOLITE AFTER REPEATED ADMINISTRATION OF DIAZEPAM.
000B35 01-13

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03

UPTAKE OF 3,4 DIMETHOXYPHENYLETHYLAMINE-1-14C (14C-DMPEA) BY RAT TISSUES IN VITRO.
001229 02-03

EFFECT OF L DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
0022B4 03-03

TLP-607

CLINICAL EXPERIENCE IN USING TLP 607 (PENFLURIDOL) FOR ACUTE SCHIZOPHRENIA.
000524 01-0B

CLINICAL EXPERIENCE IN USING PENFLURIOOL (TLP-607) FOR SCHIZOPHRENIA.
000559 01-08

CLINICAL EXPERIENCE IN USING TLP-607 FOR CHRONIC SCHIZOPHRENIA.
000569 01-08

TMA-2

QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C-METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03

TOFENACIN

A COMPARATIVE TRIAL OF ORPHENADRINE AND TOFENACIN IN THE CONTROL OF DEPRESSION AND EXTRAPYRAMIDAL SIDE-EFFECTS ASSOCIATED WITH FLUPHENAZINE-DECANOATE THERAPY
001821 02-11

TOLBUTAMIDE

PLASMA PROTEIN BINDING OF DIAZEPAM AND TOLBUTAMIDE IN CHRONIC ALCOHOLICS.
00086B 01-13

TOLERABLE

TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04

TOLERANCE

PREVENTION AND REVERSAL OF TOLERANCE TO BARBITURATES BY INTRAVENTRICULAR INJECTION OF HEMICHOLINIUM-3.
000062 01-03

TOLERANCE PATTERN OF THE ANOREXIGENIC ACTION OF AMPHETAMINES, FENFLURAMINE, PHENMETRAZINE AND DIETHYLPROPION IN RATS.
000109 01-03

COCAINE: TOLERANCE TO ITS CONVULSANT AND CARDIORESPIRATORY STIMULATING EFFECTS IN THE MONKEY.
000167 01-03

MORPHINE ANALGESIC TOLERANCE; ITS SITUATION SPECIFICITY SUPPORTS A PAVLOVIAN CONDITIONING MODEL.
000227 01-03

DEVELOPMENT OF TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF MESCALINE INTRAVENTRICULARLY ADMINISTERED TO RABBITS.
000324 01-04

SYSTEMATIC ASSESSMENT OF TOLERANCE TO PENTOBARBITAL BY PELLET IMPLANTATION.
000342 01-04

TOLERANCE AND LIMITED CROSS-TOLERANCE TO THE EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) AND LYSERGIC-ACID-DIETHYLAMIDE-25 (LSD) ON FOOD REWARDED BAR PRESSING IN THE RAT.
000363 01-04

TEMPORAL RELATIONSHIP OF THE INDUCTION OF TOLERANCE AND PHYSICAL DEPENDENCE AFTER CONTINUOUS INTOXICATION WITH MAXIMUM TOLERABLE DOSES OF ETHANOL IN RATS.
000370 01-04

FACTORS INFLUENCING TOLERANCE TO D-AMPHETAMINE-INDUCED ANOREXIA IN RATS.
0003B4 01-04

ACUTE TOLERANCE TO HYPOTHERMIA IN RATS PRODUCED BY DL-3-(1,1 DIMETHYLHEPTYL)-6ALPHA,BETA,7,8,10A ALPHA HEXAHYDRO-1-HYDROXYDIMETHYL-9H-DIBENZOPYRAN-9-ONE (LILLY-109514).
000398 01-04

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

VARIOUS ASPECTS OF HIGH DOSES OF POTASSIUM CHLORAZEPATE AND CERTAIN NEUROLEPTICS ON PSYCHOMOTOR TOLERANCE
000702 01-10

ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-1

TOLERANCE AND DEPENDENCE INDUCED BY MORPHINE-LIKE PITUITARY PEPTIDES IN RATS.
00114B 02-0

ON THE POSSIBLE ROLE OF BRAIN PROTEIN SYNTHESIS IN FUNCTIONAL BARBITURATE TOLERANCE.
00123B 02-0

THE EFFECT OF THIAZOL-4-YLMETHOXYAMINE, A HISTIDINE-DECARBOXYLASE INHIBITOR, ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE IN MICE.
001243 02-0

STUDIES ON TOLERANCE DEVELOPED TO SINGLE-DOSES OF MORPHINE IN MICE
001244 02-0

ENHANCED DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL BY DESIPRAMINE INHIBITION OF PENTOBARBITAL METABOLISM
001280 02-0

IS THE INDUCTION OF MICROCOSMAL LIVER ENZYMES CAUSATIVE OF TOLERANCE TO BARBITURATES?
001364 02-0

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT.
001411 02-03

DISCRIMINATIVE STIMULUS PROPERTIES OF FENTANYL AND MORPHINE: TOLERANCE AND DEPENDENCE
001461 02-04

THE ROLE OF REINFORCEMENT LOSS IN TOLERANCE TO CHRONIC DELTA9-TETRAHYDROCANNABINOL EFFECTS ON OPERANT BEHAVIOR OF RHESUS-MONKEYS.
001476 02-04

RELATIONSHIP BETWEEN PHYSICAL DEPENDENCE AND TOLERANCE OF MORPHINE IN THE RAT.
0014B2 02-04

ACUTE FUNCTIONAL TOLERANCE TO THE MOTOR IMPAIRMENT EFFECTS OF DI-N-PROPYLACETATE.
001533 02-04

ACQUISITION AND LOSS OF BEHAVIORALLY AUGMENTED TOLERANCE TO ETHANOL IN THE RAT.
001537 02-04

THE SOMATOSENSORY EVOKED POTENTIAL AS A MEASURE OF TOLERANCE TO ALCOHOL
001941 02-13

LONG-TERM THERAPY WITH SINQUAN: INVESTIGATION OF TOLERANCE WITH SYSTEMATIC LABORATORY CONTROL.
002071 02-15

TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
0022B2 03-03

THE EXISTENCE OF TOLERANCE TO AND CROSS-TOLERANCE BETWEEN D-AMPHETAMINE AND METHYLPHENIDATE FOR THEIR EFFECTS ON MILK CONSUMPTION AND ON DIFFERENTIAL REINFORCEMENT OF LOW RATE PERFORMANCE IN THE RAT.
002332 03-03

DOES THE INDUCTION OF MICROSOMAL LIVER ENZYMES CAUSE TOLERANCE OF BARBITURATES?
002360 03-03

CORTICAL EVOKED POTENTIALS AS A PARAMETER OF THE DEVELOPMENT OF TISSUE TOLERANCE AND PHYSICAL DEPENDENCE.
002366 03-03

ROLE OF EXPERIENCE IN ACQUISITION AND LOSS OF TOLERANCE TO THE EFFECT OF DELTA9-THC ON SPACED RESPONDING.
002495 03-04

DOES TOLERANCE DEVELOP TO LOW DOSES OF D-AMPHETAMINE AND L-AMPHETAMINE ON LOCOMOTOR ACTIVITY IN RATS
002554 03-04

SEASONAL VARIATION IN DEVELOPMENT OF TOLERANCE TO MORPHINE.
002B45 03-13

QUANTITATIVE ASSESSMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE IN MICE.
003140 04-03

TOLERANCE TO THE INCREASE OF STRIATAL HOMOVANILLIC-ACID ELICITED BY SEVERAL ANORECTIC DRUGS.
0031B6 04-03

REVERSE TOLERANCE TO STIMULANT-INDUCED ABNORMAL BEHAVIOR.
003196 04-03

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
00322B 04-03

NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

BRAIN PEPTIDES WITH OPIATE ANTAGONIST ACTION: THEIR POSSIBLE ROLE IN TOLERANCE AND DEPENDENCE.
003309 04-03

INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE.
003332 04-03

INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE.
003334 04-03

SITE OF ACTION OF DEVELOPMENT OF PARTIAL TOLERANCE TO MORPHINE IN CATS
003367 04-04

MORPHINE LOWERING OF SELF-STIMULATION THRESHOLDS. LACK OF TOLERANCE WITH LONG TERM ADMINISTRATION.
0033B2 04-04

TOLERANCE AND CROSS-TOLERANCE TO THE EFFECTS OF AMPHETAMINE ISOMERS ON SEIZURE SUSCEPTIBILITY.
0033B9 04-04

TOLERANCE TO THE EFFECTS OF DELTA9-THC ON SHUTTLE-BOX PERFORMANCE AND BODY TEMPERATURE.
00339B 04-04

MORPHINE TOLERANCE ACQUISITION AS AN ASSOCIATIVE PROCESS.
003462 04-04

FACILITATION BY DEXAMETHASONE OF TOLERANCE TO ETHANOL IN THE RAT.
0034B6 04-04

EFFECTS OF PRIOR EXPERIENCE AND FUNCTIONAL DISTURBANCE ON ACUTE AND CHRONIC TOLERANCE TO METHYLPHENIDATE
0034B7 04-04

GENOTYPE AND TEST EXPERIENCE AS DETERMINANTS OF SENSITIVITY AND TOLERANCE TO MORPHINE.
003494 04-05

DETERMINING OPTIMUM DOSE AND ACUTE TOLERANCE OF TRIAZOLAM.
003754 04-14

TOLERANT

ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-03

ENKEPHALIN-INDUCED INHIBITION OF CORTICAL NEURONES AND THE LACK OF THIS EFFECT IN MORPHINE TOLERANT/DEPENDENT RATS.
00142B 02-03

IS TOLERANCE TO DELTA9-THC CELLULAR OR METABOLIC? THE SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL AND ITS METABOLITES IN BRAINS OF TOLERANT AND NON-TOLERANT RATS.
003211 04-03

TOLOXATONE

EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-03

TOLPERISONE

REVERSIBLE ADRENERGIC ALPHA-RECEPTOR BLOCKING ACTION OF 2,4 DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE).
001216 02-03

TONIC

EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON TONIC IMMOBILITY IN DUCKS AND GUINEA-PIGS.
000453 01-04

TONIC INHIBITORY INFLUENCE OF SUPRASPINAL MONOAMINERGIC SYSTEM ON RECURRENT INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
001355 02-03

AMPHETAMINE ATTENUATION OF TONIC IMMOBILITY IN CHICKENS.
001449 02-04

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
001506 02-04

EFFECTS OF ANTICHOLINERGICS ON THE HABITUATION OF TONIC IMMOBILITY IN CHICKENS.
001511 02-04

CHOLINERGIC BLOCKADE AND TONIC IMMOBILITY IN CHICKENS.
0033B7 04-04

TONIC INHIBITORY INFLUENCE OF A SUPRASPINAL MONOAMINERGIC SYSTEM ON PRESYNAPTIC INHIBITION OF AN EXTENSOR MONOSYNAPTIC REFLEX.
003456 04-04

TOO-FREQUENT

BARBITURATE HYPNOTICS, A TOO-FREQUENT AND NONSOOTHING PRESCRIPTION
001043 01-17

TOOL

THE USE OF METHADONE AS A TREATMENT TOOL FOR OPIATE ADDICTS: A TWO-YEAR FOLLOW-UP STUDY.
003025 03-17

TOOLS

NOMIFENSINE AND ITS DERIVATIVES AS POSSIBLE TOOLS FOR STUDYING AMINE UPTAKE.
003305 04-03

PHARMACOLOGICAL AGENTS AS TOOLS IN PSYCHIATRIC RESEARCH.
003B61 04-17

TOPICAL

ACUTE DOSE RESPONSE OF INTRAOCULAR PRESSURE TO TOPICAL AND ORAL CANNABINOIDS.
003161 04-03

TOPOGRAPHIC

TOPOGRAPHIC AND PHARMACOLOGICAL STUDY OF THE MESOCORTICAL DOPAMINERGIC SYSTEM.
000240 01-03

TOPOGRAPHICAL

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. II. DISTRIBUTION AND CHARACTERISTICS OF DOPAMINE ADENYLATE-CYCLASE -- INTERACTION OF D-LSD WITH DOPAMINERGIC RECEPTORS.
001150 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

TORECAN
THERAPEUTIC POSSIBILITIES OF NORTRIPTYLINE AND TORECAN.
002785 03-11

TOURETTES
THE EFFECTS OF HALOPERIDOL UPON TEMPORAL INFORMATION PROCESSING BY PATIENTS WITH TOURETTES SYNDROME.
002901 03-15

TOXIC
THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05

TOXIC REACTIONS TO LITHIUM AND HALOPERIDOL.
002055 02-15

EFFECT OF MELLARIL ON LIVER LYSOSOMES IN RATS WITH ACUTE TOXIC HEPATITIS.
002287 03-03

TOXICITIES
MANAGEMENT OF TRICYCLIC ANTIDEPRESSANT TOXICITIES.
002949 03-15

TOXICITY
TOXICITY AND TEMPERATURE RESPONSES INDUCED BY D-AMPHETAMINE AND COCAINE IN DEVELOPING MICE.
000454 01-05

SEX AS A FACTOR IN METABOLISM, TOXICITY, AND EFFICACY OF PHARMACODYNAMIC AND CHEMOTHERAPEUTIC AGENTS.
000822 01-13

CLINICAL TOXICITY OF RESERPINE IN HOSPITALIZED PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
000976 01-15

THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
001282 02-03

PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE.
001621 02-05

PROPRANOLOL IN COCAINE TOXICITY.
001852 D2-11

LITHIUM TOXICITY WITH LOW SERUM LEVELS: REPORT OF A CASE.
0D2D63 02-15

TOXICITY OF TRICHLOROBUTADIENE IN SUBACUTE EXPERIMENTS.
0D256B D3-05

LONG-TERM TOXICITY STUDY OF METHYLMERCURIC-CHLORIDE IN MONKEYS (REPORT V).
0D2569 03-05

EXPERIMENTAL STUDY OF NOZEPAM TOXICITY.
0D2572 03-05

TOXICITY AND SIDE-EFFECTS OF ANTIPSYCHOTIC, ANTIMANIC, AND ANTIDEPRESSANT MEDICATIONS.
D02884 03-15

DIAZEPAM: RADIOPROTECTIVE ACTION AND EFFECT ON TOXICITY AND RADIOPROTECTIVE POWER OF CYSTEAMINE.
DD3139 04-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ON AMPHETAMINE AGGREGATE TOXICITY IN MICE.
D03491 04-05

A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

MATERNAL BEHAVIOR: A DETERMINANT OF AMPHETAMINE TOXICITY IN RATS.
0035D7 D4-05

SUDDEN TOXICITY OF METHADONE IN MONKEYS: BEHAVIORAL AND ELECTROPHYSIOLOGICAL EVIDENCE.
0D3509 04-05

IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-13

TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.
D0378B D4-15

LSD TOXICITY: A SUSPECTED CAUSE OF DEATH.
0D3790 04-15

DISULFIRAM TOXICITY AND CARBON-DISULFIDE POISONING.
003819 04-15

THE INFLUENCE OF NALOXONE ON BARBITURATE ANESTHESIA AND TOXICITY IN THE RAT.
003860 04-17

TOXICOLOGICAL
5-METHOXYDIMETHYLTRYPTAMINE: BEHAVIORAL AND TOXICOLOGICAL EFFECTS IN ANIMALS.
000022 D1-02

TOXICOLOGICAL STUDIES ON METOPROLOL.
00D457 01-D5

COMPARATIVE EVALUATION OF METHODS FOR DETERMINING THE ORIENTATION REACTION OF RATS IN A TOXICOLOGICAL EXPERIMENT.
002582 D3-06

TOXICOLOGY
TOXICOLOGY OF PHENCYCLIDINE IN MICE.
DD1391 02-D3

ON THE TOXICOLOGY OF CARBROMAL.
0D2843 03-13

TOXICOPATHIC
TOXICOPATHIC HALLUCINATORY SYNDROMES IN CHILDREN.
000942 01-15

TOXIOCOMANIA
TOXIOCOMANIA IN HALLUCINOGENIC DRUGS.
001059 01-17

TPN-12
A DOUBLE-BLIND COMPARISON OF TPN-12 AND CHLORPROMAZINE ON SCHIZOPHRENIA.
000552 01-08

CLINICAL EFFECT OF TPN-12 FOR SCHIZOPHRENICS -- COMPARED WITH HALOPERIDOL BY A DOUBLE-BLIND TEST.
000562 D1-08

TR-10
PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
D01117 02-02

TRACER
EFFECT OF OXOTREMORINE AND SODIUM PENTOBARBITONE ON THE PHARMACOKINETICS OF INTRAVENOUS TRACER DOSES OF RADIOACTIVE CHOLINE.
003230 D4-03

TRACKING
TRACKING DIFFICULTIES AND PARANOID IDEATION DURING HASHISH AND ALCOHOL INTOXICATION.
D019BD D2-14

EFFECTS OF TWO DIFFERENT DOSES OF AN ANTIDEPRESSANT COMPARED TO PLACEBO ON TRACKING BEHAVIOR IN HUMANS.
002000 D2-14

TRACT
IS GLUTAMIC-ACID THE PYRAMIDAL TRACT NEUROTRANSMITTER?.
0D1392 D2-03

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
0D3195 04-D3

EFFECT OF DIAZEPAM ON PYRAMIDAL TRACT AND ELECTROMYOGRAPHIC MULTIPLE-UNIT ACTIVITIES OF CATS WITH CHRONIC EPILEPTOGENIC FOCI.
D03313 D4-D3

TRACTION
EFFECTS OF CENTRAL DEPRESSANTS ON ROTA-ROD AND TRACTION PERFORMANCE IN MICE.
003416 04-04

TRACTUS
EFFECTS OF POSTERIOR HYPOTHALAMIC STIMULATION ON MULTIPLE-UNIT DISCHARGES AT THE BARORECEPTOR SENSITIVE NUCLEUS TRACTUS SOLITARIUS OF CATS.
002407 03-D3

TRADE-NAME
GENERIC AND TRADE-NAME ANTIPSYCHOTIC DRUGS: CLINICAL EQUIVALENCE.
001682 02-08

TRADITIONAL
LOCOMOTOR ACTIVITY AND EXPLORATION: THE USE OF TRADITIONAL MANIPULATORS TO DISSOCIATE THESE TWO BEHAVIORS IN THE RAT.
DD1538 D2-04

TRAINED
EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04

TRAINING
EFFECTS OF RESERPINE ON ACQUISITION AND RETENTION OF DISCRIMINATED ESCAPE TRAINING. (PH.D. DISSERTATION).
DD0365 01-04

PUROMYCIN-INDUCED RETENTION DEFICIT IN GOLDFISH AS A FUNCTION OF ATTAINED TRAINING PERFORMANCE LEVEL.
D01590 D2-04

AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 D2-10

ASPECTS OF PSYCHOSOCIAL RECOVERY UNDER RELAXANT THERAPY -- AUTOGENIC TRAINING -- IN MARGINAL PSYCHIATRY.
0D2723 03-10

TRAITS
EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
D0196D D2-14

TRAITS OF THE DEVELOPMENT OF A TOLERANCE FOR NITRAZEPAM AND PHENOBARBITAL UNDER EXPERIMENTAL CONDITIONS.
0D2282 03-D3

DYNAMICS OF CLINICOPATHOPHYSIOLOGICAL TRAITS OF SENILE PSYCHOSIS UNDER THE INFLUENCE OF AZAFEN
0027D1 D3-09

TRANQUILIZER
CLINICAL EXPERIENCE OF A NEW TRANQUILIZER, N-DESMETHYLDIAZEPAM (A-101) -- FOR NEUROSES.
000697 01-10
COMPARATIVE STUDY OF THE TRANQUILIZER EFFECT OF FLUSPIRILENE AND DIAZEPAM.
000698 01-10
APPLICATION OF THE NEUROLEPTIC PIMOZIDE (ORAP-R-6238) FOR TRANQUILIZER INDICATIONS IN A CONTROLLED STUDY.
000701 01-10
COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11
PERSONALITY SPECIFIC EFFECT OF A TRANQUILIZER
001987 02-14
NEW TRANQUILIZER LABELS STIR MATERNAL ANXIETY.
00214B 02-17
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-17
AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002709 03-10
AMITRIPTYLINE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002716 03-10

TRANQUILIZERS
TRANQUILIZERS OR ANTIDEPRESSANTS FOR CHRONIC SCHIZOPHRENICS: A LONG-TERM STUDY.
000572 01-0B
PSYCHIATRY, MEDICINE, AND SLEEP -- SLEEPING DRUGS AND TRANQUILIZERS.
000B91 01-14
THE EFFECT OF MINOR TRANQUILIZERS ON PSYCHOMOTOR PERFORMANCE.
000997 01-15
THE PROTECTIVE ACTION OF CERTAIN ANESTHETICS AND TRANQUILIZERS AGAINST THE EFFECTS OF HYPERBARIC OXYGEN.
001349 02-03
LONG-TERM TRANQUILIZERS: AN ALTERNATIVE FOR PRACTICE.
001801 02-10
PUBLIC INTEREST REPORT NO. 19 -- THE OVERUSE OF TRANQUILIZERS IN OLDER PATIENTS.
001B20 02-11
HOW TRANQUILIZERS WORK.
001926 02-13
EXPERIMENTAL PSYCHOLOGICAL STUDY OF THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND A TEST DRUG) ON PERSONALITY TRAITS.
001960 02-14
TRANQUILIZERS IN GENERAL PRACTICE.
002144 02-17
HOW TRANQUILIZERS ACT ON THE BRAIN.
002322 03-03
DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11
EXTRAPYRAMIDAL SIDE-EFFECT OF CERTAIN TRANQUILIZERS.
002913 03-15
TRANQUILIZERS: PHARMACOLOGICAL ASPECTS.
003035 03-17
CHANGES IN PRESCRIBING PATTERNS OF MINOR TRANQUILIZERS.
003037 03-17

TRANQUILIZING
ANALGESIC AND TRANQUILIZING ACTIVITY OF 5,B DISUBSTITUTED 1-TETRALONE MANNICH-BASES.
003075 04-02

TRANQUILLIZERS
EFFECTS OF BENZODIAZEPINE TRANQUILLIZERS ON THE SOCIAL RESPONSES OF RATS.
000452 01-04
THE INTERACTION BETWEEN CLONIDINE AND VARIOUS NEUROLEPTIC AGENTS AND SOME BENZODIAZEPINE TRANQUILLIZERS.
003312 04-03

TRANSAMINASE
EFFECTS OF GABACULINE, A NEW POTENT INHIBITOR OF GAMMA-AMINOBUTYRATE TRANSAMINASE, ON THE BRAIN GAMMA-AMINOBUTYRATE CONTENT AND CONVULSIONS IN MICE.
003215 04-03

TRANSAMINE
PECULIARITIES OF THE ACTION OF SODIUM-OXYBUTYRATE, AMPHETAMINE, TRANSAMINE AND L-DOPA ON PHYSICAL PERFORMANCE CAPACITY OF ANIMALS UNDER MULTIPLE LOAD CONDITIONS.
002289 03-03

TRANSFER
PLACENTAL TRANSFER OF CENTRAL NERVOUS-SYSTEM DEPRESSANTS IN SHEEP
000464 01-05
STATE-DEPENDENT LEARNING PRODUCED BY CHLORDIAZEPOXIDE AND ITS TRANSFER AT DIFFERENT DOSE LEVELS.
001488 02-04
THE PLACENTAL TRANSFER OF DRUGS DURING CHILDBIRTH: A POSSIBLE INFLUENCE ON THE NEWBORN.
001892 02-13
THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIDONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION
003293 04-03

TRANSIENT
DELAY OF ONSET OF TRANSIENT AMNESIA AFTER HYPOXIA.
002416 03-04
TRANSIENT DEMENTIA SYMPTOMS CAUSED IN ONE CASE BY ETHOPROPAZINE.
002931 03-15

TRANSIENTS
ORAL TAURINE EFFECTS ON INHIBITORY BEHAVIOR: RESPONSE TRANSIENTS TO STEP-LIKE SCHEDULE CHANGES.
001560 02-04

TRANSMEMBRANEOUS
EFFECT OF PROPRANOLOL AND RELATED DRUGS ON TRANSMEMBRANEOUS PH DIFFERENCES IN LIPOSOMES.
003080 04-03

TRANSMISSION
THE EFFECTS OF NARCOTIC ANALGESICS AND NARCOTIC ANTAGONISTS ON GANGLIONIC TRANSMISSION IN THE RAT.
000098 01-03
ON THE EFFECT OF THE IONOPHORE-X-537A ON NEUROMUSCULAR TRANSMISSION IN THE RAT.
000131 01-03
INFLUENCE OF NARCOTIC ANALGESICS ON CORTICAL CONTROL OVER TRANSMISSION OF IMPULSES ALONG THE AFFERENT PATHS OF THE SCIATIC NERVE.
001168 02-03
SOME NEW VISTAS ON NEURONAL COMMUNICATION MECHANISMS: IMPACT ON THE NEUROPHARMACOLOGY OF GABA TRANSMISSION. (UNPUBLISHED PAPER).
001173 02-03
ANTICHOLINERGIC AND MEMBRANE ACTIVITIES OF AMANTADINE IN NEUROMUSCULAR TRANSMISSION.
001304 02-03
EFFECTS OF TWO BENZODIAZEPINES, PHENOBARBITONE, AND BACLOFEN ON SYNAPTIC TRANSMISSION IN THE CAT CUNEATE NUCLEUS.
001332 02-03
BIOCHEMICAL PLASTICITY OF SYNAPTIC TRANSMISSION: A CRITICAL REVIEW OF DALES PRINCIPLE.
001351 02-03
A CEREBELLAR MODEL TO STUDY THE ACTIONS OF DIAZEPAM AND MUSCIMOL ON GAMMA-AMINOBUTYRIC-ACID MEDIATED TRANSMISSION. (UNPUBLISHED PAPER).
002212 03-03
ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION.
003117 04-03
THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-03
NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: ANIMAL EXPERIMENTS.
003310 04-03
NEUROLEPTICS AND CATECHOLAMINERGIC TRANSMISSION IN THE BRAIN: CLINICAL STUDIES.
003716 04-13
VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
003717 04-13
REDUCED CATECHOLAMINERGIC TRANSMISSION AND CLINICAL EFFECTS OF NEUROLEPTICS.
00371B 04-13

TRANSMITTER
TRANSMITTER METABOLISM IN SUBSTANTIA-NIGRA AFTER INHIBITION OF DOPAMINERGIC NEURONES BY BUTYROLACTONE.
001234 02-03

TRANSMITTERS
THE TOXIC EFFECT OF SODIUM-GLUTAMATE ON RAT RETINA: CHANGES IN PUTATIVE TRANSMITTERS AND THEIR CORRESPONDING ENZYMES.
001626 02-05
PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 02-13

TRANSPLANT
AFFECTIVE PSYCHOSES FOLLOWING RENAL TRANSPLANT.
001733 02-09

TRANSPLANTATION
DEPRESSION DURING RENAL DIALYSIS AND FOLLOWING TRANSPLANTATION
003028 03-17

TRANSPORT
AMINO-ACID TRANSPORT INHIBITION: BRAIN AND BEHAVIORAL CORRELATES.
000406 01-04
INTERACTION OF CENTRAL NERVOUS-SYSTEM DRUGS WITH SYNAPTOSOMAL TRANSPORT PROCESSES
001160 02-03
TRYPTOPHAN TRANSPORT IN BRAIN SYNAPTOSOMES EFFECTS OF L DOPA.
001185 02-03
DISTRIBUTION OF LITHIUM BETWEEN ERYTHROCYTES AND PLASMA IN VITRO STUDY OF THE TRANSPORT OF LITHIUM INTO HUMAN ERYTHROCYTES
001915 02-13
REGIONAL TRANSPORT OF TRYPTOPHAN IN RAT BRAIN
003125 04-03
EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE AND 5 HYDROXYTRYPTAMINE
003247 04-03

TRANSSYNAPTIC
THE TRANSSYNAPTIC REGULATION OF ACETYLCHOLINE METABOLISM IN NUCLEI OF RAT BRAIN PHARMACOLOGICAL IMPLICATIONS (UNPUBLISHED PAPER)
002584 03-06

TRANSVERSE
ACUTE INTRAVENOUS INFUSION IN FREELY MOVING RATS THROUGH THE SAGITTAL AND TRANSVERSE SINUSES
000020 01-02

TRANYLCYPROMINE
EFFECTS OF TRANYLCYPROMINE ON 5 HT UPTAKE AND ITS INTERACTION WITH P-CPA ON RAT BRAIN 5 HT
001211 02-03
EFFECTS OF ALPHA METHYLTYROSINE AND P-CHLOROPHENYLALANINE ON OPEN FIELD BEHAVIOR IN RATS GIVEN TRANYLCYPROMINE STEREOISOMERS AND LITHIUM CARBONATE
001582 02-04
P-CHLOROPHENYLALANINE REVERSAL OF TRANYLCYPROMINE EFFECTS IN DEPRESSED PATIENTS.
002164 02-17
DIFFERENTIAL EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON INDOLEAMINES IN BRAIN
002380 03-03
SINGLE AND REPEATED ADMINISTRATION OF NEUROLEPTIC DRUGS TO RATS: EFFECTS ON STRIATAL DOPAMINE SENSITIVE ADENYLATE CYCLASE AND LOCOMOTOR ACTIVITY PRODUCED BY TRANYLCYPROMINE AND L TRYPTOPHAN OR L DOPA
002461 03-04
EFFECTS OF TRANYLCYPROMINE STEREOISOMERS CLORGYLINE AND DEPRENYL ON OPEN-FIELD ACTIVITY DURING LONG TERM LITHIUM ADMINISTRATION IN RATS
002542 03-04

TRANZENE
ANTIANXIETY ACTION OF TRANZENE 50 MG
000481 01-07

TRAPEZOID
EFFECTS OF SOME PSYCHOACTIVE DRUGS UPON THE TRAPEZOID ILLUSION PERCEPTION
002856 03-14

TRASICOR
TRASICOR IN PSYCHIATRY
001807 02-10

TRAZODONE
SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE A NEW ANTIDEPRESSANT AGENT
000233 01-03
PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE
000492 01-07
CLINICAL EVALUATION OF THE ANTIDEPRESSANT ACTION OF TRAZODONE OBSERVATIONS IN PSYCHOGERIATRICS
000683 01-10
CLINICAL AND EXPERIMENTAL STUDY ON TRAZODONE
000705 01-10
EVALUATION OF TRAZODONE IN THE TREATMENT OF ANXIETY
000719 01-10
ACTION OF TRAZODONE ON MENTAL FUNCTIONS OF THE AGED
000770 01-11
EFFECT OF TRAZODONE ON BRAIN DOPAMINE METABOLISM
001388 02-03
ANTIANXIETY EFFECTS OF TRAZODONE (A DOUBLE BLIND STUDY WITH DIAZEPAM AND PLACEBO)
001806 02-10
COMPARATIVE PSYCHOTROPIC EFFECTS OF TRAZODONE, IMIPRAMINE AND DIAZEPAM IN NORMAL SUBJECTS.
001974 02-14
TRAZODONE.
002158 02-17

TREADLE
EFFECTS OF PROMAZINE, CHLORPROMAZINE, D-AMPHETAMINE, AND PENTOBARBITAL ON TREADLE PRESSING BY PIGEONS UNDER A SIGNALLED SHOCK POSTPONEMENT SCHEDULE.
002492 03-04

TREAT
HOW TO TREAT THE PROFOUNDLY DEPRESSED PATIENT.
002686 03-09
A COMPARISON OF EQUIVALENT CLINICAL POTENCIES OF NEUROLEPTICS AS USED TO TREAT SCHIZOPHRENIA AND AFFECTIVE DISORDERS.
003903 04-17

TREATED
REGIONAL BRAIN ACETYLCHOLINE LEVELS IN RATS ACUTELY TREATED WITH ETHANOL OR RENDERED ETHANOL DEPENDENT
000008 01-01
CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS
000244 01-03
BEHAVIORAL EFFECTS ON THE PROGENY OF MICE TREATED WITH METHYLMERCURY
000432 01-04
REDUCED TURNOVER IN MESOLIMBIC DOPAMINE NEURONS IN 4-WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH PENFLURIDOL.
000459 01-05
TERATOLOGICAL STUDIES OF RABBITS AND RATS TREATED WITH THE MORPHINE DERIVATIVE CODEINE.
000462 01-05
PSYCHOSOMATIC APPROACH TO OPHTHALMOLOGIC PATIENTS TREATED WITH TRAZODONE
000492 01-07
OSTEOPENIA AND DYSREGULATION OF DIVALENT CATIONS IN LITHIUM TREATED PATIENTS
000585 01-09
DEPRESSION TREATED WITH FG-4963: RESULTS FROM AN INITIAL EXPERIMENT
000614 01-09
CLINICAL AND BIOCHEMICAL CONSIDERATIONS ON THE DEPRESSIVE STATES SUPERVENING DURING PARKINSONIAN SYNDROMES TREATED BY L DOPA
000948 01-15
ON THE EFFECT OF DOPA-DECARBOXYLASE INHIBITOR FOR THE PARKINSONS DISEASE PATIENTS TREATED BY L-DOPA FOR LONG-TERM
000970 01-15
RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIDEPRESSANTS.
001284 02-03
EFFECT OF NEUROLEPTIC DRUGS ON MOUSE JUMPING INDUCED BY L-DOPA IN AMPHETAMINE TREATED MICE
001535 02-04
THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04
REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE
001581 02-04
CONDITIONED SUPPRESSION: DISSOCIATION OF LEARNING IN BACLOFEN TREATED RATS
001589 02-04
CONDITIONED AVOIDANCE RESPONSES IN MICE SURVIVING A DOMINANT LETHAL TEST AND IN MICE TREATED NEONATALLY WITH NEUROLEPTIC DRUGS
001610 02-04
CHANGES OF BEHAVIOR IN A GROUP OF HOSPITALIZED CHRONIC SCHIZOPHRENICS TREATED WITH EMD-16139, A BENZOCHINOLIZIN DERIVATE
001690 02-08
ELECTROENCEPHALOGRAMS IN SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC DRUGS
001706 02-08
MORTALITY IN DEPRESSED PATIENTS TREATED WITH ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS
001727 02-09
EFFECT OF THYROTROPIN-RELEASING HORMONE IN COMPARISON TO PLACEBO IN DEPRESSIVE PATIENTS TREATED WITH IMIPRAMINE
001730 02-09
FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS
001782 02-09
ORPHENADRINE OVERDOSE TREATED WITH PHYSOSTIGMINE
001808 02-10
SENSITIVITY TO LITHIUM IN TREATED GRAVES DISEASE EFFECTS ON SERUM T4, T3 AND REVERSE T3.
001890 02-13

DIGIT SYMBOL PERFORMANCE IN METHADONE TREATED EX-HEROIN ADDICTS.
001956 02-14

A STUDY OF THE EEG SLEEP PATTERNS AND THE SLEEP AND DREAM EXPERIENCE OF A GROUP OF SCHIZOPHRENIC PATIENTS TREATED WITH SULPIRIDE.
001994 02-14

POST-DOPAMINE ISCHEMIA TREATED WITH CHLORPROMAZINE.
002080 02-15

EFFECT OF CHOLINERGIC DRUGS ON METHADONE-INDUCED CATALEPSY AND STEREOTYPIES IN RATS TREATED CHRONICALLY WITH METHADONE.
002199 03-03

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04

PSYCHODYNAMIC OBSERVATIONS OF A GROUP OF PATIENTS TREATED WITH LITHIUM-CARBONATE.
002670 03-09

A STUDY OF INTERDEPENDENCE BETWEEN ERYTHROCYTE LITHIUM INDEX AND THE CLINICAL STATE OF PATIENTS WITH AFFECTIVE DISORDERS TREATED PROPHYLACTICALLY WITH LITHIUM SALTS.
002696 03-09

AVERAGED EVOKED POTENTIAL PREDICTORS OF CLINICAL IMPROVEMENT IN HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE: AN INITIAL STUDY AND REPLICATION
002B63 03-14

SUICIDE ATTEMPT IN A SUBJECT TREATED WITH IDRACILAMIDE.
002924 03-15

EFFECT OF PSYCHOTROPIC THERAPY ON THROMBOGENESIS AND ON PLATELET FUNCTIONS: 4 CASES OF THROMBOEMBOLIC ACCIDENTS OCCURRING IN PATIENTS TREATED WITH NEUROLEPTICS AND ANTIDEPRESSANTS.
00292B 03-15

PLASMA AND URINARY CYCLIC-AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS.
003114 04-03

CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE.
003292 04-03

INHIBITION BY NALOXONE OF TOLERANCE AND DEPENDENCE IN MICE TREATED ACUTELY AND CHRONICALLY WITH MORPHINE.
003334 04-03

MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
003498 04-05

CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-0B

CHANGES IN PRIMARY PROCESS EXPRESSION IN HOSPITALIZED SCHIZOPHRENICS TREATED WITH PHENOTHIAZINES: TWO PROJECTIVE TASKS COMPARED.
003535 04-0B

PREDICTION OF RELAPSE IN SCHIZOPHRENIC OUTPATIENTS TREATED BY DRUG AND SOCIOTHERAPY.
003539 04-0B

ABNORMAL MOVEMENTS IN PARKINSONIANS TREATED WITH L-DOPA, AND ABNORMALITIES IN THE DOPAMINE METABOLISM.
003631 04-11

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE IN PATIENTS TREATED WITH PSYCHOTHERAPEUTIC DRUGS.
003B04 04-15

TREATING

FOUR METHODS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
000496 01-07

USE OF THE BROMPTON MIXTURE IN TREATING THE CHRONIC PAIN OF MALIGNANT DISEASE.
000B47 01-13

TREATING THE AGED WITH PSYCHOTROPIC DRUGS.
00103B 01-17

PERSONAL EXPERIENCE IN TREATING SCHIZOPHRENIC PSYCHOSIS USING FLUANXOL DEPOT
002619 03-0B

CLINICAL EVALUATION OF MIRENIL-POLFA IN TREATING SCHIZOPHRENIC PSYCHOSIS
002620 03-0B

EVALUATION OF ATROPINE THERAPY IN TREATING SCHIZOPHRENIA.
002630 03-0B

WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? ... A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED
0026B5 03-09

USE OF SIDNOCARB IN TREATING PATIENTS IN ASTHENIC OR DEPRESSIVE STATES.
002699 03-09

ATTEMPT AT TREATING PARKINSONISM WITH AGONISTS OF THE DOPAMINERGIC SYSTEM.
002751 03-11

RESULTS OF TREATING NERVOUS TICS IN CHILDREN: BASED ON ANALYSIS OF DATA OF THE PSYCHIATRIC CLINIC OF THE MILITARY MEDICAL SCHOOL.
002777 03-11

TREATING DEPRESSED CARDIAC PATIENTS.
003601 04-10

A DOUBLE-BLIND TRIAL OF NAFTIDROFURYL IN TREATING CONFUSED ELDERLY PATIENTS IN GENERAL PRACTICE.
003612 04-11

TREATMENT

APOMORPHINE SELF-INJECTION IS NOT AFFECTED BY ALPHA-METHYL-P-TYROSINE TREATMENT: SUPPORT FOR DOPAMINERGIC REWARD.
000045 01-03

ALTERATIONS OF DOPAMINERGIC NEUROTRANSMISSION AFTER CHRONIC MORPHINE TREATMENT: PRE- AND POSTJUNCTIONAL STUDIES IN STRIATAL TISSUE.
000057 01-03

CALCIUM DEPLETION OF SYNAPTOSOMES AFTER MORPHINE TREATMENT.
000070 01-03

SEARCH FOR NEW TREATMENT APPROACHES IN SCHIZOPHRENIA: IN VITRO STUDIES OF POTENTIAL N-METHYLTRANSFERASE INHIBITORS.
000090 01-03

INCREASED CNS SENSITIVITY TO FLUROTHYL AS A MEASURE OF PHYSICAL DEPENDENCE IN MICE FOLLOWING MORPHINE, PHENOBARBITAL, AND ETHANOL TREATMENT.
000114 01-03

LACK OF INFLUENCE OF THE PHASE OF ESTRUS CYCLE OR TREATMENT WITH STEROID CONTRACEPTIVE DRUGS ON CHOLINERGIC PARAMETERS IN MOUSE AND RAT BRAIN.
000149 01-03

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000192 01-03

DECADRON IN THE TREATMENT OF CEREBRAL ABSCESS: AN EXPERIMENTAL STUDY.
000206 01-03

NEUROPHYSIOLOGICAL CORRELATES OF LONG-TERM AMPHETAMINE TREATMENT IN RATS. (PH. D. DISSERTATION).
000208 01-03

EFFECTS OF COMBINED TREATMENT WITH NORTRIPTYLINE AND LORAZEPAM ON CONFLICT BEHAVIOR AND MOTILITY OF RATS.
000277 01-04

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYDROXYDOPA.
000376 01-04

THE INTERACTION BETWEEN ELECTRICALLY-INDUCED CONVULSIONS AND TOLERANCE IN THE ABSTINENCE PERIOD AFTER CHRONIC BARBITAL TREATMENT IN THE RAT.
000445 01-04

ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION.
000484 01-07

TREATMENT OF PHENOTHIAZINE-INDUCED DYSKINESIA.
000493 01-07

EEG PATTERN DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
00049B 01-07

MARKED EEG CHANGES DURING CLOZAPINE TREATMENT OF PARANOID HALLUCINATORY PSYCHOSES.
000499 01-07

PREDICTING INDIVIDUAL RESPONSES TO DRUG TREATMENT IN SCHIZOPHRENIA. A TEST DOSE MODEL.
000506 01-07

TREATMENT OF PSYCHIATRIC EMERGENCIES BY A NEW NEUROLEPTIC: SULTOPRIDE.
000510 01-07

A POSSIBLE SUBGROUP OF THE SCHIZOPHRENIC SYNDROME AND IMPLICATIONS FOR TREATMENT.
000533 01-0B

BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA (UNPUBLISHED PAPER).
000534 01-0B

INTRAMUSCULAR DOUBLE-BLIND STUDY OF DEPOT TREATMENT OF FLUSPIRILENE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
000542 01-0B

THE RELATION OF THE ACTION OF NEUROLEPTIC DRUGS TO THE EXTRAPYRAMIDAL SYSTEM AND THE EFFECTIVENESS OF LONG-ACTING NEUROLEPTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
000544 01-0B

CHANGES IN SERUM ENZYME LEVELS DURING TREATMENT WITH NEUROLEPTICS AND THYMOLEPTICS.
00054B 01-0B

DRUG IN THE AFTERCARE TREATMENT OF SCHIZOPHRENIA.
000549 01-0B

THE CONSUMPTION OF INPATIENT PSYCHIATRIC RESOURCES PRIOR TO AND DURING TREATMENT WITH A DEPOT NEUROLEPTIC, PERPHENAZINE-ENANTHATE. A MIRROR STUDY.
000553 01-08

THE CHOICE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW.
000571 01-08

RESULTS OF LEPONEX TREATMENT IN SCHIZOPHRENIA.
000574 01-08

NEUROBIOLOGICAL CONSIDERATIONS ON THE MODE OF ACTION OF LITHIUM-CARBONATE IN THE TREATMENT OF AFFECTIVE DISORDERS?.
000584 01-09

TREATMENT OF MANIA WITH BROMOCRIPTINE.
000594 01-09

A COMPARATIVE STUDY OF ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIVE STATES.
000598 01-09

FUNCTIONAL STIMULATION OF DRUGS FOR THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
000619 01-09

A PROCAINE DERIVATIVE FOR THE TREATMENT OF DEPRESSION IN AN OUTPATIENT POPULATION
000624 01-09

5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY.
000627 01-09

APPLICATION OF SINEQUAN IN THE TREATMENT OF VARIOUS CLINICAL FORMS OF DEPRESSION.
000631 01-09

COMPARATIVE STUDY OF THREE PSYCHOTROPIC DRUGS IN THE TREATMENT OF DEPRESSIONS.
000645 01-09

FOLLOW-UP OF MAINTENANCE TREATMENT FOR DEPRESSION.
00064B 01-09

CLINICAL PHYSIOLOGICAL STUDY OF DRUGS FOR THE TREATMENT OF PSYCHOSES.
000653 01-09

TREATMENT OF ANXIETY AND DEPRESSION STATES IN AGED PATIENTS. DOUBLE-BLIND COMPARISON OF THE EFFECTS OF AMITRIPTYLINE AND A FLUPHENAZINE NORTRIPTYLINE COMBINATION.
000658 01-09

EXPERIMENTALLY INDUCED PAIN IN PATIENTS WITH AND WITHOUT PHARMACOLOGICAL TREATMENT -- A METHODOLOGICAL ASPECT.
000664 01-09

THE TREATMENT OF LIFE THREATENING CARDIOPULMONARY ILLNESS AND LIFE THREATENING DEPRESSIVE ILLNESS: SUICIDE EQUIVALENTS?.
000667 01-09

PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS IN GYNECOLOGY.
000674 01-10

TREATMENT OF OBSESSIONAL AND PHOBIC NEUROSES WITH RO-5-3350 (LEXOTAN).
0006B0 01-10

TREATMENT OF NIGHTMARES.
0006B4 01-10

DRUG THERAPY FOR SOCIOPATHIC OFFENDERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYDROCHLORIDE. (PH.D. DISSERTATION).
0006B5 01-10

PIMOZIDE IN THE TREATMENT OF STRESS-INDUCED PSYCHIC AND FUNCTIONAL DISORDERS: A DOUBLE-BLIND COMPARISON WITH CHLOPOXIDE AND PLACEBO.
000691 01-10

CARDIAC NEUROSIS: TREATMENT WITH A NEW BENZODIAZEPINE (LEXOTAN).
000703 01-10

RED-BLOOD CELL LITHIUM INDEX AND LONG-TERM MAINTENANCE TREATMENT.
000704 01-10

LEXOTANIL (RO-5-3350) IN THE PSYCHOSOMATIC TREATMENT OF PATIENTS WITH FUNCTIONAL ABDOMINAL DISORDERS.
000708 01-10

CLINICAL TREATMENT OF POSTPARTUM DELIRIUM WITH PERFENAZINE AND LITHIUM-CARBONATE.
000709 01-10

TREATMENT OF THE DEPRESSED PATIENT IN THE HOME.
00071B 01-10

EVALUATION OF TRAZODONE IN THE TREATMENT OF ANXIETY.
000719 01-10

COMPARISON OF THE THERAPEUTIC ACTION OF CHLORMETHIAZOLE AND PROMAZINE IN THE TREATMENT OF GERIATRIC PSYCHOSES.
000724 01-11

THE USE OF DIPOTASSIUM CHLORAZEPATE AT HIGH DOSAGE IN TREATMENT OF OBESITY.
00073B 01-11

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF THE NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE.
000741 01-11

POST-DETOXIFICATION DRUG TREATMENT OF ANXIETY AND DEPRESSION IN ALCOHOL ADDICTS.
000742 01-11

TREATMENT OF CHILDREN WITH DIFFICULTIES IN LEARNING WITH PYRITHIOXINE (ENCEPHABOL) IN JAKARTA, INDONESIA.
000743 01-11

CLINICAL STUDIES WITH PINDOLOL (CARVISKEN), A BETA-ADRENERGIC BLOCKING AGENT, IN THE TREATMENT OF SINUS TACHYCARDIA ASSOCIATED WITH THE USE OF PSYCHOTROPIC DRUGS -- A DOUBLE-BLIND STUDY.
000746 01-11

MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11

RESULTS OF L-DOPA TREATMENT IN PARKINSONISM.
000751 01-11

A TRIAL OF FENFLURAMINE IN THE TREATMENT OF THE CHRONIC ALCOHOLIC PATIENT.
000752 01-11

CLINICAL EXPERIENCES WITH THE COMBINED USE OF TWO NEUROLEPTICS, CLOTHIAPINE AND HALOPERIDOL, IN THE TREATMENT OF CERTAIN MENTAL DISEASES.
000756 01-11

COMPARISON OF BROMAZEPAM (RO-5-3350), A NEW TRANQUILIZER FOR PSYCHOSIS WITH DIAZEPAM BY A DOUBLE-BLIND CROSS-OVER EXAMINATION IN THE TREATMENT OF NEUROSIS.
000762 01-11

USE OF LEPONEX IN THE TREATMENT OF CHRONIC PSYCHIATRIC PROBLEMS: CLINICAL STUDY.
000763 01-11

USE OF DIBENZEPINE RETARD IN THE TREATMENT OF ALCOHOLIC DEPRESSION
000764 01-11

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 01-11

AGONISTS AND ANTAGONISTS IN THE TREATMENT OF DRUG ADDICTION.
000773 01-11

PERSONALITY STRUCTURE AND SEXUAL BEHAVIOR OF EPILEPTICS UNDER LONG-TERM TREATMENT WITH DPH.
000775 01-11

ACUTE AND CHRONIC PSYCHIATRIC DISEASES OF OLD AGE, THEIR DIAGNOSIS AND TREATMENT
000777 01-11

LITHIUM TREATMENT DURING ALCOHOLIC WITHDRAWAL.
00077B 01-11

TREATMENT OF CEREBRAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
000786 01-11

L-DOPA PLUS DOPA-DECARBOXYLASE INHIBITOR: SLEEP ORGANIZATION IN PARKINSONS SYNDROME BEFORE AND AFTER TREATMENT.
000801 01-13

L-DOPA TREATMENT IN PARKINSONISM. BIOCHEMICAL BASIS.
000B02 01-13

MINIMAL-BRAIN-DAMAGE SYNDROME (CHROMOSOMAL CHANGES AND LITHIUM TREATMENT).
000B03 01-13

AMANTADINE VERSUS TRIHEXYPHENIDYL IN THE TREATMENT OF NEUROLEPTIC-INDUCED PARKINSONISM.
000B1B 01-13

THE MOVEMENT PATTERN OF ORAL TARDIVE-DYSKINESIA IN RELATION TO ANTICHOLINERGIC AND ANTIDOPAMINERGIC TREATMENT.
000B20 01-13

CUMULATION IN CEREBROSPINAL FLUID OF THE N-DESMETHYL METABOLITE AFTER LONG-TERM TREATMENT WITH DIAZEPAM IN MAN
000B25 01-13

METABOLIC ADAPTATION TO ANTIDEPRESSANT DRUGS: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT IN PSYCHIATRY.
000842 01-13

PIRIBEDIL IN THE TREATMENT OF PARKINSONS DISEASE.
000848 01-13

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE.
000853 01-13

TREATMENT OF PARKINSONISM WITH A COMBINATION OF L-DOPA AND METHYLDOPA HYDRAZINE.
000870 01-13

DEANOL IN THE TREATMENT OF HYPERKINETIC CHILDREN.
000884 01-14

TREATMENT OF INSOMNIA.
000901 01-14

TREATMENT OF CHRONIC POSTTRAUMATIC ORGANIC-BRAIN-SYNDROME WITH DEXTROAMPHETAMINE: FIRST REPORTED CASE.
000904 01-14

COMPLICATIONS AND SIDE-EFFECTS IN LONG-TERM TREATMENT WITH PRACTOLOL.
000931 01-15

THERAPEUTIC RISKS IN LONG-TERM TREATMENT WITH NEUROLEPTICS AND LITHIUM
000937 01-15
CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
000943 01-15
ORAL GLUCOSE TOLERANCE TEST IN SCHIZOPHRENICS UNDER LONG-TERM NEUROLEPTIC TREATMENT.
000949 01-15
EXOGENOUS PSYCHOSIS IN A PATIENT WITH CARCINOID SYNDROME FOLLOWING TREATMENT WITH P-CHLOROPHENYLALANINE.
000952 01-15
MANGANESE AND NIACIN IN THE TREATMENT OF DRUG-INDUCED DYSKINESIAS.
000958 01-15
PSYCHIATRIC SYMPTOMS WITH INITIATION OF CARBIDOPA LEVODOPA TREATMENT.
000962 01-15
CLONAZEPAM IN THE TREATMENT OF EPILEPSY: A CONTROLLED CLINICAL TRIAL IN SIMPLE ABSENCES, BILATERAL MASSIVE EPILEPTIC MYOCLONUS, AND ATONIC SEIZURES.
000969 01-15
CORNEAL AND LENS LESIONS CAUSED BY TREATMENT WITH NEUROLEPTICS OF THE PHENOTHIAZINE TYPE.
000977 01-15
PHARMACOGENIC CHRONIC HALLUCINOSIS: A CASE OF CHRONIC HALLUCINOSIS IN LATE LIFE AFTER LONG-TERM TREATMENT WITH PSYCHOLEPTICS.
000992 01-15
PSYCHOACTIVE DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001035 01-17
ANALGESIC/CALMATIVE EFFECTS OF ACETAMINOPHEN AND PHENYLTOLOXAMINE IN TREATMENT OF SIMPLE NERVOUS TENSION ACCOMPANIED BY HEADACHE.
001041 01-17
ON THE TREATMENT OF MENTALLY DISTURBED COLLEGE STUDENTS.
001047 01-17
INDICATIONS FOR LONG-TERM PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC SYNDROMES.
001066 01-17
THE ADVANTAGES AND DISADVANTAGES OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS.
001067 01-17
LITHIUM TREATMENT. SOME DATA AND RECENT PERSPECTIVES.
001068 01-17
COMPARISON OF DANTROLENE SODIUM AND DIAZEPAM IN THE TREATMENT OF SPASTICITY.
001070 01-17
THEORY OF TREATMENT -- PHARMACOTHERAPY.
001075 01-17
DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE.
001144 02-03
THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03
BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY FOLLOWING CHRONIC TREATMENT WITH METHADONE OR CHLORPROMAZINE IN THE GUINEA-PIG.
001195 02-03
EFFECTS OF CHRONIC TREATMENT WITH AMINOOXYACETIC-ACID OR SODIUM N DIPROPYLACETATE ON BRAIN GABA LEVELS AND THE DEVELOPMENT AND REGRESSION OF COBALT EPILEPTIC FOCI IN RATS.
001196 02-03
HIGH-DOSE TREATMENT OF RATS WITH PERPHENAZINE-ENANTHATE.
001205 02-03
CHANGES IN CATECHOLAMINE CONCENTRATIONS AND SYNTHESIS RATE IN MOUSE BRAIN DURING THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH NEUROLEPTIC DRUGS.
001246 02-03
REGIONAL DISTRIBUTION OF DIAZEPAM AND ITS METABOLITES IN THE BRAIN OF CAT AFTER CHRONIC TREATMENT.
001331 02-03
CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03
EFFECTS OF CHRONIC TREATMENT WITH NEUROLEPTICS ON STRIATAL ACETYLCHOLINE CONCENTRATION.
001365 02-03
EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03
CLOZAPINE REDUCTION OF THE INITIAL DOPAMINE TURNOVER INCREASE BY REPEATED TREATMENT.
001412 02-03
EFFECT OF CHRONIC PENTOBARBITAL TREATMENT ON THE SLEEP PATTERNS OF SQUIRREL-MONKEYS.
001433 02-04
THE EFFECT OF LONG-TERM ETHANOL TREATMENT ON THE SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS-ACCUMBENS.
001478 02-04
RECEPTOR BLOCKADE AND RECEPTOR HYPERSENSITIVITY AFTER TREATMENT WITH NEUROLEPTICS
001547 02-04
GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
001568 02-04
DYSKINESIAS IN MONKEYS: INTERACTION OF METHAMPHETAMINE WITH PRIOR METHADONE TREATMENT.
001619 02-05
A STUDY OF COPPER TREATMENT AND TISSUE COPPER LEVELS IN THE MURINE CONGENITAL COPPER DEFICIENCY, MOTTLED.
001625 02-05
EFFECTS OF CYCLOPHOSPHAMIDE TREATMENT OF NEWBORN MICE ON THE DEVELOPMENT OF SWIMMING AND REFLEX BEHAVIOR AND ON ADULT BEHAVIORAL PERFORMANCE.
001635 02-05
A DOUBLE-BLIND TRIAL OF BACLOFEN AGAINST PLACEBO IN THE TREATMENT OF SCHIZOPHRENIA.
001664 02-07
TREATMENT OF PSYCHIC DISTURBANCES OF OLIGOPHRENICS WITH NEW PSYCHOACTIVE LONG-ACTING AGENT RP-19552 (PIPORTYL-PALMITATE).
001668 02-07
PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
001683 02-08
CYCLIC-GMP IN THE CSF OF PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER NEUROLEPTIC TREATMENT.
001687 02-08
PATHOLOGICAL ALTERATIONS OF THE EEG DURING TREATMENT WITH CLOZAPINE IN PATIENTS WITH SCHIZOPHRENIC SYMPTOMATOLOGY.
001692 02-08
CONTROLLED TRIAL OF PENFLURIDOL AND THIOTHIXENE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC SYNDROMES.
001693 02-08
RATIONAL TREATMENT FOR AN IRRATIONAL DISORDER: WHAT DOES THE SCHIZOPHRENIC PATIENT NEED?.
001704 02-08
HIGH DOSES OF HALOPERIDOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY.
001705 02-08
CHANGE IN DRUG CATABOLISM IN THE LIVER UNDER TREATMENT WITH PERAZINE.
001711 02-08
LITHIUM TREATMENT OF A PATIENT WITH PERIODIC CATATONIA.
001712 02-08
DIAZEPAM IN THE TREATMENT OF TARDIVE-DYSKINESIA: PRELIMINARY OBSERVATIONS.
001716 02-08
DRUG RESEARCH ON TREATMENT OF SCHIZOPHRENIA.
001721 02-08
RAPID TREATMENT OF ACUTE PSYCHOSIS.
001726 02-09
ONCE DAILY ADMINISTRATION OF FLUPHENAZINE/NORTRIPTYLINE PREPARATION IN TREATMENT OF MIXED ANXIETY/DEPRESSIVE STATES.
001735 02-09
CLINICAL AND PHARMACOLOGICAL EFFECTS OF TREATMENT WITH A NEW ANTIDEPRESSANT.
001739 02-09
TREATMENT OF DEPRESSION WITH BUTRIPTYLINE.
001743 02-09
DEPRESSION: BEHAVIORAL, BIOCHEMICAL, DIAGNOSTIC AND TREATMENT CONCEPTS.
001746 02-09
EFFECTS OF PARATHORMONE AND LITHIUM TREATMENT ON CALCIUM AND MOOD IN DEPRESSED PATIENTS.
001748 02-09
THE DRUG TREATMENT OF MOOD DISORDERS: PART I. DIAGNOSIS, BIOLOGICAL BASIS OF DRUG EFFECTS, AND GENERAL PRINCIPLES OF DRUG THERAPY IN THE AFFECTIVE DISORDERS (UNPUBLISHED PAPER).
001750 02-09
PSYCHOANALYTIC ASPECTS OF THE TREATMENT OF MANIC-DEPRESSIVE PSYCHOSIS.
001754 02-09
OUTPATIENT TREATMENT OF NEUROTIC DEPRESSION: MEDICATION AND GROUP PSYCHOTHERAPY.
001755 02-09
COMBINED SLEEP DEPRIVATION/CHLORIMIPRAMINE TREATMENT OF ENDOGENOUS DEPRESSION.
001757 02-09
LITHIUM IN THE TREATMENT OF DEPRESSION.
001761 02-09

TREATMENT OF VAGINISMUS 8Y I.V. DIAZEPAM (VALIUM) A8REACTION INTERVIEWS.
001764 02-09

STUDY OF THE IMPORTANCE OF NEUROTIC PSYCHOLOGICAL FACTORS IN THE SUCCESS OF LONG-TERM LITHIUM TREATMENT.
001766 02-09

LIFE EVENTS, DEPRESSIVE RELAPSE AND MAINTENANCE TREATMENT.
001770 02-09

THE TREATMENT OF ENDOMORPHOUS AND PSYCHOGENIC DEPRESSIONS WITH A FIXED COM8INATION OF AMITRIPTYLINE/FLUPENTHIXOL (LU-7410).
001773 02-09

TRYPTOPHAN AND ALLOPURINOL IN THE TREATMENT OF DEPRESSION.
001777 02-09

THE CURRENT ROLE OF LITHIUM IN THE TREATMENT OF AFFECTIVE DISORDERS.
001779 02-09

A NEW PSYCHOTROPIC FOR THE TREATMENT OF ANXIOUS AND DEPRESSIVE NEUROSES: NOMIFENSIN.
001785 02-10

DIAZEPAM AND PHENO8AR8ITAL IN THE TREATMENT OF ANXIETY: A CONTROLLED MULTICENTER STUDY USING PHYSICIAN AND PATIENT RATING SCALES.
001787 02-10

TREATMENT OF PHO8IC NEUROSIS WITH CLOMIPRAMINE: A CONTROLLED CLINICAL TRIAL.
001791 02-10

HALOPERIDOL IN THE TREATMENT OF PSYCHONEUROTIC ANXIOUS OUTPATIENTS.
001792 02-10

POLYGRAPHIC RECORDING OF SLEEP IN ENDOGENOUS DEPRESSIVE PATIENTS 8EFORE AND AFTER TREATMENT WITH AMITRIPTYLINE-N-OXIDE.
001794 02-10

AN ASSESSMENT OF THE EFFECTIVENESS OF AUTOGENIC TRAINING IN COMPREHENSIVE TREATMENT OF NEUROTIC AND PSYCHOPATHIC CONDITIONS.
001795 02-10

MIANSERIN IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
001798 02-10

NONPHARMACOLOGICAL FACTORS IN DRUG TREATMENT OF ANXIETY STATES.
001802 02-10

TREATMENT OF PSYCHIATRIC EMERGENCIES.
001803 02-10

A DOU8LE-8LIND COMPARISON 8ETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF NEUROTIC ANXIETY.
001810 02-10

EFFECTIVENESS OF VARIOUS METHODS IN THE TREATMENT OF SLEEP DISORDERS, 8ASED ON ELECTROPOLYGRAPHIC DATA.
001812 02-10

LITHIUM CAR8ONATE VERSUS ECT IN THE TREATMENT OF THE MANIC STATE OF IDENTICAL TWINS WITH 8IPOLAR AFFECTIVE DISEASE.
001813 02-11

EXPERIENCE IN THE TREATMENT OF ALCOHOLIC PATIENTS WITH CHLORACYZINE IN COM8INATION WITH RATIONAL PSYCHOTHERAPY.
001815 02-11

PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY: ETIOLOGY AND TREATMENT.
001817 02-11

AM8ULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CAR8AMAZEPINE: A FORMAL MULTICENTRE DOU8LE-8LIND COMPARISON WITH PLACE8O
001818 02-11

PIPAMPERONE (DIPIPERON) IN THE TREATMENT OF BEHAVIOR DISORDERS: A LARGE-SCALE MULTICENTRE EVALUATION
001825 02-11

PSYCHOLOGICAL MEDICINE. DRUGS USED IN PSYCHOLOGICAL MEDICINE: PHARMACOLOGICAL 8ASIS OF TREATMENT.
001828 02-11

AN ERGOT ALKALOID PREPARATION (HYDERGINE) IN THE TREATMENT OF DEMENTIA. CRITICAL REVIEW OF THE CLINICAL LITERATURE.
001832 02-11

THE USE OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF CHRONIC, SEVERE PAINS.
001834 02-11

DOSE EFFECT RELATIONSHIP IN TREATMENT WITH PIRACETAM.
001835 02-11

PSYCHOTHERAPEUTIC AND ANESTHESIOLOGICAL ASPECTS OF NITROUS-OXIDE USED IN THE TREATMENT OF 8ORDERLINE PSYCHOTIC STATES.
001836 02-11

TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES 8Y MEANS OF HYPERVENTILATION REPORT OF A CONTROLLED CLINICAL TRIAL.
001839 02-11

THE DRUG TREATMENT OF PARKINSONISM.
001848 02-11

FAILURE OF ACETYLMETHADOL IN TREATMENT OF NARCOTIC ADDICTS DUE TO NONPHARMACOLOGIC FACTORS.
001858 02-11

COGNITIVE DISSONANCE IN THE PLACE8O TREATMENT OF INSOMNIA -- A PILOT EXPERIMENT.
001864 02-11

A CONTROLLED STUDY OF THE TREATMENT OF NARCOTIC ADDICTION IN IRAN: A PRELIMINARY REPORT (UNPU8LISHED PAPER).
001865 02-11

HALOPERIDOL, RESERPINE, L-DOPA AND AMANTADINE IN THE TREATMENT OF HUNTINGTONS CHOREA
001893 02-13

8ACLOFEN (LIORESAL) IN THE TREATMENT OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA.
001923 02-13

HISTOCHEMICAL CHANGES IN THE BLOOD CELLS OF SCHIZOPHRENIC PATIENTS UNDER PIMOZIDE TREATMENT.
001946 02-13

INSOMNIA AND ITS TREATMENT.
001971 02-14

EXPERIENCES WITH THE USE OF DEPOT NEUROLEPTICS IN PSYCHIATRIC AFTERCARE. THE ORGANIZATION AND RESULTS OF TREATMENT WITH PIPOTIAZINE-PALMITATE IN 3-4 YEARS.
001992 02-14

RELATIONSHIP OF LITHIUM-CHLORIDE DOSE TO TREATMENT RESPONSE IN ACUTE MANIA.
001999 02-14

TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM.
002030 02-15

TREATMENT OF TRICYCLIC INTOXICATION
002064 02-15

EMERGENCE OF MYASTHENIA-GRAVIS DURING TREATMENT WITH LITHIUM-CARBONATE.
002066 02-15

CARDIAC COMPLICATIONS IN AMITRIPTYLINE POISONING: SUCCESSFUL TREATMENT WITH PHYSOSTIGMINE.
002078 02-15

TREATMENT APPROACHES TO MANIA.
002097 02-17

IMPLICATIONS OF DRUG TREATMENT FOR THE SOCIAL REHABILITATION OF SCHIZOPHRENIC PATIENTS.
002116 02-17

SHORT-TERM AND LONG-TERM CLINICAL EVALUATION OF A NON-AMPHETAMINIC ANOREXIANT (MAZINDOL) IN THE TREATMENT OF O8ESITY
002117 02-17

PSYCHOTROPIC DRUGS IN OPIOID ADDICTS ON METHADONE TREATMENT.
002119 02-17

ANXIETY AND DEPRESSION: DIFFERENTIAL DIAGNOSIS AND TREATMENT IN DAILY PRACTICE.
002134 02-17

THE IDENTIFICATION AND TREATMENT OF ADULT 8RAIN DYSFUNCTION
002143 02-17

INFLUENCE OF NONPHARMACOLOGICAL FACTORS ON ADMINISTRATION OF NEUROLEPTICS IN THE STATIONARY TREATMENT OF ACUTE PSYCHIATRIC CONDITIONS.
002153 02-17

THE USE OF STIMULANT DRUGS IN THE TREATMENT OF HYPERACTIVITY
002170 02-17

THE THERAPISTS HAND8OOK: TREATMENT METHODS OF MENTAL DISORDERS.
002178 02-17

APPARENT PROTEIN KINASE ACTIVITY IN OLIGODENDROGLIAL CHROMATIN AFTER CHRONIC MORPHINE TREATMENT.
002324 03-03

DEFICIENT GO-NO-GO DISCRIMINATION LEARNING IN RATS UNDER THE TREATMENT OF CHLORDIAZEPOXIDE.
002475 03-04

DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS
002511 03-04

OPERANT 8EHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6-HYDROXYDOPAMINE TREATMENT.
002519 03-04

ALTERATIONS IN THE EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS ON GENERAL ACTIVITY IN RATS FOLLOWING CHRONIC MORPHINE TREATMENT
002541 03-04

EFFECT OF CHRONIC TREATMENT OF METHYLMERCURIC-CHLORIDE ON THE CENTRAL-NERVOUS-SYSTEM IN RATS
002565 03-05

8EHAVIORAL EFFECTS OF WITHDRAWAL OF FLUPHENAZINE AFTER LONG-TERM TREATMENT.
002578 03-05

L-DOPA AND (-) DEPRENIL IN THE TREATMENT OF PARKINSONS DISEASE A LONG-TERM STUDY
002588 03-07

GAMMA-HYDROXYBUTYRATE IN THE TREATMENT OF NARCOLEPSY: A PRELIMINARY REPORT
002590 03-07
AN ERGOT DERIVATIVE IN THE TREATMENT OF PARKINSONS DISEASE.
002592 03-07
FIRST CLINICAL IMPRESSIONS AFTER USE OF SULTOPRIDE FOR TREATMENT OF MANIC STATES OF AGITATION.
002597 03-07
PIPERACETAZINE VERSUS THIORIDAZINE IN THE TREATMENT OF ORGANIC-BRAIN-DISEASE A CONTROLLED DOUBLE BLIND STUDY.
002598 03-07
RESULTS OF LEPONEX TREATMENT.
002601 03-07
SAFEGUARDS IN THE TREATMENT OF SCHIZOPHRENIA WITH PROPRANOLOL.
002607 03-07
COMPARATIVE STUDY OF THE THERAPEUTIC EFFECTIVENESS OF MIRENIL-PROLONGATUM AND MODITEN-DEPOT IN TREATMENT OF SCHIZOPHRENIA.
00260B 03-08
CHANGES IN THE PHYSICAL AND CHEMICAL PROPERTIES OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIC CHILDREN.
002616 03-08
CHANGE IN THE INTERPHASE ELECTRIC POTENTIAL OF BLOOD DURING PHARMACOLOGICAL TREATMENT OF CHILDREN FOR SCHIZOPHRENIA.
002617 03-08
DEPRESSION SYMPTOM SCALE FOR EVALUATING THE SUCCESS OF NEUROLEPTIC TREATMENT.
002633 03-08
TREATMENT OF SCHIZOPHRENIA AND SCHIZOPHRENIC PSYCHOSIS AT JAROSLAW HOSPITAL IN 1972.
002642 03-08
CLINICAL EVALUATION OF PIMOZIDE AND PIPORTIL IN TREATMENT OF CHRONIC SCHIZOPHRENIA.
002645 03-08
LOXAPINE SUCCINATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
002648 03-08
COMPARATIVE EVALUATION OF MAINTENANCE TREATMENT IN CHRONIC SCHIZOPHRENIA USING FLUPHENAZINE AND FLUPENTHIXOL IN SLOW-RELEASE FORM.
002650 03-08
COMPARATIVE EVALUATION OF MODITEN-DEPOT AND CONVENTIONAL MAINTENANCE TREATMENT USING NEUROLEPTICS.
002651 03-08
RESULTS OF MODITEN-DEPOT TREATMENT IN CHRONIC SCHIZOPHRENIA.
002660 03-08
CLINICAL EVALUATION OF MODITEN-DEPOT AND THIORIDAZINE-PROLONGATUM IN TREATMENT OF SCHIZOPHRENIA.
002664 03-08
ADVERSE REACTIONS IN TREATMENT WITH LITHIUM-CARBONATE AND HALOPERIDOL.
002665 03-09
TREATMENT OF DEPRESSION WITH LUDIOMIL CIBA.
002669 03-09
THE TREATMENT OF PATHOLOGICAL PANIC STATES WITH PROPRANOLOL.
002677 03-09
PRELIMINARY STUDY OF THE TREATMENT OF ENDOGENOUS DEPRESSION WITH BROMOERGOCRYPTINE.
002694 03-09
AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION.
002697 03-09
MEASUREMENT OF 5-HYDROXYINDOLE COMPOUNDS DURING L-5-HTP TREATMENT IN DEPRESSED PATIENTS.
002700 03-09
LITHIUM IN PREVIOUS TREATMENT FAILURES.
002703 03-09
CHLORIMIPRAMINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION.
002704 03-09
AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002709 03-10
CLINICAL EVALUATION OF AMITRIPTYLINE HYDROCHLORIDE IN THE TREATMENT OF DEPRESSION.
002713 03-10
CLINICAL EVALUATION OF AMITRIPTYLINE IN THE TREATMENT OF PSYCHOGENIC DISTURBANCES.
002714 03-10
AMITRIPTYLINE IN THE TREATMENT OF ANXIETY AND INSOMNIA, AND AS A TRANQUILIZER.
002716 03-10
MAZINDOL (TERONAC) IN THE TREATMENT OF PREDOMINANTLY ALIMENTARY OBESITY.
002719 03-10
PYRITHIOXINE (ENCEPHABOL) IN THE TREATMENT OF PATIENTS WITH ORGANIC PSYCHOSYNDROME IN INVOLUTION CLINICAL, EEG AND EXPERIMENTAL PSYCHOLOGICAL STUDY.
002724 03-10
PROPRANOLOL IN THE TREATMENT OF ANXIETY
002731 03-10
IMPORTANCE OF PROMOTIL IN FOLLOW-UP TREATMENT OF ALCOHOLICS.
002740 03-11
TREATMENT OF NIGHTMARES.
002744 03-11
USE OF THIORIDAZINE RETARD IN PSYCHIATRIC TREATMENT.
002748 03-11
APHASIA IN A CHILD WITH EPILEPSY. IMPROVEMENT UNDER ANTIEPILEPTIC TREATMENT.
002752 03-11
TREATMENT OF DRUG-INDUCED PSYCHOSIS WITH DIPHENYLHYDANTOIN.
002761 03-11
DOXEPIN AND DIAZEPAM IN THE TREATMENT OF HOSPITALIZED GERIATRIC PATIENTS.
002770 03-11
USE OF PSYCHOPHARMACEUTICALS FOR THE TREATMENT OF ABNORMAL BEHAVIOR OF OLIGOPHRENIC EPILEPTICS.
002772 03-11
DRUG TREATMENT OF MENTAL DISORDERS.
002780 03-11
SOME PROBLEMS OF THE TREATMENT OF BRONCHIAL ASTHMA.
002781 03-11
TREATMENT OF NEUROLEPTIC SYNDROME WITH AN EXTENDED ACTION FORM OF BIPERIDEN HYDROCHLORIDE: 9 MONTH STUDY OF 55 HOSPITALIZED PATIENTS.
0027B7 03-11
LONG-TERM TREATMENT OF ERETHISMIC MENTAL RETARDATION WITH OXAZEPAM 50.
0027BB 03-11
PATHOPHYSIOLOGICAL ASPECTS CONCERNING THE TREATMENT OF THE APALLIC SYNDROME.
0027B9 03-11
BETA-ADRENERGIC BLOCKING AGENTS IN THE TREATMENT OF PSYCHOSES. A REPORT ON 17 CASES.
002790 03-11
TREATMENT OF GILLES-DE-LA-TOURETTES SYNDROME WITH HALOPERIDOL.
002791 03-11
DIAGNOSIS AND TREATMENT OF MINIMAL-BRAIN-DYSFUNCTION IN ADULTS.
002794 03-11
COMBINED TREATMENT OF PARKINSONISM PATIENTS WITH LEVOPA, MEDANTANE, AND ANTICHOLINERGIC AGENTS.
002795 03-11
EVOKED POTENTIAL, STIMULUS INTENSITY, AND DRUG TREATMENT IN HYPERKINESIS.
002B17 03-13
URINARY CYCLIC-AMP IN RELATION TO LITHIUM TREATMENT IN MANIC-DEPRESSIVE ILLNESS.
002B37 03-13
SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN.
002BB9 03-15
DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT
002B93 03-15
DIETHYLSTILBESTROL IN THE TREATMENT OF RAPE VICTIMS.
002899 03-15
PHYSOSTIGMINE TREATMENT OF DELIRIUM INDUCED BY ANTICHOLINERGICS.
002903 03-15
CLUBBING -- A SIDE-EFFECT OF LONG-TERM PHENOTHIAZINES TREATMENT
002905 03-15
INFLUENCE OF PSYCHOTROPIC DRUG TREATMENT UPON PENTAMETHYLENETETRAZOL THRESHOLD IN NONEPILEPTIC PSYCHOTIC PATIENTS.
00290B 03-15
DISCONTINUANCE OF ASSOCIATED ANTIPARKINSONIAN DRUGS IN LONG-TERM NEUROLEPTIC TREATMENT.
002923 03-15
A CASE PRESENTING SOME REACTIVE CLINICAL SIGNS DURING TREATMENT OF L-DOPA
002930 03-15
TARDIVE-DYSKINESIA: MANIFESTATIONS, INCIDENCE, ETIOLOGY, AND TREATMENT.
002935 03-15
PSEUDOPSYCHOTIC RELAPSES IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
002945 03-15
PHARMACOLOGICAL TREATMENT OF AFFECTIVE DISORDERS.
002962 03-17
DEPRESSIVE STATES INDUCED BY DRUGS OF ABUSE: CLINICAL EVIDENCE, THEORETICAL MECHANISMS AND PROPOSED TREATMENT. PART II.
002971 03-17

TREATMENT OF DISTURBANCES OF SLEEP WITH FLURAZEPAM, NITRAZEPAM, AND ALLYPROPYMAL.
002976 03-17

THE CONCEPT OF TARGET SYMPTOMS FOR DRUG TREATMENT IN PSYCHIATRY.
002996 03-17

INTERACTIONS OF DRUGS AND OTHER APPROACHES IN THE TREATMENT OF THE MENTALLY ILL.
003008 03-17

RESULTS OF SCHIZOPHRENIA TREATMENT OVER A FIVE-YEAR PERIOD.
003018 03-17

THE USE OF METHADONE AS A TREATMENT TOOL FOR OPIATE ADDICTS: A TWO-YEAR FOLLOW-UP STUDY.
003025 03-17

DRUGS USED IN THE TREATMENT OF MENTAL DISORDER.
003030 03-17

RECENT ADVANCES IN THE TREATMENT AND PREVENTION OF ADVERSE REACTIONS TO LITHIUM.
003031 03-17

HYSTERICAL AND HYSTERIA-LIKE REACTIONS DURING NEUROLEPTIC TREATMENT FOR SCHIZOPHRENIA.
003036 03-17

TREATMENT OF MIGRAINE ATTACKS WITH AN ANALGESIC COMBINATION (MERSYNOOL).
003039 03-17

BRAIN MONOAMINE-OXIDASE ACTIVITY AFTER CHRONIC ETHANOL TREATMENT OF RATS.
003076 04-02

ALTERATIONS IN BRAIN CYCLIC GUANOSINE 3:5 MONOPHOSPHATE LEVELS AFTER ACUTE AND CHRONIC TREATMENT WITH ETHANOL.
003177 04-03

CHANGES IN DOPAMINE SYNTHESIS RATE IN THE SUPERSENSITIVITY PHASE AFTER TREATMENT WITH A SINGLE-DOSE OF NEUROLEPTICS.
00317B 04-03

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM AND BRAIN UPTAKE OF DELTA-AMINOLAEVULINIC-ACID IN RATS.
003237 04-03

CHANGES OF THE FORMATION OF C-AMP AND THE CONTENT OF NORADRENALINE (NA) IN RAT BRAIN AFTER TREATMENT WITH IMIPRAMINE (IMI), RESERPINE (RES) AND ALPHA-METHYL-P-TYROSINE (ALPHA-MPT).
003269 04-03

OPEN-FIELD BEHAVIOUR IN SHEEP FOLLOWING TREATMENT WITH THE NEUROLEPTICS AZAPERONE AND ACETYLPROMAZINE.
003405 04-04

NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN
003447 04-04

EFFECT OF CHRONIC CHLORPROMAZINE ADMINISTRATION OR PRIOR TREATMENT WITH RESERPINE ON BRAIN APOMORPHINE CONCENTRATIONS AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR IN THE RAT.
003467 04-04

HYPOTHALAMIC SELF-STIMULATION UNDER THE CHRONIC MORPHINE TREATMENT IN THE RAT.
003490 04-04

ANTISCHIZOPHRENIC DRUGS: CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR BINDING IN BRAIN.
003493 04-05

SELECTIVE SUPPRESSION OF DRINKING DURING A LIMITED PERIOD FOLLOWING AVERSIVE DRUG TREATMENT IN RATS.
003497 04-05

ACTIVITY PATTERN AND CONVULSIONS IN THE ABSTINENCE PERIOD AFTER BARBITAL TREATMENT IN THE RAT.
003512 04-05

PENFLURIDOL VERSUS ORAL FLUPHENAZINE IN THE MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENICS.
003519 04-07

TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY WITH METHYSERGIDE: NEUROPSYCHOLOGIC IMPROVEMENT IN FIVE PATIENTS.
003524 04-07

EFFICACY OF LOXAPINE IN THE TREATMENT OF PARANOID SCHIZOPHRENIA.
003527 04-08

A POSITIVE RESPONSE TO RAPID TREATMENT.
003532 04-0B

ANTIPARKINSONIAN AGENTS AND LONG-TERM NEUROLEPTIC TREATMENT: EFFECT OF G-31406, ORPHENADRINE AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY.
003537 04-0B

PENFLURIDOL, A PERORAL LONG-ACTING NEUROLEPTIC, FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO RELAPSE.
003544 04-08

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.
003545 04-08

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN THE TREATMENT OF REMITTED SCHIZOPHRENICS. II. RATING SCALE DATA.
003547 04-08

CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS: PLASMA CONCENTRATION AND COAGULATION FACTORS.
003548 04-08

PHARMACOLOGICAL TREATMENT OF THE MODERATELY ANXIOUS AND DEPRESSED PATIENT.
003556 04-09

THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS.
003559 04-09

ONCE-DAILY TREATMENT FOR MIXED ANXIETY/DEPRESSIVE STATES: A COMPARISON OF SLOW-RELEASE AMITRIPTYLINE AND FLUPHENAZINE WITH NORTRIPTYLINE.
003564 04-09

CONTROLLED TRIAL OF NOMIFENSIN (HOE-984) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY.
003570 04-09

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION.
003573 04-09

SIGNIFICANCE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DEPRESSIVE DISORDERS.
003576 04-09

SYSTEMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
003579 04-10

LSD TREATMENT IN A SEVERE CASE OF COMPULSIVE NEUROSIS.
003583 04-10

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL GERIATRIC PATIENT. A CASE REPORT.
003587 04-10

A DOUBLE-BLIND STUDY OF PRAZEPAM VERSUS PLACEBO IN SINGLE DAILY DOSES IN THE TREATMENT OF ANXIETY
003589 04-10

BRIEF TREATMENT OF ANXIOUS PATIENTS WITH HALAZEPAM IN HIGH DOSES.
003591 04-10

THE SYSTEMIC USE OF PROCAINE IN THE TREATMENT OF THE ELDERLY: A REVIEW.
003595 04-10

NONSPECIFIC FACTORS IN DRUG TREATMENT.
003598 04-10

A COMPARISON OF MAPROTILINE AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
003604 04-10

A DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.
003606 04-10

HYDROXYZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL.
003614 04-11

PHENYTOIN AS A TREATMENT OF OBESITY ASSOCIATED WITH COMPULSIVE EATING.
003622 04-11

NARCOTIC ANTAGONIST TREATMENT OF ADDICT PAROLEES -- THE FAILURE OF AN EFFECTIVE APPROACH.
003623 04-11

GANGLIOSIDES IN THE TREATMENT OF MENTAL DETERIORATION: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
003634 04-11

SUCCESSFUL USE OF BROMOCRIPTINE IN THE TREATMENT OF A PATIENT WITH CHRONIC PORTASYSTEMIC ENCEPHALOPATHY.
003635 04-11

PSYCHOACTIVE DRUGS IN THE TREATMENT OF THE AGED
00363B 04-11

HYPERSOMNIA IN MYOTONIC DYSTROPHY: TREATMENT WITH METHYLPHENIDATE.
003640 04-11

THE EVALUATION OF BELLERGAL TABLETS COMPARED TO LIBRIUM AND PLACEBO IN THE TREATMENT OF SYMPTOMS OF ANXIETY TENSION STATES ASSOCIATED WITH FUNCTIONAL GASTROINTESTINAL DISORDERS.
003642 04-11

CLONAZEPAM IN THE TREATMENT OF ABSENCE SEIZURES: A DOUBLE-BLIND CLINICAL TRIAL
003643 04-11

AMITRIPTYLINE AND METHYLPHENIDATE TREATMENT OF BEHAVIORALLY DISORDERED CHILDREN.
003652 04-11

MONOAMINE METABOLITES IN CEREBROSPINAL FLUID AND SEROTONIN UPTAKE INHIBITION DURING TREATMENT WITH CHLORIMIPRAMINE.
003654 04-13

THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

REDUCTION IN PLASMA NOREPINEPHRINE DURING FENFLURAMINE TREATMENT.
003666 04-13

DEPRESSIVE SUBTYPES, BLOOD PRESSURE CHANGES AND RESPONSE TO TREATMENT.
003669 04-13

PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT.
003692 04-13

THE SIGNIFICANCE OF THE CEREBRAL DOPAMINE METABOLISM IN THE PATHOGENESIS AND TREATMENT OF PSYCHOTIC DISORDERS.
003720 04-13

LEVODOPA TREATMENT IN PRESENILE DEMENTIA.
003738 04-14

PROTRIPTYLINE: AN EFFECTIVE AGENT IN THE TREATMENT OF THE NARCOLEPSY CATAPLEXY SYNDROME AND HYPERSOMNIA.
003748 04-14

SOME PROBLEMS IN THE TREATMENT OF DEPRESSION WITH PHARMACOLOGICAL AGENTS.
003778 04-15

LITHIUM TREATMENT IN THE ELDERLY. I. CLINICAL USAGE.
003781 04-15

FIRST-DEGREE ATRIOVENTRICULAR BLOCK DURING LITHIUM-CARBONATE TREATMENT.
003796 04-15

TREATMENT OF TRICYCLIC OVERDOSE PATIENTS.
003811 04-15

THE BEHAVIORAL TREATMENT OF INSOMNIA: AN ALTERNATIVE TO DRUG THERAPY.
003821 04-15

A REVIEW OF NEUROTOXICITY OF LITHIUM DURING THERAPEUTIC TREATMENT.
003829 04-15

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS: PHARMACOLOGICAL APPROACH.
003845 04-17

DRUG TREATMENT IN THE ELDERLY: PROBLEMS AND PRESCRIBING RULES.
003851 04-17

THE TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS: AN INVESTIGATION OF SOME CURRENT ASSUMPTIONS.
003852 04-17

THE MEDICAL ECONOMICS OF LITHIUM TREATMENT FOR MANIC-DEPRESSIVES.
003854 04-17

MEDITATION, PROTEIN, DIET, AND MEGAVITAMINS IN THE TREATMENT OF A PROGRESSIVE, IATROGENIC CARDIAC AND PSYCHOTIC CONDITION.
003856 04-17

PHENOMENOLOGY AND TREATMENT OF DEPRESSION.
003858 04-17

LITHIUM IN THE TREATMENT OF A MANIC PATIENT WITH MULTIPLE-SCLEROSIS: A CASE REPORT.
003879 04-17

TREATMENTS

A POSSIBLE COMMON MECHANISM OF ACTION OF ANTIDEPRESSANT TREATMENTS.
000250 01-03

BEHAVIORAL AND PHARMACOLOGICAL TREATMENTS FOR OBESITY: AN EXPERIMENTAL COMPARISON
000768 01-11

THE INTERACTION BETWEEN SPONTANEOUS CONVULSIONS AND TOLERANCE TO HEXOBARBITAL IN THE ABSTINENCE AFTER CHRONIC BARBITAL TREATMENTS IN THE RAT
001411 02-03

TREATMENTS OF SCHIZOPHRENIA WITH TRIFLUPROMAZINE DEPOT.
002661 03-08

NEUROTIC DEPRESSION AN EMPIRICAL GUIDE TO TWO SPECIFIC DRUG TREATMENTS.
002721 03-10

DEPRESSION: A NEW ANIMAL MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.
003071 04-02

LONG-TERM TREATMENTS OF PSYCHOTIC STATES.
003613 04-11

TREMOR

THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03

CHARACTERISTICS OF SUSTAINED TREMOR INDUCED BY NICOTINE IN PILOCARPINE TREATED ANIMALS.
000244 01-03

EFFECT OF CORETAL-POLFA (OXPRENOLOL) ON PARKINSONIAN TREMOR AND BENIGN ESSENTIAL TREMOR
000734 01-11

EFFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHOLIC PATIENTS.
000782 01-11

PERIODIC STRUCTURE OF PHYSIOLOGICAL AND PATHOLOGICAL TREMOR.
002089 02-16

PROPRANOLOL IN BENIGN ESSENTIAL TREMOR.
002878 03-14

DIRECT QUANTITATIVE MEASUREMENT OF TREMOR: INITIAL RESULTS OF A NEW MEASURING PROCEDURE IN PATIENTS UNDER LITHIUM TREATMENT.
002893 03-15

RIGIDITY, TREMOR, AND MYOCLONUS IN THE RAT IMMEDIATELY FOLLOWING INJECTIONS OF P-CHLOROAMPHETAMINE.
003162 04-03

TREMORINE

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
003228 04-03

TREMOROGENIC

TREMOROGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE AND THEIR SUPPRESSION BY DOPAMINE.
001438 02-04

TREMORS

PROSTAGLANDIN-E2 AND CYCLIC NUCLEOTIDES IN RAT CONVULSIONS AND TREMORS.
002210 03-03

THE EFFECT OF BETA-ADRENERGIC BLOCKADE (PROPRANOLOL) ON DIFFERENT TREMORS.
002753 03-11

THERAPEUTIC EFFICACY OF PROPRANOLOL AGAINST TREMORS AND OTHER EXTRAPYRAMIDAL EFFECTS CAUSED BY PARKINSONIGENIC PSYCHOTROPIC DRUGS.
002885 03-15

TRENDS

NEW TRENDS OF BETA-BLOCKERS IN ACTIONS AND APPLICATIONS.
000869 01-13

PRESENT AND FUTURE TRENDS IN PSYCHOTROPIC DRUGS.
001037 01-17

TRH

THYROTROPIN-RELEASING HORMONE (TRH): RESTORATION OF OXOTREMORINE TREMOR IN MICE.
000146 01-03

TRH EFFECTS ON ENDOGENOUSLY DEPRESSED MALES.
000669 01-09

THE CONTRASTING ACTIONS OF TRH AND CYCLOHEXIMIDE IN ALTERING THE EFFECTS OF CENTRALLY ACTING DRUGS: EVIDENCE FOR THE NON INVOLVEMENT OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE.
001226 02-03

TRH POTENTIATES EXCITATORY ACTIONS OF ACETYLCHOLINE ON CEREBRAL CORTICAL NEURONES.
001425 02-03

TRH BY SLOW, CONTINUOUS INFUSION: AN ANTIDEPRESSANT?.
001781 02-09

INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001840 02-11

EFFECT OF THYROTROPIN-RELEASING HORMONE (TRH) AND ANTIDEPRESSANT AGENTS ON BRAINSTEM AND HYPOTHALAMIC MULTIPLE-UNIT ACTIVITY IN THE CAT.
002485 03-04

ANTAGONISM OF ISOLATION-INDUCED AGGRESSION IN MICE BY THYROTROPIN-RELEASING HORMONE (TRH).
002494 03-04

ANTAGONISM OF THE ANALEPTIC ACTIVITY OF THYROTROPIN-RELEASING HORMONE (TRH) BY AGENTS WHICH ENHANCE GABA TRANSMISSION.
003117 04-03

IDENTIFICATION BY MICROINJECTION OF TRH SENSITIVE SITES IN THE CATS BRAINSTEM THAT MEDIATE RESPIRATORY, TEMPERATURE AND OTHER AUTONOMIC CHANGES.
003226 04-03

THYROTROPIN-RELEASING HORMONE (TRH) IN CHRONIC SCHIZOPHRENIA. A CONTROLLED STUDY.
003546 04-08

TREATMENT OF ENDOGENOUS DEPRESSIONS WITH THYROTROPIN-RELEASING HORMONE (TRH) UNDER ORAL ADMINISTRATION
003573 04-09

TRIAZINE

PHARMACOLOGICAL STUDIES ON TRIAZINE DERIVATIVES V. SEDATIVE AND NEUROLEPTIC ACTIONS OF 2-AMINO-4 (4(2 HYDROXYETHYL)-PIPERAZIN-1-YL) 6-TRIFLUOROMETHYL-S-TRIAZINE (TR-10).
001117 02-02

TRIAZOLAM

PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUTPATIENTS WITH INSOMNIA.
000490 01-07

HYPNOTIC EFFICACY OF TRIAZOLAM: SLEEP LABORATORY EVALUATION OF INTERMEDIATE TERM EFFECTIVENESS.
00074B 01-11
THE COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, DIAZEPAM, AND PLACEBO IN INPATIENT INSOMNIACS.
000B7B 01-14
TRIAZOLAM: AN EFFECTIVE HYPNOTIC IN GENERAL PRACTICE.
001964 02-14
DETERMINING OPTIMUM DOSE AND ACUTE TOLERANCE OF TRIAZOLAM.
003754 D4-14

TRIAZOLOBENZODIAZEPINE
EFFECT OF A TRIAZOLOBENZODIAZEPINE DERIVATIVE, ESTAZOLAM, ON ALL-NIGHT SLEEP PATTERN.
0D09D2 01-14
POTENTIATION OF EFFECTS OF CATECHOLAMINES AND SYMPATHETIC STIMULATION BY TRIAZOLOBENZODIAZEPINE.
DD2245 03-03

TRICHLOROBUTADIENE
TOXICITY OF TRICHLOROBUTADIENE IN SUBACUTE EXPERIMENTS.
00256B 03-05

TRICYCLIC
THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
00D107 01-03
ACTIVITY OF LIVER MICROSOMAL MONOOXYGENASES ON SOME EPOXIDE FORMING TRICYCLIC DRUGS. I. KINETICS IN VITRO.
0D0190 01-03
EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS AND LITHIUM ON NOREPINEPHRINE TURNOVER IN BRAIN.
00021B D1-D3
CONCENTRATION OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA, HEART AND SKELETAL MUSCLE AFTER THEIR INTRAVENOUS INFUSION TO ANESTHETIZED RABBITS.
00045B 01-05
EVALUATION TECHNIQUES IN THE STUDY OF TRICYCLIC ANTIDEPRESSANTS.
000476 01-06
BLOOD SERUM DENSITIES OF TRICYCLIC ANTIDEPRESSANTS -- VIEWS GAINED THROUGH THERAPEUTIC USE.
0005B1 01-09
PROGRESS TOWARDS A COMPREHENSIVE PLASMA ASSAY FOR THE TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS.
D0D61D D1-D9
THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
D00615 01-09
THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.
0D062B 01-09
SOME ASPECTS OF THE METABOLISM OF TRICYCLIC ANTIDEPRESSANTS.
00D63B 01-09
PSYCHOPHARMACOLOGICAL DRUG DENSITIES IN THE BLOOD SERUM -- DENSITIES OF TRICYCLIC ANTIDEPRESSANTS AND THEIR MEANING.
000654 01-09
THE MEASUREMENT OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS.
D00655 01-09
TRICYCLIC ANTIDEPRESSANTS, TRYPTOPHAN AND AFFECTIVE DISORDER.
D00657 01-09
WHAT ARE TRICYCLIC ANTIDEPRESSANT DRUGS?
D0D661 01-09
DO TRICYCLIC ANTIDEPRESSANTS WORK?
DDD662 D1-D9
EFFECTS OF CLOMIPRAMINE AND OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
DDD665 D1-D9
RATING SCALES AS PREDICTORS OF RESPONSE TO TRICYCLIC ANTIDEPRESSANTS.
DDDBBD D1-14
CONVULSIVE ACCIDENTS AND EEG MODIFICATIONS IN THE COURSE OF TREATMENT BY TRICYCLIC ANTIDEPRESSANTS.
D00943 01-15
DYSKINESIAS ASSOCIATED WITH TRICYCLIC ANTIDEPRESSANTS.
0DD944 D1-15
MEASUREMENT OF TRICYCLIC ANTIDEPRESSANT LEVELS IN AN OUTPATIENT CLINIC.
0D1DD2 D1-16
SUICIDE WITH TRICYCLIC ANTIDEPRESSANTS.
001D19 01-17
PHYSICAL CHARACTERIZATION AND ACTIVITY IN VIVO OF POLYMORPHIC FORMS OF CHLORODIHYDRODIBENZOXAZEPINE-CARBOXAMIDE, A POTENTIAL TRICYCLIC ANTIDEPRESSANT.
DD1DB6 D2-D1
EFFECT OF TRICYCLIC ANTIDEPRESSANT DRUGS ON THE HEART.
001193 02-03
RETINAL LIPIDOSIS IN ALBINO RATS TREATED WITH CHLORPHENTERMINE AND WITH TRICYCLIC ANTIDEPRESSANTS.
0012B4 02-03
EFFECTS OF LITHIUM AND RUBIDIUM ON THE ANTINOCICEPTION AND BEHAVIOUR IN MICE: II. STUDIES ON THREE TRICYCLIC ANTIDEPRESSANTS AND PIMOZIDE.
001288 02-03
AUGMENTATION OF PENTYLENETETRAZOL-INDUCED SEIZURES BY TRICYCLIC ANTIDEPRESSANTS.
001346 02-03
INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
00140B 02-03
TRICYCLIC ANTIDEPRESSANT DRUGS AS ANTAGONISTS OF MUSCARINIC RECEPTORS IN SYMPATHETIC GANGLIA.
DD1415 D2-D3
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN
001423 02-03
THE EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND NEUROLEPTICS ON THE PERIPHERAL AND CENTRAL ACTION OF NOREPINEPHRINE IN RESERPINE TREATED MICE.
001553 02-04
EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02-07
TREATMENT OF ACUTE POISONING WITH TRICYCLIC ANTIDEPRESSIVES BY MEANS OF HYPERVENTILATION REPORT OF A CONTROLLED CLINICAL TRIAL.
001B39 02-11
THIN LAYER CHROMATOGRAPHIC DETERMINATION OF PLASMA LEVELS OF TRICYCLIC PSYCHOTROPIC DRUGS: INITIAL RESULTS ON A RELATIONSHIP TO THE CLINICAL EFFECT OF NEUROLEPTICS.
001BB9 02-13
DO TRICYCLIC ANTIDEPRESSANTS WORK?.
001939 02-13
CARDIAC EFFECTS OF DIFFERENT TRICYCLIC ANTIDEPRESSANT DRUGS.
002023 D2-15
DO TRICYCLIC ANTIDEPRESSANTS WORK?
002027 02-15
SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002039 02-15
REVERSAL OF TRICYCLIC OVERDOSAGE INDUCED CENTRAL ANTICHOLINERGIC SYNDROME BY PHYSOSTIGMINE.
00204B 02-15
TREATMENT OF TRICYCLIC INTOXICATION
002064 02-15
SODIUM-BICARBONATE AND TRICYCLIC ANTIDEPRESSANT POISONING.
002067 02-15
TRICYCLIC ANTIDEPRESSANT CARDIOTOXICITY.
002073 02-15
EVIDENCE IN FAVOR OF AN ANTICHOLINERGIC MECHANISM OF ACTION OF TRICYCLIC ANTIDEPRESSANT DRUGS.
002224 03-D3
EPOXIDE-DIOL PATHWAY IN THE METABOLISM OF TRICYCLIC DRUGS.
D02240 03-03
NEUROCHEMICAL MECHANISMS OF TRICYCLIC ANTIDEPRESSANTS OF THE IMIPRAMINE GROUP.
0D22B3 03-03
THE BIOLOGICAL DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.
002356 D3-03
TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES IN VENTRICULAR AUTOMATICITY.
D02562 03-05
PREDICTION OF TRICYCLIC ANTIDEPRESSANT RESPONSE A CRITICAL REVIEW
0D2667 03-D9
WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED.
0026B5 D3-09
SODIUM BICARBONATE TREATMENT FOR TRICYCLIC ANTIDEPRESSANT ARRHYTHMIAS IN CHILDREN
DD2BB9 03-15
THE EFFECT OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS ON THE HEART AND CIRCULATION.
D02B90 03-15
COMBINING TRICYCLIC AND MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS.
DD2936 D3-15
MANAGEMENT OF TRICYCLIC ANTIDEPRESSANT TOXICITIES.
0D2949 03-15

CHLOROQUINE, QUININE, PROCAINE, QUINIDINE, TRICYCLIC ANTIDEPRESSANTS, AND METHYLXANTHINES AS PROSTAGLANDIN AGONISTS AND ANTAGONISTS.
003012 03-17

INFLUENCE OF IMIPRAMINE AND VARIOUS STEROIDS ON HEPATIC IN VITRO N-DEMETHYLATION OF TRICYCLIC ANTIDEPRESSANTS.
003105 04-03

EFFECTS OF SEVERAL TRICYCLIC ANTIDEPRESSANTS ON THE HEMODYNAMICS AND MYOCARDIAL CONTRACTILITY OF THE ANESTHETIZED DOGS.
003183 04-03

TRICYCLIC ANTIDEPRESSANT DRUGS: ATTENUATION OF EXCITATORY EFFECTS OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON ACOUSTIC STARTLE RESPONSE.
003372 04-04

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH DEPRIVATION-INDUCED FLUID CONSUMPTION BY RATS
003489 04-04

SYSTEMATIC STUDIES IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH TRICYCLIC ANTIDEPRESSANTS.
003579 04-10

IS PHYSOSTIGMINE EFFECTIVE FOR CARDIAC TOXICITY OF TRICYCLIC ANTIDEPRESSANT DRUGS
003659 04-13

LACK OF EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON SERUM PROLACTIN LEVELS.
003689 04-13

IN VIVO INHIBITION OF PLATELET MAO ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS.
003712 04-13

OVERDOSING THE TRICYCLIC OVERDOSE PATIENT
003768 04-15

TREATMENT OF TRICYCLIC OVERDOSE PATIENTS.
003811 04-15

A REVIEW OF COMBINED TRICYCLIC AND MAOI THERAPY
003846 04-17

TRICYCLIC ANTIDEPRESSANTS AND CENTRAL MONOAMINE METABOLISM.
003902 04-17

TRICYCLIC-INDUCED
TRICYCLIC-INDUCED MYOCLONUS.
003802 04-15

TRICYCLICS
IF SPEED KILLS, TRICYCLICS MASSACRE.
001734 02-09

THE ACTION OF TRICYCLICS (ALONE OR IN COMBINATION WITH METHYLPHENIDATE) UPON SEVERAL SYMPTOMS OF NARCOLEPSY
002782 03-11

ANTIDEPRESSANTS AND PAIN: A REVIEW OF THE PHARMACOLOGICAL DATA SUPPORTING THE USE OF CERTAIN TRICYCLICS IN CHRONIC PAIN
003883 04-17

TRIETHYLENE-GLYCOL-DINITRATE
SOME NEUROTOXIC PROPERTIES OF TRIETHYLENE-GLYCOL-DINITRATE A COMPARISON WITH DECAMETHONIUM.
000034 01-03

TRIFLUBAZAM
EFFECT OF THE 1,5 BENZODIAZEPINES, CLOBAZAM AND TRIFLUBAZAM, ON THE SLEEP OF MAN
001657 02-07

TRIFLUOPERAZINE
EFFECT OF PROLONGED TRIFLUOPERAZINE, IMIPRAMINE AND HALOPERIDOL ADMINISTRATION ON SERUM CHOLESTEROL AN EXPERIMENTAL STUDY IN RABBITS.
001612 02-05

A DOUBLE BLIND COMPARATIVE TRIAL OF LOXAPINE AND TRIFLUOPERAZINE IN ACUTE AND CHRONIC SCHIZOPHRENIC PATIENTS.
001698 02-08

ELECTROCHEMICAL EVIDENCE FOR INTERACTION BETWEEN CHLORPROMAZINE HYDROCHLORIDE AND TRIFLUOPERAZINE HYDROCHLORIDE AND THE FLAVIN COENZYMES
002184 03-01

TRIFLUOPERAZINE-INDUCED
NEUROCHEMICAL ASPECTS OF THE CORRECTIVE ACTION OF PHTHORACIZINE IN RATS WITH TRIFLUOPERAZINE-INDUCED CATALEPSY
002395 03-03

TRIFLUPROMAZINE
TREATMENTS OF SCHIZOPHRENIA WITH TRIFLUPROMAZINE DEPOT
002661 03-08

TRIFTAZINE
HEALTH STATUS IN PERSONS ENGAGED IN THE PRODUCTION OF TRIFTAZINE.
002914 03-15

TRIGEMINAL
DIFFERENTIAL EFFECT OF MORPHINE ON TRIGEMINAL NUCLEUS VERSUS RETICULAR AVERSIVE STIMULATION INDEPENDENCE OF NEGATIVE EFFECTS FROM STIMULATION PARAMETERS.
002527 03-04

DIFFERENTIAL EFFECT OF MORPHINE ON STIMULATION OF PRIMARY VERSUS HIGHER ORDER TRIGEMINAL TERMINALS
003257 04-03

TRIGGERED
NEUROLEPTIC INDUCED AKATHISIA AND DYSTONIA TRIGGERED BY ALCOHOL
002056 02-15

TRIHEXYPHENIDYL
AMANTADINE VERSUS TRIHEXYPHENIDYL IN THE TREATMENT OF NEUROLEPTIC INDUCED PARKINSONISM
000818 01-13

EFFECT OF TRIHEXYPHENIDYL ON EXCITABILITY OF PLANTAR FLEXOR ALPHA MOTOR NEURONS IN DRUG INDUCED PARKINSONIAN RIGIDITY
000999 01-15

MOOD ELEVATING EFFECT OF TRIHEXYPHENIDYL AND BIPERIDEN IN INDIVIDUALS TAKING ANTIPSYCHOTIC MEDICATION
003798 04-15

TRIHYDROXYLATED
THE SYNTHESIS OF POSSIBLE DIHYDROXYLATED AND TRIHYDROXYLATED CHLORPROMAZINE METABOLITES
001094 02-01

TRIIMIPRAMINE
SERUM CONCENTRATIONS OF TRIIMIPRAMINE IN HEALTHY SUBJECTS.
000918 01-14

TRIIODOTHYRONINE
EFFECTS OF LITHIUM TRIIODOTHYRONINE, AND PROPRANOLOL ON HUMAN SOMATOSENSORY EVOKED POTENTIALS.
003710 04-13

TRIMETHOZINE
TRIMETHOZINE IN A GERIATRIC MILIEU
000479 01-07

TRIMETHYLANILINIUM
THERMAL DECOMPOSITION OF 1,3 DIMETHYL DERIVATIVE OF PHENOBARBITAL IN TRIMETHYLANILINIUM HYDROXIDE.
003047 04-01

TRIMETHYLDIHYDROURIC-ACID
METABOLISM OF 1,3 7 TRIMETHYLDIHYDROURIC-ACID IN THE RAT- NEW METABOLIC PATHWAY OF CAFFEINE
001128 02-03

TRIOXAZINE
REACTION TIME OF NORMAL INDIVIDUALS TO LONG-TERM TRIOXAZINE.
001880 02-13

TRISEDYL
EFFECT OF REPEATED APPLICATION OF AMINAZINE, MAJEPTIL, AND TRISEDYL ON PROTEIN SYNTHESIS IN DIFFERENT STRUCTURES OF THE RAT BRAIN
002306 03-03

TRITIUM
ALTERATIONS IN SOCIAL BEHAVIOR IN THE RAT DURING CHRONIC LOW-LEVEL EXPOSURE TO LEAD AND TRITIUM.
001485 02-04

TRIVARIATE
AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES
001618 02-05

TRIVASTAL
TREATMENT OF CEREBRAL INSUFFICIENCY SYMPTOMS IN THE ELDERLY: RANDOMIZED COMPARATIVE STUDY OF TRIVASTAL.
000786 01-11

TROPATEPINE
A NEW SYNTHETIC ANTIPARKINSON AGENT TROPATEPINE HYDROCHLORIDE, IN EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS
000961 01-15

A CLINICAL TRIAL OF TROPATEPINE CHLORHYDRATE AS A CORRECTOR OF SECONDARY NEUROLEPTIC SYNDROMES
001031 01-17

TROPINES
INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS
001426 02-03

TROUBLE
NITRAZEPAM LASTINGLY EFFECTIVE BUT TROUBLE ON WITHDRAWAL.
002848 03-14

TRYPANOSOMA
CYTOCHROME-P-450 AND DRUG METABOLISMS IN TRYPANOSOMA CRUZI: EFFECTS OF PHENOBARBITAL
001121 02-03

TRYPTAMINE
PRESENCE AND METABOLISM OF BETA-PHENYLETHYLAMINE, P-TYRAMINE M-TYRAMINE AND TRYPTAMINE IN THE BRAIN OF THE DOMESTIC FOWL.
000138 01-03

EFFECT OF TRYPTAMINE ANTAGONISTS ON SELF-STIMULATION INTERACTION WITH AMPHETAMINE
003386 04-04

TRYPTAMINE BIMODAL ACTIONS ON THE EEG AND BEHAVIOR OF RABBITS
003440 04-04

EFFECTS OF TRYPTAMINE ON THE CDNDITIONED AVOIDANCE RESPONSE IN RATS.
003478 04-04

TRYPTAMINERGIC
EFFECT OF TRYPTAMINERGIC DRUGS DN ELECTROSHOCK FIGHTING BEHAVIOUR IN RATS.
002417 03-04

TRYPTAMINES
URINARY EXCRETION OF N,N DIMETHYLATED TRYPTAMINES IN CHRDNIC SCHIZOPHRENIA: A REVIEW OF THE PRESENT STATUS OF THE HYPDTHESIS.
002798 03-12

TRYPTOLINE
TRYPTOLINE INHIBITIDN OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
002278 03-03
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DDPAMINERGIC MECHANISMS.
003192 04-03

TRYPTOLINES
THE TRYPTOLINES: EFFECT OF INTRAVENTRICULAR ADMINISTRATION ON SPONTANEOUS MOTOR ACTIVITY DF RATS.
001500 02-04

TRYPTOPHAN
THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN, BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03
THE STIMULANT ACTION OF TRYPTDPHAN MONDAMINE-DXIDASE INHIBITOR COMBINATIONS: SUPPRESSION OF SELF-STIMULATIDN
000340 01-04
FDUR METHDDS OF TREATING SENILE MELANCHOLY WITH TRYPTOPHAN AND LITHIUM.
000496 01-07
TRICYCLIC ANTIDEPRESSANTS, TRYPTOPHAN AND AFFECTIVE DISORDER.
000657 01-09
STUDY OF FREE AND TOTAL TRYPTOPHAN IN PLASMA. ITS INTEREST IN PSYCHIATRY.
000815 01-13
EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND DTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM.
001176 02-03
TRYPTOPHAN TRANSPORT IN BRAIN SYNAPTOSOMES: EFFECTS OF L-DOPA.
001185 02-03
COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
00122B 02-03
EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03
EFFECTS OF P-CHLORDPHENYLALANINE AND TRYPTOPHAN ON LEARNING OF A BRIGHTNESS DISCRIMINATION IN RATS.
001556 02-04
AN ELECTROPHYSIOLOGICAL STUDY DN THE EFFECTS OF TRYPTOPHAN AND CORTISOL ON SCHIZDPHRENIC AND OTHER MENTALLY ILL PATIENT GROUPS AND ON NORMAL SUBJECTS.
0016B4 02-08
TRYPTDPHAN AND ALLOPURINOL IN THE TREATMENT OF DEPRESSION
001777 02-09
TRYPTOPHAN AND SERDTONIN IN SCHIZOPHRENIA
0018B3 02-13
EFFECT OF L-DOPA ON SEROTONIN METABOLISM IN RAT BRAIN: PRECURSOR TRYPTOPHAN LEVELS IN VARIOUS TISSUES.
002284 03-03
SEROTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTDPHAN INJECTIONS, AND A TRYPTDPHAN-FREE DIET DN MOUSE-KILLING BEHAVIOR BY RATS. (PH D. DISSERTATION).
002452 03-04
CLINICAL EFFECTS OF TRYPTOPHAN IN CHRONIC SCHIZOPHRENIC PATIENTS.
002629 03-0B
TDTAL AND FREE PLASMA TRYPTOPHAN LEVELS IN PATIENTS WITH AFFECTIVE DISORDERS: EFFECTS OF A PERIPHERAL DECARBOXYLASE INHIBITOR, M5T-1RB.
002672 03-09
TOTAL AND NDNBDUND TRYPTOPHAN IN UNIPOLAR ILLNESS.
002693 03-09
POTENTIATION OF THE ANTIDEPRESSANT ACTION OF CLDMIPRAMINE BY TRYPTDPHAN
002B44 03-13
REGIONAL TRANSPORT OF TRYPTOPHAN IN RAT BRAIN
003125 04-03
INFLUENCE OF DIAZEPAM AND IMIPRAMINE DN THE UPTAKE DF TRYPTOPHAN IN SLICES OF DIFFERENT PARTS OF THE RAT BRAIN
003174 04-03
TRYPTDPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECDVERY FRDM ASPHYXIA.
003303 04-03
TRYPTOPHAN NICOTINAMIDE CDMBINATION IN DEPRESSION.
003553 04-09

TRYPTOPHAN-FREE
SERDTONERGIC MECHANISMS AND PREDATORY AGGRESSION: THE EFFECTS PRODUCED BY P-CPA, TRYPTOPHAN INJECTIONS, AND A TRYPTOPHAN-FREE DIET ON MOUSE-KILLING BEHAVIOR BY RATS. (PH.D. DISSERTATION).
002452 03-04

TRYPTOPHAN-HYDROXYLASE
COINCIDENCE OF BLDCKADE OF SYNAPTOSDMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03
TRYPTOPHAN-HYDROXYLASE IN DISCRETE BRAIN NUCLEI: COMPARISON OF ACTIVITY IN VITRO AND IN VIVO.
00016B 01-03
EFFECT OF SHORT-TERM AND LONG-TERM TREATMENT WITH COCAINE ON RAT BRAIN TRYPTOPHAN-HYDROXYLASE.
001399 02-03

TUBERAL
EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO.
001219 02-03

TUBERCLE
EFFECT OF STRUCTURAL ANALOGS DF BUTACLAMOL (A NEW ANTIPSYCHDTIC DRUG) DN STRIATAL HOMDVANILLIC-ACID AND ADENYL-CYCLASE OF DLFACTDRY TUBERCLE IN RATS.
001335 02-03

TUMORS
SINGLE-AGENT CHEMDTHERAPY OF BRAIN TUMORS: A FIVE-YEAR REVIEW
002792 03-11

TUNNEL
DRUG ADDICTION: LIGHT AT THE END OF THE TUNNEL?
003422 04-04

TURBIDITY
F-INDUCED CHANGES AND ITS REVERSAL BY ITP IN MEMBRANE TURBIDITY AND ADENYLATE-CYCLASE ACTIVITY OF CHICK BRAIN MICROSOMES.
000037 01-03

TV-STORED
TIME-BLIND ANALYSIS OF TV-STORED INTEPVIEWS: AN OBJECTIVE METHOD TO STUDY ANTIDEPRESSIVE DRUG EFFECTS.
002692 03-09

TWIN
EFFECT OF MORPHINE ON RESPONSE TO PAIN: A TWIN STUDY.
003374 04-04

TWINS
LITHIUM CARBONATE VERSUS ECT IN THE TREATMENT DF THE MANIC STATE OF IDENTICAL TWINS WITH BIPOLAR AFFECTIVE DISEASE.
001813 02-11
IDENTICAL PSYCHOSIS IN A PAIR OF MONOZYGOTIC TWINS.
002966 03-17

TWITCHES
EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE
000298 01-04
EFFECTS OF AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04
HEAD TWITCHES INDUCED BY BENZODIAZEPINES AND THE ROLE OF BIOGENIC AMINES.
001552 02-04
5-METHOXYTRYPTAMINE-INDUCED HEAD TWITCHES IN RATS.
002573 03-05

TWO-CHOICE
THE EFFECTS OF A MARIJUANA EXTRACT ON TWO-CHOICE DISCRIMINATION LEARNING IN THE SQUIRREL-MONKEY
000270 01-04

TWO-WAY
DIFFERENTIAL EFFECTS OF MDRPHINE ON TWO-WAY AVOIDANCE IN SELECTIVELY BRED RAT STRAINS.
001575 02-04
THREE MAIN FACTORS IN RAT SHUTTLE BEHAVIOR: THEIR PHARMACOLOGY AND SEQUENTIAL ENTRY IN DPERATION DURING A TWO-WAY AVOIDANCE SESSION
002478 03-04

TYBAMATE
INTERNAL AND EXTERNAL STRESS, TYBAMATE, AND SECOBARBITAL: AN EXPERIMENTAL INVESTIGATION OF THEIR INTERACTIDN
001977 02-14

TYPE-A
TETRAHYDRD-BETA-CARBOLINES: SPECIFIC INHIBITORS OF TYPE-A MONOAMINE-OXIDASE IN RAT BRAIN
003219 04-03

TYPE-B
INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
001213 02-03
EVIDENCE FOR A SINGLE CATALYTIC BINDING SITE ON HUMAN BRAIN TYPE-B MONOAMINE-OXIDASE.
001937 02-13

TYRAMINE
AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE
002277 03-03
INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR.
002530 03-04
STUDIES OF THE FATE OF TYRAMINE IN DOGS: THE EFFECT OF MONOAMINE-OXIDASE INHIBITION, PORTAFEMORAL SHUNT AND CORONARY ARTERY LIGATION ON THE KINETICS OF TYRAMINE.
00313B 04-03
EFFECTS OF D-AMPHETAMINE AND ANTIPSYCHOTIC DRUG ADMINISTRATION ON STRIATAL TYRAMINE LEVELS IN THE MOUSE.
003187 04-03

TYROSINE
CATECHOLAMINE FORMATION IN BRAIN FROM PHENYLALANINE AND TYROSINE -- EFFECTS OF PSYCHOTROPIC DRUGS AND OTHER AGENTS.
000041 01-03
EFFECTS OF RAPID DEPLETION OF PHENYLALANINE AND TYROSINE ON SLEEP AND BEHAVIOR.
0002B1 01-04

TYROSINE-HYDROXYLASE
STIMULATION OF TYROSINE-HYDROXYLASE ACTIVITY BY CYCLIC-AMP IN SYNAPTOSOMES AND IN SOLUBLE STRIATAL ENZYME PREPARATIONS.
000007 01-01
GABA-MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY USE OF INTRANIGRAL MUSCIMOL.
000104 01-03
EFFECT OF CHLORPROMAZINE ON TYROSINE-HYDROXYLASE IN RAT BRAIN STRIATUM AND BEEF ADRENAL MEDULLA.
000177 01-03
REVERSIBLE CHANGES IN THE ACCUMULATION AND ACTIVITIES OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN NEURONS OF NUCLEUS LOCUS-COERULEUS DURING THE RETROGRADE REACTION
000211 01-03
CHOLINE-ACETYLTRANSFERASE, GLUTAMATE-DECARBOXYLASE AND TYROSINE-HYDROXYLASE IN THE COCHLEA AND COCHLEAR NUCLEUS OF THE GUINEA-PIG.
0010B5 02-01
ELEVATION OF TYROSINE-HYDROXYLASE ACTIVITY IN SYMPATHETIC NEURONS AFTER RESERPINE: THE ROLE OF THE CENTRAL-NERVOUS-SYSTEM.
001149 02-03
GABA MEDIATED CONTROL OF RAT NEOSTRIATAL TYROSINE-HYDROXYLASE REVEALED BY INTRANIGRAL MUSCIMOL.
002191 03-02
FAILURE OF BENZOCTAMINE TO INFLUENCE THE ACTIVITY OF RAT STRIATUM TYROSINE-HYDROXYLASE.
002223 03-03
EFFECTS OF NEUROLEPTICS ON TYROSINE-HYDROXYLASE OF SYNAPTOSOMES OF THE RAT HYPOTHALAMUS.
002314 03-03
THE EFFECT OF A SINGLE-DOSE OF RESERPINE ADMINISTERED PRIOR TO INCUBATION ON THE DEVELOPMENT OF TYROSINE-HYDROXYLASE ACTIVITY IN CHICK SYMPATHETIC GANGLIA.
003137 04-03

U-MAZE
EFFECT OF PSYCHOSTIMULANTS ON RATS RELEARNING OF THE DIRECTION OF AVOIDANCE IN A U-MAZE.
0002B4 01-04

U-31889
PILOT OPEN-LABEL STUDY OF ALPRAZOLAM(U-31BB9) IN ANXIOUS ALCOHOLIC OUTPATIENTS.
003617 04-11

ULCER
STUDY OF THE PROTECTIVE EFFECT OF VITAMIN-A ON STRESS ULCER IN THE RAT.
000223 01-03
EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF SULPIRIDE ON THE RESTRAINT ULCER IN THE RAT
00023B 01-03
EXPERIMENTAL AND THERAPEUTICAL EFFECTS OF SULPIRIDE ON THE GASTRIC AND DUODENAL ULCER.
00072B 01-11
PSYCHOPHARMACOLOGY OF THE PEPTIC ULCER.
000759 01-11
ACTIONS OF SULPIRIDE ON GASTRIC MOTILITY AND ACID SECRETION IN DUODENAL ULCER PATIENTS.
000B05 01-13
THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 04-03

ULCERATION
EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04
CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
00239B 03-03
THE PHARMACEUTICAL MANAGEMENT OF GASTRIC ULCERATION. (PH.D. DISSERTATION).
002773 03-11

ULTRADIAN
EFFECT OF METHYLPHENIDATE ON SLEEP STAGES AND ULTRADIAN RHYTHMS IN HYPERACTIVE CHILDREN
003637 04-11

ULTRASONIC
A NEW ANALGESIC TESTING METHOD USING ULTRASONIC STIMULATION: I. EFFECTS OF NARCOTIC AND NONNARCOTIC ANALGESICS.
0021B0 02-17

ULTRASTRUCTURAL
ULTRASTRUCTURAL STUDIES OF CHLORAMPHENICOL-INDUCED NEUROPATHY IN EXPERIMENTAL ANIMALS.
000147 01-03
ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03
PATHOLOGICAL STUDIES ON THE BRAIN LESIONS OF RATS INDUCED BY CHRONIC ADMINISTRATION OF DISULFIRAM -- WITH SPECIAL REFERENCE TO THE ULTRASTRUCTURAL ASPECTS OF DISULFIRAM PSYCHOSIS.
002579 03-05
ULTRASTRUCTURAL CHANGES IN THE NERVOUS SYSTEM OF RABBITS POISONED WITH METHYLMERCURY.
003500 04-05

UNANESTHETIZED
MORPHINE OPPOSED EFFECTS OF NALOXONE IN UNANESTHETIZED DOGS.
001252 02-03
EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-03

UNANSWERED
AGING AND DEPRESSION: SOME UNANSWERED QUESTIONS.
001752 02-09

UNCONDITIONED
UNCONDITIONED TASTE-AVERSION TO QUININE INDUCED BY INJECTIONS OF NACL AND LICL: DISSOCIATION OF AVERSION FROM CELLULAR DEHYDRATION.
003202 04-03

UNCONTROLLED
EFFECT OF FLUPENTHIXOL ON DEPRESSION WITH SPECIAL REFERENCE TO COMBINATION USE WITH TRICYCLIC ANTIDEPRESSANTS: AN UNCONTROLLED PILOT STUDY WITH 45 PATIENTS.
001661 02-07

UNCROWDED
A COMPARISON OF THE ACUTE TOXICITY OF SOME CENTRALLY ACTING DRUGS MEASURED UNDER CROWDED AND UNCROWDED CONDITIONS.
003496 04-05

UNDERSTANDING
ON THE RELEVANCE OF ANIMAL STUDIES ON LITHIUM TO THE UNDERSTANDING OF LITHIUM THERAPY.
00212B 02-17

UNDERWATER
HIPPOCAMPAL RSA (THETA), APNEA, BRADYCARDIA AND EFFECTS OF ATROPINE DURING UNDERWATER SWIMMING IN THE RAT.
003324 04-03

UNDESIRABLE
UNDESIRABLE EFFECT OF BETA-STIMULANT DERIVATIVES? EMERGENCE OF AN ACUTE PSYCHIATRIC SYMPTOMATOLOGY IN SOME MENTAL PATIENTS.
000945 01-15
AVOIDING UNDESIRABLE PHYSICAL SIDE-EFFECTS DURING THERAPY WITH PSYCHOTROPIC DRUGS.
000971 01-15

UNDRUGGED
EFFECTS OF UNDRUGGED PARTNERS ON SCOPOLAMINE-INDUCED CHANGES IN ACTIVITY AND SOCIABILITY
001595 02-04

UNIFYING
PEPTIDE TRANSMITTERS: A UNIFYING HYPOTHESIS FOR EUPHORIA, RESPIRATION, SLEEP, AND THE ACTION OF LITHIUM.
001B91 02-13

UNILATERAL
THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04
CIRCLING BEHAVIOR AFTER NARCOTIC DRUGS AND DURING NALOXONE PRECIPITATED ABSTINENCE IN RATS WITH UNILATERAL NIGRAL LESIONS.
000349 01-04
A BEHAVIOURAL MODEL OF THE GABA FACILITATING ACTION OF BENZODIAZEPINES: ROTATIONAL BEHAVIOUR AFTER UNILATERAL INTRANIGRAL INJECTION OF CHLORDIAZEPOXIDE.
001601 02-04
THE ROLES OF NORADRENALINE AND DOPAMINE IN CONTRAVERSIVE CIRCLING BEHAVIOUR SEEN AFTER UNILATERAL ELECTROLYTIC LESIONS OF THE LOCUS-COERULEUS.
002234 03-03
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04
THE EFFECT OF DIPHENYLHYDANTOIN ON SELF-STIMULATION IN RATS PRODUCED BY UNILATERAL MULTIPLE DORSAL RHIZOTOMY.
003379 04-04
PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED BY D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION
003413 04-04

UNILATERALLY
ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AS A POSSIBLE MEDIATOR OF ROTATIONAL BEHAVIOUR INDUCED BY DOPAMINERGIC RECEPTOR STIMULATION IN RATS LESIONED UNILATERALLY IN THE SUBSTANTIA-NIGRA.
002355 03-03

UNIPOLAR
A DOUBLE-BLIND COMPARISON OF LITHIUM-CARBONATE AND LUDIOMIL IN THE PROPHYLAXIS OF UNIPOLAR AFFECTIVE ILLNESS.
000589 01-09
RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE AND RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN.
000592 01-09
LITHIUM PROPHYLAXIS OF DEPRESSION IN BIPOLAR-I, BIPOLAR-II, AND UNIPOLAR PATIENTS.
000603 01-09
ON PROPHYLAXIS IN UNIPOLAR AFFECTIVE DISORDER.
002157 02-17
TOTAL AND NONBOUND TRYPTOPHAN IN UNIPOLAR ILLNESS.
002693 03-09

UNIT
DOSE-RESPONSE RELATIONSHIPS BETWEEN SYSTEMICALLY ADMINISTERED L-TRYPTOPHAN OR L-5-HYDROXYTRYPTOPHAN AND RAPHE UNIT ACTIVITY IN THE RAT.
000016 01-01
EARLY CLINICAL DRUG EVALUATION UNIT.
000678 01-10
CHILDRENS PSYCHOPHARMACOLOGY UNIT
000729 01-11
EFFECTS OF SOME PUTATIVE NEUROTRANSMITTERS ON UNIT ACTIVITY OF TUBERAL HYPOTHALAMIC NEURONS IN VITRO
001219 02-03
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE AND PHYSOSTIGMINE.
001277 02-03
ELECTROPHYSIOLOGICAL EVIDENCE AGAINST NEGATIVE NEURONAL FEEDBACK FROM THE FOREBRAIN CONTROLLING MIDBRAIN RAPHE UNIT ACTIVITY.
00129B 02-03
ACTIONS OF OPIATES UPON SINGLE UNIT ACTIVITY IN THE CORTEX OF NAIVE AND TOLERANT RATS.
001357 02-03
PENFLURIDOL IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC PATIENTS IN A BRIEF THERAPY UNIT.
0016B3 02-0B
PSYCHIATRIC RESEARCH IN THE MRC BRAIN METABOLISM UNIT
001776 02-09
THE EFFECT OF MORPHINE ON SINGLE UNIT ACTIVITY OF MIDBRAIN DORSAL RAPHE IN CATS.
0022B1 03-03
EFFECT OF UNIT DOSE AND ROUTE OF ADMINISTRATION ON SELF-ADMINISTRATION OF MORPHINE
002543 03-04
UNIT ACTIVITY OF AMYGDALA AND HIPPOCAMPAL NEURONS: EFFECTS OF MORPHINE AND BENZODIAZEPINES.
003113 04-03
THE USE OF SODIUM AMYTAL INTERVIEWS IN A SHORT-TERM COMMUNITY ORIENTED INPATIENT UNIT
003B41 04-16

UNITED-STATES
DRUGS REQUESTED BY DEFENDANT DID NOT IMPAIR ABILITY TO STAND TRIAL. UNITED-STATES V. HATRACK, 408 F.SUPP. 476. U.S. DISTRICT COURT. D. NEW-JERSEY. FEBRUARY 19, 1976.
002150 02-17
USE OF TRANQUILIZER INSUFFICIENT TO SHOW LACK OF COMPETENCY FOR TRIAL. UNITED-STATES V. SMITH, 521 F.2D 374 (KANSAS). U.S. COURT OF APPEALS. TENTH CIRCUIT. AUGUST 22, 1975.
002152 02-17

UNITS
ACTIONS OF THE P-CHLOROPHENYL DERIVATIVE OF GABA, LIORESAL, ON NOCICEPTIVE AND NON-NOCICEPTIVE UNITS IN THE SPINAL CORD OF THE CAT.
001235 02-03
EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX.
003256 04-03

UNLIMITED
CHARACTERISTICS OF UNLIMITED ACCESS TO SELF-ADMINISTERED STIMULANT INFUSIONS IN DOGS.
002524 03-04
SELF-ADMINISTRATION OF CODEINE PLUS ACETYLSALICYLIC-ACID IN RHESUS-MONKEYS WITH UNLIMITED ACCESS TO THE DRUGS.
003175 04-03

UNNECESSARY
REDUCING UNNECESSARY ANTIPARKINSON MEDICATION IN ANTIPSYCHOTIC THERAPY.
003572 04-09

UNPUNISHED
INTERACTION OF D-AMPHETAMINE WITH PENTOBARBITAL AND CHLORDIAZEPOXIDE: EFFECTS ON PUNISHED AND UNPUNISHED BEHAVIOR OF PIGEONS.
002422 03-04

UNRESTRAINED
EFFECTS OF SOME DRUGS ON THE CORONARY CIRCULATION IN UNANESTHETIZED AND UNRESTRAINED DOGS.
002390 03-03
THE RESULTS OF PENICILLIN-G ADMINISTRATION ON CHRONIC UNRESTRAINED CATS: ELECTROGRAPHIC AND BEHAVIORAL OBSERVATIONS.
003452 04-04

UNSAFE
GLUTETHIMIDE -- AN UNSAFE ALTERNATIVE TO BARBITURATE HYPNOTICS.
002919 03-15

UNSATURATED
HASHISH. UNSATURATED SIDE-CHAIN ANALOGUES OF DELTA8-TETRAHYDROCANNABINOL WITH POTENT BIOLOGICAL ACTIVITY
001339 02-03

UNSTRESSED
EFFECTS OF LITHIUM ON OPEN-FIELD BEHAVIOR IN STRESSED AND UNSTRESSED RATS.
00033B 01-04

UNSUBSTITUTED
EFFECT OF TRYPTOLINE, AN UNSUBSTITUTED BETA-CARBOLINE, ON SEROTONERGIC AND DOPAMINERGIC MECHANISMS.
003192 04-03

UNTRAINED
EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04

UNTREATED
DOPAMINE CORRELATES OF NEUROLOGICAL AND PSYCHOLOGICAL STATUS IN UNTREATED PARKINSONISM.
001831 02-11

UNWANTED
UNWANTED EFFECTS OF LONG-TERM MEDICATION IN SCHIZOPHRENIA AND DEPRESSION
001064 01-17

UP-507-04
ACTIVITY OF ANORECTIC DRUGS (AMPHETAMINE), AMFERPRAMONE AND UP-507-04) ON TWO MODELS OF OBESITY IN ANIMALS.
001474 02-04

UPDATED
PRACTICAL CONSIDERATIONS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE: AN UPDATED REVIEW
003764 04 15

UPDATING
UPDATING PSYCHOTROPIC DRUG THERAPY
002109 02-17

UPRIGHT
SALIVARY AND URINARY LITHIUM CLEARANCE WHILE RECUMBENT AND UPRIGHT
003706 04 13

UPTAKE
EFFECT OF RESERPINE, DESIPRAMINE AND PHENYTOIN ON DIGOXIN INDUCED ARRHYTHMIAS AND MYOCARDIAL UPTAKE OF DIGOXIN IN GUINEA-PIGS.
000032 01-03

CORTICAL AND STRIATAL IN VIVO UPTAKE AND METABOLISM OF PLASMA CHOLINE IN THE RAT EFFECTS OF HALOPERIDOL AND APOMORPHINE
000035 01-03

THE EFFECTS OF CHLORPROMAZINE ON SERUM TRYPTOPHAN BRAIN TRYPTOPHAN UPTAKE AND BRAIN SEROTONIN SYNTHESIS IN THE RAT.
000047 01-03

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
000105 01-03

THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA).
000107 01-03

COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03

REGIONAL UPTAKE OF NEUROTOXIC AND NONTOXIC AMINO-ACIDS IN VIVO BY THE INFANT MOUSE BRAIN
000194 01-03

MEPIPRAZOLE, A NEW PSYCHOTROPIC DRUG: EFFECTS ON UPTAKE AND RETENTION OF MONOAMINES IN RAT BRAIN SYNAPTOSOMES.
000202 01-03

COMPARATIVE STUDY OF THE EFFECTS OF MIANSERIN, A TETRACYCLIC ANTIDEPRESSANT, AND OF IMIPRAMINE ON UPTAKE AND RELEASE OF NEUROTRANSMITTERS IN SYNAPTOSOMES.
000207 01-03

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE
000212 01-03

INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES.
000213 01-03

ON THE LONG-LASTING INHIBITORY EFFECT OF N-(2-CHLOROETHYL) N-ETHYL-2-BROMOBENZYLAMINE (DSP-4) ON THE ACTIVE UPTAKE OF NORADRENALINE.
000214 01-03

SELECTIVE INHIBITION OF SEROTONIN UPTAKE BY TRAZODONE, A NEW ANTIDEPRESSANT AGENT.
000233 01-03

EFFECT OF NISOXETINE ON UPTAKE OF CATECHOLAMINES IN SYNAPTOSOMES ISOLATED FROM DISCRETE REGIONS OF RAT BRAIN
000263 01-03

DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE.
000513 01-07

PLATELET UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN DEPRESSION.
000612 01-09

THE INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH THE BIOGENIC AMINE UPTAKE SYSTEMS IN THE CENTRAL-NERVOUS-SYSTEM.
000615 01-09

EFFECTS OF CLOMIPRAMINE AND OTHER TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE AND TURNOVER.
000665 01-09

COMPARISON OF THE INHIBITION OF 5-HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS.
000933 01-15

EFFECT OF DOXEPIN ON UPTAKE AND EFFLUX OF SEROTONIN IN HUMAN BLOOD PLATELETS.
000963 01-15

EFFECTS OF P-CHLORO-BETA-PHENYLETHYLAMINE ON THE UPTAKE AND RELEASE OF PUTATIVE AMINE NEUROTRANSMITTERS IN RAT BRAIN
001135 02-03

EFFECTS OF TETRAHYDRO-BETA-CARBOLINES ON MONOAMINE-OXIDASE AND SEROTONIN UPTAKE IN MOUSE BRAIN
001156 02-03

CALCIUM UPTAKE INTO RAT PHEOCHROMOCYTOMA CELLS
001165 02-03

UPTAKE OF 5 HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION
001187 02-03

INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE.
001207 02-03

EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTION WITH P CPA ON RAT BRAIN 5 HT.
001211 02-03

COMPARISON OF THE EFFECTS OF MAPROTILINE (LUDIOMIL R) AND CLOMIPRAMINE (ANAFRANIL R) ON SEROTONIN UPTAKE AND TRYPTOPHAN BINDING IN PLASMA.
001228 02-03

UPTAKE OF 3,4 DIMETHOXYPHENYLETHYLAMINE-1-14C (14C-DMPEA) BY RAT TISSUES IN VITRO.
001229 02-03

MOLECULAR GEOMETRY OF INHIBITORS OF THE UPTAKE OF CATECHOLAMINES AND SEROTONIN IN SYNAPTOSOMAL PREPARATIONS OF RAT BRAIN
001265 02-03

POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03

EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03

EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2-DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS
001329 02-03

THE EFFECTS OF CERTAIN DRUGS ON THE UPTAKE AND RELEASE OF (3H)NORADRENALINE IN RAT WHOLE BRAIN HOMOGENATES.
001337 02-03

SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT.
001347 02-03

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
001377 02-03

EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES.
001387 02-03

ON THE SELECTIVE INHIBITION OF SEROTONIN UPTAKE IN VIVO BY ORG-6582.
001393 02-03

TOPOGRAPHICAL DISTRIBUTION OF DOPAMINERGIC INNERVATION AND OF DOPAMINERGIC RECEPTORS IN THE RAT STRIATUM. I. MICROESTIMATION OF (3H)DOPAMINE UPTAKE AND DOPAMINE CONTENT IN MICRODISCS.
001397 02-03

UPTAKE AND METABOLISM OF 3-METHOXYTYRAMINE IN THE CAT BRAIN.
001638 02-05

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-06

SEX SPECIFIC DIFFERENCES IN CHLORIMIPRAMINE INHIBITION OF SEROTONIN UPTAKE IN HUMAN PLATELETS.
001952 02-13

EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03

UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
002268 03-03

AGGRESSIVE BEHAVIOR, BRAIN NORADRENALINE CONTENT AND TYRAMINE UPTAKE OF ISOLATED MICE -- EFFECTS OF CHRONIC ADMINISTRATION OF L-DOPA AND SAFRAZINE.
002277 03-03

TRYPTOLINE INHIBITION OF SEROTONIN UPTAKE IN RAT FOREBRAIN HOMOGENATES.
002278 03-03

THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
002397 03-03

INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
002450 03-04

INFLUENCE OF ADRENALECTOMY ON STEREOTYPY AND BRAIN TYRAMINE UPTAKE IN METHAMPHETAMINE TREATED RATS -- EFFECTS OF L-DOPA, MAOI AND ALPHA-MMT, IN PARTICULAR
002530 03-04

ALTERATIONS IN HUMAN PLATELET SEROTONIN UPTAKE FOLLOWING THE ADDITION OF THROMBIN AND A23187. (UNPUBLISHED PAPER).
002804 03-13

UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION A COMPARATIVE KINETIC ANALYSIS.
002846 03-13

NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR LU-10-171
003054 04-01

THE EFFECT OF DESIPRAMINE ON THE UPTAKE OF MESCALINE BY CORTICAL SYNAPTOSOMES
003095 04-03

IN VITRO STUDIES IN SYNAPTOSOMES OF RAT STRIATUM A8OUT THE EFFECTS OF MORPHINE ON UPTAKE ANO RELEASE OF C14-OOPAMINE.
003104 04-03

THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 4SCA+ + UPTAKE ANO RELEASE IN SYNAPTIC TERMINALS.
003136 04-03

ANTIDEPRESSANT ORUGS ANO DOPAMINE UPTAKE IN OIFFERENT BRAIN REGIONS.
003146 04-03

IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES.
0031S8 04-03

INFLUENCE OF DIAZEPAM ANO IMIPRAMINE ON THE UPTAKE OF TRYPTOPHAN IN SLICES OF OIFFERENT PARTS OF THE RAT BRAIN.
003174 04-03

EFFECT OF A SELECTIVE 5-HT UPTAKE INHI8ITOR -- LU-10-171 -- ON RAT BRAIN S-HT TURNOVER.
003179 04-03

ACTIONS OF FENFLURAMINE ON GLUCOSE UPTAKE IN VITRO ANO IN VIVO.
00318S 04-03

EFFECT OF NARCOTICS ON THE UPTAKE OF SEROTONIN PRECURSORS BY THE RAT BRAIN.
003204 04-03

LACK OF EFFECT OF PHENOBARBITONE TREATMENT ON METABOLISM ANO BRAIN UPTAKE OF OELTA-AMINOLAEVULINIC-ACIO IN RATS.
003237 04-03

EFFECTS OF MAZINOOL ANO O-FENFLURAMINE ON S-HYOROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOO PLATELETS.
003241 04-03

EFFECTS OF ALKYLTETRAHYOROCARBAZOLE-ETHANAMINES ANO RELATEO COMPOUNOS, POTENTIAL ANTIOEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS.
003243 04-03

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF SEROTONIN UPTAKE BY BETA-CARBOLINES INTO SYNAPTOSOMES FROM RAT BRAIN
0032SS 04-03

EFFECTS OF MATERNAL ETHANOL INGESTION ON AMINE UPTAKE INTO SYNAPTOSOMES OF FETAL ANO NEONATAL RAT BRAIN.
003299 04-03

NOMIFENSINE AND ITS OERIVATIVES AS POSSIBLE TOOLS FOR STUOYING AMINE UPTAKE.
00330S 04-03

MONOAMINE METABOLITES IN CEREBROSPINAL FLUIO ANO SEROTONIN UPTAKE INHIBITION OURING TREATMENT WITH CHLORIMIPRAMINE.
0036S4 04-13

INITIAL CLINICAL TRIAL BASEO ON BIOCHEMICAL METHODOLOGY OF ZIMFLIDINE (A SEROTONIN UPTAKE INHIBITOR) IN DEPRESSEO PATIENTS.
003709 04-13

EFFFCTS OF METHOXYAMPHETAMINES ON THE UPTAKE ANO RELEASE OF (3H)5-HYOROXYTRYPTAMINE BY HUMAN BLOOO PLATELETS.
003715 04-13

UPTAKES

FFFFCTS OF VINCA ALKALOIOS ON UPTAKES OF AMINO-ACIOS BY RAT BRAIN SYNAPTOSOMES.
000199 01-03

URIDINE

THF EFFECT OF COROYCEPIN ON THE APPEARANCE OF (3H)RNA IN THE GOLOFISH OPTIC TECTUM FOLLOWING INTRAOCULAR INJECTION OF (3H)URIOINF
001247 02-03

URINARY

REOUCTION BY PROPRANOLOL OF RAISED URINARY OUTPUT OF MHPG IN HYPERACTIVE RATS
000231 01-03

LOW URINARY DOPAMINE ANO PREDICTION OF PHENOTHIAZINE-INDIJCFD PARKINSONISM- A PRELIMINARY REPORT.
00093S 01-15

URINARY EXCRETION OF 3 MFTHOXY 4-HYDROXYPHENYLGLYCOL IN DEPRESSFD PATIENTS- MOOIFICATIONS BY AMPHETAMINE ANO LITHIUM
001729 02-09

URINARY EXCRFTION OF N,N DIMETHYLATED TRYPTAMINES IN CHRONIC SCHIZOPHRFNIA A REVIEW OF THE PRESENT STATUS OF THE HYPOTHESIS.
00279B 03-12

PHENOBARBITONF INDUCEO URINARY EXCRETIONS OF D-GLUCARIC-ACID AND 6BETA HYDROXYCORTISOL IN MAN
002B22 03-13

URINARY CYCLIC AMP IN RELATION TO LITHIUM TREATMENT IN MANIC DEPRESSIVE ILLNESS.
002B37 03-13

PLASMA AND URINARY CYCLIC AMP LEVELS IN NORMAL AND LITHIUM TREATED RATS
003114 04-03

PLATELET ANO PLASMA AMINE OXIOASE INHIBITION ANO URINARY AMINE EXCRETION CHANGES OURING PHENELZINE TREATMENT.
003692 04-13

SALIVARY ANO URINARY LITHIUM CLEARANCE WHILE RECUMBENT AND UPRIGHT.
003706 04-13

3. SOCIAL LIFE, CIGARETTE SMOKING, ANO URINARY PH.
003707 04-13

URINE

IOENTIFICATION OF 10,11 EPOXIOE AND OTHER CYCLOBENZAPRINE METABOLITES ISOLATEO FROM RAT URINE.
000046 01-03

QUANTITATIVE OETERMINATION OF METOPROLOL IN PLASMA ANO URINE BY GAS CHROMATOGRAPHY.
000470 01-06

SYNTHESIS ANO CHARACTERIZATION OF A CATECHOL METABOLITE OF GLUTETHIMIOE (OORIOEN) IN HUMAN URINE.
000799 01-13

A NOTE ON THE ASSAY OF CHLORPROMAZINE-N-OXIOE ANO ITS SULPHOXIOE IN PLASMA AND URINE.
000811 01-13

IDENTIFICATION AND QUANTITATIVE GLC OETERMINATION OF IPRONIAZIO IN HUMAN URINE.
000814 01-13

OIBENZEPINE ANO ITS METABOLITES IN BLOOO, MUSCLE, LIVER, VITREOUS BODY ANO URINE FROM FATAL POISONING.
000934 01-15

NOVEL METABOLITE OF NITRAZEPAM IN THE RABBIT URINE.
002357 03-03

THE RENAL HANOLING OF LITHIUM: RELATION BETWEEN LITHIUM CLEARANCE, SOOIUM CLEARANCE ANO URINE FLOW IN RATS WITH OIABETES-INSIPIDUS.
003300 04-03

URTICARIA

SEVERE NEUTROPENIA URTICARIA WITH ANTIOEPRESSANT THERAPY
002907 03-15

USA

ETHICS IN ORUG RESEARCH IN THE USA.
003006 03-17

USAGE

AMITRIPTYLINE IN PSYCHIATRIC THERAPY: EIGHT YEARS OF USAGE IN HOSPITAL PRACTICE.
0006S6 01-09

PRESCRIPTIVE GUIDANCE FOR USAGE OF PSYCHOPHARMACEUTICALS.
001020 01-17

LITHIUM TREATMENT IN THE ELOERLY I. CLINICAL USAGE.
003781 04-15

USERS

A NEUROPSYCHOLOGICAL STUOY OF POLYORUG USERS.
000894 01-14

NEUROPSYCHOLOGICAL ANO EEG OISTURBANCES IN POLYDRUG USERS.
002044 02-15

ELECTROENCEPHALOGRAPHIC ALTERATIONS IN MARIHUANA USERS.
002831 03-13

UTERUS

BETA AORENERGIC BLOCKING AGENTS AS POTENT ANTAGONISTS OF MESCALINE-INOUCED CONTRACTIONS IN THE RAT UTERUS.
002269 03-03

UTILITY

PHENYLALKYLAMINES WITH POTENTIAL PSYCHOTHERAPEUTIC UTILITY. 1 2-AMINOOIMETHOXYMETHPHENYLBUTANE.
001114 02-02

UTILIZATION

PERIPHERAL EFFECTS OF THE AMPHETAMINE-TYPE ANORECTIC ORUGS: INHIBITION OF CATECHOLAMINE-INOUCEO LIPOLYSIS, RESPIRATION, GLUCOSE UTILIZATION IN THE ADIPOSE TISSUE OF MAN ANO RAT.
001192 02-03

EFFECTS OF O-LYSERGIC-ACIO-OIETHYLAMIOE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE RAT (UNPUBLISHEO PAPER).
002367 03-03

UTILIZING

STUOIES ON THE SITE OF ACTION OF CLONIOINE UTILIZING A SYMPATHETIC CHOLINERGIC SYSTEM.
000144 01-03

ORUG THERAPY FOR SOCIOPATHIC OFFENOERS: AN EXPERIMENTAL TREATMENT PROGRAM UTILIZING IMIPRAMINE HYOROCHLORIOE (PH D OISSERTATION).
000685 01-10

UV-SPECTROPHOTOMETRY

CHARACTERIZATION OF INTERACTIONS OF PHENOTHIAZINES AND RELATED DRUGS WITH LIPIDS BY UV-SPECTROPHOTOMETRY
002S83 03-06

U31889

PILOT OPEN LABEL STUOY WITH ALPRAZOLAM (U31BB9) IN OUTPATIENTS WITH NEUROTIC DEPRESSION
0006B2 01-10

V-TYPE
DIFFERENTIAL EFFECTS OF MORPHINE ON RESPONSES OF DORSAL HORN LAMINA V-TYPE CELLS ELICITED BY A AND C FIBRE STIMULATION IN THE SPINAL CAT
001274 02-03
EFFECTS OF MORPHINE UPON THE LAMINA V-TYPE CELLS ACTIVITIES IN THE DORSAL HORN OF THE DECEREBRATE CAT.
001275 02-03

VAGINISMUS
TREATMENT OF VAGINISMUS BY I.V. DIAZEPAM (VALIUM) ABREACTION INTERVIEWS.
001764 02-09

VAGRAN-50
A NEW MEDICATION OF THE ANTIDEPRESSANT GROUP: VAGRAN-50 (PROPIZEPINE-HYDROCHLORIDE).
000477 01-07
VAGRAN-50: A SITUATIONAL ANTIDEPRESSANT.
001790 02-10

VALIDATION
VALIDATION OF A PHYSICIAN RATING SCALE FOR INVESTIGATION OF ANTIANXIETY EFFECTS OF DRUGS.
003588 04-10

VALINE
SUPPRESSION OF AMPHETAMINE-INDUCED HYPOTHERMIA BY THE NEUTRAL AMINO-ACID VALINE.
002219 03-03

VALIUM
TREATMENT OF VAGINISMUS BY I.V. DIAZEPAM (VALIUM) ABREACTION INTERVIEWS.
001764 02-09
HALLUCINATIONS FOLLOWING WITHDRAWAL OF VALIUM.
002894 03-15

VALPROATE
EFFECT OF SODIUM VALPROATE ON TARDIVE-DYSKINESIA.
001838 02-11
HAS SODIUM VALPROATE HYPNOTIC EFFECTS?.
001961 02-14

VALUE
THE POTENTIAL VALUE OF BIOCHEMICAL PARAMETERS IN THE DIAGNOSIS AND MEDICATION OF AFFECTIVE DISORDERS.
000652 01-09
ANIMAL PSYCHOPHARMACOLOGICAL PROCEDURES: PREDICTIVE VALUE FOR DRUG EFFECTS IN MENTAL AND EMOTIONAL DISORDERS.
002435 03-04
SLEEP DISORDERS IN PATIENTS WITH SEVERE MENTAL DEPRESSION: DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF THE VALUE OF PIPAMPERONE (DIPIPERON).
003549 04-09
COMPARATIVE VALUE OF RATING AND SELF-RATING SCALES IN DRUG TRIALS.
003592 04-10
THE VALUE OF PHENOBARBITAL IN THE CHILD WHO HAS HAD A SINGLE FEBRILE SEIZURE: A CONTROLLED PROSPECTIVE STUDY.
003651 04-11
THE VALUE OF SELF-RATING SCALES IN DRUG TRIALS.
003840 04-16

VALUES
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
AN APPROXIMATION TO THE MAXIMUM MODULUS OF THE TRIVARIATE T WITH A COMPARISON TO THE EXACT VALUES.
001618 02-05
QUANTITATIVE CORRELATIONS BETWEEN ALBUMIN BINDING CONSTANTS AND CHROMATOGRAPHIC RM VALUES OF PHENOTHIAZINE DERIVATIVES.
003053 04-01
PHARMACOCHEMICAL ANALYSIS OF RADIOCRYSTALLOGRAPHIC DATA ON POLYCYCLIC PSYCHOTROPIC AMINES. II. COMPARISON OF THE PARAMETRIC VALUES.
003058 04-01

VARIABILITY
DRUG EFFECTS ON HEART-RATE AND HEART RATE VARIABILITY DURING A PROLONGED REACTION TASK.
001912 02-13
VARIABILITY OF PSYCHOTROPIC DRUG RESPONSE: THE CONTRIBUTION OF BIOCHEMICAL PHARMACOLOGY TO ITS ELUCIDATION
002811 03-13

VARIABLE
VARIABLE TEMPORAL GRADIENTS OF RETROGRADE AMNESIA. CONTINGENCY ON TASKS AND SPECIES
001440 02-04
VARIABLE INTERVAL RESPONDING MAINTAINED BY INTRAVENOUS CODEINE AND ETHANOL INJECTIONS IN THE RHESUS MONKEY
001454 02-04
EFFECTS OF SCOPOLAMINE ON VARIABLE INTERTRIAL INTERVAL SPATIAL ALTERNATION AND MEMORY IN THE RAT.
002462 03-04

VARIABLES
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MOTIVATIONAL AND NEUROHUMORAL VARIABLES
000355 01-04
PERSISTENCE OF RELAPSE OF MORPHINE SEEKING BEHAVIOR IN RATS: THE RELATIVE ROLE OF CERTAIN BIOLOGICAL VARIABLES.
000417 01-04
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16
CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE.
003533 04-08
THE CONCENTRATION PATTERN OF NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM BY THIORIDAZINE TREATMENT AND ITS RELATIONSHIP TO PHYSIOLOGICAL AND CLINICAL VARIABLES.
003655 04-13

VARIATION
INDEPENDENT VARIATION OF BETA-ADRENERGIC RECEPTOR BINDING AND CATECHOLAMINE-STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT ERYTHROCYTES.
000071 01-03
DOSE-DEPENDENT DUAL EFFECT OF MORPHINE ON ELECTROPHYSIOLOGIC CORRELATES OF POSITIVE REINFORCEMENT (REWARD CONTINGENT POSITIVE VARIATION: RCPV) IN THE CAT.
001291 02-03
THE CONTINGENT NEGATIVE VARIATION AND PSYCHOLOGICAL FINDINGS IN CHRONIC HEPATIC ENCEPHALOPATHY.
001920 02-13
DETERMINATION OF VARIATION IN THE SPEED OF CONDUCTION OF MOTOR FIBERS AND OF THE DIPHENYLHYDANTOIN (PHENYTOIN) AND DIAZEPAM (FAUSTAN) EFFECT ON IT.
002826 03-13
SEASONAL VARIATION IN DEVELOPMENT OF TOLERANCE TO MORPHINE.
002845 03-13
NATURE OF SEASONAL VARIATION IN DEVELOPMENT OF ACUTE TOLERANCE TO MORPHINE.
003277 04-03

VARIATIONS
EFFECTS OF PSYCHOTROPIC DRUGS ON PHYSIOLOGICAL VARIATIONS AND PSYCHOMETRIC SCORES DURING ATTENTION
000875 01-14
LUSCHER TEST AND ANXIETY: VARIATIONS IN CHROMATIC CHOICES WHILE IN A STATE OF ANXIETY.
000886 01-14
GENETIC AND ONTOGENETIC VARIATIONS IN LOCOMOTOR ACTIVITY FOLLOWING TREATMENT WITH SCOPOLAMINE OR D-AMPHETAMINE.
001568 02-04
COMPARISON OF PLASMA LITHIUM LEVELS AND THEIR INTERINDIVIDUAL VARIATIONS WITH COATED LITHIUM-CARBONATE TABLETS AND A MEDIUM-SLOW RELEASE LITHIUM SULPHATE PREPARATION (LITHIONIT DURETTER).
003699 04-13

VAS-DEFERENS
PERSISTENT ENHANCEMENT OF POTASSIUM-INDUCED RESPONSES OF THE RAT VAS-DEFERENS BY DESIPRAMINE.
001361 02-03
NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL.
003261 04-03

VASCULAR
THE MECHANISM OF ACTION OF NICOTINE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
003229 04-03

VASOACTIVE
VASOACTIVE SUBSTANCES RELEVANT TO MIGRAINE.
001034 01-17

VASOPRESSIN
BEHAVIORAL AND BIOCHEMICAL RESPONSES OF MICE TO THE INTRAVENTRICULAR ADMINISTRATION OF ACTH ANALOGS AND LYSINE VASOPRESSIN
000407 01-04
BEHAVIORAL EFFECTS OF INTRAVENTRICULARLY ADMINISTERED VASOPRESSIN AND VASOPRESSIN FRAGMENTS.
001107 02-02
TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
001641 02-05
THE EFFECT OF PROLONGED VASOPRESSIN ADMINISTRATION ON THE LEVEL AND METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN AND KIDNEYS
001642 02-05

EFFECT OF DESGLYCINAMIDE LYSINE VASOPRESSIN (DG-LVP) ON SEXUALLY MOTIVATED T-MAZE BEHAVIOR OF THE MALE RAT.
003356 04-04

PARALLEL CHANGES IN BEHAVIOUR AND HIPPOCAMPAL SEROTONIN METABOLISM IN RATS FOLLOWING TREATMENT WITH DESGLYCINAMIDE LYSINE VASOPRESSIN.
003447 04-04

VASOREGULATOR

1D35-MD (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY.
001013 01-17

VECTORS

EXPERIMENTAL AND CLINICAL VECTORS IN PHARMACOLOGY.
003013 03-17

VEHICLE

BEHAVIORAL AND METABOLIC INTERACTION OF PROPYLENE GLYCOL VEHICLE AND DELTA9-TETRAHYDROCANNABINOL.
001385 02-03

VENOM

SNAKE VENOM ACTION: ARE ENZYMES INVOLVED IN IT?
003337 04-03

VENTILATORY

EFFECT OF DIAZEPAM ON VENTILATORY RESPONSES.
D00960 01-15

VENTRAL

SPECIFIC MONOAMINE SYSTEMS AS REWARD PATHWAYS: EVIDENCE FOR THE HYPOTHESIS THAT ACTIVATION OF THE VENTRAL MESENCEPHALIC DOPAMINERGIC NEURONES AND NORADRENERGIC NEURONES OF THE LOCUS-COERULEUS COMPLEX WILL SUPPORT SELF-STIMULATION RESPONDING.
000081 01-D3

BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN.
000184 D1-03

EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE ON DORSAL AND VENTRAL HYPOTHALAMIC SELF-STIMULATION IN THREE INBRED STRAINS OF MICE.
001455 02-D4

THE EFFECTS OF DESTRUCTION OF NORADRENERGIC ASCENDING VENTRAL BUNDLES AND TETRABENAZINE ON FORMATION OF STRESS-INDUCED GASTRIC ULCER.
003233 D4-D3

VENTRALIS-TEGMENTI

PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF INTRACRANIAL SELF-STIMULATION: ROLES OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS WITH ELECTRODES EITHER IN AREA VENTRALIS-TEGMENTI ON IN LATERAL HYPOTHALAMUS.
000234 D1-D3

VENTRICLE

REGIONAL STUDY OF CEREBRAL VENTRICLE SENSITIVE SITES TO ANGIOTENSIN II.
000123 01-D3

SLEEP INDUCED BY DRUGS INJECTED INTO THE INFERIOR HORN OF THE LATERAL CEREBRAL VENTRICLE IN DOGS.
003399 04-D4

VENTRICLES

GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES
000378 01-04

VENTRICULAR

TRICYCLIC ANTIDEPRESSANTS AND CARDIAC CONDUCTION: CHANGES IN VENTRICULAR AUTOMATICITY.
DD2562 03-05

VENTROLATERAL

ANATOMICAL ANALYSIS OF VENTROLATERAL THALAMIC INPUT TO PRIMATE MOTOR CORTEX
000431 01-D4

VERATRINE

EFFECT OF VERATRINE ALKALOIDS ON THE EFFLUX OF EXTRAGRANULAR NORADRENALINE FROM RABBIT ATRIA
DD1324 02-03

VERATRUM

THERAPEUTIC CONTINUITY OF THE MILLENIA. JUSTIFICATION OF THE ANCIENT USE OF VERATRUM (ALBUM) BY DISCOVERIES OF MODERN PSYCHOPHARMACOLOGY
0021B2 03-01

VERBAL

THE EFFECTS OF A NEW NOOTROPIC SUBSTANCE ON THE CAPACITY FOR VERBAL MEMORY AND LEARNING IN NORMAL MAN
DD0887 01-14

VERIFICATION

VERIFICATION OF THE MONOAMINE HYPOTHESIS WITH THE AID OF DRUGS AND OTHER METHODS OF ANTIDEPRESSANT THERAPY: DIRECT INFLUENCING OF THE TRANSMISSION PROCESS.
DD3717 D4-13

VERIFICATION OF THE MA HYPOTHESIS WITH THE AID OF DRUGS: MA PRECURSORS AND SYNTHESIS INHIBITORS.
003752 04-14

VERRUCULOGEN

VERRUCULOGEN: A NEW SUBSTANCE FOR DECREASING OF GABA LEVELS IN CNS.
000126 01-03

VERTICAL

LITHIUM EFFECTS ON VERTICAL ACTIVITY IN RATS: A REPLY TO D. F SMITH.
001520 02-04

REEXAMINATION OF VERTICAL ACTIVITY IN RATS TREATED WITH LITHIUM-CHLORIDE.
0D1581 02-04

VERTICAL GAZE PALSY IN BARBITURATE INTOXICATION.
003773 D4-15

VESICLES

INDIRECT AND DIRECT INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY AMPHETAMINE IN STORAGE VESICLES AND SYNAPTOSOMES.
000150 01-D3

ALTERATION BY METHADONE OF CATECHOLAMINE UPTAKE AND RELEASE IN ISOLATED RAT ADRENOMEDULLARY STORAGE VESICLES.
0D1377 02-03

INFLUENCE OF SOME PRODUCTIVE TROPINES ON ABSORPTION OF NORADRENALINE BY SYNAPTIC VESICLES OF THE HYPOTHALAMUS.
001426 02-03

ULTRASTRUCTURAL CHANGES OF THE RAT CEREBELLUM DUE TO PENTETRAZOL AND PHENOBARBITAL ADMINISTRATION -- IN SPECIAL REFERENCES TO THE CHANGES OF SYNAPTIC VESICLES ASSOCIATED WITH CONVULSIVE SEIZURES.
002275 03-03

VESPARAX

PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A SOURCE OF COMPLICATIONS IN VESPARAX INTOXICATION.
000466 01-05

VESSELS

AUTONOMIC NERVES, MAST CELLS, AND AMINE RECEPTORS IN HUMAN BRAIN VESSELS. A HISTOCHEMICAL AND PHARMACOLOGICAL STUDY.
002114 02-17

VESTIBULAR

SENSITIVITY OF COMPONENTS OF THE CENTRAL VESTIBULAR COMPLEX TO PENTOBARBITAL.
D03225 D4-D3

VETERANS

POLYPHARMACY IN THE PSYCHIATRIC TREATMENT OF ELDERLY HOSPITALIZED PATIENTS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
000772 D1-11

VIABILITY

THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-D5

VIBRISSAL

VIBRISSAL ANESTHESIA AND THE SUPPRESSION OF INTRUDER ELICITED AGGRESSION IN RATS.
0D0325 01-04

VICTIMS

DIETHYLSTILBESTROL IN THE TREATMENT OF RAPE VICTIMS.
002899 03-15

VIDEO

NEW STRATEGIES OF PSYCHIATRIC DIAGNOSIS USING AUDIOVISUAL TECHNIQUES: 1. USE OF TIME BLIND VIDEO ANALYSIS FOR EVALUATION OF ANTIDEPRESSANT DRUG TRIALS.
DDD651 01-09

INVESTIGATIONS WITH A BEHAVIOR ORIENTED ASSESSMENT SCALE FOR DEPRESSIVE INHIBITION AND AGITATION: RESULTS OF A VIDEO DOCUMENTED AMITRIPTYLINE MIANSERIN STUDY.
DD2D95 D2-16

VIDEOTAPED

STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS.
DD1772 02-09

VIGILANCE

RESIDUAL EFFECTS OF HYPNOTIC DRUGS: EVIDENCE FOR INDIVIDUAL DIFFERENCES ON VIGILANCE.
0DD910 01-14

MEDICATION: INCREASED VIGILANCE NEEDED.
002053 02-15

VIGILANCE AND AROUSAL IN DEPRESSIVE STATES.
0D2712 03-1D

ALTERATIONS IN THE VIGILANCE PERFORMANCE OF CHILDREN RECEIVING AMITRIPTYLINE AND METHYLPHENIDATE PHARMACOTHERAPY
DD2767 03-11

VILOXAZIN

VILOXAZIN (VIVALAN-ICI) -- A STRUCTURALLY NEW ANTIDEPRESSANT
DD267B D3-09

VILOXAZINE
NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS
000302 01-04
EFFECTS OF VILOXAZINE, AN ANTIDEPRESSANT AGENT ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.
001279 02-03
DOUBLE-BLIND COMPARATIVE STUDY WITH THE NEW ANTIDEPRESSANT VILOXAZINE AND IMIPRAMINE IN 50 HOSPITALIZED FEMALE PATIENTS.
001744 02-09
STUDY OF A NEW ANTIDEPRESSANT (VILOXAZINE) WITH THE HELP OF TIME SERIES ANALYSIS OF VIDEOTAPED INTERVIEWS
001772 02-09
CHEMOTHERAPY OF MELANCHOLIA BY SEQUENTIAL ASSOCIATION OF A NEUROLEPTIC AND VILOXAZINE
002668 03-09
CONTROLLED TRIAL OF NOMIFENSIN (HOE-9B4) AND VILOXAZINE IN THE TREATMENT OF DEPRESSION IN THE ELDERLY
003570 04-09

VIMINOL
CORRELATION BETWEEN ANALGESIA AND THE DECREASE OF ACETYLCHOLINE TURNOVER RATE IN CORTEX AND HIPPOCAMPUS ELICITED BY MORPHINE, MEPERIDINE, VIMINOL R2 AND AZIDOMORPHINE.
001430 02-03

VINBLASTINE
PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE
001621 02-05

VINCA
EFFECTS OF VINCA ALKALOIDS ON UPTAKES OF AMINO-ACIDS BY RAT BRAIN SYNAPTOSOMES.
000199 01-03

VINCAMIN
CLINICAL STUDY OF THE EFFECTS OF VINCAMIN IN SENILE DEMENTIA SYNDROME.
000735 01-11

VINCRISTINE
PHENOBARBITAL AND SKF-525-A ON VINBLASTINE AND VINCRISTINE TOXICITY IN MICE.
001621 02-05

VINYL-ETHERS
VINYL-ETHERS OF CHOLINE AND CONGENERS
000067 01-03

VIOLENT
A RAT MODEL OF VIOLENT ATTACK BEHAVIOR (PH.D DISSERTATION).
002531 03-04

VIROLA
DE PLANTIS TOXICARIIS E MUNDO NOVO TROPICALE COMMENTATIONES XIII. FURTHER NOTES ON VIROLA AS AN ORALLY ADMINISTERED HALLUCINOGEN
001093 02-01

VISCERAL
MOTOR AND VISCERAL LEARNING DEFICITS IN RESERPINE-TREATED RATS.
000319 01-04
THE EFFECT OF MATERNAL ALCOHOL CONSUMPTION ON THE VIABILITY AND VISCERAL DEVELOPMENT OF THE NEWBORN RAT.
003499 04-05

VISITATION
THE RELATIONSHIP OF PROGRAM PARTICIPATION AND VISITATION TO ADAPTIVE BEHAVIOR AND SOCIALIZATION OF INSTITUTIONALIZED MENTALLY RETARDED PERSONS (PH.D. DISSERTATION)
001040 01-17

VISUAL
DIFFERENTIAL EFFECTS OF THE ACQUISITION ENHANCING DRUG PYRROLIDONE ACETAMIDE (PIRACETAM) ON THE RELEASE OF PROLINE FROM VISUAL AND PARIETAL RAT CEREBRAL CORTEX IN VITRO
001307 02-03
ACUTE AND CHRONIC SINGLE-DOSE EFFECTS OF LSD-25 ON VISUAL DISCRIMINATION IN RATS
001623 02-05
EFFECTS OF ETHANOL ON SCALP VISUAL EVOKED POTENTIALS
00194B 02-13
BIOELECTRIC REACTIONS TO VISUAL STIMULI IN THE BRAIN OF THE STURGEON ACIPENSER-GULDENSTADTI
002394 03-03
OPERANT BEHAVIORAL OBSERVATION ON VISUAL AND AUDITORY EFFECTS OF DRUGS.
002546 03-04
INITIAL ALTERATIONS OF NEURONAL RESPONSES DURING STRYCHNINE EPILEPTOGENESIS IN VISUAL CORTEX
003131 04-03
EFFECT OF SECOBARBITAL AND CHLORPROMAZINE ON CORTICAL AND SUBCORTICAL VISUAL EVOKED POTENTIALS IN THE MONKEY
003242 04-03
EFFECTS OF LSD ON THE RESPONSES OF SINGLE UNITS IN CAT VISUAL CORTEX
003256 04-03
EFFECTS OF PRETRIAL AND POSTTRIAL CAFFEINE ADMINISTRATIONS ON SIMULTANEOUS VISUAL DISCRIMINATION IN THREE INBRED STRAINS OF MICE.
003362 04-04
CHANGES IN PSYCHOPATHOLOGY IN RELATION TO EEG VARIABLES AND VISUAL AVERAGED EVOKED RESPONSES (V.AER) IN SCHIZOPHRENIC PATIENTS TREATED WITH PENFLURIDOL OR THIOTHIXENE
003533 04-08
COMPARISON BETWEEN PHYSICIAN AND PATIENT COMPLETED VISUAL ANALOGUE SCALES.
003897 04-17

VISUALLY
VISUALLY EVOKED POTENTIALS IN CORTICAL AND SUBCORTICAL BRAIN STRUCTURES OF CONSCIOUS RABBITS WITH CHRONICALLY IMPLANTED ELECTRODES: STANDARDIZED NORMAL VALUES AND THE INFLUENCE OF SOME PSYCHOPHARMACOLOGICAL AGENTS ON THEM.
000473 01-06
CLASSIFICATION OF PSYCHOACTIVE DRUGS BY VISUALLY EVOKED POTENTIALS IN RABBITS BY MEANS OF MULTIPLE DISCRIMINANT ANALYSIS: A POSSIBLE WAY OF PREDICTING THE CLINICAL EFFICACY OF NEW PSYCHOACTIVE DRUGS.
001645 02-06

VITAMIN-A
STUDY OF THE PROTECTIVE EFFECT OF VITAMIN-A ON STRESS ULCER IN THE RAT.
000223 01-03

VITAMIN-B6
THE EFFECT OF L-DOPA AND VITAMIN-B6 IN SCHIZOPHRENIA.
002634 03-08
EFFECTS OF L-DOPA AND VITAMIN-B6 ON ELECTROENCEPHALOGRAMS OF SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT
002B47 03-13

VITAMIN-C
DREAMING, FENFLURAMINE, AND VITAMIN-C.
003691 04-13

VITAMINS
VITAMINS, NEUROLEPTICS, AND ANTIPARKINSONIAN DRUGS IN CATECHOLAMINE EXCRETION.
000B72 01-13

VITREOUS
DIBENZEPINE AND ITS METABOLITES IN BLOOD, MUSCLE, LIVER, VITREOUS BODY AND URINE FROM FATAL POISONING.
000934 01-15

VIVALAN
NOISE STRESS AND THE EFFECTS OF VILOXAZINE (VIVALAN), A NEW ANTIDEPRESSANT ON OPEN-FIELD ACTIVITY IN RATS.
000302 01-04

VIVALAN-ICI
VILOXAZIN (VIVALAN-ICI) -- A STRUCTURALLY NEW ANTIDEPRESSANT
00267B 03-09

VMA
THE RATE OF EXCRETION OF VMA IN DEPRESSED PATIENTS BEFORE AND AFTER THE ADMINISTRATION OF METHIONINE
0005B7 01-09

VMAX
REGULATION OF THE PROTEIN KINASE IN RAT PINEAL: INCREASED VMAX IN SUPERSENSITIVE GLANDS. (UNPUBLISHED PAPER).
002414 03-03

VMH
NEMBUTAL TREATMENT OF THE VMH (RAT): EFFECTS ON FEEDING AND SEXUAL BEHAVIOUR.
003444 04-04

VOLATILE
IDENTIFICATION OF SOME VOLATILE ENDOGENOUS CONSTITUENTS IN RAT BRAIN TISSUE AND THE EFFECTS OF LITHIUM-CARBONATE AND CHLORAL HYDRATE.
001564 02-04

VOLUMES
ON CHANGING BLOOD DENSITIES OF ANTISEIZURE DRUGS TAKEN IN LARGE VOLUMES.
002950 03-15

VOLUNTEER
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT (PH D DISSERTATION).
002956 03-16

VOLUNTEERS
ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS (UNPUBLISHED PAPER)
003705 04-13
EFFECTS OF MARIHUANA ON REACTION TIME AND SHORT-TERM MEMORY IN HUMAN VOLUNTEERS.
003746 04-14

FREE-LIVING VOLUNTEERS MOTIVATIONS AND ATTITUDES TOWARD PHARMACOLOGIC STUDIES IN MAN.
003868 04-17

VOMITING
VOMITING DURING NEUROLEPTIC WITHDRAWAL IN CHILDREN.
003758 04-14

VORACIOUSNESS
BENZODIAZEPINE-INDUCED VORACIOUSNESS IN CATS AND INHIBITION OF AMPHETAMINE ANOREXIA.
000099 01-03

VTA
SELF-STIMULATION OF THE MFB OR VTA AFTER MICROINJECTION OF HALOPERIDOL INTO THE PREFRONTAL CORTEX OF THE RAT.
003432 04-04

WA-335
DETERMINATION OF PSYCHOACTIVITY AND CEREBRAL BIOAVAILABILITY OF DANITRACENE (WA-335) BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS.
002873 03-14

WA-335-BS
EFFECT OF THE ANTHRACENE DERIVATIVE DANITRACENE (WA-335-BS) IN COMPARISON TO AMITRIPTYLINE IN DEPRESSIVE PATIENTS.
001760 02-09

WAIS
WAIS FUNCTIONING OF CIRRHOTIC AND NON-CIRRHOTIC ALCOHOLICS.
003827 04-15

WAKIN
THE EFFECT OF OMETINE ON LEARNED BEHAVIOR IN THE WAKIN GOLDFISH.
002514 03-04

WAKING
EFFECT OF INTRACISTERNAL ADMINISTRATION OF PROSTAGLANDIN-E1 ON WAKING AND SLEEP IN THE RAT.
000165 01-03

WALLS
THE PSYCHIATRIC SECTOR AND THE WALLS OF THE ASYLUM.
002638 03-08

WAR
THE WAR OVER MARIJUANA.
002882 03-14

WARD
PSYCHOPHARMACOLOGY RESEARCH WARD. TEN YEARS EXPERIENCE.
001076 01-17
INDIVIDUAL DRUG SUPPLY IN A PSYCHOGERIATRIC WARD: AN EVALUATION OF THE SYSTEM.
003842 04-16

WARNING
PENTAZOCINE ADDICTION: A WARNING.
003832 04-15

WATER
THE EFFECTS OF CHRONIC LITHIUM-CHLORIDE ADMINISTRATION ON COMPLEX SCHEDULE PERFORMANCE, ACTIVITY, AND WATER INTAKE IN THE ALBINO RAT.
000304 01-04
COMPARATIVE EFFECTS OF VARIOUS NATURALLY OCCURRING CANNABINOIDS ON FOOD, SUCROSE AND WATER CONSUMPTION BY RATS.
000426 01-04
COMPULSIVE WATER DRINKING DURING DEPRESSIVE REACTION
000688 01-10
EFFECTS OF WATER DEPRIVATION AND PRIOR LICL EXPOSURE IN CONDITIONING TASTE AVERSIONS.
001597 02-04
THE EFFECTS OF ADMINISTERING LITHIUM-CARBONATE ON THE BALANCE OF NA, K AND WATER IN MANIC-DEPRESSIVE PATIENTS.
001774 02-09
CHANGES IN SEROTONIN METABOLISM OF THE RAT BRAIN AND GASTRIC ULCERATION FOLLOWING WATER IMMERSION STRESS.
002398 03-03
EFFECTS OF ANTIANXIETY DRUGS ON THE WATER INTAKE IN TRAINED AND UNTRAINED RATS AND MICE.
002544 03-04
INFLUENCE OF AMYLOPECTINE SULFATE ON GASTRIC MUCOSA IN NORMAL OR WATER IMMERSION STRESSED RATS.
002547 03-04
WATER POISONING AND DIABETES-INSIPIDUS: A PROPOS COMPULSIVE WATER DRINKING AND DYSTHYMIA
002717 03-10
THE INFLUENCE OF LITHIUM ON WATER BINDING ABILITY, CONSISTENCY AND MACROMOLECULES IN THE RAT BRAIN
003132 04-03
PHENOBARBITAL DRINKING CURVES AFTER VARIED WATER DEPRIVATION
003458 04-04

WAVE
MONOAMINE OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT.
000108 01-03

WAVES
INTERACTION OF PSYCHOTROPIC AGENTS WITH CENTRAL NEUROTRANSMITTERS AS REVEALED BY THEIR EFFECTS ON PGO WAVES IN THE CAT.
001230 02-03
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO WAVES OCCURRING IN REM SLEEP AND ON THE RESERPINE-INDUCED PGO WAVES.
002259 03-03
AMINE REPLETION IN THE RESERPINIZED CAT: EFFECT UPON PGO WAVES AND REM SLEEP.
003106 04-03

WEAK
A STUDY OF MUSCARINIC RECEPTOR HETEROGENEITY WITH WEAK ANTAGONISTS.
000097 01-03

WEB
THE IMPACT OF DRUG THERAPY UPON PSYCHIATRY: A WEB OF PARADOXES.
003877 04-17

WEEKENDS
SLEEP ANALYSIS DURING DRUG-FREE WEEKENDS IN CHRONIC SCHIZOPHRENIC PATIENTS.
002092 02-16

WEIGHT
DISSOCIATION OF GUSTATORY AND WEIGHT REGULATORY RESPONSES TO QUININE FOLLOWING LATERAL HYPOTHALAMIC LESIONS.
001536 02-04
FAT CELL NUMBER AND WEIGHT GAIN IN LITHIUM TREATED PATIENTS.
001782 02-09
MESORIDAZINE IN HUNTINGTONS DISEASE (CHOREA): EFFECT ON WEIGHT, DYSKINESIA, AND MENTAL FUNCTION
001826 02-11
TREATMENT OF EXCESSIVE WEIGHT GAIN IN PATIENTS TAKING LITHIUM.
002030 02-15
CHANGES IN THE BODY WEIGHT OF RAT ON CONTINUOUS INJECTIONS OF MORPHINE, PETHIDINE, OR PENTAZOCINE.
002575 03-05
CENTRAL ACTION AND A SPECIES COMPARISON OF THE ESTROGENIC EFFECTS OF AN ANTIESTROGEN ON EATING AND BODY WEIGHT.
003260 04-03
A COMPARISON OF THE EFFECTS OF NALOXONE UPON BODY WEIGHT LOSS AND SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR IN MORPHINE-DEPENDENT RATS.
003388 04-04
WEIGHT REDUCTION IN SCHIZOPHRENICS BY MOLINDONE.
003536 04-08
NEUROLEPTIC DRUG EFFECTS ON CHILDRENS BODY WEIGHT AND HEIGHT
003645 04-11
AN INVESTIGATION INTO THE SHORT-TERM EFFECTS OF CLOMIPRAMINE (ANAFRANIL) ADMINISTERED IN LOW DOSES, ON WEIGHT.
003657 04-13

WEST-AFRICAN
CONSTITUENTS OF WEST-AFRICAN MEDICINAL PLANTS. XV. DINKLACORINE, A NEW BIPHENYL-DIBENZODIOXIN ALKALOID FROM TILIACORA-DINKLAGEI.
001084 02-01

WHEAT
WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS
001702 02-08
WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001717 02-08
WHEAT GLUTEN -- SCHIZOPHRENIA FINDINGS.
001718 02-08

WHEEL-RUNNING
THE SEDATIVE EFFECTS OF NICOTINAMIDE ON GERBIL WHEEL-RUNNING ACTIVITY.
002423 03-04

WHEEL-SPINNING
THE EFFECTS OF ANOROGEN ON WHEEL-SPINNING ACTIVITY IN INFANT RATS.
002537 03-04

WILLINGNESS
PHARMACOLOGICAL TESTING IN A CORRECTIONAL INSTITUTION: THE IMPACT OF CONTENT VARIABLES ON WILLINGNESS TO VOLUNTEER, PERSONALITY ADJUSTMENT AND INFORMED CONSENT. (PH.D. DISSERTATION).
002956 03-16

WISH
DRUG REFUSAL IN SCHIZOPHRENIA AND THE WISH TO BE CRAZY.
002942 03-15

WISTAR
THE BILIARY EXCRETION OF (3H) LYSERGIC-ACID-DIETHYLAMIDE IN WISTAR AND GUNN RATS.
001134 02-03

WITHDRAWAL
EFFECT OF PHARMACOLOGICAL INTERFERENCE WITH VARIOUS NEUROPATHWAYS ON BLOCKADE OF MORPHINE WITHDRAWAL HYPOTHERMIA BY MORPHINE AND BY CONDITIONAL STIMULUS.
000091 01-03
THE EFFECTS OF BILATERAL CINGULATE CORTEX LESIONS ON MORPHINE WITHDRAWAL SYMPTOMS IN RATS.
000243 01-03
EFFECTS OF DRUGS AFFECTING ENDOGENOUS AMINES OR CYCLIC NUCLEOTIDES ON ETHANOL WITHDRAWAL HEAD TWITCHES IN MICE.
000298 01-04
CHANGES IN THE SOCIAL BEHAVIOUR OF LABORATORY MICE DURING ADMINISTRATION AND ON WITHDRAWAL FROM NONATAXIC DOSES OF ETHYLALCOHOL.
000305 01-04
WITHDRAWAL FROM ETHANOL: SIMPLE QUANTITATIVE BEHAVIORAL TESTS FOR ITS EVALUATION.
000403 01-04
A CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC SCHIZOPHRENIC PATIENTS.
000530 01-08
LITHIUM TREATMENT DURING ALCOHOLIC WITHDRAWAL.
000778 01-11
EFFECT OF PROPRANOLOL ON ACUTE WITHDRAWAL TREMOR IN ALCOHOLIC PATIENTS.
000782 01-11
PHYSIOLOGICAL DEPENDENCE ON, AND SYMPTOMS OF WITHDRAWAL FROM, CHLORMETHIAZOLE.
000981 01-15
THE DEMONSTRATION OF A CHANGE IN ADRENERGIC RECEPTOR SENSITIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF MICE AFTER WITHDRAWAL FROM LONG-TERM TREATMENT WITH HALOPERIDOL.
001194 02-03
CORRELATION BETWEEN THE IN VIVO AND AN IN VITRO EXPRESSION OF OPIATE WITHDRAWAL PRECIPITATED BY NALOXONE: THEIR ANTAGONISM BY LAMBDA-DELTA9-TETRAHYDROCANNABINOL.
001208 02-03
SUPPRESSION BY 1,3 BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS.
001287 02-03
CHANGES IN THE STRIATAL ADENYLATE-CYCLASE ACTIVITY FOLLOWING ACUTE AND CHRONIC MORPHINE TREATMENT AND DURING WITHDRAWAL.
001336 02-03
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF RAT STRIATA DURING ETHANOL AND BARBITURATE WITHDRAWAL.
001363 02-03
THE ROLE OF DOPAMINE IN WITHDRAWAL JUMPING IN MORPHINE-DEPENDENT RATS.
001447 02-04
ENHANCEMENT OF MORPHINE WITHDRAWAL AND APOMORPHINE-INDUCED AGGRESSION BY CLONIDINE.
001492 02-04
DRINKING PATTERNS AS PREDICTORS OF ALCOHOL WITHDRAWAL REACTIONS IN DBA/2J MICE.
001497 02-04
INCREASED AGGRESSION IN RATS AFTER WITHDRAWAL OF LONG-TERM USED OXAZEPAM.
001509 02-04
CHANGES IN DIURNAL TEMPERATURE AND FEEDING PATTERNS OF RATS DURING REPEATED INJECTIONS OF HEROIN AND WITHDRAWAL.
001598 02-04
DOPAMINERGIC INFLUENCE ON WITHDRAWAL JUMPING BEHAVIOR IN MORPHINE-DEPENDENT MICE.
001600 02-04
THE EFFECT OF PROLONGED ETHANOL ADMINISTRATION AND ITS WITHDRAWAL ON CATECHOLAMINE TURNOVER IN THE RAT BRAIN.
001631 02-05
TURNOVER OF CATECHOLAMINES IN SOME REGIONS OF THE RAT BRAIN DURING PROLONGED VASOPRESSIN ADMINISTRATION AND AFTER ITS WITHDRAWAL.
001641 02-05
AMBULANT TREATMENT OF ALCOHOL WITHDRAWAL SYMPTOMS WITH CARBAMAZEPINE A FORMAL MULTICENTRE DOUBLE-BLIND COMPARISON WITH PLACEBO
001818 02-11
INFLUENCING DEPRESSIVE CONDITIONS OF THE ALCOHOL WITHDRAWAL SYNDROME WITH TRH (THYROTROPIN-RELEASING HORMONE).
001840 02-11
CONTROL OF ACUTE ALCOHOLIC WITHDRAWAL SYMPTOMS. A COMPARATIVE STUDY OF HALOPERIDOL AND CHLORDIAZEPOXIDE
001850 02-11
HEROIN WITHDRAWAL SYNDROME IN NEWBORNS
001851 02-11
ARE ANTICHOLINERGICS NECESSARY AS A LONG-TERM THERAPY IN NEUROLEPTIC-INDUCED PARKINSON SYNDROME? A WITHDRAWAL STUDY
002035 02-15
CATATONIA-LIKE SYMPTOMATOLOGY AND WITHDRAWAL DYSKINESIAS
002043 02-15
ALLEVIATION OF NARCOTIC WITHDRAWAL BY CONDITIONAL STIMULI
002292 03-03
A COMPARISON OF WITHDRAWAL IN RATS IMPLANTED WITH DIFFERENT TYPES OF MORPHINE PELLETS
002311 03-03
EFFECTS OF CHOLINERGIC AGONISTS AND ANTAGONISTS ON MORPHINE WITHDRAWAL SYNDROME.
002469 03-04
ACTIVITY OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM DURING PRECIPITATED MORPHINE WITHDRAWAL INVESTIGATED IN RATS WITH ACUTE UNILATERAL INACTIVATION OF THE STRIATUM.
002491 03-04
WITHDRAWAL CHARACTERISTICS FOLLOWING CHRONIC PENTOBARBITAL DOSING IN CAT.
002516 03-04
DIMINISHED REACTION TO A NOVEL STIMULUS DURING AMPHETAMINE WITHDRAWAL IN RATS.
002532 03-04
BEHAVIORAL EFFECTS OF WITHDRAWAL OF FLUPHENAZINE AFTER LONG-TERM TREATMENT.
002578 03-05
SULPIRIDE IN WITHDRAWAL OF NONALCOHOLIC DRUG ADDICTS.
002593 03-07
DOUBLE-BLIND STUDY OF THE EFFECT OF PROPRANOLOL AGAINST PLACEBO IN THE WITHDRAWAL SYNDROME OF ALCOHOLICS, HYPNOTICS, TRANQUILIZERS, ANALGETICS, AND OPIATES -- A PRELIMINARY REPORT.
002754 03-11
ON THE THERAPY OF WITHDRAWAL SYMPTOMS IN CHRONIC ALCOHOLISM WITH OXAZEPAM.
002758 03-11
NITRAZEPAM: LASTINGLY EFFECTIVE BUT TROUBLE ON WITHDRAWAL.
002848 03-14
ANTAGONISM BETWEEN ANTIPARKINSONIAN DRUGS AND NEUROLEPTICS: SEVERAL EXPERIENCES OF WITHDRAWAL, INCLUDING A PERSONAL EXPERIENCE. PART 2.
002887 03-15
HALLUCINATIONS FOLLOWING WITHDRAWAL OF VALIUM.
002894 03-15
ACUTE CORONARY SYNDROMES AFTER SUDDEN PROPRANOLOL WITHDRAWAL: NO EVIDENCE OF A REBOUND HYPERINOTROPIC EFFECT IN HEALTHY SUBJECTS.
002922 03-15
WITHDRAWAL REACTION TO DIAZEPAM.
002927 03-15
DOPAMINERGIC MECHANISMS IN PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT RATS.
003086 04-03
THE EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF DEXTROAMPHETAMINE ON SEIZURE THRESHOLD AND ENDOGENOUS CATECHOLAMINE CONCENTRATIONS AND THEIR RATES OF BIOSYNTHESIS IN MICE.
003252 04-03
NORADRENERGIC SUPERSENSITIVITY IN THE RAT VAS-DEFERENS DURING BARBITAL WITHDRAWAL.
003261 04-03
ALTERED SENSITIVITY OF THE RAT CENTRAL-NERVOUS-SYSTEM TO NEUROTRANSMITTERS DURING PRECIPITATED MORPHINE WITHDRAWAL
003272 04-03
EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND WITHDRAWAL ON ADENOSINE 3:5-MONOPHOSPHATE AND GUANOSINE 3:5-MONOPHOSPHATE LEVELS IN THE RAT BRAIN
003316 04-03
INDUCTION OF TOLERANCE AND WITHDRAWAL IN RATS RECEIVING MORPHINE IN THE SPINAL SUBARACHNOID SPACE
003332 04-03
THE EFFECT OF DIET ON ETHANOL WITHDRAWAL SYMPTOMATOLOGY
003346 04-04
CHANGES IN SENSITIVITY TO OPERANT EFFECTS OF DOPAMINERGIC AND CHOLINERGIC AGENTS FOLLOWING MORPHINE WITHDRAWAL IN RATS
003390 04-04
EVIDENCE FOR THE ROLE OF BRAIN NOREPINEPHRINE AND DOPAMINE IN REBOUND PHENOMENON SEEN DURING WITHDRAWAL AFTER REPEATED EXPOSURE TO BENZODIAZEPINES
003449 04-04
HYDROXYZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL
003614 04-11
THIORIDAZINE HCL VS. CHLORDIAZEPOXIDE HCL IN CONTROLLING SYMPTOMS ATTRIBUTABLE TO ALCOHOL WITHDRAWAL
003639 04-11
NALOXONE PRECIPITATED WITHDRAWAL. A METHOD FOR RAPID INDUCTION ONTO NALTREXONE
003745 04-14
VOMITING DURING NEUROLEPTIC WITHDRAWAL IN CHILDREN.
003758 04-14

NEONATAL BARBITURATE WITHORAWAL.
003769 04-15
DIAZEPAM WITHDRAWAL PSYCHOSIS: A CASE REPORT.
003772 04-15
BENZODIAZEPINES AND WITHDRAWAL PSYCHOSIS: REPORT OF THREE CASES.
003817 04-15
ACUTE HYPERTENSION AFTER A8RUPT WITHDRAWAL OF ANTIPSYCHOTIC MEDICATION
003833 04-15
WITHDRAWAL FROM BENZODIAZEPINE THERAPY.
003872 04-17
WITHDRAWAL FROM METHADONE MAINTENANCE. RATE OF WITHDRAWAL AND EXPECTATION
003898 04-17

WITHDRAWAL-INDUCED
MORPHINE-INDUCED ROTATION (CIRCLING BEHAVIOR) IN RATS AND MICE: SPECIES DIFFERENCES, PERSISTENCE OF WITHDRAWAL-INOUCED ROTATION AND ANTAGONISM BY NALOXONE
003434 04-04

WOMEN
RED-BLOOD-CELL CATECHOL-O-METHYLTRANSFERASE ANO RESPONSE TO IMIPRAMINE IN UNIPOLAR DEPRESSIVE WOMEN.
000592 01-09
DRUG STUOIES WITH WOMEN, THE ELDERLY, AND GROUPS.
000865 01-13
RISK FACTORS FOR MYOCARDIAL INFARCTION IN YOUNG WOMEN
000966 01-15
PLASMA CONCENTRATIONS OF PROTRIPTYLINE AND CLINICAL EFFECTS IN DEPRESSEO WOMEN
000994 01-15

WORK
DO TRICYCLIC ANTIDEPRESSANTS WORK?
000662 01-09
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INDUCED BY ADRENALINE AND PHYSICAL WORK
000B26 01-13
INFLUENCE OF METOPROLOL AND PROPRANOLOL ON HEMODYNAMIC EFFECTS INOUCEO BY PHYSICAL WORK AND ISOPRENALINE.
000B27 01-13
DO GERIATRIC DRUGS WORK?.
001824 02-11
HOW TRANQUILIZERS WORK
001926 02-13
DO TRICYCLIC ANTIDEPRESSANTS WORK?.
001939 02-13
OO TRICYCLIC ANTIDEPRESSANTS WORK?
002027 02-15
PSYCHOPHARMACOLOGY AND SOCIAL WORK SKILLS
003BB4 04-17

WORKSHOP
WORKSHOP ON P-CHLOROAMPHETAMINE
000246 01-03

WORLD
THE INTERNATIONAL REFERENCE CENTER FOR INFORMATION ON PSYCHOTROPIC DRUGS OF THE WORLD HEALTH ORGANIZATION (WHO). (SUMMARY).
002137 02-17

WRONG
WHOS GOT THE WRONG IDEA ABOUT TREATING DEPRESSION? . A CHANGE OF ATTITUDE TO MAOI TRICYCLIC COMBINATIONS IS OBVIOUSLY NEEDED
0026B5 03-09

X-RAY
APPLICATION OF ENERGY DISPERSION X-RAY ANALYSIS TO ELECTRON MICROSCOPIC AUTORADIOGRAPHY DISTRIBUTION OF PSYCHOTROPIC DRUGS IN THE CENTRAL-NERVOUS-SYSTEM.
0025B6 03-06

XANTHINES
OPIATES, CYCLIC NUCLEOTIOES, AND XANTHINES.
002225 03-03

XANTHONE
STRUCTURE-ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES INTRODUCTION TO PARTS X XII, AND PART X ACRIDONE DERIVATIVES
000017 01-01
STRUCTURE ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES PART XI LENGTHENING OF THE BASIC CHAIN
00001B 01 01
STRUCTURE ACTIVITY RELATIONSHIPS IN CENTRALLY STIMULATING XANTHONE DERIVATIVES PART XII SOME OPEN MODELS AND CONCLUSIVE REMARKS.
000247 01-03

XENON-133
EFFECT OF ORAL PAPAVERINE ON CEREBRAL BLOOD FLOW IN NORMALS EVALUATION BY THE XENON 133 INHALATION METHOD
002096 02-16

Y-MAZE
PERSEVERATION AND ROTATIONAL BEHAVIOR ELICITED 8Y D-AMPHETAMINE IN A Y-MAZE EXPLORATORY TASK: DIFFERENTIAL EFFECTS OF INTRAPERITONEAL AND UNILATERAL INTRAVENTRICULAR ADMINISTRATION
003413 04-04

YOHIMBINE
INTERACTION BETWEEN YOHIM8INE ALKALOIDS AND AMPHETAMINE IN MICE.
003501 04-05

YOUNG
ORUG EFFECTS ON SUCCESSIVE DISCRIMINATION LEARNING IN YOUNG CHICKENS.
000110 01-03
EFFECT OF METHAMPHETAMINE ON MOTOR ACTIVITY IN YOUNG ANO OLD MICE.
000320 01-04
RISK FACTORS FOR MYOCAROIAL INFARCTION IN YOUNG WOMEN
000966 01-15
HIGH DOSES OF HALOPERIOOL IN THE TREATMENT OF 5 YOUNG SCHIZOPHRENICS IN A THERAPEUTIC COMMUNITY
001705 02-08
A8SORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. (UNPUBLISHEO PAPER).
003705 04-13
MYOCLONUS IN THE YOUNG AFTER 5-HYDROXYTRYPTOPHAN
003771 04-15

YOUNGSTERS
THE EFFECTS OF METHYLPHENIDATE AND THIORIOAZINE UPON ATTENTION, AROUSAL, AND ACTIVITY IN MENTALLY RETARDED YOUNGSTERS. (PH.D. DISSERTATION).
000781 01-11

ZIMELIDINE
INITIAL CLINICAL TRIAL BASED ON BIOCHEMICAL METHODOLOGY OF ZIMELIDINE (A SEROTONIN UPTAKE INHIBITOR) IN OEPRESSED PATIENTS.
003709 04-13

ZINC
USE OF RAOIOACTIVE COPPER ANO RAOIOACTIVE ZINC IN PSYCHIATRIC OIAGNOSIS.
002983 03-17

ZK-62-711
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHOOIESTERASES IN HOMOGENATES ANO TISSUE SLICES FROM RAT BRAIN.
002358 03-03

ZONA-COMPACTA
A QUANTITATIVE CORRELATION BETWEEN SINGLE UNIT ACTIVITY AND FLUORESCENCE INTENSITY OF DOPAMINE NEURONS IN ZONA-COMPACTA OF SUBSTANTIA-NIGRA, AS DEMONSTRATED UNDER THE INFLUENCE OF NICOTINE ANO PHYSOSTIGMINE
001277 02-03

ZOXAZOLAMINE
EFFECT OF 7,8 BENZOFLAVONE ON THE DURATION OF ZOXAZOLAMINE PARALYSIS ANO HEXOBARBITAL HYPNOSIS IN RATS.
000259 01-03

ZWITTERION
THE IONIZATION OF PHENOLIC AMINES, INCLUDING APOMORPHINE, DOPAMINE ANO CATECHOLAMINES ANO AN ASSESSMENT OF ZWITTERION CONSTANTS.
000001 01-01

1-ACYL-GLYCEROPHOSPHORYLCHOLINE
THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION ON ARACHIOONYL TRANSFER TO 1-ACYL-GLYCEROPHOSPHORYLCHOLINE IN RAT BRAIN SYNAPTOSOMAL FRACTION
003293 04-03

1-TETRALONE
ANALGESIC ANO TRANQUILIZING ACTIVITY OF 5,8 DISUBSTITUTED 1-TETRALONE MANNICH-BASES.
003075 04-02

10-N-ACYLAMINOPHENOTHIAZINE
EFFECT OF SAS (A NEW 10-N-ACYLAMINOPHENOTHIAZINE) ON GASTRIC SECRETION AND ULCERATION IN RATS.
001534 02-04

10-PIPERAZINE-DIBENZOTHIEPINS
QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS (QSAR) IN A SERIES OF NEUROLEPTIC 10-PIPERAZINE-DIBENZOTHIEPINS, ATAXIA IN MICE
002577 03 05

10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE
ABSORPTION, DISTRIBUTION AND ELIMINATION OF 10-3-QUINUCLIDINYLMETHYLPHENOTHIAZINE (LM-209), A NEW ANTIALLERGENIC
002392 03-03

1035-MD
1035-MO (SUREPTIL) A CEREBRAL VASOREGULATOR AND NEUROPSYCHOTROPIC AGENT: RESULTS AFTER TEN YEARS OF USE IN PSYCHIATRY
001013 01-17

14C-DELTA-9-TETRAHYDROCANNABINOL
THE PASSAGE OF 14C DELTA-9-TETRAHYDROCANNABINOL INTO THE MILK OF LACTATING SQUIRREL-MONKEYS
001167 02-03

14C-DMPEA
UPTAKE OF 3,4 DIMETHOXYPHENYLETHYLAMINE-1-14C (14C-DMPEA) BY RAT TISSUES IN VITRO.
001229 02-03

14C-GABA
THE SUBCELLULAR DISTRIBUTION OF 14C-GABA AND 3H-DOPAMINE IN THE RETINA.
001130 02-03

14C-HOMOVANILLIC-ACID
14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13

14C-IMIPRAMINE
IRREVERSIBLE PROTEIN BINDING OF 14C-IMIPRAMINE IN RATS IN VIVO.
001258 02-03

14C-L-DOPA
14C-HOMOVANILLIC-ACID IN THE CEREBROSPINAL FLUID OF PARKINSONIAN PATIENTS AFTER INTRAVENOUS 14C-L-DOPA.
001910 02-13

14C-LORAZEPAM
CLINICAL PHARMACOKINETICS OF LORAZEPAM 1. ABSORPTION AND DISPOSITION OF ORAL 14C-LORAZEPAM
001914 02-13

14C-METHOXYL
QUANTITATIVE MEASUREMENT OF DEMETHYLATION OF 14C METHOXYL LABELED DMPEA AND TMA-2 IN RATS.
002352 03-03

14C-5-HYDROXYTRYPTAMINE
INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES.
000213 01-03
UPTAKE OF 14C-5-HYDROXYTRYPTAMINE BY HUMAN AND RAT PLATELETS AND ITS PHARMACOLOGICAL INHIBITION. A COMPARATIVE KINETIC ANALYSIS.
002846 03-13

1694
ACTIVITY OF 1694 IN THE TREATMENT OF NEUROTIC STATES, WHETHER STRUCTURED OR NOT, HAVING PSYCHASTHENIC, ANXIOUS PHOBIC AND DEPRESSIVE EXPRESSION
000484 01-07
A DOUBLE-BLIND STUDY OF THE PSYCHOANALEPTIC ACTIVITY OF THE AMINEPTIC (1694) IN RETARDED CHILDREN WITHOUT CHARACTER DISORDERS.
000736 01-11
MOLECULE 1694 IN THE TREATMENT OF CHILDREN WITH CEREBRAL MOTOR DISORDERS OR DEVELOPMENTAL PSYCHOMOTOR DISORDERS.
000750 01-11
EFFECTS OF 1694 AND OTHER DOPAMINERGIC AGENTS ON CIRCLING BEHAVIOR.
003855 04-17

19366-RP
USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN SUMMARY.
002626 03-08

19552-RP
USE OF NEUROLEPTIC 19366-RP AND ITS LONG-ACTING ESTER, THE 19552-RP, ON 19 PATIENTS AT HOSPITAL CENTER OF FANN SUMMARY.
002626 03-08

2-AMINO-5-PHENYLBICYCLONONANES
BUTYROPHENONES FROM THE ISOMERIC 2-AMINO-5-PHENYLBICYCLONONANES
003068 04-02

2-AMINODIMETHOXYMETHPHENYLBUTANE
PHENYLALKYLAMINES WITH POTENTIAL PSYCHOTHERAPEUTIC UTILITY. 1 2-AMINODIMETHOXYMETHPHENYLBUTANE
001114 02-02

2-AMINOTETRALINS
INHIBITION IN VITRO OF NOREPINEPHRINE N-METHYLTRANSFERASE BY 2-AMINOTETRALINS, ANALOGS OF PHENYLETHYLAMINES WITH RIGID CONFORMATION
003051 04-01

2-BROMOLSD
EFFECTS OF LSD AND 2-BROMOLSD ON STRIATAL DOPAC LEVELS
003238 04-03
THE EFFECT OF LSD AND 2-BROMOLSD ON THE STRIATAL DOPA ACCUMULATION AFTER DECARBOXYLASE INHIBITION IN RATS
003239 04-03

2-CHLOROPHENOTHIAZINE
THE SYNTHESIS OF POSSIBLE HYDROXYLATED METABOLITES OF 2-CHLOROPHENOTHIAZINE DERIVATIVES (UNPUBLISHED PAPER)
001099 02-01

2-DEOXYGLUCOSE
EFFECT OF INSULIN AND PHENOBARBITAL ON UPTAKE OF 2 DEOXYGLUCOSE BY BRAIN SLICES AND HEMIDIAPHRAGMS.
001329 02-03

2-HALOGENOETHYLAMINE
SELECTIVE ALPHA ADRENOCEPTOR BLOCKING ACTIONS OF A NEW DERIVATIVE OF 2-HALOGENOETHYLAMINE: BROMOETHYLMETHYLENEDIOXYTETRAHYDROOIBENZAZOCINE
001248 02-03

2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS
POTENTIAL LONG-ACTING OPIATE ANTAGONISTS: PREPARATION, PHARMACOLOGICAL ACTIVITY, AND OPIATE RECEPTOR BINDING OF N SUBSTITUTED 2-HYDROXY-5-METHYL-9ALPHA-PROPYL-BENZOMORPHANS
003072 04-02

2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4
EFFECT OF COMBINED INTRODUCTION OF 2-METHYL-3-O-CHLOROPHENYL-QUINAZOLONE-4 AND PHENOBARBITAL WITH HYDROCORTISONE ON BLOOD CORTICOSTEROID CONTENT AND ATPASE ACTIVITY IN THE RAT.
002363 03-03

2-PHENYLETHYLAMINE
INHIBITION OF 2-PHENYLETHYLAMINE METABOLISM IN BRAIN BY TYPE-B MONOAMINE-OXIDASE BLOCKERS. (UNPUBLISHED PAPER).
001213 02-03
2-PHENYLETHYLAMINE AND OTHER ADRENERGIC MODULATORS.
002833 03-13

2-PROPYL-2-PENTENOIC-ACID
EFFECTS OF 2-PROPYL-2-PENTENOIC-ACID ON THE ACQUISITION OF CONDITIONED BEHAVIOR WITH NEGATIVE REINFORCEMENT IN MICE.
002501 03-04

2-PYRROLIDONE
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN
002358 03-03

2-SUBSTITUTED
SOME OXIDATION PRODUCTS OF 2-SUBSTITUTED PHENOTHIAZINES.
001081 02-01

2-THIOBARBITURATES
IR SPECTROSCOPIC CHARACTERIZATION OF 2-THIOHYDANTOINS AND 2-THIOBARBITURATES.
001089 02-01

2-THIOHYDANTOINS
IR SPECTROSCOPIC CHARACTERIZATION OF 2-THIOHYDANTOINS AND 2-THIOBARBITURATES.
001089 02-01

25-HYDROXYCHOLECALCIFEROL
THE INFLUENCE OF PHENOBARBITAL ON BIOTRANSFORMATION OF 25-HYDROXYCHOLECALCIFEROL.
000066 01-03

3-ACETYLPYRIDINE
EFFECTS OF 3-ACETYLPYRIDINE ON PUTATIVE NEUROTRANSMITTER AMINO-ACIDS IN RAT CEREBELLUM.
000196 01-03

3-CYCLOPENTYLOXY-4-METHOXYPHENYL
4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) 2-PYRROLIDONE (ZK-62-711): A POTENT INHIBITOR OF CYCLIC-AMP PHOSPHODIESTERASES IN HOMOGENATES AND TISSUE SLICES FROM RAT BRAIN
002358 03-03

3-HALODIMETHYLPYRAZOLOPYRIMIDINES
3-HALODIMETHYLPYRAZOLOPYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL-NERVOUS-SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES.
003066 04-02

3-ISOXAZOLIDONE
3-ISOXAZOLIDONE -- AN INHIBITOR OF GABA METABOLISM
000113 01-03

3-METHOXY-4-HYDROXYPHENYLGLYCOL
THE EFFECT OF PROBENECID ON THE FREE AND CONJUGATED 3-METHOXY-4-HYDROXYPHENYLGLYCOL (MHPG) IN LUMBAR CEREBROSPINAL FLUID.
001696 02-08
URINARY EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN DEPRESSED PATIENTS: MODIFICATIONS BY AMPHETAMINE AND LITHIUM
001729 02-09

3-METHOXYTYRAMINE
UPTAKE AND METABOLISM OF 3-METHOXYTYRAMINE IN THE CAT BRAIN
001638 02-05
IN VITRO UPTAKE OF 3-METHOXYTYRAMINE BY RAT BRAIN TISSUE SLICES
003158 04-03

3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE
EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-03

3-O-METHYLDOPA
METABOLISM OF 3-O-METHYLDOPA BY THE ISOLATED PERFUSED RAT LIVER.
0023BB 03-03

3H-ACETYLCHOLINE
EFFECTS OF ANESTHETICS AND SEPTAL LESIONS AND STIMULATION ON 3H-ACETYLCHOLINE FORMATION IN RAT HIPPOCAMPUS.
00003B 01-03

3H-CATECHOLAMINES
THE EFFECTS OF PHENCYCLIDINE ON THE UPTAKE OF 3H-CATECHOLAMINES BY RAT STRIATAL AND HYPOTHALAMIC SYNAPTOSOMES.
D0D1D5 D1-03

3H-DOPAMINE
INHIBITION OF THE UPTAKE OF 3H-DOPAMINE AND 14C-5-HYDROXYTRYPTAMINE IN MOUSE STRIATUM SLICES
000213 01-03
THE EFFECT OF CYCLIC NUCLEOTIDES ON THE RELEASE OF 3H-DOPAMINE FROM RAT STRIATAL SLICES.
000257 01-03
THE SUBCELLULAR DISTRIBUTION OF 14C-GABA AND 3H-DOPAMINE IN THE RETINA.
001130 02-D3
EFFECT OF NEUROLEPTICS AND OF COMBINATIONS OF D-AMPHETAMINE AND NEUROLEPTICS ON 3H-DOPAMINE UPTAKE BY HOMOGENATES FROM RAT STRIATUM.
002231 03-03
EFFECTS OF NEUROLEPTICS ON RELEASE OF 3H-DOPAMINE FROM SLICES OF RAT CORPUS-STRIATUM.
003127 04-03

3H-ESTRADIOL
INDIVIDUAL DIFFERENCES IN ESTRADIOL-INDUCED BEHAVIORS AND IN NEURAL 3H-ESTRADIOL UPTAKE IN RATS.
002450 03-04

3H-GABA
LIBERATION OF 3H-GABA FROM ISOLATED NERVE ENDINGS OF THE RAT CORTEX UNDER THE EFFECT OF PSYCHOTROPIC AGENTS.
0D2305 03-D3

3H-LEU-ENKEPHALIN
BINDING OF 3H-LEU-ENKEPHALIN IN RAT STRIATUM. PARTIAL INHIBITION BY MORPHINE OR NALOXONE
0030B9 04-03

3H-LEUCINE
INCORPORATION OF 4,5 3H-LEUCINE INTO THE NEURONS OF LOCUS-COERULEUS AND OTHER NERVE CELLS IN STRESSED RATS: EFFECT OF DIAZEPAM.
0DD13D D1-D3
UPTAKE OF 3H-LEUCINE INTO THE BRAIN AND OTHER ORGANS DURING THE CONDITIONED REACTION TO PAINFUL STIMULATION; EFFECT OF DIAZEPAM.
DD226B D3-03

3H-NA
THE EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON ARTERIAL 3H-NA UPTAKE AND ARTERIAL RESPONSIVENESS TO NORADRENALINE (NA)
D0D1D7 D1-03

3H-NOREPINEPHRINE
DIFFERENTIAL ACTIONS OF D- AND L-AMPHETAMINE ON THE METABOLISM OF 3H-NOREPINEPHRINE IN RAT BRAIN.
D0019B 01-D3

3H-PROPRANOLOL
CHARACTERISTICS AND ALTERED SENSITIVITY OF CEREBRAL BETA-ADRENOCEPTORS ASSESSED BY 3H-PROPRANOLOL BINDING.
D01302 02-03

3H-RESERPINE
IN VITRO ALTERATION OF THE SUBCELLULAR DISTRIBUTION OF 3H-RESERPINE IN THE RAT FOREBRAIN BY DELTA9-TETRAHYDROCANNABINOL.
0D1255 02-D3

3H-SEROTONIN
THE INFLUENCE OF MORPHINE ON THE KINETICS OF 3H-SEROTONIN UPTAKE BY SYNAPTOSOMES PREPARED FROM RAT HYPOTHALAMUS. (PH.D. DISSERTATION).
0D2397 D3-D3

3H-TYROSINE
ESTIMATION OF NORADRENALINE AND ITS MAJOR METABOLITES SYNTHESIZED FROM 3H TYROSINE IN THE RAT BRAIN
001650 D2-D6

39442
IMPAIRED HEPATIC HEME SYNTHESIS IN THE PHENOBARBITAL STIMULATED SELENIUM DEFICIENT RAT (39442)
D0015B 01-D3

4-BROMOPYRAZOLE
EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
D01543 02-04

4-IODOPYRAZOLE
EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
001543 02-04

4-METHOXYPHENETHYLAMINE
SELECTIVITY OF 4-METHOXYPHENETHYLAMINE DERIVATIVES AS INHIBITORS OF MONOAMINE-OXIDASE.
002279 03-03

4-METHYLPYRAZOLE
EFFECT OF PYRAZOLE, 4-METHYLPYRAZOLE, 4-BROMOPYRAZOLE AND 4-IODOPYRAZOLE ON BRAIN NORADRENALINE LEVELS OF MICE AND RATS.
D01543 02-04

45CA++
THE EFFECTS OF ELECTROSHOCK CONVULSIONS ON 45CA++ UPTAKE AND RELEASE IN SYNAPTIC TERMINALS.
D03136 04-03

5-HT
THE EFFECTS OF QUIPAZINE ON 5-HT METABOLISM IN THE RAT BRAIN.
000120 01-03
ACCUMULATION OF 5-HT IN NONTERMINAL AXONS AFTER P-CHLORO-N-METHYLAMPHETAMINE WITHOUT DEGENERATION OF IDENTIFIED 5-HT NERVE TERMINALS.
000156 D1-03
HYPOTHALAMIC NA+ AND CA++ IONS AND TEMPERATURE SET-POINT: NEW MECHANISMS OF ACTION OF A CENTRAL OR PERIPHERAL THERMAL CHALLENGE AND INTRAHYPOTHALAMIC 5-HT, NOREPINEPHRINE, PGE1 AND PYROGEN
0DD1B1 01-03
DIFFERENTIAL CIRCADIAN RHYTHMS IN PINEAL AND HYPOTHALAMIC 5-HT INDUCED BY ARTIFICIAL PHOTOPERIODS OR MELATONIN.
00D265 D1-03
5-HT AND LSD HIGH AFFINITY BINDING SITES TO BRAIN SYNAPTOSOMAL MEMBRANES.
0012D1 D2-03
EFFECTS OF TRANYLCYPROMINE ON 5-HT UPTAKE AND ITS INTERACTION WITH P-CPA ON RAT BRAIN 5-HT
0D1211 D2-03
POTENTIATION OF NIALAMIDE-INDUCED HYPERMOTILITY IN MICE BY LITHIUM AND THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FG-4963.
001273 02-03
MEASUREMENT OF 5-HT TURNOVER RATE IN DISCRETE NUCLEI OF RAT BRAIN.
002185 03-01
5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION
002429 03-04
STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS ON HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 D3-05
BLOCKADE BY MAZINDOL OF BRAIN 5-HT DEPLETION INDUCED BY P-CHLOROMETHAMPHETAMINE.
DD3109 04-03
EFFECT OF A SELECTIVE 5-HT UPTAKE INHIBITOR -- LU-10-171 -- ON RAT BRAIN 5-HT TURNOVER.
DD3179 04-03

5-HTP
BLOCKADE OF THE BEHAVIORAL EFFECTS OF 5-HTP BY THE DECARBOXYLASE INHIBITOR RO-4-4602.
000295 D1-04
5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY
D00627 01-09
CLINICAL TRIAL OF 5-HTP.
000639 01-09
KYNURENINES ANTAGONISM AGAINST 5-HTP POTENTIATED ACTION OF IMIPRAMINE AND AMITRIPTYLINE IN FROGS.
001272 D2-03
HUMAN SLEEP AND 5-HTP. EFFECTS OF REPEATED HIGH DOSES AND OF ASSOCIATION WITH BENSERAZIDE (RO-4-46D2)
002B49 03-14

5-HTP-DECARBOXYLASE
DIFFERENTIATION IN BRAIN AND LIVER DOPA/5-HTP-DECARBOXYLASE ACTIVITY AFTER L-DOPA ADMINISTRATION WITH OR WITHOUT PYRIDOXINE IN CATS.
D03254 04-03

5-HYDROXYDOPAMINE
TURNOVER OF 5-HYDROXYDOPAMINE IN ADRENERGIC NERVES.
D02157 D4-03

5-HYDROXYINDOLE

SERUM LEVELS OF 5-HYDROXYINDOLE DERIVATES AFTER ADMINISTRATION OF L-5 HYDROXYTRYPTOPHAN-ETHYL ESTER.
001922 02-13

DURATION OF THE EFFECTS OF ALPHA-ETHYL-4-METHYL-M-TYRAMINE, (H75-12) ON BRAIN 5-HYDROXYINDOLE CONCENTRATIONS IN RATS
002242 03-03

MEASUREMENT OF 5-HYDROXYINDOLE COMPOUNDS DURING L-5-HTP TREATMENT IN DEPRESSED PATIENTS.
002700 03-09

5-HYDROXYINDOLEACETIC-ACID

THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5 HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03

PROBENECID-INDUCED ACCUMULATION OF CYCLIC NUCLEOTIDES, 5-HYDROXYINDOLEACETIC-ACID, AND HOMOVANILLIC-ACID IN CISTERNAL SPINAL FLUID OF GENETICALLY NERVOUS DOGS
001125 02-03

EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

INFLUENCE OF DIELDRIN ON SEROTONIN TURNOVER AND 5-HYDROXYINDOLEACETIC-ACID EFFLUX IN MOUSE BRAIN
001369 02-03

A STUDY OF THE RELATIONSHIP BETWEEN BRAIN SEROTONIN METABOLISM AND LUMBAR FLUID 5-HYDROXYINDOLEACETIC-ACID.
003107 04-03

EFFECT OF BACLOFEN ON CEREBROSPINAL FLUID LEVELS OF 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACID.
003647 04-11

5-HYDROXYINDOLES

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON STIMULATION-INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES: MODIFICATION BY CHLORIMIPRAMINE.
000075 01-03

5-HYDROXYTRYPTAMINE

ROLE OF 5-HYDROXYTRYPTAMINE IN PROSTAGLANDIN-E1-INDUCED POTENTIATION OF HEXOBARBITONE HYPNOSIS IN ALBINO RATS.
000050 01-03

RESPONSES OF MIDBRAIN NEURONES TO MICROIONTOPHORETICALLY APPLIED 5-HYDROXYTRYPTAMINE: COMPARISON WITH THE RESPONSE TO INTRAVENOUSLY ADMINISTERED LYSERGIC-ACID-DIETHYLAMIDE.
000060 01-03

THE EFFECT OF METHYSERGIDE ON 5-HYDROXYTRYPTAMINE TURNOVER IN WHOLE BRAIN.
0000B2 01-03

EFFECTS OF CHLORPROTHIXENE ISOMERS ON PLATELET 5-HYDROXYTRYPTAMINE RECEPTORS: EVIDENCE FOR DIFFERENT 5-HYDROXYTRYPTAMINE CONFORMATIONS AT UPTAKE AND STIMULATORY SITES.
000092 01-03

INHIBITION BY 5-HYDROXYTRYPTAMINE OR ANAPHYLACTIC HISTAMINE RELEASE FROM BOVINE GRANULOCYTES.
000124 01-03

COINCIDENCE OF BLOCKADE OF SYNAPTOSOMAL 5-HYDROXYTRYPTAMINE UPTAKE AND DECREASE IN TRYPTOPHAN-HYDROXYLASE ACTIVITY: EFFECTS OF FENFLURAMINE.
000143 01-03

5-HYDROXYTRYPTAMINE AS A SENSITIZER OF SOMATIC NOCICEPTORS FOR PAIN-PRODUCING SUBSTANCES.
0001B5 01-03

POTENTIATION OF CENTRAL REWARD BY LOCALISED PERFUSION OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE
000209 01-03

Z-DIMETHYLAMINO-1-(4-BROMOPHENYL)-1-(3-PYRIDYL)PROPENE (H-102-09), A NEW SELECTIVE INHIBITOR OF THE NEURONAL 5-HYDROXYTRYPTAMINE UPTAKE.
000212 01-03

5-HYDROXYTRYPTAMINE AND THE MEDIATION OF PITUITARY ADRENOCORTICAL HORMONES IN THE EXTINCTION OF ACTIVE AVOIDANCE BEHAVIOUR.
000364 01-04

DECREASED BLOOD LEVEL OF 5-HYDROXYTRYPTAMINE BY INHIBITORS OF THE MEMBRANAL 5-HYDROXYTRYPTAMINE UPTAKE
000513 01-07

PLATELET UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN DEPRESSION.
000612 01-09

COMPARISON OF THE INHIBITION OF 5-HYDROXYTRYPTAMINE UPTAKE BY METHADONE AND ITS CONGENERS IN HUMAN PLATELETS
000933 01-15

EFFECTS OF FENFLURAMINE ON ACCUMULATION OF 5-HYDROXYTRYPTAMINE AND OTHER NEUROTRANSMITTERS INTO SYNAPTOSOMES OF RAT BRAIN
001137 02-03

EFFECT OF AMINOPHYLLINE ON TRYPTOPHAN AND OTHER AROMATIC AMINO-ACIDS IN PLASMA, BRAIN AND OTHER TISSUES AND ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM
001176 02-03

UPTAKE OF 5-HYDROXYTRYPTAMINE IN DIFFERENT PARTS OF THE BRAIN OF THE RABBIT AFTER INTRAVENTRICULAR INJECTION
0011B7 02-03

INTERACTIONS BETWEEN ANTIMIGRAINE DRUGS AND A HIGH AFFINITY UPTAKE AND STORAGE MECHANISM FOR 5-HYDROXYTRYPTAMINE
001207 02-03

5-HYDROXYTRYPTAMINE IS A SUBSTRATE FOR BOTH SPECIES OF MONOAMINE-OXIDASE IN BEEF HEART MITOCHONDRIA.
001289 02-03

EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

SEPARATELY DEVELOPING AXONAL UPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE IN THE FETAL ILEUM OF THE RABBIT
001347 02-03

EFFECT OF LITHIUM ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM IN MICE.
001370 02-03

INTERACTION OF TRICYCLIC ANTIDEPRESSANTS WITH NORADRENALINE AND 5-HYDROXYTRYPTAMINE ON PERIPHERAL PREPARATIONS IN THE RAT.
001408 02-03

EFFECTS OF INTRAVENTRICULAR INJECTIONS OF IMIPRAMINE AND 5-HYDROXYTRYPTAMINE ON TONIC IMMOBILITY IN CHICKENS.
001506 02-04

BEHAVIORAL EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE LESIONS OF ASCENDING 5-HYDROXYTRYPTAMINE PATHWAYS.
001514 02-04

IMPROVED METHOD FOR EVALUATING THE INHIBITION OF (14C)5-HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001652 02-06

POSTPONEMENT OF SYMPTOMS OF HEREDITARY MUSCULAR DYSTROPHY IN CHICKENS BY 5-HYDROXYTRYPTAMINE ANTAGONISTS.
002207 03-03

MODULATION OF ACETYLCHOLINE IN THE NEOSTRIATUM BY DOPAMINE AND 5-HYDROXYTRYPTAMINE.
002216 03-03

EFFECT OF NOMIFENSINE ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS.
002503 03-04

STUDIES ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE (SEROTONIN). VII. EFFECTS OF HALOINDOLES ON CEREBRAL 5-HT IN VARIOUS SPECIES.
002574 03-05

SPECIFIC INHIBITION OF HYPOTHALAMIC SELF-STIMULATION BY SELECTIVE REUPTAKE BLOCKADE OF EITHER 5-HYDROXYTRYPTAMINE OR NORADRENALINE.
0030B7 04-03

FURTHER OBSERVATIONS ON THE EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON THE BEHAVIOURAL RESPONSES OF RATS PRODUCED BY INCREASES IN THE FUNCTIONAL ACTIVITY OF BRAIN 5-HYDROXYTRYPTAMINE AND DOPAMINE
003160 04-03

THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03

EFFECTS OF A NEW ANTIDEPRESSANT 3-METHYL-3-PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE (TOLOXATONE) UPON 5-HYDROXYTRYPTAMINE PATHWAYS (1).
003190 04-03

CHANGES IN ELECTROCORTICAL ACTIVITY INDUCED BY THE PERFUSION OF 5-HYDROXYTRYPTAMINE INTO THE NUCLEUS OF THE SOLITARY TRACT.
003195 04-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE AND CYCLIC-AMP IN TOLERANCE TO TREMORINE ANALGESIA IN MICE.
003228 04-03

EFFECTS OF MAZINDOL AND D-FENFLURAMINE ON 5-HYDROXYTRYPTAMINE UPTAKE, STORAGE AND METABOLISM IN BLOOD PLATELETS.
003241 04-03

EFFECT OF SYMPATHOMIMETIC AMINES ON THE SYNAPTOSOMAL TRANSPORT OF NORADRENALINE, DOPAMINE, AND 5-HYDROXYTRYPTAMINE
003247 04-03

EXCITATORY AND DEPRESSANT NEURONAL RESPONSES TO NORADRENALINE, 5-HYDROXYTRYPTAMINE AND MESCALINE THE ROLE OF THE BASELINE FIRING RATE.
003295 04-03

TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE METABOLISM IN THE IMMATURE RAT BRAIN DURING RECOVERY FROM ASPHYXIA.
003303 04-03

REPEATED CHLORPROMAZINE ADMINISTRATION INCREASES A BEHAVIOURAL RESPONSE OF RATS TO 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
003396 04-04
EFFECTS OF METHOXYAMPHETAMINES ON THE UPTAKE AND RELEASE OF (3H)5-HYDROXYTRYPTAMINE BY HUMAN BLOOD PLATELETS.
003715 04-13

5-HYDROXYTRYPTAMINERGIC
EFFECTS OF ALTERED BRAIN 5-HYDROXYTRYPTAMINERGIC ACTIVITY ON BRAIN TRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC-ACID.
001292 02-03

5-HYDROXYTRYPTOPHAN
THE EFFECTS OF RESERPINE, L-DOPA AND 5-HYDROXYTRYPTOPHAN ON 5-HYDROXYINDOLEACETIC-ACID AND HOMOVANILLIC-ACIDS IN CEREBROSPINAL FLUID, BEHAVIOUR AND EEG IN CATS.
000065 01-03
THE INFLUENCE OF ENVIRONMENTAL NOVELTY AND TIME OF DAY ON THE EFFECTS INDUCED BY 5-HYDROXYTRYPTOPHAN IN MICE. (PH D. DISSERTATION).
000339 01-04
MYOCLONUS AFTER 5-HYDROXYTRYPTOPHAN IN RATS WITH LESIONS OF INDOLEAMINE NEURONS IN THE CENTRAL-NERVOUS-SYSTEM.
000430 01-04
5-HYDROXYTRYPTOPHAN (5-HTP) AND A MAOI (NIALAMIDE) IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CONTROLLED STUDY.
000627 01-09
DOUBLE-BLIND CLINICAL TRIAL OF 5-HYDROXYTRYPTOPHAN IN A CASE OF LESCH-NYHAN SYNDROME
001827 02-11
EFFECT OF APOMORPHINE PLUS 5-HYDROXYTRYPTOPHAN ON PLASMA PROLACTIN LEVELS IN MALE RATS.
002310 03-03
THE INTERACTION OF SOME KYNURENINE PATHWAY METABOLITES WITH 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE.
003166 04-03
MYOCLONUS IN THE YOUNG AFTER 5-HYDROXYTRYPTOPHAN
003771 04-15

5-HYDROXYTRYPTOPHAN-INDUCED
EFFECTS OF AMITRIPTYLINE AND ISOCARBOXAZID ON 5-HYDROXYTRYPTOPHAN-INDUCED HEAD TWITCHES IN MICE.
000392 01-04
5-HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04

5-HYDROXYTRYPTOPHAN-14C
BRAIN AND PERIPHERAL METABOLISM OF 5-HYDROXYTRYPTOPHAN-14C FOLLOWING PERIPHERAL DECARBOXYLASE INHIBITION.
000252 01-03

5-METHOXYDIMETHYLTRYPTAMINE
5-METHOXYDIMETHYLTRYPTAMINE: BEHAVIORAL AND TOXICOLOGICAL EFFECTS IN ANIMALS.
000022 01-02

5-METHOXYTRYPTAMINE
5-METHOXYTRYPTAMINE: STIMULATION OF 5-HT RECEPTORS MEDIATING THE RAT HYPERACTIVITY SYNDROME AND BLOOD PLATELET-AGGREGATION.
002429 03-04

5-METHOXYTRYPTAMINE-INDUCED
5-METHOXYTRYPTAMINE-INDUCED HEAD TWITCHES IN RATS.
002573 03-05

5-6-DHT
GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES
000378 01-04

5-7-DHT
GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES.
000378 01-04

5-7-DIHYDROXYTRYPTAMINE
5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS: INCREASED SENSITIVITY TO SEROTONIN AFTER INTRACRANIAL 5-7-DIHYDROXYTRYPTAMINE IN THE ADULT RAT.
000429 01-04
BEHAVIORAL EVIDENCE FOR SUPERSENSITIVITY FOLLOWING DESTRUCTION OF CENTRAL SEROTONERGIC NERVE TERMINALS BY 5-7-DIHYDROXYTRYPTAMINE.
000441 01-04

6-AMINODOPAMINE
THE EFFECTS OF 6-AMINODOPAMINE ON ELECTRICAL SELF-STIMULATION IN RATS
000388 01-04

6-AMINONICOTINAMIDE
DECREASED GABA AND GLUTAMATE CONCENTRATION IN RAT BRAIN AFTER TREATMENT WITH 6-AMINONICOTINAMIDE
001144 02-03

6-HYDROXYDOPA
BEHAVIORAL AND BIOCHEMICAL EFFECTS OF NEONATAL TREATMENT OF RATS WITH 6-HYDROXYDOPA.
000376 01-04

6-HYDROXYDOPAMINE
BEHAVIORAL AND NEUROCHEMICAL CHANGES FOLLOWING ADMINISTRATION OF 6-HYDROXYDOPAMINE INTO THE VENTRAL TEGMENTAL AREA OF THE MIDBRAIN
000184 01-03
THE EFFECT OF MORPHINE ON TURNING BEHAVIOUR IN RATS AND MICE WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS.
000290 01-04
INTRAVENTRICULAR 6-HYDROXYDOPAMINE LOWERS ISOLATION-INDUCED FIGHTING BEHAVIOR IN MALE MICE.
000303 01-04
CIRCLING BEHAVIOR IN RATS WITH 6-HYDROXYDOPAMINE OR ELECTROLYTIC NIGRAL LESIONS
000350 01-04
FACILITATED INTERMALE AGGRESSION IN THE MOUSE AFTER 6-HYDROXYDOPAMINE ADMINISTRATION.
000404 01-04
POTENTIATION OF MORPHINE-INDUCED SEIZURE BY 6-HYDROXYDOPAMINE
001133 02-03
THE PROTECTIVE EFFECTS OF METHYSERGIDE, 6-HYDROXYDOPAMINE AND OTHER AGENTS ON THE TOXICITY OF AMPHETAMINE, PHENTERMINE, MDA, PMA, AND STP IN MICE.
001282 02-03
6-HYDROXYDOPAMINE AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS
001300 02-03
REGIONAL BRAIN CATECHOLAMINE LEVELS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE IN THE NEONATAL RAT.
001323 02-03
ABOLITION OF NOMIFENSINE INDUCED STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF ASCENDING DOPAMINERGIC PROJECTIONS
001334 02-03
THE COMPARISON OF FLUOXETINE AND NISOXETINE WITH TRICYCLIC ANTIDEPRESSANTS IN BLOCKING THE NEUROTOXICITY OF P-CHLOROAMPHETAMINE AND 6-HYDROXYDOPAMINE IN THE RAT BRAIN
001423 02-03
AMPHETAMINE REDUCTION OF MOTOR ACTIVITY IN RATS AFTER NEONATAL ADMINISTRATION OF 6-HYDROXYDOPAMINE.
001587 02-04
EFFECTS OF INTRACEREBROVENTRICULAR INJECTION OF 5,6 DIHYDROXYTRYPTAMINE AND 6-HYDROXYDOPAMINE ON SUPRAEPENDYMAL NERVES.
001629 02-05
THE ROLE OF CENTRAL NORADRENERGIC NEURONS IN THE CONTROL OF PITUITARY ADRENOCORTICAL FUNCTION IN THE RAT. EFFECTS OF 6-HYDROXYDOPAMINE AND VARIOUS SYMPATHOMIMETIC AGENTS. (PH D DISSERTATION)
002257 03-03
THE RELATIONSHIP BETWEEN STRIATAL AND MESOLIMBIC DOPAMINE DYSFUNCTION AND THE NATURE OF CIRCLING RESPONSES FOLLOWING 6-HYDROXYDOPAMINE AND ELECTROLYTIC LESIONS OF THE ASCENDING DOPAMINE SYSTEMS OF RAT BRAIN
002436 03-04
INFLUENCE OF 6 HYDROXYDOPAMINE ON THE BEHAVIORAL EFFECTS INDUCED BY APOMORPHINE OR CLONIDINE IN RATS.
002463 03-04
OPERANT BEHAVIOURAL AND NEUROCHEMICAL EFFECTS AFTER NEONATAL 6-HYDROXYDOPAMINE TREATMENT
002519 03-04
CORRELATION BETWEEN CENTRAL CATECHOLAMINE LEVEL AND POST-DECAPITATION CONVULSION IN RATS TREATED WITH 6-HYDROXYDOPAMINE
003292 04-03
STEREOTYPED BEHAVIOUR PATTERNS AND HYPERACTIVITY INDUCED BY AMPHETAMINE AND APOMORPHINE AFTER DISCRETE 6-HYDROXYDOPAMINE LESIONS OF EXTRAPYRAMIDAL AND MESOLIMBIC NUCLEI
003368 04-04

6-HYDROXYDOPAMINE-INDUCED
EFFECTS OF DOPAMINE RECEPTOR STIMULANTS ON LOCOMOTOR ACTIVITY OF RATS WITH ELECTROLYTIC OR 6-HYDROXYDOPAMINE-INDUCED LESIONS OF THE NUCLEUS-ACCUMBENS
000264 01-03

6-OHDA
GENETIC DIFFERENCES IN ETHANOL DRINKING OF THE RAT FOLLOWING INJECTION OF 6-OHDA, 5-6-DHT OR 5-7-DHT INTO THE CEREBRAL VENTRICLES
000378 01-04
SELECTIVE 6-OHDA INDUCED DESTRUCTION OF MESOLIMBIC DOPAMINE NEURONS ABOLITION OF PSYCHOSTIMULANT-INDUCED LOCOMOTOR ACTIVITY IN RATS
001526 02-04

CHANGES IN DRUG-INDUCED STEREOTYPED BEHAVIOR AFTER 6-OHDA LESIONS IN NORADRENALINE NEURONS.
003357 04-04

6BETA-HYDROXYCORTISOL
PHENOBARBITONE-INDUCED URINARY EXCRETIONS OF D-GLUCARIC-ACID AND 6BETA-HYDROXYCORTISOL IN MAN
002822 03-13

7-HYDROXYAMINOBENZODIAZEPINES
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 75. 7-HYDROXYAMINOBENZODIAZEPINES AND DERIVATIVES.
001096 02-01

9-NOR-9-HYDROXYHEXAHYDROCANNABINOLS
9-NOR-9 HYDROXYHEXAHYDROCANNABINOLS SYNTHESIS, SOME BEHAVIORAL AND ANALGESIC PROPERTIES, AND COMPARISON WITH THE TETRAHYDROCANNABINOLS.
002404 03-03

9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL
9-NOR-9BETA-HYDROXYHEXAHYDROCANNABINOL, A CANNABINOID WITH POTENT ANTINOCICEPTIVE ACTIVITY: COMPARISONS WITH MORPHINE.
003099 04-03

9-THC
MUSCULAR DYSTROPHY IN ADULT MICE CHRONICALLY TREATED WITH 9-THC AT BEHAVIORAL DOSES.
00349B 04-05

☆U.S. GOVERNEMNT PRINTING OFFICE: 1979-281-265/1018

Computer Information Services of the National Clearinghouse for Mental Health Information

Searches of the NCMHI computer-based information system will be done on request. These reader-generated bibliographies are available without charge to anyone within the mental health community.

Requests for a printout on a topic not covered by the abstracts in this issue or other NCMHI publications should be sent directly to the Clearinghouse. The request should include the inquirer's name, address, professional affiliation, and phone number, along with a clear and specific statement of the information desired. Either a letter or the order blank below should be sent to the following address:

National Clearinghouse for Mental
Health Information
Alcohol, Drug Abuse, and
Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

Date _____

Name of requester _____

Address _____

Organization _____

Phone number (include area code) _____

Information requested (please be as specific as possible) _____

_____

_____

PSYCHOPHARMACOLOGY ABSTRACTS

Questions about Clearinghouse service should be addressed to:

Psychopharmacology Abstracts
National Clearinghouse for Mental Health Information
Alcohol, Drug Abuse, and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

For information on subscriptions and the purchase of single copies of the *Abstracts* (Vol. 7 onward), please refer to page ii of this issue.

DEPARTMENT OF
HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE

ALCOHOL, DRUG ABUSE, AND
MENTAL HEALTH ADMINISTRATION
5600 FISHERS LANE
ROCKVILLE, MARYLAND 20857

OFFICIAL BUSINESS
Penalty for private use, $300

POSTAGE AND FEES PAID
U.S. DEPARTMENT OF H.E.W.
HEW 389

Fourth-Class/Book

U.S. MAIL

NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this type of publication.

☐ Check here if your address has changed and you wish to continue receiving the type of publication. (Be sure to furnish your complete address including zip code.)

Tear off cover with address label still affixed and send to:

Alcohol, Drug Abuse, and Mental Health Administration
Printing and Publications Management Section
5600 Fishers Lane (Rm. 6-105)
Rockville, Maryland 20857

DHEW Publication No. (ADM) 79-150
Printed 1979

LIBRARY OF THE UNIVERSITY OF MISSOURI

UNIVERSITY OF ILLINOIS-URBANA
3 0112 043285409